<SEC-DOCUMENT>0001213900-23-025412.txt : 20230331
<SEC-HEADER>0001213900-23-025412.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331160115
ACCESSION NUMBER:		0001213900-23-025412
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		136
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40303
		FILM NUMBER:		23787365

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>f20f2022_inspiratech.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 19:09:16 UTC 2023 -->
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com --><!-- Created: Fri Mar 31 16:48:38 UTC 2023 --><html xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iinn="http://www.inspiratechnologies.com/20221231" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>



<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
WASHINGTON, DC 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement">&#9744;</ix:nonNumeric> REGISTRATION STATEMENT
PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric> ANNUAL REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric> TRANSITION REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric> SHELL COMPANY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File No.: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-40303</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>(Exact name of registrant as specified in its
charter)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>Translation of registrant&#8217;s name into
English: Not applicable</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>State of <ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">Israel</ix:nonNumeric> </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><i>(Jurisdiction of incorporation
or organization)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1">2 Ha-Tidhar St</ix:nonNumeric>.,</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown">Ra&#8217;anana</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode">4366504</ix:nonNumeric> <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>Tel: +<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode">972.4</ix:nonNumeric>.<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber">6230333</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><i>(Address of principal
executive offices)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName"><b>Dagi Ben-Noon</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">2 Ha-Tidhar St</ix:nonNumeric>.,</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Ra&#8217;anana</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">4366504</ix:nonNumeric> <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>Tel: +972.4.6230333</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;<i>(Name, Telephone,
E-mail and/or Facsimile number and Address of Company Contact Person)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities registered or to be registered pursuant
to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Title of each class</i></span></td> <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trading Symbol(s)</i></span></td> <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Name of each exchange on <br/>
which registered </i></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares, no par value</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IINN</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</b></span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant to purchase one Ordinary Share</b></span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IINNW</b></span></td> <td style="text-align: center">&#160;</td> <td>&#160;</td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities registered or to be registered pursuant
to Section 12(g) of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 1; Options: NewSection --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of outstanding shares of each
of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">11,338,940</ix:nonFraction> ordinary shares as of December 31,
2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric>
&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric>
&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">No</ix:nonNumeric>
&#9746;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160;No
&#9744;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 8%">&#160;</td> <td style="width: 40%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td> <td style="width: 52%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric> &#9746;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging Growth Company <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange
Act. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8224;The term &#8220;new or revised financial
accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification
after April 5, 2012.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160;&#160;&#160;&#160;No
<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. GAAP &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">International Financial Reporting
Standards as issued by the <span style="-sec-ix-hidden: hidden-fact-0">International Accounting Standards Board</span> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &#8220;Other&#8221; has been checked in response
to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9744; Item 17 &#160;&#160;&#9744;
Item 18</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this is an annual report, indicate by check
mark whether the registrant is a shell company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160;&#160;&#160;&#160;No
<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">INTRODUCTION</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</span></td></tr>
  <tr style="background-color: White">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">CAUTIONARY
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">SUMMARY
    RISK FACTORS</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii</span></td></tr>
  <tr style="background-color: White">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">PART
    I</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">IDENTITY
    OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">OFFER
    STATISTICS AND EXPECTED TIMETABLE.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">KEY INFORMATION.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">[Reserved]</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">Capitalization
    and Indebtedness.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">Reasons
    for the Offer and Use of Proceeds.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Risk Factors.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">INFORMATION
    ON THE COMPANY.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">History
    and Development of the Company.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Business
    Overview.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024">Organizational
    Structure.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025">Property,
    Plants and Equipment.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">UNRESOLVED
    STAFF COMMENTS.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_027">OPERATING
    AND FINANCIAL REVIEW AND PROSPECTS.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_028">Operating
    Results.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_029">Liquidity
    and Capital Resources.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_030">Research
    and development, patents and licenses, etc.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_031">Trend
    information</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_032">Critical
    Accounting Estimates</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_033">DIRECTORS,
    SENIOR MANAGEMENT AND EMPLOYEES.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_034">Directors
    and Senior Management.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_035">Compensation.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_036">Board
    Practices.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_037">Employees.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_038">Share
    Ownership.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_039">MAJOR
    SHAREHOLDERS AND RELATED PARTY TRANSACTIONS.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_040">Major
    Shareholders.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_041">Related
    Party Transactions.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_042">Interests
    of Experts and Counsel.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_043">FINANCIAL
    INFORMATION.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_044">Consolidated
    Statements and Other Financial Information.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_045">Significant
    Changes.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_046">THE OFFER
    AND LISTING.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_047">Offer
    and Listing Details.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_048">Plan of
    Distribution.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_049">Markets.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_050">Selling
    Shareholders.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_051">Dilution.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_052">Expenses
    of the Issue.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_053">ADDITIONAL
    INFORMATION.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_054">Share
    Capital.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_055">Memorandum
    and Articles of Association.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_056">Material
    Contracts.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_057">Exchange
    Controls.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_058">Taxation.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_059">Dividends
    and Paying Agents.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_060">Statement
    by Experts.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_061">Documents
    on Display.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_062">Subsidiary
    Information.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_063"><span style="text-decoration: none">Annual
    Report to Security Holders.</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11.</span></td>
    <td style="width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_064">QUANTITATIVE AND
    QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</a></span></td>
    <td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_065">DESCRIPTION OF SECURITIES OTHER THAN
    EQUITY SECURITIES.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_066">Debt Securities.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_067">Warrants and rights.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_068">Other Securities.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_070">PART
    II</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_071">DEFAULTS, DIVIDEND ARREARAGES AND
    DELINQUENCIES.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_072">MATERIAL MODIFICATIONS TO THE RIGHTS
    OF SECURITY HOLDERS AND USE OF PROCEEDS.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_073">CONTROLS AND PROCEDURES.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_074">[RESERVED]</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16A.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_075">AUDIT COMMITTEE FINANCIAL EXPERT.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16B.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_076">CODE OF ETHICS.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16C.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_077">PRINCIPAL ACCOUNTANT FEES AND SERVICES.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16D.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_078">EXEMPTIONS FROM THE LISTING STANDARDS
    FOR AUDIT COMMITTEES.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16E.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_079">PURCHASES OF EQUITY SECURITIES BY
    THE ISSUER AND AFFILIATED PURCHASERS.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16F.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_080">CHANGE IN REGISTRANT&#8217;S CERTIFYING
    ACCOUNTANT.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16G.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_081">CORPORATE GOVERNANCE.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16H.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_082">MINE SAFETY DISCLOSURE.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16I</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_083">DISCLOSURE REGARDING FOREIGN JURISDICTIONS
    THAT PREVENT INSPECTIONS.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_084">PART
    III</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 17.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_085">FINANCIAL STATEMENTS.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 18.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_086">FINANCIAL STATEMENTS.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 19.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_087">EXHIBITS.</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_088">SIGNATURES</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Inspira Technologies Oxy B.H.N. Ltd. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-transform: uppercase"><b>INTRODUCTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty medical
device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory support technology that is
intended to reduce the need for invasive mechanical ventilation, or IMV, which is the standard of care today for the treatment of acute
respiratory failure. Although it may be sometimes lifesaving, IMV is associated with increased risks, costs of care, extended lengths
of stay, frequent incidence of infections, ventilator dependence and mortality. Using our state-of-the-art respiratory support technology,
our goal is to set a new standard of care and to provide patients with acute respiratory failure an opportunity to maintain spontaneous
breathing and avoid the need for intubation, coma and various risks associated with the use of IMV. As part of our strategy to reach this
goal, and in parallel to pursuing regulatory approvals, we are actively working to establish collaborations with strategic partners, globally
ranked hospitals, medical device companies and distributors both for endorsement and early clinical adoption. &#160;We plan to target
ICUs, general medical units, operating theaters, emergency medical services and small urban and rural hospitals, with the goal of making
our solutions more accessible to millions of patients worldwide. We expect for these activities to support our strategy plan to reach
market penetration and adoption of our respiratory support technology. We are developing the following products:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>The INSPIRA<sup>TM</sup>
ART System</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART system (Augmented
Respiratory Technology) (also known as the ART500 or ART), described herein as the INSPIRA ART, INSPIRA ART device or INSPIRA ART system,
our flagship product, is a respiratory support technology targeting to utilize direct blood oxygenation to boost patient saturation levels
within minutes while the patient is awake &amp; spontaneously breathing. The aim of our products is to reduce the need for IMV with the
potential to reduce risks, complications and high costs and potentially allowing for larger patient populations in and beyond ICU settings.
The INSPIRA ART is being designed as a new intent of use for long-term (longer than 6 hours) respiratory support that provides assisted
extracorporeal circulation and physiologic gas exchange (oxygenation and CO2 removal) of the patient&#8217;s blood in adults with acute
respiratory failure, targeting to allow for treatment of patients while they are awake. The INSPIRA ART is being designed to potentially
prevent the need for invasive mechanical ventilation, targeting acute respiratory failure patients in intensive care units, or ICUs, and
general medical units. The next generation INSPIRA ART is expected to be submitted to FDA for regulatory approval via the pre-market approval
application, or PMA, or De Novo regulatory pathways.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>The HYLA<sup>TM</sup> Blood
Sensor</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HYLA blood sensor, described
herein as the HYLA or HYLA blood sensor, originally designed as a key and core technology for the INSPIRA ART, is being developed also
as a stand-alone device to be integrated or used in extracorporeal procedures. The HYLA is a non-invasive optical blood sensor designed
to perform real-time and continuous blood measurements, potentially minimizing the need to take actual blood samples from patients. The
HYLA&#8217;s measurements can assist physicians in the monitoring of patient&#8217;s clinical condition. The HYLA blood sensor is being
designed as a clip-on sensor, attached to the outer walls of a blood tube, which may potentially reduce risks, complications, and costs.
The HYLA blood sensor may have broad application potential, benefiting patients undergoing procedures such as cardiopulmonary bypass operations,
Extracorporeal Membrane Oxygenation, or ECMO and Cardiopulmonary bypass, pending regulatory approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>The ALICE Device&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ALICE Device (previously
referred to as the Liby or ECLS system), described herein as the ALICE, or the ALICE device, an advanced form of life support system better
known by the medical industry as a cardiopulmonary bypass system, or CPB, is being designed for use in surgical procedures requiring cardiopulmonary
bypass for 6 hours or less. The ALICE device is expected to be submitted to the U.S. Food and Drug Administration, or FDA, for 510k clearance,
during the second half of 2023. The ALICE is designed to be a new generation CPB system with potential advantages to medical device design
with ergonomic configuration and intuitive user-centric software and display to increase functionality, as well as a large touchscreen
with novel colorful graphical representation that increases the visibility and functionality of data displayed to the medical staff. The
ALICE device is being designed to be lightweight and highly durable and will be equipped with long battery life to maximize its portability.
The ALICE device, designed as a CPB, shall be indicated for use in surgical procedures requiring cardiopulmonary bypass for 6 hours or
less.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a goal to set a new
standard of care in various areas of patient care. As part of our strategy to reach these goals, and in parallel to pursuing regulatory
approvals, we are actively working to establish collaborations with strategic partners and globally ranked health centers to provide endorsement
and clinical adoption for regional deployments of our respiratory support, heart-lung bypass, ECMO and blood monitoring products and technologies.
We plan to target ICUs, general medical units, Operating theaters, emergency medical services and small urban and rural hospitals, with
the goal of making our solutions more accessible to millions of patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an Israeli corporation
based in Ra&#8217;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd. On April 10, 2018, our name
was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira Technologies Oxy B.H.N. Ltd.
Our principal executive offices are located at 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel. Our telephone number in Israel is 972
996 644 88. Our website address is <i>www.inspira-technologies.com</i>. The information contained on, or that can be accessed through,
our website is not part of this annual report on Form 20-F. We have included our website address in this annual report on Form 20-F solely
as an inactive textual reference. Our ordinary shares, or &#8220;Ordinary Shares&#8221; and warrants to purchase one Ordinary Share, or
&#8220;Warrants,&#8221; are listed on the Nasdaq Capital Market, or Nasdaq, under the symbols &#8220;IINN&#8221; and &#8220;IINNW,&#8221;
respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-transform: uppercase"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain information included
or incorporated by reference in this annual report on Form 20-F may be deemed to be &#8220;forward-looking statements&#8221; within the
meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are often
characterized by the use of forward-looking terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221;
&#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;believe,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221;
&#8220;project&#8221; or other similar words, but are not the only way these statements are identified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking statements
may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections
of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development,
completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or
developments that we intend, expect, project, believe or anticipate will or may occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on
assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions,
expected future developments and other factors they believe to be appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Important factors that could
cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements
include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our planned level of revenues and capital expenditures;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our available cash our ability to obtain additional funding;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our ability to market and sell our products;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectation regarding the sufficiency of our existing cash and cash equivalents to fund our current operations; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to advance the development of our products and future potential product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to commercialize our products and future potential product candidates and future sales of our products or any other future potential product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our assessment of the potential of our products and future potential product candidates to treat certain indications; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our planned level of capital expenditures and liquidity; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our plans to continue to invest in research and development to develop technology for new products; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain our relationships with suppliers, manufacturers, distributors, and other partners;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">anticipated actions of the FDA, state regulators, if any, or other similar foreign regulatory agencies, including approval to conduct clinical trials, the timing and scope of those trials and the prospects for regulatory approval or clearance of, or other regulatory action with respect to our products or services; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory environment and changes in the health policies and regimes in the countries in which we intend to operate, including the impact of any changes in regulation and legislation that could affect the medical device industry; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to meet our expectations regarding the commercial supply of our products and future product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to retain key office holders; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to internally develop new inventions and intellectual property; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the overall global economic environment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of competition and new technologies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general market, political and economic conditions in the countries in which we operate;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of competition and new technologies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to internally develop new inventions and intellectual property;</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our strategy; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Readers are urged to carefully
review and consider the various disclosures made throughout this annual report on Form 20-F which are designed to advise interested parties
of the risks and factors that may affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not put undue reliance
on any forward-looking statements. Any forward-looking statements in this annual report on Form 20-F are made as of the date hereof, and
we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the section of
this annual report on Form 20-F entitled &#8220;Item 4. Information on the Company&#8221; contains information obtained from independent
industry sources and other sources that we have not independently verified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Unless
otherwise indicated, all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;Inspira&#8221; refer
to Inspira Technologies Oxy B.H.N. Ltd. References to &#8220;U.S. dollars, &#8220;dollars,&#8221; and &#8220;$&#8221; are to currency
of the United States of America, references to A$ are to Australian dollars, and references to &#8220;NIS&#8221; are to New Israeli Shekels.
We report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or the
IASB.&#160;None of the financial statements were prepared in accordance with generally accepted accounting principles in the United States.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">All
trademarks or trade names referred to in this Form 20-F are the property of their respective owners. Solely for convenience, the trademarks
and trade names in this annual report on Form 20-F are referred to without the &#174; and &#8482; symbols, but such references should not
be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.
We do not intend the use or display of other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement
or sponsorship of us by, any other companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
Form 20-F contains various depictions and illustrations of the various products we are developing. These illustrations are representative
of the current expected designs for our products and are subject to change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The&#160;risk factors&#160;described
below are a&#160;summary&#160;of the principal&#160;risk factors&#160;associated with an investment in us. These are not the only&#160;risks&#160;we
face. You should carefully consider these&#160;risk factors, together with the&#160;risk factors&#160;set forth in Item 3D. of this annual
report on Form 20-F and the other reports and documents filed by us with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a limited operating history, and we have incurred significant operating losses since our inception, and anticipate that we will incur continued losses for the foreseeable future.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not generated any revenue from product sales and may never be profitable.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising additional capital would cause dilution to our existing shareholders, and may adversely affect the rights of existing shareholders;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are highly dependent on the successful development, marketing and sale of our products and on receiving the required regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face business disruption and related risks
resulting from the outbreak of the COVID-19 pandemic, which could have a material adverse effect on our business and results of operations;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our success depends upon market acceptance of our products, our ability to develop and commercialize new products and generate revenues and our ability to identify new markets for our technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical device development is costly and involves continual technological change which may render our current or future products obsolete;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our customer acquisition strategy may not succeed;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are dependent upon third-party service providers. If such third-party service providers fail to maintain a high quality of service, the utility of our products could be impaired, which could adversely affect the penetration of our products, our business, operating results and reputation; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect to be exposed to fluctuations in currency exchange rates, which could adversely affect our results of operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We manage our business through a small number of employees and key consultants;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may need to expand our organization and we may experience difficulties in recruiting needed additional employees and consultants, which could disrupt our operations;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States or Israel;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If third-party payors do not provide adequate coverage and reimbursement for the use of our products or services or any future product candidates, our revenue will be negatively impacted;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates and operations are subject to extensive government regulation and oversight both in the United States and abroad and our failure to comply with applicable requirements could harm our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not receive, or may be delayed in receiving, the necessary clearances or approvals for our products and failure to timely obtain necessary clearances or approvals for our products would adversely affect our ability to grow our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative or regulatory reforms in the United States or the European Union may make it more difficult and costly for us to obtain regulatory clearances or approvals for our products or to manufacture, market or distribute our products after clearance or approval is obtained;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to obtain and maintain effective patent rights for our products and services, we may not be able to compete effectively in our markets. If we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price of our securities may be highly volatile, and you may not be able to resell your securities at or above the price that you paid;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal shareholders, officers and directors currently beneficially own approximately 26% of our securities and may therefore be able to exert control over matters submitted to our shareholders for approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business and operations might be adversely affected by security breaches, including any cybersecurity incidents;&#160;and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential political, economic and military instability in the State of Israel, where our headquarters, members of our management team and our research and development facilities are located, may adversely affect our results of operations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->viii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT
AND ADVISERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. <span style="text-transform: uppercase">OFFER
STATISTICS AND EXPECTED TIMETABLE</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. KEY INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_017"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Reserved]</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">[Reserved]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_018"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capitalization and Indebtedness.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_019"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reasons for the Offer and Use of Proceeds.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_020"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk Factors </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should carefully consider
the risks described below, together with all of the other information in this annual report on Form 20-F. If any of these risks actually
occurs, our business and financial condition could suffer and the price of our securities could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Risks Related to Our Financial Condition and
Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have a limited operating history, have
incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development-stage
medical device company with a limited operating history. To date, we have focused almost exclusively on developing our INSPIRA ART system,
followed by our HYLA Blood Sensor and ALICE device. We have funded our operations to date primarily through our initial public offering,
convertible loans and royalty-bearing and non-royalty bearing grants that we received from the Israeli Innovation Authority, or the IIA,
formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have only a limited operating
history upon which you can evaluate our business and prospects. In addition, we have limited experience and have not yet demonstrated
an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving
fields, particularly in the medical device industry. To date, we have not generated revenue from the sale of our product candidates (see
&#8220;Item 5. Operating and Financial Review and Prospects&#8221;) for additional information. We have incurred losses in each year since
our inception, including net losses of approximately $10.3 million and $16.9 million for the years ended December&#160;31, 2022 and 2021,
respectively. As of December 31, 2022, we had an accumulated deficit of approximately $39&#160;million. Substantially all of our operating
losses resulted from costs incurred in connection with our development of our products and from general and administrative costs associated
with our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our research and
development expenses to increase in connection with our planned expanded studies. In addition, if we obtain marketing approval for our
products, we will likely incur significant sales, marketing and outsourced manufacturing expenses, as well as continued research and development
expenses and costs associated with operating as a public company. As a result, we expect to continue to incur significant and increasing
operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing a medical device,
we are unable to predict the extent of any future losses or when we will become profitable, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to incur
significant losses until we are able to commercialize our products, which we may not be successful in achieving. We anticipate that our
expenses will increase substantially if and as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue the research and development of our products; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek regulatory and marketing approvals for our products; &#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a sales, marketing, and distribution infrastructure to commercialize our products; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to identify, assess, acquire, license, and/or develop other product candidates and subsequent generations of our current product candidate;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to maintain, protect, and expand our intellectual property portfolio;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to attract and retain skilled personnel; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">create additional infrastructure to support our operations as a public company and our product candidate development and planned future commercialization efforts; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience any delays or encounter issues with respect to any of the above, including, but not limited to, failed studies, complex results, safety issues or other regulatory challenges that require longer follow-up of existing studies or additional supportive studies in order to pursue marketing approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
amount of our future operating losses will depend, in part, on the rate of our future expenditures. Even if we obtain regulatory approval
to market our products or any future product candidates<sub>,</sub> our future revenue will depend upon the size of any markets in which
our products or any future product candidates receive approval and our ability to achieve sufficient market acceptance, pricing, reimbursement
from third-party payors for our products or any future product candidates. Further, the operating losses that we incur may fluctuate significantly
from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication
of our future performance. Other unanticipated costs may also arise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not generated any revenue from product
sales and may never be profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have no products approved for marketing in any jurisdiction and we have never generated any revenue from product sales. Our ability to
generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete
the development of, and obtain the regulatory and marketing approvals necessary to commercialize our products or any future product candidates.
We do not know when, or if, we will generate any such revenue. Our ability to generate future revenue from product sales will depend heavily
on our success in many areas, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete research and development of our products and any future product candidates in a timely and successful manner; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain regulatory and marketing approval for any product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain and enhance a commercially viable, sustainable, scalable, reproducible and transferable manufacturing process for our products and any future product candidates that is compliant with current good manufacturing practices, or cGMPs; </span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish and maintain supply and, if applicable, manufacturing relationships with third parties that can provide, in both amount and quality, adequate products to support development and the market demand for our products and any future product candidates, if and when approved; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, assessing, acquiring and/or developing new product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launch and commercialize any product candidates for which we obtain regulatory and marketing approval, either directly by establishing a sales force, marketing and distribution infrastructure, and/or with collaborators or distributors; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accurately identifying demand for our products or any future product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expose and educate physicians and other medical professionals to use our products; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain market acceptance, if and when approved, of our products and any future product candidates from the medical community and third-party payors; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure our product candidates are approved for reimbursement from governmental agencies, health care providers and insurers in jurisdictions where they have been approved for marketing; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address any competing technological and market developments that impact our products and any future product candidates or their prospective usage by medical professionals; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain, protect and expand our portfolio of intellectual property rights, including patents, patent applications, trade secrets and know-how; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">avoid and defend against third-party interference or infringement claims; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract, hire and retain qualified personnel; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">locate and lease or acquire suitable facilities to support our clinical development, manufacturing facilities and commercial expansion. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
if our products or any future product candidates are approved for marketing and sale, we anticipate incurring significant incremental
costs associated with commercializing such product candidates. Our expenses could increase beyond expectations if we are required by the
FDA, or other regulatory agencies, domestic or foreign, to change our manufacturing processes or assays or to perform studies in addition
to those that we currently anticipate. Even if we are successful in obtaining regulatory approvals to market our products or any future
product candidates, our revenue earned from such product candidates will be dependent in part upon the size of the markets in the territories
for which we gain regulatory approval for such products, the accepted price for such products, our ability to obtain reimbursement for
such products at any price, whether we own the commercial rights for that territory in which such products have been approved and the
expenses associated with manufacturing and marketing such products for such markets. Therefore, we may not generate significant revenue
from the sale of such products, even if approved. Further, if we are not able to generate significant revenue from the sale of our approved
products, we may be forced to curtail or cease our operations. Due to the numerous risks and uncertainties involved in product development,
it is difficult to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>We will need to
raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable
terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022, our
cash and cash equivalents and short-term deposits were approximately $13.9 million, not including restricted cash of $55,000, and we had
a working capital of approximately $12.4 million and an accumulated deficit of approximately $39 million. Based upon our currently expected
level of operating expenditures, we expect that our existing cash and cash equivalents, will only be sufficient to fund operations through
the next 12 months. We expect that we will require substantial additional capital to commercialize our products. In addition, our operating
plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than
planned. Our future funding requirements will depend on many factors, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress, results and costs of our ongoing and planned studies and, if applicable, clinical trials of products and any future product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost, timing and outcomes of regulatory review of products and any future product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of maintaining our own commercial-scale cGMP manufacturing facility, including costs related to obtaining and maintaining regulatory compliance, and/or engaging third-party manufacturers therefor; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, progress, results and costs of product development, testing, manufacturing, preclinical development and, if applicable, clinical trials for any other product candidates that we may develop or otherwise obtain in the future; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of our future activities, including establishing sales, marketing and distribution capabilities for any product candidates in any particular geography where we receive marketing approval for such product candidates</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms and timing of any collaborative, licensing and other arrangements that we may establish;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the level of revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any additional fundraising
efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our products and any future product candidates. In addition, future financing may not be available in sufficient amounts or on terms acceptable
to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders of our securities and
the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price
of our securities to decline. The incurrence of indebtedness could result in increased fixed payment obligations, and we may be required
to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to
acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct
our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage
than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product candidates or otherwise
agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Even
if we believe that we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions
are favorable or if we have specific strategic considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to obtain
funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development
programs or the development or commercialization, if any, of our products or any other product candidates or be unable to expand our operations
or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and
results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising additional capital would cause dilution
to our existing shareholders, and may adversely affect the rights of existing shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional capital
through a combination of private and public equity offerings, debt financings and collaborations and strategic and licensing arrangements.
To the extent that we raise additional capital through the issuance of equity or otherwise including through convertible debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights
as a shareholder. Future sales of our Ordinary Shares or of securities convertible into our Ordinary Shares, or the perception that such
sales may occur, could cause immediate dilution and adversely affect the market price of our Ordinary Shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Business and Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on the successful
development, marketing and sale of our products and on receiving the required regulatory approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products, focused on the
treatment of respiratory failure, is the basis of our business. As a result, the success of our business plan is highly dependent on our
ability to develop, manufacture and commercialize our products, and our failure to do so could cause our business to fail. Successful
commercialization of medical devices is a complex and uncertain process, dependent on the efforts of management, manufacturers, local
operators, integrators, medical professionals, third-party payors, as well as general economic conditions, among other factors. Any factor
that adversely impacts the development and commercialization of our products, will have a negative impact on our business, financial condition,
results of operations and prospects. We have limited experience in commercializing our products and we may face several challenges with
respect to our commercialization efforts, including, among others, that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not have adequate financial or other resources to complete the development of our products; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to manufacture our products in commercial quantities, at an adequate quality or at an acceptable cost; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to establish adequate sales, marketing and distribution channels; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">healthcare professionals and patients may not accept our products;&#160; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be aware of possible complications from the continued use of our products since we have limited clinical experience with respect to the actual use of our products; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to compete with existing solutions for respiratory failure; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">technological breakthroughs in the respiratory support solutions may reduce the demand for our products; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party payors may not agree to reimburse patients for any or all of the purchase price of our products, which may adversely affect patients&#8217; willingness to use our products; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may face third-party claims of intellectual property infringement; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may fail to obtain or maintain regulatory clearance or approvals in our target markets or may face adverse regulatory or legal actions even if regulatory approval is obtained. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to meet any
one or more of these challenges successfully, our ability to effectively commercialize our products and services could be limited, which
in turn could have a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face business disruption and related
risks resulting from the recent outbreak of the COVID-19 pandemic, which could have a material adverse effect on our business and results
of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been impacted by the
COVID-19 pandemic, and we cannot predict the future impacts the COVID-19 pandemic, including the emergence of new strains such as the
Omicron or Delta variant, may have on its business, results of operations and financial condition. While COVID-19 is still spreading and
the final implications of the pandemic are difficult to estimate at this stage, it is clear that it has affected the lives of a large
portion of the global population. At this time, the pandemic has caused states of emergency to be declared in various countries, travel
restrictions imposed globally, quarantines established in certain jurisdictions and various institutions and companies being closed. Numerous
government regulations and public advisories, as well as shifting social behaviors, temporarily and from time to time limited or closed
non-essential transportation, government functions, business activities and person-to-person interactions, and the duration of such trends
is difficult to predict. While certain COVID-19 mitigation actions have since been relaxed, no assurance can be made that such actions,
or other measures, will not be reimposed in the future. In addition, the U.S. government has restricted travel to the United States from
foreign nationals who have not been vaccinated against COVID-19. Although to date these restrictions have not materially impacted our
operations other than the ability to travel which resulted within some delays in our trials, demonstrations and installations, the effect
on our business, from the spread of COVID-19 and the COVID-19 mitigation actions implemented by the governments of the State of Israel,
the United States and other countries, may worsen over time.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Authorities around the world
have and may continue implementing similar restrictions on business and individuals in their jurisdictions. To date, we have taken action
to enable our employees to work remotely from home but there can be no assurance that these measures will enable us to avoid part or all
of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or in our sector in
particular.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our success depends upon market acceptance
of our products, our ability to develop and commercialize new products and generate revenues and our ability to identify new markets for
our technology. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have developed, and are
engaged in the development of, respiratory support technology. Our success will depend on the approval and acceptance of our products
and any future products in the healthcare market. We are faced with the risk that the marketplace will not be receptive to our products
or any future products over competing products and that we will be unable to compete effectively. Factors that could affect our ability
to successfully commercialize our current and any potential future products:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the challenges of developing (or acquiring externally-developed) technology solutions that are adequate and competitive in meeting the requirements of next-generation design challenges; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dependence upon referrals from physicians for the sale of our products and provision of our service. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
cannot assure that our products or any future products will gain broad market acceptance. If the market for our products fails to develop
or develops more slowly than expected, our business and operating results would be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to maintain existing strategic
relationships with Innovimed, Glo-Med, our other distributors, or are unable to identify additional distributors of our products or any
future products and technologies, our revenues may decrease.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently expect to derive
a significant amount of our revenues through our strategic relationships and distribution agreements with Innovimed Sp. z o.o, or Innovimed,
Bepex Ltd., Anita T&#233;cnica S.L, or WAAS Group and Glo-Med, as well as other distributors for the deployment of our products. If
our relationships with our distributors are terminated or impaired for any reason and we are unable to replace these relationships with
other means of distribution, we could suffer a material decrease in revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may need, or decide it
is otherwise advantageous to us, to obtain the assistance of additional distributors to market and distribute our future products and
technologies, as well as to market and distribute our existing INSPIRA ART systems, HYLA blood sensors, and ALICE device, to existing
or new markets or geographical areas. We may not be able to find additional distributors who will agree to and are able to successfully
market and distribute our systems and technologies on commercially reasonable terms, if at all. If we are unable to&#160;establish additional
distribution&#160;relationships on favorable terms, our revenues may decline. In addition, our distributors may choose to favor the products
of our competitors over ours and give preference to them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our agreements
with the aforementioned distributors, we will be responsible for obtaining and maintaining any and all regulatory approvals for our products.
If we are unable to obtain or maintain such approvals, or if the parties to the distribution agreement fail to purchase the agreed upon
products at the agreed upon pricing, it may adversely impact our relationships with these distributors, and we may never realize any revenues
from these agreements ships as a result.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Medical device development is costly and
involves continual technological change which may render our current or future products obsolete.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market for medical device
technologies and products is characterized by factors such as rapid technological change, medical advances, changing consumer requirements,
short device lifecycles, changing regulatory requirements and evolving industry standards. Any one of these factors could reduce the demand
for our devices or require substantial resources and expenditures for, among other things, research, design and development, to avoid
technological or market obsolescence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success will depend on
our ability to enhance our current technology and develop or acquire new technologies to keep pace with technological developments and
evolving industry standards, while responding to changes in customer needs. A failure to adequately develop or acquire device enhancements
or new devices that will address changing technologies and customer requirements adequately, or to introduce such devices on a timely
basis, may have a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We might have insufficient
financial resources to improve our products, advance technologies and develop new devices at competitive prices. Technological advances
by one or more competitors or future entrants into the field may result in our present services or devices becoming non-competitive or
obsolete, which may decrease revenues and profits and adversely affect our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may encounter significant
competition across our product lines and in each market in which we will sell our products and services from various companies, some of
which may have greater financial and marketing resources than we do. Our competitors may include any companies engaged in the research,
development, manufacture, and marketing of respiratory support solutions and technologies, as well as a wide range of medical device companies
that sell a single or limited number of competitive products and services or participate in only a specific market segment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our customer acquisition strategy may not
succeed and although we have executed distribution agreements with various parties in various geographic region, we may never realize
any revenues from such agreements</i>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business will be dependent
upon success in our customer acquisition strategy. To date, we have executed various distribution agreements in various geographic regions
which are subject to regulatory approvals. If we do not obtain regulatory approval, or if the parties to the distribution agreement fail
to purchase the agreed upon products at the agreed upon pricing, we may not realize any revenues from such agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if we fail to
maintain a high quality of device technology, we may fail to retain or add new customers. If we fail, our revenue, financial results and
business may be significantly harmed. Our future success depends upon expanding our commercial operations in the United States, Israel
and Europe, as well as entering additional markets to commercialize our products and any future products. We believe that our expanded
growth will depend on the further development, regulatory approval and commercialization of our products. If we fail to expand the use
of our products in a timely manner, we may not be able to expand our markets or to grow our revenue, and our business may be adversely
impacted. If people do not perceive our products to be useful and reliable, we may not be able to attract or retain new customers. A decrease
in costumer growth could render less attractive to developers, which may have a material and adverse impact on our revenue, business,
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Our business and
operations would suffer in the event of computer system failures, cyber-attacks or a deficiency in our cybersecurity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Despite
the implementation of security measures intended to secure our data against impermissible access and to preserve the integrity and confidentiality
of our data, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses,
malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet,
attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security
breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber
terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world
have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of
our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could
result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent
that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of
confidential or proprietary information, we could incur material legal claims and liability, including under data privacy laws such as
the General Data Protection Regulation, or the GDPR, damage to our reputation, and the further development of our drug candidates could
be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are dependent upon third-party manufacturers
and suppliers, which makes us vulnerable to potential supply shortages and problems, increased costs and quality or compliance issues,
any of which could harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are comprised
of a number of components. We are planning to sell an assembled product as well as its disposable respiratory support unit. The components
of the assembled product and the disposable unit consist of both proprietary and off the shelf components. Proprietary components will
be manufactured on our behalf at good manufacturing practices, or GMP, approved production plant to adhere to regulatory requirements,
whereas off the shelf components will be sourced and manufactured by GMP suppliers. GMP sub-contractors will assemble proprietary and
off the shelf components together to create our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therefore, we rely on third
parties to manufacture and supply us with proprietary custom components. Although we rely on a number of suppliers who provide us materials
and components as well as manufacture and assemble certain components of our products, we do not rely on single-source suppliers. Our
suppliers may encounter problems during manufacturing for a variety of reasons, including, for example, failure to follow specific protocols
and procedures, failure to comply with applicable legal and regulatory requirements, equipment malfunction and environmental factors,
failure to properly conduct their own business affairs, and infringement of third-party intellectual property rights, any of which could
delay or impede their ability to meet our requirements. Our reliance on these third-party suppliers also subjects us to other risks that
could harm our business, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not currently a major customer of many of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to obtain an adequate supply in a timely manner or on commercially reasonable terms;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our suppliers, especially new suppliers, may make errors in manufacturing that could negatively affect the efficacy or safety of our products or cause delays in shipment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may have difficulty locating and qualifying alternative suppliers;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">switching components or suppliers may require product redesign and possibly submission to the FDA or other similar foreign regulatory agencies, which could impede or delay our commercial activities;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one or more of our suppliers may be unwilling or unable to supply components of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the occurrence of a fire, natural disaster or other catastrophe impacting one or more of our suppliers may affect their ability to deliver products to us in a timely manner; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our suppliers may encounter financial or other business hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet our requirements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to quickly
establish additional or alternative suppliers, if necessary, in part because we may need to undertake additional activities to establish
such suppliers as required by the regulatory approval process. Any interruption or delay in obtaining products from our third-party suppliers,
or our inability to obtain products from qualified alternate sources at acceptable prices in a timely manner, could impair our ability
to meet the demand of our customers and cause them to switch to competing products. Given our reliance on certain suppliers, we may be
susceptible to supply shortages while looking for alternate suppliers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be exposed to geopolitical risks
related to the geopolitical and military tensions between Russia and Ukraine in Europe.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we do not currently
conduct business in Russia and Ukraine, the escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations
in the Russian Ruble has had a negative impact on worldwide markets. Such impact may negatively impact our supply chain, our operations
and future growth prospects in that region.&#160;As a result of the crisis in Ukraine,&#160;both the U.S. and other countries have implemented
sanctions against certain Russian individuals and entities. Our global operations expose us to risks that could adversely affect our business,
financial condition, results of operations, cash flows or the market price of our securities, including the potential for increased tensions
between Russia and other countries resulting from the current situation involving Russia and Ukraine, tariffs, economic sanctions and
import-export restrictions imposed, and retaliatory actions, as well as the potential negative impact on our potential business and sales
in the region. Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S. and other governments against
certain companies and individuals may hinder our ability to conduct business with potential customers and vendors in these countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited manufacturing history on
which to assess the prospects for our business and we anticipate that we will incur significant losses once we initiate our in-house manufacturing
until we are able to successfully commercialize our products globally.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our future manufacturing
operation or any current or future contracted manufacturing operations become unreliable or unavailable, we may not be able to move forward
with our intended business operations and our entire business plan could fail. There is no assurance that our manufacturing operation
or any third-party manufacturers will be able to meet commercialized scale production requirements in a timely manner or in accordance
with applicable standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to replace our manufacturing
capabilities in a timely manner.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our future manufacturing
facility or any current or future contracted manufacturing operations suffer any type of prolonged interruption, whether caused by regulator
action, equipment failure, critical facility services (such as water purification, clean steam generation or building management and monitoring
system), fire, natural disaster or any other event that causes the cessation of manufacturing activities, we may be exposed to long-term
loss of sales and profits. There are limited facilities which are capable of contract manufacturing some of our products and product candidates.
Replacement of our current manufacturing capabilities may have a material adverse effect on our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are dependent upon third-party service
providers. If such third-party service providers fail to maintain a high quality of service, the utility of our products could be impaired,
which could adversely affect the penetration of our products, our business, operating results and reputation. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The success of certain services
and products that we provide are dependent upon third-party service providers. Such service providers include manufacturers of proprietary
custom components for our products. As we expand our commercial activities, an increased burden will be placed upon the quality of such
third-party providers. If third-party providers fail to maintain a high quality of service, our products, business, reputation and operating
results could be adversely affected. In addition, poor quality of service by third-party service providers could result in liability claims
and litigation against us for damages or injuries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect to be exposed to fluctuations
in currency exchange rates, which could adversely affect our results of operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
incur expenses mainly in NIS and U.S. dollars, but our financial statements are denominated in U.S. dollars. Accordingly, we face exposure
to adverse movements in currency exchange rates. Our foreign operations will be exposed to foreign exchange rate fluctuations as the financial
results are translated from the functional currency into U.S. dollars. Specifically, the U.S. dollar cost of our operations in Israel
is influenced by any movements in the currency exchange rate of the NIS. Such movements in the currency exchange rate may have a negative
effect on our financial results. If the U.S. dollar weakens against foreign currencies, the translation of these foreign currency denominated
transactions will result in increased operating expenses and net losses. Similarly, if the U.S. dollar strengthens against foreign currencies,
the translation of these foreign currency denominated transactions will result in decreased operating expenses and net losses. As exchange
rates vary, sales and other operating results, when translated, may differ materially from our or the capital market&#8217;s expectations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-U.S. governments often impose strict
price controls, which may adversely affect our future profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
may be subject to rules and regulations in the United States and non-U.S. jurisdictions relating to our products or any future products.
In some countries, including countries of the European Union, or the EU, each of which has developed its own rules and regulations, pricing
may be subject to governmental control under certain circumstances. In these countries, pricing negotiations with governmental agencies
can take considerable time after the receipt of marketing approval for a medical device candidate. To obtain reimbursement or pricing
approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other
available products.<b>&#160;</b>If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, we may be unable to achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>We manage our business
through a small number of employees and key consultants.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 28, 2023, we had
thirty-eight (38) full-time employees (including our senior management team), three (3) part-time employees, and three (3) additional
independent contractors and consultants. Our future growth and success depend to a large extent on the continued services of members of
our current management including, in particular, Dagi Ben-Noon, our Chief Executive Officer, and Joe Hayon, our President. Any of our
employees and consultants may leave our company at any time, subject to certain notice periods. The loss of the services of any of our
executive officers or any key employees or consultants would adversely affect our ability to execute our business plan and harm our operating
results. Our operational success will substantially depend on the continued employment of senior executives, technical staff and other
key personnel. The loss of key personnel may have an adverse effect on our operations and financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>We may need to
expand our organization and we may experience difficulties in recruiting needed additional employees and consultants, which could disrupt
our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As our development and commercialization
plans and strategies develop and because we are leanly staffed, we may need additional managerial, operational, sales, marketing, financial,
legal and other resources. The competition for qualified personnel in the medical device industry is intense. Due to this intense competition,
we may be unable to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement
personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management may need to
divert its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities.
We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational
mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could
require significant capital expenditures and may divert financial resources from other projects, such as the development of additional
medical device products. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our
ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial
performance and our ability to commercialize medical device products and services and compete effectively will depend, in part, on our
ability to effectively manage any future growth.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>International expansion of our business
exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the
United States or Israel.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than our headquarters
and other operations which are located in Israel (as further described below), our business strategy incorporates significant international
expansion, particularly in anticipated expansion of regulatory approvals of our products. Doing business internationally involves a number
of risks, including but not limited to:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us to obtain regulatory approvals for the use of our products and services in various countries;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional potentially relevant third-party patent rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in staffing and managing foreign operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities associated with managing multiple regulatory, governmental and reimbursement regimes;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits in our ability to penetrate international markets;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain expenses including, among others, expenses for travel, translation and insurance; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, or the FCPA, its books and records provisions or its anti-bribery provisions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face intense competition, and we may
be unable to effectively compete in our industry.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market participants in
the ICU and the acute respiratory care space include Boston Scientific Corporation (NYSE: BSX), ResMed Inc., (NYSE: RMD), Masimo Corporation
(Nasdaq: MASI), Becton, Dickinson and Company (NYSE: BDX), Chart Industries, Inc. (Nasdaq: GTLS), Philips Healthcare, Medtronic plc (NYSE:
MDT), Fisher &amp; Paykel Healthcare Corporation Limited, Dr&#228;gerwerk AG &amp; Co. KGaA, Dr&#228;gerwerk AG, Hamilton Medical AG,
Smiths Medical Inc., Siemens Healthineers AG ADR (Nasdaq: SMMNY), Baxter International (NYSE: BAX), Getinge, GE Healthcare, Terumo Corporation
(TYO: 4543, Nikkei 225 Component), LivaNova PLC, Fresenius SE &amp; Co. KGaA, Johnson &amp; Johnson, Resuscitec, and Spectrum Medical.
These companies have either developed or acquired respiratory care devices and solutions, such as ventilators, ECMO devices and blood
sensors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aforementioned companies, have substantially
greater brand recognition, research and development, and regulatory capabilities, as well as financial, technical, manufacturing, marketing
and human resources than we do and significantly greater experience and infrastructure in the research and development of medical devices,
obtaining FDA and other regulatory clearances of those devices and commercializing those devices around the world. Further, some of these
companies hold significant market share. Their dominant market position and significant control over the market could significantly limit
our ability to introduce or effectively market and generate sales of our products.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our competitors have
long histories and strong reputations within the industry. They have significantly greater brand recognition, financial and human resources
than we do. They also have more experience and capabilities in researching and developing testing devices, obtaining and maintaining regulatory
clearances and other requirements, manufacturing and marketing those products than we do. There is a significant risk that we may be unable
to overcome the advantages held by our competition, and our inability to do so could lead to the failure of our business. In addition,
we may be unable to develop additional products in the future or to keep pace with developments and innovations in the market and lose
market share to our competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competition in the medical
devices and more specifically respiratory support technologies and solutions markets is intense, which can lead to, among other things,
price reductions, longer selling cycles, lower product margins, loss of market share and additional working capital requirements. To succeed,
we must, among other critical matters, gain consumer acceptance for our products, as compared to other solutions currently available in
the market for the treatment of respiratory failure and potential future medical devices incorporating our principal technology or offering
other advanced respiratory support solutions. If our competitors offer significant discounts on certain products and solutions, we may
need to lower our prices or offer other favorable terms in order to compete successfully. Moreover, any broad-based changes to our prices
and pricing policies could make it difficult to generate revenues or cause our revenues to decline. Moreover, if our competitors develop
and commercialize products and solutions that are more effective or desirable than products and solutions that we may develop, we may
not convince our customers to use our products and solutions. Any such changes would likely reduce our commercial opportunity and revenue
potential and could materially adversely impact our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If third-party payors do not provide adequate
coverage and reimbursement for the use of our </i></b>products <b><i>or any future products, our revenue will be negatively impacted.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are not yet approved
for third-party payor coverage or reimbursement. Such reimbursement may vary based on the particular device used in providing services
and is based on the identity of the third-party. Our ability to obtain and maintain a leading position in the medical device market, and
specifically in the respiratory care market, depends on our relationships with private third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
expect to engage with private third parties to allow our customers to receive reimbursement from insurance companies for our products.
The loss of a significant number of private third-party contracts may have an adverse effect on our revenues, which could have an adverse
effect on our business, financial condition and results of operations. Over the past few years, reimbursement rates from certain third
parties have declined, in some cases significantly. There can be no assurance that this trend will not continue or apply on more third
parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, private third
parties may not reimburse any new products offered by us or reimburse those new products at commercially viable rates. The failure to
receive reimbursement at adequate levels for our existing or future products may adversely affect demand for those products, our revenues
and expected growth. This could have an adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to litigation for a variety
of claims, which could adversely affect our results of operations, harm our reputation or otherwise negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to litigation
for a variety of claims arising from our normal business activities. These may include claims, suits, and proceedings involving labor
and employment, wage and hour, commercial and other matters. The outcome of any litigation, regardless of its merits, is inherently uncertain.
Any claims and lawsuits, and the disposition of such claims and lawsuits, could be time-consuming and expensive to resolve, divert management
attention and resources, and lead to attempts on the part of other parties to pursue similar claims. Any adverse determination related
to litigation could adversely affect our results of operations, harm our reputation or otherwise negatively impact our business. In addition,
depending on the nature and timing of any such dispute, a resolution of a legal matter could materially affect our future operating results,
our cash flows or both.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>We could become
subject to product liability, warranty or similar claims and product recalls that could be expensive, divert management&#8217;s attention
and harm our business reputation and financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business exposes us to
an inherent risk of potential product liability, warranty or similar claims and product recalls. The medical device industry has historically
been litigious, and we face financial exposure to product liability, warranty or similar claims if the use of any of our products were
to cause or contribute to injury or death. There is also the possibility that defects in the design or manufacture of any of our products
might necessitate a product recall. Although we plan to maintain product liability insurance, the coverage limits of these policies may
not be adequate to cover future claims. In the future, we may be unable to maintain product liability insurance on acceptable terms or
at reasonable costs and such insurance may not provide us with adequate coverage against potential liabilities. A product liability claim,
regardless of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to our reputation, customer
dissatisfaction and frustration and a substantial diversion of management attention. A successful claim brought against us in excess of,
or outside of, our insurance coverage could have a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business may be impacted by changes
in general economic conditions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is subject to
risks arising from changes in domestic and global economic conditions, including adverse economic conditions in markets in which we operate,
which may harm our business. For example, the current COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and
international markets. If our future customers significantly reduce spending in areas in which our technology and products are utilized,
or prioritize other expenditures over our technology and products, our business, financial condition, results of operations and prospects
would be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruption to the global economy
could also result in a number of follow-on effects on our business, including a possible slow-down resulting from lower customer expenditures;
inability of customers to pay for products, solutions or services on time, if at all; more restrictive export regulations which could
limit our potential customer base; negative impact on our liquidity, financial condition and share price, which may impact our ability
to raise capital in the market, obtain financing and secure other sources of funding in the future on terms favorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the occurrence
of catastrophic events, such as hurricanes, storms, earthquakes, tsunamis, floods, medical epidemics and other catastrophes that adversely
affect the business climate in any of our markets could have a material adverse effect on our business, financial condition and results
of operations. Some of our operations are located in areas that have been in the past, and may be in the future, susceptible to such occurrences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Unstable market and economic conditions
may have serious adverse consequences on our business, financial condition and&#160;share&#160;price.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global economy, including
credit and financial&#160;markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit
availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates
and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and
extreme volatility in the capital&#160;markets. Similarly, the conflict between Ukraine and Russia created extreme volatility in the global
capital&#160;markets&#160;and is expected to have further global economic consequences, including disruptions of the global supply chain
and energy&#160;markets. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely.
If the equity and credit&#160;markets&#160;deteriorate, including as a result of political unrest or war, it may make any necessary debt
or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Further, inflation
can adversely affect us by increasing our costs. Increased cost of living around the world has caused and may cause increased costs, such
as higher wages, increase direct service costs, increased freight costs and costs of components, and higher manufacturing costs. Any significant
increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations
and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our management team has limited experience
managing a public company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most members of our management
team have limited experience managing a publicly traded company, interacting with public company investors and complying with the increasingly
complex laws pertaining to public companies in the United States. Our management team may not successfully or efficiently manage our transition
to being a public company subject to significant regulatory oversight and reporting obligations under the U.S. federal securities laws
and the continuous scrutiny of securities analysts and investors. These new obligations and constituents will require significant attention
from our senior management and could divert their attention away from the day-to-day management of our business, which could adversely
affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We incur significant increased costs as
a result of the listing of our securities for trading on Nasdaq. Our management is required to devote substantial time to new compliance
initiatives as well as compliance with ongoing U.S. requirements.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company in the
United States, we incur additional significant accounting, legal and other expenses that we did not incur prior to being a public company
in the United States. We also incur costs associated with corporate governance requirements of the SEC, as well as requirements under
Section 404 and other provisions of the Sarbanes-Oxley Act. These rules and regulations increase our legal and financial compliance costs,
introduce new costs such as investor relations, stock exchange listing fees and shareholder reporting, and make some activities more time
consuming and costly. The implementation and testing of such processes and systems may require us to hire outside consultants and incur
other significant costs. Any future changes in the laws and regulations affecting public companies in the United States, including Section
404 and other provisions of the Sarbanes-Oxley Act, and the rules and regulations adopted by the SEC, for so long as they apply to us,
will result in increased costs to us as we respond to such changes. These laws, rules and regulations could make it more difficult or
more costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept
reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements
could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees,
or as executive officers.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are not able to attract and retain
highly skilled managerial, scientific, technical and marketing personnel, we may not be able to implement our business model successfully.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific
personnel. We are highly dependent upon our senior management as well as other employees, consultants and scientific and medical collaborators.
Our management team must be able to act decisively to apply and adapt our business model in the rapidly changing markets in which we will
compete. In addition, we will rely upon technical and scientific employees or third-party contractors to effectively establish, manage
and grow our business. Consequently, we believe that our future viability will depend largely on our ability to attract and retain highly
skilled managerial, sales, scientific and technical personnel. In order to do so, we may need to pay higher compensation or fees to our
employees or consultants than currently expected and such higher compensation payments may have a negative effect on our operating results.
Competition for experienced, high-quality personnel in the medical device field is intense. We may not be able to hire or retain the necessary
personnel to implement our business strategy. Our failure to hire and retain quality personnel on acceptable terms could impair our ability
to develop new products and services and manage our business effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we engage in future acquisitions or strategic
partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities,
and subject us to other risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may evaluate various acquisition
opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies
or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased operating expenses and cash requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the assumption of additional indebtedness or contingent liabilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance of our equity securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to certain U.S. and foreign
anticorruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences
for violations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among other matters, U.S.
and foreign anticorruption, anti-money laundering, export control, sanctions and other trade laws and regulations, which are collectively
referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants,
consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly,
corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws
can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments,
breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials
and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S.
activities to increase over time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent
registrations and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our personnel,
agents or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business and operations might be adversely
affected by security breaches, including any cybersecurity incidents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on the efficient
and uninterrupted operation of our computer and communications systems, and those of our consultants, contractors and vendors, which we
use for, among other things, sensitive company data, including our intellectual property, financial data and other proprietary business
information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While certain of our operations
have business continuity and disaster recovery plans and other security measures intended to prevent and minimize the impact of IT-related
interruptions, our IT infrastructure and the IT infrastructure of our consultants, contractors and vendors are vulnerable to damage from
cyberattacks, computer viruses, unauthorized access, electrical failures and natural disasters or other catastrophic events. We could
experience failures in our information systems and computer servers, which could result in an interruption of our normal business operations
and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents or security breaches
can cause interruptions in our operations and can result in a material disruption of our product development activities and other business
operations. The loss of data from completed or future studies or clinical trials could result in delays in our research, development or
regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or
security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur regulatory investigations and redresses, penalties and liabilities and the development of our product candidates
could be delayed or otherwise adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even though we believe we
carry commercially reasonable business interruption and liability insurance, we might suffer losses as a result of business interruptions
that exceed the coverage available under our insurance policies or for which we do not have coverage. For example, we are not insured
against terrorist attacks or cyberattacks. Any natural disaster or catastrophic event could have a significant negative impact on our
operations and financial results. Moreover, any such event could delay the development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in laws or regulations relating
to data protection, or any actual or perceived failure by us to comply with such laws and regulations or our privacy policies, could materially
and adversely affect our business or could lead to government enforcement actions and significant penalties against us, and adversely
impact our operating results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to receive health
information and other highly sensitive or confidential information and data of patients and other third parties (e.g., healthcare providers
who refer patients for scans), which we expect to compile and analyze. Collection and use of this data might raise privacy and data protection
concerns, which could negatively impact our business. There are numerous federal, state and international laws and regulations regarding
privacy, data protection, information security, and the collection, storing, sharing, use, processing, transfer, disclosure, and protection
of personal information and other data, and the scope of such laws and regulations may change, be subject to differing interpretations,
and may be inconsistent among countries and regions we intend to operate in (e.g., the United States, the European Union and Israel),
or conflict with other laws and regulations. The regulatory framework for privacy and data protection worldwide is, and is likely to remain
for the foreseeable future, uncertain and complex, and this or other actual or alleged obligations may be interpreted and applied in a
manner that we may not anticipate or that is inconsistent from one jurisdiction to another and may conflict with other rules or practices
including ours. Further, any significant change to applicable laws, regulations, or industry practices regarding the collection, use,
retention, security, or disclosure of data, or their interpretation, or any changes regarding the manner in which the consent of relevant
users for the collection, use, retention, or disclosure of such data must be obtained, could increase our costs and require us to modify
our services and candidate products, possibly in a material manner, which we may be unable to complete, and may limit our ability to store
and process patients&#8217; data or develop new services and features.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In particular, we will be
subject to U.S. data protection laws and regulations (i.e., laws and regulations that address privacy and data security) at both the federal
and state levels. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been
an increasing focus on privacy and data security issues. Numerous federal and state laws, including state data breach notification laws,
state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, and disclosure of health-related
and other personal information. Failure to comply with such laws and regulations could result in government enforcement actions and create
liability for us (including the imposition of significant civil or criminal penalties), private litigation and/or adverse publicity that
could negatively affect our business. For instance, California enacted the California Consumer Privacy Act (CCPA) on June 28, 2018, which
took effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security
obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right
of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential
liability, and many similar laws have been proposed at the federal level and in other states.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we expect to
obtain health information that is subject to privacy and security requirements under the Health Information Technology for Economic and
Clinical Health, or HITECH, and its implementing regulations. The Privacy Standards and Security Standards under HIPAA establish a set
of standards for the protection of individually identifiable health information by health plans, health care clearinghouses and certain
health care providers, referred to as Covered Entities, and the business associates with whom Covered Entities enter into service relationships
pursuant to which individually identifiable health information may be exchanged. Notably, whereas HIPAA previously directly regulated
only Covered Entities, HITECH makes certain of HIPAA&#8217;s privacy and security standards also directly applicable to Covered Entities&#8217;
business associates. As a result, both Covered Entities and business associates are now subject to significant civil and criminal penalties
for failure to comply with Privacy Standards and Security Standards. As part of our normal operations, we expect to collect, process and
retain personal identifying information regarding patients, including as a business associate of Covered Entities, so we expect to be
subject to HIPAA, including changes implemented through HITECH, and we could be subject to criminal penalties if we knowingly obtain or
disclose individually identifiable health information in a manner that is not authorized or permitted by HIPAA. A data breach affecting
sensitive personal information, including health information, also could result in significant legal and financial exposure and reputational
damages that could potentially have an adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HIPAA requires Covered Entities
(like many of our potential customers) and business associates, like us, to develop and maintain policies and procedures with respect
to protected health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards
to protect such information. HITECH expands the notification requirement for breaches of patient-identifiable health information, restricts
certain disclosures and sales of patient-identifiable health information and provides for civil monetary penalties for HIPAA violations.
HITECH also increased the civil and criminal penalties that may be imposed against Covered Entities and business associates and gave state
attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and its implementing
regulations and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Additionally, certain states have
adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Internationally, many jurisdictions
have or are considering enacting privacy or data protection laws or regulations relating to the collection, use, storage, transfer, disclosure
and/or other processing of personal data, as well as certification requirements for the hosting of health data specifically. Such laws
and regulations may include data hosting, data residency or data localization requirements (which generally require that certain types
of data collected within a certain country be stored and processed within that country), data export restrictions, international transfer
laws (which prohibit or impose conditions upon the transfer of such data from one country to another), or may require companies to implement
privacy or data protection and security policies, enable users to access, correct and delete personal data stored or maintained by such
companies, inform individuals of security breaches that affect their personal data or obtain individuals&#8217; consent to use their personal
data. For example, European legislators adopted the EU&#8217;s General Data Protection Regulation (2016/679), or GDPR, which became effective
on May 25, 2018, and are now in the process of finalizing the ePrivacy Regulation to replace the European ePrivacy Directive (Directive
2002/58/EC as amended by Directive&#160;2009/136/EC). The GDPR, supplemented by national laws and further implemented through binding
guidance from the European Data Protection Board, imposes more stringent EU data protection requirements and provides for significant
penalties for noncompliance. Further, the United Kingdom&#8217;s initiating a process to leave the EU has created uncertainty with regard
to the regulation of data protection in the United Kingdom. In particular, the United Kingdom has brought the GDPR into domestic law with
the Data Protection Act 2018 which will remain in force, even if and when the United Kingdom leaves the EU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Virtually every jurisdiction
in which we expect to operate has established its own data security and privacy legal framework with which we must, and our target customers
will need to, comply, including the rules and regulation mentioned above. We may also need to comply with varying and possibly conflicting
privacy laws and regulations in other jurisdictions. As a result, we could face regulatory actions, including significant fines or penalties,
adverse publicity and possible loss of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we are preparing to
implement various measures intended to enable us to comply with applicable privacy or data protection laws, regulations and contractual
obligations, these measures may not always be effective and do not guarantee compliance. Any failure or perceived failure by us to comply
with our contractual or legal obligations or regulatory requirements relating to privacy, data protection, or information security may
result in governmental investigations or enforcement actions, litigation, claims, or public statements against us by consumer advocacy
groups or others and could result in significant liability, cause our customers, partners or patients to lose trust in us, and otherwise
materially and adversely affect our reputation and business. Furthermore, the costs of compliance with, and other burdens imposed by,
the laws, regulations, and policies that are applicable to the businesses of our customers or partners may limit the adoption and use
of, and reduce the overall demand for, our products and services. Additionally, if third parties we work with violate applicable laws,
regulations, or agreements, such violations may put the data we have received at risk, could result in governmental investigations or
enforcement actions, fines, litigation, claims, or public statements against us by consumer advocacy groups or others and could result
in significant liability, cause our customers, partners or patients to lose trust in us, and otherwise materially and adversely affect
our reputation and business. Further, public scrutiny of, or complaints about, technology companies or their data handling or data protection
practices, even if unrelated to our business, industry or operations, may lead to increased scrutiny of technology companies, including
us, and may cause government agencies to enact additional regulatory requirements, or to modify their enforcement or investigation activities,
which may increase our costs and risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to Product
Development and Regulatory Approval</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates and operations are
subject to extensive government regulation and oversight both in the United States and abroad and our failure to comply with applicable
requirements could harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our products and
any future products we develop to be regulated by the FDA as medical devices. Our product candidates are subject to extensive regulation
in the United States and elsewhere, including by the FDA and its foreign counterparts, the U.S. Department of Justice, or the DOJ, and
the U.S. Health and Human Services-Office of the Inspector General, or the HHS. The FDA and foreign regulatory agencies regulate, among
other things, with respect to medical devices: design, development and manufacturing; testing, labeling, content and language of instructions
for use and storage; clinical trials; product safety; establishment registration and device listing; marketing, sales and distribution;
pre-market clearance and approval; conformity assessment procedures; record keeping procedures; advertising and promotion; recalls and
field safety corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if
they were to occur, could lead to death or serious injury; post-market approval studies; and product import and export.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulations our product
candidate is subject to are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions
on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales for any approved product.
Failure to comply with applicable regulations could jeopardize our ability to sell our future products, if cleared or approved, and result
in enforcement actions such as: warning or untitled letters; fines; injunctions; consent decrees; civil penalties; customer notifications;
termination of distribution; recalls or seizures of products; administrative detention of medical devices believed to be adulterated or
misbranded; delays in the introduction of products into the market; operating restrictions; total or partial suspension of production;
refusal to grant future clearances or approvals for new products, new intended uses or modifications to our products; withdrawals or suspensions
of current approvals, resulting in prohibitions on sales of our products; and in the most serious cases, criminal prosecution or penalties.
The occurrence of any of these events would have a material adverse effect on our business, financial condition and results of operations
and could result in shareholders losing their entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not receive, or may be delayed in
receiving, the necessary clearances or approvals for our products and failure to timely obtain necessary clearances or approvals for our
products would adversely affect our ability to grow our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, before
we can market a new medical device, or a new use of, new claim for or significant modification to an existing product, we must first receive
either clearance under Section 510(k) (which we must receive for our ALICE device) of the Federal Food, Drug, and Cosmetic Act, or the
FDCA, and/or approval of a PMA from the FDA, unless an exemption applies. In the 510(k) clearance process, before a device may be marketed,
the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a legally-marketed &#8220;predicate&#8221;
device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior
to May&#160;28, 1976 (pre-amendments device), a device that was originally on the U.S. market pursuant to an approved PMA and later down-classified,
or a 510(k)-exempt device. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate
device, and either have the same technological characteristics as the predicate device or have different technological characteristics
and not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes required to support
substantial equivalence. In the process of obtaining PMA approval, the FDA must determine that a proposed device is safe and effective
for its intended use based, in part, on extensive data, including, but not limited to, technical, pre-clinical, clinical trial, manufacturing
and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining,
life-supporting or implantable devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Modifications to products
that are approved through a PMA application generally require FDA approval. Similarly, certain modifications made to products cleared
through a 510(k) may require a new 510(k) clearance. Both the PMA approval and the 510(k) clearance process can be expensive, lengthy
and uncertain. The FDA&#8217;s 510(k) clearance process usually takes from three to twelve months but can last longer. The process of
obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even
longer, from the time the application is submitted to the FDA. In addition, a PMA generally requires the performance of one or more clinical
trials. The FDA may not approve or clear any device which we may seek to have approved or cleared. Any delay or failure to obtain necessary
regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they
may include significant limitations on the indicated uses for the device or other restrictions or requirements, which may limit the market
for the device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, we expect
to take a multi-step approach to the regulatory clearance process. As a first step, we intend to submit a Q-Submission, or Q-Sub, application
to the FDA for our advanced INSPIRA ART system model. The pre-IDE program was established in 1995, to provide sponsors a mechanism to
obtain FDA feedback on future Investigational Device Exemption, or IDE, applications prior to their submission. An IDE allows an investigational
device to be used in order to collect safety and effectiveness data required to support a premarket approval application or a premarket
notification submission to Food and Drug Administration. Over time, the pre-IDE program evolved to include feedback on PMAs, Humanitarian
Device Exemptions, or HDEs, De Novo requests, and 510(k) submissions, as well as to address whether a clinical study requires submission
of an IDE. To capture this evolution, the Secretary of Health and Human Services&#8217; (HHS) 2012 Commitment Letter to Congress regarding
the Medical Device User Fee Amendments of 2012 (MDUFA III) included FDA&#8217;s commitment to institute a structured process for managing
these interactions, referring to them as Pre-Submissions, or Pre-Subs. The Pre-Submission Guidance, published on February 18, 2014, implemented
the broader Q-Program, which includes Pre-Subs, as well as additional opportunities to engage with the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the Medical Device
User Fee Amendments of 2017, or the MDUFA IV, industry and the FDA agreed to refine the Q-Sub Program by changing the scheduling of Pre-Sub
meetings and amending performance goals on the timing of FDA feedback for Pre-Subs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Early interaction with the
FDA on planned non-clinical and clinical studies, risk determination, and careful consideration of the FDA&#8217;s feedback may improve
the quality of subsequent submissions, shorten total review times, and facilitate the development process for new devices. The FDA believes
that interactions provided within Pre-Subs are likely to contribute to a more transparent review process for the FDA and the submitter.
We intend to align and update our regulatory and clinical plans based on the FDA&#8217;s feedback as part of this Q-sub process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also intend to submit a
510(k) application for our ALICE device model. The review process is an iterative process and may be more costly and time consuming than
we expect and we may not ultimately be successful in completing the review process and our 510(k) application may not be cleared by the
FDA in a timely manner or at all. If cleared, any modification to our ALICE device that has not been previously cleared may require us
to submit a new 510(k) premarket notification and obtain clearance, or submit a PMA and obtain FDA approval prior to implementing the
change. Specifically, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that
would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of
a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&#8217;s
decision. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary. We may make modifications
or add additional features in the future that we believe do not require a new 510(k) clearance or approval of a PMA. If the FDA disagrees
with our determination and requires us to submit new 510(k) notifications or PMA applications for modifications to our previously cleared
products for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall
the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. If the
FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we
had expected, product introductions or modifications could be delayed or canceled, which could adversely affect our ability to grow our
business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA can delay, limit or
deny clearance or approval of a medical device for many reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our product candidates are safe or effective for their intended uses;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the disagreement of the FDA or the applicable foreign regulatory body with the design or the interpretation of data from pre-clinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious and unexpected adverse effects experienced by participants in our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the manufacturing process or facilities we use may not meet applicable requirements; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to sell our products
in member countries of the European Economic Area, or EEA, our products must comply with the General Safety and Performance Requirements
of the EU Medical Devices Regulation (Regulation (EU) 2017/745). Compliance with these requirements is a prerequisite to be able to affix
the Conformit&#233; Europ&#233;ene, or CE, mark to our products, without which they cannot be sold or marketed in the EEA. To demonstrate
compliance with the general safety and performance requirements we must undergo a conformity assessment procedure, which varies according
to the type of medical device and its classification. Except for low-risk medical devices (Class&#160;I non-sterile, non-measuring devices),
where the manufacturer can issue a European Community, or EC, Declaration of Conformity based on a self-assessment of the conformity of
its products with the general safety and performance requirements of the EU Medical Devices Regulation, a conformity assessment procedure
requires the intervention of an organization accredited by a member state of the EEA to conduct conformity assessments, or a Notified
Body. Depending on the relevant conformity assessment procedure, the Notified Body would typically audit and examine the technical file
and the quality system for the manufacture, design and final inspection of our devices. The Notified Body issues a certificate of conformity
following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer
and their conformity with the general safety and performance requirements. This certificate entitles the manufacturer to affix the CE
mark to its medical devices after having prepared and signed a related EC Declaration of Conformity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our products may also
need to comply with the following European Directives in order to be sold in the EEA:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROHS Directive 2011/65/EU of the European Parliament and of the Council of June 8, 2011 on the restriction of the use of certain hazardous substances in electrical and electronic equipment, as amended by (EU) 2017/2102.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WEEE Directive 2012/19/EU of the European Parliament and of the Council of July 4, 2012 on waste electrical and electronic equipment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RED Directive 2014/53/EU of the European Parliament and of the Council of April 16, 2014 on the harmonization of the laws of the Member States relating to the making available on the market of radio equipment and repealing Directive 1999/5/EC Text with EEA relevance. Applicable as of June 13, 2016. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery Directive 2006/42/EC of the European Parliament and of the Council of May 17, 2006 on machinery, and amending Directive 95/16/EC</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation)&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products may be required
to comply with additional EU Directives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a general rule, demonstration
of conformity of medical devices and their manufacturers with the general safety and performance requirements and essential requirements
must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal
conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions
of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of
its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.
If we fail to remain in compliance with applicable European laws, regulations and directives, we would be unable to continue to affix
the CE mark to our products, which would prevent us from selling them within the EEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with post-marketing regulatory
requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product
from the market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we receive regulatory clearance
or approval of the products or other future products, we will remain subject to ongoing and pervasive regulatory requirements governing,
among other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, import, export, registration,
and listing of devices. For example, we will be required to submit periodic reports to the FDA as a condition of 510(k)&#160;clearance.
These reports include information about failures and certain adverse events associated with the device after its clearance. Failure to
submit such reports, or failure to submit the reports in a timely manner, could result in enforcement action by the FDA. Following its
review of the periodic reports, the FDA might ask for additional information or initiate further investigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulations to which we
are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to continue
or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have obtained the proper regulatory
clearance to market a device, we have ongoing responsibilities under FDA regulations and applicable foreign laws and regulations. The
FDA, state and foreign regulatory authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements
could result in enforcement action by the FDA, state or foreign regulatory authorities, which may include any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled letters or warning letters;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls, termination of distribution, administrative detention, or seizure of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer notifications or repair, replacement or refunds;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating restrictions or partial suspension or total shutdown of production;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in or refusal to grant our requests for future clearances or approvals or foreign marketing authorizations of new products, new intended uses, or modifications to existing products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawals or suspensions of product clearances or approvals, resulting in prohibitions on sales of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these sanctions could
result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business,
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the FDA or state
or foreign authorities may change their clearance and approval policies, adopt additional regulations or revise existing regulations,
or take other actions, which may prevent or delay clearance or approval of our future products under development on a timely basis. Such
policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain new clearances or approvals,
increase the costs of compliance or restrict our ability to maintain any approvals we are able to obtain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products must be manufactured in accordance
with federal, state and foreign regulations, and we could be forced to recall our devices or terminate production if we fail to comply
with these regulations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The methods used in, and the
facilities used for, the manufacture of our products must comply with the Quality System Regulation, or ISO 13485 standard requirements,
as basic reference for requirements to establish a Quality Management System for the company, which is a complex regulatory scheme that
covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging,
handling, storage, distribution, installation, servicing and shipping of medical devices. As manufacturers of electron radiation-emitting
products, we are also responsible for compliance with the radiological health regulations and certain radiation safety performance standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, we are required
to verify that our suppliers maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory
requirements. The FDA enforces the Quality System (QS) Regulation, or QSR through periodic announced or unannounced inspections of medical
device manufacturing facilities, which may include the facilities of subcontractors. Our products are also subject to similar state regulations
and various laws and regulations of foreign countries governing manufacturing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our third-party manufacturers
may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our products. In addition,
failure to comply with applicable FDA or state or foreign requirements or later discovery of previously unknown problems with our products
or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties;
suspension or withdrawal of approvals; seizures or recalls of our products; total or partial suspension of production or distribution;
administrative or judicially imposed sanctions; the FDA&#8217;s refusal to grant pending or future clearances or approvals for our products;
clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us, our suppliers or our employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these actions could
significantly and negatively affect supply of our products. If any of these events occurs, our reputation could be harmed, we could be
exposed to product liability claims and we could lose customers and experience reduced sales and increased costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The misuse or off-label use of our products
may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations,
fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly
to our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advertising and promotion
of our future products that obtains approval in the United States may be heavily scrutinized by the FDA, the DOJ, HHS, state attorneys
general, members of Congress, and the public. In addition, advertising and promotion of any future product that obtains approval outside
of the United States will be heavily scrutinized by comparable foreign regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that, if cleared
or approved, our products will be cleared by the requisite regulatory authorities for specific indications. We expect to train our marketing
personnel and direct sales force to not promote our devices for uses outside of the FDA-approved indications for use, or any other regulatory
authority approved indications for use in a relevant territory, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician
from using our devices off-label, when in the physician&#8217;s independent professional medical judgment, he or she deems it appropriate.
There may be increased risk of injury to patients if physicians attempt to use our devices off-label. Furthermore, the use of our devices
for indications other than those approved by the FDA or approved by any foreign regulatory body may not effectively treat such conditions,
which could harm our reputation in the marketplace among healthcare providers and patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA or any state or
foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label use, it could request
that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition
of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or criminal
penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority,
such as false claims laws, if they consider our business activities to constitute promotion of an off-label use, which could result in
significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion
from participation in government healthcare programs and the curtailment of our operations. We may become subject to such actions and,
if we are not successful in defending against such actions, those actions may have a material adverse effect on our business, financial
condition and results of operations. Equivalent laws and potential consequences exist in foreign jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if our products
are cleared or approved, healthcare providers may misuse our products or use improper techniques if they are not adequately trained, potentially
leading to injury and an increased risk of product liability. If our devices are misused or used with improper technique, we may become
subject to costly litigation by our customers or their patients. As described above, product liability claims could divert management&#8217;s
attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products may cause or contribute to
adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, or any other regulatory authority
in a relevant territory, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial
condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily
or at the direction of the FDA or another governmental authority, could have a negative impact on us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our products or our other
future products receive clearance or approval, we will be subject to the FDA&#8217;s medical device reporting regulations and similar
foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that
one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction
were to recur, could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date
we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware
within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if
it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product.
If we fail to comply with our reporting obligations, the FDA or other regulatory bodies could take action, including warning letters,
untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance
or approval, seizure of our products or delay in clearance or approval of future products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and foreign regulatory
bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design
or manufacture of a product or in the event that a product poses an unacceptable risk to health. Generally, a regulator&#8217;s authority
to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death.
We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us
could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design
deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors
may occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depending on the corrective
action we take to redress a product&#8217;s deficiencies or defects, the FDA and any other regulatory authority may require, or we may
decide, that we will need to obtain new clearances or approvals for the device before we may market or distribute the corrected device.
Seeking such clearances or approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not
adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters,
product seizure, injunctions, administrative penalties or civil or criminal fines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Companies are required to
maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals
or corrections for our products in the future that we determine do not require notification of the FDA or to any other regulatory authority
in a relevant territory. If the FDA or any other regulatory authority in a relevant territory, disagrees with our determinations, it could
require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our
reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action,
whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract
management from operating our business and may harm our reputation and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>We may be subject,
directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security
laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many federal, state and foreign
healthcare laws and regulations apply to medical devices. We may be subject to certain federal and state regulations, including the federal
healthcare programs&#8217; Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving,
or paying any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, ordering or arranging for or recommending
the purchase or order of any item or service for which payment may be made, in whole or in part, under a federal healthcare program such
as Medicare and Medicaid; the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and
civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or
knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with
the delivery of, or payment for, healthcare benefits, items or services; the federal Civil Monetary Penalties Law, which authorizes the
imposition of substantial civil monetary penalties against an entity that engages in activities including, among others (1) knowingly
presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way;
(2) arranging for or contracting with an individual or entity that is excluded from participation in federal healthcare programs to provide
items or services reimbursable by a federal healthcare program; (3) violations of the federal Anti-Kickback Statute; or (4) failing to
report and return a known overpayment; the federal False Statements Statute, which prohibits knowingly and willfully falsifying, concealing,
or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using
any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry, in connection
with the delivery of or payment for healthcare benefits, items, or services; the federal civil False Claims Act, or the FCA, which prohibits,
among other things, knowingly presenting, or causing to be presented claims for payment of government funds that are false or fraudulent,
or knowingly making, using or causing to be made or used a false record or statement material to such a false or fraudulent claim, or
knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government;
and other federal and state false claims laws. The FCA prohibits anyone from knowingly presenting, conspiring to present, making a false
statement in order to present, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for
items or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary
items or services. This law also prohibits anyone from knowingly underpaying an obligation owed to a federal program. Increasingly, U.S.
federal agencies are requiring nonmonetary remedial measures, such as corporate integrity agreements in FCA settlements. The DOJ announced
in 2016 its intent to follow the &#8220;Yates Memo,&#8221; taking a far more aggressive approach in pursuing individuals as FCA defendants
in addition to corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The majority of states also
have statutes similar to the federal Anti-Kickback Statute and false claims laws that apply to items and services reimbursed under Medicaid
and other state programs, or, in several states, that apply regardless of whether the payer is a government entity or a private commercial
entity. The Federal Open Payments, or Physician Payments Sunshine Act, program requires manufacturers of products for which payment is
available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program, to track and report annually to the federal
government (for disclosure to the public) certain payments and other transfers of value made to physicians and teaching hospitals as well
as disclosure of payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests
held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations. Our
failure to appropriately track and report payments to the government could result in civil fines and penalties, which could adversely
affect the results of our operations. In addition, several U.S. states and localities have enacted legislation requiring medical device
companies to establish marketing compliance programs, file periodic reports with the state, and/or make periodic public disclosures on
sales, marketing, pricing, clinical trials, and other activities. Other state laws prohibit certain marketing-related activities including
the provision of gifts, meals or other items to certain healthcare providers. Many of these laws and regulations contain ambiguous requirements
that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions
could be subject to the penalty provisions of the pertinent federal and state laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The medical device industry
has been under heightened scrutiny as the subject of government investigations and enforcement actions involving manufacturers who allegedly
offered unlawful inducements to potential or existing customers in an attempt to procure their business, including arrangements with physician
consultants. If our operations or arrangements are found to be in violation of such governmental regulations, we may be subject to civil
and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs and the curtailment of our operations. All of
these penalties could adversely affect our ability to operate our business and our financial results.<b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we do not obtain and maintain international
regulatory registrations, clearances or approvals for our products, we will be unable to market and sell our products outside of the United
States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of our products outside
of the United States are subject to foreign regulatory requirements that vary widely from country to country. Approval procedures vary
among countries and can involve additional testing. The time required to obtain approval outside of the United States may differ substantially
from that required to obtain FDA approval. While the regulations of some countries may not impose barriers to marketing and selling our
products or only require notification, others require that we obtain the clearance or approval of a specified regulatory body. Complying
with foreign regulatory requirements, including obtaining registrations, clearances or approvals, can be expensive and time-consuming,
and we may not receive regulatory clearances or approvals in each country in which we plan to market our products or we may be unable
to do so on a timely basis. The time required to obtain registrations, clearances or approvals, if required by other countries, may be
longer than that required for FDA clearance or approval, and requirements for such registrations, clearances or approvals may significantly
differ from FDA requirements. If we modify our products, we may need to apply for additional regulatory clearances or approvals before
we are permitted to sell the modified product. In addition, we may not continue to meet the quality and safety standards required to maintain
the authorizations that we have received. If we are unable to maintain our authorizations in a particular country, we will no longer be
able to sell the applicable product in that country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory clearance or approval
by the FDA does not ensure registration, clearance or approval by regulatory authorities in other countries, and registration, clearance
or approval by one or more foreign regulatory authorities does not ensure registration, clearance or approval by regulatory authorities
in other foreign countries or by the FDA. However, a failure or delay in obtaining registration or regulatory clearance or approval in
one country may have a negative effect on the regulatory process in others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legislative or regulatory reforms in the
United States or the European Union may make it more difficult and costly for us to obtain regulatory clearances or approvals for our
products or to manufacture, market or distribute our products after clearance or approval is obtained.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, legislation
is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulation of medical devices.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take
other actions, which may prevent or delay approval or clearance of our future products under development or impact our ability to modify
our currently cleared products on a timely basis. Over the last several years, the FDA has proposed reforms to its 510(k) clearance process,
and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult
for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced forthcoming
steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things,
the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k)&#160;pathway toward the use of newer
predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance
pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate
devices that are more than 10&#160;years old. In May 2019, the FDA solicited public feedback on these proposals. The FDA requested public
feedback on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices
that were used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may
work with Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted,
could impose additional regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs
of compliance, or restrict our ability to maintain our current clearances, or otherwise create competition that may negatively affect
our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2019, the FDA
finalized guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain,
well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device
meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety
and performance of their medical devices to specific predicate devices in the clearance process. The FDA has developed and maintains a
list device types appropriate for the &#8220;safety and performance based&#8221; pathway and will continue to develop product-specific
guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the
guidance documents, where feasible. The FDA may establish performance criteria for classes of devices for which we or our competitors
seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact
our ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similarly, particular common
specifications, or sets of technical and/or clinical requirements (other than a standard) that provide a means of complying with the legal
obligations applicable to a device, process or system, are issued by the EU&#8217;s competent authorities and are mandatory as part of
the CE certification process. The EU competent authorities may establish performance criteria for classes of devices for which we or our
competitors seek or currently have received certification and it is unclear the extent to which such performance standards, if established,
could impact our ability to obtain new CE certifications or otherwise create competition that may negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, FDA or any other
relevant regulatory authority, regulations and guidance are often revised or reinterpreted by the FDA or any other regulatory authority,
in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of
existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance
or approval for, manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal
interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among
other things, require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement
or discontinuance of our products; or additional record keeping.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s and other
regulatory authorities&#8217; policies may change, and additional government regulations may be promulgated that could prevent, limit
or delay regulatory clearance or approval of our future products. We cannot predict the likelihood, nature or extent of government regulation
that may arise from future legislation or administrative action, either in the United States or abroad. For example, certain policies
of the Biden administration, as well as decisions by the United States&#8217; legislative or judicial branches may impact our business
and industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 27, 2020, the United
States Supreme Court reversed a Federal Circuit decision that previously upheld Congress&#8217; denial of $12 billion in &#8220;risk corridor&#8221;
funding. Congress may consider additional legislation to repeal, or repeal and replace, other elements of the&#160;Patient Protection
and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA, On June 17, 2021, the U.S. Supreme
Court dismissed a challenge on procedural grounds that argued that the&#160;PPACA is unconstitutional in its entirety because the individual
mandate was repealed by Congress. Thus, the&#160;PPACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling,
on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health
insurance coverage through the&#160;PPACA marketplace. The executive order also instructed certain governmental agencies to review and
reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration
projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health
insurance coverage through Medicaid or the&#160;PPACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction
Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage
in PPACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning
in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program.
It is possible that the&#160;PPACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges
and the healthcare reform measures of the Biden administration will impact the&#160;PPACA and our business. We continue to evaluate the&#160;PPACA
and its possible repeal and replacement, as the extent to which any such changes may impact our business or financial condition remains
uncertain. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if
we are not able to maintain regulatory compliance, we may lose any marketing approval or clearance that we may have obtained and we may
not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European Union, similar
political, economic and regulatory developments may affect our ability to profitably commercialize any of our product candidates, if approved.
In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state
level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare
in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is
almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers
have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context.
In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement
of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those
wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate
post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval.&#160;Political,
economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement
has been obtained. Reference pricing used by various EU member states, and parallel trade, i.e., arbitrage between low-priced and high-priced
member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations
for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.&#160;In
international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted
price ceilings on specific products and therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April&#160;5, 2017, the
European Parliament passed the Medical Devices Regulation (Regulation 2017/745), which became effective on May 26, 2021 and repeals and
replaces the EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA member states,
the regulations would be directly applicable, i.e., without the need for adoption of EEA member state laws implementing them, in all EEA
member states and are intended to eliminate current differences in the regulation of medical devices among EEA member States. The Medical
Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework
across the EEA for medical devices and ensure a high level of safety and health while supporting innovation. Among other things, the Medical
Devices Regulation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthen the rules on placing devices on the market and reinforce surveillance once they are available;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish explicit provisions on manufacturers&#8217; responsibilities for follow-up regarding the quality, performance and safety of devices placed on the market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthened rules for the assessment of certain high-risk devices, which may have to undergo an additional check by experts before they are placed on the market.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These modifications may have
an effect on the way we conduct our business in the EEA. We expect that these and other healthcare reform measures that may be adopted
in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price
that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result
in a similar reduction in payments from private payors. Further, there is no guarantee that we can use existing reimbursement codes or
receive reimbursement at all. The implementation of cost containment measures or other healthcare reforms may prevent us from being able
to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained. We cannot predict what healthcare
reform initiatives may be adopted in the future. However, it is possible that there will be further legislation or regulation that could
harm the business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative and regulatory reform
measures may have a material adverse effect on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our industry is highly regulated
and changes in law may adversely impact our business, operations or financial results. The Patient Protection and Affordable Care Act,
as amended by the Health Care and Education Reconciliation Act, or the PPACA, is a sweeping measure intended to, among other things, expand
healthcare coverage within the United States, primarily through the imposition of health insurance mandates on employers and individuals
and expansion of the Medicaid program. Several provisions of the law may affect us and increase certain of our costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been adopted since the PPACA was enacted. These changes include aggregate reductions in Medicare payments to providers of
2% per fiscal year, which went into effect on April 1, 2013. These reductions went into effect in April 2013 and, due to subsequent legislative
amendments to the statute, will remain in effect until 2031.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2013, President
Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several
types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three
to five years. These and new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material
adverse effect on our customers and, accordingly, our financial operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that the PPACA,
as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and an additional
downward pressure on the reimbursement our customers may receive for our products. Further, there have been, and there may continue to
be, judicial and Congressional challenges to certain aspects of the PPACA. For example, the U.S. Tax Cuts and Jobs Act of 2017, or TCJA,
includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual
mandate.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the PPACA is unconstitutional
in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling,
on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 26, 2021 through
August 15, 2021 for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructed
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. In addition, on August 16, 2022, President Biden
signed the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals
purchasing health insurance coverage in PPACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221;
under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly
established manufacturer discount program. Additional legislative and regulatory changes and judicial challenges to the PPACA, its implementing
regulations and guidance and its policies, remain possible. However, it remains unclear how any new legislation, regulation or challenges
in court might affect the prices we may obtain for any of our products for which regulatory approval is obtained. Any reduction in reimbursement
from Medicare and other government programs may result in a similar reduction in payments from private payers. The implementation of cost
containment measures or other healthcare reforms may prevent us from being able to generate significant revenue, attain profitability
or commercialize our products in scale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the delivery
of healthcare in the European Union, including the establishment and operation of health services, is almost exclusively a matter for
national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to
the delivery of health care and the pricing and reimbursement of products in that context. Coupled with ever-increasing EU and national
regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our products or
any future product candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for
which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently unable to
predict what additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect
recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval
of such proposals or reforms could result in a decrease in the price of our securities or limit our ability to raise capital or to enter
into collaboration agreements for the further development and potential commercialization of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disruptions at the FDA and other government
agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and
other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely
manner or at all, which could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of the FDA to
review and clear or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory,
regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other
events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated
in recent years as a result. In addition, government funding of other government agencies that fund research and development activities
is subject to the political process, which is inherently fluid and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruptions at the FDA and
other agencies may also slow the time necessary for new medical devices or modifications to cleared or approved medical devices to be
reviewed and/or approved by necessary government agencies, which would adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Separately, in response to
the COVID-19 pandemic, on March&#160;10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities
and, on March&#160;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. As of
May 26, 2021, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic
in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing
facilities with FDA quality standards. However, the FDA may not be able to maintain this pace and delays or setbacks are possible in the
future, including where a pre-approval inspection or an inspection of clinical sites is required and the FDA is unable to complete such
required inspection during the review period. Regulatory authorities outside the United States may adopt similar restrictions or other
policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs or if global health concerns prevent the
FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly
impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have
a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Environmental, social and corporate governance
(ESG) issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition
and results of operations and damage our reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is an increasing focus
from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally, public interest and
legislative pressure related to public companies&#8217; ESG practices continue to grow. If our ESG practices fail to meet regulatory requirements
or investor, customer, consumer, employee or other stakeholders&#8217; evolving expectations and standards for responsible corporate citizenship
in areas including environmental stewardship, support for local communities, Board of Director and employee diversity, human capital management,
employee health and safety practices, product quality, supply chain management, corporate governance and transparency, our reputation,
brand and employee retention may be negatively impacted, and our customers and suppliers may be unwilling to continue to do business with
us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Customers, consumers, investors
and other stakeholders are increasingly focusing on environmental issues, including climate change, energy and water use, plastic waste
and other sustainability concerns. Concern over climate change may result in new or increased legal and regulatory requirements to reduce
or mitigate impacts to the environment. Changing customer and consumer preferences or increased regulatory requirements may result in
increased demands or requirements regarding plastics and packaging materials, including single-use and non-recyclable plastic products
and packaging, other components of our products and their environmental impact on sustainability, or increased customer and consumer concerns
or perceptions (whether accurate or inaccurate) regarding the effects of substances present in certain of our products. Complying with
these demands or requirements could cause us to incur additional manufacturing, operating or product development costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not adapt to or comply
with new regulations, or fail to meet evolving investor, industry or stakeholder expectations and concerns regarding ESG issues, investors
may reconsider their capital investment in our Company, and customers and consumers may choose to stop purchasing our products, which
could have a material adverse effect on our reputation, business or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to Our
Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
effective patent rights for our products and services, we may not be able to compete effectively in our markets. If we are unable to protect
the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success and future revenue
growth will depend, in part, on our ability to protect our patent rights. In addition to the protection afforded by any patents that may
be granted, historically, we have relied on trade secret protection and confidentiality agreements with our employees, consultants, and
contractors to protect proprietary know-how that is not patentable or that we elect not to patent, processes that are not easily known,
knowable or easily ascertainable, and for which patent infringement is difficult to monitor and enforce and any other elements of our
product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered
by patents. However, agreements may be breached, trade secrets may be difficult to protect, and we may not receive adequate remedies for
any breach. In addition, our trade secrets and intellectual property may otherwise become known or be independently discovered by competitors
or other unauthorized third parties.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no guarantee that
the patent applications that we submitted with regards to our technologies will result in patent registration. In the event of failure
to complete patent registration, our developments will not be proprietary, which might allow other entities to manufacture our products
or design our services and compete with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, there is no assurance
that all potentially relevant prior art relating to our patent applications has been found, which can invalidate a patent or prevent a
patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our products
or services, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found
unenforceable or invalidated. Furthermore, even if they are unchallenged, our patent applications and any future patents may not adequately
protect our intellectual property, products or services and provide exclusivity for our new products or services or prevent others from
designing around our claims. Furthermore, there is no guarantee that third parties will not infringe or misappropriate our patents or
similar proprietary rights. In addition, there can be no assurance that we will not have to pursue litigation against other parties to
assert its rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot obtain and maintain
effective patent rights for our products and services, we may not be able to compete effectively, and our business and results of operations
would be harmed.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot provide any assurances
that our trade secrets and other confidential proprietary information will not be disclosed in violation of our confidentiality agreements
or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information
and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets and intellectual property could
impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our
trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties for misappropriating
any trade secret.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property rights of third parties
could adversely affect our ability to commercialize our products and services, and we might be required to litigate or obtain licenses
from third parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available
on commercially reasonable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is inherently difficult
to conclusively assess our freedom to operate without infringing on third-party rights. Our competitive position may be adversely affected
if existing patents or patents resulting from patent applications issued to third parties or other third-party intellectual property rights
are held to cover our products or services or elements thereof, or our manufacturing or uses relevant to our development plans. In such
cases, we may not be in a position to develop or commercialize products or services or our product candidates (and any relevant services)
unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned or enter into
a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may also be pending
patent applications that if they result in issued patents, could be alleged to be infringed by our new products or services. If such an
infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our new products
or services or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable
terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that we
have failed to identify relevant third-party patents or applications. For example, U.S. patent applications filed before November 29,
2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until
patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing
for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications
covering our new products or services could have been filed by others without our knowledge. Additionally, pending patent applications
which have been published can, subject to certain limitations, be later amended in a manner that could cover our services, our new products
or the use of our new products. Third-party intellectual property right holders may also actively bring infringement claims against us.
We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully
settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation
and may be prevented from or experience substantial delays in pursuing the development of and/or marketing our new products or services.
If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing
our new products or services that are held to be infringing. We might, if possible, also be forced to redesign our new products so that
we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could
require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party claims of intellectual property
infringement may prevent or delay our development and commercialization efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our avoiding infringement of the patents and proprietary rights of third parties. Numerous U.S. and foreign issued patents
and pending patent applications, which are owned by third parties, exist in the fields in which we are developing new products and services.
If our business expands and more patents are issued, the risk increases that our products and services may be subject to claims of infringement
of the patent rights of third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may assert that
we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims
to materials, designs or methods of manufacture related to the use or manufacture of our products or services. There may be currently
pending patent applications or continued patent applications that may later result in issued patents that our products or services may
infringe. In addition, third parties may obtain patents or services in the future and claim that use of our technologies infringes upon
these patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any third-party patents
were held by a court of competent jurisdiction to cover aspects of our processes for designs, or methods of use, the holders of any such
patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license or until
such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license may not be available on commercially
reasonable terms or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parties making claims against
us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one
or more of our products or services. Defense of these claims, regardless of their merit, would involve substantial litigation expense
and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against
us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties,
redesign our infringing products or services, or obtain one or more licenses from third parties, which may be impossible or require substantial
time and monetary expenditure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent policy and rule changes could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Changes
in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of any
patents that may issue from our patent applications or narrow the scope of our patent protection. The laws of foreign countries may not
protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often
lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until
18 months after filing, or in some cases not at all. We therefore cannot be certain that we were the first to file the invention claimed
in our owned and licensed patent or pending applications, or that we or our licensor were the first to file for patent protection of such
inventions. Assuming all other requirements for patentability are met, in the United States prior to March 15, 2013, the first to make
the claimed invention without undue delay in filing, is entitled to the patent, while generally outside the United States, the first to
file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith
Act&#8221;), enacted on September 16, 2011, the United States has moved to a first to file system. The Leahy-Smith Act also includes a
number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. In general,
the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of any issued patents, all of which could have a material adverse effect on our business and financial
condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be involved in lawsuits to protect
or enforce our intellectual property, which could be expensive, time consuming, and unsuccessful. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe our
intellectual property. If we were to initiate legal proceedings against a third-party to enforce a patent covering one of our new products
or services, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent
litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity
challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement.
Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant
information from the United States Patent and Trademark Office, or USPTO, or made a misleading statement, during prosecution. Under the
Leahy-Smith Act, the validity of U.S. patents may also be challenged in post-grant proceedings before the USPTO. The outcome following
legal assertions of invalidity and unenforceability is unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Derivation proceedings initiated
by third parties or brought by us may be necessary to determine the priority of inventions and/or their scope with respect to our patent
or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to
attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license
on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have
a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs,
license necessary technology from third parties, or enter into development partnerships that would help us bring our new products or services
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results
of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative,
it could have a material adverse effect on the price of our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims challenging
the inventorship of our intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, collaborators or other third parties have an interest in, or right to compensation, with respect to our current
patent and patent applications, future patents or other intellectual property as an inventor or co-inventor. For example, we may have
inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our products or services.
Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting, and defending
patents on products and services, as well as monitoring their infringement in all countries throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries can be less extensive than those in the United States. In addition,
the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United
States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may use our technologies
develop their own products or services in jurisdictions where we have not obtained patent protection to and may export infringing products
or services to territories where we have patent protection, but where patents are not enforced as strictly as they are in the United States.
These products or services may compete with our products or services. Future patents or other intellectual property rights may not be
effective or sufficient to prevent them from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection,
which could make it difficult for us to stop the marketing of competing products or services in violation of our proprietary rights generally.
Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert
our efforts and attention from other aspects of our business, could put our future patents at risk of being invalidated or interpreted
narrowly, put the issuance of our patent applications at risk, and could provoke third parties to assert claims against us. We may not
prevail in any lawsuits that we initiate, and any damages or other remedies that we may be awarded, may not be commercially meaningful.
Accordingly, our efforts to monitor and enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the Ownership of our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of our securities is likely
to continue to be highly volatile, and you may not be able to resell your Ordinary Shares at or above the price that you paid.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since we completed our initial
public offering in July 2021, the trading price of our Ordinary Shares and Warrants have been volatile and is likely to continue to be
volatile. The stock market in general, and the market for medical device companies in particular, has experienced extreme volatility that
has often been unrelated to the operating performance of particular companies, which has resulted in decreased stock prices for many companies
notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors,
including potentially worsening economic conditions, inflation and other adverse effects , may negatively affect the market price of our
securities, regardless of our actual operating performance. As a result of this volatility, you may not be able to sell your securities
at or above the price you paid. The following factors, in addition to other risk factors described in this section, may have a significant
impact on the market price of our securities:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160; &#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">inability to obtain the approvals necessary to commence further clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unsatisfactory results of clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of innovations or new products by us or our competitors; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse actions taken by regulatory authorities with respect to our clinical trials, manufacturing supply chain or sales and marketing activities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any adverse changes to our relationship with manufacturers or suppliers; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any intellectual property infringement actions in which we may become involved; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achievement of expected product sales and profitability or our failure to meet expectations; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our commencement of, or involvement in, litigation; </span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any major changes in our board of directors or management; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit and retain qualified regulatory, research and development personnel; </span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislation in the United States relating to the sale or pricing of medical devices; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the depth of the trading market in our Ordinary Shares and Warrants; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions resulting from a local or worldwide pandemic, such as COVID-19 or other health epidemic, geopolitical actions, including war and terrorism, or natural disasters; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the granting or exercise of employee stock options or other equity awards; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in investors and securities analysts&#8217; perception of the business risks and conditions of our business. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the stock market
in general, and the Nasdaq in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of small companies. Broad market and industry factors may negatively affect the market price of our Ordinary
Shares, regardless of our actual operating performance. Further, a systemic decline in the financial markets and related factors beyond
our control may cause our share price to decline rapidly and unexpectedly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales of our Ordinary Shares could
reduce the market price of our securities.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Substantial sales of our Ordinary
Shares on Nasdaq may cause the market price of our securities to decline. Sales by us or our security holders of substantial amounts of
our Ordinary Shares, or the perception that these sales may occur in the future, could cause a reduction in the market price of our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of any additional
Ordinary Shares or any securities that are exercisable for or convertible into Ordinary Shares, may have an adverse effect on the market
price of our Ordinary Shares and will have a dilutive effect on our existing shareholders and holders of Ordinary Shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our principal shareholders, officers and
directors currently beneficially own 26% of our Ordinary Shares. They may therefore be able to exert control over matters submitted to
our shareholders for approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 28, 2023, our
principal shareholders, officers and directors beneficially own approximately 26% of our Ordinary Shares. As a result, these shareholders,
if they acted together, could influence matters requiring approval by our shareholders, including the election of directors and the approval
of mergers or other business combination transactions. The interests of these shareholders may not always coincide with our interests
or the interests of other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never paid cash dividends on our
share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends, and we do not anticipate paying cash dividends in the foreseeable future. Therefore, you should not rely on an investment
in our securities as a source for any future dividend income.&#160;Our board of directors has complete discretion as to whether to distribute
dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any,
will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any,
received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board
of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The JOBS Act will allow us to postpone the
date by which we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information
we provide in our reports filed with the SEC, which could undermine investor confidence in our company and adversely affect the market
price of our securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For so long as we remain an
&#8220;emerging growth company&#8221; as defined in the JOBS Act, we take advantage of certain exemptions from various requirements that
are applicable to public companies that are not &#8220;emerging growth companies&#8221; including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the provisions of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor&#8217;s report on the financial statements.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to take advantage
of these exemptions until we are no longer an &#8220;emerging growth company.&#8221; We will remain an emerging growth company until the
earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the date of the completion of our initial
public offering, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed
to be a large accelerated filer, as defined in the rule under the Exchange Act, and (2)&#160;the date on which we have issued more than
$1.0&#160;billion in non-convertible debt during the prior three-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict if investors
will find our securities less attractive because we may rely on these exemptions. If some investors find our securities less attractive
as a result, there may be a less active trading market for our securities, and our market prices may be more volatile and may decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a &#8220;foreign private issuer&#8221;
we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise applicable SEC and Nasdaq
requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our status as a foreign private
issuer also exempts us from compliance with certain SEC laws and regulations and certain regulations of Nasdaq, including the proxy rules,
the short-swing profits recapture rules, and certain governance requirements such as independent director oversight of the nomination
of directors and executive compensation. In addition, we are not required under the Exchange Act to file current reports and financial
statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act
and we are generally exempt from filing quarterly reports with the SEC. Also, although the Israeli Companies Law, 5759-1999, or the Companies
Law, requires us to disclose the annual compensation of our five most highly compensated senior officers on an individual basis (rather
than on an aggregate basis), this disclosure will not be as extensive as that required of a U.S. domestic issuer. Furthermore, as a foreign
private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These exemptions and leniencies
will reduce the frequency and scope of information and protections to which you are entitled as an investor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The determination of foreign
private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter and,
accordingly, the next determination will be made with respect to us on June 30, 2023. In the future, we would lose our foreign private
issuer status if a majority of our shareholders, directors or management are U.S. citizens or residents and we fail to meet additional
requirements necessary to avoid loss of foreign private issuer status. The regulatory and compliance costs to us under U.S. securities
laws as a U.S. domestic registrant may be significantly higher.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be a &#8220;passive foreign investment
company,&#8221; or PFIC, for U.S. federal income tax purposes in the current taxable year or may become one in any subsequent taxable
year. There generally would be negative tax consequences for U.S. taxpayers that are holders of the securities if we are or were to become
a PFIC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the projected composition
of our income and valuation of our assets, we do not believe we were a PFIC for 2023, we do not expect to be a PFIC in 2023, and we do
not expect to become a PFIC in the future, although there can be no assurance in this regard. The determination of whether we are a PFIC
is made on an annual basis and will depend on the composition of our income and assets from time to time. We will be treated as a PFIC
for U.S. federal income tax purposes in any taxable year in which either (1) at least 75% of our gross income is &#8220;passive income&#8221;
or (2) on average at least 50% of our assets by value produce passive income or are held for the production of passive income. Passive
income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities
and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes
amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether a
non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly,
at least a 25% interest (by value) is taken into account. The tests for determining PFIC status are applied annually, and it is difficult
to make accurate projections of future income and assets which are relevant to this determination. In addition, our PFIC status may depend
in part on the market value of the securities. Accordingly, there can be no assurance that we currently are not or will not become a PFIC
in the future. If we are a PFIC in any taxable year during which a U.S. taxpayer holds the securities, such U.S. taxpayer would be subject
to certain adverse U.S. federal income tax rules. In particular, if the U.S. taxpayer did not make an election to treat us as a &#8220;qualified
electing fund&#8221;, or QEF, or make a &#8220;mark-to-market&#8221; election, then &#8220;excess distributions&#8221; to the U.S. taxpayer,
and any gain realized on the sale or other disposition of our securities by the U.S. taxpayer: (1) would be allocated ratably over the
U.S. taxpayer&#8217;s holding period for our securities; (2) the amount allocated to the current taxable year and any period prior to
the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each
of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that
year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such
other taxable year. In addition, if the U.S. Internal Revenue Service, or the IRS, determines that we are a PFIC for a year with respect
to which we have determined that we were not a PFIC, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election.
U.S. taxpayers that have held our securities during a period when we were a PFIC will be subject to the foregoing rules, even if we cease
to be a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer
can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions thereto. We
do not intend to notify U.S. taxpayers that hold our securities if we believe we will be treated as a PFIC for any taxable year in order
to enable U.S. taxpayers to consider whether to make a QEF election. In addition, we do not intend to furnish such U.S. taxpayers annually
with information needed in order to complete IRS Form 8621 and to make and maintain a valid QEF election for any year in which we or any
of our subsidiaries are a PFIC. U.S. taxpayers that hold our securities are strongly urged to consult their tax advisors about the PFIC
rules, including tax return filing requirements and the eligibility, manner, and consequences to them of making a QEF or mark-to-market
election with respect to our securities in the event that we are a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to securities litigation,
which is expensive and could divert management attention.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, companies that
have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the
target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#8217;s
attention and resources, which could seriously hurt our business. Any adverse determination in litigation could also subject us to significant
liabilities.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations
or publish negative reports regarding our business or our securities, our share price and trading volume could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our securities will be influenced by the research
and reports that industry or securities analysts may publish about us, our business, our market or our competitors. We do not have any
control over these analysts and we cannot provide any assurance that analysts will cover us or provide favorable coverage. If any of the
analysts who may cover us adversely change their recommendation regarding our securities, or provide more favorable relative recommendations
about our competitors, the price of our securities would likely decline. If any analyst who may cover us were to cease coverage of our
company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the price
of our securities or trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Risks
Related to Israeli Law and Our Operations in Israel</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Potential
political, economic and military instability in the State of Israel, where our headquarters, members of our management team and our research
and development facilities are located, may adversely affect our results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive offices, research and development laboratories and manufacturing facility are located in Ra&#8217;anana, Israel. In addition,
the majority of our key employees, officers and directors are residents of Israel. Accordingly, political, economic and military conditions
in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts have
taken place between Israel and groups in its neighboring countries, Hamas (an Islamist militia and political group that has control in
the Gaza Strip) and Hezbollah (an Islamist militia and political group based in Lebanon). In addition, several countries, principally
in the Middle East, restrict doing business with Israel, and additional countries may impose restrictions on doing business with Israel
and Israeli companies whether as a result of hostilities in the region or otherwise. Any hostilities involving Israel, terrorist activities,
political instability or violence in the region or the interruption or curtailment of trade or transport between Israel and its trading
partners could adversely affect our operations and results of operations and the market price of our securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle
East. Although the Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by
terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or, if maintained, will be sufficient
to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business,
financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
some Israeli citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until
they reach the age of 40 (or older for certain reservists) and, in the event of a military conflict, may be called to active duty. In
response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that
there will be military reserve duty call-ups in the future. Our operations could be disrupted by such call-ups, which may include the
call-up of members of our management. Such disruption could materially adversely affect our business, prospects, financial condition
and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the newly elected Israeli government has announced plans to significantly reduce the Israeli Supreme Court&#8217;s judicial oversight, including
reducing its ability to strike down legislation that it deems unreasonable, and plans to increase political influence over the selection
of judges. These plans have prompted protests of Israeli citizens and criticism of leading Israeli business leaders as well as some foreign
leaders. If such government plans are eventually enacted, they may cause operational challenges for us since we are headquartered in
Israel and the majority of our employees are located in Israel. In addition, if foreign policy is negatively impacted with regard to
Israel, this could impact our business with suppliers and customers which could in turn adversely impact our reputation, results of operations
or financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
termination or reduction of tax and other incentives that the Israeli government provides to Israeli companies may increase our costs
and taxes.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli government currently provides tax and capital investment incentives to Israeli companies, as well as grant and loan programs
relating to research and development and marketing and export activities. In recent years, the Israeli government has reduced the benefits
available under these programs and the Israeli governmental authorities may in the future further reduce or eliminate the benefits of
these programs. We may take advantage of these benefits and programs in the future; however, there can be no assurance that such benefits
and programs will be available to us. If we qualify for such benefits and programs and fail to meet the conditions thereof, the benefits
could be canceled and we could be required to refund any benefits we might already have enjoyed and become subject to penalties. Additionally,
if we qualify for such benefits and programs and they are subsequently terminated or reduced, it could have an adverse effect on our
financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be required to pay monetary remuneration to our Israeli employees for their inventions, even if the rights to such inventions have
been duly assigned to us. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into agreements with our Israeli employees pursuant to which such individuals agree that any inventions created in the scope of
their employment are either owned exclusively by us or are assigned to us, depending on the jurisdiction, without the employee retaining
any rights. A portion of our intellectual property has been developed by our Israeli employees during their employment for us. Under
the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee during the course of his or her employment
and within the scope of said employment are considered &#8220;service inventions.&#8221; Service inventions belong to the employer by
default, absent a specific agreement between the employee and employer otherwise. The Patent Law also provides that if there is no agreement
regarding the remuneration for the service inventions, even if the ownership rights were assigned to the employer, the Israeli Compensation
and Royalties Committee, or the Committee, a body constituted under the Patent Law, shall determine whether the employee is entitled
to remuneration for these inventions. The Committee has not yet determined the method for calculating this Committee-enforced remuneration.
While it has previously been held that an employee may waive his or her rights to remuneration in writing, orally or by conduct, litigation
is pending in the Israeli labor court is questioning whether such waiver under an employment agreement is enforceable. Although our Israeli
employees have agreed that we exclusively own any rights related to their inventions, we may face claims demanding remuneration in consideration
for employees&#8217; service inventions. As a result, we could be required to pay additional remuneration or royalties to our current
and/or former employees, or be forced to litigate such claims, which could negatively affect our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
received Israeli government grants for certain of our research and development activities, the terms of which may require us to pay royalties
and to satisfy specified conditions in order to manufacture products and transfer technologies outside of Israel. If we fail to satisfy
these conditions, we may be required to pay penalties and refund grants previously received.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
research and development efforts have been financed in part through royalty-bearing and non-royalty-bearing grants in an aggregate amount
of $800,000 that we received from the IIA as of December 31, 2022. With respect to the royalty-bearing grants we are committed to pay
royalties at a rate of 3% on sales proceeds from our products that were developed under IIA programs up to the total amount of grants
received, linked to the U.S. dollar and bearing interest at an annual rate of LIBOR applicable to U.S. dollar deposits. LIBOR and other
similar &#8220;benchmark&#8221; interest rates are currently the subject of recent and ongoing national, international and other regulatory
guidance and proposals for reform, which may cause such &#8220;benchmarks&#8221; to perform differently than in the past, or to disappear
entirely, or have other consequences which cannot be predicted. Due to the accrual of interest, the total amount of the grants that will
be repaid through royalties will increase until repayments begin. We are further required to comply with the requirements of the Israeli
Encouragement of Industrial Research, Development and Technological Innovation Law, 5744-1984, as amended, and related regulations, or
the Research Law, with respect to those past grants. When a company develops know-how, technology or products using IIA grants, the terms
of these grants and the Research Law restrict the transfer or license of such know-how, and the transfer of manufacturing or manufacturing
rights of such products, technologies or know-how outside of Israel, without the prior approval of the IIA. Therefore, the discretionary
approval of an IIA committee would be required for any transfer or license to third parties inside or outside of Israel of know how or
for the transfer outside of Israel of manufacturing or manufacturing rights related to those aspects of such technologies. We may not
receive those approvals. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits us to transfer
technology or development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer or license of IIA-supported technology or know-how outside of Israel and the transfer of manufacturing of IIA-supported products,
technology or know-how outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred
or licensed technology or know-how, our research and development expenses, the amount of IIA support, the time of completion of the IIA-supported
research project and other factors. These restrictions and requirements for payment may impair our ability to sell, license or otherwise
transfer our technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to
any product or technology outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving
the transfer outside of Israel of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be
reduced by any amounts that we are required to pay to the IIA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to enforce covenants not-to-compete under current Israeli law that might result in added competition for our products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have non-competition agreements with all of our employees, all of which are governed by Israeli law. These agreements prohibit our employees
from competing with or working for our competitors, generally during their employment and for up to 12 months after termination of their
employment. However, Israeli courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce
those provisions for relatively brief periods of time in restricted geographical areas, and only when the employee has obtained unique
value to the employer specific to that employer&#8217;s business and not just regarding the professional development of the employee.
If we are not able to enforce non-compete covenants, we may be faced with added competition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
of Israeli law and our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition
of, us, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals
for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types
of transactions. For example, a merger may not be consummated unless at least 50&#160;days have passed from the date on which a merger
proposal is filed by each merging company with the Israel Registrar of Companies and at least 30&#160;days have passed from the date
on which the shareholders of both merging companies have approved the merger. In addition, a majority of each class of securities of
the target company must approve a merger. Moreover, a tender offer for all of a company&#8217;s issued and outstanding shares can only
be completed if the acquirer receives positive responses from the holders of at least 95% of the issued share capital. Completion of
the tender offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless,
following consummation of the tender offer, the acquirer would hold at least 98% of our outstanding shares. Furthermore, the shareholders,
including those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the
tender offer, claim that the consideration for the acquisition of the shares does not reflect their fair market value, and petition an
Israeli court to alter the consideration for the acquisition accordingly, unless the acquirer stipulated in its tender offer that a shareholder
that accepts the offer may not seek such appraisal rights, and the acquirer or the company published all required information with respect
to the tender offer prior to the tender offer&#8217;s response date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not
have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free
share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances
but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years
from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain
restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires,
the tax becomes payable even if no disposition of the shares has occurred. These provisions could delay, prevent or impede an acquisition
of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
may be difficult to enforce a judgment of a U.S. court against us and our executive officers and directors in Israel or the United States,
to assert U.S. securities laws claims in Israel or to serve process on our executive officers and directors and these experts.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in Israel. Substantially all of our executive officers and directors reside outside of the United States, and all of
our assets and most of the assets of these persons are located outside of the United States. Therefore, a judgment obtained against us,
or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be
collectible in the United States and may not be enforced by an Israeli court. It also may be difficult for you to effect service of process
on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally,
it may be difficult for an investor, or any other person or entity, to initiate an action with respect to U.S. securities laws in Israel.
Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most
appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that
Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must
be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be
governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty
associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign
court.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Your
rights and responsibilities as a shareholder will be governed in key respects by Israeli laws, which differs in some material respects
from the rights and responsibilities of shareholders of U.S. companies.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights and responsibilities of the holders of our securities are governed by our amended and restated articles of association and by
Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders
in U.S. companies. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising
its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in such company,
including, among other things, in voting at a general meeting of shareholders on matters such as amendments to a company&#8217;s amended
and restated articles of association, increases in a company&#8217;s authorized share capital, mergers and acquisitions and related party
transactions requiring shareholder approval, as well as a general duty to refrain from discriminating against other shareholders. In
addition, a shareholder who is aware that it possesses the power to determine the outcome of a vote at a meeting of the shareholders
or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company.
There is limited case law available to assist us in understanding the nature of these duties or the implications of these provisions.
These provisions may be interpreted to impose additional obligations and liabilities on holders of our securities that are not typically
imposed on shareholders of U.S. companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>INFORMATION ON THE COMPANY</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_022"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>History and Development of the Company.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an Israeli corporation based in Ra&#8217;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd.
On April 10, 2018, our name was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira
Technologies Oxy B.H.N. Ltd. On July 16, 2021, our Ordinary Shares and the warrants issued in our initial public offering were listed
for trade on Nasdaq under the symbols &#8220;IINN&#8221; and &#8220;IINNW,&#8221; respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel. Our telephone number in Israel is 972 996
644 88. Our website address is <i>www.inspira-technologies.com</i>. The information contained on our website or available through our
website is not incorporated by reference into and should not be considered a part of this annual report on Form 20-F, and the reference
to our website in this annual report on Form 20-F is an inactive textual reference only. Puglisi &amp; Associates is our agent in the
United States, and its address is 850 Library Avenue, Suite 204, Newark, Delaware 19711.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act of 1933, as amended, or the Securities
Act, as modified by the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting
requirements applicable to other public companies that are not &#8220;emerging growth companies&#8221; such as not being required to
comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. We
could remain an &#8220;emerging growth company&#8221; for up to five years, or until the earliest of (a)&#160;the last day of the first
fiscal year in which our annual gross revenues exceeds $1.07&#160;billion, (b)&#160;the date that we become a &#8220;large accelerated
filer&#8221; as defined in Rule&#160;12b-2 under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, which would
occur if the market value of our securities that is held by non-affiliates exceeds $700&#160;million as of the last business day of our
most recently completed second fiscal quarter, or (c)&#160;the date on which we have issued more than $1&#160;billion in nonconvertible
debt during the preceding three-year period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a foreign private issuer as defined by the rules under the Securities Act and the Exchange Act. Our status as a foreign private issuer
also exempts us from compliance with certain laws and regulations of the SEC and certain regulations of the Nasdaq Stock Market, including
the proxy rules, the short-swing profits recapture rules, and certain governance requirements such as independent director oversight
of the nomination of directors and executive compensation. In addition, we are not required to file annual, quarterly and current reports
and financial statements with the SEC as frequently or as promptly as U.S. domestic companies registered under the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, 2021, and 2020 our capital expenditures amounted to $263,000, $182,000, and $23,000, respectively. Our current capital expenditures
are primarily for computers, research and development equipment and office improvements substantially all in Israel, and we expect to
finance these expenditures primarily from cash on hand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_023"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Overview.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a specialty medical device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory
support technology that is intended to reduce the need for (IMV, which is the standard of care today for the treatment of acute respiratory
failure. Although it may be sometimes lifesaving, IMV is associated with increased risks, costs of care, extended lengths of stay, frequent
incidence of infections, ventilator dependence and mortality. Using our state-of-the-art respiratory support technology, our goal is
to set a new standard of care and to provide patients with acute respiratory failure an opportunity to maintain spontaneous breathing
and avoid the need for intubation, coma and various risks associated with the use of IMV. As part of our strategy to reach this goal,
and in parallel to pursuing regulatory approvals, we are actively working to establish collaborations with strategic partners, globally
ranked hospitals, medical device companies and distributors both for endorsement and early clinical adoption. &#160;We plan to target
ICUs, general medical units, operating theaters, emergency medical services and small urban and rural hospitals, with the goal of making
our solutions more accessible to millions of patients worldwide. We expect for these activities to support our strategy plan to reach
market penetration and adoption of our respiratory support technology. We are developing the following products:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
INSPIRA<sup>TM</sup> ART System</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center; width: 19%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_002.jpg"/>&#160;</span></td>
  <td style="width: 81%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                         INSPIRA ART system, our flagship product, is a respiratory support technology targeting to utilize direct blood
                         oxygenation to boost patient saturation levels within minutes while the patient is awake &amp; spontaneously
                         breathing. The aim of our products is to reduce the need for invasive mechanical ventilation, or IMV, with the
                         potential to reduce risks, complications and high costs and potentially allowing for larger patient populations
                         in and beyond ICU settings. The INSPIRA ART is being designed as a new intent of use for long-term (longer than
                         6 hours) respiratory support that provides assisted extracorporeal circulation and physiologic gas exchange
                         (oxygenation and CO2 removal) of the patient&#8217;s blood in adults with acute respiratory failure, targeting
                         to allow for treatment of patients while they are awake. The INSPIRA ART is being designed to potentially prevent
                         the need for invasive mechanical ventilation, targeting acute respiratory failure patients in intensive care
                         units, or ICUs, and general medical units. The next generation INSPIRA ART is expected to be submitted to FDA
                         for regulatory approval via the PMA or De Novo regulatory pathways.</span></p>

&#160;</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
HYLA<sup>TM</sup> Blood Sensor</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 27%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_003.jpg"/>&#160;</span></td>
    <td style="text-align: justify; width: 73%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The HYLA blood
    sensor, originally designed as a key and core technology for the INSPIRA ART, is being developed also as a stand-alone device to
    be integrated or used in extracorporeal procedures. The HYLA is a non-invasive optical blood sensor designed to perform real-time
    and continuous blood measurements, potentially minimizing the need to take actual blood samples from patients. The HYLA&#8217;s measurements
    can assist physicians in the monitoring of patient&#8217;s clinical condition. The HYLA blood sensor is being designed as a clip-on
    sensor, attached to the outer walls of a blood tube, that may potentially reduce risks, complications, and costs. The HYLA blood
    sensor may have broad application potential, benefiting patients undergoing procedures such as cardiopulmonary bypass operations,
    ECMO and Cardiopulmonary bypass, pending regulatory approvals.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
ALICE Device</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 33%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_004.jpg"/>&#160;</span></td>
    <td style="width: 67%; font-size: 10pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            ALICE Device, an advanced form of life support system better known by the medical industry
                                            as a cardiopulmonary bypass system, or CPB, is being designed for use in surgical procedures
                                            requiring cardiopulmonary bypass for 6 hours or less. The ALICE device is expected to be
                                            submitted to the FDA for 510k clearance, during the second half of 2023. The ALICE is designed
                                            to be a new generation CPB system with potential advantages to medical device design with
                                            ergonomic configuration and intuitive user-centric software and display to increase functionality,
                                            as well as a large touchscreen with novel colorful graphical representation that increases
                                            the visibility and functionality of data displayed to the medical staff. The ALICE device
                                            is being designed to be lightweight and highly durable and will be equipped with long battery
                                            life to maximize its portability. The ALICE device, designed as a CPB, shall be indicated
                                            for use in surgical procedures requiring cardiopulmonary bypass for 6 hours or less.</span></p>

</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Products</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
INSPIRA&#8482; ART System</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing the INSPIRA ART system, a cost effective early extracorporeal respiratory support system intended to function as an external
&#8220;artificial lung&#8221; for deteriorating respiratory patients. The INSPIRA ART, our flagship product, is an extracorporeal blood
oxygenation device designed to revolutionize the respiratory care industry, potentially impacting the lives of millions of patients worldwide.
The next generation INSPIRA ART is expected to be submitted to the FDA for regulatory approval via the PMA or De Novo pathways.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 19%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_005.jpg"/>&#160;</span></td>
    <td style="width: 81%; font-size: 10pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            INSPIRA ART is intended to provide deteriorating patients with respiratory failure early
                                            oxygen saturation elevation and stabilization which is key in preventing IMV, which is currently
                                            the standard of care for the treatment of respiratory failure. Although it may be considered
                                            lifesaving, I<span style="background-color: white">MV requires intubating the patient and
                                            placing them into a medical induced coma. Therefore, IMV treatment is confined to ICUs and
                                            is associated with increased costs of care, extended lengths of stay in the hospital, frequent
                                            incidence of infections, ventilator dependence and mortality. </span>Using our state-of-the-art
                                            respiratory support technology, our goal is to set a new standard of care and to provide
                                            patients with acute respiratory failure an opportunity to remain awake, maintain spontaneous
                                            breathing and avoid the various risks associated with the use of IMV. As part of our strategy
                                            to reach this goal, and in parallel to pursuing regulatory approvals, we are actively working
                                            to establish collaborations with strategic partners and globally ranked healthcare centers,
                                            to provide endorsement and clinical adoption for regional deployments of our respiratory
                                            support technology. We plan to target ICUs, general medical units, emergency medical services
                                            and small urban and rural hospitals.</span></p>

&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
strategic objective is to create and lead the early blood oxygenation market as a new treatment option that bridges the current treatment
gap between non-invasive measures (such as oxygen masks, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">bilevel
positive airway pressure, or <span style="background-color: white">BiPap, continuous positive airway pressure, or CPAP, and high-flow
nasal cannulas) and IMV. Multiple growth drivers, such as the potential for INSPIRA ART to increase accessibility to treating millions
of patients in small urban and rural hospitals, general medical units, emergency rooms and emergency medical units by unlocking the dependency
on IMV and ICUs. as we expect for patients to be treated while awake as opposed to being in a state of coma. Millions of patients are
placed on IMV annually, and, therefore, we believe that the INSPIRA ART has a potential total addressable market of several billion dollars,
based on a targeted patient treatment cost of a few thousand dollars for each disposable respiratory support unit sold, multiplied by
the number of patients on IMV annually (approximate patient population with respiratory failure and acute exacerbation of chronic lung
disease). The market size and cost assumptions may be impacted by recurring revenue and high volume, mass production and sale of the
disposable respiratory support unit, without including the base revenue derived from the INSPIRA ART system itself.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Need
for INSPIRA ART</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Conditions
leading to respiratory insufficiency (a condition in which the lungs cannot perform sufficient gas exchange to support the body&#8217;s
metabolism) and respiratory failure happen quickly and are initially hard to observe. These conditions are often caused by a disease
or injury that affects breathing, such as pneumonia. Acute respiratory failure requires emergency treatment and is among the leading
causes of death globally.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a report published in 2017, the World Health Organization, or WHO, estimates that over 400 million people globally are affected by respiratory
insufficiency. Each year, an estimated 20 million people worldwide receive IMV, which is primarily attributed to acute respiratory failure
(69%) and chronic lung disease (10%). In a 2017 report in the Forum of International Respiratory Societies, the global respiratory care
devices market size was estimated to reach approximately $29.86 billion by 2025. The major factors influencing this growth include the
high prevalence of respiratory diseases, the rapid growth of the aging population, the high prevalence of smoking, rising urbanization
and pollution levels and western lifestyle changes.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic further exposed the weaknesses and disadvantages of IMV, which has both a high association with considerable medical
risks and iatrogenic complications that further burdens the healthcare system with long hospital stays and high costs of treatment. COVID-19
has seen the failure of some of the most advanced healthcare systems worldwide in their ability to respond flexibly, quickly and at scale
to rapid growth in demand for respiratory support. COVID-19 led to a rise in the number of intensive care unit, or ICU, admissions worldwide
of patients suffering from respiratory failure and requiring respiratory support solutions, such as IMV.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INSPIRA
ART - Redefining Artificial Respiration</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early
oxygen saturation elevation and stabilization are key in preventing IMV. Our vision is to become the new standard of care for deteriorating
patients with respiratory failure. Therefore, we have developed a direct blood oxygenation technology called ART (Augmented Respiration
Technology). Our device, the INSPIRA ART, utilizes a minimally invasive dual lumen cannula which is inserted into the jugular vein to
withdraw blood and pump it through our extracorporeal direct blood oxygenation unit and then reinfuse the oxygen enriched blood back
into the patients circulatory system via the same dual lumen cannula and insertion point to elevate and stabilize oxygen saturation levels
within minutes. The INSPIRA ART&#8217;s structure provides the potential to extend respiratory treatment beyond ICU environments making
acute respiratory treatment available in regions and medical facilities without the need for ICUs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Using
the INSPIRA ART, patients can experience relief within a few minutes of treatment. The INSPIRA ART will enable patients to be treated
while awake, mobile and breathing spontaneously. Accordingly, our INSPIRA ART system has the potential to reduce patients&#8217; length
of stay in ICU, rehabilitation period in the hospital, and re-admissions as compared to IMV. The INSPIRA ART system has yet to be tested
in humans and, as such, these claims of a potential advantage in humans are unproven and speculative.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
completed and tested the first lab unit of our INSPIRA ART in 2020. Throughout 2020, approximately 40 pre-clinical in-vivo feasibility
testing within a series of studies were performed in conjunction with our team and headed by the veterinary team at LAHAV CRO in Israel
to examine the feasibility of direct blood oxygenation to preempt the need for IMV. The main goal of these studies was to use our INSPIRA
ART and show temporary increase of oxygen gas exchange during respiratory failure by transferring clinically significant amounts of oxygen
to the venous blood, while simultaneously extracting quantities of carbon dioxide. To date, the INSPIRA ART has not been tested on humans
and any future testing on humans will be subject to the request of the appropriate regulators, including the FDA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_006.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
of INSPIRA ART</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
INSPIRA ART system is designed to rebalance oxygen saturation levels while patients are awake and breathing spontaneously.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_007.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_008.jpg" style="width: 640px; height: 360px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
1: Description of How INSPIRA ART Works</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Figure
1 above depicts how we expect our INSPIRA ART to work. Our INSPIRA ART system is based on our proprietary technology, which allows for
direct blood oxygenation boosting a patient&#8217;s oxygen saturation levels within minutes. Enriched blood will be able to effectively
remove carbon dioxide and bond high concentrations of oxygen.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_009.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INSPIRA
ART Key Sources - Technological Features and Components</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_010.jpg"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
2: INSPIRA ART Key Sources</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The diameter of the cannula
    depends on the flow volume required to perform the treatment. As the volume of flow decreases, the cannula diameter is reduced accordingly.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected amount required
    to provide respiratory support and may differ due to patient condition or other factors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perfusionist &#8211; operates
    a heart-lung machine (extracorporeal respiratory system), which is an artificial blood pump, which propels oxygenated blood to the
    patient&#8217;s tissues.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initiation system is a novel semi-auto priming system, designed to minimize human errors and prevents the need for a perfusionist to
assemble disposable parts, and makes the system applicable in non-ICU settings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_011.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
3: ART Key Sources</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of the INSPRIA ART&#8217;s proprietary non-invasive blood sensors using optical technology and machine learning (ML) based
algorithms advanced during 2022. We identified the technology as an opportunity to also develop as a stand-alone product (the HYLA blood
Sensor), with a clinical commenced in the first quarter of 2023 at Sheba Medical Center. As a prospective data collection clinical study,
it is designed to integrate clinical research into the product development cycle.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also progressing several partnering opportunities for the manufacturing of key technological components of the INSPIRA ART system
and ALICE device. In December 2022, we announced the signing of an Original Equipment Manufacturing, or OEM, agreement with Terumo Cardiovascular,
a division of the leading global medical device company, Terumo Corporation. Terumo Corporation operates in over 160 countries and regions
around the world, providing patients in a variety of medical settings with over 50,000 products and services. Terumo Cardiovascular are
experts in the field of oxygenation systems, heart-lung machines and monitoring systems. The agreement provides for the manufacture of
a flow mechanism that is intended to be integrated into our products for use in the extracorporeal circulation of the blood during the
oxygenation process. Per the agreement, we will be responsible for obtaining and maintaining approval to market and distribute the flow
mechanism component. The agreement is set for a term of three years from its effective date and, unless terminated earlier for cause
or upon 120 days&#8217; written notice, renews thereafter for an additional period of time as mutually agreed by the parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expected
Regulatory Strategy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our regulatory strategy, for the key component sources we intend to pursue a Class II 510(k) pathway based on the assumption that
we do not currently expect to require human trials for FDA clearance. We are taking a multi-step approach to the regulatory clearance
process. In January 2022, we listed a component of our INSPIRA ART system and ALICE device on the FDA Class I 510(k) exempt list. The
component is intended to reduce the potential complications associated with jugular vein cannula movement, occurring during a change
of a patient&#8217;s posture in bed and/or during transportation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
pre-submission of the INSPIRA ART system is expected for the second half of 2023. Verification and Validation, or V&amp;V, testing process
is expected to be conducted during the first half of 2024. A FiH clinical study (which may be conducted outside of the U.S, is expected
for the second half of 2024. In 2025, we plan to either conduct a pilot clinical study (that may also occur outside of the U.S.) or seek
to receive FDA IDE (Investigational Device Exemption) which allows the investigational device to be used in a clinical study in order
to collect safety and effectiveness data within the U.S.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in
its intended use, will require a new 510(k), de novo or PMA. We are planning to apply for the break-through device designation with the
FDA for the INSPIRA ART.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
INSPIRA ART, subject to regulatory approvals, is intended to be a commercial respiratory support system. When and if we receive the necessary
regulatory approvals, we plan to deploy the first INSPIRA ART in ICUs. We expect to commercially launch our INSPIRA ART in the United
States, subject to the receipt of the FDA clearance, and in Europe following the receipt of the CE Mark.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milestones
Achieved in 2022 include:</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professor Daniel Brodie, Director of Critical Care
    from New-York Columbia &#8211; Presbyterian Hospital, joined our Advisory Board</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signing of an exclusive summary distribution agreement
    with Glo-Med for the distribution of the HYLA and disposable units across six states in the U.S., including Texas, New Jersey, New
    York, Florida, North Carlina and South Carolina</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signing of an exclusive distribution agreement with
    Innovimed for deployment of the HYLA in hospital units and operating theaters in Poland, Czech Republic, and Slovakia.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listed a component of its
    INSPIRA ART system and ALICE device on the FDA Class I 510(k) exempt list</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointed Daniella Yeheskely-Hayon
    PhD, an expert in the field of artificial lung as the new Chief Technology Officer (CTO)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revealed the development
    of the HYLA blood sensor</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revealed the new design
    for the ALICE device</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed HYLA blood sensor
    in-vivo study, in preparation of planned clinical study</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted patent by the Israeli
    Patent Office for key safety component for the INSPIRA ART System</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed agreement with Sheba
    Medical Center to be the first site for the HYLA blood sensor&#8217;s clinical study</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Began manufacturing of
    the ALICE device, ahead of planned 2023 FDA submission</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed strategic OEM agreement with Terumo Cardiovascular</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company intends to execute on strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing
agreements, and agreements that may be executed in the future. The pre-conditional distribution agreements are for a period of up to
seven years and subject to completion of development, and the required regulatory approvals or clearances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Targeted
Milestones (2023-2025):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are planning to advance our pipeline of products over the next two years, with a clear strategy towards FDA regulatory approvals and
initial market penetration and adoption.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the first quarter of 2023, we commenced a HYLA blood prospective data collection clinical study at Sheba Medical Center on up to 100
patients undergoing open-heart surgery, designed to integrate clinical research into the product development cycle. We will perform Verification
and Validation (V&amp;V) testing prior to FDA submission via the 510(k) pathway, expected to occur in the first half of 2024. Following
FDA clearance, initial market penetration and adoption is expected to occur during 2025, alongside the receipt of initial sales orders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ALICE device has commenced its V&amp;V testing process, with FDA submission via the 510(k) pathway, expected for the second half of 2023.
Following FDA clearance, initial market penetration and adoption is expected to occur during 2024, alongside the receipt of initial sales
orders. The ALICE device will also be the first of our products to be integrated with the HYLA blood sensor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
flagship technology, the INSPIRA ART, which received patent approval of its novel convertible dual lumen cannula in January 2023, expects
to receive additional patent results relating to its technology throughout the year. FDA pre-submission of the INSPIRA ART system is
expected for the second half of 2023. The V&amp;V testing process is expected to be conducted during the first half of 2024. A first
in-human (FiH) clinical study (which may be conducted outside of the U.S.), is expected for the second half of 2024. In 2025, we plan
to either conduct a pilot clinical study (that may also occur outside of the U.S.) or seek to receive FDA Investigational Device Exemption,
or IDE, which allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data within
the USA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img alt="" src="image_012.jpg"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Industry
Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview
of Respiratory Failure </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Respiratory
failure is a condition in which the blood either does not have enough oxygen, has too much carbon dioxide, or both. During inhalation,
the lungs take in oxygen. The oxygen passes into blood via the lungs, which carries it to the body&#8217;s organs that need oxygen to
function. Carbon dioxide is removed from the blood during exhaling. An excess of carbon dioxide in blood can harm the body&#8217;s organs.
Inadequate gas exchange during breathing can lead to respiratory insufficiency, which may lead to hypoxemia and hypercarbia, which are
potentially life-threatening conditions. Diseases that affect breathing, such as chronic obstructive pulmonary disease, or COPD, and
various conditions that affect nerves and muscles controlling breathing, can cause respiratory failure. Respiratory failure is the acute
condition of respiratory insufficiency and is classified as either Type I (involves low oxygen blood levels, and normal or low carbon
dioxide levels) or Type II (involves low oxygen blood levels, with high carbon dioxide levels). According to an article from 2020 by
the Office of Disease Prevention and Health Promotion, titled &#8220;Respiratory Diseases,&#8221; currently approximately 15 million
American adults have been diagnosed with COPD and it is believed that millions more suffer from COPD but have not been diagnosed and
are not being treated. COPD is the fourth leading cause of death in the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Key Problem the INSPIRA ART system plans to solve in relation to the risks and complications related to Mechanical Ventilation (IMV)
</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 42%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Invasive
    Mechanical Ventilation&#160; </b></span></td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 42%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INSPIRA
    ART </b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Procedure </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Invasive mechanical ventilation
    is defined as&#160;the delivery of positive pressure to the lungs via an endotracheal or tracheostomy tube. During mechanical ventilation,
    sedation and analgesia are required.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient can remain awake
    and breathe spontaneously while a minimally invasive cannula is inserted&#160;into the patient&#8217;s jugular vein for the purpose
    of extracorporeal oxygenation and carbon dioxide removal.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Induced Coma </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medically inducing a patient
    into a coma requires sedation and analgesia to enable intubation for the delivery of oxygen using positive pressure into the lungs.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
        are awake and spontaneously breathing (No induced coma):</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Delirium
    can be prevented</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Muscle
    loss can be prevented</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Patient
    can eat and drink</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Patient
    can communicate their symptoms and needs to the medical staff</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Patient
can communicate with family and friends</span>&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complications &amp; Mortality Rate </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Increased
    mortality</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Prolonged
    duration of ventilation</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Ventilator-induced
    lung injury (VILI)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Ventilator-associated
    pneumonia (VAP)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Ventilator-induced
    diaphragmatic&#160;dysfunction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Pneumothorax
    &amp; tracheomalacia</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Delirium</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Muscular
    atrophy</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Inability
    to wean patient from ventilator</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bypassing
        lungs may improve patient outcomes &amp; is expected to potentially reduce iatrogenic complications:</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Reduced
    Ventilator -Induced lung Injury</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Reduced
    ventilator-induced diaphragmatic dysfunction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Reduced
    Ventilator Associated Pneumonia (affecting 5-40% of patients receiving IMV for more than two days)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital Days </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May require prolonged hospital
    stays resulting from invasive mechanical ventilation complications. </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital stays are expected
    to be reduced as a result of IMV avoidance. </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weaning </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients have to be weaned
    off IMV, extending ICU stay. </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No need for weaning off
    the ventilator. This may contribute to reducing ICU and hospital stays. </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-admissions </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A 40% re-admission rate
    with patients eventually dying due to the consequences of prolonged IMV. </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter treatment times
    will potentially reduce complications and improve patient outcomes, reducing re-admissions. </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Location </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Can only be administered
    in an ICU setting </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable in ICU and might
    also be utilized in non-ICU settings (Including Ambulatory) </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staff </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requires highly specialized
    medical staff only available in ICU </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Might be used by less qualified
    medical staff. Minimizes need for a perfusionist</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Table
1: Comparison of IMV to our INSPIRA ART</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our INSPIRA ART remains in development, has not been tested in humans, and is not cleared or approved by the FDA or similar foreign regulatory
bodies, we believe that our INSPIRA ART system has competitive advantages over FDA-approved treatments because our INSPIRA ART presents
a change to existing solutions, which have significant health risks, which are discussed in detail below. While any potential benefits
of our INSPIRA ART system as compared to IMV have yet to be observed in human trials, our INSPIRA ART is designed to provide a less invasive
and traumatic alternative to IMV, which requires patients to undergo intrusive intubation and medically induced coma, and often adds
complications to already diseased lungs. Unlike IMV, our INSPIRA ART does not require intrusive intubation and inducing a patient into
a medical coma, which means that the patient can be treated while staying awake, mobile and breathing spontaneously. Moreover, we believe
our INSPIRA ART is a system with multiple potential modalities because it can potentially be used independently in ICUs and general medical
units and in combination with IMV in ICUs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
available solutions used to provide respiratory support include oxygen masks and BiPap masks for mild to moderate cases of respiratory
insufficiency, and IMV in more severe cases of respiratory failure, when other, less invasive methods cannot provide a satisfactory solution.
IMV performs the work of breathing by providing air to the patient based on controlled pressure, flow and volume. According to an article
from 2016 by RT Magazine, titled &#8220;Managing the Patient on Mechanical Ventilation,&#8221; IMV is one of the most common interventions
used in the ICUs, with more than half of the patients being placed on invasive mechanical ventilators within the first 24 hours of their
admission to the ICU.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decisions
about the initiation and timing of invasive mechanical ventilation can be difficult and early discussion with critical care doctors is
essential. Appropriateness of ventilatory support may also be an issue requiring advanced discussion with patients and families. Once
a decision to intubate has been made, the transition from an awake and self-ventilating patient to controlled invasive ventilation can
be very difficult in the critically ill. Most patients will have evidence of developing or established organ dysfunction, particularly
cardiovascular dysfunction (ischaemic heart disease, sepsis), and commonly such patients are hypovolaemic. Both anesthetic induction
agents and positive pressure ventilation, which decreases venous return, produce cardiovascular depression and peri-intubation hypotension
is common. In addition, cessation of spontaneous ventilation can lead to very rapid desaturation in such patients, due to their marginal
respiratory reserve and circulatory problems.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are several types of approaches for IMV: laryngeal mask airway, or LMA, standard endotracheal tube, or ET, tracheostomy and extracorporeal
membrane oxygenation, or ECMO. During the process for ECMO, large cannulas are used that require fluoroscopy, an imaging technique, for
initial positioning of the cannula, as this is a dangerous process that needs to be done very accurately. Also, IMV may lead to life
threatening complications, including ventilator-induced lung injury, or VILI, ventilator associated pneumonia, or VAP, pneumothorax and
tracheomalacia. Patients are also predisposed to develop extrapulmonary complications, such as pressure sores and muscular atrophy. When
a patient is put on IMV, the patient is given tranquilizers and sedatives to lower the discomfort associated with non-physiological positive-pressure
ventilation. Tranquilizers and sedatives prevent the patient from coughing, eliminating secretion or the ability to communicate with
his family. Once the individual no longer requires IMV support, they are gradually weaned from the ventilator. They must have adequate
oxygenation, carbon dioxide elimination, respiratory muscle strength and reserve the ability to protect their airway. Unfortunately,
since respiratory muscles atrophy during the ventilation process, returning to normal is quite difficult.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VILI
can result in pulmonary edema, barotrauma and worsening hypoxemia that itself can prolong IMV and lead to multi-system organ dysfunction,
thus, increasing chances of mortality. Alveolar overdistension, atelectrauma and biotrauma are the principal mechanisms of VILI. Alveolar
injury results in high alveolar permeability, interstitial and alveolar edema, alveolar hemorrhage, hyaline membranes, loss of functional
surfactant and alveolar collapse. Thus, adopting a ventilator strategy that reduces VILI is an important goal in ventilatory management.
VAP, a type of hospital acquired pneumonia which is also a common and serious problem in the ICUs, develops more than 48 hours after
endotracheal intubation. VAP is associated with an increased risk of death. All-cause mortality associated with VAP has ranged from 20
to 50% in different studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
enhanced awareness of the complex and heterogeneous pulmonary pathophysiology of the various lung syndromes has illuminated the shortcomings
of conventional IMV. In the United States alone, approximately 40% of the 5.7 million patients admitted annually to ICUs are placed on
IMV; up to 70% of these patients end up dying either from the underlying disorder or from complications stemming from IMV. With a growing
elderly population and more people being exposed to smoking and pollution, the population requiring IMV support is growing rapidly. Given
this situation, attention has been focused on novel supportive measures for managing acute pulmonary failure, which would not have the
shortcomings of already available techniques described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ECMO
is a technique used for gas exchange in patients who are refractory to ventilator support, when lung function can be only maintained
at the expense of further structural lung damage or severe hemodynamic compromise. The guidelines for considering ECMO include hypoxic
respiratory failure due to any cause (primary or secondary), when the mortality risk is above 50%. The utilization of ECMO is limited
by technical complexity, as demonstrated below in Figure 4, resource implications and associated complications which include hemolysis,
blood-borne infections, air-embolism, blood loss, and others. Moreover, an ongoing effort is aimed towards determining which patients
will obtain the largest outcome benefit from ECMO, as some studies demonstrated IMV-equivocal results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Respiratory
failure and the use of currently available solutions to provide patients with respiratory support are also associated with increased
costs of care and extended lengths of stay. In the United States, COPD alone results in 1.5 million emergency department visits, and
726,000 hospitalizations each year. The Centers for Disease Control and Prevention reports annual financial cost of COPD to be $29.5
billion in direct healthcare medical expenditures and roughly $20 billion in indirect morbidity/mortality costs in the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_013.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
4: a patient connected to an ECMO device. Source: clevelandclinic.org.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to an article published in June 2020 by MarketWatch, total hospital stay costs for a patient admitted to ICU may reach hundreds of thousands
U.S. dollars, especially if infection is suspected. The daily direct cost of treatment for IMV is $1,500 in ICU. For each mechanically
ventilated patient, additional time is required for weaning off the device, thus, incurring even more hospital resources and costs. Additionally,
IMV patients are commonly subject to complications due to exposure to infections, such as VAP, with 8% to 28% of ICU patients requiring
an additional several days of treatment until healed by antibiotics, and mortality rates may reach 33% to 50%. Current IMV treatments
require medical specialists and a team of nurses. The longer a person remains in the ICU, the higher the probability that person will
require prolonged ventilation, which in turn exposes the patients to further ventilation-associated complications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
INSPIRA ART Respiratory Support Solution</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product, the INSPIRA ART system, is a form of respiratory support that utilizes extra-corporeal direct blood oxygenation to elevate
and stabilize declining oxygen saturation levels while the patient remains awake, mobile, and breathing spontaneously with their compromised
lungs. Unlike other IMV alternatives, our INSPIRA ART is a minimally invasive solution which utilizes a single dual lumen cannula inserted
into the jugular vein to withdraw blood that is passed through an external unit designed to filter deoxygenated blood and return it highly
oxygenated to the patient&#8217;s circulatory system. The INSPIRA ART is designed to assure the patient&#8217;s body and vital organs
receive the necessary amount of oxygen. We designed our INSPIRA ART system as a low cost, high volume solution for critical care patients
requiring advanced respiratory support. It is intended to provide an alternative to IMV, so that patients with respiratory failure will
be able to recover from their lung condition without being subjected to the risk of developing the various common complications brought
on by intubation and IMV. Our goal is to support healthcare systems by providing a practical and portable solution facilitating the treatment
of respiratory failure, without the need for IMV, and with the ability to deploy INSPIRA ART systems in and outside of ICUs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
INSPIRA ART is designed to oxygenate blood directly, and works in tandem with the underperforming lung, supporting the patients while
they are being treated for their underlying medical condition. We believe this unique approach minimizes or prevents mechanical ventilator
associated complications and allows the lungs to rehabilitate as the patient is kept awake and free of sedatives. Further, the technology
is highly applicable in a variety of settings, which makes it highly accessible, extending acute respiratory care that is currently limited
to the ICU, to an ambulatory treatment that can be administered in all hospital wards as well as in ambulances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_014.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
5: our INSPIRA ART.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
5 above is a depiction of how we expect our INSPIRA ART to look like once we construct it. Our INSPIRA ART is a unit package that will
contain all the inner systems. The INSPIRA ART includes a dual lumen cannula inserted into the patient&#8217;s right jugular vein. The
system&#8217;s centrifugal pump is activated to pump blood through the dual lumen cannula&#8217;s outlet drainage tube. The blood is
circulated through the system&#8217;s oxygenator, providing the blood with an enriched oxygen content and decreased carbon dioxide levels.
In a closed system, the oxygenated blood is circulated back through the cannula&#8217;s inlet reinfusion tube. The system&#8217;s dual
lumen cannula has numerous proprietary characteristics that makes it superior in comparison to existing commercial cannulas, including
(i) a smaller diameter (the part that enters the jugular vein), 16-21Fr (depending on flow rate required), (ii) safer structure, reducing
risk of air embolism, (iii) short length eliminating the need for positioning through radiography, (iv) low cost of manufacturing, and
(v) simplicity of cannulation and application. The cannula consists of one lumen that drains blood (outer lumen) and one that reinfuses
the blood into the cardiovascular system (inner lumen). The cannula is inserted in the inner jugular vein and positioned in the junction
between the subclavian and the superior vena cava.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our INSPIRA ART has unique advantages in comparison to currently available solutions used to provide respiratory support, there are numerous
potential risks that might be associated with the use of our INSPIRA ART system. Such risks may include low blood flow that could be
associated with generation of thrombi, mechanical damage to the superior vena cava, generation of a systemic inflammatory response due
to bio-compatibility issues, allergic reactions to catheter or its components, decreased venous returns, local venous bleeding following
the extraction of our INSPIRA ART or erroneous puncture of an artery during the insertion of our product. Additionally, any foreign material
in a body increases the risk of infections and the patient&#8217;s membrane might be clogged for a short period of time. Finally, an
individual patient&#8217;s requirements for gas exchange might significantly differ from the average, which means that the use of our
INSPIRA ART might not meet minimum requirements for blood saturation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_015.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
6: our proprietary INSPIRA ART dual lumen cannula.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a respiratory support technology, our lead product has the following unique advantages:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Simplicity
    of administration and minimal invasiveness</i></b>: one of the main advantages of our INSPIRA ART system is that there is no need
    for an induced coma because there is no intubation involved, and the treated patient stays awake. Subject to regulatory clearances,
    our product will enable small medical teams to perform a simple bedside procedure, inserting our dual lumen cannula into the jugular
    vein. Simplicity of administration and minimal invasiveness allow for treatment to be applied at an early stage, thus preventing
    the need for invasive MV and reducing the need for medically induced coma and blood thinners, which, in turn, reduces medical complications
    and side effects from IMV, such as blood clotting, hospital days and costs.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible dual
    lumen cannula</i>: </b>our convertible dual lumen cannula device uniquely intravascularly converts a single-lumen cannula into a
    dual lumen cannula after initial insertion, thus allowing for the same incision point to potentially have multiple uses. The convertible
    dual lumen cannula is designed to allow for switching from a single lumen to a dual lumen cannula, and vice versa, without the need
    for new incisions required when changing or adding additional cannulas. Our convertible dual lumen is designed to potentially allow
    for fast action and reduced risk, complications and additional infection points. Further, our INSPIRA ART cannula <sub>&#160;</sub>has
    numerous proprietary characteristics that makes it superior in comparison to existing commercial cannulas, such as small diameter
    16-21Fr (depending on flow rate required) that allows the lumen to be injected directly into a patient&#8217;s jugular vein while
    the patient is awake and breathing spontaneously, short length that eliminates the need for positioning that requires fluoroscopy
    or other imaging and simplicity of cannulation and application.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compact and portable
    allowing for deployment in various settings</i></b>: our INSPIRA ART is relatively small in size, which allows it to be used both
    in ICU and non-ICU settings, including hospital wards and ambulatory settings, without significant financial burden.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_016.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
development team is now working on prototype designs (including design, specifications, operational parameters and components). This
will allow us to progress towards the first production of the final product so that it can undergo safety tests prior to regulatory submissions
to the FDA and foreign regulatory agencies, including CE in future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Study
Results &#8211; INSPIRA ART</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed pre-clinical feasibility in-vivo studies. In addition, we intend to continue to perform studies for testing and control
purposes, including new purchased and manufactured components, process integration and automation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
2020, approximately 40 pre-clinical in-vivo feasibility tests in a series of studies were performed in conjunction with our team and
headed by the veterinary team at LAHAV CRO in Israel to examine the feasibility of direct blood oxygenation to preempt the need for IMV.
The main goal of these studies was to use our INSPIRA ART lab unit and show temporary increase of oxygen gas exchange during respiratory
failure by transferring clinically significant amounts of oxygen to the venous blood, while simultaneously extracting quantities of carbon
dioxide.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
researchers placed seven large-white X landrace pigs (chosen due to resemblance of the anatomy, size scale and other characteristics
to humans), each weighing approximately 90 to130 kilograms, into an artificial state of hypoxemia (a state when an individual has abnormally
low levels of oxygen in blood) with oxygen saturation levels dropping up to 80%. The oxygen gas concentration was lowered by mixing pure
oxygen with medical air and N2O to reduce the oxygen concentration levels to approximately 15%. The aim of oxygen decrease was to mimic
a state of respiratory failure of compromised sick lungs. When oxygen saturation level drops below 90%, many doctors will consider using
IMV to increase the oxygen level.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, pre-clinical feasibility in-vivo tests were conducted at Lahav C.R.O. in Israel, to test the INSPIRA ART&#8217;s ability
to rebalance oxygen saturation levels within minutes. In 20 out of the 25 hypoxemic induced events, INSPIRA ART treatment was provided
with a blood flow rate of 1-1.5 liter per minute. The researchers used our INSPIRA ART lab unit, which was primed and then connected
to pigs with our proprietary dual lumen cannula, through the right jugular veins of the pigs. Our proprietary dual lumen cannula allowed
simultaneous venous drainage and reinfusion of blood via the jugular vein. Our INSPIRA ART includes a centrifugal pump activated to pump
blood from the pig&#8217;s right jugular vein through the dual lumen cannula&#8217;s outlet drainage tube. The blood was circulated through
the system&#8217;s oxygenator, providing the blood with an enriched oxygen content and decreased carbon dioxide levels. In a closed system,
the oxygenated blood was circulated back through the cannula&#8217;s inlet reinfusion tube.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pig&#8217;s oxygen saturation was monitored at several intervals with blood sampling taken from the testing points. Our INSPIRA ART immediately
elevated and stabilized the pigs&#8217; oxygen saturation level, taking into account the possibility of subjects responding differently
to a treatment. The procedure was repeated multiple times on multiple subjects and at different periods to measure and prove consistency
and repeatability of elevated and stabilized blood oxygenation levels following the activation of our INSPIRA ART. This effect was achieved
in all of our pre-clinical in-vivo tests (studies). Moreover, our proprietary dual lumen cannula was inserted and removed without complications.
Inspection of the cannulas used in studies demonstrated intact structures without any sign of damage to the structure or unique characteristics.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INSPIRA
ART - Pre-clinical Studies Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><img alt="" src="image_017.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_018.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_019.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><img alt="" src="image_020.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><img alt="" src="image_021.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_022.jpg" style="width: 625px; height: 352px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img alt="" src="image_023.jpg"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, we completed an animal study that was conducted at Lahav C.R.O by leading ICU and respiratory specialists, who are members
of our Scientific Advisory Board. The completion of the animal study is an additional important step toward initiating human studies
using the HYLA blood sensor. During the animal study, the HYLA&#160;blood sensor performed measurements of blood parameters with results
being compared to numerous blood samples taken and analyzed using a routine blood gas analyzer, which is considered the standard of care
used by hospitals today. The animal study was performed following prior successful ex-vivo data obtained with the HYLA&#160;blood sensor
in our laboratory. The lab results, accompanied by the encouraging animal study data, are important steps toward human studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INSPIRA
ART</b> - <b>Market Opportunity</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
WHO estimates that in 2017, over 400 million people globally were affected by respiratory insufficiency. Approximately 20 million patients
annually are admitted to ICUs, requiring acute respiratory care. The respiratory care devices market size is expected to reach $29.86
billion by 2025, from $16.09 billion in 2019. The major factors influencing this growth include the high prevalence of respiratory diseases,
the rapid growth of the aging population, the high prevalence of smoking, rising urbanization and pollution levels, the increasing incidence
of pre-term births and lifestyle changes. This estimate does not include the expected spike due to the COVID-19 pandemic.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Growth
of the global respiratory care device market, which consists of therapeutic devices such as IMV and ECMO, monitoring devices, diagnostic
devices, and consumables and accessories, is driven by the (i) rise in the geriatric population, which is prone to respiratory disorders;
(ii) high prevalence of chronic respiratory diseases; and (iii) increase in government expenditures on the healthcare industry due to
an improving of standard of care and extending the availability of treatment to more regions and areas. The aforementioned factors magnify
the need for available and accessible respiratory treatment to support a growing medical need with more people being diagnosed annually
with respiratory disorders as well as suffering from respiratory insufficiencies. However, a number of limitations are associated with
the use of IMV, including its high cost of mechanical ventilators and risks associated with the use of IMV such as the rise in prevalence
of ventilator-associated pneumonia, or VAP, which hinder the market growth. The urgency to provide medical treatment and save lives are
driving factors that increase the need for respiratory treatment for respiratory failure and insufficiency. The limitations, risks and
costs associated with current solutions are at multiple levels adding excessive strain and burden on the healthcare system, having both
a direct and indirect impact on patient outcomes. This may provide new opportunities for existing market participants and for the entry
of new companies with new technological solutions which are high in demand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle
East and Africa. In 2019, North America accounted for the largest share of the respiratory care devices market. In the United States
alone, more than 5.7 million people annually require ICU admission, up to 40% of which require IMV, which is the current standard of
care in use since the 1950s, pursuant to an article in the <i>Clinical Infectious Diseases</i> medical journal published in August 2020
by Oxford University Press, titled &#8220;Patient Characteristics and Outcomes of 11,721 Patients with Coronavirus Disease 2019 (COVID-19)
Hospitalized Across the Unites States.&#8221; With a growing elderly population and more people being exposed to smoking and pollution,
the population requiring treatment is growing overwhelmingly. According to recent estimates in an article &#8220;Acute Respiratory Distress
Syndrome: Advances in Diagnosis and Treatment&#8221; published in February 2018 by JAMA, ARDS accounts for 10% of intensive care unit
admissions, representing more than 3 million patients with ARDS annually. Pursuant to an article &#8220;The High Cost of Surviving Respiratory
Distress Syndrome&#8221; published in April 2017 by John Hopkins Medicine, ARDS affects approximately 200,000 Americans every year, and
ARDS survivors often have long-lasting impairments such as cognitive dysfunction, mental health issues and physical impairments, all
of which may affect employment. According to an article &#8220;Diagnosis and Management of Acute Respiratory Distress Syndrome in a Time
of COVID-19,&#8221; published in 2020 by the <i>Diagnostics (Basel)</i>, ARDS is a serious clinical illness, defined by severe hypoxemic
respiratory failure, which continues to be associated with significant morbidity, mortality, and healthcare resource utilization. According
to the same source, ARDS comprises 7&#8211;10% of admissions and 15&#8211;25% of mechanically ventilated patients in the intensive care
unit (ICU), is fatal in 30&#8211;50% of patients, and costs on average over USD 90,000 per patient&#8217;s ICU stay. According to an
article &#8220;How COVID-19 Will Impact Employer-Sponsored Health Plans&#8221; by BKS Partners, the median total cost of an admission
for a respiratory condition requiring 96 hours or more of ventilation is $88,114. Due to its growing geriatric population and environmental
conditions that have favored the spread of respiratory disease, COVID-19 severely affected the region and induced enormous growth in
the demand for respiratory care devices. As a result, participants in this and adjacent markets have focused on or collaborated to expand
the manufacturing of critical care instruments and respiratory care devices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Worldwide
demand for mechanical ventilators has increased substantially, due to the COVID-19 outbreak, resulting in a surge in ICU admissions worldwide.
This exponential increase in COVID-19 cases across the world requires long-term and short-term respiratory support and increased demand
for new solutions. Even prior to COVID-19, approximately 20 million patients were treated annually with IMV in ICUs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following graphs provide information regarding factors that we believe are driving the market for our products:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_024.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Factors
that May Accelerate Adoption:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_025.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Potential in the U.S. Market:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspira
is focused on penetrating the U.S. market. Every year, hundreds of thousands are treated in ICUs for acute respiratory failure on Invasive
Mechanical Ventilators. We believe that this population may be potential candidates for treatment by our INSPIRA ART system.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inspira
Business Model&#160;and GTM Strategy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><img alt="" src="image_026.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
3: Our Business Model</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
believe that we may potentially provide the INSPIRA ART and disposable respiratory support units together and separately. Therefore,
we are planning to work with the hospitals based on an operation expense (OPEX) model, as opposed to a capital expense (CAPEX) model.
This strategy will allow us to reduce the need for CAPEX hospital budgets to deploy the entire systems.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
parallel to pursuing regulatory approval for our INSPIRA ART system, we are implementing a go-to-market strategy establishing and growing
multiple recurring revenue streams across medical sectors and markets, and in a variety of geographical territories.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To
this end, we seek to enter into strategic distribution agreements internationally to collaborate with local distribution networks to
form a platform for implementation of our go-to-market strategy. Distribution companies with which we have already entered into such
agreements include Innovimed (covering Poland, Czech Republic &amp; Slovakia), Bepex, Anita T&#233;cnica S.L, or WAAS Group (covering
Spain and Portugal) and Glo-Med (covering Texas, New Jersey, New York, Florida, North Carlina and South Carolina). The signed agreements
are for a period of three to seven years and are conditional on the completion of product development and receipt of regulatory approvals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we intend to execute on strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements,
and agreements that may be executed in the future. The pre-conditional distribution agreements are for a period of up to seven years
and subject to completion of development, and the required regulatory approvals or clearances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
addition,</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i<span style="background-color: white">n December
2022, we entered into an exclusive OEM, agreement with Terumo Cardiovascular, a division of Terumo Corporation, a leading global medical
device company. The agreement provides for the manufacture of a flow mechanism that is intended to be integrated into our products for
use in the extracorporeal circulation of the blood during the oxygenation process. This may also include integration into our INSPIRA
ART system.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Third-Party
Reimbursement</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 28, 2023, we do not have any third-party reimbursement agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ICUs
represent one of the largest clinical cost centers in hospitals. IMV accounts for a significant share of this cost. There is a relative
dearth of information quantifying the impact of ventilation on daily ICU cost. Therefore, we determine daily costs of ICU care and identify
incremental cost of IMV per ICU day and further differentiate cost by underlying diseases. We expect that the reimbursement will be based
on a diagnosis-related groups, or DRG, system. A DRG system classifies hospital cases into groups that are clinically similar and are
expected to use similar amounts of hospital resources. The amount per episode of care is fixed for patients within a single DRG category
(based on an average cost), regardless of the actual cost of care for that individual episode, but the amount may vary across the DRGs.
We intend to pursue a strategy that is based on the CMS guidelines and MS-DRG system as of April 1, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Table
3: MS-DRG Payments for Selected COVID-19 Treatments.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_027.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Go
To Market Strategy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
go-to-market strategy is based upon providing affordable products, based on a razor-blade business model based on disposables to maximize
our market reach while enhancing affordability and accessibility to medical care worldwide. We focus on this effort comprehensively,
understanding a multidisciplinary approach is necessary to achieve our goals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img alt="" src="image_028.jpg"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Our
go-to-market strategy includes, but is not limited to:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pursuing world-wide
    regulatory approvals</i></b><i>: </i>we plan to pursue regulatory approvals in the United States, Europe, Asia, South America, Africa
    and the Middle East. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Collaborating with
    leading medical centers and health organizations</i></b>: we are working with leading medical centers and health organizations to
    reach regional deployment of the INSPIRA ART. This also includes collaborations with top ranked hospitals to expose our INSPIRA ART
    and attain both clinical endorsement and adoption of use in acute respiratory care. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Identifying potential
    customer profiles</i></b>: we will be targeting leading medical centers that are interested in acquiring the key components of our
    INSPIRA ART for blood enrichment applications. We will be also targeting emergency medical services to offer our INSPIRA ART system
    for early saturation elevation and stabilization in awake patients. Potentially, our INSPIRA ART system can be used to treat patients
    with respiratory failure to prevent IMV. Moreover, potentially, our INSPIRA ART can be used together with IMV to reduce the risk
    of ventilator induced lung injury by reducing IMV pressure level in lungs and shorten weaning period. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Strategic
partners</i></b>: we have entered into discussions to establish collaborations with leading medical device companies, manufacturers and
distributors and have signed certain distribution agreements. The development of a strategic team, which may include strategic partners
or generate a strategic investment, is key in order to enable our company to rapidly deploy the INSPIRA ART to meet potentially growing
demand as well as reach and service clientele internationally, subject to regulatory approval. We intend to target similar agreements
with distributors in additional territories across the globe, including the U.S., Europe, and Asia.</span>&#160;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investing in marketing
    and public relations to increase awareness of our solution</i></b>: in order to drive market demand for the INSPIRA ART, we are building
    our pre-commercialization infrastructure to support sales following regulatory approvals. We are focusing our efforts within the
    medical community to introduce our product and technology to leading hospitals, military branches and government bodies. We also
    believe that our INSPIRA ART has potential for use outside of the ICU, so we also intend to focus on conventional hospital wards
    as well as ambulatory settings. Although our INSPIRA ART remains in development, has not yet been used in humans, and is not cleared
    or approved by the FDA or similar foreign regulatory bodies, we believe that due to the potential ease of use and affordability of
    the INSPIRA ART, we will also be able to target smaller urban and rural hospitals that do not have ICUs, in order to make acute respiratory
    care accessible to patients living outside of major city centers.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Garnering
        appropriate reimbursement and insurance coverage</i></b>: it is paramount for us to receive reimbursement and insurance coverage
        to enable hospitals and medical centers to provide treatment utilizing the INSPIRA ART. With intensive care becoming increasingly
        expensive, the INSPIRA ART may provide treatment at significantly reduced cost and without compromising quality of care to patients.
        We are working on a health economics model as part of the reimbursement strategy. Our goal is to publish medical literature to
        provide the Centers for Medicare and Medicaid Services, or CMS, actual data, presented by us together with top-ranking hospitals.
        The data collected will be used to demonstrate our INSPIRA ART&#8217;s efficiency and reduced cost of treatment. We intend to
        pursue reimbursement under specified Medicare Severity-Diagnosis Related Group, or MS-DRG, and have already begun discussions
        with some of the required parties. We plan to explore using existing Current Procedural Terminology, or CPT Codes using a &#8220;New
        Approach&#8221; to an existing procedure, because potentially certain codes selected for COVID-19 may be relevant for the INSPIRA
        ART.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Working
to Establish Distribution Partners in the U.S. and Europe</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, we entered into an exclusive distribution agreement with Anita T&#233;cnica S.L. (WAAS Group), one of Spain&#8217;s leading
distributors and technical service providers of medical equipment and supplies. According to the agreement, Anita T&#233;cnica S.L.
(WAAS Group) is committed to purchase a minimum of 1,040 INSPIRA ART devices and 35,360 disposable units for deployment at hospitals
and medical centers within a seven-year period, subject to regulatory approval for the sale and marketing of the INSPIRA ART devices
in Spain and Portugal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, we signed an exclusive summary distribution agreement with Innovimed Sp. z o.o, or Innovimed, a master distributor specializing
in state-of-the-art medical solutions in Eastern Europe, Middle East and Africa. The agreement has an initial term of 7 years, subject
to completion of product development and regulatory approval. The parties will collaborate on the marketing and deployment of the INSPIRA
ART device. In order to maintain exclusivity in the territory, Innovimed has committed to purchase minimum orders of 1,552 INSPIRA ART
devices and 59,040 disposable units for deployment at hospitals and medical centers, subject to regulatory approvals for the sale and
marketing of the INSPIRA ART devices in Poland, Czech Republic and Slovakia.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, we entered into an exclusive summary distribution agreement with Glo-Med, a company that aims to meet the continuously
growing demand for innovative medical devices and related products, for distribution across six states in the United States (Texas, New
Jersey, New York, Florida, North Carolina, and South Carolina). The summary distribution agreement will be followed by a more comprehensive
agreement. The agreement entered with Glo-Med has an initial term of 7 years, subject to the completion of product development and relevant
regulatory approval. The parties will collaborate on the marketing and deployment of the INSPIRA ART. Pursuant to the agreement, and
in order to maintain exclusivity in the territory, Glo-Med has committed to purchase a minimum order of 2,121 INSPIRA ART systems and
131,413 disposable units for deployment at hospitals and medical centers over a period of 7 years, subject to regulatory approvals for
the sale and marketing of the INSPIRA ART systems in the 6 states in the United States, as mentioned above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, we entered into a summary distribution agreement with Bepex Ltd., or Bepex, that includes the potential future deployment
of our INSPIRA ART systems, designed to prevent the need for invasive mechanical ventilation. Bepex is a leading Israeli medical technology
company that imports, markets and services medical equipment for global medical device companies such as Hamilton (mechanical ventilators)
and LivaNova (ECMO-Extracorporeal Membrane Oxygenation systems). As part of the collaboration with Bepex, the first systems are slated
for deployment at the largest medical centers in Israel. The summary distribution agreement with Bepex is expected to be followed by
a more comprehensive agreement. The agreement has an initial term of seven years, subject to the completion of product development and
relevant regulatory approvals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, we entered into an exclusive summary distribution agreement with Glo-Med, for the distribution of the HYLA blood sensor device
and disposable units across 6 states in the United States (Texas, New Jersey, New York, Florida, North Carlina and South Carolina). The
summary distribution agreement will be followed by a more comprehensive agreement. The agreement has an initial term of three years,
subject to completion of product development and regulatory approvals. The parties will collaborate on the marketing and deployment of
the HYLA&#160;blood sensor. Pursuant to the agreement, and in order to maintain exclusivity in the territory, Glo-Med has committed to
purchase a minimum order of 3,889 HYLA&#160;blood sensors and 264,873 disposable units for deployment at hospitals and medical centers,
subject to regulatory approvals for the sale and marketing of the HYLA&#160;blood sensor device in the 6 states within the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2022, we signed an exclusive summary distribution agreement for the HYLA&#8482; blood sensor with Innovimed. The summary distribution
agreement would be followed by a more comprehensive definitive agreement. The agreement has an initial term of five years, subject to
the completion of product development and the receipt of regulatory approvals. The parties will collaborate on the marketing and deployment
of the HYLA blood sensor. In order to maintain exclusivity in the territory, Innovimed has committed to purchase a minimum order of 1,364
HYLA blood sensors and 128,511 disposable units for deployment in hospital units and operating theaters in Poland, Czech Republic and
Slovakia.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we intend to execute on strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements,
and agreements that may be executed in the future. The pre-conditional distribution agreements are for a period of up to seven year and
subject to completion of development, and the required regulatory approvals or clearances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek patent protection as well as other effective intellectual property rights for our products and technologies in the United States
and internationally. Our policy is to pursue, maintain and defend intellectual property rights developed internally and to protect the
technology, inventions and improvements that are commercially important to the development of our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property portfolio consists of three patent families that includes total of two (2) granted patents, one in the USA and
one in Israel; and seven (7) pending patent applications that includes three (3) International applications (PCTs), three (3) US utility
patent applications, and one (1) European patent application. Six (6) additional National Phase filing (2 in Europe, 2 in China and 2
in Japan) are expected to be filed during the next two months. Our portfolio also includes four registered Israeli trademarks for &#8216;INSPIRA&#8217;
text and logo, for &#8216;INSPIRA ART&#8217;, and for our slogan &#8216;INSPIRA. BREATHING EMPOWERED.&#8217;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_029.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table comprises our technology patents:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: Black 1.5pt solid; width: 20%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Serial No.</b></span></td>
<td style="width: 1%">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; width: 19%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
<td style="width: 1%">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; width: 19%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
<td style="width: 1%">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; width: 19%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
<td style="width: 1%">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; width: 19%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comments</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IL 286271</b></span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Cannula Fixation Device &#160;</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 10, 2021</span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renewal fees paid up to 6th year.</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PCT/IL2022/050902</b></span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Cannula Fixation Device &#160;</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 18, 2022</span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing fees paid</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US 17/931,134</b></span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Cannula Fixation Device &#160;</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 10, 2022</span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed </span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PPH </span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EP 22856981.0&#160; </b></span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Cannula Fixation Device &#160;</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 21, 2023</span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PCT IL2021/051335</b></span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 10, 2021</span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US 11,541,159</b></span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 10, 2021</span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRACK 1</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US 18/062,610</b></span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A transformable dual lumen cannula into a single lumen cannula and methods of use</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 7, 2022</span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CIP was filed based on the provisional application for &#8220;Transformable dual lumen cannula and methods of use&#8221;</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PCT/IL2021/051431</b></span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use&#160;</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 1, 2021</span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US 17/905,413</b></span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use&#160;</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 1, 2022</span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">filed</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sys with the auto priming</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table contains our technology trademarks:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td colspan="7"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INSPIRA Technologies Trademarks list</b></span></td></tr>
<tr style="vertical-align: top">
<td colspan="7">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: Black 1.5pt solid; text-indent: -10pt; padding-left: 10pt; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Serial
No.</b></span></td>
<td style="width: 1%"><b>&#160;</b></td>
<td style="border-bottom: Black 1.5pt solid; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Mark</b></span></td>
<td style="width: 1%"><b>&#160;</b></td>
<td style="border-bottom: Black 1.5pt solid; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
Date</b></span></td>
<td style="width: 1%"><b>&#160;</b></td>
<td style="border-bottom: Black 1.5pt solid; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL 343013</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSPIRA (text)</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 31, 2021</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Reg. No. 1665374</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSPIRA (text)</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 28, 2022</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered in EUROPE, <br/>
AUSTRALIA, CHINA and ENGLAND</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL343015</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSPIRA logo</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 31, 2021</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Reg. No. 1665373</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSPIRA logo</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 28, 2022</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered in EUROPE,<br/>
 AUSTRALIA, CHINA and ENGLAND</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL 343014</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSPIRA ART</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 31, 2021</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
Reg. No. 1678453</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ART</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 28, 2022</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered in EUROPE, <br/>
AUSTRALIA, RUSSIAN<br/>
 FEDERATION and ENGLAND</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL 347306 </span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BREATHING. EMPOWERED.</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 30, 2021</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered </span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International filing pending</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BREATHING. EMPOWERED.</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 30, 2022</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on trade secrets, know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain
that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed
by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially
useful in protecting our technology.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, in part, on an intellectual property portfolio that supports future revenue streams and erects barriers to our competitors.
We are maintaining and building our patent portfolio through filing new patent applications, prosecuting existing applications, and licensing
and acquiring new patents and patent applications.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
these measures, any of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or
misappropriated. Intellectual property and proprietary rights may not be sufficient to permit us to take advantage of current market
trends or otherwise to provide competitive one. For more information, see &#8220;Item 3.D. &#8211; Risk Factors&#8212;Risks Related to
our Intellectual Property.&#8221;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development and Governmental Grants</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain an active internal research and development process, which also includes clinical activities and regulatory affairs. Our research
and development team consists of twenty-seven people as of December 31, 2022. We spent $8,054,000 and $3,909,000 for research and development
and related expenses during the year ended December 31, 2022 and the year ended December&#160;31, 2021, respectively. The increase in
research and development expenses is primarily attributable to <span style="background-color: white">an increase of $1,799,000 in salaries
and related personnel expenses and an increase of $543,000 in share based payment expenses reflecting an increase in the number of research
and development employees. moreover, there was an increase of $433</span>,000&#160;<span style="background-color: white">in subcontractors
expenses related to the development projects the company process by outsource and additional significant increase of $890</span>,000&#160;in
<span style="background-color: white">materials and related expenses using for inhouse development.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development efforts have been financed in part through grants in an aggregate amount of approximately $800,372 that we received
from the IIA as of March 28, 2023. We received this grant for the development of a blood oxygenation system with the goal of providing
respiratory support through direct blood oxygenation and elevation of the oxygen saturation level while removing carbon dioxide. There
is no repayment mechanism, however, once we reach commercialization stage, we will be obliged to pay royalties for the grant at a rate
of 3% from our revenues to an accumulated royalty earnings of $800,372. Following the full payment of such royalties, there is generally
no further liability for royalty payment. Nonetheless, the restrictions under the Innovation Law will continue to apply even after our
company has repaid the full amount of royalty payable pursuant to the grants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Production
and Manufacturing Activities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
INSPIRA ART system and or ALICE device are comprised of a number of components. We are planning to sell an assembled product as well
as a disposable respiratory support unit. The components of the assembled product and the disposable unit consist of both proprietary
and off the shelf components. Proprietary components will be manufactured on our behalf at good manufacturing practices, or GMP, approved
production plant to adhere to regulatory requirements, whereas off the shelf components will be sourced by Inspira team. GMP sub-contractors
will assemble proprietary and off the shelf components together to create our INSPIRA ART system and or ALICE device.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2022, we signed a strategic OEM agreement with Terumo Cardiovascular. The agreement provides for the manufacture of a flow mechanism
that is intended to be integrated into our products for use in the extracorporeal circulation of the blood during the oxygenation process.
This may also include integration into the INSPIRA ART system. In addition, we have begun discussions relating to additional contracted
manufacturing and distribution agreements with leading turnkey OEM vendors that provide end-to-end solutions. The outsourcing of the
supply chain management (such as manufacturing, logistics, shipping and after-market support) reduces capital expenditure, lead times
and costs, while providing us with flexibility and agility.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in December 2022, we announced that our ALICE device is being contract manufactured by an end-to-end solution provider that
offers New Product Introduction, NPI, services to mass production capabilities for leading medical electronic device companies. This
includes full turn-key manufacturing, full system integration, including Printed Circuit Board, or PCB, manufacturing, assembly services,
testing and packaging in facilities that meet Good Manufacturing Practices, or GMP, compliance. ALICE device manufactured are to undergo
the Verification and Validation phase prior to its planned 2023 submission to the FDA (FDA) for 510(k) clearance. If FDA clearance is
obtained, the ALICE device production line will be extended for Low-Rate Initial Production, or LWRIP, which is an important operational
stage in developing infrastructure to support serial manufacturing, quality control and shipping. Additional units are expected to be
assembled for the targeted future first deployments of the ALICE devices in the U.S. and Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
medical device industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary
products. There are many medical device companies, biotechnology companies, public and private universities and research organizations
actively engaged in the research and development of products that may be similar to our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market participants in the ICU and the acute respiratory care space include Boston Scientific Corporation (NYSE: BSX), ResMed Inc., (NYSE:
RMD), Masimo Corporation (Nasdaq: MASI), Becton, Dickinson and Company (NYSE: BDX), Chart Industries, Inc. (Nasdaq: GTLS), Philips Healthcare,
Medtronic plc (NYSE: MDT), Fisher &amp; Paykel Healthcare Corporation Limited, Dr&#228;gerwerk AG &amp; Co. KGaA, Dr&#228;gerwerk AG,
Hamilton Medical AG, Smiths Medical Inc., Siemens Healthineers AG ADR (Nasdaq: SMMNY), Baxter International (NYSE: BAX), Getinge, GE
Healthcare, Terumo Corporation (TYO: 4543, Nikkei 225 Component), LivaNova PLC, Fresenius SE &amp; Co. KGaA, Johnson &amp; Johnson, Resuscitec,
Spectrum Medical etc. These companies have either developed or acquired respiratory care devices and solutions, such as ventilators,
ECMO devices and blood sensors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aforementioned companies, have substantially greater brand recognition, R&amp;D, and regulatory capabilities and financial, technical,
manufacturing, marketing and human resources than we do and significantly greater experience and infrastructure in the research and development
of medical devices, obtaining the FDA and other regulatory clearances of those devices and commercializing those devices around the world.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Inspira Technologies Products </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
flagship product is the INSPIRA ART system, aimed to be a breakthrough technology that restructures the approach of acute respiratory
care, increasing its accessibility, safety and medical outcomes for patients worldwide. In order to achieve this goal, hawse have recognized
the need for the development of additional products to support this same effort. To this end, we are also developing the ALICE device,
an extracorporeal blood circulation device designed to provide cardiac and pulmonary support and the HYLA blood sensor, a non-invasive
optical blood sensor being developed using machine learning based algorithms to measure blood parameters during extracorporeal procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
go-to-market strategy for the ALICE device and HYLA blood sensor is in-line with our focus and being based upon providing affordable
products, based on a razor-blade business model to maximize our market reach while enhancing affordability and accessibility to medical
care worldwide. We focus on this effort comprehensively, understanding a multidisciplinary approach to achieve its goals. From a base
business-model to industry endorsements fueled by important clinical studies that evidence our product&#8217;s effectiveness and safety
of use, we are driven to forge forward towards achieving successful market penetration and adoption of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, we entered into a collaboration and license agreement with B.G. Negev Technologies and Applications Ltd., or BGN, a wholly-owned
subsidiary of Ben-Gurion University of the Negev in Beer Sheva. To date, we and BGN have developed and characterized a stable polymeric
microbubbles, or MBs, platform that releases oxygen on demand. The development process required in-depth research to evaluate the procedures
for oxygen engulfment in MBs and observe oxygen release at the required rates. This novel proposed technology will be further developed
with the aim to integrate it into the INSPIRA ART system. The defined X2 system is designed to extend the life of oxidizers and potentially
prevent blood clotting in the INSPIRA ART system. The project is currently in a moratorium until further notice.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
HYLA Blood Sensor</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
HYLA blood sensor is a non-invasive optical blood sensor designed to perform real-time and continuous blood measurements, potentially
minimizing the need to take actual blood samples from patients. The HYLA&#8217;s measurements can potentially assist physicians in the
monitoring of patient&#8217;s clinical condition. The HYLA blood sensor is being designed as a clip-on sensor, attached to the outer
walls of a blood tube, that may potentially reduce risks, complications, and costs. The HYLA blood sensor may have broad application
potential, benefiting patients undergoing procedures such as cardiopulmonary bypass operations, Extracorporeal Membrane Oxygenation,
or ECMO and Cardiopulmonary bypass, pending regulatory approvals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_030.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, we entered into an exclusive summary distribution agreement with Glo-Med, for the distribution of the HYLA blood sensor device
and disposable units across 6 states in the United States (Texas, New Jersey, New York, Florida, North Carlina and South Carolina). The
summary distribution agreement will be followed by a more comprehensive agreement. The agreement has an initial term of three years,
subject to completion of product development and regulatory approvals. The parties will collaborate on the marketing and deployment of
the HYLA blood sensor. Pursuant to the agreement, and in order to maintain exclusivity in the territory, Glo-Med has committed to purchase
a minimum order of 3,889 HYLA blood sensors and 264,873 disposable units for deployment at hospitals and medical centers, subject to
regulatory approvals for the sale and marketing of the HYLA blood sensor device in the 6 states within the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2022, we signed an exclusive summary distribution agreement for the HYLA&#8482; blood sensor with Innovimed. The summary distribution
agreement would be followed by a more comprehensive definitive agreement. The agreement has an initial term of five years, subject to
the completion of product development and the receipt of regulatory approvals. The parties will collaborate on the marketing and deployment
of the HYLA blood sensor. In order to maintain exclusivity in the territory, Innovimed has committed to purchase a minimum order of 1,364
HYLA blood sensors and 128,511 disposable units for deployment in hospital units and operating theaters in Poland, Czech Republic and
Slovakia.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we intend to execute on strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements
and agreements that may be executed in the future. The pre-conditional distribution agreements are for a period of up to seven years
and subject to completion of development, and the required regulatory approvals or clearances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the first quarter of 2023, the HYLA blood sensor will commence a prospective data collection Clinical Study at Sheba Medical Center on
up to 100 patients undergoing open-heart surgery, designed to integrate clinical research into the product development cycle. Verification
and Validation (V&amp;V) testing is expected to be completed prior to FDA submission via the 510(k) pathway in the first half of 2024.
Following FDA clearance, initial market penetration and adoption is planned to occur during 2025, alongside the receipt of initial sales
orders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on in-house estimates that the market size for the HYLA blood sensor is ~1.2m applicable procedures annually, including Acute Respiratory
Failure (VV-ECMO) and VA ECMO and Heart Surgery.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
HYLA blood sensor, subject to regulatory approvals, is intended to be a commercial product. If we receive the necessary regulatory approvals,
we plan to deploy the first HYLA blood sensor in ICUs and/or operating theaters. We expect to commercially launch our HYLA blood sensor
in the United States, subject to the receipt of FDA clearance, and in Europe following the receipt of the CE Mark.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
ALICE Device </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ALICE Device, an advanced form of life support system better known by the medical industry as CPB, is being designed for use in surgical
procedures requiring cardiopulmonary bypass for six hours or less.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ALICE device has commenced its V&amp;V testing process, with FDA submission via the 510(k) pathway planned for the second half of 2023.
Following FDA clearance, initial market penetration and adoption is planned to occur during 2024, alongside the receipt of initial sales
orders. The ALICE device will also be the first of our products to be integrated with the HYLA blood sensor during 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ALICE is designed to be a new generation CPB system with potential advantages to medical device design with ergonomic configuration and
intuitive user-centric software and display to increase functionality, as well as a large touchscreen with novel colorful graphical representation
that increases the visibility and functionality of data displayed to the medical staff. The ALICE device is being designed to be lightweight
and highly durable and will be equipped with long battery life to maximize its portability. The ALICE device, designed as a CPB, shall
be indicated for use in surgical procedures requiring CPB for six hours or less.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_031.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the ALICE device is being contract manufactured by an end-to-end solution provider that offers NPI services to mass production
capabilities for leading medical electronic device companies. This includes full turn-key manufacturing, full system integration, including
PCB manufacturing, assembly services, testing and packaging in facilities that meet GMP compliance. The ALICE device is expected to undergo
the V&amp;V phase prior to its planned submission in the second half of 2023 to the FDA for 510(k) pathway with clearance expected in
2024. If FDA clearance is obtained, the ALICE device production line will be extended for Low-Rate Initial Production, or LWRIP, which
is an important operational stage in developing infrastructure to support serial manufacturing, quality control and shipping. Additional
units are expected to be assembled for the targeted future first deployments of the ALICE devices in the U.S. and Israel. We believe,
and according to and Emergen Research report published in December 2022 entitled &#8220;Extracorporeal Membrane Oxygenation Machine Market
By Product (ECMO Machines and Software), By Component (Pumps, Oxygenators, Controllers, Cannulas and Accessories), By Patient Type, By
Application, and By Region Forecast to 2030,&#8221;, the market size applicable to the ALICE device is $673 million by 2026, which includes,
according to the Extracorporeal Life Support Organization,15,000-20,000 procedures in the U.S. in 337 Hospitals in the U.S. with extracorporeal
experience.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ALICE device, subject to regulatory approvals, is intended to be a commercial CPB device. When and if we receive the necessary regulatory
approvals, we plan to deploy the first ALICE device in operating theaters. We expect to commercially launch our ALICE device in the United
States, subject to the receipt of the FDA clearance, and in Europe following the receipt of the CE Mark.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation and Product Approval </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products and our operations are subject to regulation by numerous worldwide regulatory bodies including the FDA and comparable international
regulatory agencies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are subject to regulation as medical devices under the Federal Food, Drug, and Cosmetic Act, or FDCA, as implemented and enforced
by the FDA. The FDA regulates the development, design, non-clinical and clinical research, manufacturing, safety, efficacy, labeling,
packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, import, export, adverse event reporting,
advertising, promotion, marketing and distribution, and import and export of medical devices to ensure that medical devices distributed
domestically are safe and effective for their intended uses and otherwise meet the requirements of the FDCA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to U.S. regulations, we are subject to a variety of regulations in the European Economic Area, or the EEA, governing clinical
trials and the commercial sales and distribution of our products. Whether or not we have or are required to obtain FDA clearance or approval
for a product, we will be required to obtain authorization before commencing clinical trials and to obtain marketing authorization or
approval of our products under the comparable regulatory authorities of countries outside of the United States before we can commence
clinical trials or commercialize our products in those countries. The approval process varies from country to country and the time may
be longer or shorter than that required for FDA clearance or approval. Medical devices are generally subject to varying levels of regulatory
control based on risk level of the device.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FDA
Premarket Clearance and Approval Requirements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
an exemption applies, each medical device commercially distributed in the United States requires FDA clearance of a 510(k) premarket
notification, granting of a de novo request, or approval of an application for premarket approval, or PMA. Under the FDCA, medical devices
are classified into one of three classes&#8212;Class&#160;I, Class&#160;II or Class&#160;III&#8212;depending on the degree of risk associated
with each medical device and the extent of regulatory controls needed to ensure its safety and effectiveness. Class&#160;I includes devices
with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s General
Controls for medical devices, which include compliance with the applicable portions of the QSR, facility registration and product listing,
reporting of adverse medical events, and truthful and non-misleading labeling. Class&#160;II devices are subject to the FDA&#8217;s General
Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls
can include performance standards, post-market surveillance, patient registries and FDA guidance documents. While most Class&#160;I devices
are exempt from the 510(k) premarket notification requirement, manufacturers of most Class&#160;II devices are required to submit to
the FDA a premarket notification under Section&#160;510(k) of the FDCA requesting permission to commercially distribute the device. The
FDA&#8217;s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
510(k) Process</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 510(k) process, the manufacturer must submit to the FDA a premarket notification demonstrating that the device is &#8220;substantially
equivalent&#8221; to either a device that was legally marketed prior to May&#160;28, 1976, the date upon which the Medical Device Amendments
of 1976 were enacted, and for which a pre-market approval, or PMA, is not required, a device that has been reclassified from Class&#160;III
to Class&#160;II or Class&#160;I, or another commercially available device that was cleared through the 510(k) process. To be &#8220;substantially
equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological
characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or
effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a 510(k) premarket notification is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information
for substantive review, the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive
review. By statute, the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification.
As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are
cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial
equivalence, which may significantly prolong the review process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance
to commercially market the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously
cleared device, the device is automatically designated under the FDCA as a Class&#160;III device. The device sponsor must then fulfill
more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the de novo
process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a
predicate device.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a device receives 510(k) marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would
constitute a major change or modification in its intended use, will require a new 510(k) marketing clearance or, depending on the modification,
a de novo grant or PMA approval. The FDA requires each manufacturer to determine whether the proposed change requires submission of a
510(k) (or a PMA) in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination.
Many minor modifications today are accomplished by a manufacturer documenting the change in an internal letter-to-file. The FDA can review
these letters to file during an inspection. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer
to cease marketing and/or request the recall of the modified device until 510(k) clearance, de novo grant or PMA approval is obtained.
In these circumstances, we may be subject to significant regulatory fines or penalties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>De
Novo Classification</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
device types that the FDA has not previously classified as Class&#160;I, II or III are automatically classified under the FDCA into Class&#160;III
regardless of the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a route to market for
low to moderate risk medical devices that are automatically placed into Class&#160;III due to the absence of a predicate device, called
the &#8220;Request for Evaluation of Automatic Class&#160;III Designation,&#8221; or the de novo classification procedure. This procedure
allows a manufacturer whose novel device is automatically classified into Class&#160;III to request down-classification of its medical
device into Class&#160;I or Class&#160;II on the basis that the device presents low or moderate risk, rather than requiring the submission
and approval of a PMA application. Prior to the enactment of the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA,
a medical device could be eligible for de novo classification only if the manufacturer first submitted a 510(k) premarket notification
and received a determination from the FDA that the device was not substantially equivalent to a legally marketed predicate device. FDASIA
streamlined the de novo classification pathway by permitting manufacturers to request de novo classification directly without first submitting
a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination. Under FDASIA, the FDA is required
to classify the device within 120 days following receipt of the de novo application. If the manufacturer seeks reclassification into
Class&#160;II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance
of the safety and effectiveness of the medical device. In addition, the FDA may reject the request if it identifies a legally marketed
predicate device that would be appropriate for a 510(k) notification, determines that the device is not low to moderate risk, or that
general controls would be inadequate to control the risks and special controls cannot be developed. After a device receives de novo classification,
any modification that could significantly affect its safety or efficacy, or that would constitute a major change or modification in its
intended use, will require a new 510(k) clearance or, depending on the modification, another de novo petition or even PMA approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trials</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are almost always required to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations
of investigational devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s Investigational
Device Exemption, or IDE, regulations which govern investigational device labeling, prohibit promotion of the investigational device,
and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device
presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE
application to the FDA, which must become effective prior to commencing human clinical trials. A significant risk device is one that
presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining
human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human
health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such
as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically
sound. The IDE will automatically become effective 30&#160;days after receipt by the FDA unless the FDA notifies the company that the
investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification,
the FDA may permit a clinical trial to proceed under a conditional approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the study must be approved by, and conducted under the oversight of, an Institutional Review Board, or IRB. The IRB is responsible
for the initial and continuing review of the study and may pose additional requirements for the conduct of the study. If an IDE application
is allowed to go into effect by the FDA and the study approved by the reviewing IRB(s), human clinical trials may begin at a specific
number of investigational sites with a specific number of subjects as set forth in the study protocol. If the device presents a non-significant
risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate
review from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators
obtain informed consent, and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee
that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data
derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement
must be submitted to, and allowed to go into effect by, the FDA before a sponsor or investigator may make a change to the investigational
plan that may affect its scientific soundness, study plan or the rights, safety or welfare of human subjects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting
clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping
and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators
in the clinical study are also subject to FDA regulations and must obtain patient informed consent, follow the investigational plan and
study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements.
Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons,
including a belief that the risks to study subjects outweigh the anticipated benefits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-market
Regulation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a device is cleared or approved for marketing, numerous and extensive regulatory requirements may continue to apply. These include but
are not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annual and updated establishment
    registration and device listing with the FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QSR requirements, which
    require manufacturers to follow stringent design, testing, control, documentation, complaint handling and other quality assurance
    procedures during all aspects of the design and manufacturing process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advertising and promotion
    requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on sale, distribution
    or use of a device;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 49px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 25px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling and marketing
    regulations, which require that promotion is truthful, not misleading, and provides adequate directions for use and that all claims
    are substantiated, and also prohibit the promotion of products for unapproved or &#8220;off-label&#8221; uses and impose other restrictions
    on labeling;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Physician Sunshine
    Act and various state and foreign laws on reporting remunerative relationships with health care customers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback
    Statute (and similar state laws) prohibiting, among other things, soliciting, receiving, offering or providing remuneration intended
    to induce the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as Medicare
    or Medicaid. A person or entity does not have to have actual knowledge of this statute or specific intent to violate it to have committed
    a violation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal False Claims
    Act (and similar state laws) prohibiting, among other things, knowingly presenting, or causing to be presented, claims for payment
    or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation
    to pay or transmit money or property to the federal government or knowingly concealing, or knowingly and improperly avoiding or decreasing,
    an obligation to pay or transmit money to the federal government. The government may assert that a claim that includes items or services
    resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false
    claims statute;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clearance or approval of
    product modifications to legally marketed devices that could significantly affect safety or effectiveness or that would constitute
    a major change in intended use;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medical device reporting
    regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death
    or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute
    to a death or serious injury, if the malfunction were to recur;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">correction, removal and
    recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals
    if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complying with the federal
    law and regulations requiring Unique Device Identifiers on devices and also requiring the submission of certain information about
    each device to the FDA&#8217;s Global Unique Device Identification Database;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s recall
    authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing
    laws and regulations if there is a reasonable probability that the use of the device would cause a serious, adverse health consequence
    or death; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market surveillance
    activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional
    safety and effectiveness data for the device.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory
requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning letters, untitled
    letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls, withdrawals, or
    administrative detention or seizure of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating restrictions
    or partial suspension or total shutdown of production;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing or delaying requests
    for 510(k) marketing clearance or PMA approvals of new products or modified products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawing 510(k) clearances
    or PMA approvals that have already been granted;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to grant export
    or import approvals for our products; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, or the EU, we will be required to comply with the new Medical Device Regulation, or the MDR. The MDR was published
in May 2017 with a 3-year transition period, which has been extended. The CE Mark required to sell medical devices in the European Union
is affixed following conformity assessment and either approval from the appointed independent Notified Body or through self-certification
by the manufacturer for particular class I devices. The selected pathway to CE marking is based on product risk classification. CE Marking
indicates conformity to the applicable General Safety and Performance Requirements for the MDR. The MDR change multiple aspects of the
existing regulatory framework for CE marking, such as increased clinical evidence requirements and other new requirements, including
Unique Device Identification as well as many other post-market obligations. MDR also significantly modifies and increases the compliance
requirements for the industry and will require significant investment over the next few years to implement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also required to comply with the regulations of every other country where we commercialize products before we can launch or maintain
new products on the market. Many countries that previously did not have medical device regulations, or had minimal regulations, are now
introducing them. For example, India is in the process of expanding its current regulations to include all medical device categories
while many countries in the Middle East and Southeast Asia are introducing new regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other worldwide regulatory agencies and competent authorities actively monitor compliance to local laws and regulations through
review and inspection of design and manufacturing practices, record-keeping, reporting of adverse events, labeling and promotional practices.
The FDA can ban certain medical devices, detain or seize adulterated or misbranded medical devices, order repair, replacement or refund
of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable
risks of substantial harm to the public health. The FDA may also enjoin and restrain a company for certain violations of the FDCA and
the Safe Medical Devices Act pertaining to medical devices or initiate action for criminal prosecution of such violations. Regulatory
agencies and authorities in the countries where we do business can halt production in or distribution within their respective country
or otherwise take action in accordance with local laws and regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
sales of medical devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate
from lawful performance standards, are subject to FDA export requirements. Additionally, exported devices are subject to the regulatory
requirements of each country to which the device is exported. Some countries do not have medical device regulations, but in most foreign
countries, medical devices are regulated. Frequently, regulatory approval may first be obtained in a foreign country prior to application
in the U.S. due to differing regulatory requirements; however, other countries, such as China, for example, require approval in the country
of origin first.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
countries outside of the United States require that product approvals be recertified on a regular basis, generally every five years.
The recertification process requires that we evaluate any device changes and any new regulations or standards relevant to the device
and, where needed, conduct appropriate testing to document continued compliance. Where recertification applications are required, they
must be approved in order to continue selling our products in those countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Planned
Regulatory Filings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, our products have not been tested on humans and any future testing on humans will be subject to the request of the appropriate
regulators, including the FDA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are taking a multi-step approach to the regulatory clearance process. In January 2022, we listed a component of the INSPIRA ART system
and ALICE device on the U.S. Food and Drug Administration Class I 510(k) exempt list. The component is intended to reduce the potential
complications associated with jugular vein cannula movement, occurring during a change of a patient&#8217;s posture in bed and/or during
transportation. This will be followed by Class II 510(k) filings in the second half of 2023 for the ALICE device for use as a cardiopulmonary
bypass device , based on predicates, which we do not currently expect to require human trials for FDA clearance. Any modification that
could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use,
will require a new marketing clearance, depending on the modification, 510(k), a de novo or other type of approval. We are planning to
apply for the break-through device designation with the FDA for the INSPIRA ART.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also planning additional applications in relation to multi-function sources of INSPIRA ART, which will be our commercial respiratory
support system. When and if we receive clearance, we plan to deploy the first INSPIRA ART systems and ALICE devices in ICUs and/or operating
theatres.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
as a part of our strategy to bring our device to market and streamline reimbursement coding and clinical adoption of the INSPIRA ART
that offers a new intent of use, we will collaborate with top ranking hospitals to perform a human observational study focused on (pending
approvals) : (i) proving that the INSPIRA ART can prevent patient deterioration resulting in the need for invasive MV, and (i) assisting
in weaning patients off MV.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_024"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organizational Structure.
    </b>&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an Israeli corporation based in Ra&#8217;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd.
On April 10, 2018, our name was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira
Technologies Oxy B.H.N. Ltd. Our principal executive offices are located at 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel. Our telephone
number in Israel is +972 996 644 88. Our website address is www.inspira-technologies.com. The information contained on our website or
available through our website is not incorporated by reference into and should not be considered a part of this Annual Report, and the
reference to our website in this Annual Report is an inactive textual reference only. The SEC also maintains an Internet website that
contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our
filings with the SEC will also be available to the public through the SEC&#8217;s website at www.sec.gov.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we do not have any subsidiaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_025"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property, Plant and Equipment. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
main business activities are conducted in Israel. Our offices, research and development and manufacturing facilities are located at Melisron
(Millennium Building), 2 Ha-Tidhar St., Ra&#8217;anana 4366504, Israel, where we occupy approximately 670 square meters. Our lease ends
in August 2027. Our monthly rent payment starting from January 2022 is approximately NIS 44,220 (approximately $14,218).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the upcoming year , we will consider renting an additional 200&#160;square meters in the same building, at the same price per meter,
to allow us to grow and extend our labs to be suitable for the conduct of our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4A. UNRESOLVED STAFF COMMENTS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 5.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_028"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating Results.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated
financial statements and the related notes included elsewhere in this annual report on Form 20-F. The discussion below contains forward-looking
statements that are based upon our current expectations and are subject to uncertainty and changes in circumstances. Actual results may
differ materially from these expectations due to inaccurate assumptions and known or unknown risks and uncertainties, including those
identified in &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and under &#8220;Risk Factors&#8221; elsewhere in this
annual report on Form 20-F. Our discussion and analysis for the year ended December 31, 2021 compared to the year ended December 31,
2020 can be found in our annual report on Form 20-F for the fiscal year ended December 31, 2021, filed with the SEC on March 31, 2022.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a specialty medical device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory
support technology that is intended to reduce the need for (IMV, which is the standard of care today for the treatment of acute respiratory
failure. Although it may be sometimes lifesaving, IMV is associated with increased risks, costs of care, extended lengths of stay, frequent
incidence of infections, ventilator dependence and mortality. Using our state-of-the-art respiratory support technology, our goal is
to set a new standard of care and to provide patients with acute respiratory failure an opportunity to maintain spontaneous breathing
and avoid the need for intubation, coma and various risks associated with the use of IMV. As part of our strategy to reach this goal,
and in parallel to pursuing regulatory approvals, we are actively working to establish collaborations with strategic partners, globally
ranked hospitals, medical device companies and distributors both for endorsement and early clinical adoption. &#160;We plan to target
ICUs, general medical units, operating theaters, emergency medical services and small urban and rural hospitals, with the goal of making
our solutions more accessible to millions of patients worldwide. We expect for these activities to support our strategy plan to reach
market penetration and adoption of our respiratory support technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception in 2018, we have incurred operating losses. Our operating loss for the years ended December 31, 2021 and 2022 were $13.4
million and $14.7 million, respectively; and our net loss for the same period was $17 million and $10 million. As of December 31, 2022,
we had an accumulated deficit of $39&#160;million. We expect to continue to incur significant expenses and operating losses for the foreseeable
future, and our losses may fluctuate significantly from year to year. We anticipate that our expenses will increase significantly in
connection with our ongoing activities, as we:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue clinical development
    of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">file new applications seeking
    regulatory approval for the products&#160;pursuant to FDA&#8217;s Section&#160;510(K) or other regulatory pathway in the United States;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to invest in the
    preclinical research and development of any future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a commercial
    infrastructure to support the marketing, sale and distribution of the products if they receive regulatory approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire additional research
    and development and general and administrative personnel to support our operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain, expand and protect
    our intellectual property portfolio; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to incur costs
    associated with operating as a public company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any product candidates approved for sale and have not generated any revenue from product sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 16, 2021, we closed our initial public offering, or IPO, whereby we sold 2,909,091 Ordinary Shares and 3,345,455 tradable warrants
(inclusive of 436,364 tradable warrants pursuant to the exercise of an overallotment option granted to the underwriters). The aggregate
gross proceeds received by us from the IPO were $16 million, before underwriting discounts and other offering costs. Prior to our IPO,
we financed our operations primarily through convertible debt, as well as grants from the Israel Innovation Authority, or the IIA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Current
Outlook</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have financed our operations to date primarily through </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proceeds
from sales of our Ordinary Shares, <span style="background-color: white">convertible notes and loans and from grants from the IIA. We
have incurred losses and generated negative cash flows from operations since inception in 2018. Since inception, we have not generated
any revenue and we do not expect to generate significant revenues in the near future.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of December 31, 2022, our cash and cash equivalents and cash deposits were $13.9 million. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 16, 2021, we closed our initial public offering. The aggregate gross proceeds received by us from the IPO were $16 million, before
underwriting discounts and other offering costs. In October 2021, some investors exercised their tradable warrants, with an aggregate
gross proceeds of $9.3 million received by us as a result.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;We
have an effective Form F-3 registration statement (File No. 333-266748), filed under the Securities Act of 1933, as amended, with the
SEC using a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may, from time to time, sell our ordinary
shares and warrants to purchase ordinary shares, and units of two or more of such securities in one or more offerings up to a total dollar
amount of $50,000,000. To date, we have not yet sold any securities pursuant to the effective Form F-3 registration statement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our existing cash and cash equivalents as of December 31, 2022 will enable us to fund our operating expenses and capital
expenditure requirements for at least the next 12 months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds
sooner than planned. Our future capital requirements will depend on many factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress and costs
    of our research and development activities;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of manufacturing
    our products;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting,
    enforcing and defending patent claims and other intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential costs of
    contracting with third parties to provide marketing and distribution services for us or for building such capacities internally;
    and</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the magnitude of our general
    and administrative expenses.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Until
we can generate significant recurring revenues and profit, we expect to satisfy our future cash needs through equity raises. We cannot
be certain that additional funding will be available to us when needed, on acceptable terms, if at all. If funds are not available, we
may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect
to our product candidates. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Expenses</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
current operating expenses consist of three components&#160;&#8212;&#160;research and development expenses, general and administrative
expenses and marketing expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated revenue from the sale of any product, and we do not expect to generate significant revenue within the next
year at least.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses, net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
research and development expenses consist primarily of salaries and related personnel expenses, share-based compensation expenses, materials
costs consultants and other third parties who support the developments of our products and other related research and development expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, we received the approval of the IIA for its participation in certain development expenses carried out by the Company, within
the framework of determined budgets and time periods. Through December 31, 2022 and December 31, 2021, we received a total of $800,371
and we do not expect to receive any additional grants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following tables discloses the breakdown of research and development expenses:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">U.S. dollars in thousands</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Share based compensation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,311</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,768</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,533</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">929</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">IIA participation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(255</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8,054</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,909</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
expect that our research and development expenses will materially increase as we continue to develop our products and recruit additional
research and development employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">General
and administrative expenses consist primarily of salaries and related expenses, share based compensation, professional service fees for
accounting and booking, legal fees, facilities, travel expenses and other general and administrative expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following tables discloses the breakdown of general and administrative expenses:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic">Unaudited</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">U.S. dollars in thousands</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">share-based compensation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,093</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,581</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,522</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,390</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Related IPO expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,265</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Directors&#8217; fees and share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,113</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,142</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">545</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,391</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,572</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Comparison
of the Years Ended December 31, 2022 and 2021 </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
of Operations</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarizes our results of operations for the years ended December&#160;31, 2022 and 2021:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><i>U.S. dollars in thousands</i></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,054</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,909</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,572</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and Marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,951</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,770</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,432</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,497</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,523</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,955</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Loss attributable to holders of Ordinary Shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,273</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,955</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
research and development expenses for the year ended December 31, 2022, amounted to $8,054,000 representing an increase of $4,145,000,
or 106%, compared to $3,909,000 for the year ended December 31, 2021. There was an increase of $1,799,000 in salaries and related personnel
expenses and an increase of $543,000 in share based payment expenses reflecting an increase in the number of research and development
employees with the efforts to support the research and trials, and an increase of $433</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,000&#160;<span style="background-color: white">in
subcontractors&#8217; expenses related to development projects we process by outsourcing, and additional increase of $</span>890,000&#160;in
<span style="background-color: white">materials and related expenses using in-house personnel.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
research and development expenses for the year ended December 31, 2022, includes IIA grants in the amount of $255,000. According to International
Accounting Standard 20 &#8220;Government Grants&#8221;, or IAS, 20, a liability is recognized at its fair value in accordance with the
market interest rate prevailing at the time of receiving the grant. The difference between the consideration received and the liability
recognized at inception was treated as a government grant and recognized as a reimbursement of research expenses or a reduction in capitalized
development costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and administrative expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Our
general and administrative expenses totaled $5,391,000 for year ended December 31, 2022, a decrease of $2,181,000, or 29%, compared to
$7,572,000 for the year ended December 31, 2021. The decrease was primarily attributable to a decrease of $1,488,000 in employees share-based
compensation expenses and a decrease of $1,265,000 in related IPO expenses which took place in 2021 . s.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Sales and marketing
expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Marketing
expenses for the year ended December 31, 2022, amounted to $1,325,000 representing a decrease of $626,000, or 32%, compared to $1,951,000
for the year ended December 31, 2021. The decrease is attributable to a decrease of $685,000 in employee share-based compensation expenses.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">As
a result of the foregoing, our operating loss for year ended December 31, 2022, amounted to $14,770,000 representing an increase] of $1,338,000,
or 10.0%, compared to $13,432,000 for the year ended December 31, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financial expenses </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expenses consist
materially of revaluation of liability in connection to IIA grants, and bank fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized financial expenses
for the year ended <span style="background-color: white">December 31, 2022, amounting to $181,000 representing a decrease of $3,343,000,
or 95%, compared to $</span>3,524,000 <span style="background-color: white">for the year ended December 31, 2021. </span>The decrease
was primarily due to a change in the fair value of financial liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financial income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial income consists
of deposit interest, revaluation of financial liabilities presented at fair value and foreign currency changes reflections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized financial income
for the year ended <span style="background-color: white">December 31, 2022, amounting to $4,678,000, representing an increase of $4,677,000
compared to $</span>1,000 <span style="background-color: white">for the year ended December 31, 2021. </span>The increase was primarily
due to a change in the fair value of financial liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Total comprehensive loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
exchange profits arising on translation to presentation currency for the year ended December 31, 2022 amounted to $2,138,000 compared
to profits arising on translation to presentation currency of $845,000 for the year ended December 31, 2021, which resulted from volatility
in the dollar exchange rate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">As
a result of the foregoing, our total comprehensive loss for the year ended December 31, 2022, amounted to $12,411,000 representing a decrease
of $3,699,000, or 23%, compared to $16,110,000 for the year ended December 31, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_029"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Capital Resources</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Overview </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">As
of December 31, 2022, we had $13,900,000 in cash, cash equivalents and cash deposits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
table below presents our cash flows for the year ended December 31, 2022 and December 31, 2021:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><i>U.S. dollars in thousands</i></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net cash (used) in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,380</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,877</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash (used) in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,249</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(246</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash (used) provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(399</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,422</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,028</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,299</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Net
cash used in operating activities of $7,380,000 during the year ended December 31, 2022 and net cash used in operating activities of $7,877,000
during the year ended December 31, 2021 was primarily used for payment of salaries and related personnel expenses, materials expenses,
subcontractors, travel and office maintenance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Net
cash used in investing activities of $7,249,000 during the year ended December 31, 2022, consisted mostly of $7,000,000 investment in
cash deposits and $304,000, used for purchasing property and equipment. Net cash used in investing activities of $246,000 during the year
ended December 31, 2021, consisted mainly of a short time restricted deposit in amount of $70,000 and $176,000 used for purchasing property
and equipment</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financing Activities </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used by financing
activities of $399,000 <span style="background-color: white">during the year ended December 31, 2022</span>, consisted only of principal
paid on lease liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Net
cash provided by financing activities of $</span>30,422,000 <span style="background-color: white">during the year ended December 31, 2021,
</span>consisted mainly of $14,658,000 of net proceeds from our IPO, $8,721,000 of net proceeds from the exercise of tradable warrants,
$7,208,000 of net proceeds from convertible loan and simple agreements for future equity and Principal paid on lease liabilities of $199,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;We
have an effective Form F-3 registration statement (File No. 333-266748), filed under the Securities Act of 1933, as amended, with the
SEC using a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may, from time to time, sell our ordinary
shares and warrants to purchase ordinary shares, and units of two or more of such securities in one or more offerings up to a total dollar
amount of $50,000,000. To date, we have not yet sold any securities pursuant to the effective Form F-3 registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_030"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.C </b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and development, patents and licenses, etc.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of our research
and development programs and the amounts that we have incurred over the last two years pursuant to those programs, please see &#8220;Item
5. Operating and Financial Review and Prospects&#8212; A. Operating Results&#8212; Operating Expenses&#8212; Research and Development
Expenses, net&#8221; and &#8220;Item 5. Operating and Financial Review and Prospects&#8212; A. Operating Results&#8212; Comparison of
the year ended December 31, 2022 to the year ended December 31, 2021&#8212; Research and Development Expenses.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_031"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.D </b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trend Information</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 pandemic has
impacted companies in Israel and around the world, and as its trajectory remains highly uncertain. As of the date of this annual report,
our management continues to examine the impacts of COVID-19 and are unable to estimate the full extent of its possible effects. No significant
adverse effect on our operations and on the results of our operation, is apparent at this stage. However, we cannot predict the duration
and severity of the outbreak and its containment measures. Further, we cannot predict impacts, trends and uncertainties involving the
pandemic&#8217;s effects on economic activity, the size of our labor force, our third-party partners, our investments in marketable securities,
and the extent to which our revenue, income, profitability, liquidity, or capital resources may be materially and adversely affected.
See also &#8220;Item 3.D. &#8211; Risk Factors&#8211; We face business disruption and related risks resulting from the COVID-19 pandemic,
which has had a material adverse effect on our business and results of operations.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_032"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical Accounting Estimates</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We describe our significant
accounting policies more fully in Note 2 to our financial statements for the year ended December 31, 2022. We believe that the accounting
policies below are critical in order to fully understand and evaluate our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We prepare our financial statements
in accordance with IFRS, as issued by the IASB. At the time of the preparation of the financial statements, our management is required
to use estimates, evaluations, and assumptions which affect the application of the accounting policy and the amounts reported for assets,
obligations, income, and expenses. Any estimates and assumptions are continually reviewed. The changes to the accounting estimates are
credited during the period in which the change to the estimate is made.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 6.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_034"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors and Senior Management.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding our executive officers, key employees and directors as of the date of this annual report on Form 20-F:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 60%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hayon</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yafit Tehila</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi Shabtai</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operations Officer and VP of Research and Development</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniella Yechezkeli Hayon </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Technology Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prof. Benad Goldwasser <sup>(1) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Amit <sup>(1) (2) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tal Parnes <sup>(1) (2) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limor Rozen <sup>(1) (2) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Compensation Committee</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Audit Committee and Financial Statement Examination Committee</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director (as defined under Nasdaq Stock Market rules)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Dagi Ben-Noon, Chief
Executive Officer, Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Dagi Ben-Noon</i> has
served as our Chief Executive Officer since July 2020 and as a director since March 2020. Prior to that, Mr. Ben-Noon served as our Chief
Operations Officer from March 2018 to June 2020. Mr. Ben-Noon founded our company together with Dr. Udi Nussinovitch and Mr. Joe Hayon
in July 2017. Mr. Ben-Noon has over 15 years of experience in product development from idea inception to illustration, design, manufacturing
and product launch. Mr. Ben-Noon co-founded Nano Dimension Ltd. (Nasdaq: NNDN) and served as the company&#8217;s chief operating officer
and director from July 2012 to October 2017. As Nano Dimension Ltd.&#8217;s chief operating officer, Mr. Ben-Noon was in charge of the
company&#8217;s research and development, operations, production, quality and information technology. Mr. Ben-Noon has a BSc in Mechanical
Engineering from the Ben-Gurion University of the Negev in Beer Sheva, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Joe Hayon, President
and Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Joe Hayon</i> has served
as our President and Chief Financial officer since July 2020 and as a director since November 2020. Prior to that, Mr. Hayon served as
our Chief Executive Officer from March 2018 to June 2020. Mr. Hayon founded our company together with Dr. Udi Nussinovitch and Mr. Dagi
Ben-Noon in July 2017. Mr. Hayon has over 20 years of experience in managerial roles. From 2001 to 2005, Mr. Hayon worked as a treasurer
and cost accountant at Sanmina Ltd. (formerly known as Elscint). From 2006 to 2007, Mr. Hayon worked as chief financial officer for Arazim
Group. He worked for Plasan Sasa Ltd. from 2007 to 2018 as the company&#8217;s chief information officer and group controller. Mr. Hayon
has a B.A. in Business and Economics and an MBA with a major in Marketing and Finance, both from the University of Manchester, as well
as a Business Management Diploma from Damelin College.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Yafit Tehila, Chief Financial Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Ms. Yafit Tehila </i>has served as our Chief Financial Officer since August 2022. Prior
to becoming our CFO, Ms. Tehila served as our Vice President of Finance and Legal since February 2021. Ms. Tehila served as Director of
Finance at Nano Dimension Ltd. (NASDAQ: NNDM) from November 2020 through February 2021 and Financial Controller from February 2016 through
November 2020. Ms. Tehila served as Financial Controller at Migdal Capital Markets from August 2010 through November 2016. Ms. Tehila
received has a B.A. in Accounting, Economics and business management from Tel Aviv University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Avi Shabtai, Chief
Operations Officer and Vice President of Research and Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Avi Shabtai</i> has
served as our Chief Operations Officer since July 2020 and as our Vice President of Research and Development since June 2019. Mr. Shabtai&#8217;s
expertise lies in engineering, testing, quality management, regulation, risk management and production across a product&#8217;s life cycle
from concept to production. He has over 25 years of experience in management of high-tech companies, particularly in their research and
development and operations departments, including roles of vice president of research and development and vice president of quality and
engineering. From July 2015 to March 2018, Mr. Shabtai worked as vice president of research and development at Nano Dimension Ltd. (Nasdaq:
NNDN). Prior to that, Mr. Shabtai worked as vice president of research and development at ZutaCore from April 2018 to May 2019. Mr. Shabtai
is qualified as software quality engineer by the ALD College and the Israeli Standard Institute.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Daniella Yeheskely-Hayon, PhD, Chief Technology
Officer.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Daniella Yeheskely-Hayon
</i>has served as our Chief Technology Officer since January 2022. Dr. Yeheskely-Hayon has comprehensive project management experience
in biomedical engineering as well as in key roles within medical device companies. Since June 2016, Dr.&#160;Yeheskely-Hayon&#160;has
served as the director of research and development and chief of operations at O2Cure Ltd., a medical device company that specializes
in the development of long-term oxygenators and respiratory assist devices for hospitals. From October 2009 to May 2016, Dr. Yeheskely-Hayon
served as a senior research associate at the Technion Department of Biomedical Engineering. Dr. Yeheskely-Hayon holds a PhD in Biology
from the Technion Institute, Israel and an MBA from ONO academic college.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Prof. Benad Goldwasser,
MD MBA, Chairman of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Benad Goldwasser
</i>has served as chairman of our board of directors since February 2021. <span style="background-color: white">Prof. Goldwasser is a
urologic surgeon, inventor, entrepreneur and venture capital investor with vast experience in leading high growth, publicly traded medical
companies. In 1993, Prof. Goldwasser co-founded Vidamed Inc., which was acquired by Medtronic Inc. (NYSE: MDT). In 1994, Prof. Goldwasser
co-founded Medinol Ltd., in partnership with Boston Scientific (NYSE: BSX). Prof. Goldwasser has served as chairman of the board of directors
of Save Foods, Inc. (OTC: SAFO) since May 2018 and as chairman of the board of directors of ScoutCam Inc. (OTC: SCTC) since March 2019,
and as a member of the board of directors of Innoventric Ltd. since September 2017. Prior to that, Prof. Goldwasser has served as chairman
of the board of directors of Medigus Ltd. (Nasdaq and TASE: MDGS) from September 2018 to December 2019, and as a consultant to Shanghai-Israel
Investment Fund from May 2016 to May 2019. In 2016, Prof. Goldwasser launched a venture capital fund partnered with Shanghai Alliance
Investment Ltd (SAIL), a Shanghai Government investment company. Prof. Goldwasser has also served on the board of directors of BioCanCell
Ltd. (TASE: BICL) from 2013 to 2016. Prof. Goldwasser holds an MD and MBA from Tel Aviv University. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white"><b>Lior
Amit, Director</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white"><i>Mr.
Lior Amit</i> has served on our board of directors since August 1, 2021. Since 2014, Mr. Amit has served as a private financial advisor
for both high net worth individuals and companies and serves as a director in Scoutcam Inc., ICIC, an Israeli credit insurance company,
Nirplex and Ronimar LTD. Mr. Amit was the CFO of the BBR Saatchi &amp; Saatchi advertising group in Israel from 1996 to 2013, helping
to turn it into a leading local advertising company including advertising agencies, media operations and digital and content, growing
from 40 employees to 250 employees. Mr. Amit holds a Master of Business Administration ((Finance and Insurance) and a B.A. in Economics
and Accounting from the Tel Aviv University. Mr. Amit is a Certified Public accountant in Israel and holds an advisor license with the
Israeli Securities Authority.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Limor Rozen, Director
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"><i>Mrs.
Limor Rozen</i> has served on our board of directors since July 16, 2021. Mrs. Rozen has been working a senior consultant at Vecon Ltd.
from 2019. Prior to that, Mrs. Rozen was co-founded and served as a chief executive officer and &#160;general manager of zzoo from 2017
to 2020. From 2012 to 2017, Mrs. Rozen served as a chief operating officer of 365 Technologies Ltd. Mrs. Rozen also served as VP of product
and customer projects of Collarity in Palo Alto, California from 2006 to 2011, served as senior team leader at Right Order</span>, Inc.<span style="background-color: white">,
San Jose, California from 2000 to 2006 and as a team leader at Comverse Technology, Inc between 1999 to 2004. Mrs. Rozen holds an MBA
with specialization in Technology Management from University of Phoenix, Phoenix, Arizona, and a B.A. in Computer Science from Bar-Ilan
University. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tal Parnes, Director </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Tal Parnes</i> <span style="background-color: white">has
served on our board of directors since July 16, 2021 Mr. Parnes co-founded and served as a chief executive officer and president of Zuta-Core
Ltd. from 2016 to 2020. Prior to that, Mr. Parnes co-founded and served as a chief executive officer of HQL Pharmaceuticals Ltd. from
2010 to 2015.&#160; Mr. Parnes also served as chief operating officer of Silynx Communications Inc. from 2007 to 2009, served as a vice
president of operations of Wavion Inc. from 2005 to 2006 and vice president of operations of Atrica Ltd. from 2002 to 2004. Between 1999
to 2001, Mr. Parnes also served as a chief financial officer and business development director of Printlife Ltd. Mr. Parnes holds a B.A.
in Economics and History from Tel Aviv University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Scientific Advisory Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a Scientific Advisory
Board of several active physicians and experts in the fields of: respiratory disease, pulmonary diseases, cardiac disease and laboratory
animal science. The Scientific Advisory Board consults and assists us in the aforementioned fields by conducting clinical research and
participating in pre-clinical studies. The members of our Scientific Advisory Board receive compensation in the form of cash payments
or option grants. All members of the Scientific Advisory Board provided us with their consent to be named in this annual report on Form
20-F and any materials related hereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Dr.
Avraham Abutbul, M.D.,</i> <span style="background-color: white">has held numerous positions at the Hadassah Medical Center in Jerusalem,
Israel, since 2008. Currently, Dr. Abutbul has served a senior physician the Hadassah Medical Center&#8217;s Medical Intensive Care Unit
and its Pulmonology Institute since 2017, in addition to leading the Hadassah Medical Center&#8217;s nationwide research of chronic obstructive
pulmonary disease. Prior to his current roles, Dr. Abutbul completed fellowship at the Institute of Pulmonology in 2016 and the General
Intensive Care Unit in 2014. Dr. Abutbul also completed residency at the Department of Internal Medicine in 2012. Dr. Abutbul is a lecturer
at the Hebrew University of Jerusalem, Israel and at the Hadassah Medical School, Jerusalem, Israel. Dr. Abutbul received his B.Med.Sc.
from the  Ruth and Bruce Rappaport Faculty of Medicine in Haifa, Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Professor
Daniel Brodie</i> is the Section Chief for Critical Care within the Division of Pulmonary, Allergy and Critical Care Medicine, the Director
of the Adult ECMO Program and the Director of the Center for Acute Respiratory Failure at the Columbia University/New York-Presbyterian
Hospital. Prof. Brodie is the President-elect of the Extracorporeal Life Support Organization (ELSO) and the chairman of the Executive
Committee of the International ECMO Network (ECMONet),two leading international organizations spearheading scientific knowledge in the
field of extracorporeal life support. He is currently on the Steering Committee of numerous ongoing and upcoming clinical trials in the
field. In addition, Prof. Brodie serves as a member of the National Heart, Lung, and Blood Institute&#8217;s (NHLBI) Protocol Review Committee
for the Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. Prof. Brodie has served as a reviewer in influential scientific
journals, including the New England Journal of medicine, Lancet and JAMA. Prof Brodie has authored more than 300 peer-reviewed publications
and book chapters and has delivered nearly 400 invited lectures throughout the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Eddy Fan</i> is an
associate professor in the Interdepartmental Division of Critical Care Medicine and the Institute of Health Policy, Management and Evaluation
at the University of Toronto and a staff intensivist at the University Health Network/Mount Sinai Hospital in Toronto, Ontario. Prof.
Fan currently is the medical director of the extracorporeal life support program at the Toronto General Hospital. Dr. Fan received an
undergraduate degree from the University of Toronto, his medical degree from the University of Western Ontario and a doctorate in clinical
investigation from Johns Hopkins University. Among his most significant publications are: (1) &#8220;An Official American Thoracic Society/European
Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients
with Acute Respiratory Distress Syndrome&#8221; in the American Journal of Respiratory and Critical Care Medicine; (2) &#8220;Veno-venous
extracorporeal membrane oxygenation for acute respiratory failure: a clinical review from an international group of experts.&#8221; in
Intensive Care Medicine; and (3) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in
intensive care units in 50 countries&#8221; published in JAMA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Orit Cohen Jacob</i>
is veterinary surgeon with a unique certified specialty in laboratory animal medicine. Dr. Jacob held numerous positions at the Israel
Institute for Biological Research in Ness Ziona, Israel, for 16 years, while leading the establishment of the biggest pre-clinical animal
facility and laboratories in Israel. At the Israel Institute for Biological Research, Dr. Jacob founded a GMP stable facility, for anti-serum
production for the State of Israel. Dr. Jacob participated as a surgeon and advisor, in her field of expertise, in a wide variety of research
studies, related to homeland security from 1999 to 2015. Dr. Jacob was a member of the national animal experimentation council of the
ministry of health, and head of the national ethics committee for animal experimentations from 2013 to 2018. Currently, Dr. Jacob is the
co-owner and chief executive officer of SeruMed GMP Ltd., which has been the sole manufacturer and provider of the anti-venom serum against
viper and echis snakes to the Ministry of Health of Israel since 2016. Furthermore, Dr. Jacob is the owner of BioSphera Consulting Ltd.,
through which she has been providing knowledge to bio-tech companies in all aspects of pre-clinical research, facility establishment,
GMP regulations, ethics and science since 2016.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Yigal Kassif</i> is
a cardiac surgeon at the <span style="background-color: white">Chaim Sheba Medical Center at Tel HaShomer </span>in Ramat Gan, Israel.
Dr. Kassif has been a senior surgeon since 1995, specializing in adult cardiac surgery, heart Transplantation and assist devices. Dr.
Kassif has been serving as the director of the ECMO program in the <span style="background-color: white">Chaim Sheba Medical Center at
Tel HaShomer</span> since 2019, and in September 2019, he was appointed the first chairman of the Israel ECMO Society. In 2008, Dr. Kassif
was one of the entrepreneurs of Leviticus Cardio Ltd., a start-up company that developed wireless technology for Left Ventricular Assist
Device. From 2018 to 2020, Dr. Kassif served as a consultant in Serenno Medical, a start-up company that developed electronic urine output
and abdominal pressure measurement for the purpose of &#8220;no touch technique&#8221; in the ICU environment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Stefan Ledot</i> is
an expert in various clinical fields including critical care medicine, anesthesia, extracorporeal support and echocardiography. During
his career, he has undertaken a large number of educational duties, including advanced cardiovascular life support (ACLS) instruction,
critical care module for physiotherapists instruction, critical care module nursing school instruction, among others. Dr. Ledot is a highly
appreciated speaker in the critical care space. Dr. Ledot completed his accreditation for transesophageal echocardiography (TOE) from
the European Association of Cardiovascular Imaging and holds a European Diploma in Intensive Care. Dr. Ledot has served as a senior clinician
in critical care and anesthetics at&#160;Royal Brompton &amp; Harefield Hospitals in the United Kingdom and became the director of the
extracorporeal membrane oxygenation (ECMO) service and critical care. The Royal Brompton ECMO service is one of the largest in Europe
and has been recognized as a center of excellence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Yael Lichter </i>is
Director of the Medical Intensive Care Unit at Tel Aviv Sourasky Medical Center, where she completed her residency training in Internal
Medicine and Intensive Care. She also serves as Treasurer of the Israeli ECMO Society. Dr. Lichter served as a Captain in the IDF Medical
Corps, as a field doctor in combat units. She completed her medical training at the Tel Aviv University the Sackler Faculty of Medicine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Sharon Marx</i> obtained
a PhD in physical organic chemistry from the Hebrew University, Jerusalem in 1996. Since 1996, Dr. Marx has worked at the Israel Institute
for Biological Research in the physical chemistry department. Dr. Marx was a fellow at the Israel Institute for Biological Researchand
is currently serving as the physical chemistry department head. From 2008 to 2010, Dr. Marx was an Assistant Professor (on sabbatical)
at the University of Pennsylvania and developed biocompatible fuel cells while there. Her research interests include: sensor and biosensors
development, chemical sensor networks, molecularly imprinted polymers, chemiresistors, sensors for gas phase (air pollution, toxic materials)
and sensors for water quality.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Dekel Stavi </i>has
considerable experience in leading Extracorporeal Life Support programs, and treating cardio and hemato-oncology patients in the ICU.
Prior to joining Critical Care at the University of Toronto, he served as a senior intensive care physician at the Tel Aviv Sourasky Medical
Center in Israel where he initiated its institutional extracorporeal membrane oxygenation (ECMO) program. Dr. Stavi&#8217;s notable publications
include &#8220;Outcomes of prolonged mechanical ventilation in patients who underwent bedside percutaneous dilatation tracheostomy in
intermediate care units &#8211; a single center study&#8221; and &#8220;Outcome and survival following tracheostomy in patients &#8805; 85
years old.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Family Relationships</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
between any members of our executive management and our directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Arrangements for
Election of Directors and Members of Management</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our executive management
or our directors were selected. See &#8220;Item 7.B. - Related Party Transactions&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_035"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
all compensation paid by us to our five most highly compensated officers for the year ended December&#160;31, 2022. The table does not
include any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All amounts reported in the tables below reflect the cost to the Company,
in  U.S. Dollars, for the year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Amounts paid in NIS are translated into U.S. dollars at the rate of NIS 3.36 = U.S. $1.00, based on the average representative
rate of exchange between the NIS and the U.S. dollar as reported by the Bank of Israel during such period of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Salary,<br/>
 bonuses<br/> and</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Related</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Benefits</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pension,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Retirement</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>and Other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Similar</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Benefits</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share<br/> Based<br/> Compensation<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Non, <i>Chief Executive Officer</i></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">369,425</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">828,825</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hayon, <i>President and Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">384,099</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">828,825</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yafit Tehila, <i>Chief Financial Officer</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">265,044</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">231,309</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi Shabtai, <i>Chief Operations Officer and VP of Research and Development</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">310,421</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">844,090</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Daniella Yeheskely-Hayon, Phd, Chief Technology Officer</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">237,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">135,962</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For so long as we qualify
as a foreign private issuer, we will not be required to comply with the proxy rules applicable to U.S. domestic companies regarding disclosure
of the compensation of certain executive officers on an individual basis. Pursuant to the Companies Law, as a public company we are required
to disclose the annual compensation of our five most highly compensated officers on an individual basis. This disclosure will not be as
extensive as that required of a U.S. domestic issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Employment Agreements
with Executive Officers </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into written
employment agreements with each of our executive officers. All of these agreements contain customary provisions regarding noncompetition,
confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited
under applicable law. In addition, we entered into indemnification agreements, with each executive officer and director pursuant to which
we indemnify each of them up to a certain amount and to the extent that these liabilities are not covered by directors and officers insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
a description of the terms of our options and option plans, see &#8220;Item 6.E. Share Ownership&#8212;Equity Incentive Plan.<span style="font-variant: small-caps">&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_036"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Practices. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Introduction</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors consists
of six members. We believe that Professor Benad Goldwasser, Limor Rozen, Lior Amit, and Tal Parnes are &#8220;independent&#8221; for purposes
of the Nasdaq Stock Market rules. Our amended and restated articles of association provide that the number of board of directors&#8217;
members shall be set by the general meeting of the shareholders provided that it will consist of not less than three and not more than
twelve. Pursuant to the Companies Law, the management of our business is vested in our board of directors. Our board of directors may
exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers
are responsible for our day-to-day management and have individual responsibilities established by our board of directors. Pursuant to
the Companies Law, our Chief Executive Officer is appointed by, and serves at the discretion of, our board of directors, subject to the
employment agreement that we have entered into with him. All other executive officers are appointed by our Chief Executive Officer. Their
terms of employment are subject to the approval of the board of directors&#8217; compensation committee and of the board of directors,
and are subject to the terms of any applicable employment agreements that we may enter into with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each director, except external
directors that may be required to be appointed under the Companies Law under certain circumstances, will hold office until the next annual
general meeting of our shareholders following his or her appointment, or until he or she resigns or unless he or she is removed by a majority
vote of our shareholders at a general meeting of our shareholders or upon the occurrence of certain events, in accordance with the Companies
Law and our amended and restated articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under certain
circumstances, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on
our board of directors or in addition to the acting directors (subject to the limitation on the number of directors), until the next annual
general meeting or special general meeting in which directors term may be terminated. External directors may be elected for up to two
additional three-year terms after their initial three-year term under the circumstances described below, with certain exceptions as described
in &#8220;External Directors&#8221; below. External directors may be removed from office only under the limited circumstances set forth
in the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, any
shareholder holding at least one percent of our outstanding voting power may suggest nominating a director in an Annual General Meeting
of the shareholders. However, any such shareholder may make such a suggestion only if a written notice of such shareholder&#8217;s intent
to make such nomination has been given to our board of directors. Any such notice must include certain information, including the consent
of the proposed director nominee to serve as our director if elected, and a declaration that the nominee signed declaring that he or she
possesses the requisite skills and has the availability to carry out his or her duties. Additionally, the nominee must provide details
of such skills, and demonstrate an absence of any limitation under the Companies Law that may prevent his or her election, and affirm
that all of the required election-information is provided to us, pursuant to the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
board of directors must determine the minimum number of directors who are required to have accounting and financial expertise. In determining
the number of directors required to have such expertise, our board of directors must consider, among other things, the type and size of
the company and the scope and complexity of its operations. Our board of directors has determined that the minimum number of directors
of our company who are required to have accounting and financial expertise is one.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors must
elect one director to serve as the chairman of the board of directors to preside at the meetings of the board of directors, and may also
remove that director as chairman. Pursuant to the Companies Law, neither the chief executive officer nor any of his or her relatives is
permitted to serve as the chairman of the board of directors, and a company may not vest the chairman or any of his or her relatives with
the chief executive officer&#8217;s authorities. In addition, a person who reports, directly or indirectly, to the chief executive officer
may not serve as the chairman of the board of directors; the chairman may not be vested with authorities of a person who reports, directly
or indirectly, to the chief executive officer; and the chairman may not serve in any other position in the company or a controlled company,
but he or she may serve as a director or chairman of a controlled company. However, the Companies Law permits a company&#8217;s shareholders
to determine, for a period not exceeding three years from each such determination, that the chairman or his or her relative may serve
as chief executive officer or be vested with the chief executive officer&#8217;s authorities, and that the chief executive officer or
his or her relative may serve as chairman or be vested with the chairman&#8217;s authorities. Such determination of a company&#8217;s
shareholders requires either: (1) the approval of at least a majority of the shares of those shareholders present and voting on the matter
(other than controlling shareholders and those having a personal interest in the determination) (shares held by abstaining shareholders
shall not be considered); or (2) that the total number of shares opposing such determination does not exceed 2% of the total voting power
in the company. Currently, we have a separate chairman and chief executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors may,
subject to the provisions of the Companies Law, delegate some of its powers to committees of the board, and it may, from time to time,
revoke such delegation or alter the composition of any such committees, subject to certain limitations. Unless otherwise expressly provided
by the board of directors, the committees shall not be empowered to further delegate such powers. The composition and duties of our audit
committee, financial statement examination committee and compensation committee are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors oversees
how management monitors compliance with our risk management policies and procedures, and reviews the adequacy of the risk management framework
in relation to the risks faced by us. The board of directors is assisted in its oversight role by an internal auditor. The internal auditor
undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to our audit
committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>External Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Companies Law, except as provided below, companies incorporated under the laws of the State of Israel that are publicly traded, including
Israeli companies with shares listed on the Nasdaq, are required to appoint at least two external directors who meet the qualification
requirements set forth in the Companies Law. The definitions of an external director under the Companies Law and independent director
under Nasdaq Stock Market rules are similar such that it would generally be expected that our two external directors will also comply
with the independence requirement under Nasdaq Stock Market rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to regulations under the Companies Law, the board of directors of a company such as us is not required to have external directors if:
(i) the company does not have a controlling shareholder (as such term is defined in the Companies Law); (ii) a majority of the directors
serving on the board of directors are &#8220;independent,&#8221; as defined under Nasdaq Rule 5605(a)(2); and (iii) the company follows
Nasdaq Rule 5605(e)(1), which requires that the nomination of directors be made, or recommended to the board of directors, by a Nominating
Committee of the board of directors consisting solely of independent directors, or by a majority of independent directors. The Company
meets all these requirements. Our board of directors has resolved to adopt the corporate governance exemption set forth above, and accordingly
we will not have external directors as members of our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Alternate Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
amended and restated articles of association provide, as allowed by the Companies Law, that any director may, subject to the conditions
set thereto including approval of the nominee by our board of directors, appoint a person as an alternate to act in his place, to remove
the alternate and appoint another in his place and to appoint an alternate in place of an alternate whose office is vacated for any reason
whatsoever. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who is already serving as a
director or a person who is already serving as an alternate director for another director, may not be appointed as an alternate director.
Nevertheless, a director who is already serving as a director may be appointed as an alternate director for a member of a committee of
the board of directors so long as he or she is not already serving as a member of such committee, and if the alternate director is to
replace an external director, he or she is required to be an external director and to have either &#8220;financial and accounting expertise&#8221;
or &#8220;professional expertise,&#8221; depending on the qualifications of the external director he or she is replacing. A person who
does not have the requisite &#8220;financial and accounting experience&#8221; or the &#8220;professional expertise,&#8221; depending on
the qualifications of the external director he or she is replacing, may not be appointed as an alternate director for an external director.
A person who is not qualified to be appointed as an independent director, pursuant to the Companies Law, may not be appointed as an alternate
director of an independent director qualified as such under the Companies Law. Unless the appointing director limits the time or scope
of the appointment, the appointment is effective for all purposes until the appointing director ceases to be a director or terminates
the appointment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
established two standing committees, the audit committee and the compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must establish an audit committee. The audit committee must be comprised of at least three directors,
including all of the external directors, if applicable, (one of whom must serve as chair of the committee). The audit committee may not
include the chairman of the board; a director employed by the company or by a controlling shareholder of the company or by an entity controlled
by a controlling shareholder; a controlling shareholder or a relative of a controlling shareholder; a director employed by or providing
services on a regular basis to the company, to a controlling shareholder or to an entity controlled by a controlling shareholder, or a
director who derives most of his or her income from a controlling shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee is comprised
of&#160;Lior Amit, Limor Rozen and Tal Parnes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
audit committee is responsible for, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether there are deficiencies in the business management practices of our company, and making recommendations to the board of directors to improve such practices; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under Companies Law) and establishing the approval process for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; (see &#8220;Item 6.C. Directors, Senior Management and Employees&#8212;Board Practices&#8212;Approval of Related Party Transactions under Israeli law&#8221;); </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining the approval process for transactions that are &#8220;non-negligible&#8221; (i.e., transactions with a controlling shareholder that are classified by the audit committee as non-negligible, even though they are not deemed extraordinary transactions), as well as determining which types of transactions would require the approval of the audit committee, optionally based on criteria which may be determined annually in advance by the audit committee;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining our internal controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment of our auditor;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for the handling of employees&#8217; complaints as to deficiencies in the management of our business and the protection to be provided to such employees; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments thereto.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee may not
conduct any discussions or approve any actions requiring its approval (see &#8220;Item 6.C. Directors, Senior Management and Employees&#8212;Board
Practices&#8212;Approval of Related Party Transactions under Israeli law&#8221;); &#8220;), unless at the time of the approval a majority
of the committee&#8217;s members are present.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
adopted an audit committee charter setting forth, among others, the responsibilities of the audit committee consistent with the rules
of the SEC and Nasdaq Listing Rules (in addition to the requirements for such committee under the Companies Law), including, among others,
the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in accordance with Israeli law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the engagement or termination of the person filling the office of our internal auditor, reviewing the services provided by our internal auditor and reviewing effectiveness of our system of internal control over financial reporting;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and monitoring, if applicable, legal matters with significant impact, finding of regulatory authorities&#8217; findings, receive reports regarding irregularities and legal compliance, acting according to &#8220;whistleblower policy&#8221; and recommend to our board of directors if so required.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq Stock Market Requirements for Audit
Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Nasdaq Stock Market
rules, we are required to maintain an audit committee consisting of at least three members, all of whom are independent and are financially
literate and one of whom has accounting or related financial management expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the members of our audit committee include Lior Amit,
Tal Parnes and Limor Rozen. Mr. Amit serves as the chairman of our audit committee. All members of our audit committee meet the requirements
for financial literacy under the Nasdaq Stock Market rules. Our board of directors has determined that each member of our audit committee
is an audit committee financial expert as defined by the SEC rules and has the requisite financial experience as defined by the Nasdaq
Stock Market rules.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
audit committee also carries out the duties of a financial statement examination committee. As such, the audit committee is responsible
for: (i) estimations and assessments made in connection with the preparation of financial statements; (ii) internal controls related to
the financial statements; (iii) completeness and propriety of the disclosure in the financial statements; (iv) the accounting policies
adopted and the accounting treatments implemented in material matters of the company; and (v) value evaluations, including the assumptions
and assessments on which evaluations are based and the supporting data in the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must establish a compensation committee. The compensation committee must be comprised of at least
three directors, including all of the external directors (if any). The compensation committee is subject to the same Companies Law restrictions
as the audit committee as to: (a) who may not be a member of the committee; and (b)&#160;who may not be present during committee deliberations
as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee,
acting pursuant to a written charter, consists of Lior Amit, Limor Rozen and Tal Parnes. Tal Parnes serves as the chairman of our compensation
committee. Our compensation committee complies with the provisions of the Companies Law, the regulations promulgated thereunder, and our
amended and restated articles of association, on all aspects referring to its independence, authorities and practice. Our compensation
committee follows home country practice as opposed to complying with the compensation committee membership and charter requirements prescribed
under the Nasdaq Stock Market rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
reviews and recommends to our board of directors: with respect to our executive officers&#8217; and directors&#8217;: (1) annual base
compensation; (2) annual incentive bonus, including the specific goals and amounts; (3) equity compensation; (4) employment agreements,
severance arrangements, and change in control agreements and provisions; (5) retirement grants and/or retirement bonuses; and (6) any
other benefits, compensation, compensation policies or arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duties of the compensation
committee include the recommendation to the company&#8217;s board of directors of a policy regarding the terms of engagement of office
holders, to which we refer as a compensation policy. Every three years (or following five years from its initial public offering), such
policy must be adopted by the company&#8217;s board of directors, after considering the recommendations of the compensation committee.
The compensation policy is then brought for approval by our shareholders, which requires a special majority (see &#8220;Item 6.C. Directors,
Senior Management and Employees&#8212;Board Practices&#8212;Approval of Related Party Transactions under Israeli law&#8221;). Under the
Companies Law, the board of directors may adopt the compensation policy if it is not approved by the shareholders, provided that after
the shareholders oppose the approval of such policy, the compensation committee and the board of directors revisit the matter and determine
that adopting the compensation policy is in our best interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 17, 2021, a general
meeting of our shareholders approved the adoption of a compensation policy for our officers and directors for a period of five years,
or the compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy serves
as the basis for decisions concerning the financial terms of employment or engagement of executive officers and directors, including exculpation,
insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy
relates to certain factors, including advancement of our objectives, our business and long-term strategy and creation of appropriate incentives
for executives. It also considers, among other things, our risk management, size and the nature of our operations. The compensation policy
further considers the following additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the education, skills, expertise and accomplishments of the relevant director or executive;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the director&#8217;s or executive&#8217;s roles and responsibilities and prior compensation agreements with him or her;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between the cost of the terms of service of an office holder and the average median compensation of the other employees of the company (including those employed through manpower companies), including the impact of disparities in salary upon work relationships in our company;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility of reducing variable compensation at the discretion of the board of directors; and the possibility of setting a limit on the exercise value of non-cash variable compensation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as to severance compensation, the period of service of the director or executive, the terms of his or her compensation during such service period, our performance during that period of service, the person&#8217;s contribution towards the achievement of our goals and the maximization of our profits, and the circumstances under which the person is leaving the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy also
includes the following principles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with the exception of office holders who report directly to the chief executive officer, the link between variable compensation and long-term performance and measurable criteria;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation at the time of its grant;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conditions under which a director or executive are required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company&#8217;s financial statements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum holding or vesting period for variable, equity-based compensation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum limits for severance compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy also
considers appropriate incentives from a long-term perspective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee
is responsible for: (1) recommending the compensation policy to a company&#8217;s board of directors for its approval (and subsequent
approval by the shareholders); and (2) duties related to the compensation policy and to the compensation of a company&#8217;s office holders,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the board of directors periodic updates to the compensation policy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing implementation of the compensation policy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether the terms of compensation of certain office holders need not be brought to approval of the shareholders; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve the terms of compensation of office holders that require the committee&#8217;s approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation policy is
designed to promote our long-term goals, work plan and policy, retain, motivate and incentivize our directors and executive officers,
while considering the risks that our activities involve, our size, the nature and scope of our activities and the contribution of an officer
to the achievement of our goals and maximization of profits, and align the interests of our directors and executive officers with our
long-term performance. To that end, a portion of an executive officer compensation package is targeted to reflect our short and long-term
goals, as well as the executive officer&#8217;s individual performance. On the other hand, our compensation policy includes measures designed
to reduce the executive officer&#8217;s incentives to take excessive risks that may harm us in the long-term, such as limits on the value
of cash bonuses and equity-based compensation, limitations on the ratio between the variable and the total compensation of an executive
officer and minimum vesting periods for equity-based compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation policy also
addresses our executive officer&#8217;s individual characteristics (such as his or her respective position, education, scope of responsibilities
and contribution to the attainment of our goals) as the basis for compensation variation among our executive officers, and considers the
internal ratios between compensation of our executive officers and directors and other employees. For example, the compensation that may
be granted to an executive officer may include: base salary, annual bonuses, equity-based compensation, benefits and retirement and termination
of service arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer&#8217;s base salary. In addition,
our compensation policy provides for maximum permitted ratios between the total variable (cash bonuses and equity-based compensation)
and non-variable (base salary) compensation components, in accordance with an officer&#8217;s respective position with the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An annual cash bonus may be
awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may
be granted to subordinate officeholders may be based entirely on a discretionary evaluation. Our Chief Executive Officer will be entitled
to recommend performance objectives to such executive officers, and such performance objectives will be approved by our compensation committee
(and, if required by law, by our board of directors).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The performance measurable
objectives of our chairman and Chief Executive Officer is determined annually by our compensation committee and board of directors. A
less significant portion of the chairman&#8217;s and/or the Chief Executive Officer&#8217;s annual cash bonus may be based on a discretionary
evaluation of the chairman&#8217;s or the Chief Executive Officer&#8217;s respective overall performance by the compensation committee
and the board of directors based on quantitative and qualitative criteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The equity-based compensation
under our compensation policy for our executive officers (including members of our board of directors) is designed in a manner consistent
with the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives being to enhance the
alignment between the executive officers&#8217; interests with our long-term interests and those of our shareholders and to strengthen
the retention and the motivation of executive officers in the long term. Our compensation policy provides for executive officer compensation
in the form of share options or other equity-based awards, such as restricted shares and phantom, options, in accordance with our equity
incentive plan then in place. Share options granted to executive officers are subject to vesting periods in order to promote long-term
retention of the awarded executive officers. The equity-based compensation is granted from time to time and be individually determined
and awarded according to the performance, educational background, prior business experience, qualifications, role and the personal responsibilities
of the executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our compensation
policy contains compensation recovery provisions which allows us under certain conditions to recover bonuses paid in excess, enables our
Chief Executive Officer to approve an immaterial change in the terms of employment of an executive officer (provided that the changes
of the terms of employment are in accordance our compensation policy) and allows us to exculpate, indemnify and insure our executive officers
and directors subject to certain limitations set forth thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation policy also
provides for compensation to the members of our board of directors either: (i) in accordance with the amounts provided in the Companies
Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief
for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be amended from time to time; or (ii)
in accordance with the amounts determined in our compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Internal Auditor </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of an Israeli public company must appoint an internal auditor nominated by the audit committee. Our internal auditor
Chaim Yechezkely, CPA (Isr) who has been serving as our internal auditor since October 2021, is a Certified Public Accountant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of the internal auditor
is to examine, among other things, whether a company&#8217;s actions comply with the law and proper business procedure. The audit committee
is required to oversee the activities, and to assess the performance of the internal auditor as well as to review the internal auditor&#8217;s
work plan. An internal auditor may not be an interested party or office holder, or a relative of any interested party or office holder,
and may not be a member of the company&#8217;s independent accounting firm or its representative. The Companies Law defines an interested
party as a holder of 5% or more of the outstanding shares or voting rights of a company, any person or entity that has the right to appoint
at least one director or the general manager of the company or any person who serves as a director or as the general manager of a company.
Our internal auditor is not an interested party in the Company and not our employee, but partner of a firm which specializes in internal
auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Remuneration of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, remuneration
of directors is subject to the approval of the compensation committee, thereafter by the board of directors and thereafter, unless exempted
under the regulations promulgated under the Companies Law, by the general meeting of the shareholders. In case the remuneration of the
directors is in accordance with regulations applicable to remuneration of the external directors then such remuneration shall be exempt
from the approval of the general meeting. Where the director is also a controlling shareholder, the requirements for approval of transactions
with controlling shareholders apply. In our 2021 general meeting of shareholders, we instituted a yearly fixed fee in the amount of $40,000
for all of our directors other than the chairman and the directors who are not also officeholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fiduciary Duties of Office Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
a duty of care and a duty of loyalty on all office holders of a company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of care requires
an office holder to act with the level of care with which a reasonable office holder in the same position would have acted under the same
circumstances. The duty of care of an office holder includes a duty to use reasonable means to obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information on the profitability of a given action brought for his approval or performed by him by virtue of his position; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all other important information pertaining to these actions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of loyalty of an
office holder requires an office holder to act in good faith and for the benefit of the company, and includes a duty to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any conflict of interest between the performance of his duties in the company and his performance of his other duties or personal affairs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any action that is competitive with the company&#8217;s business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or others; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder has received due to his position as an office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Insurance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
company may obtain insurance for any of its office holders against the following liabilities incurred due to acts he or she performed
as an office holder, if and to the extent provided for in the company&#8217;s articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach of his or her duty of care to the company or to another person, to the extent such a breach arises out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of his or her duty of loyalty to the company, provided that the office holder acted in good faith and had reasonable cause to assume that his or her act would not prejudice the company&#8217;s interests; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed upon him or her in favor of another person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have directors&#8217;
and officers&#8217; liability insurance, providing total coverage of $5 million for the benefit of the Company and all of our directors
and officers, in respect of which we paid a twelve-month premium of approximately $387,500, which expires in July 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Indemnification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law and the
Israeli Securities Law, 5728-1968, or the Securities Law, provide that a company may indemnify an office holder against the following
liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance
of an event or following an event, provided its articles of association include a provision authorizing such indemnification:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed on him or her in favor of another person by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement or arbitrator&#8217;s award approved by a court;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, expended by the office holder (a) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (1) no indictment (as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (2) no financial liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; or (b) in connection with a monetary sanction; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, expended by the office holder or imposed on him or her by a court: (1) in proceedings that the company institutes, or that another person institutes on the company&#8217;s behalf, against him or her; (2) in a criminal proceeding of which he or she was acquitted; or (3) as a result of a conviction for a crime that does not require proof of criminal intent; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees. An &#8220;Administrative Procedure&#8221; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law also permits
a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates to financial liability
imposed on him or her, as described above, then the undertaking should be limited and shall detail the following foreseen events and amount
or criterion:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to events that in the opinion of the board of directors can be foreseen based on the company&#8217;s activities at the time that the undertaking to indemnify is made; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into indemnification
agreements with all of our directors and with all members of our senior management. Each such indemnification agreement provides the office
holder with indemnification permitted under applicable law and up to a certain amount, and to the extent that these liabilities are not
covered by directors and officers insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exculpation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, an
Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but may exculpate in advance
an office holder from his or her liability to the company, in whole or in part, for damages caused to the company as a result of a breach
of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exculpation is included
in its articles of association. Our amended and restated articles of association provide that we may exculpate, in whole or in part, any
office holder from liability to us for damages caused to the company as a result of a breach of his or her duty of care, but prohibit
an exculpation from liability arising from a company&#8217;s transaction in which our controlling shareholder or officer has a personal
interest. Subject to the aforesaid limitations, under the indemnification agreements, we exculpate and release our office holders from
any and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Limitations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law provides
that we may not exculpate or indemnify an office holder nor enter into an insurance contract that would provide coverage for any liability
incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless (in the case of indemnity
or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable basis to believe that the act would
not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out intentionally or recklessly
(as opposed to merely negligently); (3) any act or omission committed with the intent to derive an illegal personal benefit; or (4) any
fine, monetary sanction, penalty or forfeit levied against the office holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, exculpation,
indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors
and, with respect to certain office holders or under certain circumstances, also by the shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association permit us to exculpate (subject to the aforesaid limitation), indemnify and insure our office holders to the fullest extent
permitted or to be permitted by the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing descriptions
summarize the material aspects and practices of our board of directors. For additional details, we also refer you to the full text of
the Companies Law, as well as of our amended and restated articles of association, which is an exhibit to this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no service contracts
between us or our Subsidiary, on the one hand, and our directors in their capacity as directors, on the other hand, providing for benefits
upon termination of service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Approval of Related Party Transactions under
Israeli Law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Companies Law, we may approve an action by an office holder from which the office holder would otherwise have to refrain, as described
above, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder acts in good faith and the act or its approval does not cause harm to the company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder disclosed the nature of his or her interest in the transaction (including any significant fact or document) to the company at a reasonable time before the company&#8217;s approval of such matter.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of an Office
Holder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Companies Law requires that an office holder disclose to the company, promptly, and, in any event, not later than the board meeting at
which the transaction is first discussed, any direct or indirect personal interest that he or she may have and all related material information
known to him or her relating to any existing or proposed transaction by the company. If the transaction is an extraordinary transaction,
the office holder must also disclose any personal interest held by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder&#8217;s relatives; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any corporation in which the office holder or his or her relatives holds 5% or more of the shares or voting rights, serves as a director or general manager or has the right to appoint at least one director or the general manager.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">An
office holder is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative
in a transaction that is not considered an extraordinary transaction. Under the Companies Law, an extraordinary transaction is a transaction:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not in the ordinary course of business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not on market terms; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that is likely to have a material effect on the company&#8217;s profitability, assets or liabilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Companies Law does not specify to whom within us nor the manner in which required disclosures are to be made. We require our office holders
to make such disclosures to our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Companies Law, once an office holder complies with the above disclosure requirement, the board of directors may approve a transaction
between the company and an office holder, or a third party in which an office holder has a personal interest, unless the articles of association
provide otherwise and provided that the transaction is in the company&#8217;s interest. If the transaction is an extraordinary transaction
in which an office holder has a personal interest, first the audit committee and then the board of directors, in that order, must approve
the transaction. Under specific circumstances, shareholder approval may also be required. Generally, a person who has a personal interest
in a matter which is considered at a meeting of the board of directors or the audit committee may not be present at such a meeting unless
the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present in order to present
the transaction that is subject to approval. A director who has a personal interest in a transaction, which is considered at a meeting
of the board of directors or the audit committee, may not be present at this meeting or vote on this matter, unless a majority of members
of the board of directors or the audit committee, as the case may be, has a personal interest. If a majority of the board of directors
has a personal interest, then shareholder approval is generally also required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of a Controlling
Shareholder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Companies Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public company.
Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private
placement in which a controlling shareholder has a personal interest, as well as transactions for the provision of services whether directly
or indirectly by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions
concerning the terms of engagement and compensation of a controlling shareholder or a controlling shareholder&#8217;s relative, whether
as an office holder or an employee, require the approval of the audit committee or the compensation committee, as the case may be, the
board of directors and a majority of the shares voted by the shareholders of the company participating and voting on the matter in a shareholders&#8217;
meeting. In addition, the shareholder approval must fulfill one of the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any extraordinary
transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three
years requires the aforementioned approval every three years; however, such transactions can be approved for a longer term, provided that
the audit committee determines that such longer term is reasonable under the circumstances. In addition, under Companies Law regulations,
subject to certain terms, such transactions can be extended or approved after three years only by the audit committee and the board of
directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Companies Law requires that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction
with a controlling shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the
vote in question. Failure to so indicate will result in the invalidation of that shareholder&#8217;s vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
term &#8220;controlling shareholder&#8221; is defined in the Companies Law as a shareholder with the ability to direct the activities
of the company, other than by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder
holds 50% or more of the voting rights in a company or has the right to appoint 50% or more of the directors of the company or its general
manager. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder
who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company.
For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Approval of the Compensation of Directors and
Executive Officers</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation of, or an
undertaking to indemnify, insure or exculpate, an office holder who is not a director requires the approval of our compensation committee,
followed by the approval of the company&#8217;s board of directors, and, if such compensation arrangement or an undertaking to indemnify,
insure or exculpate is inconsistent with our compensation policy, or if the said office holder is the chief executive officer of the company
(subject to a number of specific exceptions), then such arrangement is subject to the approval of our shareholders, subject to a special
majority requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Directors</i>. Under the
Companies Law, the compensation of our directors requires the approval of our compensation committee, the subsequent approval of the board
of directors and, unless exempted under the regulations promulgated under the Companies Law, the approval of the general meeting of our
shareholders. If the compensation of our directors is inconsistent with our stated compensation policy, then, provided that those provisions
that must be included in the compensation policy according to the Companies Law have been considered by the compensation committee and
board of directors, shareholder approval by a special majority will be required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Executive officers other
than the chief executive officer.</i>&#160;The Companies Law requires the approval of the compensation of a public company&#8217;s executive
officers (other than the chief executive officer) in the following order: (i) the compensation committee, (ii) the company&#8217;s board
of directors, and (iii) only if such compensation arrangement is inconsistent with the company&#8217;s stated compensation policy, the
company&#8217;s shareholders by a special majority. However, if the shareholders of the company do not approve a compensation arrangement
with an executive officer that is inconsistent with the company&#8217;s stated compensation policy, the compensation committee and board
of directors may override the shareholders&#8217; decision if each of the compensation committee and the board of directors provide detailed
reasons for their decision.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Chief executive officer.</i>&#160;Under
the Companies Law, the compensation of a public company&#8217;s chief executive officer is required to be approved by: (i) the company&#8217;s
compensation committee; (ii) the company&#8217;s board of directors, and (iii) the company&#8217;s shareholders by a special majority.
However, if the shareholders of the company do not approve the compensation arrangement with the chief executive officer, the compensation
committee and board of directors may override the shareholders&#8217; decision if each of the compensation committee and the board of
directors provides detailed reasons for their decision. In addition, the compensation committee may exempt the engagement terms of a candidate
to serve as the chief executive officer from shareholders&#8217; approval, if the compensation committee determines that the compensation
arrangement is consistent with the company&#8217;s stated compensation policy, that the chief executive officer did not have a prior business
relationship or affiliation with the company or a controlling shareholder of the company, and that subjecting the approval to a shareholder
vote would impede the company&#8217;s ability to attain the candidate to serve as the company&#8217;s chief executive officer (and provide
detailed reasons for the latter).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval of each of the
compensation committee and the board of directors, with regard to the office holders and directors above, should be in accordance with
the company&#8217;s stated compensation policy; however, under special circumstances, the compensation committee and the board of directors
may approve compensation terms of a chief executive officer that are inconsistent with the company&#8217;s compensation policy provided
that they have considered those provisions that must be included in the compensation policy according to the Companies Law and that shareholder
approval was obtained by a special majority requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Duties of Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Companies Law, a shareholder has a duty to refrain from abusing his power in the company and to act in good faith and in an acceptable
manner in exercising his rights and performing his obligations toward the company and other shareholders, including, among other things,
in voting at general meetings of shareholders (and at shareholder class meetings) on the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendment of the articles of association;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase in the company&#8217;s authorized share capital;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">merger; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of related party transactions and acts of office holders that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
shareholder also has a general duty to refrain from oppressing other shareholders. The remedies generally available upon a breach of contract
will also apply to a breach of the above-mentioned duties, and in the event of oppression of other shareholders, additional remedies are
available to the injured shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, any controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any
shareholder that, under a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder,
or has another power with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not describe
the substance of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event
of a breach of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_037"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 31, 2020, we had
seven full-time employees and two part-time employees. On December 31, 2021, we had twenty-three full-time employees and three part-time
employees. On December 31, 2022, we had thirty-two full time employees and five part time employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of&#160;December 31, 2022,
we had five members of senior management (including our Chief Executive Officer), who are full-time employees of the Company. In addition,
we had twenty-seven full-time employees, five part-time and three additional independent contractor consultants located in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our employees located
in Israel are represented by labor unions or covered by collective bargaining agreements. However, in Israel, we are subject to certain
Israeli labor laws, regulations and national labor court precedent rulings, as well as certain provisions of collective bargaining agreements
applicable to us by virtue of extension orders issued in accordance with relevant labor laws by the Israeli and Industry of Economy and
which apply such agreement provisions to our employees even though they are not part of a union that has signed a collective bargaining
agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our employment and
consulting agreements include employees&#8217; and consultants&#8217; undertakings with respect to non-competition and assignment to us
of intellectual property rights developed in the course of employment and confidentiality. The enforceability of such provisions is limited
by Israeli law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><div><a id="a_038"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share Ownership. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 7.A. Major
Shareholders&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Incentive Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Our
2019 Equity Incentive Plan, or the 2019 Plan, was adopted by our board of directors on December 2019 (although no options were granted
until April 20, 2020) and amended on September 14, 2021. The 2019 Plan provides for the grant of options to our directors, employees,
officers, consultants and service providers who are our employees, officers, directors or consultants, as well as those of our affiliated
companies. In September 2021, our board of directors approved an amendment to the 2019 Plan to provide for the grant of restricted share
units, or &#8220;RSUs.&#8221; As of March 28, 2023, the total number of Ordinary Shares reserved for the exercise of options under our
2019 Plan was 4,180,898. The shares subject to our 2019 Plan may be either authorized but unissued Ordinary Shares or reacquired Ordinary
Shares, subject to applicable laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
<span style="background-color: white">2019 Plan</span> is administered by the committee, consisting of our board of directors, regarding
the granting of options and the terms of option grants, including exercise price, method of payment, vesting schedule, acceleration of
vesting and the other matters necessary in the administration of this plan. Eligible employees, officers and directors, as well as those
of our affiliated companies, would qualify for provisions of Section 102 of the Israeli Income Tax Ordinance of 1961 (New Version), or
the Tax Ordinance. Section&#160;102 of the Tax Ordinance allows employees, directors and officers who are not controlling shareholders
and are considered Israeli residents to receive favorable tax treatment for compensation in the form of shares or options. Section&#160;102
includes two alternatives for tax treatment involving the issuance of options or shares to a trustee for the benefit of the grantees and
also includes an additional alternative for the issuance of options or shares directly to the grantee. Section&#160;102(b)(2) of the Ordinance,
the most favorable tax treatment for the grantee, permits the issuance to a trustee under the &#8220;capital gain track.&#8221; However,
under this track we are not allowed to deduct an expense with respect to the issuance of the options or shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
consultants and those of our affiliated companies and our employees, directors and/or officers and those of our affiliated companies who
are controlling shareholders prior to and/or after the issuance of Ordinary Shares underlying the options may only be granted options
under section&#160;3(i) of the Tax Ordinance, which does not provide for similar tax benefits. In addition, the committee may, in its
sole discretion, grant restricted shares to our service providers, subject to terms and conditions of our 2019 Plan and the applicable
restricted shares agreement between the service provider and us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
a default, our 2019 Plan provides that upon termination of a service provider&#8217;s engagement for any reason, other than in the event
of death, disability or cause, all unvested options will terminate and the underlying Ordinary Shares will revert to our 2019 Plan, and
all vested options will generally be exercisable for 90 days following such termination, subject to the terms of the 2019 Plan and the
governing option agreement. Notwithstanding the foregoing, in the event the engagement is terminated for cause (including, inter alia,
due to dishonesty toward us or our affiliate, substantial malfeasance or nonfeasance of duty and conduct substantially prejudicial to
our or our affiliate&#8217;s business; or any substantial breach by the optionee of his or her service agreement) all options granted
to such service provider, whether vested or unvested, will not be exercisable and will terminate on the date of the termination of his
service agreement. If a service provider&#8217;s engagement with us is terminated six months following any exercise, payment or delivery
pursuant to an option or restricted share, the service provider shall pay to us the amount of any gain realized or payment received as
a result of the rescinded exercise, payment or delivery. Upon termination of a service agreement due to death or disability, all the options
vested at the time of termination and within 60 days after the date of such termination, will generally be exercisable for 12 months,
or such other period as determined by the plan administrator, subject to the terms of the 2019 Plan and the governing option agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
we are party to a merger, acquisition, reorganization or consolidation in which we are not the surviving entity or the sale, transfer,
exchange or other disposition of all or substantially all of our shares or assets, outstanding options and shares acquired under the 2019
Plan will be subject to the agreement of merger or consolidation, which will provide for one or more of the following: (i)&#160;the assumption
of such options by the surviving corporation or its parent, (ii)&#160;the substitution by the surviving corporation or its parent of new
options, or (iii)&#160;in the event that the successor entity neither assumes nor substitutes all outstanding options, then the option
shall terminate as of the date of a merger, acquisition, reorganization or consolidation in which we are not the surviving entity or the
sale, transfer, exchange or other disposition of all or substantially all of our shares or assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_039"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 7.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_040"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Major Shareholders. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The following table sets forth information regarding beneficial ownership
of our Ordinary Shares as of March 28, 2023 by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person, or group of affiliated persons, known to us to be the beneficial owner of more than 5% of our outstanding Ordinary Shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors and executive officers; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all of our directors and executive officers as a group.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Beneficial ownership is determined
in accordance with the rules of the SEC and includes voting or investment power with respect to Ordinary Shares. Ordinary Shares issuable
under share options or warrants that are exercisable within 60 days after </span>March 28, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Except
as indicated in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with
respect to all shares shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise
noted below, each beneficial owner&#8217;s address is: c/o Inspira Technologies Oxy B.H.N. Ltd., 2 Ha-Tidhar St., Ra&#8217;anana, 4366504
Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No.&#160;of&#160;Shares<br/> Beneficially<br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage <br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt; font-weight: bold">Holders of more than 5% of our voting securities:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon <sup>(1) *</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,399,842</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11.86</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hayon <sup>(2) * </sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,399,842</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.86</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left">Directors and senior management who are not 5% holders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi Shabtai <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">419,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.55</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yafit Tehila <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,066</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniella Yehezkely Hayon <sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.25</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tal Parnes <sup>(6) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,735</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.24</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limor Rozen <sup>(7) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benad Goldwasser <sup>(8) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,738</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.72</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Amit <sup>(8)*</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">All Executive Officers and Directors and holder of more than 5% of our voting securities, as a group (8 persons)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,484,198</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28..7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates director of the Company.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 57,159&#160;Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and 51,139 RSUs that will be vested within 60 days. Mr. Ben-Noon&#8217;s options expiration date is April 20, 2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 57,159&#160;Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share&#160;and 51,139 RSUs that will be vested within 60 days. Mr. Hayon&#8217;s options expiration date is April 20,2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 57,144 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.97 (approximately $0.29) per share , options to purchase 57,143 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and 2,778 RSUs that will be vested within 60 days. Mr. Shabtai&#8217;s options have expiration dates ranging from April 20,2030 to December 20, 2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 9,827 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and 7,578 RSUs that will be vested within 60 days. Ms. Tehila&#8217;s options expiration date is March 16, 2031.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 3,889 RSUs that will be vested within 60 days.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 9,402 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and 1,667 RSUs that will be vested within 60 days. Mr. Parnas&#8217;s options expiration date is April 20,2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 4,701 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and 1,667 RSUs that will be vested within 60 days. Mrs. Rozen&#8217;s options expiration date is April 20,2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 61,225 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and 23,513 RSUs that will be vested within 60 days. Mr. Goldwasser options expiration date is March 16, 2031.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 1,667 RSUs that will be vested within 60 days.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in Percentage Ownership by Major
Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no significant
change in the percentage ownership held by any major shareholders during the past three years, other than decreases in their relative
percentage of ownership as a result of our initial public offering in July 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Record Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 30, 2024, there
were 23 shareholders of record of our Ordinary Shares, which were located in Israel. <b>&#160;</b>We are not controlled by another corporation,
by any foreign government or by any natural or legal persons except as set forth herein, and there are no arrangements known to us which
would result in a change in control of our company at a subsequent date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_041"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related Party Transactions.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6.B. Compensation&#8221;
for compensation to our directors and officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment and Service Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have entered into written employment agreements with each of our executive officers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition
provisions may be limited under applicable law. In addition, we have entered into agreements with each executive officer and director
pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent that these liabilities are not covered
by directors and officers insurance. Some members of our senior management are eligible for bonuses each year. The bonuses are payable
upon meeting objectives and targets that are set by our Chief Executive Officer and approved annually by our board of directors that also
set the bonus targets for our Chief Executive Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Options/RSUs </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
our inception, we have granted options to purchase our Ordinary Shares and RSUs to our officers and certain of our directors. Such option
agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe our option
plans under &#8220;Item 6.E. Directors, Senior Management and Employees&#8212;Share Ownership&#8212;Equity Incentive Plan.&#8221; If the
relationship between us and an executive officer or a director is terminated, except for cause (as defined in the various option plan
agreements), options that are vested will generally remain exercisable for three months after such termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shareholders Loans</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 20, 2019, we entered into an initial public offering implementation deed, or the IPO Deed, with InSense Medical Pty Ltd., or IML,
the Founders and Newburyport Partners Pty Ltd., or Newburyport. Despite the similarity between our company&#8217;s name and IML&#8217;s
name, IML was not and has never been our subsidiary. IML was a newly formed corporation under the laws of the State of Victoria, Australia,
incorporated for the purpose of facilitating an initial public offering on the Australian Securities Exchange, or ASX. Pursuant to the
IPO Deed, we agreed to pursue an initial public offering on the ASX, and Newburyport agreed to fund such initial public offering on the
ASX as well as our operations by selling IML&#8217;s Ordinary Shares to private investors for proceeds in a minimum aggregate amount of
A$5 (approximately $3.357) million and a maximum aggregate of A$5.5 (approximately $3.692) million and advance the proceeds of such sale
to us as a convertible loan. Within six weeks from May 20, 2019 and subject to successful fundraising by IML, we and our shareholders
would exchange all of our shares and rights to purchase our shares for shares and rights to purchase shares of IML. Pursuant to the IPO
Deed, we were allowed to use the proceeds of the convertible loan to develop our technology and pay for accrued expenses, administration
consultant costs in Australia and the costs associated with the initial public offering on the ASX.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
July 1, 2019, we entered into a convertible bridge loan agreement, or the 2019 CLA, with IML, according to which we were to receive a
loan in the minimum amount of $2.44 million and the maximum amount of up to $2.79 million. The 2019 CLA did not include an option of cash
repayment. As of December 31, 2020, we received from IML approximately $2.374 million (A$3.536), out of which we returned $377,000 (A$559,000)
to IML for fundraising expenses. The loan bore interest of 2.56% and was provided in Australian dollars. Pursuant to the 2019 CLA, we
agreed to repay the loan by converting the principal amount and accrued interest amount to our Ordinary Shares at a price per share of
A$5.15 (approximately $3.45) or A$5.9 (approximately $3.91) upon the earlier of (i) an initial public offering on the ASX; or (ii) a merger,
an acquisition or passage of twelve months from July 1, 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
July 18, 2019, we modified the IPO Deed, or the Deed of Variation, to reduce the amount that Newburyport had to raise to a minimum aggregate
amount of A$3.5 (approximately $2.35) million and a maximum aggregate amount of A$4 (approximately $2.68) million. Subject to Newburyport
securing the initial commitments in the minimum amount of A$3.5 million by July 26, 2019, the Deed of Variation specified that the timing
to receive the funds from the private placement of IML&#8217;s shares would be as provided in the budget of the 2019 CLA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When we were considering pursuing
an initial public offering on the ASX, we were focused on another type of product &#8211; an intravenous oxygenation device. However,
the development of this product did not progress as quickly as we planned. On the other hand, we progressed with our INSPIRA ART ahead
of our plans, reducing the time to market by approximately two years. As we are focusing on the commercialization of our INSPIRA ART in
the U.S. market, we decided to pursue an initial public offering on Nasdaq rather than the ASX. Therefore, on November 27, 2020, we entered
into an agreement, or the Termination Agreement, with IML, the Founders and Newburyport to terminate the IPO Deed, the Deed of Variation
and the 2019 CLA, or the Previous Agreements. Pursuant to the Termination Agreement, we agreed to convert the loan amount and the interest
accrued under the 2019 CLA as of November 27, 2020, into 676,061 of our Ordinary Shares, at price per share of A$5.15 (approximately $3.45)
or A$5.88 (approximately $3.91), and to issue to Newburyport or its affiliates 80,273 of our Ordinary Shares as promoter shares, and options
to purchase 28,572 of our Ordinary Shares, to Daniel Goldstein, who promoted our contract with IML, at an exercise price of NIS 0.37 (approximately
$0.12 per share. We also issued 169,016 warrants to IML, exercisable upon our initial public offering on the Nasdaq Capital Market. IML&#8217;s
warrants are exercisable for three years. IML purchased its shares and distributed its holdings of our shares as a dividend to its shareholders
following our initial public offering on the Nasdaq Capital Market. Each party to the Termination Agreement agreed to release each other
party to the Termination Agreement from all the claims related to the IPO Deed, Deed of Variation and CLA. In addition, we agreed to hire
Newburyport and Peter Marks, another affiliate of IML, as our business developers to identify, introduce and promote us to potential investors,
approved by us in writing at our sole discretion. We promised to pay cash commission in the amount of 7% from the net proceeds of received
by us from an investment consummated within 12 months of our introduction to the investor by Newburyport or Peter Marks. As of November
28, 2021, we have paid Newburyport and Peter Marks A$403,000 (approximately $321,000) each, as cash commission for investor introductions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_042"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interests of Experts and Counsel.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_043"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 8.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>FINANCIAL INFORMATION.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_044"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements and Other Financial Information.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 18. Financial
Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of outcome, litigation
can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. We are
not currently party to, and our property is not the subject of, any material legal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 6, 2021, Exchange
Listing, LLC, or Exchange, filed a complaint in New York state court against us in connection with a contract between the parties. The
contracted related to certain consulting services provided to us by Exchange in preparation for our initial public offering. On September
9, 2021, we removed the case to the United States District Court for the Southern District of New York. On October 15, 2021, Exchange
filed an amended complaint, or the Amended Complaint, asserting eight causes of action: fraud in the inducement, unjust enrichment, quantum
meruit, breach of the covenant of good faith and fair dealing, common law fraud, breach of written and oral contracts. Exchange seeks
damages of $1,000,000 plus interest, legal fees, attorneys&#8217; fees, and the issuance of at least 73,321 of our ordinary shares. On
December 16, 2021, we filed a Motion to Dismiss the Amended Complaint for failure to state a claim upon which relief can be granted based
on the language of the parties&#8217; written contract. On January 28, 2022, Exchange Listing voluntarily dismissed the matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2022, Exchange
filed a complaint in the Federal Court for the Southern District of New York against us and our Chief Financial Officer, Joe Hayon, in
connection with a contract between the parties pursuant to which Exchange provided certain consultancy services to us in preparation for
our initial public offering. The precise damages sought are unclear, however Exchange is seeking approximately $250,000 plus 75,000 Ordinary
Shares or the cash equivalent. On July 1, 2022, we filed a motion to dismiss for failure to state a claim upon relief can be granted based
on the language of the written contract between the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 8, 2023, the court
issued an order granting our motion in part and denying it in part. Specifically, the court dismissed all claims against Joe Hayon and
he is no longer a party in the action. The court also dismissed the breach of contract action (Count I) to the extent it was based improper
termination or frustration. The Court also dismissed Count IV (Quantum Merit on the written agreement), Count VI (Breach of Implied Covenant
of Good Faith) and Count VII (Fraud in the Inducement). The court allowed Count 1 (breach of written agreement based on alleged anticipatory
repudiation), Count II (breach of alleged oral agreement), Count III (Promissory Estoppel to the extent based on alleged oral agreement)
and Count V (Quantum Meruit based on alleged oral agreement) to survive the pleading or early dismissal stage. We will continue to defend
ourselves vigorously with respect to this matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 12, 2021, we terminated
our employment agreement with Dr. Udi Nussinovitch, who is one of our founders who served as our Chief Scientific Officer since March
2018. On February 24, 2022, we sued Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and former officer
of the Company. On November 9, 2022, we received notice of a complaint filed by Mr.&#160;Nussinovitch, as well as a complaint filed with
the regional labor court in Tel Aviv on November 8, 2022. Mr. Nussinovitch has alleged certain deficiencies in the Registrant&#8217;s&#160;<span style="background-color: white">Extraordinary
General Meeting of Shareholders held on Friday, December 17, 2021, resulting from his status as a minority shareholder. In addition, with
respect to the labor dispute, Mr.&#160;</span>Nussinovitch is seeking renumeration and the issuance of ordinary shares.&#160;<span style="background-color: white">We
</span>strongly disagree with the claims and believe we have meritorious defenses and will vigorously defend itself against the claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash
dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including
our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board
of directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
further restrictions on our ability to declare and pay dividends. Under the Companies Law, we may declare and pay dividends only if, upon
the determination of our board of directors, there is no reasonable concern that the distribution will prevent us from being able to meet
the terms of our existing and foreseeable obligations as they become due. Under the Companies Law, the distribution amount is further
limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according
to our then last reviewed or audited financial statements, provided that the end of the period to which the financial statements relate
is not more than six months prior to the date of distribution. In the event that we do not meet such earnings criteria, we may seek the
approval of a court in order to distribute a dividend. The court may approve our request if it is convinced that there is no reasonable
concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment of dividends may be
subject to Israeli withholding taxes. See &#8220;Item 10.E. Taxation&#8221;, for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_045"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant Changes.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No significant change, other
than as otherwise described in this annual report on Form 20-F, has occurred in our operations since the date of our consolidated financial
statements included in this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_046"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 9.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>THE OFFER AND LISTING</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_047"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offer and Listing Details.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since July 16, 2021, our Ordinary
Shares and Warrants have been traded on the Nasdaq Capital Market under the symbols &#8220;IINN&#8221; and &#8220;IINNW,&#8221; respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_048"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan of Distribution.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_049"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Markets.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares and Warrants
trade on the Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_050"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selling Shareholders.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_051"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dilution.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_052"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expenses of the Issue.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_053"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 10.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ADDITIONAL INFORMATION</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_054"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share Capital.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_055"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Memorandum and Articles of Association.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of our amended and
restated articles of association is attached as Exhibit 1.1 to this annual report on Form 20-F. The information called for by this Item
is set forth in Exhibit 2(d) to this annual report on Form 20-F and is incorporated by reference into this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_056"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material Contracts. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have not entered into any material contract within the two years prior to the date of this Annual Report, other than contracts entered
into in the ordinary course of business, as otherwise described herein in &#8220;Item 4.A. History and Development of the Company&#8221;
above, &#8220;Item 4.B. Business Overview&#8221; above, &#8220;Item 6.C Board Practices &#8211; Indemnification,&#8221; &#8220;Item 6.E
Share Ownership &#8211; Equity Incentive Plan,&#8221; &#8220;Item 7.A. Major Shareholders,&#8221; or &#8220;Item 7.B. Related Party Transactions,&#8221;
above, or as otherwise described below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspira Technologies Oxy B.H.N. 2019 Equity Incentive Plan, filed as Exhibit 10.2 to Amendment No. 7 to Form F-1 (File No. 333-253920) on July 1, 2021. See Item 6.E &#8220;<i>Share Ownership</i>&#8221; for more information about this document.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement dated November 27, 2020, by and among the Company, Insense Medical Pty Ltd., Udi Nussinovitch, Joe Hayon, Dagi Ben-Noon and Newburyport Partners Pty Ltd., filed as Exhibit 10.4 to Amendment No. 7 to Form F-1 (File No. 333-253920) on July 1, 2021. See Item 6.B &#8220;<i>Related Party Transactions</i>&#8221; for more information about this document.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_057"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange Controls.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on payments of dividends or other distributions with respect to our securities or the proceeds from the
sale of the shares, except for the obligation of Israeli residents to file reports with the Bank of Israel regarding certain transactions.
However, legislation remains in effect pursuant to which currency controls can be imposed by administrative action at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ownership or voting of
our securities by non-residents of Israel, except with respect to citizens of countries that are in a state of war with Israel, is not
restricted in any way by our memorandum of association or amended and restated articles of association or by the laws of the State of
Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_058"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify; text-indent: 17.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taxation.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
following is a description of the material Israeli income tax consequences of the ownership of our </span>securities<span style="background-color: white">.
The following also contains a description of material relevant provisions of the current Israeli income tax structure applicable to companies
in Israel, with reference to its effect on us. To the extent that the discussion is based on new tax legislation which has not been subject
to judicial or administrative interpretation, there can be no assurance that the tax authorities will accept the views expressed in the
discussion in question. The discussion is not intended, and should not be taken, as legal or professional tax advice and is not exhaustive
of all possible tax considerations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition
of our </span>securities<span style="background-color: white">. Shareholders should consult their own tax advisors concerning the tax
consequences of their particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign
or other taxing jurisdiction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General Corporate Tax Structure in Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Israeli
companies are generally subject to corporate tax. As of January 2016, the corporate tax rate was 25%. As of January 1, 2017, the corporate
tax rate was reduced to 24% and as of January 1, 2018, the corporate tax rate is 23%. However, the effective tax rate payable by a company
that derives income from a Preferred Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli company
are generally subject to the prevailing corporate tax rate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Capital
gains derived by an Israeli resident company are subject to tax at the prevailing corporate tax rate. Under Israeli tax legislation, a
corporation will be considered as an &#8220;Israeli resident company&#8221; if it meets one of the following: (i) it was incorporated
in Israel; or (ii) the control and management of its business are exercised in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Law for the Encouragement of Industry (Taxes),
5729-1969</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax
benefits for &#8220;Industrial Companies.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
Industry Encouragement Law defines an &#8220;Industrial Company&#8221; as an Israeli resident-company, of which 90% or more of its income
in any tax year, other than income from defense loans, is derived from an &#8220;Industrial Enterprise&#8221; owned by it. An &#8220;Industrial
Enterprise&#8221; is defined as an enterprise whose principal activity in a given tax year is industrial production.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
following corporate tax benefits, among others, are available to Industrial Companies:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amortization of the cost of purchased a patent, rights to use a patent, and know-how, which are used for the development or advancement of the company, over an eight-year period, commencing on the year in which such rights were first exercised;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under limited conditions, an election to file consolidated tax returns with related Israeli Industrial Companies; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses related to a public offering are deductible in equal amounts over three years.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Eligibility
for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits and Grants for Research and
Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Under
the Israeli Encouragement of Research, Development and Industrial Initiative Technology Law, 5744-1984, as amended, and related regulations,
or the Research Law, research and development programs which meet specified criteria and are approved by the IIA are eligible for grants
of up to 50% of the project&#8217;s expenditure, as determined by the research committee, in exchange for the payment of royalties from
the revenues generated from the sale of products and related services developed, in whole or in part pursuant to, or as a result of, a
research and development program funded by the IIA. The royalties are generally at a range of 3.0% to 5.0% of revenues until the entire
IIA grant is repaid, together with an annual interest generally equal to the 12 months London Interbank Offered Rate applicable to dollar
deposits that is published on the first business day of each calendar year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
terms of the Research Law also require that the manufacture of products developed with government grants be performed in Israel. The transfer
of manufacturing activity outside Israel may be subject to the prior approval of the IIA. Under the regulations of the Research Law, assuming
we receive approval from the Chief Scientist to manufacture our IIA-funded products outside Israel, we may be required to pay increased
royalties. The increase in royalties depends upon the manufacturing volume that is performed outside of Israel as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Manufacturing Volume Outside of Israel</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Royalties to <br/> the Chief <br/> Scientist<br/> as&#160;a <br/> Percentage <br/> of Grant</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Up to 50%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">120</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Between 50% and 90%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">90% and more</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">If
the manufacturing is performed outside of Israel by us, the rate of royalties payable by us on revenues from the sale of products manufactured
outside of Israel will increase by 1% over the regular rates. If the manufacturing is performed outside of Israel by a third party, the
rate of royalties payable by us on those revenues will be equal to the ratio obtained by dividing the amount of the grants received from
the Office of the Chief Scientist and our total investment in the project that was funded by these grants. The transfer of no more than
10% of the manufacturing capacity in the aggregate outside of Israel is exempt under the Research Law from obtaining the prior approval
of the IIA. A company requesting funds from the IIA also has the option of declaring in its IIA grant application an intention to perform
part of its manufacturing outside Israel, thus avoiding the need to obtain additional approval. On January 6, 2011, the Research Law was
amended to clarify that the potential increased royalties specified in the table above will apply even in those cases where the IIA approval
for transfer of manufacturing outside of Israel is not required, namely when the volume of the transferred manufacturing capacity is less
than 10% of total capacity or when the company received an advance approval to manufacture abroad in the framework of its IIA grant application.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
know-how developed within the framework of the Chief Scientist plan may not be transferred to third parties outside Israel without the
prior approval of a governmental committee charted under the Research Law. The approval, however, is not required for the export of any
products developed using grants received from the Chief Scientist. The IIA approval to transfer know-how created, in whole or in part,
in connection with an IIA-funded project to third party outside Israel where the transferring company remains an operating Israeli entity
is subject to payment of a redemption fee to the IIA calculated according to a formula provided under the Research Law that is based,
in general, on the ratio between the aggregate IIA grants to the company&#8217;s aggregate investments in the project that was funded
by these IIA grants, multiplied by the transaction consideration. The transfer of such know-how to a party outside Israel where the transferring
company ceases to exist as an Israeli entity is subject to a redemption fee formula that is based, in general, on the ratio between the
aggregate IIA grants to the total financial investments in the company, multiplied by the transaction consideration. According to the
January 2011 amendment, the redemption fee in case of transfer of know-how to a party outside Israel will be based on the ratio between
the aggregate IIA grants received by the company and the company&#8217;s aggregate R&amp;D expenses, multiplied by the transaction consideration.
According to regulations promulgated following the 2011 amendment, the maximum amount payable to the IIA in case of transfer of know how
outside Israel shall not exceed 6 times the value of the grants received plus interest, and in the event that the receiver of the grants
ceases to be an Israeli corporation such payment shall not exceed six times the value of the grants received plus interest, with a possibility
to reduce such payment to up to three times the value of the grants received plus interest if the R&amp;D activity remains in Israel for
a period of three years after payment to the IIA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Transfer
of know-how within Israel is subject to an undertaking of the recipient Israeli entity to comply with the provisions of the Research Law
and related regulations, including the restrictions on the transfer of know-how and the obligation to pay royalties, as further described
in the Research Law and related regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">These
restrictions may impair our ability to outsource manufacturing, engage in change of control transactions or otherwise transfer our know-how
outside Israel and may require us to obtain the approval of the IIA for certain actions and transactions and pay additional royalties
to the IIA. In particular, any change of control and any change of ownership of our </span>securities <span style="background-color: white">that
would make a non-Israeli citizen or resident an &#8220;interested party,&#8221; as defined in the Research Law, requires a prior written
notice to the IIA in addition to any payment that may be required of us for transfer of manufacturing or know-how outside Israel. If we
fail to comply with the Research Law, we may be subject to criminal charges.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits for Research and Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Israeli
tax law allows, under certain conditions, a tax deduction for expenditures, including capital expenditures, for the year in which they
are incurred. Expenditures are deemed related to scientific research and development projects, if:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expenditures are approved by the relevant Israeli government ministry, determined by the field of research;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development must be for the promotion of the company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development is carried out by or on behalf of the company seeking such tax deduction.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
amount of such deductible expenses is reduced by the sum of any funds received through government grants for the finance of such scientific
research and development projects. No deduction under these research and development deduction rules is allowed if such deduction is related
to an expense invested in an asset depreciable under the general depreciation rules of the income Tax Ordinance, 1961. Expenditures not
so approved are deductible in equal amounts over three years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">From
time to time, we may apply the Office of the Chief Scientist for approval to allow a tax deduction for all research and development expenses
during the year incurred. There can be no assurance that such application will be accepted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Law for the Encouragement of Capital Investments,
5719-1959</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives
for capital investments in production facilities (or other eligible assets).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
Investment Law grants tax benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221;
(as such terms are defined in the Investment Law) The definition of a Preferred Company includes a company incorporated in Israel that
is not fully owned by a governmental entity, and that has, among other things, Preferred Enterprise status and is controlled and managed
from Israel. A Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to its income derived by its Preferred
Enterprise, unless the Preferred Enterprise is located in a specified development zone, in which case the rate will be 7.5%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Dividends
paid out of income attributed to a Preferred Enterprise are generally subject to withholding tax at source at the rate of 20% or such
lower rate as may be provided in an applicable tax treaty. However, if such dividends are paid to an Israeli company, no tax is required
to be withheld.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of our Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Capital
Gains Taxes Applicable to Non-Israeli Resident Shareholders. A non-Israeli resident who derives capital gains from the sale of shares
in an Israeli resident company will be exempt from Israeli tax so long as the shares were not held through a permanent establishment that
the non-resident maintains in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemption if Israeli residents:
(i) have a controlling interest of 25% or more in such non-Israeli corporation or (ii) are the beneficiaries of, or are entitled to, 25%
or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Additionally,
a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax
treaty. For example, under Convention Between the Government of the United States of America and the Government of the State of Israel
with respect to Taxes on Income, as amended, or the United States-Israel Tax Treaty, the sale, exchange or other disposition of shares
by a shareholder who is a United States resident (for purposes of the treaty) holding the shares as a capital asset and is entitled to
claim the benefits afforded to such a resident by the U.S.-Israel Tax Treaty, or a Treaty U.S. Resident, is generally exempt from Israeli
capital gains tax unless: (i) the capital gain arising from such sale, exchange or disposition is attributed to real estate located in
Israel; (ii) the capital gain arising from such sale, exchange or disposition is attributed to royalties; (iii) the capital gain arising
from the such sale, exchange or disposition is attributed to a permanent establishment in Israel, under certain terms; (iv) such Treaty
U.S. Resident holds, directly or indirectly, shares representing 10% or more of the voting capital during any part of the 12-month period
preceding the disposition, subject to certain conditions; or (v) such Treaty U.S. Resident is an individual and was present in Israel
for 183 days or more during the relevant taxable year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">In
some instances where our shareholders may be liable for Israeli tax on the sale of their </span>securities<span style="background-color: white">,
the payment of the consideration may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate
that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Taxation
of Non-Israeli Shareholders on Receipt of Dividends. Non-Israeli residents are generally subject to Israeli income tax on the receipt
of dividends paid on our </span>securities <span style="background-color: white">at the rate of 25%, which tax will be withheld at source,
unless relief is provided in a treaty between Israel and the shareholder&#8217;s country of residence. With respect to a person who is
a &#8220;substantial shareholder&#8221; at the time of receiving the dividend or on any time during the preceding twelve months, the applicable
tax rate is 30%. A &#8220;substantial shareholder&#8221; is generally a person who alone or together with such person&#8217;s relative
or another person who collaborates with such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the &#8220;means
of control&#8221; of the corporation. &#8220;Means of control&#8221; generally include the right to vote, receive profits, nominate a
director or an executive officer, receive assets upon liquidation, or order someone who holds any of the aforesaid rights how to act,
regardless of the source of such right. However, a distribution of dividends to non-Israeli residents is subject to withholding tax at
source at a rate of 20% if the dividend is distributed from income attributed to a Preferred Enterprise, unless a reduced tax rate is
provided under an applicable tax treaty. For example, under the United States-Israel Tax Treaty, the maximum rate of tax withheld at source
in Israel on dividends paid to a holder of our </span>securities <span style="background-color: white">who is a Treaty U.S. Resident is
25%. However, generally, the maximum rate of withholding tax on dividends, not generated by a Preferred Enterprise, that are paid to a
United States corporation holding 10% or more of the outstanding voting capital throughout the tax year in which the dividend is distributed
as well as during the previous tax year, is 12.5%, provided that not more than 25% of the gross income for such preceding year consists
of certain types of dividends and interest. Notwithstanding the foregoing, dividends distributed from income attributed to a Preferred
Enterprise are not entitled to such reduction under the tax treaty but are subject to a withholding tax rate of 15% for a shareholder
that is a U.S. corporation, provided that the condition related to our gross income for the previous year (as set forth in the previous
sentence) is met. If the dividend is attributable partly to income derived from a Preferred Enterprise, and partly to other sources of
income, the withholding rate will be a blended rate reflecting the relative portions of the two types of income. We cannot assure you
that we will designate the profits that we may distribute in a way that will reduce shareholders&#8217; tax liability.<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>U.S. FEDERAL INCOME TAX CONSIDERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THE FOLLOWING SUMMARY IS INCLUDED
HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD
CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE
OF ORDINARY SHARES INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE CHANGES IN THE TAX LAWS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the limitations
described in the next two paragraphs, the following discussion summarizes the material U.S. federal income tax consequences to a &#8220;U.S.
Holder&#8221; arising from the purchase, ownership and sale of our securities, the &#8220;securities&#8221;. For this purpose, a &#8220;U.S.
Holder&#8221; is a holder of securities that is: (1) an individual citizen or resident of the United States, including an alien individual
who is a lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal income tax
laws; (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other than a partnership
that is not treated as a U.S. person under any applicable U.S. Treasury regulations) created or organized under the laws of the United
States or the District of Columbia or any political subdivision thereof; (3) an estate, the income of which is includable in gross income
for U.S. federal income tax purposes regardless of source; (4) a trust if a court within the United States is able to exercise primary
supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the
trust; or (5) a trust that has a valid election in effect to be treated as a U.S. person to the extent provided in U.S. Treasury regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary is for general
information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations
that may be relevant to a decision to purchase our securities. This summary generally considers only U.S. Holders that will own our securities
as capital assets. Except to the limited extent discussed below, this summary does not consider the U.S. federal tax consequences to a
person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer&#8217;s status as a U.S. Holder. This
summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final, temporary and proposed U.S. Treasury
regulations promulgated thereunder, administrative and judicial interpretations thereof, and the U.S./Israel Income Tax Treaty, all as
in effect as of the date hereof and all of which are subject to change, possibly on a retroactive basis, and all of which are open to
differing interpretations. We will not seek a ruling from the IRS with regard to the U.S. federal income tax treatment of an investment
in our securities by U.S. Holders and, therefore, can provide no assurances that the IRS will agree with the conclusions set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion does not address
all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based on such holder&#8217;s particular
circumstances and in particular does not discuss any estate, gift, generation-skipping transfer, state, local, excise or foreign tax considerations.
In addition, this discussion does not address the U.S. federal income tax treatment of a U.S. Holder who is: (1) a bank, life insurance
company, regulated investment company, or other financial institution or &#8220;financial services entity;&#8221; (2) a broker or dealer
in securities or foreign currency; (3) a person who acquired our securities in connection with employment or other performance of services;
(4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder that holds our securities as a hedge or as part
of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for U.S. federal income tax purposes;
(6) a tax-exempt entity; (7) real estate investment trusts or grantor trusts; (8) a U.S. Holder that expatriates out of the United States
or a former long-term resident of the United States; or (9) a person having a functional currency other than the U.S. dollar. This discussion
does not address the U.S. federal income tax treatment of a U.S. Holder that owns, directly or constructively, at any time, securities
representing 10% or more of our voting power. Additionally, the U.S. federal income tax treatment of partnerships (or other pass-through
entities) or persons who hold securities through a partnership or other pass-through entity are not addressed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each prospective investor
is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing, holding or disposing
of our securities, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Taxation of Dividends
Paid on Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to pay dividends
in the foreseeable future and Holders of Warrants are not entitled to dividends. In the event that we do pay dividends, and subject to
the discussion under the heading &#8220;Passive Foreign Investment Companies&#8221; below and the discussion of &#8220;qualified dividend
income&#8221; below, a U.S. Holder, other than certain U.S. Holders that are U.S. corporations, will be required to include in gross income
as ordinary income the amount of any distribution paid on Ordinary Shares (including the amount of any Israeli tax withheld on the date
of the distribution), to the extent that such distribution does not exceed our current and accumulated earnings and profits, as determined
for U.S. federal income tax purposes. The amount of a distribution which exceeds our earnings and profits will be treated first as a non-taxable
return of capital, reducing the U.S. Holder&#8217;s tax basis for the Ordinary Shares to the extent thereof, and then capital gain. We
do not expect to maintain calculations of our earnings and profits under U.S. federal income tax principles and, therefore, U.S. Holders
should expect that the entire amount of any distribution generally will be reported as dividend income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, preferential tax
rates for &#8220;qualified dividend income&#8221; and long-term capital gains are applicable for U.S. Holders that are individuals, estates
or trusts. For this purpose, &#8220;qualified dividend income&#8221; means, inter alia, dividends received from a &#8220;qualified foreign
corporation.&#8221; A &#8220;qualified foreign corporation&#8221; is a corporation that is entitled to the benefits of a comprehensive
tax treaty with the United States which includes an exchange of information program. The IRS has stated that the Israel/U.S. Tax Treaty
satisfies this requirement and we believe we are eligible for the benefits of that treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our dividends
will be qualified dividend income if our Ordinary Shares are readily tradable on the Nasdaq Capital Market or another established securities
market in the United States. Dividends will not qualify for the preferential rate if we are treated, in the year the dividend is paid
or in the prior year, as a PFIC, as described below under &#8220;Passive Foreign Investment Companies.&#8221; A U.S. Holder will not be
entitled to the preferential rate: (1) if the U.S. Holder has not held our Ordinary Shares for at least 61 days of the 121 day period
beginning on the date which is 60 days before the ex-dividend date, or (2) to the extent the U.S. Holder is under an obligation to make
related payments on substantially similar property. Any days during which the U.S. Holder has diminished its risk of loss on our Ordinary
Shares are not counted towards meeting the 61-day holding period. Finally, U.S. Holders who elect to treat the dividend income as &#8220;investment
income&#8221; pursuant to Code section 163(d)(4) will not be eligible for the preferential rate of taxation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of a distribution
with respect to our Ordinary Shares will be measured by the amount of the fair market value of any property distributed, and for U.S.
federal income tax purposes, the amount of any Israeli taxes withheld therefrom. Cash distributions paid by us in NIS will be included
in the income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend is includible
in the income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal income tax purposes equal to such
U.S. dollar value. If the U.S. Holder subsequently converts the NIS into U.S. dollars or otherwise disposes of them, any subsequent gain
or loss in respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Taxation of the
Disposition of Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided under the
PFIC rules described below under &#8220;Passive Foreign Investment Companies,&#8221; upon the sale, exchange or other disposition of our
securities, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder&#8217;s tax
basis for the securities in U.S. dollars and the amount realized on the disposition in U.S. dollar (or its U.S. dollar equivalent determined
by reference to the spot rate of exchange on the date of disposition, if the amount realized is denominated in a foreign currency). The
gain or loss realized on the sale, exchange or other disposition of securities will be long-term capital gain or loss if the U.S. Holder
has a holding period of more than one year at the time of the disposition. Individuals who recognize long-term capital gains may be taxed
on such gains at reduced rates of tax. The deduction of capital losses is subject to various limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Passive Foreign
Investment Companies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special U.S. federal income
tax laws apply to U.S. taxpayers who own shares of a corporation that is a PFIC. We will be treated as a PFIC for U.S. federal income
tax purposes for any taxable year that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75% or more of our gross income (including our pro rata share of gross income for any company, in which we are considered to own 25% or more of the shares by value), in a taxable year is passive; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At least 50% of our assets, averaged over the year and generally determined based upon fair market value (including our pro rata share of the assets of any company in which we are considered to own 25% or more of the shares by value) are held for the production of, or produce, passive income.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For this purpose, passive
income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities transactions and from
notional principal contracts. Cash is treated as generating passive income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we will not
be a PFIC for the current taxable year, although we have not determined whether we will be a PFIC in the foreseeable future. The tests
for determining PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets which are
relevant to this determination. In addition, our PFIC status may depend in part on the market value of our securities. Accordingly, there
can be no assurance that we currently are not or will not become a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we currently are or become
a PFIC, each U.S. Holder who has not elected to mark the shares to market (as discussed below), would, upon receipt of certain distributions
by us and upon disposition of our securities at a gain:&#160;(1) have such distribution or gain allocated ratably over the U.S. Holder&#8217;s
holding period for the securities, as the case may be; (2) the amount allocated to the current taxable year and any period prior to the
first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of
the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year,
and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other
taxable year. In addition, when shares of a PFIC are acquired by reason of death from a decedent that was a U.S. Holder, the tax basis
of such shares would not receive a step-up to fair market value as of the date of the decedent&#8217;s death, but instead would be equal
to the decedent&#8217;s basis if lower, unless all gain were recognized by the decedent. Indirect investments in a PFIC may also be subject
to these special U.S. federal income tax rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PFIC rules described above
would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has held the securities while we
are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder who has made such a QEF election
is required for each taxable year that we are a PFIC to include in income such U.S. Holder&#8217;s pro rata share of our ordinary earnings
as ordinary income and such U.S. Holder&#8217;s pro rata share of our net capital gains as long-term capital gain, regardless of whether
we make any distributions of such earnings or gain. In general, a QEF election is effective only if we make available certain required
information. The QEF election is made on a shareholder-by-shareholder basis and generally may be revoked only with the consent of the
IRS. We do not intend to notify U.S. Holders if we believe we will be treated as a PFIC for any tax year. In addition, we do not intend
to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and to make and maintain a valid QEF election
for any year in which we or any of our Subsidiaries are a PFIC. Therefore, the QEF election will not be available with respect to our
securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the PFIC rules
described above would not apply if we were a PFIC and a U.S. Holder made a mark-to-market election. A U.S. Holder of our securities which
are regularly traded on a qualifying exchange, including the Nasdaq Capital Market, can elect to mark the securities to market annually,
recognizing as ordinary income or loss each year an amount equal to the difference as of the close of the taxable year between the fair
market value of the securities and the U.S. Holder&#8217;s adjusted tax basis in the securities. Losses are allowed only to the extent
of net mark-to-market gain previously included income by the U.S. Holder under the election for prior taxable years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who hold our
securities during a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC. U.S. Holders are
strongly urged to consult their tax advisors about the PFIC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tax on Net Investment Income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who are individuals,
estates or trusts will generally be required to pay a 3.8% Medicare tax on their net investment income (including dividends on and gains
from the sale or other disposition of our securities), or in the case of estates and trusts on their net investment income that is not
distributed to beneficiaries of the estate or trust. In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder&#8217;s
total adjusted income exceeds applicable thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Information Reporting
and Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder may be subject
to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition of securities. In general, backup
withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will not apply
with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations. Backup withholding is
not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder, provided that the
required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to recently enacted
legislation, a U.S. Holder with interests in &#8220;specified foreign financial assets&#8221; (including, among other assets, our securities,
unless such securities are held on such U.S. Holder&#8217;s behalf through a financial institution) may be required to file an information
report with the IRS if the aggregate value of all such assets exceeds $50,000 on the last day of the taxable year or $75,000 at any time
during the taxable year (or such higher dollar amount as may be prescribed by applicable IRS guidance); and may be required to file a
Report of Foreign Bank and Financial Accounts, or FBAR, if the aggregate value of the foreign financial accounts exceeds $10,000 at any
time during the calendar year. You should consult your own tax advisor as to the possible obligation to file such information report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_059"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends and Paying Agents.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_060"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statement by Experts.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><div><a id="a_061"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Documents on Display.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements file reports with the SEC.
The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with the
SEC. Our filings with the SEC are also available to the public through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors
and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange
Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with
the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act. However, we file
with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form
20-F containing financial statements audited by an independent registered public accounting firm, and may submit to the SEC, on a Form
6-K, unaudited quarterly financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
www.inspira-technologies.com. Information contained on, or that can be accessed through, our website and the other websites referenced
above do not constitute a part of this annual report on Form 20-F. We have included these website addresses in this annual report on Form
20-F solely as inactive textual references.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_062"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiary Information.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Not
applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_063"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Annual Report to Security Holders</b></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not
applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_064"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 11.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary course of
our operations, we are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Quantitative and Qualitative Disclosure About
Market Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to market risks
in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse
changes in financial market prices and rates. Our current investment policy is to invest available cash in bank deposits with banks that
have a credit rating of at least A-minus. Accordingly, a substantial majority of our equivalents is held in deposits that bear interest.
Given the current low rates of interest we receive, we will not be adversely affected if such rates are reduced. Our market risk exposure
is primarily a result of NIS/U.S. dollar exchange rates, which is discussed in detail in the following paragraph.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign Currency Exchange Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate primarily in Israel,
and approximately 80% of our expenses are denominated in NIS. We are therefore exposed to market risk, which represents the risk of loss
that may impact our financial position due to adverse changes in financial market prices and rates. We are subject to fluctuations in
foreign currency rates in connection with these arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently partially hedge
our foreign currency exchange rate risk to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal
operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interest Rate Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not anticipate undertaking
any significant long-term borrowings. At present, our investments consist primarily of cash and cash equivalents, and short-term deposits.
The primary objective of our investment activities is to preserve principal while maximizing the income that we receive from our investments
without significantly increasing risk and loss. Our investments may be exposed to market risk due to fluctuation in interest rates, which
may affect our interest income and the fair market value of our investments, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impact of Inflation and Currency Fluctuations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inflation generally affects
us by increasing our NIS-denominated expenses, including salaries and benefits, as well as facility rental costs and payment to local
suppliers. We do not believe that inflation had a material effect on our business, financial condition or results of operations during
the year ended December 31, 2022.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_065"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 12.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_066"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Debt Securities.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_067"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants and rights.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_068"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Securities.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_069"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>American Depositary Shares. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_070"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_071"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_072"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2021, we completed
our initial public offering, or IPO, of Ordinary Shares and warrants pursuant to Registration Statement on Form F-1, as amended (Registration
No. 333-253920), whereby we sold 2,909,091 Ordinary Shares and 3,345,455 tradable warrants (inclusive of 436,364 tradable warrants pursuant
to the exercise of an overallotment option granted to the underwriters). All of these Ordinary Shares and warrants were sold at a combined
price of $5.50 per unit, yielding an aggregate net proceeds received by us from the IPO were $14 million, after underwriting discounts
and other offering costs. The net proceeds from the offering have been used, and are expected to continue to be used, as described in
the final prospectus filed with the SEC on July 15, 2021, under File No. 333-253920 and 333-257880.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><div><a id="a_073"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 15. CONTROLS AND PROCEDURES</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures
(as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2022, or the Evaluation Date. Based
on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective
in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under
the Exchange Act and that such information is accumulated and communicated to management, including our principal executive and financial
officers, as appropriate to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Management&#8217;s Annual Report on Internal
Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the
Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial
Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework and criteria
established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
as of the end of the period covered by this report. Based on that evaluation, our management has concluded that our internal control over
financial reporting was effective as of December 31, 2022 at providing reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c) Attestation Report of the Registered Public
Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This annual report does not
include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting
due to an exemption for EGCs provided in the JOBS Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d) Changes in Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_074"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16. [RESERVED]</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_075"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM&#160;16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
determined that each member of our audit committee is an audit committee financial expert, as defined under the rules under the Exchange
Act, and is independent in accordance with applicable Exchange Act rules and Nasdaq Stock Market rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_076"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM&#160;16B. CODE OF ETHICS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a written
code of ethics that applies to our officers and employees, including our principal executive officer, principal financial officer, principal
controller and persons performing similar functions as well as our directors. Our Code of Business Conduct and Ethics is posted on our
website at www.icecure-medical.com. Information contained on, or that can be accessed through, our website does not constitute a part
of this annual report on Form 20-F and is not incorporated by reference herein. If we make any amendment to the Code of Business Conduct
and Ethics or grant any waivers, including any implicit waiver, from a provision of the code, we will disclose the nature of such amendment
or waiver on our website to the extent required by the rules and regulations of the SEC including the instructions to Item 16B of Form
20-F. We have not granted any waivers under our Code of Business Conduct and Ethics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_077"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM&#160;16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ziv Haft., Certified Public
Accountants, Isr., BDO member firm, an independent registered public accounting firm, has served as our principal independent registered
public accounting firm for each of the two years ended December 31, 2021 and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding fees paid by us to Ziv Haft and/or other BDO member firms for all services, including audit services, for the years
ended December 31, 2021 and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees <sup>(1) </sup></span></td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">119.5</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">140.5</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">119.5</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">140.5</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes professional services rendered in connection with the audit of our annual financial statements, review of our interim financial statements.&#160;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pre-Approval of Auditors&#8217; Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee has a
pre-approval policy for the engagement of our independent registered public accounting firm to perform certain audit and non-audit services.
Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the audit committee
pre-approves annually a catalog of specific audit and non-audit services in the categories of audit services, audit-related services and
tax services that may be performed by our independent registered public accounting firm. If a type of service, that is to be provided
by our auditors, has not received such general pre-approval, it will require specific pre-approval by our audit committee. The policy
prohibits retention of the independent registered public accounting firm to perform the prohibited non-audit functions defined in applicable
SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><div><a id="a_078"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_079"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_080"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_081"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16G. CORPORATE GOVERNANCE</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Nasdaq Stock Market
rules, we may elect to follow certain corporate governance practices permitted under the Companies Law in lieu of compliance with corresponding
corporate governance requirements otherwise imposed by the Nasdaq Stock Market rules for U.S. domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Israeli
law and practice and subject to the exemption set forth in Rule&#160;5615 of the Nasdaq Stock Market rules, we have elected to follow
the provisions of the Companies Law, rather than the Nasdaq Stock Market rules, with respect to the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Quorum</i>. While the Nasdaq Stock Market rules require that the quorum for purposes of any meeting of the holders of a listed company&#8217;s ordinary voting stock, as specified in the company&#8217;s bylaws, be no less than 33 1/3% of the company&#8217;s outstanding ordinary voting stock, under Israeli law, a company is entitled to determine in its articles of association the number of shareholders and percentage of holdings required for a quorum at a shareholders meeting. Our amended and restated articles of association provide that a quorum of two or more shareholders holding at least 25% of the voting rights in person or by proxy is required for commencement of business at a general meeting. However, the quorum set forth in our amended and restated articles of association with respect to an adjourned meeting consists of at least one shareholder present in person or by proxy.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation of officers.</i>&#160;Israeli law and our amended and restated articles of association do not require that the independent members of our board of directors (or a compensation committee composed solely of independent members of our board of directors) determine an executive officer&#8217;s compensation, as is generally required under the Nasdaq Stock Market rules with respect to the chief executive officer and all other executive officers. Instead, compensation of executive officers is determined and approved by our compensation committee and our board of directors, and in certain circumstances by our shareholders, either in consistency with our office holder compensation policy or, in special circumstances in deviation therefrom, taking into account certain considerations stated in the Companies Law. See &#8220;Item 6.C. Directors, Senior Management and Employees&#8212;Board Practices&#8212;Approval of Related Party Transactions under Israeli law&#8221; for additional information.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shareholder approval.</i>&#160;We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather than seeking approval for corporation actions in accordance with Nasdaq Listing Rule&#160;5635. In particular, under this Nasdaq Stock Market rule, shareholder approval is generally required for: (i)&#160;an acquisition of shares/assets of another company that involves the issuance of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii)&#160;the issuance of shares leading to a change of control; (iii)&#160;adoption/amendment of equity compensation arrangements (although under the provisions of the Companies Law there is no requirement for shareholder approval for the adoption/amendment of the equity compensation plan); and (iv)&#160;issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors/officers/5% shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares. By contrast, under the Companies Law, shareholder approval is required for, among other things: (i)&#160;transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company), for which approvals of the compensation committee, board of directors and shareholders are all required, (ii)&#160;extraordinary transactions with controlling shareholders of publicly held companies, which require the special approval, and (iii)&#160;terms of employment or other engagement of the controlling shareholder of us or such controlling shareholder&#8217;s relative, which require special approval. In addition, under the Companies Law, a merger requires approval of the shareholders of each of the merging companies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Approval of Related Party Transactions</i>. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transaction as set forth in the Companies Law, which requires the approval of the audit committee, or the compensation committee, as the case may be, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our board of directors as required under the Nasdaq Stock Market rules. See &#8220;Item 6.C. Directors, Senior Management and Employees&#8212;Board Practices&#8212;Approval of Related Party Transactions under Israeli law&#8221; for additional information.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Annual Shareholders Meeting.&#160;</i> As opposed to the Nasdaq Stock Market Rule 5620(a), which mandates that a listed company hold its annual shareholders meeting within one year of the company&#8217;s fiscal year-end, we are required, under the Companies Law, to hold an annual shareholders meeting each calendar year and within 15 months of the last annual shareholders meeting.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distribution of periodic reports to shareholders; proxy solicitation.</i>&#160;As opposed to the Nasdaq Stock Market rules, which require listed issuers to make such reports available to shareholders in one of a number of specific manners, Israeli law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. In addition to making such reports available on a public website, we currently make our audited consolidated financial statements available to our shareholders at our offices and will only mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt from the SEC&#8217;s proxy solicitation rules.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholder approval is generally
required for officer compensation in the event (i) approval by our Board of Directors and our compensation committee is not consistent
with our office holder compensation policy, or (ii) compensation required to be approved is that of our chief executive officer or an
executive officer who is also the controlling shareholder of our company (including an affiliate thereof). Such shareholder approval shall
require a majority vote of the shares present and voting at a shareholders meeting, provided either (i) such majority includes a majority
of the shares held by non-controlling shareholders who do not otherwise have a personal interest in the compensation arrangement that
are voted at the meeting, excluding for such purpose any abstentions disinterested majority, or (ii) the total shares held by non-controlling
and disinterested shareholders voted against the arrangement does not exceed 2% of the voting rights in our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, approval of
the compensation of an executive officer who is also a director requires a simple majority vote of the shares present and voting at a
shareholders meeting, if consistent with our office holder compensation policy. Our compensation committee and board of directors may,
in special circumstances, approve the compensation of an executive officer (other than a director, a chief executive officer or a controlling
shareholder) or approve the compensation policy despite shareholders&#8217; objection, based on specified arguments and taking shareholders&#8217;
objection into account. Our compensation committee may further exempt an engagement with a nominee for the position of chief executive
officer, who meets the non-affiliation requirements set forth for an external director, from requiring shareholder approval, if such engagement
is consistent with our office holder compensation policy and our compensation committee determines based on specified arguments that presentation
of such engagement to shareholder approval is likely to prevent such engagement. To the extent that any such transaction with a controlling
shareholder is for a period exceeding three years, approval is required once every three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director or executive officer
may not be present when the board of directors of a company discusses or votes upon a transaction in which he or she has a personal interest,
except in case of ordinary transactions, unless the chairman of the board of directors determines that he or she should be present to
present the transaction that is subject to approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Independent directors. </i>Israeli law does not require that a majority of the directors serving on our Board of Directors be &#8220;independent,&#8221; as defined under Nasdaq Listing Rule 5605(a)(2), and rather requires we have at least two external directors who meet the requirements of the Companies Law, as described above under &#8220;Item 6. C. Board Practices &#8211; External Directors.&#8221; Notwithstanding Israeli law, we believe that a majority of our directors are currently &#8220;independent&#8221; under the Nasdaq Stock Market rules. We are required, however, to ensure that all members of our audit committee are &#8220;independent&#8221; under the applicable Nasdaq and SEC criteria for independence (as we cannot exempt ourselves from compliance with that SEC independence requirement, despite our status as a foreign private issuer), and we must also ensure that a majority of the members of our audit committee are &#8220;unaffiliated directors&#8221; as defined in the Companies Law. Furthermore, Israeli law does not require, nor do our independent directors conduct, regularly scheduled meetings at which only they are present, which the Nasdaq Stock Market rules otherwise require.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shareholder approval. </i>We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather than seeking approval for corporation actions in accordance with Nasdaq Listing Rule 5635. In particular, under this Nasdaq Stock Market rule, shareholder approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment of equity compensation arrangements (although under the provisions of the Companies Law there is no requirement for shareholder approval for the adoption/amendment of the equity compensation plan); and (iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors/officers/5% shareholders) if such equity is issued (or sold) below a specified minimum price. By contrast, under the Companies Law, shareholder approval is required for, among other things: (i) transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company), for which approvals of the compensation committee, board of directors and shareholders are all required, subject to applicable relief, (ii) extraordinary transactions with controlling shareholders of publicly held companies, which require the special approval, and (iii) terms of employment or other engagement of the controlling shareholder of us or such controlling shareholder&#8217;s relative, which require special approval. In addition, under the Companies Law, a merger requires approval of the shareholders of each of the merging companies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Approval of Related Party Transactions</i>. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transaction as set forth in the Companies Law, which requires the approval of the audit committee, or the compensation committee, as the case may be, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our board of directors as required under the Nasdaq Stock Market rules.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Annual Shareholders Meeting.</i> As opposed to the Nasdaq Stock Market Rule 5620(a), which mandates that a listed company hold its annual shareholders meeting within one year of the company&#8217;s fiscal year-end, we are required, under the Companies Law, to hold an annual shareholders meeting each calendar year and within 15 months of the last annual shareholders meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_082"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16H. MINE SAFETY DISCLOSURE</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_083"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_084"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_085"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 17.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>FINANCIAL STATEMENTS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have elected to provide
financial statements and related information pursuant to Item&#160;18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_086"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 18.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>FINANCIAL STATEMENTS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements and the related notes required by this Item are included in this annual report on Form 20-F beginning on page&#160;F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_087"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 19.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>EXHIBITS. </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; text-align: left; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021066318/ea152692ex99-1_inspiratech.htm">Amended and Restated Articles of Association of Inspira Technologies Oxy B.H.N. Ltd. (filed as Exhibit 99.1 to Form 6-K (File No. 001-40303) filed on December 20, 2021 and incorporated herein by reference).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="f20f2022ex2-1_inspiratech.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities.</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-1_inspiratech.htm">Form of Indemnification Agreement. (filed as Exhibit 10.1 to Form F-1 (File No. 333-253920) filed on March 12, 2021 and incorporated herein by reference).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021054754/ea149458ex10-2_inspiratech.htm">Inspira Technologies Oxy B.H.N. Ltd. (formerly known as: InSense Medical Ltd.) 2019 Equity Incentive Plan (amended on September 14, 2021), filed as Exhibit 10.2 to Post-Effective Amendment No. 1 to Form F-1 (File No. 333-253920) filed on October 27, 2021, and incorporated herein by reference.</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021066318/ea152692ex99-2_inspiratech.htm">Inspira Technologies Oxy B.H.N. Ltd. Compensation Policy for Company&#8217;s Executives, filed as Exhibit 99.2 to Form 6-K (File No. 001-4030) filed on December 20, 2021, and incorporated herein by reference.</a></span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex4-4_inspiratech.htm">Form of Warrant (filed as Exhibit 4.4 to form F-1 (File No. 333-253920) filed on July 1, 2021 and incorporated herein by reference).</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-7_inspiratech.htm">Form of Simple Agreement for Future Equity (filed as Exhibit 10.7 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference)</a></span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021034372/ea143325ex10-8_inspiratec.htm">Shareholder Loan Agreement, dated March 1, 2018, by and between the Company and Dagi Ben-Noon (filed as Exhibit 10.8 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference).</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-8_inspiratech.htm">Form of Convertible Loan Agreement (filed as Exhibit 10.9 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference)</a></span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="f20f2022ex12-1_inspiratech.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="f20f2022ex12-2_inspiratech.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.</span></a></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="f20f2022ex13-1_inspiratech.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350.</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="f20f2022ex13-2_inspiratech.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350.</span></a></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="f20f2022ex15-1_inspiratech.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Ziv Haft, a member firm of BDO, independent registered public accounting firm.</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following financial information from the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2022, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance sheets as of December 31, 2022, December 31, 2021 and December 31, 2020; (ii) Consolidated Statements of Comprehensive Loss as of December 31, 2022, December 31, 2021 and December 31, 2020; (iii) Consolidated Statement of Changes in Shareholders&#8217; Equity as of December 31, 2022, December 31, 2021 and December 31, 2020; (iv) Consolidated Statements of Cash Flows as of December 31, 2022, December 31, 2021 and December 31, 2020; and (v) Notes to the consolidated financial statements.</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_088"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
annual report on Form 20-F filed on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 31, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap">/s/ Dagi Ben-Noon</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">TABLE OF CONTENTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><a href="#a_001"><span style="font-size: 10pt">Report of Independent Registered Public Accounting Firm (BDO <ix:nonNumeric contextRef="c0" name="dei:AuditorName">Ziv Haft</ix:nonNumeric>; Tel-Aviv, Israel; PCAOB#<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">1185</ix:nonNumeric>)</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-2</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 90%"><a href="#a_002"><span style="font-size: 10pt">Statements of financial position</span></a></td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: center"><span style="font-size: 10pt">F-3</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><a href="#a_003"><span style="font-size: 10pt">Statements of comprehensive loss</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-4</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><a href="#a_004"><span style="font-size: 10pt">Statements of changes in shareholders&#8217; equity</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-5</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><a href="#a_006"><span style="font-size: 10pt">Statements of cash flows</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-8</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><a href="#a_009"><span style="font-size: 10pt">Notes to the financial statements</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-10-F-37</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">________________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">____________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The amounts are stated in thousands of U.S. dollars</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 128; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">To The Board of Directors and Shareholders of Inspira
Technologies Oxy B.H.N. Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ha-Tidhar Street 2, Rananna, Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Opinion on the Financial Statements&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying statements of
financial position of Inspira Technologies Oxy B.H.N. Ltd. (formerly: Insense Medical Ltd.) (the &#8220;Company&#8221;) as of December
31, 2022 and 2021, the related statements of comprehensive loss, changes in shareholders&#8217; equity, and cash flows for each of the
three years in the period ended December 31, 2022, and the related notes (collectively, the &#8220;Financial Statements&#8221;). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31,
2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31,
2022, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis for Opinion</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to
be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well
as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 65%"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation"><span style="font-size: 10pt">Tel-Aviv, Israel</span></ix:nonNumeric></td> <td style="width: 35%; text-align: center"><span style="font-size: 10pt">/s/ Ziv Haft</span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-size: 10pt">March 31, 2023</span></td> <td style="text-align: center"><span style="font-size: 10pt">Certified Public Accountants (Isr.)</span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-size: 10pt">We have served as the Company&#8217;s auditor since 2018.</span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">BDO Member Firm /s/</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd">6,783</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd">23,749</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deposits</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd">7,120</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="3" unitRef="usd">591</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="3" unitRef="usd">759</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd">14,494</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd">24,508</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Non-Current Assets:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right of use assets, net</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DeferredTaxAssets" scale="3" unitRef="usd">1,107</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DeferredTaxAssets" scale="3" unitRef="usd">1,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd">411</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd">202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd">1,518</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd">1,362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd">16,012</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd">25,870</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Trade accounts payables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd">150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other accounts payables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentPayables" scale="3" unitRef="usd">1,217</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentPayables" scale="3" unitRef="usd">725</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd">329</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd">281</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial liabilities at fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialLiabilities" scale="3" unitRef="usd">368</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialLiabilities" scale="3" unitRef="usd">3,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd">2,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd">4,314</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Non-Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd">728</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd">900</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan from the Israeli Innovation Authority</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="iinn:LoanFromTheIsraeliInnovationAuthority" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="iinn:LoanFromTheIsraeliInnovationAuthority" scale="3" unitRef="usd">302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non- current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="3" unitRef="usd">1,126</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="3" unitRef="usd">1,202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Shareholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share capital and additional paid in capital</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd">53,814</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd">48,935</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange reserve</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="3" sign="-" unitRef="usd">1,928</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="3" unitRef="usd">210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd">39,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd">28,791</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Shareholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">12,822</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">20,354</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities and Shareholders&#8217; Equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd">16,012</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd">25,870</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%">/s/ Yafit Tehila</td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%">/s/ Dagi Ben-Noon</td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt">March 28, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yafit Tehila<br/>
Chief Financial Officer</p></td>
    <td>&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dagi Ben-Noon<br/>
Chief Executive Officer</p></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Date of approval of financial statements</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The accompanying notes are an integral part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands except for loss per
share)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd">8,054</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd">3,909</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd">3,873</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:SalesAndMarketingExpenses" scale="3" unitRef="usd">1,325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:SalesAndMarketingExpenses" scale="3" unitRef="usd">1,951</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd">5,391</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd">7,572</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd">2,447</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="3" sign="-" unitRef="usd">51</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" unitRef="usd">14,770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" unitRef="usd">13,432</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" unitRef="usd">6,269</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Finance expense</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinanceExpense" scale="3" unitRef="usd">181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinanceExpense" scale="3" unitRef="usd">3,524</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinanceExpense" scale="3" unitRef="usd">959</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" sign="-" unitRef="usd">4,678</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" sign="-" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left">Loss before tax</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" unitRef="usd">10,273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" unitRef="usd">16,955</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" unitRef="usd">7,228</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperations" scale="3" unitRef="usd">10,273</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperations" scale="3" unitRef="usd">16,955</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperations" scale="3" unitRef="usd">7,228</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Other comprehensive loss, net of tax:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Items that will not be reclassified to profit or loss:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Exchange (losses)profits arising on translation to presentation currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="3" unitRef="usd">2,138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="3" sign="-" unitRef="usd">845</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="3" unitRef="usd">599</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" unitRef="usd">12,411</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" unitRef="usd">16,110</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" unitRef="usd">7,827</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Weighted average number of ordinary shares</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares">10,794,594</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares">5,306,225</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares">1,967,790</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-11; -sec-ix-hidden: hidden-fact-10; -sec-ix-hidden: hidden-fact-9">Basic and diluted loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares">0.95</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares">3.2</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares">3.67</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The accompanying notes are an integral part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">For the year ended December 31, 2022:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Share Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share capital and<br/> Additional
    Paid in Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustments arising from translating
    financial operation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance as of January&#160;1, 2022:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares">10,091,706</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">48,935</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">210</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">28,791</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">20,354</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd">10,273</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd">10,273</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="3" unitRef="usd">2,138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="3" unitRef="usd">2,138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalComprehensiveLoss" scale="3" sign="-" unitRef="usd">2,138</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalComprehensiveLoss" scale="3" sign="-" unitRef="usd">10,273</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalComprehensiveLoss" scale="3" sign="-" unitRef="usd">12,411</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share based compensation to exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationToExercise" scale="0" unitRef="shares">7,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">*</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">RSUs vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodSharesRestrictedStockUnit" scale="0" unitRef="shares">1,240,204</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Share based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd">4,879</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd">4,879</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Balance as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares">11,338,940</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">53,814</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">1,928</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">39,064</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">12,822</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">Less than thousand dollars</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The accompanying notes are an integral part
of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">For the year ended December 31, 2021:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Ordinary Share Capital</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>Additional</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Adjustments arising from translating</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Paid in Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> financial operation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; font-weight: bold; text-align: left">Balance as of January&#160;1,
    2021:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares">2,661,095</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">304</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">10,463</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">635</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">11,836</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">1,704</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd">16,955</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd">16,955</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="3" sign="-" unitRef="usd">845</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="3" sign="-" unitRef="usd">845</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Total comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalComprehensiveLoss" scale="3" unitRef="usd">845</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalComprehensiveLoss" scale="3" sign="-" unitRef="usd">16,955</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalComprehensiveLoss" scale="3" sign="-" unitRef="usd">16,110</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Par value cancellation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ParValueCancellations" scale="3" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ParValueCancellations" scale="3" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Initial Public Offering (&#8220;IPO&#8221;)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareIssuanceOfInitialPublicOffering" scale="0" unitRef="shares">2,931,472</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="iinn:InitialPublicOffering" scale="3" unitRef="usd">9,852</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:InitialPublicOffering" scale="3" unitRef="usd">9,852</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Conversion of financial liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ConversionOfFinancialLiabilityinShares" scale="0" unitRef="shares">2,113,905</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfConvertibleInstruments" scale="3" unitRef="usd">10,041</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfConvertibleInstruments" scale="3" unitRef="usd">10,041</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Tradable warrants exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="iinn:TradableWarrantsExerciseinShares" scale="0" unitRef="shares">1,705,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TradableWarrantsExercise" scale="3" unitRef="usd">11,447</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TradableWarrantsExercise" scale="3" unitRef="usd">11,447</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">RSUs vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodSharesRestrictedStockUnit" scale="0" unitRef="shares">655,603</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share based compensation to exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationToExercise" scale="0" unitRef="shares">24,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">*</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd">6,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd">6,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Balance as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares">10,091,706</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">48,935</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">210</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">28,791</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">20,354</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Less than thousand dollars</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The accompanying notes are an integral part
of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">For the year ended December 31, 2020:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Ordinary Share Capital</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Adjustments arising from translating</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Paid in Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> financial operation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; font-weight: bold">Balance as of January&#160;1, 2020:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares">1,904,762</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">36</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">4,608</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">4,641</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd">7,228</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd">7,228</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">--</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="3" unitRef="usd">599</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="3" unitRef="usd">599</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Total comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalComprehensiveLoss" scale="3" sign="-" unitRef="usd">599</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalComprehensiveLoss" scale="3" sign="-" unitRef="usd">7,228</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalComprehensiveLoss" scale="3" sign="-" unitRef="usd">7,827</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Share split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareSplit" scale="3" unitRef="usd">215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareSplit" scale="3" sign="-" unitRef="usd">215</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd">3,896</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd">3,896</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Share based compensation to exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="iinn:OptionsExercise" scale="3" unitRef="usd">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="iinn:OptionsExercise" scale="3" sign="-" unitRef="usd">9</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Conversion of convertible loan to shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c30" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ConversionOfConvertibleLoanToSharesinShares" scale="0" unitRef="shares">756,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ConversionOfConvertibleLoanToShares" scale="3" unitRef="usd">77</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ConversionOfConvertibleLoanToShares" scale="3" unitRef="usd">6,791</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ConversionOfConvertibleLoanToShares" scale="3" unitRef="usd">6,868</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: justify">Balance as of December 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares">2,661,095</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd">10,463</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">635</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">11,836</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd">1,704</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The accompanying notes are an integral part
of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CASH FLOW</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">CASH FLOW FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 64%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd">10,273</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd">16,955</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd">7,228</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Adjustments to reconcile net loss to net cash provided
    by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd">361</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd">203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" unitRef="usd">204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd">4,879</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd">6,630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd">3,896</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Revaluation of financial liabilities accounted at fair
    value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ChangeInFairValueOfFinancialLiabilitiesAtFairValue" scale="3" sign="-" unitRef="usd">2,592</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ChangeInFairValueOfFinancialLiabilitiesAtFairValue" scale="3" unitRef="usd">2,313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ChangeInFairValueOfFinancialLiabilitiesAtFairValue" scale="3" unitRef="usd">689</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Changes of financial liabilities - IPO non-cash expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFairValueGainsLosses" scale="3" unitRef="usd">219</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Change in connection to loan from the Israeli Innovation
    Authority</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfLoanFromTheIsraeliInnovationAuthority" scale="3" sign="-" unitRef="usd">180</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Financial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinanceExpensesReceivedClassifiedAsOperatingActivitiy" scale="3" sign="-" unitRef="usd">459</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinanceExpensesReceivedClassifiedAsOperatingActivitiy" scale="3" unitRef="usd">92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinanceExpensesReceivedClassifiedAsOperatingActivitiy" scale="3" unitRef="usd">12</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Changes in operating assets and liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Decrease (increase) in other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" scale="3" sign="-" unitRef="usd">468</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" scale="3" unitRef="usd">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Increase (decrease) in trade accounts payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd">71</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd">87</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" sign="-" unitRef="usd">70</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Increase in other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd">604</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd">148</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd">408</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used
    in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">7,380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">7,877</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">1,876</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">CASH FLOW FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Purchase of property, plant, and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd">176</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd">23</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Payment of deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:PaymentOfDeposit" scale="3" unitRef="usd">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:PaymentOfDeposit" scale="3" sign="-" unitRef="usd">70</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:PaymentOfDeposit" scale="3" sign="-" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1.5pt">Change of deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" sign="-" unitRef="usd">7,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used
    in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">7,249</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">246</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Principal paid on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DividendsPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd">399</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DividendsPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd">199</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DividendsPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd">176</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Receipt of simple agreements for future equity (SAFE) and
    convertible loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" scale="3" unitRef="usd">7,208</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" scale="3" unitRef="usd">2,157</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Receipt of IPO funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ReceiptOfIPOFunds" scale="3" sign="-" unitRef="usd">14,658</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Receipt of warrants exercise funds, net from fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ReceiptOfWarrantsExerciseFundsNetFromFees" scale="3" unitRef="usd">8,721</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Loan from the Israeli Innovation
    Authority</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="3" unitRef="usd">34</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="3" unitRef="usd">308</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided
    by (used in) financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" sign="-" unitRef="usd">399</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd">30,422</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd">2,289</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Net increase (decrease) in cash and
    cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd">15,028</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" unitRef="usd">22,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" unitRef="usd">387</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash
    equivalents at the beginning of the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd">23,749</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd">496</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd">96</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Effects of exchange
    rate changes on cash and cash equivalents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" sign="-" unitRef="usd">1,938</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" unitRef="usd">954</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" unitRef="usd">13</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Cash and cash
    equivalents at the end of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd">6,783</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd">23,749</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd">496</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The accompanying notes are an integral part of the financial statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CASH FLOW</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">APPENDIX A &#8211; NON-CASH TRANSACTIONS:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Conversion of convertible loans to equity</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="3" unitRef="usd">10,041</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tradable warrants at the IPO date</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TradableWarrantsLiability" scale="3" sign="-" unitRef="usd">4,373</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tradable warrants financial liability at the IPO date</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TradableWarrantsDerivativeLiability" scale="3" sign="-" unitRef="usd">234</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share based compensation &#8211; underwriters fees at the IPO date</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationUnderwritersFees" scale="3" unitRef="usd">198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants exercise to equity &#8211; financial liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" unitRef="usd">656</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercise &#8211; allocation from liability to equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:WarrantsExerciseLiabilityIssuance" scale="3" unitRef="usd">2,070</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalNonCashTransactions" scale="3" unitRef="usd">8,358</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">APPENDIX B - AMOUNT PAID DURING THE PERIOD:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Interest paid</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxesPaidRefund" scale="3" unitRef="usd">37</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxesPaidRefund" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxesPaidRefund" scale="3" unitRef="usd">45</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The accompanying notes are an integral part of the financial statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - GENERAL:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_2" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inspira Technologies Oxy B.H.N. Ltd (formerly: Insense Medical Ltd.)
    (the &#8220;Company&#8221;) was incorporated in Israel and commenced its operations on February 27, 2018. The Company&#8217;s functional
    currency is the New Israeli Shekel (&#8220;NIS&#8221;).</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_3" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company operates in the
medical technology industry in the field of respiratory support technology engaged in the research, development, manufacturing related
activities, and go to market activities of proprietary products and technologies. The Company is developing the following products:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_4" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(*)The INSPIRA ART (Augmented
Respiratory Technology), which is a respiratory support technology targeted toward utilizing direct blood oxygenation to boost patient
saturation levels within minutes while the patient is awake and spontaneously breathing. The aim is to reduce the need for invasive mechanical
ventilation, with the potential to reduce risks, complications and high costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_5" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(*) The HYLA blood sensor,
which is a non-invasive optical blood sensor designed to perform real-time and continuous blood measurements, potentially minimizing
the need to take actual blood samples from patients.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_6" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(*)The ALICE Device, an advanced
form of life support system better known by the medical industry as a cardiopulmonary bypass system is being designed for use in surgical
procedures requiring cardiopulmonary bypass for six hours or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_7" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company&#8217;s products are in the development stage. The ALICE
    device and the INSPIRA ART has not yet been tested or used in humans and the Company&#8217;s products have not been approved by the
    U.S. Food and Drug Administration (the &#8220;FDA&#8221;). </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -14.15pt">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_8" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On July 16, 2021, the Company completed its IPO on the Nasdaq Capital Market, whereby the Company sold <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="iinn:NumberOfShares" scale="0" unitRef="shares">2,909,091</ix:nonFraction> ordinary shares, no par value (the &#8220;Ordinary Shares&#8221;) and <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="iinn:TradableWarrantsShares" scale="0" unitRef="shares">3,345,455</ix:nonFraction> tradable warrants (inclusive of <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="iinn:WarrantsPursuantShares" scale="0" unitRef="shares">436,364</ix:nonFraction> tradable warrants pursuant to the exercise of an overallotment option granted to the underwriters). The aggregate proceeds received by the Company from the IPO were approximately <ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateProceedsAmount" scale="3" unitRef="usd">14,490</ix:nonFraction>, after deducting underwriting discounts and commissions and additional offering costs totaled in approximately <ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AdditionalOfferingCosts" scale="3" unitRef="usd">1,543</ix:nonFraction>. On July 16, 2021, following the closing of the IPO, the Company issued <ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="iinn:OrdinaryShares" scale="0" unitRef="shares">2,113,905</ix:nonFraction> Ordinary Shares and <ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="iinn:WarrantsShares" scale="0" unitRef="shares">1,149,582</ix:nonFraction> non-tradable warrants to investors and 16,587 non-tradeable warrants to brokers in connection with the conversion of Company&#8217;s previously issued financial liabilities at fair value.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_9" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In October 2021, investors exercised
<ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="iinn:TradableWarrantsShares" scale="0" unitRef="shares">1,705,000</ix:nonFraction> tradable warrants Company. The total proceeds received by the Company from this exercise were approximately <ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="iinn:InvestorsExercise" scale="3" unitRef="usd">9,377</ix:nonFraction>. The Company
paid fees of <ix:nonFraction contextRef="c37" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfPaidFees" scale="-2" unitRef="pure">7</ix:nonFraction>% in the amount of <ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="iinn:PaidFeesAmount" scale="3" unitRef="usd">656</ix:nonFraction> according to the terms of a contract with a promoter in connection with the IPO for which the Company
recorded a financial liability (note 8(3)).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_10" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The Company has not generated any revenue since its inception and the Company&#8217;s products are in the development stage. The Company&#8217;s operating loss for the years ended December 31, 2021 and 2022 were $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OperatingLeaseIncome" scale="6" unitRef="usd">13.4</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OperatingLeaseIncome" scale="6" unitRef="usd">14.8</ix:nonFraction>&#160;million, respectively and the Company&#8217;s net loss for the same period was $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="6" unitRef="usd">16.9</ix:nonFraction> million and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="6" unitRef="usd">10.3</ix:nonFraction> million, respectively. As of December 31, 2022, the Company had an accumulated deficit of $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="6" unitRef="usd">39.1</ix:nonFraction>&#160;million. The Company funds its operations through the proceeds of the IPO.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -14.15pt">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_11" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s
management intends to seek additional funding through public offerings, which will be utilized to fund product development and continue
operations. The Company does not have any material financial obligations as of the balance date. The Company believes that it has sufficient
resources to operate in the foreseeable future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_12" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify">The Ukraine Conflict</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_13" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Although we do not currently conduct
business in Russia and Ukraine, the escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations in
the Russian Ruble has had a negative impact on worldwide markets. Such impact may negatively impact our supply chain, our operations
and future growth prospects in that region.&#160;As a result of the crisis in Ukraine,&#160;both the U.S. and other countries have implemented
sanctions against certain Russian individuals and entities. Our global operations expose us to risks that could adversely affect our
business, financial condition, results of operations, cash flows or the market price of our securities, including the potential for increased
tensions between Russia and other countries resulting from the current situation involving Russia and Ukraine, tariffs, economic sanctions
and import-export restrictions imposed, and retaliatory actions, as well as the potential negative impact on our potential business and
sales in the region. Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S. and other governments against
certain companies and individuals may hinder our ability to conduct business with potential customers and vendors in these countries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">6.</td><td style="text-align: justify">These financial statements were authorized by the
                                            board of directors on March 28, 2023.</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_2" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New standards, interpretations and amendments
not yet effective.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_3" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are a number of standards, amendments to
standards, and interpretations which have been issued by the IASB that are effective in future accounting periods that the Company has
decided not to adopt early.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_4" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2020, the IASB issued amendments to
IAS 1, which clarify the criteria used to determine whether liabilities are classified as current or non-current. These amendments clarify
that current or non-current classification is based on whether an entity has a right at the end of the reporting period to defer settlement
of the liability for at least twelve months after the reporting period. The amendments also clarify that &#8217;settlement&#8217; includes
the transfer of cash, goods, services, or equity instruments unless the obligation to transfer equity instruments arises from a conversion
feature classified as an equity instrument separately from the liability component of a compound financial instrument. The amendments
were originally effective for annual reporting periods beginning on or after 1 January 2022. However, in May 2020, the effective date
was deferred to annual reporting periods beginning on or after 1 January 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_5" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In its June 2021 meeting, the IASB tentatively
decided to amend the requirements of IAS 1 with respect to the classification of liabilities subject to conditions and disclosure of
information about such conditions and to defer the effective date of the 2020 amendment by at least one year.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_6" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is currently assessing the impact
of these new accounting standards and amendments. The Company will assess the impact of the final amendments to IAS 1 on classification
of its liabilities once the those are issued by the IASB.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_7" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not believe that the amendments
to IAS 1, in its present form, will have a significant impact on the classification of its liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_8" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not expect any other standards
issued by the IASB, but not yet effective, to have a material impact on the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_9" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of preparation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_10" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_9"><ix:nonNumeric contextRef="c0" continuedAt="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock-c0_cont_1" escape="true" name="iinn:UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of estimates and assumptions in the preparation
of the financial statements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_11" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_10"><ix:continuation id="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets
and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results
could differ from those estimates. See also Note 3.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_12" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_11"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and cash equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_13" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_12"><ix:continuation id="_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash equivalents are considered by the Company
to be highly-liquid investments, including, short-term deposits with banks, the maturity of which does not exceed three months at the
time of deposit and which are not restricted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES
(CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_14" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_13"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Loss per share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_15" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_14"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss per share is calculated
as net loss attributed to the Company, divided by the weighted average number of ordinary shares, adjusted for any bonus element.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_16" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_15"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted (loss) earnings per share is determined
by adjusting the earnings or loss attributable to common shareholders and the weighted average number of common shares outstanding for
the effects of dilutive instruments, which includes stock options, as if their dilutive effect was at the beginning of the period. The
calculation of the diluted number of common shares assumes that proceeds received from the exercise of &#8220;in-the- money&#8221; stock
options and common share purchase warrants are used to purchase common shares of the Company at their average market price for the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_17" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_16"><ix:continuation id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In periods that the Company reports a net loss,
any stock options or warrants outstanding are excluded from the calculation of diluted loss per share as their inclusion would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_18" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_17"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Functional and foreign currency</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_19" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_18"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s functional currency is NIS.
However, the presentation currency is the U.S. dollar (&#8220;USD&#8221;). Transactions and balances are converted into USD in accordance
with the principles set forth by International Accounting Standard (IAS) 21 &#8220;The Effects of Changes in Foreign Exchange Rates.&#8221;
Accordingly, transactions and balances have been converted as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_20" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_19"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Assets and liability items were reported at closing rate of exchange
    at the statements of financial position date.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_21" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_20"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Other comprehensive income items were reported at annual average rate
    of exchange at the statements of financial position date.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_22" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_21"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Share capital, capital reserve and other capital movement items were
    at rate of exchange as of the date of recognition of those items.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_23" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_22"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Accumulated deficit was based on the opening balance for the beginning
    of the reporting period in addition to the movements mentioned above.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_24" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_23"><ix:continuation id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Rate of exchange rate differentials created was recognized in other
    comprehensive income and accumulated in equity.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_25" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_24"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Fair value measurement</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_26" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_25"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Fair value is the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability
takes place either:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.5in; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_27" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_26"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">A.</span></td><td style="text-align: justify"><span style="font-size: 10pt">In
                                            the principal market for the asset or liability, or</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_28" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_27"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">B.</span></td><td style="text-align: justify"><span style="font-size: 10pt">In
                                            the absence of a principal market, in the most advantageous market for the asset or liability.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_29" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_28"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The principal or the
most advantageous market must be accessible by the Company in order to measure an asset or liability by its fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_30" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_29"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The fair value of an
asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming
that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a
market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another
market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_31" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_30"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">When there are no quoted
prices in active markets for identical assets or liabilities, the Company uses valuation techniques that are appropriate in the circumstances
and for which sufficient data is available to measure fair value, maximizing the use of relevant observable inputs and minimizing the
use of unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_32" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_31"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Classification by fair
value hierarchy Assets and liabilities measured in the statement of financial position at fair value are grouped into classes with similar
characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_33" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_32"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;1&#160;-&#160;Quoted prices (unadjusted)
in active markets for identical assets or liabilities.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_34" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_33"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;2&#160;- Inputs other than quoted
prices included within Level 1 that are observable either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_35" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_34"><ix:continuation id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;3&#160;- Inputs that are not based
on observable market data (valuation techniques that use inputs that are not based on observable market data).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_36" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_35"><ix:nonNumeric contextRef="c0" continuedAt="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_1" escape="true" name="ifrs-full:ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Financial instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_37" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_36"><ix:continuation continuedAt="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_2" id="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Financial
                                            assets</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_38" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_37"><ix:continuation continuedAt="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_3" id="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">The Company
classifies its financial assets into the following category, based on the business model for managing the financial asset and its contractual
cash flow characteristics. The Company&#8217;s accounting policy for the relevant category is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_39" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_38"><ix:continuation continuedAt="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_4" id="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">Amortized
cost: other types of financial assets where the objective is to hold these assets in order to collect contractual cash flows and the
contractual cash flows are solely payments of principal and interest. They are initially recognized at fair value including direct transaction
costs and are subsequently carried at amortized cost using the effective interest rate method, less provision for impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -17.85pt; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_40" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_39"><ix:continuation continuedAt="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_5" id="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Financial
                                            Liabilities</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_41" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_40"><ix:continuation continuedAt="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_6" id="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company classifies its financial
liabilities, including trade accounts payable and other accounts payable, which are initially recognized at fair value and subsequently
carried at amortized cost using the effective interest method. The financial liabilities at fair value (see also Notes 8 and 19) are
measured at fair value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_42" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_41"><ix:continuation continuedAt="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_7" id="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">3.</span></td>
    <td><span style="font-size: 10pt"><span style="text-decoration: underline">De-recognition</span></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_43" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_42"><ix:continuation continuedAt="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_8" id="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Financial
                                            assets - The Company derecognizes a financial asset when the contractual rights to the cash
                                            flows from the financial asset expire or it transfers the rights to receive the contractual
                                            cash flows.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_44" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_43"><ix:continuation continuedAt="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_9" id="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Financial
                                            Liabilities - The Company derecognizes a financial liability when its contractual obligations
                                            are discharged or cancelled or expire.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_45" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_44"><ix:continuation continuedAt="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_10" id="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Impairment of financial assets</span></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_46" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_45"><ix:continuation continuedAt="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_11" id="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">The Company
does not have any assets which require a recognition of expected credit losses (&#8220;ECL&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_47" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_46"><ix:continuation id="_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Cash and
cash equivalents are subject to the impairment requirements of IFRS 9, the Company did not identify impairment for the cash and cash
equivalent.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_48" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_47"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Property, plant, and equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_49" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_48"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Items of property, plant
and equipment are initially recognized at cost including directly attributable costs. Depreciation is calculated on a straight-line basis,
over the useful lives of the assets at annual rates as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_50" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_49"><ix:nonNumeric contextRef="c4" escape="true" name="iinn:ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Annual depreciation rate (%)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c38" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRateInPercentage" scale="-2" unitRef="pure">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Development equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c39" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRateInPercentage" scale="-2" unitRef="pure">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c40" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRateInPercentage" scale="-2" unitRef="pure">6</ix:nonFraction>-<ix:nonFraction contextRef="c41" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRateInPercentage" scale="-2" unitRef="pure">15</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c42" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRateInPercentage" scale="-2" unitRef="pure">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_51" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_50"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Subsequent costs are
included in the asset&#8217;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future
economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount
of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to statement
of the comprehensive loss during the reporting period in which they are incurred. The assets&#8217; residual values and useful lives
are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset&#8217;s carrying amount is written down immediately
to its recoverable amount if the asset&#8217;s carrying amount is higher than its estimated recoverable amount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_52" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_51"><ix:continuation id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Gains and losses on
disposals are determined by comparing proceeds with carrying amount. These are included in statement of the comprehensive loss.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_53" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_52"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Impairment of non-financial
assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_54" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_53"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Non-financial assets
are subject to impairment test whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.
Where the carrying value of the non-financial asset exceeds its recoverable amount (i.e., the higher of value in use and fair value less
costs to dispose), the asset is written down and impairment charge is recognized accordingly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_55" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_54"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Where it is not possible
to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset&#8217;s cash-generating unit
(i.e., the smallest group of assets to which the asset belongs that generates cash inflow that is largely independent of cash inflows
from other assets).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Impairment of non-financial
assets (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_56" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_55"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">An impairment loss allocated
to an asset, is reversed only if there have been changes in the estimates used to determine the asset&#8217;s recoverable amount since
the last impairment loss was recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_57" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_56"><ix:continuation id="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Reversal of an impairment
loss, as above, is limited to the lower of the carrying amount of the asset that would have been determined (net of depreciation or amortization)
had no impairment loss been recognized for the asset in prior years and the asset&#8217;s recoverable amount. After an impairment of
non-financial asset is recognized, the Company examines at each reporting date whether there are indications that the impairment which
was recognized in the past no longer exists or should be reduced. The reversal of impairment loss of an asset is recognized in statement
of the comprehensive loss. Impairment charges are included in general and administrative expenses in the statement of the comprehensive
loss. During the years ended December 31, 2022 and 2021, no impairment charges of non-financial assets were recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_58" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_57"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Research and development costs</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_59" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_58"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Expenditure on research
activities is recognized in statement of the comprehensive loss as incurred. Development expenditures is recognized as an intangible
asset when the Company can demonstrate:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_60" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_59"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The product is technically
and commercially feasible.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_61" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_60"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The Company intends to complete
the product so that it will be available for use or sale.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_62" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_61"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The Company has the ability
to use the product or sell it.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_63" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_62"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The Company has the technical,
financial and other resources to complete the development and to use or sell the product.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_64" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_63"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The Company can demonstrate that the product will generate future economic benefits.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_65" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_64"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The Company is able to measure reliably the expenditure attributable to the product during the
    development.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_66" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_65"><ix:continuation id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the years ended
December 31, 2021 and 2022, the Company&#8217;s research and development costs were not capitalized as they did not meet the criteria
set forth in IAS&#160;38.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_67" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_66"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Segment reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_68" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_67"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An operating segment is a component of the Company
which fulfills the following criteria:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_69" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_68"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">1.</td><td style="text-align: justify">It is engaged in business operations
                                            from which it may derive income, and with respect to which it may bear expenses.</td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_70" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_69"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">Its operating results are reviewed on
                                            a regular basis by the Company&#8217;s chief operational decision maker, in order to reach
                                            decisions regarding the resources allocated to it, and in order to assess its performance.</td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_71" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_70"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">3.</td><td style="text-align: justify">Separate financial information is available
                                            for the above.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_72" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_71"><ix:continuation id="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company concluded that it has one operating
segment.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_73" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_72"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Share based payment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_74" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_73"><ix:continuation id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company measures
the share based expense and the cost of equity-settled transactions with employees and service providers by reference to the fair value
of the equity instruments at the date at which they are granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_75" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_74"><ix:nonNumeric contextRef="c0" continuedAt="iinn_OptionsPolicyTextBlock-c0_cont_1" escape="true" name="iinn:OptionsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Options</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_76" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_75"><ix:continuation continuedAt="iinn_OptionsPolicyTextBlock-c0_cont_2" id="iinn_OptionsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The fair value is determined
using an accepted options pricing model. The model is based on share price, grant date and on assumptions regarding expected volatility,
expected life of the options, expected dividend, and a no risk interest rate. The options were granted before the Company became public
and had no quoted price per share from a trading market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_77" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_76"><ix:continuation continuedAt="iinn_OptionsPolicyTextBlock-c0_cont_3" id="iinn_OptionsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company selected
the Black-Scholes model as the Company&#8217;s option pricing model to estimate the fair value of the Company&#8217;s options awards.
The option-pricing model requires a number of assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_78" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_77"><ix:continuation continuedAt="iinn_OptionsPolicyTextBlock-c0_cont_4" id="iinn_OptionsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Expected dividend
yield</i> - The expected dividend yield assumption is based on the Company&#8217;s historical experience and expectation of no future
dividend payouts. The Company has not historically paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_79" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_78"><ix:continuation continuedAt="iinn_OptionsPolicyTextBlock-c0_cont_5" id="iinn_OptionsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Volatility</i>&#160;-
The expected volatility is based on similar companies&#8217; stock volatility.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_80" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_79"><ix:continuation continuedAt="iinn_OptionsPolicyTextBlock-c0_cont_6" id="iinn_OptionsPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Risk free interest
rate</i>&#160;- The risk-free interest rate is based on the yield of governmental bonds with equivalent terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_81" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_80"><ix:continuation id="iinn_OptionsPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Contractual term</i>&#160;-
An option&#8217;s contractual term is the amount of time the holder has to exercise the option, per the contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_82" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_81"><ix:nonNumeric contextRef="c0" continuedAt="iinn_RestrictedShareUnitsPolicyTextBlock-c0_cont_1" escape="true" name="iinn:RestrictedShareUnitsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Restricted Share
Units (&#8220;RSUs&#8221;) </b>- The fair value is measured by multiplying the number of the restricted shares units granted to employees,
directors, and subcontractors by the quoted share price as of the grant date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_83" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_82"><ix:continuation id="iinn_RestrictedShareUnitsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The granted options
are settled in equity instruments and not in cash. The fair value of the options at the date of grant is charged to the statement of
comprehensive loss over the vesting period. Non-market vesting conditions are considered by adjusting the number of equity instruments
expected to vest at each reporting date so that, ultimately, the cumulative amount recognized over the vesting period is based on the
number of options that eventually vest. Non-vesting conditions and market vesting conditions are factored into the fair value of the
options granted. As long as all other vesting conditions are satisfied, a charge is made irrespective of whether the market vesting conditions
are satisfied. The cumulative expense is not adjusted for failure to achieve a market vesting condition or where a non-vesting condition
is not satisfied. Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options,
measured immediately before and after the modification, is also charged to the statement of comprehensive loss over the remaining vesting
period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_84" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_83"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForGovernmentGrants-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Government grants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_85" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_84"><ix:continuation id="_DescriptionOfAccountingPolicyForGovernmentGrants-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Israel Innovation
Authority (&#8220;IIA&#8221;) provided government grants to the Company for certain research and development activities. The Company
may be required to pay royalties to the IIA in the future if it generates sales from the related research and development activity. The
grant was recognized as a liability in the financial statements. When the loan bears a below-market rate of interest, the liability is
recognized at its fair value in accordance with the market interest rate prevailing at the time of receiving the grant. The difference
between the consideration received and the liability recognized at inception was treated as a government grant and recognized as a reimbursement
of research expenses. The repayment of the liability to the state is reviewed every reporting period, with changes in the liability resulting
from a change in the expected royalties recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_86" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_85"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Current taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_87" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_86"><ix:continuation id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_88" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_87"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Deferred tax</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_89" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_88"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Significant management
judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the estimated timing and level
of future taxable profits together with future tax planning strategies. Deferred taxes are recognized in respect of temporary differences
between the carrying amounts of assets and liabilities in the financial statements and the amounts attributable for tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_90" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_89"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Deferred taxes are measured
at the tax rates that are expected to apply in the period when the temporary differences are reversed based on tax laws that have been
enacted or substantively enacted at the end of the reporting period. Deferred taxes are recognized in profit or loss, except when they
relate to items recognized in other comprehensive income or directly in equity. Deferred tax assets are reviewed at the end of each reporting
period and reduced to the extent that it is not probable that they will be utilized. In addition, temporary differences (such as carry
forward losses) for which deferred tax assets have not been recognized are reassessed and deferred tax assets are recognized to the extent
that their recoverability is probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_91" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_90"><ix:continuation id="_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Any resulting reduction
or reversal is recognized on &#8220;income tax&#8221; within the statement of comprehensive income. All deferred tax assets and liabilities
are presented in the statement of financial position as non-current items, respectively. Deferred taxes are offset in the statement of
financial position if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred
taxes relate to the same taxpayer and the same taxation authority.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_92" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_91"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Employee benefits</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_93" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_92"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company has several
employee benefit plans for Israeli employees:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_94" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_93"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Short-term employee benefits:
Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions, which
are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_94"><ix:continuation id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Post-employment benefits: The
plans are normally financed by contributions to insurance companies and classified as defined contribution plans. The Company has contributed
for all of its employees&#8217; contribution plans pursuant to Section 14 to the Severance Pay Law since 2018 under which the Company
pays fixed contributions and will not have any legal or constructive obligation to pay further contributions if the fund does not hold
sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods.</span></td>
</tr></table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfAccountingJudgementsAndEstimatesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt; background-color: white"><b>NOTE
3 - CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt; background-color: white"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfAccountingJudgementsAndEstimatesExplanatory-c0_cont_2" id="_DisclosureOfAccountingJudgementsAndEstimatesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Share based payments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfAccountingJudgementsAndEstimatesExplanatory-c0_cont_3" id="_DisclosureOfAccountingJudgementsAndEstimatesExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The fair value of share
options was estimated by using a Black Scholes model approach, which was aimed to model the value of the Company&#8217;s equity over
time. A change of the estimation can cause to recognition or reversal of share based compensation expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfAccountingJudgementsAndEstimatesExplanatory-c0_cont_4" id="_DisclosureOfAccountingJudgementsAndEstimatesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Financial liabilities
at fair value</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfAccountingJudgementsAndEstimatesExplanatory-c0_cont_5" id="_DisclosureOfAccountingJudgementsAndEstimatesExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The fair value of financial
liabilities at fair value was estimated by using a Black Scholes model and Monte-Carlo simulation approach, which was aimed to model
the value of the Company&#8217;s assets over time. The simulation approach was designed to take into account the terms and conditions
financial liability, which are described in Note 8 and Note 20, as well as the capital structure of the Company and the volatility of
its assets. The valuation was performed based on management&#8217;s assumptions and projections.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfAccountingJudgementsAndEstimatesExplanatory-c0_cont_6" id="_DisclosureOfAccountingJudgementsAndEstimatesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Determination of
lease incremental borrowing rate</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfAccountingJudgementsAndEstimatesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company measures
the incremental borrowing rate by analyzing similar borrowing that could be obtained from an independent valuation under comparable terms
and conditions. A change of the estimation can cause to an increase or decrease in the measurement of a right-of-use asset and lease
liability.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfDepositsFromBanksExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfDepositsFromBanksExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 4 &#8211; DEPOSITS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfDepositsFromBanksExplanatory-c0_cont_2" id="_DisclosureOfDepositsFromBanksExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">The deposits are three short-term bank deposits
with maturities of more than three months but less than one year. The deposits are in dollars and bear annual interest.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfDepositsFromBanksExplanatory-c0_cont_3" id="_DisclosureOfDepositsFromBanksExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">On May 10, 2022, the Company deposited <ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepositsFromBanks" scale="0" unitRef="usd">2,000</ix:nonFraction>
with an annual interest rate of <ix:nonFraction contextRef="c43" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure">3.02</ix:nonFraction>% for a period of 9 months. As of December 31, 2022, the value of the deposit is <ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="iinn:DepositValue" scale="0" unitRef="usd">2,039</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfDepositsFromBanksExplanatory-c0_cont_4" id="_DisclosureOfDepositsFromBanksExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">On August 11, 2022, the Company deposited
<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepositsFromBanks" scale="0" unitRef="usd">2,000</ix:nonFraction> with an annual interest rate of <ix:nonFraction contextRef="c44" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure">4.39</ix:nonFraction>% for a period of 12 months. As of December 31, 2022, the value of the deposit is <ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="iinn:DepositValue" scale="0" unitRef="usd">2,034</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfDepositsFromBanksExplanatory-c0_cont_5" id="_DisclosureOfDepositsFromBanksExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">On August 24, 2022, the Company deposited
<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepositsFromBanks" scale="0" unitRef="usd">3,000</ix:nonFraction> with an annual interest rate of <ix:nonFraction contextRef="c45" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure">4.47</ix:nonFraction>% for a period of 9 months. As of December 31, 2022, the value of the deposit is <ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="iinn:DepositValue" scale="0" unitRef="usd">3,047</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfDepositsFromBanksExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">As of December 31, 2022 total deposits amounted
to <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepositsFromBanks" scale="0" unitRef="usd">7,120</ix:nonFraction>.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfOtherNoncurrentAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 5 - OTHER CURRENT ASSETS:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_DisclosureOfOtherNoncurrentAssetsExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd">256</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd">426</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Institutions" scale="3" unitRef="usd">276</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Institutions" scale="3" unitRef="usd">210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" scale="3" unitRef="usd">56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" scale="3" unitRef="usd">120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:OthersCurrentAssets" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:OthersCurrentAssets" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="3" unitRef="usd">591</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="3" unitRef="usd">759</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfPropertyPlantAndEquipmentExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 - PROPERTY AND EQUIPMENT, NET:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfPropertyPlantAndEquipmentExplanatory-c0_cont_2" id="_DisclosureOfPropertyPlantAndEquipmentExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">For the year ended December 31, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfPropertyPlantAndEquipmentExplanatory-c0_cont_3" id="_DisclosureOfPropertyPlantAndEquipmentExplanatory-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock-c0_cont_1" escape="true" name="iinn:ScheduleOfPropertyAndEquipmentNetTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">84</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">7</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">64</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">81</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">236</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd">30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd">191</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd">40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate deference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDeferenceCost" scale="3" sign="-" unitRef="usd">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDeferenceCost" scale="3" sign="-" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDeferenceCost" scale="3" sign="-" unitRef="usd">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDeferenceCost" scale="3" sign="-" unitRef="usd">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDeferenceCost" scale="3" sign="-" unitRef="usd">41</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0in">At December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">121</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">229</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">499</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">At January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">34</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd">61</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate deference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDeferenceAccumulatedDepreciation" scale="3" sign="-" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDeferenceAccumulatedDepreciation" scale="3" sign="-" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDeferenceAccumulatedDepreciation" scale="3" sign="-" unitRef="usd">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDeferenceAccumulatedDepreciation" scale="3" sign="-" unitRef="usd">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0in">At December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">51</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">88</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NetBookValue" scale="3" unitRef="usd">70</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NetBookValue" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NetBookValue" scale="3" unitRef="usd">204</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NetBookValue" scale="3" unitRef="usd">108</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NetBookValue" scale="3" unitRef="usd">411</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_DisclosureOfPropertyPlantAndEquipmentExplanatory-c0_cont_4" id="_DisclosureOfPropertyPlantAndEquipmentExplanatory-c0_cont_3"><ix:continuation continuedAt="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock-c0_cont_2" id="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-size: 10pt">Less than thousand dollars</span></ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfPropertyPlantAndEquipmentExplanatory-c0_cont_5" id="_DisclosureOfPropertyPlantAndEquipmentExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">For the year ended December 31, 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfPropertyPlantAndEquipmentExplanatory-c0_cont_6" id="_DisclosureOfPropertyPlantAndEquipmentExplanatory-c0_cont_5"><ix:continuation continuedAt="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock-c0_cont_3" id="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">At January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">7</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">19</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">54</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd">62</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd">0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd">58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd">62</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd">182</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">At December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">81</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd">236</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">At January 1, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">*</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd">15</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd">25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">At December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccumulatedDepreciation" scale="3" unitRef="usd">34</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NetBookValue" scale="3" unitRef="usd">62</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NetBookValue" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NetBookValue" scale="3" unitRef="usd">56</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NetBookValue" scale="3" unitRef="usd">78</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NetBookValue" scale="3" unitRef="usd">202</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation id="_DisclosureOfPropertyPlantAndEquipmentExplanatory-c0_cont_6"><ix:continuation id="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-size: 10pt">Less than one thousand dollars</span></ix:footnote></td>
</tr></table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfTradeAndOtherPayablesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 - OTHER ACCOUNTS PAYABLE:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_DisclosureOfTradeAndOtherPayablesExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfOtherAccountPayableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employees salaries and related liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="iinn:EmployeesSalariesAndRelatedLiabilities" scale="3" unitRef="usd">396</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="iinn:EmployeesSalariesAndRelatedLiabilities" scale="3" unitRef="usd">339</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentPayablesToRelatedParties" scale="3" unitRef="usd">332</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentPayablesToRelatedParties" scale="3" unitRef="usd">275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="3" unitRef="usd">470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="3" unitRef="usd">82</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentPayables" scale="3" unitRef="usd">1,217</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentPayables" scale="3" unitRef="usd">725</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfGovernmentGrantsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfGovernmentGrantsExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 - LIABILITY IN RESPECT OF GOVERNMENT
GRANTS:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGovernmentGrantsExplanatory-c0_cont_2" id="_DisclosureOfGovernmentGrantsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received the approval of the IIA
for its participation in certain development expenses carried out by the Company, within the framework of determined budgets and time
periods. The total amount the Company received during 2020 and 2021 was <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" unitRef="usd"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" unitRef="usd">800</ix:nonFraction></ix:nonFraction> (NIS <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" unitRef="ils"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" unitRef="ils">2,722,628</ix:nonFraction></ix:nonFraction>).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGovernmentGrantsExplanatory-c0_cont_3" id="_DisclosureOfGovernmentGrantsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with its commitment, the Company
is obliged to pay the IIA royalties of <ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="iinn:PayRoyaltiesPercentage" scale="-2" unitRef="pure">3</ix:nonFraction>% of sales, constituting the revenues derived from sales of the Company&#8217;s ART system that
was financed by the IIA, up to the total amount of the grant actually received, all linked to the exchange rate of the USD and bears
an annual interest linked to the LIBOR. Therefore, the total amount of the grants that will be repaid through royalties and will increase
until repayments begin.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfGovernmentGrantsExplanatory-c0_cont_4" id="_DisclosureOfGovernmentGrantsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The difference between the consideration received
and the liability recognized at inception (present value) was treated as a government grant according to IAS 20 and recognized as a reimbursement
of research expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfGovernmentGrantsExplanatory-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfReimbursementOfResearchExpensesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">At January 1, 2022</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GovernmentGrants" scale="3" unitRef="usd">302</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GovernmentGrants" scale="3" unitRef="usd">372</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amounts received during the year, non- capitalized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd">107</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDifferences" scale="3" sign="-" unitRef="usd">41</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDifferences" scale="3" unitRef="usd">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amounts recognized as an offset from research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" scale="3" unitRef="usd">255</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Revaluation of the liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfTheLiability" scale="3" unitRef="usd">137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfTheLiability" scale="3" unitRef="usd">68</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GovernmentGrants" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GovernmentGrants" scale="3" unitRef="usd">302</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 - FINACIAL LIABILITIES AT FAIR VALUE:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_2" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfFinancialLiabilities"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Non-tradable warrants (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalFinancialLiabilities" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalFinancialLiabilities" scale="3" unitRef="usd">196</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-tradable warrants, SAFE and CLA (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalFinancialLiabilities" scale="3" unitRef="usd">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalFinancialLiabilities" scale="3" unitRef="usd">1,393</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tradable warrants (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalFinancialLiabilities" scale="3" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalFinancialLiabilities" scale="3" unitRef="usd">1,493</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial liability (4)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalFinancialLiabilities" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalFinancialLiabilities" scale="3" unitRef="usd">133</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalFinancialLiabilities" scale="3" unitRef="usd">368</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalFinancialLiabilities" scale="3" unitRef="usd">3,215</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>




</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_3" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt">Non Tradable Warrants</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_4" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As part of an agreement signed in
2019, the convertible loan investors received, upon conversion in 2020 <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:ConversionToShares" scale="0" unitRef="shares">756,333</ix:nonFraction> Ordinary Shares and non-tradable warrants to purchase
an additional <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:AdditionalOrdinaryShare" scale="0" unitRef="shares">169,019</ix:nonFraction> ordinary shares upon consummation of an IPO on the Nasdaq. The warrants will be converted into Ordinary Shares
of the Company at an exercise price equal to the initial public offering price which was $<ix:nonFraction contextRef="c0" decimals="1" format="ixt:num-dot-decimal" name="iinn:ProceedFromIssuanceInitialPublicOffering" scale="0" unitRef="usd">5.5</ix:nonFraction> and are exercisable for three years after
the IPO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_5" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The warrants were designated to be measured at
fair value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_6" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 2021, as part of the IPO,
the investors received the specified warrants. As of December 31, 2022 the fair value of the warrants was <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:FairValueOfTheWarrant" scale="0" unitRef="usd">3</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -14.15pt"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_7" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>2.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt">Non-tradable warrants, SAFE and
Convertible Loan Investors</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -14.15pt">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_8" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 16, 2021, following the IPO, the Company
issued <ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="iinn:AggregateProceeds" scale="0" unitRef="usd">2,113,905</ix:nonFraction> Ordinary Shares, <ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="iinn:WarrantsShares" scale="0" unitRef="shares">1,149,582</ix:nonFraction> non-tradable warrants to investors and <ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="iinn:WarrantsShares" scale="0" unitRef="shares">16,587</ix:nonFraction> non-tradeable warrants to brokers in connection
with the conversion of Company&#8217;s convertible loan and SAFE according to its terms. The fair value of the shares was classified
as equity with total value of <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PlanAssetsAtFairValue" scale="0" unitRef="usd">10,041</ix:nonFraction> at the conversion date. The non-tradable warrants were designated to be measured at fair value through
profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_9" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The non-tradable warrants fair value as of December
31, 2022 is <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:NontradableWarrantFairValue" scale="0" unitRef="usd">35</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_10" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>3.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Tradable warrants</b></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_11" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify">The Company sold <ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="iinn:TradableWarrants" scale="0" unitRef="shares">3,345,455</ix:nonFraction> tradable
warrants in the IPO. <ix:nonNumeric contextRef="c0" name="iinn:PublicOfferingPriceDescription">The tradable warrants have an exercise price of $5.5 and they are exercisable for five years after the initial public
offering date.</ix:nonNumeric> In October 2021, investors exercised <ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="iinn:InvestorsExercisedTradableWarrants" scale="0" unitRef="shares">1,705,000</ix:nonFraction> tradable warrants whereby the Company issued <ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="iinn:OrdinarySharesIssued" scale="0" unitRef="shares">1,705,000</ix:nonFraction> Ordinary Shares
to such investors. The total proceeds received by the Company from this exercise were approximately <ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="iinn:TotalProceedsReceived" scale="0" unitRef="usd">9,377</ix:nonFraction>. The net proceeds after fees
deducting were approximately <ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="iinn:DeductingFees" scale="0" unitRef="usd">8,721</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_12" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt">As of December 31, 2022,
the Company has <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:TradableWarrants" scale="0" unitRef="shares">1,640,455</ix:nonFraction> tradable warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_13" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The tradable warrants were designated to be measured at
fair value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_14" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The tradable warrants fair value as
of December 31, 2022 is <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:TradableWarrantsFairValue" scale="0" unitRef="usd">304</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_15" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>4.</b></span></td>
    <td><span style="font-size: 10pt"><b>Financial Liability</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_16" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Financial liability to pay <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iinn:FinancialLiabilityToPay" scale="-2" unitRef="pure">7</ix:nonFraction>% fees
on the fundings that will be received from exercises of tradable warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_17" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Financial liability was designated to be measured at fair
value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Financial liability fair value
as of December 31, 2022 is <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:FinancialDerivativesFairValue" scale="0" unitRef="usd">26</ix:nonFraction>.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 - EQUITY (DEFICT):</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_2" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Share capital:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_3" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Number of shares as of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Number of shares as of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares">100,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares">11,338,940</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares">100,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares">10,091,706</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_4" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company&#8217;s incorporation in February
2018 and before the IPO, the Company issued the following Ordinary Shares: (i) an aggregate of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:AggregateOfOrdinaryShares" scale="0" unitRef="shares">27,566</ix:nonFraction> Ordinary Shares for no consideration
to the Company&#8217;s founders and certain advisors; (ii) <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="iinn:OrdinaryShare" scale="0" unitRef="shares">1,877,196</ix:nonFraction> Ordinary Shares as bonus shares for no consideration to existing
shareholders; (iii) an aggregate of <ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="iinn:AggregateOfOrdinaryShares" scale="0" unitRef="shares">756,333</ix:nonFraction> Ordinary Shares investors. See Note 8(1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_5" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 18, 2021, the Company&#8217;s shareholders
approved a <ix:nonNumeric contextRef="c78" name="iinn:StockholdersEquityReverseSplit">12.5</ix:nonNumeric> to <ix:nonNumeric contextRef="c79" name="iinn:StockholdersEquityReverseSplit">1</ix:nonNumeric> reverse split of all shares (issued and unissued) on the basis that every 12.5 Ordinary Shares in the capital of
the Company be consolidated into 1 Ordinary Share, such that the authorized share capital of the Company following such consolidation
is NIS <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="iinn:AuthorizedShareCapital" scale="0" unitRef="ils">310,000,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares">24,800,000</ix:nonFraction> Ordinary Shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_6" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company&#8217;s shareholders
approved an amendment to the structure of the Company&#8217;s share capital (both authorized and issued) by cancelling the par value
in addition to implementing an additional reverse split at a ratio of <ix:nonNumeric contextRef="c81" name="iinn:StockholdersEquityReverseSplit">2.94</ix:nonNumeric> to <ix:nonNumeric contextRef="c82" name="iinn:StockholdersEquityReverseSplit">1</ix:nonNumeric>, pursuant to which holders of our Ordinary Shares received
one Ordinary Share for every 2.94&#160;Ordinary Shares held.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_7" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company&#8217;s shareholders
approved an amendment to the structure of the Company&#8217;s share capital (both authorized and issued) by cancelling the par value
of the Company&#8217;s shares such that each Ordinary Share with par value of NIS <ix:nonFraction contextRef="c80" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="ilsPershares">0.125</ix:nonFraction> will become one Ordinary Share with no par value.
The authorized share capital of the Company following the reverse stock split is NIS <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="iinn:AuthorizedShareCapital" scale="0" unitRef="ils">310,000,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares">8,435,375</ix:nonFraction> Ordinary Shares,
with no par value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_8" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company&#8217;s shareholders
approved an increase in the authorized share capital of the Company to <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="iinn:OrdinaryShare" scale="0" unitRef="shares">15,000,000</ix:nonFraction> Ordinary Shares of no par value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_9" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2021, the Company completed its IPO
on Nasdaq Capital Market whereby the Company sold <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="iinn:SoldOrdinaryShares" scale="0" unitRef="shares">2,909,091</ix:nonFraction> Ordinary Shares and <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="iinn:tradableWarrants" scale="0" unitRef="shares">3,345,455</ix:nonFraction> tradable warrants (inclusive of <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="iinn:tradableWarrants" scale="0" unitRef="shares">436,364</ix:nonFraction> tradable
warrants pursuant to the exercise of an overallotment option granted to the underwriters).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_10" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the IPO, the Company issued <ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="iinn:OrdinaryShare" scale="0" unitRef="shares">2,113,905</ix:nonFraction>
Ordinary Shares and <ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="iinn:NontradableWarrants" scale="0" unitRef="shares">1,149,582</ix:nonFraction> non-tradable warrants to investors and <ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="iinn:NontradableWarrants" scale="0" unitRef="shares">16,587</ix:nonFraction> non-tradeable warrants to brokers in connection with the
conversion of Company&#8217;s previously issued financial liabilities, see note 8(2).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_11" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate proceeds received by the Company
from the IPO were approximately <ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateProceedsReceived" scale="3" unitRef="usd">14,490</ix:nonFraction>, after deducting underwriting discounts and commissions and additional offering direct costs totaled
in approximately <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" unitRef="usd">1,543</ix:nonFraction>. The gross proceeds were <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:GrossProceeds" scale="3" unitRef="usd">16,033</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c0" name="iinn:TradableWarrantsDescription"><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_12" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total non-cash direct expenses in IPO were as
following: (i) fair value of 436,364 tradable warrants that were granted to underwriters totaled 589; (ii) The Company issued 145,455
non-tradable warrants as underwriters fees; the warrants will be converted into Ordinary Shares of the Company at an exercise price equal
to 125% of the initial public offering price and be exercisable for three years after the initial public offering. As of the date of
the IPO, the tradable warrants fair value was 264; and (iii) the Company agreed to pay to a promoter 7% of the proceeds from the exercise
of tradable warrants. The payment was measured according to IFRS 2 at the grant date. As of the IPO date, the fair value of the financial
liability was 310.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_13" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total non-cash expenses were <ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherMaterialNoncashItems" scale="3" unitRef="usd">1,163</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 - EQUITY (DEFICT) (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_14" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company had non-direct expenses
as following: (i) cash expenses amounted to <ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NondirectCashExpenses" scale="3" unitRef="usd">722</ix:nonFraction> and (i) non-cash expenses amounted to <ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="3" unitRef="usd">123</ix:nonFraction> (<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="iinn:OrdinaryShare" scale="0" unitRef="shares">22,382</ix:nonFraction> Ordinary Shares issued to service providers).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_15" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total IPO expanse direct and non direct, cash
and non-cash were: <ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="iinn:CashAndNoncash" scale="3" unitRef="usd">3,551</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_16" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total IPO expenses allocated to the profit and
loss were <ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd">1,265</ix:nonFraction>. Total IPO expenses deducted from the equity were <ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExpensesDeductedFromEquity" scale="3" unitRef="usd">2,286</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_17" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year 2021 the Company issued an aggregate
amount of <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="iinn:AggregateAmount" scale="0" unitRef="shares">655,601</ix:nonFraction> Ordinary Shares in connection to vested RSUs and additional <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="iinn:AdditionalOrdinaryShares" scale="0" unitRef="shares">24,631</ix:nonFraction> Ordinary Shares in connection to options exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_18" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 17, 2021, the Company&#8217;s shareholders
approved an increase in the authorized share capital of the Company to <ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares">100,000,000</ix:nonFraction> Ordinary Shares of no-par value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_19" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31 2022, the Company
issued an aggregate amount of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:AggregateAmount" scale="0" unitRef="shares">1,240,204</ix:nonFraction> Ordinary Shares in connection to vested RSUs and an additional <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:AdditionalOrdinaryShares" scale="0" unitRef="shares">7,030</ix:nonFraction> Ordinary Shares in connection
to option exercises.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_20" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Loss per share:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_21" id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share has been calculated using the
weighted average number of shares in issue during the relevant financial periods, the weighted average number of equity shares in issue
and profit for the period as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_21"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfLossPerShare"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" unitRef="usd">10,273</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" unitRef="usd">16,955</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" unitRef="usd">7,228</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Total number of Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="0" unitRef="shares">11,338,940</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="0" unitRef="shares">10,091,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="0" unitRef="shares">2,661,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted average number of Ordinary Shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits" scale="0" unitRef="shares">10,794,594</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="iinn:AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits" scale="0" unitRef="shares">5,306,225</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="iinn:AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits" scale="0" unitRef="shares">1,967,790</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-108; -sec-ix-hidden: hidden-fact-107; -sec-ix-hidden: hidden-fact-106">Basic and diluted loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares">0.95</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares">3.2</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares">3.67</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfResearchAndDevelopmentExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11 - RESEARCH AND DEVELOPMENT EXPENSES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_DisclosureOfResearchAndDevelopmentExpenseExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfResearchAndDevelopmentExpenses"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Share based payment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedPayment" scale="3" unitRef="usd">2,311</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedPayment" scale="3" unitRef="usd">1,768</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedPayment" scale="3" unitRef="usd">2,230</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:SalaryAndRelatedExpenses" scale="3" unitRef="usd">3,332</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:SalaryAndRelatedExpenses" scale="3" unitRef="usd">1,533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:SalaryAndRelatedExpenses" scale="3" unitRef="usd">1,237</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Subcontractors" scale="3" unitRef="usd">929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Subcontractors" scale="3" unitRef="usd">496</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Subcontractors" scale="3" unitRef="usd">125</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:MaterialsAndRelatedExpenses" scale="3" unitRef="usd">1,094</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:MaterialsAndRelatedExpenses" scale="3" unitRef="usd">204</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:MaterialsAndRelatedExpenses" scale="3" unitRef="usd">440</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DepreciationExpenses" scale="3" unitRef="usd">238</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DepreciationExpenses" scale="3" unitRef="usd">134</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DepreciationExpenses" scale="3" unitRef="usd">196</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">IIA participation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:IIAParticipation" scale="3" sign="-" unitRef="usd">255</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:IIAParticipation" scale="3" sign="-" unitRef="usd">383</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:OtherResearchAndDevelopmentExpenses" scale="3" unitRef="usd">150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:OtherResearchAndDevelopmentExpenses" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:OtherResearchAndDevelopmentExpenses" scale="3" unitRef="usd">28</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><b>Total</b></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ResearchDevelopmentExpenses" scale="3" unitRef="usd">8,054</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ResearchDevelopmentExpenses" scale="3" unitRef="usd">3,909</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ResearchDevelopmentExpenses" scale="3" unitRef="usd">3,873</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="iinn_SalesAndMarketingExpensesTextBlock-c0_cont_1" escape="true" name="iinn:SalesAndMarketingExpensesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SALES AND MARKETING EXPENSES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="iinn_SalesAndMarketingExpensesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Share based payment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" unitRef="usd">501</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" unitRef="usd">1,186</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WagesAndSalaries" scale="3" unitRef="usd">287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WagesAndSalaries" scale="3" unitRef="usd">220</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professionals&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd">521</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd">520</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="3" unitRef="usd">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="3" unitRef="usd">25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseByNature" scale="3" unitRef="usd">1,325</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseByNature" scale="3" unitRef="usd">1,951</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfGeneralAndAdministrativeExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_DisclosureOfGeneralAndAdministrativeExpenseExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfGeneralAndAdministrativeExpenses"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Share based payment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedPayments" scale="3" unitRef="usd">1,093</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedPayments" scale="3" unitRef="usd">2,581</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedPayments" scale="3" unitRef="usd">818</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" unitRef="usd">1,522</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" unitRef="usd">1,390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" unitRef="usd">154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Related NASDAQ IPO expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" scale="3" unitRef="usd">1,265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" scale="3" unitRef="usd">1,235</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Director&#8217;s fees and share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" unitRef="usd">1,113</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" unitRef="usd">1,142</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">723</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">545</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">140</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceExpense" scale="3" unitRef="usd">565</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceExpense" scale="3" unitRef="usd">363</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="3" unitRef="usd">103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="3" unitRef="usd">91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="3" unitRef="usd">77</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Depreciations" scale="3" unitRef="usd">123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Depreciations" scale="3" unitRef="usd">84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Depreciations" scale="3" unitRef="usd">7</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TravelExpense" scale="3" unitRef="usd">106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TravelExpense" scale="3" unitRef="usd">65</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TravelExpense" scale="3" unitRef="usd">12</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" unitRef="usd">46</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><b>Total</b></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd">5,391</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd">7,572</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd">2,447</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinanceIncomeExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 &#8211; FINANCIAL (INCOME) AND EXPENSES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinanceIncomeExpenseExplanatory-c0_cont_2" id="_DisclosureOfFinanceIncomeExpenseExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfFinancialIncomeTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Revaluation of financial liabilities at fair value through profit or loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" scale="3" sign="-" unitRef="usd">2,592</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign currency transaction income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ForeignCurrencyTransactionLossNet" scale="3" sign="-" unitRef="usd">1,774</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest on deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnDeposits" scale="3" unitRef="usd">308</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnDeposits" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalIncome" scale="3" sign="-" unitRef="usd">4,678</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalIncome" scale="3" sign="-" unitRef="usd">1</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="margin: 0">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation id="_DisclosureOfFinanceIncomeExpenseExplanatory-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfFinancialExpenses"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Revaluation of financial liabilities at fair value through profit or loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" scale="3" unitRef="usd">2,183</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" scale="3" unitRef="usd">893</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign currency transaction loss, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ForeignCurrencyTransactionLossNet" scale="3" unitRef="usd">1,186</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revaluation of liability in respect of government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfLiabilityInRespectOfGovernmentGrants" scale="3" unitRef="usd">138</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfLiabilityInRespectOfGovernmentGrants" scale="3" unitRef="usd">69</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfLiabilityInRespectOfGovernmentGrants" scale="3" unitRef="usd">40</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance expense in respect of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinanceExpenseInRespectOfLeaseLiability" scale="3" unitRef="usd">37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinanceExpenseInRespectOfLeaseLiability" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinanceExpenseInRespectOfLeaseLiability" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="3" unitRef="usd">80</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="3" unitRef="usd">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalExpenses" scale="3" unitRef="usd">181</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalExpenses" scale="3" unitRef="usd">3,524</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalExpenses" scale="3" unitRef="usd">959</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 - TAXES ON INCOME: </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfIncomeTaxExplanatory-c0_cont_2" id="_DisclosureOfIncomeTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>Taxes on
income:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfIncomeTaxExplanatory-c0_cont_3" id="_DisclosureOfIncomeTaxExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">Israeli corporate
tax rate was <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure">23</ix:nonFraction></ix:nonFraction>% in 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfIncomeTaxExplanatory-c0_cont_4" id="_DisclosureOfIncomeTaxExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net operating losses carry forwards</b>:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfIncomeTaxExplanatory-c0_cont_5" id="_DisclosureOfIncomeTaxExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company has carried
forward tax losses of approximately <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:CarriedForwardTaxLosse" scale="3" unitRef="usd">11,540</ix:nonFraction>, which may be carried forward and offset against taxable income for an indefinite period in
the future. The Company did not recognize deferred tax assets relating to carry forward losses in the financial statements because their
utilization in the foreseeable future is not probable. As of December 31, 2022, the Company has temporary differences of <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxAssetS" scale="3" unitRef="usd">2,838</ix:nonFraction> for which
no deferred tax asset was recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfIncomeTaxExplanatory-c0_cont_6" id="_DisclosureOfIncomeTaxExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Theoretical tax:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfIncomeTaxExplanatory-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfTheoreticalTaxTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Loss before taxation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:LossBeforeTaxation" scale="3" sign="-" unitRef="usd">10,273</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:LossBeforeTaxation" scale="3" sign="-" unitRef="usd">16,955</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:LossBeforeTaxation" scale="3" sign="-" unitRef="usd">7,228</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Theoretical tax credit at applicable statutory rate: <ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="iinn:TheoreticalTaxCreditAtApplicableStatutoryRate" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="iinn:TheoreticalTaxCreditAtApplicableStatutoryRate" scale="-2" unitRef="pure">23</ix:nonFraction></ix:nonFraction>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" scale="3" sign="-" unitRef="usd">2,363</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" scale="3" sign="-" unitRef="usd">3,900</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" scale="3" sign="-" unitRef="usd">1,662</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-allowable expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NonallowableExpenses" scale="3" sign="-" unitRef="usd">1,804</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NonallowableExpenses" scale="3" sign="-" unitRef="usd">2,070</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NonallowableExpenses" scale="3" unitRef="usd">4,733</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" scale="3" sign="-" unitRef="usd">559</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" scale="3" sign="-" unitRef="usd">1,830</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" scale="3" sign="-" unitRef="usd">3,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Income tax benefit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfLeasesExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 16 - LEASES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_2" id="_DisclosureOfLeasesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has lease contracts for office facilities
and vehicles used in its operations. Leases of vehicles generally have lease terms up to <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="iinn:leaseTerms">three years</ix:nonNumeric>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_3" id="_DisclosureOfLeasesExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases vehicles for three-year periods
from several different leasing companies and from time to time changes the number of leased vehicles according to its current needs.
The leased vehicles are used by the Company&#8217;s management, and other employees whose employment agreements include an obligation
of the Company to put a vehicle at their disposal. The Company accounted for the arrangement between it and the leasing companies as
a lease arrangement in the scope of IFRS 16 and for the arrangement between it and its employees as an arrangement in the scope of IAS
19, Employee Benefits. The agreements with the leasing companies do not contain extension and/or termination options that the Company
is reasonably certain to exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_4" id="_DisclosureOfLeasesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A lease liability in the amount of <ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="iinn:LeaseLiabilityAmount" scale="3" unitRef="usd">281</ix:nonFraction> and right-of-use
asset in the amount of <ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="3" unitRef="usd">345</ix:nonFraction> have been recognized in the statement of financial position as of December 31, 2022 in respect of leases of
vehicles.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c0" name="iinn:DescriptionOfLeaseAgreement"><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_5" id="_DisclosureOfLeasesExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases offices in Ra&#8217;anana
are for a period of 69 months. The contractual period of the aforesaid lease agreement ends in August 2027. The Company has an option
to terminate the contract after 45 months with a penalty in amount of NIS 500,000 that will be diminish in NIS 30,000 in each month from
the 45<sup>th</sup> month of the contract. The Company does not currently expect to exercise the termination option in the lease agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_6" id="_DisclosureOfLeasesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A lease liability in the amount of <ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="iinn:LeaseLiabilityAmount" scale="3" unitRef="usd">776</ix:nonFraction> and right-of-use
asset in the amount of <ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="3" unitRef="usd">762</ix:nonFraction> have been recognized in the statement of financial position as of December 31, 2022 in respect of leases of
offices.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_7" id="_DisclosureOfLeasesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Set out below are the carrying amounts of right-of-use assets recognized
and the movements during the period:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_8" id="_DisclosureOfLeasesExplanatory-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfRightofuseAssets"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office&#160;facility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vehicles</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd">1,047</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd">113</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd">1,160</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" unitRef="usd">416</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" unitRef="usd">416</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c107" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinancialExpense" scale="3" sign="-" unitRef="usd">114</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinancialExpense" scale="3" sign="-" unitRef="usd">26</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinancialExpense" scale="3" sign="-" unitRef="usd">140</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsInvestmentProperty" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsInvestmentProperty" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c107" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" unitRef="usd">171</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" unitRef="usd">129</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" unitRef="usd">300</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd">762</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd">345</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd">1,107</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_9" id="_DisclosureOfLeasesExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Set out below are the carrying amounts of lease liabilities and the
movements during the period:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_10" id="_DisclosureOfLeasesExplanatory-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfLeaseLiabilities"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd">1,181</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd">275</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd">153</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd">367</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd">1,176</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd">273</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Accretion of interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinancialExpenses" scale="3" sign="-" unitRef="usd">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinancialExpenses" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDifference" scale="3" sign="-" unitRef="usd">138</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDifference" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExchangeRateDifference" scale="3" unitRef="usd">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd">27</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd">99</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:PrincipalPayment" scale="3" sign="-" unitRef="usd">350</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:PrincipalPayment" scale="3" sign="-" unitRef="usd">214</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:PrincipalPayment" scale="3" sign="-" unitRef="usd">171</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd">1,057</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd">1,181</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd">275</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 16 - LEASES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_11" id="_DisclosureOfLeasesExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following are the amounts recognized in profit or loss:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_12" id="_DisclosureOfLeasesExplanatory-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfProfitOrLoss"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Depreciation expense of right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" sign="-" unitRef="usd">300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" sign="-" unitRef="usd">196</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" sign="-" unitRef="usd">196</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest expense on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total amount recognized in profit or loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalAmountRecognizedInProfitOrLoss" scale="3" unitRef="usd">300</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalAmountRecognizedInProfitOrLoss" scale="3" unitRef="usd">196</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TotalAmountRecognizedInProfitOrLoss" scale="3" unitRef="usd">201</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfLeasesExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had total cash outflows for leases
of <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="3" unitRef="usd">350</ix:nonFraction> in 2022 and <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="3" unitRef="usd">214</ix:nonFraction> in 2021. The Company also had non-cash additions to right-of-use assets and lease liabilities of <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:LeaseLiabilityAmount" scale="3" unitRef="usd">416</ix:nonFraction> in 2022 and
<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="3" unitRef="usd">1,176</ix:nonFraction> in 2021.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 17 - SHARE BASED PAYMENT:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the Company established a share
option plan (the &#8220;Plan&#8221;). Under the Plan, total of <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="pure">602,989</ix:nonFraction> options were granted until December 31, 2022. As of December 31,
2022, a total of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:GrantTotalShares" scale="0" unitRef="shares">500,772</ix:nonFraction> options to subscribe Ordinary Shares that have been granted to employees, consultants and directors are outstanding.<br/>
A total of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodSharesRestrictedStockUnit" scale="0" unitRef="shares">3,707,542</ix:nonFraction> RSUs that have been granted to employees, consultants and directors, <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:RestrictedStockUnitVested" scale="0" unitRef="shares">1,895,808</ix:nonFraction> RSUs are vested as of December 31,
2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_3" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 20, 2020 a total of <ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="iinn:TotalOrdinaryShares" scale="0" unitRef="shares">478,747</ix:nonFraction> options
to subscribe Ordinary Shares have been granted to employees and consultants. <ix:nonNumeric contextRef="c0" name="iinn:GrantOptionDescription">The exercise price per share to 123,719 and 355,029 options
was USD 0.0029 (AUD 0.052) and USD 2.67 (AUD 4.2), respectively. The vesting period is up to 3 years from the grant date, according to
the various vesting periods: from an immediate one and up to 3 years. Contractual life of the options under the Plan is 10 years. The
options were granted under section 102 of the Israeli Tax Ordinance which enables the employee to pay 25% of capital gain tax upon exercise.
&#160;In October 2020, 73,380 options were canceled.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_4" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 17, 2020, the Israeli Taxes Authority
(ITA) approved a ruling request from the Company for a tax-free amendment of the commercial terms of the outstanding options, including
(i) a reduction of the exercise price to NIS <ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="iinn:ExercisePrice" scale="0" unitRef="usdPershares">0.37</ix:nonFraction> per share, and (ii) a shortening of the vesting schedules.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_5" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company implemented IFRS 2-Share based payment
on options terms change.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_6" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2020, the board of directors
granted a total of <ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="iinn:GrantedTotalOption" scale="0" unitRef="shares">56,653</ix:nonFraction> options to subscribe Ordinary Shares to employees and consultants. The vesting period is up to <ix:nonNumeric contextRef="c5" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement">3 years</ix:nonNumeric> from
the grant date. The exercise price per share was NIS <ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="iinn:ExercisePrice" scale="0" unitRef="ilsPershares">0.37</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_7" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contractual life of the options under the Plan
is <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="iinn:ContractualLife">10</ix:nonNumeric> years. The options were granted under section 102 of the Israeli Tax Ordinance which enables the employee to pay <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iinn:CapitalGainTax" scale="-2" unitRef="pure">25</ix:nonFraction>% of capital
gain tax upon exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_8" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 21, 2021, <ix:nonNumeric contextRef="c115" name="iinn:NontradableSharesOptions">the Company&#8217;s board
of directors approved a grant of 13,605 non-tradable shares options which are exercisable to 13,605 Ordinary shares to employees and
a total of 21,768 share options which are exercisable to 21,768 Ordinary Shares to consultants. The vesting period is three years commencing
on the grant date. The exercise price per share was NIS 0.37($0.12). The contractual life of the options under the Plan is ten years.
The options to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital
gain tax upon exercise.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 17 - SHARE BASED PAYMENT (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_9" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2021, the Company&#8217;s board
of directors approved a grant of <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="iinn:NontradableShares" scale="0" unitRef="shares">81,633</ix:nonFraction> non-tradable shares options to a director, which are exercisable to <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="iinn:ExercisableOrdinaryShares" scale="0" unitRef="shares">81,633</ix:nonFraction> Ordinary Shares. The
share options vesting period is up to <ix:nonNumeric contextRef="c116" format="ixt-sec:durwordsen" name="iinn:VestingPeriod">three years</ix:nonNumeric> from the grant date. The exercise price per share was NIS 0.37 ($<ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="ilsPershares">0.12</ix:nonFraction>). The contractual
life of the options under the Plan is <ix:nonNumeric contextRef="c116" format="ixt-sec:durwordsen" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">ten years</ix:nonNumeric>. The options were granted under Section 102 of the Israeli Tax Ordinance, which enables
the employee to pay a <ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="iinn:CapitalGainTax" scale="-2" unitRef="pure">25</ix:nonFraction>% capital gain tax upon exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_10" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2021, the Company&#8217;s board
of directors resolved to increase the pool of options available under the Plan to <ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="iinn:OptionsEquity" scale="-2" unitRef="pure">25</ix:nonFraction>% of the Company&#8217;s equity, on a fully diluted
basis. As a result of the increase, the number of authorized Ordinary Shares available pursuant the Plan was <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="iinn:AuthorizedOrdinaryShares" scale="0" unitRef="shares">4,180,898</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_11" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On November 2, 2021, the Company&#8217;s board of directors approved
a grant of <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="iinn:GrantTotal" scale="0" unitRef="shares">2,658,188</ix:nonFraction> RSUs to employees and officers. The RSUs represents the right to receive Ordinary Shares at a future time and vest
over a period of <ix:nonNumeric contextRef="c121" format="ixt-sec:durwordsen" name="iinn:VestOverPeriod">three years</ix:nonNumeric>. The RSUs were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay
a <ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="iinn:CapitalGainTax" scale="-2" unitRef="pure">25</ix:nonFraction>% capital gain tax upon exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_12" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2021, the Company&#8217;s
board of directors approved a grant of <ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="iinn:GrantTotal" scale="0" unitRef="shares">10,000</ix:nonFraction> RSUs to the Company&#8217;s advisory board. The RSUs represents the right to receive
Ordinary Shares at a future time and vest over a period of <ix:nonNumeric contextRef="c122" format="ixt-sec:durwordsen" name="iinn:VestOverPeriod">three years</ix:nonNumeric>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_13" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On March 24, 2022, <ix:nonNumeric contextRef="c123" name="iinn:RestrictedStockUnitEmployeesDescription">the Company&#8217;s board of directors approved
a grant of 536,141 RSUs to employees and a grant of 22,500 RSUs to the Company&#8217;s advisory board members and an additional consultant.
The RSUs represent the right to receive Ordinary Shares at a future time. 555,500 of the RSUs in this grant, vest over a period of three
years, with a 1-year cliff period, and 3,141 RSUs vested immediately on the grant date. The RSUs to employees were granted under Section
102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_14" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2022, <ix:nonNumeric contextRef="c123" name="iinn:BoardOfDirectorsDescription">the Company&#8217;s board
of directors approved a grant of 29,400 Ordinary Shares options to medical board members, which are exercisable to 29,400 Ordinary Shares.
The share options vesting period is up to three years from the grant date. The exercise price per share was NIS 10.84 ($3.08). The contractual
life of the options under the Plan is ten years.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 14.2pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_15" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On April 6, 2022, <ix:nonNumeric contextRef="c124" name="iinn:BoardOfDirectorsDescription">the Company&#8217;s board of directors approved
a grant of 285,713 fully vested RSUs to an officer. The RSUs represent the right to receive Ordinary Shares. The RSUs were granted under
Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_16" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On May 19, 2022, <ix:nonNumeric contextRef="c125" name="iinn:BoardOfDirectorsDescription">the Company&#8217;s board of directors approved a
grant of 30,000 RSUs to an employee. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period
of three years, with a 1-year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax
Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_17" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On November 22, 2022, <ix:nonNumeric contextRef="c126" name="iinn:BoardOfDirectorsDescription">the Company&#8217;s board of directors approved
a grant of 165,000 RSUs to employees. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period
of three years, with a 1-year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax
Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 17 - SHARE BASED PAYMENT (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_18" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_17"><ix:nonNumeric contextRef="c0" continuedAt="iinn_FairValueAssumptionsDescription-c0_cont_1" name="iinn:FairValueAssumptionsDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all granted options was estimated
by using the Black Scholes model, which was aimed to model the value of the Company&#8217;s assets over time. The simulation approach
was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and
the volatility of its assets, on the date of grant based on certain assumptions. Those conditions are, among others:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_19" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_18"><ix:continuation continuedAt="iinn_FairValueAssumptionsDescription-c0_cont_2" id="iinn_FairValueAssumptionsDescription-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The expected volatility is
between 50%-52.4%</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_20" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_19"><ix:continuation continuedAt="iinn_FairValueAssumptionsDescription-c0_cont_3" id="iinn_FairValueAssumptionsDescription-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The dividend rate 0%; and</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_21" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_20"><ix:continuation id="iinn_FairValueAssumptionsDescription-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(iii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Expected term &#8211; three
years.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_22" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation was completed with the assistance
of an independent valuator based on management&#8217;s assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_23" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2022, the Company recorded share
based payment expenses to employees, directors and subcontractors in the amount of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors" scale="0" unitRef="usd">4,879</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_24" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;The options to services providers and advisers outstanding as
of December 31, 2022, as&#160;follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_25" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_24"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" unitRef="pure">87,833</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c130" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="iinn:GrantedNumberOfOptions" scale="0" unitRef="shares">29,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c131" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">10.84</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ExercisedNumberOfOptions" scale="0" sign="-" unitRef="shares">2,721</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c131" decimals="2" format="ixt:num-dot-decimal" name="iinn:ExercisedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" unitRef="pure">114,512</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c132" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">3.058</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ExercisableOptionsNumberOfOptions" scale="0" unitRef="shares">82,257</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c132" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.71</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_26" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2022, the Company recorded share
based payment expenses of option to services providers and advisers in the amount of <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="iinn:ShareBasedPaymentExpenses" scale="0" unitRef="usd">54</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_27" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The RSUs to services providers and advisers outstanding as of December
31, 2022 as&#160;follows:</p><div>

</div></ix:continuation><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_28" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_27"><ix:nonNumeric contextRef="c0" continuedAt="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding-c0_cont_1" escape="true" name="iinn:ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c140" decimals="INF" format="ixt:num-dot-decimal" name="iinn:OutstandingAtBeginningOfYears" scale="0" unitRef="shares">10,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="INF" format="ixt:num-dot-decimal" name="iinn:Granted" scale="0" unitRef="shares">22,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c141" decimals="INF" format="ixt:num-dot-decimal" name="iinn:Vested" scale="0" sign="-" unitRef="shares">14,234</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c142" decimals="INF" format="ixt:num-dot-decimal" name="iinn:OutstandingAtBeginningOfYears" scale="0" unitRef="shares">18,266</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Vested as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c141" decimals="INF" format="ixt:num-dot-decimal" name="iinn:RestrictedStockUnitVested" scale="0" unitRef="shares">14,234</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 17 - SHARE BASED PAYMENT (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_29" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the
Company recorded share based payment expenses of RSUs to services providers and advisers in the amount of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:ShareBasedPaymentExpenses" scale="0" unitRef="usd">33</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_30" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options to employees and directors outstanding as of December
31, 2022, as&#160;follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_31" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_30"><ix:continuation continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_2" id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/>
    December 31, 2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of options</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted average Exercise
    price NIS</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="font-size: 10pt">Outstanding at beginning of year </span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" unitRef="pure">448,120</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ExercisedNumberOfOptions" scale="0" unitRef="shares">4,309</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="iinn:ExercisedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">(<span style="font-size: 10pt"><ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="3" sign="-" unitRef="pure">57,551</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="iinn:ForfeitedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Outstanding as of December 31, 2022</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" unitRef="pure">386,260</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Exercisable options</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ExercisableOptionsNumberOfOptions" scale="0" unitRef="shares">342,757</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_32" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_31"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">During the year ended December 31, 2022, the Company recorded share
based payment expenses of options to employees and directors in the amount of <ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="iinn:ShareBasedPaymentExpenses" scale="0" unitRef="usd">174</ix:nonFraction></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_33" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The RSUs to employees and directors outstanding as of December 31,
2022, as&#160;follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_34" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_33"><ix:continuation continuedAt="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding-c0_cont_2" id="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c143" decimals="INF" format="ixt:num-dot-decimal" name="iinn:OutstandingAtBeginningOfYears" scale="0" unitRef="shares">2,002,587</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="iinn:Granted" scale="0" unitRef="shares">1,016,854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="iinn:Forfeited" scale="0" sign="-" unitRef="shares">65,626</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Vested</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="iinn:Vested" scale="0" sign="-" unitRef="shares">1,225,973</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c145" decimals="INF" format="ixt:num-dot-decimal" name="iinn:OutstandingAtBeginningOfYears" scale="0" unitRef="shares">1,727,842</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Vested as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="iinn:RestrictedStockUnitVested" scale="0" unitRef="shares">1,881,574</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_35" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the
Company recorded share based payment expenses of RSUs to employees and directors in the amount of <ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="iinn:ShareBasedPaymentExpenses" scale="0" unitRef="usd">4,618</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 17 - SHARE BASED PAYMENT (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_36" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_35"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options to services providers and advisers outstanding as of December
31, 2021, as&#160;follows:</p><div>

</div></ix:continuation><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_37" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_36"><ix:continuation continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_3" id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" unitRef="pure">165,987</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reclassified to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="iinn:NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares" scale="0" sign="-" unitRef="shares">71,260</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="iinn:ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="iinn:GrantedNumberOfOptions" scale="0" unitRef="shares">16,326</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ExercisedNumberOfOptions" scale="0" sign="-" unitRef="shares">20,086</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="iinn:ExercisedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="3" sign="-" unitRef="pure">3,134</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="iinn:ForfeitedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" unitRef="pure">87,833</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c130" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ExercisableOptionsNumberOfOptions" scale="0" unitRef="shares">62,715</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c130" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p></ix:continuation></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_38" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_37"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The RSUs to services providers and advisers outstanding as of December
31, 2021, as&#160;follows:</p><div>

</div></ix:continuation><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_39" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_38"><ix:continuation continuedAt="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding-c0_cont_3" id="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding at beginning of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; padding-bottom: 1.5pt">Granted</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c147" decimals="INF" format="ixt:num-dot-decimal" name="iinn:Granted" scale="0" unitRef="shares">10,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c140" decimals="INF" format="ixt:num-dot-decimal" name="iinn:OutstandingAtBeginningOfYears" scale="0" unitRef="shares">10,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable RSUs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_40" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_39"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options to employees and directors outstanding as of December
31, 2021, as&#160;follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_41" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_40"><ix:continuation id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" unitRef="pure">296,038</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reclassified to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="iinn:NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares" scale="0" unitRef="shares">71,260</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="iinn:ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="iinn:GrantedNumberOfOptions" scale="0" unitRef="shares">95,238</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ExercisedNumberOfOptions" scale="0" sign="-" unitRef="shares">4,544</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="iinn:ExercisedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="3" sign="-" unitRef="pure">9,872</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="iinn:ForfeitedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="3" unitRef="pure">448,120</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ExercisableOptionsNumberOfOptions" scale="0" unitRef="shares">347,069</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares">0.37</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_42" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_41"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The restricted shares units to employees and directors outstanding
as of December 31, 2021, as&#160;follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_42"><ix:continuation id="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding at beginning of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c149" decimals="INF" format="ixt:num-dot-decimal" name="iinn:Granted" scale="0" unitRef="shares">2,658,188</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Vested</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c149" decimals="INF" format="ixt:num-dot-decimal" name="iinn:Vested" scale="0" sign="-" unitRef="shares">655,601</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c143" decimals="INF" format="ixt:num-dot-decimal" name="iinn:OutstandingAtBeginningOfYears" scale="0" unitRef="shares">2,002,587</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>






</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfRelatedPartyExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 18 - RELATED PARTIES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_2" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The following transactions arose with related parties:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_3" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Transactions and balances with related parties</span><b>:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_4" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Shareholders and other related
parties&#8217; benefits</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_5" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salary and related expenses &#8211; officers and directors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" unitRef="usd">1,923</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" unitRef="usd">1,042</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" unitRef="usd">795</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share based payment &#8211; officers and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedPaymentEmployeesAndDirectors" scale="3" unitRef="usd">3,745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedPaymentEmployeesAndDirectors" scale="3" unitRef="usd">5,876</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedPaymentEmployeesAndDirectors" scale="3" unitRef="usd">1,805</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_6" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Balances with related parties</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_DisclosureOfRelatedPartyExplanatory-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:BalancesWithRelatedPartiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature of transaction</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%">Officers</td><td style="width: 1%">&#160;</td>
    <td style="width: 64%; text-align: left"><ix:nonNumeric contextRef="c150" name="iinn:NatureOfTransactionSalariesAndRelated">Salaries and related</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c150" continuedAt="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany-c150_cont_1" name="iinn:NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany">(292</ix:nonNumeric></td><td style="width: 1%; text-align: left"><ix:continuation id="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany-c150_cont_1">)</ix:continuation></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c151" continuedAt="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany-c151_cont_1" name="iinn:NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany">(317</ix:nonNumeric></td><td style="width: 1%; text-align: left"><ix:continuation id="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany-c151_cont_1">)</ix:continuation></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Directors</td><td>&#160;</td>
    <td style="text-align: left"><ix:nonNumeric contextRef="c152" name="iinn:NatureOfTransactionSalariesAndRelated">Compensation for directors</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c152" continuedAt="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany-c152_cont_1" name="iinn:NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany">(40</ix:nonNumeric></td><td style="text-align: left"><ix:continuation id="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany-c152_cont_1">)</ix:continuation></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c153" continuedAt="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany-c153_cont_1" name="iinn:NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany">(57</ix:nonNumeric></td><td style="text-align: left"><ix:continuation id="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany-c153_cont_1">)</ix:continuation></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 19 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_2" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is exposed to a variety of financial
risks, which result from its financing, operating and investing activities. The objective of financial risk management is to contain,
where appropriate, exposures in these financial risks to limit any negative impact on the Company&#8217;s financial performance and position.
The Company&#8217;s financial instruments are its cash and other current assets, convertible loan, payables and other payables. The main
purpose of these financial instruments is to raise finance for the Company&#8217;s operation. The Company actively measures, monitors,
and manages its financial risk exposures by various functions pursuant to the segregation of duties and principals. The risks arising
from the Company&#8217;s financial instruments are mainly credit risk and currency risk. The risk management policies employed by the
Company to manage these risks are discussed below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_3" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Credit risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_4" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Credit risk arises when a failure by counterparties
to discharge their obligations could reduce the amount of future cash inflows from financial assets on hand at the balance sheet date.
The Company closely monitors the activities of its counterparties and controls the access to its intellectual property which enables
it to ensure the prompt collection. The Company&#8217;s main financial assets are cash and cash equivalents and deposits represent the
Company&#8217;s maximum exposure to credit risk in connection with its financial assets. Wherever possible and commercially practical,
the Company holds cash with major financial institutions in Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 19 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_5" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amount of financial assets represents
the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_6" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" scale="3" unitRef="usd">6,783</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" scale="3" unitRef="usd">23,749</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" scale="3" unitRef="usd">7,120</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets (Restricted deposits)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" unitRef="usd">56</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" unitRef="usd">120</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="3" unitRef="usd">13,959</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="3" unitRef="usd">23,869</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_7" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Currency risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_8" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currency risk is the risk that the value of financial
instruments will fluctuate due to changes in foreign exchange rates. Currency risk arises when future commercial transactions and recognized
assets and liabilities are denominated in a currency that is not the Company&#8217;s functional currency. The Company exposed to foreign
exchange risk arising from currency exposure primarily with respect to the USD. The Company&#8217;s policy is not to enter into any currency
hedging transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_9" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of the Company&#8217;s foreign
currency denominated monetary liability at the reporting date are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_10" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfForeignCurrencyDenominatedMonetaryLiability"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" scale="3" unitRef="usd">3,766</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" scale="3" unitRef="usd">19,391</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Deposit" scale="3" unitRef="usd">7,120</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="3" unitRef="usd">10,886</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="3" unitRef="usd">19,391</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" unitRef="usd">368</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" unitRef="usd">3,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinancialAssets" scale="3" unitRef="usd">368</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinancialAssets" scale="3" unitRef="usd">3,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" unitRef="usd">10,518</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" unitRef="usd">16,176</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_11" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sensitivity analysis</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_12" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iinn:strengtheningPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% strengthening of the NIS against the following
currencies would have increased (decreased) equity and the income statement by the amounts shown below. This analysis assumes that all
other variables, in particular interest rates, remain constant. For a <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iinn:weakeningPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% weakening of the NIS against the relevant currency, there would
be an equal and opposite impact on the profit and other equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_13" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_12"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfSensitivityAnalysis"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/>
 December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/>
 December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c156" decimals="-3" format="ixt:num-dot-decimal" name="iinn:SensitivityAnalysis" scale="3" unitRef="usd">1,051</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="iinn:SensitivityAnalysis" scale="3" unitRef="usd">1,617</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">AUD</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c158" decimals="-3" format="ixt:num-dot-decimal" name="iinn:SensitivityAnalysis" scale="3" unitRef="usd">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c159" decimals="-3" format="ixt:num-dot-decimal" name="iinn:SensitivityAnalysis" scale="3" unitRef="usd">205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">GB Pound</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" name="iinn:SensitivityAnalysis" scale="3" unitRef="usd">45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="-3" format="ixt:num-dot-decimal" name="iinn:SensitivityAnalysis" scale="3" unitRef="usd">53</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 19 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_14" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity risks:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_15" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity risk is the risk that arises when the
maturity of assets and the maturity of liabilities do not match. An unmatched position potentially enhances profitability but can also
increase the risk of loss. The Company has procedures to minimize such loss by maintaining sufficient cash and other highly liquid current
assets and by having available an adequate amount of committed credit facilities. As of the balance sheet date, the Company has a negative
working capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_16" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables detail the Company&#8217;s
remaining contractual maturity for its financial liabilities. The tables have been drawn up based on the undiscounted cash flows of financial
liabilities based on the earliest date on which the Company can be required to pay.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_17" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">As of December 31, 2022:</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_18" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_17"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Up to <br/>
1 year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Between<br/> 1 and 3<br/>
 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">More than<br/> 3 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Other payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd">719</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" unitRef="usd">381</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" unitRef="usd">635</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" unitRef="usd">374</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd">150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan from the IIA</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" scale="3" unitRef="usd">24</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c164" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" scale="3" unitRef="usd">776</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd">1,250</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd">659</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c164" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd">1,150</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_19" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">As of December 31, 2021:</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>




</div><ix:continuation id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_19"><ix:continuation id="_DisclosureOfFinancialLiabilitiesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Up to <br/>
1 year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Between <br/>
1 and 3<br/> years</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">More than<br/> 3 years</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Other payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c165" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd">611</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" unitRef="usd">305</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" unitRef="usd">537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="3" unitRef="usd">678</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan from the IIA</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" scale="3" unitRef="usd">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" scale="3" unitRef="usd">868</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c165" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd">1,009</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd">544</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd">1,546</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 20 - COMMITMENTS AND CONTINGENCIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_2" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Commitments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_3" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">The Company has a bank guarantee in the amount of 63 for
the offices it rents. In accordance with the guarantee, the Company has a pledged deposit in the same amount as of December 31, 2022.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_4" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">2.</td><td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">In
July 2022, the Company entered into an agreement with a contractor for the development of the HYLA&#8482; blood sensor. Total payment
agreed in the contract is 710. According to the agreement with the developer, the development cost will be paid in a few tranches considering
the development lifecycle, which was defined as five phases for each of the blood parameters to be measured by the sensor.</p></td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_5" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_4"><p style="margin-left: 0.5in; margin-top: 0; margin-bottom: 0">The Company is entitled to terminate the contract upon reaching the third phase.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_6" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">As of December 31, 2022, part of the development outputs
reached the second phase and part are on the third phase. Approximately half of the contract total amount was recorded as development
expenses as of December 31, 2022. An amount of <ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Prepayments" scale="3" unitRef="usd">75</ix:nonFraction> was paid as prepayment.</td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_7" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_8" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">In the normal course of business, various legal claims and
other contingent matters may arise. Management believes that any liability that may arise from such matters would not have a material
adverse effect on the Company&#8217;s results of operations or financial condition as of and for the years ended December 31, 2022, and
2021.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_9" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">On March 4, 2022, Exchange Listing, LLC, or Exchange, filed
a complaint in the Federal Court for the Southern District of New York against us in connection with a contract between the parties.
The contract related to certain consulting services provided to us by Exchange in preparation for our initial public offering.The complaint
is against us and, and the Company president and former Chief Financial Officer, Joe Hayon, in connection with a contract between the
parties pursuant to which Exchange provided certain consultancy services to us in preparation for our initial public offering. The precise
damages sought are unclear, however Exchange is seeking approximately <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:ExchangeAmount" scale="0" unitRef="shares">250,000</ix:nonFraction> plus <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:OrdinaryShares" scale="0" unitRef="shares">75,000</ix:nonFraction> Ordinary Shares or the cash equivalent. As
of the date of this annual report, we have not been formally served with the complaint. On July 1, 2022, the Company filed a motion to
dismiss for failure to state a claim upon relief can be granted based on the language of the written contract between the parties. On
March 8, 2023, the court issued an order granting our motion in part and denying it in part. Specifically, the court dismissed all claims
against Joe Hayon and he is no longer a party in the action. The court also dismissed the breach of contract action (Count I) to the
extent it was based improper termination or frustration. The Court also dismissed Count IV (Quantum Merit on the written agreement),
Count VI (Breach of Implied Covenant of Good Faith) and Count VII (Fraud in the Inducement). The court allowed Count 1 (breach of written
agreement based on alleged anticipatory repudiation), Count II (breach of alleged oral agreement), Count III (Promissory Estoppel to
the extent based on alleged oral agreement) and Count V (Quantum Meruit based on alleged oral agreement) to survive the pleading or early
dismissal stage. The Company will continue to defend itself vigorously with respect to this matter.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_10" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">On
November 9, 2022, the Company received notice of a complaint filed by Udi Nussinovitch, the Registrant&#8217;s former Chief Scientific
Officer, in Tel-Aviv District Court, as well as a complaint filed with the regional labor court in Tel Aviv on November 8, 2022. Mr.
Nussinovitch has alleged certain deficiencies in the Company&#8217;s&#160;Extraordinary General Meeting of Shareholders held on Friday,
December 17, 2021, resulting from his status as a minority shareholder. In addition, with respect to the labor dispute, Mr.&#160;Nussinovitch
is seeking renumeration and the issuance of Ordinary Shares.&#160;Previously, on February 24, 2022, the Company filed a claim against
Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and former officer of the Company.</p></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">As of the balance date, the Company believes that the claims
will result in no payments by the Company.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 21 - FAIR VALUE MEASUREMENT:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_2" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair value hierarchy </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_3" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables detail the Company&#8217;s
assets and liabilities, measured or disclosed at fair value, using a three-level hierarchy, based on the lowest level of input that is
significant to the entire fair value measurement, being:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_4" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1: Quoted prices (unadjusted) in active
markets for identical assets or liabilities that the entity can access at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_5" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2: Inputs other than quoted prices included
within Level 1 that are observable for the asset or liability, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_6" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3: Unobservable inputs for the asset or liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_7" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">As of December 31, 2022:</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_8" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Non-tradable Warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c175" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NontradableWarrantFairValue" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-tradable warrants of SAFE and Convertible Loan investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157"><div>&#160;</div></div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c175" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" scale="3" unitRef="usd">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158"><div>&#160;</div></div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tradable warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c177" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c177" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssets" scale="3" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c178" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssets" scale="3" unitRef="usd">64</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_9" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">As of December 31, 2021:</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_10" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_9"><ix:continuation id="_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Non-tradable Warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c181" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NontradableWarrantFairValue" scale="3" unitRef="usd">196</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-tradable warrants of SAFE and Convertible Loan investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166"><div>&#160;</div></div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" scale="3" unitRef="usd">1,393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167"><div>&#160;</div></div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd">133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tradable warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c183" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd">1,493</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c183" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssets" scale="3" unitRef="usd">1,493</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c184" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssets" scale="3" unitRef="usd">1,722</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_11" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the fair value measurement
of the warrant&#8217;s securities in the table above, was estimated using the Black Scholes model, based on assumptions for the variables
that are required as of the warrants&#8217; valuation date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_12" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs that were used in the both items
of non-tradable warrants valuation were: risk-free interest rate between <ix:nonFraction contextRef="c168" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">5.04</ix:nonFraction>% and <ix:nonFraction contextRef="c169" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">5.26</ix:nonFraction>%, expected volatility between <ix:nonFraction contextRef="c168" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">56.5</ix:nonFraction>%-<ix:nonFraction contextRef="c170" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">57.8</ix:nonFraction>% , expected
dividend yield of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure">0</ix:nonFraction>% and expected term of warrants of <ix:nonNumeric contextRef="c168" format="ixt-sec:duryear" name="iinn:ExpectedTermOfWarrants">1.54</ix:nonNumeric>-<ix:nonNumeric contextRef="c169" format="ixt-sec:duryear" name="iinn:ExpectedTermOfWarrants">2.54</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 21 - FAIR VALUE MEASUREMENT (C<span style="text-transform: uppercase">ont</span>.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_13" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2021, the fair value measurement
of the SAFE and the warrant&#8217;s securities in the table above, was estimated using the Black Scholes model, based on a variety of
significant unobservable inputs a thus represent a level 2 measurement within the fair value hierarchy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_14" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs that were used in both items of
non-tradable warrants valuation were: risk-free interest rate between <ix:nonFraction contextRef="c171" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">0.19</ix:nonFraction>% and <ix:nonFraction contextRef="c172" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">0.73</ix:nonFraction>%, expected volatility between <ix:nonFraction contextRef="c171" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">55.3</ix:nonFraction>%-<ix:nonFraction contextRef="c172" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">57.8</ix:nonFraction>%, expected
dividend yield of <ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure">0</ix:nonFraction>% and expected term of warrants of <ix:nonNumeric contextRef="c171" format="ixt-sec:duryear" name="iinn:ExpectedTermOfWarrants">2.54</ix:nonNumeric>-3.<ix:nonNumeric contextRef="c172" format="ixt-sec:duryear" name="iinn:ExpectedTermOfWarrants">54</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_15" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of trade and other receivables
and trade and other payables are assumed to approximate their fair values due to their short-term nature.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_16" id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Movements in level 2 liability during 2021 is
set out below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory-c0_cont_16"><ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfMovementsInLevel2LiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">SAFE</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Convertible loan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Financial Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c186" decimals="-3" format="ixt:num-dot-decimal" name="iinn:BalanceAtBeginning" scale="3" unitRef="usd">219</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c187" decimals="-3" format="ixt:num-dot-decimal" name="iinn:BalanceAtBeginning" scale="3" unitRef="usd">1,273</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="iinn:BalanceAtBeginning" scale="3" unitRef="usd">1,492</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gains (losses) recognized in profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c190" decimals="-3" format="ixt:num-dot-decimal" name="iinn:GainslossesRecognizedInProfitLoss" scale="3" sign="-" unitRef="usd">19</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c191" decimals="-3" format="ixt:num-dot-decimal" name="iinn:GainslossesRecognizedInProfitLoss" scale="3" unitRef="usd">2,330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c192" decimals="-3" format="ixt:num-dot-decimal" name="iinn:GainslossesRecognizedInProfitLoss" scale="3" unitRef="usd">612</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="-3" format="ixt:num-dot-decimal" name="iinn:GainslossesRecognizedInProfitLoss" scale="3" unitRef="usd">450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:GainslossesRecognizedInProfitLoss" scale="3" unitRef="usd">3,373</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c191" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Addition" scale="3" unitRef="usd">4,161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c192" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Addition" scale="3" unitRef="usd">3,047</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Addition" scale="3" unitRef="usd">310</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Addition" scale="3" unitRef="usd">7,518</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c192" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd">60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd">60</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c191" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments" scale="3" sign="-" unitRef="usd">6,680</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c192" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments" scale="3" sign="-" unitRef="usd">3,361</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c193" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments" scale="3" sign="-" unitRef="usd">656</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments" scale="3" sign="-" unitRef="usd">10,697</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Adjustments arising from translating financial operation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c190" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AdjustmentsArisingFromTranslatingFinancialOperations" scale="3" sign="-" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c191" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AdjustmentsArisingFromTranslatingFinancialOperations" scale="3" sign="-" unitRef="usd">45</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c192" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AdjustmentsArisingFromTranslatingFinancialOperations" scale="3" sign="-" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c193" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AdjustmentsArisingFromTranslatingFinancialOperations" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AdjustmentsArisingFromTranslatingFinancialOperations" scale="3" sign="-" unitRef="usd">24</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance as of December,31 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c186" decimals="-3" format="ixt:num-dot-decimal" name="iinn:BalanceAtEnding" scale="3" unitRef="usd">196</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c187" decimals="-3" format="ixt:num-dot-decimal" name="iinn:BalanceAtEnding" scale="3" unitRef="usd">1,039</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c188" decimals="-3" format="ixt:num-dot-decimal" name="iinn:BalanceAtEnding" scale="3" unitRef="usd">354</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c189" decimals="-3" format="ixt:num-dot-decimal" name="iinn:BalanceAtEnding" scale="3" unitRef="usd">133</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="iinn:BalanceAtEnding" scale="3" unitRef="usd">1,722</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 164; Options: Last --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div></div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentAccountingStandard">International Financial Reporting Standards</ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-2" name="iinn:SalesAndMarketingExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-3" name="ifrs-full:OtherGainsLosses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="ifrs-full:OtherGainsLosses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="ifrs-full:FinanceIncomeCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-8" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-9" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="usdPershares">0.95</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-10" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="usdPershares">3.67</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="1" id="hidden-fact-11" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="usdPershares">3.2</ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-12" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-13" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-14" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-15" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-16" name="iinn:OptionsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-17" name="iinn:OptionsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-18" name="iinn:OptionsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-19" name="iinn:OptionsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-20" name="iinn:StockIssuedDuringPeriodValueRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-21" name="iinn:StockIssuedDuringPeriodValueRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-22" name="iinn:StockIssuedDuringPeriodValueRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-23" name="iinn:StockIssuedDuringPeriodValueRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-24" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-25" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-26" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-27" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-28" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-29" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-30" name="iinn:TotalComprehensiveLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-31" name="iinn:TotalComprehensiveLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-32" name="iinn:ParValueCancellations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-33" name="iinn:ParValueCancellations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-34" name="iinn:ParValueCancellations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-35" name="iinn:InitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-36" name="iinn:InitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-37" name="iinn:InitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-38" name="ifrs-full:IssueOfConvertibleInstruments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-39" name="ifrs-full:IssueOfConvertibleInstruments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-40" name="ifrs-full:IssueOfConvertibleInstruments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-41" name="iinn:TradableWarrantsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-42" name="iinn:TradableWarrantsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-43" name="iinn:TradableWarrantsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-44" name="iinn:StockIssuedDuringPeriodValueRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-45" name="iinn:StockIssuedDuringPeriodValueRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-46" name="iinn:StockIssuedDuringPeriodValueRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-47" name="iinn:StockIssuedDuringPeriodValueRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-48" name="iinn:StockIssuedDuringPeriodValueRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-49" name="iinn:OptionsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-50" name="iinn:OptionsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-51" name="iinn:OptionsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-52" name="iinn:OptionsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-53" name="iinn:OptionsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-54" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-55" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-56" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-57" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-58" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-59" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-60" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-61" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-62" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-63" name="iinn:TotalComprehensiveLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-64" name="iinn:TotalComprehensiveLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-65" name="iinn:ShareSplit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-66" name="iinn:ShareSplit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-67" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-68" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-69" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-70" name="iinn:OptionsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-71" name="iinn:OptionsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-72" name="iinn:OptionsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-73" name="iinn:ConversionOfConvertibleLoanToShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-74" name="iinn:ConversionOfConvertibleLoanToShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-75" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-76" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-77" name="ifrs-full:AdjustmentsForFairValueGainsLosses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-78" name="ifrs-full:AdjustmentsForFairValueGainsLosses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-79" name="iinn:RevaluationOfLoanFromTheIsraeliInnovationAuthority" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-80" name="iinn:RevaluationOfLoanFromTheIsraeliInnovationAuthority" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-81" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-82" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-83" name="iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-84" name="iinn:ReceiptOfIPOFunds" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-85" name="iinn:ReceiptOfIPOFunds" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-86" name="iinn:ReceiptOfWarrantsExerciseFundsNetFromFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-87" name="iinn:ReceiptOfWarrantsExerciseFundsNetFromFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-88" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-89" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-90" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-91" name="iinn:TradableWarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-92" name="iinn:TradableWarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-93" name="iinn:TradableWarrantsDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-94" name="iinn:TradableWarrantsDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-95" name="iinn:ShareBasedCompensationUnderwritersFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-96" name="iinn:ShareBasedCompensationUnderwritersFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-97" name="ifrs-full:ProceedsFromExerciseOfOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-98" name="ifrs-full:ProceedsFromExerciseOfOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-99" name="iinn:WarrantsExerciseLiabilityIssuance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-100" name="iinn:WarrantsExerciseLiabilityIssuance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-101" name="iinn:TotalNonCashTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-102" name="iinn:TotalNonCashTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-103" name="iinn:AccumulatedDepreciation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-104" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-105" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-106" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="usdPershares">0.95</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-107" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="usdPershares">3.67</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="1" id="hidden-fact-108" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="usdPershares">3.2</ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-109" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-110" name="ifrs-full:WagesAndSalaries" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-111" name="ifrs-full:FeeAndCommissionExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-112" name="ifrs-full:OtherExpenseByNature" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-113" name="ifrs-full:ExpenseByNature" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-114" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-115" name="ifrs-full:KeyManagementPersonnelCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-116" name="ifrs-full:InsuranceExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c90" id="hidden-fact-117" name="ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c91" id="hidden-fact-118" name="ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-119" name="iinn:ForeignCurrencyTransactionLossNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-120" name="iinn:ForeignCurrencyTransactionLossNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-121" name="ifrs-full:InterestIncomeOnDeposits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-122" name="ifrs-full:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-123" name="ifrs-full:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-124" name="iinn:TotalIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-125" name="ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-126" name="iinn:ForeignCurrencyTransactionLossNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-127" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-128" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-129" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c107" id="hidden-fact-130" name="ifrs-full:AdditionsToRightofuseAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c107" id="hidden-fact-131" name="ifrs-full:DisposalsInvestmentProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-132" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-133" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-134" name="iinn:FinancialExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-135" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-136" name="ifrs-full:InterestExpenseOnLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-137" name="ifrs-full:InterestExpenseOnLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c131" id="hidden-fact-138" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c131" id="hidden-fact-139" name="iinn:ForfeitedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c146" id="hidden-fact-140" name="iinn:OutstandingAtBeginningOfYears" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c147" id="hidden-fact-141" name="iinn:ExercisableRSUs" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-142" name="iinn:OutstandingAtBeginningOfYears" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c155" id="hidden-fact-143" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-144" name="iinn:Deposit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c163" id="hidden-fact-145" name="ifrs-full:OtherPayables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c164" id="hidden-fact-146" name="ifrs-full:OtherPayables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c163" id="hidden-fact-147" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c164" id="hidden-fact-148" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c162" id="hidden-fact-149" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c166" id="hidden-fact-150" name="ifrs-full:OtherPayables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c167" id="hidden-fact-151" name="ifrs-full:OtherPayables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c166" id="hidden-fact-152" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c167" id="hidden-fact-153" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c165" id="hidden-fact-154" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-155" name="iinn:NontradableWarrantFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c176" id="hidden-fact-156" name="iinn:NontradableWarrantFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-157" name="iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c176" id="hidden-fact-158" name="iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c177" id="hidden-fact-159" name="ifrs-full:FinancialLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c179" id="hidden-fact-160" name="ifrs-full:FinancialLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c178" id="hidden-fact-161" name="ifrs-full:WarrantLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c179" id="hidden-fact-162" name="ifrs-full:WarrantLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c179" id="hidden-fact-163" name="ifrs-full:CurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c180" id="hidden-fact-164" name="iinn:NontradableWarrantFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c182" id="hidden-fact-165" name="iinn:NontradableWarrantFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c180" id="hidden-fact-166" name="iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c182" id="hidden-fact-167" name="iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c183" id="hidden-fact-168" name="ifrs-full:FinancialLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c185" id="hidden-fact-169" name="ifrs-full:FinancialLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c184" id="hidden-fact-170" name="ifrs-full:WarrantLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c185" id="hidden-fact-171" name="ifrs-full:WarrantLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c185" id="hidden-fact-172" name="ifrs-full:CurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c188" id="hidden-fact-173" name="iinn:BalanceAtBeginning" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c189" id="hidden-fact-174" name="iinn:BalanceAtBeginning" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c190" id="hidden-fact-175" name="iinn:Addition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c190" id="hidden-fact-176" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c193" id="hidden-fact-177" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c190" id="hidden-fact-178" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001837493</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="iinn-20221231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><ix:relationship fromRefs="hidden-fact-16 hidden-fact-49" toRefs="ix_0_footnote"></ix:relationship>
<ix:relationship fromRefs="hidden-fact-103" toRefs="ix_1_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2021-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:ComputersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:LeaseholdImprovementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="iinn:InvestmentNameAxis">iinn:WarrantsToInvestorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="iinn:InvestmentNameAxis">iinn:WarrantsToBrokersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iinn:InitialPublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:NontradableWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:NontradableWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:NontradableWarrantsSAFEAndCLAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:NontradableWarrantsSAFEAndCLAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:TradableWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:TradableWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:FinancialLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:FinancialLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iinn:InvestorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-18</xbrli:startDate>
    <xbrli:endDate>2021-03-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-18</xbrli:startDate>
    <xbrli:endDate>2021-03-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iinn:OverallotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iinn:BrokersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRoJ/travtspQJClWcUZpCKKwHPCOss3tqo6SbRlG2Msx2Mu7jhsbM1rEkd29demw7xoQFJ8QNNTzH6TXzpr7OuPNceEmvURO78QMp9NjY3po4ETx9F6sRViSfWYVo2UAZNSzfpm7SWSs] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-02</xbrli:startDate>
    <xbrli:endDate>2021-11-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-02</xbrli:startDate>
    <xbrli:endDate>2021-11-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-02</xbrli:startDate>
    <xbrli:endDate>2021-11-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-01</xbrli:startDate>
    <xbrli:endDate>2022-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-04-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-01</xbrli:startDate>
    <xbrli:endDate>2022-11-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iinn:AdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iinn:DirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">iinn:RSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">iinn:EmployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">iinn:EmployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">iinn:DirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">iinn:DirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">iinn:USDMemberMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">iinn:USDMemberMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">iinn:AUDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">iinn:AUDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">iinn:PoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">iinn:PoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">iinn:UpTo1YearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">iinn:Between1And3YearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">iinn:MoreThan3YearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">iinn:UpTo1YearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">iinn:Between1And3YearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">iinn:MoreThan3YearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">iinn:fairValueMeasurementAtLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">iinn:fairValueMeasurementAtLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">iinn:fairValueMeasurementAtLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:SAFEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ConvertibleLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:FinancialDerivativeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:SAFEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ConvertibleLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:FinancialDerivativeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit><xbrli:unit id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit></ix:resources></ix:header>

</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>f20f2022ex2-1_inspiratech.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Description of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
of Inspira Technologies Oxy B.H.N. Ltd. (the &ldquo;Company&rdquo;) share capital, provisions of articles of association (&ldquo;Articles<FONT STYLE="background-color: white">&rdquo;)
as may be amended and restated from time to time, and Israeli law</FONT> are summaries and do not purport to be complete, and is qualified
in its entirety by reference to, the provisions of our Articles as well as the Israeli law and any other documents referenced in the summary
and from which the summary is derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of December 31, 2022, our authorized share capital consisted of 100,000,000 Ordinary Shares, no par value (&ldquo;Ordinary Shares&rdquo;),
of which 11,388,640 Ordinary Shares were issued and outstanding as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
registration number with the Israeli Registrar of Companies is 515806495.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Name of Exchange on which Registered</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares are listed
on Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;IINN&rdquo; since July 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our warrants to purchase our
Ordinary Shares (&ldquo;Warrants&rdquo;) have been trading on Nasdaq under the symbol &ldquo;IINNW&rdquo; since July 2021. Each Warrant
is exercisable at the exercise price of $5.50 per share and will expire five years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No transfer of shares shall
be registered unless a proper writing or instrument of transfer (in any customary form or any other form satisfactory to the board of
directors &ldquo;Board of Directors&rdquo;) has been submitted to the Company (or its transfer agent), together with any share certificate(s)
and such other evidence of title as the Board of Directors may reasonably require. The Board of Directors, may, from time to time, prescribe
a fee for the registration of a transfer, and may approve other methods of recognizing the transfer of shares in order to facilitate the
trading of the Company&rsquo;s shares on the Nasdaq or on any other stock exchange on which the Company&rsquo;s shares are then listed
for trading. The ownership or voting of our Ordinary Shares by non-residents of Israel is not restricted in any way by our Articles or
the laws of the State of Israel, except for ownership by nationals of certain countries that are, or have been, in a state of war with
Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liability to Further Capital Calls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors may
make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to shares held by
such shareholders which is not payable at a fixed time. Such shareholder has to pay the amount of every call so made upon him or her.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, our Board
of Directors must consist of at least three and not more than twelve directors, including two external directors, if any, which will be
elected if and when required under the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than external directors,
if any (who shall be elected and serve in office in strict accordance with the provisions of the Companies Law), directors of the Company
shall be elected solely at an Annual General Meeting and shall serve in their office until the next Annual General Meeting, or until they
cease to serve in their office in accordance with the provisions of the Articles or any law, whichever is earlier. Prior to every Annual
General Meeting of the Company, and subject to clauses (a) and (f) of the Company&rsquo;s articles, the Board of Directors (or a committee
thereof) shall select, by a resolution adopted by a majority of the Board of Directors (or such committee), a number of persons to be
proposed to the shareholders for election as Directors at such Annual General Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if a director&rsquo;s
office becomes vacant, the remaining serving directors may continue to act in any manner, provided that the number of the serving directors
shall not be less than three (3). If the number of serving Directors is lower than their minimal one, the Board shall not be permitted
to act, they may only act in an emergency or to fill the office of director which has become vacant up to a number equal to the minimum
number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">External directors, if any,
are elected for an initial term of three years, and may be elected thereafter for up to two additional three-year terms under certain
circumstances, and may be removed from office pursuant to the terms of the Companies Law. Under certain circumstances, the term of office
for external directors for Israeli companies traded on certain foreign stock exchanges, including the Nasdaq Stock Market, may be extended
indefinitely in increments of additional three-year terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividend Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors may
from time to time declare, and cause the Company to pay, such dividend as may appear to the Board of Directors to be justified by the
profits of the Company and as permitted by the Companies Law. The Board of Directors shall determine the time for payment of such dividends
and the record date for determining the shareholders entitled thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according
to our then last reviewed or audited consolidated financial statements, provided that the date of the financial statements is not more
than six months prior to the date of the distribution, or we may distribute dividends that do not meet such criteria only with Israeli
court approval. In each case, we are only permitted to distribute a dividend if our Board of Directors and the court, if applicable, determines
that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations
as they become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shareholder Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months
after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred
to in our Articles as special meetings. Our Board of Directors may call special meetings whenever it sees fit, at such time and place,
within or outside of Israel, as it may determine. In addition, the Companies Law provides that our Board of Directors is required to convene
a special meeting upon the written request of (i) any two of our directors or one-quarter of the members of our Board of Directors or
(ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding issued shares and 1% or more of our
outstanding voting power or (b) 5% or more of our outstanding voting power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, one
or more shareholders holding at least 1% of the voting rights at the general meeting may request that the Board of Directors include a
matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at the
general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are
the shareholders of record on a date to be decided by the Board, which according to the Companies Law may be between four and forty days
prior to the date of the meeting, as applicable according to the matters on the general meeting agenda. According to the Companies Law,
resolutions regarding the following matters must be passed at a general meeting of the Company&rsquo;s shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">amendments to the Company&rsquo;s amended and restated Articles;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the exercise of the Board&rsquo;s powers by a general meeting if the Board&rsquo;s is unable to exercise its powers and the exercise of any of its powers is required for the Company&rsquo;s proper management;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">appointment or termination of the Company&rsquo;s auditors;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">appointment of Directors (other than in the cases specified in the Company&rsquo;s amended and restated articles of association;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">approval of acts and transactions requiring general meeting approval pursuant to the provisions of the Companies Law and any other applicable law;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">increases or reductions of the Company&rsquo;s authorized share capital;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">a merger (as such term is defined in the Companies Law) ; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">dissolution of the company by the court, voluntary dissolution, or by voluntary dissolution in an expedited procedure.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, we are
not required to give notice to our registered shareholders pursuant to the Companies Law, unless otherwise required by law. The Companies
Law requires that a notice of any annual or special general meeting be provided 14 or 21 days (as applicable) prior to the meeting, and
if the agenda of the meeting includes certain matters prescribed under the Companies Law and the regulations promulgated thereafter, among
others, the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, approval
of the Company&rsquo;s general manager to serve as the chairman of the Board of Directors or an approval of a merger, notice must be provided
at least 35 days prior to such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Voting Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Every shareholder shall have
one vote for each share held by him of record, on every resolution, without regard to whether the vote thereon is conducted by a show
of hands, by written ballot or by any other means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Quorum Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As permitted under the Companies
Law and as stated in the Company&rsquo;s Articles, the quorum required for the Company&rsquo;s general meetings consists of two or more
shareholders, present in person or by proxy and holding shares conferring in the aggregate at least twenty five percent (25%) of the voting
power of the Company. If within half an hour of the time set forth for the general meeting a quorum is not present, the general meeting
shall stand adjourned either (i) to the same day of the following week, at the same hour and in the same place (ii) to such other date,
time and place as prescribed in the notice to the shareholders and in such adjourned meeting or (iii) to such day and at such time and
place as the chairperson of the general meeting shall determine (which may be earlier or later than the date pursuant to clause (i) above).
If no quorum is present within half an hour of the time arranged, any number of shareholders participating in the meeting, shall constitute
a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a special general meeting
was called following the request of a shareholder according to applicable law, and within half an hour a legal quorum has not been formed,
the meeting shall be canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Vote Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles provide that
all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our Articles.
Under the Companies Law, each of (i) the approval of an extraordinary transaction with a controlling shareholder and (ii) the terms of
employment or other engagement of the controlling shareholder of the company or such controlling shareholder&rsquo;s relative (even if
not extraordinary) requires the approval described under &ldquo;<FONT STYLE="background-color: white">Item 6.</FONT>C. <FONT STYLE="background-color: white"><I>Directors,
Senior Management and Employees</I></FONT><I>&mdash;Board Practices&mdash; Fiduciary Duties of Office Holders</I> and Approval of Related
Party Transactions under Israeli Law &mdash; Disclosure of Personal Interests of an Office Holder.&rdquo; Certain transactions with respect
to remuneration of our office holders and directors require further approvals described under &ldquo;<FONT STYLE="background-color: white">Item
6. Directors, Senior Management and Employees</FONT>&mdash;C. Board Practices&mdash; Fiduciary Duties of Office Holders and Disclosure
of Personal Interests of an Office Holder.&rdquo; Another exception to the simple majority vote requirement is a resolution for the voluntary
winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law,
which requires the approval of the court and the approval of the majority of the shareholders voting their shares, other than abstainees,
holding at least 75% of the voting rights represented at the meeting, in person, by proxy or by voting deed and voting on the resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Access to Corporate Records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, shareholders
are entitled to have access to: minutes of the Company&rsquo;s general meetings; the Company&rsquo;s shareholders register and principal
shareholders register, articles of association and annual audited financial statements; and any document that the Company is required
by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. These documents are publicly available
and may be found and inspected at the Israeli Registrar of Companies. In addition, shareholders may request to be provided with any document
related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law.
The Company may deny this request if the Company believes it has not been made in good faith or if such denial is necessary to protect
the Company&rsquo;s interest or protect a trade secret or patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special or Class Rights; Modification of Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time the share capital
of the Company is divided into different classes of shares, the rights attached to any class, unless otherwise provided by the Companies
Law or the Company&rsquo;s Articles, may be modified or cancelled by the Company by a resolution of the General Meeting of the holders
of all shares as one class, without any required separate resolution of any class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of our Articles
relating to General Meetings shall, mutatis mutandis, apply to any separate General Meeting of the holders of the shares of a particular
class, it being clarified that the requisite quorum at any such separate General Meeting shall be two or more shareholders present in
person or by proxy and holding not less than 15 percent of the issued shares of such class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise provided
by Company&rsquo;s Articles, an increase in the authorized share capital, the creation of a new class of shares, an increase in the authorized
share capital of a class of shares, or the issuance of additional shares thereof out of the authorized and unissued share capital, shall
not be deemed to modify or derogate or cancel the rights attached to previously issued shares of such class or of any other class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Acquisitions under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Full Tender Offer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, as a result of an acquisition
of shares, the acquirer will hold more than 90% of an Israeli public company&rsquo;s outstanding shares or of certain class of shares,
the acquisition must be made by means of a tender offer for all of the outstanding shares, or for all of the outstanding shares of such
class, as applicable. In general, if less than 5% of the outstanding shares, or of applicable class, are not tendered in the tender offer
and more than half of the offerees who have no personal interest in the offer tendered their shares, all the shares that the acquirer
offered to purchase will be transferred to it by operation of law. However, a tender offer will also be accepted if the shareholders who
do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares.
Any shareholders that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may request, by
petition to an Israeli court, (i) appraisal rights in connection with a full tender offer, and (ii) that the fair value should be paid
as determined by the court, for a period of six months following the acceptance of the offer. However, the acquirer is entitled to stipulate,
under certain conditions, that tendering shareholders will forfeit such appraisal rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Special Tender Offer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law also provides
that, subject to certain exceptions, an acquisition of shares in an Israeli public company must be made by means of a &ldquo;special&rdquo;
tender offer if as a result of the acquisition (1) the purchaser would become a holder of 25% or more of the voting rights in the company,
unless there is already another holder of at least 25% or more of the voting rights in the company or (2) the purchaser would become a
holder of 45% or more of the voting rights in the company, unless there is already a holder of more than 45% of the voting rights in the
company. These requirements do not apply if, in general, the acquisition (1) was made in a private placement that received shareholders&rsquo;
approval, subject to certain conditions, (2) was from a holder of 25% or more of the voting rights in the company which resulted in the
acquirer becoming a holder of 25% or more of the voting rights in the company, or (3) was from a holder of more than 45% of the voting
rights in the company which resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company. A &ldquo;special&rdquo;
tender offer must be extended to all shareholders. In general, a &ldquo;special&rdquo; tender offer may be consummated only if (1) at
least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired by the offeror and (2) the offer is accepted
by a majority of the offerees who notified the company of their position in connection with such offer (excluding the offeror, controlling
shareholders, holders of 25% or more of the voting rights in the company or anyone on their behalf, or any person having a personal interest
in the acceptance of the tender offer). If a special tender offer is accepted, then the purchaser or any person or entity controlling
it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase
of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the
offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Merger</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law includes
provisions that allow a merger transaction and requires that each company that is a party to the merger have the transaction approved
by its board of directors and, unless certain requirements described under the Companies Law are met, a vote of the majority of its shareholders,
and, in the case of the target company, also a majority vote of each class of its shares. For purposes of the shareholder vote of each
party, unless a court rules otherwise, the merger will not be deemed approved if shares representing a majority of the voting power present
at the shareholders meeting and which are not held by the other party to the merger (or by any person or group of persons acting in concert
who holds 25% or more of the voting power or the right to appoint 25% or more of the directors of the other party) vote against the merger.
If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder or if the controlling shareholder has a personal
interest in the merger, then the merger is instead subject to the same Special Majority (as defined below) approval that governs all extraordinary
transactions with controlling shareholders. Upon the request of a creditor of either party to the proposed merger, the court may delay
or prevent the merger if it concludes that there exists a reasonable concern that as a result of the merger the surviving company will
be unable to satisfy the obligations of any of the parties to the merger, and may further give instructions to secure the rights of creditors.
If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the
exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the petition of holders of
at least 25% of the voting rights of a company. For such petition to be granted, the court must find that the merger is fair and reasonable,
taking into account the value of the parties to the merger and the consideration offered to the shareholders. In addition, a merger may
not be completed unless at least (1) 50 days have passed from the time that the requisite proposals for approval of the merger were filed
with the Israeli Registrar of Companies by each merging company; and (2) 30 days have passed since the merger was approved by the shareholders
of each merging company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &ldquo;Special Majority&rdquo;
will be defined as described in section 275(a)(3) of the Companies Law as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">at least a majority of the shares held by shareholders who are not controlling shareholders and do not have personal interest in the merger have voted in favor of the proposal (shares held by abstaining shareholders shall not be considered); or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the total number of shares voted against the merger does not exceed 2% of the aggregate voting rights of the company.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Borrowing Powers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law and our Articles, our Board of Directors may exercise all powers and take all actions that are not required under law or under our
Articles to be exercised or taken by a certain organ of the Company, including the power to borrow money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles enable us to
increase or reduce our authorized share capital. Any such changes are subject to the provisions of the Companies Law and must be approved
by a resolution duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital,
such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both
our Board of Directors and an Israeli court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Warrants were issued in
registered form pursuant to the warrant agent agreement dated July 13, 2021, by and between the Company and VStock Transfer, LLC, as warrant
agent (the &ldquo;Warrant Agreement&rdquo;). You should review a copy of the Warrant Agreement and the form of warrant included therein,
as publicly disclosed, for a complete description of the terms and conditions of the Warrants and the Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Duration and Exercise Price Adjustments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants will expire at
5:00 p.m., New York City time on July 16, 2026. The exercise price and number of Ordinary Shares issuable upon exercise is subject to
appropriate adjustments in the event of stock dividends, stock splits, reorganizations or other events affecting our Ordinary Shares and
the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exercisability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants may be exercised
upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form
completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by paying
in full, in lawful money of the United States by wire transfer to the warrant agent, for the number of Warrants being exercised. The warrant
holders do not have the rights or privileges of a shareholder of the Company and any voting rights until they exercise their Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fractional Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No fractional shares will
be issued in connection with the exercise of a Warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to
the fractional amount multiplied by the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transferability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to applicable laws,
each warrant may be transferred at the option of the holder upon surrender of the warrant to the Company or its designated agent together
with a written assignment substantially in the form attached to the warrant as an exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Agent</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrant agent for our
Warrants is VStock Transfer, LLC, Inc. <FONT STYLE="background-color: white">Its address is </FONT>18 Lafayette Pl, Woodmere, NY 11598,
United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exchange Listing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Warrants are listed on
Nasdaq under the symbol &ldquo;IINNW.&rdquo;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">6</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>f20f2022ex12-1_inspiratech.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="margin: 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) or 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Dagi Ben-Noon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this annual report on Form 20&ndash;F of Inspira Technologies Oxy B.H.N. Ltd. (the &ldquo;company&rdquo;);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent function):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 60%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Date: March 31, 2023</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt">Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>f20f2022ex12-2_inspiratech.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) or 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Yafit Tehila, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this annual report on Form 20&ndash;F of Inspira Technologies Oxy B.H.N. Ltd. (the &ldquo;company&rdquo;);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent function):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 60%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Date: March 31, 2023</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Yafit Tehila</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt">Yafit Tehila </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>f20f2022ex13-1_inspiratech.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>18 U.S.C. Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2022 (the &ldquo;Report&rdquo;) by Inspira Technologies Oxy B.H.N.
Ltd. (the &ldquo;company&rdquo;), the undersigned, as the Chief Executive Officer of the company, hereby certifies pursuant to 18 U.S.C.
Section 1350, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) the Report fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Date: March 31, 2023</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>6
<FILENAME>f20f2022ex13-2_inspiratech.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 13.2</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>18 U.S.C. Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2022 (the &ldquo;Report&rdquo;) by Inspira Technologies Oxy B.H.N.
Ltd. (the &ldquo;company&rdquo;), the undersigned, as the Chief Financial Officer of the company, hereby certifies pursuant to 18 U.S.C.
Section 1350, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) the Report fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Date: March 31, 2023</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Yafit Tehila</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Yafit Tehila </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>f20f2022ex15-1_inspiratech.htm
<DESCRIPTION>CONSENT OF ZIV HAFT, A MEMBER FIRM OF BDO, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 49%"><IMG SRC="ex15-1_001.jpg" ALT=""></TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 49%"></TD></TR>
</TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Inspira Technologies Oxy B.H.N. Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">2 Ha-Tidhar St.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Rananna 4366504, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8&nbsp;(No. 333-259057) and Form F-3 (No. 333-266748) of Insipra Technologies Oxy B.H.N Ltd (&ldquo;the Company&rdquo;)
of our report dated March 31, 2023, relating to the financial statements of the Company which appears in this Annual Report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">/s/ Ziv Haft</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Certified Public Accountants (Isr.)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">BDO Member Firm</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Tel Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">March 31, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>iinn-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 19:09:14 UTC 2023 -->
<xs:schema elementFormDefault="qualified" xmlns:iinn="http://www.inspiratechnologies.com/20221231" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" targetNamespace="http://www.inspiratechnologies.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20221231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20221231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20221231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20221231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet" id="iinn_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement" id="iinn_r_ConsolidatedIncomeStatement">
        <link:definition>002 - Statement - Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals" id="iinn_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>003 - Statement - Statements of Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3" id="iinn_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Statements of Changes in Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow" id="iinn_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Statements of Cash Flow</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/General" id="iinn_r_General">
        <link:definition>006 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies" id="iinn_r_SignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/CriticalAccountingEstimatesandJudgements" id="iinn_r_CriticalAccountingEstimatesandJudgements">
        <link:definition>008 - Disclosure - Critical Accounting Estimates and Judgements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/Deposits" id="iinn_r_Deposits">
        <link:definition>009 - Disclosure - Deposits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssets" id="iinn_r_OtherCurrentAssets">
        <link:definition>010 - Disclosure - Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet" id="iinn_r_PropertyandEquipmentNet">
        <link:definition>011 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayable" id="iinn_r_OtherAccountsPayable">
        <link:definition>012 - Disclosure - Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrants" id="iinn_r_LiabilityinRespectofGovernmentGrants">
        <link:definition>013 - Disclosure - Liability in Respect of Government Grants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue" id="iinn_r_FinacialLiabilitiesatFairValue">
        <link:definition>014 - Disclosure - Finacial Liabilities at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/EquityDefict" id="iinn_r_EquityDefict">
        <link:definition>015 - Disclosure - Equity (Defict)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses" id="iinn_r_ResearchandDevelopmentExpenses">
        <link:definition>016 - Disclosure - Research and Development Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses" id="iinn_r_SalesandMarketingExpenses">
        <link:definition>017 - Disclosure - Sales and Marketing Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses" id="iinn_r_GeneralandAdministrativeExpenses">
        <link:definition>018 - Disclosure - General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses" id="iinn_r_FinancialIncomeandExpenses">
        <link:definition>019 - Disclosure - Financial (Income) and Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/TaxesonIncome" id="iinn_r_TaxesonIncome">
        <link:definition>020 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/Leases" id="iinn_r_Leases">
        <link:definition>021 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareBasedCompensation" id="iinn_r_ShareBasedCompensation">
        <link:definition>022 - Disclosure - Share Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/RelatedParties" id="iinn_r_RelatedParties">
        <link:definition>023 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagement" id="iinn_r_FinancialInstrumentsandRiskManagement">
        <link:definition>024 - Disclosure - Financial Instruments and Risk Management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingencies" id="iinn_r_CommitmentsandContingencies">
        <link:definition>025 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FairValueMeasurement" id="iinn_r_FairValueMeasurement">
        <link:definition>026 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy" id="iinn_r_AccountingPoliciesByPolicy">
        <link:definition>027 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables" id="iinn_r_SignificantAccountingPoliciesTables">
        <link:definition>028 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables" id="iinn_r_OtherCurrentAssetsTables">
        <link:definition>029 - Disclosure - Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables" id="iinn_r_PropertyandEquipmentNetTables">
        <link:definition>030 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables" id="iinn_r_OtherAccountsPayableTables">
        <link:definition>031 - Disclosure - Other Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsTables" id="iinn_r_LiabilityinRespectofGovernmentGrantsTables">
        <link:definition>032 - Disclosure - Liability in Respect of Government Grants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables" id="iinn_r_FinacialLiabilitiesatFairValueTables">
        <link:definition>033 - Disclosure - Finacial Liabilities at Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/EquityDefictTables" id="iinn_r_EquityDefictTables">
        <link:definition>034 - Disclosure - Equity (Defict) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables" id="iinn_r_ResearchandDevelopmentExpensesTables">
        <link:definition>035 - Disclosure - Research and Development Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables" id="iinn_r_SalesandMarketingExpensesTables">
        <link:definition>036 - Disclosure - Sales and Marketing Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables" id="iinn_r_GeneralandAdministrativeExpensesTables">
        <link:definition>037 - Disclosure - General and Administrative Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables" id="iinn_r_FinancialIncomeandExpensesTables">
        <link:definition>038 - Disclosure - Financial (Income) and Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeTables" id="iinn_r_TaxesonIncomeTables">
        <link:definition>039 - Disclosure - Taxes on Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/LeasesTables" id="iinn_r_LeasesTables">
        <link:definition>040 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareBasedCompensationTables" id="iinn_r_ShareBasedCompensationTables">
        <link:definition>041 - Disclosure - Share Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/RelatedPartiesTables" id="iinn_r_RelatedPartiesTables">
        <link:definition>042 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables" id="iinn_r_FinancialInstrumentsandRiskManagementTables">
        <link:definition>043 - Disclosure - Financial Instruments and Risk Management (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FairValueMeasurementTables" id="iinn_r_FairValueMeasurementTables">
        <link:definition>044 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/GeneralDetails" id="iinn_r_GeneralDetails">
        <link:definition>045 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" id="iinn_r_ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable">
        <link:definition>046 - Disclosure - Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/DepositsDetails" id="iinn_r_DepositsDetails">
        <link:definition>047 - Disclosure - Deposits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofotherCurrentAssetsTable" id="iinn_r_ScheduleofotherCurrentAssetsTable">
        <link:definition>048 - Disclosure - Other Current Assets (Details) - Schedule of other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable" id="iinn_r_ScheduleofpropertyandequipmentnetTable">
        <link:definition>049 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable" id="iinn_r_ScheduleofotheraccountspayableTable">
        <link:definition>050 - Disclosure - Other Accounts Payable (Details) - Schedule of other accounts payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsDetails" id="iinn_r_LiabilityinRespectofGovernmentGrantsDetails">
        <link:definition>051 - Disclosure - Liability in Respect of Government Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofreimbursementofresearchexpensesTable" id="iinn_r_ScheduleofreimbursementofresearchexpensesTable">
        <link:definition>052 - Disclosure - Liability in Respect of Government Grants (Details) - Schedule of reimbursement of research expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails" id="iinn_r_FinacialLiabilitiesatFairValueDetails">
        <link:definition>053 - Disclosure - Finacial Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable" id="iinn_r_ScheduleoffinacialliabilitiesatfairvalueTable">
        <link:definition>054 - Disclosure - Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/EquityDefictDetails" id="iinn_r_EquityDefictDetails">
        <link:definition>055 - Disclosure - Equity (Defict) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable" id="iinn_r_ScheduleofsharecapitalTable">
        <link:definition>056 - Disclosure - Equity (Defict) (Details) - Schedule of share capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable" id="iinn_r_ScheduleoflosspershareTable">
        <link:definition>057 - Disclosure - Equity (Defict) (Details) - Schedule of loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable_Parentheticals" id="iinn_r_ScheduleoflosspershareTable_Parentheticals">
        <link:definition>058 - Disclosure - Equity (Defict) (Details) - Schedule of loss per share (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable" id="iinn_r_ScheduleofresearchanddevelopmentexpensesTable">
        <link:definition>059 - Disclosure - Research and Development Expenses (Details) - Schedule of research and development expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable" id="iinn_r_ScheduleofsalesandMarketingExpensesTable">
        <link:definition>060 - Disclosure - Sales and Marketing Expenses (Details) - Schedule of sales and Marketing Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable" id="iinn_r_ScheduleofgeneralandadministrativeexpensesTable">
        <link:definition>061 - Disclosure -  General and Administrative Expenses (Details) - Schedule of general and administrative expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable" id="iinn_r_ScheduleoffinancialincomeTable">
        <link:definition>062 - Disclosure - Financial (Income) and Expenses (Details) - Schedule of financial income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable" id="iinn_r_ScheduleoffinancialexpensesTable">
        <link:definition>063 - Disclosure - Financial (Income) and Expenses (Details) - Schedule of financial expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails" id="iinn_r_TaxesonIncomeDetails">
        <link:definition>064 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable" id="iinn_r_ScheduleoftheoreticaltaxTable">
        <link:definition>065 - Disclosure - Taxes on Income (Details) - Schedule of theoretical tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable_Parentheticals" id="iinn_r_ScheduleoftheoreticaltaxTable_Parentheticals">
        <link:definition>066 - Disclosure - Taxes on Income (Details) - Schedule of theoretical tax (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/LeasesDetails" id="iinn_r_LeasesDetails">
        <link:definition>067 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable" id="iinn_r_ScheduleofrightofuseassetsTable">
        <link:definition>068 - Disclosure - Leases (Details) - Schedule of right-of-use assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable" id="iinn_r_ScheduleofleaseliabilitiesTable">
        <link:definition>069 - Disclosure - Leases (Details) - Schedule of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable" id="iinn_r_ScheduleofprofitorlossTable">
        <link:definition>070 - Disclosure - Leases (Details) - Schedule of profit or loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails" id="iinn_r_ShareBasedCompensationDetails">
        <link:definition>071 - Disclosure - Share Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" id="iinn_r_ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable">
        <link:definition>072 - Disclosure - Share Based Compensation (Details) - Schedule of options to services providers and advisers outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" id="iinn_r_ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable">
        <link:definition>073 - Disclosure - Share Based Compensation (Details) - Schedule of RSUs to services providers and advisers outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRoJ/travtspQJClWcUZpCKKwHPCOss3tqo6SbRlG2Msx2Mu7jhsbM1rEkd29demw7xoQFJ8QNNTzH6TXzpr7OuPNceEmvURO78QMp9NjY3po4ETx9F6sRVj/y0gHO+IkZSmmdUQjftc6iJqEp6aw7Ak=] CSR-->
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable" id="iinn_r_ScheduleofshareholdersandotherrelatedpartiesbenefitsTable">
        <link:definition>074 - Disclosure - Related Parties (Details) - Schedule of shareholders and other related parties&#8217; benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable" id="iinn_r_ScheduleofbalanceswithrelatedpartiesTable">
        <link:definition>075 - Disclosure - Related Parties (Details) - Schedule of balances with related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementDetails" id="iinn_r_FinancialInstrumentsandRiskManagementDetails">
        <link:definition>076 - Disclosure - Financial Instruments and Risk Management (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" id="iinn_r_ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable">
        <link:definition>077 - Disclosure - Financial Instruments and Risk Management (Details) - Schedule of financial assets represents the maximum credit exposure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable" id="iinn_r_ScheduleofforeigncurrencydenominatedmonetaryliabilityTable">
        <link:definition>078 - Disclosure - Financial Instruments and Risk Management (Details) - Schedule of foreign currency denominated monetary liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable" id="iinn_r_ScheduleofsensitivityanalysisTable">
        <link:definition>079 - Disclosure - Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable" id="iinn_r_ScheduleofcashflowsoffinancialliabilitiesTable">
        <link:definition>080 - Disclosure - Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails" id="iinn_r_CommitmentsandContingenciesDetails">
        <link:definition>081 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FairValueMeasurementDetails" id="iinn_r_FairValueMeasurementDetails">
        <link:definition>082 - Disclosure - Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable" id="iinn_r_ScheduleofwarrantsTable">
        <link:definition>083 - Disclosure - Fair Value Measurement (Details) - Schedule of warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable" id="iinn_r_Scheduleofmovementsinlevel2liabilityTable">
        <link:definition>084 - Disclosure - Fair Value Measurement (Details) - Schedule of movements in level 2 liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xs:element name="StatementsOfChangesInShareholdersEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_StatementsOfChangesInShareholdersEquityAbstract"/>
  <xs:element name="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract"/>
  <xs:element name="DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract"/>
  <xs:element name="ScheduleOfStraightLineBasisOverTheUsefulLivesOfTheAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfStraightLineBasisOverTheUsefulLivesOfTheAssetsAbstract"/>
  <xs:element name="DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract"/>
  <xs:element name="DisclosureOfDepositsFromBanksTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfDepositsFromBanksTextBlockAbstract"/>
  <xs:element name="DisclosureOfOtherNonCurrentAssetsTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract"/>
  <xs:element name="ScheduleOfOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfOtherCurrentAssetsAbstract"/>
  <xs:element name="DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="DisclosureOfTradeAndOtherPayablesTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract"/>
  <xs:element name="ScheduleOfOtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfOtherAccountsPayableAbstract"/>
  <xs:element name="DisclosureOfGovernmentGrantsTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfGovernmentGrantsTextBlockAbstract"/>
  <xs:element name="ScheduleOfReimbursementOfResearchExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfReimbursementOfResearchExpensesAbstract"/>
  <xs:element name="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract"/>
  <xs:element name="ScheduleOfFinacialLiabilitiesAtFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinacialLiabilitiesAtFairValueAbstract"/>
  <xs:element name="DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract"/>
  <xs:element name="ScheduleOfShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfShareCapitalAbstract"/>
  <xs:element name="ScheduleOfLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfLossPerShareAbstract"/>
  <xs:element name="DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract"/>
  <xs:element name="ScheduleOfResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
  <xs:element name="SalesAndMarketingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SalesAndMarketingExpensesAbstract"/>
  <xs:element name="ScheduleOfSalesAndMarketingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfSalesAndMarketingExpensesAbstract"/>
  <xs:element name="DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="DisclosureOfFinanceIncomeCostTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract"/>
  <xs:element name="ScheduleOfFinancialIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinancialIncomeAbstract"/>
  <xs:element name="ScheduleOfFinancialExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinancialExpensesAbstract"/>
  <xs:element name="DisclosureOfIncomeTaxTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfIncomeTaxTextBlockAbstract"/>
  <xs:element name="ScheduleOfTheoreticalTaxAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfTheoreticalTaxAbstract"/>
  <xs:element name="DisclosureOfLeasesTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfLeasesTextBlockAbstract"/>
  <xs:element name="ScheduleOfRightOfUseAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfRightOfUseAssetsAbstract"/>
  <xs:element name="ScheduleOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfProfitOrLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfProfitOrLossAbstract"/>
  <xs:element name="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
  <xs:element name="ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract"/>
  <xs:element name="ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract"/>
  <xs:element name="DisclosureOfRelatedPartyTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfRelatedPartyTextBlockAbstract"/>
  <xs:element name="ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract"/>
  <xs:element name="ScheduleOfBalancesWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
  <xs:element name="DisclosureOfFinancialInstrumentsTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract"/>
  <xs:element name="ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureAbstract"/>
  <xs:element name="ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract"/>
  <xs:element name="ScheduleOfSensitivityAnalysisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfSensitivityAnalysisAbstract"/>
  <xs:element name="ScheduleOfCashFlowsOfFinancialLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfCashFlowsOfFinancialLiabilitiesAbstract"/>
  <xs:element name="DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract"/>
  <xs:element name="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract"/>
  <xs:element name="ScheduleOfWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfWarrantsAbstract"/>
  <xs:element name="ScheduleOfMovementsInLevel2LiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfMovementsInLevel2LiabilityAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract3"/>
  <xs:element name="ItemsThatWillNotBeReclassifiedToProfitOrLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ItemsThatWillNotBeReclassifiedToProfitOrLossAbstract"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract4"/>
  <xs:element name="ChangesDuringThePeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesDuringThePeriodAbstract"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract5"/>
  <xs:element name="ChangesDuringThePeriodAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesDuringThePeriodAbstract0"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract6"/>
  <xs:element name="ChangesDuringThePeriodAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesDuringThePeriodAbstract1"/>
  <xs:element name="ChangesInOperatingAssetsAndLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesInOperatingAssetsAndLiabilityAbstract"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract10"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_CostAbstract"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract11"/>
  <xs:element name="AccumulatedDepreciationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AccumulatedDepreciationAbstract"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract12"/>
  <xs:element name="NetBookValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NetBookValueAbstract"/>
  <xs:element name="CostAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_CostAbstract0"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract14"/>
  <xs:element name="AccumulatedDepreciationAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AccumulatedDepreciationAbstract0"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract16"/>
  <xs:element name="NetBookValueAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NetBookValueAbstract0"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract17"/>
  <xs:element name="AssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AssetsAbstract0"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract18"/>
  <xs:element name="LoanFromTheIsraeliInnovationAuthority" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_LoanFromTheIsraeliInnovationAuthority"/>
  <xs:element name="ResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ResearchAndDevelopmentExpenses"/>
  <xs:element name="SalesAndMarketingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_SalesAndMarketingExpenses"/>
  <xs:element name="GeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_GeneralAndAdministrativeExpenses"/>
  <xs:element name="FinanceExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinanceExpense"/>
  <xs:element name="TotalComprehensiveLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TotalComprehensiveLoss"/>
  <xs:element name="OptionsExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_OptionsExercise"/>
  <xs:element name="ShareBasedCompensationToExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationToExercise"/>
  <xs:element name="StockIssuedDuringPeriodValueRestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits"/>
  <xs:element name="StockIssuedDuringPeriodSharesRestrictedStockUnit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit"/>
  <xs:element name="ParValueCancellations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ParValueCancellations"/>
  <xs:element name="InitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_InitialPublicOffering"/>
  <xs:element name="ShareIssuanceOfInitialPublicOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareIssuanceOfInitialPublicOffering"/>
  <xs:element name="ConversionOfFinancialLiabilityinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ConversionOfFinancialLiabilityinShares"/>
  <xs:element name="TradableWarrantsExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TradableWarrantsExercise"/>
  <xs:element name="TradableWarrantsExerciseinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TradableWarrantsExerciseinShares"/>
  <xs:element name="ShareSplit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareSplit"/>
  <xs:element name="ConversionOfConvertibleLoanToShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ConversionOfConvertibleLoanToShares"/>
  <xs:element name="ConversionOfConvertibleLoanToSharesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ConversionOfConvertibleLoanToSharesinShares"/>
  <xs:element name="ChangeInFairValueOfFinancialLiabilitiesAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue"/>
  <xs:element name="RevaluationOfLoanFromTheIsraeliInnovationAuthority" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority"/>
  <xs:element name="FinanceExpensesReceivedClassifiedAsOperatingActivitiy" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy"/>
  <xs:element name="PaymentOfDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_PaymentOfDeposit"/>
  <xs:element name="ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan"/>
  <xs:element name="ReceiptOfIPOFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ReceiptOfIPOFunds"/>
  <xs:element name="ReceiptOfWarrantsExerciseFundsNetFromFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees"/>
  <xs:element name="TradableWarrantsLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TradableWarrantsLiability"/>
  <xs:element name="TradableWarrantsDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TradableWarrantsDerivativeLiability"/>
  <xs:element name="ShareBasedCompensationUnderwritersFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationUnderwritersFees"/>
  <xs:element name="WarrantsExerciseLiabilityIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_WarrantsExerciseLiabilityIssuance"/>
  <xs:element name="TotalNonCashTransactions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TotalNonCashTransactions"/>
  <xs:element name="SalesAndMarketingExpensesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SalesAndMarketingExpensesTextBlock"/>
  <xs:element name="UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock"/>
  <xs:element name="OptionsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OptionsPolicyTextBlock"/>
  <xs:element name="RestrictedShareUnitsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RestrictedShareUnitsPolicyTextBlock"/>
  <xs:element name="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock"/>
  <xs:element name="ScheduleOfOtherAccountPayableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfOtherAccountPayableTextBlock"/>
  <xs:element name="ScheduleOfReimbursementOfResearchExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfFinancialLiabilities" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinancialLiabilities"/>
  <xs:element name="ScheduleOfLossPerShare" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfLossPerShare"/>
  <xs:element name="ScheduleOfResearchAndDevelopmentExpenses" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfResearchAndDevelopmentExpenses"/>
  <xs:element name="ScheduleOfSalesAndMarketingExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpenses" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfGeneralAndAdministrativeExpenses"/>
  <xs:element name="ScheduleOfFinancialIncomeTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinancialIncomeTableTextBlock"/>
  <xs:element name="ScheduleOfFinancialExpenses" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinancialExpenses"/>
  <xs:element name="ScheduleOfTheoreticalTaxTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
  <xs:element name="ScheduleOfRightofuseAssets" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfRightofuseAssets"/>
  <xs:element name="ScheduleOfLeaseLiabilities" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfLeaseLiabilities"/>
  <xs:element name="ScheduleOfProfitOrLoss" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfProfitOrLoss"/>
  <xs:element name="ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding"/>
  <xs:element name="ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock"/>
  <xs:element name="BalancesWithRelatedPartiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_BalancesWithRelatedPartiesTableTextBlock"/>
  <xs:element name="ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure"/>
  <xs:element name="ScheduleOfForeignCurrencyDenominatedMonetaryLiability" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability"/>
  <xs:element name="ScheduleOfSensitivityAnalysis" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfSensitivityAnalysis"/>
  <xs:element name="ScheduleOfMovementsInLevel2LiabilityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems"/>
  <xs:element name="AnnualDepreciationRateInPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AnnualDepreciationRateInPercentage"/>
  <xs:element name="Institutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_Institutions"/>
  <xs:element name="OthersCurrentAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_OthersCurrentAssets"/>
  <xs:element name="PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable"/>
  <xs:element name="PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems"/>
  <xs:element name="ExchangeRateDeferenceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExchangeRateDeferenceCost"/>
  <xs:element name="AccumulatedDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AccumulatedDepreciation"/>
  <xs:element name="ExchangeRateDeferenceAccumulatedDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExchangeRateDeferenceAccumulatedDepreciation"/>
  <xs:element name="NetBookValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_NetBookValue"/>
  <xs:element name="EmployeesSalariesAndRelatedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_EmployeesSalariesAndRelatedLiabilities"/>
  <xs:element name="ExchangeRateDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExchangeRateDifferences"/>
  <xs:element name="RevaluationOfTheLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_RevaluationOfTheLiability"/>
  <xs:element name="FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable"/>
  <xs:element name="FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems"/>
  <xs:element name="TotalFinancialLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TotalFinancialLiabilities"/>
  <xs:element name="EquityDefictDetailsScheduleofsharecapitalTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_EquityDefictDetailsScheduleofsharecapitalTable"/>
  <xs:element name="EquityDefictDetailsScheduleofsharecapitalLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EquityDefictDetailsScheduleofsharecapitalLineItems"/>
  <xs:element name="EquityDefictDetailsScheduleoflosspershareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_EquityDefictDetailsScheduleoflosspershareTable"/>
  <xs:element name="EquityDefictDetailsScheduleoflosspershareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EquityDefictDetailsScheduleoflosspershareLineItems"/>
  <xs:element name="AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits"/>
  <xs:element name="EquityDefictDetailsScheduleoflosspershareParentheticalsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsTable"/>
  <xs:element name="EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems"/>
  <xs:element name="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable"/>
  <xs:element name="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems"/>
  <xs:element name="ShareBasedPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedPayment"/>
  <xs:element name="SalaryAndRelatedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_SalaryAndRelatedExpenses"/>
  <xs:element name="Subcontractors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_Subcontractors"/>
  <xs:element name="MaterialsAndRelatedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_MaterialsAndRelatedExpenses"/>
  <xs:element name="DepreciationExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DepreciationExpenses"/>
  <xs:element name="IIAParticipation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_IIAParticipation"/>
  <xs:element name="OtherResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_OtherResearchAndDevelopmentExpenses"/>
  <xs:element name="ResearchDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ResearchDevelopmentExpenses"/>
  <xs:element name="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable"/>
  <xs:element name="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems"/>
  <xs:element name="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable"/>
  <xs:element name="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems"/>
  <xs:element name="ShareBasedPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedPayments"/>
  <xs:element name="Depreciations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_Depreciations"/>
  <xs:element name="FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable"/>
  <xs:element name="FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems"/>
  <xs:element name="ForeignCurrencyTransactionLossNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ForeignCurrencyTransactionLossNet"/>
  <xs:element name="TotalIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TotalIncome"/>
  <xs:element name="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable"/>
  <xs:element name="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems"/>
  <xs:element name="RevaluationOfLiabilityInRespectOfGovernmentGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants"/>
  <xs:element name="FinanceExpenseInRespectOfLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinanceExpenseInRespectOfLeaseLiability"/>
  <xs:element name="TotalExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TotalExpenses"/>
  <xs:element name="TaxesonIncomeDetailsScheduleoftheoreticaltaxTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxTable"/>
  <xs:element name="TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems"/>
  <xs:element name="LossBeforeTaxation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_LossBeforeTaxation"/>
  <xs:element name="NonallowableExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_NonallowableExpenses"/>
  <xs:element name="TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
  <xs:element name="TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable"/>
  <xs:element name="TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems"/>
  <xs:element name="TheoreticalTaxCreditAtApplicableStatutoryRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate"/>
  <xs:element name="LeasesDetailsScheduleofrightofuseassetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_LeasesDetailsScheduleofrightofuseassetsTable"/>
  <xs:element name="LeasesDetailsScheduleofrightofuseassetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_LeasesDetailsScheduleofrightofuseassetsLineItems"/>
  <xs:element name="FinancialExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialExpense"/>
  <xs:element name="LeasesDetailsScheduleofleaseliabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_LeasesDetailsScheduleofleaseliabilitiesTable"/>
  <xs:element name="LeasesDetailsScheduleofleaseliabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems"/>
  <xs:element name="FinancialExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialExpenses"/>
  <xs:element name="ExchangeRateDifference" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExchangeRateDifference"/>
  <xs:element name="PrincipalPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_PrincipalPayment"/>
  <xs:element name="LeasesDetailsScheduleofprofitorlossTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_LeasesDetailsScheduleofprofitorlossTable"/>
  <xs:element name="LeasesDetailsScheduleofprofitorlossLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_LeasesDetailsScheduleofprofitorlossLineItems"/>
  <xs:element name="TotalAmountRecognizedInProfitOrLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TotalAmountRecognizedInProfitOrLoss"/>
  <xs:element name="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"/>
  <xs:element name="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems"/>
  <xs:element name="GrantedNumberOfOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GrantedNumberOfOptions"/>
  <xs:element name="ExercisedNumberOfOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisedNumberOfOptions"/>
  <xs:element name="ExercisedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisedWeightedAverageExercisePrice"/>
  <xs:element name="ForfeitedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ForfeitedWeightedAverageExercisePrice"/>
  <xs:element name="ExercisableOptionsNumberOfOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisableOptionsNumberOfOptions"/>
  <xs:element name="NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares"/>
  <xs:element name="ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"/>
  <xs:element name="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems"/>
  <xs:element name="OutstandingAtBeginningOfYears" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_OutstandingAtBeginningOfYears"/>
  <xs:element name="Granted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_Granted"/>
  <xs:element name="Vested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_Vested"/>
  <xs:element name="RestrictedStockUnitVested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RestrictedStockUnitVested"/>
  <xs:element name="Forfeited" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_Forfeited"/>
  <xs:element name="ExercisableRSUs" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisableRSUs"/>
  <xs:element name="RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable"/>
  <xs:element name="RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems"/>
  <xs:element name="ShareBasedPaymentEmployeesAndDirectors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedPaymentEmployeesAndDirectors"/>
  <xs:element name="RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable"/>
  <xs:element name="RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems"/>
  <xs:element name="NatureOfTransactionSalariesAndRelated" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NatureOfTransactionSalariesAndRelated"/>
  <xs:element name="NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany"/>
  <xs:element name="FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable"/>
  <xs:element name="FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems"/>
  <xs:element name="Deposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_Deposit"/>
  <xs:element name="FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable"/>
  <xs:element name="FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems"/>
  <xs:element name="SensitivityAnalysis" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_SensitivityAnalysis"/>
  <xs:element name="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable"/>
  <xs:element name="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems"/>
  <xs:element name="FairValueMeasurementDetailsScheduleofwarrantsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FairValueMeasurementDetailsScheduleofwarrantsTable"/>
  <xs:element name="FairValueMeasurementDetailsScheduleofwarrantsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems"/>
  <xs:element name="NontradableWarrantFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NontradableWarrantFairValue"/>
  <xs:element name="NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors"/>
  <xs:element name="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable"/>
  <xs:element name="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems"/>
  <xs:element name="BalanceAtBeginning" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_BalanceAtBeginning"/>
  <xs:element name="GainslossesRecognizedInProfitLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_GainslossesRecognizedInProfitLoss"/>
  <xs:element name="Addition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_Addition"/>
  <xs:element name="AdjustmentsArisingFromTranslatingFinancialOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AdjustmentsArisingFromTranslatingFinancialOperations"/>
  <xs:element name="BalanceAtEnding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_BalanceAtEnding"/>
  <xs:element name="NumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_NumberOfShares"/>
  <xs:element name="TradableWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_TradableWarrantsShares"/>
  <xs:element name="WarrantsPursuantShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_WarrantsPursuantShares"/>
  <xs:element name="AggregateProceedsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregateProceedsAmount"/>
  <xs:element name="AdditionalOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AdditionalOfferingCosts"/>
  <xs:element name="OrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OrdinaryShares"/>
  <xs:element name="WarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_WarrantsShares"/>
  <xs:element name="InvestorsExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_InvestorsExercise"/>
  <xs:element name="PercentageOfPaidFees" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfPaidFees"/>
  <xs:element name="PaidFeesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_PaidFeesAmount"/>
  <xs:element name="DepositValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DepositValue"/>
  <xs:element name="PayRoyaltiesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PayRoyaltiesPercentage"/>
  <xs:element name="InvestmentNameDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_InvestmentNameDomain"/>
  <xs:element name="FinacialLiabilitiesatFairValueDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FinacialLiabilitiesatFairValueDetailsTable"/>
  <xs:element name="FinacialLiabilitiesatFairValueDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinacialLiabilitiesatFairValueDetailsLineItems"/>
  <xs:element name="ConversionToShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ConversionToShares"/>
  <xs:element name="AdditionalOrdinaryShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AdditionalOrdinaryShare"/>
  <xs:element name="ProceedFromIssuanceInitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ProceedFromIssuanceInitialPublicOffering"/>
  <xs:element name="FairValueOfTheWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FairValueOfTheWarrant"/>
  <xs:element name="AggregateProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregateProceeds"/>
  <xs:element name="TradableWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TradableWarrants"/>
  <xs:element name="PublicOfferingPriceDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PublicOfferingPriceDescription"/>
  <xs:element name="InvestorsExercisedTradableWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_InvestorsExercisedTradableWarrants"/>
  <xs:element name="OrdinarySharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OrdinarySharesIssued"/>
  <xs:element name="TotalProceedsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TotalProceedsReceived"/>
  <xs:element name="DeductingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeductingFees"/>
  <xs:element name="TradableWarrantsFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TradableWarrantsFairValue"/>
  <xs:element name="FinancialLiabilityToPay" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialLiabilityToPay"/>
  <xs:element name="FinancialDerivativesFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialDerivativesFairValue"/>
  <xs:element name="EquityDefictDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_EquityDefictDetailsTable"/>
  <xs:element name="EquityDefictDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EquityDefictDetailsLineItems"/>
  <xs:element name="AggregateOfOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregateOfOrdinaryShares"/>
  <xs:element name="OrdinaryShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OrdinaryShare"/>
  <xs:element name="StockholdersEquityReverseSplit" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_StockholdersEquityReverseSplit"/>
  <xs:element name="AuthorizedShareCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AuthorizedShareCapital"/>
  <xs:element name="SoldOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_SoldOrdinaryShares"/>
  <xs:element name="tradableWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_tradableWarrants"/>
  <xs:element name="NontradableWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NontradableWarrants"/>
  <xs:element name="AggregateProceedsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregateProceedsReceived"/>
  <xs:element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_GrossProceeds"/>
  <xs:element name="TradableWarrantsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TradableWarrantsDescription"/>
  <xs:element name="NondirectCashExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_NondirectCashExpenses"/>
  <xs:element name="CashAndNoncash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_CashAndNoncash"/>
  <xs:element name="ExpensesDeductedFromEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExpensesDeductedFromEquity"/>
  <xs:element name="AggregateAmount" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregateAmount"/>
  <xs:element name="AdditionalOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AdditionalOrdinaryShares"/>
  <xs:element name="CarriedForwardTaxLosse" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_CarriedForwardTaxLosse"/>
  <xs:element name="DeferredTaxAssetS" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeferredTaxAssetS"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_LeasesDetailsTable"/>
  <xs:element name="LeasesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_LeasesDetailsLineItems"/>
  <xs:element name="leaseTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_leaseTerms"/>
  <xs:element name="LeaseLiabilityAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_LeaseLiabilityAmount"/>
  <xs:element name="DescriptionOfLeaseAgreement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DescriptionOfLeaseAgreement"/>
  <xs:element name="ShareBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareBasedCompensationDetailsTable"/>
  <xs:element name="ShareBasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationDetailsLineItems"/>
  <xs:element name="GrantTotalShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GrantTotalShares"/>
  <xs:element name="TotalOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TotalOrdinaryShares"/>
  <xs:element name="GrantOptionDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GrantOptionDescription"/>
  <xs:element name="ExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePrice"/>
  <xs:element name="GrantedTotalOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GrantedTotalOption"/>
  <xs:element name="ContractualLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ContractualLife"/>
  <xs:element name="CapitalGainTax" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_CapitalGainTax"/>
  <xs:element name="NontradableSharesOptions" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NontradableSharesOptions"/>
  <xs:element name="NontradableShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NontradableShares"/>
  <xs:element name="ExercisableOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisableOrdinaryShares"/>
  <xs:element name="VestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_VestingPeriod"/>
  <xs:element name="OptionsEquity" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OptionsEquity"/>
  <xs:element name="AuthorizedOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AuthorizedOrdinaryShares"/>
  <xs:element name="GrantTotal" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GrantTotal"/>
  <xs:element name="VestOverPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_VestOverPeriod"/>
  <xs:element name="RestrictedStockUnitEmployeesDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RestrictedStockUnitEmployeesDescription"/>
  <xs:element name="BoardOfDirectorsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_BoardOfDirectorsDescription"/>
  <xs:element name="FairValueAssumptionsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FairValueAssumptionsDescription"/>
  <xs:element name="ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors"/>
  <xs:element name="ShareBasedPaymentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedPaymentExpenses"/>
  <xs:element name="strengtheningPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_strengtheningPercentage"/>
  <xs:element name="weakeningPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_weakeningPercentage"/>
  <xs:element name="ExchangeAmount" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExchangeAmount"/>
  <xs:element name="FairValueMeasurementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FairValueMeasurementDetailsTable"/>
  <xs:element name="FairValueMeasurementDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FairValueMeasurementDetailsLineItems"/>
  <xs:element name="ExpectedTermOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExpectedTermOfWarrants"/>
  <xs:element name="InvestmentNameAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="iinn_InvestmentNameAxis"/>
  <xs:element name="AUDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AUDMember"/>
  <xs:element name="AdvisersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AdvisersMember"/>
  <xs:element name="Between1And3YearsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_Between1And3YearsMember"/>
  <xs:element name="BrokersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_BrokersMember"/>
  <xs:element name="ComputersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ComputersMember"/>
  <xs:element name="ConvertibleLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ConvertibleLoanMember"/>
  <xs:element name="DevelopmentEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DevelopmentEquipmentMember"/>
  <xs:element name="DirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DirectorsMember"/>
  <xs:element name="EmployeesAndDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EmployeesAndDirectorsMember"/>
  <xs:element name="EmployeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EmployeesMember"/>
  <xs:element name="FinancialDerivativeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialDerivativeMember"/>
  <xs:element name="FinancialExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialExpensesMember"/>
  <xs:element name="FinancialIncomeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialIncomeMember"/>
  <xs:element name="FinancialLiabilityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialLiabilityMember"/>
  <xs:element name="FurnitureAndOfficeEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FurnitureAndOfficeEquipmentMember"/>
  <xs:element name="InitialPublicOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_InitialPublicOfferingMember"/>
  <xs:element name="InvestorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_InvestorsMember"/>
  <xs:element name="LeaseholdImprovementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_LeaseholdImprovementMember"/>
  <xs:element name="MoreThan3YearsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_MoreThan3YearsMember"/>
  <xs:element name="NontradableWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NontradableWarrantsMember"/>
  <xs:element name="NontradableWarrantsSAFEAndCLAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NontradableWarrantsSAFEAndCLAMember"/>
  <xs:element name="OverallotmentOptionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OverallotmentOptionMember"/>
  <xs:element name="PoundMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PoundMember"/>
  <xs:element name="ProvidersAndAdvisersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ProvidersAndAdvisersMember"/>
  <xs:element name="RSUMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RSUMember"/>
  <xs:element name="SAFEMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SAFEMember"/>
  <xs:element name="TradableWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TradableWarrantsMember"/>
  <xs:element name="USDMemberMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_USDMemberMember"/>
  <xs:element name="UpTo1YearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UpTo1YearMember"/>
  <xs:element name="WarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_WarrantsMember"/>
  <xs:element name="WarrantsToBrokersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_WarrantsToBrokersMember"/>
  <xs:element name="WarrantsToInvestorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_WarrantsToInvestorsMember"/>
  <xs:element name="fairValueMeasurementAtLevel2Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_fairValueMeasurementAtLevel2Member"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>iinn-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 19:09:14 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ConsolidatedBalanceSheet" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ConsolidatedIncomeStatement" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ConsolidatedCashFlow" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofotheraccountspayableTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofresearchanddevelopmentexpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofsalesandMarketingExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_DeferredTaxAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentPayables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_LoanFromTheIsraeliInnovationAuthority" xlink:href="iinn-20221231.xsd#iinn_LoanFromTheIsraeliInnovationAuthority"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="iinn_LoanFromTheIsraeliInnovationAuthority" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_SharePremium" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_OtherReserves" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_RetainedEarnings" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="iinn_ResearchAndDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_ResearchAndDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="iinn_ResearchAndDevelopmentExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpenses" xlink:href="iinn-20221231.xsd#iinn_SalesAndMarketingExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="iinn_SalesAndMarketingExpenses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralAndAdministrativeExpenses" xlink:href="iinn-20221231.xsd#iinn_GeneralAndAdministrativeExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="iinn_GeneralAndAdministrativeExpenses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_OtherGainsLosses" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceExpense" xlink:href="iinn-20221231.xsd#iinn_FinanceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="iinn_FinanceExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceIncomeCost" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromContinuingOperations" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_ProfitLossFromContinuingOperations" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_DepreciationExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue" xlink:href="iinn-20221231.xsd#iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRoJ/travtspQJClWcUZpCKKwHPCOss3tqo6SbRlG2Msx2Mu7jhsbM1rEkd29demw7xoQFJ8QNNTzH6TXzpr7OuPNceEmvURO78QMp9NjY3po4ETx9F6sRVjuqqmbzul+x4S9+/YBad2BUDY2g7XwPkU=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority" xlink:href="iinn-20221231.xsd#iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy" xlink:href="iinn-20221231.xsd#iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="iinn_PaymentOfDeposit" xlink:href="iinn-20221231.xsd#iinn_PaymentOfDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="iinn_PaymentOfDeposit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" xlink:href="iinn-20221231.xsd#iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees" xlink:href="iinn-20221231.xsd#iinn_ReceiptOfWarrantsExerciseFundsNetFromFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DividendsPaidClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_DividendsPaidClassifiedAsFinancingActivities" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="iinn_ReceiptOfIPOFunds" xlink:href="iinn-20221231.xsd#iinn_ReceiptOfIPOFunds"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="iinn_ReceiptOfIPOFunds" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalNonCashTransactions" xlink:href="iinn-20221231.xsd#iinn_TotalNonCashTransactions"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_TotalNonCashTransactions" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsLiability" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_TotalNonCashTransactions" xlink:to="iinn_TradableWarrantsLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsDerivativeLiability" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsDerivativeLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_TotalNonCashTransactions" xlink:to="iinn_TradableWarrantsDerivativeLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationUnderwritersFees" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationUnderwritersFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_TotalNonCashTransactions" xlink:to="iinn_ShareBasedCompensationUnderwritersFees" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_TotalNonCashTransactions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsExerciseLiabilityIssuance" xlink:href="iinn-20221231.xsd#iinn_WarrantsExerciseLiabilityIssuance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_TotalNonCashTransactions" xlink:to="iinn_WarrantsExerciseLiabilityIssuance" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentPayables"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesSalariesAndRelatedLiabilities" xlink:href="iinn-20221231.xsd#iinn_EmployeesSalariesAndRelatedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentPayables" xlink:to="iinn_EmployeesSalariesAndRelatedLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPayablesToRelatedParties" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentPayablesToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentPayables" xlink:to="ifrs-full_NoncurrentPayablesToRelatedParties" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentPayables" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentPayables" xlink:to="ifrs-full_OtherPayables" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable">
    <loc xlink:type="locator" xlink:label="iinn_ResearchDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_ResearchDevelopmentExpenses"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPayment" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPayment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_ResearchDevelopmentExpenses" xlink:to="iinn_ShareBasedPayment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_SalaryAndRelatedExpenses" xlink:href="iinn-20221231.xsd#iinn_SalaryAndRelatedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_ResearchDevelopmentExpenses" xlink:to="iinn_SalaryAndRelatedExpenses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_Subcontractors" xlink:href="iinn-20221231.xsd#iinn_Subcontractors"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_ResearchDevelopmentExpenses" xlink:to="iinn_Subcontractors" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_MaterialsAndRelatedExpenses" xlink:href="iinn-20221231.xsd#iinn_MaterialsAndRelatedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_ResearchDevelopmentExpenses" xlink:to="iinn_MaterialsAndRelatedExpenses" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_DepreciationExpenses" xlink:href="iinn-20221231.xsd#iinn_DepreciationExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_ResearchDevelopmentExpenses" xlink:to="iinn_DepreciationExpenses" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_IIAParticipation" xlink:href="iinn-20221231.xsd#iinn_IIAParticipation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_ResearchDevelopmentExpenses" xlink:to="iinn_IIAParticipation" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_OtherResearchAndDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_OtherResearchAndDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_ResearchDevelopmentExpenses" xlink:to="iinn_OtherResearchAndDevelopmentExpenses" order="7" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WagesAndSalaries"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_WagesAndSalaries" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_FeeAndCommissionExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature" order="4" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>iinn-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 19:09:14 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ConsolidatedBalanceSheet" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ConsolidatedIncomeStatement" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ShareholdersEquityType2or3" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ConsolidatedCashFlow" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_General" roleURI="http://www.inspiratechnologies.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_SignificantAccountingPolicies" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_CriticalAccountingEstimatesandJudgements" roleURI="http://www.inspiratechnologies.com/role/CriticalAccountingEstimatesandJudgements"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_Deposits" roleURI="http://www.inspiratechnologies.com/role/Deposits"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_OtherCurrentAssets" roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_PropertyandEquipmentNet" roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_OtherAccountsPayable" roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_LiabilityinRespectofGovernmentGrants" roleURI="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrants"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinacialLiabilitiesatFairValue" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_EquityDefict" roleURI="http://www.inspiratechnologies.com/role/EquityDefict"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ResearchandDevelopmentExpenses" roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_SalesandMarketingExpenses" roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_GeneralandAdministrativeExpenses" roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinancialIncomeandExpenses" roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_TaxesonIncome" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_Leases" roleURI="http://www.inspiratechnologies.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ShareBasedCompensation" roleURI="http://www.inspiratechnologies.com/role/ShareBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_RelatedParties" roleURI="http://www.inspiratechnologies.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinancialInstrumentsandRiskManagement" roleURI="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_CommitmentsandContingencies" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FairValueMeasurement" roleURI="http://www.inspiratechnologies.com/role/FairValueMeasurement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_AccountingPoliciesByPolicy" roleURI="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_SignificantAccountingPoliciesTables" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_OtherCurrentAssetsTables" roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_PropertyandEquipmentNetTables" roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_OtherAccountsPayableTables" roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_LiabilityinRespectofGovernmentGrantsTables" roleURI="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinacialLiabilitiesatFairValueTables" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_EquityDefictTables" roleURI="http://www.inspiratechnologies.com/role/EquityDefictTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ResearchandDevelopmentExpensesTables" roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_SalesandMarketingExpensesTables" roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_GeneralandAdministrativeExpensesTables" roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinancialIncomeandExpensesTables" roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_TaxesonIncomeTables" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_LeasesTables" roleURI="http://www.inspiratechnologies.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ShareBasedCompensationTables" roleURI="http://www.inspiratechnologies.com/role/ShareBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_RelatedPartiesTables" roleURI="http://www.inspiratechnologies.com/role/RelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinancialInstrumentsandRiskManagementTables" roleURI="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FairValueMeasurementTables" roleURI="http://www.inspiratechnologies.com/role/FairValueMeasurementTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofotherCurrentAssetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofotherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofpropertyandequipmentnetTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofotheraccountspayableTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofreimbursementofresearchexpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofreimbursementofresearchexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoffinacialliabilitiesatfairvalueTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofsharecapitalTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoflosspershareTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoflosspershareTable_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofresearchanddevelopmentexpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofsalesandMarketingExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofgeneralandadministrativeexpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoffinancialincomeTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoffinancialexpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoftheoreticaltaxTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoftheoreticaltaxTable_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofrightofuseassetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofleaseliabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofprofitorlossTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofshareholdersandotherrelatedpartiesbenefitsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofbalanceswithrelatedpartiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofforeigncurrencydenominatedmonetaryliabilityTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofsensitivityanalysisTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofcashflowsoffinancialliabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofwarrantsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_Scheduleofmovementsinlevel2liabilityTable" roleURI="http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_GeneralDetails" roleURI="http://www.inspiratechnologies.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_DepositsDetails" roleURI="http://www.inspiratechnologies.com/role/DepositsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_LiabilityinRespectofGovernmentGrantsDetails" roleURI="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinacialLiabilitiesatFairValueDetails" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_EquityDefictDetails" roleURI="http://www.inspiratechnologies.com/role/EquityDefictDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_TaxesonIncomeDetails" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_LeasesDetails" roleURI="http://www.inspiratechnologies.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ShareBasedCompensationDetails" roleURI="http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinancialInstrumentsandRiskManagementDetails" roleURI="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_CommitmentsandContingenciesDetails" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FairValueMeasurementDetails" roleURI="http://www.inspiratechnologies.com/role/FairValueMeasurementDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_CurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_DeferredTaxAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_NoncurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentPayables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_LoanFromTheIsraeliInnovationAuthority" xlink:href="iinn-20221231.xsd#iinn_LoanFromTheIsraeliInnovationAuthority"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="iinn_LoanFromTheIsraeliInnovationAuthority" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LoanFromTheIsraeliInnovationAuthority" xlink:to="ifrs-full_NoncurrentLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_SharePremium" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_Equity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ResearchAndDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_ResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="iinn_ResearchAndDevelopmentExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpenses" xlink:href="iinn-20221231.xsd#iinn_SalesAndMarketingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="iinn_SalesAndMarketingExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralAndAdministrativeExpenses" xlink:href="iinn-20221231.xsd#iinn_GeneralAndAdministrativeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="iinn_GeneralAndAdministrativeExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherGainsLosses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceExpense" xlink:href="iinn-20221231.xsd#iinn_FinanceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="iinn_FinanceExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_ProfitLossBeforeTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_ProfitLossFromContinuingOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="ifrs-full_OtherComprehensiveIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_AdditionalPaidinCapitalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract" xlink:href="iinn-20221231.xsd#iinn_ChangesDuringThePeriodAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="iinn_ChangesDuringThePeriodAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalComprehensiveLoss" xlink:href="iinn-20221231.xsd#iinn_TotalComprehensiveLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_TotalComprehensiveLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareSplit" xlink:href="iinn-20221231.xsd#iinn_ShareSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ShareSplit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ParValueCancellations" xlink:href="iinn-20221231.xsd#iinn_ParValueCancellations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ParValueCancellations" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_InitialPublicOffering" xlink:href="iinn-20221231.xsd#iinn_InitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_InitialPublicOffering" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareIssuanceOfInitialPublicOffering" xlink:href="iinn-20221231.xsd#iinn_ShareIssuanceOfInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ShareIssuanceOfInitialPublicOffering" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="ifrs-full_IssueOfConvertibleInstruments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ConversionOfFinancialLiabilityinShares" xlink:href="iinn-20221231.xsd#iinn_ConversionOfFinancialLiabilityinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ConversionOfFinancialLiabilityinShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsExercise" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_TradableWarrantsExercise" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsExerciseinShares" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsExerciseinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_TradableWarrantsExerciseinShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OptionsExercise" xlink:href="iinn-20221231.xsd#iinn_OptionsExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_OptionsExercise" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationToExercise" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationToExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ShareBasedCompensationToExercise" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ConversionOfConvertibleLoanToShares" xlink:href="iinn-20221231.xsd#iinn_ConversionOfConvertibleLoanToShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ConversionOfConvertibleLoanToShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ConversionOfConvertibleLoanToSharesinShares" xlink:href="iinn-20221231.xsd#iinn_ConversionOfConvertibleLoanToSharesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ConversionOfConvertibleLoanToSharesinShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits" xlink:href="iinn-20221231.xsd#iinn_StockIssuedDuringPeriodValueRestrictedStockUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit" xlink:href="iinn-20221231.xsd#iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_DepreciationExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue" xlink:href="iinn-20221231.xsd#iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority" xlink:href="iinn-20221231.xsd#iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy" xlink:href="iinn-20221231.xsd#iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesInOperatingAssetsAndLiabilityAbstract" xlink:href="iinn-20221231.xsd#iinn_ChangesInOperatingAssetsAndLiabilityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="iinn_ChangesInOperatingAssetsAndLiabilityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesInOperatingAssetsAndLiabilityAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesInOperatingAssetsAndLiabilityAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesInOperatingAssetsAndLiabilityAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesInOperatingAssetsAndLiabilityAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PaymentOfDeposit" xlink:href="iinn-20221231.xsd#iinn_PaymentOfDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="iinn_PaymentOfDeposit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DividendsPaidClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_DividendsPaidClassifiedAsFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" xlink:href="iinn-20221231.xsd#iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ReceiptOfIPOFunds" xlink:href="iinn-20221231.xsd#iinn_ReceiptOfIPOFunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="iinn_ReceiptOfIPOFunds" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees" xlink:href="iinn-20221231.xsd#iinn_ReceiptOfWarrantsExerciseFundsNetFromFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsLiability" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="iinn_TradableWarrantsLiability" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsDerivativeLiability" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsDerivativeLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="iinn_TradableWarrantsDerivativeLiability" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationUnderwritersFees" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationUnderwritersFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="iinn_ShareBasedCompensationUnderwritersFees" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsExerciseLiabilityIssuance" xlink:href="iinn-20221231.xsd#iinn_WarrantsExerciseLiabilityIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="iinn_WarrantsExerciseLiabilityIssuance" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalNonCashTransactions" xlink:href="iinn-20221231.xsd#iinn_TotalNonCashTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="iinn_TotalNonCashTransactions" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefund" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefund" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/General">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/CriticalAccountingEstimatesandJudgements">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/Deposits">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfDepositsFromBanksTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDepositsFromBanksExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDepositsFromBanksExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfDepositsFromBanksExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrants">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGovernmentGrantsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGovernmentGrantsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/EquityDefict">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses">
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_SalesAndMarketingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpensesTextBlock" xlink:href="iinn-20221231.xsd#iinn_SalesAndMarketingExpensesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SalesAndMarketingExpensesAbstract" xlink:to="iinn_SalesAndMarketingExpensesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfIncomeTaxTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfIncomeTaxTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/Leases">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfLeasesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfLeasesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfLeasesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareBasedCompensation">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/RelatedParties">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfRelatedPartyTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfRelatedPartyTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagement">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FairValueMeasurement">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock" xlink:href="iinn-20221231.xsd#iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OptionsPolicyTextBlock" xlink:href="iinn-20221231.xsd#iinn_OptionsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_OptionsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RestrictedShareUnitsPolicyTextBlock" xlink:href="iinn-20221231.xsd#iinn_RestrictedShareUnitsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_RestrictedShareUnitsPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:to="iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract" xlink:to="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOtherAccountPayableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfOtherAccountPayableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:to="iinn_ScheduleOfOtherAccountPayableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGovernmentGrantsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:to="iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialLiabilities" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" xlink:to="iinn_ScheduleOfFinancialLiabilities" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/EquityDefictTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLossPerShare" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:to="iinn_ScheduleOfLossPerShare" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfResearchAndDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract" xlink:to="iinn_ScheduleOfResearchAndDevelopmentExpenses" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables">
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_SalesAndMarketingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SalesAndMarketingExpensesAbstract" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpenses" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpenses" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialIncomeTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract" xlink:to="iinn_ScheduleOfFinancialIncomeTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialExpenses" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract" xlink:to="iinn_ScheduleOfFinancialExpenses" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncomeTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfIncomeTaxTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfIncomeTaxTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfLeasesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfLeasesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfRightofuseAssets" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfLeasesTextBlockAbstract" xlink:to="iinn_ScheduleOfRightofuseAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLeaseLiabilities" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfLeasesTextBlockAbstract" xlink:to="iinn_ScheduleOfLeaseLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfProfitOrLoss" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfLeasesTextBlockAbstract" xlink:to="iinn_ScheduleOfProfitOrLoss" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/RelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfRelatedPartyTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfRelatedPartyTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_BalancesWithRelatedPartiesTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_BalancesWithRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="iinn_BalancesWithRelatedPartiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSensitivityAnalysis" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfSensitivityAnalysis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="iinn_ScheduleOfSensitivityAnalysis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FairValueMeasurementTables">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:to="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable">
    <loc xlink:type="locator" xlink:label="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems" xlink:href="iinn-20221231.xsd#iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" xlink:href="iinn-20221231.xsd#iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems" xlink:to="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" xlink:to="ifrs-full_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ComputersMember" xlink:href="iinn-20221231.xsd#iinn_ComputersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="iinn_ComputersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DevelopmentEquipmentMember" xlink:href="iinn-20221231.xsd#iinn_DevelopmentEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="iinn_DevelopmentEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FurnitureAndOfficeEquipmentMember" xlink:href="iinn-20221231.xsd#iinn_FurnitureAndOfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="iinn_FurnitureAndOfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_LeaseholdImprovementMember" xlink:href="iinn-20221231.xsd#iinn_LeaseholdImprovementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="iinn_LeaseholdImprovementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AnnualDepreciationRateInPercentage" xlink:href="iinn-20221231.xsd#iinn_AnnualDepreciationRateInPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems" xlink:to="iinn_AnnualDepreciationRateInPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofotherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Institutions" xlink:href="iinn-20221231.xsd#iinn_Institutions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="iinn_Institutions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OthersCurrentAssets" xlink:href="iinn-20221231.xsd#iinn_OthersCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="iinn_OthersCurrentAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_OthersCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" xlink:href="iinn-20221231.xsd#iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable" xlink:href="iinn-20221231.xsd#iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" xlink:to="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DevelopmentEquipmentMember" xlink:href="iinn-20221231.xsd#iinn_DevelopmentEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="iinn_DevelopmentEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_CostAbstract" xlink:href="iinn-20221231.xsd#iinn_CostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" xlink:to="iinn_CostAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_CostAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_CostAbstract" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExchangeRateDeferenceCost" xlink:href="iinn-20221231.xsd#iinn_ExchangeRateDeferenceCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_CostAbstract" xlink:to="iinn_ExchangeRateDeferenceCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AccumulatedDepreciationAbstract" xlink:href="iinn-20221231.xsd#iinn_AccumulatedDepreciationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" xlink:to="iinn_AccumulatedDepreciationAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AccumulatedDepreciation" xlink:href="iinn-20221231.xsd#iinn_AccumulatedDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_AccumulatedDepreciationAbstract" xlink:to="iinn_AccumulatedDepreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_AccumulatedDepreciationAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExchangeRateDeferenceAccumulatedDepreciation" xlink:href="iinn-20221231.xsd#iinn_ExchangeRateDeferenceAccumulatedDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_AccumulatedDepreciationAbstract" xlink:to="iinn_ExchangeRateDeferenceAccumulatedDepreciation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NetBookValueAbstract" xlink:href="iinn-20221231.xsd#iinn_NetBookValueAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" xlink:to="iinn_NetBookValueAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NetBookValue" xlink:href="iinn-20221231.xsd#iinn_NetBookValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_NetBookValueAbstract" xlink:to="iinn_NetBookValue" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOtherAccountsPayableAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesSalariesAndRelatedLiabilities" xlink:href="iinn-20221231.xsd#iinn_EmployeesSalariesAndRelatedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOtherAccountsPayableAbstract" xlink:to="iinn_EmployeesSalariesAndRelatedLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPayablesToRelatedParties" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentPayablesToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_NoncurrentPayablesToRelatedParties" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_OtherPayables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_NoncurrentPayables" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofreimbursementofresearchexpensesTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfReimbursementOfResearchExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:to="ifrs-full_GovernmentGrants" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExchangeRateDifferences" xlink:href="iinn-20221231.xsd#iinn_ExchangeRateDifferences"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:to="iinn_ExchangeRateDifferences" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfTheLiability" xlink:href="iinn-20221231.xsd#iinn_RevaluationOfTheLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:to="iinn_RevaluationOfTheLiability" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable">
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems" xlink:href="iinn-20221231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable" xlink:href="iinn-20221231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableWarrantsMember" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="iinn_NontradableWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableWarrantsSAFEAndCLAMember" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantsSAFEAndCLAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="iinn_NontradableWarrantsSAFEAndCLAMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsMember" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="iinn_TradableWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialLiabilityMember" xlink:href="iinn-20221231.xsd#iinn_FinancialLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="iinn_FinancialLiabilityMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalFinancialLiabilities" xlink:href="iinn-20221231.xsd#iinn_TotalFinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems" xlink:to="iinn_TotalFinancialLiabilities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable">
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsScheduleofsharecapitalLineItems" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleofsharecapitalLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsScheduleofsharecapitalTable" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleofsharecapitalTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_EquityDefictDetailsScheduleofsharecapitalLineItems" xlink:to="iinn_EquityDefictDetailsScheduleofsharecapitalTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_EquityDefictDetailsScheduleofsharecapitalTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsScheduleofsharecapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsScheduleofsharecapitalLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable">
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareLineItems" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleoflosspershareLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareTable" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleoflosspershareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareLineItems" xlink:to="iinn_EquityDefictDetailsScheduleoflosspershareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareLineItems" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareLineItems" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits" xlink:href="iinn-20221231.xsd#iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareLineItems" xlink:to="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareLineItems" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsTable" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems" xlink:to="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable">
    <loc xlink:type="locator" xlink:label="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:href="iinn-20221231.xsd#iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable" xlink:href="iinn-20221231.xsd#iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPayment" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="iinn_ShareBasedPayment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SalaryAndRelatedExpenses" xlink:href="iinn-20221231.xsd#iinn_SalaryAndRelatedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="iinn_SalaryAndRelatedExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Subcontractors" xlink:href="iinn-20221231.xsd#iinn_Subcontractors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="iinn_Subcontractors" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_MaterialsAndRelatedExpenses" xlink:href="iinn-20221231.xsd#iinn_MaterialsAndRelatedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="iinn_MaterialsAndRelatedExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DepreciationExpenses" xlink:href="iinn-20221231.xsd#iinn_DepreciationExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="iinn_DepreciationExpenses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_IIAParticipation" xlink:href="iinn-20221231.xsd#iinn_IIAParticipation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="iinn_IIAParticipation" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OtherResearchAndDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_OtherResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="iinn_OtherResearchAndDevelopmentExpenses" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ResearchDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_ResearchDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="iinn_ResearchDevelopmentExpenses" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable">
    <loc xlink:type="locator" xlink:label="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:href="iinn-20221231.xsd#iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable" xlink:href="iinn-20221231.xsd#iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:to="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WagesAndSalaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:to="ifrs-full_WagesAndSalaries" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:to="ifrs-full_FeeAndCommissionExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:to="ifrs-full_OtherExpenseByNature" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:to="ifrs-full_ExpenseByNature" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable">
    <loc xlink:type="locator" xlink:label="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:href="iinn-20221231.xsd#iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable" xlink:href="iinn-20221231.xsd#iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPayments" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="iinn_ShareBasedPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_ProfessionalFeesExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_InsuranceExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_RentalExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Depreciations" xlink:href="iinn-20221231.xsd#iinn_Depreciations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="iinn_Depreciations" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_TravelExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRoJ/travtspQJClWcUZpCKKwHPCOss3tqo6SbRlG2Msx2Mu7jhsbM1rEkd29demw7xoQFJ8QNNTzH6TXzpr7OuPNceEmvURO78QMp9NjY3po4ETx9F6sRVgDFNcXfDy2pzQ4FUAT9Lly] CSR-->
    <loc xlink:type="locator" xlink:label="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:to="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialIncomeMember" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="iinn_FinancialIncomeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:to="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ForeignCurrencyTransactionLossNet" xlink:href="iinn-20221231.xsd#iinn_ForeignCurrencyTransactionLossNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:to="iinn_ForeignCurrencyTransactionLossNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:to="ifrs-full_InterestIncomeOnDeposits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:to="ifrs-full_OtherIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalIncome" xlink:href="iinn-20221231.xsd#iinn_TotalIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherIncome" xlink:to="iinn_TotalIncome" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable">
    <loc xlink:type="locator" xlink:label="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:to="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialExpensesMember" xlink:href="iinn-20221231.xsd#iinn_FinancialExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="iinn_FinancialExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:to="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ForeignCurrencyTransactionLossNet" xlink:href="iinn-20221231.xsd#iinn_ForeignCurrencyTransactionLossNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:to="iinn_ForeignCurrencyTransactionLossNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants" xlink:href="iinn-20221231.xsd#iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:to="iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceExpenseInRespectOfLeaseLiability" xlink:href="iinn-20221231.xsd#iinn_FinanceExpenseInRespectOfLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:to="iinn_FinanceExpenseInRespectOfLeaseLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:to="ifrs-full_OtherExpenseByNature" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalExpenses" xlink:href="iinn-20221231.xsd#iinn_TotalExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="iinn_TotalExpenses" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable">
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:href="iinn-20221231.xsd#iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxTable" xlink:href="iinn-20221231.xsd#iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:to="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_LossBeforeTaxation" xlink:href="iinn-20221231.xsd#iinn_LossBeforeTaxation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:to="iinn_LossBeforeTaxation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NonallowableExpenses" xlink:href="iinn-20221231.xsd#iinn_NonallowableExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:to="iinn_NonallowableExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20221231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems" xlink:href="iinn-20221231.xsd#iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable" xlink:href="iinn-20221231.xsd#iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems" xlink:to="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate" xlink:href="iinn-20221231.xsd#iinn_TheoreticalTaxCreditAtApplicableStatutoryRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems" xlink:to="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable">
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofrightofuseassetsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsScheduleofrightofuseassetsTable" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofrightofuseassetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="iinn_LeasesDetailsScheduleofrightofuseassetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_LeasesDetailsScheduleofrightofuseassetsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OfficeBuildingMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficeBuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="srt_OfficeBuildingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_VehiclesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialExpense" xlink:href="iinn-20221231.xsd#iinn_FinancialExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="iinn_FinancialExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsInvestmentProperty" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsInvestmentProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="ifrs-full_DisposalsInvestmentProperty" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsScheduleofleaseliabilitiesTable" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofleaseliabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="iinn_LeasesDetailsScheduleofleaseliabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_LeasesDetailsScheduleofleaseliabilitiesTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialExpenses" xlink:href="iinn-20221231.xsd#iinn_FinancialExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="iinn_FinancialExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExchangeRateDifference" xlink:href="iinn-20221231.xsd#iinn_ExchangeRateDifference"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="iinn_ExchangeRateDifference" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PrincipalPayment" xlink:href="iinn-20221231.xsd#iinn_PrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="iinn_PrincipalPayment" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable">
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsScheduleofprofitorlossLineItems" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofprofitorlossLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsScheduleofprofitorlossTable" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofprofitorlossTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_LeasesDetailsScheduleofprofitorlossLineItems" xlink:to="iinn_LeasesDetailsScheduleofprofitorlossTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_LeasesDetailsScheduleofprofitorlossTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofprofitorlossLineItems" xlink:to="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofprofitorlossLineItems" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalAmountRecognizedInProfitOrLoss" xlink:href="iinn-20221231.xsd#iinn_TotalAmountRecognizedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsScheduleofprofitorlossLineItems" xlink:to="iinn_TotalAmountRecognizedInProfitOrLoss" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable">
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ProvidersAndAdvisersMember" xlink:href="iinn-20221231.xsd#iinn_ProvidersAndAdvisersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="iinn_ProvidersAndAdvisersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesAndDirectorsMember" xlink:href="iinn-20221231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="iinn_EmployeesAndDirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares" xlink:href="iinn-20221231.xsd#iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice" xlink:href="iinn-20221231.xsd#iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_GrantedNumberOfOptions" xlink:href="iinn-20221231.xsd#iinn_GrantedNumberOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_GrantedNumberOfOptions" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisedNumberOfOptions" xlink:href="iinn-20221231.xsd#iinn_ExercisedNumberOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_ExercisedNumberOfOptions" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisedWeightedAverageExercisePrice" xlink:href="iinn-20221231.xsd#iinn_ExercisedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_ExercisedWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ForfeitedWeightedAverageExercisePrice" xlink:href="iinn-20221231.xsd#iinn_ForfeitedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_ForfeitedWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisableOptionsNumberOfOptions" xlink:href="iinn-20221231.xsd#iinn_ExercisableOptionsNumberOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_ExercisableOptionsNumberOfOptions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable">
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ProvidersAndAdvisersMember" xlink:href="iinn-20221231.xsd#iinn_ProvidersAndAdvisersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="iinn_ProvidersAndAdvisersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesAndDirectorsMember" xlink:href="iinn-20221231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="iinn_EmployeesAndDirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OutstandingAtBeginningOfYears" xlink:href="iinn-20221231.xsd#iinn_OutstandingAtBeginningOfYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_OutstandingAtBeginningOfYears" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Granted" xlink:href="iinn-20221231.xsd#iinn_Granted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_Granted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Forfeited" xlink:href="iinn-20221231.xsd#iinn_Forfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_Forfeited" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Vested" xlink:href="iinn-20221231.xsd#iinn_Vested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_Vested" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisableRSUs" xlink:href="iinn-20221231.xsd#iinn_ExercisableRSUs"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_ExercisableRSUs" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RestrictedStockUnitVested" xlink:href="iinn-20221231.xsd#iinn_RestrictedStockUnitVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_RestrictedStockUnitVested" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable">
    <loc xlink:type="locator" xlink:label="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems" xlink:href="iinn-20221231.xsd#iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable" xlink:href="iinn-20221231.xsd#iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems" xlink:to="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentEmployeesAndDirectors" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPaymentEmployeesAndDirectors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems" xlink:to="iinn_ShareBasedPaymentEmployeesAndDirectors" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems" xlink:href="iinn-20221231.xsd#iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable" xlink:href="iinn-20221231.xsd#iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems" xlink:to="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesMember" xlink:href="iinn-20221231.xsd#iinn_EmployeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="iinn_EmployeesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DirectorsMember" xlink:href="iinn-20221231.xsd#iinn_DirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="iinn_DirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NatureOfTransactionSalariesAndRelated" xlink:href="iinn-20221231.xsd#iinn_NatureOfTransactionSalariesAndRelated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems" xlink:to="iinn_NatureOfTransactionSalariesAndRelated" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany" xlink:href="iinn-20221231.xsd#iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems" xlink:to="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable">
    <loc xlink:type="locator" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" xlink:to="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CreditRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CreditRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" xlink:to="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_FinancialAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_AssetsAbstract0" xlink:href="iinn-20221231.xsd#iinn_AssetsAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract" xlink:to="iinn_AssetsAbstract0" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_AssetsAbstract0" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Deposit" xlink:href="iinn-20221231.xsd#iinn_Deposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_AssetsAbstract0" xlink:to="iinn_Deposit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_AssetsAbstract0" xlink:to="ifrs-full_FinancialAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract" xlink:to="ifrs-full_LiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DerivativeFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_OtherFinancialAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtFairValue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract" xlink:to="ifrs-full_FinancialAssetsAtFairValue" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable">
    <loc xlink:type="locator" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems" xlink:to="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyInWhichInformationIsDisplayedAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable" xlink:to="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FunctionalOrPresentationCurrencyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FunctionalOrPresentationCurrencyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:to="ifrs-full_FunctionalOrPresentationCurrencyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FunctionalOrPresentationCurrencyMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FunctionalOrPresentationCurrencyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:to="ifrs-full_FunctionalOrPresentationCurrencyMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_USDMemberMember" xlink:href="iinn-20221231.xsd#iinn_USDMemberMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FunctionalOrPresentationCurrencyMember" xlink:to="iinn_USDMemberMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AUDMember" xlink:href="iinn-20221231.xsd#iinn_AUDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FunctionalOrPresentationCurrencyMember" xlink:to="iinn_AUDMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PoundMember" xlink:href="iinn-20221231.xsd#iinn_PoundMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FunctionalOrPresentationCurrencyMember" xlink:to="iinn_PoundMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SensitivityAnalysis" xlink:href="iinn-20221231.xsd#iinn_SensitivityAnalysis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems" xlink:to="iinn_SensitivityAnalysis" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable">
    <loc xlink:type="locator" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:to="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_UpTo1YearMember" xlink:href="iinn-20221231.xsd#iinn_UpTo1YearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="iinn_UpTo1YearMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Between1And3YearsMember" xlink:href="iinn-20221231.xsd#iinn_Between1And3YearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="iinn_Between1And3YearsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_MoreThan3YearsMember" xlink:href="iinn-20221231.xsd#iinn_MoreThan3YearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="iinn_MoreThan3YearsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:to="ifrs-full_OtherPayables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:to="ifrs-full_GrossLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable">
    <loc xlink:type="locator" xlink:label="iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueMeasurementDetailsScheduleofwarrantsTable" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsScheduleofwarrantsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:to="iinn_FairValueMeasurementDetailsScheduleofwarrantsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FairValueMeasurementDetailsScheduleofwarrantsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableWarrantFairValue" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:to="iinn_NontradableWarrantFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:to="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:to="ifrs-full_WarrantLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:to="ifrs-full_CurrentFinancialAssets" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable">
    <loc xlink:type="locator" xlink:label="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsMember" xlink:href="iinn-20221231.xsd#iinn_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="iinn_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SAFEMember" xlink:href="iinn-20221231.xsd#iinn_SAFEMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="iinn_SAFEMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ConvertibleLoanMember" xlink:href="iinn-20221231.xsd#iinn_ConvertibleLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="iinn_ConvertibleLoanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialDerivativeMember" xlink:href="iinn-20221231.xsd#iinn_FinancialDerivativeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="iinn_FinancialDerivativeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_BalanceAtBeginning" xlink:href="iinn-20221231.xsd#iinn_BalanceAtBeginning"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="iinn_BalanceAtBeginning" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_GainslossesRecognizedInProfitLoss" xlink:href="iinn-20221231.xsd#iinn_GainslossesRecognizedInProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="iinn_GainslossesRecognizedInProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Addition" xlink:href="iinn-20221231.xsd#iinn_Addition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="iinn_Addition" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AdjustmentsArisingFromTranslatingFinancialOperations" xlink:href="iinn-20221231.xsd#iinn_AdjustmentsArisingFromTranslatingFinancialOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="iinn_AdjustmentsArisingFromTranslatingFinancialOperations" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_BalanceAtEnding" xlink:href="iinn-20221231.xsd#iinn_BalanceAtEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="iinn_BalanceAtEnding" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_NumberOfShares" xlink:href="iinn-20221231.xsd#iinn_NumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="iinn_NumberOfShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsShares" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="iinn_TradableWarrantsShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsPursuantShares" xlink:href="iinn-20221231.xsd#iinn_WarrantsPursuantShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="iinn_WarrantsPursuantShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateProceedsAmount" xlink:href="iinn-20221231.xsd#iinn_AggregateProceedsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="iinn_AggregateProceedsAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AdditionalOfferingCosts" xlink:href="iinn-20221231.xsd#iinn_AdditionalOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="iinn_AdditionalOfferingCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_OrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="iinn_OrdinaryShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsShares" xlink:href="iinn-20221231.xsd#iinn_WarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="iinn_WarrantsShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_InvestorsExercise" xlink:href="iinn-20221231.xsd#iinn_InvestorsExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="iinn_InvestorsExercise" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfPaidFees" xlink:href="iinn-20221231.xsd#iinn_PercentageOfPaidFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="iinn_PercentageOfPaidFees" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PaidFeesAmount" xlink:href="iinn-20221231.xsd#iinn_PaidFeesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="iinn_PaidFeesAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OperatingLeaseIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingLeaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="ifrs-full_OperatingLeaseIncome" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/DepositsDetails">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfDepositsFromBanksTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepositsFromBanks" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepositsFromBanks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:to="ifrs-full_DepositsFromBanks" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:to="ifrs-full_BorrowingsInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DepositValue" xlink:href="iinn-20221231.xsd#iinn_DepositValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:to="iinn_DepositValue" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsDetails">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGovernmentGrantsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:to="ifrs-full_RevenueFromGovernmentGrants" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PayRoyaltiesPercentage" xlink:href="iinn-20221231.xsd#iinn_PayRoyaltiesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:to="iinn_PayRoyaltiesPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails">
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:href="iinn-20221231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_InvestmentNameAxis" xlink:href="iinn-20221231.xsd#iinn_InvestmentNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:to="iinn_InvestmentNameAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_InvestmentNameDomain" xlink:href="iinn-20221231.xsd#iinn_InvestmentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="iinn_InvestmentNameAxis" xlink:to="iinn_InvestmentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_InvestmentNameDomain_0" xlink:href="iinn-20221231.xsd#iinn_InvestmentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="iinn_InvestmentNameAxis" xlink:to="iinn_InvestmentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsToInvestorsMember" xlink:href="iinn-20221231.xsd#iinn_WarrantsToInvestorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_InvestmentNameDomain" xlink:to="iinn_WarrantsToInvestorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsToBrokersMember" xlink:href="iinn-20221231.xsd#iinn_WarrantsToBrokersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_InvestmentNameDomain" xlink:to="iinn_WarrantsToBrokersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_InitialPublicOfferingMember" xlink:href="iinn-20221231.xsd#iinn_InitialPublicOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="iinn_InitialPublicOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ConversionToShares" xlink:href="iinn-20221231.xsd#iinn_ConversionToShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_ConversionToShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AdditionalOrdinaryShare" xlink:href="iinn-20221231.xsd#iinn_AdditionalOrdinaryShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_AdditionalOrdinaryShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ProceedFromIssuanceInitialPublicOffering" xlink:href="iinn-20221231.xsd#iinn_ProceedFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_ProceedFromIssuanceInitialPublicOffering" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueOfTheWarrant" xlink:href="iinn-20221231.xsd#iinn_FairValueOfTheWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_FairValueOfTheWarrant" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateProceeds" xlink:href="iinn-20221231.xsd#iinn_AggregateProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_AggregateProceeds" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsShares" xlink:href="iinn-20221231.xsd#iinn_WarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_WarrantsShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PlanAssetsAtFairValue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="ifrs-full_PlanAssetsAtFairValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableWarrantFairValue" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_NontradableWarrantFairValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrants" xlink:href="iinn-20221231.xsd#iinn_TradableWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_TradableWarrants" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PublicOfferingPriceDescription" xlink:href="iinn-20221231.xsd#iinn_PublicOfferingPriceDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_PublicOfferingPriceDescription" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_InvestorsExercisedTradableWarrants" xlink:href="iinn-20221231.xsd#iinn_InvestorsExercisedTradableWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_InvestorsExercisedTradableWarrants" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinarySharesIssued" xlink:href="iinn-20221231.xsd#iinn_OrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_OrdinarySharesIssued" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalProceedsReceived" xlink:href="iinn-20221231.xsd#iinn_TotalProceedsReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_TotalProceedsReceived" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DeductingFees" xlink:href="iinn-20221231.xsd#iinn_DeductingFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_DeductingFees" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsFairValue" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_TradableWarrantsFairValue" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialLiabilityToPay" xlink:href="iinn-20221231.xsd#iinn_FinancialLiabilityToPay"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_FinancialLiabilityToPay" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialDerivativesFairValue" xlink:href="iinn-20221231.xsd#iinn_FinancialDerivativesFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_FinancialDerivativesFairValue" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/EquityDefictDetails">
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsTable" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_EquityDefictDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_EquityDefictDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_EquityDefictDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_EquityDefictDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_InvestorsMember" xlink:href="iinn-20221231.xsd#iinn_InvestorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="iinn_InvestorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OverallotmentOptionMember" xlink:href="iinn-20221231.xsd#iinn_OverallotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="iinn_OverallotmentOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_InitialPublicOfferingMember" xlink:href="iinn-20221231.xsd#iinn_InitialPublicOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="iinn_InitialPublicOfferingMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_BrokersMember" xlink:href="iinn-20221231.xsd#iinn_BrokersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="iinn_BrokersMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateOfOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_AggregateOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_AggregateOfOrdinaryShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinaryShare" xlink:href="iinn-20221231.xsd#iinn_OrdinaryShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_OrdinaryShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StockholdersEquityReverseSplit" xlink:href="iinn-20221231.xsd#iinn_StockholdersEquityReverseSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_StockholdersEquityReverseSplit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AuthorizedShareCapital" xlink:href="iinn-20221231.xsd#iinn_AuthorizedShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_AuthorizedShareCapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SoldOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_SoldOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_SoldOrdinaryShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_tradableWarrants" xlink:href="iinn-20221231.xsd#iinn_tradableWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_tradableWarrants" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableWarrants" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_NontradableWarrants" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateProceedsReceived" xlink:href="iinn-20221231.xsd#iinn_AggregateProceedsReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_AggregateProceedsReceived" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_GrossProceeds" xlink:href="iinn-20221231.xsd#iinn_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_GrossProceeds" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsDescription" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_TradableWarrantsDescription" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherMaterialNoncashItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherMaterialNoncashItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="ifrs-full_OtherMaterialNoncashItems" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NondirectCashExpenses" xlink:href="iinn-20221231.xsd#iinn_NondirectCashExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_NondirectCashExpenses" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_CashAndNoncash" xlink:href="iinn-20221231.xsd#iinn_CashAndNoncash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_CashAndNoncash" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExpensesDeductedFromEquity" xlink:href="iinn-20221231.xsd#iinn_ExpensesDeductedFromEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_ExpensesDeductedFromEquity" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateAmount" xlink:href="iinn-20221231.xsd#iinn_AggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_AggregateAmount" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AdditionalOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_AdditionalOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_AdditionalOrdinaryShares" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfIncomeTaxTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfIncomeTaxTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ApplicableTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="ifrs-full_ApplicableTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_CarriedForwardTaxLosse" xlink:href="iinn-20221231.xsd#iinn_CarriedForwardTaxLosse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="iinn_CarriedForwardTaxLosse" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetS" xlink:href="iinn-20221231.xsd#iinn_DeferredTaxAssetS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="iinn_DeferredTaxAssetS" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsTable" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_LeasesDetailsLineItems" xlink:to="iinn_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_LeasesDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_VehiclesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseReceivablesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseReceivablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_LeaseReceivablesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_leaseTerms" xlink:href="iinn-20221231.xsd#iinn_leaseTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsLineItems" xlink:to="iinn_leaseTerms" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_LeaseLiabilityAmount" xlink:href="iinn-20221231.xsd#iinn_LeaseLiabilityAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsLineItems" xlink:to="iinn_LeaseLiabilityAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsLineItems" xlink:to="ifrs-full_RightofuseAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DescriptionOfLeaseAgreement" xlink:href="iinn-20221231.xsd#iinn_DescriptionOfLeaseAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsLineItems" xlink:to="iinn_DescriptionOfLeaseAgreement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LeasesDetailsLineItems" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationDetailsTable" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_ShareBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedCompensationDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedCompensationDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedCompensationDetailsTable" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysOwnEquityInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_EntitysOwnEquityInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysOwnEquityInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_EntitysOwnEquityInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RSUMember" xlink:href="iinn-20221231.xsd#iinn_RSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:to="iinn_RSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AdvisersMember" xlink:href="iinn-20221231.xsd#iinn_AdvisersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="iinn_AdvisersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DirectorsMember" xlink:href="iinn-20221231.xsd#iinn_DirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="iinn_DirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_GrantTotalShares" xlink:href="iinn-20221231.xsd#iinn_GrantTotalShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_GrantTotalShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit" xlink:href="iinn-20221231.xsd#iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RestrictedStockUnitVested" xlink:href="iinn-20221231.xsd#iinn_RestrictedStockUnitVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_RestrictedStockUnitVested" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_TotalOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_TotalOrdinaryShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_GrantOptionDescription" xlink:href="iinn-20221231.xsd#iinn_GrantOptionDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_GrantOptionDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice" xlink:href="iinn-20221231.xsd#iinn_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_ExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_GrantedTotalOption" xlink:href="iinn-20221231.xsd#iinn_GrantedTotalOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_GrantedTotalOption" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ContractualLife" xlink:href="iinn-20221231.xsd#iinn_ContractualLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_ContractualLife" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_CapitalGainTax" xlink:href="iinn-20221231.xsd#iinn_CapitalGainTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_CapitalGainTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableSharesOptions" xlink:href="iinn-20221231.xsd#iinn_NontradableSharesOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_NontradableSharesOptions" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableShares" xlink:href="iinn-20221231.xsd#iinn_NontradableShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_NontradableShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisableOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_ExercisableOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_ExercisableOrdinaryShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_VestingPeriod" xlink:href="iinn-20221231.xsd#iinn_VestingPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_VestingPeriod" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OptionsEquity" xlink:href="iinn-20221231.xsd#iinn_OptionsEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_OptionsEquity" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AuthorizedOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_AuthorizedOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_AuthorizedOrdinaryShares" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_GrantTotal" xlink:href="iinn-20221231.xsd#iinn_GrantTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_GrantTotal" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_VestOverPeriod" xlink:href="iinn-20221231.xsd#iinn_VestOverPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_VestOverPeriod" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RestrictedStockUnitEmployeesDescription" xlink:href="iinn-20221231.xsd#iinn_RestrictedStockUnitEmployeesDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_RestrictedStockUnitEmployeesDescription" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_BoardOfDirectorsDescription" xlink:href="iinn-20221231.xsd#iinn_BoardOfDirectorsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_BoardOfDirectorsDescription" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueAssumptionsDescription" xlink:href="iinn-20221231.xsd#iinn_FairValueAssumptionsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_FairValueAssumptionsDescription" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors" xlink:href="iinn-20221231.xsd#iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentExpenses" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPaymentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_ShareBasedPaymentExpenses" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementDetails">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_strengtheningPercentage" xlink:href="iinn-20221231.xsd#iinn_strengtheningPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="iinn_strengtheningPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_weakeningPercentage" xlink:href="iinn-20221231.xsd#iinn_weakeningPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="iinn_weakeningPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Prepayments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Prepayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:to="ifrs-full_Prepayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExchangeAmount" xlink:href="iinn-20221231.xsd#iinn_ExchangeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:to="iinn_ExchangeAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_OrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:to="iinn_OrdinaryShares" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FairValueMeasurementDetails">
    <loc xlink:type="locator" xlink:label="iinn_FairValueMeasurementDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueMeasurementDetailsTable" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FairValueMeasurementDetailsLineItems" xlink:to="iinn_FairValueMeasurementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MeasurementAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MeasurementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FairValueMeasurementDetailsTable" xlink:to="ifrs-full_MeasurementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedMeasurementMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_AggregatedMeasurementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedMeasurementMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_AggregatedMeasurementMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FairValueMeasurementDetailsTable" xlink:to="ifrs-full_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_fairValueMeasurementAtLevel2Member" xlink:href="iinn-20221231.xsd#iinn_fairValueMeasurementAtLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="iinn_fairValueMeasurementAtLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExpectedTermOfWarrants" xlink:href="iinn-20221231.xsd#iinn_ExpectedTermOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FairValueMeasurementDetailsLineItems" xlink:to="iinn_ExpectedTermOfWarrants" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>iinn-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 19:09:14 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US">Total non- current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperations_lbl" xml:lang="en-US">Total net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperations" xlink:to="ifrs-full_ProfitLossFromContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl1" xml:lang="en-US">Ordinary shares, issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at the end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalNonCashTransactions" xlink:href="iinn-20221231.xsd#iinn_TotalNonCashTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iinn_TotalNonCashTransactions_lbl" xml:lang="en-US">Total non cash transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalNonCashTransactions" xlink:to="iinn_TotalNonCashTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:to="iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract_lbl" xml:lang="en-US">Critical Accounting Estimates and Judgements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract" xlink:to="iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfDepositsFromBanksTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfDepositsFromBanksTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of Deposits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:to="iinn_DisclosureOfDepositsFromBanksTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of Other Current Assets Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract" xlink:to="iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule of Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="iinn_ScheduleOfOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of Property Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract" xlink:to="iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl" xml:lang="en-US">Beginning Balance, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl0" xml:lang="en-US">Ending Balance, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_AccumulatedDepreciation" xlink:href="iinn-20221231.xsd#iinn_AccumulatedDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="iinn_AccumulatedDepreciation_lbl" xml:lang="en-US">Beginning Balance, Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccumulatedDepreciation" xlink:to="iinn_AccumulatedDepreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="iinn_AccumulatedDepreciation_lbl0" xml:lang="en-US">Ending Balance, Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccumulatedDepreciation" xlink:to="iinn_AccumulatedDepreciation_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:to="iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOtherAccountsPayableAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfOtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfOtherAccountsPayableAbstract_lbl" xml:lang="en-US">Schedule of Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfOtherAccountsPayableAbstract" xlink:to="iinn_ScheduleOfOtherAccountsPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentPayables_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPayables" xlink:to="ifrs-full_NoncurrentPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGovernmentGrantsTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfGovernmentGrantsTextBlockAbstract_lbl" xml:lang="en-US">Liability in Respect of Government Grants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:to="iinn_DisclosureOfGovernmentGrantsTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfReimbursementOfResearchExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfReimbursementOfResearchExpensesAbstract_lbl" xml:lang="en-US">Schedule of Reimbursement of Research Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:to="iinn_ScheduleOfReimbursementOfResearchExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_GovernmentGrants_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GovernmentGrants" xlink:to="ifrs-full_GovernmentGrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_GovernmentGrants_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GovernmentGrants" xlink:to="ifrs-full_GovernmentGrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract_lbl" xml:lang="en-US">Finacial Liabilities at fair value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" xlink:to="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" xml:lang="en-US">Classes of financial liabilities [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract_lbl" xml:lang="en-US">Equity (Defict) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:to="iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract_lbl" xml:lang="en-US">Research and Development Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract" xlink:to="iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ResearchDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_ResearchDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iinn_ResearchDevelopmentExpenses_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ResearchDevelopmentExpenses" xlink:to="iinn_ResearchDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_SalesAndMarketingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SalesAndMarketingExpensesAbstract_lbl" xml:lang="en-US">Sales and Marketing Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesAbstract" xlink:to="iinn_SalesAndMarketingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ExpenseByNature_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_ExpenseByNature_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of General and Administrative Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract" xlink:to="iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract_lbl" xml:lang="en-US">Financial (Income) and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract" xlink:to="iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xml:lang="en-US">Categories of financial liabilities [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfIncomeTaxTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfIncomeTaxTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfIncomeTaxTextBlockAbstract_lbl" xml:lang="en-US">Taxes on income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="iinn_DisclosureOfIncomeTaxTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfLeasesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfLeasesTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfLeasesTextBlockAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfLeasesTextBlockAbstract" xlink:to="iinn_DisclosureOfLeasesTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">At January 1, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl0" xml:lang="en-US">As of December 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US">At January 1, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl0" xml:lang="en-US">As of December 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl1" xml:lang="en-US">Financial liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract_lbl" xml:lang="en-US">Share Based Payment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US">Number of options Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl0" xml:lang="en-US">Number of options Outstanding ending year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average Exercise price NIS Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average Exercise price NIS Outstanding ending year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_OutstandingAtBeginningOfYears" xlink:href="iinn-20221231.xsd#iinn_OutstandingAtBeginningOfYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="iinn_OutstandingAtBeginningOfYears_lbl" xml:lang="en-US">Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OutstandingAtBeginningOfYears" xlink:to="iinn_OutstandingAtBeginningOfYears_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="iinn_OutstandingAtBeginningOfYears_lbl0" xml:lang="en-US">Outstanding as of December 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OutstandingAtBeginningOfYears" xlink:to="iinn_OutstandingAtBeginningOfYears_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfRelatedPartyTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfRelatedPartyTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfRelatedPartyTextBlockAbstract_lbl" xml:lang="en-US">Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="iinn_DisclosureOfRelatedPartyTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US">Classes of financial instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract_lbl" xml:lang="en-US">Financial Instruments and Risk Management [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US">Types of risks [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyInWhichInformationIsDisplayedAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis_lbl" xml:lang="en-US">Currency in which information is displayed [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:to="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl" xml:lang="en-US">Liabilities arising from financing activities [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:to="iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract_lbl" xml:lang="en-US">Fair Value Measurement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:to="iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherCurrentAssets_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract" xlink:to="iinn_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">Non-Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US">Right of use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract0" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract0" xlink:to="iinn_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Trade accounts payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US">Other accounts payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xml:lang="en-US">Financial liabilities at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract1" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract1" xlink:to="iinn_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Non-Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LoanFromTheIsraeliInnovationAuthority" xlink:href="iinn-20221231.xsd#iinn_LoanFromTheIsraeliInnovationAuthority"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_LoanFromTheIsraeliInnovationAuthority_lbl" xml:lang="en-US">Loan from the Israeli Innovation Authority</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LoanFromTheIsraeliInnovationAuthority" xlink:to="iinn_LoanFromTheIsraeliInnovationAuthority_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract2" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract2" xlink:to="iinn_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US">Share capital and additional paid in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US">Foreign exchange reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ResearchAndDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_ResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ResearchAndDevelopmentExpenses" xlink:to="iinn_ResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpenses" xlink:href="iinn-20221231.xsd#iinn_SalesAndMarketingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SalesAndMarketingExpenses_lbl" xml:lang="en-US">Sales and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpenses" xlink:to="iinn_SalesAndMarketingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralAndAdministrativeExpenses" xlink:href="iinn-20221231.xsd#iinn_GeneralAndAdministrativeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpenses" xlink:to="iinn_GeneralAndAdministrativeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceExpense" xlink:href="iinn-20221231.xsd#iinn_FinanceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinanceExpense_lbl" xml:lang="en-US">Finance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceExpense" xlink:to="iinn_FinanceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract3" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract3" xlink:to="iinn_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive loss, net of tax:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ItemsThatWillNotBeReclassifiedToProfitOrLossAbstract" xlink:href="iinn-20221231.xsd#iinn_ItemsThatWillNotBeReclassifiedToProfitOrLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ItemsThatWillNotBeReclassifiedToProfitOrLossAbstract_lbl" xml:lang="en-US">Items that will not be reclassified to profit or loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ItemsThatWillNotBeReclassifiedToProfitOrLossAbstract" xlink:to="iinn_ItemsThatWillNotBeReclassifiedToProfitOrLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted average number of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Basic and diluted loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl0" xml:lang="en-US">Basic loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Basic and diluted loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract4" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract4" xlink:to="iinn_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract" xlink:href="iinn-20221231.xsd#iinn_ChangesDuringThePeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesDuringThePeriodAbstract_lbl" xml:lang="en-US">Changes during the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ChangesDuringThePeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalComprehensiveLoss" xlink:href="iinn-20221231.xsd#iinn_TotalComprehensiveLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TotalComprehensiveLoss_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalComprehensiveLoss" xlink:to="iinn_TotalComprehensiveLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OptionsExercise" xlink:href="iinn-20221231.xsd#iinn_OptionsExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OptionsExercise_lbl" xml:lang="en-US">Share based compensation to exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OptionsExercise" xlink:to="iinn_OptionsExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationToExercise" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationToExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationToExercise_lbl" xml:lang="en-US">Share based compensation to exercise (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationToExercise" xlink:to="iinn_ShareBasedCompensationToExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits" xlink:href="iinn-20221231.xsd#iinn_StockIssuedDuringPeriodValueRestrictedStockUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits_lbl" xml:lang="en-US">RSUs vesting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits" xlink:to="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit" xlink:href="iinn-20221231.xsd#iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit_lbl" xml:lang="en-US">RSUs vesting (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit" xlink:to="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit_lbl0" xml:lang="en-US">Restricted stock unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit" xlink:to="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US">Share based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract5" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract5" xlink:to="iinn_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract0" xlink:href="iinn-20221231.xsd#iinn_ChangesDuringThePeriodAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesDuringThePeriodAbstract0_lbl" xml:lang="en-US">Changes during the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract0" xlink:to="iinn_ChangesDuringThePeriodAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ParValueCancellations" xlink:href="iinn-20221231.xsd#iinn_ParValueCancellations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ParValueCancellations_lbl" xml:lang="en-US">Par value cancellation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ParValueCancellations" xlink:to="iinn_ParValueCancellations_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_InitialPublicOffering" xlink:href="iinn-20221231.xsd#iinn_InitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_InitialPublicOffering_lbl" xml:lang="en-US">Initial Public Offering (&#8220;IPO&#8221;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InitialPublicOffering" xlink:to="iinn_InitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareIssuanceOfInitialPublicOffering" xlink:href="iinn-20221231.xsd#iinn_ShareIssuanceOfInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareIssuanceOfInitialPublicOffering_lbl" xml:lang="en-US">Initial Public Offering (&#8220;IPO&#8221;) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareIssuanceOfInitialPublicOffering" xlink:to="iinn_ShareIssuanceOfInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfConvertibleInstruments_lbl" xml:lang="en-US">Conversion of financial liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ifrs-full_IssueOfConvertibleInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ConversionOfFinancialLiabilityinShares" xlink:href="iinn-20221231.xsd#iinn_ConversionOfFinancialLiabilityinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ConversionOfFinancialLiabilityinShares_lbl" xml:lang="en-US">Conversion of financial liability (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionOfFinancialLiabilityinShares" xlink:to="iinn_ConversionOfFinancialLiabilityinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsExercise" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TradableWarrantsExercise_lbl" xml:lang="en-US">Tradable warrants exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsExercise" xlink:to="iinn_TradableWarrantsExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsExerciseinShares" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsExerciseinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TradableWarrantsExerciseinShares_lbl" xml:lang="en-US">Tradable warrants exercise (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsExerciseinShares" xlink:to="iinn_TradableWarrantsExerciseinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract6" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract6" xlink:to="iinn_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract1" xlink:href="iinn-20221231.xsd#iinn_ChangesDuringThePeriodAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesDuringThePeriodAbstract1_lbl" xml:lang="en-US">Changes during the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="iinn_ChangesDuringThePeriodAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareSplit" xlink:href="iinn-20221231.xsd#iinn_ShareSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareSplit_lbl" xml:lang="en-US">Share split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareSplit" xlink:to="iinn_ShareSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ConversionOfConvertibleLoanToShares" xlink:href="iinn-20221231.xsd#iinn_ConversionOfConvertibleLoanToShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ConversionOfConvertibleLoanToShares_lbl" xml:lang="en-US">Conversion of convertible loan to shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionOfConvertibleLoanToShares" xlink:to="iinn_ConversionOfConvertibleLoanToShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ConversionOfConvertibleLoanToSharesinShares" xlink:href="iinn-20221231.xsd#iinn_ConversionOfConvertibleLoanToSharesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ConversionOfConvertibleLoanToSharesinShares_lbl" xml:lang="en-US">Conversion of convertible loan to shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionOfConvertibleLoanToSharesinShares" xlink:to="iinn_ConversionOfConvertibleLoanToSharesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOW FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Share based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue" xlink:href="iinn-20221231.xsd#iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue_lbl" xml:lang="en-US">Revaluation of financial liabilities accounted at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue" xlink:to="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl" xml:lang="en-US">Changes of financial liabilities - IPO non-cash expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority" xlink:href="iinn-20221231.xsd#iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority_lbl" xml:lang="en-US">Change in connection to loan from the Israeli Innovation Authority</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority" xlink:to="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy" xlink:href="iinn-20221231.xsd#iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy_lbl" xml:lang="en-US">Financial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy" xlink:to="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesInOperatingAssetsAndLiabilityAbstract" xlink:href="iinn-20221231.xsd#iinn_ChangesInOperatingAssetsAndLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesInOperatingAssetsAndLiabilityAbstract_lbl" xml:lang="en-US">Changes in operating assets and liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesInOperatingAssetsAndLiabilityAbstract" xlink:to="iinn_ChangesInOperatingAssetsAndLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US">Decrease (increase) in other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Increase (decrease) in trade accounts payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US">Increase in other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract7" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract7" xlink:to="iinn_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOW FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PaymentOfDeposit" xlink:href="iinn-20221231.xsd#iinn_PaymentOfDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PaymentOfDeposit_lbl" xml:lang="en-US">Payment of deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PaymentOfDeposit" xlink:to="iinn_PaymentOfDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl" xml:lang="en-US">Change of deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract8" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract8" xlink:to="iinn_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" xlink:href="iinn-20221231.xsd#iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan_lbl" xml:lang="en-US">Receipt of simple agreements for future equity (SAFE) and convertible loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" xlink:to="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees" xlink:href="iinn-20221231.xsd#iinn_ReceiptOfWarrantsExerciseFundsNetFromFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees_lbl" xml:lang="en-US">Receipt of warrants exercise funds, net from fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees" xlink:to="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Loan from the Israeli Innovation Authority</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract9" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract9" xlink:to="iinn_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effects of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US">Conversion of convertible loans to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsLiability" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TradableWarrantsLiability_lbl" xml:lang="en-US">Tradable warrants at the IPO date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsLiability" xlink:to="iinn_TradableWarrantsLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsDerivativeLiability" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsDerivativeLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TradableWarrantsDerivativeLiability_lbl" xml:lang="en-US">Tradable warrants financial liability at the IPO date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsDerivativeLiability" xlink:to="iinn_TradableWarrantsDerivativeLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationUnderwritersFees" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationUnderwritersFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationUnderwritersFees_lbl" xml:lang="en-US">Share based compensation &#8211; underwriters fees at the IPO date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationUnderwritersFees" xlink:to="iinn_ShareBasedCompensationUnderwritersFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US">Warrants exercise to equity &#8211; financial liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsExerciseLiabilityIssuance" xlink:href="iinn-20221231.xsd#iinn_WarrantsExerciseLiabilityIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_WarrantsExerciseLiabilityIssuance_lbl" xml:lang="en-US">Warrants exercise &#8211; allocation from liability to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsExerciseLiabilityIssuance" xlink:to="iinn_WarrantsExerciseLiabilityIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefund" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxesPaidRefund_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefund" xlink:to="ifrs-full_IncomeTaxesPaidRefund_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherGainsLosses_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_OtherGainsLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0" xml:lang="en-US">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl" xml:lang="en-US">Exchange (losses)profits arising on translation to presentation currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl0" xml:lang="en-US">Other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchase of property, plant, and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DividendsPaidClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DividendsPaidClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Principal paid on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_DividendsPaidClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ReceiptOfIPOFunds" xlink:href="iinn-20221231.xsd#iinn_ReceiptOfIPOFunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_ReceiptOfIPOFunds_lbl" xml:lang="en-US">Receipt of IPO funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReceiptOfIPOFunds" xlink:to="iinn_ReceiptOfIPOFunds_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US">Ordinary Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl0" xml:lang="en-US">Ordinary Share Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl1" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl2" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Adjustments arising from translating financial operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionalPaidinCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalPaidinCapitalMember" xlink:to="ifrs-full_AdditionalPaidinCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock_lbl" xml:lang="en-US">Schedule of straight-line basis, over the useful lives of the assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock" xlink:to="iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract10" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract10" xlink:to="iinn_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AnnualDepreciationRateInPercentage" xlink:href="iinn-20221231.xsd#iinn_AnnualDepreciationRateInPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AnnualDepreciationRateInPercentage_lbl" xml:lang="en-US">Annual depreciation rate in percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AnnualDepreciationRateInPercentage" xlink:to="iinn_AnnualDepreciationRateInPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US">CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDepositsFromBanksExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDepositsFromBanksExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDepositsFromBanksExplanatory_lbl" xml:lang="en-US">DEPOSITS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDepositsFromBanksExplanatory" xlink:to="ifrs-full_DisclosureOfDepositsFromBanksExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US">Schedule of other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Institutions" xlink:href="iinn-20221231.xsd#iinn_Institutions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Institutions_lbl" xml:lang="en-US">Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Institutions" xlink:to="iinn_Institutions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_lbl" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_lbl0" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_OthersCurrentAssets" xlink:href="iinn-20221231.xsd#iinn_OthersCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OthersCurrentAssets_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OthersCurrentAssets" xlink:to="iinn_OthersCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock" xlink:to="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CostAbstract" xlink:href="iinn-20221231.xsd#iinn_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_CostAbstract_lbl" xml:lang="en-US">Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CostAbstract" xlink:to="iinn_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Additions, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExchangeRateDeferenceCost" xlink:href="iinn-20221231.xsd#iinn_ExchangeRateDeferenceCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExchangeRateDeferenceCost_lbl" xml:lang="en-US">Exchange rate deference, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeRateDeferenceCost" xlink:to="iinn_ExchangeRateDeferenceCost_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract11" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract11" xlink:to="iinn_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AccumulatedDepreciationAbstract" xlink:href="iinn-20221231.xsd#iinn_AccumulatedDepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AccumulatedDepreciationAbstract_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccumulatedDepreciationAbstract" xlink:to="iinn_AccumulatedDepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation, Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExchangeRateDeferenceAccumulatedDepreciation" xlink:href="iinn-20221231.xsd#iinn_ExchangeRateDeferenceAccumulatedDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExchangeRateDeferenceAccumulatedDepreciation_lbl" xml:lang="en-US">Exchange rate deference, Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeRateDeferenceAccumulatedDepreciation" xlink:to="iinn_ExchangeRateDeferenceAccumulatedDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract12" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract12" xlink:to="iinn_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NetBookValueAbstract" xlink:href="iinn-20221231.xsd#iinn_NetBookValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NetBookValueAbstract_lbl" xml:lang="en-US">Net book value:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract" xlink:to="iinn_NetBookValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NetBookValue" xlink:href="iinn-20221231.xsd#iinn_NetBookValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NetBookValue_lbl" xml:lang="en-US">Ending Balance, Net book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValue" xlink:to="iinn_NetBookValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CostAbstract0" xlink:href="iinn-20221231.xsd#iinn_CostAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_CostAbstract0_lbl" xml:lang="en-US">Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CostAbstract0" xlink:to="iinn_CostAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract13" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract13" xlink:to="iinn_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract14" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract14" xlink:to="iinn_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AccumulatedDepreciationAbstract0" xlink:href="iinn-20221231.xsd#iinn_AccumulatedDepreciationAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AccumulatedDepreciationAbstract0_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccumulatedDepreciationAbstract0" xlink:to="iinn_AccumulatedDepreciationAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract15" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract15" xlink:to="iinn_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract16" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract16" xlink:to="iinn_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NetBookValueAbstract0" xlink:href="iinn-20221231.xsd#iinn_NetBookValueAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NetBookValueAbstract0_lbl" xml:lang="en-US">Net book value:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract0" xlink:to="iinn_NetBookValueAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">OTHER ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOtherAccountPayableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfOtherAccountPayableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfOtherAccountPayableTextBlock_lbl" xml:lang="en-US">Schedule of other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfOtherAccountPayableTextBlock" xlink:to="iinn_ScheduleOfOtherAccountPayableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesSalariesAndRelatedLiabilities" xlink:href="iinn-20221231.xsd#iinn_EmployeesSalariesAndRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EmployeesSalariesAndRelatedLiabilities_lbl" xml:lang="en-US">Employees salaries and related liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesSalariesAndRelatedLiabilities" xlink:to="iinn_EmployeesSalariesAndRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPayablesToRelatedParties" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentPayablesToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentPayablesToRelatedParties_lbl" xml:lang="en-US">Related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPayablesToRelatedParties" xlink:to="ifrs-full_NoncurrentPayablesToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherPayables_lbl0" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGovernmentGrantsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGovernmentGrantsExplanatory_lbl" xml:lang="en-US">LIABILITY IN RESPECT OF GOVERNMENT GRANTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:to="ifrs-full_DisclosureOfGovernmentGrantsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of reimbursement of research expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock" xlink:to="iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Amounts received during the year, non- capitalized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExchangeRateDifferences" xlink:href="iinn-20221231.xsd#iinn_ExchangeRateDifferences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExchangeRateDifferences_lbl" xml:lang="en-US">Exchange rate differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeRateDifferences" xlink:to="iinn_ExchangeRateDifferences_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfTheLiability" xlink:href="iinn-20221231.xsd#iinn_RevaluationOfTheLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RevaluationOfTheLiability_lbl" xml:lang="en-US">Revaluation of the liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfTheLiability" xlink:to="iinn_RevaluationOfTheLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_lbl" xml:lang="en-US">FINACIAL LIABILITIES AT FAIR VALUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialLiabilities" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfFinancialLiabilities_lbl" xml:lang="en-US">Schedule of finacial liabilities at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialLiabilities" xlink:to="iinn_ScheduleOfFinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalFinancialLiabilities" xlink:href="iinn-20221231.xsd#iinn_TotalFinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TotalFinancialLiabilities_lbl" xml:lang="en-US">Total financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalFinancialLiabilities" xlink:to="iinn_TotalFinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl" xml:lang="en-US">EQUITY (DEFICT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US">Schedule of share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US">Ordinary shares, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl0" xml:lang="en-US">Authorized share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLossPerShare" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfLossPerShare_lbl" xml:lang="en-US">Schedule of loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLossPerShare" xlink:to="iinn_ScheduleOfLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_lbl" xml:lang="en-US">Loss for the period (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl" xml:lang="en-US">Total number of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits" xlink:href="iinn-20221231.xsd#iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits_lbl" xml:lang="en-US">Weighted average number of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits" xlink:to="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract17" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract17" xlink:to="iinn_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfResearchAndDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Schedule of research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfResearchAndDevelopmentExpenses" xlink:to="iinn_ScheduleOfResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPayment" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedPayment_lbl" xml:lang="en-US">Share based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPayment" xlink:to="iinn_ShareBasedPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SalaryAndRelatedExpenses" xlink:href="iinn-20221231.xsd#iinn_SalaryAndRelatedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SalaryAndRelatedExpenses_lbl" xml:lang="en-US">Salary and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalaryAndRelatedExpenses" xlink:to="iinn_SalaryAndRelatedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Subcontractors" xlink:href="iinn-20221231.xsd#iinn_Subcontractors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Subcontractors_lbl" xml:lang="en-US">Subcontractors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Subcontractors" xlink:to="iinn_Subcontractors_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_MaterialsAndRelatedExpenses" xlink:href="iinn-20221231.xsd#iinn_MaterialsAndRelatedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_MaterialsAndRelatedExpenses_lbl" xml:lang="en-US">Materials and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MaterialsAndRelatedExpenses" xlink:to="iinn_MaterialsAndRelatedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DepreciationExpenses" xlink:href="iinn-20221231.xsd#iinn_DepreciationExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DepreciationExpenses_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DepreciationExpenses" xlink:to="iinn_DepreciationExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_IIAParticipation" xlink:href="iinn-20221231.xsd#iinn_IIAParticipation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_IIAParticipation_lbl" xml:lang="en-US">IIA participation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IIAParticipation" xlink:to="iinn_IIAParticipation_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OtherResearchAndDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_OtherResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OtherResearchAndDevelopmentExpenses" xlink:to="iinn_OtherResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpensesTextBlock" xlink:href="iinn-20221231.xsd#iinn_SalesAndMarketingExpensesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SalesAndMarketingExpensesTextBlock_lbl" xml:lang="en-US">SALES AND MARKETING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesTextBlock" xlink:to="iinn_SalesAndMarketingExpensesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of sales and Marketing Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US">Share based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WagesAndSalaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US">Salary and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl" xml:lang="en-US">Professionals&#8217; fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherExpenseByNature_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherExpenseByNature_lbl0" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpenses" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Schedule of general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpenses" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPayments" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedPayments_lbl" xml:lang="en-US">Share based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPayments" xlink:to="iinn_ShareBasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US">Professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US">Related NASDAQ IPO expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US">Director&#8217;s fees and share based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Salary and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US">Insurance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RentalExpense_lbl" xml:lang="en-US">Office maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Depreciations" xlink:href="iinn-20221231.xsd#iinn_Depreciations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Depreciations_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Depreciations" xlink:to="iinn_Depreciations_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TravelExpense_lbl" xml:lang="en-US">Travel abroad</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TravelExpense" xlink:to="ifrs-full_TravelExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US">FINANCIAL (INCOME) AND EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialIncomeTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfFinancialIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of financial income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialIncomeTableTextBlock" xlink:to="iinn_ScheduleOfFinancialIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability_lbl" xml:lang="en-US">Revaluation of financial liabilities at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:to="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ForeignCurrencyTransactionLossNet" xlink:href="iinn-20221231.xsd#iinn_ForeignCurrencyTransactionLossNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ForeignCurrencyTransactionLossNet_lbl" xml:lang="en-US">Foreign currency transaction income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ForeignCurrencyTransactionLossNet" xlink:to="iinn_ForeignCurrencyTransactionLossNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iinn_ForeignCurrencyTransactionLossNet_lbl0" xml:lang="en-US">Foreign currency transaction loss, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ForeignCurrencyTransactionLossNet" xlink:to="iinn_ForeignCurrencyTransactionLossNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalIncome" xlink:href="iinn-20221231.xsd#iinn_TotalIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TotalIncome_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalIncome" xlink:to="iinn_TotalIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialExpenses" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfFinancialExpenses_lbl" xml:lang="en-US">Schedule of financial income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialExpenses" xlink:to="iinn_ScheduleOfFinancialExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants" xlink:href="iinn-20221231.xsd#iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants_lbl" xml:lang="en-US">Revaluation of liability in respect of government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants" xlink:to="iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceExpenseInRespectOfLeaseLiability" xlink:href="iinn-20221231.xsd#iinn_FinanceExpenseInRespectOfLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinanceExpenseInRespectOfLeaseLiability_lbl" xml:lang="en-US">Finance expense in respect of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceExpenseInRespectOfLeaseLiability" xlink:to="iinn_FinanceExpenseInRespectOfLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalExpenses" xlink:href="iinn-20221231.xsd#iinn_TotalExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TotalExpenses_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalExpenses" xlink:to="iinn_TotalExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl" xml:lang="en-US">Schedule of theoretical tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LossBeforeTaxation" xlink:href="iinn-20221231.xsd#iinn_LossBeforeTaxation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_LossBeforeTaxation_lbl" xml:lang="en-US">Loss before taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LossBeforeTaxation" xlink:to="iinn_LossBeforeTaxation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xml:lang="en-US">Theoretical tax credit at applicable statutory rate: 23%</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate" xlink:href="iinn-20221231.xsd#iinn_TheoreticalTaxCreditAtApplicableStatutoryRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate_lbl" xml:lang="en-US">Theoretical tax credit at applicable statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate" xlink:to="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NonallowableExpenses" xlink:href="iinn-20221231.xsd#iinn_NonallowableExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NonallowableExpenses_lbl" xml:lang="en-US">Non-allowable expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonallowableExpenses" xlink:to="iinn_NonallowableExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20221231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl" xml:lang="en-US">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfRightofuseAssets" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfRightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfRightofuseAssets_lbl" xml:lang="en-US">Schedule of right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfRightofuseAssets" xlink:to="iinn_ScheduleOfRightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialExpense" xlink:href="iinn-20221231.xsd#iinn_FinancialExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinancialExpense_lbl" xml:lang="en-US">Exchange rate differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialExpense" xlink:to="iinn_FinancialExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLeaseLiabilities" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfLeaseLiabilities_lbl" xml:lang="en-US">Schedule of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLeaseLiabilities" xlink:to="iinn_ScheduleOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Accretion of interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExchangeRateDifference" xlink:href="iinn-20221231.xsd#iinn_ExchangeRateDifference"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExchangeRateDifference_lbl" xml:lang="en-US">Exchange rate differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeRateDifference" xlink:to="iinn_ExchangeRateDifference_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PrincipalPayment" xlink:href="iinn-20221231.xsd#iinn_PrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PrincipalPayment_lbl" xml:lang="en-US">Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrincipalPayment" xlink:to="iinn_PrincipalPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfProfitOrLoss" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfProfitOrLoss_lbl" xml:lang="en-US">Schedule of profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfProfitOrLoss" xlink:to="iinn_ScheduleOfProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US">Interest expense on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalAmountRecognizedInProfitOrLoss" xlink:href="iinn-20221231.xsd#iinn_TotalAmountRecognizedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TotalAmountRecognizedInProfitOrLoss_lbl" xml:lang="en-US">Total amount recognized in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalAmountRecognizedInProfitOrLoss" xlink:to="iinn_TotalAmountRecognizedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">SHARE BASED COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US">Schedule of RSUs to services providers and advisers outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GrantedNumberOfOptions" xlink:href="iinn-20221231.xsd#iinn_GrantedNumberOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_GrantedNumberOfOptions_lbl" xml:lang="en-US">Number of options Granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrantedNumberOfOptions" xlink:to="iinn_GrantedNumberOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average Exercise price NIS Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisedNumberOfOptions" xlink:href="iinn-20221231.xsd#iinn_ExercisedNumberOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisedNumberOfOptions_lbl" xml:lang="en-US">Number of options Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisedNumberOfOptions" xlink:to="iinn_ExercisedNumberOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisedWeightedAverageExercisePrice" xlink:href="iinn-20221231.xsd#iinn_ExercisedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price NIS Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisedWeightedAverageExercisePrice" xlink:to="iinn_ExercisedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of options Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ForfeitedWeightedAverageExercisePrice" xlink:href="iinn-20221231.xsd#iinn_ForfeitedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ForfeitedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price NIS Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ForfeitedWeightedAverageExercisePrice" xlink:to="iinn_ForfeitedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisableOptionsNumberOfOptions" xlink:href="iinn-20221231.xsd#iinn_ExercisableOptionsNumberOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisableOptionsNumberOfOptions_lbl" xml:lang="en-US">Number of options Exercisable options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisableOptionsNumberOfOptions" xlink:to="iinn_ExercisableOptionsNumberOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average Exercise price NIS Exercisable options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares" xlink:href="iinn-20221231.xsd#iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares_lbl" xml:lang="en-US">Number of options Reclassified to employees and directors (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares" xlink:to="iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice" xlink:href="iinn-20221231.xsd#iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price NIS Reclassified to employees and directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice" xlink:to="iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding_lbl" xml:lang="en-US">Schedule of RSUs to services providers and advisers outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding" xlink:to="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Granted" xlink:href="iinn-20221231.xsd#iinn_Granted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Granted_lbl" xml:lang="en-US">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Granted" xlink:to="iinn_Granted_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Vested" xlink:href="iinn-20221231.xsd#iinn_Vested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Vested_lbl" xml:lang="en-US">Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Vested" xlink:to="iinn_Vested_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RestrictedStockUnitVested" xlink:href="iinn-20221231.xsd#iinn_RestrictedStockUnitVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RestrictedStockUnitVested_lbl" xml:lang="en-US">Vested as of December 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnitVested" xlink:to="iinn_RestrictedStockUnitVested_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iinn_RestrictedStockUnitVested_lbl0" xml:lang="en-US">Restricted stock unit vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnitVested" xlink:to="iinn_RestrictedStockUnitVested_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_Forfeited" xlink:href="iinn-20221231.xsd#iinn_Forfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Forfeited_lbl" xml:lang="en-US">Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Forfeited" xlink:to="iinn_Forfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisableRSUs" xlink:href="iinn-20221231.xsd#iinn_ExercisableRSUs"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisableRSUs_lbl" xml:lang="en-US">Exercisable RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisableRSUs" xlink:to="iinn_ExercisableRSUs_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US">RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock_lbl" xml:lang="en-US">Schedule of shareholders and other related parties&#8217; benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock" xlink:to="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US">Salary and related expenses &#8211; officers and directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentEmployeesAndDirectors" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPaymentEmployeesAndDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedPaymentEmployeesAndDirectors_lbl" xml:lang="en-US">Share based payment &#8211; officers and directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentEmployeesAndDirectors" xlink:to="iinn_ShareBasedPaymentEmployeesAndDirectors_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_BalancesWithRelatedPartiesTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_BalancesWithRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_BalancesWithRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of balances with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BalancesWithRelatedPartiesTableTextBlock" xlink:to="iinn_BalancesWithRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NatureOfTransactionSalariesAndRelated" xlink:href="iinn-20221231.xsd#iinn_NatureOfTransactionSalariesAndRelated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NatureOfTransactionSalariesAndRelated_lbl" xml:lang="en-US">Nature of transaction, Salaries and related</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NatureOfTransactionSalariesAndRelated" xlink:to="iinn_NatureOfTransactionSalariesAndRelated_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany" xlink:href="iinn-20221231.xsd#iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany_lbl" xml:lang="en-US">Nature of transaction, Compensation for directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany" xlink:to="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure_lbl" xml:lang="en-US">Schedule of financial assets represents the maximum credit exposure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure" xlink:to="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US">Other current assets (Restricted deposits)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_FinancialAssets_lbl0" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability_lbl" xml:lang="en-US">Schedule of foreign currency denominated monetary liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability" xlink:to="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AssetsAbstract0" xlink:href="iinn-20221231.xsd#iinn_AssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AssetsAbstract0_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AssetsAbstract0" xlink:to="iinn_AssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Deposit" xlink:href="iinn-20221231.xsd#iinn_Deposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Deposit_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Deposit" xlink:to="iinn_Deposit_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract18" xlink:href="iinn-20221231.xsd#iinn_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract18" xlink:to="iinn_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DerivativeFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xml:lang="en-US">Financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativeFinancialLiabilities" xlink:to="ifrs-full_DerivativeFinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherFinancialAssets_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinancialAssets" xlink:to="ifrs-full_OtherFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtFairValue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsAtFairValue_lbl" xml:lang="en-US">Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValue" xlink:to="ifrs-full_FinancialAssetsAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSensitivityAnalysis" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfSensitivityAnalysis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfSensitivityAnalysis_lbl" xml:lang="en-US">Schedule of sensitivity analysis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSensitivityAnalysis" xlink:to="iinn_ScheduleOfSensitivityAnalysis_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SensitivityAnalysis" xlink:href="iinn-20221231.xsd#iinn_SensitivityAnalysis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SensitivityAnalysis_lbl" xml:lang="en-US">Sensitivity analysis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SensitivityAnalysis" xlink:to="iinn_SensitivityAnalysis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of cash flows of financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossLeaseLiabilities" xlink:to="ifrs-full_GrossLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_lbl" xml:lang="en-US">Loan from the IIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableWarrantFairValue" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NontradableWarrantFairValue_lbl" xml:lang="en-US">Non-tradable Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrantFairValue" xlink:to="iinn_NontradableWarrantFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iinn_NontradableWarrantFairValue_lbl0" xml:lang="en-US">Non-tradable warrants fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrantFairValue" xlink:to="iinn_NontradableWarrantFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors_lbl" xml:lang="en-US">Non-tradable warrants of SAFE and Convertible Loan investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" xlink:to="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantLiability_lbl" xml:lang="en-US">Tradable warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of movements in level 2 liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock" xlink:to="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_BalanceAtBeginning" xlink:href="iinn-20221231.xsd#iinn_BalanceAtBeginning"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_BalanceAtBeginning_lbl" xml:lang="en-US">Balance as of December 31, 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BalanceAtBeginning" xlink:to="iinn_BalanceAtBeginning_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GainslossesRecognizedInProfitLoss" xlink:href="iinn-20221231.xsd#iinn_GainslossesRecognizedInProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_GainslossesRecognizedInProfitLoss_lbl" xml:lang="en-US">Gains (losses) recognized in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GainslossesRecognizedInProfitLoss" xlink:to="iinn_GainslossesRecognizedInProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Addition" xlink:href="iinn-20221231.xsd#iinn_Addition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Addition_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Addition" xlink:to="iinn_Addition_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments_lbl" xml:lang="en-US">Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments" xlink:to="ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AdjustmentsArisingFromTranslatingFinancialOperations" xlink:href="iinn-20221231.xsd#iinn_AdjustmentsArisingFromTranslatingFinancialOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AdjustmentsArisingFromTranslatingFinancialOperations_lbl" xml:lang="en-US">Adjustments arising from translating financial operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdjustmentsArisingFromTranslatingFinancialOperations" xlink:to="iinn_AdjustmentsArisingFromTranslatingFinancialOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_BalanceAtEnding" xlink:href="iinn-20221231.xsd#iinn_BalanceAtEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_BalanceAtEnding_lbl" xml:lang="en-US">Balance as of December,31 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BalanceAtEnding" xlink:to="iinn_BalanceAtEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl" xml:lang="en-US">Amounts recognized as an offset from research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestIncomeOnDeposits_lbl" xml:lang="en-US">Interest on deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnDeposits" xlink:to="ifrs-full_InterestIncomeOnDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsInvestmentProperty" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsInvestmentProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DisposalsInvestmentProperty_lbl" xml:lang="en-US">Disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsInvestmentProperty" xlink:to="ifrs-full_DisposalsInvestmentProperty_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialExpenses" xlink:href="iinn-20221231.xsd#iinn_FinancialExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_FinancialExpenses_lbl" xml:lang="en-US">Financial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialExpenses" xlink:to="iinn_FinancialExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Depreciation expense of right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ComputersMember" xlink:href="iinn-20221231.xsd#iinn_ComputersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ComputersMember_lbl" xml:lang="en-US">Computers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ComputersMember" xlink:to="iinn_ComputersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DevelopmentEquipmentMember" xlink:href="iinn-20221231.xsd#iinn_DevelopmentEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DevelopmentEquipmentMember_lbl" xml:lang="en-US">Development equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DevelopmentEquipmentMember" xlink:to="iinn_DevelopmentEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FurnitureAndOfficeEquipmentMember" xlink:href="iinn-20221231.xsd#iinn_FurnitureAndOfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US">Furniture and office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FurnitureAndOfficeEquipmentMember" xlink:to="iinn_FurnitureAndOfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LeaseholdImprovementMember" xlink:href="iinn-20221231.xsd#iinn_LeaseholdImprovementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_LeaseholdImprovementMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeaseholdImprovementMember" xlink:to="iinn_LeaseholdImprovementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OfficeEquipmentMember_lbl" xml:lang="en-US">Furniture and office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableWarrantsMember" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NontradableWarrantsMember_lbl" xml:lang="en-US">Non-tradable warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrantsMember" xlink:to="iinn_NontradableWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableWarrantsSAFEAndCLAMember" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantsSAFEAndCLAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NontradableWarrantsSAFEAndCLAMember_lbl" xml:lang="en-US">Non-tradable warrants, SAFE and CLA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrantsSAFEAndCLAMember" xlink:to="iinn_NontradableWarrantsSAFEAndCLAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsMember" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TradableWarrantsMember_lbl" xml:lang="en-US">Tradable warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsMember" xlink:to="iinn_TradableWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialLiabilityMember" xlink:href="iinn-20221231.xsd#iinn_FinancialLiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinancialLiabilityMember_lbl" xml:lang="en-US">Financial liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialLiabilityMember" xlink:to="iinn_FinancialLiabilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialIncomeMember" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinancialIncomeMember_lbl" xml:lang="en-US">Financial income [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialIncomeMember" xlink:to="iinn_FinancialIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialExpensesMember" xlink:href="iinn-20221231.xsd#iinn_FinancialExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinancialExpensesMember_lbl" xml:lang="en-US">Financial Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialExpensesMember" xlink:to="iinn_FinancialExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OfficeBuildingMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficeBuildingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OfficeBuildingMember_lbl" xml:lang="en-US">Office facility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficeBuildingMember" xlink:to="srt_OfficeBuildingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_VehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_VehiclesMember" xlink:to="ifrs-full_VehiclesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ProvidersAndAdvisersMember" xlink:href="iinn-20221231.xsd#iinn_ProvidersAndAdvisersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ProvidersAndAdvisersMember_lbl" xml:lang="en-US">Providers and advisers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProvidersAndAdvisersMember" xlink:to="iinn_ProvidersAndAdvisersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesAndDirectorsMember" xlink:href="iinn-20221231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Employees and directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesAndDirectorsMember" xlink:to="iinn_EmployeesAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesMember" xlink:href="iinn-20221231.xsd#iinn_EmployeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EmployeesMember_lbl" xml:lang="en-US">Officers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesMember" xlink:to="iinn_EmployeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DirectorsMember" xlink:href="iinn-20221231.xsd#iinn_DirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DirectorsMember_lbl" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DirectorsMember" xlink:to="iinn_DirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CreditRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CreditRiskMember_lbl" xml:lang="en-US">Credit risk [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_USDMemberMember" xlink:href="iinn-20221231.xsd#iinn_USDMemberMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_USDMemberMember_lbl" xml:lang="en-US">USD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_USDMemberMember" xlink:to="iinn_USDMemberMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AUDMember" xlink:href="iinn-20221231.xsd#iinn_AUDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AUDMember_lbl" xml:lang="en-US">AUD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AUDMember" xlink:to="iinn_AUDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PoundMember" xlink:href="iinn-20221231.xsd#iinn_PoundMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PoundMember_lbl" xml:lang="en-US">GB Pound [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PoundMember" xlink:to="iinn_PoundMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UpTo1YearMember" xlink:href="iinn-20221231.xsd#iinn_UpTo1YearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UpTo1YearMember_lbl" xml:lang="en-US">Up to 1 year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UpTo1YearMember" xlink:to="iinn_UpTo1YearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Between1And3YearsMember" xlink:href="iinn-20221231.xsd#iinn_Between1And3YearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Between1And3YearsMember_lbl" xml:lang="en-US">Between 1 and 3 years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Between1And3YearsMember" xlink:to="iinn_Between1And3YearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_MoreThan3YearsMember" xlink:href="iinn-20221231.xsd#iinn_MoreThan3YearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_MoreThan3YearsMember_lbl" xml:lang="en-US">More than 3 years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MoreThan3YearsMember" xlink:to="iinn_MoreThan3YearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsMember" xlink:href="iinn-20221231.xsd#iinn_WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsMember" xlink:to="iinn_WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SAFEMember" xlink:href="iinn-20221231.xsd#iinn_SAFEMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SAFEMember_lbl" xml:lang="en-US">SAFE [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SAFEMember" xlink:to="iinn_SAFEMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ConvertibleLoanMember" xlink:href="iinn-20221231.xsd#iinn_ConvertibleLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ConvertibleLoanMember_lbl" xml:lang="en-US">Convertible loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConvertibleLoanMember" xlink:to="iinn_ConvertibleLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialDerivativeMember" xlink:href="iinn-20221231.xsd#iinn_FinancialDerivativeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinancialDerivativeMember_lbl" xml:lang="en-US">Financial Liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialDerivativeMember" xlink:to="iinn_FinancialDerivativeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_InvestmentNameAxis" xlink:href="iinn-20221231.xsd#iinn_InvestmentNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_InvestmentNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InvestmentNameAxis" xlink:to="iinn_InvestmentNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis_lbl" xml:lang="en-US">Classes of entity&apos;s own equity instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MeasurementAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MeasurementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MeasurementAxis_lbl" xml:lang="en-US">Measurement [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NumberOfShares" xlink:href="iinn-20221231.xsd#iinn_NumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NumberOfShares_lbl" xml:lang="en-US">Number of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberOfShares" xlink:to="iinn_NumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsShares" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TradableWarrantsShares_lbl" xml:lang="en-US">Tradable warrants shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsShares" xlink:to="iinn_TradableWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsPursuantShares" xlink:href="iinn-20221231.xsd#iinn_WarrantsPursuantShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_WarrantsPursuantShares_lbl" xml:lang="en-US">Warrants pursuant shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsPursuantShares" xlink:to="iinn_WarrantsPursuantShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateProceedsAmount" xlink:href="iinn-20221231.xsd#iinn_AggregateProceedsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregateProceedsAmount_lbl" xml:lang="en-US">Aggregate proceeds amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateProceedsAmount" xlink:to="iinn_AggregateProceedsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AdditionalOfferingCosts" xlink:href="iinn-20221231.xsd#iinn_AdditionalOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AdditionalOfferingCosts_lbl" xml:lang="en-US">Additional offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOfferingCosts" xlink:to="iinn_AdditionalOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_OrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OrdinaryShares_lbl" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinaryShares" xlink:to="iinn_OrdinaryShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iinn_OrdinaryShares_lbl0" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinaryShares" xlink:to="iinn_OrdinaryShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsShares" xlink:href="iinn-20221231.xsd#iinn_WarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_WarrantsShares_lbl" xml:lang="en-US">Warrants shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsShares" xlink:to="iinn_WarrantsShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iinn_WarrantsShares_lbl0" xml:lang="en-US">Non-tradable warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsShares" xlink:to="iinn_WarrantsShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_InvestorsExercise" xlink:href="iinn-20221231.xsd#iinn_InvestorsExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_InvestorsExercise_lbl" xml:lang="en-US">Total proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InvestorsExercise" xlink:to="iinn_InvestorsExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfPaidFees" xlink:href="iinn-20221231.xsd#iinn_PercentageOfPaidFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfPaidFees_lbl" xml:lang="en-US">Percentage of paid fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfPaidFees" xlink:to="iinn_PercentageOfPaidFees_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PaidFeesAmount" xlink:href="iinn-20221231.xsd#iinn_PaidFeesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PaidFeesAmount_lbl" xml:lang="en-US">Paid fees, amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PaidFeesAmount" xlink:to="iinn_PaidFeesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OperatingLeaseIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingLeaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OperatingLeaseIncome_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingLeaseIncome" xlink:to="ifrs-full_OperatingLeaseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepositsFromBanks" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepositsFromBanks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepositsFromBanks_lbl" xml:lang="en-US">Deposit amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepositsFromBanks" xlink:to="ifrs-full_DepositsFromBanks_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US">Annual interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DepositValue" xlink:href="iinn-20221231.xsd#iinn_DepositValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DepositValue_lbl" xml:lang="en-US">Deposit value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DepositValue" xlink:to="iinn_DepositValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US">Total amount received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PayRoyaltiesPercentage" xlink:href="iinn-20221231.xsd#iinn_PayRoyaltiesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PayRoyaltiesPercentage_lbl" xml:lang="en-US">Royalties, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PayRoyaltiesPercentage" xlink:to="iinn_PayRoyaltiesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ConversionToShares" xlink:href="iinn-20221231.xsd#iinn_ConversionToShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ConversionToShares_lbl" xml:lang="en-US">Conversion to ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionToShares" xlink:to="iinn_ConversionToShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AdditionalOrdinaryShare" xlink:href="iinn-20221231.xsd#iinn_AdditionalOrdinaryShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AdditionalOrdinaryShare_lbl" xml:lang="en-US">Additional ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOrdinaryShare" xlink:to="iinn_AdditionalOrdinaryShare_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ProceedFromIssuanceInitialPublicOffering" xlink:href="iinn-20221231.xsd#iinn_ProceedFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ProceedFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Initial public offering price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProceedFromIssuanceInitialPublicOffering" xlink:to="iinn_ProceedFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueOfTheWarrant" xlink:href="iinn-20221231.xsd#iinn_FairValueOfTheWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FairValueOfTheWarrant_lbl" xml:lang="en-US">Fair value of the warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueOfTheWarrant" xlink:to="iinn_FairValueOfTheWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateProceeds" xlink:href="iinn-20221231.xsd#iinn_AggregateProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregateProceeds_lbl" xml:lang="en-US">Aggregate proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateProceeds" xlink:to="iinn_AggregateProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PlanAssetsAtFairValue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PlanAssetsAtFairValue_lbl" xml:lang="en-US">Fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PlanAssetsAtFairValue" xlink:to="ifrs-full_PlanAssetsAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrants" xlink:href="iinn-20221231.xsd#iinn_TradableWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TradableWarrants_lbl" xml:lang="en-US">Tradable warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrants" xlink:to="iinn_TradableWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PublicOfferingPriceDescription" xlink:href="iinn-20221231.xsd#iinn_PublicOfferingPriceDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PublicOfferingPriceDescription_lbl" xml:lang="en-US">Public offering price, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PublicOfferingPriceDescription" xlink:to="iinn_PublicOfferingPriceDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_InvestorsExercisedTradableWarrants" xlink:href="iinn-20221231.xsd#iinn_InvestorsExercisedTradableWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_InvestorsExercisedTradableWarrants_lbl" xml:lang="en-US">Investors exercised tradable warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InvestorsExercisedTradableWarrants" xlink:to="iinn_InvestorsExercisedTradableWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinarySharesIssued" xlink:href="iinn-20221231.xsd#iinn_OrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OrdinarySharesIssued_lbl" xml:lang="en-US">Ordinary Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesIssued" xlink:to="iinn_OrdinarySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalProceedsReceived" xlink:href="iinn-20221231.xsd#iinn_TotalProceedsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TotalProceedsReceived_lbl" xml:lang="en-US">Total proceeds received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalProceedsReceived" xlink:to="iinn_TotalProceedsReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeductingFees" xlink:href="iinn-20221231.xsd#iinn_DeductingFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DeductingFees_lbl" xml:lang="en-US">Deducting fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeductingFees" xlink:to="iinn_DeductingFees_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsFairValue" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TradableWarrantsFairValue_lbl" xml:lang="en-US">Tradable warrants fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsFairValue" xlink:to="iinn_TradableWarrantsFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialLiabilityToPay" xlink:href="iinn-20221231.xsd#iinn_FinancialLiabilityToPay"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinancialLiabilityToPay_lbl" xml:lang="en-US">Financial liability to pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialLiabilityToPay" xlink:to="iinn_FinancialLiabilityToPay_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialDerivativesFairValue" xlink:href="iinn-20221231.xsd#iinn_FinancialDerivativesFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinancialDerivativesFairValue_lbl" xml:lang="en-US">Financial derivatives fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialDerivativesFairValue" xlink:to="iinn_FinancialDerivativesFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateOfOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_AggregateOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregateOfOrdinaryShares_lbl" xml:lang="en-US">Aggregate of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateOfOrdinaryShares" xlink:to="iinn_AggregateOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinaryShare" xlink:href="iinn-20221231.xsd#iinn_OrdinaryShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OrdinaryShare_lbl" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinaryShare" xlink:to="iinn_OrdinaryShare_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_StockholdersEquityReverseSplit" xlink:href="iinn-20221231.xsd#iinn_StockholdersEquityReverseSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_StockholdersEquityReverseSplit_lbl" xml:lang="en-US">Reverse split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockholdersEquityReverseSplit" xlink:to="iinn_StockholdersEquityReverseSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AuthorizedShareCapital" xlink:href="iinn-20221231.xsd#iinn_AuthorizedShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AuthorizedShareCapital_lbl" xml:lang="en-US">Authorized share capital (in New Shekels)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AuthorizedShareCapital" xlink:to="iinn_AuthorizedShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Ordinary share par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SoldOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_SoldOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SoldOrdinaryShares_lbl" xml:lang="en-US">Sold ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SoldOrdinaryShares" xlink:to="iinn_SoldOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_tradableWarrants" xlink:href="iinn-20221231.xsd#iinn_tradableWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_tradableWarrants_lbl" xml:lang="en-US">Tradable warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_tradableWarrants" xlink:to="iinn_tradableWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableWarrants" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NontradableWarrants_lbl" xml:lang="en-US">Non-tradable warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrants" xlink:to="iinn_NontradableWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateProceedsReceived" xlink:href="iinn-20221231.xsd#iinn_AggregateProceedsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregateProceedsReceived_lbl" xml:lang="en-US">Aggregate proceeds received (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateProceedsReceived" xlink:to="iinn_AggregateProceedsReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions_lbl" xml:lang="en-US">Additional offering costs total (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GrossProceeds" xlink:href="iinn-20221231.xsd#iinn_GrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrossProceeds" xlink:to="iinn_GrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsDescription" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TradableWarrantsDescription_lbl" xml:lang="en-US">Tradable warrants, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsDescription" xlink:to="iinn_TradableWarrantsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherMaterialNoncashItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherMaterialNoncashItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherMaterialNoncashItems_lbl" xml:lang="en-US">Total non-cash expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherMaterialNoncashItems" xlink:to="ifrs-full_OtherMaterialNoncashItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NondirectCashExpenses" xlink:href="iinn-20221231.xsd#iinn_NondirectCashExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NondirectCashExpenses_lbl" xml:lang="en-US">Non-direct cash expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NondirectCashExpenses" xlink:to="iinn_NondirectCashExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems_lbl" xml:lang="en-US">Non-cash expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CashAndNoncash" xlink:href="iinn-20221231.xsd#iinn_CashAndNoncash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_CashAndNoncash_lbl" xml:lang="en-US">Cash and non-cash (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CashAndNoncash" xlink:to="iinn_CashAndNoncash_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Profit and loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExpensesDeductedFromEquity" xlink:href="iinn-20221231.xsd#iinn_ExpensesDeductedFromEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExpensesDeductedFromEquity_lbl" xml:lang="en-US">Expenses deducted from equity (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpensesDeductedFromEquity" xlink:to="iinn_ExpensesDeductedFromEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateAmount" xlink:href="iinn-20221231.xsd#iinn_AggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregateAmount_lbl" xml:lang="en-US">Aggregate amount ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateAmount" xlink:to="iinn_AggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AdditionalOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_AdditionalOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AdditionalOrdinaryShares_lbl" xml:lang="en-US">Additional ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOrdinaryShares" xlink:to="iinn_AdditionalOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ApplicableTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CarriedForwardTaxLosse" xlink:href="iinn-20221231.xsd#iinn_CarriedForwardTaxLosse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_CarriedForwardTaxLosse_lbl" xml:lang="en-US">Carried forward tax losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CarriedForwardTaxLosse" xlink:to="iinn_CarriedForwardTaxLosse_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetS" xlink:href="iinn-20221231.xsd#iinn_DeferredTaxAssetS"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DeferredTaxAssetS_lbl" xml:lang="en-US">No deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetS" xlink:to="iinn_DeferredTaxAssetS_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_leaseTerms" xlink:href="iinn-20221231.xsd#iinn_leaseTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_leaseTerms_lbl" xml:lang="en-US">Lease terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_leaseTerms" xlink:to="iinn_leaseTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LeaseLiabilityAmount" xlink:href="iinn-20221231.xsd#iinn_LeaseLiabilityAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_LeaseLiabilityAmount_lbl" xml:lang="en-US">Lease liability amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeaseLiabilityAmount" xlink:to="iinn_LeaseLiabilityAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US">Right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DescriptionOfLeaseAgreement" xlink:href="iinn-20221231.xsd#iinn_DescriptionOfLeaseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DescriptionOfLeaseAgreement_lbl" xml:lang="en-US">Lease agreement description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DescriptionOfLeaseAgreement" xlink:to="iinn_DescriptionOfLeaseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Total cash outflows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Granted options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GrantTotalShares" xlink:href="iinn-20221231.xsd#iinn_GrantTotalShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_GrantTotalShares_lbl" xml:lang="en-US">Grant total share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrantTotalShares" xlink:to="iinn_GrantTotalShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TotalOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_TotalOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TotalOrdinaryShares_lbl" xml:lang="en-US">Total ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalOrdinaryShares" xlink:to="iinn_TotalOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GrantOptionDescription" xlink:href="iinn-20221231.xsd#iinn_GrantOptionDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_GrantOptionDescription_lbl" xml:lang="en-US">Grant option, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrantOptionDescription" xlink:to="iinn_GrantOptionDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice" xlink:href="iinn-20221231.xsd#iinn_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePrice_lbl" xml:lang="en-US">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice" xlink:to="iinn_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GrantedTotalOption" xlink:href="iinn-20221231.xsd#iinn_GrantedTotalOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_GrantedTotalOption_lbl" xml:lang="en-US">Grand total option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrantedTotalOption" xlink:to="iinn_GrantedTotalOption_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ContractualLife" xlink:href="iinn-20221231.xsd#iinn_ContractualLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ContractualLife_lbl" xml:lang="en-US">Contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ContractualLife" xlink:to="iinn_ContractualLife_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CapitalGainTax" xlink:href="iinn-20221231.xsd#iinn_CapitalGainTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_CapitalGainTax_lbl" xml:lang="en-US">Capital gain tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CapitalGainTax" xlink:to="iinn_CapitalGainTax_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableSharesOptions" xlink:href="iinn-20221231.xsd#iinn_NontradableSharesOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NontradableSharesOptions_lbl" xml:lang="en-US">Non-tradable shares options, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableSharesOptions" xlink:to="iinn_NontradableSharesOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NontradableShares" xlink:href="iinn-20221231.xsd#iinn_NontradableShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NontradableShares_lbl" xml:lang="en-US">Non-tradable shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableShares" xlink:to="iinn_NontradableShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisableOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_ExercisableOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisableOrdinaryShares_lbl" xml:lang="en-US">Exercisable ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisableOrdinaryShares" xlink:to="iinn_ExercisableOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_VestingPeriod" xlink:href="iinn-20221231.xsd#iinn_VestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_VestingPeriod_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_VestingPeriod" xlink:to="iinn_VestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Exercise price per share (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OptionsEquity" xlink:href="iinn-20221231.xsd#iinn_OptionsEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OptionsEquity_lbl" xml:lang="en-US">Options equity percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OptionsEquity" xlink:to="iinn_OptionsEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AuthorizedOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_AuthorizedOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AuthorizedOrdinaryShares_lbl" xml:lang="en-US">Ordinary shares, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AuthorizedOrdinaryShares" xlink:to="iinn_AuthorizedOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GrantTotal" xlink:href="iinn-20221231.xsd#iinn_GrantTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_GrantTotal_lbl" xml:lang="en-US">Grant total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrantTotal" xlink:to="iinn_GrantTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_VestOverPeriod" xlink:href="iinn-20221231.xsd#iinn_VestOverPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_VestOverPeriod_lbl" xml:lang="en-US">Vest over period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_VestOverPeriod" xlink:to="iinn_VestOverPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RestrictedStockUnitEmployeesDescription" xlink:href="iinn-20221231.xsd#iinn_RestrictedStockUnitEmployeesDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RestrictedStockUnitEmployeesDescription_lbl" xml:lang="en-US">Restricted Stock Unit Employees Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnitEmployeesDescription" xlink:to="iinn_RestrictedStockUnitEmployeesDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_BoardOfDirectorsDescription" xlink:href="iinn-20221231.xsd#iinn_BoardOfDirectorsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_BoardOfDirectorsDescription_lbl" xml:lang="en-US">Board of directors, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BoardOfDirectorsDescription" xlink:to="iinn_BoardOfDirectorsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueAssumptionsDescription" xlink:href="iinn-20221231.xsd#iinn_FairValueAssumptionsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FairValueAssumptionsDescription_lbl" xml:lang="en-US">Description of fair value assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueAssumptionsDescription" xlink:to="iinn_FairValueAssumptionsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors" xlink:href="iinn-20221231.xsd#iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors_lbl" xml:lang="en-US">Expenses to employees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors" xlink:to="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentExpenses" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPaymentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedPaymentExpenses_lbl" xml:lang="en-US">Share based payment expenses of option to services (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentExpenses" xlink:to="iinn_ShareBasedPaymentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_strengtheningPercentage" xlink:href="iinn-20221231.xsd#iinn_strengtheningPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_strengtheningPercentage_lbl" xml:lang="en-US">Strengthening percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_strengtheningPercentage" xlink:to="iinn_strengtheningPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_weakeningPercentage" xlink:href="iinn-20221231.xsd#iinn_weakeningPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_weakeningPercentage_lbl" xml:lang="en-US">Weakening percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_weakeningPercentage" xlink:to="iinn_weakeningPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Prepayments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Prepayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Prepayments_lbl" xml:lang="en-US">Prepayment paid (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Prepayments" xlink:to="ifrs-full_Prepayments_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExchangeAmount" xlink:href="iinn-20221231.xsd#iinn_ExchangeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExchangeAmount_lbl" xml:lang="en-US">Exchange amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeAmount" xlink:to="iinn_ExchangeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk-free interest rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Expected dividend yield, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExpectedTermOfWarrants" xlink:href="iinn-20221231.xsd#iinn_ExpectedTermOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExpectedTermOfWarrants_lbl" xml:lang="en-US">Expected term of warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpectedTermOfWarrants" xlink:to="iinn_ExpectedTermOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US">Basis of preparation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock" xlink:href="iinn-20221231.xsd#iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock_lbl" xml:lang="en-US">Use of estimates and assumptions in the preparation of the financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock" xlink:to="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Functional and foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements_lbl" xml:lang="en-US">Financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" xlink:to="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property, plant, and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRoJ/travtspQJClWcUZpCKKwHPCOss3tqo6SbRlG2Msx2Mu7jhsbM1rEkd29demw7xoQFJ8QNNTzH6TXzpr7OuPNceEmvURO78QMp9NjY3po4ETx9F6sRVhawVTRJu6GPL28h20ybcMGoGdEpdE3z6o=] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xml:lang="en-US">Impairment of non-financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US">Segment reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US">Share based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OptionsPolicyTextBlock" xlink:href="iinn-20221231.xsd#iinn_OptionsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OptionsPolicyTextBlock_lbl" xml:lang="en-US">Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OptionsPolicyTextBlock" xlink:to="iinn_OptionsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RestrictedShareUnitsPolicyTextBlock" xlink:href="iinn-20221231.xsd#iinn_RestrictedShareUnitsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RestrictedShareUnitsPolicyTextBlock_lbl" xml:lang="en-US">Restricted Share Units (&#8220;RSUs&#8221;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedShareUnitsPolicyTextBlock" xlink:to="iinn_RestrictedShareUnitsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" xml:lang="en-US">Government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl" xml:lang="en-US">Current taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_lbl" xml:lang="en-US">Deferred tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsToInvestorsMember" xlink:href="iinn-20221231.xsd#iinn_WarrantsToInvestorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_WarrantsToInvestorsMember_lbl" xml:lang="en-US">Investors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToInvestorsMember" xlink:to="iinn_WarrantsToInvestorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsToBrokersMember" xlink:href="iinn-20221231.xsd#iinn_WarrantsToBrokersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_WarrantsToBrokersMember_lbl" xml:lang="en-US">Warrants to brokers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToBrokersMember" xlink:to="iinn_WarrantsToBrokersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_InitialPublicOfferingMember" xlink:href="iinn-20221231.xsd#iinn_InitialPublicOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_InitialPublicOfferingMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InitialPublicOfferingMember" xlink:to="iinn_InitialPublicOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_InvestorsMember" xlink:href="iinn-20221231.xsd#iinn_InvestorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_InvestorsMember_lbl" xml:lang="en-US">Investors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InvestorsMember" xlink:to="iinn_InvestorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OverallotmentOptionMember" xlink:href="iinn-20221231.xsd#iinn_OverallotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OverallotmentOptionMember_lbl" xml:lang="en-US">Overallotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OverallotmentOptionMember" xlink:to="iinn_OverallotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_BrokersMember" xlink:href="iinn-20221231.xsd#iinn_BrokersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_BrokersMember_lbl" xml:lang="en-US">Brokers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BrokersMember" xlink:to="iinn_BrokersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseReceivablesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseReceivablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseReceivablesMember_lbl" xml:lang="en-US">Offices [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseReceivablesMember" xlink:to="ifrs-full_LeaseReceivablesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AdvisersMember" xlink:href="iinn-20221231.xsd#iinn_AdvisersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AdvisersMember_lbl" xml:lang="en-US">Advisers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdvisersMember" xlink:to="iinn_AdvisersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RSUMember" xlink:href="iinn-20221231.xsd#iinn_RSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RSUMember_lbl" xml:lang="en-US">RSU [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RSUMember" xlink:to="iinn_RSUMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_fairValueMeasurementAtLevel2Member" xlink:href="iinn-20221231.xsd#iinn_fairValueMeasurementAtLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_fairValueMeasurementAtLevel2Member_lbl" xml:lang="en-US">Fair Value Measurement Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_fairValueMeasurementAtLevel2Member" xlink:to="iinn_fairValueMeasurementAtLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US">Equity [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, plant and equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US">Ranges [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" xlink:href="iinn-20221231.xsd#iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" xlink:to="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems" xlink:href="iinn-20221231.xsd#iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems" xlink:to="iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable" xlink:href="iinn-20221231.xsd#iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable_lbl" xml:lang="en-US">Property and Equipment, Net (Details) - Schedule of property and equipment, net [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable" xlink:to="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" xlink:href="iinn-20221231.xsd#iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems_lbl" xml:lang="en-US">Property and Equipment, Net (Details) - Schedule of property and equipment, net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" xlink:to="iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesMember_lbl" xml:lang="en-US">Financial liabilities, class [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_FinancialLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable" xlink:href="iinn-20221231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems" xlink:href="iinn-20221231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsScheduleofsharecapitalTable" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleofsharecapitalTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EquityDefictDetailsScheduleofsharecapitalTable_lbl" xml:lang="en-US">Equity (Defict) (Details) - Schedule of share capital [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EquityDefictDetailsScheduleofsharecapitalTable" xlink:to="iinn_EquityDefictDetailsScheduleofsharecapitalTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsScheduleofsharecapitalLineItems" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleofsharecapitalLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EquityDefictDetailsScheduleofsharecapitalLineItems_lbl" xml:lang="en-US">Schedule of Share Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EquityDefictDetailsScheduleofsharecapitalLineItems" xlink:to="iinn_EquityDefictDetailsScheduleofsharecapitalLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareTable" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleoflosspershareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareTable_lbl" xml:lang="en-US">Equity (Defict) (Details) - Schedule of loss per share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareTable" xlink:to="iinn_EquityDefictDetailsScheduleoflosspershareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareLineItems" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleoflosspershareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareLineItems_lbl" xml:lang="en-US">Schedule of Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareLineItems" xlink:to="iinn_EquityDefictDetailsScheduleoflosspershareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsTable" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsTable_lbl" xml:lang="en-US">Equity (Defict) (Details) - Schedule of loss per share (Parentheticals) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsTable" xlink:to="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems_lbl" xml:lang="en-US">Schedule of Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems" xlink:to="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable" xlink:href="iinn-20221231.xsd#iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable_lbl" xml:lang="en-US">Research and Development Expenses (Details) - Schedule of research and development expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable" xlink:to="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:href="iinn-20221231.xsd#iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems_lbl" xml:lang="en-US">Schedule of research and development expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable" xlink:href="iinn-20221231.xsd#iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable_lbl" xml:lang="en-US">Sales and Marketing Expenses (Details) - Schedule of sales and Marketing Expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable" xlink:to="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:href="iinn-20221231.xsd#iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems_lbl" xml:lang="en-US">Schedule of Sales and Marketing Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:to="iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable" xlink:href="iinn-20221231.xsd#iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable_lbl" xml:lang="en-US">General and Administrative Expenses (Details) - Schedule of general and administrative expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable" xlink:to="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:href="iinn-20221231.xsd#iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xml:lang="en-US">Financial liabilities, category [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable_lbl" xml:lang="en-US">Financial (Income) and Expenses (Details) - Schedule of financial income [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable" xlink:to="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems_lbl" xml:lang="en-US">Financial (Income) and Expenses (Details) - Schedule of financial income [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:to="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable_lbl" xml:lang="en-US">Financial (Income) and Expenses (Details) - Schedule of financial expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable" xlink:to="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems_lbl" xml:lang="en-US">Financial (Income) and Expenses (Details) - Schedule of financial expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:to="iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxTable" xlink:href="iinn-20221231.xsd#iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxTable_lbl" xml:lang="en-US">Taxes on Income (Details) - Schedule of theoretical tax [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxTable" xlink:to="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:href="iinn-20221231.xsd#iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems_lbl" xml:lang="en-US">Schedule of theoretical tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:to="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable" xlink:href="iinn-20221231.xsd#iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable_lbl" xml:lang="en-US">Taxes on Income (Details) - Schedule of theoretical tax (Parentheticals) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable" xlink:to="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems" xlink:href="iinn-20221231.xsd#iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems_lbl" xml:lang="en-US">Schedule of theoretical tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems" xlink:to="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsScheduleofrightofuseassetsTable" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofrightofuseassetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LeasesDetailsScheduleofrightofuseassetsTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of right-of-use assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeasesDetailsScheduleofrightofuseassetsTable" xlink:to="iinn_LeasesDetailsScheduleofrightofuseassetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofrightofuseassetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LeasesDetailsScheduleofrightofuseassetsLineItems_lbl" xml:lang="en-US">Leases (Details) - Schedule of right-of-use assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="iinn_LeasesDetailsScheduleofrightofuseassetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsScheduleofleaseliabilitiesTable" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofleaseliabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LeasesDetailsScheduleofleaseliabilitiesTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of lease liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeasesDetailsScheduleofleaseliabilitiesTable" xlink:to="iinn_LeasesDetailsScheduleofleaseliabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems_lbl" xml:lang="en-US">Schedule of Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsScheduleofprofitorlossTable" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofprofitorlossTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LeasesDetailsScheduleofprofitorlossTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of profit or loss [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeasesDetailsScheduleofprofitorlossTable" xlink:to="iinn_LeasesDetailsScheduleofprofitorlossTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsScheduleofprofitorlossLineItems" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofprofitorlossLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LeasesDetailsScheduleofprofitorlossLineItems_lbl" xml:lang="en-US">Schedule of profit or loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeasesDetailsScheduleofprofitorlossLineItems" xlink:to="iinn_LeasesDetailsScheduleofprofitorlossLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable_lbl" xml:lang="en-US">Share Based Compensation (Details) - Schedule of options to services providers and advisers outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" xlink:to="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems_lbl" xml:lang="en-US">Share Based Compensation (Details) - Schedule of options to services providers and advisers outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable_lbl" xml:lang="en-US">Share Based Compensation (Details) - Schedule of RSUs to services providers and advisers outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" xlink:to="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems_lbl" xml:lang="en-US">Share Based Compensation (Details) - Schedule of RSUs to services providers and advisers outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable" xlink:href="iinn-20221231.xsd#iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable_lbl" xml:lang="en-US">Related Parties (Details) - Schedule of shareholders and other related parties&#8217; benefits [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable" xlink:to="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems" xlink:href="iinn-20221231.xsd#iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems_lbl" xml:lang="en-US">Schedule of shareholders and other related parties&#8217; benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems" xlink:to="iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xml:lang="en-US">Financial instruments, class [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable" xlink:href="iinn-20221231.xsd#iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable_lbl" xml:lang="en-US">Related Parties (Details) - Schedule of balances with related parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable" xlink:to="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems" xlink:href="iinn-20221231.xsd#iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems_lbl" xml:lang="en-US">Schedule of balances with related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems" xlink:to="iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US">Risks [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable_lbl" xml:lang="en-US">Financial Instruments and Risk Management (Details) - Schedule of financial assets represents the maximum credit exposure [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" xlink:to="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems_lbl" xml:lang="en-US">Financial Instruments and Risk Management (Details) - Schedule of financial assets represents the maximum credit exposure [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" xlink:to="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FunctionalOrPresentationCurrencyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FunctionalOrPresentationCurrencyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FunctionalOrPresentationCurrencyMember_lbl" xml:lang="en-US">Functional or presentation currency [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FunctionalOrPresentationCurrencyMember" xlink:to="ifrs-full_FunctionalOrPresentationCurrencyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable_lbl" xml:lang="en-US">Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable" xlink:to="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems_lbl" xml:lang="en-US">Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems" xlink:to="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_lbl" xml:lang="en-US">Liabilities arising from financing activities [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable_lbl" xml:lang="en-US">Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable" xlink:to="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems_lbl" xml:lang="en-US">Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:to="iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueMeasurementDetailsScheduleofwarrantsTable" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsScheduleofwarrantsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FairValueMeasurementDetailsScheduleofwarrantsTable_lbl" xml:lang="en-US">Fair Value Measurement (Details) - Schedule of warrants [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueMeasurementDetailsScheduleofwarrantsTable" xlink:to="iinn_FairValueMeasurementDetailsScheduleofwarrantsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems_lbl" xml:lang="en-US">Fair Value Measurement (Details) - Schedule of warrants [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:to="iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable_lbl" xml:lang="en-US">Fair Value Measurement (Details) - Schedule of movements in level 2 liability [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable" xlink:to="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems_lbl" xml:lang="en-US">Schedule of movements in level 2 liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_InvestmentNameDomain" xlink:href="iinn-20221231.xsd#iinn_InvestmentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_InvestmentNameDomain_lbl" xml:lang="en-US">InvestmentName [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InvestmentNameDomain" xlink:to="iinn_InvestmentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US">Entity&apos;s total for related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:href="iinn-20221231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsTable_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsLineItems_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US">Share capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsTable" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EquityDefictDetailsTable_lbl" xml:lang="en-US">Equity (Defict) (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EquityDefictDetailsTable" xlink:to="iinn_EquityDefictDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityDefictDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EquityDefictDetailsLineItems_lbl" xml:lang="en-US">Equity (Defict) (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EquityDefictDetailsLineItems" xlink:to="iinn_EquityDefictDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsTable" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeasesDetailsTable" xlink:to="iinn_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LeasesDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LeasesDetailsLineItems_lbl" xml:lang="en-US">Leases (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeasesDetailsLineItems" xlink:to="iinn_LeasesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysOwnEquityInstrumentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember_lbl" xml:lang="en-US">Entity&apos;s own equity instruments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:to="ifrs-full_EntitysOwnEquityInstrumentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationDetailsTable" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationDetailsTable_lbl" xml:lang="en-US">Share Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationDetailsTable" xlink:to="iinn_ShareBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Share Based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationDetailsLineItems" xlink:to="iinn_ShareBasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedMeasurementMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedMeasurementMember_lbl" xml:lang="en-US">Aggregated measurement [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AggregatedMeasurementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueMeasurementDetailsTable" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FairValueMeasurementDetailsTable_lbl" xml:lang="en-US">Fair Value Measurement (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueMeasurementDetailsTable" xlink:to="iinn_FairValueMeasurementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueMeasurementDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FairValueMeasurementDetailsLineItems_lbl" xml:lang="en-US">Fair Value Measurement (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueMeasurementDetailsLineItems" xlink:to="iinn_FairValueMeasurementDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AdditionalOfferingCosts_lbl0" xml:lang="en-US">The amount of additional offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOfferingCosts" xlink:to="iinn_AdditionalOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AdditionalOrdinaryShare_lbl0" xml:lang="en-US">Additional ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOrdinaryShare" xlink:to="iinn_AdditionalOrdinaryShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AdditionalOrdinaryShares_lbl0" xml:lang="en-US">Additional ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOrdinaryShares" xlink:to="iinn_AdditionalOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AggregateAmount_lbl0" xml:lang="en-US">Aggregate amount of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateAmount" xlink:to="iinn_AggregateAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AggregateOfOrdinaryShares_lbl0" xml:lang="en-US">Aggregate ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateOfOrdinaryShares" xlink:to="iinn_AggregateOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AggregateProceeds_lbl0" xml:lang="en-US">Aggregate proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateProceeds" xlink:to="iinn_AggregateProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AggregateProceedsReceived_lbl0" xml:lang="en-US">Aggregate proceeds received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateProceedsReceived" xlink:to="iinn_AggregateProceedsReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AnnualDepreciationRateInPercentage_lbl0" xml:lang="en-US">Annual depreciation rate in percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AnnualDepreciationRateInPercentage" xlink:to="iinn_AnnualDepreciationRateInPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits_lbl0" xml:lang="en-US">Anti-dilutive potentially dilutive securities after the Reverse Stock Splits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits" xlink:to="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AuthorizedShareCapital_lbl0" xml:lang="en-US">The amount of authorized share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AuthorizedShareCapital" xlink:to="iinn_AuthorizedShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_BalancesWithRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">Balances with related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BalancesWithRelatedPartiesTableTextBlock" xlink:to="iinn_BalancesWithRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_BoardOfDirectorsDescription_lbl0" xml:lang="en-US">Board of directors description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BoardOfDirectorsDescription" xlink:to="iinn_BoardOfDirectorsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_CapitalGainTax_lbl0" xml:lang="en-US">Capital gain tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CapitalGainTax" xlink:to="iinn_CapitalGainTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_CarriedForwardTaxLosse_lbl0" xml:lang="en-US">Carried forward tax losses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CarriedForwardTaxLosse" xlink:to="iinn_CarriedForwardTaxLosse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_CashAndNoncash_lbl0" xml:lang="en-US">Cash and non-cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CashAndNoncash" xlink:to="iinn_CashAndNoncash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue_lbl0" xml:lang="en-US">The amount of change in fair value of  financial liability at fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue" xlink:to="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ContractualLife_lbl0" xml:lang="en-US">Contractual life.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ContractualLife" xlink:to="iinn_ContractualLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ConversionOfConvertibleLoanToShares_lbl0" xml:lang="en-US">The amount of conversion of convertible loan to shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionOfConvertibleLoanToShares" xlink:to="iinn_ConversionOfConvertibleLoanToShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ConversionOfConvertibleLoanToSharesinShares_lbl0" xml:lang="en-US">The shares of conversion of convertible loan to shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionOfConvertibleLoanToSharesinShares" xlink:to="iinn_ConversionOfConvertibleLoanToSharesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ConversionOfFinancialLiabilityinShares_lbl0" xml:lang="en-US">The change in equity resulting from the issuing of conversion of financial liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionOfFinancialLiabilityinShares" xlink:to="iinn_ConversionOfFinancialLiabilityinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ConversionToShares_lbl0" xml:lang="en-US">Conversion to shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionToShares" xlink:to="iinn_ConversionToShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DeductingFees_lbl0" xml:lang="en-US">The amount of deducting fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeductingFees" xlink:to="iinn_DeductingFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DeferredTaxAssetS_lbl0" xml:lang="en-US">Deferred tax asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetS" xlink:to="iinn_DeferredTaxAssetS_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_Deposit_lbl0" xml:lang="en-US">The amount of deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Deposit" xlink:to="iinn_Deposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DepositValue_lbl0" xml:lang="en-US">The amount of deposit liabilities from customers held by the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DepositValue" xlink:to="iinn_DepositValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_Depreciations_lbl0" xml:lang="en-US">Depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Depreciations" xlink:to="iinn_Depreciations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DescriptionOfLeaseAgreement_lbl0" xml:lang="en-US">The description of lease agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DescriptionOfLeaseAgreement" xlink:to="iinn_DescriptionOfLeaseAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_EmployeesSalariesAndRelatedLiabilities_lbl0" xml:lang="en-US">Employees, salaries and related liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesSalariesAndRelatedLiabilities" xlink:to="iinn_EmployeesSalariesAndRelatedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExchangeAmount_lbl0" xml:lang="en-US">The amount of exchange amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeAmount" xlink:to="iinn_ExchangeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExchangeRateDeferenceAccumulatedDepreciation_lbl0" xml:lang="en-US">Exchange rate deference, Accumulated depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeRateDeferenceAccumulatedDepreciation" xlink:to="iinn_ExchangeRateDeferenceAccumulatedDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExchangeRateDeferenceCost_lbl0" xml:lang="en-US">Exchange rate deference, Cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeRateDeferenceCost" xlink:to="iinn_ExchangeRateDeferenceCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExchangeRateDifference_lbl0" xml:lang="en-US">Exchange rate differences.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeRateDifference" xlink:to="iinn_ExchangeRateDifference_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExpectedTermOfWarrants_lbl0" xml:lang="en-US">Expected term of warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpectedTermOfWarrants" xlink:to="iinn_ExpectedTermOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors_lbl0" xml:lang="en-US">The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors" xlink:to="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExpensesDeductedFromEquity_lbl0" xml:lang="en-US">Expenses deducted from equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpensesDeductedFromEquity" xlink:to="iinn_ExpensesDeductedFromEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FairValueAssumptionsDescription_lbl0" xml:lang="en-US">Fair value assumptions description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueAssumptionsDescription" xlink:to="iinn_FairValueAssumptionsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FairValueOfTheWarrant_lbl0" xml:lang="en-US">Fair value of the warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueOfTheWarrant" xlink:to="iinn_FairValueOfTheWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FinanceExpense_lbl0" xml:lang="en-US">Finance expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceExpense" xlink:to="iinn_FinanceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy_lbl0" xml:lang="en-US">Financial expenses are expenses associated with any financing the company incurs, including interest from debt. Tax expenses are reported below the profit before tax line and are the expenses owed to authorities as a result of profits generated in the accounting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy" xlink:to="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FinancialDerivativesFairValue_lbl0" xml:lang="en-US">Financial derivatives fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialDerivativesFairValue" xlink:to="iinn_FinancialDerivativesFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FinancialExpenses_lbl0" xml:lang="en-US">Financial expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialExpenses" xlink:to="iinn_FinancialExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FinancialLiabilityToPay_lbl0" xml:lang="en-US">Financial liability to pay.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialLiabilityToPay" xlink:to="iinn_FinancialLiabilityToPay_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_Forfeited_lbl0" xml:lang="en-US">Forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Forfeited" xlink:to="iinn_Forfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_GeneralAndAdministrativeExpenses_lbl0" xml:lang="en-US">General and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpenses" xlink:to="iinn_GeneralAndAdministrativeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_GrantOptionDescription_lbl0" xml:lang="en-US">Grant option description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrantOptionDescription" xlink:to="iinn_GrantOptionDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_GrossProceeds_lbl0" xml:lang="en-US">Gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrossProceeds" xlink:to="iinn_GrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_InitialPublicOffering_lbl0" xml:lang="en-US">The amount of initial public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InitialPublicOffering" xlink:to="iinn_InitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_Institutions_lbl0" xml:lang="en-US">Institution amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Institutions" xlink:to="iinn_Institutions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_InvestorsExercisedTradableWarrants_lbl0" xml:lang="en-US">Investors exercised tradable warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InvestorsExercisedTradableWarrants" xlink:to="iinn_InvestorsExercisedTradableWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_LoanFromTheIsraeliInnovationAuthority_lbl0" xml:lang="en-US">The amount of loan from the israeli innovation authority.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LoanFromTheIsraeliInnovationAuthority" xlink:to="iinn_LoanFromTheIsraeliInnovationAuthority_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_LossBeforeTaxation_lbl0" xml:lang="en-US">Loss before taxation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LossBeforeTaxation" xlink:to="iinn_LossBeforeTaxation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NonallowableExpenses_lbl0" xml:lang="en-US">Non-allowable expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonallowableExpenses" xlink:to="iinn_NonallowableExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NondirectCashExpenses_lbl0" xml:lang="en-US">Non-direct cash expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NondirectCashExpenses" xlink:to="iinn_NondirectCashExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NontradableShares_lbl0" xml:lang="en-US">Non-tradable shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableShares" xlink:to="iinn_NontradableShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NontradableSharesOptions_lbl0" xml:lang="en-US">Non-tradable shares options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableSharesOptions" xlink:to="iinn_NontradableSharesOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NontradableWarrantFairValue_lbl1" xml:lang="en-US">Non-tradable warrants fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrantFairValue" xlink:to="iinn_NontradableWarrantFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NontradableWarrants_lbl0" xml:lang="en-US">Non-tradable warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrants" xlink:to="iinn_NontradableWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors_lbl0" xml:lang="en-US">Non-tradable warrants of SAFE and Convertible Loan investors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" xlink:to="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NumberOfShares_lbl0" xml:lang="en-US">Number of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberOfShares" xlink:to="iinn_NumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OptionsExercise_lbl0" xml:lang="en-US">The amount of options exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OptionsExercise" xlink:to="iinn_OptionsExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OptionsPolicyTextBlock_lbl0" xml:lang="en-US">Options policy text block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OptionsPolicyTextBlock" xlink:to="iinn_OptionsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OrdinaryShare_lbl0" xml:lang="en-US">Ordinary shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinaryShare" xlink:to="iinn_OrdinaryShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OrdinaryShares_lbl1" xml:lang="en-US">Number of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinaryShares" xlink:to="iinn_OrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OrdinarySharesIssued_lbl0" xml:lang="en-US">Ordinary Shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesIssued" xlink:to="iinn_OrdinarySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OtherResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">OtherResearchAndDevelopmentExpense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OtherResearchAndDevelopmentExpenses" xlink:to="iinn_OtherResearchAndDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OthersCurrentAssets_lbl0" xml:lang="en-US">Others.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OthersCurrentAssets" xlink:to="iinn_OthersCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OutstandingAtBeginningOfYears_lbl1" xml:lang="en-US">Outstanding at beginning of year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OutstandingAtBeginningOfYears" xlink:to="iinn_OutstandingAtBeginningOfYears_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ParValueCancellations_lbl0" xml:lang="en-US">Par value cancellation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ParValueCancellations" xlink:to="iinn_ParValueCancellations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PayRoyaltiesPercentage_lbl0" xml:lang="en-US">Pay royalties, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PayRoyaltiesPercentage" xlink:to="iinn_PayRoyaltiesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PaymentOfDeposit_lbl0" xml:lang="en-US">Payment of deposit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PaymentOfDeposit" xlink:to="iinn_PaymentOfDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfPaidFees_lbl0" xml:lang="en-US">Percentage of paid fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfPaidFees" xlink:to="iinn_PercentageOfPaidFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ProceedFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">The cash inflow associated with the amount received from entity&apos;s first offering of stock to the public.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProceedFromIssuanceInitialPublicOffering" xlink:to="iinn_ProceedFromIssuanceInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PublicOfferingPriceDescription_lbl0" xml:lang="en-US">Public offering price, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PublicOfferingPriceDescription" xlink:to="iinn_PublicOfferingPriceDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ReceiptOfIPOFunds_lbl0" xml:lang="en-US">Receipt of IPO funds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReceiptOfIPOFunds" xlink:to="iinn_ReceiptOfIPOFunds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees_lbl0" xml:lang="en-US">Receipt of warrants exercise funds, net from fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees" xlink:to="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">Research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ResearchAndDevelopmentExpenses" xlink:to="iinn_ResearchAndDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RestrictedShareUnitsPolicyTextBlock_lbl0" xml:lang="en-US">Restricted Share Units policy text block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedShareUnitsPolicyTextBlock" xlink:to="iinn_RestrictedShareUnitsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RestrictedStockUnitEmployeesDescription_lbl0" xml:lang="en-US">Restricted stock unit employees description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnitEmployeesDescription" xlink:to="iinn_RestrictedStockUnitEmployeesDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RestrictedStockUnitVested_lbl1" xml:lang="en-US">Restricted stock unit vested.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnitVested" xlink:to="iinn_RestrictedStockUnitVested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority_lbl0" xml:lang="en-US">Revaluation of loan from the Israeli Innovation Authority.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority" xlink:to="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SalesAndMarketingExpenses_lbl0" xml:lang="en-US">Sales and marketing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpenses" xlink:to="iinn_SalesAndMarketingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SalesAndMarketingExpensesTextBlock_lbl0" xml:lang="en-US">Sales and Marketing Expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesTextBlock" xlink:to="iinn_SalesAndMarketingExpensesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfFinancialIncomeTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure financial income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialIncomeTableTextBlock" xlink:to="iinn_ScheduleOfFinancialIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfFinancialLiabilities_lbl0" xml:lang="en-US">Tabular disclosure of financial liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialLiabilities" xlink:to="iinn_ScheduleOfFinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock_lbl0" xml:lang="en-US">Schedule of movements in level 2 liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock" xlink:to="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfOtherAccountPayableTextBlock_lbl0" xml:lang="en-US">Schedule of other account payable [Text Block].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfOtherAccountPayableTextBlock" xlink:to="iinn_ScheduleOfOtherAccountPayableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl0" xml:lang="en-US">Sales and Marketing Expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl0" xml:lang="en-US">Schedule of theoretical tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SensitivityAnalysis_lbl0" xml:lang="en-US">Sensitivity analysis.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SensitivityAnalysis" xlink:to="iinn_SensitivityAnalysis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationToExercise_lbl0" xml:lang="en-US">The shares of share based compensation to exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationToExercise" xlink:to="iinn_ShareBasedCompensationToExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationUnderwritersFees_lbl0" xml:lang="en-US">Share based compensation &#8211; underwriters fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationUnderwritersFees" xlink:to="iinn_ShareBasedCompensationUnderwritersFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedPaymentEmployeesAndDirectors_lbl0" xml:lang="en-US">Share based payment - employees and directors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentEmployeesAndDirectors" xlink:to="iinn_ShareBasedPaymentEmployeesAndDirectors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedPaymentExpenses_lbl0" xml:lang="en-US">Share based payment expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentExpenses" xlink:to="iinn_ShareBasedPaymentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedPayments_lbl0" xml:lang="en-US">Share based payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPayments" xlink:to="iinn_ShareBasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareIssuanceOfInitialPublicOffering_lbl0" xml:lang="en-US">The shares of initial public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareIssuanceOfInitialPublicOffering" xlink:to="iinn_ShareIssuanceOfInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareSplit_lbl0" xml:lang="en-US">The amount of share split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareSplit" xlink:to="iinn_ShareSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock_lbl0" xml:lang="en-US">Shareholders and other related parties&#8217; benefits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock" xlink:to="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SoldOrdinaryShares_lbl0" xml:lang="en-US">Sold ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SoldOrdinaryShares" xlink:to="iinn_SoldOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit_lbl1" xml:lang="en-US">Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit" xlink:to="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits_lbl0" xml:lang="en-US">The amount of restricted stock units under share based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits" xlink:to="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_StockholdersEquityReverseSplit_lbl0" xml:lang="en-US">Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockholdersEquityReverseSplit" xlink:to="iinn_StockholdersEquityReverseSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl0" xml:lang="en-US">Temporary differences and tax losses for which no Deferred Tax Asset is recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate_lbl0" xml:lang="en-US">Theoretical tax credit at applicable statutory rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate" xlink:to="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TotalAmountRecognizedInProfitOrLoss_lbl0" xml:lang="en-US">Total amount recognized in profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalAmountRecognizedInProfitOrLoss" xlink:to="iinn_TotalAmountRecognizedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TotalComprehensiveLoss_lbl0" xml:lang="en-US">Total comprehensive loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalComprehensiveLoss" xlink:to="iinn_TotalComprehensiveLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TotalExpenses_lbl0" xml:lang="en-US">The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the &apos;function of expense&apos; form for its analysis of expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalExpenses" xlink:to="iinn_TotalExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TotalFinancialLiabilities_lbl0" xml:lang="en-US">Total financial liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalFinancialLiabilities" xlink:to="iinn_TotalFinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TotalIncome_lbl0" xml:lang="en-US">The amount of operating income that the entity does not separately disclose in the same statement or note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalIncome" xlink:to="iinn_TotalIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TotalNonCashTransactions_lbl0" xml:lang="en-US">Total non cash transactions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalNonCashTransactions" xlink:to="iinn_TotalNonCashTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TotalOrdinaryShares_lbl0" xml:lang="en-US">Number of total ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalOrdinaryShares" xlink:to="iinn_TotalOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TotalProceedsReceived_lbl0" xml:lang="en-US">Total proceeds received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalProceedsReceived" xlink:to="iinn_TotalProceedsReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TradableWarrants_lbl0" xml:lang="en-US">Tradable warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrants" xlink:to="iinn_TradableWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TradableWarrantsDerivativeLiability_lbl0" xml:lang="en-US">Tradable warrants derivative - Liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsDerivativeLiability" xlink:to="iinn_TradableWarrantsDerivativeLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TradableWarrantsDescription_lbl0" xml:lang="en-US">Tradable warrants, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsDescription" xlink:to="iinn_TradableWarrantsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TradableWarrantsExercise_lbl0" xml:lang="en-US">Tradable warrants exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsExercise" xlink:to="iinn_TradableWarrantsExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TradableWarrantsExerciseinShares_lbl0" xml:lang="en-US">The shares of tradable warrants exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsExerciseinShares" xlink:to="iinn_TradableWarrantsExerciseinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TradableWarrantsFairValue_lbl0" xml:lang="en-US">Tradable warrants fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsFairValue" xlink:to="iinn_TradableWarrantsFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TradableWarrantsLiability_lbl0" xml:lang="en-US">Tradable warrants - liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsLiability" xlink:to="iinn_TradableWarrantsLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TradableWarrantsShares_lbl0" xml:lang="en-US">Tradable warrants shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsShares" xlink:to="iinn_TradableWarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for use of estimates and assumptions in the preparation of the financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock" xlink:to="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_WarrantsExerciseLiabilityIssuance_lbl0" xml:lang="en-US">Warrants exercise &#8211; liability issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsExerciseLiabilityIssuance" xlink:to="iinn_WarrantsExerciseLiabilityIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_WarrantsPursuantShares_lbl0" xml:lang="en-US">Warrants pursuant shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsPursuantShares" xlink:to="iinn_WarrantsPursuantShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_WarrantsShares_lbl1" xml:lang="en-US">Number of warrants shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsShares" xlink:to="iinn_WarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_leaseTerms_lbl0" xml:lang="en-US">Lease terms.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_leaseTerms" xlink:to="iinn_leaseTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_strengtheningPercentage_lbl0" xml:lang="en-US">Strengthening percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_strengtheningPercentage" xlink:to="iinn_strengtheningPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_tradableWarrants_lbl0" xml:lang="en-US">Tradable warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_tradableWarrants" xlink:to="iinn_tradableWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_weakeningPercentage_lbl0" xml:lang="en-US">Weakening percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_weakeningPercentage" xlink:to="iinn_weakeningPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US">Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ResearchAndDevelopmentExpenses" xlink:to="iinn_ResearchAndDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ReceiptOfIPOFunds_lbl1" xml:lang="en-US">Receipt Of IPOFunds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReceiptOfIPOFunds" xlink:to="iinn_ReceiptOfIPOFunds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialLiabilityToPay_lbl1" xml:lang="en-US">Financial Liability To Pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialLiabilityToPay" xlink:to="iinn_FinancialLiabilityToPay_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl0" xml:lang="en-US">Fee and commission expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DirectorsMember_lbl0" xml:lang="en-US">Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DirectorsMember" xlink:to="iinn_DirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NetBookValue_lbl0" xml:lang="en-US">Net Book Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValue" xlink:to="iinn_NetBookValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_VestOverPeriod_lbl0" xml:lang="en-US">Vest Over Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_VestOverPeriod" xlink:to="iinn_VestOverPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AUDMember_lbl0" xml:lang="en-US">AUDMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AUDMember" xlink:to="iinn_AUDMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfProfitOrLossAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfProfitOrLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfProfitOrLossAbstract_lbl" xml:lang="en-US">Schedule Of Profit Or Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfProfitOrLossAbstract" xlink:to="iinn_ScheduleOfProfitOrLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0" xml:lang="en-US">Cash flows from (used in) decrease (increase) in short-term deposits and investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsInvestmentProperty_lbl0" xml:lang="en-US">Disposals, investment property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsInvestmentProperty" xlink:to="ifrs-full_DisposalsInvestmentProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_fairValueMeasurementAtLevel2Member_lbl0" xml:lang="en-US">fair Value Measurement At Level2 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_fairValueMeasurementAtLevel2Member" xlink:to="iinn_fairValueMeasurementAtLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UpTo1YearMember_lbl0" xml:lang="en-US">Up To1 Year Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UpTo1YearMember" xlink:to="iinn_UpTo1YearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TotalIncome_lbl1" xml:lang="en-US">Total Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalIncome" xlink:to="iinn_TotalIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PoundMember_lbl0" xml:lang="en-US">Pound Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PoundMember" xlink:to="iinn_PoundMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Institutions_lbl1" xml:lang="en-US">Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Institutions" xlink:to="iinn_Institutions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinancialExpenses_lbl0" xml:lang="en-US">Schedule Of Financial Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialExpenses" xlink:to="iinn_ScheduleOfFinancialExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl0" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SalesAndMarketingExpensesTextBlock_lbl1" xml:lang="en-US">Sales And Marketing Expenses Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesTextBlock" xlink:to="iinn_SalesAndMarketingExpensesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_BalanceAtBeginning_lbl0" xml:lang="en-US">Balance At Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BalanceAtBeginning" xlink:to="iinn_BalanceAtBeginning_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ConvertibleLoanMember_lbl0" xml:lang="en-US">Convertible Loan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConvertibleLoanMember" xlink:to="iinn_ConvertibleLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AdditionalOfferingCosts_lbl1" xml:lang="en-US">Additional Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOfferingCosts" xlink:to="iinn_AdditionalOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained earnings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits_lbl1" xml:lang="en-US">Stock Issued During Period Value Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits" xlink:to="iinn_StockIssuedDuringPeriodValueRestrictedStockUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SensitivityAnalysis_lbl1" xml:lang="en-US">Sensitivity Analysis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SensitivityAnalysis" xlink:to="iinn_SensitivityAnalysis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RestrictedStockUnitVested_lbl2" xml:lang="en-US">Restricted Stock Unit Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnitVested" xlink:to="iinn_RestrictedStockUnitVested_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_BoardOfDirectorsDescription_lbl1" xml:lang="en-US">Board Of Directors Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BoardOfDirectorsDescription" xlink:to="iinn_BoardOfDirectorsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PrincipalPayment_lbl0" xml:lang="en-US">Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrincipalPayment" xlink:to="iinn_PrincipalPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesDuringThePeriodAbstract_lbl0" xml:lang="en-US">Changes During The Period Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ChangesDuringThePeriodAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AuthorizedOrdinaryShares_lbl0" xml:lang="en-US">Authorized Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AuthorizedOrdinaryShares" xlink:to="iinn_AuthorizedOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OptionsExercise_lbl1" xml:lang="en-US">Options Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OptionsExercise" xlink:to="iinn_OptionsExercise_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory_lbl0" xml:lang="en-US">Disclosure of general hedge accounting [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_lbl0" xml:lang="en-US">Current receivables due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregateProceedsAmount_lbl0" xml:lang="en-US">Aggregate Proceeds Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateProceedsAmount" xlink:to="iinn_AggregateProceedsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Amortisation, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfStraightLineBasisOverTheUsefulLivesOfTheAssetsAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfStraightLineBasisOverTheUsefulLivesOfTheAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfStraightLineBasisOverTheUsefulLivesOfTheAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Straight Line Basis Over The Useful Lives Of The Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfStraightLineBasisOverTheUsefulLivesOfTheAssetsAbstract" xlink:to="iinn_ScheduleOfStraightLineBasisOverTheUsefulLivesOfTheAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl1" xml:lang="en-US">Basic earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ProceedFromIssuanceInitialPublicOffering_lbl1" xml:lang="en-US">Proceed From Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProceedFromIssuanceInitialPublicOffering" xlink:to="iinn_ProceedFromIssuanceInitialPublicOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Property And Equipment Net Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock" xlink:to="iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NetBookValueAbstract_lbl0" xml:lang="en-US">Net Book Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract" xlink:to="iinn_NetBookValueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_BrokersMember_lbl0" xml:lang="en-US">Brokers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BrokersMember" xlink:to="iinn_BrokersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionalPaidinCapitalMember_lbl0" xml:lang="en-US">Additional paid-in capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalPaidinCapitalMember" xlink:to="ifrs-full_AdditionalPaidinCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Other inflows (outflows) of cash, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NontradableShares_lbl1" xml:lang="en-US">Nontradable Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableShares" xlink:to="iinn_NontradableShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl0" xml:lang="en-US">Interest expense on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLossPerShareAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLossPerShareAbstract" xlink:to="iinn_ScheduleOfLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract18" xlink:to="iinn_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract16" xlink:to="iinn_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OverallotmentOptionMember_lbl0" xml:lang="en-US">Overallotment Option Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OverallotmentOptionMember" xlink:to="iinn_OverallotmentOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract17" xlink:to="iinn_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue_lbl1" xml:lang="en-US">Change In Fair Value Of Financial Liabilities At Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue" xlink:to="iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0" xml:lang="en-US">Disclosure of classes of share capital [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfShareCapitalAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfShareCapitalAbstract_lbl" xml:lang="en-US">Schedule Of Share Capital Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfShareCapitalAbstract" xlink:to="iinn_ScheduleOfShareCapitalAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TradableWarrantsDerivativeLiability_lbl1" xml:lang="en-US">Tradable Warrants Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsDerivativeLiability" xlink:to="iinn_TradableWarrantsDerivativeLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Interest paid, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl0" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Profit (loss), attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CarriedForwardTaxLosse_lbl1" xml:lang="en-US">Carried Forward Tax Losse</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CarriedForwardTaxLosse" xlink:to="iinn_CarriedForwardTaxLosse_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AccumulatedDepreciation_lbl1" xml:lang="en-US">Accumulated Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccumulatedDepreciation" xlink:to="iinn_AccumulatedDepreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Date of grant of share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CapitalGainTax_lbl1" xml:lang="en-US">Capital Gain Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CapitalGainTax" xlink:to="iinn_CapitalGainTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestIncomeOnDeposits_lbl0" xml:lang="en-US">Interest income on deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnDeposits" xlink:to="ifrs-full_InterestIncomeOnDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_WarrantsPursuantShares_lbl1" xml:lang="en-US">Warrants Pursuant Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsPursuantShares" xlink:to="iinn_WarrantsPursuantShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisableOptionsNumberOfOptions_lbl0" xml:lang="en-US">Exercisable Options Number Of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisableOptionsNumberOfOptions" xlink:to="iinn_ExercisableOptionsNumberOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TravelExpense_lbl0" xml:lang="en-US">Travel expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TravelExpense" xlink:to="ifrs-full_TravelExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems_lbl0" xml:lang="en-US">Other adjustments for non-cash items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Non-current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseByNature_lbl0" xml:lang="en-US">Expenses, by nature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_ExpenseByNature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl0" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AdditionalOrdinaryShare_lbl1" xml:lang="en-US">Additional Ordinary Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOrdinaryShare" xlink:to="iinn_AdditionalOrdinaryShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationToExercise_lbl1" xml:lang="en-US">Share Based Compensation To Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationToExercise" xlink:to="iinn_ShareBasedCompensationToExercise_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CostAbstract0_lbl0" xml:lang="en-US">Cost Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CostAbstract0" xlink:to="iinn_CostAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DepreciationExpenses_lbl0" xml:lang="en-US">Depreciation Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DepreciationExpenses" xlink:to="iinn_DepreciationExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_WarrantsToInvestorsMember_lbl0" xml:lang="en-US">Warrants To Investors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToInvestorsMember" xlink:to="iinn_WarrantsToInvestorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RestrictedShareUnitsPolicyTextBlock_lbl1" xml:lang="en-US">Restricted Share Units Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedShareUnitsPolicyTextBlock" xlink:to="iinn_RestrictedShareUnitsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_lbl0" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0" xml:lang="en-US">Expected dividend as percentage, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl0" xml:lang="en-US">Disclosure of significant accounting policies [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of finance income (cost) [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl0" xml:lang="en-US">Gross lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossLeaseLiabilities" xlink:to="ifrs-full_GrossLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPaymentExpenses_lbl1" xml:lang="en-US">Share Based Payment Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentExpenses" xlink:to="iinn_ShareBasedPaymentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl0" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl0" xml:lang="en-US">Other reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl0" xml:lang="en-US">Par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Sales And Marketing Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercised Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisedWeightedAverageExercisePrice" xlink:to="iinn_ExercisedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareIssuanceOfInitialPublicOffering_lbl1" xml:lang="en-US">Share Issuance Of Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareIssuanceOfInitialPublicOffering" xlink:to="iinn_ShareIssuanceOfInitialPublicOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentPayables_lbl0" xml:lang="en-US">Other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl0" xml:lang="en-US">Expense from share-based payment transactions with employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TotalProceedsReceived_lbl1" xml:lang="en-US">Total Proceeds Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalProceedsReceived" xlink:to="iinn_TotalProceedsReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GrantOptionDescription_lbl1" xml:lang="en-US">Grant Option Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrantOptionDescription" xlink:to="iinn_GrantOptionDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGovernmentGrantsExplanatory_lbl0" xml:lang="en-US">Disclosure of government grants [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:to="ifrs-full_DisclosureOfGovernmentGrantsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions_lbl0" xml:lang="en-US">Additional provisions, other provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ItemsThatWillNotBeReclassifiedToProfitOrLossAbstract_lbl0" xml:lang="en-US">Items That Will Not Be Reclassified To Profit Or Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ItemsThatWillNotBeReclassifiedToProfitOrLossAbstract" xlink:to="iinn_ItemsThatWillNotBeReclassifiedToProfitOrLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract10" xlink:to="iinn_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of other non-current assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract11" xlink:to="iinn_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract14" xlink:to="iinn_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract15" xlink:to="iinn_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract12" xlink:to="iinn_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract13" xlink:to="iinn_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficeBuildingMember_lbl0" xml:lang="en-US">Office Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficeBuildingMember" xlink:to="srt_OfficeBuildingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxAssets_lbl0" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Exercise price of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for segment reporting [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialExpensesMember_lbl0" xml:lang="en-US">Financial Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialExpensesMember" xlink:to="iinn_FinancialExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NumberOfShares_lbl1" xml:lang="en-US">Number Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberOfShares" xlink:to="iinn_NumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExchangeAmount_lbl1" xml:lang="en-US">Exchange Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeAmount" xlink:to="iinn_ExchangeAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PaidFeesAmount_lbl0" xml:lang="en-US">Paid Fees Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PaidFeesAmount" xlink:to="iinn_PaidFeesAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Rsus To Services Providers And Advisers Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants_lbl0" xml:lang="en-US">Revaluation Of Liability In Respect Of Government Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants" xlink:to="iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock_lbl1" xml:lang="en-US">Use Of Estimates And Assumptions In Preparation Of Financial Statements Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock" xlink:to="iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan_lbl0" xml:lang="en-US">Receipt Of Simple Agreements For Future Equity SAFEAnd Convertible Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" xlink:to="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AdditionalOrdinaryShares_lbl1" xml:lang="en-US">Additional Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOrdinaryShares" xlink:to="iinn_AdditionalOrdinaryShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_StatementsOfChangesInShareholdersEquityAbstract" xlink:href="iinn-20221231.xsd#iinn_StatementsOfChangesInShareholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StatementsOfChangesInShareholdersEquityAbstract_lbl" xml:lang="en-US">Statements Of Changes In Shareholders Equity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StatementsOfChangesInShareholdersEquityAbstract" xlink:to="iinn_StatementsOfChangesInShareholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TradableWarrantsExerciseinShares_lbl1" xml:lang="en-US">Tradable Warrants Exercisein Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsExerciseinShares" xlink:to="iinn_TradableWarrantsExerciseinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PublicOfferingPriceDescription_lbl1" xml:lang="en-US">Public Offering Price Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PublicOfferingPriceDescription" xlink:to="iinn_PublicOfferingPriceDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl0" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract2" xlink:to="iinn_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract1" xlink:to="iinn_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract4" xlink:to="iinn_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract3" xlink:to="iinn_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl0" xml:lang="en-US">Non-current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract0" xlink:to="iinn_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl0" xml:lang="en-US">Description of accounting policy for determining components of cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract9" xlink:to="iinn_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Increase (decrease) through transfers from construction in progress, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract6" xlink:to="iinn_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract5" xlink:to="iinn_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareSplit_lbl1" xml:lang="en-US">Share Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareSplit" xlink:to="iinn_ShareSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract8" xlink:to="iinn_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract7" xlink:to="iinn_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OrdinaryShares_lbl2" xml:lang="en-US">Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinaryShares" xlink:to="iinn_OrdinaryShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Current trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinanceExpense_lbl1" xml:lang="en-US">Finance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceExpense" xlink:to="iinn_FinanceExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_MoreThan3YearsMember_lbl0" xml:lang="en-US">More Than3 Years Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MoreThan3YearsMember" xlink:to="iinn_MoreThan3YearsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability_lbl0" xml:lang="en-US">Accumulated increase (decrease) in fair value of financial liability, attributable to changes in credit risk of liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:to="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ResearchDevelopmentExpenses_lbl0" xml:lang="en-US">Research Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ResearchDevelopmentExpenses" xlink:to="iinn_ResearchDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OptionsPolicyTextBlock_lbl1" xml:lang="en-US">Options Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OptionsPolicyTextBlock" xlink:to="iinn_OptionsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany_lbl0" xml:lang="en-US">Nature Of Transaction Compensation For Directors Not Employed By The Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany" xlink:to="iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Deposit_lbl1" xml:lang="en-US">Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Deposit" xlink:to="iinn_Deposit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExchangeRateDeferenceAccumulatedDepreciation_lbl1" xml:lang="en-US">Exchange Rate Deference Accumulated Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeRateDeferenceAccumulatedDepreciation" xlink:to="iinn_ExchangeRateDeferenceAccumulatedDepreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SalaryAndRelatedExpenses_lbl0" xml:lang="en-US">Salary And Related Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalaryAndRelatedExpenses" xlink:to="iinn_SalaryAndRelatedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Sales And Marketing Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_USDMemberMember_lbl0" xml:lang="en-US">USDMember Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_USDMemberMember" xlink:to="iinn_USDMemberMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CashAndNoncash_lbl1" xml:lang="en-US">Cash And Noncash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CashAndNoncash" xlink:to="iinn_CashAndNoncash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_lbl0" xml:lang="en-US">Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_weakeningPercentage_lbl1" xml:lang="en-US">weakening Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_weakeningPercentage" xlink:to="iinn_weakeningPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Between1And3YearsMember_lbl0" xml:lang="en-US">Between1 And3 Years Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Between1And3YearsMember" xlink:to="iinn_Between1And3YearsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Granted_lbl0" xml:lang="en-US">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Granted" xlink:to="iinn_Granted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_WarrantsToBrokersMember_lbl0" xml:lang="en-US">Warrants To Brokers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToBrokersMember" xlink:to="iinn_WarrantsToBrokersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors_lbl1" xml:lang="en-US">Expense From Sharebased Payment Transactions With Employeesand Directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors" xlink:to="iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract" xlink:to="iinn_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TradableWarrantsMember_lbl0" xml:lang="en-US">Tradable Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsMember" xlink:to="iinn_TradableWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TradableWarrantsShares_lbl1" xml:lang="en-US">Tradable Warrants Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsShares" xlink:to="iinn_TradableWarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_BalanceAtEnding_lbl0" xml:lang="en-US">Balance At Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BalanceAtEnding" xlink:to="iinn_BalanceAtEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract_lbl" xml:lang="en-US">Schedule Of Shareholders And Other Related Parties Benefits Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:to="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_VehiclesMember_lbl0" xml:lang="en-US">Vehicles [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_VehiclesMember" xlink:to="ifrs-full_VehiclesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl2" xml:lang="en-US">Number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregateProceedsReceived_lbl1" xml:lang="en-US">Aggregate Proceeds Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateProceedsReceived" xlink:to="iinn_AggregateProceedsReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NontradableWarrantFairValue_lbl2" xml:lang="en-US">Nontradable Warrant Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrantFairValue" xlink:to="iinn_NontradableWarrantFairValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DevelopmentEquipmentMember_lbl0" xml:lang="en-US">Development Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DevelopmentEquipmentMember" xlink:to="iinn_DevelopmentEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl0" xml:lang="en-US">Proceeds from issue of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors_lbl1" xml:lang="en-US">Nontradable Warrants Of SAFEAnd Convertible Loan Investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" xlink:to="iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl0" xml:lang="en-US">Current prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NetBookValueAbstract0_lbl0" xml:lang="en-US">Net Book Value Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract0" xlink:to="iinn_NetBookValueAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TradableWarrantsDescription_lbl1" xml:lang="en-US">Tradable Warrants Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsDescription" xlink:to="iinn_TradableWarrantsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfOtherAccountPayableTextBlock_lbl1" xml:lang="en-US">Schedule Of Other Account Payable Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfOtherAccountPayableTextBlock" xlink:to="iinn_ScheduleOfOtherAccountPayableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregateProceeds_lbl1" xml:lang="en-US">Aggregate Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateProceeds" xlink:to="iinn_AggregateProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Addition_lbl0" xml:lang="en-US">Addition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Addition" xlink:to="iinn_Addition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialLiabilityMember_lbl0" xml:lang="en-US">Financial Liability Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialLiabilityMember" xlink:to="iinn_FinancialLiabilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl1" xml:lang="en-US">Gains (losses) on exchange differences on translation of foreign operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GainslossesRecognizedInProfitLoss_lbl0" xml:lang="en-US">Gainslosses Recognized In Profit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GainslossesRecognizedInProfitLoss" xlink:to="iinn_GainslossesRecognizedInProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl0" xml:lang="en-US">Key management personnel compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_leaseTerms_lbl1" xml:lang="en-US">lease Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_leaseTerms" xlink:to="iinn_leaseTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationUnderwritersFees_lbl1" xml:lang="en-US">Share Based Compensation Underwriters Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationUnderwritersFees" xlink:to="iinn_ShareBasedCompensationUnderwritersFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NatureOfTransactionSalariesAndRelated_lbl0" xml:lang="en-US">Nature Of Transaction Salaries And Related</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NatureOfTransactionSalariesAndRelated" xlink:to="iinn_NatureOfTransactionSalariesAndRelated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NontradableWarrantsMember_lbl0" xml:lang="en-US">Nontradable Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrantsMember" xlink:to="iinn_NontradableWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Reclassified To Employees And Directors Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice" xlink:to="iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExpectedTermOfWarrants_lbl1" xml:lang="en-US">Expected Term Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpectedTermOfWarrants" xlink:to="iinn_ExpectedTermOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OthersCurrentAssets_lbl1" xml:lang="en-US">Others Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OthersCurrentAssets" xlink:to="iinn_OthersCurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority_lbl1" xml:lang="en-US">Revaluation Of Loan From The Israeli Innovation Authority</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority" xlink:to="iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GrossProceeds_lbl1" xml:lang="en-US">Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrossProceeds" xlink:to="iinn_GrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OperatingLeaseIncome_lbl0" xml:lang="en-US">Operating lease income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingLeaseIncome" xlink:to="ifrs-full_OperatingLeaseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreditRiskMember_lbl0" xml:lang="en-US">Credit risk [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfMovementsInLevel2LiabilityAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfMovementsInLevel2LiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfMovementsInLevel2LiabilityAbstract_lbl" xml:lang="en-US">Schedule Of Movements In Level2 Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfMovementsInLevel2LiabilityAbstract" xlink:to="iinn_ScheduleOfMovementsInLevel2LiabilityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_tradableWarrants_lbl1" xml:lang="en-US">tradable Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_tradableWarrants" xlink:to="iinn_tradableWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl0" xml:lang="en-US">Equity [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeductingFees_lbl1" xml:lang="en-US">Deducting Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeductingFees" xlink:to="iinn_DeductingFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl1" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TotalAmountRecognizedInProfitOrLoss_lbl1" xml:lang="en-US">Total Amount Recognized In Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalAmountRecognizedInProfitOrLoss" xlink:to="iinn_TotalAmountRecognizedInProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AccumulatedDepreciationAbstract0_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccumulatedDepreciationAbstract0" xlink:to="iinn_AccumulatedDepreciationAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GrantTotalShares_lbl0" xml:lang="en-US">Grant Total Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrantTotalShares" xlink:to="iinn_GrantTotalShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentAssets_lbl1" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability_lbl0" xml:lang="en-US">Schedule Of Foreign Currency Denominated Monetary Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability" xlink:to="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialIncomeAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinancialIncomeAbstract_lbl" xml:lang="en-US">Schedule Of Financial Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialIncomeAbstract" xlink:to="iinn_ScheduleOfFinancialIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfRightOfUseAssetsAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfRightOfUseAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfRightOfUseAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Right Of Use Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfRightOfUseAssetsAbstract" xlink:to="iinn_ScheduleOfRightOfUseAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments_lbl0" xml:lang="en-US">Increase (decrease) in fair value measurement, entity&apos;s own equity instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments" xlink:to="ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeferredTaxAssetS_lbl1" xml:lang="en-US">Deferred Tax Asset S</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetS" xlink:to="iinn_DeferredTaxAssetS_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayables_lbl0" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfCashFlowsOfFinancialLiabilitiesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfCashFlowsOfFinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfCashFlowsOfFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Cash Flows Of Financial Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfCashFlowsOfFinancialLiabilitiesAbstract" xlink:to="iinn_ScheduleOfCashFlowsOfFinancialLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 1 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FurnitureAndOfficeEquipmentMember_lbl0" xml:lang="en-US">Furniture And Office Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FurnitureAndOfficeEquipmentMember" xlink:to="iinn_FurnitureAndOfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ConversionToShares_lbl1" xml:lang="en-US">Conversion To Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionToShares" xlink:to="iinn_ConversionToShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems_lbl0" xml:lang="en-US">Taxeson Income Details Scheduleoftheoreticaltax Parentheticals Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems" xlink:to="iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EmployeesAndDirectorsMember_lbl0" xml:lang="en-US">Employees And Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesAndDirectorsMember" xlink:to="iinn_EmployeesAndDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ForeignCurrencyTransactionLossNet_lbl1" xml:lang="en-US">Foreign Currency Transaction Loss Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ForeignCurrencyTransactionLossNet" xlink:to="iinn_ForeignCurrencyTransactionLossNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl0" xml:lang="en-US">Derivative financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativeFinancialLiabilities" xlink:to="ifrs-full_DerivativeFinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtFairValue_lbl0" xml:lang="en-US">Financial assets, at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValue" xlink:to="ifrs-full_FinancialAssetsAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExchangeRateDifferences_lbl0" xml:lang="en-US">Exchange Rate Differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeRateDifferences" xlink:to="iinn_ExchangeRateDifferences_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfSensitivityAnalysis_lbl0" xml:lang="en-US">Schedule Of Sensitivity Analysis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSensitivityAnalysis" xlink:to="iinn_ScheduleOfSensitivityAnalysis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DividendsPaidClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Dividends paid, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_DividendsPaidClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl0" xml:lang="en-US">Expense relating to leases of low-value assets for which recognition exemption has been used</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl1" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureAbstract_lbl" xml:lang="en-US">Schedule Of Financial Assets Represents The Maximum Credit Exposure Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureAbstract" xlink:to="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl0" xml:lang="en-US">Proceeds from exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Forfeited_lbl1" xml:lang="en-US">Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Forfeited" xlink:to="iinn_Forfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfRightofuseAssets_lbl0" xml:lang="en-US">Schedule Of Rightofuse Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfRightofuseAssets" xlink:to="iinn_ScheduleOfRightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LossBeforeTaxation_lbl1" xml:lang="en-US">Loss Before Taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LossBeforeTaxation" xlink:to="iinn_LossBeforeTaxation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfProfitOrLoss_lbl0" xml:lang="en-US">Schedule Of Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfProfitOrLoss" xlink:to="iinn_ScheduleOfProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl0" xml:lang="en-US">Tax expense (income) at applicable tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentalExpense_lbl0" xml:lang="en-US">Rental expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ConversionOfFinancialLiabilityinShares_lbl1" xml:lang="en-US">Conversion Of Financial Liabilityin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionOfFinancialLiabilityinShares" xlink:to="iinn_ConversionOfFinancialLiabilityinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding_lbl0" xml:lang="en-US">Schedule Of Restricted Shares Units To Employees And Directors Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding" xlink:to="iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl2" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl1" xml:lang="en-US">Property, plant and equipment, revalued assets, at cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl0" xml:lang="en-US">Profit (loss) before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AuthorizedShareCapital_lbl1" xml:lang="en-US">Authorized Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AuthorizedShareCapital" xlink:to="iinn_AuthorizedShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AdjustmentsArisingFromTranslatingFinancialOperations_lbl0" xml:lang="en-US">Adjustments Arising From Translating Financial Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdjustmentsArisingFromTranslatingFinancialOperations" xlink:to="iinn_AdjustmentsArisingFromTranslatingFinancialOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_VestingPeriod_lbl0" xml:lang="en-US">Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_VestingPeriod" xlink:to="iinn_VestingPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExchangeRateDifference_lbl1" xml:lang="en-US">Exchange Rate Difference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeRateDifference" xlink:to="iinn_ExchangeRateDifference_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure_lbl0" xml:lang="en-US">Schedule Of Financial Assets Represents The Maximum Credit Exposure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure" xlink:to="iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinanceExpenseInRespectOfLeaseLiability_lbl0" xml:lang="en-US">Finance Expense In Respect Of Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceExpenseInRespectOfLeaseLiability" xlink:to="iinn_FinanceExpenseInRespectOfLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract_lbl" xml:lang="en-US">Schedule Of Theoretical Tax Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="iinn_ScheduleOfTheoreticalTaxAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PayRoyaltiesPercentage_lbl1" xml:lang="en-US">Pay Royalties Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PayRoyaltiesPercentage" xlink:to="iinn_PayRoyaltiesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherExpenseByNature_lbl1" xml:lang="en-US">Other expenses, by nature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SalesAndMarketingExpenses_lbl1" xml:lang="en-US">Sales And Marketing Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpenses" xlink:to="iinn_SalesAndMarketingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NondirectCashExpenses_lbl1" xml:lang="en-US">Nondirect Cash Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NondirectCashExpenses" xlink:to="iinn_NondirectCashExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 3 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesDuringThePeriodAbstract1_lbl0" xml:lang="en-US">Changes During The Period Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="iinn_ChangesDuringThePeriodAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 2 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl0" xml:lang="en-US">Description of accounting policy for government grants [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TotalOrdinaryShares_lbl1" xml:lang="en-US">Total Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalOrdinaryShares" xlink:to="iinn_TotalOrdinaryShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSensitivityAnalysisAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfSensitivityAnalysisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfSensitivityAnalysisAbstract_lbl" xml:lang="en-US">Schedule Of Sensitivity Analysis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSensitivityAnalysisAbstract" xlink:to="iinn_ScheduleOfSensitivityAnalysisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialDerivativesFairValue_lbl1" xml:lang="en-US">Financial Derivatives Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialDerivativesFairValue" xlink:to="iinn_FinancialDerivativesFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidRefund_lbl0" xml:lang="en-US">Income taxes paid (refund)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefund" xlink:to="ifrs-full_IncomeTaxesPaidRefund_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ContractualLife_lbl1" xml:lang="en-US">Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ContractualLife" xlink:to="iinn_ContractualLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Depreciation Is Calculated On AStraight Line Basis Over The Useful Lives Of The Assets At Annual Rates Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock" xlink:to="iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for deferred income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of financial liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl0" xml:lang="en-US">Adjustments for fair value losses (gains)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ForfeitedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Forfeited Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ForfeitedWeightedAverageExercisePrice" xlink:to="iinn_ForfeitedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of general and administrative expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OrdinaryShare_lbl1" xml:lang="en-US">Ordinary Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinaryShare" xlink:to="iinn_OrdinaryShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDepositsFromBanksExplanatory_lbl0" xml:lang="en-US">Disclosure of deposits from banks [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDepositsFromBanksExplanatory" xlink:to="ifrs-full_DisclosureOfDepositsFromBanksExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits_lbl1" xml:lang="en-US">Antidilutive Potentially Dilutive Securities After The Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits" xlink:to="iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl0" xml:lang="en-US">Finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock_lbl1" xml:lang="en-US">Shareholders And Other Related Parties Benefits Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock" xlink:to="iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AdvisersMember_lbl0" xml:lang="en-US">Advisers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdvisersMember" xlink:to="iinn_AdvisersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EmployeesSalariesAndRelatedLiabilities_lbl1" xml:lang="en-US">Employees Salaries And Related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesSalariesAndRelatedLiabilities" xlink:to="iinn_EmployeesSalariesAndRelatedLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NontradableSharesOptions_lbl1" xml:lang="en-US">Nontradable Shares Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableSharesOptions" xlink:to="iinn_NontradableSharesOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl0" xml:lang="en-US">Issued capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl0" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinancialExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Financial Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialExpensesAbstract" xlink:to="iinn_ScheduleOfFinancialExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ConversionOfConvertibleLoanToShares_lbl1" xml:lang="en-US">Conversion Of Convertible Loan To Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionOfConvertibleLoanToShares" xlink:to="iinn_ConversionOfConvertibleLoanToShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl0" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_WarrantsShares_lbl2" xml:lang="en-US">Warrants Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsShares" xlink:to="iinn_WarrantsShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentPayablesToRelatedParties_lbl0" xml:lang="en-US">Non-current payables to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPayablesToRelatedParties" xlink:to="ifrs-full_NoncurrentPayablesToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesDuringThePeriodAbstract0_lbl0" xml:lang="en-US">Changes During The Period Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract0" xlink:to="iinn_ChangesDuringThePeriodAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisedNumberOfOptions_lbl0" xml:lang="en-US">Exercised Number Of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisedNumberOfOptions" xlink:to="iinn_ExercisedNumberOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregateAmount_lbl1" xml:lang="en-US">Aggregate Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateAmount" xlink:to="iinn_AggregateAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CostAbstract_lbl0" xml:lang="en-US">Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CostAbstract" xlink:to="iinn_CostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialIncomeMember_lbl0" xml:lang="en-US">Financial Income Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialIncomeMember" xlink:to="iinn_FinancialIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for taxes other than income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseReceivablesMember_lbl0" xml:lang="en-US">Lease receivables [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseReceivablesMember" xlink:to="ifrs-full_LeaseReceivablesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl1" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_lbl0" xml:lang="en-US">Cash and cash equivalents if different from statement of financial position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_InvestmentNameAxis_lbl0" xml:lang="en-US">Investment Name Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InvestmentNameAxis" xlink:to="iinn_InvestmentNameAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_IIAParticipation_lbl0" xml:lang="en-US">IIAParticipation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IIAParticipation" xlink:to="iinn_IIAParticipation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl0" xml:lang="en-US">Short-term employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Subcontractors_lbl0" xml:lang="en-US">Subcontractors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Subcontractors" xlink:to="iinn_Subcontractors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Vested_lbl0" xml:lang="en-US">Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Vested" xlink:to="iinn_Vested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Balances With Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="iinn_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl0" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FairValueAssumptionsDescription_lbl1" xml:lang="en-US">Fair Value Assumptions Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueAssumptionsDescription" xlink:to="iinn_FairValueAssumptionsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl1" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_lbl2" xml:lang="en-US">Financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold improvements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfLeaseLiabilities_lbl0" xml:lang="en-US">Schedule Of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLeaseLiabilities" xlink:to="iinn_ScheduleOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TradableWarrantsExercise_lbl1" xml:lang="en-US">Tradable Warrants Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsExercise" xlink:to="iinn_TradableWarrantsExercise_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GeneralAndAdministrativeExpenses_lbl1" xml:lang="en-US">General And Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpenses" xlink:to="iinn_GeneralAndAdministrativeExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Depreciations_lbl1" xml:lang="en-US">Depreciations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Depreciations" xlink:to="iinn_Depreciations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_WarrantsExerciseLiabilityIssuance_lbl1" xml:lang="en-US">Warrants Exercise Liability Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsExerciseLiabilityIssuance" xlink:to="iinn_WarrantsExerciseLiabilityIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfLossPerShare_lbl0" xml:lang="en-US">Schedule Of Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLossPerShare" xlink:to="iinn_ScheduleOfLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ProvidersAndAdvisersMember_lbl0" xml:lang="en-US">Providers And Advisers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProvidersAndAdvisersMember" xlink:to="iinn_ProvidersAndAdvisersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NonallowableExpenses_lbl1" xml:lang="en-US">Nonallowable Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonallowableExpenses" xlink:to="iinn_NonallowableExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLeaseLiabilitiesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLeaseLiabilitiesAbstract" xlink:to="iinn_ScheduleOfLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_lbl1" xml:lang="en-US">Short-term deposits, not classified as cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinancialIncomeTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Financial Income Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialIncomeTableTextBlock" xlink:to="iinn_ScheduleOfFinancialIncomeTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialDerivativeMember_lbl0" xml:lang="en-US">Financial Derivative Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialDerivativeMember" xlink:to="iinn_FinancialDerivativeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InsuranceExpense_lbl0" xml:lang="en-US">Insurance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Movements In Level2 Liability Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock" xlink:to="iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl1" xml:lang="en-US">Number of shares authorised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OptionsEquity_lbl0" xml:lang="en-US">Options Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OptionsEquity" xlink:to="iinn_OptionsEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisableRSUs_lbl0" xml:lang="en-US">Exercisable RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisableRSUs" xlink:to="iinn_ExercisableRSUs_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Disposals, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentPayables_lbl0" xml:lang="en-US">Trade and other non-current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPayables" xlink:to="ifrs-full_NoncurrentPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl0" xml:lang="en-US">Additions to right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_InvestorsExercise_lbl0" xml:lang="en-US">Investors Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InvestorsExercise" xlink:to="iinn_InvestorsExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherGainsLosses_lbl0" xml:lang="en-US">Other gains (losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_OtherGainsLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Reimbursement Of Research Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock" xlink:to="iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements_lbl0" xml:lang="en-US">Explanation of measurement bases used in preparing financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" xlink:to="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl0" xml:lang="en-US">Depreciation and amortisation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0" xml:lang="en-US">Risk free interest rate, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TotalNonCashTransactions_lbl1" xml:lang="en-US">Total Non Cash Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalNonCashTransactions" xlink:to="iinn_TotalNonCashTransactions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPaymentEmployeesAndDirectors_lbl1" xml:lang="en-US">Share Based Payment Employees And Directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentEmployeesAndDirectors" xlink:to="iinn_ShareBasedPaymentEmployeesAndDirectors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit_lbl2" xml:lang="en-US">Stock Issued During Period Shares Restricted Stock Unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit" xlink:to="iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_InitialPublicOffering_lbl1" xml:lang="en-US">Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InitialPublicOffering" xlink:to="iinn_InitialPublicOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0" xml:lang="en-US">Disclosure of related party [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExpensesDeductedFromEquity_lbl1" xml:lang="en-US">Expenses Deducted From Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpensesDeductedFromEquity" xlink:to="iinn_ExpensesDeductedFromEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RevaluationOfTheLiability_lbl0" xml:lang="en-US">Revaluation Of The Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfTheLiability" xlink:to="iinn_RevaluationOfTheLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AnnualDepreciationRateInPercentage_lbl1" xml:lang="en-US">Annual Depreciation Rate In Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AnnualDepreciationRateInPercentage" xlink:to="iinn_AnnualDepreciationRateInPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PaymentOfDeposit_lbl1" xml:lang="en-US">Payment Of Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PaymentOfDeposit" xlink:to="iinn_PaymentOfDeposit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FairValueOfTheWarrant_lbl1" xml:lang="en-US">Fair Value Of The Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueOfTheWarrant" xlink:to="iinn_FairValueOfTheWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinancialAssets_lbl0" xml:lang="en-US">Other financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinancialAssets" xlink:to="ifrs-full_OtherFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NontradableWarrants_lbl1" xml:lang="en-US">Nontradable Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrants" xlink:to="iinn_NontradableWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl0" xml:lang="en-US">Disclosure of leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GrantTotal_lbl0" xml:lang="en-US">Grant Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrantTotal" xlink:to="iinn_GrantTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DepositValue_lbl1" xml:lang="en-US">Deposit Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DepositValue" xlink:to="iinn_DepositValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinancialLiabilities_lbl1" xml:lang="en-US">Schedule Of Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialLiabilities" xlink:to="iinn_ScheduleOfFinancialLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialExpense_lbl0" xml:lang="en-US">Financial Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialExpense" xlink:to="iinn_FinancialExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_strengtheningPercentage_lbl1" xml:lang="en-US">strengthening Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_strengtheningPercentage" xlink:to="iinn_strengtheningPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl0" xml:lang="en-US">Trade and other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherMaterialNoncashItems_lbl0" xml:lang="en-US">Other material non-cash items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherMaterialNoncashItems" xlink:to="ifrs-full_OtherMaterialNoncashItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl0" xml:lang="en-US">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_lbl0" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of equity [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LeaseholdImprovementMember_lbl0" xml:lang="en-US">Leasehold Improvement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeaseholdImprovementMember" xlink:to="iinn_LeaseholdImprovementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Equity and liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl0" xml:lang="en-US">Income from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TradableWarrants_lbl1" xml:lang="en-US">Tradable Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrants" xlink:to="iinn_TradableWarrants_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinacialLiabilitiesAtFairValueAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinacialLiabilitiesAtFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinacialLiabilitiesAtFairValueAbstract_lbl" xml:lang="en-US">Schedule Of Finacial Liabilities At Fair Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinacialLiabilitiesAtFairValueAbstract" xlink:to="iinn_ScheduleOfFinacialLiabilitiesAtFairValueAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPayments_lbl1" xml:lang="en-US">Share Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPayments" xlink:to="iinn_ShareBasedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NontradableWarrantsSAFEAndCLAMember_lbl0" xml:lang="en-US">Nontradable Warrants SAFEAnd CLAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NontradableWarrantsSAFEAndCLAMember" xlink:to="iinn_NontradableWarrantsSAFEAndCLAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RestrictedStockUnitEmployeesDescription_lbl1" xml:lang="en-US">Restricted Stock Unit Employees Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnitEmployeesDescription" xlink:to="iinn_RestrictedStockUnitEmployeesDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PlanAssetsAtFairValue_lbl0" xml:lang="en-US">Plan assets, at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PlanAssetsAtFairValue" xlink:to="ifrs-full_PlanAssetsAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GovernmentGrants_lbl1" xml:lang="en-US">Government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GovernmentGrants" xlink:to="ifrs-full_GovernmentGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AssetsAbstract0_lbl0" xml:lang="en-US">Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AssetsAbstract0" xlink:to="iinn_AssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_InitialPublicOfferingMember_lbl0" xml:lang="en-US">Initial Public Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InitialPublicOfferingMember" xlink:to="iinn_InitialPublicOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees_lbl1" xml:lang="en-US">Receipt Of Warrants Exercise Funds Net From Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees" xlink:to="iinn_ReceiptOfWarrantsExerciseFundsNetFromFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AccumulatedDepreciationAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccumulatedDepreciationAbstract" xlink:to="iinn_AccumulatedDepreciationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SAFEMember_lbl0" xml:lang="en-US">SAFEMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SAFEMember" xlink:to="iinn_SAFEMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_InvestorsExercisedTradableWarrants_lbl1" xml:lang="en-US">Investors Exercised Tradable Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InvestorsExercisedTradableWarrants" xlink:to="iinn_InvestorsExercisedTradableWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl0" xml:lang="en-US">Equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialExpenses_lbl1" xml:lang="en-US">Financial Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialExpenses" xlink:to="iinn_FinancialExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OutstandingAtBeginningOfYears_lbl2" xml:lang="en-US">Outstanding At Beginning Of Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OutstandingAtBeginningOfYears" xlink:to="iinn_OutstandingAtBeginningOfYears_lbl2"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfWarrantsAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfWarrantsAbstract_lbl" xml:lang="en-US">Schedule Of Warrants Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfWarrantsAbstract" xlink:to="iinn_ScheduleOfWarrantsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares_lbl0" xml:lang="en-US">Number Of Options Reclassified To Employees And Directorsin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares" xlink:to="iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl0" xml:lang="en-US">Borrowings, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EmployeesMember_lbl0" xml:lang="en-US">Employees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesMember" xlink:to="iinn_EmployeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate_lbl1" xml:lang="en-US">Theoretical Tax Credit At Applicable Statutory Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate" xlink:to="iinn_TheoreticalTaxCreditAtApplicableStatutoryRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SoldOrdinaryShares_lbl1" xml:lang="en-US">Sold Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SoldOrdinaryShares" xlink:to="iinn_SoldOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl0" xml:lang="en-US">Dilutive effect of share options on number of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl0" xml:lang="en-US">Professional fees expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ParValueCancellations_lbl1" xml:lang="en-US">Par Value Cancellations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ParValueCancellations" xlink:to="iinn_ParValueCancellations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl0" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfPaidFees_lbl1" xml:lang="en-US">Percentage Of Paid Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfPaidFees" xlink:to="iinn_PercentageOfPaidFees_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Options To Services Providers And Advisers Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfConvertibleInstruments_lbl0" xml:lang="en-US">Issue of convertible instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ifrs-full_IssueOfConvertibleInstruments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TradableWarrantsFairValue_lbl1" xml:lang="en-US">Tradable Warrants Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsFairValue" xlink:to="iinn_TradableWarrantsFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WagesAndSalaries_lbl0" xml:lang="en-US">Wages and salaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="iinn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl1" xml:lang="en-US">Temporary Differences And Tax Losses For Which No Deferred Tax Asset Is Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantLiability_lbl0" xml:lang="en-US">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RSUMember_lbl0" xml:lang="en-US">RSUMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RSUMember" xlink:to="iinn_RSUMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Research And Development Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:to="iinn_ScheduleOfResearchAndDevelopmentExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1" xml:lang="en-US">Tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpenses_lbl0" xml:lang="en-US">Schedule Of General And Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpenses" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl0" xml:lang="en-US">Other current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExchangeRateDeferenceCost_lbl1" xml:lang="en-US">Exchange Rate Deference Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExchangeRateDeferenceCost" xlink:to="iinn_ExchangeRateDeferenceCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl0" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GrantedTotalOption_lbl0" xml:lang="en-US">Granted Total Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrantedTotalOption" xlink:to="iinn_GrantedTotalOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of general information about financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregateOfOrdinaryShares_lbl1" xml:lang="en-US">Aggregate Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateOfOrdinaryShares" xlink:to="iinn_AggregateOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssets_lbl1" xml:lang="en-US">Financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl0" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl0" xml:lang="en-US">Profit (loss) from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl0" xml:lang="en-US">Other current financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TotalExpenses_lbl1" xml:lang="en-US">Total Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalExpenses" xlink:to="iinn_TotalExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OrdinarySharesIssued_lbl1" xml:lang="en-US">Ordinary Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesIssued" xlink:to="iinn_OrdinarySharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Theoretical Tax Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisableOrdinaryShares_lbl0" xml:lang="en-US">Exercisable Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisableOrdinaryShares" xlink:to="iinn_ExercisableOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ComputersMember_lbl0" xml:lang="en-US">Computers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ComputersMember" xlink:to="iinn_ComputersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OtherResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US">Other Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OtherResearchAndDevelopmentExpenses" xlink:to="iinn_OtherResearchAndDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentFinancialAssets_lbl0" xml:lang="en-US">Current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl0" xml:lang="en-US">Other tax effects for reconciliation between accounting profit and tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LeaseLiabilityAmount_lbl0" xml:lang="en-US">Lease Liability Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeaseLiabilityAmount" xlink:to="iinn_LeaseLiabilityAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_InvestorsMember_lbl0" xml:lang="en-US">Investors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_InvestorsMember" xlink:to="iinn_InvestorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ConversionOfConvertibleLoanToSharesinShares_lbl1" xml:lang="en-US">Conversion Of Convertible Loan To Sharesin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionOfConvertibleLoanToSharesinShares" xlink:to="iinn_ConversionOfConvertibleLoanToSharesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_WarrantsMember_lbl0" xml:lang="en-US">Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsMember" xlink:to="iinn_WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LoanFromTheIsraeliInnovationAuthority_lbl1" xml:lang="en-US">Loan From The Israeli Innovation Authority</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LoanFromTheIsraeliInnovationAuthority" xlink:to="iinn_LoanFromTheIsraeliInnovationAuthority_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy_lbl1" xml:lang="en-US">Finance Expenses Received Classified As Operating Activitiy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy" xlink:to="iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperations_lbl0" xml:lang="en-US">Profit (loss) from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperations" xlink:to="ifrs-full_ProfitLossFromContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl0" xml:lang="en-US">Non-current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Depreciation, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TotalFinancialLiabilities_lbl1" xml:lang="en-US">Total Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalFinancialLiabilities" xlink:to="iinn_TotalFinancialLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesInOperatingAssetsAndLiabilityAbstract_lbl0" xml:lang="en-US">Changes In Operating Assets And Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesInOperatingAssetsAndLiabilityAbstract" xlink:to="iinn_ChangesInOperatingAssetsAndLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl0" xml:lang="en-US">Current accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StockholdersEquityReverseSplit_lbl1" xml:lang="en-US">Stockholders Equity Reverse Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockholdersEquityReverseSplit" xlink:to="iinn_StockholdersEquityReverseSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">Schedule Of Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfResearchAndDevelopmentExpenses" xlink:to="iinn_ScheduleOfResearchAndDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TotalComprehensiveLoss_lbl1" xml:lang="en-US">Total Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TotalComprehensiveLoss" xlink:to="iinn_TotalComprehensiveLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DescriptionOfLeaseAgreement_lbl1" xml:lang="en-US">Description Of Lease Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DescriptionOfLeaseAgreement" xlink:to="iinn_DescriptionOfLeaseAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GrantedNumberOfOptions_lbl0" xml:lang="en-US">Granted Number Of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GrantedNumberOfOptions" xlink:to="iinn_GrantedNumberOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TradableWarrantsLiability_lbl1" xml:lang="en-US">Tradable Warrants Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsLiability" xlink:to="iinn_TradableWarrantsLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepositsFromBanks_lbl0" xml:lang="en-US">Deposits from banks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepositsFromBanks" xlink:to="ifrs-full_DepositsFromBanks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl0" xml:lang="en-US">Adjustments for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract_lbl" xml:lang="en-US">Schedule Of Foreign Currency Denominated Monetary Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract" xlink:to="iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePrice_lbl0" xml:lang="en-US">Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice" xlink:to="iinn_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems_lbl0" xml:lang="en-US">Equity Defict Details Scheduleoflosspershare Parentheticals Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems" xlink:to="iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Prepayments_lbl0" xml:lang="en-US">Prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Prepayments" xlink:to="ifrs-full_Prepayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl0" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl0" xml:lang="en-US">Applicable tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">Schedule Of General And Administrative Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPayment_lbl0" xml:lang="en-US">Share Based Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPayment" xlink:to="iinn_ShareBasedPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_MaterialsAndRelatedExpenses_lbl0" xml:lang="en-US">Materials And Related Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MaterialsAndRelatedExpenses" xlink:to="iinn_MaterialsAndRelatedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Impairment loss recognised in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_BalancesWithRelatedPartiesTableTextBlock_lbl1" xml:lang="en-US">Balances With Related Parties Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BalancesWithRelatedPartiesTableTextBlock" xlink:to="iinn_BalancesWithRelatedPartiesTableTextBlock_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>iinn-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 19:09:14 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ConsolidatedBalanceSheet" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ConsolidatedIncomeStatement" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ShareholdersEquityType2or3" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ConsolidatedCashFlow" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_General" roleURI="http://www.inspiratechnologies.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_SignificantAccountingPolicies" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_CriticalAccountingEstimatesandJudgements" roleURI="http://www.inspiratechnologies.com/role/CriticalAccountingEstimatesandJudgements"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_Deposits" roleURI="http://www.inspiratechnologies.com/role/Deposits"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_OtherCurrentAssets" roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_PropertyandEquipmentNet" roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_OtherAccountsPayable" roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_LiabilityinRespectofGovernmentGrants" roleURI="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrants"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinacialLiabilitiesatFairValue" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_EquityDefict" roleURI="http://www.inspiratechnologies.com/role/EquityDefict"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ResearchandDevelopmentExpenses" roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_SalesandMarketingExpenses" roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_GeneralandAdministrativeExpenses" roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinancialIncomeandExpenses" roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_TaxesonIncome" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_Leases" roleURI="http://www.inspiratechnologies.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ShareBasedCompensation" roleURI="http://www.inspiratechnologies.com/role/ShareBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_RelatedParties" roleURI="http://www.inspiratechnologies.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinancialInstrumentsandRiskManagement" roleURI="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_CommitmentsandContingencies" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FairValueMeasurement" roleURI="http://www.inspiratechnologies.com/role/FairValueMeasurement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_AccountingPoliciesByPolicy" roleURI="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_SignificantAccountingPoliciesTables" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_OtherCurrentAssetsTables" roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_PropertyandEquipmentNetTables" roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_OtherAccountsPayableTables" roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_LiabilityinRespectofGovernmentGrantsTables" roleURI="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinacialLiabilitiesatFairValueTables" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_EquityDefictTables" roleURI="http://www.inspiratechnologies.com/role/EquityDefictTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ResearchandDevelopmentExpensesTables" roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_SalesandMarketingExpensesTables" roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_GeneralandAdministrativeExpensesTables" roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinancialIncomeandExpensesTables" roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_TaxesonIncomeTables" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_LeasesTables" roleURI="http://www.inspiratechnologies.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ShareBasedCompensationTables" roleURI="http://www.inspiratechnologies.com/role/ShareBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_RelatedPartiesTables" roleURI="http://www.inspiratechnologies.com/role/RelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinancialInstrumentsandRiskManagementTables" roleURI="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FairValueMeasurementTables" roleURI="http://www.inspiratechnologies.com/role/FairValueMeasurementTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofotherCurrentAssetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofotherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofpropertyandequipmentnetTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofotheraccountspayableTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofreimbursementofresearchexpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofreimbursementofresearchexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoffinacialliabilitiesatfairvalueTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofsharecapitalTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoflosspershareTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoflosspershareTable_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofresearchanddevelopmentexpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofsalesandMarketingExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofgeneralandadministrativeexpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoffinancialincomeTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoffinancialexpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoftheoreticaltaxTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoftheoreticaltaxTable_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofrightofuseassetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofleaseliabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofprofitorlossTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofshareholdersandotherrelatedpartiesbenefitsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofbalanceswithrelatedpartiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofforeigncurrencydenominatedmonetaryliabilityTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofsensitivityanalysisTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofcashflowsoffinancialliabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ScheduleofwarrantsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_Scheduleofmovementsinlevel2liabilityTable" roleURI="http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_GeneralDetails" roleURI="http://www.inspiratechnologies.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_DepositsDetails" roleURI="http://www.inspiratechnologies.com/role/DepositsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_LiabilityinRespectofGovernmentGrantsDetails" roleURI="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinacialLiabilitiesatFairValueDetails" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_EquityDefictDetails" roleURI="http://www.inspiratechnologies.com/role/EquityDefictDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_TaxesonIncomeDetails" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_LeasesDetails" roleURI="http://www.inspiratechnologies.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_ShareBasedCompensationDetails" roleURI="http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FinancialInstrumentsandRiskManagementDetails" roleURI="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_CommitmentsandContingenciesDetails" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#iinn_r_FairValueMeasurementDetails" roleURI="http://www.inspiratechnologies.com/role/FairValueMeasurementDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_CurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_DeferredTaxAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_NoncurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentPayables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanFromTheIsraeliInnovationAuthority" xlink:href="iinn-20221231.xsd#iinn_LoanFromTheIsraeliInnovationAuthority"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="LoanFromTheIsraeliInnovationAuthority" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanFromTheIsraeliInnovationAuthority" xlink:to="ifrs-full_NoncurrentLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_SharePremium" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_ResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ResearchAndDevelopmentExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesAndMarketingExpenses" xlink:href="iinn-20221231.xsd#iinn_SalesAndMarketingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="SalesAndMarketingExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpenses" xlink:href="iinn-20221231.xsd#iinn_GeneralAndAdministrativeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="GeneralAndAdministrativeExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherGainsLosses" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpense" xlink:href="iinn-20221231.xsd#iinn_FinanceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="FinanceExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_ProfitLossBeforeTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_ProfitLossFromContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="ifrs-full_OtherComprehensiveIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="StatementsOfChangesInShareholdersEquityAbstract" xlink:href="iinn-20221231.xsd#iinn_StatementsOfChangesInShareholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsOfChangesInShareholdersEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_IssuedCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_AdditionalPaidinCapitalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesDuringThePeriodAbstract" xlink:href="iinn-20221231.xsd#iinn_ChangesDuringThePeriodAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ChangesDuringThePeriodAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalComprehensiveLoss" xlink:href="iinn-20221231.xsd#iinn_TotalComprehensiveLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="TotalComprehensiveLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareSplit" xlink:href="iinn-20221231.xsd#iinn_ShareSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ShareSplit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParValueCancellations" xlink:href="iinn-20221231.xsd#iinn_ParValueCancellations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ParValueCancellations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOffering" xlink:href="iinn-20221231.xsd#iinn_InitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="InitialPublicOffering" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuanceOfInitialPublicOffering" xlink:href="iinn-20221231.xsd#iinn_ShareIssuanceOfInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ShareIssuanceOfInitialPublicOffering" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ifrs-full_IssueOfConvertibleInstruments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfFinancialLiabilityinShares" xlink:href="iinn-20221231.xsd#iinn_ConversionOfFinancialLiabilityinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ConversionOfFinancialLiabilityinShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradableWarrantsExercise" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="TradableWarrantsExercise" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradableWarrantsExerciseinShares" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsExerciseinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="TradableWarrantsExerciseinShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsExercise" xlink:href="iinn-20221231.xsd#iinn_OptionsExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="OptionsExercise" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationToExercise" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationToExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ShareBasedCompensationToExercise" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfConvertibleLoanToShares" xlink:href="iinn-20221231.xsd#iinn_ConversionOfConvertibleLoanToShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ConversionOfConvertibleLoanToShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfConvertibleLoanToSharesinShares" xlink:href="iinn-20221231.xsd#iinn_ConversionOfConvertibleLoanToSharesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ConversionOfConvertibleLoanToSharesinShares" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueRestrictedStockUnits" xlink:href="iinn-20221231.xsd#iinn_StockIssuedDuringPeriodValueRestrictedStockUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="StockIssuedDuringPeriodValueRestrictedStockUnits" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockUnit" xlink:href="iinn-20221231.xsd#iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockUnit" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_DepreciationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfFinancialLiabilitiesAtFairValue" xlink:href="iinn-20221231.xsd#iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ChangeInFairValueOfFinancialLiabilitiesAtFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfLoanFromTheIsraeliInnovationAuthority" xlink:href="iinn-20221231.xsd#iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="RevaluationOfLoanFromTheIsraeliInnovationAuthority" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpensesReceivedClassifiedAsOperatingActivitiy" xlink:href="iinn-20221231.xsd#iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="FinanceExpensesReceivedClassifiedAsOperatingActivitiy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesInOperatingAssetsAndLiabilityAbstract" xlink:href="iinn-20221231.xsd#iinn_ChangesInOperatingAssetsAndLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ChangesInOperatingAssetsAndLiabilityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilityAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilityAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilityAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilityAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfDeposit" xlink:href="iinn-20221231.xsd#iinn_PaymentOfDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="PaymentOfDeposit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DividendsPaidClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_DividendsPaidClassifiedAsFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" xlink:href="iinn-20221231.xsd#iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceiptOfIPOFunds" xlink:href="iinn-20221231.xsd#iinn_ReceiptOfIPOFunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ReceiptOfIPOFunds" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ReceiptOfWarrantsExerciseFundsNetFromFees" xlink:href="iinn-20221231.xsd#iinn_ReceiptOfWarrantsExerciseFundsNetFromFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ReceiptOfWarrantsExerciseFundsNetFromFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradableWarrantsLiability" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="TradableWarrantsLiability" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradableWarrantsDerivativeLiability" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsDerivativeLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="TradableWarrantsDerivativeLiability" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationUnderwritersFees" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationUnderwritersFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ShareBasedCompensationUnderwritersFees" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExerciseLiabilityIssuance" xlink:href="iinn-20221231.xsd#iinn_WarrantsExerciseLiabilityIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="WarrantsExerciseLiabilityIssuance" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalNonCashTransactions" xlink:href="iinn-20221231.xsd#iinn_TotalNonCashTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="TotalNonCashTransactions" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefund" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefund" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/General">
    <loc xlink:type="locator" xlink:label="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/CriticalAccountingEstimatesandJudgements">
    <loc xlink:type="locator" xlink:label="DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/Deposits">
    <loc xlink:type="locator" xlink:label="DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfDepositsFromBanksTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDepositsFromBanksExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDepositsFromBanksExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfDepositsFromBanksExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherNonCurrentAssetsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfOtherNonCurrentAssetsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrants">
    <loc xlink:type="locator" xlink:label="DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGovernmentGrantsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGovernmentGrantsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/EquityDefict">
    <loc xlink:type="locator" xlink:label="DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses">
    <loc xlink:type="locator" xlink:label="DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses">
    <loc xlink:type="locator" xlink:label="SalesAndMarketingExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_SalesAndMarketingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="SalesAndMarketingExpensesTextBlock" xlink:href="iinn-20221231.xsd#iinn_SalesAndMarketingExpensesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesAndMarketingExpensesAbstract" xlink:to="SalesAndMarketingExpensesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses">
    <loc xlink:type="locator" xlink:label="DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses">
    <loc xlink:type="locator" xlink:label="DisclosureOfFinanceIncomeCostTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinanceIncomeCostTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="DisclosureOfIncomeTaxTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfIncomeTaxTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/Leases">
    <loc xlink:type="locator" xlink:label="DisclosureOfLeasesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfLeasesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfLeasesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareBasedCompensation">
    <loc xlink:type="locator" xlink:label="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/RelatedParties">
    <loc xlink:type="locator" xlink:label="DisclosureOfRelatedPartyTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfRelatedPartyTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagement">
    <loc xlink:type="locator" xlink:label="DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FairValueMeasurement">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock" xlink:href="iinn-20221231.xsd#iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsPolicyTextBlock" xlink:href="iinn-20221231.xsd#iinn_OptionsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OptionsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedShareUnitsPolicyTextBlock" xlink:href="iinn-20221231.xsd#iinn_RestrictedShareUnitsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RestrictedShareUnitsPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:to="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherNonCurrentAssetsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfOtherNonCurrentAssetsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract" xlink:to="ScheduleOfPropertyAndEquipmentNetTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountPayableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfOtherAccountPayableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:to="ScheduleOfOtherAccountPayableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGovernmentGrantsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfReimbursementOfResearchExpensesTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:to="ScheduleOfReimbursementOfResearchExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialLiabilities" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" xlink:to="ScheduleOfFinancialLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/EquityDefictTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLossPerShare" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:to="ScheduleOfLossPerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfResearchAndDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract" xlink:to="ScheduleOfResearchAndDevelopmentExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables">
    <loc xlink:type="locator" xlink:label="SalesAndMarketingExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_SalesAndMarketingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesAndMarketingExpensesAbstract" xlink:to="ScheduleOfSalesAndMarketingExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpenses" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract" xlink:to="ScheduleOfGeneralAndAdministrativeExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfFinanceIncomeCostTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialIncomeTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinanceIncomeCostTextBlockAbstract" xlink:to="ScheduleOfFinancialIncomeTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialExpenses" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinanceIncomeCostTextBlockAbstract" xlink:to="ScheduleOfFinancialExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncomeTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfIncomeTaxTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfIncomeTaxTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTheoreticalTaxTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="ScheduleOfTheoreticalTaxTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfLeasesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfLeasesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRightofuseAssets" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfLeasesTextBlockAbstract" xlink:to="ScheduleOfRightofuseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseLiabilities" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfLeasesTextBlockAbstract" xlink:to="ScheduleOfLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfProfitOrLoss" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfLeasesTextBlockAbstract" xlink:to="ScheduleOfProfitOrLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/RelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfRelatedPartyTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfRelatedPartyTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BalancesWithRelatedPartiesTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_BalancesWithRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="BalancesWithRelatedPartiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfForeignCurrencyDenominatedMonetaryLiability" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="ScheduleOfForeignCurrencyDenominatedMonetaryLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSensitivityAnalysis" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfSensitivityAnalysis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="ScheduleOfSensitivityAnalysis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FairValueMeasurementTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementsInLevel2LiabilityTableTextBlock" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:to="ScheduleOfMovementsInLevel2LiabilityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStraightLineBasisOverTheUsefulLivesOfTheAssetsAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfStraightLineBasisOverTheUsefulLivesOfTheAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" xlink:href="iinn-20221231.xsd#iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems" xlink:href="iinn-20221231.xsd#iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStraightLineBasisOverTheUsefulLivesOfTheAssetsAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ComputersMember" xlink:href="iinn-20221231.xsd#iinn_ComputersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ComputersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentEquipmentMember" xlink:href="iinn-20221231.xsd#iinn_DevelopmentEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="DevelopmentEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FurnitureAndOfficeEquipmentMember" xlink:href="iinn-20221231.xsd#iinn_FurnitureAndOfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="FurnitureAndOfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseholdImprovementMember" xlink:href="iinn-20221231.xsd#iinn_LeaseholdImprovementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="LeaseholdImprovementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AnnualDepreciationRateInPercentage" xlink:href="iinn-20221231.xsd#iinn_AnnualDepreciationRateInPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems" xlink:to="AnnualDepreciationRateInPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofotherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherCurrentAssetsAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherCurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Institutions" xlink:href="iinn-20221231.xsd#iinn_Institutions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherCurrentAssetsAbstract" xlink:to="Institutions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherCurrentAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OthersCurrentAssets" xlink:href="iinn-20221231.xsd#iinn_OthersCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherCurrentAssetsAbstract" xlink:to="OthersCurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OthersCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable" xlink:href="iinn-20221231.xsd#iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" xlink:href="iinn-20221231.xsd#iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentEquipmentMember" xlink:href="iinn-20221231.xsd#iinn_DevelopmentEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="DevelopmentEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable" xlink:to="PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CostAbstract" xlink:href="iinn-20221231.xsd#iinn_CostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" xlink:to="CostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateDeferenceCost" xlink:href="iinn-20221231.xsd#iinn_ExchangeRateDeferenceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ExchangeRateDeferenceCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract" xlink:href="iinn-20221231.xsd#iinn_AccumulatedDepreciationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" xlink:to="AccumulatedDepreciationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciation" xlink:href="iinn-20221231.xsd#iinn_AccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="AccumulatedDepreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateDeferenceAccumulatedDepreciation" xlink:href="iinn-20221231.xsd#iinn_ExchangeRateDeferenceAccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="ExchangeRateDeferenceAccumulatedDepreciation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciation_0" xlink:href="iinn-20221231.xsd#iinn_AccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="AccumulatedDepreciation_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NetBookValueAbstract" xlink:href="iinn-20221231.xsd#iinn_NetBookValueAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems" xlink:to="NetBookValueAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetBookValue" xlink:href="iinn-20221231.xsd#iinn_NetBookValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetBookValueAbstract" xlink:to="NetBookValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsPayableAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeesSalariesAndRelatedLiabilities" xlink:href="iinn-20221231.xsd#iinn_EmployeesSalariesAndRelatedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="EmployeesSalariesAndRelatedLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPayablesToRelatedParties" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentPayablesToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_NoncurrentPayablesToRelatedParties" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_OtherPayables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_NoncurrentPayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofreimbursementofresearchexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfReimbursementOfResearchExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:to="ifrs-full_GovernmentGrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateDifferences" xlink:href="iinn-20221231.xsd#iinn_ExchangeRateDifferences"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:to="ExchangeRateDifferences" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfTheLiability" xlink:href="iinn-20221231.xsd#iinn_RevaluationOfTheLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:to="RevaluationOfTheLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReimbursementOfResearchExpensesAbstract" xlink:to="ifrs-full_GovernmentGrants_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinacialLiabilitiesAtFairValueAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinacialLiabilitiesAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable" xlink:href="iinn-20221231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable"/>
    <loc xlink:type="locator" xlink:label="FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems" xlink:href="iinn-20221231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinacialLiabilitiesAtFairValueAbstract" xlink:to="FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NontradableWarrantsMember" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="NontradableWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NontradableWarrantsSAFEAndCLAMember" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantsSAFEAndCLAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="NontradableWarrantsSAFEAndCLAMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradableWarrantsMember" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="TradableWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialLiabilityMember" xlink:href="iinn-20221231.xsd#iinn_FinancialLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="FinancialLiabilityMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable" xlink:to="FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TotalFinancialLiabilities" xlink:href="iinn-20221231.xsd#iinn_TotalFinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems" xlink:to="TotalFinancialLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareCapitalAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDefictDetailsScheduleofsharecapitalTable" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleofsharecapitalTable"/>
    <loc xlink:type="locator" xlink:label="EquityDefictDetailsScheduleofsharecapitalLineItems" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleofsharecapitalLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="EquityDefictDetailsScheduleofsharecapitalTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleofsharecapitalTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleofsharecapitalTable" xlink:to="EquityDefictDetailsScheduleofsharecapitalLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleofsharecapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleofsharecapitalLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLossPerShareAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDefictDetailsScheduleoflosspershareTable" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleoflosspershareTable"/>
    <loc xlink:type="locator" xlink:label="EquityDefictDetailsScheduleoflosspershareLineItems" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleoflosspershareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="EquityDefictDetailsScheduleoflosspershareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleoflosspershareTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleoflosspershareTable" xlink:to="EquityDefictDetailsScheduleoflosspershareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleoflosspershareLineItems" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleoflosspershareLineItems" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits" xlink:href="iinn-20221231.xsd#iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleoflosspershareLineItems" xlink:to="AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleoflosspershareLineItems" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfLossPerShareAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDefictDetailsScheduleoflosspershareParentheticalsTable" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="EquityDefictDetailsScheduleoflosspershareParentheticalsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleoflosspershareParentheticalsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleoflosspershareParentheticalsTable" xlink:to="EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable" xlink:href="iinn-20221231.xsd#iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable"/>
    <loc xlink:type="locator" xlink:label="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:href="iinn-20221231.xsd#iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:to="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable" xlink:to="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPayment" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="ShareBasedPayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalaryAndRelatedExpenses" xlink:href="iinn-20221231.xsd#iinn_SalaryAndRelatedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="SalaryAndRelatedExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Subcontractors" xlink:href="iinn-20221231.xsd#iinn_Subcontractors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="Subcontractors" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaterialsAndRelatedExpenses" xlink:href="iinn-20221231.xsd#iinn_MaterialsAndRelatedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="MaterialsAndRelatedExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepreciationExpenses" xlink:href="iinn-20221231.xsd#iinn_DepreciationExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="DepreciationExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IIAParticipation" xlink:href="iinn-20221231.xsd#iinn_IIAParticipation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="IIAParticipation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherResearchAndDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_OtherResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="OtherResearchAndDevelopmentExpenses" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchDevelopmentExpenses" xlink:href="iinn-20221231.xsd#iinn_ResearchDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems" xlink:to="ResearchDevelopmentExpenses" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSalesAndMarketingExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable" xlink:href="iinn-20221231.xsd#iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable"/>
    <loc xlink:type="locator" xlink:label="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:href="iinn-20221231.xsd#iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable" xlink:to="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WagesAndSalaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:to="ifrs-full_WagesAndSalaries" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:to="ifrs-full_FeeAndCommissionExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:to="ifrs-full_OtherExpenseByNature" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems" xlink:to="ifrs-full_ExpenseByNature" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable" xlink:href="iinn-20221231.xsd#iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable"/>
    <loc xlink:type="locator" xlink:label="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:href="iinn-20221231.xsd#iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:to="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable" xlink:to="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPayments" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ShareBasedPayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_ProfessionalFeesExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_InsuranceExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RentalExpense"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRoJ/travtspQJClWcUZpCKKwHPCOss3tqo6SbRlG2Msx2Mu7jhsbM1rEkd29demw7xoQFJ8QNNTzH6TXzpr7OuPNceEmvURO78QMp9NjY3po4ETx9F6sRVgk7D/Gu4qmzCrYDfkE0B8ZDGGxJ0s0KXQ=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_RentalExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Depreciations" xlink:href="iinn-20221231.xsd#iinn_Depreciations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="Depreciations" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_TravelExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialIncomeAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable"/>
    <loc xlink:type="locator" xlink:label="FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAbstract" xlink:to="FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FinancialIncomeMember" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="FinancialIncomeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable" xlink:to="FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:to="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyTransactionLossNet" xlink:href="iinn-20221231.xsd#iinn_ForeignCurrencyTransactionLossNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:to="ForeignCurrencyTransactionLossNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:to="ifrs-full_InterestIncomeOnDeposits" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems" xlink:to="ifrs-full_OtherIncome" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="TotalIncome" xlink:href="iinn-20221231.xsd#iinn_TotalIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherIncome" xlink:to="TotalIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialExpensesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable"/>
    <loc xlink:type="locator" xlink:label="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialExpensesAbstract" xlink:to="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FinancialExpensesMember" xlink:href="iinn-20221231.xsd#iinn_FinancialExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="FinancialExpensesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable" xlink:to="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:to="ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyTransactionLossNet" xlink:href="iinn-20221231.xsd#iinn_ForeignCurrencyTransactionLossNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:to="ForeignCurrencyTransactionLossNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfLiabilityInRespectOfGovernmentGrants" xlink:href="iinn-20221231.xsd#iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:to="RevaluationOfLiabilityInRespectOfGovernmentGrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenseInRespectOfLeaseLiability" xlink:href="iinn-20221231.xsd#iinn_FinanceExpenseInRespectOfLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:to="FinanceExpenseInRespectOfLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems" xlink:to="ifrs-full_OtherExpenseByNature" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalExpenses" xlink:href="iinn-20221231.xsd#iinn_TotalExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="TotalExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsScheduleoftheoreticaltaxTable" xlink:href="iinn-20221231.xsd#iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxTable"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:href="iinn-20221231.xsd#iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="TaxesonIncomeDetailsScheduleoftheoreticaltaxTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsScheduleoftheoreticaltaxTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsScheduleoftheoreticaltaxTable" xlink:to="TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LossBeforeTaxation" xlink:href="iinn-20221231.xsd#iinn_LossBeforeTaxation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:to="LossBeforeTaxation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonallowableExpenses" xlink:href="iinn-20221231.xsd#iinn_NonallowableExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:to="NonallowableExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20221231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:to="TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable" xlink:href="iinn-20221231.xsd#iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems" xlink:href="iinn-20221231.xsd#iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable" xlink:to="TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheoreticalTaxCreditAtApplicableStatutoryRate" xlink:href="iinn-20221231.xsd#iinn_TheoreticalTaxCreditAtApplicableStatutoryRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems" xlink:to="TheoreticalTaxCreditAtApplicableStatutoryRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRightOfUseAssetsAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfRightOfUseAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofrightofuseassetsTable" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofrightofuseassetsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofrightofuseassetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightOfUseAssetsAbstract" xlink:to="LeasesDetailsScheduleofrightofuseassetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofrightofuseassetsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_OfficeBuildingMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficeBuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="srt_OfficeBuildingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_VehiclesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofrightofuseassetsTable" xlink:to="LeasesDetailsScheduleofrightofuseassetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialExpense" xlink:href="iinn-20221231.xsd#iinn_FinancialExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="FinancialExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsInvestmentProperty" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsInvestmentProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="ifrs-full_DisposalsInvestmentProperty" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofrightofuseassetsLineItems" xlink:to="ifrs-full_LeaseLiabilities_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseLiabilitiesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofleaseliabilitiesTable" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofleaseliabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilitiesAbstract" xlink:to="LeasesDetailsScheduleofleaseliabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofleaseliabilitiesTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofleaseliabilitiesTable" xlink:to="LeasesDetailsScheduleofleaseliabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialExpenses" xlink:href="iinn-20221231.xsd#iinn_FinancialExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="FinancialExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateDifference" xlink:href="iinn-20221231.xsd#iinn_ExchangeRateDifference"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="ExchangeRateDifference" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="PrincipalPayment" xlink:href="iinn-20221231.xsd#iinn_PrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="PrincipalPayment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofleaseliabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfProfitOrLossAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfProfitOrLossAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofprofitorlossTable" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofprofitorlossTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofprofitorlossLineItems" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsScheduleofprofitorlossLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProfitOrLossAbstract" xlink:to="LeasesDetailsScheduleofprofitorlossTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofprofitorlossTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofprofitorlossTable" xlink:to="LeasesDetailsScheduleofprofitorlossLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofprofitorlossLineItems" xlink:to="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofprofitorlossLineItems" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalAmountRecognizedInProfitOrLoss" xlink:href="iinn-20221231.xsd#iinn_TotalAmountRecognizedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofprofitorlossLineItems" xlink:to="TotalAmountRecognizedInProfitOrLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ProvidersAndAdvisersMember" xlink:href="iinn-20221231.xsd#iinn_ProvidersAndAdvisersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ProvidersAndAdvisersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesAndDirectorsMember" xlink:href="iinn-20221231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="EmployeesAndDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable" xlink:to="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares" xlink:href="iinn-20221231.xsd#iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice" xlink:href="iinn-20221231.xsd#iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantedNumberOfOptions" xlink:href="iinn-20221231.xsd#iinn_GrantedNumberOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="GrantedNumberOfOptions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisedNumberOfOptions" xlink:href="iinn-20221231.xsd#iinn_ExercisedNumberOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ExercisedNumberOfOptions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisedWeightedAverageExercisePrice" xlink:href="iinn-20221231.xsd#iinn_ExercisedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ExercisedWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForfeitedWeightedAverageExercisePrice" xlink:href="iinn-20221231.xsd#iinn_ForfeitedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ForfeitedWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisableOptionsNumberOfOptions" xlink:href="iinn-20221231.xsd#iinn_ExercisableOptionsNumberOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ExercisableOptionsNumberOfOptions" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ProvidersAndAdvisersMember" xlink:href="iinn-20221231.xsd#iinn_ProvidersAndAdvisersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ProvidersAndAdvisersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesAndDirectorsMember" xlink:href="iinn-20221231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="EmployeesAndDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable" xlink:to="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OutstandingAtBeginningOfYears" xlink:href="iinn-20221231.xsd#iinn_OutstandingAtBeginningOfYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="OutstandingAtBeginningOfYears" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="Granted" xlink:href="iinn-20221231.xsd#iinn_Granted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="Granted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Forfeited" xlink:href="iinn-20221231.xsd#iinn_Forfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="Forfeited" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Vested" xlink:href="iinn-20221231.xsd#iinn_Vested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="Vested" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingAtBeginningOfYears_0" xlink:href="iinn-20221231.xsd#iinn_OutstandingAtBeginningOfYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="OutstandingAtBeginningOfYears_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisableRSUs" xlink:href="iinn-20221231.xsd#iinn_ExercisableRSUs"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="ExercisableRSUs" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockUnitVested" xlink:href="iinn-20221231.xsd#iinn_RestrictedStockUnitVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems" xlink:to="RestrictedStockUnitVested" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable" xlink:href="iinn-20221231.xsd#iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems" xlink:href="iinn-20221231.xsd#iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:to="RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable" xlink:to="RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentEmployeesAndDirectors" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPaymentEmployeesAndDirectors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems" xlink:to="ShareBasedPaymentEmployeesAndDirectors" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable" xlink:href="iinn-20221231.xsd#iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems" xlink:href="iinn-20221231.xsd#iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeesMember" xlink:href="iinn-20221231.xsd#iinn_EmployeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="EmployeesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DirectorsMember" xlink:href="iinn-20221231.xsd#iinn_DirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="DirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable" xlink:to="RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NatureOfTransactionSalariesAndRelated" xlink:href="iinn-20221231.xsd#iinn_NatureOfTransactionSalariesAndRelated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems" xlink:to="NatureOfTransactionSalariesAndRelated" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany" xlink:href="iinn-20221231.xsd#iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems" xlink:to="NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureAbstract" xlink:to="FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CreditRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_CreditRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable" xlink:to="FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" xlink:to="ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_FinancialAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="AssetsAbstract0" xlink:href="iinn-20221231.xsd#iinn_AssetsAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract" xlink:to="AssetsAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Deposit" xlink:href="iinn-20221231.xsd#iinn_Deposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="Deposit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="ifrs-full_FinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract" xlink:to="ifrs-full_LiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DerivativeFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_OtherFinancialAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtFairValue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract" xlink:to="ifrs-full_FinancialAssetsAtFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSensitivityAnalysisAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfSensitivityAnalysisAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSensitivityAnalysisAbstract" xlink:to="FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyInWhichInformationIsDisplayedAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable" xlink:to="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="USDMemberMember" xlink:href="iinn-20221231.xsd#iinn_USDMemberMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:to="USDMemberMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AUDMember" xlink:href="iinn-20221231.xsd#iinn_AUDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:to="AUDMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PoundMember" xlink:href="iinn-20221231.xsd#iinn_PoundMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:to="PoundMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable" xlink:to="FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SensitivityAnalysis" xlink:href="iinn-20221231.xsd#iinn_SensitivityAnalysis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems" xlink:to="SensitivityAnalysis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashFlowsOfFinancialLiabilitiesAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfCashFlowsOfFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:href="iinn-20221231.xsd#iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashFlowsOfFinancialLiabilitiesAbstract" xlink:to="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="UpTo1YearMember" xlink:href="iinn-20221231.xsd#iinn_UpTo1YearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="UpTo1YearMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Between1And3YearsMember" xlink:href="iinn-20221231.xsd#iinn_Between1And3YearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="Between1And3YearsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MoreThan3YearsMember" xlink:href="iinn-20221231.xsd#iinn_MoreThan3YearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="MoreThan3YearsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable" xlink:to="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:to="ifrs-full_OtherPayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:to="ifrs-full_GrossLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementDetailsScheduleofwarrantsTable" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsScheduleofwarrantsTable"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsAbstract" xlink:to="FairValueMeasurementDetailsScheduleofwarrantsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofwarrantsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofwarrantsTable" xlink:to="FairValueMeasurementDetailsScheduleofwarrantsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NontradableWarrantFairValue" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:to="NontradableWarrantFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:to="NontradableWarrantsOfSAFEAndConvertibleLoanInvestors" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:to="ifrs-full_WarrantLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofwarrantsLineItems" xlink:to="ifrs-full_CurrentFinancialAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementsInLevel2LiabilityAbstract" xlink:href="iinn-20221231.xsd#iinn_ScheduleOfMovementsInLevel2LiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInLevel2LiabilityAbstract" xlink:to="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WarrantsMember" xlink:href="iinn-20221231.xsd#iinn_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SAFEMember" xlink:href="iinn-20221231.xsd#iinn_SAFEMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="SAFEMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleLoanMember" xlink:href="iinn-20221231.xsd#iinn_ConvertibleLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ConvertibleLoanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialDerivativeMember" xlink:href="iinn-20221231.xsd#iinn_FinancialDerivativeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="FinancialDerivativeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable" xlink:to="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BalanceAtBeginning" xlink:href="iinn-20221231.xsd#iinn_BalanceAtBeginning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="BalanceAtBeginning" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainslossesRecognizedInProfitLoss" xlink:href="iinn-20221231.xsd#iinn_GainslossesRecognizedInProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="GainslossesRecognizedInProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Addition" xlink:href="iinn-20221231.xsd#iinn_Addition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="Addition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsArisingFromTranslatingFinancialOperations" xlink:href="iinn-20221231.xsd#iinn_AdjustmentsArisingFromTranslatingFinancialOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="AdjustmentsArisingFromTranslatingFinancialOperations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BalanceAtEnding" xlink:href="iinn-20221231.xsd#iinn_BalanceAtEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems" xlink:to="BalanceAtEnding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfShares" xlink:href="iinn-20221231.xsd#iinn_NumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="NumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradableWarrantsShares" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="TradableWarrantsShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsPursuantShares" xlink:href="iinn-20221231.xsd#iinn_WarrantsPursuantShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="WarrantsPursuantShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateProceedsAmount" xlink:href="iinn-20221231.xsd#iinn_AggregateProceedsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="AggregateProceedsAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalOfferingCosts" xlink:href="iinn-20221231.xsd#iinn_AdditionalOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="AdditionalOfferingCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_OrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="OrdinaryShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsShares" xlink:href="iinn-20221231.xsd#iinn_WarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="WarrantsShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorsExercise" xlink:href="iinn-20221231.xsd#iinn_InvestorsExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="InvestorsExercise" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPaidFees" xlink:href="iinn-20221231.xsd#iinn_PercentageOfPaidFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="PercentageOfPaidFees" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaidFeesAmount" xlink:href="iinn-20221231.xsd#iinn_PaidFeesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="PaidFeesAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OperatingLeaseIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingLeaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="ifrs-full_OperatingLeaseIncome" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralHedgeAccountingTextBlockAbstract" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/DepositsDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfDepositsFromBanksTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepositsFromBanks" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepositsFromBanks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:to="ifrs-full_DepositsFromBanks" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:to="ifrs-full_BorrowingsInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepositValue" xlink:href="iinn-20221231.xsd#iinn_DepositValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDepositsFromBanksTextBlockAbstract" xlink:to="DepositValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfGovernmentGrantsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:to="ifrs-full_RevenueFromGovernmentGrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PayRoyaltiesPercentage" xlink:href="iinn-20221231.xsd#iinn_PayRoyaltiesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGovernmentGrantsTextBlockAbstract" xlink:to="PayRoyaltiesPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="FinacialLiabilitiesatFairValueDetailsTable" xlink:href="iinn-20221231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract" xlink:to="FinacialLiabilitiesatFairValueDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOfferingMember" xlink:href="iinn-20221231.xsd#iinn_InitialPublicOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="InitialPublicOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentNameAxis" xlink:href="iinn-20221231.xsd#iinn_InvestmentNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsTable" xlink:to="InvestmentNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentNameDomain" xlink:href="iinn-20221231.xsd#iinn_InvestmentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentNameAxis" xlink:to="InvestmentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WarrantsToInvestorsMember" xlink:href="iinn-20221231.xsd#iinn_WarrantsToInvestorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentNameAxis" xlink:to="WarrantsToInvestorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToBrokersMember" xlink:href="iinn-20221231.xsd#iinn_WarrantsToBrokersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentNameAxis" xlink:to="WarrantsToBrokersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsTable" xlink:to="FinacialLiabilitiesatFairValueDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConversionToShares" xlink:href="iinn-20221231.xsd#iinn_ConversionToShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="ConversionToShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalOrdinaryShare" xlink:href="iinn-20221231.xsd#iinn_AdditionalOrdinaryShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="AdditionalOrdinaryShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedFromIssuanceInitialPublicOffering" xlink:href="iinn-20221231.xsd#iinn_ProceedFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="ProceedFromIssuanceInitialPublicOffering" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfTheWarrant" xlink:href="iinn-20221231.xsd#iinn_FairValueOfTheWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="FairValueOfTheWarrant" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateProceeds" xlink:href="iinn-20221231.xsd#iinn_AggregateProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="AggregateProceeds" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsShares" xlink:href="iinn-20221231.xsd#iinn_WarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="WarrantsShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PlanAssetsAtFairValue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="ifrs-full_PlanAssetsAtFairValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NontradableWarrantFairValue" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrantFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="NontradableWarrantFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TradableWarrants" xlink:href="iinn-20221231.xsd#iinn_TradableWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="TradableWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicOfferingPriceDescription" xlink:href="iinn-20221231.xsd#iinn_PublicOfferingPriceDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="PublicOfferingPriceDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorsExercisedTradableWarrants" xlink:href="iinn-20221231.xsd#iinn_InvestorsExercisedTradableWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="InvestorsExercisedTradableWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesIssued" xlink:href="iinn-20221231.xsd#iinn_OrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="OrdinarySharesIssued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalProceedsReceived" xlink:href="iinn-20221231.xsd#iinn_TotalProceedsReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="TotalProceedsReceived" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeductingFees" xlink:href="iinn-20221231.xsd#iinn_DeductingFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="DeductingFees" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradableWarrantsFairValue" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="TradableWarrantsFairValue" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialLiabilityToPay" xlink:href="iinn-20221231.xsd#iinn_FinancialLiabilityToPay"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="FinancialLiabilityToPay" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialDerivativesFairValue" xlink:href="iinn-20221231.xsd#iinn_FinancialDerivativesFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsLineItems" xlink:to="FinancialDerivativesFairValue" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/EquityDefictDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDefictDetailsTable" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDefictDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_EquityDefictDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract" xlink:to="EquityDefictDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InvestorsMember" xlink:href="iinn-20221231.xsd#iinn_InvestorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="InvestorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OverallotmentOptionMember" xlink:href="iinn-20221231.xsd#iinn_OverallotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="OverallotmentOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOfferingMember" xlink:href="iinn-20221231.xsd#iinn_InitialPublicOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="InitialPublicOfferingMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BrokersMember" xlink:href="iinn-20221231.xsd#iinn_BrokersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="BrokersMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsTable" xlink:to="EquityDefictDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AggregateOfOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_AggregateOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="AggregateOfOrdinaryShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShare" xlink:href="iinn-20221231.xsd#iinn_OrdinaryShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="OrdinaryShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityReverseSplit" xlink:href="iinn-20221231.xsd#iinn_StockholdersEquityReverseSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="StockholdersEquityReverseSplit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AuthorizedShareCapital" xlink:href="iinn-20221231.xsd#iinn_AuthorizedShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="AuthorizedShareCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SoldOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_SoldOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="SoldOrdinaryShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="tradableWarrants" xlink:href="iinn-20221231.xsd#iinn_tradableWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="tradableWarrants" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NontradableWarrants" xlink:href="iinn-20221231.xsd#iinn_NontradableWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="NontradableWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateProceedsReceived" xlink:href="iinn-20221231.xsd#iinn_AggregateProceedsReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="AggregateProceedsReceived" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="iinn-20221231.xsd#iinn_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="GrossProceeds" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradableWarrantsDescription" xlink:href="iinn-20221231.xsd#iinn_TradableWarrantsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="TradableWarrantsDescription" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherMaterialNoncashItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherMaterialNoncashItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="ifrs-full_OtherMaterialNoncashItems" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NondirectCashExpenses" xlink:href="iinn-20221231.xsd#iinn_NondirectCashExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="NondirectCashExpenses" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAndNoncash" xlink:href="iinn-20221231.xsd#iinn_CashAndNoncash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="CashAndNoncash" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpensesDeductedFromEquity" xlink:href="iinn-20221231.xsd#iinn_ExpensesDeductedFromEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="ExpensesDeductedFromEquity" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateAmount" xlink:href="iinn-20221231.xsd#iinn_AggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="AggregateAmount" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_AdditionalOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDefictDetailsLineItems" xlink:to="AdditionalOrdinaryShares" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfIncomeTaxTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfIncomeTaxTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ApplicableTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="ifrs-full_ApplicableTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CarriedForwardTaxLosse" xlink:href="iinn-20221231.xsd#iinn_CarriedForwardTaxLosse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="CarriedForwardTaxLosse" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetS" xlink:href="iinn-20221231.xsd#iinn_DeferredTaxAssetS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="DeferredTaxAssetS" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfLeasesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfLeasesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_LeasesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfLeasesTextBlockAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_VehiclesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseReceivablesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseReceivablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_LeaseReceivablesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="LeasesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="leaseTerms" xlink:href="iinn-20221231.xsd#iinn_leaseTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="leaseTerms" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilityAmount" xlink:href="iinn-20221231.xsd#iinn_LeaseLiabilityAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="LeaseLiabilityAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="ifrs-full_RightofuseAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfLeaseAgreement" xlink:href="iinn-20221231.xsd#iinn_DescriptionOfLeaseAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="DescriptionOfLeaseAgreement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsTable" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_ShareBasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="ShareBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AdvisersMember" xlink:href="iinn-20221231.xsd#iinn_AdvisersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="AdvisersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DirectorsMember" xlink:href="iinn-20221231.xsd#iinn_DirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="DirectorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysOwnEquityInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_EntitysOwnEquityInstrumentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RSUMember" xlink:href="iinn-20221231.xsd#iinn_RSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="RSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="ShareBasedCompensationDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantTotalShares" xlink:href="iinn-20221231.xsd#iinn_GrantTotalShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="GrantTotalShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockUnit" xlink:href="iinn-20221231.xsd#iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockUnit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockUnitVested" xlink:href="iinn-20221231.xsd#iinn_RestrictedStockUnitVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="RestrictedStockUnitVested" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_TotalOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="TotalOrdinaryShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantOptionDescription" xlink:href="iinn-20221231.xsd#iinn_GrantOptionDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="GrantOptionDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="iinn-20221231.xsd#iinn_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="ExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantedTotalOption" xlink:href="iinn-20221231.xsd#iinn_GrantedTotalOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="GrantedTotalOption" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractualLife" xlink:href="iinn-20221231.xsd#iinn_ContractualLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="ContractualLife" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalGainTax" xlink:href="iinn-20221231.xsd#iinn_CapitalGainTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="CapitalGainTax" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NontradableSharesOptions" xlink:href="iinn-20221231.xsd#iinn_NontradableSharesOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="NontradableSharesOptions" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NontradableShares" xlink:href="iinn-20221231.xsd#iinn_NontradableShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="NontradableShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisableOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_ExercisableOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="ExercisableOrdinaryShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingPeriod" xlink:href="iinn-20221231.xsd#iinn_VestingPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="VestingPeriod" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsEquity" xlink:href="iinn-20221231.xsd#iinn_OptionsEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="OptionsEquity" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AuthorizedOrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_AuthorizedOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="AuthorizedOrdinaryShares" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantTotal" xlink:href="iinn-20221231.xsd#iinn_GrantTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="GrantTotal" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestOverPeriod" xlink:href="iinn-20221231.xsd#iinn_VestOverPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="VestOverPeriod" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockUnitEmployeesDescription" xlink:href="iinn-20221231.xsd#iinn_RestrictedStockUnitEmployeesDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="RestrictedStockUnitEmployeesDescription" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BoardOfDirectorsDescription" xlink:href="iinn-20221231.xsd#iinn_BoardOfDirectorsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="BoardOfDirectorsDescription" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAssumptionsDescription" xlink:href="iinn-20221231.xsd#iinn_FairValueAssumptionsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="FairValueAssumptionsDescription" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors" xlink:href="iinn-20221231.xsd#iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentExpenses" xlink:href="iinn-20221231.xsd#iinn_ShareBasedPaymentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="ShareBasedPaymentExpenses" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="strengtheningPercentage" xlink:href="iinn-20221231.xsd#iinn_strengtheningPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="strengtheningPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="weakeningPercentage" xlink:href="iinn-20221231.xsd#iinn_weakeningPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsTextBlockAbstract" xlink:to="weakeningPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Prepayments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Prepayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:to="ifrs-full_Prepayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeAmount" xlink:href="iinn-20221231.xsd#iinn_ExchangeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:to="ExchangeAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShares" xlink:href="iinn-20221231.xsd#iinn_OrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract" xlink:to="OrdinaryShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FairValueMeasurementDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:href="iinn-20221231.xsd#iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementDetailsTable" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementDetailsLineItems" xlink:href="iinn-20221231.xsd#iinn_FairValueMeasurementDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract" xlink:to="FairValueMeasurementDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MeasurementAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MeasurementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsTable" xlink:to="ifrs-full_MeasurementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedMeasurementMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_AggregatedMeasurementMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="fairValueMeasurementAtLevel2Member" xlink:href="iinn-20221231.xsd#iinn_fairValueMeasurementAtLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementAxis" xlink:to="fairValueMeasurementAtLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsTable" xlink:to="FairValueMeasurementDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedTermOfWarrants" xlink:href="iinn-20221231.xsd#iinn_ExpectedTermOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementDetailsLineItems" xlink:to="ExpectedTermOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="iinn-20221231.xsd#iinn_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !] 68# 2(  A$! Q$!_\0
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MC(Y%2.S0["...#3'A('3-,/7WIPD9:073W(6CIARO!K;TFPAU>XFADN5MC'
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M6HD=NC)%AN#FIJ2EIFJ%%6(M6OEM'LH[ZY6UZ-"LK!#G_9SBJ,LNT;5Y8TQ
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IQA?2E:A?XC2(OF,03C S4'>EI8+E0((CZT4MYU1.RBBG'8QK64['_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #- &X# 2(  A$! Q$!_\0
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M3M"X,3Q1R$ \9R1G\J][H#<S/$(SX>OA_P!,2:\7O?\ 4/\ 2O:M?_Y%^_\
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M\M^*8_XG]K_UZC_T(T >9W'4UU&D-$NF1[PN[_=R<5R]R.372:7C^SHLC/%
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B^'O@)? ]G=J][]JN+IE+L%VJH4'  _&NSHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "/ *\# 2(  A$! Q$!_\0
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MFK40.OUWXHZYJ8>*T*V$!XQ%RY'^]7"2.\TC/([.[')9CDFGE2S8 R:58B&
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I*  . !VIQIV=V9SK75D0R*>M .1[U.#FK=EI@N)?,;B,=>>M:W.8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #/ ,,# 2(  A$! Q$!_\0
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MJS?;<0.GN1P?QJK.)FG&9MVOB6,(R2Q-"[G)DBYY^AK;CN;+5%5!Y-RI'(.
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110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #2 '@# 2(  A$! Q$!_\0
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M/)&?I7@\#>*+75KG45NY-UP6,Q:3<LBM][()KK;4^)+;3(WT62,7[N)6D<#
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M6T\1Z5?EOL=VL^WJ44X'XXQ7@-A9_;KZ&V'&]L$^@[U[#I,4%C:QP0H$11@
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M73P6%M>PEV0]-Z=Q[XH ^A:*0$$ CH:* *VIC=I5V/6%_P"1KQ2?[IKVV_\
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M1&5VCZ!MO^/6+/\ <'\J*2U_X](?]P?RHJ#02\7=8W"^L;#]*\0GB)'6O=2
M00>AKR?5]--IJ$\!&-KG'T[4 <(8V!(]":88C6U=6>R<G'#<U"MFTCA$0LQZ
M "@!OAZ/;K$9_P!DUW=K_KQ]#6!INCM9RK/,P$F,*@[?6M^U_P!>/H: /,_C
M,/W>E?[TG\A7ENF_ZR7\/YUZE\9O]3I7^_)_):\MTW_6R_0?SH ZDR7S(0TK
M!6QD%P.G2H)0WWGE5VZ<-DTC3.P(^4 ]<**CJFR(Q2Z6+5K*4/W<CN*N'4@(
MUB3(0')SZUE_,JY[&DS6D:KBK(B5&,G=EF\D$FP#MFNL\#ZC<ZK\1+.>Z<,Z
MVDB# QP%KB\,06P2!U-=3\/'$'CJW;&0+>4<D#L*SE)R9HHJ*/INV&+6(?[
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MIQ_%<N7_ $Z5V-G96NGVZV]G;Q6\*]$B4*/R% #XX(HON1JOT%2444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %? G # 2(  A$! Q$!_\0
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M&QPP[USDK7VD'R[E?/MN@:KME>*XW6<H]3"Y_E6<J=O>B=%/%IOV=1:]GO\
M\'Y"R1R6SE)0<=C25>-_:SKY5TIB;MN''X&JDD*Q O%(LL7^R>E92A?IJ>OA
ML:H>[)WCWZKU&44<$9'2BL3VD[ZH****!A1110 4444 >?4445]:?A 4444
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M'CN+B!D/6)XF88_,C\*3*3.+NO 5F^DWVHZ#K]EK$=@N^ZAC1XY(TSC< PY
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M.0?S%3^(=9;Q#X@O=7DMHK:2[D,KQ19VACUQGU/-17<61N JC6,E9EBU/9W
MM+ZWN6A280RK(8G^Z^#G:?8U!14C-3Q!KUWXCU^]UB\VK/=R;V5?NJ.@49[
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MH((^E6'[_4_R%!M9,WM7U^UO&MH['P_IVF+#+YN8-[NY /!9B3CVHE\:WO\
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M9X9$:33LL"%(E;\/X:[XSJJ*3@?*5L/@959.%?2_]?B>/^'GEL-\_D&02H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCN.HH UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*DUP8I JON/S!E/W\1@D 9Y-5]2\6ZC:BX2/)EA>X# VYX7<HB.<8)(;(]:
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M% &E6;<Z_I5GJ L+B]CCN2%.QLX&[A<GH,XXR:NVT;Q6L4<LGF2(@5G_ +Q
MY-<SK.BZI?7^J0V\5L;34H(8FFDD.8MN[<0N.3@\<CF@#J\CGGI42W$3S21*
MWSQ@%N" ,].>AZ5P\G@V^:XU-ILW'GF0I(MP$,BLP*JWR'.W:!@DCCW-9WB+
M1-5BMK874<,J3*B3+#"S1#;$RD;0C8R2,?+P?2@#T[(]:9)*D43RNP"("6/H
M!7$Q^$[F8"]M8UL+B61#&S,?-@A^R>5L)'</@D#KC/6JD?@K4$TY(GMK:?[R
MR6LT_P"Z+&/8)1A1@@Y/3)SG.: .\BOK6=;<QSH?M$?F1#."ZX!R!^(_.K&0
M>]<C=^%[F:/161+;[39V$EH;@_?A9HU D0XSP5]NM/T;0;^PL=3$=O9VDEQ;
MI%%;HQ>+S%5@9&X'WB1GOA1GF@#JLC&<C%,DGCBDC1F.Z1MJ@ G)P3^' /6N
M$LO">K6Z0,(K598[\W$:LRF.)"L88; H&<JQ&W!!/7DU8A\+:BJR1,D*VOVJ
M6546;$K*\,B'=(%!)W.,$@D"@#L_M$/VA8/-3SF4N$SR5! )QZ9(J!-3LI)X
M88[A'>8.4"G.[8<-S[$US6C>&KNRU+2KVZM+%GM[>:W+(JJ\2LZLA&% )P"#
MC'7ZU27P,QMOLS65BBQ"\\LIP&>4@QN1C@CI[8XH [W/..])D<\CCK7):/X;
MO[/Q+)J-Y+YN2S"82\D,H&QAMR0"..<=^M5G\+W^QP]C8W)6]:>9GD(-^A9R
M%D^7C;N7 .1E?2@#M\CUHR/7K7"0>!IF\DWJV\[QO;8)=CLC5W9T!/;:P7W
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M07'@>::"1([Z&%KF,QW6("X;]YORNYL@YX).?7M0!T,NOZ7!J<VG37L4=U#
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MV;[(;-_/$FS>!LQGE>0:Z'2=5M-;TFVU.Q<O;7*!XV*E3CW!Z'MB@"[1110
M4444 %%%% !1110 4444 %%%% !1169J4ERDZ!#*L/EL0T*Y8R9&T'VZT :=
M&:BMC*UK";@!9B@,@'0-CG]:X3Q5I&J-JFL:GI]M/,SVD5JT*?\ +>-MV[;_
M +2$AOID=Z /0**Y#26US_A(D6X-X$#S+<I(H%NL0'[HQG^\?ES_ ,"SVJG=
M+XJACNI[66\EFF^T@1N%VQJLB^7L&.#LW8]: .[I-R[]FX;B,XSSBO/MWBGS
M;)%NKS[,=QCE,#%@WF#"R#&2-N>3@?E5[P_#JDGBG[5?I?[Q;3)*9U B1S*"
M!&1VVC_)S0!V*RQNSJCJS(<, <E3[^E.) !)( '4FO-H[#7-+^U+;'5 \TUQ
M-;E K;Y_-.WS21]S;M//&-WM726UMJA\/ZU)=2W,UY,9Q#%( 511N"!%QT(Q
MUSF@#I@01D<BBN!FLO$,UM<KYVH 3K/ (5*HJ)Y *%<#@[^,^^*DMKC7(9;2
MU2/4WAD:S*O+'G:@R)@Y/0^O?IB@#N5974,K!E(R"#D&@L%&6( Z<UYIIBZ]
M9Z#':I#K'E+;01R>9\CP2\[MF 24 "Y '<>]6K>VUR1_M%TE^UW/;:>3'(H,
M099OWN5QA6 P3]21[ 'H5%>?P'Q//B/S=3C>1XA>,Z*!&QG4-Y/'W?+W9ZC&
M#UKH]"O)UB?2[QKB2\B\YP\JY)B$K+&6;IDJ ??K0!N*P90RD$'D$=Z REBH
M8;@,D9Y K@-/A\3PI:2AKM6C%K$+8HJQ8,/[PD =G_(U%IG]M6U[_:+Q:O)G
M[&MWYT0+M@3>8J =5#,G3\.* /1:1F"J68@*!DDG@"O/[>?Q2UJSRIJ(O_L.
MZT0HOEF0A]WF]MP^7 ^F.]5K^/Q!<:%-;RR:O+!-;W"QK#%B7S2BA4DW#)4Y
M?G ';/2@#TH$$9'(HKFM3^WQR:/$!?)9B,B;[$ 7\P!=@;T7[V??&:PXV\43
M;D$FI1RNR+=ED4+&WGH/W/'3R]^>O&#UH ]!HKAEC\0V$4SF34[T,EW'Y;,H
M8!)0(64A>&*$G/.<=*EAGUL>#B)XK][G[6T:NI*2K#O.US\I)XQVR: .TI-R
M[]FX;L9QGG%<+9CQ1+':W<\MZL\:6J^054(Y)82EQCGC:3SQ4WANVU*;6+F>
M\.I)+)8+')+<J $FWL6$>/X1D$=NE ':T5Y[;3^-9&*M'.CM$S(75=JO"A7!
M/_31RK?0=J@N)_%$>@.8O[3EN3N:(A"&CD6,':PV_.&;/H!@C/2@#T@L%4LQ
M  Y)/:EK@M0A\1L-1D5KR59C=Q) R*T:H(<QD#'4OW/7.*BU2X\0Z7#?WPN+
MS8SW:*C!=D:@@0E1C@DDX/?- 'H5%<_X/GDGT:0SW5Q/.ES(L@G.6B.<A,X&
M< CGO704 %%%% !1110 4R6))XFBD7<C#!%/HH \0\56]WX,\;+>3NTFCZD%
M@9S_ ,LF'W3]*V*[KQAX=@\4>&+W3)5!>2,^4W]UQT/YUY7X3OY+_P .V[7&
M?M,!:WFSUWH<?X4 =-:?ZU/I7BGQ?'_%7+_UZI_-J]C>]ATZTEO;@D0P1M(^
M.N .U?/'BG6;C7]8GU"XX,APB=D4=%% %W3D#6F6D95PN<*3VJPPB"X7S"?4
M@ 59\*M*WA#5<--C=%G8@(^]W8]*K2#GH?Q.:=B5*[L-R2 "3@=.:<(B1DX
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M3;N#8(R00"01UJK;>+K"ZNVMD6;S2V(H_)<.1L5MS*5&T?,.?<4 =!2!0"2
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M3$8IT.*5I"PQ5*UB6I7.E^&HQ\2=,QSC=7TW7S-\,QGXD:9]&KZ9J2PHHHH
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M% !1110 5XET^)WB\>KPG_QTU[;7B4Q*?%'Q8 A;/D'C']TT 6?$//A75/\
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MRY$4!B5/? (/\J -E6#H&'0C(XQ2UF0:Y;SRV<?DW"-=[_+#H.-O)S@G%:=
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M('M85N;XV8>59!&WR$;<?>XSM_'G-7(]4\5FS^TSSFWE>1X3"UIE(?W(8.<
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M5*$$_-UPF.<CGIP*T+?PMY*PQ2W2RP03O+"I@4$!@_#'N?G//M7144 <S?\
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MLDL6\W'0'MBH7L+UT"_;3QCGIZY/ZB@"9)+Q@ R[2""25ZCG/X]*'EO 9-L
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M_/N7_@+_ ,C?HK _X3?PQ_T&[/\ [^4?\)OX8_Z#=G_W\H]K#^9?>'U'%?\
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M&B78DB615C6201!SR Q&0.*K#4+P0F(74VPD$C>>V?\ $TPW=PRJIN)2%;<
M7/!]?K1>(<M?JU]S+R:#>NT60B1RX*2.< @]/TYIAT*_ R8AW_B'8XJH+NY"
MA1<2@ ;0-YZ>E N[D9Q<2C(P?G/(HO'L'+7_ )E]S_S+Y\/:@))%$:E8\[FW
M<  XS^-,?0M0C*AX=NX@#)]3@5!%JE[$CJMQ(0Z[3N.<?3/2HC=W+#!N)2,
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BZN8V*[EZ'W%0U)-/)<3-+,Q>1N2Q[U'0]]"HWY5S;G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #S FP# 2(  A$! Q$!_\0
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M[C_^)KCJ*.2/8.:7<['_ (6MXX_Z&&?_ +]Q_P#Q-'_"UO''_0PS_P#?N/\
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M< $#I]*['7-6'ASPY) FS[5/N8LK9W$]_P#ZU<1X;T^/_2-7U#YK>V^=L_\
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M;-S=3%<JF#^[7:!E<G//2MR?XA:=/!'&^DW,HD>U^U1RW.8RD"X&P#[I/?\
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MNS>>WNHI2(OD55/SRB4QO&/<8W9]*YZV\6Z_9N[6^JW$9>-(S@C[J#"_0@<
M]:CLO%&N:=%;QVFJ7,*6\K3Q!6^Z[##-]2#2M+N%X]CH/#NA:/%J_B2/49%O
M(]*MI#$=C;)'#A=Q (.!GCGO6CJWP]MIM>N8[6[2R2XN7M["W\MG#,D2NVYO
MX1S[UP,%_=VWVCR9W3[2ACFP?OJ3D@_B!6BOB[Q B72KJUR!='=-AOO';M)]
MC@8XH<97NF"<;:HZ6T^%E]?6L5U;W\303>0T;;#\R.!O?Z(2 :Y_2?#UMJ-K
MJ]W-J0@M=.VC>(2YE+,54 #U./SJO;^*==M;>"W@U2YCA@A>")%;A(W^\H]C
M5""^NK:UGMH)WCAGVF5%/#;3E?R/--*7<+Q._LOAK:)/ VI:C<1V\L%PQ40[
M9$DBCW\C)XP>AP>.U8>I^"CIGAJ+5GU. R20Q7"VYPK/'(3MV\Y) P2,=^M4
M6\9^(WNH+EM6N#- S-&_'!888].<CKGK52Y\0:K>:>MA<WKRVR]$8 XYR!G&
M<9/3I22EW!N/8S:***T("BBB@ HHHH **** /2_@7_R49?\ KTE_I7TY7S'\
M"_\ DHR_]>DO]*^G*XJ_QG71^$K7[[+.3U8;1]3Q533$']FJP_Y;REL^Q/'Z
M 4NM2^7:@ \_,P_ <?KBK-M (;>VB'2.,#]*Y^IL<+XZ07OBG1=/'.]PS#VS
MC^6:[;35_<ESU8EC^)S_ (5PMVYO?B5/*.1:0LJ^QVX_F]>@6VR&V4$@ <"H
MANV;U6^6,>R+%%9.K:_:Z3")+AUC4]-QY/T'6N/O_&]Q?V=T+&S+[%!7>Q7.
M3CMS5.21DHMGH+S*N<$ #JQ. *Y?6?&^BZ,CLTINYE.-L?0'TS7%6&KZAJEJ
MNFR//%Y<>]OWF^9N>G/"CG\JLKI5R%']FV$:/&1@RKOD^H)^6A2OJ)HCN=<\
M5^*HS]EM3I]H>KW#>6JC^9^O%9CVWA+1V\S4-1DU6\!R8;<_(&]S_P#7-:[>
M$=2U-]VK:F0@Z1 [L_T_+-:EC\.--B7?%#*SD9WR #/T_P#U4U.2^'0EPB_B
M.2D\9ZI)$8/#NDQ6;.<!T3Y\>I/2LZ^\/:S_ &=::CXAU-Y8KFZ19$,V @()
M&??.*]+L_"%[+,@OFMK>SC;/DV^6>0>C,<#![X%:OB;2--UC0)],NI8[5'7,
M;#&8V'1@/:A=RM-C T?PE:V6-\"B90"<_,QS[]OPKE?B?''X?U7P]XDBBQ.D
MQMY@G!DC'(4D_C71:;>^+K>-[6ZCL=4MXOEBOMQ@+>A8-P?J*YSQCX6USQ[J
M-I:38@TRV<9F1>'=N#@MC./4<4KA8U(_',^HP1K)+#!+(N4L[5M[A>Q8CD#V
M.*W].6Z&F7$0\Q93B=-QS@CJ,>XJ#PIX%TOP[YUE OS189R.K$]R?\*ZY8$@
M3$*[<'.!WHL%SR#QU")XI)X1^XN5&X8X!Q_G\17&Z;<3:<MM>QKPCAD;.<,I
MY'^>QKV;5] 6^@O[5$.T@36X/OG<H^ASCZUYYX7A$.KW^B7,*R1WB$K&XZR#
MT]#CD?2O+Q<&I*2/J,JQ<(T90FK_ -?Y?D>C>'IX)(8FB*F"X3S8L?PG^[^!
MJ;Q@N[PW<E>FP-]/F%<1X+O&TW5I=$NB3Y9,ULQ_BC/W@/?O]0:[7Q1YMSX4
MU(68$CO 98C]/O#\N:]&,N:/,?/5J?LZKCT_0QM"UF:Z\/VUY91()91^\!Z[
MQP!^."/;(K<L8[*Z66YCB42[R0_1AN&<'Z5P?A0S0>&%MYKNW,CY,/D@C:,Y
M&??/>NQT>]^U[9D&Q;J,,0.JN#AA^>:OH9224G8Z#3)6N],EA( =2>M>:>,G
MSKX7^[ H_4UZ!IS&RU22VDX1CQ]#7GWCF%[?Q;<JRD(40QD]UQ_CFF09VCR;
M/%&C\]3(OZ&O1+F9+>%II7"1QC+,W0"O,+.7R]?T5_\ IN1^?']:]$UJT>]T
MR:"-!(_#"-G*!R#G:2.F: +]E]CE5;TVDDAQN63(0'^IJ1-8BO8Y&L%*X;:_
MF#:$([8/>N'M/B/%IFVP\5Z3=:3,%'5#) 1T!#KGCBNHLKRVOM2%Y;IFP-L"
M'((WN3Q@$=AGKZB@9?CM3*Q=F+L?XV&3^%2+JVE:;<FV\Y#?8X65]N?^!'C\
M!4%Q>2R#;'A$].Y_&J9"2D)<1@QD\G:&Q^% CL=-FDNK9979<D?P8QUJ]\WL
M:P]$TS2+)6DL4$;2 ;B"1NK< ]":8!SZ4TDYZ4^FMUH ^&J***]0\X**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#TOX%_\ )1E_Z])?Z5].
M5\Q_ O\ Y*,O_7I+_2OILD*"20 .YKBK_&=='X3$U<?:-0A@[91/S;)_1:V'
M8)EB>U<S?ZK:VNH&[EF4^7(2JCG=\N!_6N5U7QQ-=RF.W?RE_P!GEO\ ZU<K
MFD=,8-FM:6":/>7^IZQ=11/=2;EC4[FP&R..^<#\J@U#Q?=S9BTV'R$Z>=*-
MSGZ#H*YIKHN3/<R$%OXI&RQJO+K%O$ORN O][N:S3Z(W<6W=ER2 S3&XO)GF
ME/5I#DTR>>6T DA"I$P\N;<<?(>X]P<&JEM+J6IOML;4A3_RUE'ZXKH]+\!R
M7KB74)WN#UP3A15)$R:2L9VB7:;BUG'&!OVM((OF88P?G/0'-=3-J-GIV'^P
M7CJ,9:1]H/\ ,_K6[8^&+&S\K"8$9W!%X7/OZUM[0.@%6DS%LX%?%-Y(Q73]
M/2($_>6&25_Y5*+SQ3.A"QWC*?2!8V_,FNZII<#O3L*YQUIIOB&Y8"Y$L47?
MS+S!_)1_6M./PXP.7NA%D\^2G/UW-DYK=WYI":+(5R"*TAA55"EB/XG.X_K4
M=\?DA'_39/YU:JM>I\L)9@H$JG)I@RA&=OB2Z3^_$#^1_P#KUJ"+C<YVBN8U
MC5ETW6S?0A9@L!4J&&"3C'/X5R,_BR9/.EU.6XOII9,Q:= WR)Z9(Y.?3-2W
M8:5SO[R\MOLUQ)&X>.$Y,B#. >",UY+XHMY[;6'N$ CN8'619$/WAU5Q]:OR
M^,M5TS4+:XU=[2VLL^6^EP$';&>"7/0$=0HYKI-3TZWNM)< K,]O%E)>[V['
M*D?3BL:L.>-CJP]3V-1-]3C]8=[^RL_$5@-MU ^\A?X7ZLOT/4?C7?Z)>QZG
MI,-S:$;)QYD:GHDG\2'V/-><:1-]@U&?3;DC[-<\9[ _PM6WX7N)-$UV;1Y2
M5M[K][;G/W9!U K&A.WNLZ,32O>W37Y&3XQMD\/O8/9N5MS,&B4R8*JQ.Y>>
MXR1^%:GA34B;VZM2PWQN+J,?7AP/Q&?QKH/$&EZ?K5L4O(-Z[C-$-H)CE ^9
M0#Z\$5P\-Y'9^)K:_B5A"3Y;Y &1]T]/P-==];'G[JYZ5?3(SB6-_F!!'J!Z
M5@?$"WDO]+TO588V<J&ADVC)'IG\OUK0>>U&!)*R$'"*!G.?>KZP/>:-<6"\
M-D.A;@;A1%B:/#M3U(V%]H[#AA=CK]17K@OY@>=K?45S^H:1;SSHM]:(TT+[
MD9ARI'<&M!)MP[9':AOL-(TS>I(NV6$$>AY'ZU*+N)NI(^HK,CWRR+&B,SL<
M +R372:?X=(Q)>]>HB']30FV#217MK:6[&81E?[QZ5=&B2$?-,@^@K:2-44*
MJA5'0 <"G;:T((;$?9(1')\^!C(%7%G@[';^E5F6F%:+ :(=6^ZZG\:JR:C
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M-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]'^"/_)0E_Z]
M9?Z5](;J^;?@F<?$%3_TZR_TKZ-W5Q5_C.NC\)&)AYLEN%92"'!/0Y]/Q_G7
MFWC#2I]*OY;JWW'2K]\W,*CA),8W?C_.O2)5W8=1\Z=/?U%%Q;17]HV4#JPQ
M+&PZUS2CS*QTPDXNZ/$?!'B63PKK;Z1?MFR))C?&>#T(]1ZBO<M+O;/4(!)
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M3M.@L;=KFZML11L'+ (V]E*\8SCCH,FDIOL/E7<\[J1X)8XTDDB=$D&Y&92
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M/X+''C]?^O63^E?16[%?.?P9./'J_P#7K)_2OH?=7%7^,ZZ/PDNZD#.C%XF
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MD#U7((/\ZGT3P^VF0N;N]N;R1SDM.V3UR,#HI_6M.VM;>PA2*!  B[5XZ#T
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(_O?THHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
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MJT444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=B[G\MB!Z\=*YOPW"7DG$A)5'QD^W&?TKH]10M;%"V"!U'?G%8_AEDB:0R,
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M[DY%=5@Y_ TPU:G);,S=.$MT<U'X(T.)0H@F8#^],2:YC6[&UL_$BV4*>5;
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M=8-5FI+W.;FNN6_2-K7U/2]9UJRT'3GO]0D,<"D+D*223T  INB:[8>(=/\
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M+S/3-?\ $^E^&HH9-3F:-9F*IM0L3CKTJAI?Q \-ZO=I:VU_MF<X194*;CZ
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M"VN\J.VXC]#40^UQ2"4*C..C%%)'XXI.Z*BUU)8-0EO=$TZZNX6MYYXQ(\+
M@J3V.?PK OEE_L=4A/[S<>G48[UL:O/.UE:SMC<I9G &"2/_ -=8.H7OV;2(
MIL[<N,L>G/3/M2EL:TFN;5:$=C+.]_I\$\LA.]AA^@R.<?7%=%I=TL%K),[
M(L@]\#S'%<Y?W\$<^E7\3(Z"Y0/@_<W<?S]:U;'<MMJ$<2,9(7D<(#RV&#X'
MX,:B%];FE=IV:*-]#XDN[VZ;[4HM5D9HY!+M"KDX!X]*U;6RNK2%KE[XS[
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MAX>.]^MSICFU5)1<4TH<C6NJUU]4]4>6VG@NX\5^+-9U+7H;NT@\P); -M+
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MV,02(^P95F#9(]S67:Z-8S^&=<OI8B]TL]V\<I8[HBK,1L_N\C/%1SS_ #_
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MV.&X96V_(<_+GMD@#\:I3:3;Z?\  (GAX2G3A3>DE>[7G+IZ+IN;RNK E6!
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MP,#:PY'%7Z*7*MK%*M43YE)WW^>WY%2PTVUTV-TME<;SN=GD9V8^Y8DU(UG
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M^M_AGXIA\4^#+.;S ;RV007*9Y#J,9_$<U\D5O\ A'Q?J?@W6%U#3G!##;-
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MM",X_>#^'GUKE[VT:QOI[1Y(I&A<H7A<.C8[JPZCWIII["::(****8@HHHH
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M#1/BAX1\.V][ ]EI4,[-,'&PO+O;KTSMVBN)\+S0IX5\?J\D:M+:*$!8 O\
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M#IL=O.EQ=)$;5D'(()SCZ5Y514M7U12=M#V_P_?6D7B/P*[W$!2+0)U?=(
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M$K6_V?'. -H7/UXI>\/0B@T+5;EV2#3[B1ER"%3.,-M/Z\?6AM"U5'D1M/N
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M2"T\-:O>7T%JMC,KS;<,R'"@D#)_$_6F6V@WU[!>R6L9F-I($=$!+'.[D?\
M?)K7;QU=R7 EFL8)!O64QM(X4RJP8.,'CD<CH:SM,\0RZ8\[_9(9FEF2X4N6
M&R1"2I&",C)Z'K1[P>Z0W.@:C;K(ZV[S0QHCO+&I*KN4-C\ 1FI+;PQK%SJ,
M-E]@GCEEV\NAPH+;<G\3]:NCQE>A5?[+;FXB4K#-\V8P556^7.#D*.O2GIXT
MF208TRU\CS?/\G?)CSM^_?G=GJ/N]*7O#M$QH=)NKEITMXS*\4@C*H"<GGGV
M'RGK5)U9'9&&&4X(]#6OIOB"?3)9G6!'$TRS,"S+R-W (/3YC69<S_:;J:<Q
MI'YKL^R,85<G. .PJE<EV(J***8A\2+)*J-(L:L<%VSA?<XK<O/"5];Q7$D$
MD5Y]F9%F%N&)3<A<'D=,#]:P.M;J>*;Q+I[@00[FF24CG&5B,0'7IAB?K2=^
MA2MU,N?3[RU2%I[:6-9O]667&[I_B/S%6U\.:PTYA_L^=75PC!EQM)QU].HS
MZ9YJ75?$ESJS6K31(C0$,=K':[ *,XZ#A1TJR/&%\+>YC\F,-/<27 <,P*%R
M"R]?F' X-+4-#-FT34H+N2U>SD,J,RD*-W*G:<$=>2!^-++H.K0Q/+)IUPJ(
MVUFV=#G&/KD@5IQ^,)8FD:+3;8.TCNC;W/EAW5V4<\_,O4\\U!:^*[ZS96BC
MBWKYFTMDX+R!R>O8J*/>#W2*T\,:M=WAMOL<L152[NZG:HVD\D?[IJA;Z?>7
M<$DUO;2RQ1_?95R!6^WC:Y:5F:P@8 EHD:1R(F*LI(YYR'/!XJAIGB2YTO3)
M+&*)&1I#*K[BK(Q 4].H( X-'O!H0MX>U=)6CDT^X1D3>^Y,;5SC)_'BIK?P
MOJEQ<21);N !)L<J0)"F<@=^Q_*I+CQ5>7-K+ T,(665I21NSDR^;CKTSQ]*
M==>*I[R5YWLH!=-%) 9E9_\ 5OGC&<<;CSU]:/>#W3._L75,.?L%Q\DGE-\A
MR&SC'YD?G1JFDW.D2P17:[)9H5FV=U!SP??BML>.]0"IBWA#HX96#,!MXRI&
M>0=O?UK%U74O[3FA86T=O'!"L,<<;,P"@D]6))/-"OU!V*%%%%42%%%% 'W/
M1117EGHA1110!D>*O^10UO\ Z\)__1;5\7+]T?2OM'Q5_P BAK?_ %X3_P#H
MMJ^+E^Z/I77A]F<U?H+76:;INB7.EZ>U[,!-*1$0LRIY>Z1P6;C)P IY]:Y.
MKBZ7=26\$T4+2+-TVJ>/GV ?B>*Z&8(ZJV\-Z')Y;R7)P;99/)%PGF,=P#MU
MQP,D#/UJ)-.\/-%=6B*,JMJQO'N1E%8CS&5>AQGIR:YQM$U)+47+6,P@.2'*
M\<#)/Y"ICX>U'R(9$MGD>0.QB53N0*>2?KGBIMYE7\CK+70]!L]1>12LAB!#
MQRW4>R,%'PXSG>"0O'8GZ5@:/:Z7+HDTVH-N:)I'6)951GPJ[1GKC)/Y5DOI
M-]')%&]G*KRQF6-2O+(!G<!Z8YJ:'0M2F,;?8YDC=E7S&0X&[&#ZXY'YT6\P
MOY'3S:)H;&&&V2.8PBY7<+Q4:Y=9/D4DG"_(<Y[XK/M++28[O7;=5CNA#L-I
M(\P7 $B[B.@;"D_4"L*ZTJ]LH8YKFTEBBE^X[K@-QGC\.:J8II>8K^1WKZ)X
M;U#4KJY6;RU,DO\ HR7"<@3%=RG@?=Y"_P!*X-PH=@I)4$X)]*3 ]**:5A-W
M"BBBF(**** -#09X+7Q#IMQ<B,P1W,;2>8,J%##)-=5+>:%JT<=SJ$]L]P(@
MLPED<,J?.3Y?]Y\[>O;\:X_3K3[=J=M:<_OI5CX.#R<5H+X=E&L:983W,4:W
M[(%F4%E0,0.O1B,\X[\5+2N4FS3U*+PHFAR3V,H:_*!EAW-P9,<?6/:V?7<*
MET]O#]U::>+T6*216;+M+%"\HDY\P_[A.T^M9D/A.YN=A@N[61'$C@@G(C1M
MI<C'0G@=ZGM?!5W+(OVF[M[>'S'B>3E@K*KL.W(.P\BIT[CU[%V.YT'3UFDM
M4LI+>2QD01R2N97D)'RN!T'ICKBE:/P?YQMRT0A#E_/5WW$>=@)]/+Y]>_6L
MM?"%^UI'=--;1PM'YS,[D;(\$ACQR"!V]1ZT2>%IIO$%WI>GRI+]G,?S.V,A
MMN6Z=!NR3Z<T:=QZ]C9#>'?LKVC2V"RLRRF-)'-N9@D@'S==G*Y]S5MM%T"/
M1O[2@M(;JWDG"MM=MR#>JL4)ZC[P Z]#6$/!TT5I</?74=K+#%+*0WS#Y #M
M('0G-5->T%M(97AN5FMG94&&RR/Y:N0PQU^;M19=&&MMB?6+&RT3Q+:I&T$U
MI"ZJ_.[S-C8=F'8$@X'I6O=77ARZS:7AM%A26>19+1F^0&52JIVP5+&L";PO
M?0WUA:M)#NO59HW)*J-N=V[(R,8JS_PB%RJE_M5M.GE[P8),XRI9"<CH0#^5
M/3N+7L7(Y-$LO&-LUJ]JEH()5D?S28F8HX7)'(SE0:M%O#CVRVJ2V)>)VD2*
M61Q!O98@_P W4KP^WW%9?_"%W@DDB^T6SL#M61)/W88.48,2,\$&H+CPG>06
M[SI=6<\:1^:QBD)PI0N#R.X!_*EIW'KV-<6_@_Y-LL!MR_R,\CB4MN;B0=H\
M;>1S6'XHGMKC4X#:O;LD=I%&WV=B8PP7D*3R1FK"^#KS8SRWMC#M!8B20@[1
MM!/3_:%8=U;26=Y/:S "6&1HW .1D'!_E325]Q-Z;$-%%%60%=K%>:%=167G
M/#'<06D4/F*S!G)BD#*>W#;!^-<56];>$K^[6!89;=IYMF(-_P Z[P3'GC'S
M8X^H]:F5NI2N=9J5GHGA^5K&>VM?L]P(T8EW&]1.,GURJ=^A/(KD["'2/LE]
MYLENTBW "F9V!\CG+1XZOTX-2+X/U*5LB:!HQD>;O)&06#*.,DC8QP.PI_\
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MC&*G3N5KV->V'A*UU:WFMY+/]T\;H\TS;"@<$D@<B0+GCO6'I4^E21ZK%?\
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M_P"%0:W+H[W>BVT,EF;.&5Q,+=V95C:7())YR5ZU$_@V5IYH+2[CN#%Y;/*
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M_P! #5?_  #D_P */^$6\1?] #5?_ .3_"OM&BCZP^P>P7<^+O\ A%O$7_0
MU7_P#D_PH_X1;Q%_T -5_P# .3_"OM&BCZP^P>P7<^+O^$6\1?\ 0 U7_P
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M6\1?] #5?_ .3_"C_A%O$7_0 U7_ , Y/\*^T:*/K#[![!=SXN_X1;Q%_P!
M#5?_  #D_P */^$6\1?] #5?_ .3_"OM&BCZP^P>P7<^+O\ A%O$7_0 U7_P
M#D_PH_X1;Q%_T -5_P# .3_"OM&BCZP^P>P7<^+O^$6\1?\ 0 U7_P  Y/\
M"C_A%O$7_0 U7_P#D_PK[1HH^L/L'L%W/B[_ (1;Q%_T -5_\ Y/\*/^$6\1
M?] #5?\ P#D_PK[1HH^L/L'L%W/B[_A%O$7_ $ -5_\  .3_  H_X1;Q%_T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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D0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ!(NTY!P>*5U>Q:IS<'42T6E_-FC1113("BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N!\ _\BWK_ /U^W'\J
M[ZN!\! _\(YKW!_X_;C^585/XD?G^1ZV$_W2MZT__2F<GX;#^&](T/Q7"#]F
M=WM-14?W"YVM^']!797CK)\7='=&#(VF.58=",M3/ &GP:I\,HK"Z3=#/YJ,
M/JQY_K7/>%?M]O\ $>PTK4$8RZ9:RVRR'_EI'R5/TP17'%.$8+H[??\ \$^B
MKRCB*V)D_CIJHO6+V_\  7=>C1K75S/X*\:ZGJU]8RW&EZEL/VN%=Q@(['V_
M^M7;:7J&FZK9-?:9+#+%+RSQC!)Q_%WS]:Q[CQWH%M=W5CJ<DEG+"Q5DN(3B
M0>JX!!!K'\ 6^_5=?U2RMWMM&NW7[+&R[0Q&<L!V'^/M71"2C/EB[IW]4>3B
M*,JV&=:O!PE%12?V9K1)6[VUTNM-4BOX US1M-\&2)J-_:1$7$I:*1QN()_N
M]31X-@D3P+XBN!$T5E<O<2VD;#&(]AQ@>G^%2?#?0M*O/#0NKK3;6:X%S*/,
MEB#-@'CK7::VH7P[J*J  +24  =/D-12A)PC)]$S;'XFE#%5:--.\IQNW:VC
M6R7KN^FAP\/_ "0H_P#7FW_H9JM+XPT2]\#V^@V\<EYJ,UHEM';^41^\V@ Y
M/'!YS[59A!_X461C_ES;_P!#-:EWH,>N_#6RA6,?:X[*.6W<##+($!&#[]/Q
MJ+2:7+_*CI<Z$)2=9.WMI6:=K.V[[K:]FM+ZFWX<LY=$\*6-K?2#S+:#]ZV<
MA<<D9]NGX5YU/IT^K>%M3\8HA%\;X7EL2.1#&< ?ED_A6KJ/BJ;4OAA;&(DZ
ME?LM@1T/F=&_,#]:U+?P!-!IR6*^)M56W$?EF)679@CD8QTJI?O$HP5TE^>Q
MC0;P<IUL1)1G*?9NZB[R6G1MV]"QXFNO[<^&EU=6B-)]JM5=$0%CDD9&!Z<U
M9\8PRS:):+%&[L+ZV8A5)( D&367\.9I+*#4_#EPQ,VEW)5"?XHV)(/\_P Z
M[BMX+VD>9]5;[CS,1/ZG7]E%749.2\U)*WX6.!N]+O?^$IFT%('.D7]RFHRR
M ':H'+Q^GS.JG'N:V_#$4L>H^(FDC= ^I%D+*1N'EIR/45T=%5&DHN]S"KCY
M5*?LW'HE\T[W]79+Y#9)$BB>21@J("S$]@*\CGTZ?5O"VI^,40B^-\+RV)'(
MAC. /RR?PKL_B%J$MIX8>TMLFZU&1;2(#K\W7],_G56W\ 30:<EBOB;55MQ'
MY9B5EV8(Y&,=*QK)U)<J5[+\7L>CELX86BJ\Y\KE)=&[QC\2T[MV-JXU"+5?
M!-Q?PG]W<6#R#VRAX_"N%T'QMH%CX"M=*N0]Q=^2T7V80DAV).!D\=Q5[PM-
M)9^&/$OARX8F;2UF5"?XHV5B#_/\ZO\ AS1;?7?A796%Q&I\R!@C$<HVYL,/
MH:GFG-IQWL_S.E4L/A83A63<%4C9IVT<6T_/1KMZFGX$TB\T7PE:V=^-L^6<
MQYSL#'(6L[30/^%O:S_V#X_YK5OX?ZK-J'AP6UX6^VZ?(;6<-URO0_E_*JNF
M_P#)7M9_[!\?\UJU;DI\NUU^3.62J+$8OVOQ<LMMOBCMY6L=K7$^,/\ D<_!
M_P#U\R?R6NVK@O'MY!IWB7PK>W3^7;PW$C2/@G:,+Z5I7=H7\U^:./*8N6*2
M6[C/_P!(D=%XIT2SUO0+N"YA1G6)FBDQ\R,!D$&N;T?QA+9?#&SU29#<WF?L
ML2,>9'W%5R?PY^E2:OXZM=5T^?3O#<5QJ%_<(8D,<3!(]PP69CTQ5/Q!X2GL
MOAM86$,1NI;"5+B>./\ Y:==^/S/Y5C.5Y.=/HOZ_4]+"T%"E3P^-TYJB:3W
M2L[^B;Y5TO\ B7-1O_&'A[3QK-]=Z?>6\9#7-G%%L**3@[6SSC/>KGB#Q'>"
M_P!&TW29[>V;4T,JW=RNY54 $ #NQS7/J_PPDMED\I"[ ?Z/^],F?3;ZUT7B
M2X\)I!:Z/KL8B@,(>W9T8*@'&%<=& '2DF^5VDK:=?UZ7*E3@JL.:A*_O?82
MTMI[MWS<KU\UH[FMIB:U:6=T-6NK6Z=,M#+#&4)&/XEZ=?2N?TSQC<I\-6\1
M7R)+<IO 5%VJQW[5_I4'@B>=X]=@M[FYN]#B.+&>XR2>#N )Y('%8MDTJ_ R
M7RT1LEPX?'"^9R1GOZ4.H[)Q[/SV"."A[24*J3?M*:T7+I)-M6Z>:[FEK6I>
M--$T6WU:?4]/:.9T62%;;_4[^F#GYL5I^(]>US0Y/#]M D%Y=W;-',BKM61@
M!C!/W1DYKF(+G0\61U?4/$4FG6[(\,-[;%8E/\.Y@/F KI/%4B3^*/!LL3!X
MWN7967D$%1@U*D^5M/MUOU-ITH*K3A.FG\;;Y>5.T6TM^EM=?\R*?6/%'AW5
M=,;6I[*ZL;^<6[+;QE3"[=,'N/KZ5W=<5\103%X?X_YB\/\ 6NUKIIW4I1OM
M8\3&\LZ%&LHI.7->RLM'9:>C"BBBMSRPHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *14500J@ G)P*6B@!%544*JA0.P&*-B
M[]^T;L8SCG%+10%R.6WAFQYL,<F.F]0<5(  , 8%%% [O8155!A5"CT Q2D9
M&#THHH$-\M-FS8NS&-N.*<    , =J** N,$48QB-.#D?*.#ZT^BB@=[C0BA
MBP4!CU(')IU%% @HHHH 1D5B"R@D'(R.AI:** &^6FYFV+ENIQUI5544*H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS? +_LQX/\ZKWNGR&WW27;N05'W%[D ]J -:BJM@GE6YBWLP1V4%CDXS5J@
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M+:GJ5Q82FRDDBB6826<YE0J21@D@<@C\<TK#N;]%%%(84444 %%%% !1110
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MS65T(C"SQJK!TSG!# C(.<'W-4Y_"PE:YCCU.[BM;S'VN!=I\X[0I.XC*E@
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M ($^VH=*7_DS/-SXO\6W#?N?"MR#_M7&/TXIO]M>/K@;4\/6R#TDG8_R:O3
MH P  *6GRON3[>'2FOQ_S/,L_$B4_+::7!GW+?S)H_L?XC3<M?Z7!G^[;#(_
M(5Z;13Y?,7UCM&/W'FJ^%?'\H^?Q4D2^D40']!2_\(!XIG_X^/&=Z/7:,?R-
M>DT4<J)^L3Z6^Y'FZ?"J:0$W?BO5W)/(23 /YDU(/@[HKG-QJ6JS_P"]./\
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MN[36=3M[];---R$MFB5@Y6,.=Y//.<#&,5I#PI83ZO?7]["D[7$J.HRPX55
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MT; R=LRG'..Q]Q61H7Z*** "BBB@ HHHH **** "BBHDNH)+J6V256GB56=
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M"Q1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:\DVGQR>3/,=WEAT7*OCN#TQ[UJVUW%=HS1$Y4[75A@J?0BI GHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO]G3_
M )F+_MW_ /:E>Z5X7^SI_P S%_V[_P#M2O=*UK?&S.E\*"BL[7Y+R+P]J,FG
M@F\6W<P[1D[MIQ@>M<-"L(LIYXM8MPAM1^ZL;J269I]R^6Q#'AMW&.^X@]*A
M1N4W8]%EN(8&B6614:5]D8)^\V,X'Y&I:\TDBBNK73KGQ"<:A#JH74=\K)'
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M(H<N% 8]3CDTZB@"M?V4>H:?/92,Z13H8W,9P=IZ@?45.B+%&L:*%10%4#H
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M%UB22,@N.#G(-:R6=Y+Q<S1JA5<K$I!SW&23Q6CBBG< HHHI %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+P6/G+<3A$D,T>/+974,-O&>AK*V+_='Y4>P7<?M'V/M#_A*?#W_ $'M+_\
M R/_ !H_X2GP]_T'M+_\#(_\:^,0B_W1^5+L7^Z/RI>Q7<M2N?9O_"4^'O\
MH/:7_P"!D?\ C1_PE/A[_H/:7_X&1_XU\9[%_NC\J4(O]T?E2]DNY:U/LO\
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MKX]V+_='Y4NQ?[H_*D:+!I]3[!_X2;0/^@YIO_@7'_C1_P )-H'_ $'--_\
M N/_ !KX_P!B_P!T?E2[%_NC\JFY:P,7]H^O_P#A)M _Z#FF_P#@7'_C2_\
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M2?XU\K #TIV!Z4OKTOY2UPI2?_+U_<CZG_X2'1/^@QI__@2G^-'_  D.B?\
M08T__P "4_QKY9 'I2@9( &2> !4_7Y?REKA*E_S]?W(^I?^$AT3_H,:?_X$
MI_C1_P )#HO_ $&-/_\  E/\:^8FL[A&VF!\YQPN>?3BFK;S,&*Q.0O7Y>E+
MZ_+^4I<)4'_R^?W+_,^G_P#A(-%_Z#&G_P#@2G^-+_PD&B_]!C3_ /P)3_&O
MF1K*Z12S6TJ@+N)*'@>M/ETV\A2)Y(&59L;">^:/[0G_ "_F/_5'#_\ /]_=
M'_,^F/\ A(-%_P"@QI__ ($I_C1_PD&B_P#08T__ ,"4_P :^96L+I1DP..O
M;TZTGV.X$JQ>4V]EW!?44O[0G_+^8_\ 5##_ //]_<O\SZ;_ .$@T7_H,:?_
M .!*?XT?\)!HO_08T_\ \"4_QKYF-A=*H8P/@X_7I49MIP"?)?"D@X7ICK1_
M:$_Y?S!<(8=[5W]R_P SZ=_X2#1?^@QI_P#X$I_C1_PD&B_]!C3_ /P)3_&O
MF+[+<?\ /&3K@?*>33EL[AT=EB;"8W9X//3CK1_:$_Y1_P"J&'_Y_/[E_F?3
M?_"0:+_T&-/_ / E/\:/^$@T7_H,:?\ ^!*?XU\Q_9+@QF3R)-@(!.T]3_\
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M\H?ZGX>Z7MG=^2_S/IC_ (2#1?\ H,:?_P"!*?XT?\)!HO\ T&-/_P# E/\
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&%%%(H__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $D IL# 2(  A$! Q$!_\0
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M\CW]S0!JJ=R@^HI:0# I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8 2##?E6>/!:][E?^^/_ *];^F6 TVS%N'W@$G.,=: +E%%% !1110 4444
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MM-U^085OJ*?#J9CE%O?)Y,IZ-_"WN#0!I44@.1D'(I: "BBB@ HHHH ****
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M^ON?>I:*3/24&$4'T%.HHH&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5!>C-G*/:IZ:Z[T9?48H Y:XL(;R2_AF'RFZ#D]QR!FJD9O/#^H'*
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M*FHH IV=FUHSA9F>(XV(W\-7*** "BBB@ HHHH **** "BBB@ HHHH ****
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M:YGPM\/8O"]U)-;2EO,V[]Q))QG&.PZUVL5D3UH I^4N.M-$8SBM462T];-
M>E &<ENK58CL5)S5S[.O85(JA10 R.%8QP*EHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I&Z4M% %.2)V)P:KM9L36IBC H QFLG%020,G6M_:/2HI8 ]
M&"%).*L+:NPZ5H+9*&S5E8PHQB@#,6Q:IXK4H:O8%+0 U!@4ZBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I" :6B@!NQ?2C8*=10
MFT4N*** # I-H]*6B@!-H]*-H]*6B@!-H]*,#TI:* &[!Z4[%%% !1110 44
M44 %%%% !1110 5YSXLGUO4/B7I'A_3M>NM*MI["6=VMXT8LRD8SN!KT:N,\
M3>#=2U;Q18Z_I&MC3;NUMWM\M;B4%6.3P: ,'2_B#J.AVFL66OJ-1N]*U."P
M^T0@1F99?NL1T!'?%=1-XRVZYKNDVVESW-SI5O%/A)%7SO,Z 9X&.Y-9$WPM
MMW\*7NF#5;E]3O+I+V;4I5!=YD.5)7I@=,57?X7WEY!XA;4O$<UQ>:U;0PRS
MK"$\LQG(P ?N]L>E &1XK^(5QJG@7Q;:1P/IFK:9#!(7M[I95VO(N"KH>N,@
MBNL^(NK7^C?##4-2TZY>WO8H8BDR@$@ET!Z^Q-80^$;R:9KMO-JL"RZM:P6[
M?9K-8HXO*8,"%![XKL?%?AD>)_!UWH!N3 )XT3S@N<;6!Z?\!H BU3Q2NAP>
M'5G@>>35KJ&S#*0-C.N=Q]N*R=5^)EKI4/B"5],N)1HUY!:.J,,RF3&"OTST
MJ"]\!:]JFC6UO?\ B=9+[3[N*[T^Y2T51"R C#+GY@<_I4#?"V>;2]:MKO7I
M+FYU6]M[R6X>$*0T9!(P.,'&!Z#% $5S\6;RUDU*"7P?J*W6G(+BYC,J8C@(
MR')]?:KVL?%*SL9;>*PL3>2/8#490]RD CA(R "Q^9SSA1Z5=U'P(+_5/$E[
M]N*?VU8I9[=F?*V@C=[]:RKOX7R+<Z?>Z;J-JEW;V$=C-]MLDN(Y53[K!3]U
MOI0!8NOB>KW&F6^CZ%>ZG+J.F_VC"L;JFU,X(;/3&*W-)\86FK^!CXH@AD2
M6\DS0O\ >4IG<OYJ15>V\'-#XGL-:DO59[;2FTYHTA$:L2V[> .%^@JQX4\)
MQ>'/!T7AZ:;[7$HE#LR[=X=F8C'_  +% ',>"H?%?B#3M/\ %M[XFE5+IC.=
M*BMT\GRLD; ?O9P.N>M7K'XCO)XA31]1T5K.>>WEG@"W<<IQ&NYE<*?D;'8U
M%HWP^UG0XTTNT\6W*^'XV8QVOD+YJJ<G9YG7;S5+P_\ "9]&U*PNI=6AE%C#
M<01B.T6-I%E4C=(P.6;GJ: +6A?%0:Q>Z(LWA^]LK+62R6EU*ZE6D4$D8'..
M.M16OQ:6>6UED\.WT6FS:@=.-ZSJ567<5&!U(XJ_8_#L6>G^$+7^T"W_  CT
MS2[O+_UV0>/;K42_#0+X9M='_M(_N-8_M3S/+Z_.7V8_'K0!/>_$BVL]$\2:
MF=.F9=#OOL3H'&93E1N'H/FJA8:]J%OX^\=.D=Q?1VL&GM;V8E"A2\9W8+'"
MCN3[5%K7PJN]3FUV&V\1RVNEZO<"[GM1 K$RY&?FZ[>.GTJ[K7PT&KR^)I!J
MDD+:U':*-J9$9@&,'GY@W<4 :OA#QHOB>[U.QELOLE[IS()D6=9D8."05=>#
MTYK@_BKXJO=,\7VVG)JUY!:M9$QQ:=(J.MR6PAE)'"'C]:[;P;X(?POJFJ:C
M+>0SRZBL0>."V6".,H"/E5>V"*S?$GPVGU76]3U#3M5BMDU:%8+^WN;43JP7
M@,N3\IH Z'P=J4EWHD=G?:A#>ZO8JL.H/%R%EQG'H>#VKH:X[P'X'D\#0W=G
M%JCWME,PD02Q 2*^,$EAU' P.U=C0 4444 %%%% !1110 4444 %%%% !7G/
MQ:UZ^T2#05M-6GTN&[OO*N;B",.ZQ[>P(->C5SGB?PJ/$=[HER;DP_V9>"ZV
M[,^9QC'M0!Q$6LRP>(_!)B\1WFHV,OVUI[F=?+,H5<_,H X7''%;.G?% 7EU
MIDDV@WEMI.JSFWL;]W4B1^=N5'*AL<5N:[X1BUSQ'H^J2S[(]/2=&@"\2B1-
MIY[5S^D_#*ZL[C2;:^U^2[T;1I_M%C:>0J,'YV[W'W@N>* %'Q=TM+72)+FR
MF@FOM0>PEA9QFV9&VLS'N.5_.NG\.>)8_$DFJ&WMGC@L;Q[-9F8$3,GWB!V
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M:O(? 'P]U=]'\,W&O:G.EKI;M<P:6\ 5HI=S8W-U([@>]>O4 %%%% !1110
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M6' ;@ER/O'&?;FL/X?>"KC3=<\6Z@D<]BDLTEII9G0'RHMQ<LJGC:6(QZXH
M35OB=K$WP[N_$>D:1%%AHS#(;F.8*K'!WJ#D,.F/>M.]^)DNG1V%K/H__$VF
MM#=SVTEW'$L48[[V."6[**KP_"GS=.\0Q7^IQ_:=8C1&-G;"&*,H<A]@."Q/
M4U)>_#;4+N?3M3.L6DFL6]K]DFDN;!989D!RIV$\,/44 32_%&*9=%&D:'>Z
MC-J]F]U;QQLJE=AP0V>F.>:KZ3\6H]3N=(+^'[ZVL-2G-HEW(Z[5G&<K@<D9
M&,UN6_@UX_$.B:O+?(\FFV4MJR1P+&LA?JP4<+]!67:?#(6ND:'8?VFS?V7J
M;W^_R_\ 6;F+;?;KUH ] HHHH **** "BBB@ HHHH *Q/%7BO3?!VCG4]4,O
MD^8L:I"NYV8]@,C/K6W7F'C>+6=?^(.DZ;I>G07<&EV[WDRWCM'"SN"B_, <
MD DX]Z /1-/U.UU/2K?4K:4&UN(EE1SQ\I&>?2N>/CJ S>((H=-N[A]&ECB=
M8 &:7> <J/;->3"/5;7P-:>']9L[O[!HFN+%J4=N&8-:G++@@9903R?I4-Q;
M06G@[X@R:9:W=IITEW:M:><CQDID<C=SCT]J /H=9D:/>6"X +!CROUI6EC5
MD5I$#/\ =!89;Z5X/XDO)]._X3W2Y+34)+K58+>6R\F!W5U"#<0PX &.:MZP
MB6/C31KV.#^UKV2*R@?3;FUE+P  'S89 -HQU;/H<T >OZ=KVEZM/>P6-Y'-
M+92F&X5<C8XZCG^E5O$GB6U\.^&[O6V0W4-N 2L3#)R0.OXUX];V>G>&Y_'\
M/_".S76H"4O;VX20*]JQ7/S+U4$Y(!R<5E?9KF31?&\-C:C[%<6-M)%'96DL
M4+OO /EJ^23U&>] 'OM]K<%EX>N=7VF2.WMS.T:L-W"[L>QIVD:S!JVAV.J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHH) !). .IH **CBGAN%+0RI( <$HP./RJ2@ HHHH
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MO:@"6BBB@ HHHH **** "BBFR21Q*&D=4!( +'')Z"@!U%%% !1110 4444
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M1D=<>]5]/US7M0EBM$O;:U(6*)(&N4C9X3"I+)'MRS$DX(.!BO4UBC4 +&H
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M(-H^98]F&8Y)W;NOTQ7H\4<&GV*1J1'!!&!EC]U5'<_05,K*ZAU(92,@CN*
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M<<]B]L\F QC<,&1L'J/O#\J ,-O'%W!X9L[N[2SAOKJ\DM=Q+&&/8S MTW'
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M8+*>\L?(M+5[6$I$P9P64@MSZ+@@=^:T+[PKJE]XDM[R:]CELH;U;E$=G^5
MC+Y83.T=<Y[T ;K>(](3S=U_%^ZMENWZG$39VMT[X/O6FK!E#*<@C(KS^V^'
MEU"UMYE_&ZI<;9<J<O;*5*)]047/;DUZ#0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ??7MQ=Q&.R0O,J."RX[8SU/2LWPOH\MC9Z@SPWMK/=R;B+F6)R"$"@J(@%
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MU'3+>\,+PF9 WEO]Y?8^]6/)B\MH_+38V<KM&#GKQ3Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH "
M 1@C(-(JJBA5 "C@ #@4M% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #_ I(# 2(  A$! Q$!_\0
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M-7SP"3C/%=A_PJCQ"9D6-[1XF.#*).%'K@\T >Q> R#X"T0 @D6J9YI_@/\
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MPY;Z;<:?'8G[+<$-(AD8Y(Z'KQ1I?@#PYHVH17UC8F.XBSL;S&..,=S7344
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !574--L
MM5M&M=0M8KF!CDQRJ&&:M44 <2WPG\(C4H+^WL'M9H9!(H@E(7(.>1720Z%8
MP$E$?GKES6E10!BZAX>%[;-!#?3VJN,,T8!;'?!/3ZU=TG2;/0],ATZPB\JW
MA&%&<D^I)[D^M7:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 5SOB3PS=Z])&UMXAU'2U$312QVVPI*K>H8'GWKHJ*
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MS4T%I;6ID-O;Q0^:V^3RT"[V]3CJ>.M $U%(S*N-S 9.!D]32@Y&10 4444
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MKJNU=V  0!T&.PH UK1)TLH$N9?-G6-1))M W-CDX'3FIJ** "BBB@ HHHH
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MY(SG!/-=%3))8XMOF2(FY@J[F R3T ]Z 'T444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %? G # 2(  A$! Q$!_\0
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M+'JO\)_"GB[,9Q<H4_VQRO\ ]:@"U12*ZNNY6##U!I: "BBB@ IDDBQ(7<X
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M+)O^6+,?7I0!HAP>]5KV#S(_-BXG3E2._L?:LQ]90G]W"P^I/^%,_MF<#Y4
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M3!]N:]1GACN;>2"5=T<BE'7.,@C!%9%SX0T&\T2TT>XT]7L;,*+=/,<-%M&
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M1K]K!;:E9B6.!@\.QVC:,CCY60@C\#46H^$]#U;3[2QOK!98+,!;;YV5X@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX[!1112 **** "LW5=!L-:>U>]6X\RU9GA>"ZE@9&(VD@QLIZ$CZ$^IK2HH
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M/FQP<<>I KC*I0B^A+E)=3T+_A=?CC_H(P?^ L?^%/E^-7C=)G4:A!@,0/\
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MS+Y2XPTK;Q_#L:/D'AF;FEOO#/@:]NKR:UU>UL[:&US"D-VH,DF^8$[9&8G
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M%_PNOQQ_T$8/_ 6/_"I(_C3XV:.8G4(,JF1_HL?7<!Z>]><U-#_JKC_KF/\
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M@D\'TK2L/$V@-XBLKR?P_96]I:Q7+- R"5)W,+>6K#9_ST P3G&1Z9J7&/\
M*-2EW+W_  NOQQ_T$8/_  %C_P */^%U^./^@C!_X"Q_X5H_:/AG/=6=E))"
MFG6;S*9FMIA+<*_D,K,R -D$SJ-VX +TY%95G>^"6T*_TZ=3 S06<D4JB5C)
M<+;R^:6],/(5 & 3M/*@TK1_E'>7\Q)_PNOQQ_T$8/\ P%C_ ,*/^%U^./\
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M^4/"NFZ9>B234_+$:7,<>Z6;RTP8IVP3D8RT:#K_ #KZO\1_\BOJW_7E-_Z
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MG^K=?^=?B?4-%?+W_";>*/\ H/:A_P!_VH_X3;Q1_P!![4/^_P"U'UN/8/\
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MMTREP_4E\-6+^\^F**^7O^$V\4?]![4/^_[4?\)MXH_Z#VH?]_VI?6X]B_\
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M:EMO^/J'_?7^=)SD]&RXX>E3;E"-F;/A.VT:;4Y)M?EC2P@CW,C2,ID8D*
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M=H=AX7@O/$MQ8RVTMLC+%!(V1N/&1UZ\#->,33W6L:K<7DX:2[NI<[0,GD\
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M  #Y(^P7G_/I/_W[-'V"\_Y])_\ OV:^MZ*/JB[A_K++_GW^/_ /DC[!>?\
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M)_\ OV:^MZ*EX7F=W(Z:7$"I1Y84K+U?^1\D?8+S_GTG_P"_9H^P7G_/I/\
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MA"<AA@CYC72T45V15DD?+UJGM*DI]VW]X4444S(**** "BBB@ HHHH ****
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M7'::8)X([N+<S2#EG^\#W!],'B@#S'QBP;XD3;\LJQ(,9[8J""6!)V9D&S&
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M>3W'I4W@_P"%MCX6U&+43=O<72*5 "!4&1@GUKOJ* "BBB@"AKO_ "+^I?\
M7K+_ .@&OE*OJW7?^1?U+_KUE_\ 0#7RE7)B-T?091\,_5!1117*>V%%%% !
M1110 4444 %:6F:E_9&M&\\GS=HE39NVYW(R=<'INS^%9M;.@:K'HOB1-0E5
MV2+S1A.N61E'<=R.]-;D5/A>ES=F^(<D\=NC6+1M!+&R2Q3*'"+"\>SYD((S
M([<@_>(QWJ&3QM/,KVMAI<5O:-;7,3P0X)*N)B#NVY"IYI.WI\I/&>+T_BWP
MS=R7%Q<:3++=37$<N^:!)?E CR,[@>-KC&?F!RW4X6U\5>%M/NFNK73KGSO+
MDC4M:0C&1. 3@XY$J C'1.]:W_O' H)+2DR&7XD2&]%]#I4272"18BTIV*'=
M&)*J%);Y",Y&0><XJA;>,(;.WU*UATB,6NHRS/,IF.Y5=<(JD #Y"6.2#G/0
M=:C\7:UI&M213:=;/#-YLK2DVT<(8,V5SM+%F[$DX] ,FN9J92=]S>G0IN-W
M&W_ .NU#QP=0FN96TX1M-!=0864!0)I-X. H!8=">K<$\U'I/C:;2[:PM1:!
MK>VB9)/+E\N24EY&4[P,@#S/N]#@^M<K14\\KW-/J]/EY;:'>-\2/,CN5DTM
MW:99$7==96-6DD< *4Z8D"D="(UZ8JGK?CR76M)O;"2SDC%Q)O#"XR% E9U4
MC;R &"]ON@^U<?13<Y,2PM).Z05(W_'LG^^W\EJ.I&_X]D_WV_DM0;LZ/3_&
MMYIMA:6=M"B)!;2PLZXWNS&4HV[&0%,N0OJO7GBW-X]65])9M$M7^PE2WFN6
MW$!,E./DSLSSN&3^?&T57/(Q>'IMWL=]:?$K[%8+:IIT\K*1B>XO-\A^<L<G
M8,]<4R;XB037%I+_ &1-$+;=MC@OC&C$H%!8!.2,<'/0D5PE%/VDB?JE&]['
M9R^/$EUB>_\ [,>,2VKVXCCN=A7=(T@.X+N&"PX&,XZ]JOO\38WEFE;1Y#+(
MKJ)/M@W(&P<@^7U!'![<<'%>>T4>TD#PM)]#L?$OC&+7M$\M;<0W<MQF3!W$
M0H,HI; SEW<_@*XZBBI;;=V:TZ<::Y8[!4L7^KG_ -P?^A"HJEB_U<_^X/\
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MM3!#JHNLFYB,'F$X[[=PP/N_W<CKU/4T!=EW[-!_SQC_ .^11]F@_P">,?\
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M/;:A)*\D5P(P2&1=V0#L8$'CIN*G_"@+LN?9H/\ GC'_ -\BC[-!_P \8_\
MOD5F"VUW[/@WUOYV!R$^7OGM],?C]:N"*]&H%_-0VI))0GG[H [>H/?O0%V3
M_9H/^>,?_?(H^S0?\\8_^^166EGK2A";Z,NL>W!Y!;<.OR\C:/KFGK;ZV(EW
M7L'F;QN.P8*\Y[=?N_E0%V:/V:#_ )XQ_P#?(H^S0?\ /&/_ +Y%4H;?5$\\
MRW2.S0A8CV5\<DC;TR?R XJ)[35Q=*T=XGDA]V&;DCGC[OH?H/2@+LTOLT'_
M #QC_P"^11]F@_YXQ_\ ?(JG/#JKW4IAN(4@(_=@CY@=IZ_+TW8_"FQ6^J+$
M-]RGF&<,YSD;-H! ^7@Y!(H"[+WV:#_GC'_WR*/LT'_/&/\ [Y%9HMM::$^9
M=P^:/NA>%/7K\O\ N^W7BF"RUIL^9>1_,K9VN1\QCVC'R\<\]?PS0%V:OV:#
M_GC'_P!\BC[-!_SQC_[Y%9]O;ZK#,@DN%>)I"7.<E5P.F1Z@CO\ >SVIXMM2
MW7(-RGEND@B /*L3\ISCL* NS2    & .@HK)6UUA9LK=Q>6TJL0_P Q"\Y
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M3XCL,$8XFP?SHY7V"Z-!HM;C93]H25#*F0BJ&"8.[J .3C_ZU*MOK7FAFN(
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M +^4?\)OX8_Z#=G_ -_*/:P_F7WA]1Q7_/N7_@+_ ,C?HK _X3?PQ_T&[/\
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9G_>V_!LP**<[M)(TCG+,223W--K([C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &( C0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#UW5]2NK34
M/*AD"IY8.-H//-%EJ=W/#EY 6#$'Y1^%5/$'_(6/_7)?YFH],.#*/<&M::3>
MIA)NY?BU&[,VUI 1_NBD@U.\:[F@>5<C.WY1VJN!BZ].:K73&+4V=<9!#<_2
MMJD4FK(B,G8R/B+XFUSP]X?@U+3KM(VBNXTG!C#;HVX[].:Q4\>:_%\2[32Y
MKM&TR\MP\:>4HPQ4D<]>HJ#X@:[%J?AK4M+;3F29D^^9,A2IR"/R_6N-U*\Q
M+X)UX'G:L3M_NG_]=%6C*%N96N*C7C53Y7>Q[E_;%]_SV'_? I?[8O\ _GLO
M_? J@_+G'0G(I*Y[%W9?_MF^_P">P_[X% U?4'28(VZ01[D"H"2=P!X^A-4,
M$KG!/X5<T^ZCM9W>7)!0D;1DX R?TI-#BW<LG4-6&/DDZ?\ /*F'5=37J6'U
MCJ>+Q5I3Q*RRR[9%#HVPX*GH1[5*GB32R1FZ/T*&E<TY7W*7]L7PZR?G'_\
M6H_MF]/_ "V7_OD5I'7=,? 6\3\0:@FOK&9?EG@8^^*=T+E?<JC6+S_GJ/\
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MO,Z_]\"K::WJ!4$S#G_8%848^05?C'RI]*WBV9,T?[:U#_GL/^^!2_VS?_\
M/4?]\"J6!3@*N[$71K%_C_7#_O@4Y]7O@>)1T'\(JCC-./S$?E3NP-%-4O#'
MDRC.?[H]*:NJWI/^M'_?(JJCX&W'7/\ *F@<T-L:+IU6\_YZC_OD4#5;P_\
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M.85C6MTY'%:47^L6J4:/$5\U=F<;03G.>WM5^$%W 7J.O2A2N5:Q/J(W:)J
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MN)]]NZ[6"[",G(XJDB&V7/&TWV=M*F(W;($./7BJ/AUA<7UY=LV&GB0A",X
M.,YJUXRN+9CI6;F#:L**YW@[#COBL[P]J-K;7TD%U-#$KLL<99_]82PP !TK
M/D;=[%IZ6.I+VEO-%#<)//<3, L<*C@GH"35?_A(-"%^]B+68W:$@PE@#UQQ
MV/-&JQ?9_%4,K.0%G15!/3)K$CT22;Q/?W/F+Y;S$LFS<=\;'&/3AL4,T25C
MIAJ%MG"Z-<_\"(%-.IVBY)THX[DR \=Z&B=U8%6 8$'M540-##Y?VC:JJ54,
M5'&*=F9\Q6LY5E7Q*RQ>4IC)"=0HP>*S]%7=+9H#C]VW\JM::P:#Q(58,-F
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M:7=LD\<@ 99!Q^'I]:E\A1VJ55Z9[4I.XXJQSMSX+>V=I=-E\^,G/DR'#K[
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M #"3#=JU[(W-OMQ*^ >H/-#:8ES)G4:IX;T;7%)O].B:7H)XQY<@^A%<??\
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M*K!5;,B'N:'&6#"0*Z,K(>CJ<BNCL<LZ<$@]<=JR-'^#6I:1>)<1^(XP$^]
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MUDF;MSXKUF=MTVIRR-D$$@=1TJH^NZC(Y=M0N-[\E@_)^M8U]:WNGHCWUO)
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M-:O?%.IG?\:M*QFW=ESO3&/R,?8TI.*8Y_=O]#_*LS81/^/:+_=6G$]:8/\
MCWB_W5I2: -E/]4G^Z**1/\ 5)_NBBL38XGQMG[8V%!*QJWZFLFPD&![\UL^
M*UWZP4(X,*_S-<U8,\1$;DED^4GUH;T FN8MMPP]>158,4DR.U:MR@D"L0"<
M8S6=+;LIRIIIDLF$JN 1P:3S'C;<#^-5 70U,LH<8:@#1AO=V Q^AKE_$\*O
MXSL'(_=:II\UC(>Q8 LM:S ]16!XLF>+3++4,G=IU]%.3_LDA6_0T6"XGP8N
MR-,U?2)21);7 9?;L?U%>DL"@VN,@]Z\E\(RC1OB_J=B#B*]C9T'0'(W#^M>
MNJ^X8/Y'D&HDM2D84\KZ/J<=YM+6Y.V3'=3US6T[R2R!^#$1E2.ZGI3+BU\Z
M)T51(C#F-NWTK/TB=DWZ4SE9(LF)7Z[/0?2I6@WJ7Y%V'/5>].7 _B)!Z5(J
MG9Y;D9[$>E18,1Z9!IIV8B3'<5(C<'))I@.>1TIPR:UN23QGW)J"\Z#ZBE5F
MW;13;O(501S28#5(QC%7K4UGKU%6[9\/BH6X^A9N"#@^AJ,#O2SM@4B-E01^
M(JI"19MQUKG?$$N_4M/MM[H"SL2AY(P!S^=='%QGCM7G?BC4S;>-H(F&8EA$
M>[/(=CG'TZ4-OE&MS8U&W:/3IP9)),!3\Y^[@]JQ!DC.,UUNU;NQ/ (DC.0?
MI7&?VO %"I VX<99MM*"N*<N4O(S8QD8]"*E<JRE>3W'K7/7>N/',(EA^8\K
MM'7WR:@:XUN]^6.06J'^).7_ #Z5T1AW.:5370WVN'M1NW!2!U? _G55M4@)
M#RSJ3GI&"<UAQ>$+^=Q-)?/(QY/F=:Z"QT*2W3$C@^I9?ZUG*;6R-84XO63.
M>UN[FO)(DM+"=TC!P9#L#$^W:N6O_P#A([3,L^D_Z*HRS6ISM'K7LT&DPMC=
M@U>;2('A:/S6B9EQOB.& ]1FN)T^:5V>E'$<D5&.QX9I<=GJ\@V2N9&_@E;D
M_3L:Z6W\+VTAPP;/LQ%'CCP!<Z6S:UHP\Z$D&X@B0@H>\B@=O4#O4W@OQ@+^
M>+3]4EB!.%AGE4<GLKD?H?SI\MBG><>:)T,.G:M$B_9VMI0.TJD']*O13:Q#
M\DEDBC_9) -=)#%'%QY:*P]#4[7L$)"R2(I/0$ULCBD<Y'=ZED;+./W#3G_"
MM.&&ZGPQB53Z%ZT#<V+\L\:^YQ4\5Q:.=L4L3O\ W589JB2O':SJO^K5CZ%Q
MBF&+4@3MLHC[_:!_A5F:_C@5OW+EAT!&,UE+XEA,A1XVB;..>:9-T73:ZO(@
MV?8X']),N,?A3_[.U$IS=6Y?T"$"HDU4, 0V0:F%_NQ@FF+0KG2M2+'=/ %]
MB14T>DW* $M$^#D@-UK*\3ZA/%I<3(Q4FZC7\"2"*Y9+J:'QKH)$T@5[B4.N
M[Y6PIQD>U TKGITS1@%RH#%3E"W)XZ9]/>O!_%VH7<Z/(Z/&)9B)&7HJC_EG
M[5ZY:RF^U/[;("T<0,: ]">_X#^M8/B[0+=U$\"B*UG.V9 F520]&/L3Q2JQ
MLK(Z<!5BY\S7H<</ 4M]X5M]<&J+%-/F58Y$RB#&!SV(Q7*F475S(ZR;"^$=
M%)VM@8)_''ZUH:GJFIV.DS^'Y;R2"TC<K]G1<X![ ]=ISFL*WB6",;[AHU"D
M@-&5/'M[]*YI6Z'T%%35W-W3V.CTF^BNPMC*X2X4?N7(SNV_U'3W%%S'&DKI
M-!:/D_.S-D].@]J@4+H6F_:R,7MVA6-9/OQ*>I/^>IK2\.:'H.I:#%=WT%S)
M=CEV,I"'+$*!CV I1<U+]V[,=2=*%+FK1YHWT7ZE2;4Y L,:7:01Q@ )&N5;
M'3.:OCQ&#]FN'VA7#!_?'%97B[PTL#6D.A6-P]S-*Z,D3-)G&!T/3KUJRW@_
M7=+TNVEO;1I$Z.D6',/NP'2MJ:FFVV>9C*V'J4XJG&Q:_P"$CGFN$@L5W2R-
MM0!.2?J>V*M&_8SB2\UZV\D #R8(LL3ZESU^@%<_;R_8;^WN4 8Q/G;W/8BI
M5ABCE(0YB!RH*_T/0BMDVF>39'5Z!.L^GZ]+$V8W^9&Q@D8-4[^^?3K4W:CY
MDP!^(J;P^0NDZT!TP,#VP:2:S2_<6LN2C<X^@K-_$:=#:;1]/: 3RM/)\F]@
M92 3CVJC8Z'HNHP0:A/HZ>:RY7S=VY1U'!/!JY$;R& 0K*NT<8*BD/VDJ0]T
MRA!G/0*!6AG8EN+.*VM)YK6P@,X0[5V?>;T)]*P?&&%\ S_:5@6X;RSL3 (;
M=GCOP*MV^I()H]\-Q]GG.VVO&D#1W#>PZ@$=S]*\P\2J1XEG#$Y$K<%C@<5<
M-9$25D/M@#&A Q75>"S_ ,2%3W\YL?BU<O:C]ROL!73^#1GP_'_UU_FYKHK[
M(BGU/:]/XTRU_P"N2_RJP>E5['_D'6O_ %R7^53$U"V,WN!IN>1]:4FF _,/
MK3 MD\U'*?W3_P"Z:<3R:BF/[F3_ '361J.Z11CV'\J">*1NB?A_*D)H W$_
MU2?[HHH3_51_[HHK$W./\5#.KDCJ(E_F:Y.9S%J;#)VR*&'U'6NK\2,#KI0_
M\\4./Q/Y5S.IKY<<<N,F-\<=@:;6@D]334^9;\>F:KN/:I-/D#H!FGR)S^-2
M@9GNF/K4>T=Q^-770-P1SZU6>(J?:J3$,VL.AJAKEE_:&@ZA9XYE@8#Z@9'Z
M@5>SCO3E.&'/&:8CS&ZOO(\2^$=?S@311I*WN/D;^=>QVVH%)7B;JK$=:\6\
M2V9C\+7$(&)-+U)U7V1_F7]:]'L[W[9965ZI_P!?;I)GW*C/ZYI-#.VBD2==
MP.&IEQ")-LFP/+&<HW\0/L:PK6^(. Q5A6Y;W2S $,-_I4-6*N) PN(4NH#E
M3G()Y4C@K^!J<@'Z'I55;=;>ZEEC.(+A@TB#^"3IN'L>]6PNW,9'T-(!H4J>
M!D5(.1P,4N"!Q1C(ZTTP:)(D"C<>:KWG)J9#@=:@NCDBJ$1CZU9MSS50'GM^
M-68#@Y%0MPZ$EPPW ?-^=-618B"7V@]JBED!D))P!WJE<.KEG=U5%&69C@*!
MU)K0G8U[G5K2RMS,[APO)P>W^->4Z[<IJ&N/J!4J9)@RIG.T#&!4VK:Y;WTX
M2WD9[>/[JQ@G>WJ33;&PGO") @C!/5^33L)R?0[31=02?2H6C5^&* LG&<XZ
MUQ\Q*:@UK'&)K@2-N)'R1C/?U)KJM!D:&WNHSUBN-P^A%026"PW$UQ&A(D8R
M$XYYK.G()QN8T>DB:X\V0DM_>-;]O8P6Z!I"JCU8X%-M4\VY4DJJKDY+<* ,
MDDGH*X#Q[XUBO%DTG1I%FC VRW8R%^B>OUK>,95'9&;Y8*[.TO?%FFVBXM2+
MB3H-G;\?2I4UV2807)@'EL"K1*W!/K7A%K?:E9X"RK*@YVNM=!:^,=3@A\I+
M:/RSSMW<9K;ZM)K8S]O!=3V&37;.UM3-!N+DX\D]0?7-<\OB"Y^TEW7>6.6P
M3FO/Y/%FJ. (X;:/'MNK-N=9UFY!#WKJ#U$8VU<<')$/%1[GMEEXABNE:U=F
MBG9?W8DXR>PS7FGBS04M]2%]IJ;8KK<ZIZ2K_K(\=B.H]0?:N3M[_4+&4O#=
M2,V<GS#N&:WKSQA+J&G2V]W9D3R[&\Z)L8D7[KX_O8X/L:QJX25M#LPN,C&5
MGLST+P!XP75M.:PNW/VZ!?D9CS(HZ@^X_E6W=*;K=DYYR*\9M;N2WN8M9M?W
M<L3C[2B] ?[X'H>_M]*[F7XC6-O)LFLYHVP#E%W*P]17-2C*3<4M3JQ<%"TU
MLS6GLV(. 2?<U6>&7:,QX<='4X(K//Q&T=\YCN?PBQ4;^/M%89$=X?\ 9$>#
M^=="HU.QYKJP[FVFJ:S!$(A<^=&#G9-R?^^NM/GU"*Y4--$\,O?"[@:Y9_'M
M@V?*TZZ89XW.%JE)XZN2Q\C3H%7_ *:.216L</4?0AUX+J=U:7Z(=OGH?3YL
M']:VK:Y)QSC/?.:\;NO%.K70(!MXQ_L1"JD?B#7X"3#J4@!.2&&16GU*9"Q4
M+GL/BR<IH408<B]@^8?[QKG[L[O&?AZ+>R![F12PZC(/2N;;QO?:Q;6^F7]O
M&&^T12"=&/S;3T(]\UMZDX@\8Z/=RL([:"^PTK=L]/<US5*4H.SW.RG4A)-]
M#O-3UFQ\,VMJLD,TB2,8TVX&#[_6LV^\4M)HINI-%DDL+H-$09QGT^8#[OM2
MZIJ%I=S!U5#+9.2ZSK@QD_Q$>F.AKF;6YBN=8U!VO'5KY(XXXEC^260'!+>@
MQ6+=WH=%.DHQ3;MV(O$%O!96L%W=/#_:#JL:,S A3V+COM!ZUR]J\=W?/<W5
MS]IBMF)>?M.X/ 4=@...YQ6QK]K;76N7=R(4\Q4&[DN7P/X5[]*M:-HJZ-IE
MEKKQ+*+F4,E@ISY,;' D]F!Y([5SN#;/6IXI1A9F/=Z+>7T)US6S+9:82/EB
MP9A'G@[3T7W/)/:NHMH+"V:]M=+5TT]/(:%2VXD$ YS[DDUS_B#7893J'EQI
M<02EB[N?D9^/N#N,C/UJUX2DN)-%D>Y8M,PB+%O3<<#\L5K345HCEQ=6I4BI
M2T\CN]%8_P!I7A4[20V<=>HK94,N2A(/?WKC;B^2QO6:2:6(.SJ#$.6.1P?:
MJ=KKEY(LIN+@\2L$RV/D[5H>8]SNA96J2^?]EMEE[R% #6=JMIH=Z,7\44C@
M@YB^^<>XKDYM;A4?O;M/IO+&LV?Q+&A816UQ,J$&1P-JA2>H[DCK32$;-J8U
M/B,6Z!(05VIZ#!XI+$9U1 >>#_Z#65X4NC?:!J]R009<$@C![]?>MBPXU9<=
M@?\ T&LG\2-EL:V!TQ5#7(W?P_?B,,7,)^Y]['<#\*TFRV,_G3-I#'!&:LDQ
M=6$<^D::MH0ZSS0>1LZ%5P21[ #K7FOB?YO$]PRC@S-_*O5OLEAIK7-[%"(I
M&7]X^X\+UP!V'TKRBYS?ZU+(HR-Q.?5FY'Y#^=;4E>1G-Z$MN"L8SZ5TW@\_
M\4Y%C_GH/_0C6 (FEF6&)=TCG:@_#_#-;WA$JN@Q)G_EJ!Q_O&MZ_1&=/J>U
M69_T"V_ZY+_*IB:@M#BPMO\ KDO\JE)K-$/<"::/O#ZT$TT?>7ZTR2UGK44W
M^I?Z4_-13']R_P!*R-R1_P"$>](3Q0Y^8?6FL>* -^/_ %4?^Z**2+_41_[H
MHK$W.#\62%/$_MY"_P S5&>,3PLN?O#&:E\;';XD#=O(7G\35:TEWQ@GG%=,
MH^XF8)^\5]+E(^4\$'!'O6K+R0>Q&:Q6Q;:HZ*2$;#C\:VN98!CJ*Y3<A]<T
MUE#=J>RD>M)@CFF(JO'[5#M(-7CSVJ)D&33$<+XCLS+=:_: ?\?E@MU&!W>,
M\_I4W@6Z%YX,M.<M;.T)]AG(_G6KKT2PZKHEXP_=F5[.4_[,BD?SKF/AUFSO
MM>T60_-%+O4'V)4_IBFP.U![YYJU!>F,C=Q[U59=M-QW%(#IX+V&=,2<'&"1
MWJS8WNZ62SFP98QNC?\ YZ)Z_4=ZY&.:2-@5;!]ZG>_E\R&XC 6>%LJW8CNI
M'H:EQ'<[4#</EIC#%0Z;J*:E:":-0C# DCSRI]/IZ5;()%240A@!4-SV^M3L
MN#@BJ]R/DR/6J)(QZ5(C;5;M4:\ <TR>7"@*/F;\ZE;CZ#'<MDY  ZDG%<IK
M<MUK,AL[7]W8J?WCD?-,?Z**W;J(S@P^;MP?G _EFA(H(0,98CTK0R9D:=X>
MBA0%TW8]>!^5:K*ENHVA545'J&K1V%L\]S)%!"O\;G]/7/TKAM2\>6>QFLQ+
M=2D?+E=JK]3WJXTYSV1,IQANST+3%V7MQGI( P_2JUSKT=AKMQIUQ=6ZD89%
M<A64$9&<]161X?UF[NDTNX>:UC^T6I)_W@<$8KE/B+"TOB=)YEC/F6ZX9><X
MX_ U=##.4^5D5L0HPYD=;XQU'35\+Z@+>_@^U74(A$$;@L22,\#H,9S7DJP#
M  &%%3)$JGA #ZU*%KVZ&&5)6/%Q&*=1E8P*%/':G"(*H&.@JQLR.E+MS74H
M(Y/:,K^72&+VJULP!ZTA3TI\B$IE!XORJ,19-7WCXQ3 E9.F;*H,MI&M)!.!
MN4?+(O\ >3O^57+JS3[,OE'=&HWPD<_N^X_#^51J@W#C-6-/D",VGOP/OPD^
MG3'ZD?E7E8BC[&I&K';J?1X'$+$T)8:>]KHS1!QTI1#CM5QXS'*\9!!4D8-1
M[>:]6,4U='SDW*,G%]"N8P!TI5CQ4V.:<!5J)FYLA\ND*=:GQQ4]K92WS2+#
ML#*A=O,?: !U/O\ 2JDXQ5V.'-)V1%:Q;7A=5^?SHR3Z*&_S^E>@26[MK][J
M(@2X&G S)%)SEL#H.G S@>M<VNG'2].N%NTE$UT(?LK+$VWAP7)8CY<@ #UK
MJ-0$UE%-J%M(KQR2#[5 YX9%'53V8>E>%BJJG+W?0]_!T7IS]-3/U:]L+FW2
M\B<K=71!G20X98P. ^>,@DT>&[S3+C7[*TMW@O+R<E8[=R0H.,ELCT KE;W4
M/MLZ03)'+%(Q<JZ],^]26FF:6;Z&2W@FM)%<?O;64AT'<CWQFI>&Y5Z&OMW4
MG;N>B3W%A9:LLUQID=J(;KR%EY*R7. 5PQZ#'&.F:X'Q+J:V8U+31/,UO//O
M+@_ZMCC,8]@>OK6MJGB>!M)N+"VN%FM(&"V%TXWEN^Y@?XU/\ZY&30]=U93(
M;N*X1VWCY=A)/<^]<JI3F]%H=7M52?F9/VN"-$"*[O&^]&Z* .V*]%\+7:WN
MF7-PH($@C8@C'.[D?3T]JXN'P5KDU[#;LD4:R/AI"^0@ZEB.X !-=EX=BM[:
M&^AM4D2V79Y7F-N9EW??;W;KCL"*;I*GHD*>(E6=Y%GQ:3YD.#@^=)_(5S83
M=][/H*Z'Q=,8;N)O)$@,CC!. .!TKFYFE?YK9C;[N7$AW#/;%"BVM$9Z<UF[
M$GDJF,@#)P..I]*NA)0R$VUP($7>TY0JB^P)ZGOCZUDZ=->Z5-)<0ZA'EU*,
MS0^8 <YX)X#?2I+F\:YA,=YJ-U-$S%@)'(49]NF?>KC"36N@YN,9:.Z.H\/[
M1IFO[)$D7?\ *Z'*L.>16I9'&L\'U_\ 0:PO",44'AS5(XLB)=H7)SQ@XJU?
M6MW>_NK)B)MVXD-CY O/UKF:]])FE_=NCJ'N(HCNDFC"^A85GW&O:?;DEIPW
M/1>:Y2[T.YT^UNYK[$D]LJN\+2[2%8XY'KT-80U2V5"OV*W4YXD+$D__ %JW
MY8+J8W?8Z?6O$7VVU:"RRJMPSD<US$,,=K'\IW,,YYZ$]_K3&U6 @ 6,3>N2
M16A;:Q::M=V&G7&AV^3((%E5R-JD^G<Y[UI&I&.R)<)/=AHTDUMJ%OJ@B4V:
M3O:/(_02-$Q 'OSU[9J]X/0_V(A4$XFP<=CDG-=8=*TK6?#-II-J%M[33KMF
M)MSEO/ ((?/?!SGO4=CX1TK2XDC1KM]HYWRD!OJ!43DY.XXJVAZ':G_0[<?]
M,D_E4I)'4<UPFH^(M6@U*QT^U.(W7YL  !1^N,#M74:/,\]@6DE,I\Q@&/I5
M1E?0SE!K4T":13\Z_6D)I%/SK]:MD+<LYS4<Q_<M^'\Z<34<Q_=GZC^=8FQ*
MY^<?6FD\&FN?G'XTC-P: .DA_P!1'_NBBDA_U$?^Z**Q-SS[QRN=>R.ODK_,
MUAV,I#@$]?6MGQ==>9XKDLS!(NVV1EF/W7R3\H^G7\:YR,^5*0?6NZE[U.QS
M3TE<NZFFUH;@=5.T_0UJV,F^(#VK.G GTZ1>F!N^F.<TNC7&^-3GC&>M<,U9
MG1%W1L JP_H:8T2GV^E(893(Q0$KUZ9IQ\Q1\RD?G2&1&(]FS]:B9'[ &K7&
M*3G.,4[B.;\4PRS^&+[8C>; %N(^.Z,#_+-<;:3)9_%F&92!!JL 8'L2ZY_F
M*]5,*7"O#( 4D4QMGN#P?YUXKK_F6%IX?U'D3:=<O:2'O^[?C]*:V$>ING)X
MJNXQVK4DCCE DC(V2*'7'H1D?SJI+#Z4"*3-ZU$SD=*EDC(JNPP?2F,L66IR
MZ;="XB&>TB=G7T^M=[:7$%]:1W5M)OC<<8_A/H1ZUYLS #[I/T%6=)UN;1[P
MRQ12O"YQ/#M^\/4>XJ6KC1Z-SCD54O@%@&#U:K=M/%=6R3POOBD&Y<]1['T-
M5-394MQ@%F+#Y>U)#94\P!2<XQW/-5)I)6!6W!#M]Z1AR/8>E<_XJ\6Q^'((
MXXT2XU*09BA;[D2]F8=_85YE<>)-?NG9Y=6G!;DB,[0:Z:6&G-7.:IB(0=F>
MP27:V4):ZEBC0<EG( ^ON:X[6/B-# _D:1;BYD/WIG)"#Z=S7 RO<7)WW4\L
MY'W?,<MC\*6., ECU-=U/!)?%J<=3&?REG5-2OM;N5EOYA(4'R@<*H]AZU6$
M>34JIQ4H4"O1A2459'FSK.3NS9T>]-O_ &.XP)+>ZDB5C]T*ZYY_$5:\7^<=
M0@^T'=-M)9AT([5EVB.UI(T8W-!<13,N,C83M/'XBMKQC'Y>I6PRI/DX(7ID
M&N>,$JYO.;="YS>WM3]M %. KT4CRFQH' ]Z7%+_ (4C,JCD@4[I#LWL+CDG
MM2$4UIHU',J#\141OK?./-4G_9YJ74@MV6J=1[(E89XJ(C!XZT+<A^(XII/]
MU#4J6>HS_-'IUQSW;BL95Z:^T:PP]5]!H&#1(KG$B8\R([DSZ=Q^578]"UJ1
M?ELD'?#2<GVK DUJ&&0I(-LBDAESD@C@BN>K6HU(.#9V8>%:C5C4BM4;EV1<
M1Q7:_==0&'N*J]0?3O3]$O;*:QFM&5M\[$Q,>QZC/IS3M'LTU">XM]1F>UD@
M4M^ZZ9ST/J>]<>&QT8P<9[K0]/,,NDYJK3VGKZ/J0X)^;MV%']*W3H&CY_Y"
MMP?>FG0M%'_,4N*Z/K]/L>7]0J=S%_"K5FL?G^?.&\F)6#E>O(XP/K5]M%T?
M/&HW/Y4U=-L1!/$;J58M_P L@^\<#IC]:4\53JP<6M!QPU2C.,D]2=+C7[NU
MMY+[5E73K]FCBCD<_,8L'IV [57U+7([F:58$DM/,A87RN^Z*3& '4=5:NFU
M;2Q#X-T:2UFC:VL@3(Y.2ZR8!P1T((Y%<+# ;ZXO439&9%"*Y'"AFR21Z8%>
M3-+F7+W/H*#:ISD]TE^+(VTJ^2>-XE20#  5NHQD'FI7FEATQMF?M5Z?)B7N
MJ_Q-_GM5R^OXKA(+6UF+ */.<+M78HY]^:QGN77==I)Y<DA,4! RR)_$0/7M
MFMI5*DOW?<SH4XI.JUMMZC9?+46]O$RF)6QG^\>Y/UK>@U%XD"J>,8KFUA/E
MX(VJ?7[QJ:,-G 9OP-;JM&GIN<TH2J/F9U^BW[2ZG(6.=EI.X]B$/-'A:X0:
M1>SR8 157K@N<C"CU)-4/#T(34I [2;I+.=1@_[!JGHVGRWMR5M_.DL]/S-Q
MS^]VYW'Z=JYZM7G3=C:G#ET+GBN\O+VYBD-I-:*IR8KA"&WD<CZ8Q4^A2Z1'
MI<!U;3(KB63?FY6X.U6!^577MQTJIK<LMWJY=W>20@L7;)/*CFJ5U#'8VL=Q
M'('N0F+I<?+*O_Q0'.:YO:.W*:\BO<]#N&T^RLT:&P41*$;RTD^0$]\=ZH7>
MIQO:Q?8M.TTB3=O2="Y4 X[\$DU0BG5O#EQM?,/[LIZ 9JK"2T<&&#JJ,#MY
M*Y:AM@D:6@*L.C:PB*JJN% 7H.#TK.\7S7,&D.UD9!-YZJ6B^]M*G-:&B$?V
M5K6WG,@%0:_)Y=C(=^T^</F_ UGU-.AQVB:=J%Q:ZU";>XDNY88PJRMEF(8$
M@D^PS5Z+PEK#$B6&&# !.]\\'CM71>&R;G4[]XY.)&0+(,_W3SS6\X"W+HN6
M"Q* S=2.F3[U9!B:=\,;FYMHYY]2"B09Q%'P![D]:V;/X86MG>17L-S,]Q"P
MD1&? 8CI]*[#33_Q*[3_ *YBK0:MDD8.;N>01:KJ/A/6M<22))?MC+=(DV5V
MMDJ1_O?S%;=MXAU*]C9W:*$!L 1IT^4G^>*T/%*)=^-DAEC1TM_#\]S\RC[S
M,0"??@5RFB[ELDRQ^\.#S_">:S:LS2+NCT?PFD6H>&=-U"[BBN;V1"6N'3+'
M)/'MVKH1L4!514']U14, 5+:%45541K@(,#H*?NKH2LCGD[L>30A_>K]:CW4
ML9_>K3>PEN62:CE/R?\  A_.G$U%*?E _P!H5B;$CG][36/!I'/[W\#36/!H
M ZRW_P"/>/\ W111;_\ 'M%_N#^5%8FYYSXZU&ST_6]UY>PP(8E $C]3D]OZ
MUS]RNU@PQ@X(QTQZBJ'Q6\(:CXB\?>? L,=O]BC3SIFX!W-G []JT(;.6UTF
MVM9IC/+#&(S*5P7([UTT)6=CGFD6[.0.I1\$'C![C^M5M.5K*[>V?^ _*3W4
M]*CM)"LF.>O2K%[\L]O<CHPV-_2BO&SN53ET,[X@&[M["QU.SN[J#RG\F;[.
MY7(/3([\UQT/BG78F 37;K(Z"5L_H17I.M6']L^$[^SP2[1;XR.H9>1_*O#X
MKFXDM9!(00"%&1_$.3_*N>.QJ]#M$\;^+(Y$_P!.MYH<'?YMNI;/;&*M1_$'
M6% \^UL9CW(4H?TKC;>2"1TEF1XT8-N$3D'I@'\Z5GGC&8[Z-_1+E.3[!AS3
ML*YW2?$:<']YI$1]UF(KG]=N8M=T#Q%+%#Y7EW,=XL>[=LW<-BLN"662/,]F
M\)QQM;<I]Q6IH")<ZC=:>?N7]E+#@C&64;E_E1:P'5:1XNM(?#.C&Z@N997M
M "\2@CY>#^/ J<^,=(;[T=XGUBS7G>E-)+X.A +B6QO6C..H5QG^8-+]ONX^
M"R2>SBG8+G?OXJT9@<-<_P#?FJQ\1Z5)*$VW.S'^L,?0_2N2>\2-U62(\J"2
MG(!J2.:VF/$@!/8\46"Z.ANO$%N$_P!"MYKJ3L&/EJ/ZUSFH:YXJD.U?)M(N
MF+>/Y@/][O5Q8@1D$'Z'-.PRJ55B,\8--.PFKGJ>ES26$<,?F,T+QHLA/\1P
M/FJMXSUY?#FD+<%!-/+)Y<",<+OQG)]A^M6XXOW$2GLBC]*YGX@0V][::7;7
M0+ ,[X_(4U:Z;(=[61YC<33WUW+=W4QFN)F+22'J?\!31'["HM12VTZ^EA26
M0HN",CGD50;5X$Z><3[#%>S"O343QY8>I*3-793PGM^-9$5[=7/,491/[S_X
M5>TV%[C4+>*_E;RIS@,IP%/O^%$L9!;(%@JCW9:+*O5E'U-(;B!>LJ#Z'-=.
MN@^'+=L.\DQ'4YZU80:%;#]WIZ'T+<UB\P[(T67=V4_!$EO=ZO=P-*RJUHX)
MV'GD<"K'BVTDCGTU+""XO-UN2YVXPV:Z'PK?0SZX1';Q0)% TF5'7D #]:L^
M-=2DM=0M([9E"&$DD<<YKC>+DY\RW.Q82*AR/8\[CT?Q!/\ <T](QZR/S4X\
M+ZX5S-=VL7L!FM"75[AOOW./^!52DU-/XKC)^I--XNM+=A'"4H[1&_\ "*..
M;K63CN$&*D'AC1(QF2ZN)C_OFJKZG /^>A]\8JG/KJ1Q22)"'*CH6Z_E63JU
M'NS54J:V1NQZ=X>MQ\MAO;_;;-3K<6,(_<:?;KZ?)7,_VAJ4^C?:[6T_?EP%
MB$9;Y>>?KTJ[%I?B6Z "6L['KE4V#D=.:SYY&G(C<.KSJ (TCC'^R@%59M7N
M3PUUM[CYL9J&+P1XBG.95CC'K+/R*M3?#R6XM/L]UK-K;_,"6C!9ACMFBXN5
M&<VKQ[T#WA#%@!@]_?VKEK^U1]4NI%9"6E8Y4Y!KT#3O ?A[2IHYKC69[TH<
M[&C^1O8CN*T;NT\(O/YLU@9708 C41+CZ"FF)V6QYI9H8RT8^9BI90I_B7G_
M !K>MKB.6&2[ =YS&(V2-=Q<DC''TK?U*319=+FM=*T:."Y&UX9@2SAE.1^8
M!'XU@0/+"@O[!67['M=WC'S")CE'(_V6.T^U8334N9'JT)QJ4G3D6(;'4[PC
M[/I5ZX/1C$1C\ZTX?!WB";DVJ1#^]+(!^E:BZKXCUBU:ZMY+FYC#8<6N-RM]
M._L:YJ?Q$$=S>QZH-DAC9W4X# X()'H:T335S@E"<9.+W1LKX*ND&;S6+"W'
M?#;B*$T+2C:(MWJ4QD3<\2Q+Q,/<^G%9%OK6C2D%[I8]W4."I_.MVT:VN[-3
M!.'2&*6,R1R C!&1].]:0:::1R5HRC*+?<36OL*>'\Z2LR+).J7*8V1LRKN5
M@G0$\C/?;7+:*F_4EXR&>-/T/;\:V706^E:H$EDF&(2IE<-@C/3'L:YZUN?L
M$5Q>*V)Q,%B /1@OWOH,TFTI*_F=E%2G2J<O5I%%K:2WD>T+_OY7*RN3PB@_
MR%7&LV,FY8]H "J6Q@**GTZT5HI;F[.X3(=V1G /3(]S^E6K?1?M4#65K\L<
M #3!B6\R1NB ]L"MZ-)N]2;T_K0QQ&(2M1I]/Z;,G(9BD$<EPP[KPH^F:FCT
MK5'&X"W@'7YY!G]*FN+/4-&F^S7DJ$[=R#HP'I4\,H==WFHI]#S3G52^!)$P
M@VO>;':%!+:>*=/6XNMYE9HBJC .Y2,?CFM/P-;-9:1J4,CE)I)-SC=C.. ,
M>W2L*ZGE@OK&5<%Q=1N"AR2%()KIA:QVWB;6(U'RI\Z ^C$,/YUS3G*;NV;1
MBHJR*=\G_%02, =HC"DXZ?*,52:-VD+*JM_"5;@$'M6QJ*DZK?E0?O1C &>-
MM,BLV6W>X>WE,$8WL^TX 4YSSTJ+%7,2W-Q;^$[RWD$0BAG-NP+'S-P;Y5&.
M._6NB\.:(J60D>YF3S,AX44*<YQRW6LS0+5M0\,ZG*0/FN/M3@$94%@0<=P>
M/SKM])T:6*$+]IB9/,)W8.3SS@4:L3:1SNFE?(\0B, (+G"@=!CBFW4ICO;-
MUP72_B(#)N!YY!'?C-,T8YT[71G)^T]_K6KHN3XIL@<'$Y//^Z:S^T4W[I!:
M./\ A,=;8OO;[<5SGH-I 4#L!4H.;B0]?D_J:S-,;/BO7&)/-^?_ $$U?MG#
MM*Q_NG^=:$+8[33FQIMJ/^F8JUNJCIY/]FVN?^>8JUNX-;)G,]SDM5'F>-M>
MEZB#PZ(_IN8FN5TK/V2,')QC&.WRUU&H2 ^)O&94XV:/"I/H<$US.C<6\(!X
MZX'^Y4,V@>O*V$C'HB_R%+NJ(-A4_P!T?R%&:W1SLDS3HV_>K4.:=&?WHH>P
M+<M%JBD/W/\ >%*34<AY3_>%8FP]F_>?A2,W!IC']X?I2,< T#.TMO\ CUB_
MW!126G_'I#_N"BL38\2^*M[JT'C,QVE^L%O]DC;!<+SEN?6L#PCJ5P=6EL[N
M_6Z-Q'E%$F[##GK]*TOB^BGQ\S%03]BBY(_VFKB;*Y.GZA;78(7RI%8D\<$\
MUM!V,I(])9?+G('3K5V1?M%@ZCEE&X?45'>JH99$Y##((]*DLW4$#'!ZUUU%
MS0N91=I%_1Y@R(3R#VKR'Q-H=Q9^(KS3X4RB2M(K'@ /R/KBO4=-/D74D/9'
MP/I6+\0D^RW.G:A' '\Y6@=NRD#()_#(KSGS+2)UQ46_>V.!CT6]E55&U0H
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M;F1!]G0;%'N:YP:':NI61KB93P59NOY5I?0AV3*W@IXWTZX7+&7>V]V.>,G
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M?.H6>,@8 QAA7.PLMK\4KI%XM]9M#(ON73=_,5*>A=C*M]%N=3O;PVMWLNH
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M6DB^92<#'T[UPCW>I7*'SYII7<<A>%0?XUZGX,U&;5]'CMKLRK=6RA3YJ_?
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M'!']*JZGK[>;)9:44FF0[)[H\Q6X!Y /\3=>!6%;+/#8RPB<6]M*V9Y$&)9
M/X W9?6M#3M)FU.*-5C^Q:4APFT;2_\ NC^9-38=SK=6O;:^E2/3[B.ZW1J
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MX0Q4RR?(O'7KU-5AKMU<6OGQ(B D<'D]:U[OPA/J=T;C4[U44MN6!&^1">I
MJS%X:T.T0++<R2@?PKFJT$<K-J-Y(C!KD@X) 7UQ6/#_ &Q>X_T::8GUR*]+
M1-#L^8=/5R.[TR;Q);VJD+]DM\>P)I7 Y#2O#.K-?V]S-IP9(COV$]3CC\NM
M=./#^IN=\LD%N#URV>*I3>-89;B*WCO'EDE?8BIP"3[U3O/$4<"LQF4N,@(
MQ+'T&:EI-ZHI-EY_!>A,X:\:&0@[@L8VJ#ZX%7H-/T&R7$-B'QW*@5QEYXBO
M([4^8=ET_P!R*+G'UJA -;U./$@N=YR,DD+BJM8D[Z?4-,C!V1P1X^\1R1_]
M>LZ7Q'960^T)<&)N=K!L$_1:C7P[?WME:6]CIC6J1J?/\TYWL>^?UJ5?ATGG
M_:K_ %*&)SP0J@XQZ9H S;SQO>74(CD,UP,Y!F<#)[9Q^E8DGB?5)V*PHD8Z
M (NXFNYM_#/A:P&6\VZ;.<'H3_2KZWFF:>@-KIMK#CNZ@G]:5BKZW/-%L/$V
MKO\ NX[N16[DE15Z#X8:S<GS+J=;<]BS9(KLKGQ>S HDX Z?NQ7-7WC-Y,HL
M4[KW).T&F)ZNYH6G@BSTU7-WXBG#2+ME\ERHD'^UZU<CTGPK9?,MB]ZP_BE;
M</UKBCXBO+B0)"B*<X 12V/SJ2WCN+MV%[>S1(,G"]S3L([=_$EGIP*V]I8V
MRKTP!D"HX]<UC5K:>ZT^.:YBB<(?*&SDC/R@]?K7"!/+)1H(T7!82MR<CL<U
MIVOC#6[>V58]1")C$8>-3M]U']:EM(I1;UZ":EK.HVTQ-YI=U!(1]ZZ1N?R[
M5G)KL[,NYD:/.<)QGVK>T3QQJ=E-<07@GU>&4@JLK!BA[XXZ'TIFOK::L4N;
M30YM,ED8))*<;'Z]%[-[U2?<35F5);*RU&-6-YM\P94.25)[CCI6=<>'KNSE
M( GB;&04<X_ BM=+2/0].)CLV5BP5=YR68CJ?2K$7B58K>.*YC(*+P4;*TR3
M-TV\\66\J1V5[<LH_AE^=1^==)<O=3M#/J]X)9H5S%!%\L<9[D^K']*QKCQ5
M$H*H;AA_=5:QY-2FU-BA 2+N@_F: +^IZX&(*2;(P<!]N22.RC^M7=&\8ZBM
MRJ2SO=P]&BN,#C_98=/ITKDEVW%TY=BJ*=B >@JR+2$,&W*0/FP>_P!:A[7-
M81YI*/<ZBX#^-O'*6\:2BP@7&TC&V!>6)]V/%=C(J7/BVRMR,1V47FLN,;1U
MQ^@KRQ[Z\NI!>0O);G)0&%R#@?S%=IX?O)[3PIKGB"ZE>>X2$1QR2'<68C_]
M5%"Z3D]QYDXN<:,/A7Z&[KMW!!HLK7D"W$5UN\V$]7'7CT/3!]:X%M,F6PN(
MM+>2_LMPE$6,3VYZD.G<$=QQQ5F;Q)J=_HRWNH10">& ,JQ+@,['"#'J3S^%
M1:O8,/#FFZM;2/#?6W[MWC8JS*>G([@_SHJJUFMQ82;FY1D]-D:&L1A-9O(2
M=GG6GF 'Y<G:'''K\I%;7ANX6YT>SR5)MXRA&<XP21_.LF7Q)/?66DWZI;2;
MA]GO$GB5R)%(!;)YY4_SK0\,:@TMKJ,9MK.!X& "P1;0V21DY/M7IU6ZF'4K
M?UL<*@J5=Q>Y4\4QSWNES0VT,EQ-(=HCC7)S_3ZU@:%ID&ESR#4I(I[LLI^P
MPOG8?^FKCC\!S70>+;NY_L2X1;B1%*'A&V#]*XGPR%6XE4#:-R_RKS=>4[5N
M+J^OWXMC=M*5FN9Y )BH\N-$X"*.BC Z?UK=\,:C/J&M6L\[-FXTML!C]W:W
M\JI:4B/H212QI(JS2J5< \[S5F-S:>(-+NE 54D$+8&  ^1_/%1Y%G0ZN\<=
MS$TB;UW*"N<?P5A:_'8Q1>9I_F^0VPOYJXP_.1Q6WXA3,T2>C#C'^R:YG6!Y
M.C2DY4B12O8 <\5M36J,IMF>LH-2!JR4GZ<U=CE]ZZV8H['PY_R!+C_KX6L_
M6_O(?]L_TK0\-_\ ($F/K<+6;K[;(U;.,R$?I7GP_BG5/X#$OK1=0L9+<X#D
M;HV/9A7+Z1=?8KX"7*HQV2 ]JZ1[D8(SS6)JED93]JA7<Y^^@[_[5=E2#^)'
M/"2^%FU>L$4MUQ^OI63N:-W0?\\@N?<G)I+6\-W;I$[8DC/S9X) Z5-@2R!4
MP6)QQT ]ZB4[[%*-MQ]II<D]A?7^"+:Q0%VQUD8@*H]\<UW7AL$Z7:<?Q'^8
MJK+$L/PEF$:X47 #G^\Q<?-5OPY-"=,MHEE590^"N><Y&/Y5DU96-$[G93*D
MA.8U/X=.:@>UM\ F+:.F5;%/!:21PI+,">!S32P(((/3.#3(*[6,8&4D9"#R
M,<&KNCQR1R7 :0NH"@579FP/KV[CTJSI?F9N-YW<C'RXP/2DV-(T'/6H3<10
MQ/O8 [2?<T]C566%9;E,@<(?YU-PL1:!'Y.CQH>IDD;_ +Z8FM(@8/TJO9QB
M*V"]@3_.IF/RGZ4#/1[+_CQM_P#KFO\ *BBR_P"/&W_ZYK_*BH-#SGQIJ>GP
M^+)X)+-);J.VB9F<_P +%L?D17.OXF* K D$?LBY-9WQ8O#HOQ7L]0N(O,L9
M[-(9 3PPW-G/TR#5U+FR\[[/;O;E^N(QU&/6FKWL2S0$LDMOY\S9E<98XJO
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M);ZBML)YBD8X+I_K'13W(]A6?K)N-/O! MVS(T(D5\!<YKH3I<@A$=_X@*Q
M8*0J%S4:6WARV((@ENW48#2'=@4)DLXL/),1S+(<]!DFJT7@S6;^X=X[4JK-
MD&2O0&\0PVGRV]G;0+V)Y-9]QXLD9B/M9)Z8B7%.X&;8?#>\@N(+FXO8X&B<
M2)D#&X>M;-QX=TF2[^U:GJ1N9SQ\HP![*HZ5D/JSSG)R0>\C9JA=:W;PY1[Q
M0PZJBY-&H'61+X?L<M!8&5L??D.,T2>*%C!6V@MHL#C8N[%>=MJLMX_EVD%U
M='MP<5K:7:ZCIQFO-7@%M Z8B4D D@CG]<46 V+WQ7,&\N6:7<!R@(0=,UAO
MXEEN2P@B4[>I8[C5H:#HVL7$NI3:T\,TGW($7[FT8RWUQ6?;:#J%V6FLK4O&
MXPLA.U&P>QHT @N-4U*6-O\ 23$,?\LP!5"U\]QOG>1RS9!=L\9KH4\&7TO-
MY?V]LIZ@?-4\GAO0+.%?M^KSE0,*8_DY'\_I0Y)%QBY.QD,54Y8@<XY-4F@R
MX\E3+D\[%.5K:T>\L8I6:6VBF4IP9%SSG@UHR^(R@Q:PQ1CT1 *RC/F5[&U:
MBZ+Y;W,*WTG6+A<1V,B#H20%!JVOA6^(!N+R& #U;<1^%.NM>O)%=WD<*O7!
MK'EUB\E<;EPK.!R<DBK,KW-D>'-'B;==ZE/<,/X5&!4G_%/69W1:>CN/XYGR
M:YS[1,V]3+N(ZL.!CZ57NUWVTFYL_+WH2$VWN=6_B185(MXH(E_V$ K+O]>N
MKN+RS*=I.3CV.:REP0,#+8&<#-*<+G/R^@/6F(?)?R74DGG.-VW>5'0CI^=2
M)&3R>O?%0QV;RECY#,6&%9CM"]ZN+9''[VX8#^Y$./SJD2Q"8XADNJX[=33%
M_>SI*MKYL:$$H_[M&'H3UQ5E(H(6 BA4'U;DTYF+&F)(J_8H?->0I'$K,2(8
M 2J ]@3U%0:A)'#:,D480DX+=6./_KU;DE4'8"68]%3DG_"J<]K<W&JPV'D2
M>>#S#CYP?O$8K*IM8[,*E[3F?17(T+K##:<EE(4?B.:[W7D&F>!M&TMCM:\D
M,\H']WC^F*YG2+#[7JMI9-:W,5X\XW-(?W>P\<#KG-=+X^N4F\10V2!2+=!#
M$K= <<DGV K9*T4CRZTW.K*7R^\YF\M'E@"6K%?*G,TC(NXE@N$_++$^YK0U
M1A%X BD8DJDR<#OSR/QK$\R9K^S-I/M-_O>-7?9M1?XW^O;UK<U([_ UOCDB
MX5C^&36,FWJSLI14+*)RNGRF.\"X9(9B<QD_=[$?K74^%9S'K4UOC_7H4Q_M
M+R*YE889?#,%W%%)]O29YIY-V0Z%N!CMCO6A:7?V;4K:^B/#[9/Q!P1^5>M@
MWST)TW\CGQS_ 'L*WR?R-OQ._F:?='/RA#@^N!7)^'>))OJO\JZ_Q,B'3[@(
M!L$+L"/3%<?X=^9IR3_=KSK>ZS9?$:^G'R9]0M]JD173/M89^5@#4US$LEGJ
M31*Q:VMDN$)Z@JX.?;O4$+>7KUZ,\/#&Q_#(K<\/Q)>:M=V[<I/8M$>>QX_K
M6*W-62^()1->6KIRLD:R Y[%<_UKF=;#MHES(N3#'*BNPZ!CDC/H:N"Y+Z?I
MPF(\VT1[68GLT9(Y^H K(US4&O=.N7BU 2Q$)N@50%Z_>P.E:1OS(F7PLPE8
M Y_G5A)N.,5F Y&YL[1P!ZGO^%6@D+1LV\_4&NQROL<J5MST;PT3_83'K^^4
M_I6;XBB>:*%-P1!(Q9CV&*T?"XQH/!/^M7^58WBY_+L.6(W.1]>!@UQT;>W5
MSIJ)^R:0NF:%?:C );"VM1:D\7%Q(/F]\=?TK1ET."T,:W<L=U(3SY2;%^@/
M6LKX=,O]H7>^-C(+7,; \ Y&>/I70:Q*1=0BNK$8B5W%;&%*C%*_4YVW\'Z3
MJ%Y(XDG@DP'!!#+R:AOO#-UINMQ06:S7D4L6Y&6/:5(.""!Z5NZ#-MOI=W0(
M!^M;T6JQ1:G#I[L5>[0M&V>I!QM_&N:FY-Z&\TDM2DOAZZ?P/+HMU/#;W,UT
MLR@'?M08//OD5)I/A_3=#NI;N,/>7,@&6N.$4@Y^5:=K^N6_AV1(+NSN&N)0
M'C08"L"<9W?S%2Z?=2:A+;LT"HCR$;%.>!QUIR;ZDI::$1\0:M>ZI<VYS'9(
M-JK$NT$_AS6XD(-NF>&V@$^G%7!"D6X11HH)S\H&349C^]QU]Z@K0H20$(1'
MSZ9/W:M6 *"3<<%@.IZTI0,#@\CVI!&#G(!QTQQ4NXU8MDD\@<5"S#[2/]RH
M6#KRNX#U!J(M,) ^X;@,?,.U1J.Q>@;,0'?)J4D!3ZXKD=5D\1Q3I+HUS"BX
M)DCF3<&/]*ICQ7XIM%;[;X>@N0!RUO(5)_ U5Q6/H.R_X\+?_KFO\J*ATB=K
MC1K*8PLADA1BC=5R.E%!1Y1\7])T_5KBZB+.-36V1H,#C(+':?J,BN?\$RS7
M?A:R$]J(I(LH),#,J9X/UZBNQ\=Z>EUXLWNTV#;H,(V!U-9[JEK;B*-0N1C
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MC$*(B_[(IQ<FF24TL54#S)F(_NI\H_.ITBAA&4B53Z]:&=5QN8 ^]/AAN;C
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M\B0;,_B>M:7A+P[<W+37^HW;) CF)88F!=S@'/LF#UISK48^['85.G5?O,]
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MT _QK->2YO)#%8JJ1#K,Z@LWN > />B<$$6S0UO1(->TW['. D@RT$O>-O\
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M(L0]6.33UM8B,R,\Q'7)P/RK119%R+S59B$W2'_9&:<8K@\D"(>I.35OY1D
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MMM'W ^=S_A77V,,-A MO:Q)'$!DC.68^I/<TYU84X\L C&4W>1I0)!:6T=M
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M\9R"?6G+$T2X50X'.!P<?UJ5,299"".C CG_ /70!&L74D;B#ABI^44[RL#
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('VHHHI%'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #G 9L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?(WCG'_"P=>)SC[?+T_WJ5XH)'&V
M\=@Q95!<<' _^O\ G2>.!GQ]X@_["$O_ *%65):1Q@$S,..<Q$ 'TS51=NAE
M4@Y-6=AC2R3.!*P)!(' '\JV+&"-UPQY4$@8K$P%? ;</4"M2UN4B(D9L%0<
MJ>_%;4FKZF.(C)QT*]Y&$F./F4C_ ":F$%L?#$EP;64W N0BS@'8%QG;G/\
M2DG9)$=QUV''YU(LJ?\ "*21?;2'^U _9L#D8Z^O]**MKZ%TK\JN<W/P;C_=
M_H*REK5N>/M'^[_2LI:YSH/8?A2XCT&Y+;MIN3T/?;Q7LEJQ:VC)/)49KR#X
M3(S>';@IC<+EL9Z'Y17KUJ,6R#T&*?0E;G-^-M!N]2MH;[34$EW;9!B)QYJ'
MJ/K7!0:K:QN+2YWV5R./)N5V'\#T->UQ]ZH:IH=AJ\+17UI#<H>TJ<CZ'K2*
M/,R<?EQ7DP[_ %/\Z]:\7^!)= T:XU/P_>W,$<'S2VCG>FSH2OH1G->2HIP%
MP2W3% '?_!^U>?QW#(H.V*,[C]2!7T_7C?P6\-O9P2:E.F))OF'LHX'YDD_A
M7LE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R1XW'_%>^(/^PA+_P"A
M5A?C6YXU8?\ "P/$2]_[0EQ^=9:S*B;4B7D<LW)H&DF5P.>*>69NIZ4O D!1
M<#/ SFGRQA&(YR!SG@YHN'+=7&>8=A7UIF.*LV]I)<$%2H7=M+$_=XSDU$0-
MBXQG)SQS3O<.2RN9EWUN/]W^E92UK7G6X_W?Z5DBD(]J^$?_ "+L_P#U\G_T
M$5ZS;?ZA:\A^$EQ#_8\]KO G\TR[#U*D 9'J,@UZ];?ZA: +4?>G4R/H:P_%
MWB6+PUH[3[E^U2Y6!6Z ]V/L/U.!0!ROQ2\5QVFGR:);OF20#[00?Q"?CU/M
M]:XCP+X1DUF\6ZN4;[,K<C'WS_=']?\ Z]0Z'H5_XPU9KR8N+8.297Y)R>3[
MD_YZ5]#^%?#\&EV4+B((%7$2>@]3[F@#5T?3ETZP2((%<@%@.@]!^%:5%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'R%XW./B)XA/IJ$O\Z74K&]TR
M[$%Y:6Y<(C_NU^4AAD=*3QOS\0_$?_80E_G5OQ5#'%JZ$65S;?Z-!]Y]W\'U
M/\^U-(B4FFD8;D,<A GL#3<4JD,?;-3+"K'&]0?2D61 LN<,1D8.#UI,5.T<
M:<$Y(&>#U-1MC=\O2@+F5?<-/_N_TK)%:^H8W3?[O/Y5D"@#<T+5IM/O(&6=
MX3&V8IEY,1/7CNI[BOI3PMJO]M^&[2_*JKR!ED53P'4D''MD9'UKY6CZBOI+
MX8#'@"Q_WY?_ $,T =I'T.3@>IKPG7KZ7QYXY-M"[?8U;:I'\,*GK_P(\_B/
M2O4_'&JG1O!.IW*-ME=/(C/^TYV_R)-</\(="^V/)=,O,\FP-Z(O7^M 'J'A
M/P[#!;1.(E2VB&$0#[Q']*[6F1QI%&L:*%11@ =A3Z "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#Y#\:\_$;Q&/^HA+5><:I=/YTQN)F5 F_=NP
MJC ''8"K'C3_ )*1XD_["$E5I;9N6$T((&3P8R>/0@4T)VN4AP<BI5.>1UJ+
M%2Q1L[?*#2!M+<7%+BGA#Z'--Q0.]S)U'AIO]T5D"MG5%V^8?[R"L84 3Q?>
M%?2GPR_Y$#3_ />E_P#0S7S7%]X5]*?#/_D0-._WI?\ T8U &+\9[DQ^&=.M
M@>)KS<W_  %#_C75_"&R6W\/VSXPX@!/_ CFN)^-A_XE^BC_ *;2G_QT5Z/\
M+TV^&K<^MM%_(T =U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ?(?C/_DI/B7_L(251_?LA0R,4.,@MQ6[\2M,DTOXI:TKJ0ETZW,9/<,N3
M^N1^%<\"1W- *W41E*M@U8@G,<90C@G(^M0LK!CN'/>D%--H4DI%QV3;D<$=
M>>M1,=Q![XYJ'=ZTJOMY/3O3;N*,;%'6"#&!Z1\_]]5AK6SJIW;\=-@K' I,
M:5B:+[P^M?2WPW&WP#I@]1(?_'VKYJB'S#ZU]'^"!M\ Z(V&+;'PH8KG+'N*
M0SFOC:W^CZ(O^W,?T6O4/AHNWPO:_P#7O%_(UY7\:_\ 4Z$._P"^Z_1*]9^'
M:[?#=L/^G>+^1H Z^BBB@ HHHH **** "BBB@ HHHH **** "BBC- !1110
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M/]WNWX_XUKK82W9!N@%B'W8%/'_ C_05I+;^PH R!9>U2"T]JUA /2E\D>E
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M*** #%)BBB@ HQ110 8HQ110 8I,444 &*,444 &*7%%% !BC%%% !BC%%%
M!BEQ110 8HQ110 8HQ110 N*,444 %+BBB@ HQ110 N*,444 &**** "BBB@
M Q1BBB@!,48HHH ,48HHH ,4F*** #%&*** #%&*** #%&*** #%&*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #B 1<# 2(  A$! Q$!_\0
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M?@CTH W**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*'(Z5EZQH.G:_:M!?6ZMD8W8Y% A?#OBW2O$MHLME<(SX&Y/0^G-;]?/FO\
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M KV0E6TC$Q<N!U?&[&>,X[XQGWJU2"EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFNLHJ51774UEF-3>&C;NWO=I)7U3MW]6S#\)277]@16MZCK<V3-:N74C>$.
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M3?\ "M;V P2>:T=QB/8=QR[8XZU'J%L;7Q M[>W.HVUI<64<:S6F<(ZDY5\
MD9SD?C7:T4W25EKL3',)*4G;XFW]]O)]NQQQLK=;33Y=/^VSK+K$<TLEPK;V
M.""W(&!P.<5HM;RR>*-4(C;;)I\:*Q'!;+\9_&N@HIJFE_7]=S.6-E+IT:^]
MI]EMRV.-M;K39_"-C::@E[$UJL22,D,BO;RJ.&R!Q@@\C(Y]ZU_#5S>7-K<_
M:9))H4F*VUQ+%Y;RQX')&!WR,X&<9K;HHC!IIW"KBHU(RBH[N^][7=W;3KZ[
M=+ZA1116IPA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M29'J*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAFD:A)I6JV]Y&2#&XW =U/4?E7N2L&4,#D$9% "T444 %%%% !1110 4444
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MS%7C;(]QW!^M 'N]%065W'?6,%U%]R5 X_&IZ "BBB@ HHHH **** "BBB@
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M=5_*/_XJCV4^P>TCW/7:*\B_X:$\._\ 0)U7\H__ (JC_AH3P[_T"=5_*/\
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M7\H__BJT]E/L1[2/<]=HKR+_ (:$\._] G5?RC_^*H_X:$\._P#0)U7\H_\
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M (JC_AH3P[_T"=5_*/\ ^*H]E/L'M(]SUVO-?B5N_M6RS]SR#CZ[N?Z5F?\
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M4'' SD9XJL)I K*';#=>>M FD&<.PR,'FI]G5_F+^L82^E+3[^_GZ%G[(A4
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M@^-+2+[+;O;+.3*6#>:#O8@].4QM[],\9K 'A2[%Q';2WEE%<-$TSQ/+S%&
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MZU;PY%#FSL[$E+-Q;[XRS"38H <$8SNW'.3^55K?P0?L=Q)=7#+<)=B&*)
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MM5FL6N[4""W%Q+.6(1$(!YXSGD#&.]%MX6OKN6..&2W;S$CD1M_!5Y?*4_\
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M ?A56BJ2L2W<****8@K[/TO_ ) ]C_U[Q_\ H(KXPK[/TO\ Y ]C_P!>\?\
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M*+H1PEKF62%9R\\:-Y>$=MV21GMV]*?R%\S#'BG5UM!;+<JL2N'7;&H*X?>
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M2T(M 76590S3>9CD%>-N?P[TOD/YF'=:]KUM>3I<WDD<^Y/,5E7*E 0N..,
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M<#DD8!7/X<4K^0[>9S.H>)[V\O!/"([+:R.$@&,NH(#GU;#&GW7BO69'M?\
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M1L[F29F28NA&UU!&?+\L$C'.%XQ31XIU@2-)]I4L9!)S$N =NS &.%VX!'3
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M26T%T;BVCMI8GE\Z0LJJ$"ELY'/##ID=JBM?"VH7>L7>G(80]HNZ60M\@7(
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M^O)J['XEUB.W: 7TA1H'MR6^9C&S;BN3SUY]JKZ1]F_M:V^V2K%;[_G=H]X
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MW%F^9[QA=WZ[<;)@NS;[_P 39_V_:N;JEJ)Z&O/XGU:Y!$ER/F1T?;&J[]X
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M!9]SF3?:M),D&V0R36YMTC6+EXG.[ &.YZ8J1_$FLQ*EN\^QH1Y;9B <X4H
MYQDX4D#/2MMM?M(?'.GZDEQ T,%HD3R1PD('$14[5(Z;JFBU/PXHMY94LI%
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M]C0G@K4C!$[S6L3R2K$L;N0<DL <XQ_ W&<]/6L^;Q#J4X96F4*QSM2,*/\
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M\NSGO?[6M'LX4),P1^7#A"@7&<Y(YZ8K)34[Z.6XE2ZD62Y.Z9@<%SNW9/\
MP( U->:]JFH+(MU>/(DBA'7:J@@-NZ  ?>YSW-.S%=%JT\-3WEA:W4=S%BX,
MGR[6/E[%9CN(& 2%.!U[U/%X1N)(;5S?6R/=-"D$9#$NTBA@.F!@'DUFVVNZ
MG9P0PVUVT4<,GF(%5?O<C)XYX)X.1R:L1^)M4&HV]Y<3_:6@E654D "Y48'
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M_P"%8>-_^A;O/S3_ .*HYX]PY)=CDJ*ZW_A6'C?_ *%N\_-/_BJ/^%8>-_\
MH6[S\T_^*HYX]PY)=CDJ*ZW_ (5AXW_Z%N\_-/\ XJC_ (5AXW_Z%N\_-/\
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M HHHH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7G^^/I453S(S,
M"!GBH_+?^Z: &44_RW_NFCRW_NF@!E%/\M_[IH\M_P"Z: &44_RW_NFCRW_N
MF@!E%/\ +?\ NFCRW_NF@!E%/\M_[IH\M_[IH 913_+?^Z:/+?\ NF@!E%/\
MM_[IH\M_[IH 913_ "W_ +IH\M_[IH 913_+?^Z:/+?^Z: +5%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYRW$X1)#-'CRV5U##;QGH:RMB_W1^5'L%W'[1]C[0_X2GP]_T'M+_P# R/\
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M^-+_ ,)-H'_0<TW_ ,"X_P#&OD (O]T?E2[%_NC\J7,:++HO[1]??\)-H/\
MT&]-_P# N/\ QH_X2;0?^@WIO_@7'_C7R%L7^Z/RI0B_W1^53SEK+(O[3/KS
M_A)=!_Z#>F_^!:?XT?\ "2Z#_P!!O3?_  *3_&OD38O]T?E2A%_NC\J7M'V+
M650?VG]R/KK_ (270?\ H-Z;_P"!2?XT?\)+H/\ T&]-_P# I/\ &OD;8O\
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MT?VA/^7\Q?ZH8?\ Y_O[E_F?3G_"0:+_ -!C3_\ P)3_ !H_X2#1?^@QI_\
MX$I_C7S"\$L:*[QLJ, 5)'!SG'\C4R:?=2)N6(D9(Z@<CK1_:$_Y0?"&'2NZ
M[^Y?YGTQ_P )!HO_ $&-/_\  E/\:/\ A(-%_P"@QI__ ($I_C7S D4CRB)4
M8R$XV@<YIYM+@,JF)LL,@8[>M']H2_E&^#Z"WK/[E_F?3G_"0:+_ -!C3_\
MP)3_ !H_X2#1?^@QI_\ X$I_C7S*MA=L%*VTI#' ^0\\9_E48@F+%1$Y88R-
MIR,T?VA/^7\P7!^'?_+]_='_ #/I[_A(-%_Z#&G_ /@2G^-'_"0:+_T&-/\
M_ E/\:^81;SD@"&0DX_A/?I0MO,Y 2)V).T84]?2C^T)?RA_J?0_Y_/[E_F?
M3W_"0:+_ -!C3_\ P)3_ !H_X2#1?^@QI_\ X$I_C7R^Z-'(R.-K*<$'L:FN
M[.2S:-9&C8R()!L;/!Z9H_M"7\H?ZGT+I>V>ODCZ:_X2#1?^@QI__@2G^-'_
M  D&B_\ 08T__P "4_QKY=HI?VC+^4K_ %-H_P#/Y_<O\SBZ***^L/R@*V]4
M\1/J>E1V+6RQA#"=X;.?+C*?KG-%%*P[EC_A*(E229-. OVM!9I<&8E4CV;"
M0F,$D9Y/3-.AU/24\(V-A>VGVJ1+N:0B*4QR1@J@'.",'!XQVHHI<J'S,?#X
MTE@F#)8QK#')$8(E<XB2..1 N>I_UA)/K5"UU>S;3(;#5-/:[CMF9K=XYO*9
M QRRDX.5SSZC)YHHHY4',R'7-6_MK4S>"UCM1Y4<2PQDE5"*%&,_2L^BBD:(
M44M%%2S6(M****EFT1:<***AFT0%.HHJ&;1%I:**AFR%I:**EFT1:6BBH9M$
M6EHHJ6;(44M%%0S>(Z@445#-D.I1114LUB+2T45#-HBBE'6BBH9O$6EHHJ6;
M1%I>U%%0S:(HIU%%2S9"BEHHJ&;(6E%%%0S:(M****EFR%%+114,VB**?&[1
MR*Z'#*00?0BBBH9LC1BUF>,$"&#:01M"8'/_ -?FGKKEU]HBE.T[""PQ]X@D
MY/OS111S2[@J%)_9&W6L7%RTP(41R\;",XILNK7,ZPK((F$1! ,8^;'3=Z]3
M^=%%0Y,VC1II*RV%.K7!()2$D9ZIUX(_3)Q]:'U>YDE61UA8HNU08QQQC/UH
MHHYF/V-/L(^JSR1>6T<)&02=G)QZT+J]TC%E**#(9" O&3U_"BBCF8>QI[6)
M)-<NI$V@1ID?,57&>O\ B:8=8NOM2W \H.%50!&,87IQ111S2[B5"DOLH<=:
MO"Q8,@8G)(7&?3^= UN\ ',9XP24'(QC!HHHYI=P]A2_E18;Q'=;(=B1J\:E
M22H((X[8]A^55/[5N//,I6(L45.4&/EZ'ZT44.<GU%'#TH[1$;5+I@ 7& %7
M&.RG(_6G/K%X\TDN\*T@P^T8W#!&#Z]:**.9]RO8T_Y412:A/+;"W<J8E(*C
M;]W /3\Z?_:<WF%C'"0<Y4IP<@ G]!112YF/V4.PQ+^:*X%S'A9^29,9.3WI
M[ZI<O/YI*!N/NK@<-N_G111S,/90;O8L76O7,\YD1516'*XR/\\5 FK74=U]
MH7RP^0<;!@X! R._4T44^>7<E4*25E$E?7;YXFCW1@'J0@!_/K2+KMZL?EYB
M*$@D&,<X '],_6BBCGEW%]7I?RHSY)&EE>1_O.Q8_4T^XN)+J<S2D%R .!C@
0  ?H***FYMRHBHHHH&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1\\DITS5;_A&[ I$A#M&@ 9"05E ;< P[X)/YUL44 9AT&Q,+P"/%N]P+AH
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M!;(Y]N/6MBL>'P];PWL%T)I2\>"^<?O&RQW$XSGYCTXZ>E;% !1110 4444
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M8GY5,&T\%F/W\]Z ->UTG3_MTVHQJ)))2N"1PNQ=G'Y'KZFK9L+4^3^Y4>2
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M [T 6**A>\MHW='N(5>-=SJ7 *CU/H*@.KZ<+A(/ML&^2)IE_>#!13@MGT%
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M17)6JZNK1N8KED2[/EP,&4&,[>2=Q(V_-C.0>>.F)-<LKV\FU"%(I[B"6)&
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MC>2)8P&3HVT CG/R\@\_@14!UVYN]0%M9SP^69O+,JKOP/(\SCG&<UTH '0
M4!0.@ H Y4^(YYYK**.14>XA42( !Y;-$7#+DY.#[8[=:S;2YOK 6LWVJ:;=
M96H)E8 1F3>7<Y.,\#K7>;1G.!GUQ1@$8P,4 <J^K:C<65XCW$5I=QVQ,21@
M.924)WIZ]!TR,YIT.M:@;J"&)HKA%2,[F=%-P&7+,O/4'C@=C74;1D' XZ4;
M5X^4<=.* .=T&_FOM5G>2[28-902%(Q@1,S297ZCIZ\<UT=( !T %+0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 9'_  E7AW_H/:7_ .!D?^-'_"5>
M'?\ H/:7_P"!D?\ C7Q=M7T'Y4;5]!^5=?U==SF]OY'VC_PE7AW_ *#VE_\
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M!D?^-?&>Q?[H_*E"+_='Y4O9+N6M3[+_ .$H\/?]!W3/_ N/_&C_ (2CP_\
M]!W3/_ N/_&OC78O]T?E2A%_NC\JGV9:C<^R?^$H\/\ _0=TS_P+C_QI?^$H
M\/\ _0=TS_P+C_QKXV"+_='Y4NQ?[H_*ER&BI)]3[(_X2CP__P!!W3/_  +C
M_P :/^$G\/\ _0=TS_P+C_QKXXV+_='Y4NQ?[H_*IY2U03ZGV-_PD_A__H.Z
M9_X%Q_XT?\)/X?\ ^@YIG_@7'_C7QUL7^Z/RI=B_W1^5*Q:PJ?4^Q/\ A)]
M_P"@YIG_ (%Q_P"-'_"3Z!_T'-,_\"X_\:^/=B_W1^5+L7^Z/RI&BP:?4^P?
M^$FT#_H.:;_X%Q_XT?\ "3:!_P!!S3?_  +C_P :^/\ 8O\ ='Y4NQ?[H_*I
MN6L#%_:/K_\ X2;0/^@YIO\ X%Q_XTO_  DV@?\ 0<TW_P "X_\ &OD (O\
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M@SIW_@4G^-?*(4>@I=H]!4_6WV+7#=-_\O']R/JW_A(]#_Z#.G?^!2?XT?\
M"1:'_P!!G3__  *3_&OE/ ]!2@#T%+ZY+L6N&:;_ .7C^Y'U9_PD6A_]!G3_
M /P*3_&C_A(M$_Z#.G_^!2?XU\J8'H*4 >@J?KLNQHN%J3_Y>O[D?57_  D6
MB?\ 09T__P "D_QH_P"$BT3_ *#&G_\ @4G^-?*P ]*=@>E+Z]+^4M<*4G_R
M]?W(^I_^$AT3_H,:?_X$I_C1_P )#HG_ $&-/_\  E/\:^60!Z4H&2 !DG@
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MCRB)48R$XV@<YIYM+@,JF)LL,@8[>M']H2_E&^#Z"WK/[E_F?3G_  D&B_\
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@/)?3R0-"Q&QE13@8X7./YT44KLU<(NUUL5J***11_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***"<#)Z4 %%<5=_$
MK31>RVFD:;JFMO"VV5]/@WQJ?3>2 3]*B_X6)>_]"-XF_P"_"?\ Q=5RL#NJ
M*X7_ (6)>_\ 0C>)O^_"?_%T?\+$O?\ H1O$W_?A/_BZ.5BN=U17"_\ "Q+W
M_H1O$W_?A/\ XNC_ (6)>_\ 0C>)O^_"?_%T<K"YW5%<+_PL2]_Z$;Q-_P!^
M$_\ BZ/^%B7O_0C>)O\ OPG_ ,71RL+G=45PO_"Q+W_H1O$W_?A/_BZ/^%B7
MO_0C>)O^_"?_ !='*PN=U17"_P#"Q+W_ *$;Q-_WX3_XNC_A8E[_ -"-XF_[
M\)_\71RL+G=45PO_  L2]_Z$;Q-_WX3_ .+H_P"%B7O_ $(WB;_OPG_Q='*P
MN=U1114C"BBB@ HH)P":Y2#QMY]DNH+H.J?8""WVA51@%!P6VAMV./2HE.,=
MSHHX:K63=-7MZ==MVCJZ*AM+J"^M(KJVD62"50Z.O0@U-5[F#33L]PHHHH$%
M%%4M7O6TW1[R^1 [6\+R!2< D#.*3=E=E0BYR48[O0NT5FC4YC9Z;.ME-,;S
M9O\ *P1"&7.XY["M*A-/8<Z<H;^?X.P4454L+R2\29I+.:V,<K1@2XRX!X88
M[&B_02BVG+L6Z***9(452U>];3='O+Y$#M;PO(%)P"0,XJ6QN#=Z?;7+*%,T
M2R$#MD TKJ]C3V<N3VG2]OG:Y8HKG[GQ.1?7%KIVE7FHFV;9/)!M54;&=N6(
MR<=A6A_;-K'HHU6Z$MK;A=SB="K)SC!'UJ5.+ZFDL+6BDW'?;:^NVE[Z]-#0
MHHHJSG"BBLO4]5>PU+2K58E<7T[1,Q.-N$+9'Y4FTE=FE.G*I+ECOK^"O^AJ
M454BO))-3GM#9S)'$BLMPV-DA/8>XJW0G<F47'<****9(45!>W<5A8SWDYQ%
M!&TCGV S64VNRV/A6'6-2M\2,B,\,/\ #O( '/ID9_&I<DMS:%"I42<5N[+U
M-RBBBJ,0HHHH **J:E>26-C)<16<UVZXQ##C<V3CC-6QR*5];%<K4>;H%%%%
M,D**R]>U.71]/6^6-'@CE3[1NSE8B<%A[C(/TS6H"",@Y!I75[&CIR4%/H[_
M (?\.%%%%,S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KC/'5U=7TNG>%-/F:&XU9V^T2H?FBMEY<CW/0?C79UQVGK]N^*FKW)^
M9;"QBMD/]TN2Q_E2O8VI0OS2[*_Z?J=+I>EV6BZ;#I^GVZ06T*[411^I]3[U
M<HHIF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-]P_2O/_"GB
M)K;P;9V5II6H7=VL;*@6W(B8[C_&>,>]>@,,J1[5C>$]/N=*\+V-C>($N(E8
M.H;('S$]?QK&<9.:MIH_T/1P]6E##S4US/FC97MTEVZ'.W-GJOA_PUX:TJSO
M%AO&NUAD<#*?,')&.X';Z"KFMRS>%-$"Q:K<R3WMS'"+F\;S/))^\X 'H"<>
MM:VO:=<W]UHTEN@9;6^6:7+8P@5AGWZBG>)-)GU73XOLCHEY:SI<VYD^Z74]
M#[$9'XU#IM*7+TM;[CKABH3E2=6UI.3EHM^9M7T>FWR[G*R:M;:9<65QI?B"
M^U"1ITCN+:<LXE1C@L/E^4C.>.*ZN[\3Z-87;VMS?+'.A 9"C'&?H*AMM2UV
M>:*.3P^MN-P$LKW:E5'<K@9/Z5NX'I503UL_P?\ F88JI3;C[2-[7VE&[UTO
M:-M.FESF+Z6ZUGQ2^CQ7D]I9VMLL\[6YVR2LY(5=W88!/%+JFG3Z;X1UN*34
M;B\B-M(8OM&"\8VG(W?Q#ZT[4;'4M/\ $G]MZ9:K>)/ (+FW,@1OE.5=2>#U
M(Q4ES'K.K^'M5AN;*&VDG@>.V@$N]N5(^9NG)].E3;XKIWU-5*WLG"24%RWV
MO>ZOTO\ /:WW%.ZN[BVT_P )+!,\:S7$$<H4_?7RB<'VX%%^-2U#QN^FPZE-
M:V0L4EE$6-Q.\CY3_"3W/I5B]TB\FM?#2)&I:QN(I)_F'RA8RIQZ\FK4>G7*
M^,YM2*#[*]BL(;=SO#DXQ]*.5O3T_(:JTXKF35[3[/7G5OG;8IZ.]UIWBB\T
M22\FN[7[,EU T[;GCRQ4J6[CC(S5*#7[NQ\(Z[J4CM<3VU[<1PB0YQ\^U!]!
MD5LIIUR/&DNI%!]E:P6 -NYWAR<8^E9L/AFXNO#&M:5=D0O>7<\L3@[L!GW(
M?T'%)J:TCY_\ <:F'DU*K;7V=_O?-MY6O8M6OAV_B%O<MK]^UX"K3;F#12?W
MEV8P!V&.14&NBPBOG?4_$]S9[@/*MX9Q%L]\ 9;\>*FM+[Q.ZV]M-H]O%*I4
M3W37(:,@=2JCYLD= <8JK%9ZMI&NZK<0:3%J OI1)%<&94,8V@;&SSM&,\9Z
MTW:VB?XBAS^T;J3C=+2SAKKWM9=UUMHBK:ZG-JGPUU>2>X%RT27,"SXQYJKD
M*Q]R,5U6C?\ (#T__KVC_P#017/6&AZG%X,UBPN8XOMUV]RZB-OD)?)&#V'/
M>NDTV%[;2[2"4 21PHC '."% -.DI73?;]3+'2I<LXTVK<[:MVY5^%[G.O;Z
MOX9O[VZL+0:EI=U,;B6!&VSPN?O%<\,#C..M5/&%Q:^(/ ,^I6=Y<+"J@[$;
M:&.]05=?4'MZUJR:EXFMY)HCH,%U\Q\F:&["(5[;@PR#Z]:IGPM>'P-J&EM+
M$=0O7>X<KD1B1FW;1[< 5$DVG&-[69U4JD85*=:JXJ2E'5-.ZZMK796ULGY7
M5R37+>?0/!>JS6VHWLDPBWI+/+N9#P.#CBKGBF[N+3P9?W5O,\4Z6^Y9%/(/
M'-)/;WWB+PY?6%_9?V?)-$8US*) 3CKQVS61JT/BG6?#,VD_V9!;3&'9+,TX
M99<8X0#IGU/2JDVD^5/5:?B9T(QG*'M91O&=Y7:V]WY-:/;[C0UJ\O)[W1M&
MM+E[9[Y6EGN$QO6-%!(7/0DD#/UK-U#2[G3/%7AT?VE<75F]R^V.Y;>Z/Y;<
MANI!'8UK:SI=^;C2=4TZ-);O3]RM [[1+&Z@, >QX!%5)[77M6U[1[Z>QBM+
M.TG9C"90\G*$;B1QCG&!GKFE--MW3O=?=H7AZD8QBXRBH\L[WM?F]ZW2^UK6
MTW+MI>SGQEK%O),YMH+6!TC)X4G=DCZXKF++6K/6[-M0U#Q+>65S,S-#!;$J
MENN2%!&TACW.:ZRTTVXC\6:K?2HOV6YMX8T.[DE=V[C\16;I<.M^&[,:5%I(
MU"UA9A;3QW"H=A)(5PW0C.,C-*2EUVU[_+8*4Z*3Y+<UH=8KH^;XDU>]K]?Q
M*K:WJE[X%MKT-,DGGB*[N+>+YQ$&(:1%([@ ].,UN>'H[0PR7%AK-QJ-M(!@
M2S"78>_/49]#4L]WK46FV\\>F02W1;]_;+<8VKS]UB,$]/2J&B:;>?\ "17N
MLSV,>G1SP+%]F1PQD8$GS'QQGM5I-277[S&I*$Z,[6BKMJSB[ZK2UK^C6E@\
M=,3X:-O_  W-S! W^ZTB@T>.P!X/N@.@>+_T8M2^-K62Y\*W;PJ6FMBMR@'<
MQL&_D#1XAMY?$'A)ETX+(UR(I(\M@%=RMU^E$TVY+R_S%A91C&A)NR4W?_R5
M_D5_$<NI/K^AV.GWS6@N1.)6 S\H4'('][TS38X[K0O%6G6:ZA=7=GJ$<H=+
MI][(Z $,I]\D$5H:AIUS<>)M%O8T!@M5G$K%L$;E ''?D4:EI]S<^)=%O8D!
M@M?.\UBV"-R@#COS0XN[?FOT"%:')"F[6Y)7T6_O6N[7OM;7\Q[>*-&6^^Q-
M?*+CS/*V;&^]G&,XQUJKH]Y<0>)-7TF\G>0 K=VK.?\ EDW!4>RL#^==#@>E
M<OXMT;4KZ2UO-&V"\57MI2S;?W,@P3]5."*J?,ES;V,,-["<G2?NJ2M=M:-:
MI[:+=?,R[C5-1E\'ZSKD=W*@GN1]CP?]7"KJ@(_WN3^-;5U=W.G^,[$23NUA
MJ,#0A"?E29?F!'^\N1^%+KNAR2^#7T?38P62...-20,A67O]!5CQ+ID^I:/B
MS"_;K:1+BV).!YB'(&?0C(_&HY9+Y6_6_P#7H=7MJ$VEHE)R731-147\FD[_
M .(RK[7)X-5US4%D8V&D6@C$0/RR3GYCGZ#:/QIT/A_5+K2DO)=?OTU62,2@
MHX$*,1G;Y>,%>WK5BQ\.O)X1N=-U A;J_$DETRG.)'))QZXX'X5!#<^*X-,7
M31I,#7:((EO?M(\HX& Y7[V>^*5GO.^OY_\ #6+YXVY<.XIQ:5W;6*6^JU3E
MS-]6K$UM?'Q'\/I+FX15DN+.195'0, 0<?B,U?\ "]RUWX5TJ=SEVM8\GU(&
M*SKVVC\+_#R>TC<R-#:F)6[O(W'3W9JV=&LCINB6-D?O00)&WU &?UJX7YE?
M>VIRXAT_8R=/X74?+Z6_X*+U%%%;GEA1110 450FUO2;>9H9M4LHI4.&1[A%
M*GW!-,_X2+1/^@QI_P#X$I_C4\T>YLJ%5JZ@_N?^1I45F_\ "1:)_P!!C3__
M  )3_&C_ (2+1/\ H,:?_P"!*?XT<\>X?5ZW\C^Y_P"1I45F_P#"1:)_T&-/
M_P# E/\ &C_A(M$_Z#&G_P#@2G^-'/'N'U>M_(_N?^1I45F_\)%HG_08T_\
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M_OR*/^$-\-?] .Q_[\BMRBCV<.R^X/KF)_Y^2_\  G_F8?\ PAOAK_H!V/\
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M&G6D^N'3Y'FE0R^6)8B%"J#\SG<.@&3VZ4>Q@'M9'T5_PO'P1_S]WG_@(_\
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M.RC)-0)>HSJCQRQ%CA?,3 )]*LU4OO\ EV_Z[K_6LF;P2;LT6Z***9F%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?'>I>&O$/]LWDL>A:H1]I=E86<A!^8X/2OL2N(E^
M+G@J":2&36 'C8JP\E^"#@]JUIR:O97,YI.SO:Q\UMX>\3NK*VAZJ0S;C_H<
MG)_[YH_X1[Q-DG^PM5Y.3_H4G_Q-?2/_  N'P/\ ]!D?]^7_ ,*/^%P^!_\
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MM_UW7^M6ZJ7W_+M_UW7^M9O8WI_&OZZ,MT444S,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH .U?$^I -KMZK9P;F0<?[QK[8[5\3:H2NMWS#J+F0_^/&NFAUL8U6DXM[$
M;6C$MLZ D#/?'6D-J560LX!10<8ZYIAF=P0P#9)/3IFE-RY39\NW&,8K2U7N
M;.>#;;L^OWZ_\#K^IH:3I":B\BR3% DL"90 Y$D@4_EFKK>&[>*?Y[PF%Y&%
MN_"^<NS<F"> 2>.> 0:R;34[FQ9VMRB[VC<@H#RC!E_44\:U=FQBLI!#-;12
M/(D<L88 OU_#OCL:U]XX9<E]-C030(OL#SS?:;=M\R[I  L1100']VSCCVXJ
M=O"T2P3N9I<1E\R?+MC"PI)EAU.2^WCIQ6+?:K=ZB@2Y=657+@*N,$A1^6%
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M@3_H7K+\V_QH_P"%8>!/^A>LOS;_ !H]M'L'LI=SYIG\2+/.\YM"'9KG&).
MLQ)QTZ@GKWI$\2;;81?9>D?EY\S_ *9>7GI^-?2__"L/ G_0O67YM_C1_P *
MP\"?]"]9?FW^-'MH=@]E+N?+IU?,DK^3CS+'['][IP!N_3I5P^)27G8VQ/F_
M]-.G[KR_3\:^EO\ A6'@3_H7K+\V_P :/^%8>!/^A>LOS;_&CVT>P>REW/FC
M_A),SSNUJ2D\C,X$G(4Q[" <=>^:=_PDD:21M#9E1#)!)$&DS@QJ5YXYR#[8
MKZ5_X5AX$_Z%ZR_-O\:/^%8>!/\ H7K+\V_QH]M#L'LI=SYG_P"$A!$D<D<T
MUNT918)738"=QR0$'0MD8P??FL*OK7_A6'@3_H7K+\V_QH_X5AX$_P"A>LOS
M;_&FJ\5T$Z+?4^2J*^M?^%8>!/\ H7K+\V_QH_X5AX$_Z%ZR_-O\:?UB/8/8
M/N?)5%?6O_"L/ G_ $+UE^;?XT?\*P\"?]"]9?FW^-'UB/8/8/N?)5%?6O\
MPK#P)_T+UE^;?XT?\*P\"?\ 0O67YM_C1]8CV#V#[GF/[/'_ "&=;_Z]X_\
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MDDA=<$Y4@CCJ:35;5KVRN[59#&TT;('';(K"?PY,T:&.18I9)-MSNE:0/"0
MRC@8)"CM3)-_[1!N<>='E "PW#Y<],^E4)?[(FG-O)-"TM_MD">9S*(R,$>P
MP*S'\,.\,\1=7+,=CO*2"IE5R&3'HN.IZ"K7]B2"\>7$$D4C7 :,DK\DNWH0
M.OR_K0!L++#(BNCQLK'Y2I!!/M2//;K'O>6(( #EF&,'H?I6/-I%_)H'V5+F
M);V*7S+:1LD(!P QP"W!/..>*I6_A6>UB5%N%98)L6Z!RO[@*0JL<'D%F/0T
M =*T\"$JTT2E5W$%@,#U^E/4I(@92K(PR".016 ?#C)!,D+JA,ENR?.<E8U
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M#(\<,+.I'!W#J/Q_G1:45H/FH59)23?2_P#7KV[%&:\22T-M'%L3[0TRY;.
M0 !^&.M3-J@-J(_)(?[-]G+;^" V0<8IUYI?V73XK@EE<R"-XV()!*A@>.GT
MK4ETBT%_=&.-E2,,GER# R8RP(^A'\J2C(N56@DNN_WZ+_(HR:ZL[@S0,RD
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M 06/0=*WKG6+<_:/)* LCB)U1MR[F7"\], '&.F35;3=3BM+2*)FQ^\F:0;
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M=_\ "'_D<9/^O5_YBM\-_&CZGE9U_P BZM_A?Z'NE%%%?2'XL%%%% !1110
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M/_08N/\ OTO^-'_"EK'_ *#%Q_WZ7_&O4**/JE'^4/\ 6',_^?K^Y?Y'E_\
MPI:Q_P"@Q<?]^E_QH_X4M8_]!BX_[]+_ (UZA11]4H_RA_K#F?\ S]?W+_(\
MO_X4M8_]!BX_[]+_ (T?\*6L?^@Q<?\ ?I?\:]0HH^J4?Y0_UAS/_GZ_N7^1
MY?\ \*6L?^@Q<?\ ?I?\:/\ A2UC_P!!BX_[]+_C7J%%'U2C_*'^L.9_\_7]
MR_R/+_\ A2UC_P!!BX_[]+_C1_PI:Q_Z#%Q_WZ7_ !KU"BCZI1_E#_6',_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5=-7F1TQ%'Y2P-;^6<X,;$D@GKWZ^U&H>Z/.A72,HGDMX0S*JF20#=D*>/7
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MC_A1_P *&\7?\]=._P"_Q_PH]I#N'LY=CR^BO4/^%#>+O^>NG?\ ?X_X4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&)M;6UEO))(+=4&THH+E2""2!D=!T]* )9-9TZ*66*2Z16A#&3(.%VC<>>G
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MO2ZCKMCIUK<322AF@5F,:@D\+N[#C@CGIS5>/PW"D1C-S*5:.6)U 4*4D R
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MSW]*A;PS UQ#*)V418(18DV@[2.!C@'.2!P30OAJ)(T"7<ZR(VY7 7Y3O##
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M^; ^;Z'@5KT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M._?\*D6_M6.!*._8]NM/%K HP(QP,?A0+2W!R(E^G;\J (SJ-HHR9L?\!/\
MA2?VE9YQYP_(U*MI IR(ESC%'V6#&/*3&<XQWH A&JV9QF8+DX&\$9XSWIS:
ME:+ )A*&1@2N 3G'6I/LD&<^4M'V6 A08P0N<9YQF@",ZA;*P1Y0K\94]1GI
M2?VG9\YF PNXY!Z=:F^RP%V<Q+N;J<=:0VENR[3"F/I0!'_:-J A:4+O)V9_
MBQUQ2-J=DH!:X4 XP3W^E2_98,*/*7"Y  ]^M-6QME)(B&2<_3Z>E ##J=F!
MDS  ]#M/^>](=4L@&(G5MI(.T$\CK4_V: _\LEZ8Z4@M8 "/*7!SQ0!$=2M
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M]><_RJ2'4O/N(HEA=0^22V.*O44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D?\)5X=_Z#VE_
M^!D?^-'_  E7AW_H/:7_ .!D?^-?%VU?0?E1M7T'Y5U_5UW.;V_D?:/_  E7
MAW_H/:7_ .!D?^-'_"5>'?\ H/:7_P"!D?\ C7Q=M7T'Y5TS^$8+73?[0O\
M5(H+8>3PL)=V,B%P%'? '/(I.@EU&JS?0^J_^$J\._\ 0>TO_P #(_\ &C_A
M*O#O_0>TO_P,C_QKY)_X1F0^(?[*6YA\LQ?:!=%2%\G9OWXZ_=[=<\58/AS2
MDTY-2EUU!8R3O!$1:L9'*A22$[#YNI-'L8]Q^U?8^KO^$J\._P#0>TO_ ,#(
M_P#&C_A*O#O_ $'M+_\  R/_ !KY7M? TUU>QP+>VWE331)#/M.R1)$=U?U
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MH'_0<TW_ ,"X_P#&OD (O]T?E2[%_NC\J7,:++HO[1]??\)-H/\ T&]-_P#
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M1/\ H,Z?_P"!2?XU\J8'H*4 >@J?KLNQHN%J3_Y>O[D?57_"1:)_T&=/_P#
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M8. 0,COU-%%/GEW)5"DE91)7UV^>)H]T8!ZD( ?SZTBZ[>K'Y>8BA()!C'.
M!_3/UHHHYY=Q?5Z7\J,^21I97D?[SL6/U-7!J]T+=H,IL9 GW1D#&./PHHI)
/M&DJ<9636Q1HHHI%G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3DU"%(I]^Y6R-A) P>GMS6=>_$'^SM,2ZN-/!E;?$UNLI#QW(0,D# J,,V<
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M<5IT4 8__"-:<VNW.KS1":XG$0Q( 0GEYVX_$YYSR.*N-I-@T'DFUC">89@
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M:I]AD_G1'IEE$866W7="Q>-FRQ5B,$@GGH<5;HH HIHVG1F(QV<2>4-J;!C
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHKG=4\=>&]'E:*YU.)IEZQP@R$?7;TJ9245=NQK2HU*TN6G%R?DKG
M145R-G\2_"MY((QJ)A)X!GB9!^9&*ZN*:*XB66&1)(V&5=&!!'L11&<9?"[E
M5L-6H.U6#CZIH?1115& 44$@#)H!!&0<B@ HHR,XSS10 4444 %%(S*@!9@N
M3@9..:&95 +, "<<GO0%A:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHK/UV];3M U"]0X>"W=U^H4X_6DW97*A%RDHK=GE?Q(\?3S
MWDVAZ3,8[>(E+F9#@R-W4'L!T/K7F '' XI<O(^22[L>3U))KJ+.WEM;.'2I
M8Y4N[EG;RBOR-P @?C)Y!Q@\9KYV<Y5IN3/V7"X:CEF'C3IK7KW?=_+\#EL'
M&<<5TW@_QG?>%;Y=KM+I[M^^MB>,?WE]&_G5J7[1Y"Z.;(1WDT+?Z/" L>XD
MD$CN^!USZ5R<\$MM,T,T;)(IP58<BI3E2:E%F\HT<=3E2K15GYWT[K_-'U3:
M74-]9PW5M()(9D#HP[@C(J:N!^$=^]WX/:W=B?LEPT:Y[*0& _\ 'C7?5]#3
MGSP4NY^-XS#O#8B=!_9;1FZW;Q7-BJRR/&%E5U*QEQN!R RCJOK7.7FIZ_%#
M;"PL3&LJ%@B0_*GE,2W&./,7& ><UU&K7<UAI=S>0PQRF"-I2CN5R%!/4 \\
M52_M[[/J!M;Z)8\6\<Q>/<ZKN9EY.!@<#\Z)0YMG8NABE224HJ27<QI;S698
M(KM(YHI;B%G3_1\O"K31A5/'4(22#[^E2RW>MK?W5J)7CMXMXM[B2,_,_P I
M4-A3D#)],_A70PZM9SWAM8Y<R98*<?*Y7[P![D=Z1-7LW< 2':9O(5RIVL_/
M /X$5/LGW-/KL?\ GVOZ_JWW]S'U.;6!=W'D32H(H;;8(XMRLSR%7/(YPO;M
MUIJ7FI"8P7,ES';)+<()TA)=MI7R\X'3!8YQSBM*/Q%87,=I)9W$<J7)0HQR
M 58D CCKE3P<=#3H?$.G36_GI*VPHCIN0@R*QPI4'KD\4_9N][D+%Q4>5P7]
M?+_,YNXN-7NX[9;Z.=;I+NW9($A.QEP"6)QQSG//&,5+OU6\M[1KEBY\V!IH
M?+;='()!G'R@!0,CJ>F:Z4ZO9_8?M?F$Q[_+V[?FWYQMQZYXIC:W9+=-;L[J
MZ%!(2A C+C*ACT&:7LO,U>/5DE32M^O;^KFC168NO:>V[$Q. "@VG]X"=HV?
MWN>*#K=LDCJY(/R!(PI\QF;/&W'^R?RK8\PTZ*I6NK6E[,([:0RY0.653A0>
MF3V/!_*J^HZY#96MX\8:1[5&9OE.P,!G:2.^.<4 :M%9RZW:,G'FF7?L$/EG
MS"VW=]W_ '>?I2IK=A)O9)MT:1><\@!VHN">3VZ'\J -"BLO_A(+#Y5W2F5G
M\M8A&2Y;;O Q[KS3=0UD06EC/:(9EO)DC1PI(4-D[B..PH UJ*RSX@TY8&F:
M1U0*KJ3&?WBL0H9?4$D#\14EWJR6EQ90&VN&>[W;2J<)A=WS<\4 :%%8UAXD
MM+K3(;J4F)WACE*%2,[^!MSU^;(JZNJ6;6#7GFXA5MC9'*MG&TCUSQB@"Y15
M ZQ9HLAD=XS%&LDBNA!522HR/J#4;Z]8H7YE;9/]F^6,G=+_ '1ZG]* -.BL
MR3Q!IT1F\R<JL2NQ;:<'9]X#U([@4UM?MA-;Q)#<R/--Y)"Q\QG;N!8'H".:
M -6BLV]UJVLH[YMDTS641DE6),D<;L?7'-/76+-@=SM&RND;(ZD%6< J#^8H
M OT5B?\ "2VAU2*V&X021,_G,I )WHBX/0@ECS[#UJ]+J<*V_G1NI03B$LV0
M,[MIQP<\T 7:*J0:A#=6;W4 9HU!*DC <#N/:H1K$*:/;ZC.CQQ2PK,^T%A&
MI4$DGT'K0!HT5FMKEDK3*#(YBE\D[8R<R==@]3@YIL7B#3YE@99&"RA3ED(V
M;CA=WID],T :E%9FHZP-.E96AWK]FDF1@WWF3'R?4@\?2L]_%0^QP7"VI :&
M*68%B3$7D";, <D$/_WS[T ='16-=>([:VA,P22551RT2*?-!5U4C:>."XSS
MZ=:M+K%FUTML799&(3YEX#D;MA/]['.* +]%9']M-_;G]D?93]ISYF=WR^1C
M_69Q_>^7'K[5:AU 2W5_"8R!:.JY')?*!NGXXH NT5E'Q%IZJN7DW'S"4$9+
M+Y9&_/IC<*9>:_!!=6L$ ,QFN4@9@#M7<"W7IG'- &Q168FNV3VL-T#*+:9E
M"2F,A?F( /T)(%/.M601GWN5#^6C!#B1LXPOJ<@B@#0HJ&UNH;VV2XMWWQMG
M!Z<@X(_ @BN<OO%%[9_\)!NL;?&D6PG+"<GS,H6 QM&.GK0!U-%8 \5V#012
M"18V,L<<J3AD*;T+ @8/4#(SCZTW4_%4%GH=OJMO$\L$UQ#$-R,"R2, &4=3
MP<B@#H:*QAXITMI[>W661KB>22)8A&=RM'C>&_NXR#S4:^,-$<QJMV2\P!@0
M(=TX)(!0?Q#(//\ 2@#=HKEM6\<:=::/->6+?:Y$17V*K83<^P;R!\O(8<^A
MK3N/$NDVM\ME<7B1W+7*6HC8')D=-ZC\5!YH UJ*R!XETLP6UQYS?9[E_+CF
M,9V%BQ4#/N0<4^/Q#ITFE?VF)6%H2H20H1YFX@+M'?)(Q0!J45S5QXPM;361
M:W$4L=K]B-T\K1-F/$FP[AC@#UJ[+XHT>!W$MV%C1G0S%3Y>]%+,H;H2 "?P
MH V**QI?%&EP0QR2RR('B,^#&<K$,9D([+R.:=8^)]*U*Z6WM;@NSO)'&Q0A
M9&3[X4D8.* ->BN8F\:V":I!$A+61MKBXDNBC!0L6 2IQ\W)/Y5HS^(],M[I
MK5IRUR&11"B$LQ92P '?Y03[8H UJ*Q?^$HL7N]+AMUEN(]21WAGB7* (!G<
M2<CK4]EK^G:A,L5O,2TD1FB)0@2H#@LA_B&2/S'K0!IT52LM5M;^>X@A9A/;
ME?-C=2K+N&5.#V(J[0 4444 %%%% !1110 4444 %%%% !5#6[(ZEH5_9+]Z
M>W>-?J5('ZU?HI-75BHR<9*2W1\GJ9+><'!26)NA'*L#_C74Z?=330VUW'(L
M(4R(;.)BHN3C)XZ8YP<_A74?$CP!.+N;7='@,L<F7NH$&65N[J.X/<?C7F*7
M4\4#P)*ZQ.?F0'@U\].$J$VF?L6%Q5'-,/&I3:OU7;NO\G]S3.H=[G[(EUYB
MP+%;L#I^XE'VD@D#ICG)YSGI7+W5R]W-YD@48 5548"@= *5;RY2V:V69Q"W
M5 >#71^#?!%[XIO$D9'ATQ&_>W!&-P_NIZGW[5*4JK48G1.=+ TY5J[22V_R
M\W][\STWX2:>]GX.-Q(I!NYVE4'^Z %!_P#':[RHK:VAL[6*VMXQ'#$@1$7H
M !@"I:^AIPY(*/8_'<9B'B<1.L_M-L@O;5;ZPN+1V94GB:)BO4!@1Q^=5;C1
MX;B2=VED!FMT@.,<!68@_7YC53Q9>ZCIFAMJ.FQ23RVLB2R6\2;VGCSAD ]<
M'/X5R%EJ_C9]-NDNXG2ZL!'#/((,+,9) S2)P<A(^. >2>#BK.4[2VTFQTN[
M,PDA0$NZJZ(&7<<L0V-W4^O>H+SPY:W9O(Y;R2.6\ P8MJ,NTYW  <MSC<<G
M%<AKUOJUY:HTN^\Q%=+$\43DA"T6U6RHRW!YQSBM'Q8^MP^(=$N[:U811).M
MS+;*96BA/EY901C=QTYXSC)% '00>%[.VDD:.64*UTEPJ<8CVCA%XX7)8X]6
M-.D\-6DEK;0-(["W@CAC+!3]PY#$$8)_2N7DU/Q3!:FZMOM-Q-+->HL4EO\
M*B)DQ$# YXXS][.*;JNK^)+03SZ.;N]M$,<2>9;'>TDJLI., E4?RV/' )':
M@#LVTF,Z6UB#&JN<L1 F&YR<KC'Z5FVWAITN;E)KN5K)S!B(D$R>6H&6)&<Y
M Z>E<WI.H>+=4O\ 3XKYKNSB1WL[K9;A?,>*)BTH)'"L^W![XXK5TV\UZ_NM
M#-PUQ$ITV6>Y00[!).&0*&)'RYRQQQ0!K1^&+6&(1Q/Y9C96A=8D#Q[3D<X^
M;\<T^X\.PW4WGS3.]P"I#NBL 0",[2,<AC7+VU_XEETU)YK](96BC:X@>&3>
MLN_YT4B/Y1C*Y&[! /?-/BU;Q)=W#R@26>&C,-O<Q,3)"8\MG:I&\MGN,8QB
M@#JH]#ACOK6Y63;]G0JJ1QJ@.0<YP.G)..F:BETJWE@O<7S)9W99I%4KM#'@
MD-CU'3UKE8+SQ1%:17#W5[+(MG87!C>V W2RR;9E.%S@+V[=:R$75/\ A&&T
MVW2^E5OM9N8)+9E$6)\Q[3@9SD],Y!SVH ]&ET1'O&O(KF6*X,@<. #CY-A&
M".00/SJL_A:TE"(\LAB6)XBH !8.#NRV,D$L3CIFN7U#7M?EN[F/3H[^%&BZ
M26Y9HG%S&F1\NT90N<9/ R:NVVH:TGB.ZL+V>]BTZ%V%K<+;[FE;*85CM((
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M=07,45]+;)=HD=RMO'&HDV,6!QMPIY(..M'B#P'IOB'4I+^>XNH9VM1;JT+
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MK*WT^&>S9;B6=8Y8D((W1M,D9;\"XJ&X\91KH$>K0V4ZQM?+:%)DPW^M\LD
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M44 %5[:PM+-5%M;11;5V#8@! R3C/IDD_4U8HH **** "BBB@ HHHH ****
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M[:!J,FH37LGV)FD) @9F*8,03)..N1Z=#46@>'[BPU)HIL-:VMN@B !"F9T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
M)PI/I2T$9&* /E74;M[_ %.ZNY&)>>9I"3[DFM^.XC@\/)$T-P;9XY(Q<9P
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MB;!!"DBLF\\1/HD\5I+&9E_=R-+))DB YWN?]TC&/<5OWUS!;QQ)<)O2XD$
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M[LQP! 0=DCN#PJY^7IR<G@4I\2W2I//_ &>QMT,B!L8"LK;06/H3GMP/6M"
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M &+/XFE6>>*WBBF V&)SE5.9?+()[X]1CT]Z)?$$T,_SQJ98_-B.'(C+"2)
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MXUDV_BNXNH8?+LP)698) ,N(IMK,ZD<9  &.F<UOQV]@ENFFA(6CB1<0-AL
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MMXDD88+J@!(],U-10!$MM OW8(QP5X0="<D?B>33%L+-&C9+2!6B4+&1& 4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !63XHG>V\*ZK-'D.MI(5([':>:UJKW]HE_I]S9R<)/$T3?1@1_6E)732
M-*4E&I&4MDU^:/EW3.-4L_\ KLG_ *$*Z=+70SJ,LEY<1"4W$AD\PL0.3_"!
MCVZ]ZP8[*?3?$D=C<H5G@NEC<>X8?_KKIFUJSL1-$\*RS+<2 H%;=]\^X%?.
MTTE?F/V/%SE-Q=*[NNG9L?++9R0SQ64Z3A8#$HB3 R68*%7W&/?FN%961BK
MA@<$$<@UVK74?FOJ-TK6MO$/+_<-AF<<A%SD%^>3T4>]<GJ-Z+^[:<01P+@
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MSQV(&,=ABK;Z='-;VL4TLLAMY%D5V/S,R],T 4+;Q):RM=^;N186E*G8?F5
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MM,D(&P\LX)7\.#S0NN6C"V;;,([ARD<AC.TMDC'XX.*CU3P]9:M<-/.TJR&
MP9C;& 3D,/\ :'.#[FHV\,V)NK:<-*OV8QF-<@X*+M7DC(&#T'4\T 6DUFU?
M2&U3]XMJJ>9N*<E>N0*A3Q#9-*R2+/#M8H[2Q%0C!=V"?]WFG1Z';+9WENSN
MPO&+3,,+DX R !@<#\>M.FT.SN#)YH=EDE,K*3P24V$?3% #%\06;X4)<>:2
MNV'RCO8,"00/3 //L:IZ=XF2YMEEN$*NX!6%(VWDF21%&/7"=.W-6XM MX(H
MQ%(T<D+AHI$15*X!&#@?-P2#FHXO#-I B"*:X62/;LE+Y8%7=\].>9&S0!/>
M:S':H 89EDDC9HC)&0I8*6VD]CP:J67B2-UG^V 1F.,RC8I(*A$9OQ^;I4DO
MAJUGO1=2S3/)U))&2=A3KC.,'ITSS4=UX:AE6UCB=E2.Z2>0LW)"J%VCV.!G
M\: +M_JT&G".2<E8C$\K#82V% )QCZ]*9_;UKM($5SYWF>7Y'E'S,[=W3TV\
MU-J&E6^I8\\N,1O'\IQPP /\JCFT6"2Y:Y266*<N'#J1Q\FPCGU7]>: *UAX
MBMY]+CNKC*/Y<3R*J' \QMJ_K^56#KMH(S)MG*>9Y4;",XE;)&%]>0:K_P#"
M,6@ACA6>X6)4B1EWC,@C;<N3CUZ^M2/X>MI+;[.\DCPI+YL*/AA&V2>A'/)/
M7/'% $%_XGMX=/>>TCDFD"!B/+.$R^WY_3D,/PJ[?:S:Z?.(9EF9_*,S>7&6
M"H#@L3[9J"?P[;3QF/SI8U>-8I1%A=X5BPZ#CDGIV.*6_P!%:_U,3M<O' ;5
MK>1$."X9@3V]!UZT *VO6S2[(RX"W*V[2/&=I8C. >_'?I2-XDL5@,S+<!=B
MR1CRCF568*"H[\LOYBICHMH4"?/L%S]IQGC=TQ]*B3P_;*B(\LT@B18XMS#]
MVBL&"CUY49)Y.!0!+=:NEI=6$#V\Y^UEAN"\1X7=\WI3[+5K:_E$<0D4M'YL
M?F(5\Q/[R^HY'YBGWFGQ7DUO*[,KP,2N.A!!4@_4&H['28K&1'$LDIBB\B+>
M?]7'Q\H]>@Y// H 9#KEI<2M'")G(5F3"<2!3M;;ZX)I(-<M;EHUA2=W;.Y!
M&<QX;;\WIR#^1J$>&K)()X8\I'*20%505);>><9(SV.1CBG6?AZ"P9&MIYHS
MR'VD#>"Q;!&.,$G&.Q(H -%UQ=4BC62-XYV1G V$*P5MI*D]<<?G3(_$MGPK
M^:S ;W:.)MJ+YC("3VY4_P ZN6FE6]F\#1%\PQ/$N3V9@Q_4"H(_#]G%'-&K
M2XEC\MLMVWL_\W- %:7Q)'%)+%Y3MLAN)O.$9\M1$0"#W[]JL7^OP:?%.9()
MW>.W>=55.)0H!(4_C1)X>M75U$DJB1)HWP1\RRD%A[<@8J)_"]C)<SS.\I\Z
M.2,C(Z2 !N<9[<<\4 2C78!-)&R2F3<JI"L9\S)0.<CV%(/$FGLZJIF92J,S
MB([4WL57<>W((]J=_840F^TK<3+=;@_G#'4)LZ8Q@BA?#]DD,D2^8%=8PWS?
MW&+@_4DDF@"S>ZG!8R+&ZRR2,C2;(D+$*,98^W(_.JNGZN^H7]^D:#[+;A/+
M?8?WFY V0<].?2K-YIJ7<Z3B:6&58VB+1D<HV,CGZ#GM2V>F6]CYP@4JLH4%
M<\ *@0 ?@!0!@GQ;,CH9+1!%)IRW*.&./-(<B,^Q"'!JW)KTT:WKND,9@@:6
M.)\AI0$W;E/0C/&!R,5+/X7T^XTZ:QD\TQ2VR6Q(?#*J9*D'LWS'FI;G0H;P
M!)YYGB5&5(\CY2RE20<9Z$\4 4H/$4KR*A2&8%ROG1$[&_=&3CKR",'D_P!*
MCL?$\MSI%Q=F.*1TAB9-FY099!Q&0>002O/3#9K:GTV"<6X;<!!NV;3CJI4Y
M_ FJG_".6!-N'#O'"D2>6Q!5_+!"%AW(S_+TH EM=7CDT'^TYP(]D3-,@.=C
M+D,H]<$$>]91\3SII]G)<1P6MP\TD-R&W2+"R(6/W>3P!S[UJ'0;'[)/:*FV
MUFF$SPK@+G()&/0D9(^M":#8Q7RW4,?E$/YGEI@(6V%"<?[I_04 5TU*_FN-
M, 6WB2\B,C(ZEF3 !(R" >OI4MWK\%C>W4$\%P$MX8YFE5-RMO8J ,<DY%3V
M^DP6WV/8TA^R*R1;FZ*>WX  "DN](@O+F29WD7S(T1U4C!"-N7Z<D_G0 W^W
M+0726S"979E0[HSA'8956/8D?SJ"?Q%!#(D0M;II3<) R>7@KO!(;Z<&IWT2
MU;4I+X#$DN#)\JDD@8!!QD<>AJK;^%[.U4^5+*'\R*17XX,8(7C'/!.<]: '
M'Q1IX!.RYVA9'W>2<;8VVNWT!Z_6I9O$6GP/,':3;$'S($)4E%W,H/<@ T?\
M(_9_9VAS+M:"> _-_#*VYOQR.*8?#ED6N\#:MTKB0!5SEUVL0V,].V: &R^)
M+=!#LM;IVDG2$IY>&7>"0Q![<5M5G3Z-!/)YN^1) \;JP/0IG''XFM&@ HHH
MH **** "BBB@ HHHH **** "BBB@ HI&(52Q. !DTB.LD:R*<JPR#[4 .HID
M<J2QK)&P96Z$=Z?F@ HI RG.&!P<'!I<CUH **,CUHR/6@ HHR/6FI(LB!E.
M0: '449'K2!E)(SR.M "T4FY<D;AD=1FER* "BC-&1ZT %%&1ZT@96 (((/0
M@T +12%E7J0.W)I<CUH **,BDR/6@!:*,CUHR/6@ HIID575"?F;H*0R*KJF
M?F;. /:@!]%&1ZT9H **,CUHR/6@ HI"RC&6 R<<GO2Y'K0 449HS0 44F1Z
MTN: "BD) &2:175T5U.589!]J '449IKR+&C.QPJC)- #J*:SJB%V. !D_2E
M# C(/% "T49'K2;EW;=PSUQF@!:*89D4 ENK;?QI^1ZT %%&:,CUH **,CUH
MH **,CUIJR(^[:<[3@_6@!U%&1ZTA95&68 >YH 6BDR/6D1UD174Y5AD4 .H
MIK2(I&Y@,]S3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH 0@E2!UQ4"V["U\@R<;-F0,&K%% %,:>@Z.Q .5SR5Y!X_+]
M:273EE:4F1AYASGN/I^57:* *8L%5F8, 3N((4<$X_PIJ:<$7;YF[W9<]\X^
MGM5ZB@"@VG@* I4DN"=RY&!VI1IJ8P7) QU')Z=3W'%7J* */]FC9M$K ;MW
M3K3FL$9 N\Y"E0<=,G-7** *#:>1MV,.V01D'!IPTY1DB0YVX!(SCI_A5VB@
M"@-,50,/DXP2RYSU_P :=]@"R1%6. Y9R>K#L#Z\@5=HH IFP^9B)2 Q)QCH
M"0?YBHAIS?*2R9R=WRY&.?S/-:-% %)-.1"N7+!2#R.OU]3S0VGCRD56QL4J
M,#&<U=HH HKIPPI9P6PI;C.Y@<YH_LR/&&<GDGD>M7J* *C6*E54-@ ,.G3/
MIZ&F_P!G(3EB"<YP%X'(Z#\*NT4 4!IWSME\#C:0.3P!S[>U*VG Y_>%<CG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R/\ A*O#O_0>TO\
M\#(_\:/^$J\._P#0>TO_ ,#(_P#&OB[:OH/RHVKZ#\JZ_JZ[G-[?R/M'_A*O
M#O\ T'M+_P# R/\ QH_X2KP[_P!![2__  ,C_P :^+MJ^@_*NF?PC!:Z;_:%
M_JD4%L/)X6$N[&1"X"CO@#GD4G02ZC59OH?5?_"5>'?^@]I?_@9'_C1_PE7A
MW_H/:7_X&1_XU\D_\(S(?$/]E+<P^68OM NBI"^3LW[\=?N]NN>*L'PYI2:<
MFI2ZZ@L9)W@B(M6,CE0I)"=A\W4FCV,>X_:OL?5W_"5>'?\ H/:7_P"!D?\
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M_@7'_C2_\)1X?_Z#NF?^!<?^-?&P1?[H_*EV+_='Y4N0T5)/J?9'_"4>'_\
MH.Z9_P"!<?\ C1_PD_A__H.Z9_X%Q_XU\<;%_NC\J78O]T?E4\I:H)]3[&_X
M2?P__P!!W3/_  +C_P :/^$G\/\ _0<TS_P+C_QKXZV+_='Y4NQ?[H_*E8M8
M5/J?8G_"3Z!_T'-,_P# N/\ QH_X2?0/^@YIG_@7'_C7Q[L7^Z/RI=B_W1^5
M(T6#3ZGV#_PDV@?]!S3?_ N/_&C_ (2;0/\ H.:;_P"!<?\ C7Q_L7^Z/RI=
MB_W1^53<M8&+^T?7_P#PDV@?]!S3?_ N/_&E_P"$FT#_ *#FF_\ @7'_ (U\
M@!%_NC\J78O]T?E2YC19=%_:/K[_ (2;0?\ H-Z;_P"!<?\ C1_PDV@_]!O3
M?_ N/_&OD+8O]T?E2A%_NC\JGG+661?VF?7G_"2Z#_T&]-_\"T_QH_X270?^
M@WIO_@4G^-?(FQ?[H_*E"+_='Y4O:/L6LJ@_M/[D?77_  DN@_\ 0;TW_P "
MD_QH_P"$ET'_ *#>F_\ @4G^-?(VQ?[H_*G;%_NC\JGVS[%K)X/[;^Y'UO\
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MD(BE,<D8*H!S@C!P>,=J**7*A\S'P^-)8)@R6,:PQR1&")7.(DCCD0+GJ?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR3M4@\=NM;1BTT_-_=J>;5K0E"5/2RC&VB^+W;]+WWOK^1M4445T'D!1110
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MM#.DD]K(D<R!P"I;&.I]Q5I[^SCB$KW<"QE#(&,@ *C&6SZ<CGW% %BBJ_\
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MI&!!Z=.#GZUU#NL:,[L%11EF8X 'J:=0!S3>'KQKTJ6M3:O>)>-*<^:"H'R
M8QCCKG@$C%0Q^&M2M8)Q;7<6_P Y$@Y*%;522(]V#@Y8\@'@ 5U=% '/^'=
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M &A+K]NQLS/I]L5=4&X$R=W. 0V!T&1S^&.EHH X_3;:[MI[!;BVG:WTXRF
MI$=\F[(&X'@84D<$Y//%1S6=Y+;ZE9BT<074KSI,83YFXD':PZ;>,$YY':NT
MHH XU+*XGOUOKNQ='^U1S&&*$L@"(5')QEN>N!@#%1V]A>VDMB;>VGC:%G\V
M948%HVD9]FS&",-UR,&NVHH \_M]"G@L7@-G<-+&BI#.^]PX$BOAD(PN=HS@
MFK>I0ZI>Q3/%8K%-<V4MI*IC8HFX\,#C+=\Y KM:* ./EM;F2\NV%I,(9Y[>
M=6,)W Q[001TP0N0<]ZI3:'/(EVHBNL"=7LT$17RXP_F%&(]6)Y'8+Z5WM%
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MT!'F"564 D?49KLZ* .=\/G5+98;2:W?R-SL6E)/DH -J!B 7.>Y XKHJ**
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M\%OJ(DA0;U9$:+!(4N3C?UR?7BE@TW6PFH%I+T7Q24, "$F!DR-KEB-VS@8
MQFN\HH Y71K+R+B]E%AJ$-O->0O"KR'=@1J"S98G;D'(/Y5U5%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 445GQRWURTKQ26Z1+(R*&C9B0.
M,YW"@#0HJGLU+_GXM/\ OPW_ ,71LU+_ )^+3_OPW_Q=,"Y15/9J7_/Q:?\
M?AO_ (NC9J7_ #\6G_?AO_BZ +E%4]FI?\_%I_WX;_XNC9J7_/Q:?]^&_P#B
MZ +E%4]FI?\ /Q:?]^&_^+HV:E_S\6G_ 'X;_P"+H N453V:E_S\6G_?AO\
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M +\-_P#%T;-2_P"?BT_[\-_\71<+'*PSZ[;VL.][MV"B.>Y-N&D3]X^<)T/
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MM+L+M2^B'\0]''\2_B.*ZRDU8:=PHHHI#"BBB@ HHHH **** "BBB@ HHHH
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M:VNNK1CT5QD@>H/K7:T-6!.X4444AA7EWQKT^2;1=.U! 2EM,R28[!P,'\U
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MZ[0#BG-HUC#DO=LN]IT^9U',Q!(^HQQ4(T.P,OEIJ+>7#*DTL =/O*FW+<9
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M]ZEKC/B+HOBK6M.LH_"VIBRECGW3?O#&77MR/0]N]21Z)XW$2!_&-H6 &?\
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M,LNB7<UAJLLD>)MUU]GB08+>8,<G/(].GZ5K:OJ,MG/A&VQQVD]U(0H8D(
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ML75-7T?T2TNB8Q]$?<OZ4_=8M3L**Y'_ (1[Q;$"+?QJQ7M]HTV-S^8(I?\
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M#=#]#VH N45FWFLP6>IQ64A"[H7N))')"HBD G.,=_;I4R:K8O)&BW*;I,;
M>,YZ?3/;U[4 7**H+K>F.VU;Z$G('#>^,_3/&>F>*6]U:UL;A+:4OY\D;R(H
M0D$+UYQ@=>] %ZBLZTUNQN[!;M9T"E$9AG)&X9 ]_;'6I+K4X8--^VQ_OT8J
MJ!#]XLP4#\S0!=HK-FU<0S7T1MI2UI MP>1AU)8<>_R'K[4NHZO%806D@4N;
MJ9(HNN,MSDD X&* -&BJ7]KZ>$9S=Q!58*3GJ3TQZYP<8ZT1:OI\R.\=Y"RH
MNYB&X Z?SX]CQ0!=HJD-6L"L1^TI^]<QHO\ $6'48ZY%,?6+;SH(XF\TR3>2
M<<%#M+9(/; H T**@:]MD=D:>-65Q&06Z,1D#\14']K6C[#%,CJ7V,=X&W@G
M//48';K0!>HJM:7]I?*6M;A)0 "2I['H?H?6J!UX+8)?&SE-J7*EPR_*-^P'
M&><]>.U &Q156VODN$N&(\O[/*T;[CZ<Y^F"#38=6L+A0T-W$X9E52&^\6^[
MCUS@X/L: +E%9SZU9QW;1/*BQ+&7,Q;Y0=^S;]<U+%JVGS[O+NXFVJ78[N@'
M7/T[^G>@"Y15$ZSIPB60W<8#,4 .0Q;&<8ZYQSCTJ7^T+3S(4^T(3, 8R#PV
M1D8/3F@"S15*+5]/GC:2*[B9%3S"P/&WU![CW%337EO;M&LTJH9" N>F3TY[
M?C0!/16:^O:<D\,/VC>TLIA7RT9AO&<@D# Q@U*VKZ>J2NUW$$BQO8G &3C\
M>>.._% %VBJT5_:S;!'.A+N449Y+ 9(QZ@4Z>\M[9XUFE"&0@+GID\#GMSQ0
M!/15./5;"4R!+N(^4&+G=P IPW/L>OI5>#7;2X749$/[FPQYC^OR!SQVP#WH
M U**R_[89);*.:SDC-T %.Y3ABN[!&<\8P3C%6;;48)]-2^=A%&1EMY^Z0<$
M?@<B@"W150:E9DPCSU_?'"9R,GT]C[&F?VSIWE^8+N,IN*[AR,CK^ [GH.]
M%ZBLT:Y9R7<EK$Q>6*5(I,C: 6&1@GAN#VI;;6;6\U-[*W<2%(1*74\8+$?T
MZ]* -&BJ;ZK81"8R74:"''F;CC&3@?7GCZU%'KFGRRW,8F96MBHDW1LO+ $
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M0X])3:"C,(5@60!@Q1<X!RQ'?MCO5.7PU<RVEK:MJ(\F#8 OEGHD@8'ANI
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M[AXI)@L6"63;C:<\ [1USWK;HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *CZ99271N7MU,Q=7+9/++]T_44ATNR+JXAVLK%@R,5.2<GH>>>:N44
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH R/^$J\._P#0>TO_ ,#(_P#&C_A*O#O_
M $'M+_\  R/_ !KXNVKZ#\J-J^@_*NOZNNYS>W\C[1_X2KP[_P!![2__  ,C
M_P :/^$J\._]![2__ R/_&OB[:OH/RKIG\(P6NF_VA?ZI%!;#R>%A+NQD0N
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M<"58O*;>R[@OJ*7]H3_E_,?^J&'_ .?[^Y?YGTW_ ,)!HO\ T&-/_P# E/\
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$-#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>*\8IN*\B-,<@@T 7/#-_J4'BO5O#UYJ)U2"S@BGCNG15DC+E@8Y-H )XR.
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MKT.*KR?$;P^BSO&UY/';2/'=206CNML58J3(0/E'!/TYZ4C?\E>B_P"P"_\
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M[+P[XFT2VN-.TJ_TI[&2:25);NW=ID\QBQW8;:Y!/!.,]ZZ])HI))(T=6>/
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M"WD)ED&53=R>,_GCM38]9TR5I%2^MV,2EWPX^50<$_3/>ES+N/V-3^5_<_\
M(EETZQGNDNIK.WDN$^Y*\2EU^A(R*F\J/SO.\M?-V[=^.<=<9]*9;74%Y");
M:5)8\XW*<\^E4X=>L);NXM6G2.>"1HRCL 6P <C\#^E/F7<2I5'>R>F_D6KN
MQM+^,1WEK!<(#D+-&' /T-/2V@BM_L\<$:0XV^6J +CTQTI(KJ"8@12HY,8D
M&TY^4]#]#@UEGQ'#%N:ZM+FVC,;2Q-(HS(JD \9R#R, XZTG)+<J%"I/2*-&
MWT^RLU5;:SMX I)411*N">N,#O1'IUC#=M=Q65NER_WIEB4.WU;&:S'\2+%:
MF62QG$GF;%C#(=W!8D,#C@ Y&<\8K0LM1BU R&!7,:!?WA& 21G'U (S]:%.
M+T0YX>K!<TEH/N].L;_9]LL[>YV<KYT2OM^F1Q4Z(D:*D:JJ*,!5& !3+BY@
MM(3+<2I%&.-S''-57UO2XXXW>_MU60;D)<<C."?P/Y4W)+=D1ISEK&+?R9<\
MJ/SO.\M?-V[=^.<=<9]*$ABC0I'$BH22550 2>OYU1O=<L;&>*!YE>>21$$2
ML-WS' /]?I4]S?V]G(!<2)$GEF1G=P  "!_[,.:7,NX_8U-/=>NWF6(XTBC6
M.-%1%&%51@ >PJO+IEA/=+=36-M)<)]V5XE+CZ$C-.@O[6YMWG@G22),AF0Y
MP1US69;>*]+N6A_?B))H5F1Y2%!!8KCZY'ZBASBNHXX>K*]HO3?0U;JTMKV'
MR;NWBGBSG9*@=<_0TZ*"&#/E11QY !V*!P. /PJ(7]H;PV8N8C< <Q[N?6EE
MO[2"ZCM9;F))Y/N1LP!/X4[HCV<[VL^_R%M[*TL_,^S6T,'F-N?RHPNX^IQU
M-,ATRPM@1!8VT0+^8?+B5<M_>X'7WJ/^V=,Q,?MT&(1F0[Q\HSC/TSQ2C5]/
M,JQ"\A,C)O";N2,9Z?3FES+N5[&I_*_N?^1:6*-)'D6-0[XW,!RV.F3WJ*2P
MLYKI+J2T@>X0825HP77Z'J*I6GB"PN[1;L3+';F)9-[L 0"2 ".O458TW4[?
M5(99K<YCCE:+=D88KU(QVH4HO9CE0JP3<HM6W)I+.UEM?LLEM"]OC'E,@*8]
M,=*<EK;Q^5Y<$2^4NV/:@&P>@]!P*JC6M,,<CB^@V18WMO&!DX'ZU%!XATR=
M+AQ<JB02^4S/QEL9X]?_ *U'/'N'U>JU?E?W,M7&FV%W.D]Q96TTT?W))(E9
ME^A(R*G>*.4H9(U<HVY=PSM/J/>JK:OIR2I$U["'<*RC>.0>A^AJU'-'-O\
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M:E)J-M/-=0RK#<1S;RS*2%7:0$ V@YR<\^G%1MX;U1=/:VBDL]TEB;)RQ;
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M4I]68'A>Q>UM+B5RQ$DI6#>I4B%>(Q@\CBJKZ!J.H07R:I]D:>Z0IY\<K-L
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MVERD\2JFUYMI888;LJJCC:05'/0**Z:BE[.)?UVLKV>_W?UJ%%%%:'&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@D5\+M*$X#=>E+GCW+^K5;7Y=/EZ]^QKT4459SA1110 4444 %%%% !1110
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M17,-L)K@L%21SYA?*,-K@XVG@Y(SUKO:*7L5W+69R22Y5_7]:=CB;BTOI+J
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M\A3'&H7!!7+%225Z9ZUZ-10!PVG>&=:TSP;JMK;SK'J=S-*\(CV(8]TK,/G
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M^5/WA7H]G]Z_R(O[>T?_ *"UC_X$)_C5R"XANHA+;S1RQMT>-@P/XBE\J/\
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M\_TI^GK?J[_;""-JXY!YH OT444 %%%% !1110 4444 %%%% !1110 4444
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M%I%=&,R;OW;;A@X_.J\6CVL4HE!E+[]Y+.3N/'7\@: +]%%% !1110 4444
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M8ZA<3/,)(W7:F3DJ.P]OU[=*U2RJ"20 .Y-9IMK4JI&,96B[BU6U'_D%W?\
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MVJ(S7"%48C;V&>]> _ G_D?Y?^O)_P":U])UXN,_B_<=]#X#G/)D_P">;?\
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M:LGQ3_R*.M?]>$__ *+:JC\2$]CXS7[H^E+2+]T?2EKZ,\LU?"__ "-VB?\
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MTO\ R,]K_P!>4W_H<5?.8C^(_4]G#;/_  O\C3HHHJ3,**** "BBB@ HHHH
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MYI4EC9563RU?LS>E11Z_"T4;M#(F]01G&,D=,]N_)K6E5=*7,B)P4E9GR_\
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MZ'\>?R-0:'_QYS_]?4W_ *&:\Y_$COA_"E\OU-'S%]3^5*"",BEHJC ****
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M;TH."=QU%-VM_?/Y4;6_OG\JY#8=13=K?WS^5&UO[Y_*@!U>-?M"?\@?1/\
MKXD_]!%>Q@$'E_TK \4>#-(\8P6\.L+-(ENY>/RY"F"1@YQUK6C-0J*3(G'F
MBTCX_HKZ;_X4?X+_ .?>]_\  IJ/^%'^"_\ GWO?_ IJ]/Z[3\SE^KR//?V?
M_P#D<-3_ .O#_P!J+7T17*>&/AWH'A"_FO=(CN(YIHO*<R3%QMR#T/N!74[6
M_OG\J\[$5%4GS1.FG%QC9CJ*;M;^^?RHVM_?/Y5@:#JS?$'_ " KO_<_J*T
M&SRQ/X5FZ^K?V%=_.?N>GN*F?PLVP_\ &AZK\S3'W1]*^5OB]_R4W5?I'_Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M <O_ ,30 W^U=7_Z%RX_\"H?_BJ/[5U?_H7+C_P*A_\ BJ=_PDVG?W;S_P
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M,A;:4DXQN.3'G)P><]\>] '2?VKJ_P#T+EQ_X%0__%4?VKJ__0N7'_@5#_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@QI__@2G^-?,K6%THR8''7MZ=:3['<"58O*;>R[@OJ*7]H3_ )?S'_JAA_\
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M$C5XU*DE001QVQ[#\JJ?VK<>>92L18HJ<H,?+T/UHHH<Y/J*.'I1VB(VJ73
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308&.!THHJ;FW*M/(BHHHH&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %? G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#")6(ZRMS_=%+X#OX(]3U[1($NH[>*Y^W6:7-I+;MY,V68!9%4X$HDYQCD4
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MM['D?:(Y5V38'95C887L(E%:5[</>^(/$NLI<)%!H>F/9VL[YV1S.GFROGT
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M2L4A=QU521FLGPGJT^O>$M)U:Z2-)[RUCFD6($*&89. 23C\:Q8_^2J:W_V
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M$:!2(F/0[I!$=IZB,\<4 :WA'29=%\+6-I<D->%#-=,/XIW)>0_]],:VZ**
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M&4%)I<SMO?SOT_3Y'4T5Q]A=ZEI>MP6\T4\&G7T[+'%?W'G31A(2S$/O; )
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MQ?MJE[\S^_U]>[^]A1115&04444 %%%% !1110 4444 %%%% !1110 4444
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MSQN__ ^X_P#BZ+S[?C_P!\F%_G?_ (#_ /;#+K1]3ELI8LVD\UQIR6DLDTC
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MJ'_7M)_Z":^+*]3 ;2.3$;H^G/@E_P DWM_^OB7_ -"KJO&/_(E:Y_UX3?\
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M) S80$,&ED^Z0.>0<"MVB@#F[SP9:W49$6HW]I(9+EFE@,98K.VZ1/G1AM)
MQ@9&!S4K^$[0Z5+80WEY!ONH[M9XRADCD0H05W*5Q\@X(/4_AOT4 <]>>#M,
MO[.6UN6GDBEFGF<$KRTJE6_AZ#<<#\\TW0_!>G: UNUJ[%H'E==MO;P!BZJ#
ME88T4X"#!QGU)XQT=% &%>^%X;W4VO/[0O88Y)(II;6(Q^5++&04D.4+ @JG
M 8 [!D'G.9>^ [=]*_L^VN9VBDO([B8W$NXC(*SLORYW2HSJPX&9&(P2<]A1
M0!P5IX&NWU[6Y-12Q_LW4UG27RMC2RAWRF280XVC^]+(O8*!@+K:5X%TS2(U
M2"23Y5F7*6]O ")0@;*PQ(I($8P<9ZYSQCIZ* .3MOA[I-MK,FIB:X>62$P$
M.D.=IC$9_>",2'@# +$#L ,"FR?#S3)[S3;RXN9KBZL8XXA-<6UK(TJ1L60$
MM"=N-Q&8]A(QDD@$==10!A:=X4L["#589)YKM=49C="5(D#;@0WRQ(BDD$Y8
M@L>,DX&*$WP^TN?2_L+W5X08]CRN(I#(?-\YF=60HQ+9R"I'/08!'644 8"^
M$[./PO!H,%S<P0V\B2PSQ",21ND@D4@;-G##IMQCC%)>>#M-O[26VNGGEBEG
MFG<%E^9I8VC8=.F&)'O^5=!10!S>G^"M-T_PY?:)'(_V>]+&1X[>W@89 ' A
MC1>W4J3SUQC$<_@:SN;BX:34=0^SS-,ZVH,0CB:5MSE3LW9)Y^9B!DXKJ**
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MQ-_R$_#O_7^W_HF2D\!?\B'HO_7JM+XF_P"0GX=_Z_V_]$R4G@+_ )$/1?\
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M44 %%%% !1110 4444 %1W$PM[:6<J6$:%]HZG SBI*;)(D4;22,%1 69CT
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M7_<:?K^LCD_CQ_R($/\ U_Q_^@/7@'AO_D:-(_Z_8?\ T,5[_P#'C_D0(?\
MK_C_ /0'KP#PWQXHTC_K]A_]#%>]A/X+^9\]6_B'V=1117D':4=:_P"0%J'_
M %[2?^@FOBROM/6O^0%J'_7M)_Z":^+*]3 ;2.3$;H^G/@E_R3>W_P"OB7_T
M*NJ\8_\ (E:Y_P!>$W_H!KE?@E_R3>W_ .OB7_T*NJ\8_P#(E:Y_UX3?^@&O
M/Q/QS^9W8/XZ?JOS1HZ;_P @NT_ZXI_Z"*M55TW_ )!=I_UQ3_T$5:K);"G\
M3"BBBF2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !3)DCDADCE ,;*0X/0@CFGU'/"EQ;RP29V2(4;'7!&* ,V2RT:>VA621
M)(&8F/=<L59MQ)/WN3DFK]FMNEJHM'#PDL0PD+Y)))Y).><U3FT2.>V6WDN[
MDP[F9D^3#EB22?E]6/3'0=Q5VUMQ:P>4'=_F9BSXR2S%CT '4T 35\[?'_\
MY'/3O^P>O_HR2OHFOG;X_P#_ ".>G?\ 8/7_ -&25UX/^+]YC7^ Y_X/_P#)
M4]&_[;_^B)*^J:^5O@__ ,E3T;_MO_Z(DKZIJ\=_$7H3A_A"O-_CA_R3F3_K
MZB_K7I%>;_'#_DG,G_7U%_6N>A_%CZFM3X&?,U?:VE_\@BR_ZX)_Z"*^*:^U
MM+_Y!%E_UP3_ -!%=N/VB<^'ZF5XX_Y$O4_^N8_]"%;-[_QX7'_7)OY5C>./
M^1+U/_KF/_0A6S>_\>%Q_P!<F_E7DQ_B/T7ZGK3_ -UC_BE^43XEKZ5^!?\
MR3UO^OV7^2U\U5]*_ O_ ))ZW_7[+_):]S&_POF>-0^,],HHHKQCN/ECXQ?\
ME1U?Z0?^B4K:^ 7_ "/=[_V#)/\ T;%6+\8O^2HZO](/_1*5M? +_D>[W_L&
M2?\ HV*O9E_NWR.%?Q?F>U^)O^0GX=_Z_P!O_1,E)X"_Y$/1?^O5:7Q-_P A
M/P[_ -?[?^B9*3P%_P B'HO_ %ZK7S\?XK_KL?15?]QI^OZR.3^/'_)/X?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M -!M/^_9KOPE6%-/F9SUH2E:QU_P2_Y)O;_]?$O_ *%75>,?^1*US_KPF_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9Z:Q
M:,0'+QY ;YQV.".F>N: -"BJ)U>T )+-UPH*D;OE#<9]CWQ2_P!K6.QF\_ 4
M G*,.N/;W'YT 7:*ACN8YE8Q;GVYZ*1D@XP">.HJ :K:@ R%HLJ&&\=0?IF@
M"[14$EY!$Y1W(8=?E)]/;W'YBF'4K0*6\X8 W9P>F<?SH M454?4[1$+&7@
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M>A'YTY+^VD=$1RQ<X&%/IG_/UH LT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%<O_PL?P;_ -#'I_\ W]H_X6/X-_Z&/3_^_M5R
MR["YEW.HJ 65H!@6T('IY8KGO^%C^#?^ACT__O[1_P +'\&_]#'I_P#W]HY9
M=@YEW.A%E:#&+6'CI^['':E-I;$8-O%C &-@[8Q_(?E7._\ "Q_!O_0QZ?\
M]_:/^%C^#?\ H8]/_P"_M'++L',NYTJQ1H<I&JGV&.^?YTTVT!QF&,X&!E!T
MKG/^%C^#?^ACT_\ [^T?\+&\&_\ 0QZ?_P!_:.678.9=SHVMX'8L\,;,>I*@
MDTQ+&U0Y6%?NA<'D8Z]/PK _X6-X._Z&/3_^_M'_  L;P=_T,>G_ /?VCE?8
M+HZ)K6W8@M!$<>J#US2?9+;_ )]XNF/N"N>_X6+X._Z&/3_^_M'_  L7P=_T
M,>G_ /?VEROL.YT;6\+2>8T,9?.=Q49_.F)96J(%6WBP!M^X.G^0*Y__ (6+
MX._Z&*P_[^T?\+$\'_\ 0Q6'_?VBS Z+[/ /^6,?3'W1ZY_GS2I;P1D%(8U*
M]"% Q7._\+$\'_\ 0Q6'_?VC_A8G@_\ Z&*P_P"_M%F.S.A%M J%!!&%.,@(
M,''2D:TMV;+01M\H3E01@<@5S_\ PL/P?_T,5A_W]H_X6'X0_P"ABL/^_M%F
M%F=!]EM_^?>+_O@4IMH"Q8Q)DYSQUSUSZ]3^9KGO^%A^$/\ H8;#_O[2_P#"
MPO"'_0PV'_?VD/EEV.@%M   ((P!G'R#N,']*/LUN6+>1%N.<G8,G/6N?_X6
M%X0_Z&&P_P"_M'_"PO"/_0PV'_?V@.278Z%K>%V+/#&Q/4E0<]J06MN&#""(
M,,8(09&.E<__ ,+!\(_]##8?]_:/^%@^$?\ H8+#_O[0/DEV.A-O"2I,,9*8
MVY4<8Z8^E-CM8(IC+'&$<KM.W@8^G3M6#_PL'PC_ -#!8_\ ?RC_ (6!X2_Z
M&"Q_[^T![.?9F^+6W";!!$%Z8V#';_ ?D*'MX)'WO#&S]-Q4$U@?\+ \)?\
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M_E+_ ,)UX6_Z#ME_W\I<\>X_JF(_Y]R^Y_Y&Z(8E;<(T#9SD*,],?RI]<_\
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MY$6/38/\]A1]G@./W,?'(^4<?YP*Q?\ A-_#'_0;L_\ OY1_PF_AC_H-V?\
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M +^4>UA_,OO#ZCBO^?<O_ 7_ )&_16!_PF_AC_H-V?\ W\H_X3?PQ_T&[/\
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MEW?[<^]U*LVU<D'&1G'^R/RH7)UN.3Q'V5'[W_D4AIUZTWE"TG\S^Z8SGO\
MX'\C5Z_\-:EIU@M]/'']F;;M=) P8'H1CM[]^W'-1VWB#5;-BUO>/&2S.<*.
M2V">WMT[<XZFGZCXEU;58FCO+A)%888B"-"1D'&54'J!^5->SL][F<OK?M(V
..Y>7KO?Y&311169VG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>image_023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4#\32I/#)!YZ2QM#C=Y@8%<>N: )**;'(DL:R1NKHPRK*<@CU!IU !112$@
MDG '4F@!:*A-W;BT:[,\7V94+F7>-H4=3GIBLS2?%F@ZY%-+INJ6\\<+*LC
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M8:KINBK97C$<2.LV1(/9E*M^-=)K&M_#_P 4:).FK:EI4]K'N#">55DB8<'
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M#@## XR".^:Y[PMX@\5W/BWQ!!/HAD@6]B1U;44(LU,:Y"C'S<?-QBM76/\
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M\/6;"62UN)XYH'/.QMK%XS[<Y'XCM64JG*[6/0HX+VM-34M>WI>_Y?U8] #
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M$,9[\\#L,]!FG&I=-LBKA%&<:<7JV]UV=O7^O,UJ*XV?6KM8RR:DV8X%>US
M%^VON88P>O11QZYI_P!LU.0EGO)-L]U<6OE!!\BA6*D'&<@CK2]JNQ?]GSM=
MM?C_ )>7Z/4Z_( R317"6EY=_P!CJ4O3-#;VMGM5E5@S.P#$G')&,>U%MJ%W
M:V\Z6-\TTQDO-UJ(P3" 7*MTS]['7@YI>V78T>6RU2DM'Y_TORZ'=T YZ5Q5
M]JW]HRH(M0(MH6LI'DB( 4L[;LG\!GTIBZQ>I;R'[4+=XU=[:)8EQ=/YK@KT
MYZ*,#GG-'ME<E9;4:6NOS_K_ "6KT.XHKEK._P!1-_!++=,T<U_-;& H-JH
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MJG?R%+ U(N.J]YV7]6_X)T%%<G;ZW-!?1K-?K+IPFDC6[< +)^[# 9'!PVX
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MK8VEEM2+MS+RW\_\OTW.QHID2LD2*[;V"@%O4^M/K<\MA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 48'I11
M0 FU02<#)ZG%+110 8I  .@Q2T4 & .U&!Z444 &!Z4$ C!&1110 FT<<#CI
M[4N!Z444 (% Z 4  '( SZTM% ";5QC:,>F*-HXX''2EHH ,#THP"0<=***
M$  &  !Z"EHHH 0* 20!D]31M ).!D]3BEHH :$4'(4 ^H%*5!.2!FEHH"XF
M "3@9/4T     #%+10 FU>?E'/7CK1M4@#:./:EHH"XF!G.!GUI< ]J** $
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BN>\3>+;?PPUN)[2><2QR2L8BHV)& 6/S$9/S< <FB
M\\9Z3;DPV[O=WQF2!+2-=KL[YV_>P,?*V3G P: .AHKEKGQK#9RSB?3;I8K,
MQ)?S H5M7DQM!YRV-P)*YP#6CINOIJ&LZEI3V<]O<V C9]Y5E=7SM(*DX/RG
M@X/2@#8HKE_"GC6U\5-="&W: 0G"[Y 2^#AA@=UXR.<;ASS46C?$+2-5=HYU
MDL',8FC%P5(DCPYR"I(! C8D'!P* .MHKEO^$YLFM;R_AM+F;3;=_)%VFW$L
MI*@(BD[CDL!G &:9=^.8[#3]1N;G2;M)=,9!>P;XRT:, 58'=A@0>@.<\8H
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M=I;V-JD%K&(X5Y '/7G.3R:;C*.Z$FGL3T445(PHHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK_NWR7Z'#'^*>Y:G_P @J\_ZX/\ ^@FL[P=_R)VD_P#7LG\JT=3_ .05>?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %"ZMKR2
MZ,L$ZJOE%0"QX//.,>X/X4VRL[R"XWS3AX]F-NXG'MSU^O7FM&B@!GS,Q ;
M'M535=+BUC2;K3;F1Q!<QF)RF <'T-7%^^_U%*1D$ X/K33MJ!Y?_P *&\*?
M\_&I?]_A_P#$UW^AZ+!X?T2TTFSDD-O:IL0R$%L9)Y/XU"ND7)4AKQE^0KA6
M8\D ;N?H3^-:T:>7&J9)V@#)[U<JLYJTG<E12V0U@PQ\YY..E.VM_?/Y4/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *EU=_973]VSAVP<?P@
M+DG]*J)X@MG 812[.[8&.F?ZBM1?OO\ 7^E.P/2@#*_MZWRHV."[;5SCEL9X
M_P :=)KEO#+'$Z2"1]O 7@;AD<_G^1K2P/04N!0!0M]2CN[<S)&ZA0'PW<<]
M/R-0#78@XB>"7SM@=D4= >>^.U:;C[OU%/P/2@#+&NVQ. DG?.<<;>N?3^O:
M@:Y;_9VN"C^5E0I49)R,]/TK3P/04N!Z4 85UK4%S83QI')^\@?#8X'!%5_#
MEV;3P5HK+$9&>!%"CJ>*VM3 _LJ\X_Y8/_Z":S_!W_(G:3_U[)_*LO\ EY\O
MU.U?[F_\2_\ 263-KL E")%)(".2N.#Z4Y=<MV("QRGD G XSZT^ZU-;>[^S
M):RRR;0WRX Y/J:@77$(8FRF 7EV^7 &W<3UY  _&M3B'P:[;7!7RUD*LXC#
M8X+=<?E6B3AV/HH_K38]D\44ICQD!U##D<?SIX_UA^@_K0!DG7XTMA))"RNR
MAU3/WESU'_ZJD.NVZDJ\4JL.<$#I[<\_2K=]=I8VQG>-I "!M09/-43K>T_/
M83\X*X*DX*YR>?TH ?\ V[;^<(!%*9C_ ,LP!D<UAWE]&WC;3+V,%H_[.F9>
MV1O S]/Z5TMI=K=M*ODO&T9"N&QU(SV]B/SK"ND5/B'I2*H"KI\H '0#<M9U
M-EZH[<'\4_\ !+\D:G]NVXE:+!>1 "WED%1P3U_"HY/$$21R.86^4$J"P^;I
M^76M? ]!1@>@K0XC-GUJ&*>6!(WDEC&64$ #@GDGV%-.OVHED39+B/.]@.%P
M0/YD5JX'I37C21=KJ&'!P10!FOK$-L6$P"A9!'C/S$D^GIS36UV$*"(7Y&3D
M@8&,\_I]?PK30 KG SD_SIV!Z"@#,_MRW$<DCJ519EA!SDL3[?TICZ_!%'OE
MAE4'[H&"2-H;H/8]*UL#T%&!Z4 5K2[2[>7:K*T9".&[-UQ5JHT14D?:H&[Y
MCCN?6I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH 3 !)]:6BB@ HHHH 0@'K2T44 %%%% $%[
M$T]A<1)@N\3*N?4@BN3T>;Q9I.CVFGCPW;2_9XA'O_M%5W8[XV\5V=%9RA=W
MO8ZJ.)]G!TW!23=];[VMT:.9_M;Q9_T*UM_X,U_^(I#JGBME*MX5M2",$'4E
MY'_?%=/12Y'_ #/\/\B_K5/_ )\Q_P#)O_DCF?[6\6?]"M;?^#-?_B*/[5\6
M9S_PBUMG_L)K_P#$5TU%'(_YG^'^0?6J?_/F/_DW_P D<S_:WBS_ *%:V_\
M!FO_ ,11_:WBS_H5K;_P9K_\17344<C_ )G^'^0?6J?_ #YC_P"3?_)',#5/
M%:DD>%;49.3C4EY_\<J.QMM<OO%MOJ>I:7#90P6KPC9="4L6(/8#TKJZ*/9]
MV_P_R']<234*<4VFKKFZ^LF%%%%:G"%%%% "  # I:** "BBB@ P,Y[T444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<[<:I::=XNN1<M*"]A!MV0O)TDE_N@XKHJX3Q7/JB>)XX=)OX+*62"
M'S99G555 9^3D'(W8X YZ9'6@#H_^$GTO^_<_P#@'-_\31_PD^E_W[G_ , Y
MO_B:XZ77M;$3B2_GW_:76<VP@.(P'\LPY/S _)NSR.:LV/B#5=FL->WJI)'I
MR^2K&/RVN0A+&-@>5S@8//!- '4?\)/I?]^Y_P# .;_XFC_A)]+_ +]S_P"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7#>*+C4+?Q.BZ9I=M?W,\$,>VXB
MW*HS.V<Y&WD#G]#7<UP'C"\L[#Q*LMSIUS?236\,,4=O.\;9W3,>%/).WO\
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M$7^Z/RI=B_W1^5+D-%23ZGV1_P )1X?_ .@[IG_@7'_C1_PD_A__ *#NF?\
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MM'H/RI?6GV-%P]3?_+Q_<CZO_P"$CT/_ *#.G?\ @4G^-'_"1Z'_ -!G3O\
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=:I,NUT5 !CV';IVHHI)M%RIPE:ZV,^BBBD:'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>image_024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&8,?U'7TK4[54.:WO'-7]ES+V6UO\_\ @" Y4'U%+34_U:_04ZK, JA)J?\
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ML""3QUYZCD5MT47861SY\)6F21<W(/KD?X59L_#UM9W<5TCN94).<  Y!&,
M<#G.!Q6O11S,+(Y]?"T,=Y%.D[X$QDD& -ZY+;3@<_,0<GGY1Z5/=>'UO+N:
MYDO)O,D^5<*O[M-I4J..A#'\36S11S,+(P_^$8M_-+BXE4,<,B*H4KD'&,=2
M5&3U-;E%%#=PL%%%%(84444 %%5;W4['3C"+V[@M_/D$47FN%WL>@&>IJU0
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M7(_Z>(?_ $*N4_9^7;_PD'_;#_VI7.W^]2/6IPO@)2\_\CVRBBBN@\D****
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MO'<W&?-<*IW98L>WJ2:^F]*GDN?#EE<3-NEEM$=V]6* DU\DO]T_2OK+0_\
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M^ __ "4"7_KR?^:U]+5%?XR:7PA1116!J%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <!\9!GX=W(_Z;Q?^A5RWP#7']O?]L/_ &>NL^,
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MVKX"?\B1=_\ 7\__ *"M>*_$/_DHGB#_ *_'_I6E/XV<]38ZCX#_ /)0)?\
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MGYAP!D<_C7H/PWC\KX>:-&#G9"5SZX9JYSXAF./Q9ITTEX]J$L)0&241EF+
M!=Q]374?#\8\"Z4#G/EMUQG[[>E:1?[QG#7C;!4W_74Z6BO(/B9\6-:\%>*$
MTO3]/L)X3;K+OG#[LDGCA@,<5Z/X;U2;6_">GZI<1QQS75LLKI'G:"1T&><5
MO='F.$DDVM&7HM3L)Y1%#>VTDAZ(DJDG\ :LDA5))  Y)/:OE'X0P;/BGIC8
MZ&7_ - :OJ+5QG1;\?\ 3O)_Z":49*2N75HRI24620ZE8W,HB@O;>60C(5)5
M8_D#4EQ=6]H@>YGBA4G ,CA03^-?+_P/@V?$ZU;_ *=YO_0:]&_:&C\SP?I8
M]-0'_HMZ2FFKERP\HU%3>[/6K>ZM[M"]M/%,H."8W# '\*B?4["*8PR7ULDH
M."C2J&!],9KRK]GF/R_!^J#UU _^BTKR[QU!N^,^H-ZZC$?_ $"AS25PCAI2
MFX=4?6%>)>&_C-KVL_$"U\/SZ;IR6TMT\#2('W@#=R,MC/'I7MO:OE?P/#M^
M,=@W_40D/_H5*<N5HK#T/:QF^R/I+Q267PAK3(Q5A83D$'!!\MJ^=?@E=WTW
MQ*M$GO+B5/L\WRR2LP^[Z$U]%^*!GPEK(];&?_T6U?/7P5BV?$BU/_3O+_Z#
M2G.TDC7#4/:4*D^Q]-4445J>>%%%% !1110 4=J*.U #4_U:_04ZFI_JU^@I
MU !1110 4444 %%%% !1110!\S^,?^1QU?\ Z^G_ )UW/P6_X_-7_P"N<?\
M-JXGQ9%)-XTU=8HW=OM3\*I)ZUV_P85DOM85@58)&"",$'+5X5#_ 'GYO]3]
M7S9K^Q&O[L?_ &TSOC'_ ,C5:_\ 7HO_ *$U<GX3_P"1NTC_ *^H_P"8KM?B
MK876I>,[2WLX6FE-F&VKCH&;UKDM LKC3O'.EVMU&8YDNH\KD'J1W'%363^L
M-^?^1IEU2']D1A?7D>G7:1Z]\5O^1"NO^NL7_H0KY^-?0/Q6_P"1"NO^NL7_
M *$*\&EL;R"W6XEM)XX'("R/&0IR,C!^E;8W^+\CS^%Y)8%W?VG^2/HGX?\
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M$XVYZ]5?_9-?1^A_\BIIO_7C%_Z *TH*S9R9S-3ITY+NSY*?[[?4_P Z]H^
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M.*&.>-$<Y90'  /O7T145OB)I[!1116)H%%%% !1110 4444 %%%% !1110
M5B>*XDGT":%YY8-Y"AXK?SFS_NX/YUMUYG\8_$NN>&M-TN71+S[-)-,ZR'8&
MR HQU%)R4=673I2JR4([L[_2)))=&LI)5*NT"$@]>@Z\#G\*;J]O-<V8B@^Q
M>;O5A]LB,B#!Z[01SZ<UR?PFUW5O$/A![S6;G[1<BY= ^P+\H P,#ZUQG[0E
MN9_^$?P3\OVCH?\ KG4NHE'GZ&U/"U)UO8?:/8],MWM-+M;>202211*K.O0D
M#G'MZ5YIX@^*'ABP\<_V;>Z+J$^HV<Z0)<)MV GH1\PX^;TK3^"D1A^&]LAS
M_P ?$QY_WJ\E\:6>_P"+E])CK?QG_P!!J)UN6*EW.K"Y?*M5G1>\?T/I6_G>
MVTVZGCQOCA=USTR 2*\9^&?Q0\1>*/&D.EZC#8I;20R,QAA*ME1D<YKV/5!G
M2+T?],'_ /037SW\';81?$2V?'_+"7_T&E4J<LXQ[AA,'[:A5J_R(]=^)\D<
M7@UY)HO-C6XB+)N(W<],BN>^#]TMW<:U(D9C14MT5"VXJ!OXSCG\>:W/BO\
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MH8G'I@BCGC>UQ_5:S2DHFKY:^A_.CRU]#^=9D_B&PMV0$RNC0"Y\Q(R56,G
M8GL*0>(;)I'1%G9EF:  1'YW49;;ZX ZT<\>Y*PU9J_*S4\M?0_G1Y:^A_.L
MN'Q%I]S&C0-)*7E\I52,[B=N[IZ8YS4(\36QOC#M;8%VXVG?YN_;LQ^M'M(]
MREA:SNN5Z&UY:^A_.CRU]#^=9'_"3Z;D_-+M4*9',9VQY8H Q[?,"*D/B&R$
M<;[+@B52\8\HY= ,EA[8_F*.>/<3PM9;Q9I^6OH?SH\M?0_G6?-KUC JN7=T
M,*SL\:%@D;=&/H.OY&JZ:^B0:I=743QVUE,8OE0LS8QS[Y)Z4<\>X+#56K\O
M]-V_,V/+7T/YT>6OH?SK-E\06,$A28RQ[=HD+1G$989 ;T)'\Q3&\262I&YC
MN2LD+3@B(G$:XRQ]!R*.>/<%AJSVBS5\M?0_G1Y:^A_.LF#Q#;37)MT$DTA:
M0KY,1(VJ0"2?Q'UJ-O%%DMXT#1S*L<<CRNR?ZO85X(]]PH]I'N/ZI6O;E?<V
MO+7T/YT>6OH?SK*?Q'91SK;F.Y-RS%?)$)+C"[LD>F*D&OZ>T#S+*QC2&.8L
M$/1_NC_>/I1SQ[B>&K+[+-'RU]#^='EKZ'\ZP5\3Q+).;E&@BBFDCPZ'<0J!
MB<=NM76UZR214?S5)V;LIPF\X7<>V30JD7U'+"UH_9-'RU]#^='EKZ'\ZS'\
M06<=VMHZSK<L0%B,?S-D$Y'M\I_*FS^)--MV?S)) JLRA]AVLRD!@#W()HYX
M]Q+#5GM%FKY:^A_.CRU]#^=)%)YL2R;67<,X88(I]68-6T&^6OH?SH\M?0_G
M3J*!#?+7T/YT>6OH?SIU% #?+7T/YT>6OH?SIU% #?+7T/YT>6OH?SIU% #?
M+7T/YT>6OH?S-.H[4 1I&NQ>#T'>G>6OH?SH3_5K]!3J &^6OH?SH\M?0_G3
MJR;C7H;?4FLWAD.UXT,@(QE\XXSD].:3DEN:4Z<ZC:@KFIY:^A_.CRU]#^=4
M?[<TTJ6%VF,J!P<MN) P,<Y(/3TH;6M/6X:W^TKYRX!1@1@D9 )Q@$BES1[E
M>PJ_RO[B]Y:^A_.CRU]#^=9]OKMA<*0LX9U1'=8U9PNX9'('I38?$.FSO.$G
M^6$H"Y4X;> 5V^O6CGCW']7K:^Z]/(TO+7T/YT>6OH?SK._X2'23+Y?VU-_&
M1@_+EMHSQQSQS4[ZK8HK,UPN%E,) !)W@9(P.N*.:/<3H55O%_<RUY:^A_.C
MRU]#^=4GUK3HV97NT&W.2<X&%W$9Z9QSCK3(=?TNXD5([Q"S$ 9!'49'4<9'
M(]:.:/</85;7Y7]S-#RU]#^='EKZ'\ZSSK^EA58W:C<RJHVG+%L[<#'.<'D5
M7A\364\+,'6.196BV2$KG#[#@XYZCCWI<\>Y2PU9J_*_N-CRU]#^='EKZ'\Z
MQY_$UC'=^1&ZN!&7:0DA1AU3&<<\MV]*DM_$-C<113"01Q21&0>9D-PP7[N.
M>2*.>.UP>%K)7<6:GEKZ'\Z/+7T/YU4AU:QN)EAAN \C G:H.1R1SQQR#U]*
MJV_B*SE$[2MY*1RO&NX$LVS[S8QP*?/'N2L/5=_=>AJ^6OH?SH\M?0_G60_B
M.UCOS;N-L0?;Y^X;<>6),_D<5.^OZ5&DKR7L:")2\F_(V@$ D@].6'YBESQ[
ME/#5E;W7J:'EKZ'\Z/+7T/YUG2Z]I\%U+#)<QCRMJO@DD,QP%P![BG-KVF+Y
M>;M/WA 7 )Y+;1GCCGCFGSQ[D_5ZO\K^YE_RU]#^='EKZ'\ZSGUJ)3=.(9&M
MK1BL\XQA2!EN,Y./:H+CQ%'9QQ275G<1+*GF)G:?ER,YP>, Y(],^E)SBNI4
M<-5EHH_UO^1L>6OH?SH\M?0_G6-?^)K:PGGB:":00Y#.F,;A&9"!SUP!^8J[
M::DMS=/:O"\,ZQK*%8@[D/&01[C%-3BW:XI8>K&/.XZ%SRU]#^='EKZ'\ZRI
M=?AADNXWMY@]O+'$ <?.9/NXYX'UQ5RPOTOXI65&1XI6BD1L95A].#U%"DF[
M(4J%2,>:2T+/EKZ'\Z/+7T/YTZBJ,1OEKZ'\Z/+7T/YTZB@!OEKZ'\Z/+7T/
MYTZB@!OEKZ'\Z/+7T/YTZB@!OEKZ'\Z/+7T/YTZB@! H7I2T44 %%%(QVJ6Q
MG SQ0!0N]'MKRXDGE,F]TC0[3CA'WC]:C&AV\=RUS#--%,[R,S*PY#D%ATZ9
M4?2J<?B=!L,]L0)(EG4Q/OPA#'YNF" O3FK<&OVMQ9274<<I19!&N5V[R>F,
M_7OTI.FM[&JQ-1*REH-7P[9I';*FX-;JZ(S ,2K'<0<C'6F?\(S:"[-PDLH;
MY\ [6'SXW Y'(XZ'I3(_$+2-*Z6C-")HHH_F )WKDD\]!2V7B:"ZDMK=X)DN
M9E4L@7(7(!!SZ<TO9+L6L96_F9-8>'K/39%:VW #!(;#$D#&<D9'%!\/6929
M,RXFBFB;YNTC;F_7I59/%-M]HEMWAE,T=PT.V-<YQW_4?KZ5)<>)+==(>^MX
MWD&65%/RY95)//M@CZBG[);6$\75;YG)W+-SHEM=/,6>11-;?9I #U09Q]",
MFHYO#]G->M>?,)V(.X@,!\H7&",= /QJ%?$L&\;X955E!3Y>2=S+^I4XJ%O%
M]G%;H\D,VY]H0!?OMQD#GW[T>S3Z"6*J1VD6+O0?MFI&1YV6T:T%L\2'!<;B
M3GCICCCWJ5O#]F57&X,L[W",<-M9^&&",8P:9J6N#3+MEFB_T=8!(7SR6+8"
M@?@336\20 12+!(UO(7Q+D#&T9Z9SUXI>R6]A_6ZMDN;;^OU%G\,V%Q=/<L9
M1*\"P':V!@$'..F> #ZCBHD\):>A9LR,YD\T,<8#;MV0,8Z]O2I1XCMRV#!,
MH5UC=B!M5B<8SGGIU'%-;Q L%W<Q7$#*D<I12N"2HV@L>?5P,=:/91[%+&UT
MK*;)9?#]G/%/')O(G2-) ,*"$8L. ..32?\ "/6^VW!FE;[,I2#?A@B8QC!'
M/&.3SP*277XXH[20P2XN8RZ)@;NJXSS@<&HV\5:>H0D2_,ZH05Y!)P!^JGZ,
M*/9+L3];JK3F_K;\M"U=:);73.2TB"2%8)50X$B D@'\ST[$TLFBVLEG=VI,
MGEW4OG28/(/'3V^4527Q39[F+I*%QP F6W<Y7'K@$X]C4[>(;8:8M_Y,YC9R
MH4+R< DGZ8%/V:[$K$U+)<VWZ$[:1;F_DO%)267:7P <D# ()&1QZ>E9I\+(
M-0:5+F1()894F52 7+E<\8P!A>W>IO\ A*;/S&C\F?>H^8;?NMG !/3GUIDG
MBBWM1<?:XGC\IR%QSO ZD>XI.DGT+ABZL-I=+$X\-6"^?L,JB9'0A7Q@.03C
M_OD5$OA2P!E8O*3-O$G( (;;D  <<HI&/2E/B:W,R1K%+EV*JK#!?G (.< 9
M!ZT^+Q!!<ZLEA I9MQ#D] -K'C\5(H]E'L-8RLOMLFBT2WCU%+]Y)9+I2278
MCGY=N,#MBJNG^&H;;2[RSG.?M5PTQ*,?D^;* $_W<"G/XGLDF$7EW!?+!@(_
MN[< _ED?G5>?Q4JQRM%:./+4$F0C[QW?+@'VZ^]'LEV)^MU;6YNWX:HNQZ!
MDWG^?.TYE>;>Q!^9EVGC&,8'2F6WAJQM)"\.X%O]9D [N21CCY>O;%0/XJMR
M[)#$S["P=\\+A<Y]3T(X]*F'B:T+(/*FPV"" ,;2<!NOKVZT_9+L'UNKMS$:
M^$[)4F033%)8DA<';RBYQV^]R?FZU:BT.VMVE,#%!(6;&U3@MUY(R0?0^M.C
MU>)M6;3V5A)DA6QQP <9]>:H+XKB12]S:RQ1E?E((;+9(P<?2DJ2Z(<L96E\
M4F;-A91:=916D.[RXP0-QR>3G^M6*R;C7(XK>"189,RIO^9?NC<JG/OEA5=?
M%-J7YCEV\9 7E.<'=^..*M1TT,)3YFY2>K-ZBL:#Q):W&EK?QQ2F)YO)C!P"
MQ]>3P*8/%-FWEE8+EA("RXCY*COBBS)NC<HKG[CQ;91G;&&8X#Y(_AR 3^1R
M/6GCQ39E YAN A'WBO')(7\\&CE871NT5G6NLP75[-:K'*LD*[G)'R@\9&>_
M457M=>%]?V]O;P,(W5G=WQPNT,N.>X8?2BS"Z-FBBBD,*.U%':@!J?ZM?H*=
M34_U:_04Z@ K'NO#\-U?S7IE9)W:,JX493;D$ ^C D&MBLJ_UV+3GE\ZVG"1
ME1YF %8D$X4D\G@\?XTG%2T9I3JSI.\'8@C\-Q16/V4-&P6-8D=XR6"KTYSU
M'J,<U6B\.3R7%TEU=.UJTL+IG!>0I&%R3[D<_3WK4_MW3<[?M0W9P%VG)Z].
M.?NG\C2'7M/$$$_GCRIEW G[PR 1E>N>?2I]DNQNL=65_>W*D'AO[+:F&&]E
M7+QL3C ;9&$P<$<< ]>M16GA1+.%(TNV8H\4JLR#[\8P#]".WZU;3Q-I;3,C
MW*Q#?L1GX$G .1[?,.?>GMK^GK,(_-(^56)9"H ;..HY^Z>*/8Q["^O5M?>W
M]"DWAI8;75V21II[^([@<*/,^8@CTY(^F*FM=!>"PTU1<%;NT!9I2-P=W!#D
MCW))J[#K.GSSK#'<J92"0NT@\9R.1P>#QUJN=?A$"3?9YBCQ-<*1CF$8R_7W
M''6A4EV_K<'C:K5F_P"K6^ZQ7G\,I<12P/=/Y,DK3D;1GS&4J3GTY)Q_2B?P
MO!<*Z27$FQWB9@ !]Q-F/Q%2MXEL@NX+,WR,V-N,8W<'T/RG]/6ICKENMK+,
MR2>9"VR6%0"ZG(!.,].>M'LH]@6-K+:167PXINK.XENF>2T\M8\( "J9X/N<
M]?:H9/"JS!$FO7:.*=YX@$ *EGW$$]QU'XUH0:Y9S2W:%F3[*-TA8=LD9P.1
MRIZ_UILGB+2HP,W0)(#!51BQ!8+G&/4T>RCV!8ZLM5+\O/\ S?WE(^%E81HU
MZ_E0Q^7$@09"^8LG)[GY0*&\*Q/#!&]TY^SH5B(7'_+17!//.-N*MKXDTK)5
M[N-95&6C&6(YQVJ>TUFPO9S#!-NDRP"E2,[<9(XZ<CFCV,>P_KU?^;\BNFA*
MEU;SI(L3QN9',*;6DSG()SRISR#GI3!H'ER-+#=,DK^<"2@(VRL&(QZ@@8-3
M+XATUI_+^T +LWK(0=K<L" ?7Y3]>V:D&N:8QQ]K0'.,'((_ T_9KL1];J_S
M&9-X0MI-H6XE18V1D& =I6-47Z_=!IU[X3M]2E$MW.SN\WF3!5PLB[0NS'IP
MI^HJVOB/3)7@6VN!<&:41#RQG!/<^@_GVI\FOZ=#-)%/<+&Z,5(P3T[\=.A_
M*E[&/8M8^NFFI[&?9^$HK1+;_3)9'B*,TC*,R,K[\GZ]/PJM+X=O(-6DN+<"
M>-F5U$C )N\UG.\=3C=QCO6TVO:6O6\09<1C((RQ) [>H(STXIB^(]*VQF2\
MBC:0X 8]\ D9Z<9'/O2]C&VB*685N9MN]_Z\@?105O8%G(M+QV>:/:"<L,,
M>P/6D_L43F+[=.;A8H7A0;0N0PP2WJ<<>G6E'B"S-H;K$@A%P8"S+C&.K8/.
M*DDUW3(I'1[M R9W#!XQ^'7VJO9KL8_6JG?^K6_)6,T^$HCI,-DU[,[IYI>=
M@"TC.A0D_0']*T8=(3[4;JYD,LWEK$NW**JC)P,'N3DYHDUNSC>S^<F.[0ND
MF"%"\8)^I8#\:4:[IA<H+I2PXP%)).<<<<]>U"I);(J6,K3TE+O^.XP:4XN[
MZ=I(9!=[,QO#E1MX'?FI],TV+3+=XXSDR2-*Y"@ L>N .@JNGB'3GRQFVH,\
MLI!.&8'C&<#8>>E6K;4[.\<I;S"0ABIPIZC/M['FGR):V,Y5YR7*WII^&Q;H
MK'C\3:6^YFN#$BKO#R(5! )!ZCV-6)-;TV**"5[I=DZ[HB%)W#@9X'N/SJK,
MQNC0HK._MW3,@?:T^; 7 /.<8QQSU'YU9LKR'4+5;FW+&-B0"RE3P2#P?<46
M'<L4444@"BBB@ HHHH **** "D) !)Z"EH(R,'I0!AKKNBH"%VKN42D>5C.X
M<$_4$'GM3FUK2@3 $4I(QW)Y7WSG&0,?-D@C/M5]M+L6# VR89 A &,J.@_I
M]*9;Z/I]L!Y=LF0Q<,PR02<_UJM"=2G_ &YI32O;JF\+G?MC!52I4 'W.Y<4
M]=9TDR*>%93M#&+&UB/NYQ][VJRNCZ<H8+:1 ,23@=<X_P !],"E?2;)UB7R
M%"Q2K,H''S+T)]:-!ZE.^U?3[34$@>%6D#9=]G"'&1SCK@YX]:C36-"2W^SH
M8_*1?-\LJ"!D[N_?G/XUIRZ;9S3F>2VC:4XRQ'-1_P!C:=L*?9(]K  C'7O^
M?OUHN@U*G]O:,2@$L9+,H3Y.N0""!Z?-U]ZDE&DZAI:W4L2/:KDYP1@=#G';
M'6K*Z38(ZNMK&&7&T@=,#  ]L=NE+#IMI LRI$-DPVNI.01SV_$T:!J9TNO:
M5(Z1[5FC9"=Y3*C!& >/]H4O]KZ83 WV<&.=O]:(\KG &<XYZ[<UH#2[%4*"
MTB"GJ OT_P !^5"Z99*"%MHP"<XQQVZ#MT%%T&I!'=V#7QT[RXA+&?E0*,#:
M ?PZU6;7]$<JS2QL=[%&\O.65<D@X_N\_2M3[%;?:A<^2GG#)WXYR1C^55Y=
M%TZ:%HFM8]K;N@Y7=UQZ?A1H&I5_M_2&D\HN/,08\LQ_,I_NX[$\<4U];TA7
M*W$8B9)64>;$!RH&6'L,@9J\ND:>JE5M8P"NT^X]_4^_6G?V99;PYMD+ YR?
MI@_7H/RHT#4H0ZQ8"W6;[(T<8NC;KB,?*0"=Q]!C-.DU?3X+-'$)\@2;&7RL
M;,J6R5],<_0U>73;)+<0+;((@_F!<?Q>M"Z=9I!Y MT\O).TC/48_EQ1H&I0
M;6=$WS!WAS&"CDIGCC(_7I['TISZIHYTO[:_E?95?;ED& 1_G-6TTG3XVW+:
M1 []_P!W^+!&?R)_.A]+L9+1;5[9&@4Y"'D"C0-2I>ZKI=K(\-P(OE \S>O
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MT:!J6M/U:#4F=88YE*#DO&0.I& >AZ&K],>/=LPS+M;.%.,^Q]J?4E!1110
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MMKRU2ZMKB*:WD7<DL;AE8>H(H FHJO97]IJ-O]HLKJ&YAR5\R%PZY'49%6*
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MDK:NRCMN+X/Z 5I2BI229%27+&Z/.97U+Q3=S:EJM[<7$C/MSM,CNW7:B#H
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MH W]K>A_*HYC-&@,4!E;/W<[>/QK$_X1'7_^A[U;_P !X/\ XBC_ (1'7_\
MH>]6_P# >#_XB@#5$UYC_CP8'_KH*;YU[DC^SV]CY@YK,_X1'7_^A[U;_P !
MX/\ XBC_ (1'7_\ H>]6_P# >#_XB@#4,MZ!Q8$_]M!2I-=,R;K)U5OO$L/E
M_"LK_A$=?_Z'O5O_  '@_P#B*/\ A$=?_P"A[U;_ ,!X/_B* -_:WH?RHVMZ
M'\JP/^$1U_\ Z'O5O_ >#_XBC_A$=?\ ^A[U;_P'@_\ B* -_:W]T_E4D (F
M&0?RKG/^$1U__H>]6_\  >#_ .(I\7A37DE1V\<:JZJP)0V\&&'I]R@#K:**
M* "BJFJ:G::-IL^H7\PAMH%W.Y&<5R7B#Q1I-A'I?BA=6N6M)HWABMX3E90P
MSOV'JRD#K4RDEN;TJ$ZK2BM_+KV.X/2N#U+P5J@\#:GI]O?PZCK,\CRQ7EY
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M\\Y'&W.#SZ\'BJ$7B[19(UD^U;5/]Y",?7C_ #BGSZ7J4MI$D6I+!*N_<R1
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MZ/:3^84;!QU!SSQ0!I>=%C/F)C&<[A33<0A2S2HH'J<5CJ--92D+3\.%++G
MR?7TXHF.FPDQS+/&J.<$$X8@#GC\* -H2QDX$B_G38[B&5%=)4*MP#GK6/'/
MIIQY7FDJP)W<$\XQS[GI2J;"6WDE\J3&P-LWC..1Z\=Z -=;F%F*K*AQP<'O
MZ4X31E@H=<D9'/7Z5CH;&X9V99>,YRX[';T]Z>LNG+<PJ/,WJORXR<<Y_J:
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M"X_\:7_A*/#_ /T'=,_\"X_\:^-@B_W1^5+L7^Z/RI<AHJ2?4^R/^$H\/_\
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M $&]-_\  N/_ !KY"V+_ '1^5*$7^Z/RJ><M99%_:9]>?\)+H/\ T&]-_P#
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M*GZ[+L:+A:D_^7K^Y'U3_P )#H?_ $&-._\  E/\:!X@T,  :OIV!T_TE/\
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M)5B\IM[+N"^HI?VA/^7\Q_ZH8?\ Y_O[E_F?37]OZ)_T%]/_ / E/\:!K^B
M8&KZ>![7*?XU\SFPNE4,8'P<?KTJ,VTX!/DOA20<+TQUH_M"?\OY@N$,.]J[
M^Y?YGT[_ ,)!HO\ T&-/_P# E/\ &C_A(-%_Z#&G_P#@2G^-?,7V6X_YXR=<
M#Y3R:<MG<.CLL383&[/!YZ<=:/[0G_*/_5##_P#/Y_<O\SZ;_P"$@T7_ *#&
MG_\ @2G^-'_"0:+_ -!C3_\ P)3_ !KYC^R7!C,GD2; 0"=IZG_]5 M;@D@0
M29&0?E/4=J/[0G_+^8?ZGX?_ )_/[H_YGTY_PD&B_P#08T__ ,"4_P :/^$@
MT7_H,:?_ .!*?XU\Q?9;@C/D28SC[IZ^E+':7$KE$B8L!NQC'':C^T)_R_F'
M^I^'_P"?S^Y?YGTY_P )!HO_ $&-/_\  E/\:/\ A(-%_P"@QI__ ($I_C7S
M)]CN0 ?(?![XI'M+B.5XVA8.GWACIWH_M"?\OYB_U0P__/\ ?W+_ #/IS_A(
M-%_Z#&G_ /@2G^-'_"0:+_T&-/\ _ E/\:^87@EC17>-E1@"I(X.<X_D:F33
M[J1-RQ$C)'4#D=:/[0G_ "@^$,.E=UW]R_S/IC_A(-%_Z#&G_P#@2G^-'_"0
M:+_T&-/_ / E/\:^8$BD>41*C&0G&T#G-/-I<!E4Q-EAD#';UH_M"7\HWP?0
M6]9_<O\ ,^G/^$@T7_H,:?\ ^!*?XT?\)!HO_08T_P#\"4_QKYE6PNV"E;:4
MAC@?(>>,_P JC$$Q8J(G+#&1M.1FC^T)_P OY@N#\._^7[^Z/^9]/?\ "0:+
M_P!!C3__  )3_&C_ (2#1?\ H,:?_P"!*?XU\PBWG) $,A)Q_">_2A;>9R D
M3L2=HPIZ^E']H2_E#_4^A_S^?W+_ #/I[_A(-%_Z#&G_ /@2G^-'_"0:+_T&
M-/\ _ E/\:^7W1HW9'&&4D$'L:N-I-RB2LYB7RHEE8&0?=.,8]3R*%F$W]D4
MN$,/&UZSU\D?2G_"0:+_ -!C3_\ P)3_ !H_X2#1?^@QI_\ X$I_C7R[12_M
M&7\I?^IM'_G\_N7^9Q=%%%?6'Y0%;>J>(GU/2H[%K98PAA.\-G/EQE/USFBB
ME8=RQ_PE$2I),FG 7[6@LTN#,2J1[-A(3&"2,\GIFG0ZGI*>$;&PO;3[5(EW
M-(1%*8Y(P50#G!&#@\8[444N5#YF/A\:2P3!DL8UACDB,$2N<1)''(@7/4_Z
MPDGUJA:ZO9MID-AJFGM=QVS,UN\<WE,@8Y92<'*YY]1D\T44<J#F9#KFK?VU
MJ9O!:QVH\J.)88R2JA%"C&?I6?112-$**6BBI9K$6E%%%2S:(M.%%%0S:("G
M445#-HBTM%%0S9"TM%%2S:(M+114,VB+2T45+-D**6BBH9O$=0***AFR'4HH
MHJ6:Q%I:**AFT112CK114,WB+2T45+-HBTO:BBH9M$44ZBBI9LA12T45#-D+
M2BBBH9M$6E%%%2S9"BEHHJ&;1%%/C=HY%=#AE((/H1114,V1HQ:S/&"!#!M(
M(VA,#G_Z_-/77+K[1%*=IV$%AC[Q!)R??FBBCFEW!4*3^R-NM8N+EI@0HCEX
MV$9Q39=6N9UA601,(B" 8Q\V.F[UZG\Z**AR9M&C325EL*=6N"02D)(SU3KP
M1^F3CZT/J]S)*LCK"Q1=J@QCCC&?K111S,?L:?81]5GDB\MHX2,@D[.3CUH7
M5[I&+*44&0R$!>,GK^%%%',P]C3VL22:Y=2)M C3(^8JN,]?\33#K%U]J6X'
ME!PJJ (QC"].***.:7<2H4E]E#CK5X6+!D#$Y)"XSZ?SH&MW@ YC/&"2@Y&,
M8-%%'-+N'L*7\J+#>([K9#L2-7C4J25!!'';'L/RJI_:MQYYE*Q%BBIR@Q\O
M0_6BBASD^HHX>E':(C:I=, "XP JXQV4Y'ZTY]8O'FDEWA6D&'VC&X8(P?7K
M111S/N5[&G_*B*34)Y;86[E3$I!4;?NX!Z?G3_[3F\PL8X2#G*E.#D $_H**
M*7,Q^RAV&)?S17 N8\+/R3)C)R>]/?5+EY_-)0-Q]U<#AMW\Z**.9A[*#=[%
MBZUZYGG,B*J*PY7&1_GBH$U:ZCNOM"^6'R#C8,' (&1WZFBBGSR[DJA22LHD
MKZ[?/$T>Z, ]2$ /Y]:1==O5C\O,10D$@QCG  _IGZT44<\NXOJ]+^5&?)(T
ILKR/]YV+'ZFIY+Z>2!H6(V,J*<#'"YQ_.BBE=FKA%VNMBM1112*/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>image_025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %7 F(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6=K618YI1$Q &\LF,X!)!!.#[UN^'UOXC>17-O>0V@<-:B\F664 CY@65V)
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MLEO ;:)MQ.V,E3MZ\_=7D\\4V?6=+M6A6XU*SA:<!HA).JF0'H5R>?PJM?\
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M=HPZD-T)'7FI[>PMK6XGGA0B6?;YK%RQ;:-HZGTJOI6HC4GNY8KS3[JU64+
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HII=5."P'U-.H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "B@]*R[G4V4E%C9".YH MSWT4+E/O..U5WU9%(PF0?>LJ>42R;PNTGKSWJ,
M L0!UH Z2&X288!&[&2,]*FK)MK62T_?R,0!_".II_\ :$DC-C;&H4D9[T :
M,A(0E2H..IZ5E7]S*JHI*^H9#P144EV 2R.Y; ()/3U%468L<F@"=)T RZ%V
M]S6K97L<BK&%*D< =JR+<PAB9@2,< 5L6;6QVB*,*^,GN1^- %VBH)+R&*58
MV;+'TYQ4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !17GFH^(-;L]4UVR.I* M_86\$H@0?9DG;#$ @Y(!ZMD9Y
MZ<5TGA&_O+_3+L7MQ]IDMKZXMEN"BJ941R Q"@+G''  XJW!I7)4KNQOT445
M!04444 %%%% !1110 5QO_"4ZG;B2**SBOIC<WVWS9_(5(X'  R$;)P0.G;G
MUKLJK#3[(-N%G;[OG.?*7/S\OV_B[^O>JBTMQ,R=0UN^2Y\/C3K6VE@U.4B7
M[1*R,B^4T@QM5AG"GKZ =]RXNG^,[^VT$W.IV(FE^R^? \,A9ISY@CPRJGR<
MLOW=_&>,\'L)].L;J&&&XL[>:*!E>))(E98V7[I4$<$=B.E(=,L#"838VWE&
M)H2GE+M,;?>3&/NGN.AIJ4;6L*S.?N/$5]/X$U755M)M.O;:&;8)(WQN495E
M$J(2.G5!SD<XR77?BR>W\0RZ7#IHN@%<1/$\F7E6(R>628A&"<8P)&/()'7&
MY!I&FVNGO86^G6D-D^0UO'"JQMGKE0,'-1SZ#H]S=RW=QI-C+<RJ4DFDMT9W
M7;MP6(R1CC'IQ3O'L%F8ECXEU2^U;2;=+*Q6"ZBN'N/W\HDB:-T7 #Q*<X<<
M,HSGMC+/@O=2MO&,MOJ,M^EI=3,FGJ!;FW=1$&(./WP;*R'GC@>U;46B:5#'
M:QQ:991I:,7ME2W4"%B<DH,?*3D]*=%I&FP:C)J,.G6D=]*,27*0J)'''!8#
M)Z#\J7-'L%F9-WXK6RU*YLI;)S+;;Y9 KY/V98M_F@8YRQ$>/[V>?6C;>-+R
M;19KR71FMYTDC2**47(68.,_(?L^]F&#D+&1QG..G2+IL"ZQ+JGS-<20+;\X
MPJ*S-QQGDMSSV%5T\-:#'92V4>B::EK*P:2!;1 CD="5Q@D4[Q[!9F+:>,+_
M %&&22QT02B+3TNY%:X97WOO C5?+)/,9R3@XQ\I/RUT.D7YU/2X;MEC1WR&
M2-F(1@2"OS*K9!!!!4$$$$<4G]C:7]E>U_LVS^SR1K$\7D+L9%)*J1C! ).!
MVR:2TT>RL;KS[6%(0L"V\<4:A4C0$MA5 &,D\_04FXO9 KG)76JZY;(Z6NH7
M.HPW%U#;1W,44".),2-,(0P5"H"HH+EL$L,L1BM6>\U*_P#!UO<:-)?R7321
MJ[%;<7!59 LOWAY6[ ;_ &?2M"/PKX=B@F@CT#2TAF $L:V<863!R-PQS@\\
MTYO#>D2><L]A;SPRQQ1?9Y85:)(XL[$5,8 !9B/]X^P%.40LSDIO$E])+:26
M>I7HM8%A^U--%!F,FX:-_/VISD(RKY)ZJ2<*0U='HLM_)K.H*^I-?V*87>T2
M(L<^YM\<>T E5&T'<6(/&<A@+[:#H[26DC:38F2S 6V8VZ9@ Y 0X^7';%+9
M:'I&F7$EQ8:796D\@P\D%ND;,,YY(&3S2<HM:($F9.H^+#IWB*/36LQ+;D[7
MFB,I:-MA< CR_+S@#CS-V"#BL^U\6:C]ODFO+2!+:2WT]X((KCS,+<7#1^8S
M; 00""5Y'R\'DD=2^D:;+J*:C)IUH]\@PMRT*F51Z!L9_6H8O#VB6]O<00Z/
MI\<-S_KXTMD"R_[P PWXT)QML%F8&H^*+];IVL8XL06^H$PRO\LCP-&%8L%R
M.K<#U_$7[#Q!J$NHZ;9WVG00"[MA+YZ32,K2$,VQ/W>TD*H)#,IZX!"Y.K;Z
M1IEI$D5MIUI#'&K(B1P*H56QN  ' .!GUP*CM= T:QN([BTTBPMYXTV))%;(
MC*OH"!D#D\47C;8+,QM0\;1Z=?3VLUBY:W>592LF=H$8>,].?,SM [-QS45W
MXBU>"ZFBM+2"24:E!:O'=7&U4#P(Y"%(\]6/)W=STP!TLNFV$\DDDUE;2/*4
M,C/$I+E#E,DCG:22/3M27.E:=>13175A:SQSN'E66%6$C   L".2 !@GT%"<
M>P69A:!K^H7-^UG?6\9BENKY+>Y64;B(;AD"L@4  +@ Y).WGKFNHJ".SM8F
M5H[:%&5G92J $%SN<CW8\GU/6IZF33>@T%%%%2,**** "BJU]?V^G6QGN6<)
MD*%CC:1V)[*J@LQ]@#65%XS\/SBP:*_WI?E%MY%AD*,S$A59MN$8D$ ,0>#3
M46]A71O445!]J0W!@.0WJ:0R'49S#"  <D]1VJO)%]N@24%<XPQ)[U/?QD6@
M7S/E#<EN36?:132AT0_)W..* '_98;5";@Y8]%!Y'O5:V0R7"JA R< D4ZXD
M,SJK* R@ GUK4L[:.TC\UW&2.IQQ0!5O9_(4V\;EO[Q/.36;DU8OIHYKEFC&
M!Z^M5J "BBB@ J>"X,*2 #EEQGTJ"G("7 '6@#3TZU64F60$D= 1Q6M4<".D
M2JY7('\(XJMJ>JV>CVRSWLK(CR+$BI&TCNYZ*JJ"S'KP >A]*+7 NT4R&5;B
M".9 X610P$B%& (SRK $'V(!%/H Q=9UZ32=5TBS%B98M0N/LYG\T*(SM9AQ
M@EONGTZCDTFC^('U36-8TZ6R^RMITB("TH<R!EW X P..V35+7-*_MF^LY9]
M0N[1]/E\^%;?RMI?!&3O1C]UB.N.>E,L/"BVNL7FJV^IW4_VX@RQS>7M4@ +
MC:@/ &.OUR>:OW>7S)UN=713401HJ#H!BG5!1!/.\1.V/*A<Y)Z^U'F-)#SM
MC;J58]JGQFFE%;.5!SUH K@>8IBB+1J,'=ZBK5%% !1110!0N;E[,%06D9N=
MS=JM6TAEMT=L9(YQ4-[;-,A=';<!PHZ56M)Y+>W?S#N"$ )TQF@#4HIL;B2-
M77H1FG4 %%%% !1110 4444 %%%95[=2S3/;6[F.-.))5^\3_=7^IH 8_A_P
MY'+/))I&E+)<@B9FMHP903D[CCYLD \]ZT;.WM;2TC@LH88;9!A(X%"HH]@.
M!66FG,R_+!"!ZRC<3^)S4;V<D#AX_P#1I>SQ?</L5Z&JU?4-#?HJI87ANH6$
MBA)XSMD4'(SZCV/6K=2 4444 %%%% !1110 5P-KJVOWEWJ:V=U?3R1O?Q"-
M[-5@BV.PA*2;!O?(48W-QG(XS7?5F1:GI5O:I+"RI%/<RQJ(H6RTP+F0;0,Y
MRDA)QV-7%VZ"9S@O=0UJ\LI#:WWV>&^M6'GV3PE?W;^8<,H.-V.>E58W\7_8
MQ<MJ.H&3[)]I,!LHO]:),"+_ %><%>2/O< @@<'M8=4L[A[-89@YO(3<0;5)
M#QC;ELXX'SKU]:KKX@TYM1N+$23^9;$B>0VLHAC(4.0TNW8/E(/WN]5S/L3;
MS.?DO]?_ +>GC22_RLLX:V^PC[.D(B8Q.DNSYG+>7D;S]YAM&.*\EWXELM%G
M,MQJ=S.]M9S+*ELBO%)(SB5 %@?Y5VJ<>6[#=R><C?'B_1/+CD>YEB62:.%/
M.M98RS29V$!E'RG:WS_=X//%6KO7]*L;R:TNKQ(IH;8W4@8'"Q @$DXQU(XS
MGD<47?8+>9S%A+XMU& .;JYM9XM,21$DMD5)[C?*,.6C!'"H2 %QD' SBK\&
MK:I?>#+G6;;SO,NSYUJBPAI(;<D %5Q\S;,N 0<DXP1Q6S8:QI^LF>WA,N^-
M1YL%S;20N%;."4D4$J<$9Q@X/I2Z;J-I=0QI:PRQQ?O%B'DD)MC?9P1\H!_A
M!()'('!PF_(:7F<?I$=_%=-<!;Z2-[^YE^UW>G8EV_9E"OLV*1DC&%"[L8]J
MK7.K>+AHE@T#7XD+S+/<26K%F8;/+PBVA;8<OUB4_+C?T+>BRSQ0[/-E2/>P
M1-[ ;F/0#U/M4E/GZV#E\SB;K5?$">*[:%$O%LR@\_;;-)#_ *DL73$&>'P,
M&7=D$;,$&LNXU;Q<NC61@>_\S?,LUS):/N=@$\O"+:%@AR^<Q*<KC?T+>E5'
M-/%;0M-/*D42C+.[!5'U)I*:[!R^9SME?:J_C!K>X>Z>T-JK%4MF2".3:I/S
M/$-V23@B3(S@H,$UG7>H>*X]1N;6&.8QK,;6.<6P*GSBS1S9QTB4*I[$L<\B
MNSCF2626-1(#$P5BT;*"2 ?E)&&&".1D9R.H(J2ES>06.)CU#Q.?&%[!)YB6
M*^:(X_(=D*!,HRL(-NXG&<S'J1M!P!1NKWQC:1Z)MN;F1I[=)IWDM21YQ*EX
MW6*W<J@' R4/S'YSCCO;N\@L85EN9-B-+'$#@GYW<(HX]68#\:+V\M]/LY+N
MZD\N",9=L$X'T'--3\@MYF!KPU&+Q+I<]M=ZDEJ;>X5XK:'S(FE^0IO^1L9^
M;DD8V\$9.<&ZO?&-I'HFVYN9&GMTFG>2U)'G$J7C=8K=RJ <#)0_,?G../09
MIHK:"2>>5(H8E+R2.P544#)))X  [TXG ) )]AWH4[= :. U.]\2W.LZS96A
MU2*V-K.L+"+[KA 4,;>0 ,G('[QSST4XP1:CXF&M:3#%->M8,D&Y[JTD4R@L
M1+Y@6V.UAT&7C' )R"2>WT^^BU+3X+V$,(YD#!7&&7U!'8@\'W%6:.>VE@Y?
M,XC26U.[\:6UQ>G46:&&\CE2:S\N"#,D?EB.38-X95SG<_3^'I1=ZAXKCU&Y
MM88YC&LQM8YQ; J?.+-'-G'2)0JGL2QSR*[>H+>\M[N2YC@DW-;2^3*,$;7V
MJV.>O#*>/6CGZV"QQ]U'JB7]O,DNH6=NNNR"865H#YD+0-M9P(R67?M&XY'S
M9)RJE9_"%OJU@UK;W,ETUI+;S2&*:!56W<2@*H(4'YE8G#$YQD8'%=;--%;0
M23SRI%#$I>21V"JB@9))/  '>GTG/2U@MJ%%%%04%%%% &5XBBUBXT6:#0I+
M:*^DPJRW#LH13U((5OFQTXQGGG&#RH\/ZM;SZ#:-9:3'I&E[9$LQJ$I8SACM
MD9O)^? .X#"_,22>!77R:M&79+:-IRO!8'" ^F[O^&:SVN;IG>6:U25A]U8I
MLX_ @?SJU)I6$XW-01N^H%F!**.,_P!*62W2Y9G!82*<<]L52MM;6X4?+AT;
M$B$88?A5DW%RT3S*OR$':.Z^]0,E6*1+IP1F*3D^QJ"6&WM1L<OY<G7GIBF>
M8)T#F5EG5<@$8IC_ &6?;))*0_\ &,=?I0!7BM&N)\IRF<9]*O7UB\BJ8VZ#
M 7_"I[-(0&:'<!T(-33PK/&4)(]".U '-R1O$Y5P013*UVTEF!+2Y;M69-"\
M,A1Q@B@".BBB@ IT9 D4GIGFFTY#AP< \]Z .G0JR KTQQ7.^+?#]QKBZ9+:
ME3+8W7G^6UU);>8"C*0)8P60_,#D#MCO6]')'':>:P6) NYNP ]:RY=2N)OG
MC86T!.%++F1_P/ _4_2JBVG=":N6M#M+RPT*QM-0NS=WD,*I+.23O8#DY/)^
MIY/4\U->WHM%550R3/PD8/7W/H*RVNKN/!^VS*2<#SHD*G\@/YU#]IFFN9DG
M"17;)B)NJ%1W7\3R*-W<:12U76+&Q?=JNHK'*W_+.+C']33M*URUO>-)U196
M7K#,<@_U'UKEKGX9WMW<R7%QK2/*YRS&,T6WPSO;2YCN+?6D26,Y5A&:YN>K
M?X=#V?JV ]G_ !O>]-/RN>FV-\MXC H8YHSB2,]5/]1[U;K%M0T5Q;R.P,G^
MJ<J.&S_]>MJN@\8***0D 9)P!2 6BJ)OFEF,5L@;_:/2K$$+19+R%V;J30!-
M1110 54O(XR!),Y$:_PCN:6YOHK<$9#/Z"LZZU,SQ;!& .^>: ->W\LP+Y7W
M,<5)7.PWDT>U1(VT'IFN@C<21JXZ$9H =1110 454DOXXYC&48XXR*F2XCDZ
M-@YQAN#0!+1110 5BVS )&QZL-QSZGDUM5AW43QLT2<.GS)GN.W^%- >9^//
M%6K)XBFL+:ZEMK>WV@",X+D@')/XUU/@'7[S6="N!?N99+>38)2.6&,\^XJ'
M6](T;6IUEU*&2*Y4;2ZG:2/0^M:FD6EM:6:66FP&*V4Y9C_%^/<FL8TIJHY-
MZ'K5\9AIX.-&$+25M;??KYF[9\7X(_BC(/O@C'\S6I5&PCR3+_"!M7W]3_GT
MJ]6S/)"BBBD 4444 %%%% !6!::%/;^)Y[YGB-AEYH(P3N6:145SCH!A"1[R
M/[5OURU[X[T^P@EFN+2ZCC6[>SC>62"-9I$+A]K/(  -AY8KG( R>!4;O83M
MU'Z9X:N[-KU3?&U7_4V,EKM9X8-[2;2)%90?GV]#\J+SFJ,GA*_GOM=BE=3:
M:JCI]J_M"7<@:!8\FV"B)FRN<Y'!]L5IQ>,M,FGLT19?)NK+[<L[&-56/#$_
M*6#L1MY"*V,C.,U&?&<"1,9=)U..<^1Y5NRQ;Y1,Q6,@ARHRP((8@CN *OWR
M?=(]0T;5O$5I;VVLPZ?#$DX:1+:=Y-Z&.1'(+(,$[Q@8XP?F-4/^$.U6:W2:
M[OK:74S#(9I]IVO*)+=HOEQ]W;;@-SG))&<UMZ;XBN-035V;1;N Z?(T:J\L
M1,Y"!L##X!Y'7CD<]0*5MXWADT^UN[K2KZW$M@=0FYC=8(0,EB0^2/0 ;N>@
MYP)S6B#0T-,LM2?6+C5-4CM()&@6WB@M96E 4$L69V1222< 8XQU.>,&'PW?
MWF@PVPVQ20Z3?Z61/N!,DCQA'Z<H1$3GT(P#5V#X@:3<Z-<:E$C%+>58I4-U
M:C:6&0=YE\O\-^<]J1?'4#-/,NE7K6$=A;WJW*-&=ZRE@%V[LYRI'?D-T&TL
M6FN@:%2\\#)Y+1VNG:5)"EW!=16LPVQDJFV3/R-@MUS@YQS5:+P+J*7.O.T\
M3-?VMW#',9E!D,IROF*L 8A>@)D?&.!@X&[;^,;:2Y:&YTW4+((TD<DMPL95
M'1#(RG8[$G8-V0"O;.<BJUC\0=*U&PFNK2WN9GCFAA\B)X9'9I3A.5D*#)R,
M,P(QR!3O4"T2&7P- +XW-K:V,1B2S%HP7#0&.9I)BN!\I<-U'+'.:S;GP%?W
MEWKDD\6E%+Z.41J%0+(YE5T9PL((( ()9I#DD@\FM34O%&HWL,5EHNF7<=Y>
M6]T8YG,.;>6%Q&RE2^#\W&02.01N&<=A2YYQW"R9PLO@N5$;R='T22V>Y,YT
MJ1RELI:WB0L,1$%E='Q\G(<GY3Q4MKX)E@N+>ZD>VGO;?["L=V^?,"Q "7!(
M)&\ ]^<\UVM%+VDA\J. L?!6JP7M[/(=/B6XNK68BWVHK^5=+*252%,':& W
M%SD_>Y)K0\6>%[O7+TRPVVG7"M;K%&]V[!K1PY8O& C9+ @'E?NCD]*Z^BCV
MCO<.56L>?7_@2_U'4M=EE735BO[2Y@0JJ#<SE3$SJ(0V5*@Y9W.>1MZ59/A/
M4/\ A)],U2.STJRM[,)^[M-NZ-0K!D4^0'8'=QAU&.-O<]Q11[20<J.2_L:^
MU#P"+%8(%N+EC.T%XBE5#3>9M(=' 8 XY1L$=.]4]*\(:C87VAS20Z>QL$D2
M25I Y56=R%1/)&T@,HW(T8Z@J0 *[FBESL.5')2^&K^3X@0:Z!9+:Q,274(L
MS+Y+)M;]UN;YCG)EQ@#Y<C-5M?\ ".H:G;7\42Z?*MUJ/VH+.$.U/(6/@O%(
M VY3T7D'[PKMJ*.=ARHX"X\#WUZNHQ3PZ:?M>D_8S<2-YSM,(T56YB#( RY^
M^P^4$*&)-=KIT'V73H(/LEM:;$ ^SVQS''[*=J\?@*M4R25(D+NP %)R;W&D
MD/HJA'JL#N0P*CL>M7$FCD7<C@BI&/JAJ;.Z);(Q429WD'D*.WX]*OUGWJD7
M2/V\L@?F*: YW3]8AOO$\ND11K]GMHB6([L.P]A6M-+826=U):F)I+=6R4;.
MU@,X->=>'[:X/BK6;3SGM[@I(%D7JI+9!K1T70=4TO\ M">[O1Y)C?='&3B5
ML=3^=80G-].Y[N(P>&C+2:5E&R_FOO\ >;>BZE%KFGPZFD:BYA^65/7U'T[B
MNN$D+VK$(3$!TQU%>;?#B.1=(O9FR(G8!2>^%.?YUW>G&*>P6WE;+ =,\U=-
MN4$V>?CZ4*6)G3I[)_U]Q,TMN0DK1-GE<#T%/^Q6ID5B,%N=I/6F$):2Q0A
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M:M</@9'!(.* .B!# $$$'N*6LFU>ZAF$&,@'.#CI6M0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5F:K<21[8T; 8<XK3J&>UBN /,'([T <UR3ZDU*('*;U&1WQVK0AM(S>
M@18=%Y8L.*U$C2-=J* /04 <N58#)'%)7326\4JE70?6L.[LW@E( )7J#[4
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MG"T=RBS_ &I/+9@,D!LX)P"<>U<K/\,X[FV>"356".EZA*08)^T.'!^]_#M
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MDGUH 0NQZDFA3@@TE% &U%JL6T!U93CMS3)=7Q+B- 4]^M9%<?XMABN]9TR
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MZ=*&95D"*?/9_++<\J #WKNZPSX0T5A?JUO.8[\R-<PF\F\MV<Y9MF_:#GN
M".V*N+BMQ._0KS>-+)-0%A%8WUQ<F^>Q5(E3YI$C61CEG VA6SD^AXZ9I_\
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M,S--9"4-$02C??'N,=17F/,-'44?<3LWTOZ_UYL\IXVKS>[#3\6N]CU6QO\
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M<[QVV^(;L]Q679O))>*[Y;')+=A6D$GBC,0C22,=,MR13?D5&S9NA88.P#-
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5)8WC8VCL3!+C@KZ$^HK*L#/+>QQVL!N)F.%C5<YKZ*@CBU"W:&YC20KPZL
M0P]<5);:386&Y[:T@@]2B!?Y5ZJS%\G+*-SF]A:7-%F-X0T&31M!AL9=IN)F
M+S!>@+=?P XKMJJ640V><>6<<>P]*MUYLYN<G)]3H2LK(****@84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7TU2MH,GJ>*MTU$"(%48 &!3J "BD;.TX.#44%PDZ_*?F'44 34444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_Q5'_":>%?^AFT;_P #XO\ XJOCBE%3[%=S12N?8W_":>%?^AFT;_P/B_\
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M_P )7X<_Z#^E?^!D?^-'_"5^'?\ H/Z5_P"!D?\ C7RX*45/UZ78T7"E%_\
M+U_<CZB_X2KP[_T']+_\#(_\:/\ A*O#O_0?TO\ \#(_\:^7Z!2^OR_E1:X1
MH/\ Y>R^Y'U!_P )5X=_Z#VE_P#@9'_C1_PE7AW_ *#VE_\ @9'_ (U\PTM3
M_:$OY4:+@^@_^7LON1]/?\)3X>_Z#VE_^!D?^-'_  E/A[_H/:7_ .!D?^-?
M,5%+^T9?RK\2O]3:'_/V7W(^G?\ A*?#W_0>TO\ \#(_\:/^$I\/?]![2_\
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M*BC^T9?RK\0_U-H?\_9?<CZ=_P"$I\/?]![2_P#P,C_QH_X2GP]_T'M+_P#
MR/\ QKYBHH_M&7\J_$/]3:'_ #]E]R/IW_A*?#W_ $'M+_\  R/_ !H_X2GP
M]_T'M+_\#(_\:^8J*/[1E_*OQ#_4VA_S]E]R/IW_ (2GP]_T'M+_ / R/_&C
M_A*?#W_0>TO_ ,#(_P#&OF*BC^T9?RK\0_U-H?\ /V7W(^G?^$I\/?\ 0>TO
M_P #(_\ &BOF*BC^T9?RK\0_U-H?\_9?<CBZ***^L/R<*TM5URZUC;]I6)=L
MLDPV CYGVYZD\?**** )]1\27&HQ7B&TM;=KZX-Q=20A]TS;F8 [F( !8\*!
MT&<XK0OO%47FZ;);:?9S365G!%'<31OOC=$&> P5L,"1N4_E@444N5#NS,NO
M$5]>::MC-Y;1A%0O@[VVR229)SUW2MG\*MIXLN4N9+PZ?8-J$L;QRWC(YD<,
MI5B1NV;B#]X*#WZDY**+(:;, 4HHHJ6:1%I1114,WB.I:**EFT112T45#-HB
MTHHHJ&;Q%IU%%0S:(HI:**EFT1:4445#-XBTHHHJ&;1%%.HHJ&;Q%I:**EFT
M1:4445#-HBBG"BBH9M$44M%%0S>(M****AFT112T45+-HBBG445#-XBTHHHJ
M&;1%I:**AF\112BBBI9M$=0***AFT1U+114,VB+1114FH4444 %%%% !1110
G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>image_026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BLG6/$VB>'TW:KJ=O:D]$=_F/T4<UQ=W\</"<#%85OKG'>.
M' _\>(J7.*W9O3P]6IK"+9Z517E7_"^O#O\ T#M3_P"^$_\ BJ/^%]>'?^@=
MJ?\ WPG_ ,54^UAW-?J.(_D?]?,]5HKRK_A?7AW_ *!VI_\ ?"?_ !5'_"^O
M#O\ T#M3_P"^$_\ BJ/:P[A]1Q'\C_KYGJM%>5?\+Z\._P#0.U/_ +X3_P"*
MH_X7UX=_Z!VI_P#?"?\ Q5'M8=P^HXC^1_U\SU6BO*O^%]>'?^@=J?\ WPG_
M ,51_P +Z\._] [4_P#OA/\ XJCVL.X?4<1_(_Z^9ZK17E7_  OKP[_T#M3_
M .^$_P#BJ/\ A?7AW_H':G_WPG_Q5'M8=P^HXC^1_P!?,]5HKRK_ (7UX=_Z
M!VI_]\)_\51_POKP[_T#M3_[X3_XJCVL.X?4<1_(_P"OF>JT5Y5_POKP[_T#
MM3_[X3_XJC_A?7AW_H':G_WPG_Q5'M8=P^HXC^1_U\SU6BO*O^%]>'?^@=J?
M_?"?_%4?\+Z\._\ 0.U/_OA/_BJ/:P[A]1Q'\C_KYGJM%>5?\+Z\._\ 0.U/
M_OA/_BJ/^%]>'?\ H':G_P!\)_\ %4>UAW#ZCB/Y'_7S/5:*\J_X7UX=_P"@
M=J?_ 'PG_P 51_POKP[_ - [4_\ OA/_ (JCVL.X?4<1_(_Z^9ZK17E7_"^O
M#O\ T#M3_P"^$_\ BJ/^%]>'?^@=J?\ WPG_ ,51[6'</J.(_D?]?,]5HKRK
M_A?7AW_H':G_ -\)_P#%4?\ "^O#O_0.U/\ [X3_ .*H]K#N'U'$?R/^OF>J
MT5Y5_P +Z\._] [4_P#OA/\ XJC_ (7UX=_Z!VI_]\)_\51[6'</J.(_D?\
M7S/5:*\J_P"%]>'?^@=J?_?"?_%4?\+Z\._] [4_^^$_^*H]K#N'U'$?R/\
MKYGJM%>5?\+Z\._] [4_^^$_^*H_X7UX=_Z!VI_]\)_\51[6'</J.(_D?]?,
M]5HKRK_A?7AW_H':G_WPG_Q5'_"^O#O_ $#M3_[X3_XJCVL.X?4<1_(_Z^9Z
MK17E7_"^O#O_ $#M3_[X3_XJC_A?7AW_ *!VI_\ ?"?_ !5'M8=P^HXC^1_U
M\SU6BO*O^%]>'?\ H':G_P!\)_\ %4?\+Z\._P#0.U/_ +X3_P"*H]K#N'U'
M$?R/^OF>JT5Y5_POKP[_ - [4_\ OA/_ (JC_A?7AW_H':G_ -\)_P#%4>UA
MW#ZCB/Y'_7S/5:***T.,**** .-U_P 4ZW:^,;?P[HFF6EU-)9&[=[F<Q@#>
M5P, U;\+>*I]:N]3TW4]/_L_5-,9!<1"42(RL"596P.#@US/B"SU&]^,]I%I
M>I_V=.-$8F;R!+E?-/&#_.H?#Z7>@>*O$V@:G*FH7][8G4#J2J5>10"@1ER0
MN.V*UY58SN[GIXGA,'GB6,PXW>8&&W'KFFS7=M;V_GSW$44/!\QW"KS[GBO,
M-.91^S<26 ']E2C)/NU3:CH&HWVC^#]7M]-AUFTL=/03:7,X7?NC7#KGY2PQ
MT-+D0^8[C5;_ %"/^S7TA+&XBGN52=YIMH$1!R4Q]YO05H2WEK LC37,,:QX
MWEW "YZ9STKRK4K[1[_1_!LFB6;6-LGB)8WM67:T,H#[U([8/IQ5ZQ\.Z9K_
M ,5_%9U6W^U16T=J4@D),>YD;YBO0D 8&>F31RJVHN;4],CD26-9(W5T895E
M.01[&H8KZSN)W@ANH))H_OQI("R_4#I7C4E]=>'_ (<>-[+3)9(H;'5GM;;#
MG,$3[,A3V W'Z9K1/A/5U;1Y-%\'6>D7-E<Q.+Z/45=FBS\ZM@9?<,]:.3S'
MSGJL][:6TL<4]U#%))PB22!2WT!ZT7-[:V84W5S# '.%,L@7)]!FO,?$>DKH
M7B'6=;\0>'X]=T.\*.;I2&FL4  *[#_".N5.>:F\2:4R:\WBB30XO$>@3Z?&
M@AR#):H!DM&K<,"#D]#1RH.9GIX((!!R#7 ^$_B,_B#Q7?:+=Z<MH$>86DPD
MW>=Y3[6!&.#T-=;H%UI][X?L+G2>-/>!3;C!&$QP.?3I7CMK#+:>%+KQ/:H6
MNM#\275PP'5H&?;*OY'/X41BG=,)-Z6/2_'/BUO"6CQW%O:"\OIW*06Y;;NV
MJ69B?0*I/Y5IZ!K UCPS8:Q*BVXN;=9F4MPF1GK7 :C<Q>+M4\3:U#()=,T;
M2)K6S=3\KS21%I&'T7:OXUGP1KJNG?#7P]>LPTJ[M6FN(MQ"SM&@*H?49.<4
M^16%S.YZ];7EK>H7M;F&= <%HG# '\*;+>VT4PMVN85N'&4B9P&;Z#J:\^U#
M2;'PM\3/"YT&WCL_[2$\%Y;PC:DD:J&#%1QD'O[U2\&>&='\5^']5UK7(!/J
M5U?7 DN6<B2WV,0H1OX-H Z4N56N/F>QU_@#7;SQ#X)L=6U%H_M,H<R%%VKP
MQ'3Z"N@MKVTO0QM;J&<*<,8I V#[XKPVWN+K_A47@[38(C-#J&I>1/%YWE><
MFYSY9?L&(&:ZW2_#FL6WC32=2L/"]IH-K$KQ7WD7JN)XROR@HH&2",Y]Z<H+
M42D]#I/!.NWNNV^L/?-&3:ZI/:Q;%V_NT.!GU/O745POPQ_X]/$?_8=N_P#T
M*NZJ)JS*CL%%%%24%%%% !1110 4444 %%%% !1110 4444 ,EEC@A>65UCC
M12S.QP% ZDFO"_'?QIGGEDT[PM)Y4 ^5[\CYG_W >@]^OTIGQJ\=R7%Z_A;3
MIBMM#@WKJ?\ 6/U"?0=_?Z4GPN^%4>J6\.O^((B;5CNM;1N/-']]_;T'>LY7
M>B/1H4Z=*/M:NO9'$Z#X)\4>-9S=6UM+)&YR][=N0I/^\>6_#->A6/[/[F,'
M4-?"OW6W@R!^)/\ 2O;8XTAC6.-%1%&%51@ >@%.I*E'J.IF5:7PZ(\=_P"&
M?]._Z#UW_P!^5_QH_P"&?]._Z#UW_P!^5_QKV*BG[.'8Q^O8C^8\=_X9_P!.
M_P"@]=_]^5_QH_X9_P!._P"@]=_]^5_QKV*BCV<.P?7L1_,>._\ #/\ IW_0
M>N_^_*_XT?\ #/\ IW_0>N_^_*_XU[%11[.'8/KV(_F/'?\ AG_3O^@]=_\
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MD\ 9- $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3_E#DGW/ ?\ A>7C7_GYL?\ P&'^-'_"\O&O_/S8_P#@,/\ &O?O^$!\)?\
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MC4M6ESP6R43_ -E7]*^IH/!7A>V?=%X?TT,.YME/\Q6U%#%!&(X8TC0=%10
M/P%'MHKX4'LV]V>+^"/@7':2Q:AXJDCGD4AEL8CE ?\ ;;^+Z#CZU[3'&D4:
MQQHJ(H 55&  .P%.HK&4W)W9K&*CL%%%%24%%%% !1110 4444 &!Z4=:**
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M_"MW^U+3U;_OFD_M2T]3_P!\T 8G_"PO#O>YF'UMW_PI1\0?#9_Y?G'U@?\
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M^G.3_P!!->5^#CGPG8?[I_F: .VT^:=XU$I4A@>0?2KM4-/_ -3#_P "J_0
M4444 %%%% !1110 H)!!!P1T-=#8W!N;8,WWAP:YVMO2/^/1O]\T :%%%% !
M1110 4444 %%%% !7RU\6_\ DI6J?]L__0!7U+7RU\6_^2E:I_VS_P#0!6-;
MX3U<K_C/T.*! 8$C(SR/6N]BUS33=W[7.K&6PN5'V:U&\>0O]S'1<<#CKBN'
MM(/M5Y!;[U02R*A=C@+DXR3Z5V>H:=X?NHSJ-@T%RD86$VT4OV?"IG,A#<DE
M0F<=2QQTKFC<]JMRW28)?^%Y(9P(K:&5G<1)L?R>&;RV<9Y&",_A4,EYH%OH
M5PD$MN;Z2!X]T,;+NW<D$'MD#'MZ5:NM(\/2SRL9H;6.WFDF$<<ZMOAWD*JG
MN3E" >V:34=&T&Z>>: )#%:VYGD:&<-YP#,K#'9MQC_#.*K4P3CYG!U[%^S_
M /\ (8UK_KWC_P#0C7CM>Q?L_P#_ "&-:_Z]X_\ T(T4_B1>._W>7]=3WFBB
MBNT^4"N-\1Z=J[ZP\FGQS-#L2^RCXS-#G$?7^,;1CIP<UV5% '!1#Q3:PO%"
MET)S$\@4HC1#<A8_,>3()#@#I@>E)J]AKB'4;>%;V6&Y3'FQ(A>601(!NSP%
M^^#CN!7?44 <7XBTO6;Z]LY4AC*VT;M^Y+;L>9$0%.1MDVAN<$=1WIMNWBNZ
ME=)I+BV!E8.5B7@ .1L)XVG]V/K]:[:B@#B%N?%KN[F*=9EB,AB\M/*("!E5
M3UWELJ?3)]!2VI\7W>$NFEM5#D%HT0EE*,XZYZ$HGU4^M=M10!PPNO%SO,TL
M4T>$0E(HE;Y"$W;,\>8,OP3_ $K8TBUO(_!LL$B3BZ9;@J)0!(=S.5SC@$@B
MNAHH X5K?Q)9.C.]S)$\$"2R6L2^8F%?A58D$[BN3Z&FW6H^([90MV+M6DFM
MT9[>)3C*G>D:GKR,[OTKO** .&AB\1K?6][<Q79D"MNC@*JLC^0,;QT^\",]
M ?:KOAQ=8GU..ZU2"90D4\:/* #M+QE0<8YX;MVKK** "BBB@ HHHH ****
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MGO[I@T\JC"C'15]AD\]\U=.$N:[1QXW%4G1<8RNV=G11176?.A1110 4444
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M^O!XH LT5"+NV8(1<1$2'"$./F/MZU&FHVLE[+:)*&EAC$D@'(4$D<^_!XH
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M9E"MU'8=JF<>5V-(2YK,]OHHHK,T"BBB@ HHHH **** "BBB@ HHHH ****
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M,'M747M@6(95R1Q@"BWT,'$ET=B=D'WC_A0 OAE-FGR#_II_2K/C7GP)J?\
MUZG^8JY!''$NR) B#H!53QESX%U+_KU/\Z /G6Q_X_&_W/ZBNH>%44-)*Y'H
M!_B:Y>Q_X_#_ +G]171QP23 E%X')8G %-!9MZ"$J'^3.W_:ZU<%\\:;%(R1
MC<.N*IA<. XP*5XRG4U49N.Q,J:DKLFN)_.10>N<FO0?A!-+<^++Z6:1Y)#!
M&"SG)X>O.S $M&N))451T&<DG/3V]:[3X0:G;Q^,IH7F1&N-B0KGE\'.!0^:
M6H^54[)GTA1114#"BBB@ HHHH *:SA3@Y_*G5&\2N<F@!?-3^\!]>*>#GI59
MK;T9A^-9]XUU8 3(0\>X XX(S0!LT53LKX76Y",.HS5R@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\?\ BM\,M1U[4QKNB(LUPT82XMBP4MCHRD\=
M.,5[!14RBI*S-J-:5&?/$^3_ /A6?C/_ *%ZZ_-?\:/^%9^,_P#H7KK\U_QK
MZPHK+V*/0_M6KV7XGR?_ ,*S\9_]"]=?FO\ C1_PK/QG_P!"]=?FO^-?6%%'
ML4']JU>R_$^4%^&7C1F"_P#"/W(R<9+(!_.O</A;X"F\&:7<2W[(VHWA7S%0
MY6-1G"Y[GDYKOZ*J-)1=S"OCZE:/(]$%(5#=0#]:6BM3@$  &  ![4N!Z444
M (%5>B@?04%5(P5!'TI:* $VC.<#/KB@HISE1SUXZTM% "8'H*-J@DX&3U.*
M6B@!, '.!FD**225!)X/'6G44 )M7.=HSTZ5#=V5O?6Y@N8A)&2#CIR#D$$<
MBIZ* (K:UAL[9+>WC$<2#"J.U2T44 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %(RJZE6 *D8(/>EHH \>^)$.I>%[W3]7M0\NF02DSQ
M*?X3QD^N.:GAN([N".YAD$D4JAT<=P:].U33+;5].FL;I \4JE2"/6O#_#,4
M^B:EJWA:Z)+Z=-NA)[Q-T_#_ !H ZF+J:I^,!GP/J7_7JU7(NIKF/B3XBBTS
MPV-,C*O=WL>W;_<CSRQ^O04 >'V'_'X?]PUU!C<@!YXU4=!NSC\!7)V[F.]3
M'\7RFN_UR&&"6S$<-K#FTC8B-MQ)(Y)]Z:$Y6T,AU56&UP_N!BD9BQR3DT?Q
M>HJ13&"/E)]S2'<8(V;H./6N_P#@WY,?BN]1V7S)$C9 >O#<XK@B[-[#TKJO
MA</^+DV'^Z:=Q6/IJBBBD,**** "BBB@ HHHH #6)>7:3K@G" _E[_6MHUQ_
MC*'4]/T2YO=$2%[B,[RDHS\O? [T =)8VGD$R$89ACZ"KM?/OA;XF:]I3W<F
MK2QW,:$%HYI"K."?X!TXKW?3-1@U;38+ZW.8YD# 9!Q['%.P7+=%%%( HHHH
M **** "BBB@ HHHH **** "BBB@ K$\2>+=&\)VB7&KW8BWG$<:C<[_116W7
MS%\8[R:Z^(UY'(Y*6\<<<:D\*-N3C\2:SJ2Y5<Z\'AU7J<KV/43\<_">?]7J
M!_[8C_&D_P"%Z>%/^>6H?]^1_C7SC17/[:1[7]F4//[SZ._X7IX4_P">6H?]
M^1_C1_PO3PI_SRU#_OR/\:^<:*/;2#^S*'G]Y]()\<O"3. RWZ _Q&#./R-=
M[I&L6&NZ='?Z;<I<6TG1T/0]P1V/M7QE7M'[/UW-]JUJSWGR-D<H3L&R1G\O
MY"M(56W9G)B\!3ITG.'0]SJM<WB6TB1^5+([@L%C3=P,<_J*LUBZ[!KYDMY]
M ;3/.4,DBWXDVE3@Y&SG.1WKI1XC+]AJ-MJ4<K6[DF&4PRJPP4<=5(]>1^=+
M-J-G;W0M99U6<IY@3G.WGG]#^597A/2M3TNTOGU>2T>\O+Q[E_LF[RUW # W
M<]JEOM%EN]2N[Q)RADLA;1@.0-V7Y8#J/G'Y&G97"[L;*NK*&!&",@TU)8Y(
MA)'(KQGHRG(_.N9_X1F[0QR1RPM/]L,TCR.Q!3 &-N.3C..F.N:5/#\R>'K?
M38!:$V]P6:(2LL<JY/#$#(/(..>119=Q79TD$\5S!'/"X>.10R,.X/>D^T0F
MY-OY@\X()"O?:3C/Y@UQ$_A;5+2T;%PLVVWCAC5)F4[@JJ4QCE>">N?;-6QX
M5U *6\RV92^XVIE?R]NYCY>[&=HSGIU[4[+N%WV.QHS7&+X8U![AK66Y9[5(
M8GW,[ -*6 < YSC8F/JU++X1OD@V6EU&H+;GC:1]L@$CD D@X 5@.G:E9=PN
M^QV$DB1(SR.J(HR68X IV1C.>*X^?P=<36LT9G21I5D1S+([;U,:A%/T9<]/
M>M?6=,N[_1(K.U^SQ.-H=6)V@ =%..QQCCM19=QW9IRW=O##/*\R!( 3*<YV
M8&>?3BI001D'BN;M/#MQ;Z?JUNQMS+?0J#,"V6?RPI+<=,C.?>J,GA75C'=H
M+N"0S/\ >DD;YUW$\C;PPR #SP.U%EW%=]CK)[RWM719I51I,[0>^.34^:XT
M>%-3-RLLES \BK_Q\&1RYRJC;C&, J>>^>W-5-6\.:I:67^B 7/G,//0,[;C
MOD;<1]&4?4#L*?*NX7?8[VBJVGHT6FVL;1M$RPHI1FW%2 .">_UJS4%!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C_CZW&G?%C1KU!@
M:E9O;R?[3+T_I^5>P5Y/\6>/%O@YNXN)!^@H EBZFO'/B42?&%SDDX@BQ_WS
M7L<?4UX[\2_^1PN/^N$/_H- '"1?\?T7^]7=7EU<:@T+?9DB$42Q (F 0O<D
M]ZX6+_C^B_WA7:O$"FZ1SP,\+S^IIHEVZE6E52W09I*L12*B8V_-G[U"5PDV
MEH1"-B/?^==5\+1_Q<BQ]D:N:DD!(( &/2NG^%HS\1[/_KF:&$6WN?2U%%%(
MH**** "BBB@ HHHH *C>-74JP!![&I** .&UOX9:-J]U]HVM"W5D3&UOK7(C
M1/%/P\NY+S1':^TX<R6<A/W?;_&O9\4QXED7#*"*:;0FKF#X2\7V/BS3OM$
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MI-W&E8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>CZ??*XGM(BSH$9P@#%0<[<]<<=*$T%F82^*YFOVA%J-^1 (#( /-#,"=_\
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M&%'04ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $(!H50J@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML_E)"C2KNC4(-S>[;^#S5=K'Q%'%.T<MVLLTL<DS!PV!Y6"(QD8PXY'I4?\
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M6.,<_A6&/%^F 2-*MU J Y::$J,X#8Y[D$$?6EC\6Z;,R+$+ARV,E8B0K$L
MI/0$E2!19A=&[161I?B"WU3[*BP7$,T]LMSY<J8VJ>F3_A6O0U8=PHHHI %%
M%% #7C23;O16VG<N1G!]1[TZBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG)YZT3Z+8W-_]LFC9I#MRN\[&*_=)7H2*T**+L5C)/AO3#G]R^?+6-3YC90
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MA.P^;J31[&/<?M7V/J[_ (2KP[_T'M+_ / R/_&C_A*O#O\ T'M+_P# R/\
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M+[1LF-PQFE$3D9V\$9_"C^T)_P H?ZHX>U_;NWHO\SZ?_P"$@T7_ *#&G_\
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5X.54J,<]Z;112N-12U04444#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>image_027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $S ;(# 2(  A$! Q$!_\0
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ML4,DDNU2QDV?.<?+Z\9_.DG\6WEG=WR3VUO(L<EO% D,I)W2+G)..5Z\@>U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8.@HH'044 /HHHH
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M*"#(A^4A/F SD')P,CVJ&\N-9E359+:XU2)8[E?(@DM7+N &W ,J\*QQCKC
M)ZUWX4#H*6L#4@M6D>UA:5#'(44LA.2IQR,]ZGHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** &#H**!T%% #Z*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CF_P!4U25'
M-_JFJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** &#H**!T%% #Z*** "BBB@ HHHH **** "BBB@
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MMDZ?9'=FSMSNY;,2\GWX]ZECMX8F9HH41F^\54 GZT 34444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 -'044@Z"B@!]%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1S?ZIJDJ
M.;_5-4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 -'044@Z"B@!]%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 13?ZIJEJM=RQP6DTTC82-2
MS''0#DUSO_"P_#A_Y?'_ ._+?X5<:<Y_"KDRG&.[.JHKE?\ A8?AS_G\?_OR
MW^%'_"P_#G_/Z_\ WY;_  J_J]7^5D>UAW.JHKE?^%A^'/\ G]?_ +\M_A1_
MPL/PY_S^/_WY;_"CZO5_E8>UAW.JHKE?^%A^'/\ G\?_ +\M_A1_PL/PY_S^
M/_WY;_"CZO5_E8>UAW.JHK"TGQ5I.N7;6MC<-)*J%R"A7CIW^M;M92C*+M)6
M-%)-70M%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP3WI&\3ZW! QF"L@N-C3PQ@CA"Q1.QYP!GGMUK9U/7+[3]:_=V[3VGV>)FB
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M[-L_^?6'_OV*/[-L_P#GUA_[]BK=%')'L'/+N4_[-LO^?6#_ +]BK04*  ,
M= *=2?C5**6R$Y-[L6BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 T=!12#H** 'T444 %%%% !111F@ HHHH **** "BBB@ HHHH ****
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MFX_Y^)O^^S1]IN/^?B;_ +[-144<]3N'LH=D2_:KC_GXF_[[-'VFX_Y^)?\
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M1#1?^?9O^_C?XT?\(AHO_/LW_?QO\:WLT9H^K4?Y4'UFM_._O,'_ (1#1O\
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M*UU&-+<&1&QB%IW!:=0.6X]\_D<=*Z.@ HHHH :.@HI!T%% #Z*** "BBB@
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M,34K)XLE9-I"LK;3R,$$X/![\51TCPXFDWDEQYJGADC")M^4G/S'/)& !T
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J !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1CH****0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>image_028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %? G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.>:.V@D
MFE;;'&I9C["@#@OB5J;RQVF@6S8DNG#2X[(/6O+-0N$O-9;R_P#CTLE\B$>N
M.I_G6QKFN23RZEKKG][.YMK1?0=R/P%<]:P"*W4,>G+'U->S@:'-45]HZ_,X
M,34M#3=CGD.UI",(HY-:?A^S2*)]8NTR0"R(?3L/Q[?0U5M[&;5[J"S@^2-V
M^=O]D=?RKHM;2.&.*SCPD8PS>P'3/TY_.M,PJNK-4HDX6GR1<V8$SN=\DC%I
MIVW,W?'_ ->H WH?TITLL$DI8-CL #T'I3"5[2?F,U[V&I*C34$>76J>TFY"
M/O([M44KO# S%< "I"Y7^$D>JYK)OM0$CB)<F-3SN&,FMY2>RW(IT^>5C.=+
MD1O*[ ;CD@4MO(P4FKJ,DF%*,0W3C-/O;+R(U2%'+-UR.E9U))0Y7LCKK75E
M$IM-YG. 2.Q%2;_.7$;E6'\/K4'V65>2C9]J<T,BE6VD'\J\^\24I=41M)(#
MAB>/6@/D=3^=372[D#N K^GK57D"J331G).+'$YK-U*XR/)4_P"]4EY?B ;5
M!9SZ=JRC,&))5R37'B:ZMR)G30HMOG8^W@:XN$B7JQQ727$;S)'! A\N/CFM
M7P7X=$D$NJSKB-4/E[AU:K^CZ>&+LPW$-R:\V52*4H'H1B[J1Q[V[Q-M=2#2
MK&<UZ'>>'([]XX4*HTA 5ST&?6M,?!76< K?6+ ^C-_\37 ]#I1YK91G[7#_
M +PKMKY-\1'M6C)\)=9TY#=R3VK1P_.VUSG _"J5P,QT@.:TW28Y[MU*#[WI
M7=6FBVUI) Z1C?CKBL?1(0;HG'\5=E)'AH/I4C->Q&%%<)XDCW^*)S_LK7>6
M?W16/J'A#5]1U62]M[=6A<#!,BC]": .>M( ,5L6\? JEJ:-X<D":G!/%GD,
ML>Y3]".*S_\ A/?#UMQ)+<Y]H&H Z7RQ1Y=<S_PLKPUG"M=G_MB176>&KG3_
M !5"7TZ[C,@^]#(VUQ^% $/ET>7[5U \*SG_ ):1?]]'_"G#PI-WEB_[Z/\
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M;YC_ #_I^5;NHW,^K7L<?+3W#JP4_P (SA%/_ LGZ&NUB\ 6*PQAYY=P4 X
MKAPU6-.?M)ZG15@YQY$>.K;SI)P6(]*'BN-_+E%_.O9QX"TSO+,?Q%2+X$T9
M>JRM_P "KU7FT>B.18%=6>$7-I?3_*L\B)WP!DU7.BSN IEE/M@&OH,>"=$'
M_+!_^^JHZOX#MI[3&F2?9IUY&_YE;V/I4QS6[LM/,V^KJ$=$>,6VFIIT9/,D
MIZ ]!^E4Y+"X,AD+_>Z@UTNLZ1K>CRE+V*2-<\.@^5OH:P98Q+\TI9R/4UWN
MA7K)/G5O+4X/;TH2=XNYG31Q0<O+AA_"'SFJLMZS+MCC ]V%:BVL&W_5+3TM
MX0YQ&O3TJHX)_:E<B6*71'/"">=N S&KL&E<9G.?]E:V0 !@ "EQQD*3]!FN
MN-"G37--_P"1RRJ3GI$Y+4-!9-TD.73J1W%-\.^'Y-5U5(-I" Y<XZ"O4M)\
M"ZGJ4)O+_.G:8J[WDD'[QE']U?\ &IDAL],$KV<'E(>%!.6Q[GUKYK&UJ'M/
MW'_ OY'M8:G5Y/WI1URYBT^PBTVT 4!<8%)X.DM[B/4[7(,T2A_H.G]:RWL=
M1U475S;6\DQC&254D*/>HOAW;W$'B/4(9 <S6C#GN=P->?+W5R]>IUK5W.NA
MD^SW,0D^[@,OTS7L.G7"W6G6\RG(9!7DFJ6A:+2&089U*G_OLBN^\&:K:W&G
M'3!,/M=F2LD1X(!)(/TYJY).BI=;B3]]HU=?.- OC_TR->'RC]U7NFL6\EWH
M]U;PC,DD9503WKR>_P#"NL6ML\\UH5BC&6;<.!^=<YH9.A)^^_X%77SK^\A_
MW:Y?0E_>#_>/\ZZJYPLD1/0+FD!HVG05U^F?\>$=<UI]A/<6T<\2%HW&Y2.X
MKJ+&-HK1$<88#D4 %Y8VVH6S6]W DT3=5<9KR7Q?\(@PDNM'^=>IA/WA]/6O
M8J* /C+6M(GTJ4I+$ZONVA2.<U%8:Q=:)<)/;L1,ISN!(Q^5?3_COPQ:ZK:Q
MW@L%FGB;YF5?F*G^=>*:UX DF<M8+O4#.WO0!I>%/B->76I*JW$L<YZ*SEE/
MM@]:]GT;Q?;7P6*\ MYSQD_=8_TKY'O=.NM-N2"KQNA^A!KHO#7C:YL[T1ZG
M))/;O@,Y.2OO0!]=T444 %%%% '*ZYXR:PUH:'H^DSZQJ_EB62"*01I"AZ&2
M1N%S^/\ *K6AZWK5]?O::QX9FTMA$9$F6Y2XB?! V[EP0W.<$=C7/>"V,?C'
MQW;N8UU4WJRIYHZPE/W1]2H]O6KNCZ]XC7X@/X:ULZ5(G]EF_66RAD0Y\T1A
M3N<^Y_*M&ELC-/J=I17EGA#PQI?CCPH_B+7UDGU2_EG;SVE8-9A9&55CP?EV
MA0?YU?\ !WB?Q%/X%T6Y30[C6I9(I%DN8[J*/.R5T&?,8$DJH.?>DX#4B[XH
M\9>(O#4=W>-X2CN-,@D5%NO[352X9@JG9L)'+"MS0=2UZ_DG&L^'X]*5 #&R
MWRW'F'G(P%&,<?G6)\37DE^&-Y)+$89&:T9XBP)0F>+(R.#CIQ47C4-JOC#P
MQX:N))4TR]-Q-=(CE?M'EH"(R1@XYR13230KM,[NJ.M:C_8^@ZCJ?E>;]CMI
M+CR]VW?L4MC.#C..M<(VGQ>"_B'IMIX=MV6UU*QN6FTV.3"-)$H9&7<<*S$[
M<YQ6IKFJ:MJ'@GQ.FH^'I]+1=*N2KRW,4N\^6W&$8X_&ERZH?,:'@KQ<GC#2
M9;HV;65S!+Y4ULTF_;P&4AL#(*D'.*HZW\08M)\;Z;X;BT]KEKF2*.>X$NT6
M[2$[!C!W$A2>HXKG-,NX?!VO:+JEPXATO7-$B2X<]%N((@RL?JF1[D5F?9II
M%\)Z_>1[+W7/$B7K@]4C*D1)] @'YU?*K^1/,['M-%>=^*TTC5_%<FGMH6H>
M([^"V1I+1;A8[:V4DX8[F5=[?B< =*YF66ZG^ VK03/-&]OJ(MXQ+)YCPJMW
M&%7=DYV].O:I4+E.=CTKQEKMUX=T$7UI'"\IN8(<2@E</(%/0CG!KH*\Q\9>
M%].\,>!I5TV*1IY[ZS:>6:9F:=Q,OS,23R23D@?RIWA6Z>_C\1>*M2+/XELE
MF@:P<<6"J"5C0=PV =_\7/O1RKENA<SO9GIE9EYKEK8Z[IFD2I*;C45F:%E
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M?G7H%%6YW=R5#2Q1T;3(=%T6RTRW'[JUA6)3ZX&,_CUJ]116984444 %%%%
M!1110 4444 %%%% !5>^NX["PGNY2!'#&7;\!5BN)^)6I_9]%AT]' >\D^;G
M'R+R?S.!0!QMWJ4,-A/=7I9YKR3!B3EI QRVWWP:CU6\UO5;82:UJ*^'M' P
MEK&W[Z1?PYK.NKFZA+75A+#96T"".34;@9VG&=D0[GGMSS7!ZE?B[N2R23S%
MCS/<-EW]\?PB@#<O-0M;YX='T:V-OIZR#.>7E;IN8UTND"R?7&:]D$=C:J(
M?<?>Q]6S7):%;FVCDOBO$49*\?>/W?ZY_"NO\/V]U;Z=&!IGVS?EB[QE@#6M
M*FYSM_P/S(G+E5SJO[3\%V_*PF3_ ("S5)'XNT"/BTTR1CVV05FK>ZU%\MOH
M2)]+8?X5*EYXO;_4V31_[L:K_2NUX:*[?.2,?:^OW,T/^$S9SMM_#]\Y[?NZ
M#KOB.89M_"D^#T+\54\WQT_"QS#ZO_\ 7JC/8_$>=C@D*>F9 /ZUA.,(=%][
M9I%N7?[C9%QXVN%+)HMI;@#),L@&*Q/^$@\03730'6-*M\?>93D+^(JJ_A;X
M@W(*R742@\$&4FLRX\":_;MF[UG3K5O1YE6L^9>11VK>&_$]R@:7Q9;*K#/[
MNJ[^!;TY:3Q@=WN>/YUSMCX)UB\)AM_$-G.RCE8[D,0/H*N_\*OUN08DU>)?
MHS56O\R%\@N-)OM-C$LFK6MY%D@@/\PY]*;#)9QL)1<I'*.0P?!!^M5;GX5:
MD)_)74XI?EWD9([XJE-\+Y8>9C=DYQE'!!^@%0^3O^ US=CT'1_'UM"RVVJ7
M43#HLX89_P"!"MQO''AY?^8C&WTYKR)?!.B6Y O[;5RHZ\K6[I_@SP/-&-L-
MZK>CDY_3-9OEZ%*_4ZC6?%GA"_AQ=785U'R2J,,O^?2N0/B;1HW91J,$L8.
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MU KUKPQ-HFNZ.+Z**&6*5R4,L8#8Z<@\T >9KI_C5[+[.OB%?*4Y7;<?,?\
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M #<6A)Q[D=JW=.\:>'M80)%?1HS#F.;Y3_A0!2\,^/H;T+;Z@VR0<>8>"/\
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MH!5_PGX.>SN7\2>)9!<:M("^&Y6W7V]P/RH \\O-(U&]\5VL6NR;]0OF665
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MK&_X2_PS_P!#%I/_ (&Q_P#Q5'_"7^&?^ABTG_P-C_\ BJ+,+HV:*QO^$O\
M#/\ T,6D_P#@;'_\51_PE_AG_H8M)_\  V/_ .*HLPNC9HK&_P"$O\,_]#%I
M/_@;'_\ %4?\)?X9_P"ABTG_ ,#8_P#XJBS"Z-FBL;_A+_#/_0Q:3_X&Q_\
MQ5'_  E_AG_H8M)_\#8__BJ+,+HV:*QO^$O\,_\ 0Q:3_P"!L?\ \51_PE_A
MG_H8M)_\#8__ (JBS"Z-FBL;_A+_  S_ -#%I/\ X&Q__%4?\)?X9_Z&+2?_
M  -C_P#BJ+,+HV:*QO\ A+_#/_0Q:3_X&Q__ !5'_"7^&?\ H8M)_P# V/\
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M^ABTG_P-C_\ BJ+,+HV:*QO^$O\ #/\ T,6D_P#@;'_\51_PE_AG_H8M)_\
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M+@GJ>YS7I'_"7>&1_P S%I'_ (&Q_P#Q5%F%T;-%8W_"7^&?^ABTG_P-C_\
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MSUVLH8 ^^"*2=P:L5****H04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !113MC[-^T[<XW8XH ;2@$@D \=:GLK*:_N!#"O/5F/ 4=R3V%:T>I)
M8S)8Z9 MS&QVS%TR;D^GL/3\Z38TC!HK1UJTM[+4GBMGW)@$H3DQD]5)[XK.
MIK43T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** 'K#(XRL
M;D>H4TTJ1U!'.*Z&XEOCK$%C9WDEM'Y:!0CE57Y1R0.O\Z?K'EZC8>=9W-K(
ML'[VX6.-T+2/PS_,.^!P/RJ;CL<U1115""BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **FM;2YOKF.VM+>6XN)#A(HD+LQ] !R:C=&C=D=2KJ<,K#!!]#0
MVK5AJ$^G7'G0$<C:Z,,JZGJ".XJK10!T-IJFD07'VJ)+NQG*E66)$F0@]0 Q
M''YTV?5]-CNI+V&WFO+V1BYFNPJJ&/?8I(/YU@44K#N2W%Q-=W#SSR-)+(<L
MS=2:BHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H'7GI110!J:AK
MD]WY45N#:6D*[8H(F.!ZDGN3ZU1^V77_ #\S?]]FH:*5@N2M=7#J5:>5E/4%
MR0:BHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6]/
MNUL[DO)&9(G1HY%!P2K @X/8\\54HH U5N["QAG^PM<S33QF(M-&J!%/7@,V
MXGUXJM;7Z6D.([.W>?/^NE7>1]%/R_F#5.BE8=S2_M[4CQ+<>?'_ ,\IE#QC
MZ*1A?PQ4)OE2]AN[:VBMY(F#A4+%2P.0<$D_K40LKIK)KU;:8VBN(VG$9\L.
M1D*6Z9QVHM[*ZNTF>VMIIE@0R2F.,L(T'5FQT'N:- U-&.[TFWNQ?PI=&4'>
MELRKL5O=\Y(_X"/K60S%V+,<DG)I**+!<****8@HJ>ULKJ^=TM+::X:-#(ZQ
M1ERJ#JQQT [FH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** ._P#@^6'C*X*+*T@TZXV+"V)"VW^$X.&].#7=ZEX6L/$PM)[NPFGU:./2
MUN89I7-S!"S%9//((W,57)<JI (X'?P6BLY0N[IEJ=E:Q[II?@K2(M2M;BQT
M]K/[/K,EO+,\UPDDD?GR(GD2I)MX"A64@.,$YZ$Y$GA3P])I#&33@+F72;^^
M:\:>5G62&8A3C=@C'7(.<#ISGR*BER/N/G78]DU7PEX4L/$.G:='X:UF:#[3
M@W4<,GE7D/D,WROYI\QMP#8C"$C< ,XS3UCP-86>A>(BFGV4=[I[M)]I/VC[
M/Y6R,A(R9"8Y1N!*2ALE\ D#CR>BGR/N+F78]P\.:98^)OAOX9\.WS*BLLVH
M)(Q( 6*[991D<Y,<C8_W>V*D\2VEKXMG&NKHQU6^_L>SDM-,W.N8Y;F8,V(V
M#?(H49S@;LG->%T4O9ZWN/GTM8^A=&\+:%H.LR2Z#9"ZA>/4HYK\SN_V9DP%
MAX.WH6X(+'KG -8]OX=\/:)XE\/KI^DZD9/MUDUMJRPL;:<,H+!I3(RL222-
MJ)C&.1S7B5%'LWW#G78T=?\ ^1CU3_K[E_\ 0S6=116IF%%%% !1110 4444
M %%%% !7=?"G_D9=0_[!-U_Z!7"T4I*ZL-.SN>U1^"/"EQ=O9R:<MJD"Z7(U
MP+B7<_GMB13EBH!XQ@ @D\] +>J>&K2_\.V.ES:$;6XMK'67LK!'E+B998O+
M(!8LQ*_-@Y!SD#!%>%45GR/N7SKL>U:QX#T.SM=46RT6(75K;1W'FW;SO;A1
M"K2+OCD!1R22-V5;&!WQ#XIT;0[*7Q/JLOA.S^SV2:>UD$,T,,ZRC$C#8X!]
M,K@9&3DYSXW10H/N'.NQZ9XM\.>'O#LNBR::BR?VK?B]MI3*Q\JS(3;&03@_
M,S<GG"\FNH\6V$FI>+O$3:OIFLSZ;86-S=VPOKJ7[))*@0KY04)M&-P(#'(/
M45XQJ6KWVKM;-?3"4VUNEM#A%4)&OW5 4#ID^]4J?(^K#G78][T?P?HFF>([
M'4-+T@7$YO[)GB^T2$6$3P%S(/FS@N#R^X'&T<FL?7O">B_9]5O'TT/;MI]W
M>OK/G.-EX)F"P<-Y8YPNTC<=W'(KQRBER.][ASJVQ[+?>#_#TNK>)M+T_0[>
MVDTT_NKJXDN)($01%V\UEE!C8\E78;,)CD]72^#O",6MZ/I:Z)J4L-Q=6R1Z
MD(Y!;72-%N8>=YI5B>2-BIC!'8FO&**?(^X<Z['L47A+PQ?Z5&ZZ/':R7&GZ
ME*)5GF;RGMI-L; %\'(/S Y!P,!><V;CP3X43Q;I6BIH&I""2ZV?;F21+>ZB
M^SLW$OFL&?< V5"#&1CBO%**.1]PYUV/9=+T+1)O#[W]GX9LYKJ_T*6XCLSY
MLV)(Y]F8\N7!((S@Y^48(R<\I\0_#EEHT.E76G6*65K<JZB*82BY+KM#%]SL
MC+T*O'A3N/H#7"T4U%IWN)R35K!1115D!1110 4444 %%%% !1110!]'3>);
M7_A:,?APM=W5R;]9U,Z 16BBT/RQ'<3\V<GA1R>#UKE="\ Z+<^&-.NK[35E
MDF;3I/M$0F5'6:Y6-XR_FE6;:3D*B[<CD]:\;HK+V=MF:<]]T>PR>%/#0LI;
M]=$B'D6FJOY/VB;:[6TL:QLWSYY#$, 0#DXQQBX_@GPI:&>\_L*_U'?):EM.
ML$EN)+>.2#>64"56 +9^=BP&,8KQ*BGR/N'.NQ[3H^B:9IWA'4;S2M,=[:[\
M,W,CZK),2QE+G,!4'8" H/ SQUZU@VPUH?#/0CX6W^69;K^V#!MV[MWR_:,\
M>7Y?]_Y<=:\THHY!<Y[]J.B6.LZ]<PWZ32P2ZQIT,D(N)%C939J3E58#/'WL
M9]ZP8O#^CKH5W>VEM)IXGTC4?-2"ZFVL8;B-$9AO^;Y6.5/RD]A7C]%)4WW'
MSKL>RMX!T[_A);JVB\/)_9]K%FV?=-/+J*DPCS%19DSC>Q+JP3#]"5JI\2=*
MM=#'A73=.@22V@O;P0P3N"A!F0A&9C]WG&2>G4]Z\EHIJ#O=L.96V/?KZS75
M+Q[W4=+FGN;S3+]X-#U=3)+;SHJ\0;2&,;8PH !&TE<;CC(B^'^@RV"WMUI;
M6=M)ING2--YLBK%-)-MN,%F/(!P0<[>.F:\8HI>S:V8<Z['T1)HT%MX6GT\:
M;+I4-O)JGEPPW,R%E5#L8DON(8 '!.UNN,$5RFH^%/"UB=,MUT#6+R*5[-H[
M^U0B*Z# %T,K3;"6S@!50@C&3G->144*FUU!S3Z'4>/M%AT'Q*;6WCMHH7A2
M6..%)D*JW($B2LSH_J"?2N7HHK1*R(>K"BBBF(**** "BBB@#[*_X0KPI_T+
M&B_^ $7_ ,31_P (5X4_Z%C1?_ "+_XFMVBO,YGW/0LC"_X0KPI_T+&B_P#@
M!%_\31_PA7A3_H6-%_\  "+_ .)K=HHYGW"R,+_A"O"G_0L:+_X 1?\ Q-'_
M  A7A3_H6-%_\ (O_B:W:*.9]PLC"_X0KPI_T+&B_P#@!%_\31_PA7A3_H6-
M%_\  "+_ .)K=HHYGW"R,+_A"O"G_0L:+_X 1?\ Q-'_  A7A3_H6-%_\ (O
M_B:W:*.9]PLC"_X0KPI_T+&B_P#@!%_\31_PA7A3_H6-%_\  "+_ .)K=HHY
MGW"R,+_A"O"G_0L:+_X 1?\ Q-'_  A7A3_H6-%_\ (O_B:W:*.9]PLC"_X0
MKPI_T+&B_P#@!%_\31_PA7A3_H6-%_\  "+_ .)K=HHYGW"R,+_A"O"G_0L:
M+_X 1?\ Q-'_  A7A3_H6-%_\ (O_B:W:*.9]PLC"_X0KPI_T+&B_P#@!%_\
M31_PA7A3_H6-%_\  "+_ .)K=HHYGW"R,+_A"O"G_0L:+_X 1?\ Q-'_  A7
MA3_H6-%_\ (O_B:W:*.9]PLC"_X0KPI_T+&B_P#@!%_\31_PA7A3_H6-%_\
M "+_ .)K=HHYGW"R,+_A"O"G_0L:+_X 1?\ Q-'_  A7A3_H6-%_\ (O_B:W
M:*.9]PLC"_X0KPI_T+&B_P#@!%_\31_PA7A3_H6-%_\  "+_ .)K=HHYGW"R
M,+_A"O"G_0L:+_X 1?\ Q-'_  A7A3_H6-%_\ (O_B:W:*.9]PLC"_X0KPI_
MT+&B_P#@!%_\31_PA7A3_H6-%_\  "+_ .)K=HHYGW"R,+_A"O"G_0L:+_X
M1?\ Q-'_  A7A3_H6-%_\ (O_B:W:*.9]PLC"_X0KPI_T+&B_P#@!%_\31_P
MA7A3_H6-%_\  "+_ .)K=HHYGW"R,+_A"O"G_0L:+_X 1?\ Q-'_  A7A3_H
M6-%_\ (O_B:W:*.9]PLC"_X0KPI_T+&B_P#@!%_\31_PA7A3_H6-%_\  "+_
M .)K=HHYGW"R,+_A"O"G_0L:+_X 1?\ Q-'_  A7A3_H6-%_\ (O_B:W:*.9
M]PLC"_X0KPI_T+&B_P#@!%_\31_PA7A3_H6-%_\  "+_ .)K=HHYGW"R,+_A
M"O"G_0L:+_X 1?\ Q-'_  A7A3_H6-%_\ (O_B:W:*.9]PLC"_X0KPI_T+&B
M_P#@!%_\31_PA7A3_H6-%_\  "+_ .)K=HHYGW"R,+_A"O"G_0L:+_X 1?\
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M-K QKU;=N#;]_P##T[^A8+G0T54TN&2VTBR@E7;)' B.N<X(4 BK=(84444
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MC"2)&QP6S@&1.W.3Z4:AH5H?#^K".=);L#S7@WE;J0F4+.7D;H-A*?+A?IG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BN0_P"%H^"?^AAM?R;_  H_X6CX)_Z&&U_)
MO\*KDEV)YH]SKZ*Y#_A:/@G_ *&&U_)O\*/^%H^"?^AAM?R;_"CDEV#FCW.O
MHKD/^%H^"?\ H8;7\F_PH_X6CX)_Z&&U_)O\*.278.:/<Z^BN0_X6CX)_P"A
MAM?R;_"E_P"%H^"?^AAM?R;_  HY9=@YEW.NK/U(ZB'B^PC*[)-^-N=V!L^]
MVSFL'_A:/@G_ *&&U_)O\*I7OQ+\+RR1?9O$UDD8(+ [P20P/]WD8!&,CK1R
MR[#NCI89=72?:\#/$SKAI"F53)W9VGKC'3(P/6I[K^TQ:7'D>29MX\D(,';N
M&<[N,XKBH/B1HF5$_BS3BNP!F1&SG>"3RF/N[A^7UI%^)&CY4MXKT[KR K<C
M'KY?7_/-+E?8+G8P7&J_;4BFM46!G<>9U(4="<' )_K42SZQ'?(C0;XG?#%@
MI"C<<E2".-N/O<^U<I)\1=#>VD'_  E=B)?-W1$!QA>>"=G/;M5B+XE>&CM,
MGB6T^6Y)QA@3%@@ X7&>A_PHLQG2+-K@2(O;QDX&\#;ZD'^+DX /&.M31S:H
M;8M-;H)04(2(CIOPPY./NC.>.M<=:?$30XP4N/%E@\8@V+A7W;_4G:/\_G37
M\?>'1Y8A\56@Q"$9VDE//S9.T@Y^\ISG/RXX%%F.S.L6ZUW$>^PA!.-^UP=O
MT^89_P \TMO-KICQ-;0 A.&)!+-M[X.!DXKF)?B+X?\ L4,</BJR6=$*LY5B
M';(P3E#VW'ZD=:6#XE: +U3/XEL3 7=B%5N%P-H^Z#G)/X"BS#E?8Z^;[?+;
MV[Q;X9>?-C&P_P )QUS_ ! =#T/Y06\VM$[9K:!0 !OSDD[@"< _W<G_ #BN
M1;XAZ.RR+_PEE@ 0VT@,"/E./X/7'/;WI]S\0]#:XE>U\4V*(Z*%#AVVL,9X
MV<<9_/I2'RR['6&;6/[/CD^RQ"Z\SYHE8$;<'U/KCO4EW-JJ3,+:VBDCR0I.
M,_=!!^\.I)'MBN1E^)6A/J#"/Q':);@#!VG!Z9_A)]::/B'HS10[_%5CO5E,
M@4, P#,3SLZXV#\Z!\DNQULUYJ(O+F*&SWI'CRR5QNRA.<D@?>P/SI@N=;^S
MSO\ 88O,4#RDW#YCWR=W&/ZURD?Q$T9)DDG\36,R([-Y<>Y-PVD 'Y.>2#UX
MQWXJS_PL7P\;_>?$]D+7?G8JMDKCI]SCG&>?RZ4![.?9G1RSZT)9/+M8F0%@
M@R!N&X;<_-_=R:<MQK'V:X9[.'SEV^2BOD-_>SS7)2>/]$!=H/%=F&+<;PS#
M;N<]-G!P5''I]*DG\?>&Y<-_PDUJ6$4:D!Y4#,&RYX'&1QT)^E _93_E?W'5
M^=JAB#?9D5Q*PV9'*;3CG/\ >P/Z4V5]6>!"D:I(0X; 7@[AM."QQQGH3_AR
MMK\0-!BD=IO%-FX,(15PYVL ,'.WU+9_#\(V^(.E@*%\5V!X^8E#G.3T&STQ
M^-*Z#V-3^5_<==%/K!M9VDLX5F4+Y2!L[C_%GFD^TZP<_P"A1KAL=0V1\O/W
MQ_M?EVKF9/B)H4MK"8_$ME%/L)D!0D!B0<?=/ &X?E44?Q#TH7*A_$M@T0*;
MC@C(R=V!LR#C'7UZCH"Z'[&I_*_N9U N==R=UC!C/0,#QD?[7IG\JL,^IOJ*
MH(TCM%DY<8)9=I]_7'88]ZY.T^(&B126_G^*+)XE4^:NUB2><8.WZ=?>JQ\;
M:-*LWF^++=6<@J8Y'&"$8=D&!N*G _G1S(?L*O\ *_N9UOVO6E@\U["/*X+1
MJ<EA\V<88\\*._)JQ,VIB7;$L94QKEL# ;#9QDYZ[0/K7(_\)_I/EN!XJL-V
MYBG[ML8RN ?E]-WXXY-/MO'^AK<PO<>)[.2-0=ZJ&&3\W^Q_N_K2YEW#ZO6_
ME?W,ZBTFU1KO%U;!( A *LI+-D8)Y],FG1RZF);@/ C1JLAB.1ECN^4=?3^5
M<D/'^E+O;_A);!F(P,[@!]_G'E^Z'\#3K+X@:+%>'[5XCM'A8;CMW'!  P/E
M& >3[8'/)HYH]Q_5JW\C^YG023Z^RMMM$1MC@!=IYXVGEOKQT^O2G>;KJ/Q;
MHX^;@[?08_B'?/Y]ZYB#Q_IK&,R^)K%4*KO&"74\;L?)CU_/\:>WC[3&CX\4
M6"ON8\*Q&,+M'*=CN_,4<\>X_JU?^1_<_P#(ZSS]2:TE4P!;H*K)M VG(&1R
M>N=P_"HI)M;CF*Q6T,L?SD,S $?,=HZ\\8_.N5_X3O3]C'_A*M/\TK@'8V!R
M.VWTS_GD6#X]T1A.I\36A5XI F%8;').TC"YP!CN>?6CGCW#ZK7_ )']S_R.
MH635")P\,0*N@B9#]]=WS$@GCCM37EU;RK=DMXQ(4?S5)& P^[CGOC'7OS7+
M_P#"=:.KHJ>*+7R@W)8$MMW'_8Z[=O)[@^N:0^.='>U5'\3VGF[9 S+N7JN%
M/"=C2YX]Q_5,1_(_N?\ D=&LVNJ$3[- _P @W2$@'.T=@?7(_P *=+-KFV<1
MVT P6$9SRW("GKQP2?PQ7+OX\L#]SQ/IX(]5;G@?['KD_P"%2R>.=%DMXE/B
M:U$NQA(R;E!)8$$?+V (H]I'N'U/$?\ /N7W/_(ZJZ?4@ ;:)#A%.&QDMSD'
MGH,+^?6J+7'B)8'9;.)I V40LOS [NIW=OE_Q/-8=MX\TD31M<^)+)D5E)5
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M$#+++O16W@R*ZG!W=A(<?0=><RS90OT_$NR^(+:&".&7PY!$K2Q7*@JJAT5
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4IM.=VD=G<EF8Y)/<TVI-%>VI_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>image_029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#)?Q'8)XKC\-GS?M\EH;P?)\GEAMO7USVK6KSRX_P"3@;3_ +%]
MO_1QKGM L/$OBGPIJNJW'B_4K9[2YNELH[<A0"CL09#C+CMC@ 4 >R45Y+J'
MB;7M5^''A363)?0VETP.L7&F1YG2, C<HP2 6')'2EU_66T_X7-J'A;Q5=:C
MNU"!8+JXD#O&"Z@QL< D>H//- 'K-9=EK:WNN:CI8L;V)K((3<2PE8I=PS\C
M?Q8[UP.NVVN^![G1=</B;4-2^T7\5KJ%M<%?)=9#C,: ?)@] *M?VUJ?_"2_
M$>W^W3>38:?#):)NXA8PR$E?0Y /X4 >D45YAX,T_6KSPA;>*-8\97L<]SIY
MX.P6\"%>'*D<N,9))ZFL./Q';Z5XF\.OH?BS6M8COKY;6[2]5F@E1@?F1B@
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MA?)87EMJ$@DYD^[(AP-I!'3I7J% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR6!!P.,;3Z]12YJ9I[/&OJ_O*J?#?PHG72(6_P!XG_&K*>!/#$?W-%M1_P
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MAQ)-DG.__P#7V-=QYT7_ #T3_OH?Y[4G85F/HIGG1?\ /1/^^A1YT7_/1/\
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M="F,_IBK"#<>+%XP.X8+_(TEM%+<0P332LLJCY@ ,;NA[59^SCC,DI]BW6I
MB#O"T0RS;VP48Y(]\U;IB11Q_=4 ^O?\Z?0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!\,4445ZAYP4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7<_!_\ Y*?I
M7TD_] -<-7<_!_\ Y*?I7TD_] -1/X65#XD?5U%%%><=X4444 %%%% !6 VB
M7"M=W4<F;EIVDA7=M4*64D9 SDA<5OT5,HJ6YM2K2IWY>IS@T6^N'22ZF<'<
MI*I<. %WN6'&,\%1^%)IVGZDFJJTS/MA* RM,Q#KY>"H7H>><^U=)14^S6YN
M\94:<6E]Q&4?)/FG&>F!1Y<G_/8_]\BI**T..[(_+D_Y['_OD57NK2ZG,)AO
MW@V2!WVHIWKS\O/U'Y5<HI6*4VG=&7KL"SV.)5F:!<M(L7)QCT[_ $K@;^UB
MN+I'LO$CQ)&GRQRLRD=N0?\ "O3IU9[>15^\5('UQ7/VZK_:5Y+?6S*CD;!+
M#N Y/0\U<78@\[_L:02,\5_9%CU)(Y_*E?1]1:)@E[:*AYW+(W_ZJ[S41HZL
MH6VM.>=WD?X"J%ZNC1V<<T=K;B<2HQ,<>.XR:V4M-@.6LM)O()UFBU*QA=.1
M-O&1]">];%O80W6IPSZEKHN[EAMBCA7+Y]MO'YUT.D1Z/+8)/+%;22NS,S20
MY/4^U::+#-/;I9VP1$D$C.D6U2,&HE.X%^VMTCMH@\:;P@W':.N.:L445D 5
M!,/])MCZ,W_H)J>J]S(L4D+OG:&.2!G'!H +W_CWZX^=?YBK%9M]J=I%&J//
M&I8C&6'/-3KJ=HZAEG0@D@88<XIV EMO]0/JW\S4U0VG-JA((SD\CWJ:D 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?#%;6C>$?
M$'B&VDN=(TJ>\AC?RW>/& V <<GT(K%KZ#^ 7_(H:I_V$/\ VFM>A4DXQNCA
MIQ4G9GE'_"LO&W_0MWG_ ([_ (T?\*R\;?\ 0MWG_CO^-?5U%<_UB78Z/8Q/
ME'_A67C;_H6[S_QW_&C_ (5EXV_Z%N\_\=_QKZNHH^L2[![&)\H_\*R\;?\
M0MWG_CO^-'_"LO&W_0MWG_CO^-?5U%'UB78/8Q/E'_A67C;_ *%N\_\ '?\
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M-3^\*JT4 6O-3^\*/-3^\*JT4 6O-3^\*/-3^\*JT4 6O-3^\*/-3^\*JT4
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M'5:%!;S7.F&]WQR?-&1,B8'_ 'T>:U+7Q.\_BI=)"0202>:J31%\JT8!*L2
M">><=*T(O#>BP-,T6EVR&<%9"$^\"P8CZ9 ./6IH=%TRWOVOX;&%+MBQ,JCG
M+?>^F>_K0!SQO;Z3QGK$1?4VM;-8C&(956!,P[B''4DGG\J@MO&DD4VFV$L,
M0:YTZ.^%S//\JQ>46?><?>R...1D]J[!;6W62XD6% ]QCSF YDP,#/X<54.@
MZ28O*.G6Y3Y?E*9^ZNQ?P"\8]* .67Q=J][<VL%K%9QN-1AMY6<.%ECDC+C
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MH **** "BBB@ HHHH **** "BBB@ HHHH L0?ZO\:EJ*#_5_C4M 'PQ7T'\
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M&([<?ZO.1EL^U27UEXO^S:E;2WNJ:A;2"_M!%-&F'C$68GR /F+' /X4 >J
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M%>K?"[XC:)X-T"]LM32Z:6:Z\Y?)C##;L ]?45Y317I2BI*S.",G%W1]'_\
M"]/"?_/+4?\ OR/\:/\ A>GA/_GEJ/\ WY'^-?.%%9>P@:>VD?1__"]/"?\
MSRU'_OR/\:C/QM\&FX6X-K?&95*"0P#<%)!(SGIP/RKYTHH]A /;2/H[_A>G
MA/\ YY:C_P!^1_C2_P#"]/">,>5J./\ KB/\:^<**/80#VTCZ/\ ^%Z>$_\
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M_P#/+4O^_(_QK0T#XG^&?%/B.TT^SM[K[<X<1230@;1C+<YXR!7S!7<_!_\
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MA61@0RMR"#U!%$=KY4:1QJB1HH5548"@= !V%6J* *_DOZC\Z/)?U'YU8HH
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M_G'_ /$UZ[11[6?</9Q['D7_  SWX=_Z"VJ_G'_\31_PSWX=_P"@MJOYQ_\
MQ->NT4>UGW#V<>QY%_PSWX=_Z"VJ_G'_ /$T?\,]^'?^@MJOYQ__ !->NT4>
MUGW#V<>QY%_PSWX=_P"@MJOYQ_\ Q-'_  SWX=_Z"VJ_G'_\37KM%'M9]P]G
M'L>1?\,]^'?^@MJOYQ__ !-'_#/?AW_H+:K^<?\ \37KM%'M9]P]G'L>1?\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,C_A*O#O\
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M><]*!:2&,.+=BA. 0N><X_G4^S1:C<^Q/^$H\/\ _0=TS_P+C_QI?^$H\/\
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M;0,@=!TIRZM?J01<OP,#ITP1_(FBBES/N/V5.UN5?<22:YJ,DQE^TLIW[P%
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&222LC__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>image_030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %? G # 2(  A$! Q$!_\0
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M&QPP[USDK7VD'R[E?/MN@:KME>*XW6<H]3"Y_E6<J=O>B=%/%IOV=1:]GO\
M\'Y"R1R6SE)0<=C25>-_:SKY5TIB;MN''X&JDD*Q O%(LL7^R>E92A?IJ>OA
ML:H>[)WCWZKU&44<$9'2BL3VD[ZH****!A1110 4444 >?4445]:?A 4444
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M5]O)?U^)DQ^'K18@DKS3$?Q.U12>&;49:WEDC;T)W TS4M6+!#;2R*I)P8V
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MV?E8&PJ4+9]<\5@;0V63(Q]X$<5W5I9/'\))--F<*P\51VSL#T_=LI-;.O\
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MTK;V_P!(;C_QRK<H]P2/-64,I4]ZS)XC&YXXKU]?@1XR YDTK_P(;_XBDE^
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M_P#LM/\ ^%.^)O\ GII__?YO_B:Y*L*LI-\I]#@:N6TJ,8RKI^5[?I?\3S\
M*  , 45Z#_PIWQ-_STT__O\ -_\ $T?\*=\3?\]-/_[_ #?_ !-8?5ZO\K/9
M6;Y>E958_?\ \ \^HKT'_A3OB;_GII__ '^;_P")H_X4[XF_YZ:?_P!_F_\
MB:/J]7^5C_MC ?\ /Z/W_P# //J*]!_X4[XF_P">FG_]_F_^)H_X4[XF_P">
MFG_]_F_^)H^KU?Y6']L8#_G]'[_^ >?45Z#_ ,*=\3?\]-/_ ._S?_$T?\*=
M\3?\]-/_ ._S?_$T?5ZO\K#^V,!_S^C]_P#P#SZBO0?^%.^)O^>FG_\ ?YO_
M (FC_A3OB;_GII__ '^;_P")H^KU?Y6']L8#_G]'[_\ @'GU%>@_\*=\3?\
M/33_ /O\W_Q-'_"G?$W_ #TT_P#[_-_\31]7J_RL/[8P'_/Z/W_\ \^HKT'_
M (4[XF_YZ:?_ -_F_P#B:/\ A3OB;_GII_\ W^;_ .)H^KU?Y6']L8#_ )_1
M^_\ X!Y]17H/_"G?$W_/33_^_P W_P 31_PIWQ-_STT__O\ -_\ $T?5ZO\
M*P_MC ?\_H_?_P  \^HKT'_A3OB;_GII_P#W^;_XFC_A3OB;_GII_P#W^;_X
MFCZO5_E8?VQ@/^?T?O\ ^ >?45Z#_P *=\3?\]-/_P"_S?\ Q-'_  IWQ-_S
MTT__ +_-_P#$T?5ZO\K#^V,!_P _H_?_ , ]YHHHKZ _'PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG?/?[6H_]EJE_P -+VG_ $*\_P#X&#_XBO%_$?WA]:P* /H?_AI>T_Z%>?\
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M.U\*MS&F9&A>#.X[5^90Y*YQP":]?HHH **** "BBB@#QKXPG'B331ZVC?\
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M<.>_/ KSW0O!>M:K:ZEI\^GS6=S-$&6\N%:-8MMSY@@(Q\P;).Y2V.*]UHH
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MJ=Q%]MN%M/-149=G,65Y#$\-@/GCG/TH [&BN'EL?%L-O&D=[<R*P4RN2C2
MYD'R]!CB,G\?>GW6E^(Y4?S;N\D#2B1EBE5" DZ%0GIE W&3VH [6BL?0UU)
M)K\7XE*>=F!Y7!)4]L#@ <#/?VK8H **** "BBB@ HHHH **** "BBB@ HHH
MH I7^IPZ>\2RJQ,H<C;_ +*EC^@K&F\8VT<9E\B541AN1@-[*8V<$#/0[>#T
M-;6HV-AJ$"Q:A!#-$&W 2@8!Z?UJO_8VBY8_8[4F5L'(!W$ KC\B1CZT 41X
MN@-W!:"RN1<O,(GC.W,>6 R>>1R#QT%/U#Q3%I]_-:?V?=S&(X,D87;GRS(1
MR1_""?THN_#>CWFL6^J%S'<1/A3$ZJ&?.3GC.>,'!&0,5IRV>GRR-)+# SR'
M)9@,L2NW]5./I0!DMXQLC=O:PP333$JL*H5_>DYXSGC&#UQ4*>*W6>:"XM7B
M?[2T4+E<JX#JI'!SD;Q[5>N-'\/Q6EW<RV-KY.TF9E3/"G)Z>A':I!#HC311
M>3;E@C7"';P!N7<V>G4+^5 &;_PG%D(%=K.[61\-'$57<Z%2VX8/HIXZ]*N:
MOXA329K5Y$S;S1,V,?,6R@4>W+\YJS)H^CS*D+V=L?E4JH !PN0N/89/YTYD
MTK5XIA(D-Q'"6@<NO ^Z2,_]\]/2@#*D\;6$0!>VN 3 \VT!=P*C)4C.0<=,
M\&G7/BU(7GA:SGAECRNZ0 KO 1BO!SP''MUJ^-$T,R*_V.U+F+8"0"2F,?B,
M8&:FDL=+N&9I(+:1F)D8D YR I/Y*!^% &/+XVM(87=K*Z#[=\2':#*OS\CG
M_8;@\GCUJUJ^O2Z9_9TBVCRQW D>5%QO15C+\9('&*;JWAK1-8MHUF"1)!A@
M\)48'S8SD$8^9B/?FK4]IHNI1"UN?L]T+)@I$KAFC8C R>Q(/?KF@"@WC.Q\
MV9(X99!&$8.I7:58XW$Y^4 ]<T#QC:2SO!:VMS/)YABAV 8E8;MV"3@8VL>>
MH%7I-#T)Y)=]E:;YF D& -QSG'Y\XHN-&T4,RS6,'^E2 L"G#,,D'VZ'F@"H
M?%$5KH6F7][&=]XB,RQD#;G&2 3D@%ATS56'QK$@*75M(63S3*\(&U I8C@G
M/(4<],G%:LUGH5R;2QEBLW,*;[>$XRJ*0"5'H"!^0JH/"VB-K)U)0/,FC*F)
M678ZD$$8QD@Y)QG&>: (YO%R*)HA93QW$$;O,'"D1;2!S@\YW#&*AC\73B>)
MKG37BMV$F\JP8H%E$88G/0YZ8S6G:V>@[9K.WM[8+%^XD7;Q\V&VY[YX-/2S
MT4WL]HEO;F=U,LJA,Y#-DD]N6 .* *$?C&!Y0ITV^5&V[7VJ=P8L%P <DDJ1
MCZ59N-?*>'4U:UM//9Y(T\@2 '+2!""?49Z?A4\-OHMW C0)9RQ,=B%"""5)
MX'T);]:E&G:8E@VF?9X!:[23 <8QG.<?7G- $-EKL-YJ+6@MYH\^8(Y6QMD,
M;!7 P<\$]^M:M4+6PTNUO)+FVAMX[B907=,989QG\_SJ6;4;2W2X>68*MNNZ
M0GMP3^)X/ H M44R.:.89C<-P#@=0#R,BGT %%%% 'F_Q-7=/;_]<3_.O(E&
M&D'O7L/Q(&;B#_K@?YUY!_RVD'O3&:7AB)(Y)I<?.S8S["NWMGZ5P&AW&VZD
MBST.:[>TDR!0!N6,R2S/&AR\9 88Z$\UKZ5J%MJ(N/LKEUMYC [8^4N.N#WQ
MG&?7-<?JM^NG6>Y)5@GO'6 3M]V+@Y<_0 X]3BM'P=K6FQV\&AVS7$C0,\<4
MHMWV.@)(8OC&2#^)S751>EA,[=.*9=WEO9Q"2YGCA0D*"[8R3T J.>;RC N[
M8)95BWXSM)SCCZX'XUY?\0K.Y6[+2S2R,A^4L>GT]*TY;IOL*YZ-<WTQ^6WC
M4?[<O] *Y_5YM06!F^VR%L=$ 4?D*L:'J0U?0;2\S\[IMD]G'!_6GWL?F0$5
MQ3;;&?.GC"*8^*#>2@;K@_,0,98<9^O2M*Q_X]_PK8\<Z5NRZK\R-O6L>Q_X
M]_PJ0.8\2=1]:YVNB\2=1]:YV@ HHHH *]K_ &;/^1JUG_KQ'_H8KQ2O:_V;
M/^1JUG_KQ'_H8H ^E**1F5$+L0%49)/85%;W4-R&\IB2O4%2#@]#@]C0!-16
M=KNJG1-%N-0%L]R80N(48 N2P7 )^M9Q\8Z>NH20,&%LELD_VGJ&9RH" =2?
MF4_C0!T5%89\7:*$5S=G8T!N%;RVPR# .#CDC(XJ>?Q%IEM \TT[(J$JP,39
M!"!\8QG[I!H U:*PY/%NC12O$]RXE0#='Y+[LG'RXQG=\R\=>:;_ ,)EH@MV
MF:YD1 0 )('4M]X< C)QM;..F#0!O45S]QXRTF&"26(W%P$Q@0P.=_S*#M.,
M-C<,X]:T;;5[2[E:.$RL4F,#'RFP' )()QVP?QH OT5A7_B:/3]3NK6>V*QV
M]OY^\OAI>.B+CYO0G/!_.G0>(0L\UOJ5H]G/$8LA6\U=LA(0[@..5(YH VZ*
MS-5UNUT>6U6[;9'<,RB0]%(7/ZU3T;Q5:ZM,L)BD@DD(\K<I*OF,/C=C&[!)
MQUP* -^BL36?$]GHMRT%R#O^SF:,9^^=V-H]ZK3^);Q=,N=3MM*6:RB+;':Y
M"-(%;:3C:<<@XY_*@#I**RM5U>32='2\FMH_-:2.,QF<*BL[!>7(Z#/7%9\'
MBW[1;27::?(MK;P"6Y=Y &0E=P55Q\W&.<CJ* .EHK#@\1A)I8-3M'LYD6-\
M*WFKLD)522!QRI!S^=6=<U8:-8+<^4DA:58@))1&H+'J6(.!0!IT5S47B[SH
MDNETV5;-6BCN)'<!HG<*0-F,D#>N3QUZ&MNWOH[VWEDM07:-F0HX*$..QR..
MU %JBN;L_&%J<+JB1V,KNRH@E\W(#%<DA1C)4@>M2IXRT5XWD\Z=$1"Y9[:1
M1C:&[KR2I! ZD&@#?HK#;Q=HJ.B279CD<D%'C960@XPP(RIR,#/6FW/B[2[:
MU$Y^T$O;O<Q)Y#AI%52QQD=< GZ4 ;U%9,GB33(;=IIY9(E0$NKQ,&7$?F$$
M8SG:<TZV\0Z;=ZB-/CG(NRN[RG1E88 )!R." 02.O- &I1110 4444 %%%%
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MD?,#GN?SJ-/#VEQIL6VPO/&]O[AC]?[I(H 6QU[3M2OI;2UF\R2-2Q(4X(!
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MB%757==@;>3E3Q@'OBM%_B7K4VIWT%M8V$2V=D]Q)#,6,C,(!(%4AAN.XX(
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M962)@2<$[0&( /7MQ0!ZE17&^$O%VH>(FU#SM/6/^S4$%RD8.XW8+;T7)QM
M"XS_ 'NM:6KW^I>;I$=E'-"US(WG1XCWA0N<9;(_+GTH Z"BN&;Q-?6C3R&\
M6[+F[46ZQ M R2E(ON\D'@8/)[5:.MZC/X2BN4NHX+Z"?RKII%6(MLSNVA^
M6&" ?6@#KZ*XZ\\27<1EDAN8Q&^F1W,<4D8$D)9E!9QGG ;..!Q523Q-J4,-
MPWG-=+9\AX8UW72_: G '&< CCC- '>45B:'JDVHW=XKLC1A()8]AW!0Z9(S
M@9Y'ZUMT %%%% 'GOQ&_U\'_ %Q/\Z\>/^OE^M>P_$?_ %\'_7$_SKQ[_EM+
M]:8RM8?\AD5V[+F( ]"*XG3_ /D,BNY(_=CZ4 5=*<QRM$3RK8KMK"3" DXQ
MSFN$SY.H(_9Q@_45V.GN'B /((KTL%K<B1K:?%:V,<B:;;QP^?(9)&5>7<]S
MZ_4UII"8@69\L1S56S"QHH48P ,]ZMR/\M:R5G9 1DY;%6$X&*JAL'-3(XQD
MG '4FO.J[EHF-<5XQ^(VG>&U>UMU%[J./]4K?)'_ +Q_H*H>*_'6\2:?HTO'
M*R7*_P E_P :\9UQO(8L3EW/&>I]ZQ I>+-?N_$<[7U\L0N,A3Y2[1CM7+UI
M7:E;3)ZDC-9M(04444 %>U_LV?\ (U:S_P!>(_\ 0Q7BE>U_LV?\C5K/_7B/
M_0Q0!]*4444 4M6OGTW3GN8X!.X=$6,OL!+.%&3@X^]Z5SC^.)H85,ND$2R'
M$2)<;@WS.IR=O',9QUSD=*Z]E5QAE##.<$9J)[2VD0I);Q.AZJR @\Y_GS0!
MR$OC&XEOX1'"((/F5X]ZO-N#QJ<ICY?O'')S5I_&@CMK*9[6%OM3CY(KG>R1
MDJ Q^7&<L,KG\372_9+82&3[/%YAQEM@R<=.?P%-^PVG'^BP<,7'[L<,>I^O
MO0!S\OB&XLO#VG7\RF:22-WD5<+O*QLV/;I5>;QC=6UU-Y^GQ+#;V\[3(DY9
MS)&ZC"_*,C#9[8_#GK#!$R!#$A4=%*C I&MH&;<T,9//)0=^OYT <ROC*40S
M7%QI?D6UJBR74CS_ '$+E2P&WY@ I;MQ40\<3-YH71908PHPTP&&;:0#QP"'
M'//TKJEM+9(C$EO$L97:4"  CTQZ4&UMS)YAMXC)M"[M@S@=!GTH Y9O%EXT
M\X>VBABBCC+!)=\F_P"T-$X *@%?EZ\=:$\;2RH/)TV.1VC\]0+K@1[&?YCM
MX?"G*X.,CFNJ-M 6#&",L,X.P9'.?Y\TB6MO&"$MXE!)8X0#)/4_C0 MM.MU
M:PW" A945P#UP1FI:0 *H50 !P .U+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 1S00W";)XHY4SG:ZAA^M5-0T73M3TV;3[FU
M0VTRE75!M//7!'(J_10!#]DM_)6'R(C$IR$*# /KBG-;P.SLT,;,Z[6)4$L/
M0^HJ2B@",6\(D+B&,.5VEMHSCT^E"V\"Q&)88Q&1@J%&#^%/5E<95@PZ9!S2
MT 1/;02!@\$;!L%@R YQTS6/%X0T:+Q VMK;R&\9S+\TSE%<KM+A"=H8J,9Q
M6[2*RNH96#*>X.: (TMK>, )!&N.F$ QQC^5"VMNBJJP1*JL& "  $=#]:EI
MCS11NB/(BM(<(&8 L>N!ZT (+>!00(8P&;><*.6]?K[U6@TFSM]6N]4CC/VN
M[2..5RQ.53.T =!]X]/6KM% $9MX6B$1AC,8Z(5&/RI/LT!*GR8\J  =@X .
M0*EHH C-O"<9ACXSCY1QGK^=(;: E"88\QC"'8/E'MZ5+10!2T[2K/2EN5M(
MRGVFX>YE)8L7D;J23^'Y5<*@D$@$CH?2EHH C6W@1F988U+MN8A0,GU/O0\$
M4BE7B1@3DAE!R?6I** (C;0&8S&",RD;2^P9(],TS[#;">.80('C0QH0,87(
M.,?4"K%% $,%I!;22O#$J-,P9R.Y P/TJ:BB@ HHHH \]^(_^O@_ZXG^=>/#
M_72_6O8/B/\ Z^#_ *XG^=>/C_6R_6F,@T[_ )#-=WC]V/I7"Z;_ ,AFN]Q^
M['TI 9MXAV;QU0[A70Z/-OB4Y[5CRIG(J?0Y#&3$W\#8KT,#+W[$R.VMWXJT
MS96LZU;.*N2N%3D@ #DFNZHK,E"-*%!9F"J!DDG  KR;QG\1#J4KZ5H\I6S4
M[99U.#-[#_9_G5'XE^-KJZC@T_36VZ7<;PURC?Z\J<,H] #^=>?6SX(KQ:DK
MO0LZZSD!CYZ5B6T">(_%,4$DOEVID5"_HN<9I;F],&G.%/SR?*/ZUC6TDMO*
MLL3%2ISFLP.A^*'AU?#>N36D2XMR08O=<<&N KM-<GN==TT7=S/)/<!=C.[9
M.5Z?I7%T %%%% !7M?[-G_(U:S_UXC_T,5XI7M?[-G_(U:S_ ->(_P#0Q0!]
M(S.T<$CHA=E4D(/XCCI533KN6Z\S?M8+@AU4@9/5>>XJ]10!D>)S=CP_<?8?
M-^T%HU7RF*M@R*#@CIQGGM6&]]XAT]H],W":<1_*QA>0R;M_(?('R84'(R?;
M(KJ[V]@L+5KBX8A%(&%4L22<  #DDD@8K-_X2O1QM#7#JY3>4,+AE4$@DC'
M!&#GIWH YZ/Q'XBCA@C2WAG8622-))"ZF5]AW$ >C  CW/3BIKG4]>6ZDCE<
M;8XYHPL5NZB9U9"&#;B5^5C]=IK:D\6Z-',R-<. A</)Y3>6NW.<MC'\)QZT
M0>+-(N)HHHIY&:0A>(6PA+;0&.,*21CF@#F[[6=9OS=QQPSQ)"9#&T<3(V/+
MD&UADY(*@_B*Z#1=7O[V744NH%46#>0QC0YDD&6)7GIM*?B32CQ?I;7$<2F<
MJ3*))#"P6'RU#'><<#!S4MEKVES726MLLR7$SL6B-LZL#@$LX(XR&4Y/7(H
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M\?G1=(>VEU1I)/-::2:SPZS;EV1.HC)*!21N  )S\PKV--Q1=V-V!G'K3J*
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M[GS#D73 ,^TA7&T CG!P?2M*3PY//HD^G3R&1#>1S1AYG)" H2-V<]0QZ]Z
M+]OX<TR"=9XXY"RN)(]TC$1\DX4'H,L3C_ 4/X=TOR/*>(^7A4P7(Z%B!^<C
M?G6./#^LW$WE7=R?LB2#_5W3AI$WR-SC!'#H,9_AJ%_#&IW%G)%?;;J;-O(L
MINY%SY90F/ X'W6^;ONH V;7PSHZ6\D<*F1'RCGS2V<,N1]04'Y4_P#X1?30
ML0 F A<M%^]/[L'&47T7@<>U8TOA[7&O&D2Z 4R,T3BX<>0I=R5V]&W*RC)Z
M8J]:Z-J5EI-_:Q3B1I8X_*\Z9VPVP"0EB<C)R: -*[T:"]OQ<REL>4(V0<;M
MKAU.?8@_G55])TB&:YN3<21R)&$N'^T,"/E&&8YSNVXY]*R+7PUK<<-N[Z@Z
MW,(18V-P[!5WRELCHQVL@Y'\-.MO#.H+X;UFRD$:W%\JA,W#R9(C522Y&1D@
MGVS0!N2Z9:7-N=.N;J:67S/M6?-(D4[]P(QT / '3C%0'PEI&T*L,B?+L8I*
MP++C!4G/(.!GUK$_X1G5PXE+*\7(:U^U."8][$1^;][@D-^&.E'_  C?B(*P
M.H;YO+VFX^T.-Z[ /*V]!\P)W]>: -F/PUHTQD:$2920A#',W[AMVY@G/R_-
MR<5;;0;$V%K9J)8TM6W0NDA#H>1][KR"0?K69:Z!=Q^')]/)\AYKOSBL=PY*
MQF0,5W_>)V@C\:HR>'-:^UW<ANY)H&FW" W3(LL63A<@94KQSGG'O0!M1^'=
M(>Y-Q&A9A(3(JRDJSABPW#/)!8XSTS0WA_2[6 22F0101*I+RG 5"64GZ9//
MI67-X=U61KN073!FC80(+EPHS)DCCU3Y=W44V[T+6;A9;>(QQ6<L7W&N7<I^
MY9-G(^8;B#F@"?4_!EE>264MO<&V:#:$/WN54*I&>X ]QZBI]4\.Q:YH4-G]
MO>55G\\3.=^\_-QP>@W<8]!66?#&K37S3W31R1I=PSI$MPX4["X)'I\K+QW*
MFD/AK7RI47N)-C!9Q<N,*4(\O;T^\0V[K0!JCPOI/FO%-+*]U- 5D;S-K.OR
MAFP.!G:N>U7KKP]IMZ(%GB=HX(C#''YC;0I7;Z]<$C-9MCI%W9Z];Y+M;0_:
M&1V=GVHXCPN6Y)W*YKIJ .>'@_3Q=QRF2X:-0V^-YF/FLS*V6.>1E!QTIUEX
M2L;2U"%I)IU!"RRL6QD., 9X'SMQ[UOT4 4])TV+1](M-.@),=O$L8+=3@=3
M]:N444 %%%% !1110!GZHNK-''_9,MG&X)+_ &J-F##' &TC'/?FL32_$+#Q
M1KUAJ&J0/%:_9A"-JIL9P0R^I^;'4GK6YJ^K6^BZ>UY<)*Z*0H2)=SL3Z#O@
M9/T!I@U+2/MKP">W^T93< !G+$;>?4Y'YB@#B+3QKJBQWTUK+#JMN]Y)%9M/
MB)@D<+.Y8(O0LA"Y&2.:WM*\6SWFC:C>7=G';2VACP [,K"1$=<G&>-X!^E:
M$7B'0?/NHDN(%,"H\C!, A\[<''.?:C5/$.GZ5;V\K1-/#=(SJT&P@H "3R1
MG@C@9)["@##A\=7$OV<FR@!:)7>(3'S"2TBY08P5'EY)ST-1Q^+[Z\:SE5$"
M'[WV5MZON$1 !*]1O((_R.A;4/#XN)P9[;SFVV\@'4_> 4?FW3WHAUO1(HQ!
M;7%N4@81E48 1@ \\]AM/3/2@#(;QG+';64QAM9&N91NBBD8LB$J,$D ;P6Y
M%9]OXPU%+:!I$6X,"&60V[9\SY)/D;(^5@4!..Q%=-/XDT""U-RUU"8Q$;D%
M4R67NPXYJ4^(-$B9U-];HRQB9LG&%(')]\$>_- %-?$=P/"LNKRVT*21R; I
MF!C8;PN[<,X'.?PJC'XNOI+>>;[':B.#:C2F5MC,TIC#@[?]6,;B?2MZ*ZTG
M5($MHI8)HWR5B7_889X]CBJEKXFTJ>&9I"MM#'+]GS*R$,02,84DJ./X@* ,
MH>-+CRKB0V<!^S0ERBR'=.06&Z+(Y3Y<DGL:@D\7:A//91+!!;L9DW@2[FG4
MEO\ 5XR"/EYYR,UT,&NZ=+=30OLA, *AG*X(&[<!CT"$FG'7=#BW?Z;:J(6$
M9P?N$C./;CGVH QX/&4]X8C:6<4J[-\I$A)&(5D91QRV6V_A2Z7XNN+ZYL(Y
M[.&&.Z9E#K+O).T$  9(ZD$GCCWK8U#6+/2IXXGB8Y3S7:,#"*75=Q]LL,^P
M)JL?$FFPRW:?9Y@;0G!6(?O3OV-LYY._@].: *6I>+9[35[JPM[2*8Q1_*2Y
M7#[HQAN.F) <CTI%\57_ )RJUA"4C813E9&R7+R(-@V\C]WGG'WJU+[7;&PU
M=;*:$^:UOY[RY0!8P3URP9L8/"@U"OB6U6XT^*XL+NV_M!RL#2HF#@;@3AB5
MSGC/.?2@#)D\>#[/'+#;Q29>,,H<\@HC, <8W OC'M4%KXIU&S=OM$9NA*R0
M0@_*?.8OM'3H=O7M@>M;$7BG3[J,_8]/NKEEEE CCB0'$9PT@RP&W)&.YSTJ
M]8WFGZX=\<086[I+&6&,[DRKC\&(Y[@T 7;*=KFU65FB8DL"86W+P2.OX<^]
M6*0  8 P*6@ HHHH **** "BBB@#SOXD_P"N@_ZXG^=>/K_K)/K7K_Q*_P!=
M!_UQ/\Z\?4_/)]:8QND_\AFO05'[L?2O/M(_Y#->A+]P?2@"-A43"IV%1$4
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MZ5YWH9SJYKT1?N#Z4P&M49%/=@!R:KO-_=% "L0 <U2>3+$"IB&>HM@4\\T
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M$[11S+$OD*J3.8D9-^.@#;@"/2@#M**\\;Q#K\6I6=E-<%"Z[]WV<#?DD*C
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M/I_P;DL;LSG6E?V\C']:Z(^ I-N!J('_ &S_ /KUVU% '"GX>NW74A_W[_\
MKT@^';?]!$?]^_\ Z]=W10!PA^';G_F)#_OU_P#7J,_#=S_S$Q_WZ_\ KUW]
M% 'GQ^&KG_F)C_OU_P#7JJ/A3*+KSAJXP1@CR?\ Z]>ET4 >1ZI\%6U+0GTU
MM952MU]I@D\C/EY&&&,]ZIP_ B:.V2)M?5BA.#]G['G'7ZU[110._0\9_P"%
M%2?]!Y?_  '_ /KT?\**E_Z#R_\ @/\ _7KV:B@1YUX5^&=QX:N)7_M<3QR8
M^3R<8/YU2\0_!X:UK4^H0ZJ+<38+1^3GYNYZUZE10!XS_P **E_Z#R_^ _\
M]>NJ\"?#I_!FIW=XVI"Z\^$1;1%MQALYZUWE% !1110 4444 %%%% !1110
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MHK/']I@=8R>>H'X?A^M3V_VL2D3E"F."!CG\Z +-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%<M_PLGP7_T,NG?]_A1_PLGP7_T,NG?]_A5<K["NCJ:*Y;_A9/@O
M_H9=._[_  H_X63X+_Z&73O^_P *.5]@NCJ:*Y;_ (63X+_Z&73O^_PH_P"%
MD^"_^AET[_O\*.5]@NCJ:*Y;_A9/@O\ Z&73O^_PH_X63X+_ .AET[_O\*.5
M]@NCJ:*Y;_A9/@O_ *&73O\ O\*/^%D^"_\ H9M._P"_PHY7V"Z.IHKEO^%D
M^"_^AFTW_O\ "C_A9/@O_H9=._[_  I<K[#N=317+?\ "R?!?_0RZ=_W^%'_
M  LCP9_T,NG?]_A19@=317+_ /"R/!G_ $,NG?\ ?X4?\+'\&?\ 0RZ=_P!_
MA19CLSJ**Y?_ (6/X,_Z&33O^_PH_P"%C^#?^ADT[_O\*+,.5]CJ**Y?_A8W
M@W_H9-._[_"E_P"%C>#?^ADT[_O\*0^678Z>BN8_X6-X-_Z&33O^_P */^%B
M^#O^ADT[_O\ "@.278Z>BN8_X6+X._Z&/3O^_P */^%B^#O^ACT__O\ "@?L
MY]F=/17,_P#"Q/!W_0QZ?_W^%'_"Q/!__0QZ?_W^% >SGV?W'345S/\ PL/P
M?_T,>G_]_A1_PL/P?_T,6G_]_12NA^RJ?RO[F=-17,_\+#\(?]#%I_\ W]%+
M_P +"\(?]#%I_P#W]%%T/V-3^5_<SI:*YK_A87A#_H8M/_[^BC_A8/A'_H8;
M#_OZ*.9=P]C5_E?W/_(Z6BN;_P"%@^$?^AAL/^_HH_X6!X1_Z&&P_P"_HHYE
MW'["K_*_N?\ D=)17-_\+ \)?]##8?\ ?T4?\)_X2_Z&"P_[^BES1[A]7J_R
M/[G_ )'245SG_"?^$O\ H8+#_OZ*/^$_\)_]#!8?]_11SQ[C^KUOY']S_P C
MHZ*YS_A/O"?_ $,%A_W]%'_"?>$_^@_8_P#?T4<\>X?5JW\C^Y_Y'1T5SO\
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MG_W\H]K#^9?>'U'%?\^Y?^ O_(WZ*P/^$W\,?]!NS_[^4?\ ";^&/^@W9_\
M?RCVL/YE]X?4<5_S[E_X"_\ (WZ*P/\ A-_#'_0;L_\ OY1_PF_AC_H-V?\
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)WT+C?E7-N?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>image_031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_031.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H H # 2(  A$! Q$!_\0
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M3^ZO>D4F.+;S@<(O>G.#E01@D<+Z"G "-0[@9_A0>M-PQ;<V2[=AU-2:6'C
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M,I!Z_E6LZ+(C(ZAE88(/>LJN#ISC9*QV87-L30GS-W74Y:YL;758=I7>3PI
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MO)%+R_3S#5FRLKV]N5M["PGN9V'"0QEV/X 5KZOX;UW0(HI-7L9[-)251I%
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M%RHR()OF]@PQ_/%>9UO3^$SGN9FJ7MK9[6N)-IZJHY8_054TS6HK_4/)B@<
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M_P")H_X1+Q)_T+VK?^ 4G_Q-?67/PBQCT5L?\(EXD_Z%[5O_  "D_P#B:/\
MA$O$G_0O:M_X!2?_ !-%PL8]%;'_  B7B3_H7M6_\ I/_B:/^$2\2?\ 0O:M
M_P" 4G_Q-%PL8]!Z5L?\(EXD_P"A>U;_ , I/_B:/^$2\2?]"]JW_@%)_P#$
MT7&8U7[1]T>.XJS_ ,(EXE_Z%[5O_ *3_P")J6#PMXECD!_X1[5L'_IRD_\
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M(V;77N*NKVBQJL6^1@ ,*IJI-/+<N&E^51]U ?YU?_X1[6L<:-J _P"W5_\
M"E_X1[6_^@/J'_@*_P#A7F-/HC[JE2HQ:=2HG;S27YZF916E_P ([K?_ $!]
M0_\  5_\*/\ A'=;_P"@/J'_ ("O_A6?)+L>A[>E_.OO7^9FT5I?\([K?_0'
MU#_P%?\ PH_X1W6_^@/J'_@*_P#A1R2[![>E_.OO7^9FT5I?\([K?_0'U#_P
M%?\ PH_X1W6_^@/J'_@*_P#A1R2[![>E_.OO7^9FT5I?\([K?_0'U#_P%?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4[Z:DH:-(H<AV)  );/0#L*FU'P)>R>,I[I;8SZ9/-;21>1<I#]F$6.-I4G
MQD!2/2CECW'S/L=S=Z_IMM#?%+RWGN+.%YI;:.93( HR05SD?C6?>>,+:S\)
M6'B![:0P7A@ CW %/-( R>G&[FN.F\&^)KSQ)->W$%HJ*M]&CQ.B*ZRH1'\H
M4'/3<6)YYK9UGPKJ=]\,=,T&*&WDO;<6OF1ROB-O+*E@3Z<&CECIJ*\M3?OO
M%-A:MI1MW2]CU&]%FDMO(K*C$,<D@]MM:4.I6%S=2VL%[;2W,7^LA256=/J
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M)[]J5]4T^.^6Q>^MENWY6!IE$C?1<YKS-OAIJ!L)+:XBM+R2/P\MA!+(0<7
M<MQD<  @ ^U3ZEX1\37VO6$C0VIMK6>RF65'16Q&!Y@;Y=S-P<'.,4<L>XN9
M]CT--8TR2X%O'J-H\Q;:(UG4L3SQC.<\'\C4PO;4PRS"YA,41*R/Y@VH1U!/
M;'>O,=0\)OH'PYU&]>"W@UFTOY-3AGC7<S,)2R D#)RIVX]ZW[+PNX^%QTBY
MM#=W5Y"9KJ(2^2TDLC;W^;!P03^E)Q7<:DSJX=4TZY1'@O[659%9D*3*P8+]
MXC!Y [^E,EUK2H%C:74[.-9 "A>=0&!Z$<\Y[5YVGA7Q=#%I=T;>RN;N*"\M
M)(WE6,QQRXV,Q5<,P ^; &:P[GPMJS:C'H::/97MVOAJ.T=YY,);L7(WJ<')
M'M@U2@NXG)]CV*75=.@N5MIK^UCN'8*L3S*&+'H "<YIQU*P6_%@U[;"\(R+
M<RKYA'KMSFO(;OPIJ>I^(->TBVL+6X<1Z="VISOM>WV(,NF1DD[3T(YK;?P3
MK#Z\Z&TLS$VM)J8U<R_OA&,'RMN,YXV]<8-+D7<.9]CLM2\7:!I,(ENM5M0#
M*D)"2JQ#,<#(!X&<Y/;!]*V4=)8UDC=71@&5E.00>A!KS&7X?7:^"9K:/3;"
M35O[5-\0Y7]\@G+A2^.,KQ^->EVH86D(>%8&$:YB0Y"''W01V'2IDDMBDWU)
M:***DH**** "BBB@ HHHH **** "BBB@ HHHH **;)(D4;22,%1 69B> !U-
M><W/Q$M/%JG1?"DT_P!LG8K-<O$5%O".&D&>I/1?<T 6=;,?CJ]GTLO)_8%H
M^RX:)]OVJ8?P C^!>_J>.U4K/PCX4\+7AU*146>3"1S7TN_9Z!-W KH[*TM=
M(TV*UMU$5M;I@9/0#J2?7N37EGB?5UU_46=\_8XN(%Y&1W;ZG^5$5S,F4N57
M.YUC1].UM1+/!;WL6/E& 0/<$5R5]\+?#=UDPPW=H3T\I@P'X&L**'R<2V\L
MD+'HT4A4_IUK8L_$6N6H ^VK<*/X;F,-^HP:ET7>Z9PU*4)RYU*47Y/]-C#N
M_A)=VA,VCZXH9>BS Q-^8IL$_P 5_#L@2WFOKJ->@#"X0@?7FNU3QPL:#^T]
M,*IT+V\@8?\ ?+8/\ZZ70]8TK4W9-/D;S54,T;QE& _E2Y9K5[&E*-925ZBD
MO34\VL_CKXCTJ?[/KNC0R.OWAM:"3\CQ^E>D>#/BIH?C"X^QHLEE?D96"<CY
M_P#=8=?I1XB\,Z3XH5(=3L([CRNDF=KKGL".:\F\7>"[+P+J6FZKI%^Z?Z2I
M%O*V70@YW ^G;GUJKG8?2=%(IW(K>HS2TP"BBD8D(2!N(' ]:   #H,4M9^F
MWMQ=,PFC  0$D1LNUCU4YZD>HIVMM,N@ZBUN7$XM93'LSNW;3C&.<YIV%<NX
M!["C:H.<#/TKC#K%]IVE-<0G-M!;!W+1R.6D:3;@%\'@<XQR<4MIXAU>86I7
M;.7 (5;9OWN78-EAPA4!<@]\T^5BYD=EM'H/RHV@,6P,GO7&MKNO0VR">,*S
M*C^<MF[#<T881[0<_>XSV^M3'5/$9E>3R8TC!=O)^SL2 K1C;NSSD.W/^SQW
MHY6',CJ]B_W1R<]*7:H).!D]3BN<T34;^:_%M=AX$"L4C>%B91D_-O/ QTP?
M\*SKW5]9CU6YEBBD86Z2H(%MWVHN^,!R>CG;N( ]Z.4.8[0J"02 2.GM0%4#
M 4 >PKCGUC798U@-KOWQ+<>;'&X!3=MV_P"_G!QZ$T3Z_K*6J/''^]:9TD5K
M9P(" =JD_P 0) ^8?X4<K#F1V.T<\#FC: 20!D]?>LC4[^[MKVQB3]W%*"7D
M$+29<%<1\?=SEOF/]VL>#6=>NBB1H$+@&1VM''DOM<M%@GYL%5&[H<T<H[G7
M[%&,*..G'2C:/05P<NI:IIXN=8G6;,K*=C1OMB7REX [_,Q^IJ[9^(]1>*V4
MK]H>?85=+=L8WR!P<<*0H3(/<T<K%S(Z\JIZ@'OTH*J1R >_(KCY-7UT?8+;
M8YGN;<-*ZVI"HS*QX.3RI &#ZU"NLZQ!:Q./-;?%'NN7M7;<_EYV[!TRW!-'
M*PYCMBH)!(!(Z4%5(P0#^%8.E:AJ\^I[;V )!)YH""(@QE"F,MT.=S?E6_2:
ML-.XA4'&0#CI44]K!<Q&.:)70D$@CK@@C]0*FHI#$VJ1C:,>F*CBMH899I8X
MPLDS!I&'5B!@9_ "I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH .M%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !117.^-/%EIX/\ #TVHW!!E(*P1=W?''X>M &?\3-6AL_!F
MH6,=Y''J-['Y%K#N^>1F(& .OK63X%\(Q^$]#6)]KZA. UU*.[=E'L*\6T_P
MIXG^(6I3>(9KGRXS.%^T3,<O)V1 /3\A7ONIZFGAKP_&\S^=<I&L48/660#&
M3[=S2%<Y_P =:R50:-;-\[@-<D'&%[)]3W]OK7'!%C49/'3':E65IIY+B>1I
M)96+NQ[D]34J9+'&-O;GK73"-D<=2?,R-X8V"[T4A#N7(Z'UI3&6VX.!GGWJ
M5HPXY]<TK(Q7"X'//TJS*XQT"H?D,@/\/6O1O#VEKH^E;W4?:)L,X Z>BUS7
MAO2_MVHAY%_<0X9O<]A7=9\R?/\ #'^K?_6K"I+H=5"/VF-EFCL+.6XG8!(U
M+NQKQ'2()_B3\4(O,!-E$_VB;_9A4\#_ ($<"ND^*WBV*&$>';.0M=RX:<)_
M"OI_GUK6^ ^GQP:!J=Z\8%W-<!7;N$"@JOZD_C6)TGK72BBBJ$%%%(VX(=H!
M;' /K0 M%9VFRWLC/]J5P-HSO0+A^X7'4>].UN*:;0=1BMU9IGM9%C"]2Q4X
MQ[YIV%<N2Q17$31RQI+&W#*X# _441116\:Q0QI'&OW410 /H!7*6\>L16\!
ML8YH8HDC)A^SK&)',F'R"21\O/7WK/F;Q'<,EQ);WR-#.YBV(C.NZ(C!Z KO
MXSC]*?+YBYCOLT5QEO9Z\ETZA9+?SKC,LL84X4L2V,]NE)HNLZG=>*([*_EE
MC:.$!XM@VN^Q2<XY!!R<].0!1RAS':45RETFOI?7+V@D2)9&D5512)?FC !S
MVV[_ ,JDOK?6QJQO8.'2*- D6"D@\TY!W<\*2>*+!<Z>BN-CN/$@5'>.\8"2
M/S8S&JEG^;>%8=(Q\I!/7IWJO;RZ_JL)(-PT32D&1D5-A#2#,9';&WGU_&CE
M#F.ZHKA9O^$@FM(K)+:^>%M/:.4S[278Q'KZ-OP.M:FN7>J1:E96NGF?<UNS
M[(T4J7#H!O)Z+@MG%'*',='+#%/$T4T:21MPR.H(/U!HAAB@B6.&-(XUZ*B@
M ?@*X]6U^YOE>X2_AMXKR-MD>W)4[P1QC*?</XTR-O%*'R522'; FP+&&7H,
M^P8')Y[4<OF',=M17-:=#JJ>($>]DO'@5)HD)QL8!P59P.Y!.#[5%!!K46I3
MHLE[Y)OI96+%2ICV915)Z#=Q18=SJJ0D#J<5QD$OBF>WE9A<PF,221JR(6=@
MJ%4)QTW;AT%,O;;7KV59!%.\EI<2RPF15".?+;9\I[ X /<\\4<HN8[>BN<T
M/^V9KM)+Z6=;98R51XPI+%B,-WR!]*JW$GB<ZO);I&39&0Q"7:O"GY]_T &S
MZFCE"YUN:*X>WTW67>,/)?12+(DH;Y2L8^SD;4ST^;@BM2^&M36VG20HT=RU
MN!.ZJI,;EH]W!XZ;_P J.4+G245QDB^(H'N9U-Y)-]G$<8^78=LS@MCLYC*D
M>M4?[8UQM4:P^T3K<I;,8U\I1O<QL5!'7<#CG@<4^4.8]!HKC-47Q#)/<V4!
MOC +5@)U*@NP4$%2 ,,3D8ITD_B3[3<B-;D0*%V#R@6,7R\C/'F?>R#2Y0YC
ML:*R?#<$]OH<27*RK+OD8B8 /@NQ!('&<$5K5+*04444 %%%% !1110!G:]K
M$.@:%>:M/&\D5K&9&2/&YAZ#-4['Q/;2VD<VI1KIC3;S$D\Z-O55W,05)' [
M=>*G\3Z.WB#PSJ&DI,(6NH3&)"N0OOBN4U+X>W6L^'+;1KF?3;.""9IQ_9]J
M4R^S"'!)[DEO4<5:4;:DN]]#J?\ A*M!^VP6?]K6HN9RHCB,F&;<,KQ[@C'K
M4B>)-%DENXEU.U+VBEYQY@_=@'!)/H#P?0UQ'_"&ZUJGB74OMDEO!827%C-)
M((/FF:%0?W9S\HW#'(X[4Y/A:?L6H64EW 4EBECMKG;(94WR!\,I;9C(P< 9
MI\L>Y-Y=CIE\=>'9-2TZQBU&.634%<P,G*G:<$$]CG^1JVOBK07M;JZ75K4P
M6N/.?S!A,G _,],=:QKOPKJNHW>EWMW>V*W-O'<07 A@94:*4 ?)SD,-O4^M
M8]K\,KBVTL0+=6?VNW:W-M<E)&WB%]RK(K,1@^BXQ1:/<=Y&_#XYLI?"VK>(
M$A:2ST^:6,>4X8S!"/F7H.<U+IOC6PNXK]K^*32Y+!HUG2Y93C>,I@J2#GT'
M-45\%W3^#-;T6>^@-QJD\LS31PE40R$$@+GH,>M4+GX:E;>YMM.O(K>U-Y#?
MV]OL8*DJKM<$J0VUN",'(-%H"O(ZFX\6^'[6&WFFU:U2.Y7="V_.\9QGCWX^
MO%+>^)M,M=.GNHKF*=HTG*1*_,C1*2ZCW&.:\XU3PEK&G:S8+8Z,ES##;I^Z
MA+BWED\\R$.2^X $[LMNR>U;Q^'NH-=S ZI!]B\R^EAC\@[PURK [FS@[2W&
M!TI\L>X<TNQT=CXOT>[BLEEO(8+NZMDN!;,_S*&3?C/<X_E4%GX^\-7NC)JH
MU2*&U:5H@9CM.\=1CZ<_0UBP> -235M(GFUA);736MWCB*,"/+B\LJ!G;@G+
M9()[4V'P%JUE!9?9=2L3-8M=10>=;,R-#.<G<-WWP>XX(X-*T.X7EV.HN?%G
MA^SF$5QJ]HDAB$VTR#[A&0WTQWJ:_P!>L;&QU.Y\P3'3H3+/%$064;=P'U(K
MGM(\ 6VE0ZC!/*+NVNM-@L-IC^?;&KACGWW9 [8%5O"OA._7X<7NGZE(T>JZ
MI')Y\DH!925V)NP>RJO>E:/<=Y&AIWQ"TJY2X&HQRZ5+"D4A2Z*G<DBED*E2
M<Y /'48IVJ?$'1-/EN;>*<7-U%8&_1$/RRIR0 W3) S]*J3^ 1;:':6.B3Q6
M4BLAO&P_^E80K\S [A@G( /M5(?#F\AL8;6'4K<K_8K:3,SPG)^8L'7GCDX(
M/:JM 5Y'4:7XMT35K>WDM]1MF>9UB"+("1(5W;/K@'\JE/B?0UMDN#JEMY,B
M-(CA\AE4[6(^A.*YC4/AW-=0:A]FU&.VN94LOLTJQ?ZF2W!&[KSD$BJ]E\,[
MG2HM133=7\GS(DBLOD(\A-P>520<_.PZC!&:5H]QWEV.O@\3Z'<PM+#JEL\:
MPM<,0_W8U.UF/I@\&M2.1)HDEC8,CJ&5AW!Z5Y7?_#F]BM])LXI6F:;4IC?2
MQ A1:RD.Z-N))Y50#R>:].ELXY9H)-\J>2<JJ.54_4#K2DDMAIOJ4;GQ#:VU
M]<VK07;?98_,GF2$F-!M+<GUP*+;Q%8W$%Q(ZSV[6\/GO'<1%'\OGY@.XX/2
MJUUX:2ZO-6NS)B:\@\F([F 3]V5Y4'!ZYZ54E\,7]^F;Z]B1S%%;$6JLN(E;
M<V">=S$#V %'NAJ:YU^Q&@#6E,K6A4, (SOY.W&WKG/&*237K6"*R>XBNH&O
M)A#'')"=P8G W8S@>YJM:Z%+9:;?V*RQ7D,TQEB6]4R#YL%E?U&[)'UJD?#>
MH0Z5:VMK/:AH[X7C*P81IAMPC0#HM*R"[-)O$VG)>RVS-*OE;P93&?++(-SJ
M&[D $_@:6'Q#;3P3L(Y%FBC5_(? =RT?F!5YY.*R+WPI=W*7D/VJ+[,S7,T*
MA#O\R5&7#'., L3^5$&A7<-_)XA4'[1+;*KV;+D@"(#:O. ^X#GN.*=HBNSJ
M;:XCN[6&YA;=%*@D0^H(R*EJCHMF^GZ'86<AS)!;I&V/4* :O5#+"BBB@""\
MO+?3[*:[NI5B@A4N[MT %?-NJ7NH_%[X@);6[-%IT).PG[L,(/S.??\ K]*W
MOC=XTFNM3B\(::S,0R_:%C/+NW1?PR/Q-==X+\'Q>%]$736"F\F"RZE*OKU6
M$'T'?_Z] F;NGVUCI6EPBV18-.LXMMLIXPO>0^[=?I]:\:\:>,9M3UO=#@PP
M\(K= /\ $]?RKL?B%XKAA(TR.0A,_O=HSD]=OT[G\!7"-9Z-JY+0MY<I/_+,
MX8^Y4U<5?4SE)+?8KVWB>,MBYC9/=?F'^-;5M?VEW@V]PC'TS@_E7.W7A:\C
M#-;.EPH[#AOR-8LL$MM)MFB>-Q_>!!JU)K<S<(2^%GI*R.O!Y^M686\QU7:=
MQ. !SDUYU;:Q>V^-DY=1_#)S^O6O4OAT'UHOJ4]L(XK=MJ'.0[^WTJG-)&?L
M97.YTVS&EZ8D0 ,K<M[L:EOKR#2-*N+RX8"*WC+L3W__ %FN)^)WC*7PYIL=
MO82A-0N,A'ZF->[?7L/QKPHZIJ]_-,DFIW,AD1MWF2%@W?!!KE>NIVI)*R-K
M3;N7Q!XOGEU&0KYKM*[C&X#!8 '\!7NOP:Y\/Z@?6[_]D%>#:1:K&'N-V9'^
M5E]"*]Y^#?'A_4/^OO\ ]D6FAGI%%%%,04444 %5-3NGL=*N[J-59X86D4-T
M) SS5NHYX8[F"2"9 \4BE74]"#U% '-2>*YPEQY5@TGDK&PD'1MTQCV@9SGY
M35ZW\2VT]TL6R1=Z9"E?F5AYFX'M_P LS5O^Q--WAQ:ID#'!.#\V_P!>?FYI
MDV@:5.K+)9H06W$@D'.6/4'U=OSJKQ)U*#>,;-1N%I>M&%+&18QMP%#MW[*<
MU8U+75TS4H$>W=[>2W:626-<E &09//3YJG;2M(BC6!X(55PZJA.-P*;6 ]?
ME&/H*?<:7INIM;W,T"S&-<Q,21\IP<8[C@'!]*- U,]O%43WJ6MM9RSN;A87
MPR@*"&(?KR/E/'6F6_B^U>*U-S;3033KO,?#%%+%03CJ"0>E71H>C6HWBVBB
M!E1PV\CYP25QSQRQX'K2PZ+I#&.6&W7,3/M*NPP226'7D9SQT':CW0U*)\7V
MJ+'))#,@GB22&-E =@P8YZXZ)G'6M*PUFVU!;EH5D58,9WC:2,9SMZ@?7K1-
MH6F3HB26JXC1$0JQ4JJYV@$'(QD_G4D>FV5I]JFCC\MIUQ*^XDX ..O0#)XH
MT#4S8?%ME-Y(^S7:-+A@KH!A"F_>>>!@'WXH'BVP S+#<Q,4WH'09<$97'/5
MAT'J,5/I&B:1:6-JUI$LB"-2DSDL7!0+GGU7MTYZ5+%X>TF*)(DLH]J3+.H8
MEL.OW3R>W8=!1[H:F5)XOC1(6\EM@EVW,I0[(AACCKG=A<_C6G;Z_:W&E7.H
M!)5BM@3(I7G &[CL>*BM]+T&]=KF"VBD\EVC+#=MW G/'0_>89YZD5-IL.D3
M:=+9V.R6U(Q(A9F&&7..>Q!H=@5R"Z\3V=K.\30W#>66$C(F0@4J"QYZ?./U
MI]WKPL]2GM9+.9HXH(I%E0@[VD<HJ >N14,WAO1+0K=RQ;(+9'<JSL5Y*L6;
MG+?<'7(K0NM*L+]S+<0+(SQ^66W$97.1T/8\@]1VHT#4IWFMR#09=1LXD#Q%
M@\-QE6W*2"G&?F)X'UJA>>+F@U*6UCMHV\NWR=TO/G;XUV8]!Y@R?8UKS:%I
MD]E!9R6P,$#^9&H=@0_/S9!R3R>:;>:5HRQRW5W:6X"PM')*R\[#@G)Z_P (
MYZ\4*P.Y7B\0,E@TEU:N]PMV;,QVPW;W'<9QQCUJ#_A,+1HXYA!<I&PW['B^
M=E*;E*C/?WK7ATRQBMH8(X%$43^;&,DX;GYLGDGD\FHSH6F$(#9QX151>O
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M(SO]F,N8E9SEB%QW/O6W4RMT*5^H4445(PHHHH **** "BBB@ HHHH ****
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M2986.W;URP(&>F>13Y&',CN**Y35-?OM.UZZMQL>!X4BM5V<BY;)4$^A&?\
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M^3Y;*9C$'+'.6VYS@@8HY6',CL**:@81J'.6P,GWIU24%%%% !1110 4444
M%%%% !1110 5S6OZ!YNRZL8B90WSQJ?O ]Q[UTM% 'F;Y1VBE4AAU1Q@BGPW
MCV\@CCE4DC/E2'.1[5WU[IMIJ";;F%7/9NC#Z&N0UCP7.,R6;F8 8 SB11Z
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M+B2]Q&H\\B3S!C^Y@\<=JKW1>\;6I:UI^F:A:V]['(AN7VQSF+,>\ D MV.
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MK61[>/S)0.%_'G].U1:?--,DGF$NBMB.1DVEQCKCMSD?A5RB@#*\1H9-#N$
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M R<G\Z?11<=@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!12$@=2!2]: "BBB@ HHHH **** "BBCI0 449R,T4 %%%% !11THZT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4449H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\:^3+V?1R]Q%9V"^5(0T4SY#PYQD$<AL<XK1:7PHF3#;.V73_6Q'@+@-T/\
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M_A)-"_Z#6G?^!2?XU\R0KX>>UB^TF5)U0AA$AP3D]?TQC\:;<IH"Q,+7SW?
M*EU(&>.,>_/]*7MWV-%DU-NW-+[E_F?3O_"2:%_T&M._\"D_QI#XCT(@C^VM
M.Y]+I/\ &OFMU\->;O3SL%F.S8VT#/ ]3Q_DTN/#2DNIE9MC_(R-MW<[0/\
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M@9 Z#I3EU:_4@BY?@8'3I@C^1-%%+F?<?LJ=K<J^XDDUS49)C+]I93OW@*
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#1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>ex15-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% )(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q/%M_<:;X
M<NKJTD\N9-NUL9QD@5D> =;U#6;>]:_G\TQNH0[0, CVJ]X[_P"10O?^ _\
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M<=RI_I6OXI\56'A33?M=X2SN=L,*?>D;T'H/>O";Q/\ A%_B6ZV)*K:WX\L
M]%)'R_D<5I_%V]EN?&S6S,?+MH$5!V&X;B?U_2F\'"56-OA:N2L7.-)W^).Q
ML6WC+Q]XQN)!H-K';6ZG!9%&%^KOW^E374OQ5T&%KN:1;R%!EPJI)@?0 '\J
M],\-:;;Z5X<L+2V151(5)QW)&2?Q-:U<\L1%2M&"L=$</)QO*;N>>^"?B?;^
M(KE-.U&%;2_?B,J?W<I]!GH?:O0J^<OB'9QZ%\0+EK']T-R7*!.-C'DX_$$_
MC7T+8S-<V%O.WWI(E<_4C-&*I1BHSAM(,+5E)RA/=%BBBBN([0HHHH ****
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M ,*ZT#_GE-_W]-'_  KK0/\ GE/_ -_37644>RAV#Z]B?^?C^\Y/_A76@?\
M/*?_ +^FC_A76@?\\IO^_IKK**/90[!]>Q/_ #\?WG)CX=Z "/W4_P#W]-=5
M&BQQJB_=4 "G452BH[(QJUZM6WM)-V[A1115&(4444 %%%% !1110 4444 %
>%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639389504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSPIRA TECHNOLOGIES OXY B.H.N. LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IINN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">11,338,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001837493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Ha-Tidhar St<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ra&#8217;anana<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4366504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ziv Haft<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Ha-Tidhar St<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ra&#8217;anana<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4366504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6230333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Dagi Ben-Noon<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075636236256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Financial Position - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,783<span></span>
</td>
<td class="nump">$ 23,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Deposits</a></td>
<td class="nump">7,120<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">14,494<span></span>
</td>
<td class="nump">24,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Right of use assets, net</a></td>
<td class="nump">1,107<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total Assets</a></td>
<td class="nump">16,012<span></span>
</td>
<td class="nump">25,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade accounts payables</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Other accounts payables</a></td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Financial liabilities at fair value</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">3,215<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">2,064<span></span>
</td>
<td class="nump">4,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">728<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LoanFromTheIsraeliInnovationAuthority', window );">Loan from the Israeli Innovation Authority</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non- current liabilities</a></td>
<td class="nump">1,126<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share capital and additional paid in capital</a></td>
<td class="nump">53,814<span></span>
</td>
<td class="nump">48,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Foreign exchange reserve</a></td>
<td class="num">(1,928)<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(39,064)<span></span>
</td>
<td class="num">(28,791)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total Shareholders&#8217; Equity</a></td>
<td class="nump">12,822<span></span>
</td>
<td class="nump">20,354<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and Shareholders&#8217; Equity</a></td>
<td class="nump">$ 16,012<span></span>
</td>
<td class="nump">$ 25,870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_LoanFromTheIsraeliInnovationAuthority">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loan from the israeli innovation authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_LoanFromTheIsraeliInnovationAuthority</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075636256864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">$ 8,054<span></span>
</td>
<td class="nump">$ 3,909<span></span>
</td>
<td class="nump">$ 3,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SalesAndMarketingExpenses', window );">Sales and marketing expenses</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">1,951<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="nump">5,391<span></span>
</td>
<td class="nump">7,572<span></span>
</td>
<td class="nump">2,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Other income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="nump">14,770<span></span>
</td>
<td class="nump">13,432<span></span>
</td>
<td class="nump">6,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinanceExpense', window );">Finance expense</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">3,524<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income</a></td>
<td class="num">(4,678)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before tax</a></td>
<td class="nump">10,273<span></span>
</td>
<td class="nump">16,955<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes on income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Total net loss</a></td>
<td class="nump">10,273<span></span>
</td>
<td class="nump">16,955<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax', window );">Exchange (losses)profits arising on translation to presentation currency</a></td>
<td class="num">(2,138)<span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="num">(599)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="nump">$ 12,411<span></span>
</td>
<td class="nump">$ 16,110<span></span>
</td>
<td class="nump">$ 7,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares (in Shares)</a></td>
<td class="nump">10,794,594<span></span>
</td>
<td class="nump">5,306,225<span></span>
</td>
<td class="nump">1,967,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic and diluted loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (3.2)<span></span>
</td>
<td class="num">$ (3.67)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2021-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SalesAndMarketingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SalesAndMarketingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075636451456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Basic and diluted loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (3.2)<span></span>
</td>
<td class="num">$ (3.67)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633842704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Shareholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary Share Capital</div></th>
<th class="th"><div>Adjustments arising from translating financial operation</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (36)<span></span>
</td>
<td class="num">$ (4,608)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (4,641)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">1,904,762<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesDuringThePeriodAbstract', window );"><strong>Changes during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(7,228)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(599)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalComprehensiveLoss', window );">Total comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(599)<span></span>
</td>
<td class="num">(7,228)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareSplit', window );">Share split</a></td>
<td class="nump">215<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OptionsExercise', window );">Share based compensation to exercise</a></td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ConversionOfConvertibleLoanToShares', window );">Conversion of convertible loan to shares</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,791<span></span>
</td>
<td class="nump">6,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ConversionOfConvertibleLoanToSharesinShares', window );">Conversion of convertible loan to shares (in Shares)</a></td>
<td class="nump">756,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,896<span></span>
</td>
<td class="nump">3,896<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 304<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(635)<span></span>
</td>
<td class="num">(11,836)<span></span>
</td>
<td class="nump">10,463<span></span>
</td>
<td class="num">(1,704)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">2,661,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesDuringThePeriodAbstract', window );"><strong>Changes during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(16,955)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(16,955)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">845<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalComprehensiveLoss', window );">Total comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">845<span></span>
</td>
<td class="num">(16,955)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(16,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ParValueCancellations', window );">Par value cancellation</a></td>
<td class="num">(304)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_InitialPublicOffering', window );">Initial Public Offering (&#8220;IPO&#8221;)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,852<span></span>
</td>
<td class="nump">9,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareIssuanceOfInitialPublicOffering', window );">Initial Public Offering (&#8220;IPO&#8221;) (in Shares)</a></td>
<td class="nump">2,931,472<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Conversion of financial liability</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,041<span></span>
</td>
<td class="nump">10,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ConversionOfFinancialLiabilityinShares', window );">Conversion of financial liability (in Shares)</a></td>
<td class="nump">2,113,905<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TradableWarrantsExercise', window );">Tradable warrants exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,447<span></span>
</td>
<td class="nump">11,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TradableWarrantsExerciseinShares', window );">Tradable warrants exercise (in Shares)</a></td>
<td class="nump">1,705,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OptionsExercise', window );">Share based compensation to exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationToExercise', window );">Share based compensation to exercise (in Shares)</a></td>
<td class="nump">24,631<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodValueRestrictedStockUnits', window );">RSUs vesting</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit', window );">RSUs vesting (in Shares)</a></td>
<td class="nump">655,603<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,828<span></span>
</td>
<td class="nump">6,828<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 48,935<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">210<span></span>
</td>
<td class="num">(28,791)<span></span>
</td>
<td class="nump">$ 48,935<span></span>
</td>
<td class="nump">20,354<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">10,091,706<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesDuringThePeriodAbstract', window );"><strong>Changes during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(10,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,138)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalComprehensiveLoss', window );">Total comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,138)<span></span>
</td>
<td class="num">(10,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OptionsExercise', window );">Share based compensation to exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationToExercise', window );">Share based compensation to exercise (in Shares)</a></td>
<td class="nump">7,030<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodValueRestrictedStockUnits', window );">RSUs vesting</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit', window );">RSUs vesting (in Shares)</a></td>
<td class="nump">1,240,204<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,707,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based compensation</a></td>
<td class="nump">$ 4,879<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,879<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 53,814<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,928)<span></span>
</td>
<td class="num">$ (39,064)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,822<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">11,338,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than thousand dollars</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity resulting from the issuing of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ChangesDuringThePeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ChangesDuringThePeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ConversionOfConvertibleLoanToShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of conversion of convertible loan to shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ConversionOfConvertibleLoanToShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ConversionOfConvertibleLoanToSharesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares of conversion of convertible loan to shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ConversionOfConvertibleLoanToSharesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ConversionOfFinancialLiabilityinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity resulting from the issuing of conversion of financial liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ConversionOfFinancialLiabilityinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_InitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_InitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OptionsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of options exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OptionsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ParValueCancellations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Par value cancellation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ParValueCancellations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationToExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares of share based compensation to exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationToExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareIssuanceOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares of initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareIssuanceOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of share split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_StockIssuedDuringPeriodValueRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of restricted stock units under share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_StockIssuedDuringPeriodValueRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TotalComprehensiveLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total comprehensive loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TotalComprehensiveLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TradableWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tradable warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TradableWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TradableWarrantsExerciseinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares of tradable warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TradableWarrantsExerciseinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634542528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flow - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOW FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (10,273)<span></span>
</td>
<td class="num">$ (16,955)<span></span>
</td>
<td class="num">$ (7,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share based compensation</a></td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">6,630<span></span>
</td>
<td class="nump">3,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue', window );">Revaluation of financial liabilities accounted at fair value</a></td>
<td class="num">(2,592)<span></span>
</td>
<td class="nump">2,313<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFairValueGainsLosses', window );">Changes of financial liabilities - IPO non-cash expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority', window );">Change in connection to loan from the Israeli Innovation Authority</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy', window );">Financial expenses</a></td>
<td class="num">(459)<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesInOperatingAssetsAndLiabilityAbstract', window );"><strong>Changes in operating assets and liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Decrease (increase) in other current assets</a></td>
<td class="nump">29<span></span>
</td>
<td class="num">(468)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase (decrease) in trade accounts payables</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase in other accounts payable</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,380)<span></span>
</td>
<td class="num">(7,877)<span></span>
</td>
<td class="num">(1,876)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOW FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property, plant, and equipment</a></td>
<td class="num">(304)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PaymentOfDeposit', window );">Payment of deposit</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Change of deposit</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(7,249)<span></span>
</td>
<td class="num">(246)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidClassifiedAsFinancingActivities', window );">Principal paid on lease liabilities</a></td>
<td class="num">(399)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan', window );">Receipt of simple agreements for future equity (SAFE) and convertible loan</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,208<span></span>
</td>
<td class="nump">2,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ReceiptOfIPOFunds', window );">Receipt of IPO funds</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,658<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ReceiptOfWarrantsExerciseFundsNetFromFees', window );">Receipt of warrants exercise funds, net from fees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,721<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Loan from the Israeli Innovation Authority</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(399)<span></span>
</td>
<td class="nump">30,422<span></span>
</td>
<td class="nump">2,289<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(15,028)<span></span>
</td>
<td class="nump">22,299<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">23,749<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(1,938)<span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">6,783<span></span>
</td>
<td class="nump">23,749<span></span>
</td>
<td class="nump">496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Conversion of convertible loans to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,041<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TradableWarrantsLiability', window );">Tradable warrants at the IPO date</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,373)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TradableWarrantsDerivativeLiability', window );">Tradable warrants financial liability at the IPO date</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationUnderwritersFees', window );">Share based compensation &#8211; underwriters fees at the IPO date</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Warrants exercise to equity &#8211; financial liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsExerciseLiabilityIssuance', window );">Warrants exercise &#8211; allocation from liability to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,070<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalNonCashTransactions', window );">Total non cash transactions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,358<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Interest paid</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFairValueGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFairValueGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid by the entity, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in fair value of  financial liability at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ChangesInOperatingAssetsAndLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ChangesInOperatingAssetsAndLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial expenses are expenses associated with any financing the company incurs, including interest from debt. Tax expenses are reported below the profit before tax line and are the expenses owed to authorities as a result of profits generated in the accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PaymentOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PaymentOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ReceiptOfIPOFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receipt of IPO funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ReceiptOfIPOFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ReceiptOfWarrantsExerciseFundsNetFromFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receipt of warrants exercise funds, net from fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ReceiptOfWarrantsExerciseFundsNetFromFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation of loan from the Israeli Innovation Authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationUnderwritersFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation &#8211; underwriters fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationUnderwritersFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TotalNonCashTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total non cash transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TotalNonCashTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TradableWarrantsDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tradable warrants derivative - Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TradableWarrantsDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TradableWarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tradable warrants - liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TradableWarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_WarrantsExerciseLiabilityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise &#8211; liability issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_WarrantsExerciseLiabilityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075638037328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory', window );">GENERAL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - GENERAL:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inspira Technologies Oxy B.H.N. Ltd (formerly: Insense Medical Ltd.)
    (the &#8220;Company&#8221;) was incorporated in Israel and commenced its operations on February 27, 2018. The Company&#8217;s functional
    currency is the New Israeli Shekel (&#8220;NIS&#8221;).</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company operates in the
medical technology industry in the field of respiratory support technology engaged in the research, development, manufacturing related
activities, and go to market activities of proprietary products and technologies. The Company is developing the following products:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(*)The INSPIRA ART (Augmented
Respiratory Technology), which is a respiratory support technology targeted toward utilizing direct blood oxygenation to boost patient
saturation levels within minutes while the patient is awake and spontaneously breathing. The aim is to reduce the need for invasive mechanical
ventilation, with the potential to reduce risks, complications and high costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(*) The HYLA blood sensor,
which is a non-invasive optical blood sensor designed to perform real-time and continuous blood measurements, potentially minimizing
the need to take actual blood samples from patients.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(*)The ALICE Device, an advanced
form of life support system better known by the medical industry as a cardiopulmonary bypass system is being designed for use in surgical
procedures requiring cardiopulmonary bypass for six hours or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company&#8217;s products are in the development stage. The ALICE
    device and the INSPIRA ART has not yet been tested or used in humans and the Company&#8217;s products have not been approved by the
    U.S. Food and Drug Administration (the &#8220;FDA&#8221;). </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -14.15pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On July 16, 2021, the Company completed its IPO on the Nasdaq Capital Market, whereby the Company sold 2,909,091 ordinary shares, no par value (the &#8220;Ordinary Shares&#8221;) and 3,345,455 tradable warrants (inclusive of 436,364 tradable warrants pursuant to the exercise of an overallotment option granted to the underwriters). The aggregate proceeds received by the Company from the IPO were approximately 14,490, after deducting underwriting discounts and commissions and additional offering costs totaled in approximately 1,543. On July 16, 2021, following the closing of the IPO, the Company issued 2,113,905 Ordinary Shares and 1,149,582 non-tradable warrants to investors and 16,587 non-tradeable warrants to brokers in connection with the conversion of Company&#8217;s previously issued financial liabilities at fair value.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In October 2021, investors exercised
1,705,000 tradable warrants Company. The total proceeds received by the Company from this exercise were approximately 9,377. The Company
paid fees of 7% in the amount of 656 according to the terms of a contract with a promoter in connection with the IPO for which the Company
recorded a financial liability (note 8(3)).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The Company has not generated any revenue since its inception and the Company&#8217;s products are in the development stage. The Company&#8217;s operating loss for the years ended December 31, 2021 and 2022 were $13.4&#160;million and $14.8&#160;million, respectively and the Company&#8217;s net loss for the same period was $16.9 million and $10.3 million, respectively. As of December 31, 2022, the Company had an accumulated deficit of $39.1&#160;million. The Company funds its operations through the proceeds of the IPO.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -14.15pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s
management intends to seek additional funding through public offerings, which will be utilized to fund product development and continue
operations. The Company does not have any material financial obligations as of the balance date. The Company believes that it has sufficient
resources to operate in the foreseeable future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify">The Ukraine Conflict</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Although we do not currently conduct
business in Russia and Ukraine, the escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations in
the Russian Ruble has had a negative impact on worldwide markets. Such impact may negatively impact our supply chain, our operations
and future growth prospects in that region.&#160;As a result of the crisis in Ukraine,&#160;both the U.S. and other countries have implemented
sanctions against certain Russian individuals and entities. Our global operations expose us to risks that could adversely affect our
business, financial condition, results of operations, cash flows or the market price of our securities, including the potential for increased
tensions between Russia and other countries resulting from the current situation involving Russia and Ukraine, tariffs, economic sanctions
and import-export restrictions imposed, and retaliatory actions, as well as the potential negative impact on our potential business and
sales in the region. Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S. and other governments against
certain companies and individuals may hinder our ability to conduct business with potential customers and vendors in these countries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">6.</td><td style="text-align: justify">These financial statements were authorized by the
                                            board of directors on March 28, 2023.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general hedge accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section Hedge accounting<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g21A-24G_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075637986912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New standards, interpretations and amendments
not yet effective.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are a number of standards, amendments to
standards, and interpretations which have been issued by the IASB that are effective in future accounting periods that the Company has
decided not to adopt early.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2020, the IASB issued amendments to
IAS 1, which clarify the criteria used to determine whether liabilities are classified as current or non-current. These amendments clarify
that current or non-current classification is based on whether an entity has a right at the end of the reporting period to defer settlement
of the liability for at least twelve months after the reporting period. The amendments also clarify that &#8217;settlement&#8217; includes
the transfer of cash, goods, services, or equity instruments unless the obligation to transfer equity instruments arises from a conversion
feature classified as an equity instrument separately from the liability component of a compound financial instrument. The amendments
were originally effective for annual reporting periods beginning on or after 1 January 2022. However, in May 2020, the effective date
was deferred to annual reporting periods beginning on or after 1 January 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In its June 2021 meeting, the IASB tentatively
decided to amend the requirements of IAS 1 with respect to the classification of liabilities subject to conditions and disclosure of
information about such conditions and to defer the effective date of the 2020 amendment by at least one year.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is currently assessing the impact
of these new accounting standards and amendments. The Company will assess the impact of the final amendments to IAS 1 on classification
of its liabilities once the those are issued by the IASB.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not believe that the amendments
to IAS 1, in its present form, will have a significant impact on the classification of its liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not expect any other standards
issued by the IASB, but not yet effective, to have a material impact on the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of preparation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of estimates and assumptions in the preparation
of the financial statements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets
and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results
could differ from those estimates. See also Note 3.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and cash equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash equivalents are considered by the Company
to be highly-liquid investments, including, short-term deposits with banks, the maturity of which does not exceed three months at the
time of deposit and which are not restricted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Loss per share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss per share is calculated
as net loss attributed to the Company, divided by the weighted average number of ordinary shares, adjusted for any bonus element.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted (loss) earnings per share is determined
by adjusting the earnings or loss attributable to common shareholders and the weighted average number of common shares outstanding for
the effects of dilutive instruments, which includes stock options, as if their dilutive effect was at the beginning of the period. The
calculation of the diluted number of common shares assumes that proceeds received from the exercise of &#8220;in-the- money&#8221; stock
options and common share purchase warrants are used to purchase common shares of the Company at their average market price for the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In periods that the Company reports a net loss,
any stock options or warrants outstanding are excluded from the calculation of diluted loss per share as their inclusion would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Functional and foreign currency</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s functional currency is NIS.
However, the presentation currency is the U.S. dollar (&#8220;USD&#8221;). Transactions and balances are converted into USD in accordance
with the principles set forth by International Accounting Standard (IAS) 21 &#8220;The Effects of Changes in Foreign Exchange Rates.&#8221;
Accordingly, transactions and balances have been converted as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Assets and liability items were reported at closing rate of exchange
    at the statements of financial position date.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Other comprehensive income items were reported at annual average rate
    of exchange at the statements of financial position date.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Share capital, capital reserve and other capital movement items were
    at rate of exchange as of the date of recognition of those items.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Accumulated deficit was based on the opening balance for the beginning
    of the reporting period in addition to the movements mentioned above.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Rate of exchange rate differentials created was recognized in other
    comprehensive income and accumulated in equity.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Fair value measurement</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Fair value is the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability
takes place either:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.5in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">A.</span></td><td style="text-align: justify"><span style="font-size: 10pt">In
                                            the principal market for the asset or liability, or</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">B.</span></td><td style="text-align: justify"><span style="font-size: 10pt">In
                                            the absence of a principal market, in the most advantageous market for the asset or liability.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The principal or the
most advantageous market must be accessible by the Company in order to measure an asset or liability by its fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The fair value of an
asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming
that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a
market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another
market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">When there are no quoted
prices in active markets for identical assets or liabilities, the Company uses valuation techniques that are appropriate in the circumstances
and for which sufficient data is available to measure fair value, maximizing the use of relevant observable inputs and minimizing the
use of unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Classification by fair
value hierarchy Assets and liabilities measured in the statement of financial position at fair value are grouped into classes with similar
characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;1&#160;-&#160;Quoted prices (unadjusted)
in active markets for identical assets or liabilities.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;2&#160;- Inputs other than quoted
prices included within Level 1 that are observable either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;3&#160;- Inputs that are not based
on observable market data (valuation techniques that use inputs that are not based on observable market data).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Financial instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Financial
                                            assets</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">The Company
classifies its financial assets into the following category, based on the business model for managing the financial asset and its contractual
cash flow characteristics. The Company&#8217;s accounting policy for the relevant category is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">Amortized
cost: other types of financial assets where the objective is to hold these assets in order to collect contractual cash flows and the
contractual cash flows are solely payments of principal and interest. They are initially recognized at fair value including direct transaction
costs and are subsequently carried at amortized cost using the effective interest rate method, less provision for impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -17.85pt; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Financial
                                            Liabilities</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company classifies its financial
liabilities, including trade accounts payable and other accounts payable, which are initially recognized at fair value and subsequently
carried at amortized cost using the effective interest method. The financial liabilities at fair value (see also Notes 8 and 19) are
measured at fair value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">3.</span></td>
    <td><span style="font-size: 10pt"><span style="text-decoration: underline">De-recognition</span></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Financial
                                            assets - The Company derecognizes a financial asset when the contractual rights to the cash
                                            flows from the financial asset expire or it transfers the rights to receive the contractual
                                            cash flows.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Financial
                                            Liabilities - The Company derecognizes a financial liability when its contractual obligations
                                            are discharged or cancelled or expire.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Impairment of financial assets</span></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">The Company
does not have any assets which require a recognition of expected credit losses (&#8220;ECL&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Cash and
cash equivalents are subject to the impairment requirements of IFRS 9, the Company did not identify impairment for the cash and cash
equivalent.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Property, plant, and equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Items of property, plant
and equipment are initially recognized at cost including directly attributable costs. Depreciation is calculated on a straight-line basis,
over the useful lives of the assets at annual rates as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Annual depreciation rate (%)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Development equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">6-15</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Subsequent costs are
included in the asset&#8217;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future
economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount
of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to statement
of the comprehensive loss during the reporting period in which they are incurred. The assets&#8217; residual values and useful lives
are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset&#8217;s carrying amount is written down immediately
to its recoverable amount if the asset&#8217;s carrying amount is higher than its estimated recoverable amount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Gains and losses on
disposals are determined by comparing proceeds with carrying amount. These are included in statement of the comprehensive loss.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Impairment of non-financial
assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Non-financial assets
are subject to impairment test whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.
Where the carrying value of the non-financial asset exceeds its recoverable amount (i.e., the higher of value in use and fair value less
costs to dispose), the asset is written down and impairment charge is recognized accordingly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Where it is not possible
to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset&#8217;s cash-generating unit
(i.e., the smallest group of assets to which the asset belongs that generates cash inflow that is largely independent of cash inflows
from other assets).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">An impairment loss allocated
to an asset, is reversed only if there have been changes in the estimates used to determine the asset&#8217;s recoverable amount since
the last impairment loss was recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Reversal of an impairment
loss, as above, is limited to the lower of the carrying amount of the asset that would have been determined (net of depreciation or amortization)
had no impairment loss been recognized for the asset in prior years and the asset&#8217;s recoverable amount. After an impairment of
non-financial asset is recognized, the Company examines at each reporting date whether there are indications that the impairment which
was recognized in the past no longer exists or should be reduced. The reversal of impairment loss of an asset is recognized in statement
of the comprehensive loss. Impairment charges are included in general and administrative expenses in the statement of the comprehensive
loss. During the years ended December 31, 2022 and 2021, no impairment charges of non-financial assets were recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Research and development costs</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Expenditure on research
activities is recognized in statement of the comprehensive loss as incurred. Development expenditures is recognized as an intangible
asset when the Company can demonstrate:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The product is technically
and commercially feasible.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The Company intends to complete
the product so that it will be available for use or sale.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The Company has the ability
to use the product or sell it.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The Company has the technical,
financial and other resources to complete the development and to use or sell the product.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The Company can demonstrate that the product will generate future economic benefits.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The Company is able to measure reliably the expenditure attributable to the product during the
    development.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the years ended
December 31, 2021 and 2022, the Company&#8217;s research and development costs were not capitalized as they did not meet the criteria
set forth in IAS&#160;38.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Segment reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An operating segment is a component of the Company
which fulfills the following criteria:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">1.</td><td style="text-align: justify">It is engaged in business operations
                                            from which it may derive income, and with respect to which it may bear expenses.</td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">2.</td><td style="text-align: justify">Its operating results are reviewed on
                                            a regular basis by the Company&#8217;s chief operational decision maker, in order to reach
                                            decisions regarding the resources allocated to it, and in order to assess its performance.</td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">3.</td><td style="text-align: justify">Separate financial information is available
                                            for the above.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company concluded that it has one operating
segment.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Share based payment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company measures
the share based expense and the cost of equity-settled transactions with employees and service providers by reference to the fair value
of the equity instruments at the date at which they are granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Options</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The fair value is determined
using an accepted options pricing model. The model is based on share price, grant date and on assumptions regarding expected volatility,
expected life of the options, expected dividend, and a no risk interest rate. The options were granted before the Company became public
and had no quoted price per share from a trading market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company selected
the Black-Scholes model as the Company&#8217;s option pricing model to estimate the fair value of the Company&#8217;s options awards.
The option-pricing model requires a number of assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Expected dividend
yield</i> - The expected dividend yield assumption is based on the Company&#8217;s historical experience and expectation of no future
dividend payouts. The Company has not historically paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Volatility</i>&#160;-
The expected volatility is based on similar companies&#8217; stock volatility.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Risk free interest
rate</i>&#160;- The risk-free interest rate is based on the yield of governmental bonds with equivalent terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Contractual term</i>&#160;-
An option&#8217;s contractual term is the amount of time the holder has to exercise the option, per the contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Restricted Share
Units (&#8220;RSUs&#8221;) </b>- The fair value is measured by multiplying the number of the restricted shares units granted to employees,
directors, and subcontractors by the quoted share price as of the grant date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The granted options
are settled in equity instruments and not in cash. The fair value of the options at the date of grant is charged to the statement of
comprehensive loss over the vesting period. Non-market vesting conditions are considered by adjusting the number of equity instruments
expected to vest at each reporting date so that, ultimately, the cumulative amount recognized over the vesting period is based on the
number of options that eventually vest. Non-vesting conditions and market vesting conditions are factored into the fair value of the
options granted. As long as all other vesting conditions are satisfied, a charge is made irrespective of whether the market vesting conditions
are satisfied. The cumulative expense is not adjusted for failure to achieve a market vesting condition or where a non-vesting condition
is not satisfied. Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options,
measured immediately before and after the modification, is also charged to the statement of comprehensive loss over the remaining vesting
period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Government grants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Israel Innovation
Authority (&#8220;IIA&#8221;) provided government grants to the Company for certain research and development activities. The Company
may be required to pay royalties to the IIA in the future if it generates sales from the related research and development activity. The
grant was recognized as a liability in the financial statements. When the loan bears a below-market rate of interest, the liability is
recognized at its fair value in accordance with the market interest rate prevailing at the time of receiving the grant. The difference
between the consideration received and the liability recognized at inception was treated as a government grant and recognized as a reimbursement
of research expenses. The repayment of the liability to the state is reviewed every reporting period, with changes in the liability resulting
from a change in the expected royalties recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Current taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Deferred tax</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Significant management
judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the estimated timing and level
of future taxable profits together with future tax planning strategies. Deferred taxes are recognized in respect of temporary differences
between the carrying amounts of assets and liabilities in the financial statements and the amounts attributable for tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Deferred taxes are measured
at the tax rates that are expected to apply in the period when the temporary differences are reversed based on tax laws that have been
enacted or substantively enacted at the end of the reporting period. Deferred taxes are recognized in profit or loss, except when they
relate to items recognized in other comprehensive income or directly in equity. Deferred tax assets are reviewed at the end of each reporting
period and reduced to the extent that it is not probable that they will be utilized. In addition, temporary differences (such as carry
forward losses) for which deferred tax assets have not been recognized are reassessed and deferred tax assets are recognized to the extent
that their recoverability is probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Any resulting reduction
or reversal is recognized on &#8220;income tax&#8221; within the statement of comprehensive income. All deferred tax assets and liabilities
are presented in the statement of financial position as non-current items, respectively. Deferred taxes are offset in the statement of
financial position if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred
taxes relate to the same taxpayer and the same taxation authority.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Employee benefits</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company has several
employee benefit plans for Israeli employees:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Short-term employee benefits:
Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions, which
are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Post-employment benefits: The
plans are normally financed by contributions to insurance companies and classified as defined contribution plans. The Company has contributed
for all of its employees&#8217; contribution plans pursuant to Section 14 to the Severance Pay Law since 2018 under which the Company
pays fixed contributions and will not have any legal or constructive obligation to pay further contributions if the fund does not hold
sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639353280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Estimates and Judgements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract', window );"><strong>Critical Accounting Estimates and Judgements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt; background-color: white"><b>NOTE
3 - CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Share based payments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The fair value of share
options was estimated by using a Black Scholes model approach, which was aimed to model the value of the Company&#8217;s equity over
time. A change of the estimation can cause to recognition or reversal of share based compensation expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Financial liabilities
at fair value</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The fair value of financial
liabilities at fair value was estimated by using a Black Scholes model and Monte-Carlo simulation approach, which was aimed to model
the value of the Company&#8217;s assets over time. The simulation approach was designed to take into account the terms and conditions
financial liability, which are described in Note 8 and Note 20, as well as the capital structure of the Company and the volatility of
its assets. The valuation was performed based on management&#8217;s assumptions and projections.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Determination of
lease incremental borrowing rate</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company measures
the incremental borrowing rate by analyzing similar borrowing that could be obtained from an independent valuation under comparable terms
and conditions. A change of the estimation can cause to an increase or decrease in the measurement of a right-of-use asset and lease
liability.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075637989136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfDepositsFromBanksTextBlockAbstract', window );"><strong>Disclosure of Deposits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDepositsFromBanksExplanatory', window );">DEPOSITS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 4 &#8211; DEPOSITS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">The deposits are three short-term bank deposits
with maturities of more than three months but less than one year. The deposits are in dollars and bear annual interest.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">On May 10, 2022, the Company deposited 2,000
with an annual interest rate of 3.02% for a period of 9 months. As of December 31, 2022, the value of the deposit is 2,039.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">On August 11, 2022, the Company deposited
2,000 with an annual interest rate of 4.39% for a period of 12 months. As of December 31, 2022, the value of the deposit is 2,034.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">On August 24, 2022, the Company deposited
3,000 with an annual interest rate of 4.47% for a period of 9 months. As of December 31, 2022, the value of the deposit is 3,047.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">As of December 31, 2022 total deposits amounted
to 7,120.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDepositsFromBanksExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deposits from banks. [Refer: Deposits from banks]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDepositsFromBanksExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfDepositsFromBanksTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfDepositsFromBanksTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639294496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract', window );"><strong>Disclosure of Other Current Assets Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 5 - OTHER CURRENT ASSETS:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">256</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">426</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">591</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">759</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other non-current assets. [Refer: Other non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075637989136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract', window );"><strong>Disclosure of Property Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 - PROPERTY AND EQUIPMENT, NET:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">For the year ended December 31, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">64</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">81</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">236</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate deference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0in">At December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">499</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">At January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate deference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0in">At December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">29</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">204</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">108</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">411</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Less than thousand dollars</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">For the year ended December 31, 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">At January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">54</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">At December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">236</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">At January 1, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">*</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">At December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">62</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">56</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">78</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">202</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Less than one thousand dollars</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075636430320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 - OTHER ACCOUNTS PAYABLE:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employees salaries and related liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">339</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">470</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,217</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">725</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075637977056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability in Respect of Government Grants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfGovernmentGrantsTextBlockAbstract', window );"><strong>Liability in Respect of Government Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGovernmentGrantsExplanatory', window );">LIABILITY IN RESPECT OF GOVERNMENT GRANTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 - LIABILITY IN RESPECT OF GOVERNMENT
GRANTS:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received the approval of the IIA
for its participation in certain development expenses carried out by the Company, within the framework of determined budgets and time
periods. The total amount the Company received during 2020 and 2021 was 800 (NIS 2,722,628).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with its commitment, the Company
is obliged to pay the IIA royalties of 3% of sales, constituting the revenues derived from sales of the Company&#8217;s ART system that
was financed by the IIA, up to the total amount of the grant actually received, all linked to the exchange rate of the USD and bears
an annual interest linked to the LIBOR. Therefore, the total amount of the grants that will be repaid through royalties and will increase
until repayments begin.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The difference between the consideration received
and the liability recognized at inception (present value) was treated as a government grant according to IAS 20 and recognized as a reimbursement
of research expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">At January 1, 2022</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; text-align: right">302</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; text-align: right">372</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amounts received during the year, non- capitalized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amounts recognized as an offset from research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(255</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Revaluation of the liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">137</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">398</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">302</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGovernmentGrantsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS20_g39-39_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGovernmentGrantsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfGovernmentGrantsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfGovernmentGrantsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639380336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finacial Liabilities at Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract', window );"><strong>Finacial Liabilities at fair value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory', window );">FINACIAL LIABILITIES AT FAIR VALUE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 - FINACIAL LIABILITIES AT FAIR VALUE:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Non-tradable warrants (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">196</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-tradable warrants, SAFE and CLA (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,393</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tradable warrants (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,493</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial liability (4)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">133</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">368</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,215</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt">Non Tradable Warrants</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As part of an agreement signed in
2019, the convertible loan investors received, upon conversion in 2020 756,333 Ordinary Shares and non-tradable warrants to purchase
an additional 169,019 ordinary shares upon consummation of an IPO on the Nasdaq. The warrants will be converted into Ordinary Shares
of the Company at an exercise price equal to the initial public offering price which was $5.5 and are exercisable for three years after
the IPO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The warrants were designated to be measured at
fair value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 2021, as part of the IPO,
the investors received the specified warrants. As of December 31, 2022 the fair value of the warrants was 3.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -14.15pt"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>2.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt">Non-tradable warrants, SAFE and
Convertible Loan Investors</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -14.15pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 16, 2021, following the IPO, the Company
issued 2,113,905 Ordinary Shares, 1,149,582 non-tradable warrants to investors and 16,587 non-tradeable warrants to brokers in connection
with the conversion of Company&#8217;s convertible loan and SAFE according to its terms. The fair value of the shares was classified
as equity with total value of 10,041 at the conversion date. The non-tradable warrants were designated to be measured at fair value through
profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The non-tradable warrants fair value as of December
31, 2022 is 35.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>3.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Tradable warrants</b></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify">The Company sold 3,345,455 tradable
warrants in the IPO. The tradable warrants have an exercise price of $5.5 and they are exercisable for five years after the initial public
offering date. In October 2021, investors exercised 1,705,000 tradable warrants whereby the Company issued 1,705,000 Ordinary Shares
to such investors. The total proceeds received by the Company from this exercise were approximately 9,377. The net proceeds after fees
deducting were approximately 8,721.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt">As of December 31, 2022,
the Company has 1,640,455 tradable warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The tradable warrants were designated to be measured at
fair value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The tradable warrants fair value as
of December 31, 2022 is 304.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>4.</b></span></td>
    <td><span style="font-size: 10pt"><b>Financial Liability</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Financial liability to pay 7% fees
on the fundings that will be received from exercises of tradable warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Financial liability was designated to be measured at fair
value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Financial liability fair value
as of December 31, 2022 is 26.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075637801296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Defict)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract', window );"><strong>Equity (Defict) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">EQUITY (DEFICT)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 - EQUITY (DEFICT):</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Share capital:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Number of shares as of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Number of shares as of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">100,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">11,338,940</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">100,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">10,091,706</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company&#8217;s incorporation in February
2018 and before the IPO, the Company issued the following Ordinary Shares: (i) an aggregate of 27,566 Ordinary Shares for no consideration
to the Company&#8217;s founders and certain advisors; (ii) 1,877,196 Ordinary Shares as bonus shares for no consideration to existing
shareholders; (iii) an aggregate of 756,333 Ordinary Shares investors. See Note 8(1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 18, 2021, the Company&#8217;s shareholders
approved a 12.5 to 1 reverse split of all shares (issued and unissued) on the basis that every 12.5 Ordinary Shares in the capital of
the Company be consolidated into 1 Ordinary Share, such that the authorized share capital of the Company following such consolidation
is NIS 310,000,000 divided into 24,800,000 Ordinary Shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company&#8217;s shareholders
approved an amendment to the structure of the Company&#8217;s share capital (both authorized and issued) by cancelling the par value
in addition to implementing an additional reverse split at a ratio of 2.94 to 1, pursuant to which holders of our Ordinary Shares received
one Ordinary Share for every 2.94&#160;Ordinary Shares held.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company&#8217;s shareholders
approved an amendment to the structure of the Company&#8217;s share capital (both authorized and issued) by cancelling the par value
of the Company&#8217;s shares such that each Ordinary Share with par value of NIS 0.125 will become one Ordinary Share with no par value.
The authorized share capital of the Company following the reverse stock split is NIS 310,000,000 divided into 8,435,375 Ordinary Shares,
with no par value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company&#8217;s shareholders
approved an increase in the authorized share capital of the Company to 15,000,000 Ordinary Shares of no par value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2021, the Company completed its IPO
on Nasdaq Capital Market whereby the Company sold 2,909,091 Ordinary Shares and 3,345,455 tradable warrants (inclusive of 436,364 tradable
warrants pursuant to the exercise of an overallotment option granted to the underwriters).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the IPO, the Company issued 2,113,905
Ordinary Shares and 1,149,582 non-tradable warrants to investors and 16,587 non-tradeable warrants to brokers in connection with the
conversion of Company&#8217;s previously issued financial liabilities, see note 8(2).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate proceeds received by the Company
from the IPO were approximately 14,490, after deducting underwriting discounts and commissions and additional offering direct costs totaled
in approximately 1,543. The gross proceeds were 16,033.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total non-cash direct expenses in IPO were as
following: (i) fair value of 436,364 tradable warrants that were granted to underwriters totaled 589; (ii) The Company issued 145,455
non-tradable warrants as underwriters fees; the warrants will be converted into Ordinary Shares of the Company at an exercise price equal
to 125% of the initial public offering price and be exercisable for three years after the initial public offering. As of the date of
the IPO, the tradable warrants fair value was 264; and (iii) the Company agreed to pay to a promoter 7% of the proceeds from the exercise
of tradable warrants. The payment was measured according to IFRS 2 at the grant date. As of the IPO date, the fair value of the financial
liability was 310.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total non-cash expenses were 1,163.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company had non-direct expenses
as following: (i) cash expenses amounted to 722 and (i) non-cash expenses amounted to 123 (22,382 Ordinary Shares issued to service providers).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total IPO expanse direct and non direct, cash
and non-cash were: 3,551.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total IPO expenses allocated to the profit and
loss were 1,265. Total IPO expenses deducted from the equity were 2,286.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year 2021 the Company issued an aggregate
amount of 655,601 Ordinary Shares in connection to vested RSUs and additional 24,631 Ordinary Shares in connection to options exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 17, 2021, the Company&#8217;s shareholders
approved an increase in the authorized share capital of the Company to 100,000,000 Ordinary Shares of no-par value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31 2022, the Company
issued an aggregate amount of 1,240,204 Ordinary Shares in connection to vested RSUs and an additional 7,030 Ordinary Shares in connection
to option exercises.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Loss per share:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share has been calculated using the
weighted average number of shares in issue during the relevant financial periods, the weighted average number of equity shares in issue
and profit for the period as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,273</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,955</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,228</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Total number of Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,338,940</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,091,706</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,661,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted average number of Ordinary Shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,794,594</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,306,225</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,967,790</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-108; -sec-ix-hidden: hidden-fact-107; -sec-ix-hidden: hidden-fact-106">Basic and diluted loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(0.95</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3.2</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3.67</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639245616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract', window );"><strong>Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11 - RESEARCH AND DEVELOPMENT EXPENSES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Share based payment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,311</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,768</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,230</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,237</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">929</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">IIA participation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(255</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(383</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><b>Total</b></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8,054</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,909</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,873</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633926656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sales and Marketing Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SalesAndMarketingExpensesAbstract', window );"><strong>Sales and Marketing Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SalesAndMarketingExpensesTextBlock', window );">SALES AND MARKETING EXPENSES:</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SALES AND MARKETING EXPENSES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Share based payment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">501</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,186</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">287</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professionals&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">521</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">520</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,325</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,951</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SalesAndMarketingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SalesAndMarketingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SalesAndMarketingExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales and Marketing Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SalesAndMarketingExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639378960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract', window );"><strong>Disclosure of General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Share based payment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,093</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,581</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">818</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,522</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Related NASDAQ IPO expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Director&#8217;s fees and share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,113</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">545</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><b>Total</b></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,391</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,572</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,447</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of general and administrative expenses. [Refer: Administrative expenses]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639379376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) and Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract', window );"><strong>Financial (Income) and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">FINANCIAL (INCOME) AND EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 &#8211; FINANCIAL (INCOME) AND EXPENSES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Revaluation of financial liabilities at fair value through profit or loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,592</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign currency transaction income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,774</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest on deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(308</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(4,678</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Revaluation of financial liabilities at fair value through profit or loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">893</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign currency transaction loss, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,186</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revaluation of liability in respect of government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance expense in respect of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">80</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">181</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,524</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">959</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075636177376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfIncomeTaxTextBlockAbstract', window );"><strong>Taxes on income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 - TAXES ON INCOME: </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>Taxes on
income:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">Israeli corporate
tax rate was 23% in 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net operating losses carry forwards</b>:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company has carried
forward tax losses of approximately 11,540, which may be carried forward and offset against taxable income for an indefinite period in
the future. The Company did not recognize deferred tax assets relating to carry forward losses in the financial statements because their
utilization in the foreseeable future is not probable. As of December 31, 2022, the Company has temporary differences of 2,838 for which
no deferred tax asset was recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Theoretical tax:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Loss before taxation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(10,273</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(16,955</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,228</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Theoretical tax credit at applicable statutory rate: 23%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,363</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,900</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,662</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-allowable expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,804</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,070</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,733</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(559</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,071</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Income tax benefit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfIncomeTaxTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfIncomeTaxTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075636177376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfLeasesTextBlockAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 16 - LEASES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has lease contracts for office facilities
and vehicles used in its operations. Leases of vehicles generally have lease terms up to three years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases vehicles for three-year periods
from several different leasing companies and from time to time changes the number of leased vehicles according to its current needs.
The leased vehicles are used by the Company&#8217;s management, and other employees whose employment agreements include an obligation
of the Company to put a vehicle at their disposal. The Company accounted for the arrangement between it and the leasing companies as
a lease arrangement in the scope of IFRS 16 and for the arrangement between it and its employees as an arrangement in the scope of IAS
19, Employee Benefits. The agreements with the leasing companies do not contain extension and/or termination options that the Company
is reasonably certain to exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A lease liability in the amount of 281 and right-of-use
asset in the amount of 345 have been recognized in the statement of financial position as of December 31, 2022 in respect of leases of
vehicles.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases offices in Ra&#8217;anana
are for a period of 69 months. The contractual period of the aforesaid lease agreement ends in August 2027. The Company has an option
to terminate the contract after 45 months with a penalty in amount of NIS 500,000 that will be diminish in NIS 30,000 in each month from
the 45<sup>th</sup> month of the contract. The Company does not currently expect to exercise the termination option in the lease agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A lease liability in the amount of 776 and right-of-use
asset in the amount of 762 have been recognized in the statement of financial position as of December 31, 2022 in respect of leases of
offices.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Set out below are the carrying amounts of right-of-use assets recognized
and the movements during the period:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office&#160;facility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vehicles</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,047</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,160</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">416</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">416</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(114</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(140</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(171</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(129</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">762</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">345</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,107</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Set out below are the carrying amounts of lease liabilities and the
movements during the period:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">275</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">153</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">367</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,176</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Accretion of interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(138</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(99</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(350</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(214</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(171</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,057</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,181</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">275</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following are the amounts recognized in profit or loss:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Depreciation expense of right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">196</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">196</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest expense on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total amount recognized in profit or loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">300</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">196</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">201</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had total cash outflows for leases
of 350 in 2022 and 214 in 2021. The Company also had non-cash additions to right-of-use assets and lease liabilities of 416 in 2022 and
1,176 in 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfLeasesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfLeasesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075636454240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract', window );"><strong>Share Based Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">SHARE BASED COMPENSATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 17 - SHARE BASED PAYMENT:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the Company established a share
option plan (the &#8220;Plan&#8221;). Under the Plan, total of 602,989 options were granted until December 31, 2022. As of December 31,
2022, a total of 500,772 options to subscribe Ordinary Shares that have been granted to employees, consultants and directors are outstanding.<br/>
A total of 3,707,542 RSUs that have been granted to employees, consultants and directors, 1,895,808 RSUs are vested as of December 31,
2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 20, 2020 a total of 478,747 options
to subscribe Ordinary Shares have been granted to employees and consultants. The exercise price per share to 123,719 and 355,029 options
was USD 0.0029 (AUD 0.052) and USD 2.67 (AUD 4.2), respectively. The vesting period is up to 3 years from the grant date, according to
the various vesting periods: from an immediate one and up to 3 years. Contractual life of the options under the Plan is 10 years. The
options were granted under section 102 of the Israeli Tax Ordinance which enables the employee to pay 25% of capital gain tax upon exercise.
&#160;In October 2020, 73,380 options were canceled.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 17, 2020, the Israeli Taxes Authority
(ITA) approved a ruling request from the Company for a tax-free amendment of the commercial terms of the outstanding options, including
(i) a reduction of the exercise price to NIS 0.37 per share, and (ii) a shortening of the vesting schedules.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company implemented IFRS 2-Share based payment
on options terms change.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2020, the board of directors
granted a total of 56,653 options to subscribe Ordinary Shares to employees and consultants. The vesting period is up to 3 years from
the grant date. The exercise price per share was NIS 0.37.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contractual life of the options under the Plan
is 10 years. The options were granted under section 102 of the Israeli Tax Ordinance which enables the employee to pay 25% of capital
gain tax upon exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 21, 2021, the Company&#8217;s board
of directors approved a grant of 13,605 non-tradable shares options which are exercisable to 13,605 Ordinary shares to employees and
a total of 21,768 share options which are exercisable to 21,768 Ordinary Shares to consultants. The vesting period is three years commencing
on the grant date. The exercise price per share was NIS 0.37($0.12). The contractual life of the options under the Plan is ten years.
The options to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital
gain tax upon exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2021, the Company&#8217;s board
of directors approved a grant of 81,633 non-tradable shares options to a director, which are exercisable to 81,633 Ordinary Shares. The
share options vesting period is up to three years from the grant date. The exercise price per share was NIS 0.37 ($0.12). The contractual
life of the options under the Plan is ten years. The options were granted under Section 102 of the Israeli Tax Ordinance, which enables
the employee to pay a 25% capital gain tax upon exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2021, the Company&#8217;s board
of directors resolved to increase the pool of options available under the Plan to 25% of the Company&#8217;s equity, on a fully diluted
basis. As a result of the increase, the number of authorized Ordinary Shares available pursuant the Plan was 4,180,898.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On November 2, 2021, the Company&#8217;s board of directors approved
a grant of 2,658,188 RSUs to employees and officers. The RSUs represents the right to receive Ordinary Shares at a future time and vest
over a period of three years. The RSUs were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay
a 25% capital gain tax upon exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2021, the Company&#8217;s
board of directors approved a grant of 10,000 RSUs to the Company&#8217;s advisory board. The RSUs represents the right to receive
Ordinary Shares at a future time and vest over a period of three years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On March 24, 2022, the Company&#8217;s board of directors approved
a grant of 536,141 RSUs to employees and a grant of 22,500 RSUs to the Company&#8217;s advisory board members and an additional consultant.
The RSUs represent the right to receive Ordinary Shares at a future time. 555,500 of the RSUs in this grant, vest over a period of three
years, with a 1-year cliff period, and 3,141 RSUs vested immediately on the grant date. The RSUs to employees were granted under Section
102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2022, the Company&#8217;s board
of directors approved a grant of 29,400 Ordinary Shares options to medical board members, which are exercisable to 29,400 Ordinary Shares.
The share options vesting period is up to three years from the grant date. The exercise price per share was NIS 10.84 ($3.08). The contractual
life of the options under the Plan is ten years.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 14.2pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On April 6, 2022, the Company&#8217;s board of directors approved
a grant of 285,713 fully vested RSUs to an officer. The RSUs represent the right to receive Ordinary Shares. The RSUs were granted under
Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On May 19, 2022, the Company&#8217;s board of directors approved a
grant of 30,000 RSUs to an employee. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period
of three years, with a 1-year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax
Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On November 22, 2022, the Company&#8217;s board of directors approved
a grant of 165,000 RSUs to employees. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period
of three years, with a 1-year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax
Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all granted options was estimated
by using the Black Scholes model, which was aimed to model the value of the Company&#8217;s assets over time. The simulation approach
was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and
the volatility of its assets, on the date of grant based on certain assumptions. Those conditions are, among others:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The expected volatility is
between 50%-52.4%</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The dividend rate 0%; and</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(iii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Expected term &#8211; three
years.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation was completed with the assistance
of an independent valuator based on management&#8217;s assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2022, the Company recorded share
based payment expenses to employees, directors and subcontractors in the amount of 4,879.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;The options to services providers and advisers outstanding as
of December 31, 2022, as&#160;follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">87,833</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.84</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,721</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">114,512</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.058</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">82,257</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.71</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2022, the Company recorded share
based payment expenses of option to services providers and advisers in the amount of 54.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The RSUs to services providers and advisers outstanding as of December
31, 2022 as&#160;follows:</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,234</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,266</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Vested as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,234</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the
Company recorded share based payment expenses of RSUs to services providers and advisers in the amount of 33.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options to employees and directors outstanding as of December
31, 2022, as&#160;follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/>
    December 31, 2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of options</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted average Exercise
    price NIS</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="font-size: 10pt">Outstanding at beginning of year </span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">448,120</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">0.37</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4,309</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0.37</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">(<span style="font-size: 10pt">57,551</span></td>
    <td style="padding-bottom: 1.5pt">)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">0.37</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Outstanding as of December 31, 2022</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">386,260</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">0.37</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Exercisable options</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">342,757</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">0.37</span></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">During the year ended December 31, 2022, the Company recorded share
based payment expenses of options to employees and directors in the amount of 174</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The RSUs to employees and directors outstanding as of December 31,
2022, as&#160;follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,002,587</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,016,854</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(65,626</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Vested</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,225,973</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,727,842</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Vested as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,881,574</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the
Company recorded share based payment expenses of RSUs to employees and directors in the amount of 4,618.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options to services providers and advisers outstanding as of December
31, 2021, as&#160;follows:</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">165,987</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reclassified to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(71,260</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,086</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,134</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">87,833</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">62,715</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The RSUs to services providers and advisers outstanding as of December
31, 2021, as&#160;follows:</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding at beginning of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; padding-bottom: 1.5pt">Granted</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">10,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable RSUs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options to employees and directors outstanding as of December
31, 2021, as&#160;follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">296,038</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reclassified to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,872</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">448,120</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">347,069</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The restricted shares units to employees and directors outstanding
as of December 31, 2021, as&#160;follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding at beginning of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,658,188</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Vested</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(655,601</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,002,587</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075636454400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfRelatedPartyTextBlockAbstract', window );"><strong>Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 18 - RELATED PARTIES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The following transactions arose with related parties:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Transactions and balances with related parties</span><b>:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Shareholders and other related
parties&#8217; benefits</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salary and related expenses &#8211; officers and directors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,923</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,042</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">795</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share based payment &#8211; officers and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,876</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,805</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Balances with related parties</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature of transaction</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%">Officers</td><td style="width: 1%">&#160;</td>
    <td style="width: 64%; text-align: left">Salaries and related</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(292</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(317</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Directors</td><td>&#160;</td>
    <td style="text-align: left">Compensation for directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfRelatedPartyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfRelatedPartyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075636449152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Risk Management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract', window );"><strong>Financial Instruments and Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 19 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is exposed to a variety of financial
risks, which result from its financing, operating and investing activities. The objective of financial risk management is to contain,
where appropriate, exposures in these financial risks to limit any negative impact on the Company&#8217;s financial performance and position.
The Company&#8217;s financial instruments are its cash and other current assets, convertible loan, payables and other payables. The main
purpose of these financial instruments is to raise finance for the Company&#8217;s operation. The Company actively measures, monitors,
and manages its financial risk exposures by various functions pursuant to the segregation of duties and principals. The risks arising
from the Company&#8217;s financial instruments are mainly credit risk and currency risk. The risk management policies employed by the
Company to manage these risks are discussed below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Credit risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Credit risk arises when a failure by counterparties
to discharge their obligations could reduce the amount of future cash inflows from financial assets on hand at the balance sheet date.
The Company closely monitors the activities of its counterparties and controls the access to its intellectual property which enables
it to ensure the prompt collection. The Company&#8217;s main financial assets are cash and cash equivalents and deposits represent the
Company&#8217;s maximum exposure to credit risk in connection with its financial assets. Wherever possible and commercially practical,
the Company holds cash with major financial institutions in Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amount of financial assets represents
the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,783</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23,749</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,120</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets (Restricted deposits)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13,959</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">23,869</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Currency risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currency risk is the risk that the value of financial
instruments will fluctuate due to changes in foreign exchange rates. Currency risk arises when future commercial transactions and recognized
assets and liabilities are denominated in a currency that is not the Company&#8217;s functional currency. The Company exposed to foreign
exchange risk arising from currency exposure primarily with respect to the USD. The Company&#8217;s policy is not to enter into any currency
hedging transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of the Company&#8217;s foreign
currency denominated monetary liability at the reporting date are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,766</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19,391</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,886</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">19,391</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">368</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">368</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,518</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,176</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sensitivity analysis</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A 10% strengthening of the NIS against the following
currencies would have increased (decreased) equity and the income statement by the amounts shown below. This analysis assumes that all
other variables, in particular interest rates, remain constant. For a 10% weakening of the NIS against the relevant currency, there would
be an equal and opposite impact on the profit and other equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/>
 December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/>
 December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,051</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,617</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">AUD</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">GB Pound</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity risks:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity risk is the risk that arises when the
maturity of assets and the maturity of liabilities do not match. An unmatched position potentially enhances profitability but can also
increase the risk of loss. The Company has procedures to minimize such loss by maintaining sufficient cash and other highly liquid current
assets and by having available an adequate amount of committed credit facilities. As of the balance sheet date, the Company has a negative
working capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables detail the Company&#8217;s
remaining contractual maturity for its financial liabilities. The tables have been drawn up based on the undiscounted cash flows of financial
liabilities based on the earliest date on which the Company can be required to pay.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">As of December 31, 2022:</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Up to <br/>
1 year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Between<br/> 1 and 3<br/>
 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">More than<br/> 3 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Other payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">719</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">635</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">374</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan from the IIA</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">776</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">659</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,150</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">As of December 31, 2021:</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Up to <br/>
1 year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Between <br/>
1 and 3<br/> years</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">More than<br/> 3 years</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Other payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">611</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">678</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan from the IIA</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">868</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,009</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">544</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,546</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634050192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 20 - COMMITMENTS AND CONTINGENCIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Commitments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">The Company has a bank guarantee in the amount of 63 for
the offices it rents. In accordance with the guarantee, the Company has a pledged deposit in the same amount as of December 31, 2022.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">2.</td><td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">In
July 2022, the Company entered into an agreement with a contractor for the development of the HYLA&#8482; blood sensor. Total payment
agreed in the contract is 710. According to the agreement with the developer, the development cost will be paid in a few tranches considering
the development lifecycle, which was defined as five phases for each of the blood parameters to be measured by the sensor.</p></td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><p style="margin-left: 0.5in; margin-top: 0; margin-bottom: 0">The Company is entitled to terminate the contract upon reaching the third phase.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">As of December 31, 2022, part of the development outputs
reached the second phase and part are on the third phase. Approximately half of the contract total amount was recorded as development
expenses as of December 31, 2022. An amount of 75 was paid as prepayment.</td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">In the normal course of business, various legal claims and
other contingent matters may arise. Management believes that any liability that may arise from such matters would not have a material
adverse effect on the Company&#8217;s results of operations or financial condition as of and for the years ended December 31, 2022, and
2021.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">On March 4, 2022, Exchange Listing, LLC, or Exchange, filed
a complaint in the Federal Court for the Southern District of New York against us in connection with a contract between the parties.
The contract related to certain consulting services provided to us by Exchange in preparation for our initial public offering.The complaint
is against us and, and the Company president and former Chief Financial Officer, Joe Hayon, in connection with a contract between the
parties pursuant to which Exchange provided certain consultancy services to us in preparation for our initial public offering. The precise
damages sought are unclear, however Exchange is seeking approximately 250,000 plus 75,000 Ordinary Shares or the cash equivalent. As
of the date of this annual report, we have not been formally served with the complaint. On July 1, 2022, the Company filed a motion to
dismiss for failure to state a claim upon relief can be granted based on the language of the written contract between the parties. On
March 8, 2023, the court issued an order granting our motion in part and denying it in part. Specifically, the court dismissed all claims
against Joe Hayon and he is no longer a party in the action. The court also dismissed the breach of contract action (Count I) to the
extent it was based improper termination or frustration. The Court also dismissed Count IV (Quantum Merit on the written agreement),
Count VI (Breach of Implied Covenant of Good Faith) and Count VII (Fraud in the Inducement). The court allowed Count 1 (breach of written
agreement based on alleged anticipatory repudiation), Count II (breach of alleged oral agreement), Count III (Promissory Estoppel to
the extent based on alleged oral agreement) and Count V (Quantum Meruit based on alleged oral agreement) to survive the pleading or early
dismissal stage. The Company will continue to defend itself vigorously with respect to this matter.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">On
November 9, 2022, the Company received notice of a complaint filed by Udi Nussinovitch, the Registrant&#8217;s former Chief Scientific
Officer, in Tel-Aviv District Court, as well as a complaint filed with the regional labor court in Tel Aviv on November 8, 2022. Mr.
Nussinovitch has alleged certain deficiencies in the Company&#8217;s&#160;Extraordinary General Meeting of Shareholders held on Friday,
December 17, 2021, resulting from his status as a minority shareholder. In addition, with respect to the labor dispute, Mr.&#160;Nussinovitch
is seeking renumeration and the issuance of Ordinary Shares.&#160;Previously, on February 24, 2022, the Company filed a claim against
Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and former officer of the Company.</p></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">As of the balance date, the Company believes that the claims
will result in no payments by the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639808096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract', window );"><strong>Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 21 - FAIR VALUE MEASUREMENT:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair value hierarchy </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables detail the Company&#8217;s
assets and liabilities, measured or disclosed at fair value, using a three-level hierarchy, based on the lowest level of input that is
significant to the entire fair value measurement, being:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1: Quoted prices (unadjusted) in active
markets for identical assets or liabilities that the entity can access at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2: Inputs other than quoted prices included
within Level 1 that are observable for the asset or liability, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3: Unobservable inputs for the asset or liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">As of December 31, 2022:</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Non-tradable Warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-tradable warrants of SAFE and Convertible Loan investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157"><div>&#160;</div></div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158"><div>&#160;</div></div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tradable warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">As of December 31, 2021:</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Non-tradable Warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">196</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-tradable warrants of SAFE and Convertible Loan investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166"><div>&#160;</div></div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167"><div>&#160;</div></div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tradable warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,493</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,493</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,722</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the fair value measurement
of the warrant&#8217;s securities in the table above, was estimated using the Black Scholes model, based on assumptions for the variables
that are required as of the warrants&#8217; valuation date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs that were used in the both items
of non-tradable warrants valuation were: risk-free interest rate between 5.04% and 5.26%, expected volatility between 56.5%-57.8% , expected
dividend yield of 0% and expected term of warrants of 1.54-2.54 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2021, the fair value measurement
of the SAFE and the warrant&#8217;s securities in the table above, was estimated using the Black Scholes model, based on a variety of
significant unobservable inputs a thus represent a level 2 measurement within the fair value hierarchy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs that were used in both items of
non-tradable warrants valuation were: risk-free interest rate between 0.19% and 0.73%, expected volatility between 55.3%-57.8%, expected
dividend yield of 0% and expected term of warrants of 2.54-3.54 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of trade and other receivables
and trade and other payables are assumed to approximate their fair values due to their short-term nature.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Movements in level 2 liability during 2021 is
set out below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">SAFE</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Convertible loan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Financial Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">219</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,273</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,492</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gains (losses) recognized in profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">612</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,373</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,047</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,518</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,680</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,361</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(656</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,697</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Adjustments arising from translating financial operation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance as of December,31 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">196</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,039</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">354</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">133</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,722</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of the entity's own equity instruments. [Refer: Entity's own equity instruments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633824352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of preparation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock', window );">Use of estimates and assumptions in the preparation of the financial statements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of estimates and assumptions in the preparation
of the financial statements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets
and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results
could differ from those estimates. See also Note 3.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and cash equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash equivalents are considered by the Company
to be highly-liquid investments, including, short-term deposits with banks, the maturity of which does not exceed three months at the
time of deposit and which are not restricted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Loss per share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss per share is calculated
as net loss attributed to the Company, divided by the weighted average number of ordinary shares, adjusted for any bonus element.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted (loss) earnings per share is determined
by adjusting the earnings or loss attributable to common shareholders and the weighted average number of common shares outstanding for
the effects of dilutive instruments, which includes stock options, as if their dilutive effect was at the beginning of the period. The
calculation of the diluted number of common shares assumes that proceeds received from the exercise of &#8220;in-the- money&#8221; stock
options and common share purchase warrants are used to purchase common shares of the Company at their average market price for the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In periods that the Company reports a net loss,
any stock options or warrants outstanding are excluded from the calculation of diluted loss per share as their inclusion would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Functional and foreign currency</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Functional and foreign currency</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s functional currency is NIS.
However, the presentation currency is the U.S. dollar (&#8220;USD&#8221;). Transactions and balances are converted into USD in accordance
with the principles set forth by International Accounting Standard (IAS) 21 &#8220;The Effects of Changes in Foreign Exchange Rates.&#8221;
Accordingly, transactions and balances have been converted as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Assets and liability items were reported at closing rate of exchange
    at the statements of financial position date.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Other comprehensive income items were reported at annual average rate
    of exchange at the statements of financial position date.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Share capital, capital reserve and other capital movement items were
    at rate of exchange as of the date of recognition of those items.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Accumulated deficit was based on the opening balance for the beginning
    of the reporting period in addition to the movements mentioned above.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Rate of exchange rate differentials created was recognized in other
    comprehensive income and accumulated in equity.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Fair value measurement</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Fair value is the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability
takes place either:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.5in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">A.</span></td><td style="text-align: justify"><span style="font-size: 10pt">In
                                            the principal market for the asset or liability, or</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">B.</span></td><td style="text-align: justify"><span style="font-size: 10pt">In
                                            the absence of a principal market, in the most advantageous market for the asset or liability.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The principal or the
most advantageous market must be accessible by the Company in order to measure an asset or liability by its fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The fair value of an
asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming
that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a
market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another
market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">When there are no quoted
prices in active markets for identical assets or liabilities, the Company uses valuation techniques that are appropriate in the circumstances
and for which sufficient data is available to measure fair value, maximizing the use of relevant observable inputs and minimizing the
use of unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Classification by fair
value hierarchy Assets and liabilities measured in the statement of financial position at fair value are grouped into classes with similar
characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;1&#160;-&#160;Quoted prices (unadjusted)
in active markets for identical assets or liabilities.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;2&#160;- Inputs other than quoted
prices included within Level 1 that are observable either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;3&#160;- Inputs that are not based
on observable market data (valuation techniques that use inputs that are not based on observable market data).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements', window );">Financial instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Financial instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Financial
                                            assets</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">The Company
classifies its financial assets into the following category, based on the business model for managing the financial asset and its contractual
cash flow characteristics. The Company&#8217;s accounting policy for the relevant category is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">Amortized
cost: other types of financial assets where the objective is to hold these assets in order to collect contractual cash flows and the
contractual cash flows are solely payments of principal and interest. They are initially recognized at fair value including direct transaction
costs and are subsequently carried at amortized cost using the effective interest rate method, less provision for impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -17.85pt; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Financial
                                            Liabilities</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company classifies its financial
liabilities, including trade accounts payable and other accounts payable, which are initially recognized at fair value and subsequently
carried at amortized cost using the effective interest method. The financial liabilities at fair value (see also Notes 8 and 19) are
measured at fair value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">3.</span></td>
    <td><span style="font-size: 10pt"><span style="text-decoration: underline">De-recognition</span></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Financial
                                            assets - The Company derecognizes a financial asset when the contractual rights to the cash
                                            flows from the financial asset expire or it transfers the rights to receive the contractual
                                            cash flows.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Financial
                                            Liabilities - The Company derecognizes a financial liability when its contractual obligations
                                            are discharged or cancelled or expire.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Impairment of financial assets</span></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">The Company
does not have any assets which require a recognition of expected credit losses (&#8220;ECL&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Cash and
cash equivalents are subject to the impairment requirements of IFRS 9, the Company did not identify impairment for the cash and cash
equivalent.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant, and equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Property, plant, and equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Items of property, plant
and equipment are initially recognized at cost including directly attributable costs. Depreciation is calculated on a straight-line basis,
over the useful lives of the assets at annual rates as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Annual depreciation rate (%)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Development equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">6-15</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Subsequent costs are
included in the asset&#8217;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future
economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount
of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to statement
of the comprehensive loss during the reporting period in which they are incurred. The assets&#8217; residual values and useful lives
are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset&#8217;s carrying amount is written down immediately
to its recoverable amount if the asset&#8217;s carrying amount is higher than its estimated recoverable amount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Gains and losses on
disposals are determined by comparing proceeds with carrying amount. These are included in statement of the comprehensive loss.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Impairment of non-financial
assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Non-financial assets
are subject to impairment test whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.
Where the carrying value of the non-financial asset exceeds its recoverable amount (i.e., the higher of value in use and fair value less
costs to dispose), the asset is written down and impairment charge is recognized accordingly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Where it is not possible
to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset&#8217;s cash-generating unit
(i.e., the smallest group of assets to which the asset belongs that generates cash inflow that is largely independent of cash inflows
from other assets).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">An impairment loss allocated
to an asset, is reversed only if there have been changes in the estimates used to determine the asset&#8217;s recoverable amount since
the last impairment loss was recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Reversal of an impairment
loss, as above, is limited to the lower of the carrying amount of the asset that would have been determined (net of depreciation or amortization)
had no impairment loss been recognized for the asset in prior years and the asset&#8217;s recoverable amount. After an impairment of
non-financial asset is recognized, the Company examines at each reporting date whether there are indications that the impairment which
was recognized in the past no longer exists or should be reduced. The reversal of impairment loss of an asset is recognized in statement
of the comprehensive loss. Impairment charges are included in general and administrative expenses in the statement of the comprehensive
loss. During the years ended December 31, 2022 and 2021, no impairment charges of non-financial assets were recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Research and development costs</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Expenditure on research
activities is recognized in statement of the comprehensive loss as incurred. Development expenditures is recognized as an intangible
asset when the Company can demonstrate:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The product is technically
and commercially feasible.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The Company intends to complete
the product so that it will be available for use or sale.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The Company has the ability
to use the product or sell it.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The Company has the technical,
financial and other resources to complete the development and to use or sell the product.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The Company can demonstrate that the product will generate future economic benefits.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The Company is able to measure reliably the expenditure attributable to the product during the
    development.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the years ended
December 31, 2021 and 2022, the Company&#8217;s research and development costs were not capitalized as they did not meet the criteria
set forth in IAS&#160;38.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Segment reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An operating segment is a component of the Company
which fulfills the following criteria:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">1.</td><td style="text-align: justify">It is engaged in business operations
                                            from which it may derive income, and with respect to which it may bear expenses.</td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">2.</td><td style="text-align: justify">Its operating results are reviewed on
                                            a regular basis by the Company&#8217;s chief operational decision maker, in order to reach
                                            decisions regarding the resources allocated to it, and in order to assess its performance.</td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">3.</td><td style="text-align: justify">Separate financial information is available
                                            for the above.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company concluded that it has one operating
segment.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share based payment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Share based payment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company measures
the share based expense and the cost of equity-settled transactions with employees and service providers by reference to the fair value
of the equity instruments at the date at which they are granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OptionsPolicyTextBlock', window );">Options</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Options</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The fair value is determined
using an accepted options pricing model. The model is based on share price, grant date and on assumptions regarding expected volatility,
expected life of the options, expected dividend, and a no risk interest rate. The options were granted before the Company became public
and had no quoted price per share from a trading market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company selected
the Black-Scholes model as the Company&#8217;s option pricing model to estimate the fair value of the Company&#8217;s options awards.
The option-pricing model requires a number of assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Expected dividend
yield</i> - The expected dividend yield assumption is based on the Company&#8217;s historical experience and expectation of no future
dividend payouts. The Company has not historically paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Volatility</i>&#160;-
The expected volatility is based on similar companies&#8217; stock volatility.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Risk free interest
rate</i>&#160;- The risk-free interest rate is based on the yield of governmental bonds with equivalent terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Contractual term</i>&#160;-
An option&#8217;s contractual term is the amount of time the holder has to exercise the option, per the contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RestrictedShareUnitsPolicyTextBlock', window );">Restricted Share Units (&#8220;RSUs&#8221;)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Restricted Share
Units (&#8220;RSUs&#8221;) </b>- The fair value is measured by multiplying the number of the restricted shares units granted to employees,
directors, and subcontractors by the quoted share price as of the grant date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The granted options
are settled in equity instruments and not in cash. The fair value of the options at the date of grant is charged to the statement of
comprehensive loss over the vesting period. Non-market vesting conditions are considered by adjusting the number of equity instruments
expected to vest at each reporting date so that, ultimately, the cumulative amount recognized over the vesting period is based on the
number of options that eventually vest. Non-vesting conditions and market vesting conditions are factored into the fair value of the
options granted. As long as all other vesting conditions are satisfied, a charge is made irrespective of whether the market vesting conditions
are satisfied. The cumulative expense is not adjusted for failure to achieve a market vesting condition or where a non-vesting condition
is not satisfied. Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options,
measured immediately before and after the modification, is also charged to the statement of comprehensive loss over the remaining vesting
period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Government grants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Government grants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Israel Innovation
Authority (&#8220;IIA&#8221;) provided government grants to the Company for certain research and development activities. The Company
may be required to pay royalties to the IIA in the future if it generates sales from the related research and development activity. The
grant was recognized as a liability in the financial statements. When the loan bears a below-market rate of interest, the liability is
recognized at its fair value in accordance with the market interest rate prevailing at the time of receiving the grant. The difference
between the consideration received and the liability recognized at inception was treated as a government grant and recognized as a reimbursement
of research expenses. The repayment of the liability to the state is reviewed every reporting period, with changes in the liability resulting
from a change in the expected royalties recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory', window );">Current taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Current taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory', window );">Deferred tax</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Deferred tax</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Significant management
judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the estimated timing and level
of future taxable profits together with future tax planning strategies. Deferred taxes are recognized in respect of temporary differences
between the carrying amounts of assets and liabilities in the financial statements and the amounts attributable for tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Deferred taxes are measured
at the tax rates that are expected to apply in the period when the temporary differences are reversed based on tax laws that have been
enacted or substantively enacted at the end of the reporting period. Deferred taxes are recognized in profit or loss, except when they
relate to items recognized in other comprehensive income or directly in equity. Deferred tax assets are reviewed at the end of each reporting
period and reduced to the extent that it is not probable that they will be utilized. In addition, temporary differences (such as carry
forward losses) for which deferred tax assets have not been recognized are reassessed and deferred tax assets are recognized to the extent
that their recoverability is probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Any resulting reduction
or reversal is recognized on &#8220;income tax&#8221; within the statement of comprehensive income. All deferred tax assets and liabilities
are presented in the statement of financial position as non-current items, respectively. Deferred taxes are offset in the statement of
financial position if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred
taxes relate to the same taxpayer and the same taxation authority.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefits</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Employee benefits</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company has several
employee benefit plans for Israeli employees:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Short-term employee benefits:
Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions, which
are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Post-employment benefits: The
plans are normally financed by contributions to insurance companies and classified as defined contribution plans. The Company has contributed
for all of its employees&#8217; contribution plans pursuant to Section 14 to the Severance Pay Law since 2018 under which the Company
pays fixed contributions and will not have any legal or constructive obligation to pay further contributions if the fund does not hold
sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2021-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for taxes other than income tax. [Refer: Tax expense other than income tax expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 46<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the measurement basis (or bases) used in preparing the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OptionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options policy text block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OptionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RestrictedShareUnitsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Share Units policy text block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RestrictedShareUnitsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for use of estimates and assumptions in the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633832000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock', window );">Schedule of straight-line basis, over the useful lives of the assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Annual depreciation rate (%)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Development equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">6-15</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639266560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract', window );"><strong>Disclosure of Other Current Assets Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Schedule of other Current Assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">256</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">426</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">591</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">759</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075636449312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract', window );"><strong>Disclosure of Property Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">64</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">81</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">236</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate deference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0in">At December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">499</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">At January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate deference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0in">At December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">29</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">204</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">108</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">411</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Less than thousand dollars</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">At January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">54</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">At December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">236</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">At January 1, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">*</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">At December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">62</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">56</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">78</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">202</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Less than one thousand dollars</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075638069152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfOtherAccountPayableTextBlock', window );">Schedule of other accounts payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employees salaries and related liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">339</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">470</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,217</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">725</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfOtherAccountPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of other account payable [Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfOtherAccountPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633895328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability in Respect of Government Grants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfGovernmentGrantsTextBlockAbstract', window );"><strong>Liability in Respect of Government Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock', window );">Schedule of reimbursement of research expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">At January 1, 2022</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; text-align: right">302</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; text-align: right">372</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amounts received during the year, non- capitalized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amounts recognized as an offset from research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(255</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Revaluation of the liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">137</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">398</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">302</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfGovernmentGrantsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfGovernmentGrantsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075637810352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finacial Liabilities at Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract', window );"><strong>Finacial Liabilities at fair value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfFinancialLiabilities', window );">Schedule of finacial liabilities at fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Non-tradable warrants (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">196</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-tradable warrants, SAFE and CLA (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,393</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tradable warrants (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,493</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial liability (4)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">133</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">368</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,215</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075638027568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Defict) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract', window );"><strong>Equity (Defict) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of share capital</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Number of shares as of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Number of shares as of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">100,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">11,338,940</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">100,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">10,091,706</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfLossPerShare', window );">Schedule of loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,273</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,955</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,228</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Total number of Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,338,940</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,091,706</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,661,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted average number of Ordinary Shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,794,594</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,306,225</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,967,790</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-108; -sec-ix-hidden: hidden-fact-107; -sec-ix-hidden: hidden-fact-106">Basic and diluted loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(0.95</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3.2</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3.67</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634117648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract', window );"><strong>Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfResearchAndDevelopmentExpenses', window );">Schedule of research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Share based payment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,311</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,768</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,230</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,237</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">929</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">IIA participation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(255</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(383</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><b>Total</b></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8,054</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,909</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,873</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633821440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sales and Marketing Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SalesAndMarketingExpensesAbstract', window );"><strong>Sales and Marketing Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock', window );">Schedule of sales and Marketing Expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Share based payment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">501</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,186</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">287</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professionals&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">521</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">520</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,325</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,951</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SalesAndMarketingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SalesAndMarketingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales and Marketing Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639356448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract', window );"><strong>Disclosure of General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfGeneralAndAdministrativeExpenses', window );">Schedule of general and administrative expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Share based payment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,093</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,581</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">818</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,522</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Related NASDAQ IPO expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Director&#8217;s fees and share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,113</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">545</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><b>Total</b></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,391</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,572</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,447</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075638289616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) and Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract', window );"><strong>Financial (Income) and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfFinancialIncomeTableTextBlock', window );">Schedule of financial income</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Revaluation of financial liabilities at fair value through profit or loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,592</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign currency transaction income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,774</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest on deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(308</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(4,678</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="margin: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfFinancialExpenses', window );">Schedule of financial income</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Revaluation of financial liabilities at fair value through profit or loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">893</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign currency transaction loss, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,186</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revaluation of liability in respect of government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance expense in respect of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">80</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">181</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,524</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">959</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfFinancialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfFinancialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfFinancialIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure financial income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfFinancialIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075637978576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfIncomeTaxTextBlockAbstract', window );"><strong>Taxes on income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfTheoreticalTaxTableTextBlock', window );">Schedule of theoretical tax</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Loss before taxation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(10,273</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(16,955</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,228</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Theoretical tax credit at applicable statutory rate: 23%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,363</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,900</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,662</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-allowable expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,804</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,070</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,733</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(559</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,071</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Income tax benefit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfIncomeTaxTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfIncomeTaxTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfTheoreticalTaxTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of theoretical tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfTheoreticalTaxTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634931696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfLeasesTextBlockAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfRightofuseAssets', window );">Schedule of right-of-use assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office&#160;facility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vehicles</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,047</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,160</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">416</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">416</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(114</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(140</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(171</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(129</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">762</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">345</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,107</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfLeaseLiabilities', window );">Schedule of lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">275</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">153</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">367</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,176</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Accretion of interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(138</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(99</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(350</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(214</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(171</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,057</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,181</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">275</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfProfitOrLoss', window );">Schedule of profit or loss</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Depreciation expense of right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">196</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">196</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest expense on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total amount recognized in profit or loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">300</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">196</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">201</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfLeasesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfLeasesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634050288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract', window );"><strong>Share Based Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of RSUs to services providers and advisers outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">87,833</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.84</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,721</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">114,512</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.058</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">82,257</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.71</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/>
    December 31, 2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of options</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted average Exercise
    price NIS</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="font-size: 10pt">Outstanding at beginning of year </span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">448,120</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">0.37</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4,309</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0.37</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">(<span style="font-size: 10pt">57,551</span></td>
    <td style="padding-bottom: 1.5pt">)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">0.37</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Outstanding as of December 31, 2022</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">386,260</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">0.37</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Exercisable options</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">342,757</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">0.37</span></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">165,987</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reclassified to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(71,260</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,086</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,134</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">87,833</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">62,715</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">296,038</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reclassified to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,872</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">448,120</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">347,069</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding', window );">Schedule of RSUs to services providers and advisers outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,234</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,266</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Vested as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,234</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,002,587</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,016,854</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(65,626</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Vested</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,225,973</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,727,842</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Vested as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,881,574</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding at beginning of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; padding-bottom: 1.5pt">Granted</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">10,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable RSUs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding at beginning of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,658,188</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Vested</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(655,601</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,002,587</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634927504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfRelatedPartyTextBlockAbstract', window );"><strong>Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock', window );">Schedule of shareholders and other related parties&#8217; benefits</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salary and related expenses &#8211; officers and directors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,923</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,042</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">795</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share based payment &#8211; officers and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,876</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,805</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_BalancesWithRelatedPartiesTableTextBlock', window );">Schedule of balances with related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature of transaction</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%">Officers</td><td style="width: 1%">&#160;</td>
    <td style="width: 64%; text-align: left">Salaries and related</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(292</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(317</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Directors</td><td>&#160;</td>
    <td style="text-align: left">Compensation for directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_BalancesWithRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balances with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_BalancesWithRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfRelatedPartyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfRelatedPartyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shareholders and other related parties&#8217; benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075636355920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Risk Management (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract', window );"><strong>Financial Instruments and Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure', window );">Schedule of financial assets represents the maximum credit exposure</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,783</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23,749</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,120</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets (Restricted deposits)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13,959</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">23,869</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability', window );">Schedule of foreign currency denominated monetary liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,766</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19,391</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,886</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">19,391</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">368</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">368</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,518</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,176</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfSensitivityAnalysis', window );">Schedule of sensitivity analysis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/>
 December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/>
 December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,051</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,617</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">AUD</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">GB Pound</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Schedule of cash flows of financial liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Up to <br/>
1 year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Between<br/> 1 and 3<br/>
 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">More than<br/> 3 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Other payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">719</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">635</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">374</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan from the IIA</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">776</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">659</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,150</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Up to <br/>
1 year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Between <br/>
1 and 3<br/> years</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">More than<br/> 3 years</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Other payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">611</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">678</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan from the IIA</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">868</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,009</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">544</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,546</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfSensitivityAnalysis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfSensitivityAnalysis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075638021472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract', window );"><strong>Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Non-tradable Warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-tradable warrants of SAFE and Convertible Loan investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157"><div>&#160;</div></div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158"><div>&#160;</div></div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tradable warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Non-tradable Warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">196</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-tradable warrants of SAFE and Convertible Loan investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166"><div>&#160;</div></div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167"><div>&#160;</div></div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tradable warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,493</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,493</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,722</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock', window );">Schedule of movements in level 2 liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">SAFE</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Convertible loan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Financial Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">219</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,273</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,492</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gains (losses) recognized in profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">612</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,373</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,047</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,518</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,680</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,361</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(656</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,697</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Adjustments arising from translating financial operation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance as of December,31 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">196</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,039</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">354</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">133</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,722</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of movements in level 2 liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634508944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jul. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NumberOfShares', window );">Number of shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,909,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TradableWarrantsShares', window );">Tradable warrants shares (in Shares)</a></td>
<td class="nump">1,705,000<span></span>
</td>
<td class="nump">3,345,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsPursuantShares', window );">Warrants pursuant shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateProceedsAmount', window );">Aggregate proceeds amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AdditionalOfferingCosts', window );">Additional offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OrdinaryShares', window );">Ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,113,905<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsShares', window );">Warrants shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,149,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_InvestorsExercise', window );">Total proceeds</a></td>
<td class="nump">$ 9,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfPaidFees', window );">Percentage of paid fees</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PaidFeesAmount', window );">Paid fees, amount</a></td>
<td class="nump">$ 656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingLeaseIncome', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800<span></span>
</td>
<td class="nump">$ 13,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,300<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating lease income. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 90<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_90_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AdditionalOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AdditionalOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregateProceedsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregateProceedsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_InvestorsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_InvestorsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PaidFeesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PaidFeesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfPaidFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of paid fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfPaidFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TradableWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tradable warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TradableWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_WarrantsPursuantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants pursuant shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_WarrantsPursuantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_WarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_WarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633917952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_ComputersMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRateInPercentage', window );">Annual depreciation rate in percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_DevelopmentEquipmentMember', window );">Development equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRateInPercentage', window );">Annual depreciation rate in percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRateInPercentage', window );">Annual depreciation rate in percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRateInPercentage', window );">Annual depreciation rate in percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_LeaseholdImprovementMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRateInPercentage', window );">Annual depreciation rate in percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AnnualDepreciationRateInPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual depreciation rate in percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AnnualDepreciationRateInPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_ComputersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_ComputersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_DevelopmentEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_DevelopmentEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_LeaseholdImprovementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_LeaseholdImprovementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634486832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deposits (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 24, 2022</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>May 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfDepositsFromBanksTextBlockAbstract', window );"><strong>Disclosure of Deposits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepositsFromBanks', window );">Deposit amount</a></td>
<td class="nump">$ 7,120<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.47%<span></span>
</td>
<td class="nump">4.39%<span></span>
</td>
<td class="nump">3.02%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DepositValue', window );">Deposit value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,047<span></span>
</td>
<td class="nump">$ 2,034<span></span>
</td>
<td class="nump">$ 2,039<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepositsFromBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deposit liabilities from banks held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepositsFromBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DepositValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deposit liabilities from customers held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DepositValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfDepositsFromBanksTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfDepositsFromBanksTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634535392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets (Details) - Schedule of other Current Assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfOtherCurrentAssetsAbstract', window );"><strong>Schedule of Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">$ 256<span></span>
</td>
<td class="nump">$ 426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Institutions', window );">Institutions</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Restricted Cash</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OthersCurrentAssets', window );">Others</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Total</a></td>
<td class="nump">$ 591<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_Institutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Institution amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_Institutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OthersCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OthersCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639476864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Schedule of property and equipment, net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CostAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Beginning Balance, Cost</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, Cost</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExchangeRateDeferenceCost', window );">Exchange rate deference, Cost</a></td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Ending Balance, Cost</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciation', window );">Beginning Balance, Accumulated depreciation</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, Accumulated depreciation</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExchangeRateDeferenceAccumulatedDepreciation', window );">Exchange rate deference, Accumulated depreciation</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciation', window );">Ending Balance, Accumulated depreciation</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NetBookValueAbstract', window );"><strong>Net book value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NetBookValue', window );">Ending Balance, Net book value</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CostAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Beginning Balance, Cost</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, Cost</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExchangeRateDeferenceCost', window );">Exchange rate deference, Cost</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Ending Balance, Cost</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciation', window );">Beginning Balance, Accumulated depreciation</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, Accumulated depreciation</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExchangeRateDeferenceAccumulatedDepreciation', window );">Exchange rate deference, Accumulated depreciation</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciation', window );">Ending Balance, Accumulated depreciation</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NetBookValueAbstract', window );"><strong>Net book value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NetBookValue', window );">Ending Balance, Net book value</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CostAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Beginning Balance, Cost</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, Cost</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExchangeRateDeferenceCost', window );">Exchange rate deference, Cost</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Ending Balance, Cost</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciation', window );">Beginning Balance, Accumulated depreciation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, Accumulated depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciation', window );">Ending Balance, Accumulated depreciation</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NetBookValueAbstract', window );"><strong>Net book value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NetBookValue', window );">Ending Balance, Net book value</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_DevelopmentEquipmentMember', window );">Development equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CostAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Beginning Balance, Cost</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, Cost</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExchangeRateDeferenceCost', window );">Exchange rate deference, Cost</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Ending Balance, Cost</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciation', window );">Beginning Balance, Accumulated depreciation</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, Accumulated depreciation</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExchangeRateDeferenceAccumulatedDepreciation', window );">Exchange rate deference, Accumulated depreciation</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciation', window );">Ending Balance, Accumulated depreciation</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NetBookValueAbstract', window );"><strong>Net book value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NetBookValue', window );">Ending Balance, Net book value</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Furniture and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CostAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Beginning Balance, Cost</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, Cost</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExchangeRateDeferenceCost', window );">Exchange rate deference, Cost</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Ending Balance, Cost</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciation', window );">Beginning Balance, Accumulated depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, Accumulated depreciation</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExchangeRateDeferenceAccumulatedDepreciation', window );">Exchange rate deference, Accumulated depreciation</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccumulatedDepreciation', window );">Ending Balance, Accumulated depreciation</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NetBookValueAbstract', window );"><strong>Net book value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NetBookValue', window );">Ending Balance, Net book value</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Less than one thousand dollars</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment that would have been recognised had the revalued assets been carried under the cost model. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 77<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_77_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AccumulatedDepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AccumulatedDepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_CostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_CostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExchangeRateDeferenceAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange rate deference, Accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExchangeRateDeferenceAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExchangeRateDeferenceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange rate deference, Cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExchangeRateDeferenceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NetBookValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NetBookValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NetBookValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NetBookValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_DevelopmentEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_DevelopmentEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075637732160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Payable (Details) - Schedule of other accounts payable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfOtherAccountsPayableAbstract', window );"><strong>Schedule of Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EmployeesSalariesAndRelatedLiabilities', window );">Employees salaries and related liabilities</a></td>
<td class="nump">$ 396<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPayablesToRelatedParties', window );">Related parties</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPayables', window );">Total</a></td>
<td class="nump">$ 1,217<span></span>
</td>
<td class="nump">$ 725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current trade payables and non-current other payables. [Refer: Other non-current payables; Non-current trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_EmployeesSalariesAndRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employees, salaries and related liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_EmployeesSalariesAndRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfOtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfOtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639298640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability in Respect of Government Grants (Details)<br> &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfGovernmentGrantsTextBlockAbstract', window );"><strong>Liability in Respect of Government Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Total amount received</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">&#8362; 2,722,628<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">&#8362; 2,722,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PayRoyaltiesPercentage', window );">Royalties, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2021-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfGovernmentGrantsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfGovernmentGrantsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PayRoyaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pay royalties, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PayRoyaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075637724880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability in Respect of Government Grants (Details) - Schedule of reimbursement of research expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfReimbursementOfResearchExpensesAbstract', window );"><strong>Schedule of Reimbursement of Research Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">Beginning balance</a></td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amounts received during the year, non- capitalized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExchangeRateDifferences', window );">Exchange rate differences</a></td>
<td class="num">(41)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Amounts recognized as an offset from research and development expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RevaluationOfTheLiability', window );">Revaluation of the liability</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">Ending balance</a></td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExchangeRateDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExchangeRateDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RevaluationOfTheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RevaluationOfTheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfReimbursementOfResearchExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfReimbursementOfResearchExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633931920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finacial Liabilities at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinacialLiabilitiesatFairValueDetailsLineItems', window );"><strong>Finacial Liabilities at Fair Value (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ConversionToShares', window );">Conversion to ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AdditionalOrdinaryShare', window );">Additional ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ProceedFromIssuanceInitialPublicOffering', window );">Initial public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueOfTheWarrant', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateProceeds', window );">Aggregate proceeds</a></td>
<td class="nump">$ 2,113,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsShares', window );">Non-tradable warrants (in Shares)</a></td>
<td class="nump">1,149,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value</a></td>
<td class="nump">$ 10,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NontradableWarrantFairValue', window );">Non-tradable warrants fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TradableWarrants', window );">Tradable warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,640,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PublicOfferingPriceDescription', window );">Public offering price, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The tradable warrants have an exercise price of $5.5 and they are exercisable for five years after the initial public
offering date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_InvestorsExercisedTradableWarrants', window );">Investors exercised tradable warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,705,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OrdinarySharesIssued', window );">Ordinary Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,705,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalProceedsReceived', window );">Total proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeductingFees', window );">Deducting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TradableWarrantsFairValue', window );">Tradable warrants fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialLiabilityToPay', window );">Financial liability to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialDerivativesFairValue', window );">Financial derivatives fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_InvestmentNameAxis=iinn_WarrantsToInvestorsMember', window );">Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinacialLiabilitiesatFairValueDetailsLineItems', window );"><strong>Finacial Liabilities at Fair Value (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsShares', window );">Non-tradable warrants (in Shares)</a></td>
<td class="nump">1,149,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_InvestmentNameAxis=iinn_WarrantsToBrokersMember', window );">Warrants to brokers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinacialLiabilitiesatFairValueDetailsLineItems', window );"><strong>Finacial Liabilities at Fair Value (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsShares', window );">Non-tradable warrants (in Shares)</a></td>
<td class="nump">16,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_InitialPublicOfferingMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinacialLiabilitiesatFairValueDetailsLineItems', window );"><strong>Finacial Liabilities at Fair Value (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TradableWarrants', window );">Tradable warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,345,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PlanAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 57<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PlanAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AdditionalOrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AdditionalOrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregateProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregateProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ConversionToShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion to shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ConversionToShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeductingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deducting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeductingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FairValueOfTheWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FairValueOfTheWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinacialLiabilitiesatFairValueDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinacialLiabilitiesatFairValueDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialDerivativesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial derivatives fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialDerivativesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialLiabilityToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial liability to pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialLiabilityToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_InvestorsExercisedTradableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investors exercised tradable warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_InvestorsExercisedTradableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NontradableWarrantFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-tradable warrants fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NontradableWarrantFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary Shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ProceedFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ProceedFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PublicOfferingPriceDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering price, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PublicOfferingPriceDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TotalProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total proceeds received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TotalProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TradableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tradable warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TradableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TradableWarrantsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tradable warrants fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TradableWarrantsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_WarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_WarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_InvestmentNameAxis=iinn_WarrantsToInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_InvestmentNameAxis=iinn_WarrantsToInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_InvestmentNameAxis=iinn_WarrantsToBrokersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_InvestmentNameAxis=iinn_WarrantsToBrokersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633707792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems', window );"><strong>Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalFinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">$ 3,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iinn_NontradableWarrantsMember', window );">Non-tradable warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems', window );"><strong>Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalFinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iinn_NontradableWarrantsSAFEAndCLAMember', window );">Non-tradable warrants, SAFE and CLA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems', window );"><strong>Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalFinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iinn_TradableWarrantsMember', window );">Tradable warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems', window );"><strong>Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalFinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iinn_FinancialLiabilityMember', window );">Financial liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems', window );"><strong>Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalFinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TotalFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TotalFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iinn_NontradableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=iinn_NontradableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iinn_NontradableWarrantsSAFEAndCLAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=iinn_NontradableWarrantsSAFEAndCLAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iinn_TradableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=iinn_TradableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iinn_FinancialLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=iinn_FinancialLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633374656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Defict) (Details)<br> &#8362; / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2021 </div>
<div>ILS (&#8362;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>ILS (&#8362;) </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 16, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 17, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EquityDefictDetailsLineItems', window );"><strong>Equity (Defict) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateOfOrdinaryShares', window );">Aggregate of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OrdinaryShare', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,877,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AuthorizedShareCapital', window );">Authorized share capital (in New Shekels) | &#8362;</a></td>
<td class="nump">&#8362; 310,000,000<span></span>
</td>
<td class="nump">&#8362; 310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Authorized share capital</a></td>
<td class="nump">8,435,375<span></span>
</td>
<td class="nump">24,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary share par value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SoldOrdinaryShares', window );">Sold ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,909,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_tradableWarrants', window );">Tradable warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,345,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateProceedsReceived', window );">Aggregate proceeds received (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additional offering costs total (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GrossProceeds', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TradableWarrantsDescription', window );">Tradable warrants, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Total non-cash direct expenses in IPO were as
following: (i) fair value of 436,364 tradable warrants that were granted to underwriters totaled 589; (ii) The Company issued 145,455
non-tradable warrants as underwriters fees; the warrants will be converted into Ordinary Shares of the Company at an exercise price equal
to 125% of the initial public offering price and be exercisable for three years after the initial public offering. As of the date of
the IPO, the tradable warrants fair value was 264; and (iii) the Company agreed to pay to a promoter 7% of the proceeds from the exercise
of tradable warrants. The payment was measured according to IFRS 2 at the grant date. As of the IPO date, the fair value of the financial
liability was 310.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherMaterialNoncashItems', window );">Total non-cash expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NondirectCashExpenses', window );">Non-direct cash expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Non-cash expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CashAndNoncash', window );">Cash and non-cash (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Profit and loss (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExpensesDeductedFromEquity', window );">Expenses deducted from equity (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateAmount', window );">Aggregate amount ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,204<span></span>
</td>
<td class="nump">655,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AdditionalOrdinaryShares', window );">Additional ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,030<span></span>
</td>
<td class="nump">24,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EquityDefictDetailsLineItems', window );"><strong>Equity (Defict) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockholdersEquityReverseSplit', window );">Reverse split</a></td>
<td class="text">2.94<span></span>
</td>
<td class="text">12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EquityDefictDetailsLineItems', window );"><strong>Equity (Defict) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockholdersEquityReverseSplit', window );">Reverse split</a></td>
<td class="text">1<span></span>
</td>
<td class="text">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_InvestorsMember', window );">Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EquityDefictDetailsLineItems', window );"><strong>Equity (Defict) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateOfOrdinaryShares', window );">Aggregate of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NontradableWarrants', window );">Non-tradable warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,149,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_OverallotmentOptionMember', window );">Overallotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EquityDefictDetailsLineItems', window );"><strong>Equity (Defict) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_tradableWarrants', window );">Tradable warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_InitialPublicOfferingMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EquityDefictDetailsLineItems', window );"><strong>Equity (Defict) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OrdinaryShare', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,113,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_BrokersMember', window );">Brokers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EquityDefictDetailsLineItems', window );"><strong>Equity (Defict) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NontradableWarrants', window );">Non-tradable warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EquityDefictDetailsLineItems', window );"><strong>Equity (Defict) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OrdinaryShare', window );">Ordinary shares issued</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2021-01-01<br> -Paragraph 126<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_126_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2021-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherMaterialNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of material non-cash items other than depreciation and amortisation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherMaterialNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AdditionalOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AdditionalOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of ordinary shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregateOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregateOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregateProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregateProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AuthorizedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of authorized share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AuthorizedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_CashAndNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and non-cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_CashAndNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_EquityDefictDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_EquityDefictDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExpensesDeductedFromEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses deducted from equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExpensesDeductedFromEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NondirectCashExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-direct cash expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NondirectCashExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NontradableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-tradable warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NontradableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SoldOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sold ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SoldOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_StockholdersEquityReverseSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_StockholdersEquityReverseSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TradableWarrantsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tradable warrants, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TradableWarrantsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_tradableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tradable warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_tradableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_OverallotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_OverallotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_BrokersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_BrokersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633773168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity (Defict) (Details) - Schedule of share capital - Ordinary Share Capital [Member] - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EquityDefictDetailsScheduleofsharecapitalLineItems', window );"><strong>Schedule of Share Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Ordinary shares, authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ordinary shares, issued and outstanding</a></td>
<td class="nump">11,338,940<span></span>
</td>
<td class="nump">10,091,706<span></span>
</td>
<td class="nump">2,661,095<span></span>
</td>
<td class="nump">1,904,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_EquityDefictDetailsScheduleofsharecapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_EquityDefictDetailsScheduleofsharecapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075637698320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Defict) (Details) - Schedule of loss per share - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EquityDefictDetailsScheduleoflosspershareLineItems', window );"><strong>Schedule of Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity', window );">Loss for the period (in Dollars)</a></td>
<td class="nump">$ 10,273<span></span>
</td>
<td class="nump">$ 16,955<span></span>
</td>
<td class="nump">$ 7,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Total number of Ordinary Shares</a></td>
<td class="nump">11,338,940<span></span>
</td>
<td class="nump">10,091,706<span></span>
</td>
<td class="nump">2,661,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits', window );">Weighted average number of Ordinary Shares</a></td>
<td class="nump">10,794,594<span></span>
</td>
<td class="nump">5,306,225<span></span>
</td>
<td class="nump">1,967,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (3.2)<span></span>
</td>
<td class="num">$ (3.67)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations [member]; Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Anti-dilutive potentially dilutive securities after the Reverse Stock Splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_EquityDefictDetailsScheduleoflosspershareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_EquityDefictDetailsScheduleoflosspershareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075637773760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Defict) (Details) - Schedule of loss per share (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems', window );"><strong>Schedule of Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share</a></td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (3.2)<span></span>
</td>
<td class="num">$ (3.67)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634811744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses (Details) - Schedule of research and development expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems', window );"><strong>Schedule of research and development expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedPayment', window );">Share based payment</a></td>
<td class="nump">$ 2,311<span></span>
</td>
<td class="nump">$ 1,768<span></span>
</td>
<td class="nump">$ 2,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SalaryAndRelatedExpenses', window );">Salary and related expenses</a></td>
<td class="nump">3,332<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Subcontractors', window );">Subcontractors</a></td>
<td class="nump">929<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_MaterialsAndRelatedExpenses', window );">Materials and related expenses</a></td>
<td class="nump">1,094<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DepreciationExpenses', window );">Depreciation</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_IIAParticipation', window );">IIA participation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="num">(383)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OtherResearchAndDevelopmentExpenses', window );">Other</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ResearchDevelopmentExpenses', window );">Total</a></td>
<td class="nump">$ 8,054<span></span>
</td>
<td class="nump">$ 3,909<span></span>
</td>
<td class="nump">$ 3,873<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DepreciationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DepreciationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_IIAParticipation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_IIAParticipation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_MaterialsAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_MaterialsAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OtherResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>OtherResearchAndDevelopmentExpense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OtherResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ResearchDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ResearchDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SalaryAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SalaryAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_Subcontractors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_Subcontractors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634470480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sales and Marketing Expenses (Details) - Schedule of sales and Marketing Expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems', window );"><strong>Schedule of Sales and Marketing Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share based payment</a></td>
<td class="nump">$ 501<span></span>
</td>
<td class="nump">$ 1,186<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Salary and related expenses</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Professionals&#8217; fees</a></td>
<td class="nump">521<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Other</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="nump">$ 1,325<span></span>
</td>
<td class="nump">$ 1,951<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633701760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Details) - Schedule of general and administrative expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems', window );"><strong>Schedule of General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedPayments', window );">Share based payment</a></td>
<td class="nump">$ 1,093<span></span>
</td>
<td class="nump">$ 2,581<span></span>
</td>
<td class="nump">$ 818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional fees</a></td>
<td class="nump">1,522<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Related NASDAQ IPO expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">1,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Director&#8217;s fees and share based compensation</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">Salary and related expenses</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">545<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceExpense', window );">Insurance expenses</a></td>
<td class="nump">565<span></span>
</td>
<td class="nump">363<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RentalExpense', window );">Office maintenance</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Depreciations', window );">Depreciation</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TravelExpense', window );">Travel abroad</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Others</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="nump">$ 5,391<span></span>
</td>
<td class="nump">$ 7,572<span></span>
</td>
<td class="nump">$ 2,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from purchased insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised on rental activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TravelExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from travel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TravelExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_Depreciations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_Depreciations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634734112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) and Expenses (Details) - Schedule of financial income - Financial income [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems', window );"><strong>Financial (Income) and Expenses (Details) - Schedule of financial income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability', window );">Revaluation of financial liabilities at fair value through profit or loss</a></td>
<td class="num">$ (2,592)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ForeignCurrencyTransactionLossNet', window );">Foreign currency transaction income</a></td>
<td class="num">(1,774)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnDeposits', window );">Interest on deposits</a></td>
<td class="num">(308)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Others</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalIncome', window );">Total</a></td>
<td class="num">$ (4,678)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The accumulated increase (decrease) in the fair value of financial liabilities that is attributable to changes in the credit risk of the liabilities. [Refer: Credit risk [member]; Market risk [member]; Increase (decrease) in fair value of financial liability, attributable to changes in credit risk of liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on deposits. [Refer: Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ForeignCurrencyTransactionLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ForeignCurrencyTransactionLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TotalIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TotalIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=iinn_FinancialIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=iinn_FinancialIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634471600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) and Expenses (Details) - Schedule of financial expenses - Financial Expenses [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems', window );"><strong>Financial (Income) and Expenses (Details) - Schedule of financial expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability', window );">Revaluation of financial liabilities at fair value through profit or loss</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,183<span></span>
</td>
<td class="nump">$ 893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ForeignCurrencyTransactionLossNet', window );">Foreign currency transaction loss, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants', window );">Revaluation of liability in respect of government grants</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinanceExpenseInRespectOfLeaseLiability', window );">Finance expense in respect of lease liability</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Others</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalExpenses', window );">Total</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 3,524<span></span>
</td>
<td class="nump">$ 959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The accumulated increase (decrease) in the fair value of financial liabilities that is attributable to changes in the credit risk of the liabilities. [Refer: Credit risk [member]; Market risk [member]; Increase (decrease) in fair value of financial liability, attributable to changes in credit risk of liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinanceExpenseInRespectOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinanceExpenseInRespectOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ForeignCurrencyTransactionLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ForeignCurrencyTransactionLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TotalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TotalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=iinn_FinancialExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=iinn_FinancialExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639363744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfIncomeTaxTextBlockAbstract', window );"><strong>Taxes on income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CarriedForwardTaxLosse', window );">Carried forward tax losses</a></td>
<td class="nump">$ 11,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeferredTaxAssetS', window );">No deferred tax asset</a></td>
<td class="nump">$ 2,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_CarriedForwardTaxLosse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carried forward tax losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_CarriedForwardTaxLosse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeferredTaxAssetS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeferredTaxAssetS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfIncomeTaxTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfIncomeTaxTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634884912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - Schedule of theoretical tax - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems', window );"><strong>Schedule of theoretical tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LossBeforeTaxation', window );">Loss before taxation</a></td>
<td class="num">$ (10,273)<span></span>
</td>
<td class="num">$ (16,955)<span></span>
</td>
<td class="num">$ (7,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Theoretical tax credit at applicable statutory rate: 23%</a></td>
<td class="num">(2,363)<span></span>
</td>
<td class="num">(3,900)<span></span>
</td>
<td class="num">(1,662)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NonallowableExpenses', window );">Non-allowable expenses</a></td>
<td class="num">(1,804)<span></span>
</td>
<td class="num">(2,070)<span></span>
</td>
<td class="nump">4,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized', window );">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</a></td>
<td class="num">(559)<span></span>
</td>
<td class="num">(1,830)<span></span>
</td>
<td class="num">(3,071)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_LossBeforeTaxation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss before taxation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_LossBeforeTaxation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NonallowableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-allowable expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NonallowableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary differences and tax losses for which no Deferred Tax Asset is recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639381968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - Schedule of theoretical tax (Parentheticals)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems', window );"><strong>Schedule of theoretical tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TheoreticalTaxCreditAtApplicableStatutoryRate', window );">Theoretical tax credit at applicable statutory rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TheoreticalTaxCreditAtApplicableStatutoryRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Theoretical tax credit at applicable statutory rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TheoreticalTaxCreditAtApplicableStatutoryRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633269056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_leaseTerms', window );">Lease terms</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LeaseLiabilityAmount', window );">Lease liability amount</a></td>
<td class="nump">$ 416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DescriptionOfLeaseAgreement', window );">Lease agreement description</a></td>
<td class="text">The Company leases offices in Ra&#8217;anana
are for a period of 69 months. The contractual period of the aforesaid lease agreement ends in August 2027. The Company has an option
to terminate the contract after 45 months with a penalty in amount of NIS 500,000 that will be diminish in NIS 30,000 in each month from
the 45th month of the contract. The Company does not currently expect to exercise the termination option in the lease agreement.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Total cash outflows</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LeaseLiabilityAmount', window );">Lease liability amount</a></td>
<td class="nump">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset</a></td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseReceivablesMember', window );">Offices [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LeaseLiabilityAmount', window );">Lease liability amount</a></td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset</a></td>
<td class="nump">$ 762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 21<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DescriptionOfLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of lease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DescriptionOfLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_LeaseLiabilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_LeaseLiabilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_LeasesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_LeasesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_leaseTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_leaseTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633279952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of right-of-use assets<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LeasesDetailsScheduleofrightofuseassetsLineItems', window );"><strong>Leases (Details) - Schedule of right-of-use assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">At January 1, 2022</a></td>
<td class="nump">$ 1,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialExpense', window );">Exchange rate differences</a></td>
<td class="num">(140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsInvestmentProperty', window );">Disposals</a></td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation expense</a></td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">As of December 31, 2022</a></td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=srt_OfficeBuildingMember', window );">Office facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LeasesDetailsScheduleofrightofuseassetsLineItems', window );"><strong>Leases (Details) - Schedule of right-of-use assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">At January 1, 2022</a></td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialExpense', window );">Exchange rate differences</a></td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsInvestmentProperty', window );">Disposals</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation expense</a></td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">As of December 31, 2022</a></td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LeasesDetailsScheduleofrightofuseassetsLineItems', window );"><strong>Leases (Details) - Schedule of right-of-use assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">At January 1, 2022</a></td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialExpense', window );">Exchange rate differences</a></td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsInvestmentProperty', window );">Disposals</a></td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation expense</a></td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">As of December 31, 2022</a></td>
<td class="nump">$ 345<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsInvestmentProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in investment property resulting from disposals. [Refer: Investment property]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2021-01-01<br> -Paragraph 76<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_76_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsInvestmentProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_LeasesDetailsScheduleofrightofuseassetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_LeasesDetailsScheduleofrightofuseassetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634496768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of lease liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems', window );"><strong>Schedule of Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">At January 1, 2022</a></td>
<td class="nump">$ 1,181<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Accretion of interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialExpenses', window );">Financial expenses</a></td>
<td class="nump">24<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExchangeRateDifference', window );">Exchange rate differences</a></td>
<td class="num">(138)<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PrincipalPayment', window );">Payment</a></td>
<td class="num">(350)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">As of December 31, 2022</a></td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="nump">$ 1,181<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExchangeRateDifference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange rate differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExchangeRateDifference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634822768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of profit or loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LeasesDetailsScheduleofprofitorlossLineItems', window );"><strong>Schedule of profit or loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Depreciation expense of right-of-use assets</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalAmountRecognizedInProfitOrLoss', window );">Total amount recognized in profit or loss</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense, amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss. [Refer: Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_LeasesDetailsScheduleofprofitorlossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_LeasesDetailsScheduleofprofitorlossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TotalAmountRecognizedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount recognized in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TotalAmountRecognizedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075631688720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 06, 2022</div></th>
<th class="th">
<div>Nov. 02, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 12, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Nov. 22, 2022</div></th>
<th class="th"><div>May 19, 2022</div></th>
<th class="th"><div>Mar. 24, 2022</div></th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 21, 2021</div></th>
<th class="th">
<div>Dec. 20, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 17, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 20, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationDetailsLineItems', window );"><strong>Share Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GrantTotalShares', window );">Grant total share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit', window );">Restricted stock unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,707,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RestrictedStockUnitVested', window );">Restricted stock unit vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,895,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TotalOrdinaryShares', window );">Total ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GrantOptionDescription', window );">Grant option, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The exercise price per share to 123,719 and 355,029 options
was USD 0.0029 (AUD 0.052) and USD 2.67 (AUD 4.2), respectively. The vesting period is up to 3 years from the grant date, according to
the various vesting periods: from an immediate one and up to 3 years. Contractual life of the options under the Plan is 10 years. The
options were granted under section 102 of the Israeli Tax Ordinance which enables the employee to pay 25% of capital gain tax upon exercise.
&#160;In October 2020, 73,380 options were canceled.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExercisePrice', window );">Exercise price per share | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GrantedTotalOption', window );">Grand total option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ContractualLife', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CapitalGainTax', window );">Capital gain tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NontradableSharesOptions', window );">Non-tradable shares options, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company&#8217;s board
of directors approved a grant of 13,605 non-tradable shares options which are exercisable to 13,605 Ordinary shares to employees and
a total of 21,768 share options which are exercisable to 21,768 Ordinary Shares to consultants. The vesting period is three years commencing
on the grant date. The exercise price per share was NIS 0.37($0.12). The contractual life of the options under the Plan is ten years.
The options to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital
gain tax upon exercise.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NontradableShares', window );">Non-tradable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExercisableOrdinaryShares', window );">Exercisable ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_VestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price per share (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AuthorizedOrdinaryShares', window );">Ordinary shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,180,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GrantTotal', window );">Grant total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_VestOverPeriod', window );">Vest over period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RestrictedStockUnitEmployeesDescription', window );">Restricted Stock Unit Employees Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company&#8217;s board of directors approved
a grant of 536,141 RSUs to employees and a grant of 22,500 RSUs to the Company&#8217;s advisory board members and an additional consultant.
The RSUs represent the right to receive Ordinary Shares at a future time. 555,500 of the RSUs in this grant, vest over a period of three
years, with a 1-year cliff period, and 3,141 RSUs vested immediately on the grant date. The RSUs to employees were granted under Section
102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_BoardOfDirectorsDescription', window );">Board of directors, description</a></td>
<td class="text">the Company&#8217;s board of directors approved
a grant of 285,713 fully vested RSUs to an officer. The RSUs represent the right to receive Ordinary Shares. The RSUs were granted under
Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company&#8217;s board of directors approved
a grant of 165,000 RSUs to employees. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period
of three years, with a 1-year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax
Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.<span></span>
</td>
<td class="text">the Company&#8217;s board of directors approved a
grant of 30,000 RSUs to an employee. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period
of three years, with a 1-year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax
Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.<span></span>
</td>
<td class="text">the Company&#8217;s board
of directors approved a grant of 29,400 Ordinary Shares options to medical board members, which are exercisable to 29,400 Ordinary Shares.
The share options vesting period is up to three years from the grant date. The exercise price per share was NIS 10.84 ($3.08). The contractual
life of the options under the Plan is ten years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueAssumptionsDescription', window );">Description of fair value assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The fair value of all granted options was estimated
by using the Black Scholes model, which was aimed to model the value of the Company&#8217;s assets over time. The simulation approach
was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and
the volatility of its assets, on the date of grant based on certain assumptions. Those conditions are, among others:&#160;
(i)The expected volatility is
between 50%-52.4%
&#160;
(ii)The dividend rate 0%; and
&#160;
(iii)Expected term &#8211; three
years.
&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors', window );">Expenses to employees (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedPaymentExpenses', window );">Share based payment expenses of option to services (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=iinn_RSUMember', window );">RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationDetailsLineItems', window );"><strong>Share Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedPaymentExpenses', window );">Share based payment expenses of option to services (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_AdvisersMember', window );">Advisers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationDetailsLineItems', window );"><strong>Share Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedPaymentExpenses', window );">Share based payment expenses of option to services (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_DirectorsMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationDetailsLineItems', window );"><strong>Share Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedPaymentExpenses', window );">Share based payment expenses of option to services (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationDetailsLineItems', window );"><strong>Share Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OptionsEquity', window );">Options equity percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GrantTotal', window );">Grant total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,658,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationDetailsLineItems', window );"><strong>Share Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_VestOverPeriod', window );">Vest over period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The date on which share-based payment arrangements are granted. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph IG23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateOfGrantOfSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AuthorizedOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AuthorizedOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_BoardOfDirectorsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Board of directors description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_BoardOfDirectorsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_CapitalGainTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital gain tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_CapitalGainTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExercisableOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExercisableOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FairValueAssumptionsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assumptions description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FairValueAssumptionsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GrantOptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant option description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GrantOptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GrantTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GrantTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GrantTotalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GrantTotalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GrantedTotalOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GrantedTotalOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NontradableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-tradable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NontradableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NontradableSharesOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-tradable shares options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NontradableSharesOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OptionsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OptionsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RestrictedStockUnitEmployeesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock unit employees description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RestrictedStockUnitEmployeesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RestrictedStockUnitVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock unit vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RestrictedStockUnitVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedPaymentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedPaymentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TotalOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of total ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TotalOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_VestOverPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_VestOverPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_VestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_VestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=iinn_RSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=iinn_RSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_AdvisersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_AdvisersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=iinn_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075631574384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Details) - Schedule of options to services providers and advisers outstanding<br> pure in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=iinn_ProvidersAndAdvisersMember', window );">Providers and advisers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems', window );"><strong>Share Based Compensation (Details) - Schedule of options to services providers and advisers outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options Outstanding at beginning of year</a></td>
<td class="nump">87,833<span></span>
</td>
<td class="nump">165,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average Exercise price NIS Outstanding at beginning of year</a></td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares', window );">Number of options Reclassified to employees and directors (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS Reclassified to employees and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GrantedNumberOfOptions', window );">Number of options Granted (in Shares) | shares</a></td>
<td class="nump">29,400<span></span>
</td>
<td class="nump">16,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Weighted average Exercise price NIS Granted</a></td>
<td class="nump">$ 10.84<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExercisedNumberOfOptions', window );">Number of options Exercised (in Shares) | shares</a></td>
<td class="num">(2,721)<span></span>
</td>
<td class="num">(20,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExercisedWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS Exercised</a></td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of options Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ForfeitedWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options Outstanding ending year</a></td>
<td class="nump">114,512<span></span>
</td>
<td class="nump">87,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average Exercise price NIS Outstanding ending year</a></td>
<td class="nump">$ 3.058<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExercisableOptionsNumberOfOptions', window );">Number of options Exercisable options (in Shares) | shares</a></td>
<td class="nump">82,257<span></span>
</td>
<td class="nump">62,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average Exercise price NIS Exercisable options</a></td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=iinn_EmployeesAndDirectorsMember', window );">Employees and directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems', window );"><strong>Share Based Compensation (Details) - Schedule of options to services providers and advisers outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options Outstanding at beginning of year</a></td>
<td class="nump">448,120<span></span>
</td>
<td class="nump">296,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average Exercise price NIS Outstanding at beginning of year</a></td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares', window );">Number of options Reclassified to employees and directors (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS Reclassified to employees and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GrantedNumberOfOptions', window );">Number of options Granted (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Weighted average Exercise price NIS Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExercisedNumberOfOptions', window );">Number of options Exercised (in Shares) | shares</a></td>
<td class="nump">4,309<span></span>
</td>
<td class="num">(4,544)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExercisedWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS Exercised</a></td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of options Forfeited</a></td>
<td class="num">(57,551)<span></span>
</td>
<td class="num">(9,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ForfeitedWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS Forfeited</a></td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options Outstanding ending year</a></td>
<td class="nump">386,260<span></span>
</td>
<td class="nump">448,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average Exercise price NIS Outstanding ending year</a></td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExercisableOptionsNumberOfOptions', window );">Number of options Exercisable options (in Shares) | shares</a></td>
<td class="nump">342,757<span></span>
</td>
<td class="nump">347,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average Exercise price NIS Exercisable options</a></td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExercisableOptionsNumberOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExercisableOptionsNumberOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExercisedNumberOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExercisedNumberOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ForfeitedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ForfeitedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GrantedNumberOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GrantedNumberOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=iinn_ProvidersAndAdvisersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=iinn_ProvidersAndAdvisersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=iinn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=iinn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633325552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Details) - Schedule of RSUs to services providers and advisers outstanding - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_ProvidersAndAdvisersMember', window );">Providers and advisers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems', window );"><strong>Share Based Compensation (Details) - Schedule of RSUs to services providers and advisers outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OutstandingAtBeginningOfYears', window );">Outstanding at beginning of year</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Granted', window );">Granted</a></td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Vested', window );">Vested</a></td>
<td class="num">(14,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OutstandingAtBeginningOfYears', window );">Outstanding as of December 31, 2022</a></td>
<td class="nump">18,266<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExercisableRSUs', window );">Exercisable RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RestrictedStockUnitVested', window );">Vested as of December 31, 2022</a></td>
<td class="nump">14,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_EmployeesAndDirectorsMember', window );">Employees and directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems', window );"><strong>Share Based Compensation (Details) - Schedule of RSUs to services providers and advisers outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OutstandingAtBeginningOfYears', window );">Outstanding at beginning of year</a></td>
<td class="nump">2,002,587<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Granted', window );">Granted</a></td>
<td class="nump">1,016,854<span></span>
</td>
<td class="nump">2,658,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Forfeited', window );">Forfeited</a></td>
<td class="num">(65,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Vested', window );">Vested</a></td>
<td class="num">(1,225,973)<span></span>
</td>
<td class="num">(655,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OutstandingAtBeginningOfYears', window );">Outstanding as of December 31, 2022</a></td>
<td class="nump">1,727,842<span></span>
</td>
<td class="nump">2,002,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RestrictedStockUnitVested', window );">Vested as of December 31, 2022</a></td>
<td class="nump">1,881,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExercisableRSUs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExercisableRSUs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_Forfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_Forfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_Granted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_Granted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OutstandingAtBeginningOfYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding at beginning of year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OutstandingAtBeginningOfYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RestrictedStockUnitVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock unit vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RestrictedStockUnitVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_Vested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_Vested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_ProvidersAndAdvisersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_ProvidersAndAdvisersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iinn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639242272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - Schedule of shareholders and other related parties&#8217; benefits - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems', window );"><strong>Schedule of shareholders and other related parties&#8217; benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Salary and related expenses &#8211; officers and directors</a></td>
<td class="nump">$ 1,923<span></span>
</td>
<td class="nump">$ 1,042<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedPaymentEmployeesAndDirectors', window );">Share based payment &#8211; officers and directors</a></td>
<td class="nump">$ 3,745<span></span>
</td>
<td class="nump">$ 5,876<span></span>
</td>
<td class="nump">$ 1,805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedPaymentEmployeesAndDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment - employees and directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedPaymentEmployeesAndDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075636257440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - Schedule of balances with related parties<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=iinn_EmployeesMember', window );">Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems', window );"><strong>Schedule of balances with related parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NatureOfTransactionSalariesAndRelated', window );">Nature of transaction, Salaries and related</a></td>
<td class="text">Salaries and related<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany', window );">Nature of transaction, Compensation for directors</a></td>
<td class="text">(292)<span></span>
</td>
<td class="text">(317)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=iinn_DirectorsMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems', window );"><strong>Schedule of balances with related parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NatureOfTransactionSalariesAndRelated', window );">Nature of transaction, Salaries and related</a></td>
<td class="text">Compensation for directors<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany', window );">Nature of transaction, Compensation for directors</a></td>
<td class="text">(40)<span></span>
</td>
<td class="text">(57)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NatureOfTransactionSalariesAndRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NatureOfTransactionSalariesAndRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=iinn_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=iinn_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=iinn_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=iinn_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633702144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Risk Management (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract', window );"><strong>Financial Instruments and Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_strengtheningPercentage', window );">Strengthening percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_weakeningPercentage', window );">Weakening percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_strengtheningPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strengthening percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_strengtheningPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_weakeningPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weakening percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_weakeningPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633868576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Risk Management (Details) - Schedule of financial assets represents the maximum credit exposure - Credit risk [member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems', window );"><strong>Financial Instruments and Risk Management (Details) - Schedule of financial assets represents the maximum credit exposure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,783<span></span>
</td>
<td class="nump">$ 23,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Deposits</a></td>
<td class="nump">7,120<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other current assets (Restricted deposits)</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total</a></td>
<td class="nump">$ 13,959<span></span>
</td>
<td class="nump">$ 23,869<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634281552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Risk Management (Details) - Schedule of foreign currency denominated monetary liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AssetsAbstract0', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,766<span></span>
</td>
<td class="nump">$ 19,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Deposit', window );">Deposits</a></td>
<td class="nump">7,120<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total assets</a></td>
<td class="nump">10,886<span></span>
</td>
<td class="nump">19,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">3,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialAssets', window );">Total</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">3,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Net</a></td>
<td class="nump">$ 10,518<span></span>
</td>
<td class="nump">$ 16,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AssetsAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AssetsAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_Deposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_Deposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639246592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=iinn_USDMemberMember', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems', window );"><strong>Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SensitivityAnalysis', window );">Sensitivity analysis</a></td>
<td class="nump">$ 1,051<span></span>
</td>
<td class="nump">$ 1,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=iinn_AUDMember', window );">AUD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems', window );"><strong>Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SensitivityAnalysis', window );">Sensitivity analysis</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=iinn_PoundMember', window );">GB Pound [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems', window );"><strong>Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SensitivityAnalysis', window );">Sensitivity analysis</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SensitivityAnalysis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity analysis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SensitivityAnalysis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=iinn_USDMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=iinn_USDMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=iinn_AUDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=iinn_AUDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=iinn_PoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=iinn_PoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634618000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=iinn_UpTo1YearMember', window );">Up to 1 year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems', window );"><strong>Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="nump">$ 719<span></span>
</td>
<td class="nump">$ 611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties', window );">Loan from the IIA</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=iinn_Between1And3YearsMember', window );">Between 1 and 3 years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems', window );"><strong>Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties', window );">Loan from the IIA</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=iinn_MoreThan3YearsMember', window );">More than 3 years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems', window );"><strong>Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties', window );">Loan from the IIA</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="nump">$ 1,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 58<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables due from related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=iinn_UpTo1YearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=iinn_UpTo1YearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=iinn_Between1And3YearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=iinn_Between1And3YearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=iinn_MoreThan3YearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=iinn_MoreThan3YearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075634739792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Prepayments', window );">Prepayment paid (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExchangeAmount', window );">Exchange amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OrdinaryShares', window );">Ordinary shares</a></td>
<td class="nump">2,113,905<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Prepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables that represent amounts paid for goods and services before they have been delivered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Prepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExchangeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExchangeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075639432720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsLineItems', window );"><strong>Fair Value Measurement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsLineItems', window );"><strong>Fair Value Measurement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate, percentage</a></td>
<td class="nump">5.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility, percentage</a></td>
<td class="nump">56.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExpectedTermOfWarrants', window );">Expected term of warrant</a></td>
<td class="text">1 year 6 months 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsLineItems', window );"><strong>Fair Value Measurement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate, percentage</a></td>
<td class="nump">5.26%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExpectedTermOfWarrants', window );">Expected term of warrant</a></td>
<td class="text">2 years 6 months 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsLineItems', window );"><strong>Fair Value Measurement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility, percentage</a></td>
<td class="nump">57.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=iinn_fairValueMeasurementAtLevel2Member', window );">Fair Value Measurement Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsLineItems', window );"><strong>Fair Value Measurement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=iinn_fairValueMeasurementAtLevel2Member', window );">Fair Value Measurement Level 2 [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsLineItems', window );"><strong>Fair Value Measurement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate, percentage</a></td>
<td class="nump">0.19%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility, percentage</a></td>
<td class="nump">55.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExpectedTermOfWarrants', window );">Expected term of warrant</a></td>
<td class="text">2 years 6 months 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=iinn_fairValueMeasurementAtLevel2Member', window );">Fair Value Measurement Level 2 [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsLineItems', window );"><strong>Fair Value Measurement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate, percentage</a></td>
<td class="nump">0.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility, percentage</a></td>
<td class="nump">57.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExpectedTermOfWarrants', window );">Expected term of warrant</a></td>
<td class="text">54 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExpectedTermOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExpectedTermOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FairValueMeasurementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FairValueMeasurementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=iinn_fairValueMeasurementAtLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=iinn_fairValueMeasurementAtLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075631615760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Details) - Schedule of warrants - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems', window );"><strong>Fair Value Measurement (Details) - Schedule of warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NontradableWarrantFairValue', window );">Non-tradable Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors', window );">Non-tradable warrants of SAFE and Convertible Loan investors</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Tradable warrants</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Total</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems', window );"><strong>Fair Value Measurement (Details) - Schedule of warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NontradableWarrantFairValue', window );">Non-tradable Warrants</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors', window );">Non-tradable warrants of SAFE and Convertible Loan investors</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liability</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Tradable warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Total</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">1,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems', window );"><strong>Fair Value Measurement (Details) - Schedule of warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NontradableWarrantFairValue', window );">Non-tradable Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors', window );">Non-tradable warrants of SAFE and Convertible Loan investors</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Tradable warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NontradableWarrantFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-tradable warrants fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NontradableWarrantFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-tradable warrants of SAFE and Convertible Loan investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075633600416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Details) - Schedule of movements in level 2 liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems', window );"><strong>Schedule of movements in level 2 liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_BalanceAtBeginning', window );">Balance as of December 31, 2020</a></td>
<td class="nump">$ 1,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GainslossesRecognizedInProfitLoss', window );">Gains (losses) recognized in profit or loss</a></td>
<td class="nump">3,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Addition', window );">Additions</a></td>
<td class="nump">7,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments', window );">Conversion</a></td>
<td class="num">(10,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AdjustmentsArisingFromTranslatingFinancialOperations', window );">Adjustments arising from translating financial operation</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_BalanceAtEnding', window );">Balance as of December,31 2021</a></td>
<td class="nump">1,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=iinn_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems', window );"><strong>Schedule of movements in level 2 liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_BalanceAtBeginning', window );">Balance as of December 31, 2020</a></td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GainslossesRecognizedInProfitLoss', window );">Gains (losses) recognized in profit or loss</a></td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Addition', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments', window );">Conversion</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AdjustmentsArisingFromTranslatingFinancialOperations', window );">Adjustments arising from translating financial operation</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_BalanceAtEnding', window );">Balance as of December,31 2021</a></td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=iinn_SAFEMember', window );">SAFE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems', window );"><strong>Schedule of movements in level 2 liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_BalanceAtBeginning', window );">Balance as of December 31, 2020</a></td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GainslossesRecognizedInProfitLoss', window );">Gains (losses) recognized in profit or loss</a></td>
<td class="nump">2,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Addition', window );">Additions</a></td>
<td class="nump">4,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments', window );">Conversion</a></td>
<td class="num">(6,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AdjustmentsArisingFromTranslatingFinancialOperations', window );">Adjustments arising from translating financial operation</a></td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_BalanceAtEnding', window );">Balance as of December,31 2021</a></td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=iinn_ConvertibleLoanMember', window );">Convertible loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems', window );"><strong>Schedule of movements in level 2 liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_BalanceAtBeginning', window );">Balance as of December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GainslossesRecognizedInProfitLoss', window );">Gains (losses) recognized in profit or loss</a></td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Addition', window );">Additions</a></td>
<td class="nump">3,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments', window );">Conversion</a></td>
<td class="num">(3,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AdjustmentsArisingFromTranslatingFinancialOperations', window );">Adjustments arising from translating financial operation</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_BalanceAtEnding', window );">Balance as of December,31 2021</a></td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=iinn_FinancialDerivativeMember', window );">Financial Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems', window );"><strong>Schedule of movements in level 2 liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_BalanceAtBeginning', window );">Balance as of December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GainslossesRecognizedInProfitLoss', window );">Gains (losses) recognized in profit or loss</a></td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Addition', window );">Additions</a></td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments', window );">Conversion</a></td>
<td class="num">(656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AdjustmentsArisingFromTranslatingFinancialOperations', window );">Adjustments arising from translating financial operation</a></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_BalanceAtEnding', window );">Balance as of December,31 2021</a></td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the fair value measurement of the entity's own equity instruments. [Refer: At fair value [member]; Entity's own equity instruments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_Addition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_Addition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AdjustmentsArisingFromTranslatingFinancialOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AdjustmentsArisingFromTranslatingFinancialOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_BalanceAtBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_BalanceAtBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_BalanceAtEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_BalanceAtEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GainslossesRecognizedInProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GainslossesRecognizedInProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=iinn_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=iinn_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=iinn_SAFEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=iinn_SAFEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=iinn_ConvertibleLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=iinn_ConvertibleLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=iinn_FinancialDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=iinn_FinancialDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>f20f2022_inspiratech_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full"
  xmlns:iinn="http://www.inspiratechnologies.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="iinn-20221231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:ComputersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:LeaseholdImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2022-08-24</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iinn:InvestmentNameAxis">iinn:WarrantsToInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iinn:InvestmentNameAxis">iinn:WarrantsToBrokersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iinn:InitialPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:NontradableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:NontradableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:NontradableWarrantsSAFEAndCLAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:NontradableWarrantsSAFEAndCLAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:TradableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:TradableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:FinancialLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iinn:FinancialLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iinn:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iinn:OverallotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iinn:BrokersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-12-17</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">iinn:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-17</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-20</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-21</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-02</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-02</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-02</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-19</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iinn:AdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iinn:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">iinn:RSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:ProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">iinn:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">iinn:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">iinn:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">iinn:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">iinn:USDMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">iinn:USDMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">iinn:AUDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">iinn:AUDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">iinn:PoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">iinn:PoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">iinn:UpTo1YearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">iinn:Between1And3YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">iinn:MoreThan3YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">iinn:UpTo1YearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">iinn:Between1And3YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">iinn:MoreThan3YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">iinn:fairValueMeasurementAtLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">iinn:fairValueMeasurementAtLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">iinn:fairValueMeasurementAtLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:SAFEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ConvertibleLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:FinancialDerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:SAFEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:ConvertibleLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iinn:FinancialDerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentType contextRef="c0">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0">001-40303</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c1">2 Ha-Tidhar St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c1">Ra&#x2019;anana</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1">4366504</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c1">972.4</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1">6230333</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName contextRef="c1">Dagi Ben-Noon</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c0">2 Ha-Tidhar St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">Ra&#x2019;anana</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0">4366504</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0">IL</dei:EntityAddressCountry>
    <dei:Security12bTitle contextRef="c0">Ordinary Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">IINN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">11338940</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:AuditorName contextRef="c0">Ziv Haft</dei:AuditorName>
    <dei:AuditorFirmId contextRef="c0">1185</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="c0">Tel-Aviv, Israel</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">6783000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">23749000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">7120000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:OtherCurrentAssets contextRef="c2" decimals="-3" unitRef="usd">591000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c3" decimals="-3" unitRef="usd">759000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c2" decimals="-3" unitRef="usd">14494000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c3" decimals="-3" unitRef="usd">24508000</ifrs-full:CurrentAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c2" decimals="-3" unitRef="usd">1107000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c3" decimals="-3" unitRef="usd">1160000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="-3" unitRef="usd">411000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">202000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:NoncurrentAssets contextRef="c2" decimals="-3" unitRef="usd">1518000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c3" decimals="-3" unitRef="usd">1362000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c2" decimals="-3" unitRef="usd">16012000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c3" decimals="-3" unitRef="usd">25870000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="-3" unitRef="usd">150000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c3" decimals="-3" unitRef="usd">93000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables contextRef="c2" decimals="-3" unitRef="usd">1217000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables contextRef="c3" decimals="-3" unitRef="usd">725000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="-3" unitRef="usd">329000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c3" decimals="-3" unitRef="usd">281000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities contextRef="c2" decimals="-3" unitRef="usd">368000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities contextRef="c3" decimals="-3" unitRef="usd">3215000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c2" decimals="-3" unitRef="usd">2064000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c3" decimals="-3" unitRef="usd">4314000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c2" decimals="-3" unitRef="usd">728000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c3" decimals="-3" unitRef="usd">900000</ifrs-full:NoncurrentLeaseLiabilities>
    <iinn:LoanFromTheIsraeliInnovationAuthority contextRef="c2" decimals="-3" unitRef="usd">398000</iinn:LoanFromTheIsraeliInnovationAuthority>
    <iinn:LoanFromTheIsraeliInnovationAuthority contextRef="c3" decimals="-3" unitRef="usd">302000</iinn:LoanFromTheIsraeliInnovationAuthority>
    <ifrs-full:NoncurrentLiabilities contextRef="c2" decimals="-3" unitRef="usd">1126000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c3" decimals="-3" unitRef="usd">1202000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:SharePremium contextRef="c2" decimals="-3" unitRef="usd">53814000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c3" decimals="-3" unitRef="usd">48935000</ifrs-full:SharePremium>
    <ifrs-full:OtherReserves contextRef="c2" decimals="-3" unitRef="usd">-1928000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c3" decimals="-3" unitRef="usd">210000</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="-3" unitRef="usd">-39064000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c3" decimals="-3" unitRef="usd">-28791000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="c2" decimals="-3" unitRef="usd">12822000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" unitRef="usd">20354000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c2" decimals="-3" unitRef="usd">16012000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c3" decimals="-3" unitRef="usd">25870000</ifrs-full:EquityAndLiabilities>
    <iinn:ResearchAndDevelopmentExpenses contextRef="c0" decimals="-3" unitRef="usd">8054000</iinn:ResearchAndDevelopmentExpenses>
    <iinn:ResearchAndDevelopmentExpenses contextRef="c4" decimals="-3" unitRef="usd">3909000</iinn:ResearchAndDevelopmentExpenses>
    <iinn:ResearchAndDevelopmentExpenses contextRef="c5" decimals="-3" unitRef="usd">3873000</iinn:ResearchAndDevelopmentExpenses>
    <iinn:SalesAndMarketingExpenses contextRef="c0" decimals="-3" unitRef="usd">1325000</iinn:SalesAndMarketingExpenses>
    <iinn:SalesAndMarketingExpenses contextRef="c4" decimals="-3" unitRef="usd">1951000</iinn:SalesAndMarketingExpenses>
    <iinn:GeneralAndAdministrativeExpenses contextRef="c0" decimals="-3" unitRef="usd">5391000</iinn:GeneralAndAdministrativeExpenses>
    <iinn:GeneralAndAdministrativeExpenses contextRef="c4" decimals="-3" unitRef="usd">7572000</iinn:GeneralAndAdministrativeExpenses>
    <iinn:GeneralAndAdministrativeExpenses contextRef="c5" decimals="-3" unitRef="usd">2447000</iinn:GeneralAndAdministrativeExpenses>
    <ifrs-full:OtherGainsLosses contextRef="c5" decimals="-3" unitRef="usd">-51000</ifrs-full:OtherGainsLosses>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">14770000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c4" decimals="-3" unitRef="usd">13432000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c5" decimals="-3" unitRef="usd">6269000</ifrs-full:ProfitLossFromOperatingActivities>
    <iinn:FinanceExpense contextRef="c0" decimals="-3" unitRef="usd">181000</iinn:FinanceExpense>
    <iinn:FinanceExpense contextRef="c4" decimals="-3" unitRef="usd">3524000</iinn:FinanceExpense>
    <iinn:FinanceExpense contextRef="c5" decimals="-3" unitRef="usd">959000</iinn:FinanceExpense>
    <ifrs-full:FinanceIncomeCost contextRef="c0" decimals="-3" unitRef="usd">-4678000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c4" decimals="-3" unitRef="usd">-1000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="-3" unitRef="usd">10273000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c4" decimals="-3" unitRef="usd">16955000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c5" decimals="-3" unitRef="usd">7228000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossFromContinuingOperations contextRef="c0" decimals="-3" unitRef="usd">10273000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations contextRef="c4" decimals="-3" unitRef="usd">16955000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations contextRef="c5" decimals="-3" unitRef="usd">7228000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c0" decimals="-3" unitRef="usd">2138000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c4" decimals="-3" unitRef="usd">-845000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c5" decimals="-3" unitRef="usd">599000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:OtherComprehensiveIncome contextRef="c0" decimals="-3" unitRef="usd">12411000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c4" decimals="-3" unitRef="usd">16110000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c5" decimals="-3" unitRef="usd">7827000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:WeightedAverageShares contextRef="c0" decimals="INF" unitRef="shares">10794594</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c4" decimals="INF" unitRef="shares">5306225</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c5" decimals="INF" unitRef="shares">1967790</ifrs-full:WeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare contextRef="c0" decimals="2" unitRef="usdPershares">-0.95</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare contextRef="c4" decimals="1" unitRef="usdPershares">-3.2</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare contextRef="c5" decimals="2" unitRef="usdPershares">-3.67</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c6" decimals="INF" unitRef="shares">10091706</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c6" decimals="-3" unitRef="usd">48935000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c7" decimals="-3" unitRef="usd">210000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c8" decimals="-3" unitRef="usd">-28791000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" unitRef="usd">20354000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c11" decimals="-3" unitRef="usd">-10273000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" unitRef="usd">-10273000</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c10" decimals="-3" unitRef="usd">2138000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c0" decimals="-3" unitRef="usd">2138000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <iinn:TotalComprehensiveLoss contextRef="c10" decimals="-3" unitRef="usd">-2138000</iinn:TotalComprehensiveLoss>
    <iinn:TotalComprehensiveLoss contextRef="c11" decimals="-3" unitRef="usd">-10273000</iinn:TotalComprehensiveLoss>
    <iinn:TotalComprehensiveLoss contextRef="c0" decimals="-3" unitRef="usd">-12411000</iinn:TotalComprehensiveLoss>
    <iinn:ShareBasedCompensationToExercise contextRef="c9" decimals="INF" unitRef="shares">7030</iinn:ShareBasedCompensationToExercise>
    <iinn:StockIssuedDuringPeriodSharesRestrictedStockUnit contextRef="c9" decimals="INF" unitRef="shares">1240204</iinn:StockIssuedDuringPeriodSharesRestrictedStockUnit>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c9" decimals="-3" unitRef="usd">4879000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c0" decimals="-3" unitRef="usd">4879000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c12" decimals="INF" unitRef="shares">11338940</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c12" decimals="-3" unitRef="usd">53814000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c13" decimals="-3" unitRef="usd">-1928000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c14" decimals="-3" unitRef="usd">-39064000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="-3" unitRef="usd">12822000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c15" decimals="INF" unitRef="shares">2661095</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c15" decimals="-3" unitRef="usd">304000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c16" decimals="-3" unitRef="usd">10463000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c17" decimals="-3" unitRef="usd">-635000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c18" decimals="-3" unitRef="usd">-11836000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c19" decimals="-3" unitRef="usd">-1704000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c23" decimals="-3" unitRef="usd">-16955000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" unitRef="usd">-16955000</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c22" decimals="-3" unitRef="usd">-845000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c4" decimals="-3" unitRef="usd">-845000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <iinn:TotalComprehensiveLoss contextRef="c22" decimals="-3" unitRef="usd">845000</iinn:TotalComprehensiveLoss>
    <iinn:TotalComprehensiveLoss contextRef="c23" decimals="-3" unitRef="usd">-16955000</iinn:TotalComprehensiveLoss>
    <iinn:TotalComprehensiveLoss contextRef="c4" decimals="-3" unitRef="usd">-16110000</iinn:TotalComprehensiveLoss>
    <iinn:ParValueCancellations contextRef="c20" decimals="-3" unitRef="usd">-304000</iinn:ParValueCancellations>
    <iinn:ParValueCancellations contextRef="c21" decimals="-3" unitRef="usd">304000</iinn:ParValueCancellations>
    <iinn:ShareIssuanceOfInitialPublicOffering contextRef="c20" decimals="INF" unitRef="shares">2931472</iinn:ShareIssuanceOfInitialPublicOffering>
    <iinn:InitialPublicOffering contextRef="c21" decimals="-3" unitRef="usd">9852000</iinn:InitialPublicOffering>
    <iinn:InitialPublicOffering contextRef="c4" decimals="-3" unitRef="usd">9852000</iinn:InitialPublicOffering>
    <iinn:ConversionOfFinancialLiabilityinShares contextRef="c20" decimals="INF" unitRef="shares">2113905</iinn:ConversionOfFinancialLiabilityinShares>
    <ifrs-full:IssueOfConvertibleInstruments contextRef="c21" decimals="-3" unitRef="usd">10041000</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:IssueOfConvertibleInstruments contextRef="c4" decimals="-3" unitRef="usd">10041000</ifrs-full:IssueOfConvertibleInstruments>
    <iinn:TradableWarrantsExerciseinShares contextRef="c20" decimals="INF" unitRef="shares">1705000</iinn:TradableWarrantsExerciseinShares>
    <iinn:TradableWarrantsExercise contextRef="c21" decimals="-3" unitRef="usd">11447000</iinn:TradableWarrantsExercise>
    <iinn:TradableWarrantsExercise contextRef="c4" decimals="-3" unitRef="usd">11447000</iinn:TradableWarrantsExercise>
    <iinn:StockIssuedDuringPeriodSharesRestrictedStockUnit contextRef="c20" decimals="INF" unitRef="shares">655603</iinn:StockIssuedDuringPeriodSharesRestrictedStockUnit>
    <iinn:ShareBasedCompensationToExercise contextRef="c20" decimals="INF" unitRef="shares">24631</iinn:ShareBasedCompensationToExercise>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c21" decimals="-3" unitRef="usd">6828000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c4" decimals="-3" unitRef="usd">6828000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c6" decimals="INF" unitRef="shares">10091706</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c24" decimals="-3" unitRef="usd">48935000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c7" decimals="-3" unitRef="usd">210000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c8" decimals="-3" unitRef="usd">-28791000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" unitRef="usd">20354000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c25" decimals="INF" unitRef="shares">1904762</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c25" decimals="-3" unitRef="usd">3000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c27" decimals="-3" unitRef="usd">-36000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c28" decimals="-3" unitRef="usd">-4608000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c29" decimals="-3" unitRef="usd">-4641000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c33" decimals="-3" unitRef="usd">-7228000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" unitRef="usd">-7228000</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c32" decimals="-3" unitRef="usd">599000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c5" decimals="-3" unitRef="usd">599000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <iinn:TotalComprehensiveLoss contextRef="c32" decimals="-3" unitRef="usd">-599000</iinn:TotalComprehensiveLoss>
    <iinn:TotalComprehensiveLoss contextRef="c33" decimals="-3" unitRef="usd">-7228000</iinn:TotalComprehensiveLoss>
    <iinn:TotalComprehensiveLoss contextRef="c5" decimals="-3" unitRef="usd">-7827000</iinn:TotalComprehensiveLoss>
    <iinn:ShareSplit contextRef="c30" decimals="-3" unitRef="usd">215000</iinn:ShareSplit>
    <iinn:ShareSplit contextRef="c31" decimals="-3" unitRef="usd">-215000</iinn:ShareSplit>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c31" decimals="-3" unitRef="usd">3896000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c5" decimals="-3" unitRef="usd">3896000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <iinn:OptionsExercise contextRef="c30" decimals="-3" unitRef="usd">9000</iinn:OptionsExercise>
    <iinn:OptionsExercise contextRef="c31" decimals="-3" unitRef="usd">-9000</iinn:OptionsExercise>
    <iinn:ConversionOfConvertibleLoanToSharesinShares contextRef="c30" decimals="INF" unitRef="shares">756333</iinn:ConversionOfConvertibleLoanToSharesinShares>
    <iinn:ConversionOfConvertibleLoanToShares contextRef="c30" decimals="-3" unitRef="usd">77000</iinn:ConversionOfConvertibleLoanToShares>
    <iinn:ConversionOfConvertibleLoanToShares contextRef="c31" decimals="-3" unitRef="usd">6791000</iinn:ConversionOfConvertibleLoanToShares>
    <iinn:ConversionOfConvertibleLoanToShares contextRef="c5" decimals="-3" unitRef="usd">6868000</iinn:ConversionOfConvertibleLoanToShares>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c15" decimals="INF" unitRef="shares">2661095</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c15" decimals="-3" unitRef="usd">304000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c16" decimals="-3" unitRef="usd">10463000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c17" decimals="-3" unitRef="usd">-635000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c18" decimals="-3" unitRef="usd">-11836000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c19" decimals="-3" unitRef="usd">-1704000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" unitRef="usd">-10273000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" unitRef="usd">-16955000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" unitRef="usd">-7228000</ifrs-full:ProfitLoss>
    <ifrs-full:DepreciationExpense contextRef="c0" decimals="-3" unitRef="usd">361000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c4" decimals="-3" unitRef="usd">237000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c5" decimals="-3" unitRef="usd">203000</ifrs-full:DepreciationExpense>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c5" decimals="-3" unitRef="usd">204000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" unitRef="usd">4879000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c4" decimals="-3" unitRef="usd">6630000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c5" decimals="-3" unitRef="usd">3896000</ifrs-full:AdjustmentsForSharebasedPayments>
    <iinn:ChangeInFairValueOfFinancialLiabilitiesAtFairValue contextRef="c0" decimals="-3" unitRef="usd">-2592000</iinn:ChangeInFairValueOfFinancialLiabilitiesAtFairValue>
    <iinn:ChangeInFairValueOfFinancialLiabilitiesAtFairValue contextRef="c4" decimals="-3" unitRef="usd">2313000</iinn:ChangeInFairValueOfFinancialLiabilitiesAtFairValue>
    <iinn:ChangeInFairValueOfFinancialLiabilitiesAtFairValue contextRef="c5" decimals="-3" unitRef="usd">689000</iinn:ChangeInFairValueOfFinancialLiabilitiesAtFairValue>
    <ifrs-full:AdjustmentsForFairValueGainsLosses contextRef="c4" decimals="-3" unitRef="usd">219000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <iinn:RevaluationOfLoanFromTheIsraeliInnovationAuthority contextRef="c4" decimals="-3" unitRef="usd">-180000</iinn:RevaluationOfLoanFromTheIsraeliInnovationAuthority>
    <iinn:FinanceExpensesReceivedClassifiedAsOperatingActivitiy contextRef="c0" decimals="-3" unitRef="usd">-459000</iinn:FinanceExpensesReceivedClassifiedAsOperatingActivitiy>
    <iinn:FinanceExpensesReceivedClassifiedAsOperatingActivitiy contextRef="c4" decimals="-3" unitRef="usd">92000</iinn:FinanceExpensesReceivedClassifiedAsOperatingActivitiy>
    <iinn:FinanceExpensesReceivedClassifiedAsOperatingActivitiy contextRef="c5" decimals="-3" unitRef="usd">12000</iinn:FinanceExpensesReceivedClassifiedAsOperatingActivitiy>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="c0" decimals="-3" unitRef="usd">29000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="c4" decimals="-3" unitRef="usd">-468000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="c5" decimals="-3" unitRef="usd">10000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c0" decimals="-3" unitRef="usd">71000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c4" decimals="-3" unitRef="usd">87000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c5" decimals="-3" unitRef="usd">-70000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c0" decimals="-3" unitRef="usd">604000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c4" decimals="-3" unitRef="usd">148000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c5" decimals="-3" unitRef="usd">408000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-7380000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c4" decimals="-3" unitRef="usd">-7877000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c5" decimals="-3" unitRef="usd">-1876000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">304000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c4" decimals="-3" unitRef="usd">176000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c5" decimals="-3" unitRef="usd">23000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <iinn:PaymentOfDeposit contextRef="c0" decimals="-3" unitRef="usd">55000</iinn:PaymentOfDeposit>
    <iinn:PaymentOfDeposit contextRef="c4" decimals="-3" unitRef="usd">-70000</iinn:PaymentOfDeposit>
    <iinn:PaymentOfDeposit contextRef="c5" decimals="-3" unitRef="usd">-3000</iinn:PaymentOfDeposit>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c0" decimals="-3" unitRef="usd">-7000000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">-7249000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c4" decimals="-3" unitRef="usd">-246000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c5" decimals="-3" unitRef="usd">-26000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:DividendsPaidClassifiedAsFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">399000</ifrs-full:DividendsPaidClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidClassifiedAsFinancingActivities contextRef="c4" decimals="-3" unitRef="usd">199000</ifrs-full:DividendsPaidClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidClassifiedAsFinancingActivities contextRef="c5" decimals="-3" unitRef="usd">176000</ifrs-full:DividendsPaidClassifiedAsFinancingActivities>
    <iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan contextRef="c4" decimals="-3" unitRef="usd">7208000</iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan>
    <iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan contextRef="c5" decimals="-3" unitRef="usd">2157000</iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan>
    <iinn:ReceiptOfIPOFunds contextRef="c4" decimals="-3" unitRef="usd">-14658000</iinn:ReceiptOfIPOFunds>
    <iinn:ReceiptOfWarrantsExerciseFundsNetFromFees contextRef="c4" decimals="-3" unitRef="usd">8721000</iinn:ReceiptOfWarrantsExerciseFundsNetFromFees>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c4" decimals="-3" unitRef="usd">34000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c5" decimals="-3" unitRef="usd">308000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">-399000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c4" decimals="-3" unitRef="usd">30422000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c5" decimals="-3" unitRef="usd">2289000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c0" decimals="-3" unitRef="usd">-15028000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c4" decimals="-3" unitRef="usd">22299000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c5" decimals="-3" unitRef="usd">387000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">23749000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c19" decimals="-3" unitRef="usd">496000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c29" decimals="-3" unitRef="usd">96000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c0" decimals="-3" unitRef="usd">-1938000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c4" decimals="-3" unitRef="usd">954000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c5" decimals="-3" unitRef="usd">13000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">6783000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">23749000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c19" decimals="-3" unitRef="usd">496000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c4" decimals="-3" unitRef="usd">10041000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <iinn:TradableWarrantsLiability contextRef="c4" decimals="-3" unitRef="usd">-4373000</iinn:TradableWarrantsLiability>
    <iinn:TradableWarrantsDerivativeLiability contextRef="c4" decimals="-3" unitRef="usd">-234000</iinn:TradableWarrantsDerivativeLiability>
    <iinn:ShareBasedCompensationUnderwritersFees contextRef="c4" decimals="-3" unitRef="usd">198000</iinn:ShareBasedCompensationUnderwritersFees>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c4" decimals="-3" unitRef="usd">656000</ifrs-full:ProceedsFromExerciseOfOptions>
    <iinn:WarrantsExerciseLiabilityIssuance contextRef="c4" decimals="-3" unitRef="usd">2070000</iinn:WarrantsExerciseLiabilityIssuance>
    <iinn:TotalNonCashTransactions contextRef="c4" decimals="-3" unitRef="usd">8358000</iinn:TotalNonCashTransactions>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="c0" decimals="-3" unitRef="usd">37000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="c4" decimals="-3" unitRef="usd">6000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="c5" decimals="-3" unitRef="usd">45000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 1 - GENERAL:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Inspira Technologies Oxy B.H.N. Ltd (formerly: Insense Medical Ltd.)
    (the &#x201c;Company&#x201d;) was incorporated in Israel and commenced its operations on February 27, 2018. The Company&#x2019;s functional
    currency is the New Israeli Shekel (&#x201c;NIS&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company operates in the
medical technology industry in the field of respiratory support technology engaged in the research, development, manufacturing related
activities, and go to market activities of proprietary products and technologies. The Company is developing the following products:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;(*)The INSPIRA ART (Augmented
Respiratory Technology), which is a respiratory support technology targeted toward utilizing direct blood oxygenation to boost patient
saturation levels within minutes while the patient is awake and spontaneously breathing. The aim is to reduce the need for invasive mechanical
ventilation, with the potential to reduce risks, complications and high costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;(*) The HYLA blood sensor,
which is a non-invasive optical blood sensor designed to perform real-time and continuous blood measurements, potentially minimizing
the need to take actual blood samples from patients.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;(*)The ALICE Device, an advanced
form of life support system better known by the medical industry as a cardiopulmonary bypass system is being designed for use in surgical
procedures requiring cardiopulmonary bypass for six hours or less.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s products are in the development stage. The ALICE
    device and the INSPIRA ART has not yet been tested or used in humans and the Company&#x2019;s products have not been approved by the
    U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;). &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -14.15pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On July 16, 2021, the Company completed its IPO on the Nasdaq Capital Market, whereby the Company sold 2,909,091 ordinary shares, no par value (the &#x201c;Ordinary Shares&#x201d;) and 3,345,455 tradable warrants (inclusive of 436,364 tradable warrants pursuant to the exercise of an overallotment option granted to the underwriters). The aggregate proceeds received by the Company from the IPO were approximately 14,490, after deducting underwriting discounts and commissions and additional offering costs totaled in approximately 1,543. On July 16, 2021, following the closing of the IPO, the Company issued 2,113,905 Ordinary Shares and 1,149,582 non-tradable warrants to investors and 16,587 non-tradeable warrants to brokers in connection with the conversion of Company&#x2019;s previously issued financial liabilities at fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In October 2021, investors exercised
1,705,000 tradable warrants Company. The total proceeds received by the Company from this exercise were approximately 9,377. The Company
paid fees of 7% in the amount of 656 according to the terms of a contract with a promoter in connection with the IPO for which the Company
recorded a financial liability (note 8(3)).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company has not generated any revenue since its inception and the Company&#x2019;s products are in the development stage. The Company&#x2019;s operating loss for the years ended December 31, 2021 and 2022 were $13.4&#160;million and $14.8&#160;million, respectively and the Company&#x2019;s net loss for the same period was $16.9 million and $10.3 million, respectively. As of December 31, 2022, the Company had an accumulated deficit of $39.1&#160;million. The Company funds its operations through the proceeds of the IPO.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -14.15pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company&#x2019;s
management intends to seek additional funding through public offerings, which will be utilized to fund product development and continue
operations. The Company does not have any material financial obligations as of the balance date. The Company believes that it has sufficient
resources to operate in the foreseeable future.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;5.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Ukraine Conflict&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Although we do not currently conduct
business in Russia and Ukraine, the escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations in
the Russian Ruble has had a negative impact on worldwide markets. Such impact may negatively impact our supply chain, our operations
and future growth prospects in that region.&#160;As a result of the crisis in Ukraine,&#160;both the U.S. and other countries have implemented
sanctions against certain Russian individuals and entities. Our global operations expose us to risks that could adversely affect our
business, financial condition, results of operations, cash flows or the market price of our securities, including the potential for increased
tensions between Russia and other countries resulting from the current situation involving Russia and Ukraine, tariffs, economic sanctions
and import-export restrictions imposed, and retaliatory actions, as well as the potential negative impact on our potential business and
sales in the region. Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S. and other governments against
certain companies and individuals may hinder our ability to conduct business with potential customers and vendors in these countries.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;6.&lt;/td&gt;&lt;td style="text-align: justify"&gt;These financial statements were authorized by the
                                            board of directors on March 28, 2023.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory>
    <iinn:NumberOfShares contextRef="c34" decimals="0" unitRef="shares">2909091</iinn:NumberOfShares>
    <iinn:TradableWarrantsShares contextRef="c34" decimals="0" unitRef="shares">3345455</iinn:TradableWarrantsShares>
    <iinn:WarrantsPursuantShares contextRef="c34" decimals="0" unitRef="shares">436364</iinn:WarrantsPursuantShares>
    <iinn:AggregateProceedsAmount contextRef="c35" decimals="-3" unitRef="usd">14490000</iinn:AggregateProceedsAmount>
    <iinn:AdditionalOfferingCosts contextRef="c35" decimals="-3" unitRef="usd">1543000</iinn:AdditionalOfferingCosts>
    <iinn:OrdinaryShares contextRef="c35" decimals="0" unitRef="shares">2113905</iinn:OrdinaryShares>
    <iinn:WarrantsShares contextRef="c35" decimals="0" unitRef="shares">1149582</iinn:WarrantsShares>
    <iinn:TradableWarrantsShares contextRef="c36" decimals="0" unitRef="shares">1705000</iinn:TradableWarrantsShares>
    <iinn:InvestorsExercise contextRef="c37" decimals="-3" unitRef="usd">9377000</iinn:InvestorsExercise>
    <iinn:PercentageOfPaidFees contextRef="c37" decimals="2" unitRef="pure">0.07</iinn:PercentageOfPaidFees>
    <iinn:PaidFeesAmount contextRef="c37" decimals="-3" unitRef="usd">656000</iinn:PaidFeesAmount>
    <ifrs-full:OperatingLeaseIncome contextRef="c4" decimals="-5" unitRef="usd">13400000</ifrs-full:OperatingLeaseIncome>
    <ifrs-full:OperatingLeaseIncome contextRef="c0" decimals="-5" unitRef="usd">14800000</ifrs-full:OperatingLeaseIncome>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c4" decimals="-5" unitRef="usd">16900000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c0" decimals="-5" unitRef="usd">10300000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c2" decimals="-5" unitRef="usd">39100000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 2 &lt;/b&gt;- &lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;New standards, interpretations and amendments
not yet effective.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There are a number of standards, amendments to
standards, and interpretations which have been issued by the IASB that are effective in future accounting periods that the Company has
decided not to adopt early.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January 2020, the IASB issued amendments to
IAS 1, which clarify the criteria used to determine whether liabilities are classified as current or non-current. These amendments clarify
that current or non-current classification is based on whether an entity has a right at the end of the reporting period to defer settlement
of the liability for at least twelve months after the reporting period. The amendments also clarify that &#x2019;settlement&#x2019; includes
the transfer of cash, goods, services, or equity instruments unless the obligation to transfer equity instruments arises from a conversion
feature classified as an equity instrument separately from the liability component of a compound financial instrument. The amendments
were originally effective for annual reporting periods beginning on or after 1 January 2022. However, in May 2020, the effective date
was deferred to annual reporting periods beginning on or after 1 January 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In its June 2021 meeting, the IASB tentatively
decided to amend the requirements of IAS 1 with respect to the classification of liabilities subject to conditions and disclosure of
information about such conditions and to defer the effective date of the 2020 amendment by at least one year.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is currently assessing the impact
of these new accounting standards and amendments. The Company will assess the impact of the final amendments to IAS 1 on classification
of its liabilities once the those are issued by the IASB.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company does not believe that the amendments
to IAS 1, in its present form, will have a significant impact on the classification of its liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company does not expect any other standards
issued by the IASB, but not yet effective, to have a material impact on the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of preparation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Use of estimates and assumptions in the preparation
of the financial statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets
and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results
could differ from those estimates. See also Note 3.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash equivalents are considered by the Company
to be highly-liquid investments, including, short-term deposits with banks, the maturity of which does not exceed three months at the
time of deposit and which are not restricted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic and diluted loss per share is calculated
as net loss attributed to the Company, divided by the weighted average number of ordinary shares, adjusted for any bonus element.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Diluted (loss) earnings per share is determined
by adjusting the earnings or loss attributable to common shareholders and the weighted average number of common shares outstanding for
the effects of dilutive instruments, which includes stock options, as if their dilutive effect was at the beginning of the period. The
calculation of the diluted number of common shares assumes that proceeds received from the exercise of &#x201c;in-the- money&#x201d; stock
options and common share purchase warrants are used to purchase common shares of the Company at their average market price for the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In periods that the Company reports a net loss,
any stock options or warrants outstanding are excluded from the calculation of diluted loss per share as their inclusion would be anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Functional and foreign currency&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s functional currency is NIS.
However, the presentation currency is the U.S. dollar (&#x201c;USD&#x201d;). Transactions and balances are converted into USD in accordance
with the principles set forth by International Accounting Standard (IAS) 21 &#x201c;The Effects of Changes in Foreign Exchange Rates.&#x201d;
Accordingly, transactions and balances have been converted as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Assets and liability items were reported at closing rate of exchange
    at the statements of financial position date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Other comprehensive income items were reported at annual average rate
    of exchange at the statements of financial position date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Share capital, capital reserve and other capital movement items were
    at rate of exchange as of the date of recognition of those items.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Accumulated deficit was based on the opening balance for the beginning
    of the reporting period in addition to the movements mentioned above.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Rate of exchange rate differentials created was recognized in other
    comprehensive income and accumulated in equity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Fair value measurement&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Fair value is the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability
takes place either:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.5in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;A.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In
                                            the principal market for the asset or liability, or&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;B.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In
                                            the absence of a principal market, in the most advantageous market for the asset or liability.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The principal or the
most advantageous market must be accessible by the Company in order to measure an asset or liability by its fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The fair value of an
asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming
that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a
market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another
market participant that would use the asset in its highest and best use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;When there are no quoted
prices in active markets for identical assets or liabilities, the Company uses valuation techniques that are appropriate in the circumstances
and for which sufficient data is available to measure fair value, maximizing the use of relevant observable inputs and minimizing the
use of unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Classification by fair
value hierarchy Assets and liabilities measured in the statement of financial position at fair value are grouped into classes with similar
characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;1&#160;-&#160;Quoted prices (unadjusted)
in active markets for identical assets or liabilities.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;2&#160;- Inputs other than quoted
prices included within Level 1 that are observable either directly or indirectly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;3&#160;- Inputs that are not based
on observable market data (valuation techniques that use inputs that are not based on observable market data).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Financial
                                            assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;The Company
classifies its financial assets into the following category, based on the business model for managing the financial asset and its contractual
cash flow characteristics. The Company&#x2019;s accounting policy for the relevant category is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;Amortized
cost: other types of financial assets where the objective is to hold these assets in order to collect contractual cash flows and the
contractual cash flows are solely payments of principal and interest. They are initially recognized at fair value including direct transaction
costs and are subsequently carried at amortized cost using the effective interest rate method, less provision for impairment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -17.85pt; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Financial
                                            Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company classifies its financial
liabilities, including trade accounts payable and other accounts payable, which are initially recognized at fair value and subsequently
carried at amortized cost using the effective interest method. The financial liabilities at fair value (see also Notes 8 and 19) are
measured at fair value through profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;De-recognition&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
                                            assets - The Company derecognizes a financial asset when the contractual rights to the cash
                                            flows from the financial asset expire or it transfers the rights to receive the contractual
                                            cash flows.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
                                            Liabilities - The Company derecognizes a financial liability when its contractual obligations
                                            are discharged or cancelled or expire.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Impairment of financial assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;The Company
does not have any assets which require a recognition of expected credit losses (&#x201c;ECL&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Cash and
cash equivalents are subject to the impairment requirements of IFRS 9, the Company did not identify impairment for the cash and cash
equivalent.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Property, plant, and equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Items of property, plant
and equipment are initially recognized at cost including directly attributable costs. Depreciation is calculated on a straight-line basis,
over the useful lives of the assets at annual rates as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Annual depreciation rate (%)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Development equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;6-15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Subsequent costs are
included in the asset&#x2019;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future
economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount
of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to statement
of the comprehensive loss during the reporting period in which they are incurred. The assets&#x2019; residual values and useful lives
are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset&#x2019;s carrying amount is written down immediately
to its recoverable amount if the asset&#x2019;s carrying amount is higher than its estimated recoverable amount.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Gains and losses on
disposals are determined by comparing proceeds with carrying amount. These are included in statement of the comprehensive loss.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Impairment of non-financial
assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Non-financial assets
are subject to impairment test whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.
Where the carrying value of the non-financial asset exceeds its recoverable amount (i.e., the higher of value in use and fair value less
costs to dispose), the asset is written down and impairment charge is recognized accordingly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Where it is not possible
to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset&#x2019;s cash-generating unit
(i.e., the smallest group of assets to which the asset belongs that generates cash inflow that is largely independent of cash inflows
from other assets).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;An impairment loss allocated
to an asset, is reversed only if there have been changes in the estimates used to determine the asset&#x2019;s recoverable amount since
the last impairment loss was recognized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Reversal of an impairment
loss, as above, is limited to the lower of the carrying amount of the asset that would have been determined (net of depreciation or amortization)
had no impairment loss been recognized for the asset in prior years and the asset&#x2019;s recoverable amount. After an impairment of
non-financial asset is recognized, the Company examines at each reporting date whether there are indications that the impairment which
was recognized in the past no longer exists or should be reduced. The reversal of impairment loss of an asset is recognized in statement
of the comprehensive loss. Impairment charges are included in general and administrative expenses in the statement of the comprehensive
loss. During the years ended December 31, 2022 and 2021, no impairment charges of non-financial assets were recognized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Research and development costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Expenditure on research
activities is recognized in statement of the comprehensive loss as incurred. Development expenditures is recognized as an intangible
asset when the Company can demonstrate:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The product is technically
and commercially feasible.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company intends to complete
the product so that it will be available for use or sale.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company has the ability
to use the product or sell it.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company has the technical,
financial and other resources to complete the development and to use or sell the product.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;The Company can demonstrate that the product will generate future economic benefits.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;The Company is able to measure reliably the expenditure attributable to the product during the
    development.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During the years ended
December 31, 2021 and 2022, the Company&#x2019;s research and development costs were not capitalized as they did not meet the criteria
set forth in IAS&#160;38.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Segment reporting&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;An operating segment is a component of the Company
which fulfills the following criteria:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;It is engaged in business operations
                                            from which it may derive income, and with respect to which it may bear expenses.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Its operating results are reviewed on
                                            a regular basis by the Company&#x2019;s chief operational decision maker, in order to reach
                                            decisions regarding the resources allocated to it, and in order to assess its performance.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;3.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Separate financial information is available
                                            for the above.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company concluded that it has one operating
segment.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Share based payment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company measures
the share based expense and the cost of equity-settled transactions with employees and service providers by reference to the fair value
of the equity instruments at the date at which they are granted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The fair value is determined
using an accepted options pricing model. The model is based on share price, grant date and on assumptions regarding expected volatility,
expected life of the options, expected dividend, and a no risk interest rate. The options were granted before the Company became public
and had no quoted price per share from a trading market.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company selected
the Black-Scholes model as the Company&#x2019;s option pricing model to estimate the fair value of the Company&#x2019;s options awards.
The option-pricing model requires a number of assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Expected dividend
yield&lt;/i&gt; - The expected dividend yield assumption is based on the Company&#x2019;s historical experience and expectation of no future
dividend payouts. The Company has not historically paid cash dividends and has no foreseeable plans to pay cash dividends in the future.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Volatility&lt;/i&gt;&#160;-
The expected volatility is based on similar companies&#x2019; stock volatility.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Risk free interest
rate&lt;/i&gt;&#160;- The risk-free interest rate is based on the yield of governmental bonds with equivalent terms.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Contractual term&lt;/i&gt;&#160;-
An option&#x2019;s contractual term is the amount of time the holder has to exercise the option, per the contract.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Restricted Share
Units (&#x201c;RSUs&#x201d;) &lt;/b&gt;- The fair value is measured by multiplying the number of the restricted shares units granted to employees,
directors, and subcontractors by the quoted share price as of the grant date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The granted options
are settled in equity instruments and not in cash. The fair value of the options at the date of grant is charged to the statement of
comprehensive loss over the vesting period. Non-market vesting conditions are considered by adjusting the number of equity instruments
expected to vest at each reporting date so that, ultimately, the cumulative amount recognized over the vesting period is based on the
number of options that eventually vest. Non-vesting conditions and market vesting conditions are factored into the fair value of the
options granted. As long as all other vesting conditions are satisfied, a charge is made irrespective of whether the market vesting conditions
are satisfied. The cumulative expense is not adjusted for failure to achieve a market vesting condition or where a non-vesting condition
is not satisfied. Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options,
measured immediately before and after the modification, is also charged to the statement of comprehensive loss over the remaining vesting
period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Government grants&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Israel Innovation
Authority (&#x201c;IIA&#x201d;) provided government grants to the Company for certain research and development activities. The Company
may be required to pay royalties to the IIA in the future if it generates sales from the related research and development activity. The
grant was recognized as a liability in the financial statements. When the loan bears a below-market rate of interest, the liability is
recognized at its fair value in accordance with the market interest rate prevailing at the time of receiving the grant. The difference
between the consideration received and the liability recognized at inception was treated as a government grant and recognized as a reimbursement
of research expenses. The repayment of the liability to the state is reviewed every reporting period, with changes in the liability resulting
from a change in the expected royalties recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Current taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Deferred tax&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Significant management
judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the estimated timing and level
of future taxable profits together with future tax planning strategies. Deferred taxes are recognized in respect of temporary differences
between the carrying amounts of assets and liabilities in the financial statements and the amounts attributable for tax purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Deferred taxes are measured
at the tax rates that are expected to apply in the period when the temporary differences are reversed based on tax laws that have been
enacted or substantively enacted at the end of the reporting period. Deferred taxes are recognized in profit or loss, except when they
relate to items recognized in other comprehensive income or directly in equity. Deferred tax assets are reviewed at the end of each reporting
period and reduced to the extent that it is not probable that they will be utilized. In addition, temporary differences (such as carry
forward losses) for which deferred tax assets have not been recognized are reassessed and deferred tax assets are recognized to the extent
that their recoverability is probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Any resulting reduction
or reversal is recognized on &#x201c;income tax&#x201d; within the statement of comprehensive income. All deferred tax assets and liabilities
are presented in the statement of financial position as non-current items, respectively. Deferred taxes are offset in the statement of
financial position if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred
taxes relate to the same taxpayer and the same taxation authority.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Employee benefits&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company has several
employee benefit plans for Israeli employees:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Short-term employee benefits:
Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions, which
are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Post-employment benefits: The
plans are normally financed by contributions to insurance companies and classified as defined contribution plans. The Company has contributed
for all of its employees&#x2019; contribution plans pursuant to Section 14 to the Severance Pay Law since 2018 under which the Company
pays fixed contributions and will not have any legal or constructive obligation to pay further contributions if the fund does not hold
sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of preparation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <iinn:UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Use of estimates and assumptions in the preparation
of the financial statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets
and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results
could differ from those estimates. See also Note 3.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</iinn:UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash equivalents are considered by the Company
to be highly-liquid investments, including, short-term deposits with banks, the maturity of which does not exceed three months at the
time of deposit and which are not restricted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic and diluted loss per share is calculated
as net loss attributed to the Company, divided by the weighted average number of ordinary shares, adjusted for any bonus element.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Diluted (loss) earnings per share is determined
by adjusting the earnings or loss attributable to common shareholders and the weighted average number of common shares outstanding for
the effects of dilutive instruments, which includes stock options, as if their dilutive effect was at the beginning of the period. The
calculation of the diluted number of common shares assumes that proceeds received from the exercise of &#x201c;in-the- money&#x201d; stock
options and common share purchase warrants are used to purchase common shares of the Company at their average market price for the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In periods that the Company reports a net loss,
any stock options or warrants outstanding are excluded from the calculation of diluted loss per share as their inclusion would be anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Functional and foreign currency&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s functional currency is NIS.
However, the presentation currency is the U.S. dollar (&#x201c;USD&#x201d;). Transactions and balances are converted into USD in accordance
with the principles set forth by International Accounting Standard (IAS) 21 &#x201c;The Effects of Changes in Foreign Exchange Rates.&#x201d;
Accordingly, transactions and balances have been converted as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Assets and liability items were reported at closing rate of exchange
    at the statements of financial position date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Other comprehensive income items were reported at annual average rate
    of exchange at the statements of financial position date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Share capital, capital reserve and other capital movement items were
    at rate of exchange as of the date of recognition of those items.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Accumulated deficit was based on the opening balance for the beginning
    of the reporting period in addition to the movements mentioned above.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Rate of exchange rate differentials created was recognized in other
    comprehensive income and accumulated in equity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Fair value measurement&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Fair value is the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability
takes place either:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.5in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;A.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In
                                            the principal market for the asset or liability, or&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;B.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In
                                            the absence of a principal market, in the most advantageous market for the asset or liability.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The principal or the
most advantageous market must be accessible by the Company in order to measure an asset or liability by its fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The fair value of an
asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming
that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a
market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another
market participant that would use the asset in its highest and best use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;When there are no quoted
prices in active markets for identical assets or liabilities, the Company uses valuation techniques that are appropriate in the circumstances
and for which sufficient data is available to measure fair value, maximizing the use of relevant observable inputs and minimizing the
use of unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Classification by fair
value hierarchy Assets and liabilities measured in the statement of financial position at fair value are grouped into classes with similar
characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;1&#160;-&#160;Quoted prices (unadjusted)
in active markets for identical assets or liabilities.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;2&#160;- Inputs other than quoted
prices included within Level 1 that are observable either directly or indirectly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;3&#160;- Inputs that are not based
on observable market data (valuation techniques that use inputs that are not based on observable market data).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Financial
                                            assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;The Company
classifies its financial assets into the following category, based on the business model for managing the financial asset and its contractual
cash flow characteristics. The Company&#x2019;s accounting policy for the relevant category is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;Amortized
cost: other types of financial assets where the objective is to hold these assets in order to collect contractual cash flows and the
contractual cash flows are solely payments of principal and interest. They are initially recognized at fair value including direct transaction
costs and are subsequently carried at amortized cost using the effective interest rate method, less provision for impairment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -17.85pt; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Financial
                                            Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company classifies its financial
liabilities, including trade accounts payable and other accounts payable, which are initially recognized at fair value and subsequently
carried at amortized cost using the effective interest method. The financial liabilities at fair value (see also Notes 8 and 19) are
measured at fair value through profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;De-recognition&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
                                            assets - The Company derecognizes a financial asset when the contractual rights to the cash
                                            flows from the financial asset expire or it transfers the rights to receive the contractual
                                            cash flows.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
                                            Liabilities - The Company derecognizes a financial liability when its contractual obligations
                                            are discharged or cancelled or expire.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Impairment of financial assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;The Company
does not have any assets which require a recognition of expected credit losses (&#x201c;ECL&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Cash and
cash equivalents are subject to the impairment requirements of IFRS 9, the Company did not identify impairment for the cash and cash
equivalent.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;</ifrs-full:ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Property, plant, and equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Items of property, plant
and equipment are initially recognized at cost including directly attributable costs. Depreciation is calculated on a straight-line basis,
over the useful lives of the assets at annual rates as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Annual depreciation rate (%)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Development equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;6-15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Subsequent costs are
included in the asset&#x2019;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future
economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount
of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to statement
of the comprehensive loss during the reporting period in which they are incurred. The assets&#x2019; residual values and useful lives
are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset&#x2019;s carrying amount is written down immediately
to its recoverable amount if the asset&#x2019;s carrying amount is higher than its estimated recoverable amount.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Gains and losses on
disposals are determined by comparing proceeds with carrying amount. These are included in statement of the comprehensive loss.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <iinn:ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Annual depreciation rate (%)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Development equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;6-15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;</iinn:ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock>
    <iinn:AnnualDepreciationRateInPercentage contextRef="c38" decimals="2" unitRef="pure">0.33</iinn:AnnualDepreciationRateInPercentage>
    <iinn:AnnualDepreciationRateInPercentage contextRef="c39" decimals="2" unitRef="pure">0.20</iinn:AnnualDepreciationRateInPercentage>
    <iinn:AnnualDepreciationRateInPercentage contextRef="c40" decimals="2" unitRef="pure">0.06</iinn:AnnualDepreciationRateInPercentage>
    <iinn:AnnualDepreciationRateInPercentage contextRef="c41" decimals="2" unitRef="pure">0.15</iinn:AnnualDepreciationRateInPercentage>
    <iinn:AnnualDepreciationRateInPercentage contextRef="c42" decimals="2" unitRef="pure">0.10</iinn:AnnualDepreciationRateInPercentage>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Impairment of non-financial
assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Non-financial assets
are subject to impairment test whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.
Where the carrying value of the non-financial asset exceeds its recoverable amount (i.e., the higher of value in use and fair value less
costs to dispose), the asset is written down and impairment charge is recognized accordingly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Where it is not possible
to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset&#x2019;s cash-generating unit
(i.e., the smallest group of assets to which the asset belongs that generates cash inflow that is largely independent of cash inflows
from other assets).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;An impairment loss allocated
to an asset, is reversed only if there have been changes in the estimates used to determine the asset&#x2019;s recoverable amount since
the last impairment loss was recognized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Reversal of an impairment
loss, as above, is limited to the lower of the carrying amount of the asset that would have been determined (net of depreciation or amortization)
had no impairment loss been recognized for the asset in prior years and the asset&#x2019;s recoverable amount. After an impairment of
non-financial asset is recognized, the Company examines at each reporting date whether there are indications that the impairment which
was recognized in the past no longer exists or should be reduced. The reversal of impairment loss of an asset is recognized in statement
of the comprehensive loss. Impairment charges are included in general and administrative expenses in the statement of the comprehensive
loss. During the years ended December 31, 2022 and 2021, no impairment charges of non-financial assets were recognized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Research and development costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Expenditure on research
activities is recognized in statement of the comprehensive loss as incurred. Development expenditures is recognized as an intangible
asset when the Company can demonstrate:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The product is technically
and commercially feasible.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company intends to complete
the product so that it will be available for use or sale.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company has the ability
to use the product or sell it.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company has the technical,
financial and other resources to complete the development and to use or sell the product.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;The Company can demonstrate that the product will generate future economic benefits.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;The Company is able to measure reliably the expenditure attributable to the product during the
    development.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During the years ended
December 31, 2021 and 2022, the Company&#x2019;s research and development costs were not capitalized as they did not meet the criteria
set forth in IAS&#160;38.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Segment reporting&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;An operating segment is a component of the Company
which fulfills the following criteria:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;It is engaged in business operations
                                            from which it may derive income, and with respect to which it may bear expenses.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Its operating results are reviewed on
                                            a regular basis by the Company&#x2019;s chief operational decision maker, in order to reach
                                            decisions regarding the resources allocated to it, and in order to assess its performance.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;3.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Separate financial information is available
                                            for the above.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company concluded that it has one operating
segment.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Share based payment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company measures
the share based expense and the cost of equity-settled transactions with employees and service providers by reference to the fair value
of the equity instruments at the date at which they are granted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <iinn:OptionsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The fair value is determined
using an accepted options pricing model. The model is based on share price, grant date and on assumptions regarding expected volatility,
expected life of the options, expected dividend, and a no risk interest rate. The options were granted before the Company became public
and had no quoted price per share from a trading market.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company selected
the Black-Scholes model as the Company&#x2019;s option pricing model to estimate the fair value of the Company&#x2019;s options awards.
The option-pricing model requires a number of assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Expected dividend
yield&lt;/i&gt; - The expected dividend yield assumption is based on the Company&#x2019;s historical experience and expectation of no future
dividend payouts. The Company has not historically paid cash dividends and has no foreseeable plans to pay cash dividends in the future.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Volatility&lt;/i&gt;&#160;-
The expected volatility is based on similar companies&#x2019; stock volatility.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Risk free interest
rate&lt;/i&gt;&#160;- The risk-free interest rate is based on the yield of governmental bonds with equivalent terms.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Contractual term&lt;/i&gt;&#160;-
An option&#x2019;s contractual term is the amount of time the holder has to exercise the option, per the contract.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;</iinn:OptionsPolicyTextBlock>
    <iinn:RestrictedShareUnitsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Restricted Share
Units (&#x201c;RSUs&#x201d;) &lt;/b&gt;- The fair value is measured by multiplying the number of the restricted shares units granted to employees,
directors, and subcontractors by the quoted share price as of the grant date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The granted options
are settled in equity instruments and not in cash. The fair value of the options at the date of grant is charged to the statement of
comprehensive loss over the vesting period. Non-market vesting conditions are considered by adjusting the number of equity instruments
expected to vest at each reporting date so that, ultimately, the cumulative amount recognized over the vesting period is based on the
number of options that eventually vest. Non-vesting conditions and market vesting conditions are factored into the fair value of the
options granted. As long as all other vesting conditions are satisfied, a charge is made irrespective of whether the market vesting conditions
are satisfied. The cumulative expense is not adjusted for failure to achieve a market vesting condition or where a non-vesting condition
is not satisfied. Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options,
measured immediately before and after the modification, is also charged to the statement of comprehensive loss over the remaining vesting
period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;</iinn:RestrictedShareUnitsPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Government grants&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Israel Innovation
Authority (&#x201c;IIA&#x201d;) provided government grants to the Company for certain research and development activities. The Company
may be required to pay royalties to the IIA in the future if it generates sales from the related research and development activity. The
grant was recognized as a liability in the financial statements. When the loan bears a below-market rate of interest, the liability is
recognized at its fair value in accordance with the market interest rate prevailing at the time of receiving the grant. The difference
between the consideration received and the liability recognized at inception was treated as a government grant and recognized as a reimbursement
of research expenses. The repayment of the liability to the state is reviewed every reporting period, with changes in the liability resulting
from a change in the expected royalties recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
    <ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Current taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Deferred tax&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Significant management
judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the estimated timing and level
of future taxable profits together with future tax planning strategies. Deferred taxes are recognized in respect of temporary differences
between the carrying amounts of assets and liabilities in the financial statements and the amounts attributable for tax purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Deferred taxes are measured
at the tax rates that are expected to apply in the period when the temporary differences are reversed based on tax laws that have been
enacted or substantively enacted at the end of the reporting period. Deferred taxes are recognized in profit or loss, except when they
relate to items recognized in other comprehensive income or directly in equity. Deferred tax assets are reviewed at the end of each reporting
period and reduced to the extent that it is not probable that they will be utilized. In addition, temporary differences (such as carry
forward losses) for which deferred tax assets have not been recognized are reassessed and deferred tax assets are recognized to the extent
that their recoverability is probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Any resulting reduction
or reversal is recognized on &#x201c;income tax&#x201d; within the statement of comprehensive income. All deferred tax assets and liabilities
are presented in the statement of financial position as non-current items, respectively. Deferred taxes are offset in the statement of
financial position if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred
taxes relate to the same taxpayer and the same taxation authority.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Employee benefits&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company has several
employee benefit plans for Israeli employees:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Short-term employee benefits:
Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions, which
are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Post-employment benefits: The
plans are normally financed by contributions to insurance companies and classified as defined contribution plans. The Company has contributed
for all of its employees&#x2019; contribution plans pursuant to Section 14 to the Severance Pay Law since 2018 under which the Company
pays fixed contributions and will not have any legal or constructive obligation to pay further contributions if the fund does not hold
sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt; background-color: white"&gt;&lt;b&gt;NOTE
3 - CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Share based payments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The fair value of share
options was estimated by using a Black Scholes model approach, which was aimed to model the value of the Company&#x2019;s equity over
time. A change of the estimation can cause to recognition or reversal of share based compensation expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Financial liabilities
at fair value&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The fair value of financial
liabilities at fair value was estimated by using a Black Scholes model and Monte-Carlo simulation approach, which was aimed to model
the value of the Company&#x2019;s assets over time. The simulation approach was designed to take into account the terms and conditions
financial liability, which are described in Note 8 and Note 20, as well as the capital structure of the Company and the volatility of
its assets. The valuation was performed based on management&#x2019;s assumptions and projections.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Determination of
lease incremental borrowing rate&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company measures
the incremental borrowing rate by analyzing similar borrowing that could be obtained from an independent valuation under comparable terms
and conditions. A change of the estimation can cause to an increase or decrease in the measurement of a right-of-use asset and lease
liability.&lt;/p&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DisclosureOfDepositsFromBanksExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 4 &#x2013; DEPOSITS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"&gt;The deposits are three short-term bank deposits
with maturities of more than three months but less than one year. The deposits are in dollars and bear annual interest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"&gt;On May 10, 2022, the Company deposited 2,000
with an annual interest rate of 3.02% for a period of 9 months. As of December 31, 2022, the value of the deposit is 2,039.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"&gt;On August 11, 2022, the Company deposited
2,000 with an annual interest rate of 4.39% for a period of 12 months. As of December 31, 2022, the value of the deposit is 2,034.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"&gt;On August 24, 2022, the Company deposited
3,000 with an annual interest rate of 4.47% for a period of 9 months. As of December 31, 2022, the value of the deposit is 3,047.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;As of December 31, 2022 total deposits amounted
to 7,120.&lt;/p&gt;</ifrs-full:DisclosureOfDepositsFromBanksExplanatory>
    <ifrs-full:DepositsFromBanks contextRef="c43" decimals="0" unitRef="usd">2000</ifrs-full:DepositsFromBanks>
    <ifrs-full:BorrowingsInterestRate contextRef="c43" decimals="4" unitRef="pure">0.0302</ifrs-full:BorrowingsInterestRate>
    <iinn:DepositValue contextRef="c43" decimals="0" unitRef="usd">2039</iinn:DepositValue>
    <ifrs-full:DepositsFromBanks contextRef="c44" decimals="0" unitRef="usd">2000</ifrs-full:DepositsFromBanks>
    <ifrs-full:BorrowingsInterestRate contextRef="c44" decimals="4" unitRef="pure">0.0439</ifrs-full:BorrowingsInterestRate>
    <iinn:DepositValue contextRef="c44" decimals="0" unitRef="usd">2034</iinn:DepositValue>
    <ifrs-full:DepositsFromBanks contextRef="c45" decimals="0" unitRef="usd">3000</ifrs-full:DepositsFromBanks>
    <ifrs-full:BorrowingsInterestRate contextRef="c45" decimals="4" unitRef="pure">0.0447</ifrs-full:BorrowingsInterestRate>
    <iinn:DepositValue contextRef="c45" decimals="0" unitRef="usd">3047</iinn:DepositValue>
    <ifrs-full:DepositsFromBanks contextRef="c2" decimals="0" unitRef="usd">7120</ifrs-full:DepositsFromBanks>
    <ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 5 - OTHER CURRENT ASSETS:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;256&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;426&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Institutions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;591&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;256&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;426&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Institutions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;591&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c2" decimals="-3" unitRef="usd">256000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c3" decimals="-3" unitRef="usd">426000</ifrs-full:CurrentPrepaidExpenses>
    <iinn:Institutions contextRef="c2" decimals="-3" unitRef="usd">276000</iinn:Institutions>
    <iinn:Institutions contextRef="c3" decimals="-3" unitRef="usd">210000</iinn:Institutions>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">56000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">120000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <iinn:OthersCurrentAssets contextRef="c0" decimals="-3" unitRef="usd">3000</iinn:OthersCurrentAssets>
    <iinn:OthersCurrentAssets contextRef="c4" decimals="-3" unitRef="usd">3000</iinn:OthersCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c2" decimals="-3" unitRef="usd">591000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c3" decimals="-3" unitRef="usd">759000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 6 - PROPERTY AND EQUIPMENT, NET:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;For the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Development&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;64&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;81&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;236&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;191&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate deference&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 0in"&gt;At December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;At January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate deference&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 0in"&gt;At December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;204&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;411&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less than thousand dollars&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;For the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Development&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;At January 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;At December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;At January 1, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;*&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;At December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;56&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;78&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;202&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less than one thousand dollars&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <iinn:ScheduleOfPropertyAndEquipmentNetTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Development&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;64&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;81&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;236&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;191&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate deference&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 0in"&gt;At December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;At January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate deference&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 0in"&gt;At December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;204&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;411&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less than thousand dollars&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Development&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;At January 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;At December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;At January 1, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;*&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;At December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;56&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;78&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;202&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less than one thousand dollars&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</iinn:ScheduleOfPropertyAndEquipmentNetTableTextBlock>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c46" decimals="-3" unitRef="usd">84000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c47" decimals="-3" unitRef="usd">7000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c48" decimals="-3" unitRef="usd">64000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c49" decimals="-3" unitRef="usd">81000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c3" decimals="-3" unitRef="usd">236000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c50" decimals="-3" unitRef="usd">43000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c51" decimals="-3" unitRef="usd">30000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c39" decimals="-3" unitRef="usd">191000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c52" decimals="-3" unitRef="usd">40000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">304000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <iinn:ExchangeRateDeferenceCost contextRef="c50" decimals="-3" unitRef="usd">-6000</iinn:ExchangeRateDeferenceCost>
    <iinn:ExchangeRateDeferenceCost contextRef="c51" decimals="-3" unitRef="usd">-4000</iinn:ExchangeRateDeferenceCost>
    <iinn:ExchangeRateDeferenceCost contextRef="c39" decimals="-3" unitRef="usd">-26000</iinn:ExchangeRateDeferenceCost>
    <iinn:ExchangeRateDeferenceCost contextRef="c52" decimals="-3" unitRef="usd">-5000</iinn:ExchangeRateDeferenceCost>
    <iinn:ExchangeRateDeferenceCost contextRef="c0" decimals="-3" unitRef="usd">-41000</iinn:ExchangeRateDeferenceCost>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c53" decimals="-3" unitRef="usd">121000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c54" decimals="-3" unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c55" decimals="-3" unitRef="usd">229000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c56" decimals="-3" unitRef="usd">116000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c2" decimals="-3" unitRef="usd">499000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <iinn:AccumulatedDepreciation contextRef="c46" decimals="-3" unitRef="usd">22000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c47" decimals="-3" unitRef="usd">1000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c48" decimals="-3" unitRef="usd">8000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c49" decimals="-3" unitRef="usd">3000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c3" decimals="-3" unitRef="usd">34000</iinn:AccumulatedDepreciation>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c50" decimals="-3" unitRef="usd">33000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c51" decimals="-3" unitRef="usd">3000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c39" decimals="-3" unitRef="usd">19000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c52" decimals="-3" unitRef="usd">6000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">61000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <iinn:ExchangeRateDeferenceAccumulatedDepreciation contextRef="c50" decimals="-3" unitRef="usd">-4000</iinn:ExchangeRateDeferenceAccumulatedDepreciation>
    <iinn:ExchangeRateDeferenceAccumulatedDepreciation contextRef="c39" decimals="-3" unitRef="usd">-2000</iinn:ExchangeRateDeferenceAccumulatedDepreciation>
    <iinn:ExchangeRateDeferenceAccumulatedDepreciation contextRef="c52" decimals="-3" unitRef="usd">-1000</iinn:ExchangeRateDeferenceAccumulatedDepreciation>
    <iinn:ExchangeRateDeferenceAccumulatedDepreciation contextRef="c0" decimals="-3" unitRef="usd">-7000</iinn:ExchangeRateDeferenceAccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c53" decimals="-3" unitRef="usd">51000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c54" decimals="-3" unitRef="usd">4000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c55" decimals="-3" unitRef="usd">25000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c56" decimals="-3" unitRef="usd">8000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c2" decimals="-3" unitRef="usd">88000</iinn:AccumulatedDepreciation>
    <iinn:NetBookValue contextRef="c50" decimals="-3" unitRef="usd">70000</iinn:NetBookValue>
    <iinn:NetBookValue contextRef="c51" decimals="-3" unitRef="usd">29000</iinn:NetBookValue>
    <iinn:NetBookValue contextRef="c39" decimals="-3" unitRef="usd">204000</iinn:NetBookValue>
    <iinn:NetBookValue contextRef="c52" decimals="-3" unitRef="usd">108000</iinn:NetBookValue>
    <iinn:NetBookValue contextRef="c0" decimals="-3" unitRef="usd">411000</iinn:NetBookValue>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c57" decimals="-3" unitRef="usd">22000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c58" decimals="-3" unitRef="usd">7000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c59" decimals="-3" unitRef="usd">6000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c60" decimals="-3" unitRef="usd">19000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c19" decimals="-3" unitRef="usd">54000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c61" decimals="-3" unitRef="usd">62000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c62" decimals="-3" unitRef="usd">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c63" decimals="-3" unitRef="usd">58000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c64" decimals="-3" unitRef="usd">62000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">182000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c46" decimals="-3" unitRef="usd">84000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c47" decimals="-3" unitRef="usd">7000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c48" decimals="-3" unitRef="usd">64000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c49" decimals="-3" unitRef="usd">81000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c3" decimals="-3" unitRef="usd">236000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <iinn:AccumulatedDepreciation contextRef="c57" decimals="-3" unitRef="usd">7000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c59" decimals="-3" unitRef="usd">1000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c60" decimals="-3" unitRef="usd">1000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c19" decimals="-3" unitRef="usd">9000</iinn:AccumulatedDepreciation>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c61" decimals="-3" unitRef="usd">15000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c62" decimals="-3" unitRef="usd">1000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c63" decimals="-3" unitRef="usd">7000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c64" decimals="-3" unitRef="usd">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">25000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <iinn:AccumulatedDepreciation contextRef="c46" decimals="-3" unitRef="usd">22000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c47" decimals="-3" unitRef="usd">1000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c48" decimals="-3" unitRef="usd">8000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c49" decimals="-3" unitRef="usd">3000</iinn:AccumulatedDepreciation>
    <iinn:AccumulatedDepreciation contextRef="c3" decimals="-3" unitRef="usd">34000</iinn:AccumulatedDepreciation>
    <iinn:NetBookValue contextRef="c61" decimals="-3" unitRef="usd">62000</iinn:NetBookValue>
    <iinn:NetBookValue contextRef="c62" decimals="-3" unitRef="usd">6000</iinn:NetBookValue>
    <iinn:NetBookValue contextRef="c63" decimals="-3" unitRef="usd">56000</iinn:NetBookValue>
    <iinn:NetBookValue contextRef="c64" decimals="-3" unitRef="usd">78000</iinn:NetBookValue>
    <iinn:NetBookValue contextRef="c4" decimals="-3" unitRef="usd">202000</iinn:NetBookValue>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 7 - OTHER ACCOUNTS PAYABLE:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Employees salaries and related liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;470&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,217&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;725&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <iinn:ScheduleOfOtherAccountPayableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Employees salaries and related liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;470&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,217&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;725&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfOtherAccountPayableTextBlock>
    <iinn:EmployeesSalariesAndRelatedLiabilities contextRef="c2" decimals="-3" unitRef="usd">396000</iinn:EmployeesSalariesAndRelatedLiabilities>
    <iinn:EmployeesSalariesAndRelatedLiabilities contextRef="c3" decimals="-3" unitRef="usd">339000</iinn:EmployeesSalariesAndRelatedLiabilities>
    <ifrs-full:NoncurrentPayablesToRelatedParties contextRef="c2" decimals="-3" unitRef="usd">332000</ifrs-full:NoncurrentPayablesToRelatedParties>
    <ifrs-full:NoncurrentPayablesToRelatedParties contextRef="c3" decimals="-3" unitRef="usd">275000</ifrs-full:NoncurrentPayablesToRelatedParties>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c2" decimals="-3" unitRef="usd">470000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c3" decimals="-3" unitRef="usd">82000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:OtherPayables contextRef="c2" decimals="-3" unitRef="usd">19000</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables contextRef="c3" decimals="-3" unitRef="usd">29000</ifrs-full:OtherPayables>
    <ifrs-full:NoncurrentPayables contextRef="c2" decimals="-3" unitRef="usd">1217000</ifrs-full:NoncurrentPayables>
    <ifrs-full:NoncurrentPayables contextRef="c3" decimals="-3" unitRef="usd">725000</ifrs-full:NoncurrentPayables>
    <ifrs-full:DisclosureOfGovernmentGrantsExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 - LIABILITY IN RESPECT OF GOVERNMENT
GRANTS:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company received the approval of the IIA
for its participation in certain development expenses carried out by the Company, within the framework of determined budgets and time
periods. The total amount the Company received during 2020 and 2021 was 800 (NIS 2,722,628).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with its commitment, the Company
is obliged to pay the IIA royalties of 3% of sales, constituting the revenues derived from sales of the Company&#x2019;s ART system that
was financed by the IIA, up to the total amount of the grant actually received, all linked to the exchange rate of the USD and bears
an annual interest linked to the LIBOR. Therefore, the total amount of the grants that will be repaid through royalties and will increase
until repayments begin.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The difference between the consideration received
and the liability recognized at inception (present value) was treated as a government grant according to IAS 20 and recognized as a reimbursement
of research expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-weight: bold"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;302&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;372&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Amounts received during the year, non- capitalized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exchange rate differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(41&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Amounts recognized as an offset from research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(255&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Revaluation of the liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;137&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;398&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfGovernmentGrantsExplanatory>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c4" decimals="-3" unitRef="usd">800000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c5" decimals="-3" unitRef="usd">800000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c4" decimals="-3" unitRef="ils">2722628000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c5" decimals="-3" unitRef="ils">2722628000</ifrs-full:RevenueFromGovernmentGrants>
    <iinn:PayRoyaltiesPercentage contextRef="c5" decimals="2" unitRef="pure">0.03</iinn:PayRoyaltiesPercentage>
    <iinn:ScheduleOfReimbursementOfResearchExpensesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-weight: bold"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;302&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;372&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Amounts received during the year, non- capitalized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exchange rate differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(41&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Amounts recognized as an offset from research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(255&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Revaluation of the liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;137&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;398&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfReimbursementOfResearchExpensesTableTextBlock>
    <ifrs-full:GovernmentGrants contextRef="c3" decimals="-3" unitRef="usd">302000</ifrs-full:GovernmentGrants>
    <ifrs-full:GovernmentGrants contextRef="c19" decimals="-3" unitRef="usd">372000</ifrs-full:GovernmentGrants>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" unitRef="usd">107000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <iinn:ExchangeRateDifferences contextRef="c0" decimals="-3" unitRef="usd">-41000</iinn:ExchangeRateDifferences>
    <iinn:ExchangeRateDifferences contextRef="c4" decimals="-3" unitRef="usd">10000</iinn:ExchangeRateDifferences>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">255000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <iinn:RevaluationOfTheLiability contextRef="c0" decimals="-3" unitRef="usd">137000</iinn:RevaluationOfTheLiability>
    <iinn:RevaluationOfTheLiability contextRef="c4" decimals="-3" unitRef="usd">68000</iinn:RevaluationOfTheLiability>
    <ifrs-full:GovernmentGrants contextRef="c2" decimals="-3" unitRef="usd">398000</ifrs-full:GovernmentGrants>
    <ifrs-full:GovernmentGrants contextRef="c3" decimals="-3" unitRef="usd">302000</ifrs-full:GovernmentGrants>
    <ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 9 - FINACIAL LIABILITIES AT FAIR VALUE:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Non-tradable warrants (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-tradable warrants, SAFE and CLA (2)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tradable warrants (3)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,493&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Financial liability (4)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;133&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;368&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,215&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Non Tradable Warrants&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As part of an agreement signed in
2019, the convertible loan investors received, upon conversion in 2020 756,333 Ordinary Shares and non-tradable warrants to purchase
an additional 169,019 ordinary shares upon consummation of an IPO on the Nasdaq. The warrants will be converted into Ordinary Shares
of the Company at an exercise price equal to the initial public offering price which was $5.5 and are exercisable for three years after
the IPO.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The warrants were designated to be measured at
fair value through profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On July 2021, as part of the IPO,
the investors received the specified warrants. As of December 31, 2022 the fair value of the warrants was 3.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -14.15pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Non-tradable warrants, SAFE and
Convertible Loan Investors&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -14.15pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On July 16, 2021, following the IPO, the Company
issued 2,113,905 Ordinary Shares, 1,149,582 non-tradable warrants to investors and 16,587 non-tradeable warrants to brokers in connection
with the conversion of Company&#x2019;s convertible loan and SAFE according to its terms. The fair value of the shares was classified
as equity with total value of 10,041 at the conversion date. The non-tradable warrants were designated to be measured at fair value through
profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The non-tradable warrants fair value as of December
31, 2022 is 35.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Tradable warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify"&gt;The Company sold 3,345,455 tradable
warrants in the IPO. The tradable warrants have an exercise price of $5.5 and they are exercisable for five years after the initial public
offering date. In October 2021, investors exercised 1,705,000 tradable warrants whereby the Company issued 1,705,000 Ordinary Shares
to such investors. The total proceeds received by the Company from this exercise were approximately 9,377. The net proceeds after fees
deducting were approximately 8,721.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;As of December 31, 2022,
the Company has 1,640,455 tradable warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;The tradable warrants were designated to be measured at
fair value through profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The tradable warrants fair value as
of December 31, 2022 is 304.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Financial Liability&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Financial liability to pay 7% fees
on the fundings that will be received from exercises of tradable warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;Financial liability was designated to be measured at fair
value through profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Financial liability fair value
as of December 31, 2022 is 26.&lt;/p&gt;</ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory>
    <iinn:ScheduleOfFinancialLiabilities contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Non-tradable warrants (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-tradable warrants, SAFE and CLA (2)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tradable warrants (3)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,493&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Financial liability (4)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;133&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;368&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,215&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</iinn:ScheduleOfFinancialLiabilities>
    <iinn:TotalFinancialLiabilities contextRef="c69" decimals="-3" unitRef="usd">3000</iinn:TotalFinancialLiabilities>
    <iinn:TotalFinancialLiabilities contextRef="c70" decimals="-3" unitRef="usd">196000</iinn:TotalFinancialLiabilities>
    <iinn:TotalFinancialLiabilities contextRef="c71" decimals="-3" unitRef="usd">35000</iinn:TotalFinancialLiabilities>
    <iinn:TotalFinancialLiabilities contextRef="c72" decimals="-3" unitRef="usd">1393000</iinn:TotalFinancialLiabilities>
    <iinn:TotalFinancialLiabilities contextRef="c73" decimals="-3" unitRef="usd">304000</iinn:TotalFinancialLiabilities>
    <iinn:TotalFinancialLiabilities contextRef="c74" decimals="-3" unitRef="usd">1493000</iinn:TotalFinancialLiabilities>
    <iinn:TotalFinancialLiabilities contextRef="c75" decimals="-3" unitRef="usd">26000</iinn:TotalFinancialLiabilities>
    <iinn:TotalFinancialLiabilities contextRef="c76" decimals="-3" unitRef="usd">133000</iinn:TotalFinancialLiabilities>
    <iinn:TotalFinancialLiabilities contextRef="c0" decimals="-3" unitRef="usd">368000</iinn:TotalFinancialLiabilities>
    <iinn:TotalFinancialLiabilities contextRef="c4" decimals="-3" unitRef="usd">3215000</iinn:TotalFinancialLiabilities>
    <iinn:ConversionToShares contextRef="c0" decimals="0" unitRef="shares">756333</iinn:ConversionToShares>
    <iinn:AdditionalOrdinaryShare contextRef="c0" decimals="0" unitRef="shares">169019</iinn:AdditionalOrdinaryShare>
    <iinn:ProceedFromIssuanceInitialPublicOffering contextRef="c0" decimals="1" unitRef="usd">5.5</iinn:ProceedFromIssuanceInitialPublicOffering>
    <iinn:FairValueOfTheWarrant contextRef="c0" decimals="0" unitRef="usd">3</iinn:FairValueOfTheWarrant>
    <iinn:AggregateProceeds contextRef="c35" decimals="0" unitRef="usd">2113905</iinn:AggregateProceeds>
    <iinn:WarrantsShares contextRef="c65" decimals="0" unitRef="shares">1149582</iinn:WarrantsShares>
    <iinn:WarrantsShares contextRef="c66" decimals="0" unitRef="shares">16587</iinn:WarrantsShares>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c34" decimals="0" unitRef="usd">10041</ifrs-full:PlanAssetsAtFairValue>
    <iinn:NontradableWarrantFairValue contextRef="c0" decimals="0" unitRef="usd">35</iinn:NontradableWarrantFairValue>
    <iinn:TradableWarrants contextRef="c67" decimals="0" unitRef="shares">3345455</iinn:TradableWarrants>
    <iinn:PublicOfferingPriceDescription contextRef="c0">The tradable warrants have an exercise price of $5.5 and they are exercisable for five years after the initial public
offering date.</iinn:PublicOfferingPriceDescription>
    <iinn:InvestorsExercisedTradableWarrants contextRef="c68" decimals="0" unitRef="shares">1705000</iinn:InvestorsExercisedTradableWarrants>
    <iinn:OrdinarySharesIssued contextRef="c68" decimals="0" unitRef="shares">1705000</iinn:OrdinarySharesIssued>
    <iinn:TotalProceedsReceived contextRef="c68" decimals="0" unitRef="usd">9377</iinn:TotalProceedsReceived>
    <iinn:DeductingFees contextRef="c68" decimals="0" unitRef="usd">8721</iinn:DeductingFees>
    <iinn:TradableWarrants contextRef="c0" decimals="0" unitRef="shares">1640455</iinn:TradableWarrants>
    <iinn:TradableWarrantsFairValue contextRef="c0" decimals="0" unitRef="usd">304</iinn:TradableWarrantsFairValue>
    <iinn:FinancialLiabilityToPay contextRef="c0" decimals="2" unitRef="pure">0.07</iinn:FinancialLiabilityToPay>
    <iinn:FinancialDerivativesFairValue contextRef="c0" decimals="0" unitRef="usd">26</iinn:FinancialDerivativesFairValue>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 10 - EQUITY (DEFICT):&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;A. Share capital:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Number of shares as of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Number of shares as of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;11,338,940&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;10,091,706&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Since the Company&#x2019;s incorporation in February
2018 and before the IPO, the Company issued the following Ordinary Shares: (i) an aggregate of 27,566 Ordinary Shares for no consideration
to the Company&#x2019;s founders and certain advisors; (ii) 1,877,196 Ordinary Shares as bonus shares for no consideration to existing
shareholders; (iii) an aggregate of 756,333 Ordinary Shares investors. See Note 8(1).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 18, 2021, the Company&#x2019;s shareholders
approved a 12.5 to 1 reverse split of all shares (issued and unissued) on the basis that every 12.5 Ordinary Shares in the capital of
the Company be consolidated into 1 Ordinary Share, such that the authorized share capital of the Company following such consolidation
is NIS 310,000,000 divided into 24,800,000 Ordinary Shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 1, 2021, the Company&#x2019;s shareholders
approved an amendment to the structure of the Company&#x2019;s share capital (both authorized and issued) by cancelling the par value
in addition to implementing an additional reverse split at a ratio of 2.94 to 1, pursuant to which holders of our Ordinary Shares received
one Ordinary Share for every 2.94&#160;Ordinary Shares held.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 1, 2021, the Company&#x2019;s shareholders
approved an amendment to the structure of the Company&#x2019;s share capital (both authorized and issued) by cancelling the par value
of the Company&#x2019;s shares such that each Ordinary Share with par value of NIS 0.125 will become one Ordinary Share with no par value.
The authorized share capital of the Company following the reverse stock split is NIS 310,000,000 divided into 8,435,375 Ordinary Shares,
with no par value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 1, 2021, the Company&#x2019;s shareholders
approved an increase in the authorized share capital of the Company to 15,000,000 Ordinary Shares of no par value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 16, 2021, the Company completed its IPO
on Nasdaq Capital Market whereby the Company sold 2,909,091 Ordinary Shares and 3,345,455 tradable warrants (inclusive of 436,364 tradable
warrants pursuant to the exercise of an overallotment option granted to the underwriters).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Following the IPO, the Company issued 2,113,905
Ordinary Shares and 1,149,582 non-tradable warrants to investors and 16,587 non-tradeable warrants to brokers in connection with the
conversion of Company&#x2019;s previously issued financial liabilities, see note 8(2).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate proceeds received by the Company
from the IPO were approximately 14,490, after deducting underwriting discounts and commissions and additional offering direct costs totaled
in approximately 1,543. The gross proceeds were 16,033.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Total non-cash direct expenses in IPO were as
following: (i) fair value of 436,364 tradable warrants that were granted to underwriters totaled 589; (ii) The Company issued 145,455
non-tradable warrants as underwriters fees; the warrants will be converted into Ordinary Shares of the Company at an exercise price equal
to 125% of the initial public offering price and be exercisable for three years after the initial public offering. As of the date of
the IPO, the tradable warrants fair value was 264; and (iii) the Company agreed to pay to a promoter 7% of the proceeds from the exercise
of tradable warrants. The payment was measured according to IFRS 2 at the grant date. As of the IPO date, the fair value of the financial
liability was 310.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Total non-cash expenses were 1,163.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, the Company had non-direct expenses
as following: (i) cash expenses amounted to 722 and (i) non-cash expenses amounted to 123 (22,382 Ordinary Shares issued to service providers).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Total IPO expanse direct and non direct, cash
and non-cash were: 3,551.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Total IPO expenses allocated to the profit and
loss were 1,265. Total IPO expenses deducted from the equity were 2,286.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year 2021 the Company issued an aggregate
amount of 655,601 Ordinary Shares in connection to vested RSUs and additional 24,631 Ordinary Shares in connection to options exercise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 17, 2021, the Company&#x2019;s shareholders
approved an increase in the authorized share capital of the Company to 100,000,000 Ordinary Shares of no-par value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31 2022, the Company
issued an aggregate amount of 1,240,204 Ordinary Shares in connection to vested RSUs and an additional 7,030 Ordinary Shares in connection
to option exercises.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;B. Loss per share:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Loss per share has been calculated using the
weighted average number of shares in issue during the relevant financial periods, the weighted average number of equity shares in issue
and profit for the period as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Loss for the period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,273&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,955&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Total number of Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,338,940&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,091,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,661,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Weighted average number of Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,794,594&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,306,225&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,967,790&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108; -sec-ix-hidden: hidden-fact-107; -sec-ix-hidden: hidden-fact-106"&gt;Basic and diluted loss per share&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.95&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3.2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3.67&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Number of shares as of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Number of shares as of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;11,338,940&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;10,091,706&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesAuthorised contextRef="c12" decimals="0" unitRef="shares">100000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c12" decimals="0" unitRef="shares">11338940</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesAuthorised contextRef="c6" decimals="0" unitRef="shares">100000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c6" decimals="0" unitRef="shares">10091706</ifrs-full:NumberOfSharesOutstanding>
    <iinn:AggregateOfOrdinaryShares contextRef="c0" decimals="0" unitRef="shares">27566</iinn:AggregateOfOrdinaryShares>
    <iinn:OrdinaryShare contextRef="c4" decimals="0" unitRef="shares">1877196</iinn:OrdinaryShare>
    <iinn:AggregateOfOrdinaryShares contextRef="c77" decimals="0" unitRef="shares">756333</iinn:AggregateOfOrdinaryShares>
    <iinn:StockholdersEquityReverseSplit contextRef="c78">12.5</iinn:StockholdersEquityReverseSplit>
    <iinn:StockholdersEquityReverseSplit contextRef="c79">1</iinn:StockholdersEquityReverseSplit>
    <iinn:AuthorizedShareCapital contextRef="c80" decimals="0" unitRef="ils">310000000</iinn:AuthorizedShareCapital>
    <ifrs-full:NumberOfSharesAuthorised contextRef="c80" decimals="0" unitRef="shares">24800000</ifrs-full:NumberOfSharesAuthorised>
    <iinn:StockholdersEquityReverseSplit contextRef="c81">2.94</iinn:StockholdersEquityReverseSplit>
    <iinn:StockholdersEquityReverseSplit contextRef="c82">1</iinn:StockholdersEquityReverseSplit>
    <ifrs-full:ParValuePerShare contextRef="c80" decimals="3" unitRef="ilsPershares">0.125</ifrs-full:ParValuePerShare>
    <iinn:AuthorizedShareCapital contextRef="c83" decimals="0" unitRef="ils">310000000</iinn:AuthorizedShareCapital>
    <ifrs-full:NumberOfSharesAuthorised contextRef="c83" decimals="0" unitRef="shares">8435375</ifrs-full:NumberOfSharesAuthorised>
    <iinn:OrdinaryShare contextRef="c84" decimals="0" unitRef="shares">15000000</iinn:OrdinaryShare>
    <iinn:SoldOrdinaryShares contextRef="c34" decimals="0" unitRef="shares">2909091</iinn:SoldOrdinaryShares>
    <iinn:tradableWarrants contextRef="c34" decimals="0" unitRef="shares">3345455</iinn:tradableWarrants>
    <iinn:tradableWarrants contextRef="c85" decimals="0" unitRef="shares">436364</iinn:tradableWarrants>
    <iinn:OrdinaryShare contextRef="c67" decimals="0" unitRef="shares">2113905</iinn:OrdinaryShare>
    <iinn:NontradableWarrants contextRef="c77" decimals="0" unitRef="shares">1149582</iinn:NontradableWarrants>
    <iinn:NontradableWarrants contextRef="c86" decimals="0" unitRef="shares">16587</iinn:NontradableWarrants>
    <iinn:AggregateProceedsReceived contextRef="c35" decimals="-3" unitRef="usd">14490000</iinn:AggregateProceedsReceived>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c0" decimals="-3" unitRef="usd">1543000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <iinn:GrossProceeds contextRef="c0" decimals="-3" unitRef="usd">16033000</iinn:GrossProceeds>
    <iinn:TradableWarrantsDescription contextRef="c0">Total non-cash direct expenses in IPO were as
following: (i) fair value of 436,364 tradable warrants that were granted to underwriters totaled 589; (ii) The Company issued 145,455
non-tradable warrants as underwriters fees; the warrants will be converted into Ordinary Shares of the Company at an exercise price equal
to 125% of the initial public offering price and be exercisable for three years after the initial public offering. As of the date of
the IPO, the tradable warrants fair value was 264; and (iii) the Company agreed to pay to a promoter 7% of the proceeds from the exercise
of tradable warrants. The payment was measured according to IFRS 2 at the grant date. As of the IPO date, the fair value of the financial
liability was 310.&#160;</iinn:TradableWarrantsDescription>
    <ifrs-full:OtherMaterialNoncashItems contextRef="c35" decimals="-3" unitRef="usd">1163000</ifrs-full:OtherMaterialNoncashItems>
    <iinn:NondirectCashExpenses contextRef="c35" decimals="-3" unitRef="usd">722000</iinn:NondirectCashExpenses>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c35" decimals="-3" unitRef="usd">123000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <iinn:OrdinaryShare contextRef="c87" decimals="0" unitRef="shares">22382</iinn:OrdinaryShare>
    <iinn:CashAndNoncash contextRef="c35" decimals="-3" unitRef="usd">3551000</iinn:CashAndNoncash>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c35" decimals="-3" unitRef="usd">1265000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <iinn:ExpensesDeductedFromEquity contextRef="c35" decimals="-3" unitRef="usd">2286000</iinn:ExpensesDeductedFromEquity>
    <iinn:AggregateAmount contextRef="c4" decimals="0" unitRef="shares">655601</iinn:AggregateAmount>
    <iinn:AdditionalOrdinaryShares contextRef="c4" decimals="0" unitRef="shares">24631</iinn:AdditionalOrdinaryShares>
    <ifrs-full:NumberOfSharesAuthorised contextRef="c88" decimals="0" unitRef="shares">100000000</ifrs-full:NumberOfSharesAuthorised>
    <iinn:AggregateAmount contextRef="c0" decimals="0" unitRef="shares">1240204</iinn:AggregateAmount>
    <iinn:AdditionalOrdinaryShares contextRef="c0" decimals="0" unitRef="shares">7030</iinn:AdditionalOrdinaryShares>
    <iinn:ScheduleOfLossPerShare contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Loss for the period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,273&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,955&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Total number of Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,338,940&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,091,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,661,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Weighted average number of Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,794,594&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,306,225&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,967,790&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108; -sec-ix-hidden: hidden-fact-107; -sec-ix-hidden: hidden-fact-106"&gt;Basic and diluted loss per share&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.95&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3.2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3.67&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfLossPerShare>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c0" decimals="-3" unitRef="usd">10273000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c4" decimals="-3" unitRef="usd">16955000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c5" decimals="-3" unitRef="usd">7228000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c0" decimals="0" unitRef="shares">11338940</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c4" decimals="0" unitRef="shares">10091706</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c5" decimals="0" unitRef="shares">2661095</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <iinn:AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits contextRef="c0" decimals="0" unitRef="shares">10794594</iinn:AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits>
    <iinn:AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits contextRef="c4" decimals="0" unitRef="shares">5306225</iinn:AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits>
    <iinn:AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits contextRef="c5" decimals="0" unitRef="shares">1967790</iinn:AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits>
    <ifrs-full:BasicEarningsLossPerShare contextRef="c0" decimals="2" unitRef="usdPershares">-0.95</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare contextRef="c4" decimals="1" unitRef="usdPershares">-3.2</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare contextRef="c5" decimals="2" unitRef="usdPershares">-3.67</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 11 - RESEARCH AND DEVELOPMENT EXPENSES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Share based payment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,311&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,230&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,237&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Subcontractors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;929&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Materials and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,094&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;IIA participation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(255&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(383&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,054&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,909&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,873&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
    <iinn:ScheduleOfResearchAndDevelopmentExpenses contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Share based payment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,311&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,230&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,237&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Subcontractors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;929&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Materials and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,094&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;IIA participation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(255&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(383&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,054&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,909&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,873&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfResearchAndDevelopmentExpenses>
    <iinn:ShareBasedPayment contextRef="c0" decimals="-3" unitRef="usd">2311000</iinn:ShareBasedPayment>
    <iinn:ShareBasedPayment contextRef="c4" decimals="-3" unitRef="usd">1768000</iinn:ShareBasedPayment>
    <iinn:ShareBasedPayment contextRef="c5" decimals="-3" unitRef="usd">2230000</iinn:ShareBasedPayment>
    <iinn:SalaryAndRelatedExpenses contextRef="c0" decimals="-3" unitRef="usd">3332000</iinn:SalaryAndRelatedExpenses>
    <iinn:SalaryAndRelatedExpenses contextRef="c4" decimals="-3" unitRef="usd">1533000</iinn:SalaryAndRelatedExpenses>
    <iinn:SalaryAndRelatedExpenses contextRef="c5" decimals="-3" unitRef="usd">1237000</iinn:SalaryAndRelatedExpenses>
    <iinn:Subcontractors contextRef="c0" decimals="-3" unitRef="usd">929000</iinn:Subcontractors>
    <iinn:Subcontractors contextRef="c4" decimals="-3" unitRef="usd">496000</iinn:Subcontractors>
    <iinn:Subcontractors contextRef="c5" decimals="-3" unitRef="usd">125000</iinn:Subcontractors>
    <iinn:MaterialsAndRelatedExpenses contextRef="c0" decimals="-3" unitRef="usd">1094000</iinn:MaterialsAndRelatedExpenses>
    <iinn:MaterialsAndRelatedExpenses contextRef="c4" decimals="-3" unitRef="usd">204000</iinn:MaterialsAndRelatedExpenses>
    <iinn:MaterialsAndRelatedExpenses contextRef="c5" decimals="-3" unitRef="usd">440000</iinn:MaterialsAndRelatedExpenses>
    <iinn:DepreciationExpenses contextRef="c0" decimals="-3" unitRef="usd">238000</iinn:DepreciationExpenses>
    <iinn:DepreciationExpenses contextRef="c4" decimals="-3" unitRef="usd">134000</iinn:DepreciationExpenses>
    <iinn:DepreciationExpenses contextRef="c5" decimals="-3" unitRef="usd">196000</iinn:DepreciationExpenses>
    <iinn:IIAParticipation contextRef="c4" decimals="-3" unitRef="usd">-255000</iinn:IIAParticipation>
    <iinn:IIAParticipation contextRef="c5" decimals="-3" unitRef="usd">-383000</iinn:IIAParticipation>
    <iinn:OtherResearchAndDevelopmentExpenses contextRef="c0" decimals="-3" unitRef="usd">150000</iinn:OtherResearchAndDevelopmentExpenses>
    <iinn:OtherResearchAndDevelopmentExpenses contextRef="c4" decimals="-3" unitRef="usd">29000</iinn:OtherResearchAndDevelopmentExpenses>
    <iinn:OtherResearchAndDevelopmentExpenses contextRef="c5" decimals="-3" unitRef="usd">28000</iinn:OtherResearchAndDevelopmentExpenses>
    <iinn:ResearchDevelopmentExpenses contextRef="c0" decimals="-3" unitRef="usd">8054000</iinn:ResearchDevelopmentExpenses>
    <iinn:ResearchDevelopmentExpenses contextRef="c4" decimals="-3" unitRef="usd">3909000</iinn:ResearchDevelopmentExpenses>
    <iinn:ResearchDevelopmentExpenses contextRef="c5" decimals="-3" unitRef="usd">3873000</iinn:ResearchDevelopmentExpenses>
    <iinn:SalesAndMarketingExpensesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 12 - SALES AND MARKETING EXPENSES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Share based payment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;501&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professionals&#x2019; fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;521&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;520&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,325&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,951&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:SalesAndMarketingExpensesTextBlock>
    <iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Share based payment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;501&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professionals&#x2019; fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;521&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;520&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,325&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,951&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c0" decimals="-3" unitRef="usd">501000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c4" decimals="-3" unitRef="usd">1186000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:WagesAndSalaries contextRef="c0" decimals="-3" unitRef="usd">287000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c4" decimals="-3" unitRef="usd">220000</ifrs-full:WagesAndSalaries>
    <ifrs-full:FeeAndCommissionExpense contextRef="c0" decimals="-3" unitRef="usd">521000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionExpense contextRef="c4" decimals="-3" unitRef="usd">520000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:OtherExpenseByNature contextRef="c0" decimals="-3" unitRef="usd">16000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature contextRef="c4" decimals="-3" unitRef="usd">25000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:ExpenseByNature contextRef="c0" decimals="-3" unitRef="usd">1325000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature contextRef="c4" decimals="-3" unitRef="usd">1951000</ifrs-full:ExpenseByNature>
    <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Share based payment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,093&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,522&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Related NASDAQ IPO expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Director&#x2019;s fees and share based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;723&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Insurance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Travel abroad&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,391&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,572&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,447&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
    <iinn:ScheduleOfGeneralAndAdministrativeExpenses contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Share based payment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,093&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,522&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Related NASDAQ IPO expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Director&#x2019;s fees and share based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;723&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Insurance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Travel abroad&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,391&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,572&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,447&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfGeneralAndAdministrativeExpenses>
    <iinn:ShareBasedPayments contextRef="c0" decimals="-3" unitRef="usd">1093000</iinn:ShareBasedPayments>
    <iinn:ShareBasedPayments contextRef="c4" decimals="-3" unitRef="usd">2581000</iinn:ShareBasedPayments>
    <iinn:ShareBasedPayments contextRef="c5" decimals="-3" unitRef="usd">818000</iinn:ShareBasedPayments>
    <ifrs-full:ProfessionalFeesExpense contextRef="c0" decimals="-3" unitRef="usd">1522000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense contextRef="c4" decimals="-3" unitRef="usd">1390000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense contextRef="c5" decimals="-3" unitRef="usd">154000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="c4" decimals="-3" unitRef="usd">1265000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="c5" decimals="-3" unitRef="usd">1235000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c0" decimals="-3" unitRef="usd">1113000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c4" decimals="-3" unitRef="usd">1142000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">723000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">545000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">140000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:InsuranceExpense contextRef="c0" decimals="-3" unitRef="usd">565000</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense contextRef="c4" decimals="-3" unitRef="usd">363000</ifrs-full:InsuranceExpense>
    <ifrs-full:RentalExpense contextRef="c0" decimals="-3" unitRef="usd">103000</ifrs-full:RentalExpense>
    <ifrs-full:RentalExpense contextRef="c4" decimals="-3" unitRef="usd">91000</ifrs-full:RentalExpense>
    <ifrs-full:RentalExpense contextRef="c5" decimals="-3" unitRef="usd">77000</ifrs-full:RentalExpense>
    <iinn:Depreciations contextRef="c0" decimals="-3" unitRef="usd">123000</iinn:Depreciations>
    <iinn:Depreciations contextRef="c4" decimals="-3" unitRef="usd">84000</iinn:Depreciations>
    <iinn:Depreciations contextRef="c5" decimals="-3" unitRef="usd">7000</iinn:Depreciations>
    <ifrs-full:TravelExpense contextRef="c0" decimals="-3" unitRef="usd">106000</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense contextRef="c4" decimals="-3" unitRef="usd">65000</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense contextRef="c5" decimals="-3" unitRef="usd">12000</ifrs-full:TravelExpense>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c0" decimals="-3" unitRef="usd">43000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c4" decimals="-3" unitRef="usd">46000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c5" decimals="-3" unitRef="usd">4000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:TradeAndOtherPayables contextRef="c2" decimals="-3" unitRef="usd">5391000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c3" decimals="-3" unitRef="usd">7572000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c19" decimals="-3" unitRef="usd">2447000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 14 &#x2013; FINANCIAL (INCOME) AND EXPENSES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;Income&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Revaluation of financial liabilities at fair value through profit or loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign currency transaction income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,774&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest on deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(308&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4,678&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;Expenses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Revaluation of financial liabilities at fair value through profit or loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;893&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign currency transaction loss, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Revaluation of liability in respect of government grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance expense in respect of lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;80&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;181&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,524&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;959&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <iinn:ScheduleOfFinancialIncomeTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;Income&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Revaluation of financial liabilities at fair value through profit or loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign currency transaction income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,774&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest on deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(308&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4,678&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;</iinn:ScheduleOfFinancialIncomeTableTextBlock>
    <ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability contextRef="c89" decimals="-3" unitRef="usd">-2592000</ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability>
    <iinn:ForeignCurrencyTransactionLossNet contextRef="c92" decimals="-3" unitRef="usd">-1774000</iinn:ForeignCurrencyTransactionLossNet>
    <ifrs-full:InterestIncomeOnDeposits contextRef="c92" decimals="-3" unitRef="usd">308000</ifrs-full:InterestIncomeOnDeposits>
    <ifrs-full:InterestIncomeOnDeposits contextRef="c93" decimals="-3" unitRef="usd">1000</ifrs-full:InterestIncomeOnDeposits>
    <ifrs-full:OtherIncome contextRef="c92" decimals="-3" unitRef="usd">4000</ifrs-full:OtherIncome>
    <iinn:TotalIncome contextRef="c92" decimals="-3" unitRef="usd">-4678000</iinn:TotalIncome>
    <iinn:TotalIncome contextRef="c93" decimals="-3" unitRef="usd">-1000</iinn:TotalIncome>
    <iinn:ScheduleOfFinancialExpenses contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;Expenses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Revaluation of financial liabilities at fair value through profit or loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;893&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign currency transaction loss, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Revaluation of liability in respect of government grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance expense in respect of lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;80&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;181&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,524&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;959&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfFinancialExpenses>
    <ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability contextRef="c96" decimals="-3" unitRef="usd">2183000</ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability>
    <ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability contextRef="c97" decimals="-3" unitRef="usd">893000</ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability>
    <iinn:ForeignCurrencyTransactionLossNet contextRef="c99" decimals="-3" unitRef="usd">1186000</iinn:ForeignCurrencyTransactionLossNet>
    <iinn:RevaluationOfLiabilityInRespectOfGovernmentGrants contextRef="c98" decimals="-3" unitRef="usd">138000</iinn:RevaluationOfLiabilityInRespectOfGovernmentGrants>
    <iinn:RevaluationOfLiabilityInRespectOfGovernmentGrants contextRef="c99" decimals="-3" unitRef="usd">69000</iinn:RevaluationOfLiabilityInRespectOfGovernmentGrants>
    <iinn:RevaluationOfLiabilityInRespectOfGovernmentGrants contextRef="c100" decimals="-3" unitRef="usd">40000</iinn:RevaluationOfLiabilityInRespectOfGovernmentGrants>
    <iinn:FinanceExpenseInRespectOfLeaseLiability contextRef="c98" decimals="-3" unitRef="usd">37000</iinn:FinanceExpenseInRespectOfLeaseLiability>
    <iinn:FinanceExpenseInRespectOfLeaseLiability contextRef="c99" decimals="-3" unitRef="usd">6000</iinn:FinanceExpenseInRespectOfLeaseLiability>
    <iinn:FinanceExpenseInRespectOfLeaseLiability contextRef="c100" decimals="-3" unitRef="usd">5000</iinn:FinanceExpenseInRespectOfLeaseLiability>
    <ifrs-full:OtherExpenseByNature contextRef="c98" decimals="-3" unitRef="usd">6000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature contextRef="c99" decimals="-3" unitRef="usd">80000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature contextRef="c100" decimals="-3" unitRef="usd">21000</ifrs-full:OtherExpenseByNature>
    <iinn:TotalExpenses contextRef="c98" decimals="-3" unitRef="usd">181000</iinn:TotalExpenses>
    <iinn:TotalExpenses contextRef="c99" decimals="-3" unitRef="usd">3524000</iinn:TotalExpenses>
    <iinn:TotalExpenses contextRef="c100" decimals="-3" unitRef="usd">959000</iinn:TotalExpenses>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 15 - TAXES ON INCOME: &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;Taxes on
income:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;Israeli corporate
tax rate was 23% in 2022 and 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Net operating losses carry forwards&lt;/b&gt;:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022, the Company has carried
forward tax losses of approximately 11,540, which may be carried forward and offset against taxable income for an indefinite period in
the future. The Company did not recognize deferred tax assets relating to carry forward losses in the financial statements because their
utilization in the foreseeable future is not probable. As of December 31, 2022, the Company has temporary differences of 2,838 for which
no deferred tax asset was recognized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Theoretical tax:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Loss before taxation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(10,273&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(16,955&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Theoretical tax credit at applicable statutory rate: 23%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,363&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,900&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,662&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-allowable expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,804&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,070&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Temporary differences and tax losses for which no Deferred Tax Asset is recognized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(559&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,830&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,071&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Income tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:ApplicableTaxRate contextRef="c0" decimals="2" unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c4" decimals="2" unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <iinn:CarriedForwardTaxLosse contextRef="c0" decimals="-3" unitRef="usd">11540000</iinn:CarriedForwardTaxLosse>
    <iinn:DeferredTaxAssetS contextRef="c0" decimals="-3" unitRef="usd">2838000</iinn:DeferredTaxAssetS>
    <iinn:ScheduleOfTheoreticalTaxTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Loss before taxation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(10,273&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(16,955&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Theoretical tax credit at applicable statutory rate: 23%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,363&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,900&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,662&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-allowable expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,804&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,070&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Temporary differences and tax losses for which no Deferred Tax Asset is recognized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(559&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,830&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,071&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Income tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfTheoreticalTaxTableTextBlock>
    <iinn:LossBeforeTaxation contextRef="c0" decimals="-3" unitRef="usd">-10273000</iinn:LossBeforeTaxation>
    <iinn:LossBeforeTaxation contextRef="c4" decimals="-3" unitRef="usd">-16955000</iinn:LossBeforeTaxation>
    <iinn:LossBeforeTaxation contextRef="c5" decimals="-3" unitRef="usd">-7228000</iinn:LossBeforeTaxation>
    <iinn:TheoreticalTaxCreditAtApplicableStatutoryRate contextRef="c4" decimals="2" unitRef="pure">0.23</iinn:TheoreticalTaxCreditAtApplicableStatutoryRate>
    <iinn:TheoreticalTaxCreditAtApplicableStatutoryRate contextRef="c5" decimals="2" unitRef="pure">0.23</iinn:TheoreticalTaxCreditAtApplicableStatutoryRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c0" decimals="-3" unitRef="usd">-2363000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c4" decimals="-3" unitRef="usd">-3900000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c5" decimals="-3" unitRef="usd">-1662000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <iinn:NonallowableExpenses contextRef="c0" decimals="-3" unitRef="usd">-1804000</iinn:NonallowableExpenses>
    <iinn:NonallowableExpenses contextRef="c4" decimals="-3" unitRef="usd">-2070000</iinn:NonallowableExpenses>
    <iinn:NonallowableExpenses contextRef="c5" decimals="-3" unitRef="usd">4733000</iinn:NonallowableExpenses>
    <iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized contextRef="c0" decimals="-3" unitRef="usd">-559000</iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized>
    <iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized contextRef="c4" decimals="-3" unitRef="usd">-1830000</iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized>
    <iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized contextRef="c5" decimals="-3" unitRef="usd">-3071000</iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 16 - LEASES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has lease contracts for office facilities
and vehicles used in its operations. Leases of vehicles generally have lease terms up to three years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company leases vehicles for three-year periods
from several different leasing companies and from time to time changes the number of leased vehicles according to its current needs.
The leased vehicles are used by the Company&#x2019;s management, and other employees whose employment agreements include an obligation
of the Company to put a vehicle at their disposal. The Company accounted for the arrangement between it and the leasing companies as
a lease arrangement in the scope of IFRS 16 and for the arrangement between it and its employees as an arrangement in the scope of IAS
19, Employee Benefits. The agreements with the leasing companies do not contain extension and/or termination options that the Company
is reasonably certain to exercise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A lease liability in the amount of 281 and right-of-use
asset in the amount of 345 have been recognized in the statement of financial position as of December 31, 2022 in respect of leases of
vehicles.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company leases offices in Ra&#x2019;anana
are for a period of 69 months. The contractual period of the aforesaid lease agreement ends in August 2027. The Company has an option
to terminate the contract after 45 months with a penalty in amount of NIS 500,000 that will be diminish in NIS 30,000 in each month from
the 45&lt;sup&gt;th&lt;/sup&gt; month of the contract. The Company does not currently expect to exercise the termination option in the lease agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A lease liability in the amount of 776 and right-of-use
asset in the amount of 762 have been recognized in the statement of financial position as of December 31, 2022 in respect of leases of
offices.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Set out below are the carrying amounts of right-of-use assets recognized
and the movements during the period:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Office&#160;facility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Vehicles&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,160&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;416&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;416&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exchange rate differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(114&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(140&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(171&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(129&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;762&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;345&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,107&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Set out below are the carrying amounts of lease liabilities and the
movements during the period:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font-weight: bold"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;275&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;153&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Accretion of interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Financial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exchange rate differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(138&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(27&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(99&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(350&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(214&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(171&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,057&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,181&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following are the amounts recognized in profit or loss:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Depreciation expense of right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Interest expense on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total amount recognized in profit or loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;300&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;196&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;201&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company had total cash outflows for leases
of 350 in 2022 and 214 in 2021. The Company also had non-cash additions to right-of-use assets and lease liabilities of 416 in 2022 and
1,176 in 2021.&lt;/p&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <iinn:leaseTerms contextRef="c0">P3Y</iinn:leaseTerms>
    <iinn:LeaseLiabilityAmount contextRef="c101" decimals="-3" unitRef="usd">281000</iinn:LeaseLiabilityAmount>
    <ifrs-full:RightofuseAssets contextRef="c102" decimals="-3" unitRef="usd">345000</ifrs-full:RightofuseAssets>
    <iinn:DescriptionOfLeaseAgreement contextRef="c0">The Company leases offices in Ra&#x2019;anana
are for a period of 69 months. The contractual period of the aforesaid lease agreement ends in August 2027. The Company has an option
to terminate the contract after 45 months with a penalty in amount of NIS 500,000 that will be diminish in NIS 30,000 in each month from
the 45th month of the contract. The Company does not currently expect to exercise the termination option in the lease agreement.&#160;</iinn:DescriptionOfLeaseAgreement>
    <iinn:LeaseLiabilityAmount contextRef="c103" decimals="-3" unitRef="usd">776000</iinn:LeaseLiabilityAmount>
    <ifrs-full:RightofuseAssets contextRef="c104" decimals="-3" unitRef="usd">762000</ifrs-full:RightofuseAssets>
    <iinn:ScheduleOfRightofuseAssets contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Office&#160;facility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Vehicles&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,160&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;416&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;416&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exchange rate differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(114&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(140&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(171&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(129&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;762&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;345&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,107&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;</iinn:ScheduleOfRightofuseAssets>
    <ifrs-full:LeaseLiabilities contextRef="c105" decimals="-3" unitRef="usd">1047000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c106" decimals="-3" unitRef="usd">113000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c3" decimals="-3" unitRef="usd">1160000</ifrs-full:LeaseLiabilities>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c108" decimals="-3" unitRef="usd">416000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c0" decimals="-3" unitRef="usd">416000</ifrs-full:AdditionsToRightofuseAssets>
    <iinn:FinancialExpense contextRef="c107" decimals="-3" unitRef="usd">-114000</iinn:FinancialExpense>
    <iinn:FinancialExpense contextRef="c108" decimals="-3" unitRef="usd">-26000</iinn:FinancialExpense>
    <iinn:FinancialExpense contextRef="c0" decimals="-3" unitRef="usd">-140000</iinn:FinancialExpense>
    <ifrs-full:DisposalsInvestmentProperty contextRef="c108" decimals="-3" unitRef="usd">29000</ifrs-full:DisposalsInvestmentProperty>
    <ifrs-full:DisposalsInvestmentProperty contextRef="c0" decimals="-3" unitRef="usd">29000</ifrs-full:DisposalsInvestmentProperty>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c107" decimals="-3" unitRef="usd">171000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c108" decimals="-3" unitRef="usd">129000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c0" decimals="-3" unitRef="usd">300000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:LeaseLiabilities contextRef="c109" decimals="-3" unitRef="usd">762000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c110" decimals="-3" unitRef="usd">345000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c2" decimals="-3" unitRef="usd">1107000</ifrs-full:LeaseLiabilities>
    <iinn:ScheduleOfLeaseLiabilities contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font-weight: bold"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;275&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;153&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Accretion of interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Financial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exchange rate differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(138&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(27&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(99&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(350&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(214&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(171&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,057&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,181&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</iinn:ScheduleOfLeaseLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c3" decimals="-3" unitRef="usd">1181000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c19" decimals="-3" unitRef="usd">275000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c29" decimals="-3" unitRef="usd">153000</ifrs-full:FinancialLiabilities>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c0" decimals="-3" unitRef="usd">367000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" unitRef="usd">1176000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c5" decimals="-3" unitRef="usd">273000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c5" decimals="-3" unitRef="usd">5000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <iinn:FinancialExpenses contextRef="c0" decimals="-3" unitRef="usd">-24000</iinn:FinancialExpenses>
    <iinn:FinancialExpenses contextRef="c5" decimals="-3" unitRef="usd">5000</iinn:FinancialExpenses>
    <iinn:ExchangeRateDifference contextRef="c0" decimals="-3" unitRef="usd">-138000</iinn:ExchangeRateDifference>
    <iinn:ExchangeRateDifference contextRef="c4" decimals="-3" unitRef="usd">43000</iinn:ExchangeRateDifference>
    <iinn:ExchangeRateDifference contextRef="c5" decimals="-3" unitRef="usd">20000</iinn:ExchangeRateDifference>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">27000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">99000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <iinn:PrincipalPayment contextRef="c0" decimals="-3" unitRef="usd">-350000</iinn:PrincipalPayment>
    <iinn:PrincipalPayment contextRef="c4" decimals="-3" unitRef="usd">-214000</iinn:PrincipalPayment>
    <iinn:PrincipalPayment contextRef="c5" decimals="-3" unitRef="usd">-171000</iinn:PrincipalPayment>
    <ifrs-full:FinancialLiabilities contextRef="c2" decimals="-3" unitRef="usd">1057000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c3" decimals="-3" unitRef="usd">1181000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c19" decimals="-3" unitRef="usd">275000</ifrs-full:FinancialLiabilities>
    <iinn:ScheduleOfProfitOrLoss contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Depreciation expense of right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Interest expense on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total amount recognized in profit or loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;300&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;196&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;201&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</iinn:ScheduleOfProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c0" decimals="-3" unitRef="usd">-300000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c4" decimals="-3" unitRef="usd">-196000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c5" decimals="-3" unitRef="usd">-196000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c5" decimals="-3" unitRef="usd">5000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <iinn:TotalAmountRecognizedInProfitOrLoss contextRef="c0" decimals="-3" unitRef="usd">300000</iinn:TotalAmountRecognizedInProfitOrLoss>
    <iinn:TotalAmountRecognizedInProfitOrLoss contextRef="c4" decimals="-3" unitRef="usd">196000</iinn:TotalAmountRecognizedInProfitOrLoss>
    <iinn:TotalAmountRecognizedInProfitOrLoss contextRef="c5" decimals="-3" unitRef="usd">201000</iinn:TotalAmountRecognizedInProfitOrLoss>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">350000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c4" decimals="-3" unitRef="usd">214000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <iinn:LeaseLiabilityAmount contextRef="c0" decimals="-3" unitRef="usd">416000</iinn:LeaseLiabilityAmount>
    <ifrs-full:RightofuseAssets contextRef="c3" decimals="-3" unitRef="usd">1176000</ifrs-full:RightofuseAssets>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 17 - SHARE BASED PAYMENT:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2019, the Company established a share
option plan (the &#x201c;Plan&#x201d;). Under the Plan, total of 602,989 options were granted until December 31, 2022. As of December 31,
2022, a total of 500,772 options to subscribe Ordinary Shares that have been granted to employees, consultants and directors are outstanding.&lt;br/&gt;
A total of 3,707,542 RSUs that have been granted to employees, consultants and directors, 1,895,808 RSUs are vested as of December 31,
2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 20, 2020 a total of 478,747 options
to subscribe Ordinary Shares have been granted to employees and consultants. The exercise price per share to 123,719 and 355,029 options
was USD 0.0029 (AUD 0.052) and USD 2.67 (AUD 4.2), respectively. The vesting period is up to 3 years from the grant date, according to
the various vesting periods: from an immediate one and up to 3 years. Contractual life of the options under the Plan is 10 years. The
options were granted under section 102 of the Israeli Tax Ordinance which enables the employee to pay 25% of capital gain tax upon exercise.
&#160;In October 2020, 73,380 options were canceled.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 17, 2020, the Israeli Taxes Authority
(ITA) approved a ruling request from the Company for a tax-free amendment of the commercial terms of the outstanding options, including
(i) a reduction of the exercise price to NIS 0.37 per share, and (ii) a shortening of the vesting schedules.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company implemented IFRS 2-Share based payment
on options terms change.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 20, 2020, the board of directors
granted a total of 56,653 options to subscribe Ordinary Shares to employees and consultants. The vesting period is up to 3 years from
the grant date. The exercise price per share was NIS 0.37.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Contractual life of the options under the Plan
is 10 years. The options were granted under section 102 of the Israeli Tax Ordinance which enables the employee to pay 25% of capital
gain tax upon exercise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 21, 2021, the Company&#x2019;s board
of directors approved a grant of 13,605 non-tradable shares options which are exercisable to 13,605 Ordinary shares to employees and
a total of 21,768 share options which are exercisable to 21,768 Ordinary Shares to consultants. The vesting period is three years commencing
on the grant date. The exercise price per share was NIS 0.37($0.12). The contractual life of the options under the Plan is ten years.
The options to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital
gain tax upon exercise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 16, 2021, the Company&#x2019;s board
of directors approved a grant of 81,633 non-tradable shares options to a director, which are exercisable to 81,633 Ordinary Shares. The
share options vesting period is up to three years from the grant date. The exercise price per share was NIS 0.37 ($0.12). The contractual
life of the options under the Plan is ten years. The options were granted under Section 102 of the Israeli Tax Ordinance, which enables
the employee to pay a 25% capital gain tax upon exercise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 12, 2021, the Company&#x2019;s board
of directors resolved to increase the pool of options available under the Plan to 25% of the Company&#x2019;s equity, on a fully diluted
basis. As a result of the increase, the number of authorized Ordinary Shares available pursuant the Plan was 4,180,898.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;On November 2, 2021, the Company&#x2019;s board of directors approved
a grant of 2,658,188 RSUs to employees and officers. The RSUs represents the right to receive Ordinary Shares at a future time and vest
over a period of three years. The RSUs were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay
a 25% capital gain tax upon exercise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 2, 2021, the Company&#x2019;s
board of directors approved a grant of 10,000 RSUs to the Company&#x2019;s advisory board. The RSUs represents the right to receive
Ordinary Shares at a future time and vest over a period of three years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;On March 24, 2022, the Company&#x2019;s board of directors approved
a grant of 536,141 RSUs to employees and a grant of 22,500 RSUs to the Company&#x2019;s advisory board members and an additional consultant.
The RSUs represent the right to receive Ordinary Shares at a future time. 555,500 of the RSUs in this grant, vest over a period of three
years, with a 1-year cliff period, and 3,141 RSUs vested immediately on the grant date. The RSUs to employees were granted under Section
102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 24, 2022, the Company&#x2019;s board
of directors approved a grant of 29,400 Ordinary Shares options to medical board members, which are exercisable to 29,400 Ordinary Shares.
The share options vesting period is up to three years from the grant date. The exercise price per share was NIS 10.84 ($3.08). The contractual
life of the options under the Plan is ten years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 14.2pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;On April 6, 2022, the Company&#x2019;s board of directors approved
a grant of 285,713 fully vested RSUs to an officer. The RSUs represent the right to receive Ordinary Shares. The RSUs were granted under
Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;On May 19, 2022, the Company&#x2019;s board of directors approved a
grant of 30,000 RSUs to an employee. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period
of three years, with a 1-year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax
Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;On November 22, 2022, the Company&#x2019;s board of directors approved
a grant of 165,000 RSUs to employees. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period
of three years, with a 1-year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax
Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of all granted options was estimated
by using the Black Scholes model, which was aimed to model the value of the Company&#x2019;s assets over time. The simulation approach
was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and
the volatility of its assets, on the date of grant based on certain assumptions. Those conditions are, among others:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The expected volatility is
between 50%-52.4%&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The dividend rate 0%; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Expected term &#x2013; three
years.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The valuation was completed with the assistance
of an independent valuator based on management&#x2019;s assumptions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2022, the Company recorded share
based payment expenses to employees, directors and subcontractors in the amount of 4,879.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;The options to services providers and advisers outstanding as
of December 31, 2022, as&#160;follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;87,833&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,721&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;114,512&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.058&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Exercisable options&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;82,257&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.71&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2022, the Company recorded share
based payment expenses of option to services providers and advisers in the amount of 54.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The RSUs to services providers and advisers outstanding as of December
31, 2022 as&#160;follows:&lt;/p&gt;&lt;div&gt;

&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,234&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,266&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Vested as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,234&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2022, the
Company recorded share based payment expenses of RSUs to services providers and advisers in the amount of 33.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The options to employees and directors outstanding as of December
31, 2022, as&#160;follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt;
    December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted average Exercise
    price NIS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at beginning of year &lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;448,120&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.37&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,309&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.37&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(&lt;span style="font-size: 10pt"&gt;57,551&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.37&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;386,260&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.37&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Exercisable options&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;342,757&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.37&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;During the year ended December 31, 2022, the Company recorded share
based payment expenses of options to employees and directors in the amount of 174&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The RSUs to employees and directors outstanding as of December 31,
2022, as&#160;follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,002,587&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,016,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(65,626&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,225,973&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,727,842&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Vested as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,881,574&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2022, the
Company recorded share based payment expenses of RSUs to employees and directors in the amount of 4,618.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The options to services providers and advisers outstanding as of December
31, 2021, as&#160;follows:&lt;/p&gt;&lt;div&gt;

&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;165,987&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reclassified to employees and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(71,260&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,086&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,134&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;87,833&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Exercisable options&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;62,715&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The RSUs to services providers and advisers outstanding as of December
31, 2021, as&#160;follows:&lt;/p&gt;&lt;div&gt;

&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Exercisable RSUs&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The options to employees and directors outstanding as of December
31, 2021, as&#160;follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average Exercise price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;296,038&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reclassified to employees and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,872&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;448,120&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Exercisable options&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;347,069&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The restricted shares units to employees and directors outstanding
as of December 31, 2021, as&#160;follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,658,188&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(655,601&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,002,587&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c111" decimals="0" unitRef="pure">602989</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <iinn:GrantTotalShares contextRef="c0" decimals="0" unitRef="shares">500772</iinn:GrantTotalShares>
    <iinn:StockIssuedDuringPeriodSharesRestrictedStockUnit contextRef="c0" decimals="0" unitRef="shares">3707542</iinn:StockIssuedDuringPeriodSharesRestrictedStockUnit>
    <iinn:RestrictedStockUnitVested contextRef="c0" decimals="0" unitRef="shares">1895808</iinn:RestrictedStockUnitVested>
    <iinn:TotalOrdinaryShares contextRef="c112" decimals="0" unitRef="shares">478747</iinn:TotalOrdinaryShares>
    <iinn:GrantOptionDescription contextRef="c0">The exercise price per share to 123,719 and 355,029 options
was USD 0.0029 (AUD 0.052) and USD 2.67 (AUD 4.2), respectively. The vesting period is up to 3 years from the grant date, according to
the various vesting periods: from an immediate one and up to 3 years. Contractual life of the options under the Plan is 10 years. The
options were granted under section 102 of the Israeli Tax Ordinance which enables the employee to pay 25% of capital gain tax upon exercise.
&#160;In October 2020, 73,380 options were canceled.</iinn:GrantOptionDescription>
    <iinn:ExercisePrice contextRef="c113" decimals="2" unitRef="usdPershares">0.37</iinn:ExercisePrice>
    <iinn:GrantedTotalOption contextRef="c114" decimals="0" unitRef="shares">56653</iinn:GrantedTotalOption>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c5">3 years</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <iinn:ExercisePrice contextRef="c5" decimals="2" unitRef="ilsPershares">0.37</iinn:ExercisePrice>
    <iinn:ContractualLife contextRef="c0">P10Y</iinn:ContractualLife>
    <iinn:CapitalGainTax contextRef="c0" decimals="2" unitRef="pure">0.25</iinn:CapitalGainTax>
    <iinn:NontradableSharesOptions contextRef="c115">the Company&#x2019;s board
of directors approved a grant of 13,605 non-tradable shares options which are exercisable to 13,605 Ordinary shares to employees and
a total of 21,768 share options which are exercisable to 21,768 Ordinary Shares to consultants. The vesting period is three years commencing
on the grant date. The exercise price per share was NIS 0.37($0.12). The contractual life of the options under the Plan is ten years.
The options to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital
gain tax upon exercise.</iinn:NontradableSharesOptions>
    <iinn:NontradableShares contextRef="c116" decimals="0" unitRef="shares">81633</iinn:NontradableShares>
    <iinn:ExercisableOrdinaryShares contextRef="c116" decimals="0" unitRef="shares">81633</iinn:ExercisableOrdinaryShares>
    <iinn:VestingPeriod contextRef="c116">P3Y</iinn:VestingPeriod>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="c117" decimals="2" unitRef="ilsPershares">0.12</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c116">P10Y</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <iinn:CapitalGainTax contextRef="c116" decimals="2" unitRef="pure">0.25</iinn:CapitalGainTax>
    <iinn:OptionsEquity contextRef="c118" decimals="2" unitRef="pure">0.25</iinn:OptionsEquity>
    <iinn:AuthorizedOrdinaryShares contextRef="c119" decimals="0" unitRef="shares">4180898</iinn:AuthorizedOrdinaryShares>
    <iinn:GrantTotal contextRef="c120" decimals="0" unitRef="shares">2658188</iinn:GrantTotal>
    <iinn:VestOverPeriod contextRef="c121">P3Y</iinn:VestOverPeriod>
    <iinn:CapitalGainTax contextRef="c122" decimals="2" unitRef="pure">0.25</iinn:CapitalGainTax>
    <iinn:GrantTotal contextRef="c122" decimals="0" unitRef="shares">10000</iinn:GrantTotal>
    <iinn:VestOverPeriod contextRef="c122">P3Y</iinn:VestOverPeriod>
    <iinn:RestrictedStockUnitEmployeesDescription contextRef="c123">the Company&#x2019;s board of directors approved
a grant of 536,141 RSUs to employees and a grant of 22,500 RSUs to the Company&#x2019;s advisory board members and an additional consultant.
The RSUs represent the right to receive Ordinary Shares at a future time. 555,500 of the RSUs in this grant, vest over a period of three
years, with a 1-year cliff period, and 3,141 RSUs vested immediately on the grant date. The RSUs to employees were granted under Section
102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</iinn:RestrictedStockUnitEmployeesDescription>
    <iinn:BoardOfDirectorsDescription contextRef="c123">the Company&#x2019;s board
of directors approved a grant of 29,400 Ordinary Shares options to medical board members, which are exercisable to 29,400 Ordinary Shares.
The share options vesting period is up to three years from the grant date. The exercise price per share was NIS 10.84 ($3.08). The contractual
life of the options under the Plan is ten years.</iinn:BoardOfDirectorsDescription>
    <iinn:BoardOfDirectorsDescription contextRef="c124">the Company&#x2019;s board of directors approved
a grant of 285,713 fully vested RSUs to an officer. The RSUs represent the right to receive Ordinary Shares. The RSUs were granted under
Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</iinn:BoardOfDirectorsDescription>
    <iinn:BoardOfDirectorsDescription contextRef="c125">the Company&#x2019;s board of directors approved a
grant of 30,000 RSUs to an employee. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period
of three years, with a 1-year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax
Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</iinn:BoardOfDirectorsDescription>
    <iinn:BoardOfDirectorsDescription contextRef="c126">the Company&#x2019;s board of directors approved
a grant of 165,000 RSUs to employees. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period
of three years, with a 1-year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax
Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</iinn:BoardOfDirectorsDescription>
    <iinn:FairValueAssumptionsDescription contextRef="c0">The fair value of all granted options was estimated
by using the Black Scholes model, which was aimed to model the value of the Company&#x2019;s assets over time. The simulation approach
was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and
the volatility of its assets, on the date of grant based on certain assumptions. Those conditions are, among others:&#160;
(i)The expected volatility is
between 50%-52.4%
&#160;
(ii)The dividend rate 0%; and
&#160;
(iii)Expected term &#x2013; three
years.
&#160;</iinn:FairValueAssumptionsDescription>
    <iinn:ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors contextRef="c0" decimals="0" unitRef="usd">4879</iinn:ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;87,833&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,721&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;114,512&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.058&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Exercisable options&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;82,257&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.71&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt;
    December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted average Exercise
    price NIS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at beginning of year &lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;448,120&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.37&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,309&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.37&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(&lt;span style="font-size: 10pt"&gt;57,551&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.37&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;386,260&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.37&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Exercisable options&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;342,757&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.37&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;165,987&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reclassified to employees and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(71,260&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,086&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,134&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;87,833&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Exercisable options&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;62,715&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average Exercise price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;296,038&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reclassified to employees and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,872&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;448,120&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Exercisable options&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;347,069&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c130" decimals="-3" unitRef="pure">87833000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="c130" decimals="2" unitRef="usdPershares">0.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <iinn:GrantedNumberOfOptions contextRef="c131" decimals="INF" unitRef="shares">29400</iinn:GrantedNumberOfOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019 contextRef="c131" decimals="2" unitRef="usdPershares">10.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <iinn:ExercisedNumberOfOptions contextRef="c131" decimals="INF" unitRef="shares">-2721</iinn:ExercisedNumberOfOptions>
    <iinn:ExercisedWeightedAverageExercisePrice contextRef="c131" decimals="2" unitRef="usdPershares">0.37</iinn:ExercisedWeightedAverageExercisePrice>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c132" decimals="-3" unitRef="pure">114512000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="c132" decimals="3" unitRef="usdPershares">3.058</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <iinn:ExercisableOptionsNumberOfOptions contextRef="c131" decimals="INF" unitRef="shares">82257</iinn:ExercisableOptionsNumberOfOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="c132" decimals="2" unitRef="usdPershares">0.71</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <iinn:ShareBasedPaymentExpenses contextRef="c127" decimals="0" unitRef="usd">54</iinn:ShareBasedPaymentExpenses>
    <iinn:ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,234&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,266&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Vested as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,234&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,002,587&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,016,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(65,626&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,225,973&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,727,842&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Vested as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,881,574&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Exercisable RSUs&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,658,188&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(655,601&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,002,587&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding>
    <iinn:OutstandingAtBeginningOfYears contextRef="c140" decimals="INF" unitRef="shares">10000</iinn:OutstandingAtBeginningOfYears>
    <iinn:Granted contextRef="c141" decimals="INF" unitRef="shares">22500</iinn:Granted>
    <iinn:Vested contextRef="c141" decimals="INF" unitRef="shares">-14234</iinn:Vested>
    <iinn:OutstandingAtBeginningOfYears contextRef="c142" decimals="INF" unitRef="shares">18266</iinn:OutstandingAtBeginningOfYears>
    <iinn:RestrictedStockUnitVested contextRef="c141" decimals="INF" unitRef="shares">14234</iinn:RestrictedStockUnitVested>
    <iinn:ShareBasedPaymentExpenses contextRef="c0" decimals="0" unitRef="usd">33</iinn:ShareBasedPaymentExpenses>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c133" decimals="-3" unitRef="pure">448120000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="c133" decimals="2" unitRef="usdPershares">0.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <iinn:ExercisedNumberOfOptions contextRef="c134" decimals="INF" unitRef="shares">4309</iinn:ExercisedNumberOfOptions>
    <iinn:ExercisedWeightedAverageExercisePrice contextRef="c134" decimals="2" unitRef="usdPershares">0.37</iinn:ExercisedWeightedAverageExercisePrice>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c134" decimals="-3" unitRef="pure">-57551000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <iinn:ForfeitedWeightedAverageExercisePrice contextRef="c134" decimals="2" unitRef="usdPershares">0.37</iinn:ForfeitedWeightedAverageExercisePrice>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c135" decimals="-3" unitRef="pure">386260000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="c135" decimals="2" unitRef="usdPershares">0.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <iinn:ExercisableOptionsNumberOfOptions contextRef="c134" decimals="INF" unitRef="shares">342757</iinn:ExercisableOptionsNumberOfOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="c135" decimals="2" unitRef="usdPershares">0.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <iinn:ShareBasedPaymentExpenses contextRef="c128" decimals="0" unitRef="usd">174</iinn:ShareBasedPaymentExpenses>
    <iinn:OutstandingAtBeginningOfYears contextRef="c143" decimals="INF" unitRef="shares">2002587</iinn:OutstandingAtBeginningOfYears>
    <iinn:Granted contextRef="c144" decimals="INF" unitRef="shares">1016854</iinn:Granted>
    <iinn:Forfeited contextRef="c144" decimals="INF" unitRef="shares">-65626</iinn:Forfeited>
    <iinn:Vested contextRef="c144" decimals="INF" unitRef="shares">-1225973</iinn:Vested>
    <iinn:OutstandingAtBeginningOfYears contextRef="c145" decimals="INF" unitRef="shares">1727842</iinn:OutstandingAtBeginningOfYears>
    <iinn:RestrictedStockUnitVested contextRef="c144" decimals="INF" unitRef="shares">1881574</iinn:RestrictedStockUnitVested>
    <iinn:ShareBasedPaymentExpenses contextRef="c129" decimals="0" unitRef="usd">4618</iinn:ShareBasedPaymentExpenses>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c136" decimals="-3" unitRef="pure">165987000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="c136" decimals="2" unitRef="usdPershares">0.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <iinn:NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares contextRef="c137" decimals="INF" unitRef="shares">-71260</iinn:NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares>
    <iinn:ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice contextRef="c137" decimals="2" unitRef="usdPershares">0.37</iinn:ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice>
    <iinn:GrantedNumberOfOptions contextRef="c137" decimals="INF" unitRef="shares">16326</iinn:GrantedNumberOfOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019 contextRef="c137" decimals="2" unitRef="usdPershares">0.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <iinn:ExercisedNumberOfOptions contextRef="c137" decimals="INF" unitRef="shares">-20086</iinn:ExercisedNumberOfOptions>
    <iinn:ExercisedWeightedAverageExercisePrice contextRef="c137" decimals="2" unitRef="usdPershares">0.37</iinn:ExercisedWeightedAverageExercisePrice>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c137" decimals="-3" unitRef="pure">-3134000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <iinn:ForfeitedWeightedAverageExercisePrice contextRef="c137" decimals="2" unitRef="usdPershares">0.37</iinn:ForfeitedWeightedAverageExercisePrice>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c130" decimals="-3" unitRef="pure">87833000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="c130" decimals="2" unitRef="usdPershares">0.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <iinn:ExercisableOptionsNumberOfOptions contextRef="c137" decimals="INF" unitRef="shares">62715</iinn:ExercisableOptionsNumberOfOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="c130" decimals="2" unitRef="usdPershares">0.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <iinn:Granted contextRef="c147" decimals="INF" unitRef="shares">10000</iinn:Granted>
    <iinn:OutstandingAtBeginningOfYears contextRef="c140" decimals="INF" unitRef="shares">10000</iinn:OutstandingAtBeginningOfYears>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c138" decimals="-3" unitRef="pure">296038000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="c138" decimals="2" unitRef="usdPershares">0.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <iinn:NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares contextRef="c139" decimals="INF" unitRef="shares">71260</iinn:NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares>
    <iinn:ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice contextRef="c139" decimals="2" unitRef="usdPershares">0.37</iinn:ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice>
    <iinn:GrantedNumberOfOptions contextRef="c139" decimals="INF" unitRef="shares">95238</iinn:GrantedNumberOfOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019 contextRef="c139" decimals="2" unitRef="usdPershares">0.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <iinn:ExercisedNumberOfOptions contextRef="c139" decimals="INF" unitRef="shares">-4544</iinn:ExercisedNumberOfOptions>
    <iinn:ExercisedWeightedAverageExercisePrice contextRef="c139" decimals="2" unitRef="usdPershares">0.37</iinn:ExercisedWeightedAverageExercisePrice>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c139" decimals="-3" unitRef="pure">-9872000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <iinn:ForfeitedWeightedAverageExercisePrice contextRef="c139" decimals="2" unitRef="usdPershares">0.37</iinn:ForfeitedWeightedAverageExercisePrice>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c133" decimals="-3" unitRef="pure">448120000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="c133" decimals="2" unitRef="usdPershares">0.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <iinn:ExercisableOptionsNumberOfOptions contextRef="c139" decimals="INF" unitRef="shares">347069</iinn:ExercisableOptionsNumberOfOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="c133" decimals="2" unitRef="usdPershares">0.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <iinn:Granted contextRef="c149" decimals="INF" unitRef="shares">2658188</iinn:Granted>
    <iinn:Vested contextRef="c149" decimals="INF" unitRef="shares">-655601</iinn:Vested>
    <iinn:OutstandingAtBeginningOfYears contextRef="c143" decimals="INF" unitRef="shares">2002587</iinn:OutstandingAtBeginningOfYears>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 18 - RELATED PARTIES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;The following transactions arose with related parties:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Transactions and balances with related parties&lt;/span&gt;&lt;b&gt;:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Shareholders and other related
parties&#x2019; benefits&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salary and related expenses &#x2013; officers and directors&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,923&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;795&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Share based payment &#x2013; officers and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Balances with related parties&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Nature of transaction&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 11%"&gt;Officers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salaries and related&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(292&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(317&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Compensation for directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <iinn:ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salary and related expenses &#x2013; officers and directors&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,923&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;795&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Share based payment &#x2013; officers and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</iinn:ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c0" decimals="-3" unitRef="usd">1923000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c4" decimals="-3" unitRef="usd">1042000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c5" decimals="-3" unitRef="usd">795000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <iinn:ShareBasedPaymentEmployeesAndDirectors contextRef="c0" decimals="-3" unitRef="usd">3745000</iinn:ShareBasedPaymentEmployeesAndDirectors>
    <iinn:ShareBasedPaymentEmployeesAndDirectors contextRef="c4" decimals="-3" unitRef="usd">5876000</iinn:ShareBasedPaymentEmployeesAndDirectors>
    <iinn:ShareBasedPaymentEmployeesAndDirectors contextRef="c5" decimals="-3" unitRef="usd">1805000</iinn:ShareBasedPaymentEmployeesAndDirectors>
    <iinn:BalancesWithRelatedPartiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Nature of transaction&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 11%"&gt;Officers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salaries and related&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(292&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(317&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Compensation for directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:BalancesWithRelatedPartiesTableTextBlock>
    <iinn:NatureOfTransactionSalariesAndRelated contextRef="c150">Salaries and related</iinn:NatureOfTransactionSalariesAndRelated>
    <iinn:NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany contextRef="c150">(292)</iinn:NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany>
    <iinn:NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany contextRef="c151">(317)</iinn:NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany>
    <iinn:NatureOfTransactionSalariesAndRelated contextRef="c152">Compensation for directors</iinn:NatureOfTransactionSalariesAndRelated>
    <iinn:NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany contextRef="c152">(40)</iinn:NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany>
    <iinn:NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany contextRef="c153">(57)</iinn:NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 19 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is exposed to a variety of financial
risks, which result from its financing, operating and investing activities. The objective of financial risk management is to contain,
where appropriate, exposures in these financial risks to limit any negative impact on the Company&#x2019;s financial performance and position.
The Company&#x2019;s financial instruments are its cash and other current assets, convertible loan, payables and other payables. The main
purpose of these financial instruments is to raise finance for the Company&#x2019;s operation. The Company actively measures, monitors,
and manages its financial risk exposures by various functions pursuant to the segregation of duties and principals. The risks arising
from the Company&#x2019;s financial instruments are mainly credit risk and currency risk. The risk management policies employed by the
Company to manage these risks are discussed below.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Credit risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Credit risk arises when a failure by counterparties
to discharge their obligations could reduce the amount of future cash inflows from financial assets on hand at the balance sheet date.
The Company closely monitors the activities of its counterparties and controls the access to its intellectual property which enables
it to ensure the prompt collection. The Company&#x2019;s main financial assets are cash and cash equivalents and deposits represent the
Company&#x2019;s maximum exposure to credit risk in connection with its financial assets. Wherever possible and commercially practical,
the Company holds cash with major financial institutions in Israel.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying amount of financial assets represents
the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,783&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23,749&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other current assets (Restricted deposits)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;56&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,959&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;23,869&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Currency risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Currency risk is the risk that the value of financial
instruments will fluctuate due to changes in foreign exchange rates. Currency risk arises when future commercial transactions and recognized
assets and liabilities are denominated in a currency that is not the Company&#x2019;s functional currency. The Company exposed to foreign
exchange risk arising from currency exposure primarily with respect to the USD. The Company&#x2019;s policy is not to enter into any currency
hedging transactions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying amounts of the Company&#x2019;s foreign
currency denominated monetary liability at the reporting date are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;19,391&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Deposits&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,120&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,886&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,391&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Financial liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;368&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;368&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,518&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,176&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Sensitivity analysis&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A 10% strengthening of the NIS against the following
currencies would have increased (decreased) equity and the income statement by the amounts shown below. This analysis assumes that all
other variables, in particular interest rates, remain constant. For a 10% weakening of the NIS against the relevant currency, there would
be an equal and opposite impact on the profit and other equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt;
 December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt;
 December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-weight: bold"&gt;USD&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,051&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,617&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;AUD&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;GB Pound&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Liquidity risks:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Liquidity risk is the risk that arises when the
maturity of assets and the maturity of liabilities do not match. An unmatched position potentially enhances profitability but can also
increase the risk of loss. The Company has procedures to minimize such loss by maintaining sufficient cash and other highly liquid current
assets and by having available an adequate amount of committed credit facilities. As of the balance sheet date, the Company has a negative
working capital.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following tables detail the Company&#x2019;s
remaining contractual maturity for its financial liabilities. The tables have been drawn up based on the undiscounted cash flows of financial
liabilities based on the earliest date on which the Company can be required to pay.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;As of December 31, 2022:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Up to &lt;br/&gt;
1 year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Between&lt;br/&gt; 1 and 3&lt;br/&gt;
 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;More than&lt;br/&gt; 3 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Other payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;635&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loan from the IIA&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;24&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;776&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,250&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;659&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,150&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;As of December 31, 2021:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Up to &lt;br/&gt;
1 year&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Between &lt;br/&gt;
1 and 3&lt;br/&gt; years&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;More than&lt;br/&gt; 3 years&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Other payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;611&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;678&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loan from the IIA&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;868&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,009&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;544&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,546&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <iinn:ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,783&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23,749&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other current assets (Restricted deposits)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;56&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,959&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;23,869&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</iinn:ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate contextRef="c154" decimals="-3" unitRef="usd">6783000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate contextRef="c155" decimals="-3" unitRef="usd">23749000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents contextRef="c154" decimals="-3" unitRef="usd">7120000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c154" decimals="-3" unitRef="usd">56000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c155" decimals="-3" unitRef="usd">120000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c154" decimals="-3" unitRef="usd">13959000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c155" decimals="-3" unitRef="usd">23869000</ifrs-full:FinancialAssets>
    <iinn:ScheduleOfForeignCurrencyDenominatedMonetaryLiability contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;19,391&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Deposits&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,120&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,886&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,391&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Financial liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;368&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;368&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,518&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,176&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</iinn:ScheduleOfForeignCurrencyDenominatedMonetaryLiability>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition contextRef="c2" decimals="-3" unitRef="usd">3766000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition contextRef="c3" decimals="-3" unitRef="usd">19391000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <iinn:Deposit contextRef="c2" decimals="-3" unitRef="usd">7120000</iinn:Deposit>
    <ifrs-full:FinancialAssets contextRef="c2" decimals="-3" unitRef="usd">10886000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c3" decimals="-3" unitRef="usd">19391000</ifrs-full:FinancialAssets>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c2" decimals="-3" unitRef="usd">368000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c3" decimals="-3" unitRef="usd">3215000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:OtherFinancialAssets contextRef="c2" decimals="-3" unitRef="usd">368000</ifrs-full:OtherFinancialAssets>
    <ifrs-full:OtherFinancialAssets contextRef="c3" decimals="-3" unitRef="usd">3215000</ifrs-full:OtherFinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c2" decimals="-3" unitRef="usd">10518000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c3" decimals="-3" unitRef="usd">16176000</ifrs-full:FinancialAssetsAtFairValue>
    <iinn:strengtheningPercentage contextRef="c0" decimals="2" unitRef="pure">0.10</iinn:strengtheningPercentage>
    <iinn:weakeningPercentage contextRef="c0" decimals="2" unitRef="pure">0.10</iinn:weakeningPercentage>
    <iinn:ScheduleOfSensitivityAnalysis contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt;
 December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt;
 December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-weight: bold"&gt;USD&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,051&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,617&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;AUD&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;GB Pound&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</iinn:ScheduleOfSensitivityAnalysis>
    <iinn:SensitivityAnalysis contextRef="c156" decimals="-3" unitRef="usd">1051000</iinn:SensitivityAnalysis>
    <iinn:SensitivityAnalysis contextRef="c157" decimals="-3" unitRef="usd">1617000</iinn:SensitivityAnalysis>
    <iinn:SensitivityAnalysis contextRef="c158" decimals="-3" unitRef="usd">10000</iinn:SensitivityAnalysis>
    <iinn:SensitivityAnalysis contextRef="c159" decimals="-3" unitRef="usd">205000</iinn:SensitivityAnalysis>
    <iinn:SensitivityAnalysis contextRef="c160" decimals="-3" unitRef="usd">45000</iinn:SensitivityAnalysis>
    <iinn:SensitivityAnalysis contextRef="c161" decimals="-3" unitRef="usd">53000</iinn:SensitivityAnalysis>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Up to &lt;br/&gt;
1 year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Between&lt;br/&gt; 1 and 3&lt;br/&gt;
 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;More than&lt;br/&gt; 3 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Other payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;635&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loan from the IIA&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;24&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;776&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,250&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;659&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,150&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Up to &lt;br/&gt;
1 year&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Between &lt;br/&gt;
1 and 3&lt;br/&gt; years&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;More than&lt;br/&gt; 3 years&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Other payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;611&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;678&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loan from the IIA&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;868&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,009&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;544&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,546&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:OtherPayables contextRef="c162" decimals="-3" unitRef="usd">719000</ifrs-full:OtherPayables>
    <ifrs-full:GrossLeaseLiabilities contextRef="c162" decimals="-3" unitRef="usd">381000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c163" decimals="-3" unitRef="usd">635000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c164" decimals="-3" unitRef="usd">374000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c162" decimals="-3" unitRef="usd">150000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties contextRef="c163" decimals="-3" unitRef="usd">24000</ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties contextRef="c164" decimals="-3" unitRef="usd">776000</ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherPayables contextRef="c162" decimals="-3" unitRef="usd">1250000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c163" decimals="-3" unitRef="usd">659000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c164" decimals="-3" unitRef="usd">1150000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:OtherPayables contextRef="c165" decimals="-3" unitRef="usd">611000</ifrs-full:OtherPayables>
    <ifrs-full:GrossLeaseLiabilities contextRef="c165" decimals="-3" unitRef="usd">305000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c166" decimals="-3" unitRef="usd">537000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c167" decimals="-3" unitRef="usd">678000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c165" decimals="-3" unitRef="usd">93000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties contextRef="c166" decimals="-3" unitRef="usd">7000</ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties contextRef="c167" decimals="-3" unitRef="usd">868000</ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherPayables contextRef="c165" decimals="-3" unitRef="usd">1009000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c166" decimals="-3" unitRef="usd">544000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c167" decimals="-3" unitRef="usd">1546000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 20 - COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Commitments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company has a bank guarantee in the amount of 63 for
the offices it rents. In accordance with the guarantee, the Company has a pledged deposit in the same amount as of December 31, 2022.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.25in"/&gt;&lt;td style="text-align: justify; width: 0.25in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;In
July 2022, the Company entered into an agreement with a contractor for the development of the HYLA&#x2122; blood sensor. Total payment
agreed in the contract is 710. According to the agreement with the developer, the development cost will be paid in a few tranches considering
the development lifecycle, which was defined as five phases for each of the blood parameters to be measured by the sensor.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;p style="margin-left: 0.5in; margin-top: 0; margin-bottom: 0"&gt;The Company is entitled to terminate the contract upon reaching the third phase.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;3.&lt;/td&gt;&lt;td style="text-align: justify"&gt;As of December 31, 2022, part of the development outputs
reached the second phase and part are on the third phase. Approximately half of the contract total amount was recorded as development
expenses as of December 31, 2022. An amount of 75 was paid as prepayment.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;In the normal course of business, various legal claims and
other contingent matters may arise. Management believes that any liability that may arise from such matters would not have a material
adverse effect on the Company&#x2019;s results of operations or financial condition as of and for the years ended December 31, 2022, and
2021.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On March 4, 2022, Exchange Listing, LLC, or Exchange, filed
a complaint in the Federal Court for the Southern District of New York against us in connection with a contract between the parties.
The contract related to certain consulting services provided to us by Exchange in preparation for our initial public offering.The complaint
is against us and, and the Company president and former Chief Financial Officer, Joe Hayon, in connection with a contract between the
parties pursuant to which Exchange provided certain consultancy services to us in preparation for our initial public offering. The precise
damages sought are unclear, however Exchange is seeking approximately 250,000 plus 75,000 Ordinary Shares or the cash equivalent. As
of the date of this annual report, we have not been formally served with the complaint. On July 1, 2022, the Company filed a motion to
dismiss for failure to state a claim upon relief can be granted based on the language of the written contract between the parties. On
March 8, 2023, the court issued an order granting our motion in part and denying it in part. Specifically, the court dismissed all claims
against Joe Hayon and he is no longer a party in the action. The court also dismissed the breach of contract action (Count I) to the
extent it was based improper termination or frustration. The Court also dismissed Count IV (Quantum Merit on the written agreement),
Count VI (Breach of Implied Covenant of Good Faith) and Count VII (Fraud in the Inducement). The court allowed Count 1 (breach of written
agreement based on alleged anticipatory repudiation), Count II (breach of alleged oral agreement), Count III (Promissory Estoppel to
the extent based on alleged oral agreement) and Count V (Quantum Meruit based on alleged oral agreement) to survive the pleading or early
dismissal stage. The Company will continue to defend itself vigorously with respect to this matter.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;3.&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;On
November 9, 2022, the Company received notice of a complaint filed by Udi Nussinovitch, the Registrant&#x2019;s former Chief Scientific
Officer, in Tel-Aviv District Court, as well as a complaint filed with the regional labor court in Tel Aviv on November 8, 2022. Mr.
Nussinovitch has alleged certain deficiencies in the Company&#x2019;s&#160;Extraordinary General Meeting of Shareholders held on Friday,
December 17, 2021, resulting from his status as a minority shareholder. In addition, with respect to the labor dispute, Mr.&#160;Nussinovitch
is seeking renumeration and the issuance of Ordinary Shares.&#160;Previously, on February 24, 2022, the Company filed a claim against
Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and former officer of the Company.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;As of the balance date, the Company believes that the claims
will result in no payments by the Company.&lt;/p&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ifrs-full:Prepayments contextRef="c2" decimals="-3" unitRef="usd">75000</ifrs-full:Prepayments>
    <iinn:ExchangeAmount contextRef="c0" decimals="0" unitRef="shares">250000</iinn:ExchangeAmount>
    <iinn:OrdinaryShares contextRef="c0" decimals="0" unitRef="shares">75000</iinn:OrdinaryShares>
    <ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 21 - FAIR VALUE MEASUREMENT:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Fair value hierarchy &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following tables detail the Company&#x2019;s
assets and liabilities, measured or disclosed at fair value, using a three-level hierarchy, based on the lowest level of input that is
significant to the entire fair value measurement, being:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 1: Quoted prices (unadjusted) in active
markets for identical assets or liabilities that the entity can access at the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 2: Inputs other than quoted prices included
within Level 1 that are observable for the asset or liability, either directly or indirectly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Level 3: Unobservable inputs for the asset or liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;As of December 31, 2022:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Non-tradable Warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-tradable warrants of SAFE and Convertible Loan investors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financial liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tradable warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;As of December 31, 2021:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Non-tradable Warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-tradable warrants of SAFE and Convertible Loan investors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financial liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tradable warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,493&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,493&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,722&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022, the fair value measurement
of the warrant&#x2019;s securities in the table above, was estimated using the Black Scholes model, based on assumptions for the variables
that are required as of the warrants&#x2019; valuation date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The key inputs that were used in the both items
of non-tradable warrants valuation were: risk-free interest rate between 5.04% and 5.26%, expected volatility between 56.5%-57.8% , expected
dividend yield of 0% and expected term of warrants of 1.54-2.54 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2021, the fair value measurement
of the SAFE and the warrant&#x2019;s securities in the table above, was estimated using the Black Scholes model, based on a variety of
significant unobservable inputs a thus represent a level 2 measurement within the fair value hierarchy.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The key inputs that were used in both items of
non-tradable warrants valuation were: risk-free interest rate between 0.19% and 0.73%, expected volatility between 55.3%-57.8%, expected
dividend yield of 0% and expected term of warrants of 2.54-3.54 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying amounts of trade and other receivables
and trade and other payables are assumed to approximate their fair values due to their short-term nature.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Movements in level 2 liability during 2021 is
set out below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;SAFE&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Convertible loan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Financial Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Balance as of December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;219&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,273&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gains (losses) recognized in profit or loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;612&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;450&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Conversion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,680&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,361&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(656&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,697&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Adjustments arising from translating financial operation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(45&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(24&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance as of December,31 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;196&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,039&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;354&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;133&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,722&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Non-tradable Warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-tradable warrants of SAFE and Convertible Loan investors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financial liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tradable warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Non-tradable Warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-tradable warrants of SAFE and Convertible Loan investors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financial liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tradable warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,493&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,493&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,722&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <iinn:NontradableWarrantFairValue contextRef="c175" decimals="-3" unitRef="usd">3000</iinn:NontradableWarrantFairValue>
    <iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors contextRef="c175" decimals="-3" unitRef="usd">35000</iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors>
    <ifrs-full:FinancialLiabilities contextRef="c178" decimals="-3" unitRef="usd">26000</ifrs-full:FinancialLiabilities>
    <ifrs-full:WarrantLiability contextRef="c177" decimals="-3" unitRef="usd">304000</ifrs-full:WarrantLiability>
    <ifrs-full:CurrentFinancialAssets contextRef="c177" decimals="-3" unitRef="usd">304000</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:CurrentFinancialAssets contextRef="c178" decimals="-3" unitRef="usd">64000</ifrs-full:CurrentFinancialAssets>
    <iinn:NontradableWarrantFairValue contextRef="c181" decimals="-3" unitRef="usd">196000</iinn:NontradableWarrantFairValue>
    <iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors contextRef="c181" decimals="-3" unitRef="usd">1393000</iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors>
    <ifrs-full:FinancialLiabilities contextRef="c184" decimals="-3" unitRef="usd">133000</ifrs-full:FinancialLiabilities>
    <ifrs-full:WarrantLiability contextRef="c183" decimals="-3" unitRef="usd">1493000</ifrs-full:WarrantLiability>
    <ifrs-full:CurrentFinancialAssets contextRef="c183" decimals="-3" unitRef="usd">1493000</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:CurrentFinancialAssets contextRef="c184" decimals="-3" unitRef="usd">1722000</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c168" decimals="4" unitRef="pure">0.0504</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c169" decimals="4" unitRef="pure">0.0526</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c168" decimals="3" unitRef="pure">0.565</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c170" decimals="3" unitRef="pure">0.578</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c0" decimals="2" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <iinn:ExpectedTermOfWarrants contextRef="c168">P1Y6M14D</iinn:ExpectedTermOfWarrants>
    <iinn:ExpectedTermOfWarrants contextRef="c169">P2Y6M14D</iinn:ExpectedTermOfWarrants>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c171" decimals="4" unitRef="pure">0.0019</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c172" decimals="4" unitRef="pure">0.0073</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c171" decimals="3" unitRef="pure">0.553</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c172" decimals="3" unitRef="pure">0.578</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c173" decimals="2" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <iinn:ExpectedTermOfWarrants contextRef="c171">P2Y6M14D</iinn:ExpectedTermOfWarrants>
    <iinn:ExpectedTermOfWarrants contextRef="c172">P54Y</iinn:ExpectedTermOfWarrants>
    <iinn:ScheduleOfMovementsInLevel2LiabilityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;SAFE&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Convertible loan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Financial Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Balance as of December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;219&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,273&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gains (losses) recognized in profit or loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;612&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;450&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Conversion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,680&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,361&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(656&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,697&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Adjustments arising from translating financial operation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(45&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(24&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance as of December,31 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;196&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,039&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;354&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;133&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,722&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfMovementsInLevel2LiabilityTableTextBlock>
    <iinn:BalanceAtBeginning contextRef="c186" decimals="-3" unitRef="usd">219000</iinn:BalanceAtBeginning>
    <iinn:BalanceAtBeginning contextRef="c187" decimals="-3" unitRef="usd">1273000</iinn:BalanceAtBeginning>
    <iinn:BalanceAtBeginning contextRef="c3" decimals="-3" unitRef="usd">1492000</iinn:BalanceAtBeginning>
    <iinn:GainslossesRecognizedInProfitLoss contextRef="c190" decimals="-3" unitRef="usd">-19000</iinn:GainslossesRecognizedInProfitLoss>
    <iinn:GainslossesRecognizedInProfitLoss contextRef="c191" decimals="-3" unitRef="usd">2330000</iinn:GainslossesRecognizedInProfitLoss>
    <iinn:GainslossesRecognizedInProfitLoss contextRef="c192" decimals="-3" unitRef="usd">612000</iinn:GainslossesRecognizedInProfitLoss>
    <iinn:GainslossesRecognizedInProfitLoss contextRef="c193" decimals="-3" unitRef="usd">450000</iinn:GainslossesRecognizedInProfitLoss>
    <iinn:GainslossesRecognizedInProfitLoss contextRef="c4" decimals="-3" unitRef="usd">3373000</iinn:GainslossesRecognizedInProfitLoss>
    <iinn:Addition contextRef="c191" decimals="-3" unitRef="usd">4161000</iinn:Addition>
    <iinn:Addition contextRef="c192" decimals="-3" unitRef="usd">3047000</iinn:Addition>
    <iinn:Addition contextRef="c193" decimals="-3" unitRef="usd">310000</iinn:Addition>
    <iinn:Addition contextRef="c4" decimals="-3" unitRef="usd">7518000</iinn:Addition>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c192" decimals="-3" unitRef="usd">60000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c4" decimals="-3" unitRef="usd">60000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments contextRef="c191" decimals="-3" unitRef="usd">-6680000</ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments contextRef="c192" decimals="-3" unitRef="usd">-3361000</ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments contextRef="c193" decimals="-3" unitRef="usd">-656000</ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments contextRef="c4" decimals="-3" unitRef="usd">-10697000</ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments>
    <iinn:AdjustmentsArisingFromTranslatingFinancialOperations contextRef="c190" decimals="-3" unitRef="usd">-4000</iinn:AdjustmentsArisingFromTranslatingFinancialOperations>
    <iinn:AdjustmentsArisingFromTranslatingFinancialOperations contextRef="c191" decimals="-3" unitRef="usd">-45000</iinn:AdjustmentsArisingFromTranslatingFinancialOperations>
    <iinn:AdjustmentsArisingFromTranslatingFinancialOperations contextRef="c192" decimals="-3" unitRef="usd">-4000</iinn:AdjustmentsArisingFromTranslatingFinancialOperations>
    <iinn:AdjustmentsArisingFromTranslatingFinancialOperations contextRef="c193" decimals="-3" unitRef="usd">29000</iinn:AdjustmentsArisingFromTranslatingFinancialOperations>
    <iinn:AdjustmentsArisingFromTranslatingFinancialOperations contextRef="c4" decimals="-3" unitRef="usd">-24000</iinn:AdjustmentsArisingFromTranslatingFinancialOperations>
    <iinn:BalanceAtEnding contextRef="c186" decimals="-3" unitRef="usd">196000</iinn:BalanceAtEnding>
    <iinn:BalanceAtEnding contextRef="c187" decimals="-3" unitRef="usd">1039000</iinn:BalanceAtEnding>
    <iinn:BalanceAtEnding contextRef="c188" decimals="-3" unitRef="usd">354000</iinn:BalanceAtEnding>
    <iinn:BalanceAtEnding contextRef="c189" decimals="-3" unitRef="usd">133000</iinn:BalanceAtEnding>
    <iinn:BalanceAtEnding contextRef="c3" decimals="-3" unitRef="usd">1722000</iinn:BalanceAtEnding>
    <dei:DocumentAccountingStandard contextRef="c0" id="hidden-fact-0">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:SalesAndMarketingExpenses
      contextRef="c5"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherGainsLosses
      contextRef="c0"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherGainsLosses
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncomeCost
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c0"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c5"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="hidden-fact-9"
      unitRef="usdPershares">-0.95</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c5"
      decimals="2"
      id="hidden-fact-10"
      unitRef="usdPershares">-3.67</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c4"
      decimals="1"
      id="hidden-fact-11"
      unitRef="usdPershares">-3.2</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss
      contextRef="c9"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c10"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c9"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c11"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OptionsExercise
      contextRef="c9"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OptionsExercise
      contextRef="c10"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OptionsExercise
      contextRef="c11"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OptionsExercise
      contextRef="c0"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueRestrictedStockUnits
      contextRef="c9"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueRestrictedStockUnits
      contextRef="c10"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueRestrictedStockUnits
      contextRef="c11"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueRestrictedStockUnits
      contextRef="c0"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c20"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c21"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c22"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c20"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c21"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c23"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TotalComprehensiveLoss
      contextRef="c20"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TotalComprehensiveLoss
      contextRef="c21"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ParValueCancellations
      contextRef="c22"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ParValueCancellations
      contextRef="c23"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ParValueCancellations
      contextRef="c4"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:InitialPublicOffering
      contextRef="c20"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:InitialPublicOffering
      contextRef="c22"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:InitialPublicOffering
      contextRef="c23"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="c20"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="c22"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="c23"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TradableWarrantsExercise
      contextRef="c20"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TradableWarrantsExercise
      contextRef="c22"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TradableWarrantsExercise
      contextRef="c23"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueRestrictedStockUnits
      contextRef="c20"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueRestrictedStockUnits
      contextRef="c21"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueRestrictedStockUnits
      contextRef="c22"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueRestrictedStockUnits
      contextRef="c23"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueRestrictedStockUnits
      contextRef="c4"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OptionsExercise
      contextRef="c20"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OptionsExercise
      contextRef="c21"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OptionsExercise
      contextRef="c22"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OptionsExercise
      contextRef="c23"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OptionsExercise
      contextRef="c4"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c20"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c22"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c23"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c26"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c30"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c31"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c32"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c30"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c33"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TotalComprehensiveLoss
      contextRef="c30"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TotalComprehensiveLoss
      contextRef="c31"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareSplit
      contextRef="c32"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareSplit
      contextRef="c33"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c30"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c32"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c33"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OptionsExercise
      contextRef="c32"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OptionsExercise
      contextRef="c33"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OptionsExercise
      contextRef="c5"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ConversionOfConvertibleLoanToShares
      contextRef="c32"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ConversionOfConvertibleLoanToShares
      contextRef="c33"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c0"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c4"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="c0"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="c5"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:RevaluationOfLoanFromTheIsraeliInnovationAuthority
      contextRef="c0"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:RevaluationOfLoanFromTheIsraeliInnovationAuthority
      contextRef="c5"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c4"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c5"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan
      contextRef="c0"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ReceiptOfIPOFunds
      contextRef="c0"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ReceiptOfIPOFunds
      contextRef="c5"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ReceiptOfWarrantsExerciseFundsNetFromFees
      contextRef="c0"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ReceiptOfWarrantsExerciseFundsNetFromFees
      contextRef="c5"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="c0"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="c0"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="c5"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TradableWarrantsLiability
      contextRef="c0"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TradableWarrantsLiability
      contextRef="c5"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TradableWarrantsDerivativeLiability
      contextRef="c0"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TradableWarrantsDerivativeLiability
      contextRef="c5"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationUnderwritersFees
      contextRef="c0"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationUnderwritersFees
      contextRef="c5"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="c0"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="c5"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:WarrantsExerciseLiabilityIssuance
      contextRef="c0"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:WarrantsExerciseLiabilityIssuance
      contextRef="c5"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TotalNonCashTransactions
      contextRef="c0"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TotalNonCashTransactions
      contextRef="c5"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:AccumulatedDepreciation
      contextRef="c58"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="c0"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="c0"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="hidden-fact-106"
      unitRef="usdPershares">-0.95</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c5"
      decimals="2"
      id="hidden-fact-107"
      unitRef="usdPershares">-3.67</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c4"
      decimals="1"
      id="hidden-fact-108"
      unitRef="usdPershares">-3.2</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="c5"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:WagesAndSalaries
      contextRef="c5"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="c5"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherExpenseByNature
      contextRef="c5"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ExpenseByNature
      contextRef="c5"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="c0"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="c5"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InsuranceExpense
      contextRef="c5"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability
      contextRef="c90"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability
      contextRef="c91"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ForeignCurrencyTransactionLossNet
      contextRef="c93"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ForeignCurrencyTransactionLossNet
      contextRef="c94"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InterestIncomeOnDeposits
      contextRef="c94"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherIncome
      contextRef="c93"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherIncome
      contextRef="c94"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TotalIncome
      contextRef="c94"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability
      contextRef="c95"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ForeignCurrencyTransactionLossNet
      contextRef="c98"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c0"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c4"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c5"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="c107"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DisposalsInvestmentProperty
      contextRef="c107"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="c0"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="c4"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:FinancialExpenses
      contextRef="c4"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c5"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="c0"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="c4"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c131"
      id="hidden-fact-138"
      unitRef="pure"
      xsi:nil="true"/>
    <iinn:ForfeitedWeightedAverageExercisePrice
      contextRef="c131"
      id="hidden-fact-139"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <iinn:OutstandingAtBeginningOfYears
      contextRef="c146"
      id="hidden-fact-140"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:ExercisableRSUs
      contextRef="c147"
      id="hidden-fact-141"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:OutstandingAtBeginningOfYears
      contextRef="c148"
      id="hidden-fact-142"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="c155"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:Deposit
      contextRef="c3"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherPayables
      contextRef="c163"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherPayables
      contextRef="c164"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="c163"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="c164"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties
      contextRef="c162"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherPayables
      contextRef="c166"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherPayables
      contextRef="c167"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="c166"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="c167"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties
      contextRef="c165"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:NontradableWarrantFairValue
      contextRef="c174"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:NontradableWarrantFairValue
      contextRef="c176"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors
      contextRef="c174"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors
      contextRef="c176"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c177"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c179"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="c178"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="c179"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentFinancialAssets
      contextRef="c179"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:NontradableWarrantFairValue
      contextRef="c180"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:NontradableWarrantFairValue
      contextRef="c182"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors
      contextRef="c180"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:NontradableWarrantsOfSAFEAndConvertibleLoanInvestors
      contextRef="c182"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c183"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c185"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="c184"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="c185"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentFinancialAssets
      contextRef="c185"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:BalanceAtBeginning
      contextRef="c188"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:BalanceAtBeginning
      contextRef="c189"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:Addition
      contextRef="c190"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="c190"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="c193"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments
      contextRef="c190"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001837493</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#hidden-fact-16"
          xlink:label="hidden-fact-16"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-49"
          xlink:label="hidden-fact-49"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Less than thousand dollars</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-16"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-49"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-103"
          xlink:label="hidden-fact-103"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Less than one thousand dollars</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-103"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>131
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M4A2-4[3*71TR"ZJ'3->+.(ZK:P3U6F :ZQN$^K.Q,_K4=.T =K<N@YD3A/;
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M2!#'OWO003NF<CQ^?D7_JLD#F1D1])Z5/XJYS&\'\0#-Z8*L2_G(MK_1/:%
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MDXMS#X2;CLY0O+7S8LV5GCYV6>D?"@H3H/=+SM7!, GZ7U3Z#U!+ P04
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M ?'[,L^KUXO:P.%HIYO_ U!+ P04    "  @@']62RM#%*,(  "'+   &
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M"T\5U[IVKGT44B51?& <J61,F7X8#+\%U=73<=<$US$U3L(==%?7I4)@UX[
M\UC5)IY*?3$$*I&W/WZ%J_F^S@RP::X9P,0=-KAG</2&YH8GS_I-UQ3I9U+Y
MBX_EK^7;M-?Z'=+&[U_PA9^_$UNYR5_1_<H21?0IBOA*N70^>VIBDORMU_R+
M%%O]'NB3D%)L],<U9ZJ*9P;J[RLAY.%+UD'Y[O'T_U!+ P04    "  @@']6
M75"2KI8*  !B&   &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;)59:W/;
MNA']KE^!T4WO.!U%ULO/.)Y17C?N)''&SFVGT^D'B(1(C$F" 4#+ZJ_OV05(
M28[LM%]BB<(N=L^>?3$7*V/O7*Z4%P]E4;DW_=S[^OSPT"6Y*J4;FEI5^&5I
M;"D]OMKLT-56R92%RN)P,AH='Y925_W+"W[VS5Y>F,87NE+?K'!-64J[?JL*
MLWK3'_?;!S<ZRST].+R\J&6F;I7_L_YF\>VPTY+J4E5.FTI8M7S3GX_/W\[H
M/!_XNU8KM_59D"<+8^[HRU7ZIC\B@U2A$D\:)/[<JW>J*$@1S/@1=?:[*TEP
M^W.K_2/[#E\6TJEWIOB'3GW^IG_:%ZE:RJ;P-V;U245_CDA?8@K'_XI5.#L^
MZXND<=Z441@6E+H*?^5#Q&%+X'3TA, D"DS8[G 16_E>>GEY8<U*6#H-;?2!
M765I&*<K"LJMM_A50\Y?_J$J965Q<>BAC!X=)E'P;1"</"$XGH@OIO*Y$Q^J
M5*6["@YA16?*I#7E[>19C>]5,A33\4!,1I/),_JFG6M3UC=]WC7QK_G">8OP
M_WN?ET'';+\.2HES5\M$O>F#\T[9>]6__/VW\?'H]3,6SCH+9\]IO_SCP]</
M-_//^\QZ7O#K]?</8BQ>B:CAO#<>BJO*U=I*\5TE>64*DVGEQ/7#6KP=?AI^
M'8K//A4'E,;*%NMS.H[<4N*+2G4"F/#S\&7OP.=*_/[;Z60R>OW.E+6LUOQM
M_/JE6$DG=)486QLKO4KQ15PY*U4A9)6*Q)3(UH2>>R=0-G (B8>/E?BH%K9!
MTHO)"<5W?#H4WW'1U@WCD]=.+)N*DU46O:2Q%MK60CM!-GU%@H?+M+C-U1TN
M/8AV?KVZ;6W<41MM4&0UZ>B5T57?(@3M58HDL^MX1"RU*E)AEB@XC*8W^,TU
M-5SVVW*JRE"STE:,N"%MD@]0$>Y1Z6H@X0=(U*I9@GF-U56&0P7!UN-*I#W"
M,V#@,B.\P5E[AR*\^9&LJ*VIK5:>H,/GM$D +<GXK2#O.@V\H@UT)_MD"M1>
M^M:J.!<'?WU)0E=?;[]=W<S%_.:[.)@W&9D-"V^VG._HM'XY$*M<)SE=(7\%
M$$S.%)'$FY6TJ6B\+O1_R(A46Y1DL2B, =(/ZTQ53!0" >7;>5'C.PSI.0GD
MPF\%N>10''T.R%$(&XHKS"D4^QA%V+25O%,,DJM1H62E3..*M5B@:9%T%O"2
MNF1N&7@"4(*:2L%BY CB>B\=^H4HX9*LB#:]>UR@"[9GP):$FXVGYT2K3I75
M[@[!14;4!41#&I!%.9H$'CLT4@H!&_+IGY_G$0W*2&,'O2V8*U.]ZHPQM6<"
M;Y]&M)W.*D9:@/"4X;!#%J\\NF?,3!A8-8 A2I9*NL8JBC;,[#P 2$!6EQRG
M7H<']'J&%$3>7"[A&T*PM*9LT0].D4_SSU?O/HCWZEXGBD@N9'HOJ3;TV#PP
MN]!+U?'&K9U7I5@H[Y45=Y5956*Q9GC;G.T251(J"2BE3=T4)8H%'B[6M72N
MU0/@%HJIUD)#(6U0[, =.)YQ.)$,, @P.,#UH]&<HT\H)GFG'T1N&HO$M."C
M<\/>9'\9VV2J56V%V*H+PGG4CB#*0/52!BHD]J.LS.%O9;Q8HS8LE((RY2BM
M@D-<@/(&=<9UTD]:DTM0B'2Q'EGCAWMH"$#W_AS>#L5'"BTI>F^;3,Q3H@,U
M3\[![=[P\?U\4W.G0W%=B;\UX,_XF/LWNOB6*2$1N!I0:[CZ=DT]@:NZ=*G\
M(=[)6GL$^0O70"HSRJI(@%:',RC,D\'9Z&PP.AO#_U1SA%P.E,'B"NR75MS+
MHE$[IEZW)V_Y9-?.R,WI8#H[&LR.C@2<3.4"U035RDIP61R@UQ5-R+NEF$V/
M!]/CV9YS-2C1X!/G":Y5#\HFVK$4F ^,,844QG/H*8/A>T:B,;4@TF"$LBNK
MP7X7>YC,,JLR] O!/%4IL311>A.Q#AE.0>8-@%T!N1#;!XVA55%,9H/9V0AI
MN*3L2JE$>>)Z=VNHRBXQ317;"_5R[5Q7MV2:ZM"8X=52A52A,@8/$+C PT>W
M#HYF>XFQ:4=D<U(81Y\!5G1AESJPHE$4^/%XBN ?B4?A9//&@_'L;'!T.N%R
M^7.( #-J*!+'V"APC-,GW6GUT_&%-7<(!KF%ZEG%':(K^GB&L/)F L-_SCCD
M<V@ZT?PE3*X2:A*%E@MT0F[PTHNEU)&S-,")Z\2;!8(4D-K8W'(J[8T')Z.C
MP6@TVL/$:$<@$ ?F?R:/WMRQCT)G@^G)R4ZQZ]52PR\5YI23O[1U3I;$(GIV
M?'2,EI%PHF8MT\' DB4D=R4:RP.JDDPM#3'T"<R)W52'0W/<\J$'WW +?)-[
M@%Z+ ]0\)4X/IB^16[/=::DMKQDO"Y22]!3Q4Q7*")B)LDPUBSZ$U/UEF?UU
MT7\L&F=EH(1D",V&I-<8*1$66J_02A-5$C/B@C1F.VA3"N%Z,9X.9^C>1=':
M^&(\&YZV3P8\KBE>@1'.IWRHT&1V3$"75S14:+0%&O]?C(^'9X^N&0VG^Z\9
MBCF'^K'MD]T,SV7*$T*2-&7#$S*MU3K1S*(7T[/AN-6_&SML"R#VHV7#Y]8T
M61S-6O)OBLO> /30/Q$<#I-&72:UX*M3ZFZ[\M%]H6R%*^IF@>FN*XBN'8]7
M,!8]-HZ\H<J3;$N1'5ILS6>JM_%CU]/4J$!3;N'TA/+2$LTWA#>P)FMGS<[G
MA2QH\!(I!':5+K!*P1""#(5(>\X%URP)>IJ^$4I,.XEB+.(JU:U)AC:>4#:7
M#:9T->P=!?5_WEF)=1775$O X\6\\#GCM8(5AMT(RYTO:#*H")+> HVVPDQ%
M%]PTZ#R2D8G* F&4P]@61A$XERE3&RJD83I$>L5TWZN!$%DIQ 5_N]5R630T
MT@;(=,43;Q E%>0;0<+\1&H0MD!? SUX197)V")=Z53%W0U!NVUH;@\G2KGN
MI*@31+G&\MA+ON>P;,!/-H'OD=$!4DP)9H7B!]IP4L4]%L'"9,#9,(^+6%/X
M-MX)=@_-)SOL%B964![Q2#\>(!VYWUMJ1$PK33-:7 "=#(LX]&>2P!6)LEYV
MT%8TCV-/3;$0A(Y*&X3G9?0:_F2%61 E-WFI'FJ#WM*$C8OVH^ *C"AHOJ!V
MRJ4)V11@ZC@QV"(Y\47[MM3 ;R;ZYAXL7=+EB*Q9\9S.*T38K+%()SR4<0@4
M6!!W<)[STG8@V>QS80],L$M1X_7A322M%GY% _06R1[C&4PCC=UL%BF/EA(9
M1]W=%/=T:"_AI=7+):Q#;ZM,B3K3Q80I@FAA<WI%L%HB!*9T'4-&/\'B\'+!
M*HP!.JSI,HD8;27#KLM[6$YH;0YT>0K=8$G1O5SI./DN.OK_YB?;&LK_AGUQ
M6'E$W(QFZHJWUY:?O9:?"5<W'0?#;992/F+]Q\S+/K7F@(ZQ"&V<XYECXW1X
M#ZOB[(C1(#6V]=NI3=R'O6.N@4YM,1:.^[!IQ\&J03FTW!?BYK4P](($Q QO
M1D@W</]"[Y/$Y)1;YG2X[W7CX=9[7YB7\=MM%^P)KX"[I]T+]'EX;[PY'MZ^
MX[8,.&*O74)T-#PYZB-+^8UV^.)-S6^144R !7_,%29G2P?P^]+0[!:^T 7=
M?RM<_A=02P,$%     @ ((!_5BS7W>(Z&P  3%$  !@   !X;"]W;W)K<VAE
M971S+W-H965T."YX;6RE/%MSV[::[_@5&'>VD\S(2NRD;9JVF7&<I,=GTC0;
M-Z</._L D9"$AB)5@K2B\^O/=\.-DIQN]Z&I+!' =[^#/^ZZ_I-?6SOHSYNF
M]3^=K8=A^_S1(U^M[<;X>;>U+?RR[/J-&>#/?O7(;WMK:EJT:1Y=/G[\[:.-
M<>W9BQ_IN_?]BQ^[<6A<:]_WVH^;C>GW+VW3[7XZNS@+7WQPJ_6 7SQZ\>/6
MK.RM'3YNW_?PUZ.X2^TVMO6N:W5OES^=75T\?_D4GZ<'_N7LSF>?-6*RZ+I/
M^,=-_=/98P3(-K8:< <#_[NSU[9I<", XT_9\RP>B0OSSV'W-X0[X+(PWEYW
MS>^N'M8_G3T[T[5=FK$9/G2[?UC!YQO<K^H:3__J'3_[],F9KD8_=!M9#!!L
M7,O_-Y^%#MF"9X]/++B4!9<$-Q]$4+XR@WGQ8]_M=(]/PV[X@5"EU0"<:Y$I
MMT,/OSI8-[RX=:O6+5UEVD%?554WMH-K5_I]U[C*6?_CHP$.P4<?5;+A2][P
M\L2&%Y?ZEZX=UEZ_;FM;EQL\ N@BB)<!Q)>7]^[XRE9S_>1BIB\?7U[>L]^3
MB/(3VN_)WT-9_\_5P@\]B,O_'L.>]WYZ?&]4H>=^:RK[TQGHB+?]G3U[\?57
M%]\^_N$>R)]&R)_>M_N+VYN?W]V\N;F^>O>;OKJ^_O7CN]]NWOVLW__Z]N;Z
MYO7M,7#OW_#=K[^]UI?Z"_L^U^] N_Q@VMKTM9]IUPZV!_P&@YKE-?R@#6AJ
M#?\-7K7=H/=@3^QR:4GIYOJWM>VM-OB?;L?-PO:Z6^9;IN5ZZ%3^ ^P]/6^W
M=M5:K\V=U0MK6^V\'VVM%WL]K*V^N;I]"1_,0.=%(& 7O1R'$6%(7-_:WG6U
MY^=Q]76WV9IV#[M[5=O*@0QK1&CHM*F[+6!E^F8_US>M_J=I1S!D*)>/9^EH
M@:;$"'[1(,(,>=68WBT9VJIW@)PS>O2P"$ZI+?P-FF[A80M/]+IQ9N$:-Z!P
M(DJPW'N08#S$@Y'H>SA%=SW V9[+GT1R;W,HY%1%J!Y?%;>NB-* "IF\6L/G
M (UI-3SI!B(1L+-'NZ>%>G 8,A8_]G;;]1F-&;<E[.#M,#06@5+R;,!PK\'-
MX%Z--1YVW-D&&+=A>V*60)BC6Q.R.:JF\5U&9=CPZZ^>75Y\]T,Z6KX J:B:
ML;9>X<:@]JU?LG!6QJ]G>M5U*(6HR:ZR\ G@LW^."*IKP4R,?.#8-M9[ JY;
M-&[%Y .,XXY'%@%X'EBZ[+L-T+'JVCO;H[-32VM(3DM&(^&GFP!@6].;P39[
MWJ>D9@7"W+7$YR4= 7^.P**E:TU;.=-D6TV)J':HLAVP%QYN8/^D2<2D%H2_
M.6 %"(R%!2U^ Q3 !XEM%[FV7,[U/[J=!731ENA?3*Y#Z9@:\%([P)S$IF?U
M^/^<^X34U@'I_SF"?L$W%WH#GA,69?H[ /8& 6CVT0+@P4@9$3]@0V^9B4!8
MTFWPV\,:?O);@)XXO[93=8)G<UWVX^(/>1B87[MD3&OGJZ;S* /=4KF6@R^*
M8A806<%*M"+EFJA>AT0,*HE$3AQ&>QE5#:0$;+;I60J"$731O #_ 160<20P
M[N7@B2HH,!B:%EQ$9E>C!9\XAW+_G6L:V3?;-("+4MJ4=E1H#80H28MP(%]S
M\G9M96F?8=UY=CZ'CJ*$I^Y@'5K[A6T<R&=R"YE>!"A(=O%0\O1 3^32C'$B
MWV2TST*-@%M[0C(FX)\ S'XF^<+O.C+'D=#J$+F97H"P'+CC&1)2( 2Q0N_3
M3,"3<^?ZI?&.A!R0)$N#T'[T)%+6#P[7"X_A^,V6Y='Q+MD:E?&4+0\ /H@.
M_58^BWL??4X4SZN-:2%C("$&5#;FD[T'& X%"/G,>Y"'1FDE[% &!UZ:\6!6
M*B)J' HW'LL+U&1!<(,U 7(?RB;:DD-@D,<M>H9Z[(.Z'=B[.<2N UM"#QF(
M5Z!Z#5J.)=H \04H]Y$P<WUK+;O&=QT8!;"&U^#C"!1T=N1=[DQ#\%U/OZ#
M \@)YK!/4B9R@CJQL'H-H4"S/V\<K,.H[0[.)G1GXF;)T/HU8'*.00X8K&WG
M4?#)>"Y,^\FS(=Z@ T0/!N3@F"G3@,JB15[W-H4&1'8%B!*?9%O"C%<C]+@8
MB#7TK@*"S_7;#JS.%E5HC3^CI%=B?9L16=*4#Z Q-$TU-D#,6H%;:D&IZ!DS
MP*8+6B.&7^B" G1'#D3HM:,L$=D-S@]$. N&NQ[(@XZ*3L/(M_X#\C]XEMWM
M7B^Z=O3:<OPRUZ\$S <(PT.,2]'[32".T62MT-S3ED&FX@K8O\##+!K+7FD#
M!.;-UET#G$^">P\F^3+8?!S(1N&I@(E*[HF$G8C-X7F,C$*<'&(S4)RN^J0[
M5N@9!D..=,OU:3WOJ3%>$"W,(@+6Q"Q:5(&58F](:X6@IS AHV+%H&S[#N40
MC5)EX?PZQ5_VL^TKQS82P\S+QS^X]AQ^.4=YM7OZ[N('QDH)5JR&V7EZ._85
MA-A :M-#%"DZ&-*$^.N$VLLBBV%* )D"ES:F_V01>HAF2;!RND!P=#(?8@.$
M 7\0^YG"[PO6H"1%:'/&4R;VF;B9$6K"@Q-Z9[S@0.) U: =V3JP.'"0.P\B
M,-=OQI:*/1@VM*0X(*6MQ##5/G>I(2& G#"NB<^!XKR[N9VK&*6*-_,<&G9M
M\2C^^'%^.P<;U4#.H1\(TS_>OA)6/P29PT3 5(G7"]. 6[#1LL(YB#SDNIV&
ME>A#,9[J:WQ*D8%D*( ,;MN@5EB*.=!R[H%WH.BM$4RRNL:M! CZ 80$#S6$
MO (>$N-U4L3KM0'71K[[C=#M]>>*OM0?R'\(,NJ*P(*]&S!PPTF\4GZ>L ->
M+H%(W<X_5U]_]?VWWWW_@[XZ]+U 5G"4X!8P!4DN$O/3CB+07J):*Q JD=;,
MPQ9!!/D#Y!MZYGD\^E<*H3 M @.'E4:R0_"W/06 I!]!G1 .E<&A_QX<MR3H
ME=FZP32S\$%+!8E(P]%>^&73W7'XD\!$$DS)@O0.QDU^ G/505":[![&"+1+
M @<8/&[8SV%.X2K'=C76 BC/A2 %62'\CL8D6MT0\AT4 E"R:TY=@K\,^'B-
M_\(/2.T%?)F ^C#%C9#E> ?70&"CJ]X2T BL(/IOTBDFGSK*:8H7,XQ=R+/!
MGA@P.Q !C0 AI$DC)WWYUZ+^9$^YLA)M4W0,@*.WF.BT'#:BE=P:5Q?U 9,+
M?XO/@H[9'O*N3,-@VV&'&A7,N '"@C5@[\!!4 XH21E9O>5Q3-R$J6CC)'!.
M+B '(.!".5% )B)15!_4 '$Y&/+&@'18APQXKJ[0RZC,D*$P,S)!@.*V<2>L
MNJB7<:59@!VN+-<TIMO,0O*QZ2"M-?4=T 8TM8/(Z8OGS"43"3OR@^KD3AL(
MIL@+515FQA@UE7$Q21ZRD=(4IGLA!HGGBSUE@(E/!WQ#=%L5EQ8"X\/N-00(
M(;X[2(*.20V+Z^BIW-B2(&?K#QA!>Z)RG]P0LTAF 4 ..MAV&XBK%Q!X<QT7
M/D#N<DH@B:=8D4PVD\%@82+O*&4&;=3A^=&M!]+ \Y"P63(6&30MF#4 %JA>
MT,L.(:G'7 9A)I>&'Y!$0 M8@0J :QQ7A5NV+8>PZ,P>X.J_=,9<_XY\&&+!
MO.WTGV.'*0<9&<^! 86\?*0GB88L XQ@%>CE<[Y1*IN+Y8C9)1)?ZI2V6K>0
MM(78EJ*N+42X<"+2332J<CU828SI  PE 9:$ZGY<HI\0HV-0(LV=<4U()8+P
M)[;/L(WE-N[?@?RC%P?56%0UW2W0^]$&KMV.$B* \&6+E"P:VX.G(;LM:RS
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M7T>TWH'7U\;0SO !IO=V\3=02P,$%     @ ((!_5K.$ 59V @  6P4  !D
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M!=?!.P5D7T <[^8BQ_*&:AJ/I-B!M-D&S1Y<JZ[:D&.5'<JCEB;*3)V.Y[I
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MOGK4"Z=+_[F/M:/+@W]<TFT-#1^@]PNMW7;!#G;WO_X_4$L#!!0    ( ""
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M^S;<+ZZO@/ (+E<+>.^A]!A<VY_YUL,QF(_;3H#[ >Z;;/(RG6F=SAV\#SZ
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M0N,UIWQ,\%Y)I1' _5@(W2R,@?:F.O\74$L#!!0    ( "" ?U:40>#KU @
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MQ)PF."IK0.<K*<U>L0$._X3Q+U!+ P04    "  @@']6.2 WF8<"  "3!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R=5$UOFT 0O>=7C(B4DQ-@
M_1'7L9'LA+91&\<*Z9>J'M8P&!1@Z>XZ3OY]9Q>;NI+C0P\V.[MOWKYA>#/>
M"/FD,D0-+V51J8F3:5V/7%?%&99<78@:*SI)A2RYIE"N7%5+Y(E-*@N7>=[
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M80A@U[<J@&V1V"\OW&5A(+-2YS8JC*[!XCU;@5P6!1I4SFM+M:"X&(TB ([
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M__1[[8?.A,C:,,&I)SA*;[V0TO(3+>GIL>"/1.!HD(8_E*EJ-BB7%AB4NU+
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M]&"O1 #$@V</NO>#6@G;</ CSEUPKE) 8RA]H&FF KOB&R2^SH;KEH0B#TV
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M> S/+QIIZ#+U/L2VC[H=47VZ M'3D<   -07&<-9BA!H+9B3XEEIS) T6/$
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MV-_19Q7-1<D7ZCO("2]+GJN?<T:!U#@ GD\Y+YL+7*#],/;T?U!+ P04
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MIT JG,KIATPTES]ZW[W"S O!(EVBDSF$U;?VT,B[--I<;U7;JI]R:?>F B)
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M"B5]30 O=S%B+2R]&,![:-<!,6:_E0/GR:#V,:HK[@A0R?CD]%J[+-HS2@Z
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M7DN7-HQ699OP;FMBBAI$VJ1H>U.@LPIO#C-ZKHR]IC);)>\6W8R*[K;(7C6
MMH!Z9RS#$5Z7FJ^3)\"KUPC+:S2T1=>6V\C[&=]0>+? NY#F^HBV2Z)^_W(2
MPBV8"W>.XC@<XOHCB/PX#F" E^]>/X#8CX>Q-TU3X4IA&WI^. BQ/^@-T70
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M/TWM_OJ-LL;*9BUA[[UJ%4KU&(R3NXS#.+:UG #YYP#RSY,@?[8:=]6V,Z!
M0%U5EU)9, %[/,)*4\MNJ[-CX7W\:FUJ51=&5=)VL!0,06?'L)T$8!S;[X!*
M3$ E_^<4@]'W6OU7;P *L5,U6#S\4G8-:/,7/0%,MU6=5.LUF#$" 0YJVD[#
M2SL47F(;O*\[7EH9M3*5Z4B12V.+JK%]2P@7#<DZ'LL+Q&"!5'Q$28!,H8P+
MSP&C'\!E6-B@[%M4K?@>?MKKUC2EG<N;HNMA4Z '&% K0!.K$@ &1%NY;IL=
MK&ML0IBYO--:JLHV\O>FT_+)?$I"GP8)?3HIH6^5W1(V!?Z!#+I7U3E9F]QJ
M7-;.[B_?#K]0P"5@D36E;H&B8(21<F^;W5[51P&"LM)R"TZF.EY5!M:5(*?W
M0![BR P^%%5? HEGTFZ!V%>=;G?@H/:--;#[P71;\%_U%W@5]P6: GNZ(W+L
ML#7%5I8-\*QN.F!@H37RMP6"[]B$LV0(X 6)DMN6,./5"#TN!LR[UA0@$Y/\
M^27PYY=)_GQHK$69 9S@A#&F3*X?9TJ^J43K5Q JI:EZE.8J?P%L8Z&JHJ]
M#DNA@$H0+M$[J@-D5[0&&)3P"W7O'C@9^'B@^  UY5ZWH/VR[G<K. &(V;3
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MH")[=0P94XQQB(C!+P.-CK3&8 JCJNJ8QOFYB0LU6Z>%:9Q(-''M (2@!ZT
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M:#B@HC:\Z;ARB_5UBE[<JO4WB*]Q%0N7O.%6?L"A'-ET+O\&;'*)-7L(" ?
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M')D;)J=X)I0Y\(1B99GGFLU=7/ H9(?7WM(X15\[34*@O'@8 PLSB!GSWI!
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M' 2@FV'4&%95?@ LE:5QXI<%S6_4SH'.,Z7LSG )VB_"]!]02P,$%     @
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M;A([:N4+XFP+.VMA^2NPC,.]5JZT<*=RS/\%B(EC1Y3OB,[X4<1;S,ZASWK
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MHO$)M%]H[7:.;]"]N>D?4$L#!!0    ( "" ?U8CQ(WA#P,  (,&   9
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M01U_PUY/[O *)8P?X=C9CN,0BH.QJNV=B4';R.[+G_L\G#A,7W-@O0/SO+M
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M5Q(T-HM@%=_<%FZ_W_")X\&<]<%YLE;JBQN\J1=!Y BAP,HZ!$:OK_@2A7!
M1./O(V;0'^D,S_LG]-?>=_)ES0R^5.(/7MOM(K@*H,:&[85]KPZ_XM&?W.%5
M2AC?PJ';FR8!5'MC57LT)@8ME]V;/1[C<&9P%3UCD!P-$L^[.\BSO&.6+>=:
M'4"[W83F.MY5;TWDN'2B/%A-JYSL[/(MDDL&IA_86J"YF(>60-U26!T!;CN
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MVCG@>:F4W1KN@NZ7E?X&4$L#!!0    ( "" ?U8L.T(>V0,  /0)   9
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;*56;6_C-@S^[E]!^(#A#O#5EAV_
MI$L").UN*W#=%7W9, S[H-A,(]2V<I+2M/]^E.TZZ98:'?;%UAO)AP]%4I.=
M5 ]ZC6C@J2IK/777QFQ.?5_G:ZRX/I$;K&EG)57%#4W5O:\W"GG1"%6E'P9!
MXE=<U.YLTJQ=J=E$;DTI:KQ2H+=5Q=7S DNYF[K,?5FX%O=K8Q?\V63#[_$&
MS=WF2M',[[44HL):"UF#PM74G;/316K/-P=^$[C3!V.PGBRE?+"3BV+J!A80
MEI@;JX'3[Q'/L"RM(H+QO=/I]B:MX.'X1?N7QG?R9<DUGLGR=U&8]=3-7"AP
MQ;>EN9:[7[#S)[;Z<EGJY@N[]FQ"A_.M-K+JA E!)>KVSY\Z'@X$LN -@; 3
M"!O<K:$&Y3DW?#91<@?*GB9M=M"XVD@3.%';H-P81;N"Y,SLBZAYG0M>PD6M
MC=H2WT8#KPNX%OH!+GE-H;&+\/&6+TO4GR:^(;M6VL\[&XO61OB&#1;"I:S-
M6L-/=8'%:P4^ >Y1AR^H%^&@QG/,3R!B'H1!& [HBWH6HD9?]+]9^'.^I -T
ME_XZQD-K973<BLVO4[WA.4Y=2B"-ZA'=V0\?6!+\..##J/=A-*1]=D/Y6FQ+
M!+F"5>\/UQK)%86-1>N56:.]0*+:5I K+(0!?-I(O55XS*5!H\==HNA@M435
M1.APXIQQO6YHS>T OV_%(R\;5(F79A&$D9>.QLXY$AY!JZG'P@ ^.]\(M*)T
M4,K&H//IXS52*$1NL* \;"4^09P R3BWTI#W+/+&\=BJS9(Q#) <]R3'[R=9
M*LKYNH.5/Q.(6E**<@NHDC4:JG)0"KX4I3#/Q\@=-/9?R9TWM QP3.0FQ,[8
MB\;LWQRSP,NR?OMK!UN@=O;94>Y7(4HRTABRN.-Z/_^5>@EIBUD&+/%8F@PQ
MG_3,)^]F7MNF0-6<6"5/>?FLA3Y&[Z#&X_3^@5P!VC(%^Z%CRXRM-<RYNSD'
MY@4QHV_"4F=^1_. ]F+GYP5<R2T1/XHACH9\3GN?TW?[W$1S13U4OT[P@Y <
MHV#0P'$*[C9@)"S0[!!KJMP*J6;PNDO"#7]N^@"D; R?Z=Y\16J*KV]&QB")
M8HC2D7.K>(%[(18'K9#D-:R4K)IR='$QI]5P!&F:O&2N%]+1A)*7>23DO!-4
MPMA;H (;E122-/LGJ''T)J84LB3K(07!&.+1B$;QZ/BE]@\Z<87JOGEO:,CI
M7IBV*?>K_9-FWG;R_?'V/73)U;VH-92X(M'@)*5BH=HW1CLQ<M/T]:4T]$IH
MAFMZEJ&R!VA_):5YF5@#_4-O]C=02P,$%     @ ((!_5J$@)I>1 P  B@@
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MM\+K$T[R:J]W0S@G:76XQRC"M"P@OM\2PH\G907M/R16/P!02P,$%     @
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ML._1>__)6X:;<Q?PV6"N6\7H;T&,_4:,_<[7=2Q$2;G]="UVPJC?'!0U"$Q
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M1<UV]Z'J S'C&)6+"SAI__T.F'A@;F8(?DEL_,W'.7/AG/F BZ<T^YYO&"O
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ME^8.5A$-JM)#96OS%2J-W/;LQZTB4H5X.I&'1HTQ"2(28HWL8OV1^3G;I%$
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M@U6Z2XK]2P:'HX=7H*ZJ%W^DX]?P? DUQV_0^5(7?^5YYTO.5_?+]/DMJ[&
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MBG0ZHKD,FH[BE3U/YUSIT]DV<WU_@C !^ON"<[7IF".ZNY&3?U!+ P04
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M#7-\7(&R!O@]D]+L)G:#YKD6_P902P,$%     @ ((!_5DM0GJ3>!0  LR4
M !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&ULO9I;;]LV%,??]RD(KQA:
MH+5$RO*E<PPTUH)E:->@Z>6AV ,M'=E$)=&C:+OY]J,NEBQ9H:>":1X22=;Y
M'_%G7OZ'T?S Q;=T R#1]SA*TJO!1LKM:\M*_0W$-!WR+23JDY"+F$IU*M96
MNA5 @SPHCBQBVV,KIBP9+.;YM3NQF/.=C%@"=P*ENSBFXN$:(GZX&N#!\<('
MMM[([(*UF&_I&NY!?MK>"75F52H!BR%)&4^0@/!J\ :_]L@L"\CO^,S@D)X<
MHZPI*\Z_92>WP=7 SIX((O!E)D'5GSTL(8HR)?4<_Y:B@RIG%GAZ?%2_R1NO
M&K.B*2QY](4%<G,UF Y0 "'=1?(#/_P)98/<3,_G49K_1H?B7E?=[.]2R>,R
M6#U!S)+B+_U>@C@)4#K= :0,(*V J?U(@%,&..T,XT<"1F7 *"=3-"7GX%%)
M%W/!#TAD=RNU[""'F4>KYK,D^][OI5"?,A4G%S<LH3ZC$7K+Z(I%3#)($97H
MAC*!/M-H!^BY!Y*R*'V!7J%/]QYZ_NS%W)(J=Z9@^66>ZR(/>20/1N]X(C<I
M^B,)(.B(7UZ()Y<$O L"CD; 4M0J=.2([IIH%?_:14.$QR\1L0GN:I$^W -_
MB!R<AY.N]NC#W_ORL?!&:YRJ(SBYGF.B(WQ]JZ+1K80X_:>K+Q2I1MVILJGL
M=;JE/EP-U%R5@MC#8/';KWAL_]Z%T:289TBL@7A4(1[IU!=+GNQ!Y#.FY(B+
M0"$7#RC=4)4+/6<)NL\/.X>75KHOTD+,S<6RE6&_F+ACQW'FUOX4EJ&<#5AN
M!<O5PGH3!"Q;&52/[$E*J]N7E'M&"H]G-IZU2!G*V2 UKDB-M:1N$P5*8=KN
M5A'S$0]#$"Q9HZU@/G0!TLKU!52(34\ N4.W1<=0P@:=245GHJ63SU_[?/[B
M(9(;0 <J!$UDVH5&J]47S>2L[[0'F*%T#3#3"LQ4/\#6:P%K*D%U%.X#!)U
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MEDA)N%;HQR/D,Y"-*]2*=^X*=016*SVN2H]?L-'C+F7L"*PFXU4EXU671B_
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M!>Y.!:Y6!1_5Q).D*#:] ]F5EC,T_TB8CX0%2%CH'HC)G$XFYGE'3A$HJ*(
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M_BN$5@P)T%H4]19EMH X:K$!*QK43?MAV =:HBVB%.F2E-W^^Y&4HBJ*8F1
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M9](^T:Z+]3V4M5+QJ@/K#"I:NS=Y[.HP  2S X"P X0O =,#@*@#1&\%3#N
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MX>S1311OK&&LN=+V8X>E_J. , %ZO^!<[2?F _T_*OD'4$L#!!0    ( ""
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M'LB2L;+3*0>"+O7=/Z="=A+Z,97-(3!E(-\GE(KM0"U0MYO!/U!+ P04
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M*+W!&_4IN.W1-I"L,FUNR:1JFF:8JVL-N-Z@UE>,R7V@$[079?(34$L#!!0
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M<OI9%WG21HZ.1 XC=J^(P;#/50[Y:P*?9/1:HJV62722\0:R 8O#=RP*HO!
M0M-_AP<GTHG[TL:.+S["=ZI\/Z[G!C7=X9^'"M?R#@_SVKX>F9IG,/:H<0WH
M%7CIVS?A9?#ID.C_1/:J!,.^!,-3[.G3GNQ,0RZ0<7KJ6I)Y3N4QR+%!I5^8
MY@B'ZM$&^>B"V+&T2H-!%"?^:E?G7YS:_/V=3BE!+]T ,2Q3387M1>NM_8RZ
M=JVY9Y_0[&I'S1^:=O#=<[T4E6$2%D09#*XN/*;;8=)N4-6N'^<*J;O=LJ#Y
M"]HZT/E"*=QN;(!^HJ>_ 5!+ P04    "  @@']6HD(#N& $  "X$0  &0
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MX4&<44?2:-#?#S3(2@,0U@@THVV@&5T>:,@S^[;UNO*=4+LTWB Q#8GI2,Q
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M5^Q<]B')\V11?)S3<$93/@'[_3%)\LT?O(*7)/U>S,[MOP%02P,$%     @
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M!,GC^^::2A(GXGOP%MRKXHFV"05L!=A&/Q9 ,B HW\5+*L"&LUT<42X R2)
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M3,T"X'@:8(!G1&+:IH/6@FRSF<-Z-X?]V_E-!V/K:]KZ5=J2E%-I:W;9-2%
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M+BIN1H.VA)Z141A& 3[AX4-E@=VEQ9F[,^X6'GA$1O&0M)EW![:70)/YH:S
M[KKBC+VKKZ:(<3CJ!+1SYO=&C']T4LY!K.P%@D0)WQ:J/$/6O?4EQ0=[-&_U
MS\SEA3V!'V#*FX\'*G0ZDBB#I88,KD=:HR@O$\J&XAM['E]PI4_W]G$-5*=W
M,T"_7W*N7AMF@OI*9_H/4$L#!!0    ( "" ?U;R1;@.T@(  /\'   9
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M\ XOP[P;B+_AW;.R8KKDTA !.TP-1Q^17W>CVAE6-7X\MLKBL/EMA:\;:!>
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MP=MAAD\P2%. WQ="Z+>)Z?+MHQ[_!5!+ P04    "  @@']6TGRZ[N@"  !
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M3L=XHR=R0/M-EPK_C?F#Y0]]9$R%^K^4@; Y.*G5&NI4@U>%YP4H*.)3O2I
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M8!R@A"_9-C4?Y/XW7C>H%+B0J2Y_T;Y^-@S08JN-S&ICJR 3>?7/OM4=<6!
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M#;$3-NTQ.H[H$4QT&+!1F^G'\="S&HP.OHT_5(4_'U^C=@X@GHHP<@D@@A/
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MRZ:C&SIK]0'"/G)5?NP(QC&8'0$,RX,YP#B&A>7YG\8S0,=C,,S;P(H,4,X
MY1B6#9F47RR/G1/ICWVD410$88C-Z&1B=3#!YBT,X<>NAGD#!I8',CUMKO'5
MQBNDO0ZP-6VK$&RD>"5B(\7G&A#[O $CBNRKC>4!!K8*6.U ?GL>J"D[)PA@
M53%OV [&D2C"$*A%>XV&(3([(7SMZX/MDB"((CL"F-U!$& ([$8<P1R !PP)
M@O(]N/<^\C;O*:_Y'_+X+U!+ P04    "  @@']6EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( "" ?U;CZ'/\^ 4
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M9?TQCH=_'+\\T]ZTPW-^MOQGX>874$L! A0#%     @ ((!_5@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  @@']6I%JKR.T    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  @@']6F5R<(Q &  "<)P  $P
M        @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ""
M?U:%E79RA08  ) >   8              " @0P(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  @@']6$ZAL1@P%   ^%@  &
M        @(''#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ ((!_5BWD_Y3M!   BQ,  !@              ("!"10  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "" ?U9+%%X5B0(  *X&   8
M              " @2P9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    "  @@']69]@;8#,)  #F20  &               @('K&P  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ ((!_5DLK0Q2C"
MARP  !@              ("!5"4  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( "" ?U9=4)*NE@H  &(8   8              " @2TN
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  @@']6+-?=
MXCH;  !,40  &               @('Y.   >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ ((!_5L<K3O0N!   Q0D  !@
M ("!:50  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ""
M?U:GN6^C_ (  'L'   9              " @<U8  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ ((!_5K.$ 59V @  6P4  !D
M         ("! %P  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    "  @@']6]=U_6'\#  !+"   &0              @(&M7@  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( "" ?U;V;=^F> (  &L%
M   9              " @6-B  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ ((!_5J(4JH*J!   "PH  !D              ("!$F4
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  @@']6'2F:
M/KH%  "U#@  &0              @('S:0  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( "" ?U:40>#KU @  '(8   9
M  " @>1O  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M((!_5FS2*K[: @  'P8  !D              ("![W@  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    "  @@']6.2 WF8<"  "3!0  &0
M            @($ ?   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( "" ?U8^:(SF) ,  )T&   9              " @;Y^  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ ((!_5H^.K/ A P
M0@<  !D              ("!&8(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    "  @@']6:I%Y/.T#  !]"   &0              @(%Q
MA0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "" ?U8B
MW;[;-@8  & /   9              " @96)  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ ((!_5KU "410"P  )"L  !D
M     ("! I   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "" ?U:61LWW%QH  !M4   9              "
M@8>W  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ ((!_
M5D94"@&$ @  >P4  !D              ("!U=$  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    "  @@']6&\%0#6H"  !1!0  &0
M        @(&0U   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( "" ?U84QZ&'7@,  .X'   9              " @3'7  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ ((!_5O@2;HQM @  7P4
M !D              ("!QMH  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    "  @@']6,I"EXLX"   =!@  &0              @(%JW0
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "" ?U9!^S4E
M?P(  *D%   9              " @6_@  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ ((!_5HKPP*?U @  ' <  !D
M ("!)>,  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  @
M@']62F8S.,0"   '!@  &0              @(%1Y@  >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( "" ?U9\9,X@<@(  '\%   9
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M970T,2YX;6Q02P$"% ,4    "  @@']67K@770D$   Z#   &0
M    @(% ^0  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M "" ?U:4'0]<SP(  +X&   9              " @8#]  !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ ((!_5BP[0A[9 P  ] D  !D
M             ("!A@ ! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    "  @@']6H2 FEY$#  "*"   &0              @(&6! $ >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( "" ?U8) <P'@ 0
M )P8   9              " @5X( 0!X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ ((!_5HUHWC-8 P  > \  !D              ("!
M%0T! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  @@']6
MRA]U@)@"  #-"   &0              @(&D$ $ >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( "" ?U8=514TS@(  !P(   9
M      " @7,3 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ ((!_5C*F%F>W!P  B#8  !D              ("!>!8! 'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  @@']6\(O24+$"  "=!P
M&0              @(%F'@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( "" ?U:K4F@YSP(   \)   9              " @4XA 0!X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ ((!_5E35R8-@
M P  N@D  !D              ("!5"0! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    "  @@']62U">I-X%  "S)0  &0
M@('K)P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ""
M?U;S56Z/@0,  /D1   9              " @0 N 0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ ((!_5A!7SV.."@  :V$  !D
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M=#8P+GAM;%!+ 0(4 Q0    ( "" ?U8'-]-=% ,  'H*   9
M  " @4%) 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @
M((!_5APH7L(*!   _0X  !D              ("!C$P! 'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6Q02P$"% ,4    "  @@']6_=2N14$#  !8"P  &0
M            @('-4 $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4
M Q0    ( "" ?U8'R_-L@P,  *8+   9              " @454 0!X;"]W
M;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ ((!_5M@7A.25 @
M- <  !D              ("!_U<! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX
M;6Q02P$"% ,4    "  @@']67T5$NVD#  "7"@  &0              @('+
M6@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( "" ?U9:
M2O<59@(  -T%   9              " @6M> 0!X;"]W;W)K<VAE971S+W-H
M965T-C<N>&UL4$L! A0#%     @ ((!_5J)" [A@!   N!$  !D
M     ("!"&$! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "" ?U9:4A$&C 4  /H?   9              "
M@52" 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ ((!_
M5J1@9M;W P  WA$  !D              ("!%X@! 'AL+W=O<FMS:&5E=',O
M<VAE970W-"YX;6Q02P$"% ,4    "  @@']6\D6X#M("  #_!P  &0
M        @(%%C $ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0
M   ( "" ?U8_6RIN[0(  .4+   9              " @4Z/ 0!X;"]W;W)K
M<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ ((!_5M["<P$V @  .P4
M !D              ("!<I(! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q0
M2P$"% ,4    "  @@']627O9&= "  #@!P  &0              @('?E $
M>&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( "" ?U;2?+KN
MZ (  $ )   9              " @>:7 0!X;"]W;W)K<VAE971S+W-H965T
M-SDN>&UL4$L! A0#%     @ ((!_5K+)G_X& P  I@P  !D
M ("!!9L! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4    "  @
M@']61O:%=1$$   '%0  &0              @(%"G@$ >&PO=V]R:W-H965T
M<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( "" ?U;N%;"[I0(  '0'   9
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M;',O+G)E;'-02P$"% ,4    "  @@']6X^AS_/@%  #N-P  #P
M    @ &YMP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ((!_5B 5OA"$
M @  )C(  !H              ( !WKT! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ ((!_5HENS'XK @  NS   !,
M ( !FL ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %T 70""&0  ]L(!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>194</ContextCount>
  <ElementCount>406</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>57</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statements of Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Statements of Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statements of Changes in Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Changes in Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statements of Cash Flow</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flow</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Critical Accounting Estimates and Judgements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/CriticalAccountingEstimatesandJudgements</Role>
      <ShortName>Critical Accounting Estimates and Judgements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Deposits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/Deposits</Role>
      <ShortName>Deposits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/OtherCurrentAssets</Role>
      <ShortName>Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/OtherAccountsPayable</Role>
      <ShortName>Other Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Liability in Respect of Government Grants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrants</Role>
      <ShortName>Liability in Respect of Government Grants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Finacial Liabilities at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue</Role>
      <ShortName>Finacial Liabilities at Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Equity (Defict)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/EquityDefict</Role>
      <ShortName>Equity (Defict)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses</Role>
      <ShortName>Research and Development Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Sales and Marketing Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SalesandMarketingExpenses</Role>
      <ShortName>Sales and Marketing Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses</Role>
      <ShortName>General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Financial (Income) and Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses</Role>
      <ShortName>Financial (Income) and Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Share Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareBasedCompensation</Role>
      <ShortName>Share Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Financial Instruments and Risk Management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagement</Role>
      <ShortName>Financial Instruments and Risk Management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/OtherCurrentAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Other Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/OtherAccountsPayableTables</Role>
      <ShortName>Other Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/OtherAccountsPayable</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Liability in Respect of Government Grants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsTables</Role>
      <ShortName>Liability in Respect of Government Grants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrants</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Finacial Liabilities at Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables</Role>
      <ShortName>Finacial Liabilities at Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Equity (Defict) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/EquityDefictTables</Role>
      <ShortName>Equity (Defict) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/EquityDefict</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Research and Development Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables</Role>
      <ShortName>Research and Development Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Sales and Marketing Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables</Role>
      <ShortName>Sales and Marketing Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SalesandMarketingExpenses</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - General and Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables</Role>
      <ShortName>General and Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Financial (Income) and Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables</Role>
      <ShortName>Financial (Income) and Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/TaxesonIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/TaxesonIncome</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Share Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareBasedCompensation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/RelatedParties</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Financial Instruments and Risk Management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables</Role>
      <ShortName>Financial Instruments and Risk Management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagement</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FairValueMeasurement</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Deposits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/DepositsDetails</Role>
      <ShortName>Deposits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/Deposits</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Other Current Assets (Details) - Schedule of other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofotherCurrentAssetsTable</Role>
      <ShortName>Other Current Assets (Details) - Schedule of other Current Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable</Role>
      <ShortName>Property and Equipment, Net (Details) - Schedule of property and equipment, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Other Accounts Payable (Details) - Schedule of other accounts payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable</Role>
      <ShortName>Other Accounts Payable (Details) - Schedule of other accounts payable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/OtherAccountsPayableTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Liability in Respect of Government Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsDetails</Role>
      <ShortName>Liability in Respect of Government Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Liability in Respect of Government Grants (Details) - Schedule of reimbursement of research expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofreimbursementofresearchexpensesTable</Role>
      <ShortName>Liability in Respect of Government Grants (Details) - Schedule of reimbursement of research expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Finacial Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails</Role>
      <ShortName>Finacial Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable</Role>
      <ShortName>Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Equity (Defict) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/EquityDefictDetails</Role>
      <ShortName>Equity (Defict) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/EquityDefictTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Equity (Defict) (Details) - Schedule of share capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable</Role>
      <ShortName>Equity (Defict) (Details) - Schedule of share capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/EquityDefictTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Equity (Defict) (Details) - Schedule of loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable</Role>
      <ShortName>Equity (Defict) (Details) - Schedule of loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/EquityDefictTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Equity (Defict) (Details) - Schedule of loss per share (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable_Parentheticals</Role>
      <ShortName>Equity (Defict) (Details) - Schedule of loss per share (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/EquityDefictTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Research and Development Expenses (Details) - Schedule of research and development expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable</Role>
      <ShortName>Research and Development Expenses (Details) - Schedule of research and development expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Sales and Marketing Expenses (Details) - Schedule of sales and Marketing Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable</Role>
      <ShortName>Sales and Marketing Expenses (Details) - Schedule of sales and Marketing Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure -  General and Administrative Expenses (Details) - Schedule of general and administrative expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable</Role>
      <ShortName>General and Administrative Expenses (Details) - Schedule of general and administrative expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Financial (Income) and Expenses (Details) - Schedule of financial income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable</Role>
      <ShortName>Financial (Income) and Expenses (Details) - Schedule of financial income</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Financial (Income) and Expenses (Details) - Schedule of financial expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable</Role>
      <ShortName>Financial (Income) and Expenses (Details) - Schedule of financial expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/TaxesonIncomeTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Taxes on Income (Details) - Schedule of theoretical tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable</Role>
      <ShortName>Taxes on Income (Details) - Schedule of theoretical tax</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/TaxesonIncomeTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Taxes on Income (Details) - Schedule of theoretical tax (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable_Parentheticals</Role>
      <ShortName>Taxes on Income (Details) - Schedule of theoretical tax (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/TaxesonIncomeTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/LeasesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Leases (Details) - Schedule of right-of-use assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable</Role>
      <ShortName>Leases (Details) - Schedule of right-of-use assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/LeasesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Leases (Details) - Schedule of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/LeasesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Leases (Details) - Schedule of profit or loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable</Role>
      <ShortName>Leases (Details) - Schedule of profit or loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/LeasesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Share Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails</Role>
      <ShortName>Share Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Share Based Compensation (Details) - Schedule of options to services providers and advisers outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable</Role>
      <ShortName>Share Based Compensation (Details) - Schedule of options to services providers and advisers outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Share Based Compensation (Details) - Schedule of RSUs to services providers and advisers outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable</Role>
      <ShortName>Share Based Compensation (Details) - Schedule of RSUs to services providers and advisers outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Related Parties (Details) - Schedule of shareholders and other related parties??? benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable</Role>
      <ShortName>Related Parties (Details) - Schedule of shareholders and other related parties??? benefits</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/RelatedPartiesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Related Parties (Details) - Schedule of balances with related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable</Role>
      <ShortName>Related Parties (Details) - Schedule of balances with related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/RelatedPartiesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>076 - Disclosure - Financial Instruments and Risk Management (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementDetails</Role>
      <ShortName>Financial Instruments and Risk Management (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>077 - Disclosure - Financial Instruments and Risk Management (Details) - Schedule of financial assets represents the maximum credit exposure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable</Role>
      <ShortName>Financial Instruments and Risk Management (Details) - Schedule of financial assets represents the maximum credit exposure</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>078 - Disclosure - Financial Instruments and Risk Management (Details) - Schedule of foreign currency denominated monetary liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable</Role>
      <ShortName>Financial Instruments and Risk Management (Details) - Schedule of foreign currency denominated monetary liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>079 - Disclosure - Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable</Role>
      <ShortName>Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>080 - Disclosure - Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable</Role>
      <ShortName>Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>081 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/CommitmentsandContingencies</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>082 - Disclosure - Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FairValueMeasurementDetails</Role>
      <ShortName>Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FairValueMeasurementTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>083 - Disclosure - Fair Value Measurement (Details) - Schedule of warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable</Role>
      <ShortName>Fair Value Measurement (Details) - Schedule of warrants</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FairValueMeasurementTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="f20f2022_inspiratech.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>084 - Disclosure - Fair Value Measurement (Details) - Schedule of movements in level 2 liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable</Role>
      <ShortName>Fair Value Measurement (Details) - Schedule of movements in level 2 liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FairValueMeasurementTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentAccountingStandard, ifrs-full:DilutedEarningsLossPerShare -  f20f2022_inspiratech.htm 17442, 17451, 17452, 17453, 17548, 17549, 17550</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" original="f20f2022_inspiratech.htm">f20f2022_inspiratech.htm</File>
    <File>f20f2022ex12-1_inspiratech.htm</File>
    <File>f20f2022ex12-2_inspiratech.htm</File>
    <File>f20f2022ex13-1_inspiratech.htm</File>
    <File>f20f2022ex13-2_inspiratech.htm</File>
    <File>f20f2022ex15-1_inspiratech.htm</File>
    <File>f20f2022ex2-1_inspiratech.htm</File>
    <File>iinn-20221231.xsd</File>
    <File>iinn-20221231_cal.xml</File>
    <File>iinn-20221231_def.xml</File>
    <File>iinn-20221231_lab.xml</File>
    <File>iinn-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
    <File>image_015.jpg</File>
    <File>image_016.jpg</File>
    <File>image_017.jpg</File>
    <File>image_018.jpg</File>
    <File>image_019.jpg</File>
    <File>image_020.jpg</File>
    <File>image_021.jpg</File>
    <File>image_022.jpg</File>
    <File>image_023.jpg</File>
    <File>image_024.jpg</File>
    <File>image_025.jpg</File>
    <File>image_026.jpg</File>
    <File>image_027.jpg</File>
    <File>image_028.jpg</File>
    <File>image_029.jpg</File>
    <File>image_030.jpg</File>
    <File>image_031.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="585">http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>137
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f20f2022_inspiratech.htm": {
   "axisCustom": 1,
   "axisStandard": 15,
   "baseTaxonomies": {
    "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 585,
    "http://xbrl.sec.gov/dei/2021q4": 42
   },
   "contextCount": 194,
   "dts": {
    "calculationLink": {
     "local": [
      "iinn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "iinn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f20f2022_inspiratech.htm"
     ]
    },
    "labelLink": {
     "local": [
      "iinn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "iinn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "iinn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd"
     ]
    }
   },
   "elementCount": 622,
   "entityCount": 1,
   "hidden": {
    "http://www.inspiratechnologies.com/20221231": 78,
    "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 100,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 182
   },
   "keyCustom": 188,
   "keyStandard": 218,
   "memberCustom": 33,
   "memberStandard": 18,
   "nsprefix": "iinn",
   "nsuri": "http://www.inspiratechnologies.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDepositsFromBanksExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Deposits",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.inspiratechnologies.com/role/Deposits",
     "shortName": "Deposits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDepositsFromBanksExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Other Current Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.inspiratechnologies.com/role/OtherCurrentAssets",
     "shortName": "Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.inspiratechnologies.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Other Accounts Payable",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.inspiratechnologies.com/role/OtherAccountsPayable",
     "shortName": "Other Accounts Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Liability in Respect of Government Grants",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrants",
     "shortName": "Liability in Respect of Government Grants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Finacial Liabilities at Fair Value",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue",
     "shortName": "Finacial Liabilities at Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Equity (Defict)",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.inspiratechnologies.com/role/EquityDefict",
     "shortName": "Equity (Defict)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Research and Development Expenses",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses",
     "shortName": "Research and Development Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:SalesAndMarketingExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Sales and Marketing Expenses",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.inspiratechnologies.com/role/SalesandMarketingExpenses",
     "shortName": "Sales and Marketing Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:SalesAndMarketingExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - General and Administrative Expenses",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses",
     "shortName": "General and Administrative Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Statements of Financial Position",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
     "shortName": "Statements of Financial Position",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Financial (Income) and Expenses",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses",
     "shortName": "Financial (Income) and Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Taxes on Income",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.inspiratechnologies.com/role/TaxesonIncome",
     "shortName": "Taxes on Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.inspiratechnologies.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Share Based Compensation",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.inspiratechnologies.com/role/ShareBasedCompensation",
     "shortName": "Share Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Related Parties",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.inspiratechnologies.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Financial Instruments and Risk Management",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagement",
     "shortName": "Financial Instruments and Risk Management",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.inspiratechnologies.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Fair Value Measurement",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.inspiratechnologies.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "28",
     "role": "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:ResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
     "shortName": "Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:ResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables",
     "shortName": "Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfPropertyAndEquipmentNetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfPropertyAndEquipmentNetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfOtherAccountPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Other Accounts Payable (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.inspiratechnologies.com/role/OtherAccountsPayableTables",
     "shortName": "Other Accounts Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfOtherAccountPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfReimbursementOfResearchExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Liability in Respect of Government Grants (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsTables",
     "shortName": "Liability in Respect of Government Grants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfReimbursementOfResearchExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfFinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Finacial Liabilities at Fair Value (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables",
     "shortName": "Finacial Liabilities at Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfFinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Equity (Defict) (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.inspiratechnologies.com/role/EquityDefictTables",
     "shortName": "Equity (Defict) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Research and Development Expenses (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables",
     "shortName": "Research and Development Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Sales and Marketing Expenses (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables",
     "shortName": "Sales and Marketing Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfGeneralAndAdministrativeExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - General and Administrative Expenses (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables",
     "shortName": "General and Administrative Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfGeneralAndAdministrativeExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfFinancialIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Financial (Income) and Expenses (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables",
     "shortName": "Financial (Income) and Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfFinancialIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Statements of Comprehensive Loss (Parentheticals)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Statements of Comprehensive Loss (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfTheoreticalTaxTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Taxes on Income (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.inspiratechnologies.com/role/TaxesonIncomeTables",
     "shortName": "Taxes on Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfTheoreticalTaxTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.inspiratechnologies.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Share Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.inspiratechnologies.com/role/ShareBasedCompensationTables",
     "shortName": "Share Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Related Parties (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.inspiratechnologies.com/role/RelatedPartiesTables",
     "shortName": "Related Parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Financial Instruments and Risk Management (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables",
     "shortName": "Financial Instruments and Risk Management (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Fair Value Measurement (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.inspiratechnologies.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c34",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "iinn:NumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - General (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.inspiratechnologies.com/role/GeneralDetails",
     "shortName": "General (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c34",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "iinn:NumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "iinn:ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c38",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "iinn:AnnualDepreciationRateInPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable",
     "shortName": "Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "iinn:ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c38",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "iinn:AnnualDepreciationRateInPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DepositsFromBanks",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Deposits (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.inspiratechnologies.com/role/DepositsDetails",
     "shortName": "Deposits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DepositsFromBanks",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentPrepaidExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Other Current Assets (Details) - Schedule of other Current Assets",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofotherCurrentAssetsTable",
     "shortName": "Other Current Assets (Details) - Schedule of other Current Assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentPrepaidExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c25",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Statements of Changes in Shareholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3",
     "shortName": "Statements of Changes in Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c25",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfPropertyAndEquipmentNetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment, net",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable",
     "shortName": "Property and Equipment, Net (Details) - Schedule of property and equipment, net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c19",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfOtherAccountPayableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:EmployeesSalariesAndRelatedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Other Accounts Payable (Details) - Schedule of other accounts payable",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable",
     "shortName": "Other Accounts Payable (Details) - Schedule of other accounts payable",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfOtherAccountPayableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:EmployeesSalariesAndRelatedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromGovernmentGrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Liability in Respect of Government Grants (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsDetails",
     "shortName": "Liability in Respect of Government Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromGovernmentGrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfReimbursementOfResearchExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:GovernmentGrants",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Liability in Respect of Government Grants (Details) - Schedule of reimbursement of research expenses",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofreimbursementofresearchexpensesTable",
     "shortName": "Liability in Respect of Government Grants (Details) - Schedule of reimbursement of research expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfReimbursementOfResearchExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c19",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:GovernmentGrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "iinn:ConversionToShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Finacial Liabilities at Fair Value (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
     "shortName": "Finacial Liabilities at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "iinn:ConversionToShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfFinancialLiabilities",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:TotalFinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable",
     "shortName": "Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfFinancialLiabilities",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:TotalFinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "iinn:AggregateOfOrdinaryShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Equity (Defict) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.inspiratechnologies.com/role/EquityDefictDetails",
     "shortName": "Equity (Defict) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "iinn:AggregateOfOrdinaryShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c12",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Equity (Defict) (Details) - Schedule of share capital",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable",
     "shortName": "Equity (Defict) (Details) - Schedule of share capital",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c12",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfLossPerShare",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Equity (Defict) (Details) - Schedule of loss per share",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable",
     "shortName": "Equity (Defict) (Details) - Schedule of loss per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfLossPerShare",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Equity (Defict) (Details) - Schedule of loss per share (Parentheticals)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable_Parentheticals",
     "shortName": "Equity (Defict) (Details) - Schedule of loss per share (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Statements of Cash Flow",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow",
     "shortName": "Statements of Cash Flow",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:DepreciationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfResearchAndDevelopmentExpenses",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:ShareBasedPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Research and Development Expenses (Details) - Schedule of research and development expenses",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable",
     "shortName": "Research and Development Expenses (Details) - Schedule of research and development expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfResearchAndDevelopmentExpenses",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:ShareBasedPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Sales and Marketing Expenses (Details) - Schedule of sales and Marketing Expenses",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable",
     "shortName": "Sales and Marketing Expenses (Details) - Schedule of sales and Marketing Expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfGeneralAndAdministrativeExpenses",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:ShareBasedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure -  General and Administrative Expenses (Details) - Schedule of general and administrative expenses",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable",
     "shortName": "General and Administrative Expenses (Details) - Schedule of general and administrative expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfGeneralAndAdministrativeExpenses",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:ShareBasedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfFinancialIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Financial (Income) and Expenses (Details) - Schedule of financial income",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable",
     "shortName": "Financial (Income) and Expenses (Details) - Schedule of financial income",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfFinancialIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfFinancialExpenses",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c96",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Financial (Income) and Expenses (Details) - Schedule of financial expenses",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable",
     "shortName": "Financial (Income) and Expenses (Details) - Schedule of financial expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfFinancialExpenses",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c96",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Taxes on Income (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails",
     "shortName": "Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfTheoreticalTaxTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:LossBeforeTaxation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Taxes on Income (Details) - Schedule of theoretical tax",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable",
     "shortName": "Taxes on Income (Details) - Schedule of theoretical tax",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfTheoreticalTaxTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:LossBeforeTaxation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfTheoreticalTaxTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c4",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "iinn:TheoreticalTaxCreditAtApplicableStatutoryRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "066 - Disclosure - Taxes on Income (Details) - Schedule of theoretical tax (Parentheticals)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable_Parentheticals",
     "shortName": "Taxes on Income (Details) - Schedule of theoretical tax (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfTheoreticalTaxTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c4",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "iinn:TheoreticalTaxCreditAtApplicableStatutoryRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:leaseTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "067 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.inspiratechnologies.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:leaseTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfRightofuseAssets",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:LeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "068 - Disclosure - Leases (Details) - Schedule of right-of-use assets",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable",
     "shortName": "Leases (Details) - Schedule of right-of-use assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfRightofuseAssets",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:LeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - General",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.inspiratechnologies.com/role/General",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfLeaseLiabilities",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "069 - Disclosure - Leases (Details) - Schedule of lease liabilities",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfLeaseLiabilities",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c29",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:FinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfProfitOrLoss",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070 - Disclosure - Leases (Details) - Schedule of profit or loss",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable",
     "shortName": "Leases (Details) - Schedule of profit or loss",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfProfitOrLoss",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c111",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "071 - Disclosure - Share Based Compensation (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails",
     "shortName": "Share Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c111",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c130",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "072 - Disclosure - Share Based Compensation (Details) - Schedule of options to services providers and advisers outstanding",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable",
     "shortName": "Share Based Compensation (Details) - Schedule of options to services providers and advisers outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c136",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c140",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "iinn:OutstandingAtBeginningOfYears",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "073 - Disclosure - Share Based Compensation (Details) - Schedule of RSUs to services providers and advisers outstanding",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable",
     "shortName": "Share Based Compensation (Details) - Schedule of RSUs to services providers and advisers outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c141",
      "decimals": "INF",
      "lang": null,
      "name": "iinn:Granted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ShorttermEmployeeBenefitsExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "074 - Disclosure - Related Parties (Details) - Schedule of shareholders and other related parties\u2019 benefits",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable",
     "shortName": "Related Parties (Details) - Schedule of shareholders and other related parties\u2019 benefits",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ShorttermEmployeeBenefitsExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:BalancesWithRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c150",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:NatureOfTransactionSalariesAndRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "075 - Disclosure - Related Parties (Details) - Schedule of balances with related parties",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable",
     "shortName": "Related Parties (Details) - Schedule of balances with related parties",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:BalancesWithRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c150",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "iinn:NatureOfTransactionSalariesAndRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "iinn:strengtheningPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "076 - Disclosure - Financial Instruments and Risk Management (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementDetails",
     "shortName": "Financial Instruments and Risk Management (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "iinn:strengtheningPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c154",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "077 - Disclosure - Financial Instruments and Risk Management (Details) - Schedule of financial assets represents the maximum credit exposure",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable",
     "shortName": "Financial Instruments and Risk Management (Details) - Schedule of financial assets represents the maximum credit exposure",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c154",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfForeignCurrencyDenominatedMonetaryLiability",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "078 - Disclosure - Financial Instruments and Risk Management (Details) - Schedule of foreign currency denominated monetary liability",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable",
     "shortName": "Financial Instruments and Risk Management (Details) - Schedule of foreign currency denominated monetary liability",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfForeignCurrencyDenominatedMonetaryLiability",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.inspiratechnologies.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfSensitivityAnalysis",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c156",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:SensitivityAnalysis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "079 - Disclosure - Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable",
     "shortName": "Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfSensitivityAnalysis",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c156",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:SensitivityAnalysis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c162",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080 - Disclosure - Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable",
     "shortName": "Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c162",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Prepayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Prepayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "082 - Disclosure - Fair Value Measurement (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails",
     "shortName": "Fair Value Measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c177",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WarrantLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "083 - Disclosure - Fair Value Measurement (Details) - Schedule of warrants",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable",
     "shortName": "Fair Value Measurement (Details) - Schedule of warrants",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c177",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WarrantLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfMovementsInLevel2LiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:BalanceAtBeginning",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "084 - Disclosure - Fair Value Measurement (Details) - Schedule of movements in level 2 liability",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable",
     "shortName": "Fair Value Measurement (Details) - Schedule of movements in level 2 liability",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfMovementsInLevel2LiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "iinn:BalanceAtBeginning",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Critical Accounting Estimates and Judgements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.inspiratechnologies.com/role/CriticalAccountingEstimatesandJudgements",
     "shortName": "Critical Accounting Estimates and Judgements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_inspiratech.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 57,
   "tag": {
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability": {
     "auth_ref": [
      "r117",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The accumulated increase (decrease) in the fair value of financial liabilities that is attributable to changes in the credit risk of the liabilities. [Refer: Credit risk [member]; Market risk [member]; Increase (decrease) in fair value of financial liability, attributable to changes in credit risk of liability]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated increase (decrease) in fair value of financial liability, attributable to changes in credit risk of liability",
        "terseLabel": "Revaluation of financial liabilities at fair value through profit or loss"
       }
      }
     },
     "localname": "AccumulatedChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionalPaidinCapitalMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      },
      "en-us": {
       "role": {
        "label": "Additional paid-in capital [member]",
        "terseLabel": "Additional Paid in Capital"
       }
      }
     },
     "localname": "AdditionalPaidinCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AdditionalProvisionsOtherProvisions": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additional other provisions made. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additional provisions, other provisions",
        "terseLabel": "Additional offering costs total (in Dollars)"
       }
      }
     },
     "localname": "AdditionalProvisionsOtherProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions, Cost"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other assets",
        "terseLabel": "Decrease (increase) in other current assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFairValueGainsLosses": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for fair value losses (gains)",
        "terseLabel": "Changes of financial liabilities - IPO non-cash expenses"
       }
      }
     },
     "localname": "AdjustmentsForFairValueGainsLosses",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade accounts payable",
        "terseLabel": "Increase (decrease) in trade accounts payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "Increase in other accounts payable"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "auth_ref": [
      "r62",
      "r65",
      "r90"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated measurement [member]"
       }
      }
     },
     "localname": "AggregatedMeasurementMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation, intangible assets other than goodwill",
        "terseLabel": "Amounts received during the year, non- capitalized"
       }
      }
     },
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofreimbursementofresearchexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Corporate tax rate"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r14",
      "r90",
      "r91",
      "r93",
      "r139",
      "r141"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic and diluted loss per share (in Dollars per share)",
        "verboseLabel": "Basic loss per share (in Dollars per share)"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BorrowingsInterestRate": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings, interest rate",
        "terseLabel": "Annual interest rate"
       }
      }
     },
     "localname": "BorrowingsInterestRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r95",
      "r114",
      "r145",
      "r166",
      "r167",
      "r214"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Bottom of range [member]"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails",
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r10",
      "r73",
      "r86"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at the end of the period",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents if different from statement of financial position",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents recognised as of acquisition date",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments",
        "terseLabel": "Change of deposit"
       }
      }
     },
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r66",
      "r75"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r66",
      "r75"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "CASH FLOW FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r75"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "CASH FLOW FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails",
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of entity's own equity instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfEntitysOwnEquityInstrumentsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r124",
      "r126",
      "r128",
      "r129"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r124",
      "r126",
      "r128",
      "r129"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r130",
      "r131",
      "r144",
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable",
      "http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails",
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails",
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable",
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComputerEquipmentMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer equipment [member]",
        "terseLabel": "Computers [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CreditRiskMember": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Credit risk [member]",
        "terseLabel": "Credit risk [member]"
       }
      }
     },
     "localname": "CreditRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrencyInWhichInformationIsDisplayedAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Currency in which information is displayed [axis]"
       }
      }
     },
     "localname": "CurrencyInWhichInformationIsDisplayedAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current accrued expenses and other current liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r16",
      "r80",
      "r165"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentFinancialAssets": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current financial assets",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "CurrentFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r17",
      "r82",
      "r165"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepaid expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "CurrentPrepaidExpenses",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofotherCurrentAssetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DateOfGrantOfSharebasedPaymentArrangement": {
     "auth_ref": [
      "r169",
      "r170"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The date on which share-based payment arrangements are granted. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Date of grant of share-based payment arrangement",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "DateOfGrantOfSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DeferredTaxAssets": {
     "auth_ref": [
      "r13",
      "r15",
      "r32"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax assets",
        "terseLabel": "Right of use assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepositsFromBanks": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deposit liabilities from banks held by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Deposits from banks",
        "terseLabel": "Deposit amount"
       }
      }
     },
     "localname": "DepositsFromBanks",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense, amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss. [Refer: Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss",
        "negatedLabel": "Depreciation expense of right-of-use assets"
       }
      }
     },
     "localname": "DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r0",
      "r28",
      "r88",
      "r136",
      "r142",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation and amortisation expense",
        "negatedLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationAndAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationExpense": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "terseLabel": "Depreciation, Accumulated depreciation"
       }
      }
     },
     "localname": "DepreciationPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Derivative financial liabilities",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "DerivativeFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for deferred income tax [text block]",
        "terseLabel": "Deferred tax"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for earnings per share [text block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for employee benefits [text block]",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for fair value measurement [text block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Functional and foreign currency"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for government grants [text block]",
        "terseLabel": "Government grants"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForGovernmentGrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for impairment of non-financial assets [text block]",
        "terseLabel": "Impairment of non-financial assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property, plant, and equipment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for segment reporting."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for segment reporting [text block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "terseLabel": "Share based payment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for taxes other than income tax. [Refer: Tax expense other than income tax expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for taxes other than income tax [text block]",
        "terseLabel": "Current taxes"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Expected volatility, percentage"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk-free interest rate, percentage"
       }
      }
     },
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Basic and diluted loss per share (in Dollars per share)",
        "verboseLabel": "Diluted loss per share"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Dilutive effect of share options on number of ordinary shares",
        "terseLabel": "Total number of Ordinary Shares"
       }
      }
     },
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "terseLabel": "CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS"
       }
      }
     },
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CriticalAccountingEstimatesandJudgements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "terseLabel": "Schedule of share capital"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of commitments and contingent liabilities [text block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDepositsFromBanksExplanatory": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of deposits from banks. [Refer: Deposits from banks]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of deposits from banks [text block]",
        "terseLabel": "DEPOSITS"
       }
      }
     },
     "localname": "DisclosureOfDepositsFromBanksExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Deposits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [text block]",
        "terseLabel": "Schedule of warrants"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of finance income (cost) [text block]",
        "terseLabel": "FINANCIAL (INCOME) AND EXPENSES"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [text block]",
        "terseLabel": "Schedule of cash flows of financial liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of general and administrative expenses. [Refer: Administrative expenses]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of general and administrative expense [text block]",
        "terseLabel": "GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      }
     },
     "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for general hedge accounting."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of general hedge accounting [text block]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "DisclosureOfGeneralHedgeAccountingExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/General"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of general information about financial statements [text block]",
        "terseLabel": "Schedule of other Current Assets"
       }
      }
     },
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGovernmentGrantsExplanatory": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for government grants."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of government grants [text block]",
        "terseLabel": "LIABILITY IN RESPECT OF GOVERNMENT GRANTS"
       }
      }
     },
     "localname": "DisclosureOfGovernmentGrantsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "TAXES ON INCOME"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of investments accounted for using equity method [text block]",
        "terseLabel": "EQUITY (DEFICT)"
       }
      }
     },
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefict"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "terseLabel": "Schedule of RSUs to services providers and advisers outstanding"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other non-current assets [text block]",
        "terseLabel": "OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/OtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "RELATED PARTIES"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of research and development expense [text block]",
        "terseLabel": "RESEARCH AND DEVELOPMENT EXPENSES"
       }
      }
     },
     "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "SHARE BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of the entity's own equity instruments. [Refer: Entity's own equity instruments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of equity [text block]",
        "terseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]",
        "terseLabel": "FINACIAL LIABILITIES AT FAIR VALUE"
       }
      }
     },
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "OTHER ACCOUNTS PAYABLE"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/OtherAccountsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisposalsInvestmentProperty": {
     "auth_ref": [
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in investment property resulting from disposals. [Refer: Investment property]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, investment property",
        "negatedLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsInvestmentProperty",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, property, plant and equipment",
        "negatedLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsPaidClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid by the entity, classified as financing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends paid, classified as financing activities",
        "negatedLabel": "Principal paid on lease liabilities"
       }
      }
     },
     "localname": "DividendsPaidClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r69",
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Effects of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysOwnEquityInstrumentsMember": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments issued by the entity. It also represents the standard value for the 'Classes of entity's own equity instruments' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's own equity instruments [member]"
       }
      }
     },
     "localname": "EntitysOwnEquityInstrumentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails",
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r14",
      "r18",
      "r76",
      "r78",
      "r90",
      "r91",
      "r93"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Shareholders\u2019 Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options",
        "terseLabel": "Exercise price per share (in New Shekels per share)"
       }
      }
     },
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected dividend as percentage, share options granted",
        "terseLabel": "Expected dividend yield, percentage"
       }
      }
     },
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ExpenseByNature": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Expenses, by nature",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ExpenseByNature",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable": {
       "order": 1.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Share based payment"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to leases of low-value assets for which recognition exemption has been used",
        "terseLabel": "Related NASDAQ IPO expenses"
       }
      }
     },
     "localname": "ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The explanation of the measurement basis (or bases) used in preparing the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Explanation of measurement bases used in preparing financial statements [text block]",
        "terseLabel": "Financial instruments"
       }
      }
     },
     "localname": "ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_FeeAndCommissionExpense": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable": {
       "order": 3.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to fees and commissions."
       }
      },
      "en-us": {
       "role": {
        "label": "Fee and commission expense",
        "terseLabel": "Professionals\u2019 fees"
       }
      }
     },
     "localname": "FeeAndCommissionExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncomeCost": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income (cost)",
        "terseLabel": "Finance income"
       }
      }
     },
     "localname": "FinanceIncomeCost",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssets": {
     "auth_ref": [
      "r120",
      "r124",
      "r125",
      "r128",
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets",
        "terseLabel": "Total",
        "verboseLabel": "Total assets"
       }
      }
     },
     "localname": "FinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable",
      "http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValue": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, at fair value",
        "terseLabel": "Net"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilities": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities",
        "periodEndLabel": "As of December 31, 2022",
        "periodStartLabel": "At January 1, 2022",
        "terseLabel": "Financial liability"
       }
      }
     },
     "localname": "FinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r144",
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on exchange differences on translation of foreign operations, net of tax",
        "negatedLabel": "Exchange (losses)profits arising on translation to presentation currency",
        "negatedTerseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationNetOfTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "terseLabel": "Salary and related expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GovernmentGrants": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Government grants",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "GovernmentGrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofreimbursementofresearchexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "auth_ref": [
      "r102",
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "GrossLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r55",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss",
        "terseLabel": "Profit and loss (in Dollars)"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r26",
      "r29",
      "r30",
      "r31",
      "r50",
      "r89",
      "r137"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedLabel": "Taxes on income",
        "terseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefund": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded."
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund)",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefund",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the fair value measurement of the entity's own equity instruments. [Refer: At fair value [member]; Entity's own equity instruments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in fair value measurement, entity's own equity instruments",
        "terseLabel": "Conversion"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueMeasurementEntitysOwnEquityInstruments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill",
        "terseLabel": "Accretion of interest"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers from construction in progress, property, plant and equipment",
        "negatedLabel": "Amounts recognized as an offset from research and development expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofreimbursementofresearchexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InsuranceExpense": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from purchased insurance."
       }
      },
      "en-us": {
       "role": {
        "label": "Insurance expense",
        "terseLabel": "Insurance expenses"
       }
      }
     },
     "localname": "InsuranceExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "terseLabel": "Interest expense on lease liabilities"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestIncomeOnDeposits": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest income on deposits. [Refer: Interest income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income on deposits",
        "negatedLabel": "Interest on deposits"
       }
      }
     },
     "localname": "InterestIncomeOnDeposits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as financing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as financing activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfConvertibleInstruments": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The change in equity resulting from the issuing of convertible instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of convertible instruments",
        "terseLabel": "Conversion of financial liability"
       }
      }
     },
     "localname": "IssueOfConvertibleInstruments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Adjustments arising from translating financial operation"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "terseLabel": "Director\u2019s fees and share based compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "periodEndLabel": "As of December 31, 2022",
        "periodStartLabel": "At January 1, 2022"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LeaseReceivablesMember": {
     "auth_ref": [
      "r123",
      "r127",
      "r172"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for receivables related to leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease receivables [member]",
        "terseLabel": "Offices [Member]"
       }
      }
     },
     "localname": "LeaseReceivablesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      },
      "en-us": {
       "role": {
        "label": "Leasehold improvements [member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "auth_ref": [
      "r42",
      "r91"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 1 of fair value hierarchy [member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "Level1OfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 2 of fair value hierarchy [member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "Level2OfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 3 of fair value hierarchy [member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "Level3OfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [axis]"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MeasurementAxis": {
     "auth_ref": [
      "r62",
      "r65",
      "r90"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      }
     },
     "localname": "MeasurementAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r16",
      "r81",
      "r165"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-Current Assets:"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r17",
      "r83",
      "r165"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non- current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "Non-Current Liabilities:"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentPayables": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current trade payables and non-current other payables. [Refer: Other non-current payables; Non-current trade payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other non-current payables",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "NoncurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentPayablesToRelatedParties": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current payables to related parties",
        "terseLabel": "Related parties"
       }
      }
     },
     "localname": "NoncurrentPayablesToRelatedParties",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r107",
      "r111",
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Number of options Outstanding ending year",
        "periodStartLabel": "Number of options Outstanding at beginning of year"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "terseLabel": "Number of options Forfeited"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Granted options"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares authorised",
        "terseLabel": "Ordinary shares, authorized",
        "verboseLabel": "Authorized share capital"
       }
      }
     },
     "localname": "NumberOfSharesAuthorised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)",
        "terseLabel": "Ordinary shares, issued and outstanding"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OfficeEquipmentMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Office equipment [member]",
        "terseLabel": "Furniture and office equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OperatingLeaseIncome": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating lease income. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
       }
      },
      "en-us": {
       "role": {
        "label": "Operating lease income",
        "terseLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingLeaseIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r51",
      "r199"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]",
        "netLabel": "Ordinary Shares [Member]",
        "terseLabel": "Ordinary Share Capital",
        "verboseLabel": "Ordinary Share Capital [Member]"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable",
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherAdjustmentsForNoncashItems": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other adjustments for non-cash items",
        "terseLabel": "Non-cash expenses (in Dollars)"
       }
      }
     },
     "localname": "OtherAdjustmentsForNoncashItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r2",
      "r24",
      "r27",
      "r85"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentAssets": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current assets",
        "terseLabel": "Other current assets",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OtherCurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofotherCurrentAssetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial assets",
        "terseLabel": "Other current assets (Restricted deposits)"
       }
      }
     },
     "localname": "OtherCurrentFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "auth_ref": [
      "r12",
      "r87"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial liabilities",
        "terseLabel": "Financial liabilities at fair value"
       }
      }
     },
     "localname": "OtherCurrentFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentPayables": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other current payables",
        "terseLabel": "Other accounts payables"
       }
      }
     },
     "localname": "OtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherExpenseByNature": {
     "auth_ref": [
      "r28",
      "r151"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable": {
       "order": 4.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other expenses, by nature",
        "terseLabel": "Other",
        "verboseLabel": "Others"
       }
      }
     },
     "localname": "OtherExpenseByNature",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinancialAssets": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other financial assets",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OtherFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherGainsLosses": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other gains (losses)",
        "negatedLabel": "Other income"
       }
      }
     },
     "localname": "OtherGainsLosses",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherIncome": {
     "auth_ref": [
      "r49",
      "r151",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other income",
        "negatedLabel": "Others"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash, classified as financing activities",
        "terseLabel": "Total cash outflows"
       }
      }
     },
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherMaterialNoncashItems": {
     "auth_ref": [
      "r138",
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of material non-cash items other than depreciation and amortisation."
       }
      },
      "en-us": {
       "role": {
        "label": "Other material non-cash items",
        "terseLabel": "Total non-cash expenses (in Dollars)"
       }
      }
     },
     "localname": "OtherMaterialNoncashItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherPayables": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other payables",
        "terseLabel": "Other",
        "verboseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves",
        "terseLabel": "Foreign exchange reserve"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Par value per share",
        "terseLabel": "Ordinary share par value (in New Shekels per share)"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_PlanAssetsAtFairValue": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Plan assets, at fair value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "PlanAssetsAtFairValue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Prepayments": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered."
       }
      },
      "en-us": {
       "role": {
        "label": "Prepayments",
        "terseLabel": "Prepayment paid (in Dollars)"
       }
      }
     },
     "localname": "Prepayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, classified as financing activities",
        "terseLabel": "Loan from the Israeli Innovation Authority"
       }
      }
     },
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "iinn_TotalNonCashTransactions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "terseLabel": "Warrants exercise to equity \u2013 financial liability"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfWarrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "iinn_TotalNonCashTransactions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issue of ordinary shares",
        "terseLabel": "Conversion of convertible loans to equity"
       }
      }
     },
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      },
      "en-us": {
       "role": {
        "label": "Professional fees expense",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "ProfessionalFeesExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r23",
      "r67",
      "r77",
      "r79",
      "r139",
      "r140",
      "r165",
      "r176",
      "r178"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to owners of parent",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r116",
      "r151",
      "r152",
      "r174",
      "r175"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Loss before tax"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromContinuingOperations": {
     "auth_ref": [
      "r23",
      "r84",
      "r139",
      "r140"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from continuing operations",
        "totalLabel": "Total net loss"
       }
      }
     },
     "localname": "ProfitLossFromContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations [member]; Profit (loss) from continuing operations]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share",
        "terseLabel": "Loss for the period (in Dollars)"
       }
      }
     },
     "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r160",
      "r200"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r8",
      "r37"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of property, plant and equipment that would have been recognised had the revalued assets been carried under the cost model. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, revalued assets, at cost",
        "periodEndLabel": "Ending Balance, Cost",
        "periodStartLabel": "Beginning Balance, Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r38",
      "r161",
      "r168"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable",
      "http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r162"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedLabel": "Purchase of property, plant, and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r95",
      "r114",
      "r145",
      "r166",
      "r167",
      "r214"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails",
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r95",
      "r114",
      "r145",
      "r166",
      "r167",
      "r214"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails",
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RentalExpense": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense recognised on rental activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Rental expense",
        "terseLabel": "Office maintenance"
       }
      }
     },
     "localname": "RentalExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r156",
      "r157"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r4",
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income from government grants",
        "terseLabel": "Total amount received"
       }
      }
     },
     "localname": "RevenueFromGovernmentGrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SegmentsAxis": {
     "auth_ref": [
      "r57",
      "r96",
      "r139",
      "r159",
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "localname": "SegmentsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable",
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable",
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable_Parentheticals",
      "http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable",
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable",
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable",
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable_Parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SegmentsMember": {
     "auth_ref": [
      "r57",
      "r96",
      "r143",
      "r159",
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "localname": "SegmentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable",
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable",
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable_Parentheticals",
      "http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable",
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable",
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable",
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable_Parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharePremium": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium",
        "terseLabel": "Share capital and additional paid in capital"
       }
      }
     },
     "localname": "SharePremium",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term deposits, classified as cash equivalents",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term deposits, not classified as cash equivalents",
        "terseLabel": "Restricted Cash",
        "verboseLabel": "Deposits"
       }
      }
     },
     "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable",
      "http://www.inspiratechnologies.com/role/ScheduleofotherCurrentAssetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpense": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services."
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term employee benefits expense",
        "terseLabel": "Salary and related expenses \u2013 officers and directors"
       }
      }
     },
     "localname": "ShorttermEmployeeBenefitsExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income) at applicable tax rate",
        "terseLabel": "Theoretical tax credit at applicable statutory rate: 23%"
       }
      }
     },
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r95",
      "r114",
      "r145",
      "r166",
      "r167",
      "r214"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Top of range [member]"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails",
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Trade accounts payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "auth_ref": [
      "r154",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current receivables due from related parties. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current receivables due from related parties",
        "terseLabel": "Loan from the IIA"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivablesDueFromRelatedParties",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherPayables": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other payables",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "TradeAndOtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TravelExpense": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from travel."
       }
      },
      "en-us": {
       "role": {
        "label": "Travel expense",
        "terseLabel": "Travel abroad"
       }
      }
     },
     "localname": "TravelExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r119",
      "r121",
      "r122",
      "r146",
      "r147",
      "r148",
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_VehiclesMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Vehicles [member]",
        "terseLabel": "Vehicles [Member]"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WagesAndSalaries": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable": {
       "order": 2.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Wages and salaries",
        "terseLabel": "Salary and related expenses"
       }
      }
     },
     "localname": "WagesAndSalaries",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WarrantLiability": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Warrant liability",
        "terseLabel": "Tradable warrants"
       }
      }
     },
     "localname": "WarrantLiability",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement",
        "terseLabel": "Weighted average Exercise price NIS Exercisable options"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement",
        "terseLabel": "Weighted average Exercise price NIS Granted"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r107",
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Weighted average Exercise price NIS Outstanding ending year",
        "periodStartLabel": "Weighted average Exercise price NIS Outstanding at beginning of year"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options",
        "terseLabel": "Contractual life"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share",
        "terseLabel": "Weighted average number of ordinary shares (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_AUDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUDMember",
        "terseLabel": "AUD [Member]"
       }
      }
     },
     "localname": "AUDMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_AccumulatedDepreciation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation",
        "periodEndLabel": "Ending Balance, Accumulated depreciation",
        "periodStartLabel": "Beginning Balance, Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciation",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_AccumulatedDepreciationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation Abstract",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_Addition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Addition",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "Addition",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_AdditionalOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional offering costs.",
        "label": "Additional Offering Costs",
        "terseLabel": "Additional offering costs"
       }
      }
     },
     "localname": "AdditionalOfferingCosts",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_AdditionalOrdinaryShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional ordinary shares.",
        "label": "Additional Ordinary Share",
        "terseLabel": "Additional ordinary shares (in Shares)"
       }
      }
     },
     "localname": "AdditionalOrdinaryShare",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_AdditionalOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional ordinary shares.",
        "label": "Additional Ordinary Shares",
        "terseLabel": "Additional ordinary shares"
       }
      }
     },
     "localname": "AdditionalOrdinaryShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_AdjustmentsArisingFromTranslatingFinancialOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments Arising From Translating Financial Operations",
        "terseLabel": "Adjustments arising from translating financial operation"
       }
      }
     },
     "localname": "AdjustmentsArisingFromTranslatingFinancialOperations",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_AdvisersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisers Member",
        "terseLabel": "Advisers [Member]"
       }
      }
     },
     "localname": "AdvisersMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_AggregateAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of ordinary shares",
        "label": "Aggregate Amount",
        "terseLabel": "Aggregate amount ordinary Shares"
       }
      }
     },
     "localname": "AggregateAmount",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_AggregateOfOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate ordinary shares.",
        "label": "Aggregate Of Ordinary Shares",
        "terseLabel": "Aggregate of ordinary shares"
       }
      }
     },
     "localname": "AggregateOfOrdinaryShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_AggregateProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate proceeds.",
        "label": "Aggregate Proceeds",
        "terseLabel": "Aggregate proceeds"
       }
      }
     },
     "localname": "AggregateProceeds",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_AggregateProceedsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Proceeds Amount",
        "terseLabel": "Aggregate proceeds amount"
       }
      }
     },
     "localname": "AggregateProceedsAmount",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_AggregateProceedsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate proceeds received.",
        "label": "Aggregate Proceeds Received",
        "terseLabel": "Aggregate proceeds received (in Dollars)"
       }
      }
     },
     "localname": "AggregateProceedsReceived",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_AnnualDepreciationRateInPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual depreciation rate in percentage.",
        "label": "Annual Depreciation Rate In Percentage",
        "terseLabel": "Annual depreciation rate in percentage"
       }
      }
     },
     "localname": "AnnualDepreciationRateInPercentage",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "iinn_AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anti-dilutive potentially dilutive securities after the Reverse Stock Splits.",
        "label": "Antidilutive Potentially Dilutive Securities After The Reverse Stock Splits",
        "terseLabel": "Weighted average number of Ordinary Shares"
       }
      }
     },
     "localname": "AntidilutivePotentiallyDilutiveSecuritiesAfterTheReverseStockSplits",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_AssetsAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Abstract0",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract0",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_AuthorizedOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorized Ordinary Shares",
        "terseLabel": "Ordinary shares, authorized"
       }
      }
     },
     "localname": "AuthorizedOrdinaryShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_AuthorizedShareCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of authorized share capital.",
        "label": "Authorized Share Capital",
        "terseLabel": "Authorized share capital (in New Shekels)"
       }
      }
     },
     "localname": "AuthorizedShareCapital",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_BalanceAtBeginning": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance At Beginning",
        "terseLabel": "Balance as of December 31, 2020"
       }
      }
     },
     "localname": "BalanceAtBeginning",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_BalanceAtEnding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance At Ending",
        "terseLabel": "Balance as of December,31 2021"
       }
      }
     },
     "localname": "BalanceAtEnding",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_BalancesWithRelatedPartiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balances with related parties.",
        "label": "Balances With Related Parties Table Text Block",
        "terseLabel": "Schedule of balances with related parties"
       }
      }
     },
     "localname": "BalancesWithRelatedPartiesTableTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/RelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_Between1And3YearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Between1 And3 Years Member",
        "terseLabel": "Between 1 and 3 years [Member]"
       }
      }
     },
     "localname": "Between1And3YearsMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_BoardOfDirectorsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board of directors description.",
        "label": "Board Of Directors Description",
        "terseLabel": "Board of directors, description"
       }
      }
     },
     "localname": "BoardOfDirectorsDescription",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_BrokersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brokers Member",
        "terseLabel": "Brokers [Member]"
       }
      }
     },
     "localname": "BrokersMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_CapitalGainTax": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital gain tax.",
        "label": "Capital Gain Tax",
        "terseLabel": "Capital gain tax"
       }
      }
     },
     "localname": "CapitalGainTax",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "iinn_CarriedForwardTaxLosse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carried forward tax losses.",
        "label": "Carried Forward Tax Losse",
        "terseLabel": "Carried forward tax losses"
       }
      }
     },
     "localname": "CarriedForwardTaxLosse",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_CashAndNoncash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and non-cash.",
        "label": "Cash And Noncash",
        "terseLabel": "Cash and non-cash (in Dollars)"
       }
      }
     },
     "localname": "CashAndNoncash",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ChangeInFairValueOfFinancialLiabilitiesAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of change in fair value of  financial liability at fair value.",
        "label": "Change In Fair Value Of Financial Liabilities At Fair Value",
        "terseLabel": "Revaluation of financial liabilities accounted at fair value"
       }
      }
     },
     "localname": "ChangeInFairValueOfFinancialLiabilitiesAtFairValue",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ChangesDuringThePeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes During The Period Abstract",
        "terseLabel": "Changes during the period:"
       }
      }
     },
     "localname": "ChangesDuringThePeriodAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ChangesInOperatingAssetsAndLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes In Operating Assets And Liability Abstract",
        "terseLabel": "Changes in operating assets and liability"
       }
      }
     },
     "localname": "ChangesInOperatingAssetsAndLiabilityAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ComputersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers Member",
        "terseLabel": "Computers [Member]"
       }
      }
     },
     "localname": "ComputersMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_ContractualLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual life.",
        "label": "Contractual Life",
        "terseLabel": "Contractual life"
       }
      }
     },
     "localname": "ContractualLife",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "iinn_ConversionOfConvertibleLoanToShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of conversion of convertible loan to shares.",
        "label": "Conversion Of Convertible Loan To Shares",
        "terseLabel": "Conversion of convertible loan to shares"
       }
      }
     },
     "localname": "ConversionOfConvertibleLoanToShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ConversionOfConvertibleLoanToSharesinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares of conversion of convertible loan to shares.",
        "label": "Conversion Of Convertible Loan To Sharesin Shares",
        "terseLabel": "Conversion of convertible loan to shares (in Shares)"
       }
      }
     },
     "localname": "ConversionOfConvertibleLoanToSharesinShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_ConversionOfFinancialLiabilityinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity resulting from the issuing of conversion of financial liability.",
        "label": "Conversion Of Financial Liabilityin Shares",
        "terseLabel": "Conversion of financial liability (in Shares)"
       }
      }
     },
     "localname": "ConversionOfFinancialLiabilityinShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_ConversionToShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion to shares.",
        "label": "Conversion To Shares",
        "terseLabel": "Conversion to ordinary shares (in Shares)"
       }
      }
     },
     "localname": "ConversionToShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_ConvertibleLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Loan Member",
        "terseLabel": "Convertible loan [Member]"
       }
      }
     },
     "localname": "ConvertibleLoanMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_CostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Abstract",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "CostAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_DeductingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deducting fees.",
        "label": "Deducting Fees",
        "terseLabel": "Deducting fees"
       }
      }
     },
     "localname": "DeductingFees",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_DeferredTaxAssetS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset.",
        "label": "Deferred Tax Asset S",
        "terseLabel": "No deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetS",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_Deposit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deposits.",
        "label": "Deposit",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "Deposit",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofforeigncurrencydenominatedmonetaryliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_DepositValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deposit liabilities from customers held by the entity.",
        "label": "Deposit Value",
        "terseLabel": "Deposit value"
       }
      }
     },
     "localname": "DepositValue",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_DepreciationExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable": {
       "order": 5.0,
       "parentTag": "iinn_ResearchDevelopmentExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation Expenses",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_Depreciations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation.",
        "label": "Depreciations",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciations",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_DescriptionOfLeaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of lease agreement.",
        "label": "Description Of Lease Agreement",
        "terseLabel": "Lease agreement description"
       }
      }
     },
     "localname": "DescriptionOfLeaseAgreement",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_DevelopmentEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Equipment Member",
        "terseLabel": "Development equipment [Member]"
       }
      }
     },
     "localname": "DevelopmentEquipmentMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable",
      "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_DirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors Member",
        "terseLabel": "Directors [Member]"
       }
      }
     },
     "localname": "DirectorsMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable",
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Critical Accounting Estimates and Judgements [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfDepositsFromBanksTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Deposits [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfDepositsFromBanksTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfFinanceIncomeCostTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial (Income) and Expenses [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeCostTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfFinancialInstrumentsTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Risk Management [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of General and Administrative Expense [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfGeneralHedgeAccountingTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfGeneralHedgeAccountingTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfGovernmentGrantsTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability in Respect of Government Grants [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfGovernmentGrantsTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfIncomeTaxTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on income [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Defict) [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfLeasesTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfLeasesTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfOtherNonCurrentAssetsTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Other Current Assets Text Block [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfOtherNonCurrentAssetsTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Property Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfRelatedPartyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantAccountingPoliciesTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at fair value [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DisclosureOfTradeAndOtherPayablesTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesTextBlockAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees And Directors Member",
        "terseLabel": "Employees and directors [Member]"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees Member",
        "terseLabel": "Officers [Member]"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_EmployeesSalariesAndRelatedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees, salaries and related liabilities.",
        "label": "Employees Salaries And Related Liabilities",
        "terseLabel": "Employees salaries and related liabilities"
       }
      }
     },
     "localname": "EmployeesSalariesAndRelatedLiabilities",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_EquityDefictDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Defict) (Details) [Line Items]"
       }
      }
     },
     "localname": "EquityDefictDetailsLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_EquityDefictDetailsScheduleoflosspershareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Loss Per Share [Abstract]"
       }
      }
     },
     "localname": "EquityDefictDetailsScheduleoflosspershareLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Defict Details Scheduleoflosspershare Parentheticals Line Items",
        "terseLabel": "Schedule of Loss Per Share [Abstract]"
       }
      }
     },
     "localname": "EquityDefictDetailsScheduleoflosspershareParentheticalsLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable_Parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_EquityDefictDetailsScheduleoflosspershareParentheticalsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Defict) (Details) - Schedule of loss per share (Parentheticals) [Table]"
       }
      }
     },
     "localname": "EquityDefictDetailsScheduleoflosspershareParentheticalsTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable_Parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_EquityDefictDetailsScheduleoflosspershareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Defict) (Details) - Schedule of loss per share [Table]"
       }
      }
     },
     "localname": "EquityDefictDetailsScheduleoflosspershareTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoflosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_EquityDefictDetailsScheduleofsharecapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Capital [Abstract]"
       }
      }
     },
     "localname": "EquityDefictDetailsScheduleofsharecapitalLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_EquityDefictDetailsScheduleofsharecapitalTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Defict) (Details) - Schedule of share capital [Table]"
       }
      }
     },
     "localname": "EquityDefictDetailsScheduleofsharecapitalTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsharecapitalTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_EquityDefictDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Defict) (Details) [Table]"
       }
      }
     },
     "localname": "EquityDefictDetailsTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ExchangeAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of exchange amount.",
        "label": "Exchange Amount",
        "terseLabel": "Exchange amount"
       }
      }
     },
     "localname": "ExchangeAmount",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_ExchangeRateDeferenceAccumulatedDepreciation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate deference, Accumulated depreciation.",
        "label": "Exchange Rate Deference Accumulated Depreciation",
        "terseLabel": "Exchange rate deference, Accumulated depreciation"
       }
      }
     },
     "localname": "ExchangeRateDeferenceAccumulatedDepreciation",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ExchangeRateDeferenceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate deference, Cost.",
        "label": "Exchange Rate Deference Cost",
        "terseLabel": "Exchange rate deference, Cost"
       }
      }
     },
     "localname": "ExchangeRateDeferenceCost",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ExchangeRateDifference": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate differences.",
        "label": "Exchange Rate Difference",
        "terseLabel": "Exchange rate differences"
       }
      }
     },
     "localname": "ExchangeRateDifference",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ExchangeRateDifferences": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange Rate Differences",
        "terseLabel": "Exchange rate differences"
       }
      }
     },
     "localname": "ExchangeRateDifferences",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofreimbursementofresearchexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ExercisableOptionsNumberOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable Options Number Of Options",
        "terseLabel": "Number of options Exercisable options (in Shares)"
       }
      }
     },
     "localname": "ExercisableOptionsNumberOfOptions",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_ExercisableOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable Ordinary Shares",
        "terseLabel": "Exercisable ordinary shares"
       }
      }
     },
     "localname": "ExercisableOrdinaryShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_ExercisableRSUs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable RSUs",
        "terseLabel": "Exercisable RSUs"
       }
      }
     },
     "localname": "ExercisableRSUs",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price",
        "terseLabel": "Exercise price per share"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "iinn_ExercisedNumberOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised Number Of Options",
        "terseLabel": "Number of options Exercised (in Shares)"
       }
      }
     },
     "localname": "ExercisedNumberOfOptions",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_ExercisedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised Weighted Average Exercise Price",
        "terseLabel": "Weighted average Exercise price NIS Exercised"
       }
      }
     },
     "localname": "ExercisedWeightedAverageExercisePrice",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "iinn_ExpectedTermOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of warrant.",
        "label": "Expected Term Of Warrants",
        "terseLabel": "Expected term of warrant"
       }
      }
     },
     "localname": "ExpectedTermOfWarrants",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "iinn_ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]",
        "label": "Expense From Sharebased Payment Transactions With Employeesand Directors",
        "terseLabel": "Expenses to employees (in Dollars)"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployeesandDirectors",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ExpensesDeductedFromEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses deducted from equity.",
        "label": "Expenses Deducted From Equity",
        "terseLabel": "Expenses deducted from equity (in Dollars)"
       }
      }
     },
     "localname": "ExpensesDeductedFromEquity",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_FairValueAssumptionsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value assumptions description.",
        "label": "Fair Value Assumptions Description",
        "terseLabel": "Description of fair value assumptions"
       }
      }
     },
     "localname": "FairValueAssumptionsDescription",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FairValueMeasurementDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement (Details) [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasurementDetailsLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of movements in level 2 liability [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement (Details) - Schedule of movements in level 2 liability [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementDetailsScheduleofmovementsinlevel2liabilityTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FairValueMeasurementDetailsScheduleofwarrantsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement (Details) - Schedule of warrants [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasurementDetailsScheduleofwarrantsLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FairValueMeasurementDetailsScheduleofwarrantsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement (Details) - Schedule of warrants [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementDetailsScheduleofwarrantsTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FairValueMeasurementDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement (Details) [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementDetailsTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FairValueOfTheWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the warrants.",
        "label": "Fair Value Of The Warrant",
        "terseLabel": "Fair value of the warrants"
       }
      }
     },
     "localname": "FairValueOfTheWarrant",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_FinacialLiabilitiesatFairValueDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value (Details) [Line Items]"
       }
      }
     },
     "localname": "FinacialLiabilitiesatFairValueDetailsLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value [Line Items]"
       }
      }
     },
     "localname": "FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value (Details) - Schedule of finacial liabilities at fair value [Table]"
       }
      }
     },
     "localname": "FinacialLiabilitiesatFairValueDetailsScheduleoffinacialliabilitiesatfairvalueTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinacialLiabilitiesatFairValueDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value (Details) [Table]"
       }
      }
     },
     "localname": "FinacialLiabilitiesatFairValueDetailsTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinanceExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance expense.",
        "label": "Finance Expense",
        "terseLabel": "Finance expense"
       }
      }
     },
     "localname": "FinanceExpense",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_FinanceExpenseInRespectOfLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Expense In Respect Of Lease Liability",
        "terseLabel": "Finance expense in respect of lease liability"
       }
      }
     },
     "localname": "FinanceExpenseInRespectOfLeaseLiability",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_FinanceExpensesReceivedClassifiedAsOperatingActivitiy": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial expenses are expenses associated with any financing the company incurs, including interest from debt. Tax expenses are reported below the profit before tax line and are the expenses owed to authorities as a result of profits generated in the accounting period.",
        "label": "Finance Expenses Received Classified As Operating Activitiy",
        "terseLabel": "Financial expenses"
       }
      }
     },
     "localname": "FinanceExpensesReceivedClassifiedAsOperatingActivitiy",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_FinancialDerivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Derivative Member",
        "terseLabel": "Financial Liability [Member]"
       }
      }
     },
     "localname": "FinancialDerivativeMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_FinancialDerivativesFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial derivatives fair value.",
        "label": "Financial Derivatives Fair Value",
        "terseLabel": "Financial derivatives fair value"
       }
      }
     },
     "localname": "FinancialDerivativesFairValue",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_FinancialExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Expense",
        "terseLabel": "Exchange rate differences"
       }
      }
     },
     "localname": "FinancialExpense",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_FinancialExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial expenses.",
        "label": "Financial Expenses",
        "negatedLabel": "Financial expenses"
       }
      }
     },
     "localname": "FinancialExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_FinancialExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Expenses Member",
        "terseLabel": "Financial Expenses [Member]"
       }
      }
     },
     "localname": "FinancialExpensesMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_FinancialIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Income Member",
        "terseLabel": "Financial income [Member]"
       }
      }
     },
     "localname": "FinancialIncomeMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial (Income) and Expenses (Details) - Schedule of financial expenses [Line Items]"
       }
      }
     },
     "localname": "FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial (Income) and Expenses (Details) - Schedule of financial expenses [Table]"
       }
      }
     },
     "localname": "FinancialIncomeandExpensesDetailsScheduleoffinancialexpensesTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial (Income) and Expenses (Details) - Schedule of financial income [Line Items]"
       }
      }
     },
     "localname": "FinancialIncomeandExpensesDetailsScheduleoffinancialincomeLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial (Income) and Expenses (Details) - Schedule of financial income [Table]"
       }
      }
     },
     "localname": "FinancialIncomeandExpensesDetailsScheduleoffinancialincomeTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities [Line Items]"
       }
      }
     },
     "localname": "FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Risk Management (Details) - Schedule of cash flows of financial liabilities [Table]"
       }
      }
     },
     "localname": "FinancialInstrumentsandRiskManagementDetailsScheduleofcashflowsoffinancialliabilitiesTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Risk Management (Details) - Schedule of financial assets represents the maximum credit exposure [Line Items]"
       }
      }
     },
     "localname": "FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Risk Management (Details) - Schedule of financial assets represents the maximum credit exposure [Table]"
       }
      }
     },
     "localname": "FinancialInstrumentsandRiskManagementDetailsScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialassetsrepresentsthemaximumcreditexposureTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis [Line Items]"
       }
      }
     },
     "localname": "FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Risk Management (Details) - Schedule of sensitivity analysis [Table]"
       }
      }
     },
     "localname": "FinancialInstrumentsandRiskManagementDetailsScheduleofsensitivityanalysisTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_FinancialLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liability Member",
        "terseLabel": "Financial liability [Member]"
       }
      }
     },
     "localname": "FinancialLiabilityMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_FinancialLiabilityToPay": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial liability to pay.",
        "label": "Financial Liability To Pay",
        "terseLabel": "Financial liability to pay"
       }
      }
     },
     "localname": "FinancialLiabilityToPay",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "iinn_ForeignCurrencyTransactionLossNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transaction Loss Net",
        "terseLabel": "Foreign currency transaction income",
        "verboseLabel": "Foreign currency transaction loss, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionLossNet",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_Forfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forfeited.",
        "label": "Forfeited",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "Forfeited",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_ForfeitedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited Weighted Average Exercise Price",
        "terseLabel": "Weighted average Exercise price NIS Forfeited"
       }
      }
     },
     "localname": "ForfeitedWeightedAverageExercisePrice",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "iinn_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture And Office Equipment Member",
        "terseLabel": "Furniture and office equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_GainslossesRecognizedInProfitLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gainslosses Recognized In Profit Loss",
        "terseLabel": "Gains (losses) recognized in profit or loss"
       }
      }
     },
     "localname": "GainslossesRecognizedInProfitLoss",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_GeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative expenses.",
        "label": "General And Administrative Expenses",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of General and Administrative Expenses [Abstract]"
       }
      }
     },
     "localname": "GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses (Details) - Schedule of general and administrative expenses [Table]"
       }
      }
     },
     "localname": "GeneralandAdministrativeExpensesDetailsScheduleofgeneralandadministrativeexpensesTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_GrantOptionDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant option description.",
        "label": "Grant Option Description",
        "terseLabel": "Grant option, description"
       }
      }
     },
     "localname": "GrantOptionDescription",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_GrantTotal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Total",
        "terseLabel": "Grant total"
       }
      }
     },
     "localname": "GrantTotal",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_GrantTotalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Total Shares",
        "terseLabel": "Grant total share"
       }
      }
     },
     "localname": "GrantTotalShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_Granted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "Granted",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_GrantedNumberOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted Number Of Options",
        "terseLabel": "Number of options Granted (in Shares)"
       }
      }
     },
     "localname": "GrantedNumberOfOptions",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_GrantedTotalOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted Total Option",
        "terseLabel": "Grand total option"
       }
      }
     },
     "localname": "GrantedTotalOption",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_GrossProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds.",
        "label": "Gross Proceeds",
        "terseLabel": "Gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "GrossProceeds",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_IIAParticipation": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable": {
       "order": 6.0,
       "parentTag": "iinn_ResearchDevelopmentExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IIAParticipation",
        "terseLabel": "IIA participation"
       }
      }
     },
     "localname": "IIAParticipation",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_InitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of initial public offering.",
        "label": "Initial Public Offering",
        "terseLabel": "Initial Public Offering (\u201cIPO\u201d)"
       }
      }
     },
     "localname": "InitialPublicOffering",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_InitialPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Public Offering Member",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "InitialPublicOfferingMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails",
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_Institutions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Institution amount.",
        "label": "Institutions",
        "terseLabel": "Institutions"
       }
      }
     },
     "localname": "Institutions",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofotherCurrentAssetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_InvestmentNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Name Axis",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "InvestmentNameAxis",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_InvestmentNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "InvestmentName [Domain]"
       }
      }
     },
     "localname": "InvestmentNameDomain",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_InvestorsExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investors Exercise",
        "terseLabel": "Total proceeds"
       }
      }
     },
     "localname": "InvestorsExercise",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_InvestorsExercisedTradableWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investors exercised tradable warrants.",
        "label": "Investors Exercised Tradable Warrants",
        "terseLabel": "Investors exercised tradable warrants (in Shares)"
       }
      }
     },
     "localname": "InvestorsExercisedTradableWarrants",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_InvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investors Member",
        "terseLabel": "Investors [Member]"
       }
      }
     },
     "localname": "InvestorsMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_LeaseLiabilityAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability Amount",
        "terseLabel": "Lease liability amount"
       }
      }
     },
     "localname": "LeaseLiabilityAmount",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_LeaseholdImprovementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvement Member",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_LeasesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Line Items]"
       }
      }
     },
     "localname": "LeasesDetailsLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_LeasesDetailsScheduleofleaseliabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Liabilities [Abstract]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofleaseliabilitiesLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_LeasesDetailsScheduleofleaseliabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of lease liabilities [Table]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofleaseliabilitiesTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_LeasesDetailsScheduleofprofitorlossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of profit or loss [Abstract]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofprofitorlossLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_LeasesDetailsScheduleofprofitorlossTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of profit or loss [Table]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofprofitorlossTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_LeasesDetailsScheduleofrightofuseassetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of right-of-use assets [Line Items]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofrightofuseassetsLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_LeasesDetailsScheduleofrightofuseassetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of right-of-use assets [Table]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofrightofuseassetsTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_LeasesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "localname": "LeasesDetailsTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_LoanFromTheIsraeliInnovationAuthority": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of loan from the israeli innovation authority.",
        "label": "Loan From The Israeli Innovation Authority",
        "terseLabel": "Loan from the Israeli Innovation Authority"
       }
      }
     },
     "localname": "LoanFromTheIsraeliInnovationAuthority",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_LossBeforeTaxation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss before taxation.",
        "label": "Loss Before Taxation",
        "terseLabel": "Loss before taxation"
       }
      }
     },
     "localname": "LossBeforeTaxation",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_MaterialsAndRelatedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable": {
       "order": 4.0,
       "parentTag": "iinn_ResearchDevelopmentExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Materials And Related Expenses",
        "terseLabel": "Materials and related expenses"
       }
      }
     },
     "localname": "MaterialsAndRelatedExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_MoreThan3YearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "More Than3 Years Member",
        "terseLabel": "More than 3 years [Member]"
       }
      }
     },
     "localname": "MoreThan3YearsMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature Of Transaction Compensation For Directors Not Employed By The Company",
        "terseLabel": "Nature of transaction, Compensation for directors"
       }
      }
     },
     "localname": "NatureOfTransactionCompensationForDirectorsNotEmployedByTheCompany",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_NatureOfTransactionSalariesAndRelated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature Of Transaction Salaries And Related",
        "terseLabel": "Nature of transaction, Salaries and related"
       }
      }
     },
     "localname": "NatureOfTransactionSalariesAndRelated",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_NetBookValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Book Value",
        "terseLabel": "Ending Balance, Net book value"
       }
      }
     },
     "localname": "NetBookValue",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_NetBookValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Book Value Abstract",
        "terseLabel": "Net book value:"
       }
      }
     },
     "localname": "NetBookValueAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_NonallowableExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-allowable expenses.",
        "label": "Nonallowable Expenses",
        "terseLabel": "Non-allowable expenses"
       }
      }
     },
     "localname": "NonallowableExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_NondirectCashExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-direct cash expenses.",
        "label": "Nondirect Cash Expenses",
        "terseLabel": "Non-direct cash expenses (in Dollars)"
       }
      }
     },
     "localname": "NondirectCashExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_NontradableShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-tradable shares.",
        "label": "Nontradable Shares",
        "terseLabel": "Non-tradable shares"
       }
      }
     },
     "localname": "NontradableShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_NontradableSharesOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-tradable shares options.",
        "label": "Nontradable Shares Options",
        "terseLabel": "Non-tradable shares options, description"
       }
      }
     },
     "localname": "NontradableSharesOptions",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_NontradableWarrantFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-tradable warrants fair value.",
        "label": "Nontradable Warrant Fair Value",
        "terseLabel": "Non-tradable Warrants",
        "verboseLabel": "Non-tradable warrants fair value"
       }
      }
     },
     "localname": "NontradableWarrantFairValue",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_NontradableWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-tradable warrants.",
        "label": "Nontradable Warrants",
        "terseLabel": "Non-tradable warrants"
       }
      }
     },
     "localname": "NontradableWarrants",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_NontradableWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontradable Warrants Member",
        "terseLabel": "Non-tradable warrants [Member]"
       }
      }
     },
     "localname": "NontradableWarrantsMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_NontradableWarrantsOfSAFEAndConvertibleLoanInvestors": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-tradable warrants of SAFE and Convertible Loan investors.",
        "label": "Nontradable Warrants Of SAFEAnd Convertible Loan Investors",
        "terseLabel": "Non-tradable warrants of SAFE and Convertible Loan investors"
       }
      }
     },
     "localname": "NontradableWarrantsOfSAFEAndConvertibleLoanInvestors",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_NontradableWarrantsSAFEAndCLAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontradable Warrants SAFEAnd CLAMember",
        "terseLabel": "Non-tradable warrants, SAFE and CLA [Member]"
       }
      }
     },
     "localname": "NontradableWarrantsSAFEAndCLAMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Options Reclassified To Employees And Directorsin Shares",
        "terseLabel": "Number of options Reclassified to employees and directors (in Shares)"
       }
      }
     },
     "localname": "NumberOfOptionsReclassifiedToEmployeesAndDirectorsinShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_NumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares.",
        "label": "Number Of Shares",
        "terseLabel": "Number of shares (in Shares)"
       }
      }
     },
     "localname": "NumberOfShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_OptionsEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Equity",
        "terseLabel": "Options equity percentage"
       }
      }
     },
     "localname": "OptionsEquity",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "iinn_OptionsExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of options exercise.",
        "label": "Options Exercise",
        "terseLabel": "Share based compensation to exercise"
       }
      }
     },
     "localname": "OptionsExercise",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_OptionsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options policy text block",
        "label": "Options Policy Text Block",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "OptionsPolicyTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_OrdinaryShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares issued.",
        "label": "Ordinary Share",
        "terseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "OrdinaryShare",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_OrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ordinary shares.",
        "label": "Ordinary Shares",
        "terseLabel": "Ordinary shares (in Shares)",
        "verboseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "OrdinaryShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails",
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_OrdinarySharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary Shares issued.",
        "label": "Ordinary Shares Issued",
        "terseLabel": "Ordinary Shares issued (in Shares)"
       }
      }
     },
     "localname": "OrdinarySharesIssued",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_OtherResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable": {
       "order": 7.0,
       "parentTag": "iinn_ResearchDevelopmentExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OtherResearchAndDevelopmentExpense.",
        "label": "Other Research And Development Expenses",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_OthersCurrentAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Others.",
        "label": "Others Current Assets",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OthersCurrentAssets",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofotherCurrentAssetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_OutstandingAtBeginningOfYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding at beginning of year.",
        "label": "Outstanding At Beginning Of Years",
        "periodEndLabel": "Outstanding as of December 31, 2022",
        "periodStartLabel": "Outstanding at beginning of year"
       }
      }
     },
     "localname": "OutstandingAtBeginningOfYears",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_OverallotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Overallotment Option Member",
        "terseLabel": "Overallotment Option [Member]"
       }
      }
     },
     "localname": "OverallotmentOptionMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_PaidFeesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid Fees Amount",
        "terseLabel": "Paid fees, amount"
       }
      }
     },
     "localname": "PaidFeesAmount",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ParValueCancellations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Par value cancellation.",
        "label": "Par Value Cancellations",
        "terseLabel": "Par value cancellation"
       }
      }
     },
     "localname": "ParValueCancellations",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_PayRoyaltiesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay royalties, percentage.",
        "label": "Pay Royalties Percentage",
        "terseLabel": "Royalties, percentage"
       }
      }
     },
     "localname": "PayRoyaltiesPercentage",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "iinn_PaymentOfDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of deposit.",
        "label": "Payment Of Deposit",
        "terseLabel": "Payment of deposit"
       }
      }
     },
     "localname": "PaymentOfDeposit",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_PercentageOfPaidFees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of paid fees.",
        "label": "Percentage Of Paid Fees",
        "terseLabel": "Percentage of paid fees"
       }
      }
     },
     "localname": "PercentageOfPaidFees",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "iinn_PoundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pound Member",
        "terseLabel": "GB Pound [Member]"
       }
      }
     },
     "localname": "PoundMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_PrincipalPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal Payment",
        "terseLabel": "Payment"
       }
      }
     },
     "localname": "PrincipalPayment",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ProceedFromIssuanceInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceed From Issuance Initial Public Offering",
        "terseLabel": "Initial public offering price"
       }
      }
     },
     "localname": "ProceedFromIssuanceInitialPublicOffering",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) - Schedule of property and equipment, net [Line Items]"
       }
      }
     },
     "localname": "PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) - Schedule of property and equipment, net [Table]"
       }
      }
     },
     "localname": "PropertyandEquipmentNetDetailsScheduleofpropertyandequipmentnetTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ProvidersAndAdvisersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Providers And Advisers Member",
        "terseLabel": "Providers and advisers [Member]"
       }
      }
     },
     "localname": "ProvidersAndAdvisersMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_PublicOfferingPriceDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering price, description.",
        "label": "Public Offering Price Description",
        "terseLabel": "Public offering price, description"
       }
      }
     },
     "localname": "PublicOfferingPriceDescription",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_RSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSUMember",
        "terseLabel": "RSU [Member]"
       }
      }
     },
     "localname": "RSUMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_ReceiptOfIPOFunds": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receipt of IPO funds.",
        "label": "Receipt Of IPOFunds",
        "negatedLabel": "Receipt of IPO funds"
       }
      }
     },
     "localname": "ReceiptOfIPOFunds",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receipt Of Simple Agreements For Future Equity SAFEAnd Convertible Loan",
        "terseLabel": "Receipt of simple agreements for future equity (SAFE) and convertible loan"
       }
      }
     },
     "localname": "ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoan",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ReceiptOfWarrantsExerciseFundsNetFromFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receipt of warrants exercise funds, net from fees.",
        "label": "Receipt Of Warrants Exercise Funds Net From Fees",
        "terseLabel": "Receipt of warrants exercise funds, net from fees"
       }
      }
     },
     "localname": "ReceiptOfWarrantsExerciseFundsNetFromFees",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassified To Employees And Directors Weighted Average Exercise Price",
        "terseLabel": "Weighted average Exercise price NIS Reclassified to employees and directors"
       }
      }
     },
     "localname": "ReclassifiedToEmployeesAndDirectorsWeightedAverageExercisePrice",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of balances with related parties [Abstract]"
       }
      }
     },
     "localname": "RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties (Details) - Schedule of balances with related parties [Table]"
       }
      }
     },
     "localname": "RelatedPartiesDetailsScheduleofbalanceswithrelatedpartiesTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofbalanceswithrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of shareholders and other related parties\u2019 benefits [Abstract]"
       }
      }
     },
     "localname": "RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties (Details) - Schedule of shareholders and other related parties\u2019 benefits [Table]"
       }
      }
     },
     "localname": "RelatedPartiesDetailsScheduleofshareholdersandotherrelatedpartiesbenefitsTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses.",
        "label": "Research And Development Expenses",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ResearchDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Development Expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ResearchDevelopmentExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of research and development expenses [Abstract]"
       }
      }
     },
     "localname": "ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses (Details) - Schedule of research and development expenses [Table]"
       }
      }
     },
     "localname": "ResearchandDevelopmentExpensesDetailsScheduleofresearchanddevelopmentexpensesTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_RestrictedShareUnitsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Share Units policy text block",
        "label": "Restricted Share Units Policy Text Block",
        "terseLabel": "Restricted Share Units (\u201cRSUs\u201d)"
       }
      }
     },
     "localname": "RestrictedShareUnitsPolicyTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_RestrictedStockUnitEmployeesDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock unit employees description.",
        "label": "Restricted Stock Unit Employees Description",
        "terseLabel": "Restricted Stock Unit Employees Description"
       }
      }
     },
     "localname": "RestrictedStockUnitEmployeesDescription",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_RestrictedStockUnitVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock unit vested.",
        "label": "Restricted Stock Unit Vested",
        "terseLabel": "Vested as of December 31, 2022",
        "verboseLabel": "Restricted stock unit vested"
       }
      }
     },
     "localname": "RestrictedStockUnitVested",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_RevaluationOfLiabilityInRespectOfGovernmentGrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revaluation Of Liability In Respect Of Government Grants",
        "terseLabel": "Revaluation of liability in respect of government grants"
       }
      }
     },
     "localname": "RevaluationOfLiabilityInRespectOfGovernmentGrants",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_RevaluationOfLoanFromTheIsraeliInnovationAuthority": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revaluation of loan from the Israeli Innovation Authority.",
        "label": "Revaluation Of Loan From The Israeli Innovation Authority",
        "terseLabel": "Change in connection to loan from the Israeli Innovation Authority"
       }
      }
     },
     "localname": "RevaluationOfLoanFromTheIsraeliInnovationAuthority",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_RevaluationOfTheLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revaluation Of The Liability",
        "terseLabel": "Revaluation of the liability"
       }
      }
     },
     "localname": "RevaluationOfTheLiability",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofreimbursementofresearchexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_SAFEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SAFEMember",
        "terseLabel": "SAFE [Member]"
       }
      }
     },
     "localname": "SAFEMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_SalaryAndRelatedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable": {
       "order": 2.0,
       "parentTag": "iinn_ResearchDevelopmentExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Salary And Related Expenses",
        "terseLabel": "Salary and related expenses"
       }
      }
     },
     "localname": "SalaryAndRelatedExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_SalesAndMarketingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and marketing expenses.",
        "label": "Sales And Marketing Expenses",
        "terseLabel": "Sales and marketing expenses"
       }
      }
     },
     "localname": "SalesAndMarketingExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_SalesAndMarketingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and Marketing Expenses [Abstract]"
       }
      }
     },
     "localname": "SalesAndMarketingExpensesAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_SalesAndMarketingExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and Marketing Expenses.",
        "label": "Sales And Marketing Expenses Text Block",
        "terseLabel": "SALES AND MARKETING EXPENSES:"
       }
      }
     },
     "localname": "SalesAndMarketingExpensesTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SalesandMarketingExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Sales and Marketing Expenses [Abstract]"
       }
      }
     },
     "localname": "SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and Marketing Expenses (Details) - Schedule of sales and Marketing Expenses [Table]"
       }
      }
     },
     "localname": "SalesandMarketingExpensesDetailsScheduleofsalesandMarketingExpensesTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsalesandMarketingExpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfBalancesWithRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Balances With Related Parties Abstract"
       }
      }
     },
     "localname": "ScheduleOfBalancesWithRelatedPartiesAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfCashFlowsOfFinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash Flows Of Financial Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfCashFlowsOfFinancialLiabilitiesAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Depreciation Is Calculated On AStraight Line Basis Over The Useful Lives Of The Assets At Annual Rates Table Text Block",
        "terseLabel": "Schedule of straight-line basis, over the useful lives of the assets"
       }
      }
     },
     "localname": "ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLivesOfTheAssetsAtAnnualRatesTableTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfFinacialLiabilitiesAtFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Finacial Liabilities At Fair Value Abstract"
       }
      }
     },
     "localname": "ScheduleOfFinacialLiabilitiesAtFairValueAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Assets Represents The Maximum Credit Exposure",
        "terseLabel": "Schedule of financial assets represents the maximum credit exposure"
       }
      }
     },
     "localname": "ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposure",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Assets Represents The Maximum Credit Exposure Abstract"
       }
      }
     },
     "localname": "ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfFinancialExpenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Expenses",
        "terseLabel": "Schedule of financial income"
       }
      }
     },
     "localname": "ScheduleOfFinancialExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfFinancialExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Expenses Abstract"
       }
      }
     },
     "localname": "ScheduleOfFinancialExpensesAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfFinancialIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Income Abstract"
       }
      }
     },
     "localname": "ScheduleOfFinancialIncomeAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfFinancialIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure financial income.",
        "label": "Schedule Of Financial Income Table Text Block",
        "terseLabel": "Schedule of financial income"
       }
      }
     },
     "localname": "ScheduleOfFinancialIncomeTableTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfFinancialLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial liabilities.",
        "label": "Schedule Of Financial Liabilities",
        "terseLabel": "Schedule of finacial liabilities at fair value"
       }
      }
     },
     "localname": "ScheduleOfFinancialLiabilities",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Foreign Currency Denominated Monetary Liability",
        "terseLabel": "Schedule of foreign currency denominated monetary liability"
       }
      }
     },
     "localname": "ScheduleOfForeignCurrencyDenominatedMonetaryLiability",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Foreign Currency Denominated Monetary Liability Abstract"
       }
      }
     },
     "localname": "ScheduleOfForeignCurrencyDenominatedMonetaryLiabilityAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of General And Administrative Expenses",
        "terseLabel": "Schedule of general and administrative expenses"
       }
      }
     },
     "localname": "ScheduleOfGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of General And Administrative Expenses Abstract"
       }
      }
     },
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfLeaseLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Lease Liabilities",
        "terseLabel": "Schedule of lease liabilities"
       }
      }
     },
     "localname": "ScheduleOfLeaseLiabilities",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Lease Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Loss Per Share",
        "terseLabel": "Schedule of loss per share"
       }
      }
     },
     "localname": "ScheduleOfLossPerShare",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Loss Per Share Abstract"
       }
      }
     },
     "localname": "ScheduleOfLossPerShareAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfMovementsInLevel2LiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Movements In Level2 Liability Abstract"
       }
      }
     },
     "localname": "ScheduleOfMovementsInLevel2LiabilityAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfMovementsInLevel2LiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of movements in level 2 liability.",
        "label": "Schedule Of Movements In Level2 Liability Table Text Block",
        "terseLabel": "Schedule of movements in level 2 liability"
       }
      }
     },
     "localname": "ScheduleOfMovementsInLevel2LiabilityTableTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Options To Services Providers And Advisers Outstanding Abstract"
       }
      }
     },
     "localname": "ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfOtherAccountPayableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of other account payable [Text Block].",
        "label": "Schedule Of Other Account Payable Text Block",
        "terseLabel": "Schedule of other accounts payable"
       }
      }
     },
     "localname": "ScheduleOfOtherAccountPayableTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/OtherAccountsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfOtherAccountsPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Payable [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOtherAccountsPayableAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfOtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Current Assets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfProfitOrLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Profit Or Loss",
        "terseLabel": "Schedule of profit or loss"
       }
      }
     },
     "localname": "ScheduleOfProfitOrLoss",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfProfitOrLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Profit Or Loss Abstract"
       }
      }
     },
     "localname": "ScheduleOfProfitOrLossAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfPropertyAndEquipmentNetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Table Text Block",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentNetTableTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfReimbursementOfResearchExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reimbursement of Research Expenses [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfReimbursementOfResearchExpensesAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfReimbursementOfResearchExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Reimbursement Of Research Expenses Table Text Block",
        "terseLabel": "Schedule of reimbursement of research expenses"
       }
      }
     },
     "localname": "ScheduleOfReimbursementOfResearchExpensesTableTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LiabilityinRespectofGovernmentGrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Research And Development Expenses",
        "terseLabel": "Schedule of research and development expenses"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfResearchAndDevelopmentExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Research And Development Expenses Abstract"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentExpensesAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Restricted Shares Units To Employees And Directors Outstanding",
        "terseLabel": "Schedule of RSUs to services providers and advisers outstanding"
       }
      }
     },
     "localname": "ScheduleOfRestrictedSharesUnitsToEmployeesAndDirectorsOutstanding",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfRightOfUseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Right Of Use Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfRightOfUseAssetsAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfRightofuseAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Rightofuse Assets",
        "terseLabel": "Schedule of right-of-use assets"
       }
      }
     },
     "localname": "ScheduleOfRightofuseAssets",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Rsus To Services Providers And Advisers Outstanding Abstract"
       }
      }
     },
     "localname": "ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfSalesAndMarketingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Sales And Marketing Expenses Abstract"
       }
      }
     },
     "localname": "ScheduleOfSalesAndMarketingExpensesAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and Marketing Expenses.",
        "label": "Schedule Of Sales And Marketing Expenses Table Text Block",
        "terseLabel": "Schedule of sales and Marketing Expenses"
       }
      }
     },
     "localname": "ScheduleOfSalesAndMarketingExpensesTableTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfSensitivityAnalysis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Sensitivity Analysis",
        "terseLabel": "Schedule of sensitivity analysis"
       }
      }
     },
     "localname": "ScheduleOfSensitivityAnalysis",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfSensitivityAnalysisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Sensitivity Analysis Abstract"
       }
      }
     },
     "localname": "ScheduleOfSensitivityAnalysisAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfShareCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Capital Abstract"
       }
      }
     },
     "localname": "ScheduleOfShareCapitalAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Shareholders And Other Related Parties Benefits Abstract"
       }
      }
     },
     "localname": "ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfStraightLineBasisOverTheUsefulLivesOfTheAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Straight Line Basis Over The Useful Lives Of The Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfStraightLineBasisOverTheUsefulLivesOfTheAssetsAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfTheoreticalTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Theoretical Tax Abstract"
       }
      }
     },
     "localname": "ScheduleOfTheoreticalTaxAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_ScheduleOfTheoreticalTaxTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of theoretical tax.",
        "label": "Schedule Of Theoretical Tax Table Text Block",
        "terseLabel": "Schedule of theoretical tax"
       }
      }
     },
     "localname": "ScheduleOfTheoreticalTaxTableTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_ScheduleOfWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrants Abstract"
       }
      }
     },
     "localname": "ScheduleOfWarrantsAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_SensitivityAnalysis": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity analysis.",
        "label": "Sensitivity Analysis",
        "terseLabel": "Sensitivity analysis"
       }
      }
     },
     "localname": "SensitivityAnalysis",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ShareBasedCompensationDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationDetailsLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation (Details) - Schedule of RSUs to services providers and advisers outstanding [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation (Details) - Schedule of RSUs to services providers and advisers outstanding [Table]"
       }
      }
     },
     "localname": "ShareBasedCompensationDetailsScheduleofRSUstoservicesprovidersandadvisersoutstandingTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation (Details) - Schedule of options to services providers and advisers outstanding [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation (Details) - Schedule of options to services providers and advisers outstanding [Table]"
       }
      }
     },
     "localname": "ShareBasedCompensationDetailsScheduleofoptionstoservicesprovidersandadvisersoutstandingTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofoptionstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ShareBasedCompensationDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation (Details) [Table]"
       }
      }
     },
     "localname": "ShareBasedCompensationDetailsTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_ShareBasedCompensationToExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares of share based compensation to exercise.",
        "label": "Share Based Compensation To Exercise",
        "terseLabel": "Share based compensation to exercise (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationToExercise",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_ShareBasedCompensationUnderwritersFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "iinn_TotalNonCashTransactions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation \u2013 underwriters fees.",
        "label": "Share Based Compensation Underwriters Fees",
        "terseLabel": "Share based compensation \u2013 underwriters fees at the IPO date"
       }
      }
     },
     "localname": "ShareBasedCompensationUnderwritersFees",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ShareBasedPayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable": {
       "order": 1.0,
       "parentTag": "iinn_ResearchDevelopmentExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment",
        "terseLabel": "Share based payment"
       }
      }
     },
     "localname": "ShareBasedPayment",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ShareBasedPaymentEmployeesAndDirectors": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment - employees and directors.",
        "label": "Share Based Payment Employees And Directors",
        "terseLabel": "Share based payment \u2013 officers and directors"
       }
      }
     },
     "localname": "ShareBasedPaymentEmployeesAndDirectors",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofshareholdersandotherrelatedpartiesbenefitsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ShareBasedPaymentExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment expenses.",
        "label": "Share Based Payment Expenses",
        "terseLabel": "Share based payment expenses of option to services (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedPaymentExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ShareBasedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment.",
        "label": "Share Based Payments",
        "terseLabel": "Share based payment"
       }
      }
     },
     "localname": "ShareBasedPayments",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofgeneralandadministrativeexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ShareIssuanceOfInitialPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares of initial public offering.",
        "label": "Share Issuance Of Initial Public Offering",
        "terseLabel": "Initial Public Offering (\u201cIPO\u201d) (in Shares)"
       }
      }
     },
     "localname": "ShareIssuanceOfInitialPublicOffering",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_ShareSplit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of share split.",
        "label": "Share Split",
        "terseLabel": "Share split"
       }
      }
     },
     "localname": "ShareSplit",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholders and other related parties\u2019 benefits.",
        "label": "Shareholders And Other Related Parties Benefits Table Text Block",
        "terseLabel": "Schedule of shareholders and other related parties\u2019 benefits"
       }
      }
     },
     "localname": "ShareholdersAndOtherRelatedPartiesBenefitsTableTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/RelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of straight-line basis, over the useful lives of the assets [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheusefullivesoftheassetsTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofstraightlinebasisovertheusefullivesoftheassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_SoldOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sold ordinary shares.",
        "label": "Sold Ordinary Shares",
        "terseLabel": "Sold ordinary shares"
       }
      }
     },
     "localname": "SoldOrdinaryShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_StatementsOfChangesInShareholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements Of Changes In Shareholders Equity Abstract"
       }
      }
     },
     "localname": "StatementsOfChangesInShareholdersEquityAbstract",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "xbrltype": "stringItemType"
    },
    "iinn_StockIssuedDuringPeriodSharesRestrictedStockUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period Shares Restricted Stock Unit",
        "terseLabel": "RSUs vesting (in Shares)",
        "verboseLabel": "Restricted stock unit"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockUnit",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_StockIssuedDuringPeriodValueRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of restricted stock units under share based payment arrangement.",
        "label": "Stock Issued During Period Value Restricted Stock Units",
        "terseLabel": "RSUs vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockUnits",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_StockholdersEquityReverseSplit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders Equity Reverse Split",
        "terseLabel": "Reverse split"
       }
      }
     },
     "localname": "StockholdersEquityReverseSplit",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_Subcontractors": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable": {
       "order": 3.0,
       "parentTag": "iinn_ResearchDevelopmentExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subcontractors",
        "terseLabel": "Subcontractors"
       }
      }
     },
     "localname": "Subcontractors",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofresearchanddevelopmentexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of theoretical tax [Abstract]"
       }
      }
     },
     "localname": "TaxesonIncomeDetailsScheduleoftheoreticaltaxLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxeson Income Details Scheduleoftheoreticaltax Parentheticals Line Items",
        "terseLabel": "Schedule of theoretical tax [Abstract]"
       }
      }
     },
     "localname": "TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsLineItems",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable_Parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) - Schedule of theoretical tax (Parentheticals) [Table]"
       }
      }
     },
     "localname": "TaxesonIncomeDetailsScheduleoftheoreticaltaxParentheticalsTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable_Parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_TaxesonIncomeDetailsScheduleoftheoreticaltaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) - Schedule of theoretical tax [Table]"
       }
      }
     },
     "localname": "TaxesonIncomeDetailsScheduleoftheoreticaltaxTable",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary differences and tax losses for which no Deferred Tax Asset is recognized.",
        "label": "Temporary Differences And Tax Losses For Which No Deferred Tax Asset Is Recognized",
        "terseLabel": "Temporary differences and tax losses for which no Deferred Tax Asset is recognized"
       }
      }
     },
     "localname": "TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TheoreticalTaxCreditAtApplicableStatutoryRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Theoretical tax credit at applicable statutory rate.",
        "label": "Theoretical Tax Credit At Applicable Statutory Rate",
        "terseLabel": "Theoretical tax credit at applicable statutory rate"
       }
      }
     },
     "localname": "TheoreticalTaxCreditAtApplicableStatutoryRate",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoftheoreticaltaxTable_Parentheticals"
     ],
     "xbrltype": "percentItemType"
    },
    "iinn_TotalAmountRecognizedInProfitOrLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount recognized in profit or loss.",
        "label": "Total Amount Recognized In Profit Or Loss",
        "terseLabel": "Total amount recognized in profit or loss"
       }
      }
     },
     "localname": "TotalAmountRecognizedInProfitOrLoss",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofprofitorlossTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TotalComprehensiveLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total comprehensive loss.",
        "label": "Total Comprehensive Loss",
        "terseLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "TotalComprehensiveLoss",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TotalExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.",
        "label": "Total Expenses",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "TotalExpenses",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TotalFinancialLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total financial liabilities.",
        "label": "Total Financial Liabilities",
        "terseLabel": "Total financial liabilities"
       }
      }
     },
     "localname": "TotalFinancialLiabilities",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TotalIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note.",
        "label": "Total Income",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "TotalIncome",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinancialincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TotalNonCashTransactions": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total non cash transactions.",
        "label": "Total Non Cash Transactions",
        "totalLabel": "Total non cash transactions"
       }
      }
     },
     "localname": "TotalNonCashTransactions",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TotalOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of total ordinary shares.",
        "label": "Total Ordinary Shares",
        "terseLabel": "Total ordinary shares"
       }
      }
     },
     "localname": "TotalOrdinaryShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_TotalProceedsReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total proceeds received.",
        "label": "Total Proceeds Received",
        "terseLabel": "Total proceeds received"
       }
      }
     },
     "localname": "TotalProceedsReceived",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TradableWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tradable warrants.",
        "label": "Tradable Warrants",
        "terseLabel": "Tradable warrants (in Shares)"
       }
      }
     },
     "localname": "TradableWarrants",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_TradableWarrantsDerivativeLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "iinn_TotalNonCashTransactions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tradable warrants derivative - Liability.",
        "label": "Tradable Warrants Derivative Liability",
        "terseLabel": "Tradable warrants financial liability at the IPO date"
       }
      }
     },
     "localname": "TradableWarrantsDerivativeLiability",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TradableWarrantsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tradable warrants, description.",
        "label": "Tradable Warrants Description",
        "terseLabel": "Tradable warrants, description"
       }
      }
     },
     "localname": "TradableWarrantsDescription",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "iinn_TradableWarrantsExercise": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tradable warrants exercise.",
        "label": "Tradable Warrants Exercise",
        "terseLabel": "Tradable warrants exercise"
       }
      }
     },
     "localname": "TradableWarrantsExercise",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TradableWarrantsExerciseinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares of tradable warrants exercise.",
        "label": "Tradable Warrants Exercisein Shares",
        "terseLabel": "Tradable warrants exercise (in Shares)"
       }
      }
     },
     "localname": "TradableWarrantsExerciseinShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_TradableWarrantsFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tradable warrants fair value.",
        "label": "Tradable Warrants Fair Value",
        "terseLabel": "Tradable warrants fair value"
       }
      }
     },
     "localname": "TradableWarrantsFairValue",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TradableWarrantsLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "iinn_TotalNonCashTransactions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tradable warrants - liability.",
        "label": "Tradable Warrants Liability",
        "terseLabel": "Tradable warrants at the IPO date"
       }
      }
     },
     "localname": "TradableWarrantsLiability",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_TradableWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tradable Warrants Member",
        "terseLabel": "Tradable warrants [Member]"
       }
      }
     },
     "localname": "TradableWarrantsMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleoffinacialliabilitiesatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_TradableWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tradable warrants shares.",
        "label": "Tradable Warrants Shares",
        "terseLabel": "Tradable warrants shares (in Shares)"
       }
      }
     },
     "localname": "TradableWarrantsShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_USDMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "USDMember Member",
        "terseLabel": "USD [Member]"
       }
      }
     },
     "localname": "USDMemberMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofsensitivityanalysisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_UpTo1YearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Up To1 Year Member",
        "terseLabel": "Up to 1 year [Member]"
       }
      }
     },
     "localname": "UpTo1YearMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofcashflowsoffinancialliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for use of estimates and assumptions in the preparation of the financial statements.",
        "label": "Use Of Estimates And Assumptions In Preparation Of Financial Statements Text Block",
        "terseLabel": "Use of estimates and assumptions in the preparation of the financial statements"
       }
      }
     },
     "localname": "UseOfEstimatesAndAssumptionsInPreparationOfFinancialStatementsTextBlock",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "iinn_VestOverPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vest Over Period",
        "terseLabel": "Vest over period"
       }
      }
     },
     "localname": "VestOverPeriod",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "iinn_Vested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "Vested",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoservicesprovidersandadvisersoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_VestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "VestingPeriod",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "iinn_WarrantsExerciseLiabilityIssuance": {
     "auth_ref": [],
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "iinn_TotalNonCashTransactions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercise \u2013 liability issuance.",
        "label": "Warrants Exercise Liability Issuance",
        "terseLabel": "Warrants exercise \u2013 allocation from liability to equity"
       }
      }
     },
     "localname": "WarrantsExerciseLiabilityIssuance",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "iinn_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Member",
        "terseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Scheduleofmovementsinlevel2liabilityTable"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_WarrantsPursuantShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants pursuant shares.",
        "label": "Warrants Pursuant Shares",
        "terseLabel": "Warrants pursuant shares (in Shares)"
       }
      }
     },
     "localname": "WarrantsPursuantShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_WarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants shares.",
        "label": "Warrants Shares",
        "terseLabel": "Warrants shares (in Shares)",
        "verboseLabel": "Non-tradable warrants (in Shares)"
       }
      }
     },
     "localname": "WarrantsShares",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_WarrantsToBrokersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants To Brokers Member",
        "terseLabel": "Warrants to brokers [Member]"
       }
      }
     },
     "localname": "WarrantsToBrokersMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_WarrantsToInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants To Investors Member",
        "terseLabel": "Investors [Member]"
       }
      }
     },
     "localname": "WarrantsToInvestorsMember",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_fairValueMeasurementAtLevel2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "fair Value Measurement At Level2 Member",
        "terseLabel": "Fair Value Measurement Level 2 [Member]"
       }
      }
     },
     "localname": "fairValueMeasurementAtLevel2Member",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "iinn_leaseTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease terms.",
        "label": "lease Terms",
        "terseLabel": "Lease terms"
       }
      }
     },
     "localname": "leaseTerms",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "iinn_strengtheningPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strengthening percentage.",
        "label": "strengthening Percentage",
        "terseLabel": "Strengthening percentage"
       }
      }
     },
     "localname": "strengtheningPercentage",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "iinn_tradableWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tradable warrants.",
        "label": "tradable Warrants",
        "terseLabel": "Tradable warrants"
       }
      }
     },
     "localname": "tradableWarrants",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/EquityDefictDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "iinn_weakeningPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weakening percentage.",
        "label": "weakening Percentage",
        "terseLabel": "Weakening percentage"
       }
      }
     },
     "localname": "weakeningPercentage",
     "nsuri": "http://www.inspiratechnologies.com/20221231",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialInstrumentsandRiskManagementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of Directors [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficeBuildingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Office facility [Member]"
       }
      }
     },
     "localname": "OfficeBuildingMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofrightofuseassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss, net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r10": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r100": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "58",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "90",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_90_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r110": {
   "Clause": "v",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Clause": "vi",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "10",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "10A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10A_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r130": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Hedge accounting",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g21A-24G_TI",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_i&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r140": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "7.2.34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "56",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r150": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "9",
   "Paragraph": "7.2.42",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r152": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r153": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r154": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "70",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r155": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r156": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r157": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r158": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r159": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r16": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r160": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r161": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r162": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r163": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r164": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44D",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r165": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r166": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r167": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r168": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r169": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r17": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r170": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "IG23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r171": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r172": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r173": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r174": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r175": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r176": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r177": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r178": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r179": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r180": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r181": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r182": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r183": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r184": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r185": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r186": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r187": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r188": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r189": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r190": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r191": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r192": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r193": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r194": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r195": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r196": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r197": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r198": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r199": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r2": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r20": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r200": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r201": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r202": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r203": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "57",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_57_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r204": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "9",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r205": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r206": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r207": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r208": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r209": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r21": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r210": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r211": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r212": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r213": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r214": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r22": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r30": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r40": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "77",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_77_e&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "20",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS20_g39-39_TI",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "57",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_57_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r50": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_126_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "129",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_129_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r60": {
   "Clause": "vi",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "32A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_76_c&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_d_iii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "21",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "51",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r70": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "46",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r80": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Clause": "vi",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r90": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "115",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_d&doctype=Standard",
   "URIDate": "2021-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>138
<FILENAME>0001213900-23-025412-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-025412-xbrl.zip
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M%-EOTAQY0/7SMY>]BUUN!J_.(0TL\L-S5-YPX@Y#+TV9-/$A\)_,+[U5=<U
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MH47;>2S'=9>L6%]1>&LGAX&=[DG'[;>/.R!RB^3SO9_=95C#Z\)JW3L]+YH
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M]<-4>9&D6%!Z?TV"<[C: BQU/\-_QKSZGJ( 4'M(>G/GS9L7;,D0QNE(^61
MI\5/0^\BQ3C)LO60JHE'F8H<T%0X9 ]V_#^\&U9A8?6%L,8AD,R<SG+(N\.V
M&#TF'Z$G7OV,XSO53T$+!F@L9<IH)GT]'//4^ES_0C)I"Y\/P#95YPL?SQ(T
M A>>FX*G'?K53[F<M[H2\&S^#4O7UP(9\>ZG 3@'8+F!G^<#Z0[RC#87[1S*
M9D7H WIS<2LK1X!EL4#'@?*?O)M_1ONSG(4<9#SAXO(VAW "'")LV/N;J-#3
MQ2IH-\:#?[.I@^FRT).Z(NUUXZ?6C]FF94O7E:-'!Q"KF\%HHG(9=)I-+H\(
M C@&;+T(R]2+]&BC"&H.Q8[#;"X_7LG8ZJ4K7U[)[E">4YEXH?"L78G%\0MT
MBJV[/V.ZI1(EZV/X*4@^=./16<(*^?07W@9M:!>5I/!*Y_RCQ+&6)-MVP;EV
M8"%Y\X;>0<RB$G_B;A5,SS$[R<3&0Y!B.A4]RC,L8G_JO+%<D#N:"<8YQK@S
MI>@D>=]T%8*GJ^KQXC0G/J!X%Q>6(^W %:0S"2G;^%WLV&>7<";(.'"MTGPZ
M*\KUX&\@&?YZZOD*%0M2)JP%;+TI=P5P.%<T8) 0M22!Z0'@#]$&4J;RV"+1
M+,&1@PWCH!N&2QN.X3C9B!*16IH32!IKR:E*39.F1/MGW @"+WE7Y+<6I-:=
M4B <]K/8'!*%H"B=H9>GIOQ$Q&!C<7,'>1I$*#%\-0Q2H@G85#\8@9GE3F7$
M+ZA%*EG))C'>TP@#W;^S6AD81>!-,;*O11H6<]Y>07EIJ^HZE"^X0_FACM99
M.C:G(@F7SX?9;NURQ<4-@H>\>?GJS9712PPKW=P*2*&"O1!1CQ,FRL@&  68
M2]Q9JW52YB"#,-?S$W@G%OA S4ZOVOV5PN2FGO_8SM0[]\!P)X[TT@EI)\G_
MD<4X(-,/^93SF9C:1)[='.Q/':S\XY849^7P=+4TVO>8^[9M8I++M[H8._2U
MMF?DWC/WL87&T8U$C3$=K@LS<DR3!)3F$W]&_0"SC]/FP*DL<N$?F$T_]T(E
M87=DT%+*IO#.RJ][W1.Y*C?>]O7WNNY'1X&6O) R*R(_RYI=:&SB"A=VK4RQ
MCWR+&3 _\,%"W5#;AMI64=LPGD[!J07:P=JCGR$P^[K4"U6Z0*D47YEK-W=#
MLAN2_0F2-3$<TT!H*.@G)2-%-+%=T!V:'(VO6S4V-+BAP4L=[SI?FZ@O#, :
MA _F&S+:D%$=&:6L>SEOR!73YRJE.+1.L'!-M64 8MB2_ZPV)6(MN'$I-Q2W
MH;CE]IZ!!.(26X$CF 0S7?B;8\<A%;@6X%3TIPUXT[#R%KI ^"_%HC9T]]CH
MSDZB>,-,%RRCY48=,90_*<K6X4[!"-V$QF(U ]:!P3)+_:18>4W)7TZ^$+J"
MQBI@T<K6GBX[SS#- Y<36AG<5^"OTF$\4[PNS/SP53KAAS*52A+3I; (\+'I
MZ(';6(NWKZ;79_Z2(D==!V#[2+I\?"/!-YQD+X&K+@PUJ>@\2.+(0(QQB;AI
MF)>6C%D<8MQ29H2K,3U3+AG&.;9O\0?<Q&[*)(@P*52I;-["GP73F<<U7^C-
M6X^5Q>G:CQ">EH96DQ;E:UUO-"+"MSJN=(.5] 4N(?P[PA2^L3M?J\/[U::6
M>%4M\::4^#JT^[!S^I=DL"Y+]"_Y^:-2!55C7JG,K22PTDH&JPCPLFT_7QDN
MV\1B-\;(=2@P4>1,(F(2-Y2YDSCTT1O<T,W:T<WZD W:FHF&WN*0%J,9$G">
MKMO$J\)0<84?5D#"UM^ED7CE2L4G5W[W0%3U/3MM\3FVPH32->\BQ@?!:U@>
MW),,FMUCX=?-'G#A$6/[@\H"XP.C-+,[F.^D4._)GXE!;Y#69 R",#8BM;<,
M"W@;*<Y?'1&1.,CF[#;\]#3/Y :MMK^DYZS!FD_^3*RXJPT91+@*&Z:X@P,(
M32=TZPX]D6L[&'?8IM53GD\(48A6G@A<#0)<C7(:K*+. WBD8 ZG@<8(T=A8
M?I .PSBEXAEJSQ.XECC/+FV 9UW-LST*<#;//P]2SFC 33$#B4EJ4!N.9""+
M9L-28QFV?$J: GE+MXXUZCMIZUMO"1E?YPV??+/H'W'N<F,[@^W D0()YYC0
M"@-,FCJDX.<KVNM:;GOE]U?!24 "(=+R3!(:HYN$?XE96\34OU",7T.HUA$V
MW80:\8!@=.#/(6B^?$:_I'PP4=GJU2-*M**$L"?C-8!F< VL.0TF1$-"L(YI
M9N8\\@4\ EN7L>T4;\&H?0R.$'H73Y[ ND5;5$-#:4I_KG,95:#5DH6J@"-"
M],S]EMNUH#H$^^B0Q[IIP 5IQD]+J![<I85]OMA*BNOD*6*98X!/4Q K&B!.
M:ASD$]VL3JW.R"K6[X'JSG&7[AF989V5T(JU?8L0N=(QW%0@9#8(C<  KJ0:
MXD#(0<Y\ 4ED = #CK .W(J!S/0W]!B'H> N'US9*RU*[DAXLS[&\+!<1C[4
M?]>LX+]L+"]4R=2*-)QK+?@M(JB*?D;5T/!A>ZJPG;U1V9/V?^D[M)&,/93<
MQ3JXP*!FN2?=?F4!>.@:LZ\_4=]5R%",PIP,']9E+T,:'8^-YNW112A=^P*T
M*5-1CGM]0I8-TC0O4&/*MVD/R<4O_=K]$,-_--ZQTVWW/[28D$\0*TTVJ5#]
MELHA ,$9+-M+N$?<@_LG/E4!49F/1")P(- 013<509DE"!Y?6)1DE(ZB=>_L
MM-X<W0Y#!\C05QCG(55)?Q$J8NK:,-C:-"A; E+:18YI ?A0P,^Y\046-+;<
M/D'U4?$72'Q0S(0'(45D9@&$;VJOX(H&B;U0)!JV=U'\[+S:-XR\_WKWG8;3
M8Z@9 CNR.*ZPKYR!(A,[2W(!!X[F6MQI;,0E+\NP)ZAXL-,"H59%&*(-CY7)
MZ@=-FF(>E;$4F,( (Z2A;XH(&@1@D:@L)L[V8U%F7%NDT9P2 Q:-QC,I0C-=
M4> FK0UVJQN,)SO%5+97*F&E721^MM%GL;)N%N-P#;J&1F6!D&A8/4GFV1OU
M>NVUG>$DSX*PC65DO#LU"X96="@,<PV/;FQQ?:TI2;BHSFLDY$_4W:6?,Q<5
MJ.#G2JLVW75KL%?8/>1"SH7JAPH4#8=8'@HM7*'([/6FR&QED=EFBLA? *S<
MO1G RM4P!N\'!_U\.D7HVEZ0?G>/.6QSAS-!UD *$RX=KP(#6#IVQ9\4 ] &
M"H<A$D0V?Y7RSO$?NGM20T(ONU]UQ#.!%6./DL;+RE,ME*L0@\4MY5X7RH%[
MJY9KA8-,?+ 4%$QKW@]-D3''4/2XSF6+1C!^8$*:%.Z2.[]WU*J@.SNU]IA8
M)[IV'Z^0.<_Q,&>C?Q2$[%[D:3$UN=\YO 5%\5CK1IXJ;%,Q-D+C0Q:CO!E%
M;MX09'H#,IZ3;X!62S""32X@1. W88SMT/ EM9T01*'@T@G*8@%GJ -+9-_3
M;4W?H:_OHP<;HOY*E2(2,VB'FY326I .X2KRO!_T[:*YAOV288M2N<L(#$@#
MF,R(X)($$03AZU% LF-SHFMPHNQLRQC-Q,.H)/@?.$!&1C95@;[L89-("0@*
M:2##XDBB3/07XB)S9 SA4L.P!<82#QDND,3DKG6_U%,I/&R3P^C'P$N#E!XL
MN0?4?QQ-A'N%"+E(CCSY]*:EV?*Q2DW,:C0BU6KZY"Q<I UEWC-E]H 2J3.R
MH#\-<7 A1AN&;_R I]/H)D:#B$5#*J0 O&&$D.?#KJ9(2E8+F,2*P#2K_?6&
M%NZ;%F3*CAYJIG-1.B&6YC1<!2>TV3C04GIGVFN]< $'6@N81 U5<*[;5$Q>
MLVYH;#TUW&U?X-,QO.LHF_]Q2XXUD!JZAQ94;Y F^<P4_U&,%TD#/4J'4^A(
M-P+92U.:*02CXXF'I[]UCYH[;UP@&E]-@Z%6G]R)*J:X!O_5 @IU$Y5^1*7J
M#UE"3:W'#<,J;B34]5: \Y%$#(E\2MU\!J>G$3?9LN'._ H4?:6R49<S<HV2
MC8AF0ZOP"#RQP<NHN]5*21ZE,*>?\W**T',!WK+1<O=-0U^JXU +2Q6,7IS4
M'LZEJO4\#L]5JIUGA)0P"7R:0$]) \M,1T1XE90Q0)-*HR4(E '. UM69+Y1
M<0\XMG3#HFX(U!]/,?DZ!%,IY=IX,S%4.X8D$)7_3N_%1KZL@Q5=F,^DH+))
MD/A-K$F=:]07/3@5RPZZ(\[QK[P,3*8@+"$Z>62LNW^";))YQ_(C+E@ ETU_
M7C+'V28:</<%FN!E8ZG6>X.W49*%K=>M1>EL$;34-A3;4[.<^]7_6J/PADAO
MAD@Y3R[C1N"/..78U"C,L9'#-$OI$C*L2&6%A_(GO81D9)QOK06].?M;UQZ_
M*QEU4_9KI,P>Y ;/*I;9K1B2F>(T9B6V+3;W8XX.C@\GA&[.; WXE8/[S*/
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MMRZ#H".N"+.IN$A> 0"-NT5MB",9H41+HVO-_@X06ID'/%#UBCE_[A1FRX[
M<2K2*06]&T>*+.W($7@3]A;%O]72)K'&SY2:)^.HM+SUZ)/<))6?0E*9!TS%
MXX2 [31X08&ZKH<-1.-8>WD:P4?'$^JJ\DW,#:0K!@'@-E=/.6_B\@^;GI!R
M&MKQE/$ "#E/9&!%4A(>&+*AC2=&&RGK8XX@Z%%4J'@+U=_$[DE%+8GUD?JY
MK23YIDDQ#*X(2=IM1)40I>Z3'!;E[2H:>V.JJK$RB<7S%9D.'+G:$.+#)D1P
MU6:$6+12]]5%W, J2!D9N$29>"]5EVNZDH+4S>-+D6.U-8WFJ(&9%2?R AUH
M<6TEG,T"]+XK%C<VY!- #-5BO0*@AJWEYY12M45UJ1VI=I90J0T)_$*.+0>J
MX)$E"!SXC1F5YHX5,+8WF\REPK>8 ;@,NV%)7FDCYA\P718A/9T'&56+&,^5
M7<18=+:4JAAMZ6M(>(/(_9!)P]+Q:N:Q!A^!J-%>;A+CK.6L*#*LU!;:5B5C
M@V &4)NSJ^H7K=(UADZKN;2IK5E=J@:_V9#; R8W$[:5#+/T3LT;E=&T5A:?
M>W5%8EW6)+Q<N=TSLNQZI!D0@ZX<M\6T$P:.=4:&#.L B5A7UWACJ^6(>R!\
M;X[HGSZ";UKV39&<\GRX0TI 8*.1'OEH%7MHTWVA$]RY7EM&)1:N(\T\C!4.
MOS911D@:)K#/]0"<BHJTIK2R81P%+T8#NE_B1&'C5<,M5*N>.%AZ\,(FX/63
M.$1QIQM*M"R$&^ WZ%HOCKC'$9EX+4(W$_ 2/L["6C97%@4Q&&//.!VG!N"L
M#>;T&O+069RF@9R&+B'1-V]P1H F.%I8'E1PXRRNC0X3W3A%Y2QZU*JL$NEO
M /*;QA1SL9CD(LA'T_47H^ '5@IY<T:>*WH@2NF'05%"AL?B@<?*8V>X3L1D
ML7@B*X@7CS(Z]'9>RKD#2=V443&+$9C6KO*^K?R18R:@I#C3$S97)J%<KO=*
M64\K R>))41GH=TJ:,AJ6[*6/8PC@G2UYT%3]DE^CM"XUKZ9[ VG;/0 \I*1
M5P$WP-W4<*!E5YM*L; F+0RP3X4FN&/VQ[KD@E9!U6AID+#/7W^BN#)0]D$$
M?Z83O56X7)S2*717='EQ@5]]GY9YO&-(A+DTCZQF'IW=(@XH)!>5@'DN)B43
MSL[1 6#&FN185!J]W2@?H8F<6-.X=>7G!5:6A50YI,UH>I8EBOA0-," 1BR+
M:]"\*<UGRJZJ^3B=1@Q&FGN13.C;U,'ZKV(;J,RI6 NL&4O 7!L7%CP"_ZZ'
M&*^%MNR:>KEBVBR'EQR[<J)4(=%80MHEV.W+BB88H'<:)X;P#4IG7!I6[5#<
MSIL:;5("\$P6QTH4YE:U.?VRP%N<<&Y8;X35L52DQ)V2?! RI/QUF6W@)UB7
MCIWM@4Q%)@&!7?/,BBR^-!>6[8B"^49FZKHA<%*6M>CCK3N&YKYK)/!KE=KM
M;TKMEI7:[6]*[=:5Q*EPKL<>2YW"8W.#;5<_"'-=W%\J_DDG(-+%V&X8%/Q:
M8[TPSFM__21+U7Y?:7,XQJ1$Y3, ^4Q"F>)+P;GN7Y*Q2=I)@0W'P!/V>X#1
M77A1.@ME]SYSS9LQ3Z@;J@A;6G9LRSF+[:'PVNCB.LNZHBM9>=73*ERI0K45
MD7S]*U! %/E!]4AO87EESEQ2NT SDV#&39E@\!>]&DBKJ/PT@"+;J[C/_"0%
M+PG+\&4W$Z.GE?1VBM.P0,7T9"9CATK!+/K%U@"R*TV$!2\^3>"]$)"_CU>R
M03VR/3[[3:FMO>97A:<)YH>B&?*\0'3&9/X$OEV,4%L-T?;,M\$4P11H9I9P
M,(<!ZOC3]DV7K/^NM3[+*/W0NQ$/K!+IV3WJG^@5-0!8@/=!FUVXD5UP&(%_
MYG>\L#O?E,41*6C)3X 5PKG5'*5;HDPOEU/ICZPVW-7".L611!Y9)%BV?UTS
MV)/4&Z?6GH'E'@]SC/SP]CL9SN'38P=P"EJ0\)Z-N&B]@<T]N*]<ABY'4 0\
MVD65:\,^S^J5Y#CCO>KH &NM%V.4=GV#JH&NC$OOI7VB45%L[V,,HR3B2BO"
MPF*XN.7V"Q)<' >(I4*",0/K0K!R? O/3'DK=4SI+LC&(IV;PON1%=HMO2(:
M1=AJ'#KL.DDE+JA;_4<MV$VC!IV,'+L+#(W!?[G/+'05Z(]XRI$%B4DT, B+
MWC0I-2G_A4,UM<!.1;EQ+"Q=<'FKIV/VKGQ(I'8ET!.I,<>X='RM&N"I\3$;
M]0YF-?*CIS+IHF5K&& 0N=6&VP69(H$$V '$[CBGS;,F]&&8SK$&!E+(:-D8
MR=+T0&NSZ=B\;%-,_=@*8>ZSKLQJ964FT_#A!2M97=\I$.Z0$PEF*,WB;*D-
MB.;C(PZKI]96L25!6!*4B&H293IF2-D'0UL"5J\;WDJ]<%CCL*&9QT8SUI $
M3017J*2;8-?&!IOO(9,#XYMJ>%,+;YGL+[![*(VI*8;E0%E_\/9M2.#!DD!%
M(EQXG"KCN@:2^-.B2*U L= I-I]QN2N./%C\0V5RH=IJ-R7JEOE>'=;-@">4
M[*^Y\8;0'@VAB>IAW%FA@R(U$'.\,A6\YH4HQH80'BXAE &&*<<GH7^#G62?
MN$9>*VB"H1- (&CWIG::Q(9$'C")+(YV-T:(+D0R\%:%H6)ZGA*L+]2X7#/P
MBB>(FE1*;E@QK.6UEOK.?__;Z]V=5^\HW 7R24<;-R,I'@_)V3%"F_RX7'XY
M@K - [O!!7TD-!"$%K:/C4YF=_N&RDL\ 0,NT D#CGIG7C)6F<$$I'L(=>DZ
M2.M>6.^JQE@C*76K&GNN#B80LS:T,D0%V93BUQ873I4B=$.G4@$(^@#+Z8K8
M?Y&M#.<+0(I<J1J<HT98GJKB?*9*.)<TU'6ZXO6(?G'0LLF32+Z_;FWLDO(\
MM[X\[]YS$&M1F/=B4YBWK##OQ:8P;UU)7)=8D*HPJ6T_2)-\9K$]5:4XC/')
M0H"P+'1X!DLH,-N39W14VA0^//VM>]3<>>-BQ;&:!L-RD?#UI)(M@)RJ 'IZ
M51DZ1TV@MYP"+P"::S9>$M-#+T*WQD98E1X%.S5?\WN[< Z.")336/<*X;A7
M+.P+HM3T[. J3N&'"5>]':DP\]QS+\&Y[HVB7P,G=<(S"\VS/#]?HY-:[N^3
M(+26"[8*;!GX8BF\H.=+(H%:L/#G(;YD$5W4#IN\(^GT$@XMXF1,J?219C.D
MW"H#>\%SZM$BD\E$F#!-Q8U37 D8@B+G_C(W1.O,P;""5#7@]^,P'J!E'\]R
MGOG<<MOR&.Q+:)37AK>G&A0T3KFN?V1.@:P'ZM4!]R%AK%W<:\3E'6*37$*)
M-S@BL"V<4L<2;$B,-^75H%'R9XYV9H;G461J^)ZZ2J4\@0P/1S\-QU@$65Y\
M@0$W+\+JPX$BJ)L0']=R3P0WV"E&H6GKLZC(X&)3$ M!&B>ZWT"7I:238"31
M.Z**@0**"JAX)5/P5@DLB6=NBYR"3:60+_Y7QXBQU8)6Y$1QU$3\<8;V@ZV*
M4CPP:;ZP5CG*HZ$4OQ2BR?12ZKE :8RZJ<G_XKI13_],UXKZ>6+J7(AOLD1%
M?NHL@4/6U*Y/P5 ]O(JTW1F#GIN"*"Q. @(E^ ^T#J,8<;!S]B1PCO@ G1!?
M%46>^AX-TQ,"YJV7"C8C 9]R3!4C(DP\)<R62F<G?O&MU6_96XC$;"%7,EWJ
M</RWB$ZFGYG!BHX R+M<DXQNS\4DYG?DM2BD]^$0BY95,4Y%;Q P5IA-N$0X
M=K$K1@SS$B>8VUF]*T:N8H69)8]X6ZAECC((A0TO[\)JCH69X(UC\RIVQ%'G
M4.&X$7P.UGM-X<:9+?#P'6 5NI]2BL 4]@PNV.L&[9OD'A*4H0Y-;:O(!<4B
MA12,"K&.RPA*.A+\HYLFG@H;SN)Q%1V2EMQ!:7\!C FGA#<E#GS4/3U+>KAS
M($+=&$SPPK2KL#.A[[ M)"T-IJ',G N/A9@&B Q3HEHXQ)*!!,\$2>3G$AO@
MKN^2O&ZY9\P$#9,QR[SO2A,#=ETH=FRI^0)6$,\5E_D@B"P\?AH3[BL1W01)
M&D$^"5=,2Y22E&$$?V(X+4A8CLAC&(Z8AR+1N ..ISK2FBWE?:M(''LA,ZIO
M3\6W*&'V^/%%A,XP[8C9+1+U)(ZDP#&<\YPEW2B=T5].@<GS>!U=\@*PSE=7
MWW+Y:<I O@MS<YV%H/9540+(5BQ%,LP4 \&52$TEKMWC+=.\Z><ZR(4C)DJ]
MQ7.,3]U+C?J]%,BO]@OD"'1O"IB%#J$#%NJZ7*?7J,V"V7MKTT<%_9>4H X8
MTN,,K503($X]-(3)Q5DU(GS05([+O<]#/;J#6[S2[T:VR+6ST!NJBI%"72SG
M2E?:FG74SO!)64,5XTE+M%I"A"XUU>J\LA7"0]QV"ZU9VOH70#4<FO941 5K
M(G^ZGUSOW"S.Q$RM+'Y3#?S8JH'O&V.JB%P#&XO 0+9X9D:8,7X[6,P1:M"F
M$3N_6++#2J9S/T!BU19K+U%A?>@Y5=AC.+W2CV,,4<1K;XK20!,6V\_'D;72
M#=34@TZ*L6;BYA>0Y62 4+-D0C"C: 7.)O,T  $9Z0E1:GE_%XU13ZUF$LF<
M;%)9JX;>_:X<"122&:^*20RK1^")84 CQP9)[/F+MF/+[=KSRQ;J:"@=FEI&
MI%,@9Z2<6$O#^"*<L_NMQTHT%F/%BP O!M3&AJ>H:5%5_E.;!*4-64YNZHRT
MR4,7E7*Z?]NAG "*]$DP$^BA+E#,.3P8#N-C&#>_Z%/A@("IYJ80'9)/*85J
M3'P;R<GZR1+<$Z=*@&2G66A#I3E\@I*F&+[JJ>8-JD-9F-D24+Z.5QHF5TQ<
M*^VA[IPG<6H:^LL$L5"_3X54%DZ5(1:W/VNY_W'C5DQ441"1\P'4P _W<^:W
M&FX["C+//?O[WW;W]MX-L:[7[;<^TR]^;[?[[D=8$ON;AO2L6/$B!1K- ;HF
MC.=US4HHJ1Q^\052QX]+MT-BQMY_"4%BZ& Z\ZB16)>)(<U)0FVA@"!1[+KH
MN&3U@8X)Q'+>PMY:BN.P>X&05 C]6N34-*V[5$W"!WAWPJV. -> !ZZ7V'^Y
M2>PO2^R_W"3V'S@K_%X,B&HP1MD0-+$;9)B%LA #_7-0"+!?<9YJ!+ZB9(W"
M/VD:I%D-R&5)3!;#=$L*0MG Z[8J=\JJW!+I*^]D[)7N2?]KM]=VV[TS-YVG
MF<+1>I_^^-QV!V$<8QU5E,8:3:C]N7O8D2[]!D.E\6W0!+4CCW$!STY%Y1Z*
M6(I3U;0<C *R,.OW _-89#*;.F,)UIF?V[$A9_D;R\LMF#\8G2LB2J'60O:D
M00LAM::VC6G4;MG3;^+82H@O*RLN>+0%VRAC#6N,,<8@79B-5MHH'HP6TZCG
MF&_KRNPG">>-=",]11+(8L10'GPH@6;"PS2X.Y)NG#YY9?@5-@B[<W6 M##4
M'!-K]5! 4QXJQLE995/>"HAB"!EA)VF@/3IV2^?8H$%$I$ZS]6K&;E?]PI:S
M'-6Q5#/+.6Q]'YD'+,44B4:^)<NOUCPUSH^IXZ<-P*]YKJ%3R*>L^AW5_!-4
M0Y!52OPM%-@:>Y+MOO*^EN;WG5/+/<>$V9AD'C)CI5-EF]ABA!?@*D_5H?U2
MPEXIY3RPA"=.>52\[\B<ZE0G7[$(I-0Y)&,9B_8-+-90RQ!?"S=U ):?RN[!
MV5R[U-19.>I3AL4I:7H=NI/,4(J;C_4S\/S_<(F"GH2IZ\U %P=^[8D5L#=D
MQ%!NF+[AR5M1BI5(I3!SPZ'1K)IFPF"DAO-A6/IA:0R<%:&F20I(23P9@1&[
ML&0K\KW$%VP<JA+7U>'Z333(=J71S-&"4*,'Q6:QI6&D!1X'+<&:J(J;70;J
MP6*4,1?;$3AM0T?1>;"#/2I*$O-.>6=)WM)!,GFG0U2ICS0_OAP5JSX;ZE3+
M^J,)F\66H+!R(]:>NR:KPHGR$DO G;XK-0,MION8RV=BG1N;SBO(D.IP0ZVO
MN:HS%GYAZ [X08Q\@8X!4JV-BZ53-^&\;N'"-?+6;$B(_:Q)F/.H9/;Z?D((
M\YJO%J2 64F9S<P2&+ 08> SDA>*18+AE@+GV1&<YY\!"]\T1*QR(!&EDK<T
MB I4=*?8M!)8$%A"8)LMX*^Q<%XD $UB-@%1/KU(&5*G)18VE1A"BWMG,"\A
M<Y=<!*.P8<%8]IHR,B97#*O0%TVO)Q_PFA76#A4].'$AG <*[HYTC.6D]A*Q
M5D4L ;L%U(3G2M4O"(X1Z"D:=0,YZFKB[XL&U\[,$#<<-!)&KW' 01'2=LR9
M4/5C$B/2H#7J/J2R9RZD<Y5'IT1Z#OXTHVI(<O'@B*5]6626%S784@3=T$,1
MG,K<@C'"*"*$GF$9=I@T'([%0)CU@D7X,5?DV-1LP\[RE#!=?%TI_3&*OXJ9
M:<"<&I4%5- =%[OD%_,N5K#&PPH.1/!%"WH!$;%8)\,%TM9B)B(:\Z #7:T=
MY=.!(E3;,O?7'0 .F:#*O0"G7Q'OXFQXKQB5(">;JC&^_5-UD(B&M(XE'9XR
M=TAF9ZYC6@Y9.UA>36Z[%%3K$E+U X>-J4N2/IHAM"=N]2D4 36TK75:8\'Y
M=6SGE[F,70#S))1!K:>6U3NUE8(!I]88H@[%)K2U*FILY:'7% F;$]8GMNRD
M5QUJ*H+/8^_EWY)]K,7:E6BD'U-$52(]-5?^7(C'61'B<:\4XK$09NHB,[7$
M^>2CC:4H;V!7&S@F@N<1R&\!##C2>J+PFAINI7D^43H0"+<G6U'3MR&D$0UN
ML0+0MEEOS0!R#"/).)CR")B)ETRQ@^FTR%C45DWSG!4-$&MA(5I])**.2ST4
M#6FOH$+93I[0F&=+EU).KS)&02<FN!)U5>-X3<T.)2Y*$XXXA4*]9[X#JNH"
M1'=-Q>\H3SBO;ML0=1 "5T+WM8_)FE.##\K3A9)SFIBK!_A,$1HP*7&D#3=8
M#+RQ$CCP!;Y9F1[T=54*,$:XHSN":+4S%<]"(Z$(,3^H.#;2F0=O,,I#W4P;
M\#RM^N5Z6990I#C11%VAYK;Q&AP"V4PSBF#).>DP$L4F0_(1^(92 ZT+-),2
M%,V"/UQX'A5\9;-7QCEV-L[Q]=$"7FV*"I85%;S:%!6L)8FO\%P*5\*.3-@=
MDQ=V?9*H/90DF?;F<O+4*8NM8XT8;Y^#P]<$"09/YI(_'#Q,\:7AW%BR>)',
M.9G?=9[ETEU9F\C(BI4>H6N?*9Y5JGL.B]YDV=JB?0_[F=$XX*F40PW^# Z#
M9[IOX3Y8#R>XGAY;2*318PZA)>=L>/.( KP_VPG1B&M!R?K3>A]OW3"3J1,:
M_U.F&M-8':>270D2WS@$<62/&L:P,;H@YWF(C02B>7UOBLRKQQCSS<^#!)0W
M:#F0E8A6VL NY#SA0@X/'LP-YTD2)T$Z!9WJX7Q9%6(@<)I' C; 21E$\THH
M\+&"POD##&?G*;=X4L\L;%27WEQE#8<NG\AH=[!PIE@SW9"^<^K"QW +U=XF
M8R\R,P0Q*"+7D#\NIX*G*/4C2W[*(V*IY8H0#31)."AL9;JAP0QIN$7/)-5I
MRZ"EVC=US9O:+9N#>7$"$[B>=EFW@5NMR7SF="-''P)^.BGF5H1S:UXM(U-(
M((FG8\ +"^FE,7BJ:::/#%\T0R@!ZBF797-HT)P-T4I],Z]Y*)F*[ =&(O,N
M%&=2:(H2OP*/4,(3EETTCGHA1:FLH#J,UR[V+&!;8BY=]9-\7$IZZ[F3+?<X
M1B/?0V[GYO(PYK$K!C<WXYLB4QN>P "VSR.7QS$Y-PF-9HELP%UN:N>5.L5*
MRYWO=8Z"'G)"IU'RNO1NBC.5,N$G:LA%/GB[F>1_R/&'15,,HY@C)J-(HGEI
MFY)"N@DI7WARZV*#]<X@E;.,D%H9VAO&8S.P(AR.B.B=9HG,PTH198+$Y,BQ
M)9S,PH7KP-1/"-X/K;)*62^/.#;'S-AM@A3(<]0DW6BS4$X> *V0)KB!O@R]
M"Y,Q)UG_44:['.%57Y,X4]0#[O8,$H>9!_;QZ&NO47E]V/-<(V1H7ZW&*=2>
M'A&C-9F4Z6,@D A/M^E"^EN+D3\4/[!1(4M3?B@P@ %XG-YL>7'?835Y6M%I
M1:\H_6+N4FF#-RXR37#AE-OE148R=^&WUF@&QN6F#!V.V$.%6)K K!&=DFEY
MP-/Z6&-K$/PZ+45C)!4)&DOY!'90R6_$$44,=?LS25G)U'.&),*B6S6% S3%
M,G:@"#.(('EF<4K$4)>^P3F^K-J+!SJ"]E%S;XU;4]P4;\"3IE-B<_"G)B6!
M1A&5$=\QG:BP_&I?K2N+SRG6Y%";EB%[W^3DU<0+J6)UC 6\Q27<K8V!CJ&,
M,?SXY6M#=$OQ%BC><"LSKF28B"9>4L_3<"[P"FPA6?(2)MK."3I?\F;6PL&6
M@944'-N2/P=-+#5+I/R'RR%DSZM;Z"Q]>A:/%=?TQ.Z0DHCEH-KCC+8LK2]+
MR.MO:"O?U7+4L1(#U:EP(AASL8GMK>>H6XEDVU;F2S_"YEQSS%3;3>VG/F&<
M:/7-\MLZ0HMEJTLS]* QGZR?+0)+FTBD7A=G4)M,F38!@B!RBH66L^5:)2 \
M%?)4F<.HF8GR.XI#\UQ/GI;FE(ULT](J'!K%81A?%!E8>%06@Y3F+:'9=SY[
M1=:/2//,Q5]A.PMW1 !L(W\IZ]+\5S9 P'?3L%WLB47@UL7D0I S1BS8<*RG
M,N RP3%$)/P822>^L/%V1O #7:EK S,;]U/4=SV4,P]W;;B+>M0QT^71B29P
M+GRX55-&@+-L@A5OS#D)BB]3O5DD%8;V4HI3!TJ,=0XN%1 >&>U%,(]H+CM+
MU+IUVAO,B0WFQ$TB8J.I@S*L:%)%!_??L96PYA&8<]/17YC"8J&DEK CZ99I
MS<!=(()0IE,J&FZ?:ATI]TAB,(C)+:2"&^PB>;<!E7BX9%63:).* GL6G9@"
MB[E%CGBL[J3:T,=#I8^*%*'Q4'S&!&U;?(-4A(ZV2Z%&"F65S2,+ZDG/IRT/
M/E=8'8NQ&(P\>2,QHJK !AP-+.)EV,Y#$Q\V)/9 24Q$$$.S:7#7.<UK-O,.
M*=PRFM.?(24Y*&EOZ&]S^@_U]%/P7H83;C@J'+BD8J7HMAX=;TF4U98C$_+0
M@A]05@W->XYO'Q^UB[F\&B54)TOL,#MB15-IKAVS$Q>#BMC)ZRA7*Q70QC7D
M5\9+6K#_C55_A?" =>WU*BE>;RHIEE52O'[,E117(*Y'[!G6!L5*[N+CDJ"5
MP3HEBTU7Z>61#$S#*XL><3'JEX?.-GKUH5(%:C_*H2=Z%H7GCH*Z(HU"08+!
M!9\D\6RB2QN)8BZCK\*&#RI0QSCHH5SPF=>5IVYP*1\RI2T21!$Q+^I?#9&9
M&/$$VVT)C"&/9(R.*1Z@_NZ*,19-@D%00V:C/!P%TG%&&H<SM/5QX/N%MESO
M'&P]2 ]LWO![.'?J<&X8C[[&'Z,&ADAA"9674.T%X]</%/OO%P6V$DD%+,A
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M%E4YB[YPNU4Z]*QJAZR[(6E!L<4Y8![&R9UHZA)-?3=MZTLJ&4>S=W.W&#<
M9)2:-EI]S(@WQ+5?6L&65D\# SR#VETSRU?@F/CA4!SM4;YBLMOB!M3+1A9$
M<J1$XXVUE\EJ[+:P?)H7WS8_?"!KZ1.FZOG<2%Q7E(,!]3,I72SKJ1'<F<H[
MA"CZ)4CU0E2M(BO=;<O?\*UB(@V7:"Y<#7HO"Y_TXR\<X(<>;6<DZZU[$'HZ
M*]7ACN\!%^5(%O2QKDME][[<*]OU04G9SG(INVZ\R<(\-J=V:W73XQKY6->(
MRRM:]S&H?I?5-30C/$"W1,V):=R/4_ZQ3CFK6OWFLAF]0D)&EZ,*2<RX$*W$
M5(NEHR3_X\OBG5$Q'?VMS\#?ZJ]7%$S4Y;*<VQ#_>S19'^N,YR:KEUJP&5<_
M/,M>Y*XN/' /J2(.D=7;=&!^SVGX[OY7X]-P7&R_XQ,@5V 9<Y=KU-:Y*D]&
M*"O3T;Q\K#/NZ@:<0-+(' 0!,1 J.;R>[J>HL#L^>SKA*PGXIXB'.@:P7C.-
MR':1F(WF2,V9AA,O'M<[3L)X$.X5IC]T$LJM^XU[[(])@XQO9#G0M^$[6HX+
M]6-=J"-*S#E=H&7A'?V5SX?>E)EZLQ#MZQ6(#J>C,LMNBSHU+=EX*ZI-%=&Y
MW4^;+57/XA*+ <+2A+_:<E:YY)*E;'V:ZMW%!<<0X#,( 10!:G54AV3EDC/6
M(F=/^1-(<+7E=;4LLH8L)FT3NJ4C9_7'O"I\8E/JRD)PZ^@?F?+/MY?+X;T3
MU\X$J14JB=X8R&ZGKCE/8TQ7I1+[G #[%)((4&ZS:Z_K^/"-ZQ[\48[I\P:,
M0Y/G*N Z.9MNK>WGQ_/G9P6P*9=-\T(K!]0BVW%[.5/!4D<'7(%M?7))1;UV
M[_Y\9,5^DQ:RL_4^I!Y-@>LSL"(7:#<HMV -Z@,E=\<^((AHU(DZ0,>VU%UZ
MN"G]'0_4AS)AAU'3KX5CO'?$,1[$,=X[XA@_KEWA6@9 CC"&JG9XKY AJSU*
M2M%6A@AD^/:[[R![KXT9AYA]E+D96)9Z4S(C KKXGYS_:HKP)7I\O,+\E* W
M%$=4QLWSQZ;;Q@/@8EI378WTG\\%4D/GPIV__N_%XVAJ+O[_N\7DYZI[6LTF
M3];3TT+_\O/31_$O3\NN7C7^F^'.7\MN5O[CA\G3LXLG\2-_C'-+L_^HGKZ(
MGJR<.>?21*7W>43W.5^07L,3GG-@.>F6$[OBGW[YRT7\V/-%C!PWW>2GJEQN
M%_1J\4&J672$UJ1BO9S*5</31[_$C_]8=Q3X_7NYVCR,1F;_HEJZKV9O_1<&
MXL2';?_]_]R__]W#JZJ]J=H7D[,_R??/F]/)?_VI/!O[2#'YB5Q#&M6G@BZ,
MOPP7\9J+SG[%HWA14X97WR%&I-3G%>]R]NCG]+X73Y_^]7]I",O?J/TXA\WI
MR)W1R/T)+15Q'/[T.!N67ZIVUY^?7_[WV0^3KQ]\_54Q^6O]XD553^[??X )
M 0U3O-I?ZNORK\UU.7G^E_,X?G$A5>MZUTTN'@]&X<_- G/*OY=_8<7LNFD<
MRREO>V(3V<9'T5$X#;](M[:R4Z-IJZH%!:8=Y-3Y-I5.Y\%Z9NBF  ":Y4X0
M)YH>(T+)&@YW_.7C\Z?/LB]<+IMF%N*+=<V[%']XQU:9C$9)I^"*,>35+ UY
MP6.>]>Z%JWARTEJ[;-6KOUHG?OD*W:R",5=<<N&A0SPYB;0RXU9/#3^IU:_(
M&2]=@Q"0A(M=_+,#3 -SR!(*F/;,Z=6'=VUHJ@6?8.7:*'3H=;@WU8.#27#%
MBLZD[NC[E-);+^/EP$; (573Y2O4PX\9=9]] D<X'@R""C$68TAD8<RB</J#
MVS%-[O7KZ=!%*UJA;ZJ.6PFD+>F/FZ:K+7K,$.P^DG0J 6/!!6H0H5=_J.G[
M!.RF39L#GW$ANJ'APSE4[:,JWWOD]0$$?W_XSZ=.3%W])PKS:+<&ROD+M;P"
M)$@]#5T,2BG7^3#?/"A:$-(;.[YK1K9\#J+N[<60]J)<O%QV#=\!O0*];=CG
MEM8-J+5QV8/8&U6'HH7N/P?ZX"IZ2HVD'1C<#O0[-&$,>[9&KJ4D'KPA/3FB
M?SLF/R^S/4-Y&R-1S!H&B12,=A)XW.&2S0BP!,*\1;4$(Y:?7_./![).T=!U
MC>S"^'ZFQ:/PN1YF/B<''&UDM!Y/!ZXRSHZU<(3!4G)WXHNJVDS@.C)6/IE*
MU9181U\AXZUQ6WX9!S5XRZ04-6YI?Z+'[_CV/G>]K'G/:O#'!790YTC8,O^'
MM',(:XMC-(9]5W7?#]*ZKVM\M6;JN+!E*67Y:(+3K:_B:<?,3VC3$9]*2HU=
MQ8*>6FI<-C=):U%&Q'5@9=..O&1:<O&4>R$,U^B<RA3SB"<'! ,@C8T#M*/"
MCW]4(S1?47\<>7A7K':R[G8KXE)G93.R/?WB)%P28<69&=^-&SG399HD]AJ)
MLN2-%(ZZ)=.I3H.?']V=7,$R 1VAD,^]"]?,H."U. %KBN^6:8)!,=\0O1F$
M)O#(,"K3GFNL2\/>QSK"_&&"*V7&;%9W4B%V>FLYR#;YV!+&JY8>KP-Y\BDW
MR? =^$'GY74C;$I5NV+T J6TD@A<E8F/G$Z>QN5/!K1 P]1EVY2SDTO0RG'=
MN$M,5X[7ELF#J&1(A$YB-5=$Z51O4UT\ZU23[C3FTT"_.R<\Y;>PET2K5/EG
MJH<#*F8Q]%V]?FN9K3*<&[0Q^*Q4AXFE ;M:AHL.H=LN( 9>[IXFIH%'=UVO
M1>8A2?9 $+4:@5"G]4*D*(BB=*R97&19OZA@A]C+R]EX4Q/F7N(!C&!(JY]'
MAF?$^/D288E3!AO0_;T?/H[W2-!DG7(]$N)RC[7&^G%&VSR+MC,.:8P-XF!R
MDV$?238"H-=7LE7 MQQGC"O\MC"JTH&P6S4[9NK0UYVV5AQ$FJP]^4/H9ZAF
M@6>C-Z\3F[ZFS6=/6%#S&:5M3VR9$S:+PK:3VMRTLQ4Z(6S*XVJ!5(4G X_N
M078!\"()E32.N/28W'8[E!SU+CE10$77@LUP-^;EZ'/Q40JO-V1^3HK/\W2/
M?H'[;COE\V'JPVBW(.O+2F74LK259^<A>7?DU!]*2O[UR2D3N76UOJ)U>'@P
M08BRC,?^\'!A?%G5MS_4Z&Y !I?W&W"^!T_NE,=;B6XN>RC91,I@YH52#I%
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M>CKY']LG=*DT!V@T/< 9V%*+.2FHH3$<A9GX3H2#BK]EG5EZ\CHZ^8S+\P$
M+Q1ZC#I."GUV5EV6K7RP_ VLBUUT\;FZ'0BH0/,YMZD1TL%R-^OQ-2M?87PT
MXBXK/,N,LP^P("S?P8VJ;@)2=YPJ=S(0-[YWY]BF*P9+<T<#@P3C2@2%9;Q8
M^O5)&;^\Y--F$5T\JM['-]ZM.4E@A6)^R&S-INX*48)A,NWU">_BU G Q7T!
M"4#<)%H0?%L9.@6%D+=:DY&T;;,EH%NG1W""5Z<FZ TQ.],&X8HUS=NFI)"/
MV"EKY7_,M3ZML<[<4 .(BQ8*U#>7K!&@HEAN_?.%")"'EHSTSLI=:@#>P)8
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MP[;*SS3SD72M5?YS4<6!7/@ST;DTVN)O*8>FS4_6_M?XK)Y3=I)3X*Y&D25
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M)D>2=8X%M%*6W&/ D=QK#8/$?,KK/(NN<4,#3W2%Y&O'=^'Y(+P!(=6AT"3
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MM8<*YI-84M<<9U*1(JOX^1IJ(E*QD?$$*@ZQFJ6II94A4*^DM"1J2R::Q2#
MMD)@1 P2KF\JU\7J9POK>:]#@]";YKEQ>K<: *-#'QA=7K652N,@ZY 2PWBC
M.#G6/DJW0/Y+>E& 0B*FQV*PNFY?_V%T_<.!^OVVP>2EVR"\FVTP><DV"*^R
M#0H;@&F[BU9JK\VWV P4,7;D0^^V3MAF[Q)"!E'G=)R"[89V/QA"/L5LN[7
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M&UEI\:MQ)%!XH7$*J[J[C$8SKL2'COD)G6=$"3W;&8;<G $4V[@GF*S%PYP
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MK^_30G[M+4KRG=0Y2M>8H'U"KE_D39WI;M\_^.(>"6B^LZ5_7,*?UA(>J<%
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M2R>).*;B^[A6'#)*GE2J/J*P?@&#1S16LTXU#!6.607'RH:_S4D#H8=[&A)
MC%$Q_;=PH5PP%XJGER%=QHMGDWM???W= UH@ZQEAZS,5T5!"]@BH&NAW"]-W
M9BS(O51I21*VE#L^)?D[SCQ?Y$0L](QQ0YOB',.?&$7B+!9IEZT8CQNFY-6J
M,KFPHP@&M)GNZ"96$$DLNU0KZ1CPE99ID<2%&V*9IV!*"6/*Z%F+4H>J8\>/
ME],7T/$K0C2A,_YE%Y\POEW1*[] /6*I ]Q!Q%!Q;]VBWFP$0=:#:4,T- =H
MQP]I_S7ZXG#)DXJTK(B7*0/=P1:2FHQA2A@I,D#6 HY%378JVKY@W<4^X$0A
M8W9C!?UZ++"NF,_+$<DT@67L?3O#-5W>$8<3*'I9TXS:698V=]%?S,F[TZ,W
M[6:ZFC$;Z=CW\4$'0+A)DT0P.-V8<;CSWQ=W^Q;BOR]^-E$(@]@1J=D.A,3Q
M$[MU^F<B4>K<,E?!UIR$T@_#$-$#*$^R@JQAAQT;+] H-LELGVV!3!,#$N=R
M]KDU#CPG49T1+<@8DHINI^=DHL<S6&K^(I_5\J=!WR[J=G9"]:9<":<+2AVZ
M9:4=)U<S(2GD[N48,N\RLS<R+8G1)54\V+PO:TC\]([ 7,@\O!RYYJ.(''GF
MR=IBU$?1'-EZG$-[SM"9QLQNS7T=\3'B15==VJ]&MYAI'CD*UB'T<:QYYH<^
MPHCW70Y$>C@9HE? %]_#JH2\0ICRD* D4Q_[H:(%).X!^&"04I3ZXH'RHR\V
M(NAQ9^7#T(,JQ+__?1?-10V^-XY/9BE2?ZA1GZDN#NI>1C_WTHJ7ZJG9>P3K
M0UHTRUF\F;OXAGQ=AC(S2GS"H-.&A1[S\<#I.9*"X5ZDHG<DR&-4<6TV^^JM
M]+G=:DH^ (.2Y67*+"O34R>+([NNKK!8DIP/QG+,#LP=)C2!WIOI=-?*-*04
M3(I[B.( $D(I%@HTU1T'0YJ5CSZ5Q*C2,I7%3TN*K!6:(5USQN$?;QLOD66,
M-$"6+-,G>IYH"(:XI^Y TQ67_WQ^ E=;>;LRJTGG"4U)?[YJSQP!@$N1#"CL
M'PYLN%#1!!R8.VI1$^NF7Q5%Q SXSWDY-B$I<7BY'Z$\Y@B8?)$9B87@OL@'
MLC2V$>I9XTE:H%Q"ES7KS[]+U6D,TJWFE*H^]QCZ+'7[<&N1CFLXD$-CMQSI
MHBXEW&16?EV#&U7H2Z15.49(\?BD8+2-AGR-%DP/6J<?'CW[<S'YZ:<+2[-L
MXZ)85_LN2'=M(5RKG7!60JK>HGW6;I_FSHOO9,K?C:E=][UW._!JS6Y+ZM'*
MLIR_HK8K'7A'A.GM(99OEVC]="W6:\$\[A]A'@=A'O>/,(\/<HT?5"<6Y5^R
M*@6=:ZJC:7XTN4E9^E&M2:[>.TF<ZP=:D%"*E@[]:(IG"A^#PJD^1D.Z[Z)V
M9""UP)0?ZVKINL'%L4*6@[Y'\2C;SBK+8M-MZ=!5$^DD#D[T#?WCZ!>8_)K.
M:01H+N&B+[6?W/9][H,T;NRX[^)7&N+M$7* ;D(ASOTO'V:^47>*W]Y[2*/"
MK/)%#%9N2.JVL,I2.=DL]AT%46MN?-YU*JY@V7N]:L'< >J2Z/<LOJ(U02&5
M,%+/B6D%E2)-7L9P[8IY4A?PY;H%^SW$E,!#L&FIGQ)]JZVIEB9W%[SP<=CA
ML*'>LXECQ8S]\_1$'1VH,4;",H";./8ZIY,L->>H8-W'PQQ]GFE2-,HN:110
M$=.I2X?\Q*UY,*?3X7M YTTS("8(&(_5;7Q=Z99-W!#$9I^<O%=S<B4SP$G;
M:<F'/]$K2)2AH_>)GL<'N]G]/*WWELT)AR9)Q8@U1! SQNX5+7"IW7.IB^P.
M;2(G=MWSQ?(HIJ#EKTD=H'"#ZBP#'LM%5+ML<\N]<]($]QJ4@;B=0@'IBJ[;
M:845"95:?>/XS+WTD2O&:,5I<ETWN)\,DZA#<TZO9D^WEYCRR:=",TB%I* H
MBD)"2O(CP8L2;U$&H@RN2'T+$8M0#>1U3)>IRX;!U_[1](U$I+2:<OV\;[7M
M2_LB8(M&^SN/SU%I:,_,(_5<]#RHO(+KN$@,=[CF^W)S\BLN%&\"+ CU>0_/
M?F%SR]+D-!40ZT686=BHZFBC,)"GV-S%9N4J^C3Q!\D9SNKNJFFY7$<L"/%6
M9.WY$#')0;5+"6/6,T97;;DRTJ')=$=EI*72;N4=VB9@+NWB/G&/>9A:/:H(
M*;"FUW:""C4)%\\E\:?T-_[[A=IUN1RG%%X%HF.PG(G!<L*KP'(FCZ/#$V,O
M>FLK+B2Y);03LOO;,9"$7D*7,V4NNIFT=7Q>=MP'OW4O$52VR:_,/-#1LY#F
M6%-,WD-5!VPEO?LL'T(FVO:W+K%R%N<HK@\<WVCZ+](<+O>!LDK";2K>"[,W
MC7@W@\03LI/>AV&"IPYVEY]1.#F&3^H4YVG7!+=K)'=%!3-.7)&O EDM2T6:
M-K%Y"E1XGE4Q\*\OB3_J,HYJ<3C-*4@@JKULJ9XA]7UU&0/Y:2P_8_J54V*!
M2%OIDEWZ-?A?(%-(F]?M)MH,A&=$VH&MU*2\X5*G;&_%):FOA0Q9?"3VSD@@
MC"E+/LW=,XX'(C!9*3E55$FIS *R%C5NZK5K)KR%RD=:/L89@U+5<FXE)'5>
M?*6;W1&40!*/S<'(*)VQX6#P@T1X!B"*[D;7Y+Q>_HPHL^<[Z$87;V['?V'E
MYU3R4\%> 4.("-"@V"?R2(J<ZJ%TJAJC<]TLHP=6MG4T)O1QH9QC0K.!<GFY
MYC%-!R\=6^:YV.OC7-,J"9F/DL^SW3%;C$BA?QS ):&1#?U,L=)C'=+-361/
M;E'V2Y2'"*@&@!N!*O0C%E\-[U.>]3:?$@':@V.#P[,B\UEQG)WXCK!KZ*1J
MB"N/BB%75V@8!-RJ84\=%#YC.D-8:3 XL]SBP#(0Z4U)FZ*U+2.'9&Y;!+,8
M8XA]2C1QS&N?"3<55_#C>^V,,6K<UAV^,6_F+7G(5^:*7B[UH$P#&H.0>+TX
M%"Z#-2.(\4TU&$[Z6T:J1;'##2DME@RO 86M?10?,:\WT2#BOCUR+JL!]6X;
M'._@IK5SFS# \^AZ5W9Y1%+I'M/FBM+Z9LL]3Y.]3RD/PZSI_H%B1( ,'9?F
MB4^2!HK.7OX&3SM)F=-R[@T*!9_S"7]E\$<\$,6<2?\<!;F5I,_P:A/C\).,
MCN.CZ]-*]A%3:<^E^>XR"/G@M))B'J\T%T'Z\+J'QRA"'XTQH&*P>&0,'E"X
M^!SH:(1PJ[A%M@2><8%;6UTW4\,Z)B]RG+RO.,3YD##H5/4\!$/O&<5/U*,Z
MC,\%.=\HB5:018*-!$-@R5]L.+;5G/]6-R NS>B%TRY"A<VFHEXG^P#4G,:E
MT3F&T*T*\I*S+%]@@&L.*Y)-K-X[,IWNRDSS:G\F4$/'B2!')XN@A:K6B*M.
M5<F5>7/M]>V 2XZ=>VMS?3)28.Y6F-=K24^QQ]-2EBJ=0UAKE]8 T&/B];9_
M>+# ])\&;P"GBX9B?X)E)G=+GRX-1<T%U>&XDX\7)W^WGL5 R3E?)RN"7XJQ
MTDO;A>.QL5/R,P!.F.!1XAO-OAT<] (V+&[]=2)R+#*7O.AAR61=)- R#P=6
MB%]##LML:\D,8'^Q63SP2IB]4Z)&QV .+AQ]_$:P@3P:LBK9N'RB-N5U:\=?
M'6O'!VO'7QUKQQ_D&A\_-P<RP-.F%9;N()GXZ*XQ0IC.C%F+#+H:8SM:#AQ^
MR753NO3#V08<!'(J(2CGW%FTB=-ZIK3L&LFI:NK+6]JLCT6.)5Y9FIA3.2,'
M=ZW\.%0S^=YIN*BJ%R(0O#AX,[KF:.^=4#LY)\,N/4:V>SIY&I^R0;F8$RU<
MSPDNU5G.>#8,R-PG"7992\M$SE&9'+1,TDP,:U3>AT;4VO>C]4RVVE'&Q7>H
MH)%PSJZ^Q+6-3_2 &=]\Y^BLJB6G[+)UP;I/K+>GHE9!A)J*[@9X678KAIL<
MQT%JW 6)*?U@@:>1*">WR#%=!(3L=H<!$#OW#6R#6L%6:Y#J:GK>LU[*C-(!
M;Y2+1'J^5U*^Q<8<S&C&[5]>@3'2;1U'WM>E0G$83^YDA:NRR^;)R@ ^_S3<
M;^2WRF"JVRO-.OA0GC8-#GV 9[;*05;\N 52JW#HE*D?AVT#!L\\RP0 3T>$
MFHEPLZBR/.F>XQG[9^&3+:D$&"_<5<MKM8!4?]O5VT)YZ5-8-JMF=1Y'(].
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MJFAXTG_ 1=E#XPWB7<99)=6JVF%'='MT,1P7ZT$TJ(B/>\NY+<'56V[J+7-
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M" F&*19[,+A]>I':$,G@TIN8UR';3[,(*O2"ZJ5I[OO*62TR71MCR$3G2XL
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M=!ZTJHL3+%*>(0Z=UADY=3=)V/&=@8(6](#Z]\"=\Q\UU<A!^LU:A86O2HA
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ML%WZ\_K=R KKY&0_"1K<2L7K8C=/PJ-62]T)&CKX.I"Q0,!-\0IPQH4=I<R
M4]-HTW#@#<)]S!EN7KT5B,M$8,+)?R._P[%G300@,<BPVP.SU'/^*+Z+EM>X
MT^92KN(>10Y9%J%*"D^DS35TY79)REL2L+),@B>P+SE"S@%^=*>P*+8!FS2N
M# Y#+>#2<[38RZ;(%02%$8/I@O<I^NZ$?LO<.<'3^,^X&RP2*W'BD-O* ^4X
M-*@ )8I=>A^ABN(- >TZ3B,'>)9 J&X"O)%IS'DDX6/RGB29$ QD'Q0 :?XA
M0W!IXH]I8/0RVOYRJ230)=\^GK-,! L0!MI&BS!/D&.=<][0& +L^8GEW%#,
M!$)T-G(8M  ?$"PHR:&XG)%&3=XH9RL'#3U].*,EV; >?M*P$C<LSBZ&BTR/
M)@]O.)C"55/QQKKR-<QHT L;T^T*#Y<QP80HK0L)$@G>N4UYB4M=W^&6;#]]
M27YIS:93%@FLR*M8CR[WY$P&IM*=J\+K@'[.EH+*\XRYS,MU,LT#?F.M6N0S
MT' JCQ,,C*U0*"2OX#NT?DF#M7,;\41H\O!G'8< 6FLGW3YOH(MJREJ$,^,R
M37>NHJ1/M,!<8\EI5ZOFC)"48="U; ^Y)'-A]X9_VT3%>T+'M2SK,]EX%?X@
M[AI_)UHHR3PQDX5?@^\<K]_F!HP$'R->YF1(+0>,8A1=*Z$1&^?9#(POG,\>
M'>(2M[-69;,]JP6^;?'!C'<_8XE_#F+-2?Q +H?S_;-QN-21('D-ZLC11.@<
M6%*3+\I\9D0>"\290TXU[?9W;E251#X#XXZ4G5:J?GP0$36W:K)H]^C66O6E
M5:HS3E@HC%)(&NY/(K_BY6^]$#KMV>;Y>[5(2'2S @I/LGT^^^K>7C=N[3EZ
M+0#2.+K,*J\AVI#=94B=M'%\C'AKXR]..SB<%BC$7;3WAAL^H2YQ9\7X@=WA
MD/9<9OI9&<9K;)WT%5>GE-J4+%T78\F/,]9) DVXEL(<1K,,$-$25<$8!E,K
MK4-80C(]R!_E\ 2?D^CI?+4$TQ@8*^$$8> %:F56D_7T)_/$[2WH4DCDVC'R
M4*/N25OR=>BWG:"P.5HB";,,*\"<V3A\,0CFSK2/BG[EN-J06;<,>]',^F7+
M2KI-IKT0&XK.<)^';T,KP3Z4=2^79!TY@,,0>3.LTW27Q"2&D(*E,.#X@R8^
MJZ4_/!E8:4&:4UVGB#)2*M8$P=0Q%8;&L3Y N!V+E93Q>]-)VW^MN5B7)@G3
MD:&1,RRWL:64K6S/LE4DM)HMC=8?7$'+PCJ/Z.PH4?()$]3 \"MX_U<P+R:)
M/4 :H5ODPMAEM$Z.JAYR- :7&H=Y9@8N]\Y:V"W.9$P=0T_9_..A-ZR'CB&B
MO.=,G[/R,*$H=V.36Z:*;UW_7:N(D0YM]D[..]BW]R:XY=&=%YTUA3H"W3"F
MES'^D5<G2C<,8RICAN8N#(X, 98W\(L]VK :+_^L^+0Q=# .%,,K@(.+7Q1R
M>&5GK760Q$^I4T%FX\K8MC5PQ8^.1>VI5NFKOEC*9&?57/9D?\\3+H,&Q:L&
M="(0JK>>U N].$%RY6,R(]9*6)JQ*<026>"')@$W.^.QU*V+JGO2;1%"\3AC
MX*SSWA/5.X;'U#('_GQ.$JUF'+XL)#H,'B$ UFI1S(K3HDR-0FP=7E$VK)"\
M>7!D)T%@**']9F U7)'J3D=34LP:%TAR'7S2G1KY<@S>R-[^AOJ"6<68L;7A
M?UC76+TP+9'([()U'QV0Z)?M*BG02#7Y:077C[N(G6NC#&1O (O2C0^?B\"!
M&0086]L\OL=EN R'@^[*]41@[0!&WJE5,,H;.:I/_;B207)-6I 6O92[GC!'
MLWKQ3CKP,MI0<&P"A=N%/$9?)9!\$B_(+,,MG;,2$\#9D"I=<D*5DK=?>JY0
M4-HVSNS7P0R":&;;#(5%4I_M<"J."=BWLC($Z##'@2'RI/"+HATT,_ AT<$L
MHL\MH.52Y>)UWW$58YW=JOYQ[MN(Z"53,0A1(8[R+=2Q<=23KROL,#)[ :V@
M0!0)4:\&HJPC!GAC@E U8RC_IVH;6R#83L:\-_!3/EMT:,]+*DOO,ZF%CL8^
M+21.!4="5L!=TQ+UF,^;7%&N<_?B>=[.FF(*?85(>=3-:0K&G8UU,D2^%A4Q
MT%^!9>+&,&&5,%*:H4J)CYAA.F=G63/7$+. "ZCE(YV@#,<H6FAG*ERO<K<G
MNW*WK>5N3W;E;KMC=E5^Y?\"<$T;5;0N ''C8NJXE]HX-.[0\MR%0[K[/4.3
M:UM+? &Y:T_:YUH7R'*@^_9%'[4Z;SP6E0JR4NKL:CAJYQ[>$O<0[2D?D81!
M>G*$9#XTBRY< \/=L^MDI$;OO'&)H&^7\_3?D7/0#0WD'#:UA&1!33H9'--Z
M8%Y+\HG1P04<7\#],<SCNF;HRN[$R HR16 &UAAM5273(;>;;#@T-";(H06C
MUQ99@P)75@2!O:QAI+51"LQWL$0YT50!$\BA:6#T\CIE4VFAQ'-7]9DN+&-W
M:*@T":+DV1+ 0_)LI$*/V7=.3VM!5T6:3PLA&:-3.Y)BA>*M;=>2 :&1BDRL
MVD8J7H4J^12AFL2T"2,/$[C5/X<Y]8GE*21P$9:QA.VND(AU$F5]),?H<M,J
M()9TCZ!L_?*8C$2;P;V:@N[*ZZD&_.9>,E=$6#41W2!(=8OUKK!BZ#YDQA9S
M.V2GF=G6NWP<T&$H4XYQTJ;FLJ7!5@X3[8F&!E:KNI# O,7H.;@CO_9Q4PLA
ML>,^C#)9[&'D,*%D-2L:+N$4B0\_N9\$3ICD+9SW%34A 3C*.41<$^O*"O X
M6G;X?2X\1*\V2N 3KLB#?]H%,9\H5<&CB),7&M3@X@E:%^U2U2;2 (8G/-",
M<^R9ZG%>MJM@QRS$X8/U"J6UX$[C-W!TXJ.7^6>ZZZ[P6N;_9&DQ_^^OLO][
M</@ SE+V]_]T'A]S/2[34'SQ[OG+]-%^8%6EEP<]PN:%M-/1'?)]VJ_H.L'Y
MD%?_^M.K-R^/WKUX]6M*__?NY^?ITU<O7Q_]^K_C-MXEVT*?J:?@8[/^!+;9
M@50=1E+5">D[:?45CG%U_-]?'7S%/]/39O;SA5?HK)AW)_CHP==D HICCL!,
MMFII8O:OK^ <_JUK[/ED@3&'AQF6)+A?J?_8S>U#^NA'WZT^7++P'NU'Z]C-
MW;LO]ST_%X@#BW7S;+,\_ZG>!</!T'\:7K"_\J;I+E^2%/-_OT&PY'K9]I_9
MD;FNT_X]3QCC-#3,)?,%=\,1DHZSTRHR_-:$&?YU>/#@NP -LD(9S-,RSYH/
MZ4M R]!=_DLWWT]>5>G1JBD0_IKPEZ2KG3]_!K95+J<1YN^JY5[P\/O:%I/^
M ]C #_D1AP?;'Q$ ]?'?)WCHJFBRY%T(+_+JPSK]<?_G_5_WY26O] 4/'O,+
M'L@+7J'4#X[)6ZW<UGJ[,X:VZ%QA;%$IR&O!=5!<=C>3*CDN?<%"EG1DR6[7
M*NXY%S3_FK7S[%_!(K;KY;0N6\,(>O'BUU\-'0CO#G[]^\3^H+X>]QY]/AOF
MNHKY'3W=@$IS#,$;[D.<,B:S^##].=M[5\Q)C-.WW?YDX]@_>OCX\3<'CUQ.
M\A7C+I3YZJ0F?T@KQH+CWZ9/OCU,GSQYG#Q^]"C][COYQED^)3\QM[P./O:W
MXN]G9V?[A1S"O0A_ADQO!- $YC4L2D4F3#D[Y639@Y'W]$Z,8DPAK&@?T.QA
MI+6FG+<$G!:CA,+WJ>#P"@*G;U!0&.),P.3X*BU:AUV6,U,*C><G '0='NS]
MY.MOW>,3U4!N.-7''L+>*5*[RGX(>9*/VHA16K^?ONZ/28,4Z7]ER]4/Z9'E
MO'B-.=AT+%0R7&D]4GW C!I^6[[[YB#]I9@V4&Y'Y*.B4/IMCR$?'CR:0!"S
MYCT0LDIQG1\\^?;!@RO4+K=.D7RI9F*U ?3FR*T9A1;SK/-Q+7?)(/NZ*#34
M_E8H[V1E#N]E]\V^?.N][B,!TWOPY.'#&!=-(P7^H\D1H(XS<)+.I?%I*IA\
M_WCUXUL\AQ.]B(--K*64K)9CH>&LC=P4%>C\XR:3CQ5W:CDP=^8BDG2:-8 2
MU=,G9((!6$V<NM>2"KG!?=UI%%PX=S&+W 'Z64Q/=(S &SN4E&2(9Y?U<_1/
M@P29XWI0A$.,NVA''I&^M@W)FFE6Y>W>JP]EOK9-.3PX./0;L?$1X'\I*1"]
M(A,8S/,%Q6;F>[<74%K*%%4K?ZRT"&=-6>12W$2B(T/&'THTM,PSUW.S*)JV
M2Q9%"XN/26A=@0<K-E&=-(X66\BZJD45-D->_N7!_L&W\NQI498< ;PW#=XV
M%W(H :I1=J+,9EFB9XI[+\J<[XH$?63-^&EXTY>Y//?!X73O,+#:.(X4G(GG
M6B(>'(Y'HX<C_*#EKKC,-A&R;^VA"OM9M@6^2*<S4OETS4W7&=D!I5P0;JF^
M/="6MJ6LE.*6NCUQC>&Z.;A7N3Q-D#*%_%N[N^CU-7KX9=>4#Y+G=6\V7'W7
M(G>F!+UJ-:/%(&5TR[\\B+80JTV3H#>P.T\G,YGGTRZD(%AA3!JL;/)\C^5&
MRM-O11SO1E\WGL*S*4ZS3C>\"<^3JOZF1];"GZ3!Q6+V57A.Q-*$@NPU8SS^
MMH2KE>0N8*!!AV1!YX+Y3*%X[<[@@K2@+38L9GS[_*D43#FZZXV/J"/WMJMG
M[].7?%Q#\EJ%5""?DR=L/7IT&^VUW# 'O 7.<^6S;,6!=_U@^%[)+_+8HWO!
MKAGL*]#G8 CZY(*1Z2H$*!VL$%LCKGWV?L0L((P85-0%< \AZ!<TIRKKB2F$
M<JT4J^*/RP4L8.6>>(US6 &RB5MR;)FC>:M9?(1@ETF"##%X"1J$\*INN+F7
M37DO6)$$[7 EKI/6>%$E0,NVN N$ R$>B>0H6R8C'9( ]AR%8?@YD;J_'#Y^
M"(3N"=TAWQW*O_"$OQSJKZ/H"*L.D\:Q9[/^(CU"JT)S$0!_$JR^TU;_;4",
M= P\C+#XX$AMH5+3SNBPOCPH0U0:1@Q$D <5V3SH17"3#P;'^BQK3S@M1L^X
M\LK#SRL7UTC6+U)O^,W!KMYP6[WAHX-=O>&-.%R#A-_#7<)O2R+NQRM*^/UH
MOMFK4S2NY&=7F]O;1>#^4Y=(\7RZ=;K4Y!89$,7,5_CDU7%V[/D-&\=2$!@:
MDQB\>#)@]):.#;(0C+F38^Y,5J$8SR%8L(4-)*9FI,_,K,U^0JZ8]_=>O/S-
M@A.%E$QQI1 *CQ!UX\JJ&C$#CV2?9[[0B3R*/!H+.(/(E@E(QWS/$\H8.U[C
MLECD;7;*TZ01<)Q\T.EAU6WDM17M>]H%M+2T-JB)-.5C9B4M+A!*4'_7H7G:
M' O4\RG6 #->+')K!&<N,6;Z2,VK4JJ/):UCAKZW_?2?7"Y8JS^:[]6+/9K_
M'M('P833S<67].)QS0WF"?>KHKBL(KG:6%NM5%2BP10M\0$,Y'!U4UU=Q/)J
M?FU?*=XV0GS2_;Y"?J7*$13%C<K5B^R59:=U,8^WG[[33[6<D&0UX_&XD"K6
M?6-?\/U>P=U?_L9A74NIR%HAUG:L)7\98R?1[F(U)HE6A=+GT4C&'>9,&RK1
M4R-?\;!8SA_-U,AWT)3H]6NA"XOV1*Z/:6W@%3Q,'0<YCQA=Q2;^<5E/N6RL
MR9CGYJ1NV4M U^+8N378J#GPI(IISZXTPSXQ5UTUIY]SYQD@)KI.9V51">[C
MO%Z)@RVJ[W?:W3)CEEU!<TI>//VGQ]-T(\".(MPJQ.02$<O$1>&X+8FJ5S/:
MZ"C#;)=P/7I$@B7:T>.YP23=_K%L,J0^%I.[5LDD[17[HVXD;-JV&IY/-:8H
M;6-.1.NFG-/EFS/5A/HWGNDQP%YG@#$Y)9&(V'JPG"0:"*7CF'<&K ZIU74T
M 3O_[#F2&56L%E+T\$4&F/O][;J+/M?]NNDH<+GV]YCFIN<03[W,%Y==0(A:
M_A>_OGW]XLW1WVCW__[N)4V9_G]Z].9=^G;==OGR]L$&?UH=WV>RW+<:ZY%1
M3V;Y^7;[F&0DD1T_YJS:&YY\?:GK62R/ 0SVWU_1>C2S__ZJ0!OH_STX.-S_
M8W7\U5^'ATD,_TV7X[L'7V^ZY]<OKH@SDV[[GQXF/C\MGQ\Q7Q9E=LQ\Q*HO
M)VRC?43[ZLUFJ%!D8P%C2<+0Z;2LZ_GV@=0?UG2W9<9$/ZV1G-++!@R4O=X)
M)11[:PAURZ+JD0<[8Y9? 1>2KTACP/M<BRH"LX@,@*VC<!:3U*V@_UWO'<?$
M5;3;C.FB.LW F4O7,P+2?$.;J<DF%GU&[&V]B+>/(\#=<N]R=G!8GX\K\H0T
MLIK'W$1CWY5@I%Q[&!]G1!NW0JMZ9:F.[0,IM'LI7R,E2"8+K%GLL!(XA_)3
MM)H)G^?*6\TI'!B^A>M^A^W(@ZFKXSWT9*3W\$^!SZNV#^0Q63)D*]X?%T&X
M.XZM6[H?F!R>+ DI%LH!GP6,K=*;%JN3=5L()5QZG+4._6O[(.Z%4HI'/'UU
MB/PZK%570*'KZS&Y(?B"XM^7'[7M)_X0;1\' QO2SHJ]%7IDWCRS$[$6"QIG
MX5.V##9Y($#:Y7+.4"YT KR"V.[<N"D 8Q%RPT^$N[1]%&8U-ZE8U=B;4<M:
MEJ BR="_\U8.ED2,V=RP'-I^ZGD[?WIVM'T8 A:_X<BDIT7&"_7ZY1'&^"Q/
M?ZU/Z_"C-.F3LVP=-:HDB5U$+@04!X!NM%5SARS6G__WEX&Y^B/KA+<DVW5S
M^PS6CVSME[94_^T8\^&W7X\G538W_O,;JP_/,U:W6M9. G1*WS[\^K,.']H6
MXA^8?RU+_<0A*(%*)#(8@ (@(#:(/GKKTD*0@;:>A#>8<:)Q<8C@#2#>1E-'
MG;.&=KJ:!Z'=BL=218SB-NV9&-@,#B5';PZ>"YO"J,1R]QUB%+ACY*Z7&<9W
MJI+_XJ%["(+R*&26 /7L.5['WU[F6=MK_<<DNHS)VBV6Q9^NC3-7-E"NEIQQ
M:;$.@!%0M2S&[E,_ 6>:A*_B 0%32)M'V3J:%9G'REK6%8H8+1H],'-<Y,L!
MCP8K%JW+%CN1'K#:JZM(1K*NRV8GGI.Z1K8^/:/5D'YH?7#73QEG2='MPS4[
MQWB>.*BD=CC48!#\1"$F;^IL;B6E;#>X%TT4.)--&V? <(F*L$][.7(E/3-P
MLL &7S)E;3I=KQ@ ?F4PO!,>Q?.G+U^)K3GZ^4EJI)1C$=3]CV>1;O1-\VFA
MD=MD2QS]\N+I<_0%DC*[?9;#%PUU??XD]<.'U\B >/3)!H2._O&WH[;"S0Z
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MG2(7S#2,=I7$W3OIN=T[VSMU+A93_WA7ST?J!6]5LO]+1$-O^OB_$.3>.:]
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MS(_I24,P# %?'3BGDS0#&W!H%3/R"S(UOF]NM^TW<@"[K;JN)U2O6>TY+V9
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M!J^Q&2&]!EW'M_247 @FX]L=3,96F(QO=S 9N\/UN>;TJF^219D=MR?%*J(
M'Z1_C1-)@2I<CMGAU$I_@A)^T.W"<4_FXNBYCIGN-(<,6$2XAP_M@FI#@+(0
M#U9>199B7W9@U@,PKSA3>&6 Y*X(2W7?\?CA-^WS;78!5+KDTU#I<#=MN9R'
M%^'%@.?XM^2P[0D,Y;V?BI_O__M(=/OW)Y^(M#>"19=\/BRZ=(A%]Q$8N@D0
MAE\\>SZY;#BZ]()P=.Q\_?/MT6VSKS]S$.;"1"67/+>MQ#&'CCCFFL35/D\P
M\VK@G5^0DFB[9IV\.@6<?'YV]:MZZ7(3$;O<_-G8S@!Z]TT 4/535I0 W;WY
M\[R-9EJP4\E"=XH)UCP]*UUH<C5ZL@*]N^=UWC+H]4E&MVU>,0BEL!=,..30
MU76Z[.FKLZR9TJ/F1?V!+FX&U"0U?;*?/A.KI:C(8,CD/F9&C![$$EWVGL&:
MY9%B&LF_R71K6P:@P&W,8[(8!7_5;G-Z+Y->% Y=;%K/UZYZJ6Z.LTKS9TS_
MID_OZF315S.AV'@:C5THF %!/1>XG T*A_P#S87^0387=]CCGJ<S,1L\IM)O
MD>U*:Z4$T2.CVT]>5-F<G#-$-X\SF%R*-JKO@QL& ^*8'P4N$;&!_!$LJK9'
M869!_MW:E@8VE7WX9+VJR2 J!(*#?LH;#+?(G%74Y(G#[ :^6['( 3N*?G[.
M/SAQ:6E/BY8YK&5=%5_5C1)X;WABF\[(J";+*:VGI-I["2"O^G))QI9@F> I
M+"M/7[WFQL9Y AZ2NF^#]T5OJ4@'Y4H'TK<S1"WIDUU#=EBT5!->*V:8B%9*
MC\!^I,&"<\'8[\BO)@%]\6+[8@M<'<KD2%Z%(PH[*,<'[GGZ(KU'=F9=8M@@
M'U$)%-DH$:G6?*^&$6@U\#&1IL2D23[(1K \]9,>R]&KD^)X>#[M<23!1C+.
M"2:AM9V!8P223R;]03I=\X'5PE]:"]U]@$6!6]&">3_G9"2=T&_K92T(VUW1
MH?<&XGYX\$.XX"9 $_[;@Q\"4'UV"S^0C=7E]-.#;U)2>R6"]$=+TG SYOM@
M9XY5TC3/,:GLN*I;B]9!EF1;&*!^FI>"*">.ACRM39=U U@=)J[FR?+7IKWJ
M.BB]P<,AG4C)R9\$41['8[XOWU7I6=0](&^,\D=$D!/F))DQ0&(J (F[2.*U
MB"1^MXLD;HTD?K>+)-Z)PW79)2DG>0(&3[H4IF6^W!8Z0\2(<R\M[C/H2(G4
MU96#C"W:]W+KQW0B_#F)E;T4,BO$:7[#M:0/N/?BY6_WD\_JE^QP0L\I4'6/
M_OIJZU+MO5?\VL'-,-V\&71@CPZ_OIJXBO"E:D?(V!&12:71$=F^H-_<]045
M]<7#A H;+MM%"[DO%Q-VEL\E%+.YH+>I*MRDVI@<(=&G7J*EM1@<M@L&KLU:
M&;%@<93TQ8:)+E=U6XA3"OI2+)Q>-Q*=.&5W.<VK>0V*QY-<O#/Y=]V2/*[3
MKI_F+L@Q/IH)#X<\B*#PH<K*X[S%\QM?-;M_V[?MM11^L6O>Y""M3+.S[+TH
M)ZR+N._DEZWHJUF5UWU+3N 9*K7!Q%)4Y!<B.N%8H%U>$)&BELY9/I=9^IJP
M+*8(BPC'+*>UZAN2A=S 6?*8TC.DZV03)/:E.5B4E?\1EN&5[/)M$J6[.LLO
M*%A(T:"X["E]^M;?,%J_RKJ&IBW4@ZI+%+D" 3.X(YDI\':;DD<RO&++G;[5
M3^4C#J(YN) TB"=L]INWDU-J?#]]N>OB!J1R]*H1V$N^7L#%A<M&VEJB"\8'
MV._]6LN&Y^QI9NB:<*Z8>];UG_Z&&YE<RKCYOX>'^]]^6H_+WF=C7I#Y;?OO
M,SI23=$O>=(P-J9\B&"3Y?.[NB@O.5W"4RZ!\KY;%_GOZT"I8TWR3 G3R:1_
MOUL46124EO?P;(0^OB#C8[U<D0<D03FD5EMSGI;:^M%VV6)QUQ=PN'B<H9(W
M\\HMF@(]I[I,853[WS'V[/OA73WRNW-MJ$]\1OB[+VB4/HW"P5Q5F;X$QW-9
M=.OT#99\9R9]&3M!B=&N[QE]4<T:I*'G/.FE2<T=78W738T>&UV->>\Q^()8
MUAU=&XN6U\V>>@=B1_5<V?1'3][;O=]>_/+B_FY]LK:M9P62<KP JRKOEW5%
M3O"]WXY>[]8GDI]YD:U.FNQX26=K)I^<KULK3+NC:_6:):8[J9OL \];+G6-
MNB^S,B/QNJ-K8X[M'9T^7%@$[R5?T#7UZN2NWM8OJFQ:P%H1J+ Z/<NSR@*4
M4M!VZI1.6$ZPLX)'0-C6J#9&![Y%^"0!B K:8HDV-9='0FL2^7.Y^1J#AJVP
MA+;)H>G3 H)ZG*,.-JI=V446;Z!;_R;WM[>_U-,]RXVP1?B"+<+=$J6!"C*[
M)[9YTL]N[MRL]0I$ZLC9T>EK;T-+%3PR%=_L/3KXFHL8--.A39'XVXN7OW%Z
MB6N<NQ.:#;" YMFZO7P#_ LTY7S.T-@-"W\91W/ZC#;W]B=EL[7E6M$Q+>$*
MQT@I938=%D(:OG$4V!(JSB\7BN_E_5N_C$YH9+&0&34;QJS)::[F"[>S9+J@
M4#?0+=EI7<R!\!*OU:[H95?T<MN*7GXGMPIZY+8ONM5+2/>3: "XE*H2Z@6?
M?.!M ".5C8RG_V0%<OOUY:^U](["I#I3>: %<2#=WLI%!VLA?B-W)0)Z-9=F
M32TBPJIQ"V:D@W=Z=*=';[<>?9/O97,%T;G]ANI1"N>L">:< DZ.1\$5 ,YI
MX^*;GN-%\S44Q+QW5>BD0EKMM&L5YU5-7E+%MU_MOCVI&:&4NVP9R[/#%W01
MRW(LV!9WAW$3\);XW<3KY'"?=JKX2RNINS'++RA8O]1R/FZ] GE*SZFKDI'.
M<,"KHB5]HA8M>D\J,6+SKKL+)O[1BE6CE*$[0W19')](G9^AH_9DS-+7&/RL
MJJN]8(W:]-Z+:E;V[  <+:<*&7Y_IS-W.O-6Z\RWJ&6]]1KBC?6Q #*&]"90
MW\F\@C*0$KFPLE=4:W::D>L;Z)3;OD8OH2\=/N04$$MM"S3]DM%_-M=I/WV)
MOD5Z1.O#"$R\LNAA<=*E]'&FH,\"66%PB4'5\6<$R/@,X(S%W]]AC9('WPN'
M3U.T4K&((#5PQ/LFA)L0@#J?1[I1D]U,@]U\,).CLCL!I%PRV"AM#D9/;\PS
M!,@YA\P$[%RQ4ACOMIT8%E?%*+-Y!B(BG#4&&I;#"K<:H+' DJ4SB49@0-+0
MI ,&E&1:SPN,^RPW]"@!CQH.4^%+%'M_E7?2K\<\+5UVG"LC"[UPSPW">;-
MIE)PJ,%CT>_'O6M9JD!PS$@E-%% /6 ^I]:@VSAB"Z8,)K0@%_=$D+@8,R7
M=P/@VJQO%=9VGG>DN3&_^FP__5U:K*NU=ZKI3U6^*&@8"I(_,G.=.*\TC1''
MCD>SSCN-(=?3%HAM?IMH >CA-*[A([E?WQ-^8+G079V)@K44'G-U=$W62_T
M331OT)HM06L.41O<M-YE+M1"?U?"$312-CUG!(.&3+:&X[9/[0(4R:H7M#)
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ML%3GB3($@ZE,?*VO2*/@49KXZH$#&()O64%1@P3"RHBC3YR2L&C=NA,Q]U@
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M2,G!>?+@"1E+G:/3S1YLMN&C0(25;3[^+!DV-A,64W] G$WPI17+/?K\")4
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M:1%H)Q&Y3J5E*D?":"T84X$)Q0W.<23(DEJ,DRPW/JB '!E/?Y*;CYDZK](
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MYB+'%-M#HN]R2(VLQP2YU/A_]UT6N^Y85I(ZY6?DV8111BC[H"VJE V@!!N
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M7B=FT%E1I4M\NDLW;*GQ26!=;(9WW3RBPYI%.5H]CQBIB]J5I!.B:-"X)OU
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MHST;147+%+AKG)HZLUW>@\_'_O-J$7%I0RU)FV;FB)=YL-;VZ!GKH=V%VM+
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MX'TUWVVS8+'7V&C5 H!+VH/@K2-,L-NP-PGJ+,%(&#:WI ]WJ)X=5S)[XOK
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M#'X/A_:*J%Z1D] 5A%9"HC]V&*5S9,$#;<T1+]IV\]E1B*G'+-+01$2Y*J_
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M5(FVX.'@[+,_C](-J\(1O;;1%=J@-A >CJ^B')8<K5^*$--%C(7DKI'L#*0
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MT2Y<&!!B(+9BC?G"4?WQ1YH:I>V%1R(4@0<"R&(0+/ZITI-FLPW0*WY\[_#
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M89,OTS(+\\_+F@J"MKS"LRD4R7(<5>9 .6 /P;YFU4LC.+Q*H*5^4B[1U#=
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M!@V=8*_\;,)Q5$S63D%?U^RB\T7&-M BC9=@1N7R)DHP3-/( _D D\A-869
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MMR_=3JXBQ/<CHM\1;A>6X/_"(=_GHB\?W6+CKRVZ^W'4NYUML+)WGE[ZK($
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M'HN/FK=\2_<B='"#):!W8/,*">J8ZBJ O,T&D(W,5Q+'R45;L0Y??9<)J,+
M*$2'P<BKO+/@/$!=C5<#4K2RPY>VHR]5C!QCIS5[61L6S@!\9>"?./O2JRJ!
M5239K<9$59=U7Z5FU=T'YOWY@=WQA,@I:WY^X)W<64PDK<K5#:BRVW78$2F3
MKH:<WFE=O</&,+$4B95BFRXNF^,N_&>*]>!$(VI)XQXK&0NU7^!<J<D$ 7=7
MG#](:8V2@>H@M]L:'H$<5[F>W4J\WT"R<Z_6XO?F,#MM!.I>:=EJJ\NN@U:G
MI^:)>])ML7AN;BHZ40R V@U,TG9#'VTM4J>MR6:T[GO;D6A<T 29K;D&>OS:
M&18K$+3PJS8$K83*:U1C!$8U.Y?NB>KN9'.^OF7IM2%OV2S*A0#,.%8)P>2D
M^CHVA454-TWO@,#\)N4W\#<0^$CQCG3.;5810OI3IF.;'=WE:]'4,NV$Q[UT
M+PK..+96EH,W(U=(EWO+X8YS'D\P/QD=)Q9>YJWZS,M5+:"&;)!3%=!:RU=:
M!X1,#KH,JV?*KZ+%9F)61 IGK44&U0DA4W?'\.\M8UTY9>1><FP=5)/@UX2U
M)#*[*A 3@PR@21!^I/.;WY'<[+ZJZ@<ARNV1!06,>^FP@3@L(35FD.]^.N\&
M$'G1 T0Z 2(O>H#(,S\+*[-W6F1.C06F+>GEI[64+\^6ADV\SZU*]LUUR+8'
M>YUOWQ^#VD:T^83\;4Z*%^@;2N>F9!H>.4&8$J>F2UC2D#2Y<"9-_J9C149/
MXNR9S_AY$\(3/U1G& __$LU1+]-(4?WYEWXKK]P=-\==M\-]/_^D_;[/C;M^
M.S>5<(U-/<ZX@#!<D%FQY/+?FOAKP\E$=G]OF S(+*( B4X:9Y[J1KH![G+=
M!P[IV^^1]^X+_(+"K\B02W$ >!-=O^Q/K(;ZZ7/&&M6)TB8.18BX/"='H!YE
MI?^<K[3*.K$C['RJ8Z@O_8TF@^GIP+K)<,$25*7?54G-F-Q9J5S(36NLD?+;
M$R?8)J6?4?.&E?ODCI!G3<.AXO!:?-^;O8!8+P&Q-A*B\P153HX!X<G^3M)D
M*U%3Z"$J;3K LA$-U""XTYDS'Q[%B+.ED(+X4QI^4 R,N,T&Q J$.4_EE+!F
M2\-6.$8"N'%-O+C]V@RXP "BUG*_*C+Q_&-Z-?N\*X,AA)Q$[!KI7RV=#H3D
MF/%T8<XPQ%$6D923MB3VZ61:,\D,LE=@3N@5P5C:9^5E?ZS7Z%A?/>6IYCP?
M"F^6F86>5T#C=4"ZR9"$^XSH*A($7-CKW]%\&^_239B7$]:$"X)DE=E(L/M%
MBFUR:8H%(RH(/5_G[.POIG7:P6NR@0O#7>$FNCG;%1,[FBEL1(=1#E$R<OYK
MU;+BNP@W(,&<!-#42>'#,7^;_1I4D1$LNW4I@B@W^;#.K6H"U=5A]$)[G;;\
MDZIB%6O&IO2P!C;#3.9D' MMHJI8"D*L&X.54Q JE1@$FFZ)%6S2.K(,[1;,
M6B1P")>LB&EK=-,$<>ZW[SIMWR?=O]?D$NM"U;/+@=$]*+)ID\<VJ%I7*0+?
MW@&T[RHOL4N?M B2\H3T6N$MDRPY81P@,*UFA2;1/WCJ6@QKZKYOBPSJ$#FB
M@LN1A@_GHS(7&H#,.)B(@$H,)C:5B 6SR*VQ=)^N$N_^7272,R+_)/":)K6(
MYB9?PHS%(<*MPPV,NJ(3!BB-C<D^UB%@NB9[K0,P16D=9 PW=N,(U#+D>\@5
M:WJ4U%$)&]FDV&J%@'8S7:>ZX$8SB6N4A:;7]/+LE+:@I/"\E;R8CY11M]'"
M/UO)!<3;O HC[L)+;CK65VU A$4TK,Y]0&RM F*[W:_?WV7[/__'\>&+XY=/
M>-W;W'?1)5UT<*:F>(80RRXP,@>[C:R9DL@B-IFVDU0R%2$?U&I66B2NI,#9
M1[^N_6Y=H857W+D:V@VV-=44^C/X;9_!%0>HY<B0?<?9!<BHKM_1S-J3JK/0
MZ.',0F%\,1H :#/[EZTO.C0=E+"AP?ED;FKF_V6.*A\EB%9]E$2MX7 8,7L%
M?*AWF*R/Q;F&!\#6!"*UCHMO)5O\4^O>K1(3W.;JH-IFF=HR>G]GFF/O(NDW
M;'W#:H%(J!_F0R(%OP9H1Q:X6$@?-8<)=(IRU##="0R%44$L;V/Q"0K-0YHM
M79)+[2"4!W.4YR.%8'!A9'4J$$>9 +JE)B[TD+MAZ9H"74W#Y,JC)B56\O4,
M3DZLAC$5 "#^IJ7A37#UO16>=IB&/#69D+U?YCX@QD<]Q+@38GS40XR?S5G0
MN55M1$$?ZTX62@VSY"9KD8FUQJEA+7/JD=N+6'3K#%ES##6%7,"EPX$FMU(M
MU4O<GX%.[Z)\+?RZJX+I>H]&_8^77HPX&4WUX"9[$0C/:FAI9N",UGIP E^V
M>L-:>LT>L0LGE%V.7E5FP*$(897.I@'0EZPXFP?DN16!866<M*"!_RX;T%.F
M*FJ3;KZE%:YC>D-/#.V:ZUSU\-S;5><M,W+K1=U0@OB6A2^(9MVR0K3TSXOR
MMJ-1+VWALDF)*8+>92%G<ZKH6&*$VB>( J'E,SQ0KV6@:[#SUJ +=\I+83*[
M,,LH;%!*;=_2UCFX-=<R[&TF26C/[ZXFP.!V_LE'ZC2L8C67E  2CE1^B>\Z
MI/]"GR6(W40B]R9N 5;J0A=Y@HZV=#,7SK0F1DQ+42F,W/DNO,P590IED 08
M:H7)<@G8\E&<YB4)>G_5]ZZ$2]]*=,T#ZT2!QO5G"M#""IZ/"/N"_V26.(,B
MUZ94->=6>-J@U2O4D'V%_^&9KE?A@DDOF3TL]^J+8$! SOMTA3'0TQ3A*1?B
MQO+'81&NFHOOZ'K2>M&IZ_'O%;<GR.GO(I8P_/,M%/$K$_R]>H*_?\L$?Y $
MU./-E6U'>9VJ+ ?[KL:.BBD96322@YMW <J+%&1MN,FDK@XYCG/15R+Z(CF&
MF[PK:J_I.A[C,JL0>R"_?S34Y;8\MV@FZV'?T;GOA@&T+W?@B>_)I3:R%1T%
M"1!H X0V_>TRUIU_WZ"KNCUSR+/][EZ+\TP3$0O(;G7-#%;Y+&LKO# OXRG?
MQXA8(HTVT-6-[\0.&/A<AA=^A^!7O.@G*LO$DX?8')>F-Z@4=>*[G3$VS3%[
MCJ++-*?^#-D7Z);.EN9-JDZYX!*6A68))HBYJ=K3(6K8)IA%"ZG>PM"/"KX"
M#YX4H;V-VM^?MJY]ZVGV^8KG-N]VW?Y4 U7S<XWB.L8C335,W*+ \$LNIL0Y
M+Z0[>6[G7E)A(?DK7"1('7*%,?RD;&AK5((9&O2G:2@9#^$<-R)JF7N@4L.>
M(=J1RN?W-P7?RD"S::9X6P5>CIR&A @ .R!,IO)[O1'A%Z*$4_32OJGU83GP
MT,;!)LQ1H:FOI_ Q?NJOY+HP?Z!1"<K6WSC<I.J\G <_!$U[$F'K;O=KD E3
M/@%#L4Z7O_LM_ZEBO-7%C2/$7 Z@6OI E>K&@/NZ"+0Y%.)$6BJARAJ4A8Z)
M9S(-H"DV+:X5BVHFI6RN]7+@G\$>7?IN6;@-8AL4H!@8&E>5>G$L[;D@N*B&
MT#SE+6P&9*=ZTG6MY6D;K$ITM&(" JD^7D^)J&>ZMRR%HX!Z#250^A71-9WX
MPPPS_PIF_JO%9:N9&S6&[= 4:S=\U3=!4KVGS-YU*&:]VU&X4V%.AQ>[91(Q
M'\M0H#)VURQQ=?9L.@!E:^+2>O6GY')O)$5*12ML,EAUS6MKN64L>"?ED10F
M)8->BCZ+@TZ*,>-H;?'LUET#PIJN,:Z$QXG;O6R\2/S7:L0&S\Z+P-_=WMU!
M!E^I!.%),5B#WZD4'=0;A]9]S-FNMH! ?0WPI%(!>5$+JOI M>PE^:ZTZ J\
M-.M:V>]^ >\6&#[N \.=@>'C/C#\S,]"E\[ %KYV!3%W(8J;,>@!;)6#L@(B
MR>2?6O^LU=FLE8!TB14-KFGR5&6;:ZJH+Z,R7K#^[D5)7F8Z[WJLYHEAI-9E
MIN=IH@HD,%B$IO$4]#9=_7)B_D"T+FR)K>ANBW>-)\EC]W_NUL6<A$T?'C,2
MN##LE/QQ2,@8-%,,D7A]BVJYY 5&<Z=<H'Z$[GM]6RPX>L#,_&+C<6C/3"R6
MR"YTC2'6*_,VJK"@K; <*+;1'U;+2,("PQ*Z]POMF^N>&EVJTS3M5](Q3/X'
M[!>9LCY#HT>'/S[6D#SKXW(DWH'\<P0K&U@$A.'41_]D/I-(EM105+&Z"EV>
M=_?\]2#L'M-:W6=ZFQA/@+M=S"^Q2J9V*-:R\=A-AF9UE<?!.M+(NSB+YL+M
MV^_!?@]6]Z N[4H!@J$JKI72I>&9&+KB=9-D "EM4>6P,P@#]/E.,? PCL*D
MEI+&WV-UPY BU"F]7?X\JB9DF+6+&;FL4#&A*M^V8N5FW9?-8&_VA,",23 &
M-+(\C%$9+!>(/T >%'<*C(]#0QWZ ],?F,J!6:2Y2. E)Q" LH![[@JV&.N&
M%5%<&"@/ABG2*A]^,^_%;VE"9VF'7.Q%EQ6"FR(;H4;"(!QX$)-V1F$^:^]+
MGU?3;^=J#YCTQ@;IJH$QR7P45Z(C^5W5I:*R!-7+PBDI4#D3 N\@S[;^+#?$
MIJ?#I::?)0]UHS.FCWF:&'6)HHG1L)20TS4<,X&OC&81#-4UNVV8DWWC7^!\
M_6%N*NI+EG+0T%21B;)1.<?B,Y@3QQ$'H3RTF:(P\%B%5ZXW'>Z2/B_G;BXG
M=%7HFB)U=P%HO<DH6H!FW+L)>C?!$_ V:=0-5VW7$L-5B+G4.2<,BKS$XNL2
M! =9U.+T9(D61\EGHXMWZ!45OZ K,2E%4H7H%*6WA"NU5V3[F_\6EI_9;;B-
M)M$7-:YI!>8>5%$LU$'TLU%"5^K!F@$*,10$XNFW9;\MJ]O2UDVN:%=AN\K9
M2++#Y(UE39T((R[_:MQ@ MZX!@48 S88DT^O$]\4CJ<\ W804..:>\I^$U_E
M- 7\5Y2$HU%I,NVNPT996@,PC1)7)31::VMF1W\V^K-1.1M([3@OYZ1@2-[F
ME>*L43&.4!QK"1P(7G.+-VKO"^BW5W</R/B%K27UA(EQK]4QT%NQ7V'%VJAW
M>Z1>%UNLJ/0$1(CZ[);FU%92AFO5SQ@-W^ X:EL:J;5Y(QP9#T.5?U68TG,"
M.!6>"YZM SLW!8R^NZD!U#9)M+-G4K"^\6<##'1[7+4ZG7*PO6ND=XT\,;V8
M+H#1#F<%M1L+PJ#+-DI*2@9ARCMB=B*#<::2+5"M,ZH&QV]Q!2F2DG >I@B#
MXDHX217%[\*H523=2& <;5TQ\%CJBCUMT*,O0LS1]AI!_(G2 XR.$,MTH"&
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MP^-RI&[LA7%;XX*&GQD% _;&565G80X]Z'5SOS3%],S0F2@!1RP!!P&U$HP
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M<%^4F&E#<$G;#8IR4TP: 2R+3/V['$<CU7K]F)SBWNKNK>[Z)K>UF;2BM!0
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M]DZ9.MP+4I>.ZAP-;J]C$[O'VC(JF1IG_029,*R_*V&3XH-G%=65X8W9&9*
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M[6Q\P2Q$D'M1(@+?&"'.LNSO'_K8F=W<4\&V$X8UP]:!1$D!_Q:UB#JUG'%
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M.F)DLXI+/_9*G*J&CY,7^6O"H4PSQXI4X=HQ#!!%%?T"K.:E9<2FZ]A,+L6
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M2 <';K[WZB$1M9T(5?#2X+ MTU<99;[U"A?TA4!+D'M6<<*YG^+!2M2W'+F
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MG!X%3I5#&-MXV(1TCHL1%>4#%55TBZ):S$/O&9S+AT,C 0&IL2JH@RB6YV%
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M!E/<-MRP4B#H)E0J:3GKKC\L.7,LZ><0)]2)3J@P@KOLXK=3L-IA# C6OQ
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M>S$/!G=O+,'=\\'=&TMP]P/87[YK;!:SDF]42:"/\#L34J/R.$FKE%I@(R6
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MGR31LC]2PP G/#/G.]:M*"X0O[$0AUGEA<.FGC?LX0C(_5621GTT2:4_%OP
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M:-SBG<AEXV2F89 =O4,Z>L&FK+;\TF2WWY=E 8ZZ'^_LU6X#OQ/0D?C%HUY
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M:_,7?+J&.#04Z$0N-A+S!HV*.?JL"B.58OS8HG.O\L6:03Q]MGBZC^"+\D:
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MZ&+4R7C8X<+@Q-(D^>^>H'=>X0:51D9*4M"?Q@8Y LH!;1_YN>AQC5;1-5Y
M+T&#BDU(I6^R6@!NVN8H5K6*RV9&PKC#(PGR$5* ;C=%5KG'*Y'* [(D-CWF
M,G'>)C$U8I'Y.8X6U_3>[I\2(>AKLG*K*S77V!7W0DW1TON)._@GB]^L-SG'
MW#74-MJNOI7Z]G>IKZP_])BBO;4$=?LBD8$2)(M,Z.SZ,5M]7HO[@)5MH.8&
M3/T;N!(2[18*(:_QH5>Y,T_LC->B/E3+5UDQJ[P&D7!==ZV#!YD5+7HWG E+
MZ<81:J5C*"K7Z%JR<9["IS&2U5@QV;SURFXF[.U[V3;BM>! .)[_4UP=.Q]!
MG#WV+GOP_O+2S[1HQ'/A1?19C30AGMZ.BN"^]5;-24.:;)H<YHN =?[9991[
M)F$9#B+KX>R+Y2TEE5[=%6ZDQ@H$2TOS3S"(E"" <&Q9WA_^B4$W$.V%%1S,
M.)U:-D1?FG0R2;.@+SNB"N!:HO^63N>QU-?JE7R^LNY .3"91*GJ+D20P4^B
M\Q%SUM''\!SJ$N8\5#K!(R2Y\LO;I]>%$SA^$%A'A%'$Q2> (OBSQ8P7Y5H>
M. "U<D&GGX0!AY8'7\"73O;8<KM.A$*/KE>6$\_>%6N#^W-G4DO=^:]S:^YC
M$O*IG8];+/_OV 3H_#?:!V\/]@].>N^CPZ.]XP\'T5GO?Z*]XZ/30_ST[!#^
MM;B)VB=WV<#G>G<0O3U^__[XC\.CWZ/33Q\^]$[^&1V>XG2^_[1_L&_>'9P<
M'![!CTZBWP^.9*KAKP\TNU'O:!]_?G1\!A^?'1S!)='9<?3F(*:O3M\=?WJ_
M3U^_.; +XW[S_N!WN"'<&]>MM_^/P[V#3G30VWO'2N[=\7OXN=S%X.6?WI]%
M?QR>O8O>P5/A.AA>=/S'D;W^%#[KG>+M\=4^]D[.#O<^O>^=1+<)R\'?/QT<
M[1W #=_R99].]M[U3F%\<.N#D]-WAQ_Y;7KO#PS\YOAD__ ()^KT7>_D0"<+
M9Q"O/GC[]F#OC&[6^_CQ_>%>[\W[@^CTK'>&+WR\UWL?XW0>'/Y^A&]P?(;O
M@$-YW_OCE)[S\?CT]! O@E$<_4X/H#OKCSHO.]+PTV^G80B)6D)RWMU8-A ]
MN'*XGC0Z'";)19E,U)-TG%Z@EONSJF)>JS$,*ON/<$F-$VJ5,V+Q&:8#JI/P
M@@9HJTA:L>)37?PJO,"\"_UB/VA.1X0TC8T]L@<\]C0@1^$\:_'&OJ?G/I:[
ML]$^O:2.*Y0<B6\=#%D2SL;V#&LQ-'Z)7G57:M'@-K*(MHR47TZ.7L8H2_W[
M&&N5CY+KX6SD><*WWI;LWS2="LK#<_(Y/-U/;3@#SE7$1[ Q-F?Q##P=(_UK
M*P2O<"8W@J&5#H>I*"6+Y/T&3:=Y0J'9J15.!*$5H\O[RNNI'GQC[3NT,(*G
MTE,D;J".VXWON=$/T+\!L^3&)[E9429-]J0ODAQ6SZ>5Q D(9]JXF<8/]S-F
M=B'P.A+DGF<)._0W8#4A=KR/(9;9.2XM;2!\O;2 O?UJG:2',TNQ7T54:"MZ
MZL*.<I)(;9!OG)K[S' 4^O=L'\*S-U8H+C9CCC=<N5DY]<E;0[E"6134D[8^
M1MH2T 0WIII-L%T4O9SE T\&4M5M06N<A9PI3S9'D<@'\M:O$C"/-FID A)A
M@!F- I$>I/V =,G0W3F'L^E>3[&_\,$5[+.!:X2+M5;#H:C)\W2^4(D6!3TI
ME6LVMCA7LI[R!%IDB^JV(/C#<#W;2US/?%S/]A+7\V/N'ZP)H6 J6F%47T"]
M!SDJ!SX_$O&RRG4(D'S$++&#@NM/^:M2U1[77(!'G>85.OML(%IR?E2[>@+>
M8N/9+&9E0E(J37*CZ:<JF_CJQ+:K&7%8[NB]H(NRZT/DA=C]D:27"Q& G5B[
M(0;K G1+A16Y6!D96,>@ST6_B[&+$<H4[-^8;48=D)U$'4]S9EK-7J-GB6?%
M)/Y;8'BTY-MG4\O9QW$8JC2N=1-4JA0N.9TD-U[Z2HM7JO 1/+?&$YZ B+A)
M8TA]#9'(ZX3AK&#B<,^ [N[.5BL "G\04T$XMEM(QV@.EBQ^<'L4R$%X:)IY
MC,)D)Y$E%@?6!)H'<+=_@?$LE- 4$DO%OU'[*K;Y/7S<7R64?NC*M#4DGU <
MUSAC(+&O/\!0%=^.^>=X*[!M5HM6,MXF%F)>S$WEE&0 TX58<U/-8;7>J)@@
MDJTP@TR;E-=>B\)K%C*-M IX]]DH<)<.3TZU? B-/I7O>=N6[!W+R)Y[=9 X
M&^$NPFA]L.7@-6*>:SPC8BI/%LLHJ%&N7,B5AX?3?8'E[)91#O8*V+@L>"ZL
M2IMO$1SY1='YGA-NE5 R&)388L-3T@FEITF&YRP\GP_SM;0C8^0[B!-L=07%
M\VL)<W>-Z6=E?S96W(V0:WOWM(.7%R)?2;V@BVPXU2P3#O-U]3F;3"@@+5R&
M<20_12S>B*!NZ(V _D%!A+EL.9(ZYM!Q*(I"OV4Z'[!K_$TA, ")"T38#Q9&
MF0T)AL2[P=A2)U%[Y$;8DDG[K<6$^M3W("#3F98I2.#"?6][]K)C_JO&,=A[
M/R^+SRFEF@=I,DI+W.'>[O9FCU@'\OZ-.*A!\K^O#).A;FAI. &:?U0(U$G?
M1?KU6*H0&?"OAKU1?R;UE*Q!H>@GR8@.)=*I>"Q@_A$6YE?Q^AJWX7QX;<AT
M-%ZF X9()BS AE84/Z64&)XW@P%F>/L(.RXKF?H^ :EFK-4I%.6SY]O7+;/J
M\VN7]O)_<Q_/':9E:X4/]]<"T9*5C5YMKP2H5$^"R.>E]:1"8>( Q4_@HIW6
MV4G!=,!NW%-NL=(:5B($!_5X@*NPCN@UVAZWAZ+8#]_U) @\>PIW(;],7PAA
M5=@B+^IC%YH;)HM!Z+:K^5;;E=X?#,8:HL1?7D&5* @G]NW*V["K*&V2<)Y@
M)64G"H#V]Q^Q%P#S.0@F<+Z^EA2V(;'())JF<11%@H2!2UOAY47<6F^JX3W-
MY\I4$YG(DY_(3SJ$@X02\@4=LZ@!>/<5)9:E)P.PH*4#&*P"]D%'X84IQ@E&
MYX3P+O2KTF:7I02[W^HYL"J49Y!(L.-$*LKB0BW,.[\P+8'QD&F<#5VNOG!.
M17BLZG%@I4.X5(77F:W<5,Q>VXQ%?[0,?^'8YH>Z&B6]KO[[HR IF48*?">"
M=RY"C>_B3&S;O@3_:%"0KJ(F@;:!N 6V*/L]H>'2E '?,VXC!S]7QP86XX^D
M9):--C3+P$%J#QM-8ZYI$,%CV>-SAHR1F@0U/EVRX3)-:(LJ$0>H8]0O;V4G
M>M0:3"_A<EOL+%F/U[L[O(W<#EG%A.=!AB80D> ><3THX1W,"C5JAEX2C>+[
M%;ZQ19GX.'0%2]:3&>AUJ\3K87CI-^;$,SA 'D[:-TKT*E1VX1U\]+P%W4G\
M ]U];6OI/VDEKF4 '.U6,"!KETB3'U3";.!PSB/I@U\D1G^:E-A8L]+("*-#
MB31>*7#OE=^1CG7N'<,A<82!Q\,V<-N#[4)I!F28E=((C/"<4J "%@_L%I(I
M":C%#,G1J?8$PSJ&1%2#D0][VM77JSZW8?@F#\H0, QB9)LC<QJ[!EJ!;EO'
M:0QK[@O?FO;$S!;X5)-1V@QS^+)OJDMJ&J #T3@':HOR5M%U44VW13 BR\DG
MAQ-C9-5+M[@.O2YR$X+"I9P!Q!0UX\>'SB-NZKDHU',H!\Z)"8M<A+I:32*[
M QO:SN7JX?W8#2,WB;VM-JS!?8='$/68XW\(#$A\;&;803)IWE3,-N,CV?7.
MO;D_]_5V@'_P$_KJD]?)&FP]:#&LYQ*,A_"TX;XPLRR);DL E7NUBX@M]!(:
M90$^[5AZ9)Z<4E*79MZ#=;)^_RN'F&V4UU1PBVK(/I!CEQFK9K[&MQAE*3;;
M90RK)7E3K>6_)3^-H>!+>VS^KG41-U3$SA!3I3=W+R F 2^I'Q6X,B5:28AY
M+1.&1<CI?914@^3?ED'P0U)^3J>15WMBRUM3WRDV8_YA&^RAX\QR%WOG0=_X
MT&"GD;B08*A2-/7ZM.)O"3U<AP*C'6.X?RO?#[O!,'R<3N"/;P_WQ#10Y!:;
M>WR(/<!:]#1!$+9T3"RFOKD;;\?1S6Q8/_!I-UHNF;;%(\2V5NAL=:4N5BMX
MZ6\MX#U/0>2H\;AGFCE,S-8J7\SY:;$>7MLY'9 ?B^&GM96F=1$,.JM<J4?8
M3@L[ 1F%ADO59L71;PM!P8JY;)QA4!N36V >WW2B'A[V.#JI#'#5!/79&F24
MU4)Y1,6"\4*<CQ%:Q5)*IW-HO W R4<P+6B5KI-R4!'H2ZVPK>YKG$H-#?"4
MPHF42>PI.- P3$2 &&XTG(H:K>_'I'(-C[PDD7]NP4%7S22'0&G"2N+!W:WU
M5X,5C/$&E#]U!=O<1UP;DPA;^,NV@6ZS\AM,%6V[3W7NF-*NCO?;W91\8^Q*
M)AK1M@DE+)O(MU\=PC:ZVDCF%B\EOMT3DP) 8:%"6QNLFPZH\BKTL*3Z"49.
M/4JCH\-3^UYB0=@>=PY*%Z8M;=:=H\LZ*$YN484=1^2PV[<(H35(7([85TMU
M?2[N)SI,C;'4U #/8+@A\7V$T<KY3LI;A6]\+]@?DXA+\8WQ7YB6U=:D^#H)
M-1M%'J<,M\#6"AQ<Q\>"05KX,U=K-L?A1TLX,N8^;NZ69&#C,3=BI]_*J]89
MXC," +"==EJ'X6C6G\Y\[K!S&;W6*ZK V^N()4.>N+33OC<>;V>)QYN/Q]M9
MXO%^A/WS@( ^ I+W0T*G4\<8L@SFWY%D8X!>XC$YV#BY08=(,'%_VB6R_3K=
MT7\_=BXX=(R?84N:+E69]HL+K"@(>9N\,Q!K'-C^L.<U6Q-#,H7[J>6LH"-R
M3GS5A/'5$)@1G-B:()"'(H: "A[4G/&9HH)+*?6,3HK_&091P)H@S*2+6I\+
M-S\-7UZHW9SRC2@J7/9XFL3!K \4@0"I<B@(NT<=N+)"$2(3S'7]3>]+P>:F
M4DV.]LBA6]2&666X]B!TQZ@AJZW_QF(("@W4B$%J:X())QMU),_-2=B\@*8
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M4"J60M O]$[4Y(X\PM#*1K 01R1X;'0UC8$ROF61XX[RP#0&AQ(=S[ 7Q(@
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MH12,-^S0#Y<"5\W]H+(H?(IX3,E[3*@L:B6],58[GMNR'@T-<R28GY;B4T5
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M)2W!.]H^XW;N^HRS->B&C(V<:]N:2F[JC_\0O+1*=M9G7(_F!CU02W2&MVG
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M5,U!5 U%)94A'_BHRK]@;1NSGUD0[U/\9FH]"Y!P3Q-)0V;1P D@<,N>9AP
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M\TT+/!%@RI2'JD:5YF94VU=)F<D[>V'RFF!RI<>M+]Y4 P:BN620"E =O#R
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MZ1;%-CJKKX]&C(+73?/3PW#"1G,#WA_DBIYSX?%$W^P^"(:X 7[XBNS0!V8
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M35;,9<8^7(ME3 BXY^B/TZ9<3) PG#D:(^QLQ?- T7AU=1[&%D=U]D)_)FU
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M/;A_?U&!%[(E=NB9+.] A@_@GB-9X7D<Y#V/_=H!T"M'#4 _S,NP0:D*M%>
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M8=V[9Y'NS+0VFSOO/&2R??"WO@I$!<,5H9 !U&N8 91EO?D,H+'<[PWDWD@
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MO5( #+C22J2H>H!@:V"'64Z)!2]9JW7\9-R$OB?6&AD.!O*P*U!<%,Y,@_Y
M?L#&[NY_[N3>RMF5__PTU5-]>=C+LCM6KK.9"7;"Q['H8M="L*_W%P7ZD&#*
MJ%XEKUG&J94'@!%= WO6UL#^KU)T$:Q28A7L]OU#3.PU",#BL>EIH1J1B"M)
M$KR2<L,6"%Q)8./UN[(:,50HPZ5D"M]+F;>6Y5X:R=V>P)D,[:_C7TN;H1RG
M>TK5HDM&E1)K1O_\^.GSN?2=ENO J:124!RT<"/95W0-GEIB#5Z8<73ZY",A
M0!K-F*T-ZE"O':Z&.PPN$/4KUG\_$<G<AK&%4TU5L#3?*&^;&.0%*Q0VI9OP
M0MV:.TQWQSR5N[5;#Z?A).[?LZ(0PI\H^9%IYV,#Y*]8*5&RX5+3QHW9$KQZ
M U: \N"W4#8,?-K[7%3"K6G8GO_P+9X_/]I_^N2;/6P=/45FOZXQ)/)!B5(0
M6/)Q$:5;$P1I41)%H/;M?U#CGEL)PNZP'XFH2&_]\-6Y%V109%1E&MS&'+",
M^8K561@>MXZAZTMV$8/XWZPX")HS<5U;?US32^_!\CP6=O'^A<53;A:W<#.:
M[A5\.R[RK8";-]K-T<9 .::&X:P18_H-8LQ0OHCHWSQ2QN1+:57*F)&LJN/B
M^))'O?Y]J;MD5Z=ZUR6^#/P#1 _!(6)[[ !>C>O[,EL!$*&[.#VH;LB"R 6E
MN_=)J35UVH#P%]U8X_#$J\6"S%P>&+YA68L;TPL7IPA)I4"_WF,2B5+RN+B8
M)9]5(A?%$9);+NZ[ P[.154>#A5@9/(5G(F)Y5K5D;CG?]\?OTJI\W/#J!>&
MG5Z%OJ<9!C *YES$;BT780(UPWCSI.Z>S-8V[?">8+/7PY)XN'N(ET7!]Q)U
MQNBB+P\N=C,N LS(KC&:R\G,-0PE<W(@][I#,!'3ZXT396162)G2CZ1\,1S!
MJ4QOBZ48;E" U2\2!(H(_,3Q.#% )/K =C&'N/VWW[UG#DJPO^S,(;,S_=?9
M4I_/"7R-_?=L 1)_IG3'OTOQ'Q@E?6#X[M-GS=%GM"* GEJP0XQ03H_GGIJL
MY^(;&T*VAYK2OJ74N])L$XCAA))? 1WFP&* E^&(10A(-(,YNT>;?3AB3H5L
M"^40G.J=[[:GM(R*MQT.<J1ZY\-=E*E\G-H>?"0ZI*B^8^7OB$-P0,;$G'\!
M(\RP5E@ZP OU<\^2%WUZL0/D%>E,NKNZOYK<7?Y%FEQ_D;Y<_>WJ^\TMMNA*
M5__W]NKZ_NJ^KB/E=PHZ,G"H@"*.V+<Z32OK.+Z,O-06;\12I:W>B*)*6[Y1
MI^=65;[Q[A,;._"H.>#:<6BH)J2>,R/RT?U^QNW>LMW&]1?VE-T6J"/-Y6<J
MLDA)4$4>#0M,PM>;H)E;85-)J!K1#5&GJH;=%]YK!N:L,*1D$U8#[K4>EQSS
M*TFAT/V ,7S'=I,,%]*3>[WD0,&! J,E*8G41%+D000B:A.(E/W@9R"2VDL.
M9!PBJOWI?OV(5,$U679#3W9H"_NY<*%>-%)0LY]F0<+T(P8(-X$PV4^P(&&B
M)H-5=VJ%KVH/=-,YGMO:WU(Z-=L5*/&HHR1G/N*9Z!35>MP$*F4^[YFHU!<H
M%#W(E?V%K&S8) TV-_)P!S<@(*V]9%^TCM*:^4RG(X_2.['#G)(\N6V;2J[P
MZ72"X_G@L?JJBH-]5A,125$JD$9&@)RW06H&Y2,RZ0QJ1J ?*";_?Q#Z9#Y#
M&>C3&V=Q\S^4>1/&ID#>?:*XJD+IDL96]6>^@BEM$C+$^W7JH&VAJ<84R,4F
M@7!'RZ4BM&D^+B5;MY7WP"2T/H8JK2+[(6E!#>U]9/4T\?NI=8U<.?K7DY94
MHC*6NX.VA:5LG9N)-3B*-+VZ/5'69%:T&5DS%L!@R-%FDKJ4M-")&UMEBT6/
M]$@UH&C0;0<410THZK4#BNHAO.V8HY,?<Y2BS![OG/^]AUL%\P8_-/L/@B-Z
MO1OG ;[WV;!F?R06UO.B@83'%%M!KTIGTOWD.T@ EL__F-S]]]7#]/I;(XKG
MT].]@'+Y_>^CL#8!+K5U\S6IA6[KYA$ N\4[W$>/ME:^3L]M:^5+!3;DUQ5B
MM-']/P8JDQ]LS738*YV_Z^[RZGEE6&\DSFL>1,Q,R5RP7&^ZY\,M+)CNBJQ$
M#$MJ,.6%<1 NO!?L^_^S:!"#MFR^=-WR=^V)VL9T<WI\-B-OG7.#BG6RT$?-
M6U16'GU$3ZK2I?4C46?Q$/5P^]^-R*7$<>CL$H</1I(6I,DG\2LA(&>7UO.S
M3C?&;Y^8>UQ-OL>/[T!F(-,1G$OE .=2,%7<EN2DF 7-I?7SV[7FKNT8J55:
M$-0*E4HZWF3 *#QZW@AK,G6O)FL*'NRQY_ +"58(:#BYUX)]5AK($.')1<34
M]!/FB;!:ZPFKM1++3^J480W!9'TC)K$U PSWR?Q9-W7'Q?D2+Z0H*#/QYQ>;
MBNU)9]*WJ^NKN\EWFHR=?/DQO9[>/]Q-'J9_NRHE(QNL[R@.QRP3@PI(S2:\
MM\4R.V2VK4W'[B5(FX_=(DA3$K+YTJ/E?;M-H58&-Y8 ,] .=2N2HJH\&)],
MNKDXP+&X5A&EWE/4XI,U#4_2!+?R%7:2F'U0Y(%Z0DAC>0C5$Q@94D="Y9_!
MF(Y0 HUB]4K6<EP6Z7IR_V7R/]+T]J:RP@GA^$T_8X*MB6>3BQAE"YCH#]9W
M E>/@\/A7U^PQV?B.,1UOEHVJ/C9\H[,K"<009IL)<]T-MQ?-.<S(>9/N+%B
ML?&&>5&VFGBD*Z1OKQ$H9E]TFR >&R_4<*@10 NIG( S,K.>D6[-!#_RF?_?
MY.V'9FI/!,TX''AAF28Q+@-[BZT05)J)N)E/(>6D6;^^!I;P_3-H2.'5419!
M)D2A8V9:JZ=X7#.3:] _17,@,[F4@\(4B@.<F<[:UK#KN?F:P-]+LBPWU+3-
M=_3%Z=,;UE<U"M_*PX;<RC>+A0[G[UG3@=,F\J>Y1_ .;$#-2%:.W?K*5WGG
M3Y X%\VL#,]WSPK29G1(N/[M&<1'!?@;"[=^0J<U!5W&)XSP&T.6>D[4V/_N
M!UM[(8:D/=J6-F_<.?8U*-N&P-7;S*$2^:Y>0>(TU"W(=_6*"D[>0%W%[4S.
M]NJ:UY=1<C_3@_;K:K$@,YK-P$2&.=,-IMX_$_>5$',RFP$7, ^"F4[=G9AS
M_!(3E:DYLYYC!*:?'MWOZ#MM2NZ"*INC;5];A7JY$H[6#^18O+$K!&V\6W)+
MFU-. ^]8S6L S+$OFPK<K?:&-?MQ$#1R3R!$<4)]1G&<Z57)F9$\&"5;:2UG
M*&>4BRI9H\K]?K)C7"7:<9/Q8F/!CI46[#@*[+C?@AVG:)9L$8E;1.*,_;)?
M=9K$8Z9W44VR"0\MMC.V+]%B/U"D&XEX/[V^O/EQ]8&VRM8=K3@_<\"BWNFS
M%6=L <VU[&6Z9K#7-1OM.,&9C.@K9+O>MH^:WFC9MN*VK;AM*^XQM.)&N65W
M!!L$V UD+:2%I\$E0P>;W-!='0OG76FAZ;9$>PG NH$5/"VE%0W=298MP66S
MD[DX4+MD_)#+<3[_>3*;K9_7M CY<JF93\29FE^!,-1U"UQ_WSGMWB:N:^N/
M:WKO/5C^=RYM,@='6W?^N%GXGQ69*RH/+I)C);$T_5 3/HF7Q(WVEL0UJ(E7
M>+=C[P7[_K\1R,5?P=^&'Z79VK;!8W^3W UZ-3A(03.II-QSO!ZXR!1\1F.7
M[^R2;RR ROT=E. U<06.L2*/1EG*<,H>$"PNI1>U:UX47;K:%,#A*5I@Q('[
MU01175F.[I9=YE[&F0D4<K/],"?IQOS"]Q13T-U-QAVH_I D$"E?[B0]D;+4
MW=9&CZ@-01EN?EE.J4>;TJC"K/V.#=LX=HB?D(+1:T^"9N+0F$TK#,%H0BAJ
MY.C_)BQ(NETV@A]M=O5(628\)=*NNMICK/?EX2C]6/4]2?!$S=5DAF0R?=(S
MI+ RGF8S0UP=]LM$"MY-DX>3Y&GG6*=#D17/C!69W6HJ5FSZ\/S55G_UL60L
MVIQ6F]-J<UIM3JL9.2WQJWX_J$^#<B6Q1N:P&0F\[;R=,CX9E-^+41-9-"X2
MAOGP.3;47K)D$C=6EU<9ZLV*;%+>TF.%.%.A0.H$899YO0<BUUF]TV5;=[YW
MT[]A.:Y-G!69N?C[)PN682+JG_0$G"D]I18O9..L0A;8;4"[3<T[MM.;Q3=_
MG]_H-F.$KI<ER];D$UH@\887C:2=TLT,OU(@\9H!-L=#3![4W)8^,1!H=Z-M
MFJE-^!;]]EN?EQ1&6,!XZC5S4'>.2SXOQ6I[S9>E-W)3[)"XT^GG=AY7]4 )
M>B?C)-P6S*$"#9>1-^/D^[QE3GYMFG6&=/J\:>G5$0FE6&U)1$4&(*61G]7<
M[RH*#-9J@1IRFI:"O.C) S5]2=V)<B.'W2K(CHM!<B2@G<M\L_ :@W_E;BZ/
M>E*Q'>4#Z4QZF/Q?A#JXEE@G^4>IL.9Q^O^#X?EH6PK^N79<??'&?ZF;<X+/
M/V,?K:KE/)9/47WF"8P]*+U@5? :R^RPSJ/B  "RKFFK0"KF!)?!OEY:]JD'
M9-_4L35BZ+!7>V79FDLZKO9+PG](KYHCB<--JFGSD*N5 58L)A6U7W?P/E_Y
MGZD![;]"HSL%1F*IRXC$O-[ZQ6\8P<02*#I2!TM_S@LY"Y%</;2H]].*>J\
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M+9R/D(.)#+A0G?6C5_-A>;$J;^QU:7C.?.#55]MZWB'W U#;82]S_@Y2[I<
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M/N%#D2D3KD)6,@UZR3@ ]213)J2$S)GO43+J8YO2+>?@%Y/2O<C;9WWXM.A
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MT3',PNJ>NL6%CJF&VQT9MCLL+!Q%HT8F,RCIA<S$'H^::7D):L?+TX;Y%$_
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MNI)<N3[2)V$/<9(-HDFC\$S7R/&A9.5FNI&UFU<QPL/HP@O>P'%QZ$(&&58
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M,G,4"M(4X.HC%8_7CCMO)['/]M'D P[PZ;G+!>EKF2FY1_-#%CM]8N6T-G2
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M'9V5QE3!V"1<.DV5U+%IZ#>;VM(0!RF  Z>1?.62H'W1$E0L?!N05NN=/J6
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MC?RYML1Z6V[I&%5 !CNI&@*33MPZ+C5-KBWZHRPL6V NB7/'Q06\8K7065%
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M>.)8JM:.P O=&%RJULN 8$P3+L_UI^VWS@,3WSS?-BY,F0RIJAX @-Q,GBP
MU X P&)'()]S9^, <#\&.NNX-P\ =VYF7 9+)DEH3DJ(@<L8P +8I;U\E]1,
MX;OPCS+W75(!),W>C&8M!:.)?R17,]5< 13)OIJ3Y'1<\&)O=B::*X!C*$IS
M&=M< ;']WFFGY)JC/Y*S]7,%!-5[:TY)HSDEVZ; DE1 -+M?0+^D@DR6%^(%
M=F2YWC5]"W7Z;=LPQZ81S$JFR*5+TT4]WW$++=1NI#'O!O:JF9IW <%;.30G
MBQ<U"3 J)#+Y)<5VZ4>98%N*=#WWY:+<P"U<%,B-YH2+ N4TZTKZ([F6J>:$
MBP+E-,Q#^*-,5^2R<%$@5D(]C>;JIU(S4\T)%P7*U&4ESW%(IW*V?D[HG.8N
MC4):QMCTXCN%,%H)\)++DL4+=1/B/%OD'_I.+[D46<LK*K77>;5)NLN?K&_X
M(IC?/SP>]K!6Q(O5EP_8=6P"*<:;HAR!]LYU<!B/_7;+-G9TX0OYLL";[5XB
M1>A G&O@^!RH0F^:YQIOMEL0%*%WS&\#[FHXLIP)0@2X71=/PKA7H;>[\XL:
MG[Y5Z)WQ_(+-V+$*O1U>E!DQ^YI^21&:,N(:."XKNQ6AJ2,AW"N+42HT#<0O
M:EP.T9K0--"N&]U3NFA18I::T)20,"!R&<+4A*:'A,&>;413$YHJ2@)BFBE8
M'#\L-'<D$(Q\>F*AR22!T&?LBX5FET2<4!G$L#6AF29A0.0SI!6:=1+3#[,8
MPD+34 +!R.4@KI>"E]K2=6P)^.,NEWHI*"S^\>9F?)>"MHK!>V=G?@#CNQ0,
M%_]X<S.^1:;"NI,1+1@PO9>U)J$7+C),GUPJ3[.DNLC,%==@,2"9ZT+S4X'K
M(KLW:=M/ [,W:-M]QQWJY/3LMG=I>B-+GR CXE$?'R[#V\7B5_;Y4VA"2S34
MN9E%A::R$J+>>KP\\ Q276C*2QBX>1G=JM <5T*X[YS -@Z^,; J-,TE%.3<
MC'*1F:[H25:NZ9GV\[7K#*<TB/W<ZOGF>/6<J\=1UY&^(3UV]29*>*R*S%VE
M0? <^:\(V5++-A0"9)FJ,E61B:DT8-XX+NH.='LW)(6!463*2CRORH#'4D7F
ML83VJBS %)F>$M2KLH!19+[I7K>?T6H&X-SQ?6?8Z=.+QS2L*C+#! +<=48[
MHEMR:#61V:0;I'N!BR(;XU( 7'J$12:/UA$FTVA?-]VONA6@Z&7_"QHC2]YE
M%_-QALC<R$2FJ[@ULN,L-3,OD;DT-N958K!%YMH2'AV-T9;P=V>V\#L627=[
M@\FACW>1>;KD)B ?36#=!$0F^I*;@'(T@743$)D>%&XB8)MYT43F"(7SZ(RQ
M%)D.%,XUL\6R(3+_)YR/Y7*K44-D@E XU\RG"8A,WPGGT?DT 9$I-N$F K8)
M^<9A,6C\++998'E85!@_BVT66 K-:6WKD?RDNR[63OSF-&&@$II[V@;50^OZ
MJCQUS0VA>:5M.%TX]ABYOOG=0E\<W2[1ML^&T/S1-LSFT]PE5LE8]\WQ#GM#
M1(&M*315Q-GLQ64,V!2:">)ITN,37J%9'E[G2CZA%IK-X7B*Y03MP#9#J+V!
M[B*LFXC<PW!#V=E4*/J%V6UFUQ8W)G=:NVO@&>_F+[%R6]-S:K*DD78K:W>M
M1$7>=.<[Y,ZE7GJ"89*>Q"L*)[^\#8;(U7UG96OESC(MP;]RP[6'72+;&6(C
M"Z]N>.!6W8*/7+EM%.[Y>\?H;H3OO@5I<AE\^ZTW-2TO%NKVEX<44.,[,X1Z
M@TRB0OW!?/N('^ $;@]YX9\#I!MTNR?^*OX=_O"[8TS.\%\#?VB=_3]02P,$
M%     @ ((!_5I-8<?7A!@  2R8  !X   !F,C!F,C R,F5X,3(M,5]I;G-P
M:7)A=&5C:"YH=&WMFFU/XS@0Q]^OM-_!JG0(I% H+/>"=BL5VCTJ=0%!5[I]
MZ2:3QH=C9VVGI??I;\9)GZ L91?8ARM(E,1C>YS\9N;O-(VS_L=>\^V;QEFG
MU<9/1C^-?K??ZS0;>\4GMNZ5S8V3B_9G=MW_W.N\K\1:N6-6V\\<ZXL4+#N'
M,;O2*5=!<2)@UV!$7,&.Q6_C<MHWY68HU#';KS,'MVZ72S'$0R.&B:LT&R?-
MSFTB!L*QVD&UUM@[06<NF\M#K#M]G163[3J=X829FYT8:.=T6IY;=",$Y<!4
MFEMJ8+/Z#YD:+\%IYZK?_= ];?6[%^?L\M/5]:?6>9_U+UCG[].SUOE?'=8Z
M[;.K3[W.VS>U0[Y;>[?-=Y@VK'84%0>__)7S4]REY)_<.A%/*LUNP-I\*-@)
MJ-USK7&,$ PU,9=P=_S2T]]99+]UTNNPTTZO=WW9.NV>__6^LE_QQY>M=GMZ
M_&1/QB)R"9GN_U'Q$=KH7TU'&=%R0RZGKN&-JI11W.BWIU;E"/O5@R.AZHRF
MWK7B7RCF1]8^7"!7"XXMM=:JC3TRH'S0OC_X'?L'+M77I^BRA(^ &1@)&$.$
M=T]8QI7*N<23F3:.:<4^:).R@_TM%7&;U#\P';.NLIDPG/4A3)26>BCP2E[<
M3MA)]:QZ7F4]%U79MDN ;<GH2Z[KH4XSKB9;QA_MU!>7AG^NB@N\YV]E\QG(
M^;] <O#RD)QPBV@@!^F$W2@]EA -(2A8*2&)-%XCI1T+L3,7"AF:L%PYDP.S
MCCM(,3T1-QSO$N8I@7S%/'24,W6*U<;IPNZ>@8(0K.5F0B8IOP%&4,W&M'@N
M0F=P2DDEC.8@@U"8,$_13&%W]"0"P\:)"!-F<_HS[S\& ^4@M(!46 D\$FJ(
MM]8EN$";0>@=I'$S=$U'N$R\MWA1!I/%R["!^IF@/OR!4 .+A4)LB, Y)@$2
MC>;8;!;:A8HQ-7(G<!RA0IE'.":BN,!$@!@+(R<L0Y(H""@XI)Q37@)F[TR-
M@10)&C@@BURB :*MD3\_G?7^A)B/62SUV,ZX+](LXW2F<!I=#!;8M5-/[KFZ
MP?>9\'WW\OCVY_=ZRU@JJ;:DLQ1BE,!T' L\]!1T&3?@84-XQ$ "<<$ "1](
M81,R)[,4DS<E<#J.A VEMKD!G]:-E@5UF=$A1'C:LFWD+ *DMH"I<QLF7 V!
MM3!C7N42+;P\/MJ&'=_5ZV,Z*@X%:595T$[C,TJK"T%0<$F^K#U1O#11C!/1
M.I=" YM)]1QO<%^)^]SM5?!^7V30QNB%(Z,-%LT1$U_H'V<X( T2\MRNWX7$
MP "0QW*F0E[HW.  F&1'POJ\C5:@_#BT*9IG_,6J84!R#WBI+TI(@[*<4(O
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MO#HB2LV/]D@V2O.@4#86[[C-4T0,5^M74M:(E4]S-ZKEI]K>-ENH*&*#R2U
M2, G8\3,?U]3\A@4Q5ZHD98CH(JO^+#\VLF4^1O23.H)8.LXT472YDNT(YW?
M+UFJ#P'S:R)3QV)A<$.^&VHI>6;Q7DW_^U::$N%@UV8\Q+&4'AN>S6;\DR9\
M(C1M1."8?>0&D\=A+6 '^P>'7TV4Y8*F[U(,) ]O6*UZA-?%/V6KLZ^Y^.X;
M7-RS>\LO3*S.+<]P)1^)SE7K>O+E_CW6<9H(B%GG%L*<]LCLHI!TCV3]N^]3
MO?HK/?12&+T,5KP=1B^1_0=02P,$%     @ ((!_5L/^0.[;!@  ;R8  !X
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MT(ZF,%N!;[-/#?1.S75F#9X&S;6088 EJ\T]=.YC<MB./,@U?Q-T=<X*P]_
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M(=AN2+M.N.P+N@<Y9.S]:N(*6<6IBUR&B:Z1#QB<UHCJ2Z<Z0]S@^.[S*F*
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M9@]DBK78%9HIO=&3%H5,90FI?*H.<&3[[+VX$(U9\,P,L2.339+FHKM5*),
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M[G*E$PITQAV^+Y%D$7J=A5]QP-T&+@H?Z$I)33#@@FY(@&H]*T^1Q<!E>WS
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M!:8=M(KV H>8WE)45&AR_#:C=W:JS;M59& XLR5])O)!L"5[]S[8;$,P62$
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M7CGEK_3V$FKRJ%E+43GEJ)QR5$XY*M]BCDK^*N/HZ(K0N[";M4+-[8RTE/W
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M4(S&,#,MKU!%7/O(4=F[9J)"?<UF)R(%>:?>*<8)6%PF="S$+4 !3!O)XCM
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M^VORT"8]I\T=NLK.2A?)0K=Y9M'UJ!R/".V%_FQJQ@+#['6L8TAZKNTNX1R
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M'._P*J%*JAP/I0..T+4D+5Y^5)H4Q_KM@[?8VS[LHYA=8-(?8TP6NID^[7!
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M!6%PPDXI[>3>(U"H(D2(5"K()\W[[8I"F*^'*YZG,:SY A2J) KQR*H<A4&
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MTC&LU4L: CLBN,MS<+"K36C*P&5?6C:G)5TN2YQUK2Y):!?X"Z7>1/P7 G@
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ME56'<6H*HEUDV/#U=]#T);K^):5=1Z$,'WI<#,P"<D:G1>8-0ZXUKPV,-8F
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M'IJ6AT<;>=7D95C-K2;)&MW;YVPD^KPJ W0/$T\PBO%'XYTDJ=I][-U<_CO
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MIM('3HZ2QX#&T<_BD:#KZ-<^&ZQYAT'[IP/^:;![R5I^P59]^F6X<)[E/(-
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M=%(C8H$CCMH_X@UC<UXKEXL-(J2V$)H_/ M": ")!CBF;:RELNN4:^/RD<<
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M)7,72:$%ZFO<,P80 D&EVAIPD9F&0(<8"@"(5JKE-?N,G4\ZLN?U,WL@XU
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M>=8XGCRS%A8%PKYCRZ;@<&-/BS+;/36%^R'6-V7[2[1%/ 7-@9NB=S&'LB7
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MRUO:0+:,&1/H.F,T0K 4.E)0P%H2@]_WY,B'49(* H3A1-Z-J3Y1>DEMT)!
M\[YIBWW6\L3;1=,<]T(+N"YOV/LQJR4#G38/OCQ>D:<)(E4R\C"MW0?$1N\_
M =.O?618P+S_C@W3,KG1^V4D91K*7W(&$L8/\%#Y ]1L*O:''5UL:TI538.K
M(\"Y0PA<^W2WN'H/^!A5R=9Z6]SOZ,<J*]WG!*?*GV&<+ND)0RDX(D@309M(
MXD2C3H \VBIYGE0L)\CSA8P,_NY\<#O1WS$/?1<3QLSXN3U9*>TV]G)S(9"0
M9!7'AVH'RH&8[FE*Z$2:">'KIXW,I6+VUP0[-20=N%AT2NK F($^>=H4]_KC
M"4)+J5&,JX$K.T-1^H\#LS!ZW]-2<2Q]-EF +V.BX@21ZG0>@CYPHT]$HMD(
M 4/ E5@SSI);"KS\F):#"/83P[#)4D.14),J)- --HD37V#GPA%(X&,9,3=B
M0M#:.]0SR!QY..[F';IXI\3.STN\,<'S"<6K@\OS''&N@0JG9A!%O^\@PXI1
M5" ?"[JPPZPB+N@)@?*_S&M!1T3*_X(NW@E1D#_/2[P189 _IQ2OLU+"E.J.
M*O]L)A&-+E;L*H>?<=1HWPD)F;@5PLR1AY=YTEIA<6% J^J2MK3>%R6%G*NJ
ME&_H26C74=%7N?P._'K=?0K:NU&Q9Q5X_V)B=(0GO/ TH6YC9PRFN8W_,J]M
M_)?P-OX+RC8>HZ>O'NKJN'W@>B![P/,X](NJ9$,\<I D<)-46S8.<*(>:-T^
MW>R@9$B9=UGX4]#K6_$Y 4,%WQ,1_VOMBX!P?Y#?/(.?^%?93SM>O85M\ [&
M #W8\@=(T[ZM?]BT(>JB?XK?W7^:U^[^4WAW_PE=O!,2,O\X+_%&9&3^,;5X
MN5WY[K KG(%S NN8-T'%"N\&:KHW1CPD"W4QIN_/\6OSS_-:FW\.K\T_HV_]
M7^/%^^N\Q/MK6+R_IA:OZ81^9Q&MT\^>6J8!Y[J-F^01[H.$X1'H[:KB?[T[
M'MA)Q52;D-=&Y%O;(']15,(IK-EUO>G"29]A0S7,7-ME*%NIM!J\W3 <KK$;
M;-RDE.:GJF:Z?%;^#*5L \E*T);PQKQ>+WJJDFWLAH#=#*9U"2_6Z^/^N,M:
MFG>1'5=9(6KO:.%_72CIHFWKXO[8PK9;55V?BYKF17M;-+]K8:=.(,S^HU!X
MTE;+;</&( L7=54J(4!3>:'9PS?31D+:2I5QXY7@^&A(S88#W;M.V-":/U+8
M]D,SP?RFTSB@XA83^,,E?:2[ZC N8V@/[A1=B-;'K-N(H.)Y>#$.BR#?J2)Z
M9*Z6M)J&(K%E:R*:VP*J,01OY\'4!SVLIA+WYZQ5.#(*G!WLTVSB>73V555?
M%C5=MU7=?*Y:"=F>GS^M'F@ V4Y0AN!%C3;1B?/(YXX\A[M5'R#G;#(?J T'
M+WW>ZK-%9,S\2TD]86#\)3U4C=L$(_^,IVW* 1BB'HP[P:[20SP697G,=I&1
M+**Q$<6"%L>B#UZ7JI_!E!J\RD.]9:H'!SBAC#%-&]$+C01S;H$(Z:@077_4
MZ:">1%,8-C;"=&DES=/,=EG]Q)[>MY2/)J1TB?8\\4KVF(7*Y6+#- A[^9U9
M0<\5U]1#NEAT74].SJ&KX>7!1G)OSN1I\DMN^--"DT-Q4EI36X 4EGW/PH']
M1>ID-6E(Q=VEL+GX34M=L[%-"<,G,!RRZ1"PL93,E25C92#VC?WD.H4XHB$<
M/+(=8M;=<,"&-&W\)#\51%D-**HAXQC8N75D1Y>$0F3/TZ&U1ODP1#K6?XG<
MK.7F)@-3N0!)=@)RB+HEKW;L8Z^[X!/Y/84W"8_YL=6M4OX=*K+=5/);M2$'
M_EU"^8?/B$2O).MLMP:M!@C?9TVQ)C2K(7"ML=8HQSG.?H#H[<?A#YOC=&:Y
M;S3[G<($WE!&LFRSK=/_T34E?5N\9ZEEX,9!X&0NY75U3MMOE)9OV8D4XQ%1
MS>&H=3A%DLO:P8(A;R^KZ=9TH'3QAW%=XM3BM!49-L:=RDZITDU7U7E=_4Y#
MR[/+MEU51'9 7YX.%@SY>EE-MSQ/*N69E7EGN72;7$2A5*!,>M)$TM;-Q0T!
MZD0GWQN,D4TQSY2.Q3[S(O+&BRR+CWQ"U,F-49N/'#M?J0ZZ<7Z]_YPSX07P
M7Y%V#@PY^QC%$O94+ <3P %;V)&H#1A8#>?9#@)^%NP) =!O3LU2-".+EHB&
MJ.?\:-"F+FEC*L49W!<E^FNU.[)'0_UT5>P\07NR"%/7FHCFN,671F,?^YD\
M#*:5,?_R1=;2K0?95TJ8MR6J,5H^NF7@=O%:>$N=X*@!^W:10Y]H!K\!]:>/
M!RI.J JDQ7GM>YIZT%8QXQ)!4^1A-_\\3[J#$(-3<&AU$"<56BN=7C=9#=\\
MIR7=%&;.<R0([0D?2!@W\9QQ1J#/#M# P.S-R78^44F8*,HV%1S5Z7;RXK#Y
MWTX3<-+2&:+N363U:%G8QUL[&N>$LK)A/WX\'"?:AMU0_DH?BO4N5)E"M9J/
MM(?CMHO9QEMR;]*PAH.&\^Q*W9'E*51E@T8OZ(,,R.%BQ2[^ .?)K#*+[;:F
M6W;DW=35FM*\X5BKC\)<:\4K51V(ZD%4%]0[PLF(<0$$6$XF^L]5V0Z?V9VV
MY5S^?1=E5"#0B?!>N%&O;FZ,&0ARGLK$H$>OQUVQ@YC][I[%=A6X^3!D'V(Y
M]1VK-B'8L:^;!C) S+Q'1WB .'YX9$ !77F%-^7\;U!M;?'\.7WP,6))6#[*
MV+-0+<<*N'W-_M7X/#J68XRC%KMPS$E'$;,<U0D"B#CY8J68*!1=F'@6>0Z
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M&;\Z1TT/--@,T.RL.>2=FTOK1: ;^>L8T0_'X>%@R.'F\+*?W+DA8F8XU#!
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M?*(9 #G#6,\S-KPO#<VORYN:'C* ].]\51UVFL=FT9$%\]N^)TP@I*0A1PC
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M0M?ZX&V[4I%/1+1&5=ILPS<.4S>/Z2'U0U55%'X^OL(P&K(A52M+"34PP
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MDD;JJ-YA0(XK42XR5&G==5=12VB0JA,8M,]6K&"2;RHM&46W.L3FWW +BSU
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MX2/"8I>U<NA:<TR[W@2>03R_6_0';Y',Y6;W\V[DS48J,Q+%J_UNG2*G=!:
M\VP'^3+-UZ)]D&N)/4$A:B@.YDCU)T"@VU*2A!?H*/4.B^74V&[31"3?)Y)3
M]H#_7:Y7]AOV#["U0XO_#U!+ P04    "  @@']6H0$\;W93   F<P4 %0
M &EI;FXM,C R,C$R,S%?<')E+GAM;.U]:7/<1K+@]_<KM-HON[&AT>6QK8F9
M]Z)YR6U+(H=L6>-Y\<(!HJN[,4*C>G"0;/_ZK<+1C:,*J".!!"A&.$(2361E
M969E96;E\=?_>MCZS^Y(&'DT^-OSUW]Z]?P9"5RZ](+UWYY_OGDQNSF=SY__
MUW\^>_8??_U?+UX\>T\"$CHQ63Z[W3\[I=O=C>L]6X1.$*UHN'WV?^+M_WWV
MXMDFCG=_>?GR_O[^3R[[G<CU0A+1)'1)Q'_P[,4+!K  >1H2#O OSRY"[]E'
M)WSV]O6SU^_^\NK=7UY_]^SSXO39FU=OWF:?_,=??2_X>NM$Y!G#.XC^]KRT
MTL-MZ/^)ANN7;UZ]>ONR^,7GV6_^Y8'_H/+[]V_3WW[][MV[E^G_/?QJY(E^
MD8%]_?(?'S_<N!NR=5YX010[@<L7B+R_1.D//U#7B5-*=N+U3/H;_%\OBE][
MP7_TXO6;%V]?_^DA6C[/Z/;LV5]#ZI-KLGJ68OZ7>+\C?WL>>=N=SQ%*?[8)
MR>IOSSTO"!B0-V]>O\E _&_^D]_#WT]I$%'?6W+:GS@^W\K-AI#X^3,.^O/U
MO+()MMN=QQGO;@+JT[67<?(E_]V74E O_Q,>USD3SRVYB=G?MR2P1;<.[>5_
M]D#>VB*_7SDA^V-#8L]U_ AV!W7@8!NZV3# &^HOF;(X_W?BQ?L% _*&AF\-
M-M "[&4JXO!,.'6BS85/[RW)?0"3X@F"9:93?0/$BB_AF.RM V_%)">(9ZY+
MDR!F%\$5V[O+UC7A<RL\,/40>JFT'Y<XCV)ORW"*G&#Y<[)<IT?#Z*2I@H83
MAS.RHY%GA.WATY=P]\0ETR7A:1)RK3*+(F*$F  (((I7(=V1,-XSCG!ELN,<
M^61TD\D@0=,S%Z?HRMD[M_Q3,XK6P< )X0?/N?5\II>]X)I$.^+&=/6>,D,Q
MX"1YSPP^(SE0 @MY UQX@>-ZCE\LS+!QX@O'"W]U_,2$[AT X3B078MGA&E/
M$TFN? YV/S"F$2=T-^Q\G)$[XM/TA)P_[$@0&5T0'0#AR'GC^*G*9@[&5Y+J
M<7.DY;# C0*VRFRY]0(OBADVWAVQ0+L3))B8\$,2\%.2&:=<FYJCW0(,4E,L
MG ?FHP;9(@9H5K\'O# ^$,>,</F'D$1*[?83!G;)?7_&A-3=-74 FH  %97/
MK77F#,5FEFL- )2I6A)F=OR2U'9D$GWM15\_.H&S-O5IU> ">K?;K1<7JS#_
MB&M!$AAZ"6W0X'12<4=_9,<B"8T)+0(#I_:;7M+)/OW;W@#7%F"@2J'-R5MP
MPQ3<=<RAPM&]Z: 8(RX%!:5#)$Z*,<+M\*"P%CDL=C06 X.4;!5WQ7@/&L!!
M#3.Y]V*\%26PD(PI>S?&6 N  )IM[9Z-,=)*8$&UN\S9,=?L'1 AL>_R>8PW
MH0@84*#D?I#5N6T%":9X*MZ1,;XB*%#W4^8MF6OS\N>PCRX--\G\Y+6! ]5]
M9>?)0M<)P,#9?$H^$\39ZH0.J24$_HGY'N3 0*\8=T.6B4_HBFM1;[V)V5?D
MUHF\B-M#S-9+(K)*?)_IUXBNV+^=HUUM<@RLUNMGYU3L-5CM3@834-R.B^V.
M7@0IO(@@]R*L=M$*N)>MI'1S<N]B5_(N[+DAA H8Y3ZL%A)O>YN$47IF^3\S
MLY&4[W>K[2@MT,]96>7NAE]V-U9,5]T=W VKK:G [X-G$;^>76?GQ8X/H-L:
MT.#,DL,B/HV8ZQJF:]FCW(0V!,KV^3@:P'O84'AT"9='EQ#RI'?#[^4XM/J)
M=F>C'70?NUD?'$:GXC#"\4EMA1X$<%68NM[1,;-6P V ?3#EL! <%R0@>R [
M4RHTS/1*[#S88RZ"!^5=MZX"J8 5P,/O*>0^!%TQKP'*,1%#[,><\GGHHF3K
M -SC0HC]8,_<@Y47TY#?O"#.1@U:#P>7[GC8)8II1,([SR416_7.X[FPJ>Z^
M\]C/(YK$/,&<9^(#^!Y&*_;B7%W??!YRYP;+]6;:YPG/;*W4%PRS\-8N"V_=
MLMN;B1Z$<:.Y5@\2?IM5 43W7KRI+FV_O2[8_?F<Z;6>Z>.0[+A9S#SYF!=^
M/'C;9.N&9.EQNYCR6!F@):&W)/SUMF(WJK<.W#22Y.Z7)*#,ON2$W]* Q$ZX
M+W3]'F#7NHOUHJ48G2-V==UY/.[D^/O(@SB8,J#P+'.=:,.<T?NH)$:@5[S2
M OT<Q7LG/#Z.6VVB"JD70=K2NZQ"P M\[CR_ 3PJ7;![>$@]8R?0,S+1:P"@
M1+XH>3!'K YAV"1Z<[QUH ,_0\MS/<RWHP87S%8I)W^8(RV" B79E<=N<Q2%
M8 !E/'WWMI#BRO>0*ECXUFV.:#N\0?.#[0Z9,GBXZEUI>J_Y3A2 @O%$\ IN
MP8(6:/;:[8RZ*5=GP?*<D23>SP->F&^:IM\*KL V=TO2'WY@R%70)@\Q"99D
M62#.P0)4EJ>L96O[U*TLY_,*?!H6J_G.+?$9G59A]((_Z/]^J).^7!W.PA6_
M_AGNLUL>,>?55F4:YZBF-?H<3EJH'SL/E/DE^Y>,^*]?O'K[XLUW+U/X_#>.
M?WOATO#WXZ]D0J6'2Z&I#?9:>?D?>G/BQ4N[*4O-+*SNS G= D_VUX;(5/LE
MY+_Q<I=&>5^X&\\_2-LJI%M3]L=4@9@T7)+P;\]?\<89;$<K'FE9?L@X(<4X
M13<F8432WRS9Z29<9HX8.Y[\#VZ-W#E^5NH\$)O%JU=VA,+I5N&OL59"02C>
M&FJJ#0UC!FA;^">G/ [DK3RRG$5(W-;"Z6#+34 $](B="\9K^T-O)AJBDOQA
M!$!2QS\-)HO(EK/RC34K :YHE*L9FW]R66ZY?ZUT,XT=OWSOFG'N$\U#U$CV
ME71]=+5K;F/):8JM<<_R)1?.P[!GM;DPOFG5)?I5I@I(!V@TF[&SJ'B\\IW,
MMRWRBH=BJQR!@[TX =:VD!'LP,)H9RRMC.[P=DIZNP8>P44[+ -'PC;S.Q3
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M8?*KQ^+#5X^ :T<*&)B%TN-IQ(QZ3XP4KT\DYIN[((I%W.K01N=,ZK*NFUZ
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M*>8E*)W5;BC3.:8*%(%K>ZIKH/#PQB>:.D?RGHEMXYI$'T_$@I1OWJ9M*4#
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M1#78T/(YAKJV84<;)<!,41W67"1AX,7,RN;OB2NF+X@)A[JA8$65;9BE0!O
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M70H&*)@MWK9%(%L,L"=L04+O<J#XH?<N*6KQ>B6<10N]?[/I%R8G[ZEF9HB
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M4.Y9)7/68"[;IM*Q:_E\S/=;VZX+5@#$+(PB%AKC>.O?3"4Z49N]^]J^ZPI
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MXL6;M,4<+Z':>+L%/4_;B)[1K>,%_;&O8UT<K[93C*4<[2*C>1LQOMQ96J!
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M4 1H<"R6<"1"$/AXW>?QU>/G8H7;:<33!IF#0;:Z4]Q3D>D<2!.L-37?*YQ
M@;M_6=)+ L0,ZZH0UDF %K8N--JBA'96PK@SRC,=;Y$8OK0(NY(QIE#G"3S(
MM(NDWIFP_B[SM6K-DC$:)AA.'][?N#95TA9GD,R/]L)9OGI4CJ10D0E#ZK_
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M(-P2//R/A41%1:%<4K*2PC*"(J+"_UX"(B8A(2<C9[ASAT'X(>2A\'];N':
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M5IJCV X^JAB*X@9RH[C!N)G_ E!+ P04    "  @@']6 #PFR"03  "L$P
M#0   &EM86=E7S P,RYJ<&>=U%=0$VJW!N"$ *$K2)3>>U,(H1<!*5&,"DAH
M<0NA2%-Z%92FU""!@(0N-4!"[^!&I AL4$HHH?>J%$$$*;_^<\K-N3CGO.OR
M7?/-/+-FOHN)BWG Y=L&< , $ @$//X]@(LI@!Z CI863$M#!P:#Z>GI&)C8
MF9D8&9DXV:Y<8N?EXN?CY>+A$1"1$Q<0DA'FX9%0EI2Y(:^HJ,@OKJJIHJ A
M!U54^/,(D(Z>GHF1B8.9F4-!D$=0X?^<BW8 *QT@$5 ! @H!J%B!(%;@12>
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MIG4AS/(+5G-MWDJ]7.15!^S5Y,S4#(F^WW"9A&C?2X$.3VT5XK0C9J: &)D
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MN(<E:($(=EW!_DS#X^-,N90YQ?<?[I<%;PU&$D,3NQM>OLS'Z+J;K-5 ..'
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MPR)/O$I\ZMD6_J"JH_EWPBB_UX)!;ZN77Y.+J.\X+ V3SE)Y[OML^BLR0'1
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MD '=KKZ9$N.#</_+@XC]'TB*=[W#U&A? 6P".8L.=A*P6W7E>:(-7XV@2ZM
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M;DW;!6$6C'\%'& QSO\FP5)H,-^=SFTVV,)!G8#PR_V)8XD4BFV5TRGQ]MV
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M]DD@],PIBU(NT-@/J"("ZVWLN8H?1OH0\>+DWSIR@F-IFR.'CFO334??Y$K
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MMV?:N_)-5ODQ*.5&SZ D:GJJT6(SUW[MB/ ^@1\OU8)4D46(Y0:E\<WBYGA
MRG6\>X/W\9])% R2F%M4Z,_)I"TQ0RN[[]SZH#^2UI?C/%G<**6GT?';_0:=
MG5<KA8.9GIA>)A[#"$))P7[Y&,-]IK?B_KIV=RK. E:/XB;F50.!7V@#X6X*
M5-CUMJ^VF\(_DB[5AO!D;%,; -L%EXV+/SN;&B!S@5V?%E<B9,9Z>^7<E =/
M=N"FTUXX?T;O<$3!3XRU\YC3Z)(P<>YX(H!OSV/]3@8RRX:N,&SE6D>YP580
M]^'S(<)J.X>CH[M+WA;:4&DY>#?WXPE^N/ZC-9ZVJ#..W*PY34=F*L\64XM4
M&MXS365$UP57Z)BMO=_O/7 329"9#U>E 1(X]!6@?HM (G4*JMXU9EYPN#]_
MY*!H.EG=!9\.\MS B-@'0-%EE_E(M#^(4! ]Z$*$WUY&5#L2K4A91VQ6W$M;
M)C;Q*8'+6T-.^A-"A+<KE3VWC,V<WFLJ6Y'W85W]*B$E,Z$)?X<?]#'B<,+O
M%*NP_MU5N@\8 MBP\'9[,7>R&RRWCO80X*JXA5PIH#V5((0%DZX>)C7CI^+;
MD#!VE(8RCZ!AR];08%M*N,\7*K^);F1G;DD[S&W%-3&ADT?^B :R^B%E=+<?
M:W"Z-C+]WKDQO,8;:^K+EQFIG.+ M/5?=N*1S;7#CE\8MBF#_ETWLC??/3U3
M*VE5>7WS>9-:%-P)V-[6F;FX9[GXWDC^=M>9<[*,54Y#L7>5"!\X1%_OKV75
MELPAF7A"U%6AS*Q0*J5L8/F>P98#V%3OO\]6:VI-FE.FIZB,XK$(@=,LL&CI
M.;S)P:855R_3_ZQ+Y;'G4Y43MC;.^P7#:XH]-$Y4<(]90M!_ULOOK-&Y>,E@
M(FAF]4B#PE]_D1#/)8%7S!0SL)>:^H3\AKJ^%U7RO2\BWA4DQY1Z)-09=3'2
MXGF1(YOEC_*18O%':3(3ZBQ]Y$+$NHZ\I;]*T)6=TVX'FV57ZG"'W_;LI!QT
M\<)P\,HFNAQN^BD[:?72_SDI^#_A2K*OW7I9N:*C< M&GHJK'%R@_]@R1.8^
MODMZX.\QX'5C:B.\,XF2T5=@GRQOV=70B=L7[.A2\[UYY*)7M:"5 5ZW!:6F
M]/1FG8#S-B?)L&331*O_#WK (=F7F&ZW<&0E<8^>JI=HX'J1'\NXPC%I^U%A
MY\TB%Y.<S\"O<M9KP<P^:B9A4A#V;67E0"57G?5,9953GB XZZ.:>0PV#IMV
MA%X& C3K*YZQ%2'<'M2VBY:Q*HW]%6BH$-(P%%I*(43*M^VSFO@ PHSWLVDT
M;FFX)#I]WCTV/,( ]*G69M=(>QCZD;VX#Q"_8CYZ5_W]5X>2AT2P3VL2Q5R;
MK0%I@7V\+-O*V8<CH_U[2\_A^S'#YND.>5=/VP3!0DR*R<](U3CGGSA;\VGK
M2L$N/+.N4)-0><#5#Y)>O>)CJ +!@FDW>TM:0M ^UOY69B[=]2US.<QBIGK7
MXQI0:UP;H2'>(E@FV'0[RB-"FUP5%"S-/LF2@\,?*W_)4"O'.)L6DHH014;*
MQQ AB+3-.($8QRT(]NBI/%YV#/J$=5CI"*KY5.[[L3<9<1-$R*4?Q5!".ZA,
M W8W=OS'Q#PY3F2UF>Y/$O<_/A_)C1(YZ))P27'[DK6@?V\E&RT>40P:HPR&
MG>8G6N.5\^W!(3]M%=[#NV"OKD#41<;\L CA8(=M3LUVQ:OYJCY78T7PF/-(
M0VU]^W;,NR]4*43*_!)^J]]AKB5*VCEP5NTVFN1T3$/,*'NPR9L![X8/*)E5
ML5N1)^#:T<"[(CNMW#:QM^:,"X0VP#E*5D?6K(E=%FW';)6G,&>U66N\6&3%
M_<J&7%RX-XMC#DBJ"IM]BB4'F_I]W;SI;P=&YU.T'%YN6R<&MKA<F,@UFCFJ
MN.#)/EC7];\H@O\*W;B'&HM^DE?@=N:O;K4NU*=CNU]W_3QVAP7ANU,B,F^W
M7QHT/?J;][AD ]SQDL<H(M[;#*0/0!7&5E.]+7]UW;K1:;R)F32OF]CV=-NR
MQ)96WR5D>ZE#?>M8Y-(7<[G6(<0+9@ 4V[DR)&UCD6(,ZFU Y5:&0"$CTF<H
M!JK4:O[+@E 9QX(W:P@/[A^-EROSV7Q]U]H3FPFT1T[=I>Q0N R/I!FRY$)4
MZ:-D^O!QYAH;VGV,$RTEU(D^:7P?]6;#7O$^-7A\XYXRK-NI)E?]("42.SCM
MP '7T(?=*C;_I!I(9()U<<%R.2LF:_'(Q'$262PV/U]Z?VYRK5>?*Y:3%\V*
M^3]V\_V_!%OCV(W.>$G/ZDCRTA<&EB/8@G7%;_MTTJH"?0Q1)<*B'6%&=6W)
ME0^(ET/Q_?$*/=!N*[,5\K[?XBI4Z5L46-P%#@EQ3-!"]"EG1HO>5X!8#^]T
MKIDNAC:*+D8VCT4;H8:2G>VZST#[J5ES91F-J76Q[>/]C//JDE^5Z.5:"!_M
MY5CJ(L62B2JK)SC=AS=]F9'0$J)$+;,2/3G3H6Y5MH+*29^Y/$2046*$\"3,
M+#)$'Z+@/[W\\.E](YN%,F\]PQ\N]?&0<*G2PH:+\6PK?T=/W)3..M'>2EJV
M]*Y+A'5^N*C\A[\4E?S&1\3>Q!O-XZ-4FAQ7D3!O#@51UZ'#M$5)QF9CNAD-
M0>]E9P:]C6\C5!9)9"9\W33>].M$\ _LBGK][YKAL7+X)5T7=N 1\%8C_!YQ
M9'0$5.&<3_@?A8OCU]A%\N-X>7 :X0!X42I;^/!YB,<#YYQ64QNT($R9SKA,
MB!>9DXRBCM31; ;D613<ZVF!(-P185O06_/%]IK^$Z?Q=_<O,7VYS%F)9N(X
M>8IL;0."@(@<*^VP9F&LFY+%>NF$@<^%5U(=0T]5T&3*\RN0YAU'I(MX3ZK]
M5 )?"(.<3./P+JO_;%G9-.\W>]OW"Z]64UV8P7/0C>TL=RNR8>SC2;*@KBSM
M9R[,HYP0%4<T\#Y#G/"9W;6/[ONT55IVWJ_8>$FR9"K";C*W*W!$@OF;QY2:
M\O'[XQRTW/'Q1"NMF'R0S1":.WXXV?,!>TJP$/&=+A;S\O2XO8TTH^QJ" KB
M1I@(3,+.L<.QP-BDQXXL0X4==8$7;E?)_:M91L3&#:+_M8YA[QV..:?^6=2C
M4AO?']B8G:("YQ],CZWXT=XVZTQORK&2-!%"K%>@@WF,7HIOOW3G6AJK_=(X
M'%+F\9BRKRR\]*A5CC52<.$&<+4.@?QFI2[2[&*=]V4H?VVPUVK)(R*YI8I%
M@N*4;HD8UK"GN;BJSAB4OQLSE-+]^8;P:_!* F<$V]^KJ#GLQKVCPBU?;/ Q
M22Y.0Q S4,']?,( *,2)O9E+VI'<?\N3TE$XS$I7*KM( S\022UW\-G89I!;
M_\$<RWS&)IF_E\Y:,Z!+R5S;UP%O^3@#/>Z!0.YJ2SY"FR<<_9@5ZZHL?/@\
M)@=\_S=MLN7B.7,LL[%]V 6KEI-PE(D!,0Q'H@<QC"<:J.IBC,;"7OM[)ZYV
MQ8$OAX",QG/4'H40J^FJH;JMRKMF9Y'%WO*;P59'CF24H1P\V+'3+.XE?CV@
M0O*UH3T0Z48EN$'>])?>8#U!7^#N\'#/L/!]F=<+\@QL27YYC%=\@H$G2H^#
MHC8L7YP;"%C?EL:GIC@<98TZ=9[3N[[[R@U>CNEQ>]I^"-T6)U<))EMNS.P<
M6PW?+5-WF81_1$64[(9A91 <X/@U4G^]Z5>^8H:>X19,#[.^8=(35+[="(+/
M3>CQ>U]7$7,7FSA:]@<&D. T^&'U";_\@,-_.%?F<;:MFFQ!1HKG+@JH_93,
M3*EU"ZNDOLBRW5M9*5L5*"&U#R49JG/DW,UR;T>8(8,)6*NC'.(KPI/N(J]Q
MQ[7$G;WG,57L4G["9G%&M=-4&M3.4EI/#B\2H[P[75.\KQVTA9O8*D>:359_
MFWFFGRB-#NPB[#- ?@F#'K4,F*-/&PW]Y:&4;YC=R:)T0V2=.5_.4/?7PB^L
M4TCLAWU9[#1U\5>(UX8 HV=!2,JSJG*QC_FRVKQ:/EYO8;S!VU2&$+*4A"-?
M!,FP$!:9[73/)BQ_*Y\$\4I"=I#AUQV5W4V1_?C6<=&_VI%/CD7OK/5R6WWI
M=!Q#:#@;P[IX%T@M($IW8ZHD7_E;BI6#IT&P-^GXPWR\_6NF<:>4==T$-P4)
M/7^UPJ3%;Q22)[3T)?767<VU I6/H6. M50LL7[^(W&J)S^60!M'"W6'OE;V
M#YMS3._M:@%3GR-8D Y&*G0FP Y3Q!-.1?(D#IG;_^ZO]K(SFIU7O&$#G0O-
MU4CIC[CWONBPV<W(/!S40\'S+N$=%(MB7BH(JE0N/] 6'%TA(*&E9\!P11Q3
M0.!(P2VXWZ6X1JDHT&K4]&53N4'"7"6RZH<!Y2O0;CQ0@!B36^<B"-FN]CNR
M_1\QGVJ6R\1:*KIV!NIT>YPAW?)YQFW*-^,\:WG["!:O@)PTE?#=#A_KB5+)
M0.N*\+GQV[]:\2M!I[R&"5D\YSJG#>WVFF27_'T_+ZIGYD($*EZ!N>)_?^NH
M .-7 -K]"LS7!1O<+:O?#M\(; 63_-QQ?@6:+5^L0WAO^KV:1D:F0B&9#Z74
MULAS7DZ/WX@,>@63"+7)&'!V=2PC!UWTU1^+^?N22ZTQ!D/A*)3'%?P_6K?Q
MR6I#E,5GF7@:N,7QIC-!2E/BL2R:^>%GZLZ]U4OOYA@_&,TW%0=?I&W95Y.+
MJ;,K:0Y;:,*$/QR'WE3GVN^K?P6O7Z2)F*#$P;T"70.!)/H__C.>H$4RCSRA
MWMJ*T=)'H-PL/ XG7"4)VW**92S*O-MI"3LZ6ENSTV$Q4=H@< G/P(3+XK5%
M:,YK(7UA4!!@F,F:VDOZU)38$L9\E7]%[40AGGT7N>%ZQ/X.!M/!KX)B32;:
MS.:!!W@-6T)W/%:(]*['<0R 8Y8JT9D!T<[[/ML.96<;R_DLE0D.KA/HJ>QB
M3X]([ZR?3>Q[/^M$]RT,];JFDIIAC*7\872.E@7*(5*'#%P^" M"8UZKX$-4
M+F*;A^$A4N=PPQ].HS_Q,<N). KT=LR42+Q24284T KI+)<W^")$:?CP:&AX
MYS<KBH1P\U-&K _@>A\"_4O&IF17"KL)AB#52190^>F0\.'Q@4_!C"3#LK*S
M6UM,TW&)T\LP_F%X5=)A& J3.* $7!]& V<'59*?HKK(O@_1;>TI[46P_JI=
M%F-P'1K0S@B]BNE#D<!2+?$Y?A\VZ-7H%7] T9*K"#ZU<YQL#PL4/EX+$2UC
MA]9>GB; "N4"D69UD^>&V1R:+0B&S*_1Z;V%4:C?6]<W3$03"]UYB2;^LE&O
M2QOW3\7?$KH&8A+="C#QDF"E$BP(/_-:B1]B<QEH"U1EN+!@BUU##NL3^ YK
MR+]L$G?(#SPR=68,IQT;Q4C>.+J%;IL7JDGT'/B;AW!-_6\5I_5G3:." ]R1
MFC\.<K*M%DP*DX%MD\B99"65X$I[M!8X:Q;,$ \L2+#!IKAVP>>8,GORK&Q'
M\5]W4(,&UE> <]MQN>F?8?D:\=?2.P='.J\5B[%QXD$)ZH2U(7W-.:*48U@A
M'70P&-P19/0*=-<OE:Z^B<Z%'/GK.S.F.3>$4H0ODU=\WSTAW3A9C34 S@Z%
MN)[3([;XP-?1UZ=KK-<.4*=JR5_>I+O</*9KIKU#//&"^PFA?[3/<?K*E+>R
M&S\5OEPZ\KZS^4"GR!N&:.FU)#4\!GBQ<SB-EQS]^H8)-_SQ_%"- 5"F@9M-
MN[8]$1A[<ZKBX"E]K>HJT"I=V17,?WJM3.WN-#-!NGIJS-C85!(@]<_3<_Z:
M3R#KYU&"T])HH9&'R?+,B^1@I^ J*-)%;UC776+.S;/O?P;4ZKMI-4M*LJ19
M=!&^_ 0_;A4TM<S3)DW_II]=(R/_53Y*Y94SE"(B@5,=E)*#O:MO+,>.K,F+
M*H(<UJ.@%R+J;F)7Q-5IDP/[''=,I;DL \JR&;I0&3]-0?P!<$E3PCH-FIOF
M&8(;C!D?C2<<BQ- T9@R2<YKNZ[AIMSJL] 3N ,MW>SN '5)^FM/X37%2!.^
MO% *LEFA!-CJU;U-R2".P<$-^_ <\_0Y^9;*4,<^#MM.RM>*VB2G5#:X^V-I
MBNB>'[QQ,CMX:R$C>B5F+9C0+.DJ!/5O_1>%!;E5O_.):S',HVM-^QY[I2FS
MKP2(4Y\;'?V?\RX_7]F<V'OOO\5H0EPSSZ'4XF-6[XL&;@P43,OT(]&1E9E#
MV"=.]R]5#.I'TB)_/F(?OV7ITH_[MKIWMR)IA%,D]MO^X4G&-5?5F2.MHT;5
MV:6V@L?\$W]>N+(09J)(D N*PTT.SCM$/.A07FNE^NGE<'X_TI5^Y%#ZB33)
M-6 <VDER;K-.5B&\/$#@),-4"*H::K:"R@ZN^>&L7,Z,KF=UF-[FX,CDM5C%
M]@OBO=]35;OA-8;MUK.8XG^@M:+U,?^:<9WA46J6;4B%3>=3O;9_ZDC>%A]?
M(38^+\7*#/8:SL&>3G [7VQQ&G3-<C7B3+E\6[NT.L%Y-$%N4!VG+2O"^+5P
M4&3;3OSRHX_3LF:Z7FO6Q9$R1Q(&*'ZE!(YI;>"KSPM>G*+3#[BE*1-_1ZD8
M2_-*T,$I 2^)]E(U.E&/U,W42/.D5PD7\^5;/X24GPV[K6)I=+@1$'DP987@
MTV:Z9(@I^!\#2AQ$*CP MK)$J7W8+.TE!9:"O/VPCH4WOO10)7G.-YXXGMF?
M[O/")8TJL;B'+NOK&-_'P/>V)3U>"CFA:!H0-(:-^S' CXAHXD'2EWFJ@&_5
M2%W4:*@.;=R /N/K.+(+ZGZGQ__L A\9HYBC\J#>])AXZGDAXG(#.O=!F)=U
M:VJG3+&E2*$9K\ H$[7',[MY>S6ICQ<.H8_Y_?M$&5]ZR8_!GC"Y/_.)#VHO
M*J\ ]G+C8- ,G+UO_;P?*#@<\)C+/OYX:,)Z&1 \8/3S]BA[K'QA[8Y2=-IP
M.>PMM\*TI.@&]N]K6+1G>DRP7O:'EHTAEZA%0@\-:1*/'2R[)&BB2VMOPE(%
M=R07R2_FV1 D_8OR=VNXOUUF+#ST%T)B.U=CWU72[.<^J=DM)+*W8PW3P*NA
MJ-GUTBFH ?>%NFS(P%/;9'_M<('&<@!36\3ZX,O;;WLMWRP#/&E#J_/+]Z@C
M\J7P/;(?2*ZJBTO^0Q7 LY=[MC>D+0ZC\3M2X,W"\QC]^(3-WU+!U&!8WAF_
MM&10R]&Z[+0<=W/D/V\E#[B^ A?5'/BV5A$O=\P0E2;&=YG';LL%<M 9&HN?
M1 ;+FU[)]J6']^6!?H/]W5/Y)^+]Z21[RW&H_[R+NL#*E#1I$Q59P\P3_2N
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M"SK]HGZS(DO_D53!B V"@*]@N'PHC4$--DNP5"E:PVAM$FBL72#W<!G0HUQ
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MY!OUX"R1\[A,*[8[)S0C@N_7PY_M)?<'27 73%:2&O3I6VS-F_O(".S,KJ^
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MQ?78_XEC+]BIR-C.8HMLW"1,!:@?\Q\?B2RCO4]M:G>@?Y@-#MIMG0@W ZF
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MR<VG)QF]^T+3:T6$P+Z??OR:H#82 <Y O/GZ$/.60(Z%5MX6;Q:8 ?(FM*+
MZ/8",\7:)Z"&MYM]R(# ?AMU?SC=F07:M;^+.46"I0!+>'\'VFM?YN"SZ80!
MUL <JT8%W.J3F\I@+D[_X:H5W7QOR'Q9Z I*-86WZJ[R5KIN(C:^#Y\U]IX#
M7YF7[_DJQ(.+=Z'H;OI42(P#S&,C_OW,YU]K/Q7$ZH/XO4U&DHUOX+^)]]KK
M+&*W8 ,' Q]F4Q >2.KD_P!02P,$%     @ ((!_5C!<]>3:<   578   T
M  !I;6%G95\P,#<N:G!G[+IE5%S/M_?9.,'=H='@3N/N3G G:'!W#PD2K''7
MX$[0Q@/!W2&XN[O#\/O?>Y_[S#PC=V;-K)D74[W.6KWZ5)WZ?&OOJK-W5;_]
M?5L'8,A+RTD#H*"@ ,;O'\#;$D "@ @/CP /AXB @/#A R(2"@XJ"C(R"B$6
M-CH.*1&0C)2(A(2<FH66G)*)BH2$CH>>B8V=BXL+2,LGQ,LAR,+)Q?'/0Z 0
M/WQ 048A0$4EX* @H>#X/UW>.@&8B( K:#L8*$H -"84#";46P\ " ! P4']
MJP#^O4!!P\#"P2,@?D!"?J_0@ & AH*!@8:%@8.#A7V_Z_]^'P"+"8=%P2X&
MCZUJ@D#IC,,1%/<3D4J\I@M7;?*<FM/4Y=L')#Q\ D(BFH^T=/0,7"!N'EX^
M?@E)*6D963EY=0U-+6T=73TS<XLOEE;6-JYN[AZ>7MX^WX-#0L-^A$?$)R0F
M):>DIJ7GY1<4%A67E);5UM4W-$*:FEO^=/?T]O4/# Y-3<_,SLW_75C<V-S:
MWMG=VS\XO+B\NKZYO;M_>/Q'%Q0 !NH_RO^J+LQW7="PL#"P"/_H@H+V_*<"
M)BP<!3L\EI@J@HDS-B5'$"*.>-S/FJX/5)QJY[BF+I-(>-1<&S07_TC[E[+_
MFK!O_Y>4_3=A_ZEK$8 " _5N/!A,@ A@,W##]G[K-?3#&^!L.?!9"7C>\.S\
M!I" ?0/<G8J\?FQ:9)S:CC'[GFXX-OR*]QLLLF^<\_K2_P;HF7P#('_N!UZS
MJ;P! K;> )NVT7E@V5LT:T\!UGN]5]XWP,]O@4]WP#< MLPS<R!)X$27R,M3
MS!L@O(H[@H_J+U_A\O'O_Z/.Z;9CC'=37&O? "'56S&/!+1O@-_O-2ZX O_,
M7_2_H&"_ =::W@#WZ5M6^?%"_S_E_X<H'=\IN_\'RG=W\WJG)/Q/RK9_*%'^
M@_+PWREKWBDK_Z&T_$_*N7\H.?\;9<F_4_:_XD'>*4W^.TK]?RC'_X,2_!^4
MP'N]U7\H0_\W*/G_GZ,<M[N7VZK&]@KK.S(K.YQ:T2?V!@Z;BW*P?^_$/7._
M G;^?J ;?@,8Q;\!Y!]=FHZH"W_.RD%(I>.EI.C-L-?7UR]152)L2^BD3&V<
MV6P\BS7JI9L2RY>H<)>=E.&55#X6>@+!U\..PBIUXU^V^YM.F 2VYB/&J1SJ
M3 YV:@.49:Y+0=AU_<*$"4_#7)]_5GE!1APMACPPAW9]0ZACJ]C'Q>HU,I;F
M;TJ,!W^WD@T$RO_2@N@38*8!YV\*KH SKVXG]1G67S/6WK^%RKQ>/!\L67-/
MP*!4OVP]3!$6_/-#KW6K%13*5*#7JULWT^\UQY'I'T68HJC6.PAGD%W;V O-
MU7*TG\CZ-O@8/1>7)=LHWPUM'9A#@.H&:U&5"+?FGO+.V[]'KT5>_+25,0MU
M/Y?V1RM-)!B">/=F;GY4%28>\?1ZQ"2.><1TGY?IA46 RNVUH-,;UN+7L3JL
M^]M!+!OZ]_E.ABQ!C=0H&S$,@6>Y(OQ],W-R3-U<OD0(="[>O;ZNA63:>1,/
M0^Y[XU]6.RP_XX??J(D^^7>-DPS8!'=\G)MHXB_\V_\" HTO&"H)#\1%RJH
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M:J=0V,QD\7YLG>EZR/3U#:I3?S,,[VM2=8'5D9M];V?L\*Y_D27"MY._+_"
M2G_'/^6!N2I%^D:@TG1U3C;"5==.1X><)!]>KQ);EM_SZS% ]JK#H8E9&4<1
MD8QG=*KYZH(Y$'UU)&9.,[Z I@P 72)*B_>W5=^>VL%:7?7\_"&CT9%"RT25
MWKBN3/AC/S='A9#,7=ATW(%&U4ENM."@F ;M3C)K&H&_E#^7C;IS[=_[#ODR
MQT4'.=L2?86I3^@_U^<J.+JHX2 QB9=R-U5&_OR[O'Y'GSKD"-$0^4J9HM9,
ML_E@>%(11K0)R&<NI8YM/< 5R-[:5&8!Y#.W17.@) 5I> [7B"U%[!]#(<[9
M"T?*M5?D&2/#:,(62-XXO%*,KN@9JVHU\Q\AUCB56"AU +$^J&<;XG!'1_R$
M[>ZCHWLMD=L>MCUS ,_$;KZ_AQQYBDT2%8G;F>X"L\S8=KKTGU[4/+Q7UC/V
M8HDR\J!;;EF[@*0A T,#!>(OXE#7(%<9E6OZP+77I,RLV5$S.$*:;8<#'B67
M;1%/8\;<:.BH>'C&],F-9.G+#6EO/:W%$@XE']SB;S>Z6 *1OWZ(H9 _K=W-
MWVL+'M*M[BGQNZ1KL;_VEQOIMCWZ-V[R1HD0"A>X]QK7_\:H2/TS=W<"#C%&
M83]V-BJ;#Z!I_-.3/ 3H?.E7&<KEKXZ4$Y"*1#<,;:+EX?'PT5C/K8A)HLNK
M6K0FBG[)&ETI3+Q:THN>'B;"JHEQ-4KK5,N+<'-NJRUP+K7T0"KCC_>"_DHL
M9778@E;^LX6E^#WU\#NY0D @E98A)$N"J\KP]9F(]/5TYDS=,KLL9R.D<M[B
MO?OGG* 2APR-038WW?]5484V.63--*%!1LT?H9T=<U(*!Z JI6<H?%#?#*+
MLZ=*%9VRS(^5!<9R06E%T.5"1S!(P X[0.!I,>IP=9&R"L"Y0",I@(P4KLV:
M4ELKA'-IJ:UT]T>'LDXS(8!5O5.H!+H2!T.L:SVBSJ)X^1#>V18_[=9+;U/9
MN0$_W@JZ 4=5% [79UIFAO7'DU!%% J'<H4T#"5*,^Q-K^HH $<SPY#_\I:^
ML+$Q7F>#CMH"Z.F\V/R8S3#303IGW)(]9\BQ8_E-,D)GR&_H[$Y:2)GW71TG
M1\22"J)7J,*"W;1<5A6E&%7>^HF:$YHKN,W?AD"0LW)YE(3M( 65.IJ2(:F+
M&;A&<KV4[?K/#K*&5IZ7HUZ*-K^\=0IS"1SKK5,.][*EB*)G&7=C"CXD3G=)
M_')Y:)-W4_6*$_LK'+[8%PDIVR6OSP9M;:UUD*E3ZN8Z8PCF5ZBHA*]HOKLY
MZ,&"8D*)*7$'ZAE>D1](UNVH^&"QXR;^V3]FQN5*3NBUAILN(L_\%0U!3ZWB
M[%>=<2^Q_D%7W(V3@DW-UC<EOV>3AY(L_%6C3M= ?TG"F4F*,K7V)[5Y$B\5
MJ;30/G0[CD9"%ZAB%+5'!:=\EE0^[IX( (YHL"Y>,>KR!+5);=5'CF7NG7X4
M'=^5TGPW'%TN^O]^*+[Y'HJ[_1.*TUO7<O\=O*Y C<KBV6V9H3F>:A1!03_0
M615NUJFGLP>C) S@BKW'JPX'9MS"EL\W=J]^;P"];4%=RC6O,^D:YQ_V,5D4
M5%'HJ9FOT'DJRS?\;!?M2CZV=Z3MP::,5GDP/R;(G^%%"@W*G,:F*.+I#,K]
M5[HM@='TMGO[L=(BBZ8] 9HR? X1^;>V_6\ W8 A(8H?K(>NGYC;Q#>2)5SI
MC&H5*!@?W%[H@PJ^1'NQ-%^/0FN:),&^P&DIE)LZ8_?&G41DC(T;!T1+I5:%
MG04,/J2;/9S\:;.^QY9UP PXI\RX;0)0-P%#*.+:VT:*W6>"'UEP C)G3;X<
MBSKE9A\K[%V5JQH@AUE(1+G&\\]@*%ZV.CK$XVZ!Z;_6]/QJ5J1PXDSZ00=S
MI'EC>E)@Z.UB[XW1%YV]%Q&_$ 7>>#6M&N(<5;L0[$-E@CTT0"_V>R4HN!9M
M$-Q? KVVLB8B,R1]8U^SB4+?,50N+Z;FYI[[$.I!9M<1S*KX9 E=[\8H&UV@
M_84&RWX++ =*J"(,W*!AHR(=A?X._DX+<P,:1A*$)*S4+9:&MX,0K?)^DT;;
ML^B,?))!$;5DG"X=9W[^S3^?H!R_.>1U]X E&Z+VB>-3]M9J34_C(J5,B<%8
MN+5=*(?.UIX0X)DQ;BZ 8=E T?[:2D_<"P6K185L]-CM,2:TC='6ELHV> W/
M *_%I<?YF>I>I:D:;\Z^HKYU..3\^,I =W .&1R('EC:5?5]</YF0<*&9Q/'
M[$YFY T0>W _KYIW;_IG59)-KWU[92=GM^N6%,Z 01Z(_+&08-3W<"^QEU,4
M_MJ?+^->_CGFX>;%IDOM5#<%\ 88E@4"T[,95X'=-8:=TODD6!)@4W/4_BU=
M2#;\N6\/D8 N\\Y2_\(VXZ,+8Q5OTBR9W[GC<5U?<6>X*N+VNJ-:94ZEMJHW
M&7=O5+9N1J$/:/PKC&S?FF:<V%.>['<,X>8RX'DUJV0S?[V%_Q9?):Z7)Z>7
M=W$>7PD@332;R^,LJ6RQL(U=GUT2"7&W9>D-@-B85&SP&727:FH0O#!_43D.
MZ\4I?_$Q!;1;23R&9Q].X%+^%6J/)+L^RZLXG_'P,M%=RS*F0,T0$ZZ"0X71
M37:F!K0?@']O6:%D/G5X/VW\91GG>>I7OZA  .@0\DB6E>^EKV;(L,!$R&QN
MD;QLYTXAA^!I-#OF!7(_\,,T<RXW&O8L'2=[F7:/XA'<FG2^3]!5P%BL5YHC
MXMF-<Y0Y7_9QV'=+S6_0%.EH2MGS>,S^OL_P)&6&,P+421@AR2K\0;9B^_T^
M^N*C")*^WN*B.&VZ:@LOD$(<K>KO7L)4LP+K(D9/1(HP=ITQ?VH1^6ON/*-]
M:Y8<=46,78.U>?,;0'K.Q%@&Z>$-,*$B4FEADXW>,.O^P>&,2S]? )BNH'^%
M)?<Z-]&=\Z=Z?T[5*Z=[KB5I+OW1+H6.6H=(=$?CFO:0KY?;$.MTL*VDP7N2
M/;8UO'\O74)8NC*+L5>O+[+@D,@B9"%BZL5C^>.$)XK9]R4P(U'$#5''7G;6
MMTKK.IK&<@MG"DK>*BH/<DL &^V#IA[]C^NMK7;NIYZ[4.DGM"22>7SN4&KJ
M4:Y@ORGL^&;52='RRJU =#D&28B19C!13XKXTG&;''9_4(PBM[+0T2!=Q4LZ
M:U9V%C!2D"N9"$<.M2ET54&K*63=]**6V]QB"\$SP/M@,<MZJU(HDW,563^M
MHMJ>NDE!+!CEX3L# CD:X_!^\<#WK"R'[^76MQV$,\>+]SJ'6"/ <>X\1V'2
M H*P.SE3]#= 64OCA6>(<:0*IOP\EC[3$G7Z7T[ A/TG:<"FHA.'P'S"I,0W
MXX+)!95-5+*COG2T2D^,[%5&W\ 3  6,7QG;GJ/$&'H'HZ?*124X@[I&I?QC
M+NW,>K)WQQ]<HV4J!&+9.YB9^515B6\F8^/2[YE?2K?JO9L^BE!3(UL6YW$G
MI\KNZ57;^%T@V6Q (/Y]X)/:G,ZI?16NPT[RQ^2!OL;D$[))].&Q=6]82]@O
M;641?!BN=5-5SRH;2>>K^18F#=MQIU \L5E78>3Y.](\4$=1 2#];B.&J1,_
MG@+KQ\)!>HN20<XEXD V#@X &-V_.E[LR,A?BB2B:VRLVV#N^BD'P\H38UG"
MDR:=O+4]?M[.$XVD4=$L'M!Y YJ1V/J,]M>VW-?>F=ZL1'_LTIMO\1NW+C06
M9ST> 4+ZI0^=DR+?PL(^_UR<_::A@:WZ2[5*FUK 5*QQ73F".'ZC;-?CW,D\
MV$VVRJ)Y*A_OTD!G18'\$A[O]!- %!U.>JT8M'/]:3V5OMZG0ICC?"#[=8,*
MHE_Z'$ZZ"Z'XV"-@+HX3&$A+ G.O)707X1:9@S1:4**(R@(;+M4$:\B49M9*
M^-1F">I2E:%$\_#1BMOR%5!!MYH<#!AV+5XP6GJ 7W-:77^PSP[VZ"KW,.(\
M7\\^W)F":T\GEO:V@%!06T2%?PHA74+X!=K14+NUXEN8\[(UG+Y>,OPB$&_V
MI#%7C96'Q5VPL7004E7TM F?5JJG1->6/*U#E&E/>A9O &IS&"7^=:K!S;X/
MYZV)LXSM"<<=H]1\X1EZO*:9/+5(G)%1+BO8*[O*Z'VJ9=B;Y)I$T-7OFOXE
M8VN)&XS<KMJ34OF2=]6_0QHU38[(*_2!X!9WMU[UW5NSL[/Y)HYO/MPT14^O
M#%M;V\-5B+0^418AES6/:> "?+[KXK7,A[F=D1VV;,-O5#PWT]2&X]L^U**8
MB71#7#'\0YRN__68$D'/C8&J:G>:1N_MCHB><6NG@M=+6HJQC:BL7#;A]O+,
M&= 1/9.@H0-DVF"P]'.W4%M5AF)$Q7;R-:^)@3L.'36:?7;0AB.FE0<>D2*^
MBPQV#X31[>0#"^X"4NI?-SN8J(NE=JUSK;J?UD1C/]U]W?DE+220ZD7#S=:2
MT;]Z+_TU)KOI>3?-C$%_L=CF"]Z?,ZF6:<> 05M+[Y;-7KLNRY$*O\XWP"D&
M^WS4I^R/YR-W'RS*##+*%4);\#WE;$,?LHP^PE2?;UV =KE4!\+&QA5C>E>!
M"5)S!<GB$,_0C9\-E_ #2U2#C$'["-3GMLHJI%X!_OJ??B?OTI^RP+7VW7&/
MX%"6HB,;8WGO3;SB;N/\R\;[9YN5&%Z49RJ0%HRV1\>%D @]L[M7ARW:M'UI
MWMMJWKR(0N(/0QM2.)I8/I__2V?YZC-K%L%MZTF+Z,WK 4556EI%KQ8]> \;
M*RXBG_<9LX[M#"!B)&RY! !+W*U5NOL<[]S[!+WZNJF-UG9=/+H/0&>/BU@^
M/NKY6DX&/ ]>#8/TJT"D>U>5^0+^FV>EV[_51/K6L1M?J;.*9YW_S@P7*)D!
MW<<;P-TJ/"G<C9XI:(/>VZ'9H$TVV6VSO[.1D1FI!<SU'! #M,0C*X>3QKX]
M=CKR3/<]\C< O_OH@A:2*1:X#<G6[*-6Z*-NP9\S*)]'S00Z<V$;6=PP4<['
MB&RZ3])HN'*'Z':WQ8A(YX5. O;E>I2*9[6Z#*=@:8GCP+XR)8#=<7/7725C
MALMHUL#O0M7XR:M)_7T;?2)I@[G'"))N-I.#EOS0._4(3;!.6FVG>=1<S *-
M_9(+XK$*[8$<TJ"=WV"W.3 1\W&*L,X66?R(ZJ+=QX>H*)JF?:G/C$E/O//[
MA,\4=V$SO*'H#6VAD<)^QXBE$^_A2LU1NB<F:GO]$=/X5]P"IN;K,C(J+=L/
MHN2H3>2/6V^ >8/;A@OQH<6]8SV+]KZ?/OW(.)B9ED?@0*3%V5V.I1._BE",
MD>PPF)BYY$>\I'0N-Y#*\7Y7WPXOV>SX(5(@A/4C Y(<M7,YV9+TUG/(ET,5
MCY2)AM:6O*"FZCV5NB9OXWCMV-:,(D)'PX+T;-M64A(PAOT-TWVY9(K.^6A#
M0YL] W(^4X2<47\5%&A$9F.XE>XKI&;$+,Q"#?!XD6"87>=91NSV729.<I#U
M3",*JU", *2@7#N;+:U0*?L!]_=LV+),@$UZ<Y0-;SDE,Z=B+9CMCL>: L8Y
M@J*>=9ZW?\N0R(#+N:P+JQL32&^T=:01TK+:MRMEN'8]QT*"+C\5#\ULX@9C
M;&#L\9-2OUEWV^-0F:$5+,U@IDA%*YPD&9L==J0(8D3[G25M!8/>&T9&V'Z'
M)'*QH?,*F*L^ODEUVZ=1M7<EYZ!B\>Y7/= 0M/7D:NG_NW+E2,2(^&0.+IYK
MOC=>X[+%EHU/@2+B(T2DOOB&CM/Y*/"ICB@TP]-\3-6!PBL2*KXUB/#%%IJN
M^-?T=CPWF0%;O> 3]T0@A4ZCI<8Y6CAHMY"ELG*<!=9#:_^.F/UUWK&TDEE!
M/T($A2+Y U7")Y=(/&&K0;4]$44UF- +RVY4E9[RP)*_]<+^/8PD4C\&5:-*
MQY5?&,?0N\[P:>J=1O-KO5',O7%GGSM5Q+Z?''P6LR;CF,+6@9R/Q+?82"\K
MYQ8/#+E.MON7YV>?6?5X 4^(M* :M;D'BWO#L4!@$$J%<QTX;.I7@\"/!N0Z
MFL)++BMNK(@1#G1!L,"<=)VS>PFV21&H57K!^XO@M^5M\W.?&)LOD=5Z7@%3
M2D+5E5_!XAKDS%%!F5L=)S.=#RX1=-6?KK[]*]W^O^_ZKV5_%58#3?-01SMA
M)H_,MJUVT1D3V+I$*APKRV1=VA=][Y/CI[8 -^6%TD;=^>ASB=,E?3AZ\]:#
M^:P*XA^J268<%(?E^]LQA$N0Q";-Y'?)1@C";KQ8W$M@EJ,5AC=>C<P;0'!+
MLO\G\OBA#4_)6!JCR7S&<W0\1X$E(4%9M=4>G*$8*6^YFU88N[14 F 0*G:O
M##B/\P+N#(;=*G)A6 %ETNT&Z?2W8O553%5\8^/0B14M0SKXB*)./ZY(UE!3
M(6'O76 @Y6W'8K\08"4@-PYXY:V"T;NP;TS6PJL/UXD.A]47+SDFN('99[#W
M-#FN&LOSC,?3N6A.V37+C"G4;W#DA9Q&LADDT59ZN:?$^)E4'-4N'G@,?/6+
MTW_0GP%Z"#W-6R"$/,LX4^M51SVKN=VO$R<OCO9X/<;U7Q4S]B[V):X7X]-2
MIVS=D6:F\/N5:<D:L:&+B^WFJ=K7,S<,4P"[,P,9MAM4</?7;)SMN>*'UNA<
MFHB?\/KM;GI=C? O6%H_UI3JWH<L%#=2JB-+!\':WWD V\1N]B("BK2$%(D'
MEOQ<=]I=$S1N%JAU?R:%4VQI]JN4EBW*+-Z(CC$;(091F.NB$>\C"FJ>?%9)
MUK?G"4OMY::F^H4@N%GPA70UC[FA)#])?RB>I5LDIH9$TQ:YZ90%1)!'S_1I
MI9?-7-#>,7%O60L8S5(0VH>JO%R[_'>XH7-O1Y!, )RDT-4257<4+[[.Y!-!
ML/9K\"'L$-7X4&*1VH<AZB72UO'R#?#51_.:LXWXKNS/.$G:LAAUM00XE;(P
MR$22):)F^"X2<A%WLP<25)7R-&GX D]+#ET<O6(K\FGB9&IZ./TD&4^$(<D
M6AE ?14U+[:7\+EM[K;<Q8& @X>*SX#L;Z42BZHSK.(E!Y5Y$@*5B%[_%&O;
M VK6B.^D9GYX+&DPN*Q[+D&QQ59_\!CQ95G&S[*)M/](E$CJNWGIT"DYT(#(
M1.CP9<1F+I*C!#;;V2 ;LHE^G/'WY#EK(W]5ARQS,S6ZMDMZDQ<XE,M4T3JQ
MHR+?]^M"DB<]I#TUI'ND0N,B*&(BGJ^RR-H87C;U]9)L:\4::F^Q(VB3>.F!
M98_3.[K_=-;0B=]95\FD4O?7E\L[^@$.\0$Q8*'/C$NO4\6$+#624Z>[^KZ,
M33*QMX/RWWGPL9>J(CH?Y&(OZD067E589$E[?%W*4ZS*W1_^<+LXJ4S%H21/
MM9ZJY6LW:<PGX8829JX3(<D[C"[J]1W#? 2$E[B963[3[$MO&GBM95>BYC,P
M6_W7Z>F*// L8D.HPKVZ*1^@4?AWUL=*3XOBSNJ*SS(D7@,06/S8-\#GH02%
M*<<*-V\J[#= L?RA1%R3M!.4R,\7QL0Y80(CFQ0E=W=GU..3.3DQK>>NS52"
M]+4?VS/ H?JH);V]H)S4F .=P>E*.X7S'/6O"0[Q,&\ 18>8UU'-F*]^,H0,
M(O4B9\&.\UP]7B%NJ\"P/RY>GKK^+IN[0IK8+U"48W.\9_<WXS:[5M5RY9D?
M_C*,94 ;VC1Z7%H.)WMMV?G@ =[CBTIEL$RH1C(WPWY74M@GL0&N'A_-^6_U
MT5].;Y?DOQERZ L96_\L2!Q*H$>]0KDDL-^&6:WA&H<:#%CT]H5(MD$XDV4]
M$6OHHQRHO\)+N]YK2>U%/DN4&"PM&]K,<RC8TV8@._3UOY[#_&Z77>6ZH#(D
M3IX]1>D3877N7UEI)>CC%8R1'YLZM?9*]WD#A#'76YS?U$D7;<KMA1Y*T6(E
MYA@++VNV.W:6@,KK+#FZ;,8#)J7J<YCMW^L*WPRLVO*#?U)S&*X,<OXYH;:(
M6?EB/R(S<Z6-$/DLREQE'UKIO+W<VC:83=+4;7FTFE7 V'.P=6]K,]6+?!_!
ME57T#5ZEMGF)>K"%/?MUKT'5,6RJ.[_;V[ETJ5=P29><VF_(XO)^CZ9UBU1@
M#N&9VJ<_D^9U(F,$2X;.[JJ#/5CD$R_.[_-X6_A!>]3G4+A =HVO\EE+3;P#
M#\V]>"E.;;Y$ 33G7A-Y$0K^4JP21@IF'RG9CY/88SEG7/C*(]=E]7O4K(;+
M%*AON_$=24L7D+=1'*BAVVZJ3,^T9U@WV0T-Y1@(5]=#12XG.Z[\E>&L<HB\
M8@=J28W66_IWS-=W7- %75P0:+/IZBN;C#[.K*&EK\ZM#Y=+LE+A?^&%99+\
MMOS<[RD6-U4H@NIIH+_47=%//>X*B\T:VRFU)],N*]([#=]L+2A7,;2S/?/Q
M"^4G.:&"-X#N&\#?L_ ]V4W0Q7K(5\V4VY5A6?\KL$4@<8]&5]\:LO5W_WH-
MH8=+H34C9FU8.-NR$:DR-=/@1UW07=,XV4W:9B"BW,;<](\F3N;;\Y\35%2,
M<!2ARGQ4O^?*#+P@GUM31X7+G2YQ+N\L@2PG]P3[/ ";QO*JP_0EZ<6D[11X
MREX>8WLF%^<8]=$/\NO+=IY*YY?]Q\[6<8>(BS&W^7KC;B;&OTZ"6^F /1S\
M$4,-YS@\+>J'GPZK&LL&_!8J(^"C"S#/8/AX:878SW3JO(9[M.%AN*M==F%:
M.&0?E*>:'T^HOY3'8![!R+T./?FMF2S4#6X1>SKT5W&.T>L9_KDX=IM_ Z X
M7H_R*RP-_S6-H$XK&LI927(J07]Z@/75\%C%@$R_DN_S*\WD.-2V)W'2&=:,
M!*\GDF=6_];K;+E0;O4E[?'D+^PI=9JL'QJ-W1'>#4C%&7R6J3 XY&X)AEQF
ME"OZ9XL%[1CO[< $#8X**)0C]]?,=Z]'LM;:<"Z-028-=%MU!:@D3=,<\"@1
MA4)][LJJS_<XX^"KXL4<03WX\02$BDI(CO[Y]Z'\V@*>FUDNCS+Q>^I-<=F8
M,%@KZA[' 68B>O&?";Q"?8=MFT&VR=E+PNJG3\T$(@;@YB/YJ5.!_IJI@QST
M$^E\6U??,D9KM6'+';8@B,I>O*8\6#N$/'VP]KS>IS_R1HD;/WYU=753"B7N
M#+'CR^P@]7LF I(&$MQ'( ]'-C7X)F:OT\5UNR/?>>VS+Y$R5";_+CN8]^31
M2IGJ%1I_W"-X>%A)N+]2GCIE[%FZ8 VQ:Q/9.%+X[DO=DF!DH*]$-KZ20U^3
M)-3J[WJB:BN,FB)WWD,TV61*)AF^D<P<53CQBRK>.6@--\Z]V@8RIZ:[8C0,
M:DO(2(X^%XN]<2PM7KN/T9DY5ANZ?=4]B2W%[&!/(M;(44/ H2%O4^ZXZDSV
MU.:.IUD\N+WJM70DP*PO4@@W6TD 1Q[Z'[8!D6\86WFR5P_I92.W-=6OAFC8
MV\R6S3S\&;,;+QQ^?SF=>ZSLL=B2'4-\*F'[+8X N"DY;E.MLI[4[[<N,_B3
M?%E_ >?8<LPV>D,^]6\S0E#@I]6%S2MUC&J<(]5490$[:72M#!J^,^![4#;?
MF1X_I'O)NN$H]<1A:I"%Q6CUS]JP)<H@5JN#XP;)TSP,W,L*9%$P;45X*I3O
M5\!C0CSZ)IQ5=62;:+A;>;E!D)NG4NA3O\.4/QB>]V>?=HMQIGT9O[Y*2,K\
M7(VA_EK/A-(VE_VOYX%UQ\ \+*BJ0+GSF\9\V_*5T5)$9K>3?*_@YL0ZW$^
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M*KWW0C8P#N\>:488J3U_R/=M57R?GMB*NZYFQ8<O*(@I&:IQBB84MWDWUT.
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M>,<Q+WQ']":1/E2-;$PKICA@8!>ZZ*_.X1 @ L#B#:BSUB?9J$X-<[X^*WZ
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M&03MU-[L2[#4(7V7Z+DHK-H.JG T-$+M6>N6I[4S;V,KN,^)E?@E?+GC/),
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MWTSSU],T =)IT8O[&(.\F[O4N8?":/"W.FACVH R-)X,PQ&,@!XE1/< 3FA
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M9KT3>JGSR^T_>(#7A?\%4$L#!!0    ( "" ?U9=&T*@]($  -V1   -
M:6UA9V5?,# X+FIP9^R[=5!<7]0EVKB[6QJ7X.YT",&#N[LV[DX"08,3(#A!
M@KM;<+< C01W=Y>FF?P^FYGWOO?JR<Q?,_O6JKIUSJY;=]V[=YVU3YW]NOBZ
M <!5D)&7 <#!P0%,_UZ UV6 %  5&1D%&0D5!04%#0T5'9,0"Q,# Y,,GP"'
MD(H<^(:*G)*2FIZ#B9J6C8Z2DEF0A8V+FX^/#\@D+"[$(\;!R\?SST/@4-'0
M,#$P2;&P2'EH*&EX_E_;:S< #Q7.%OX3 APM !X/#@$/[K4?  0 X)#@_L4
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M_T'E'<HZ2'D]VWG)0#;/%G^*:WR Q_7(#V>R_@3ESYEY-)/Z1[V4(>K;U5=
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MN*UTY%K/-U?GEJA)$T%\:*0)55&R'_HD(6):VT8\O8K@+].GV^SLO1=H8EE
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M_ERW1)V7&/(A!XWC]D2C>]*W4QHP_WFKKL0M$]27C(W3]OHWFOV>K%#\^)\
M_AT%[&QPKAJE26/O%2CB"9J[YR>32/>5KB:"6W L[N450-NQ@'3IM;6V1B74
ML4RLDFV"F"!HD[<?HU4-?^P-,O='&WFVSEHS+ F.8[L(QMD!*PZ)J-RE)E,-
MU*'D3/R:1AU4_"!W38BC-M^I?4Y1L'=R"*D_D,8Z;=P-R[K"_ZVL1?Y>H$9[
M</8T?&C?H,UAP/'GY\6&*)9)D>MC0ZS)ZCUCQ<*55*TDA)H:!(1BTALA4)BG
M,04D:"4U3>4S?=](EI]"! HH\L4^9@ERP(?64<KP*49 CMIO >,2P4,?BMO$
M4T.\O1K_H&/ALFX%^37[1DLQH._W NB2<9HA7F7>0FSXEQ2L,%@?K*ZWW[P/
M8_ &7@#WC8N+NC(+=;ON\U1>$'62UX>14SSD-Y! E7ZRX=5FF7WZ[KY?<ZEQ
MQJ)%(B0SE';<P/=1)4;OK-@CV8E5C>@H"9H!^S^&^-M+[.A4M:YVKP*Z,GA)
M1H>#^Q87^+=PD YRZ-W=Q1@I+EKB[O[<R474#A_'^T5\N%BK+U0^!D57.SN$
M$,E9QQ"/D H'->C:Z!5Q=<WFMV.68W[:H-D.D1QY"M50#":TL12B#\:C#$+H
M5(W5QM"MS%=-^-"N1O*)!0N>^IG_VE!TZ4@0:=?A>S&\)?T3O!"4M7R:0#<<
M/B-:KX84];>5SST*J,A=[B/G+T;NE@/-K78,E%0YPL?EP>G[B$8NCA#_&/59
M2:?C1W(O]W=(A&K_"IWHT26R,VNY3_Y)F$-55\C(P>BUTL3DR3KR9Q9]FXYO
MUN16V86C^OK)9:PB0W._$81!WQ[;>:D'UHBW<74 #)%WY#\WY_963JO_(*KC
M3Z6MR-YEA 6#IDR,%+R>C(H::L<(=9.$D-IJS>5B*#]/,-U)Q]^IW)G\&5IL
M.KVJ<XW9?YQ;8MXUBKIKY RR>0GNRVHJ+U 2:!<_69+^58F82.]2D?2V@712
M=IQ+DDGX6#_HS6SQ+-]\^$996LJ.G-H8VUL55+0CE-M*^[=:?$7CSAHDZAXI
M3'7-09F>=8\,045D#5]9&IEOD6/#9@""!75G"'FFV!1DXG:7ATV)>E.V"9\1
M=\>CDJ]))L^G&"NGM4;;244:R173#Y\<[PDY&L 8RW+L/T.Y>^+IRXEL+[@$
M:G9<U77MFMH<G%)'MWU73JYXZX%N_1G-TI1E]S6K]G%B<<JKD>23R)V*?:2"
M:&2Q)M/RB/&_M=T?3&23=HO!)ATP"^D]P=2IK#.6[,+]I2;F'X.<'KC5VD#,
MC,/6W.#\17L-6?YQI;W!H@^)P\/+*EH,<L-WA488'XUXE/@=MHG=N*TC/4:$
MAV^$]QIL"U(%.\/+Y]34U+T,[*WU#L@=8V>,I. $WZ(_SHB*)KCVT"?)$KE=
M3:[!YDZK-O7,$LP2V\ASH@G5M>74*]75-;YE+VB(JOP^X?NSY.^3-3Y6,\86
M2^=X@Q35?5>ZH-2@Z%]"C$O79F.7QK3'QK6>K9\?1M@@QZ!?F+W+%'RU?$:&
MR;W<0\G-L;BM&OWK$R:<%N,,VT]( 81<@$0.L!8WUH+]^9.0@^5M.43#CL="
MW=6QN/Q%(?$_^>X%;=,5G([431F80\AB215:!=W=2WV) R;Y:6^7!M[.$>RI
M>Z_O-^]HULPZ>BRNLJ<,7K?^V;&QEMB-XJ?3ZUXH];% WJ3C+G]BH4Y\0L^)
M]M*NY2A<R<J<^W[]8"#3FFJ3,2[T/=5GK*EWJ-QQ4M!_JT%BP/FNY:RC=G^(
M+ HH3I@@]X*DFY\4HSW<JE/.8"??E?ZUTK8+/,N/>J+-U]+!/'-.C_:N^ZV*
M0\F@;*7U'UOW8+#>BF1!3Z$L G%*_G?N[XYTUB0QEJ')AT961!Q9!JV-8HZZ
M&BY&@7[EWO6SX&*G<*/J"(\QT<+6<.1U,D:NJWHVW^-&^6XHJWKTVQE%BYPB
M>8AW9E>)FC3A^+]O[L&7VG^AD,0[9(N..,P)?F>_W#98E!WR>66!M_(A?)0V
M0K2C3A?S0IE;OJ&97.G$_N"LM*CBS,7:Z]LKH/M[XI-Y7>.JP8=L;8SM_0H'
MRO=99V:S_#U'OWA27>_ ULND%.\_^"#,BG>ACQG\U+QF2J21.H:\ C1TV])^
MK_%E0(XY.Y3\78%_3E(<V#]UZ\)@$IU=Z$.XM-R^%'M.\A:I_$E+*W+%P]K.
M=\O1X11CIS)&J:I\%<J"V[N$3G8C8ZT=UIKO92"2<U$#5L;&!D:GT8A)>UHN
MPR/=VE388!.5"Z.)[?(C#;'85X!86AX4-'15=2]_T5B9!$^C>R$:>#X%Y=9.
M_/:S21:EZ+#M!_Z$1S[QMQ*Y>>Y6W^Y!26KW+->,,] F$&(\*33X@\V4&9Z;
M%P#"&ZF*9O7)4ZW-4WVK7T3 >.8RU$/^[;PM4&:=[GFZH>N)0&NX@R ,7DE=
M600U3]ID.-3(D3^+7936R;VOQ\^5>L(]D+,L,Z0L&*F[DE4<0Z'&T&"Q_]>)
M('!\9VZ**^?;R>4$%\DG+F241JX,=7<%W%Q[0$'@_#*LG5TMZ_32 4'HFL[L
MKU)Z!=R62ZDF,6L+ Q'IPNEKX (GP;'S4$EG=Q>.4P;F^:-NKI-5WIN]KV%Q
M9>?&,WS'R6!77](V=-+WPNZY[T1R[8L\JWS?&=DCBTM,8&\P@CI=S[IZN8^-
M;3-BY[Y=C9F3G>^K8LWU4"2X]SX_;=5XVIVP<PLT^C.6E_X*:,FN1W2$C6);
M.@<XWO-G+_.K^N<D5NL)%& >XLD[F0+M&RS%5! "=^]OJ]!9&"[.?B6?OLP&
M5$44T)P$IW@:(\]5._.]2Q.X8M_+\7XWL^V1D*, >Y,37O8PI!RUJ_U9)<TE
M'.QU(GO)!/'3)HTT<N>(,,:O+#I9&Y^ R%^\ B+9&\=H]5<^M[^TQ%>W'#Z@
MWY30*V;R)RU@"SS>O0).,0/&'J*OE8@W^:G8;\9R],4>+9_>%#S-GX><.[%_
M>2*,_YHIPV- #*/_6^-*-)2HG(33YK8'E5\)5Q/9"2INLU)\551W8/A8N/E)
M2_M$MN0 +-5+PC-09D_NT,$+% '=#V&]8'GZ5<3<:3 TN$(/G&AP2,T+@6O4
M4RZ^U>)-;4E8VK,:LEBI\.]!=$_N#SK2+\>4SEKN,V=52U9P(7]#\3N?L5Y5
MX\;QF+#A8T)SUA=/4N%7 /E4IA98:SA. #OH.DX&[/S1:D6W[3N50N+Q*?1
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M[&\RTX8WOP*,"5X!!TW57]/.XHN<%3(RO+E+!:GB2X(W?1[H8$'GH N\@U=
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M-[:D$F3#5H(4NX]B:OY$,@%J\A-(2.DBDV=@^<*C5[]Y42*+L&[Z[4$8"40
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M)D9RZQ2'B2%-0T$*<ZH(E'ZS>[K2&N\23F'T3X'@G'QBC/49U[IDIH0497)
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M2;R*)4Y.MM_K1SC0HQ45^D*T,X9Q((@W7B,$;\&59/<,^**CM[28L"@T+C/
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MQSC\%,VX->E$0LJ/4K'^;&P>)"#/CJ.8Q5V"R,:^ YMS$0**YLI"NJ;O7$(
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M"+%9$\521G>43.3A3,7_8E!)U6WURP. AV%9E:B/4I?^6MZ8P!TV*K9O&\?
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MQN9;0(8OW61\C\?",(?_[>00++:*PD_',:/HYL7+S7/-6O9>ZP)M'=E7*31
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MJHGF;=IP?9FI.-M)W&EHX@]?CQPDCKPM#[A@ZPF5((@_;R)DNE4?)/^B[&*
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MC7ALP3]GE-Q6T]3ZQLMQN7\89APGUD.>.@(YRXP<@X+BXB:GIR3-'4)PE#[
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M*1-7.3G-_'U+^OF&>7S)B,36QGNU6/1<?^+Z4MGF%<UA-HD+MG5/K]$)!@[
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MQ5P_-?_WFP>DK<MM7UPC3LFR''5*6T.&5^"-_"L0)Y9HN/\V1I2CU8G;9FA
M2,?3K\W*\?PXZ3=447)13^$N *>K/ME6KFK$^M%KWN?YPZIV;?4R=7W9"XG#
MH[^5]&F99[A J>!O!M-QS#&2BZK',]C'27BUIDOGP<IMH]A09'F'&0$Q/71'
M*-# -^97^:4Y_G3]9,)\]EQ,[ 6A7EC%ZU8!Z7!'&ZU6CF#BE]CD7!;<AR0H
M3OTGDV]5E#9%PO$:4#&>;S>ER29^D]<'T#-8 98]6O)XG8F+ZI;JTF1**?6B
M/7D4F"QS0AV;5T LBC&N1<%DXN@5."K0H_GA5X7Y\%SF-$H5]V:%BI[8Y,,
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M53"@ V^'%34<E2:R5/NI3QRBT(P;4N0N:B74*L6I1=&84F#U'3O)*G*/\F%
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MA)PUPV1V+(,/GK;]0FC;GJI(=K;YR@730&NJ!0WEFR<G=:]#N+LD*;D1F8U
M+H&$,8M/83N11A19OO#:L]_>L:1;X+;4-<($Q<O& .G1@A>/\Z%QAFAO=63*
MO6>>JEY<,8)C?#N_%UE'ZUH2_'A3)37=*+*\ [P"6[.5<-V2 GNA0C'5I9YI
M*2SS'+'&J3RV@MY_H[;/$/KVCY'S:@7V$0[8 /:;E$6CSE7Q&V9YT=#$KFUA
MR]Y[QI=S)]J>:I$8_JW+RK >K_$(2^&_^H/L/.A4N%I#3VA1&)7B+1,<2/+W
MTUA<$]1EZM[4/4$Z:)=$''/U[]R<9*51]+2PW\DUG?4<L0$5\#N@;VT Q>Z*
M/AS->BH:II@BFA,W[3VHSNCVU'J&(^G)4XN(,5HT6>22J;(N$:I;PP_,-S3O
MQGZGB3^9/(&43533\;^(:8U/SLO:\: FC-^BWOPVQ-R6U)RU2U:8(4%<=6%@
MS,?L&*A$?#CY(JLN,0G2";#?$O+1><18]U/P9(7C]3*9VTZ@3G%EF-#7G^+2
M_JNRR!W]FCI'Y^43#6_/)9B[P@DO<5O\?7P>U?+-^&HQ)?6/9%!QE"0I_JMW
MARG::X,4:S+'=SEHWN5$2XK,1A)=O@* _L3Z!([N/:I:[,.771M6LP,J,M=7
M('-]H6R!<NL5@/\5X?S#R@SOL3WEROH4YK?:45V6Q".99<)^U]6OI1FH*=N3
MVRL 23S]=T>(&8_^);KX;GMJ5%.;>6CX25%J6A1!?HY0;+CZ73^>LDP<;5+N
MC!QY!ISAXFFJZ'%'#W6E8(S6_!R+WI-,>UU4HIX[&2W+))XR@I]@$48BMV=[
MU$8<BO:B2"U,>A(+X>#M ^:!8L5LHV\0>>^M%+%Z WCWXM3P*I[)O9%?_#<S
M!L<$R5V^*$.5N4TF1*BLH2FJ0.-D@_D0;-\71O![B]1)\U8+H2*OOJ(O07."
M<YFG;FKT&"S]<[R\'">3#TM*H*#V'%J2-X$^]Z,A^5T;&^G@SQK6W=BA9GM,
MH!;-C6 W(_?KHOD:PUMS+>_: 2</#R?BL9WEGN1%DJA>A^B>!1[/'G7HU$)7
M0YI/9*JW&W:DT2YK5Y:>/YJ7&HDO6FLCN%M=CNGHNTWJFG&\=#B&,2OAYT#I
M-0$X7V&UVY3<^M#\9%32-O8*L/9W@W'<H%H2L\:QFYS+:WC?/,SO!@WQYHL3
M;ERZ;=@2:/S6I0@43H.PZ1?SO]8.&QY],Y.=\K-E0,H4*7$9+?3Z9VJT?\(J
MUX@'Y]>&]W7TVKL?:H6_XH$^F)C A1*("+F5N:6*/$-84]ZNYD-"@N.^[H[%
MU@I&\AX[<B+OI:I)S!:9;";R07I6:4<=Q)FQ>JS/-W5/4R"(C@H;ZC%@ZUZZ
M%[*S$RH'NUL)_#.WQ!4$KDB;/8%^IO=GW9"D_(5&OAB3O1$7^%'V,K$DX7I&
MI33@*F&0/.2?77Y?@X(AE'V(HH<IQH5/H7R /8%LH_TW'T3Y&[W]>C;93226
MPB8/B/U;>D*;MI@UA-@J$,EE;Z11 R/M14AR O6(F1]JP33$0P%QW,0@%H#;
MBX;>!%3LMX2$QI+M7HW'*U3WWA$X5?6?]BW&I,':$Y)<3'C6YVJ.^.+Q!W])
M2@7KM*^;4>T?4S8;Q/=0>"J96(6L'MNRA9='I7V9TBDO$UOJ&#9\.4N)#$&]
M_DM((/_O'^>.'(]0A!Y4HNW^.0YD^^/A;TMM]]2VQ]]G=IB)F_FXN;E.[$%\
M,N2&HUS+6(6--%Q-$KV-G3E;?>]YN:BYIJEE<;N0=-46!21"!$ )%B.)XZ?I
M6PT,6I2NNN>[%:PE&"7"@<I5:T,X#FU>I""0K[*(4VI%X7T[JW. EYN!BQVU
M#C?V)^J1+[^7/HAGRN-G_MS]M4_DLIM%>J4O"SOFXGI'WCP^!P<@BOXL+VX3
M*UW^_:9WWE0.=8G51D[(T"2V8\<O>8??%VEU.@I6Q>W+7/8<GAT+;:@&N?'D
M>)H>5V1DS$<DBCEMNW<:J[J2*-+VU>.CL3K<[F!3G6TF7T2RILV,_(-&Q94_
M?_3KJ'9ODIWMWRKS@"  S1L%97E$K8$I[_>/JO,7(HG!<=IXEY7/"U=>(4)(
M$&)$N-W$V!ONZS-<#4LG;68.W7PW2ZTU30/&^'5C?Q^'S'9[!\6U^[BOT3E$
MVJM+JP4_%K"(OS><(0E&MR.3D"M](H*?U?(-0LS"2I!']/*75_@QB *E(;-Z
M_Z>;*(5Y =.\YA4PFS"?0<Y/+(S_@/AS.6R8DRO@2'X*OTU?E$&S3O:6=JY]
M8V:[.5!V8Y$6DL+<?$U#0F)O.>.>.3^-^V[ B4OBC:P+,X>M!BRKXUXCR44Z
MAF5D)OD\#]);D8]R-+SS*MH?)[G(.59Y[;Y)#P/'7 L5DF+!)O@SHRS,;,J'
M_+V!FQ;4B\,!&&\""66 ]:UV,6<>7IX7EVMS9MK0<>UJ%R<2L1;"[D:'"?W/
M$S%]<E8EAR5>N,OB<-7>(QAJJT0\8@*/"9E-%2).7S)ON^>8VQ)3IS<9MF21
M56W"3N-AJ&.,0*S<3*T98GKA^2$FL_[T,+2*#Y9%=&394)S$<CZO)#MA.2,3
M)V;Y9$P2M#('88==?CDCXIC)0(=TL]2ERH];W;8NVD-]42';^/'A.BM?J;C-
M '8(#!K_X,%\RSD[A^QR]MQCR+]?K2[O0WP23B?Q*+KO7*X0'%_,DV>)=LOT
M6W?NFJ+ $B=$K'?2R@RS@N]]IRV]$[^'],XS:('2$R-Q>DX[+R)-)99];.%E
MYB,L&<("R=B.G!UC#@IHLG^5ZR@:.D?Z?;;B[.>*=O-52J:9QH/*U ?*[U2-
M+!Y-S;88FA[DI^!ZR:[<_];.=X8UN6WKAB(! 5D@"@B(-*G2B_1> D@)O0G2
MI(KT3J1+Z!T!B30!Z5V*(B"$W@E=00B]2._)#:ZU]UY[K><Y9Y]S[\_[8^9)
MGHPQWO<=<XSYS?FEG-Q^W6/ DE#5[D0(L_#3Y0C@^['A(GC^(>:'4HRRI"56
M$$SA:4?C,F*>_-6B)*OL:@>X6@7,3-C$\UB*AV[R,*\#Q5@]<MCL7;'S/M'N
M0<P$]NU:2UI?;11K=1RA&I\P;1[5]B<'88UA06+%]N$9T L+@]MN5%0&9/QQ
MJ34QGTI:K<]J1F$7H5)P[JN'+ [ 2(&H]):I7<OIL4<)0P5Z'UNJPH6R1U$&
M0:M]8<+ADKU*9@56ANN)=D:N!DR=J[%ZC6_@,K6O $/%4CGER6<[(G4>)W9*
MAV7NXF,/!Q$$!\5G#2=> -H*)AE#J>F;TC<=5-4:ZC[*?[[OGD0:/2=D*%$U
M'$B^YA3=((QMY:ZO\(" Y./EN6Z?L6WI]BB^3JA64%+2:08 %+>[#2^A6[9C
M1 /BIM& >;--72X/2KR*&^F.O:^:EU^1WWD\8&F?D96P 59.@N2&Z5I2'[[P
M7=J4?1*$T$K(KNMQCK_ALRW^!?)Z3@C_:&$!A9V7":YM4-2O,;:8TGIXS+*R
M%!(T(*D'M%1X-N70(P2CR58[H/UFX&Y2LO11@G?7J'[2Q31/0!ZI/JE'R1Z
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MC0-!:$!V=:#'C0R9%_<HR[[BOD5"/NUF'[VHJ3+9Z?%DV->X/$HZR.N5.IA
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M65O+FY9SN'V5 VWERVSMZ^OK"8!+Y9T:"I09'H$$.?IF"QLNQ 3;M%.(\+L
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MCX^*45A<B$>,@Y>/YQ\7@4-%0\/$P"3&PB+F>4?^CN?_NOWI ^"APM'!YR#
MT0#@\> 0\.#^# *H   X)+C_W@#_3X.#1T!$0D9!14/'^-L!C N AT- @$=$
M0$)"1/Q[-.CO<0 B'M*;=]S2R&\U+5!HW/%YPI*_H]*^;_A!H#5W0<=KZ1&.
MADY(1$Q"2L_ R,3,PL<O("@D+"(C*R>OH*BD_%%;1U=/W\#0RMK&UL[>P='3
MR_NSCZ^??\27R*BOT3&Q*:EIZ1F9W[*RBXI+2LO**RJK&IN:P2VM;>T=_0.#
M0\,CHV/C\PN0Q:7EE9^K.U#8[M[^P:_#H\NKZYO;N_N'WX__X 4'0(#[G^V?
M\L+[RPL>$1$!$>4?O.#@??[1 0\1Z1TW\AMI310+][<T/&&H^.^3OS?\0*/E
MU;H@L/280R>DX]NAO_P'M?_.[-\C%OY?8O;_$OO_>*T",!'@_@X> AY $G#_
MR%04BLY4(LX$9U\5F>LE_TR:[4*GIG9Y:YPX'\HQI_U14W7%N7R=M)6\DOJW
MD00$\#].^"\ #:&RJ#V$2'E.-H<\?  1 6(;*N+*C7)9=Z!6Q^,=*TTH+X,W
M+8)^4]$+*7\J"J62P]> ^W=A\)A?3O'%+KF31&+@6=U"WY3QDGTHU"@ -=LH
MAK=!&Q:V&',B+NXT7;H$[E8^^)3"5R[\LK+.(W0\'RJZ Z50D^>IS>/]D8L,
M?*_T#!A2M8*V/)E'G0F_VW3K<1&Y0[R3_%8KZV1X6P(WZ>%L6CIK126M!ZPF
MK,-WFW&AN<XD@^SI/.'E*X@KJ-DCS$/3;>-%*'$.U6L_]I/6M'*3!<3':'];
MI^S,C'^EIGHZV.SH # 5M?T!4/GVXV >5H6BN92]T\5=H0N)!'@I?)3A4ISM
M2$WX.1R<#W9$FX>^H[.+3[Z12#_0+-UOZ?C<*:)DM=_EOK;&ZD$[RC9RO+9:
M9WI,9('QLU.V:7*7Z5FX;#'O2];& 85# I\BSSQ-HJ>I%0=(F$YL?IWRU2JO
M-ZFJS%, EE!.TL>('^7?:-SW!^!AO_:KOP2[O!CA83G_U^"W;+"/8&4A=D?L
M'N)\G1+9->B4?56%:WH("!LKQ&C6E /@_P<P,'<B223EP@<Q(?#J-$6I*)$G
M-,)=U1]G3[9D!WC'G]$!B^=!4WX'S*[0/X!9Z<H:YQ3?>>/@DROQERF 8^5Z
MX6.LH107LSV@*);I_QJU"L.9K.A5F:N;*H+;6-Y$@I_OW+,X[(!TY'MK!,.^
M&0=J2\77SBZ&>HJK7%6]K';YO9$ .R-G7_:2 0+G\KWM*]8YT!\ ;)7S'N6J
MCGNASL)W)[HAT7;6P\>+,GW+\-@_,+8AJ-@)+EZ(-5O*45.QAD2&&9'RB];"
MO_5T%2X_4Y;>=[N'?=06-+L\V])\'@*XY=-)J8XE4G?-K1[,R0L]XF6W;K=I
M;XR^9XDN_OT^'B[U#V"IRO XB2'>V^E&\_8'R R) 6M'\D>+V.M?EVF)%7@:
M+3]BG1&S*%,HV:1?E[&IR6WD_'01\NUYRI_?(P2/YHVO[N>1R;#Z()ZR4"%1
M5[R)G0%V:'W'M T)S'UM. 3SU7MB,U#Y4J/MR>PN/EQ0& .7#*6%1?20^'!E
MVB?P#^";Y(YQ7F[\A^@!-XOCS>X/W4,")74AK*]VXC[T9+5?/:L#51?!&SQ+
M]BZ42P',GBR#:[J:*_F_*?-8>=^WA;QY:'JR,VNW!;\Y2S9[:'AF$46'L<.X
MG3C?6@_QP$A@_+._EO0$/EVT3WX*-@UXTJNJ3W.DI]1-<7V>)K%D).N\$\\T
MN[2IF95A#T,?[U&M*OC]:XLC.,PC!'W'6Y+,S.@#-9#)=!4P^M65D3$U^SM=
MW^15-6Y&?7HBU:8+CR36R&6MAU_@0\O;+[2(V. 1&13US;1T6&/OUJO\HI/R
M^-H?@-F%VOF'I<)%]B^7;IY16GX?#>LG2\/JN"]>YIJ6NB*APE'HCY2+FVL3
M22'H5Y=\.BRYU595">H.V%9U<]B6_"#]1PQ;^*!J+8,4@O6GAA->X^'!]-E#
MJDNHY";_Y)"(:EY.VW%R[*%7XL,EU3DIH/>?!2Q5<69(5*AP4# 92/!#1T=#
MBR /RYGBB-E$6QV16:P$S>MF?+KO.S8"=FI1><_S^Z9S,WG%' C0KX[UTG4
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MV)4)[U<?2A(60\Z\PE^I>EKJ(>4",3ZTM8NY=JQA8R3$4RY&#_RP2^R8ZHG
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MDE%HT ;^4W7=Z>\6] ]..7A>R5MLZ'0C22F8<'V2W"04D?Y>+2W7;7[F"5L
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MEKMDZ,N*.;Z[!$_2MB=%K0NTPH62A=[6#MG$E/FF0T9#"37\ #<S>XJV,71
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MZX4^_E/8XNT ED"RA_'\<79*DCJI7<\OF>=EK]HO4<S5=&^W[[VHZUN[>*N
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MF^JM P+1Z.?4D]WEELBASNMK5?><>TG9&:JJ5O_AOBMKA,#AX#Y:(R0$^/"
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M*E\=>_:TS61M\?1078?[E>>SW.Q%A"M?G/Q4F1T^UX\S$S2M/2$MDE./7+M
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ME2L::.AK=:OQOFT@SX-1>6@$\'S4:FBOK4U9)DG]F1V[]="@.@=/;<S_6=U
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MB G:"$%<PP]^6R5$#H-$YPCV92EWYWUEZ(=?QJG]^G^1Q$B(7J6E0/PY.77
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M+R>[X&K,S?AC0H%'I<(5ZF=.M%NVS7+C47K+/C*OEYX2*=1;8H:]9=\.Q6#
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M1L W.>J-]1,_]V8X>(LWZ[Y0_!5[Y9KA81S1SN?]R-0:R;"&($7\CED[D'
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M+ FU24SA'T_?.T2F;7!O3QYDL+&4L2P(!PGGLTMW33M$9DS!#;C[JC343CZ
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M6@O\5:F7D/$!W%2>R0&T'=D&R@KU5]U)\A$V:RX>[]S_:C4BS?XZ>1C )OR
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MX2'T(&VA(,@!D.@04.@0X!X "0   0/QMPWPGQL$)!0T#"P</ (BTMN VG<
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MQOVH8\5B36"GKAM_8]PW<=C)L TU1OR/4>@RF O(\U:([/:'--O(A7X"J$N
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M42,=Q^]('0\W/,>?@/9 \@GS""@= N@! W[(B'%-ZQ)HR%Y34%0V)I*P09M
M.6,/%<#TX3Y-P_G7V.6B,/B8A9)R/HI^;>Q;;7;>'QE;L:O/K[51DC]1%34*
M)PLF#\:F$$,LRH;X=  XH9U1DC00PU*$^'=%-BY>UC]"3+! =ZW$(RY>1;=,
MP1U0#?719G ,14[[)18R2Z&VB?ZF^Q3N4(W]<84[/-<<ZX;!7F+[$W[<6P6D
M-&?]K7JB%JF P+)B68H<XV,@HN2KF.<D&(!4WD]R@^X/!D 8O;7 3S(]/E?T
M1^NWNUP@7^ N,ZKNX5P3<3[!BOK2D0V#[M?YNL!-?$*A7R&<@G.4^92H<$HZ
M6,KFJ[@J5APF5F! U_%E_RNT/AC0H?YV$/F@X\T-!OP.(WE (GE0$RT\SD I
M]Y2#_6TL;E.+E[QID.0,D_Q!J=H:EZUF<8!Z%VJJJF;OP0Y8*.- -=L0PLQX
M"MGK/&6M:[_STAR\X8NXC7NN^=P^9'KNPZH PM&+$#J@@ -!]H.P?/Y\WW)S
M]WU_%UDGH9.[L*,J>9R3B%-VV7UB$Z,!Q':V4[MY& 7V)LIVU)KC8IE#:RO-
M,]K3/$3EDWY<);1DUGK*<TQL.(KH#&GGR*N0*Y!AT M3.Z'/A#C:"TSD"PT8
M$#"_'?D$WPD&^%:^'5"" 1=A!^Y@0!!3::E5C\.25]T17[T;>5B+J_J#&H^J
MJKYSNH9#Q[98[@/0N8B)B7%"O#KOIB:=Q_B#!,V^/CPJ9Q3G=@QG 0!R$J38
MTISTIJ[IQ>ZM],05NG@O=)']CV9BB^HU7Z0<+*65A0*!A(5>!)I#PSP)DL[O
M>C[:"EK:VO470C8,Y<*W_6B4<A) ^A- C]X<KJL?G/!_X")_ @/$(E_HQXIS
M+EK;DNS*=,$ <Z^D,.=I*2#VS-I7Y3'!K>9OMKSIV900Z6:V(0>(REYRYW]R
MI-(_DV:I\>+\>RT! 6?#C.,K[ZYT/Z4JU^0[A(AW4B:,C2JAU^FV;N<J>Q<^
M?N<< [-.Q=P,Q@&Z4MNS^F+A]U9TE5$CMK!;4H!]/U:E,V?F]3.3OZ;15]O%
M!PN@CERN#.-AWA(_VVLA%@),44U! 9'"KRF[9J#O(G(K4/.^TQO68SBX]/;
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M!=#'3-+2-0IJV4*99!:45RG;GWWY%^P4))[SI$6I2X,Y7<UM2UWRC-(3OOL
MC.7#02&-$G>E$Q?TYMXP3(]Z800&>PY'521E+J$S5=>P>PQ0/TA><Y-6=';N
MZ-?XQ#$S[]'^BXA3Q7"%N2%S\D*6*H1B]QL2JMG^D3@<GD'Y3FMH1_]Z\%A3
M2>RB0:_1?)O3 [? SF4/YUH!#HK L\5*P"%M\5 L^R73S87VK]V8T3;.VE(A
M8GR*;&]W+E>\$VG(L[MRP_SG>22  ?B>5E0CDDL_"#0ZA XJ;\:G6O;R:L"
MR 6AXRPP@)>'8L'SZLPEXR^2Z/B#LA73QZ(/Q0)A4AQQE2+SG*>T&/%DB/'B
MR_Y^"G!3-27\<K^Y?I:44U^\QK?FEJ@Q3+ A*+NPU">4</J,?V*1MXL^3$[$
M!0-H9G)76O^2=)I"9@^F K-I<3$BR4XI(WDF=;]D;,MWV*K9 (O08]G.&Y W
M.ZHJ:>=^6B+MT_E?H-C?VXO1!:L/VM9=/>:VLEQA _0Q:ZY^3[UYR27Q&N,O
M$?S:5#K>?<!X]GMRN\YA3TN*<$J"[R,$_:.O#2%1BCT:'#6A+\RBDT)@<NOL
M]IHF8WDLO83U9-<E0O;*"2&\(D1803?RJ=*85*?9FV&Z>B/_(@FK]/D$#$(G
MOBNSQO*+XEJ23F7M0_/TY8(Z[D,347LP=]BB14IQ=;PF:'3-;GK<,2> D"#@
M_/WEWNX:?>$/S@F<_RO.J8R?DD"L'B(@#^9KC>[VDO=%ZT!?BS71(TC"5! *
MK?"_Y.S$ #'[A"[\4ZB(<=:H-3J&\>POL7;27B )(FBD&9?C"!(=#IDA+>;=
M]_T<6^5!PE2S/6(Y^IG"?#\/!.,GU<@NZD%2?R0-;330C]GY><*V#TX2?S0/
M4L+_JA33GBOG[42J_EP6!@9PGOFZSTL#$;<HTS2,*4Q.HL0 !D?)_$WQ>8D[
M \5WYC_R7>P.Z,6GZ ,: ^52X.-@NTWID\=G6C0RS2Y9&F:,'GF+B':\57""
M7FRR@//1G=_8<U>[\I/P%/N7XH,<6K-":'^.7)*\A#S5O[K)O:&#_RC:U62=
MY$X9^^6JQ]R!T",W95@6-]\2,SJLQHSW+0*>VO^Q@-M)PQ2+_#+IY.&7* XT
MZXF.&^H-4#-=6\8U-K!%T+X>LZ7/B^P:<V_.MG0UZHXI[1T^?B?JQZG9[X')
MN0VPSPSN5"*C(<B$*G<O6$*--"BJH??Z5FA5@9E%,!-!G3("KS@ 3\BTWR>\
M@>IQ*G>QMB0G#?+P6,21]]L2DQR!KA^F+%*,ZH>Z5T=;MQW Y=!2?;!_JQ%K
MRTKW&T+6YGA,PS_4(W6U^!OPW=M3#%B^$R:B_T:U,C1>*<\(USVA/FK'F6_#
M4)XOPV";$C<DC\&IR%E/B6/<K1_SPU="!M-5HINS/N$0#$ @5(MJ"8OAQWF7
MUP$WY&URT!.QS@0O6!/UP"R;*,/[O;D!O2QY[(O]&9??^BF$Q#"H),\+I/QQ
M*J?AP;G)K#7&H[%,=6EVI<2Y!!8,8#*!KK/%9$7FXAG Q=(;8=Q1FVGAV"S@
M5$!MQ?RLYA9!2V'2GTAA">7&5Q7"9HL0!3'0*YKKZO$I_5RUNG6>,6O9WNK$
M&E\1>Q8W(3:"Y2N [1-5PR!V/E<WGI9>X_1F0Z/Z]EJ7@R4RJ?4CP'ZC7K^'
M><AUOU28V=]R=]:)#RCC,3BB-JG93\BV\:DLY[&**,S93Z")V&Q/IVN\4I<$
MQ=75_#[QM$QKH-#LF]_J_N?XU-ZH7.$Q4>+UU3X4'&_LR9L;>Z>?'Y*00$=J
MZO>T 3D_OS>PCAG!_8;>3F[%Z5:'S;:R$2QEP90W0K3BY,3F[Q_3\J_A%+P8
MXW4(U'WAE=&B#WV\-4^@,7)3)V#3LJ@$F+H2-.Q@L'C9VCHP;9HN=%VBAN<?
M.H=8EDT=O[*I)QC;;GU&%^F.[B!MA#N.L%.I":<3T/K2'*%!A,'!_%P[C*&C
MZ UHH%X@*34ZXQ/9.84C_;KG9G66;V9LS-B*6]BG4@7_] XHPX?NY-"0L5D9
MJY), "RT.LT4=_.>28IAJ>+=^1X6B)Z@FV9W9D8"&$>92V=BJEM>79.QS.FO
M'>OJ#J NMB*%6OFN[815\AQQ7+E  MU8D:AD(S@'XZ<AUMH538<=/J"\_(FQ
M2:C9U_G=BDFIQ3K*WC1,;[<%NE<,*Z6_(7L5-#*+I-("R:\+"&AW_$VSK/$&
M'6<!V.W-UIU >BVOKU*(?$5N!9NB"$2X\?UGG5<5;/); +AI>H4+O:7:]DH9
MGW?UP,\-$3M$(6LF[UFOMTD^(D?D0$78::=A:=PCE?5KMP':O'B!DP[$"XRZ
M;E'9L.$)E'&98SS+Y&%/.QZS*9%!#J6W4\MK$E0MWY;(9I,Y]'-B8&$1G 2N
M"?3QM^BDJ!.^!E-&)QGJ1/MY'^W4P6WU@-@U=;J.*R>/0!B\7UVL*,N<-:EV
M&"/CLJ4I:-PQQ#<<^D7[6(!I-@\WD: FKBM-L89XTAB8Z 1:Q,1/KH8?PU[9
MS+5  A1@0%GX2T)RN]+'6O^..;6]^9/ZV+[Z:(("*21Z-[)W+$NLC2WS3D<L
MY [^FIJFW:_DV*U<][$Z DT2#914V)J2LT$$W[E1T;AW4'E#NAHN*-+(B:2'
ME22^G_:<6$\(SU.;D?W"@(QQJ+%GC7%5>!#^($G(F6LY3^Y@74DG"6$U06-9
M%59X/;,_#6T]:NK#=KJCU_I@>S>O6?2:=6E060_T_ZB)1AN4, 6CRH1DFV/,
M]'&>T$0F(TCUM$@@+7=UZ>>>ZV#,LN,/MTSLNL!G7Z+>ZPG_^N2>Y@OQS&^Y
MXX523B9ST?0LT;*_HHI/]/--()#M OML[:)0'-AGUT;DAS,7\_U^^^M.G5(U
M)^PA!>N8(J#.O>6JCU:=ANL,_K\'27UYO]:WP85[ IU^?SZ'CNWX-MW=MB')
MTYWJN%"%'A%D1LV#W3VI8KJBIA,IY;^YZR_#[N>16)L^!$P19OOA!'\1;_@U
MJC-&3_@, A?KO(T8_OT!P[U2* '/AV0-1E\,MI;7T%UA];8O?FB>)@UTM/9M
MFTX+-P3K0;9(BXRG3#:0_?83F%1U^[M#Q14H/?K(20*(+RUS[ULW>R<P%!,#
M=]Z[$OZJ,YCHZ2=,#9-LN5P/V3LR\YG5]IEG!0,R&=DS;*V<R;)"Z(+_] UY
M\C1(Z&VU+0M].<+_[_T#2/Q__MC\300;'K3  ,IQD;<Q<&" B,7Q<=3_XY_1
MQ)ZQAQ<:FJR0?_ET$5H Q14G^$6AY#B=K&EJBTWS\&XW/BMLHY%H 0R0OC_:
M+_,DRVJ]N=\:8>S9QF!+M;[O+P5X+KK!C(;71Y'AXGERJ3[-.UQ\*ZU-<YL[
M@DQ4I=\G4WU$LS1:YBF7)X:Z>-V=2-@;&#("T)AR]S<4/<'Y,SHR$QTUU98T
M*Y^1PC3]1O2/R(@'.-<HB0%,7"-!8EY:H):\MP(?Q3,@ZR!C&4.DW>SJ<^+=
MG,9B,[$U&)!2<%B=[WF+?7O^$PS849MM/QZR>07,]]6YIX'2]KP"[_;F1P!"
MT?0?-@1LW<J*<*HK1[6<'-P\,1V;<M/B[N]^6G]NY[4QP*2D9\*U(NDZG!;P
M*OZH.F$ZF?9^:POA(WW''D;_<#3G^9<H'H+YZ.AQV-!U#(O[^XDUF0)MA@D:
M=5E[MD=UQ78FM.&H;.YC%>M: 9''+&#S<4I@Z*M&LHE]AFPZ+^*!]JJL3D2Y
MW 6R9N[(.^%BWMIA[XW6 D!Y(O*/.I)=[E0 K/W7*WK6%]H]'?)E"Y90TRJ9
M28XI=E?Q*'$(E?6Q/2*$[>0Q'W2@/22)^@PN1HEPDT-,PY+[+2[N34>^UD.H
M6EUC4U.D8N.SS@@Y'A-RR;<E/'6#ZNA[P).=]-093G"#(/%:9ZR/%]"2,S90
M V&%*H0M?P<,R!L2QH,+(W20]0EZ\M,:=+RO8]'*J@D:BZYG,/B)+%)X'':9
M:FR*5\(Y?YM IZ763J78U]CH_6Z;CN? N9RX>^K7TES17-YL+5^W=8<_>EK=
M.WD%O'[*6+'<%69,4ZT+N;4@PWFV-2W)27+V"U*ORP1G6<<^"&4N#%A7PFW^
M7KT,[=FRTO2E[:^MR7"4+<K:?/08R\&DJ20I&>4<(H5Z!6E-,%)"+YXRH$>0
M$]'?]QQ[)/ZYSE-51?A6'=:/V8#!19=SIUFJFK!E9CDA04'#QDI*\NTWDN+Z
M\=SEH^WJ$6O>1(JR&I39&"S$ 9OK/?O>C.>GYWK=(ZO&GO D8QZ#>F2W(TYF
MH9-(X:^"RTY@@, ;1FT%SU;S+_>QH*=<@Y6E(+WYS4G3*1\OJIKESFN57P6&
M2!"Q$9+CI!LQX@B46UXQ^R"OW;>+4)B7K=OW6S+N9TFLFL" ]"N?]:^:G7:"
M@PY@@. 5&+ .&UFE#0:,M[3?=^;^_0;9I_5ZUVL*ST?AGZD7F7SVU_2>-R;O
M9#(>[Q-!#^SM_Z7(J^X8Y#$(!G@I%2#\_30'N3"[HC9[-"\: W)5](N,[-^5
M%K[?,O_=H$%E0@#1*73*"$6G)(;5\\>[UK\+-D<&5X7/O!C("47.' P@^=N^
M(P3SW;?]ETNA7]G/;-<@UXP1%1].A<<#,.!^,GLT%N0N]'IC#F'TG^>47I/<
MP !^A3VZ]A3JEQN?YX/)O;?Y"9" GMC_OQYTV]X-;08B,/NYC4Q*&OF J::E
M'=2UI= MAQP;NT/<?L[A=+LOLV7JZ?Q?+YW_4N9TNK&.:""YMQ=&'%*WLM_W
MZ-;VG2%:+8=4_L> ?\I1:GK6%G61/MEKBWU#Y78VE-):OQERD$%.&R07X^GD
M;WU!7>+CVU1[YN7P^FA7?ZF$6JE?T='/^VQF\(N]]<%6S->Q8$!P-@COND?O
MYOT4&, C])"\OM3=&%2=:#104*X#!@1Z7N*\PM2TCRF /D0^F(ZC^TQHR;R\
M,77+[*[BC'A,)Y(\J]7ESQJ$_DG_4G>#!X\S?TC([?J?-?R3>B#JYLGNPA5=
MC,_#0^+K]<OQW#_--%_J6<@U8-<9ORPQT-#]#\LF3PU6O-\F0?KO3*(UM9E8
M3,S]_.7C_L_V \9<D+W/);M/MZ!K*,AO26^?&@S E*@-LKVS/W'#QCYN_S.&
MDV  \N,6\Q.2N4]JQHL<\1Q1]^)PY<Y7M3(PX,\J_J3>0]T%S92I/_IK*1A
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MWP7"X6^/?[%+W@R01[R+J6DW"\_1D#*H\7,Q@OF$VR]\6YPL%'9KA26UP^[
M7O4X)=!A:J*?*R[O84Q2%)DK8;[Y[%&*2O3YR*Y+5\K0,1ZRJ.K#!M3[G3H)
M@_E6S9J+5*Y^Y8CI+UI)ISG+R+99E4D>@_=M!]MD+NCIZ4U,7@RVHYN:,<E3
M3P?W[;<SM7 ]X9JK>L-5TS\BL-C3OYQ;97X:7 4-%#"\>!5I:"YJE=:&!9L2
MB.'%<%(6>VW(G[V0/,#?C_EYLLZD]_YL\-4N*1Y^C_YH"8NVNH*Z'?&IGR,6
M[0>U5L'<V=[_H>XMH^)<MG7A1H(%"T&#!@GNKHT$"\'=$]PUN#02(!"< ,'=
MW2&X-N[!G0:"NS?-)?N>N_;:>^UUSQG?&/?']^/]T]TUYZQI-9^J66]S^<T+
MGP\ .+S#FAB:NFI<URN%K5;KI%[ QF)=Y4YA/\)@?#^)E7AW26O=S%;D0-P2
M.]9-WF?@:-E.Z+F&Y@9/_>L@(F;]G AC#C:G26/[8; ;\QE<AK/RDCNEJ;5;
MH%+]&4OT &HC!DG*6T;.!"5"C.)N/MJ%<JMV3%:;\AJ,K8IY0GQM6J=<AK[1
M85&#C&;?)&&^[:B50'=DDTFH)T@7PS[TQ]"[6.[\]'=^[-6BA &Y. B7Q,_4
MJD^W\S[:;TE:?I#-&+-\Q;-RV-*&BM$_ )YL<M,O'R3DP>00>/5N["E49RJU
MO+3%=._.!?;MOWBF%<RC\^AXUF47B[O*N&:>G;6#4F_E8CWV Q@Q=U0SU*>9
MMAJ?M]%M^.&-,?@!%&1W9FJL=.UO[D(>+F&?4B$7-HWKNZIV2A%)->N"MJ]L
M%63K;HWE4*B6^B<YD@BC,P'M['URC@\K[N750/0;\97^SC<5UHX,P]5$&E?8
MIAT?E$ NGCB*>N@N>*/N!&(UIT@-3 1=&@%T;H=?H,.]\=((J=[+GIBY_LG-
MMFN-*YMZ-9^:K)LE[L-QJ)[7-@S?HS!'-");V#EX:E0J)EJG^S(XNIBD:1+3
M9-<U^_Y(N4N/6PLY)R-.(5S^O+\M[1JDND6#E8"I6"\(@Z_1[?+%.3M]:"SB
MY HK=D$ADII<U*HT",=3$+0[CK0%GU3IH-HNW":LZ_ +=1,,8Q\]<T7JY =
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M_NX][%E97^2*/UF;[L],-:.>XA2%>'&/\/S%=/&BAZ^E&;$8$V??86\P,0+
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M,JU:OHVTV=Q1ZQOW39'>4MM_#J[:8W#Y,78B##^[7O)0KI9^#9HW8'?X2D9
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M^R_Y"H44UX=\X/=F5D;75L<0JXC]+=%%C\?(7Z\[1_+WL=%MZ?<>FD/#(8^
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M6@*=4Y;$[?_O]IC0SH@HY!1?6"=4H;]-#)K&#'0*!I9;SY8,V,N0,<V>/P*
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M,"BG.[22-(YRS$DD]S3:R.X__]E02P,$%     @ ((!_5D(R'0 !O@  P;X
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MFX([ (PMN,;VSQQ.)]HX=5U>_7Y_TM7Z_#3ZC1A#/G-:IJ5RB*(7(.*LT>,
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MIY6":.WYW</=/+4A!\#BJ0G#92DWVANYS\[21UK59QCD3ZKS2M'5FY^KE-E
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M)97K7J4>J2UH^X!YX@T@9RHPE??<;L/2.1=XQ!#FE*7G*S71;D-[D*'RK_$
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M2L<M5DN?Y9LFGO_C73YUGMM63CWN$=]^ M&X-EZ28>YGE(EN4]^<AHU..="
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M*WG_[MNUR% M-Z;(]M*7.U"ZBI[)^[9Z=J[JJ5O#68C,TCWEADF^ 32SSL*
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M$O ;P"#I0;-GACE\;<.F><?7YIVPKS#*69GC1F487J;? "TV/9>V#%%GYF\
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MZ\(C)3PY)I9 2;%TJ^D]N+,G]:/47P4KW;.JP^8[+6--;''/DMYF.166<WO
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MP&^N+U$V1F10BN1PH9LDD>F!7DS2YER]SZ"@VJ<Y/=)?BR-M*ODGC>)4D P
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M\)I%J'AG3=0NXHKF]D0EKATRQR3Q[=JZ$;% 545!_=45# %2VA5%55$:X"#
MZ"G[JZ$K(YY.['DT(?WJ_6H]U+&?WJTWL);EDFHY3\G_  (?SIQ-12GY0/\
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M;H,BCSMQ!S*?YUHU9D1>AWMGE;"VZX\L59') [9QFO'-3USQ%I&H7DMCKR/
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MM5WU:R/RM<7<K=2H7;FN,\[;+F21RXZK&,L?;WKIYM!:QALY==F:TMI(RZO
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MYKXC^;>R:7%;J]S(N\N(OF*], XZ5LR7NGC)\B688Y,SDBJDOBBWL@1&]K;
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M:.^MO*TG4+G#*6B:U8D_3/6DN5YSY;1XD;Y&&"O/W3Z8KJE\/:Q<!&?]T5&
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ML/' ZYS72^/KE)O$4-D@4BW00Q*W0''))]@*V2M%(\NM-SJRE\OO.9O+1Y8
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M:"/<./.#RJZ(0_-L!<D'ZQ"@3"%QFTW!EEQ-+V#06&*]T"IL*7O/\F.6C-)
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M\(Z8LAWW22K/I:X!IUDJ[,V2^,R7G0:"!H0[#ARU"9.R+ J/+KJM 9$DD6\
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MM-L(6ZY;*"@:J74D&J\L2"L'G'(O7"E?D30U'J43IXAX?E5_3MIP/M5$SN:
MI.!5VS;&(D24^^M6,3.0B0R:/)=:/'W:<>::EB003$^?_?7WKS\+YE#WTTPR
M)1;^IP8IF@:A5B0]>1:WAQ2C>@-A=FNYT6A*..0GBEPFG83!?(<J/<YCK;97
M4WN-0PTX-2)C=9&;@GCA_<+B H)Y7MVJ-X"I"@&-]"!-L@/?]F51QL[->Y#7
MC'P-<2.3SZ,2NQC#C9)V*UZJXMJG,6PO&.<X2-VA$."&/>V$+*>$D,I%P-+S
MXM=5.C0TVG%XKU(3D,;7QX GT(X","'&%#FP%)R2!"8BDN[_.90[\#)]G!#
MHN2S45\()S/%\E+'1B1E,#P1V#\4[S41!?_:&9"^X;S:)[ ).!THD>EA<801
M%*0%9OWF/&/$FXWU=[>SVX%E#](&!*HAIO"1?3[6/,E]4N\2GJ[1_T;&2Y2"
MCD$1;?WQEY,=+Y4WJ;@L8=)IOZYQM@&B#BK&:?CEZPSXQ<OQ(GK-9%X85/TO
MM(K)+E&TQL5L50K^%)NQX[L[U!L/O/&@NO2<6W4CDK5IU(]*W,ARX- %A]58
MVG#F)=;BM"C3K/[@UDLAA:T=!-14A#BMM?1Y<I$W@0IC&Y:*P)#^K#5?"Y?-
MIS"A>5YF$TUIV,_A4(Z'^H3:8>P8]\$IZF=LB\LB:/UJ@S)Q,7#-\TS3BNQL
MX<C:& U/U_5:O#?=9IU-(QE!^S$QNLK=#S>(.L+27)';"+M$] _HH]NH54&9
M(Y=[9:YD@N;DV3EY7'PGG+>+T;4^?TS;:_@,W5TI-][EVCV>BIF:A(79M_D<
M]SZ&J=XMJ-!BGHZ4>(N8I9)2L($PQZCS(Y8$YXL+7)T'I0D9+=*V?9/;76=1
M@J)Q3JI7ZH1N?YYDX7&*M,T7,AU;A17,'K@[T^5U'!W-JHLN.+]"L6J^A\EV
MMXT[]2/046O%H*W=@BZ^_^'R6K4K(R/15Q[<B0>G2AO_GH!^LT)PT%3B2XYU
MMCI,GH*$V\-\>J3^)!+7S8:![2G/I)Q1H#N*L^D$,SP-"XMH_8=?OL+CQ\2(
M,T7.;HH0$_Q!H,S,Q5J,L>NR]@D7%?,'ZM,S7TE:1,>'65$[](/4.-4FT\K6
MS'I4>W]];E3AIX/NZ1F-O6!CVAE8<*K4-E[A:'"]"2H_ADGJ==^/<_&9EI]%
M._69/$C3O%3 UUI7#4B$U2=]74]?-=P1]K-M!]5I4'B%"D=NF$9F_)GG5# $
M_6(.%!VR2^N'R:"':3<W\$%XWW+%\='X3_C.['G.=%G>U:GM#H:[$SB\NNM+
M.4>"&D_>YJ)V\D"N<T<OE=F)@U=$K4D1Y/ 0D0+,P"M%KOV>:I\JX5A;$4[9
MFHA#:IOB)KYJ<N7P<F%5&A6#7(XI>HS/O'/P]E!7O_3Z.+H?S( EPG>"#"O/
MN>NYY?DMZEBK,)KGF5MNG=X0,66]>$:D'(#UE0YNF/7P\ ;JT. 5:SOZ"=)"
M4Q8=VG7/CQ(-GJL")XHC_3WZ+.O"$O2)WL4<AG@%*F58VJ.SE<_#\/0HC*=0
M9/H,*\I+U=K^5%1?&<Y/4;>'@SF\SO%KA\]X2K=*HN>.7R,=)SO8/,Y+5LA!
M*+#5=-5*\W=Y$ =#0A UG]! SM_H7%,:&C;FF=8!O?Z+$S!A.]+>W]ZH=#;+
MSJ:Q[9'D5]J >Y35V>[-WXVE[&K'ZKY/$^VDD;<3@O/Q:23#L5/.E,##FS*Q
MC5'S+7HN9N9YE7!/&LI0A*KE>1SP+<JX$TU38V-CTQ&5YP?[[F?&MHN"9!</
MRH;?(U@2TG3HL[1/8VLY#;1A&9;>(\=1^-,04E6NW6<V3DAP2Z0_+,Y3!?3D
MRW4@A#--V/]5+'9KY^$(VZEQ&WGFA3&BI2751_]HE\9A>IBJ#,&46[K/Q^I$
MB'RV'#^F-ME0'.55:;F9I+4=A<$H'__:0*2K1F>WKC!'TL+1:9<\/(\RYG?]
MS"WT@/-WR!KOXC\?YB]P5ZZQ:HJK!$?>J<X[7DO/)/VR#<RF:/AUXB+#P[]^
M<G> @'&/1CZ]LQJ/O_V2NC,_BNHV3/8&"$AU3W-HOYHR>+JW:LTYD:0\<^F;
MK(ZL \TEVZR#Z06\=ZU3G]2WB#_LO0':0WZMKU<\M^KZK;LTSAON\-M7@<&L
MXQ.SECA3DN%]!&K<BA(&]OF&;P#+(\&M6]?'5)_:T]TQJ!E)[TB\/Q45&VG@
M5+1U3%)_O9;? /_R?Y_+Y_P$/B O^\U3OZJI,%V] <*T2)DH@5<G6:.EB=^Z
MT1,GG\5C,0APD..L"?JW9L<E-B)33PL2(OAH&_5,O-U7[8;P6FS8"Y\9;O F
M9>OHP:YD8,='H(,5=R0K+0,\S&0"X[)L/G[O2@PGHN0K_\C11YX&9'_003JF
M>+68SB39?,UZU1B\%/N$[!KW&P!A(F*_A>V?GF$\(%S)5)O JAQZ _1PW"E>
MOX,R+NO(#/\3"D1%ZLQ7/#..LE!+-U^ZRB<U<K)93',^2IM0F 9)6^W/\!(?
M]'!SZ7>4<<!VM'BZY88?7K>WY:K=A#<)0TMZ%Q'K*D&8J-VDWTC:VL>:/H:7
MJ]FIVJC!!ADCK'IJC2JJ6+ ,62\K&23+K1NFRQ%L7,>($>[GTU>.)H7__,:B
MY^UA^ #,<&G#;;?^25%>'D7TO?DI4'O4TFGC$77N%*F\BA?ASOZIM^\=7)DG
MUT?\#VCLS1B;R@EZ7R(Y%RINGG06]6)U,LHUGPK_40'=/&L3.["C#4'HI?3X
M </6;'C\C&+]JFY&G89\S/G@*-"D92U!=_W!!MJHKL J.95GW:AKRZ+F1=<K
MJB#%R8?2*[)KF?6)0"MX^KN8G2;M62E8#*8- $=9@GH.D],^_24I"V.%0W[W
MMT7LVV-HB.E5]2V4>70%T?5J.13A,-BJX>ZP:&G1:L,.[Q)^TV__KZ$4QGS(
ML[S%3'T)J5;5X+'T=/&S98[ ;T&*'I#6SO3<' 4'I6"/ZV#'<ZDXKOA RZPY
M.8^4WR)!(7XY!M7[T&(^+OM= @!@>.(+8!J_8ELM)]@)P1IS=S$/]/,"S$",
MM"D!>#VWBDL./$PU%XN+=8X&%2^PJ#O.$SQ;E67_CO5#F60+>2IC9ZBIBMST
M!,K\_G1-,'*>E7938'^J :',])[Y@O[.+]]\4CIJ?93.S?S(<QN[*PAHX*5+
M;%I_DZ=-QD= B0@;_!.9T8))'UC4P7LNPSXZ)BRX5;+!,MFW_:#F3VQJZ*U"
M@=$:""L6C>KX\8'XK+@![:J/71+DK"B.#W ^HQ]J3H9G_["7OZ2 A[\/!7S%
MHPJ\GRW%E;(W<NN :[2WLNI9]NR5HN@Z'81KH 1Z900[9UO&QFPOSWP/C5/7
M/R);L(2OZD!9 >:;D[CY"+W?Q+O[L$BAVO":4ZP'G<MG<LJ?.YS?C[I[1^<C
M7,[;5<_3:DUX+0[]5%J\W)9;.&I-R#&TS59$G$3\!I IW%S5J_C.99TWU&V7
MP=$4 E)_])7D:K[8%\]$L]O6;)UA89%CR_BA.51*"HT9:_"LV*B_I)[++>P0
MZKMC]]TF0/H  H'$+>D65TDX#02)@0.G:Z=D]2QC\'UY50,'?&7K'SJIYN93
M>[NJ?JLD./T0.A$[B]FSBJYBPKM-XL:EEI[)(IIPJD+7$0JMW]2Q1I$H)J9.
MXGQ0]P30'= 7N?'E/>BEXNF'<$Z<[;W/SE5:]B<@CKA^.-^O;HI^G>U8RQ3O
M8GV@$IO@J6^WNB&@C-!:HM^BP=N<B>\,;36S$OI0W12^+M.@%1A)Y(G_B^H6
MN0A*282U9[3<HLF -<_&#ZMWCD?^ ^HU/;JN*9^,YJ;'/V&;>76EFG.'J,5#
MK!PXW;E[L&-Y!!3%XIZ+R^.7%V3,@NQ;X3!W[!2[LIN;25RR!Y%YFA<FZMJT
M.(L2J^+P\<L84PP; @;KKFG'%A8]&(\\2G\:WWWZF_O TGXU)OR/2_!B67^L
M^TPNZO5YX@5-;\R"Z%.OF9_+E<R6M,([,[^4 9*_UGD7^G&%:T?1OS6"IQ#9
M\:G'>/9_^+7>E.%7F,J.$0>DSUMN++Y.5^A^\L?%;/%UD35B'CUUFA(8-5#$
M*A,G7*A802 C#23AGS,YF-@-XF'O'5^UX7VQVO^YWU87*)^E$&?2$/EW]Q<K
M)4$G<JU3/2G9#$L](R2_\F,*(3CY/V9.^J,^/ZP8Z:P:Y9<13PGGNI0+^JFK
M>5$N]6X]"O*VECND3,,=ORYSZ8QK2YIY0_>'-VI$_#\DR4L.I1YI$WU#&$+_
MWF+")P33.)91/%F$=*T.=5]+398+D^;-ZPG::LM,>1%?=4W+'*Q,;=@JT.4W
MIUHBQ!.R/FG&Y(N56>)^EK=#M296+AXJ)N-6](.T;NXCR]4.#';'^S&TQ,O]
M-A7!IA$&8-5X+[$=_+D0JNUD@%&#/5=.HO EA(XX;E[@/7%\^PT'@7>K;O1
M59T)#V.ZON/ER3> [FF?W^6V*D2$USQ>VS1E_'+ .:;02!&=5#2"T!T9^$7F
M9UOPMWH<_6E%^3I<F3*^:Z)]D_M,)"/KIJ!B2\[J%5S#9'7FE0O>T[DFKNF]
M=""_$:JA4YQ)P%E_@*[B3ZX,Y@U"W\3W+M&BTZO[[JD;WXOR8( K1QWE0OI1
M-_9B+OSTG',,<G&F#2:I/Z9)-S@'CY(!3+90$_[T>%VY(8(_JK4(WG&#96\
MP+?!O_+Z'G><]G\7ZN7_1:7[VP/&AG5_CPU-<X;2]FH=RM1?*G>/L6CLDP#Q
M-1P)P+H<OUF=8YN2HG(3U/[!<6R)QVT;H=;!*;<P)1'\=[-_&-1Q,\9 E,9H
M+:#-8E>+0?'^P1*(WP_CRLOC4\)'R"RL/-=7W=(S-\ Z]K,(J+;\F'P:>Q$4
M>"WE6Y-*SVTONS6*J( ED/8@\$X+;GQ3:;A"XC$N8DJ,.JF70B.L-.0,Y4G=
MFH1_:0K,0HT4L^Y\E_[XY,- -%AF[*8U(W7D<(*._6GY6)GNFA$[36Y-)XS$
MJ2F2[\:4*S]GF:C1KP;700[U,OBC_P-"ZD;PZK ,=9U_\N70*2_EPKS/ID!8
M>0VNQYB>N1%%5DLHR?N[,DNE7R0KY6H%^?DQ=O_OTPVH_]5ZV%REXE96>O(N
M[F"=^A&?X*>U1J3K;=?P"8XJ.)D;JGF#2USY-J8E7J"9V/1J:5HMEN_55X,4
MS0\-.W:"\+Z)+50C5+5$O-?JIUL.%#_/9;SL0#KK$RB%#IT=-8%L$I*C@<,8
MSN>'*N/XWQ!Q%Z^4=BS*H"_;+PPE23I1O6X9#61S0YKD.=_^2.5\($32=0(4
MZ2];GRO&-;,>WZL/+/BL3"^1K;O,)<DE_)[G7*S%U8G,617WC__3R7N8<'RN
M=(A77+126U[ERNENY8"02?WJ'W'(HDX6L)<XQQO[_6P?A3%L#@9B>:FRM^=U
MX?O\,@%&;RBC^25/Z9Z]7%P7(*.SC"XP.'ZHZ9+V0#E+B26$I5P-,$18:F@%
MZC.IC"O%XH&/[# D2:/.SW7B%8K66;;)^. D%'RLF8=J4PZWN-JG]__Z/5@%
M^X:^ >;U;6MSF.+A23YHW))M-8]2/(W7_]A&D@O[@%SM7F[=2^B"NT9A7?RK
M-7\I%(%7S>ZA*.26,VF>#:T+=RDMHQ73/$^K//VJ%#ZZ;)^F%L_F*Y5,7!&P
M>RV[P8G250ZU>'P>IRF"M1$R/USSS8[:(DD2"2(T$AJ"_ZBA$8I@F=I6N"FZ
M>$UTVJ1:M=% L/R/M>E6S*@WXR]I]0[R6AP4%BR5;C%:GG$NN JPFLRXN'TF
MUX?BGKP!MJ'C$ZDJ$-V&5AOKW)Z)O#^Q4>,@21 81448Q(XFCK/#<]E=I%,"
MK<L+45>8'.%- H^C@F)JP?B(Q!OJXJN8L\F-*Z!^2J&:[FN@Q"C]?EP\AIRR
M?[?@Y;&<&._'Q$ZJ6\ZV;K+]"BA=!R\#2J \U79@?_8?9&(+L$MJV;[[WXC$
M2A'=[?H1*QK$[]VQ& 80^>A>-[D?? 0$@P7\2+H[^UE>5;5_^7VQ(]_3(A"<
M+^7_C:?_I:$@6>AEUR$RSO6M3^<L%ZC0E6C$'+4P_ET-5T,-<$/)"1/5B>:8
MB)XU&?JX\HI]$\DZ@!#=-E.&1Z;UA'J]EEEUY508_5IK*.JYLRUHG/?>"6YL
MW7>F:]<L\E0?+#3+W]_@LE4@%3[FP/&RE&+4=684..7/F.,DM>,=(=LHGQA9
M?8J^$1P%THW%@X'S(0O+;?H90K6*ZGIU=5<\J]%'W$;'F1SWILH.'//2]4J0
M ZZ>TY%X7,HL0P%U3Y<Z3<6_(U]-,_K$1ACXOL0MH*8N&-7^]8*7+G7#I=29
M8W)QU6=I]_/HOK=5VHFQ[8&[P=Z)_RI>-_KSN.[B#=!MP)<2?ZV&0KDB9!AD
MS.J#/J;8K)GP 9$)CZSH04HH<?%9=6Y9]5+F<"*6K%*O,).'5$$H$.&BG$(;
MBW<8U2*FKUKF6-6,%L_%VG*>!U?.E8[LFD+C6ZI*"K)@[&J_?;*FI/66SH>0
M0\2D$[\-V?M/2\4'F'5I!71,?;+ITA1Q79<37K#B@LII.^(4F]M&L!>[VFNZ
MFE-MU>QIL>+]3_V]W[=GF7PZ9=N3'\I&)7LVXG""R,:\6(GR@,+\OISC)R">
MD8?LN#ZA8QEY2TB_I6F>SE(_.O*:R+6O!10W;35A7)0_W\ULP<.QG*0<EKT7
M.L8,$1ND+*W<R<J7!8;4'%OB>ILE4NN'N+,SO &:O#5RY3X0C&G&*N(0-)(W
M\ +> !C0;W_B68LAJHG+])QH1%M?]^>+"EHSH$.V22P8Q"[/)4_C1']0L^)*
M3HS1@HV[RS'4\S8>,0M]QIS> %U.C"DV9DA>O^S\(!,7N$^V5GM\E#3*!*BA
M=> 7UVI<*E=3PYVX::BYAX93&^.,'5Q'O(3!X0N#^V32M_LL5<^SLM/<G_:Q
MJ)'2._%LO6;+D!4KJI?,)0G59W$%\/@V!%+ZD$E=;^B))+FKITI1/TX58 P4
M-QA*//UCY\QZ[R9U2V B:31I[J3F@^/UZO*4\46U.1RZ=-F#WY] &!1S1>+W
M&3)/.!L$%X_#T7"2Y7[)%>==L3Y,@#)HBW^*^6IZK98>;HO#V; S':&CVV=H
MID%D$'FM(E*^I'WTY1-;HRM^7+0&-W*KT?#/]:2-%O_(,_/]B[+%&^G3\32;
M@F^/\:VO.?79HEB).R/'ZO$0RHFEXU&!<CM,5!<6P#/@M1:RW<NO'D1-Z<P&
MO!I;<;Q/O9ZW79%'C5CM?)<7TB6;@\A]AV7J=J@?Y% S!TU7:%D7DX1<:F1#
M[0*]EI>R'DPP+C%NE]LGU/6 DK\U6Z+?]_]&\;FC#"(M7)_02(P)MJ,RNHVO
MF[Q#V'=^Q9E?Z$8+^FAOC26)24#)9RZ4=\>YKX&]/0R(-./Q)%2BPDV:7!9N
M-@QVRWGR@QT9]A<XH*EB) +2]_*P&(O(HSGZ<?;JG8L_VY-M3_WV(+YR?E03
MVQN#3W^\S3-91E+4C;X)D2Q6N+3$N_I#/K4D83 P']%S'RY3;\B.\:=":WYT
M^ "OV#J!4?+:]DB3DLS'>ABMYJLY^)?IS6%6H95<T>]3+MGD4].?CL8>4>/J
MH*.UW]_JOPY3)"":(BF>$W8C90L8$%N@Z9DGM>G'V4GR(44+U<39?]4E3Y20
MP)MP*R7\NC?<@SM%WK6RMV;T<B&A]B)2DGV7CBZN:/(I"U(9KNDHR<%[HT[B
MQZ$V*#FYY/<<"&T_CO\O.V;Z#;!#9-W__/>_5&(KSY@>_)\>E7420B.!*U?6
MF6PU,LS^ KI[YK3EX%#8J,LKR 0C/#*4**HIK+]-0>>B7*\2"F\WH%7_>27>
MZS6QQ8TU:;LNH#G@A.&#[7:<6Z5 J-A:6=(2W-/,6HO;J#:-6MCMU8E-99\8
M7!_#MWPJ?X'9.M5H3]*0(GU.;H9J@42BJAK4'=A6,3=-])?>Q^IU*YHN[C>
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M6F4"SB]?[F?#CY;HO6S)%7;ACE>87"1V%7E[7V*OL7"H)>]6G@9:QYCSF.6
MD$ADO =%WL<!WB/^"5Q\L< .1-+F(KIE,>!0 7%<]*HXD>1P>A(X]@^3F9Y
M;V,LR?!$K>=KPRG7-"=KGLKG^*$&FE;V/="E+:6@:YGVC<>.DXRKX$PC'K;G
M=Z@'RD.C"S(BTJD>:6BQ^*U]U<@F"<?NV4'W5'W[)M%7)^IN^@.V@6=+Y"#.
MPV2.GA[2/]P,GC^M=JU_-GM@$E"I.'=]H8[YTVM_[]OU+=ZZ.6C9F3^@_M53
M@O_+_%S\L/"TRX/8\A)%PX;4HK%0"O3 U(1T>HQO7.;[/&U2?[EE-Z%9T1N@
MX)^@S%7\IS-M_U=GBEBD?!>1N\\>!%\=!?@T6NUEA"5'FE))93X<OUCGW0<F
M;.7 =7(//H\Z[;8<EA/1IO"2;1<@N4B:X#4R?-&7OKTIAL^ 1IH4W7+ADZ'S
M/[X!,F^&2Y.9MC%<^44+\=<[[;^[EU)!2X[D"_*;RBRI$MX9M59B(T2F#D[7
MXL.TQ8YT$.GNZ=^)J,-(;^H0GIQU9ECVHG04HS3HU -VHIU?N::T^RI'2)&T
M=B-Q)=4!Q;!\'VES]PC;9X'B_"#,NFR.F-5<><Q5K,=(/TA)$S8_2QS?=-F^
M&1/)7HL#C^'V;DPV27/JVHS^T:.U]<^?#ZOSD?%P)?,1NARL+!L.6CLQ^;28
M>R?&VB+D?Y4YZ)WVB7PXEA(W&8_3MU.G94WK@RD( ,X-Z;"=UUJB(K6='8NB
M$L<)"W")I>.1!A0Q$+VE[PVP"M[4\_M1RV=W(Y73--#RU\16R.OR3K%-@J],
M4X$'/3"B*D>.F<M0)[C!@#GFBJ8R7=Z$4J<O*7"T=F;2(^Y[L6+#@5^&LT[8
M<>1\MBZDO#1/5ZMJ[RNU\V*HS/67#"K#C=)<'#-0&*?X 9;X."M.1P%K5+2B
M@56X=O@XL6HHD'4YHMQ(*UD@UM?&L;^H!!(XF'<DO>6ME>3"N'-4E_>]NF<%
M2S*;Y(E8?:&#,99=\9(429$42ZSEPZ??)ME QF*@RXLE2**&7"UD=3-D2:.A
MJB%LO%#!:QC/Q5Y2K!.&P"74)4& #,PP6<[CYUQ?F*^N@3"?M-EE>:VD$3Q^
M7UM%0-\(U&&8_K!7T^0OYF/SQ$*!3*[ :^B=31QX_M5 @IXE]P<[\!<RXLX[
MT$N)>,((/E'T6(_/DGNL)RJ&7(+*>PTY.\& SG,U"FJB4+V5U 3CR_0?/I;#
MG[\VJ*,C\Q(3^T$2V6BTWU/FPO.] 6 3B-9X*A);Z/C%#^("0QT=QUE3A6KD
M==OU)@H+)0N&FB2C9(QYGGJ=6D"O1$S4;?^55\Z]05[U@>-1(<X'6;L-EW[.
M-(9N[N QML2=R4E%T9K<?7(10>?85<N2?.WKTS&/8ALWXB.X#C ++T5R\YB3
M@Z+N3"DI2E:3R!N M_"$Z.?+ZB)OL1G.;2S^<XL;Z.70@3+**2_+JJK&<,-!
M0I$$B0Q (ZD P-^9(L!'1J M[CA5JV6L%T[2<&)RGR</BWU9_J9)([T\C< +
MX[*[/?I(Q&=7?D49N,? 9TX;K"00[T!WD13T&)+M[%-24M<O_>57YL=R0@&C
MUR&'\:,%DF*XQCR=[LV8CU1A(?3EJKB7TMU!@C_63WG6[.7F! -67-;ZTV-\
M:RT@L^]RG:F[208:/T7OKR\URGNK)%/QFV?VK*]%E4@^_U4X\Z$OW_A*];HZ
MW[(9,EW3QTCJ)0]V(_VC,2'A"3>V>3.^9<5(1&=C:WL"G0DS5BKMDR7=OQ2<
M*^,^#6R_[I6-G6+LM1M=1HO\E,E@0*YDFD3D33KK(?$.3CFZ1V6;/C+K-V\_
M).Y7*HU2 _*Y#WW%9Q/:2!A%1>+*1]?70[N"W 7X$ 3DJ9_!$1B? Z[I.^].
ME;FJP-U9CI 0MCZ1_732E +\;@ TEDUATX0<^NMSK-\G)5"R!G!5\%)'GD")
M.S!!25 JW?_#ZU&FXN:AO$Q75=BM)4-R_@JE3<@2'WPV(7>&/^[> =WK%<)S
ME(WG1U#&R*L#(Z'=^U!_YS%G[3\[7NH2.0G65>SRF(.%RYWA.0WQ%L0V'I=Q
MIZ.BD\1GR(&#I+!<1'NV6!J>/+D-KPT-L[HJ:SYE9^RDZ'6'@2":?SXB-=7)
M\831TN%*>J ?A,1GM,\["$+Z5MO&VX>\9N,D#'M4G5LQDME&/JOW>ZU5PM;
ME=BGI>35EY>ND1#CI6L=U=6ZI4, 7-8 MX1FR>0?#FL<51T7"G ".NG[*W"X
M'0!F#!TW("3(%=R^T_Z*6CBFRX"*YT,KF,$RD#P(JU>G",3PB(0/4@ S1.ID
M(ULN=-=YS<3U?Q%PI*V7*8V=-$+7070^8M!;Y!6,3K-"Q%\B<+M^UCLR0R C
M:;1O@MN9=-3R ,0O"X/81/I6B",OV"TUF&AF$'\X\0V\RZ1<0?=5Q_[18R>D
M+PGB+0GYU SRV,;YH[:S?1;=""NZ-0L'OCCY_HH0_T+&UH\@&.DU\X,"SC!E
M.[NX*R-?-)/?"\536)/,(AW3QU*K-+''A(^7MFTI\=T\L:D)48R5Y]@[=F0Y
MM:)W?2",AF/Q'_LE__]MZF_%_SW^=/X7ELC3[2.^TQ<?\U^TUK!Z&E/I"@9Q
MB]!6"M4&XG6O^A@M#5O$2X-;06,^=#G%TCE\ROIW'4(L4DE$2-/SE'MQ^WS/
M[];:8./R%Z%]*E5QT9E7;+M1PQ; NU%L=><JIUQOR7NSBL,E4XTSIN>5W[%E
MA4CACQJ_A.#GXZ[63?O>OP$@?ET1],YL3MGC&_*NN>K+EK%>#X7/]- -$L<?
M.Q#7_;O"9[J<+ 'TKZS/X'EAVU)S)U:X7V^ X*]O /3:.2#=7]673?HW  I=
MX2D5<5% &]%]0#3W8L ;0"\&G"^\CMHB'J]ZHCTF>3X.S,=6'ND?BBX8[DI=
MD2:2O34B0_!=_/ 0NJE[VWPQ#&F9HVG\BVM,_TL ^5<D^-(M)V)@8AR(TJ*8
M*>X/A*V\ 2XY8?<Z6\).XN%@V,*_*6"K-I1)^>+?1U4UGPB_ >:=7[%A]Q9;
MK(M@8WSP]<K-<U%.M#DC4G_7JH'2W]2Q,P'N'W;H-%1]JPA?2,0UJNXMMVZF
MMF3K*ZU?!-^?LGP=^3J!\%J@P(]>XNV2$\&"RXVW>5N'%UR#_-3FN7U3^ ;H
M:I^7VK6Y/WR:?L565A\9W!6;[R!<4+U:,H6]'.[?Y/D!K.6<Q,LW>!WI!VX/
M1[%5]DQV13'@CG<:3/_>^G'N7_727:"WY"%QISG^D/O/K(4IB4;]'5[K\G5!
MG\:HP9L*I/!SO__4]!>F_K<I*TS('9!U!-QDTOBX%WI)?UA<W[)BQ?\4H3I>
M</\U((,$1+=9_AO8'OY86Q"2_@:8%NL_%,<&Y':D#N O6PX^Q/RKG;J&,)=,
M]P;X2N;&3@J6H?N#6IH5ZDO5."LTG88=,0XTB1S2^J!3=L8V*R%%VE ><MWY
M6,;/2:B05/G1S&!-\&_L%):3-.]1?X(X-IS_.KJ@>&/>LJENI"/;<Y,Z&NVF
M0;AMN9W].=K/M94Z@B3CKXZWZEL1=(8N_[0W!DQ+4M9XQS"+\^:Y9/Z9W*NK
M2/V)FRTA!<-@*(+>*7M%XD*_.A+.]@W@IWBO D0ZIE9#L M"Q:*B?506QQ5Q
M7+\(/MH&,Y=:%%]CW*M@O+/:R&26>@.4A_XS7;0:'N8]K2:3\^UWMY?#?_@C
MZB3L-[%QG+[[_TK)_1"MHQ=Z2_K7L8C?  R4%Z25*;PU#XU\L0E9Y?]3@ZSM
M K?5(2Y,/F<;1$7VZ4""D><5ISZL4P#JLC?NTF@&?/R0$Q&N^A/+F+8[!B?;
M/,KE_B=:X><JWL?3XNG-];!(?;6MWHE(6TMIX",:MO+[O&"*I*B+Z5XW/"PQ
M2JW6.*KB)Q&FMB"TVAI?X''0/F[6W<U_H-4(1+BXTT;<@+P!UKM?L7?N_:!T
M*.+9NL[_ RLII'\8"#BT6G%A)_9C<+@@K0'OS[^^ B]R(@S!KYBVWZ30F5GY
MQI.=GTM$-J(,X3$6%7RHP)O_-OUR(T.+#J#C@QH:,Q5S+^K*%9<AWE3'2F#*
M1SEQ*8Y])A],BC&'&=Q;ZCX8&_A@G/F=NA1A:AD(F_AO4LH.E4#DHWR9.#C5
M-X#\/VN# UUI#64@Z4[L;X 7*[J<3:/<SJ9B%7P=)^?7RG\MD#N;ZA1Q1]\
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MZO#C9W1.JVHKJ:FK_IH$Q,')R</-(\S+*ZPJ)2:E^K]NC#: GP.8!^6"0=(
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MK*Q@5L@O7""6L%\&_*QL4BKL N<L(%<"#TNKQG# SJ<\K&WGE%&S7!=T#?K
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M^NN9%XE%9U']C])G]_O:D9DG7^Q68+X_W$O4M1O0'7XP&Y>['S3^U@/R_4Y
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MUNQD+N^YRSGWW#_>W/M]SN>O[_=YSOD\S_=\'TX?APT(6YI:F (@$ @XN;4
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MNP=W\.V6TQR2G]M6^]/LKXG%[,CL7V+_]NH'!,"@K<<#BP"&P/*:$B.:[_^
M]!Y,9EY*;0K+[)/ZQKX#%3>BN@U'S0.ZLEJ^2)7@=W._-4/CQC+E3,=;HB2+
MENX&A^W/"3);.[RP?T42>$D@S3=S@&,R:&.SG" T&1&1,DOG7[#7?.FZZAT7
MN49YE)H?.WK2&[1@0P#@.\!XM#/L="$C>G\%_B=;Z(.=M0]_5*O\!JXD(W\
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M1!^&KUZF>>^5U^.ZE,\5W=-3Z);G%G*KH>J>?&*H0*+;#!Y%$'?Y_(T_756
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M_N []:;2V,')QC5:"_>\WT2W.-KM68[QCCPJ9I,0F0/Q)ZV]Z36*YHC9S0%
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MBC"-RM'T"4D3U:+-G&/%+^YB,WBZ$B'7L7IA$%(PPUZC_%$,1@7B*^B,XZB
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MN_Y,&V2#C8>+8;>%#YTMTG%TRO0K=TSA>]/Z"(E'6]NQUW-(#$,;[BW*2CA
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MH=N'9H<J@V:>VT? 2_/[=JNMO?@L3\+SZW2U1CB0HXB)LT]ET?$2P.@'<24
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M]DP,O(@<JO'EV!9E)S=)4Z"=CG#GXBWWQCI)E9#U>3MU>)@7C0_)'[),8M,
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M7&_6+*ZD8?8D &"1FL]E2R4?](SH9*CP^_@ 8+DGEWNXX4WM@ADX-Z)RXS;
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MA626EEVJ;ZO:XY68NK5^X&4V<W$ZY?NN;AZ$ JR)RCD4% 1O-OS-BY/PU4"
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MO0%:5])4,/4GKKIL7]JV(P<#JK^2Q:LX#V9]+PKA>O?SHF9F1O?R-LMCHVI
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M<PBGS#G0TA(BU762Q/+,T!J[_H8Q!J#G*'[BOROWX_Z+,I0Y];+:WB3R5IC
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MU,#ACG-6#OECR/->AA_IQO7[2/-K@@,=G!_0H+_;YUN:G-;'O!*_%9(?]A_
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MF=/,YX$GV4 WM^VFQ,XZH:O.1>\Z29+\&+9A9]'31@4*Y%+Q JJZ"R*?'>Q
M/ !?V_P7>28Q%$]=E%S1@#B;W 5F05H<CB*$Y@^W6R&\%QZYXA>+=IP526#Y
MG<1OYT8Y0;+UE=56WY8>Q3O5#D(:]V,+/,B]]DO=74_TVZ=96E[MF'T_?A5
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M 0\THY2Y2('?7:%K7/[&T;R:HR8*T[*'^0.9O_UGAVX%ILE:6_5_KN?_VZ$
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M9W@X_TA@@E&'7"UG/5A5L*Z$7L[A.1'KG@4O,OWH1P.9<DO>;O.:HFRA6-X
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M#&+XTR=._K32\6^SQW]<&-#NMWS8>#((OMW"M'8YW"5:4F;H53-HL",F63S
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M!ZN=5:9@ZE*$))^5&^3H.WJ3$C-J1E:7B]'#O51FNE5SB_XX>L^8YR#GGAM
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MS2+$RO&(AY^?'\0L(B',*\[%Q\_[2P@:+AX> 3X!Q>W;%+P/J1_R_ML7\BM
MC(MFC1Z @48'H!.C81"C(=L!$ "@8:']<0'_<:&A8V!B8>/@XMW"1PVHO@.@
MHV%@H&-B8&%A8J+N^J'N YC$6"0/>:2P[ZJ9XM"YD/(&QF7CTC^I;"53_WG
MP/?2-0CO%OD]"LK[C$S,+*QL_ *"0L(BHM)/963EY!44-32UM'5T]?3-S"TL
MK:QM;-U>N7MX>GG[!+\)"0U[^RX\/N%]8E)R2FI:3FY>_L>"PJ+BSU^JJFMJ
MZ^H;OK6U=W1V?>_N&1H>&1T;GYB<6EQ:7EE=6]_8W#H\.CXY/3N_N+SZ91<:
M@('VOZ]_:1<QRBYT3$P,3)Q?=J&A>_X:0(R)]9 'FT1*#<?4Y2X=;R NZ9.X
M[,I6/'H^]0.REZX_;Y$S\"\R'OXR[0_+_GN&!?U?6?9WP_YAUQ1 @(&&"AX&
M,0 &SJ]8<@)N_7_:/F009+T'U RUYMO+^(U[;?)L&C[6'-1,FJ@&O[;U$XI'
M RM&(,@9]V]PYYB0  P/"72,NGX2*V8/00(A[WR1P!.A=[#];Y##5Y!O[<U(
M()NJ??Y\$7S1(*);[JFI@X\$\$G.$6^<[D+FWR"!I8U_?LKU4_VLFB$WG$-I
M_HJX21D)^-]% A&Y__3*GSW?UMUEG&$'E=R0#=E#H9L+5017S(5N,NR$WBL=
M 6=& O?DV/$S1\F^(8'?]0 OOC1& H-12T[7!U"X$74IUW];+1DR^K\YB1E(
M6WUP6 LU;PC:$"V8P.4\"]%\04I-/D7E(7Q2^'Z9IC]<V+8ZX=7H[N:XPY1H
M QN54B%W&5U#39QYD!9A=#.N@(#QVFW^G7.4N$ L4BU.X].J6=JCRSMB!M^.
ML)B!6+YPY4FC1-SZ;EFQ9OPJ;>N1-4$?^VT+_LYC2R3 COF$TJUN_5,9VUU5
MT_Z,;!AT88=438N#FZ%)(4U)I"S2M>J%4F0=3BC%CC5,BJ4FHY%\(R?</(1,
M2:?904BNJ>4IX=A!4Z#"5P:"I?S*.B$?O^I>%@U^I8<8-8_YRRO,5*VX5&V&
MSBZG5L/9H?6'(O?&R1L\$KT+TRTGQ6,=M&0[/5;?=G>9ZH.F!2LW<K4:2*:F
M0V:67K%U]S^2&\M7X2[*^U2=D^ R[U!1/F5\=3(XF!/.UN^<$]X[<JKS::2J
M1.N=H8G*3[Z[475/)D&)3$,ZEN\W>_+JS5I@0; -6S4MNJ9X915?:2M>.1)V
MSC8S\S=GM$ME@YG=[PT]4?Y*?2@CY>M)%A)YGI A@^E #WW!IZ=<WFNVJ.L>
MI3A/PDLO_@@)$!X!U%?F5H=%KDINUL^+U)C)&C^?"K'DA.?>R0EG 7**;77B
M=2>Z7<@RQAWKVA\MNYDO1XY6?L_WL]=A5UO;(%63X7T2WCM>+?+*3\(IB=^+
M/E'R9Z.([KM6TSU>HF&!0ESZ!ROW=70J<PL8L22CD4 87%A-AK3O6SC+!_3_
M3JL;H#$R,E$J\-)03<VN&\UL^<D&2F.W6/U^+H&S;)3I,N5ST[CTL<+5W^)3
M9?@DT;E2?->E>G-4T1/XT$[%E7^!4OZFASY7.B&T8#J/?+!\1 94="IYZAK.
MFA)"JO88ZR\:[KSS#?L G'6)J>; (3/Q8V*AT6RI?2'YS-N4/7"G5U>S#P9!
M$>UHU**$Y+KB07-4U!)FW3M=T=#O(!X)R/U.EX2TFC3PX(GSJ8TTD8! WV6N
MA>^K9,<P,3>KX@M(F_']H=)]<JK.1EUS9U[H(U=9L<#I#;:U6HXYTI_H'<4S
MW1*[?<X1Z9W'XO'^QP$X'YAIJ\LJ;,:%SO7YDS8H'9R2;%PGOF&90OUS,I>4
MF?QT5"-VHM]YVXD:3J=*;KI+$%52@J*D/PXE<RL9[(DNAK]951BMSEM9S9E/
MK?:C37_=F%&:5EV3ZF+ADG\1=/T\KD!^C[. 8TG3+*AM]5*^WVNIH1%V=V/L
MGI.=V^O*_C?83R)=H!\*':HY/;QSHE6)RNIF,#\W3R6JS91CJVX:U-$F/E<U
M +<B@=10MGS!Y5UZ7Q,;V7TC;NMIE33#->[\AK'7ZE?B.@E3>E/3',?5]=,,
MI2LA1K.A:.+J6VFOKIS>N-?EC3ARTPD.4;3\##J,*J#W/"0J$U.K'*E" B00
MA\VD$J^$KP_J:WDQG=ZO&BDLG-*3,?;Y]%<L[FI3I;,XY&7A1$^A<9VMRE^F
M%S /YRNWL!?X*6N6[60PO+_'>=:\5S&$!"3*SDGWRO<X42+Q..Z*VPFT$_>0
MWIP>O6L]6U#S%^"4[MS_V%:D;&?.H:[W5'=&Y4A2 \YP+IGX\ER^*6V\33ZN
MR([J;1YT#<2BVY/A<V0[XN/><]'O(/_AFGVB]&&M6Y.(<-=0M/;)"3RT>#A\
M3=EX>.=T7?MR^F56]+F^9S@WOP(W4V/U-:_1X^&:]1@.S2+'Y<C(41:!ZT80
M[G;#^^CQN]/&,W*XL>L@R1&05)P!:X%AS'VE(E*0A1U6@.">9Q@SQ96VO21E
M7<-!9W6^41S^G-$ APKA#K;?=XA4!]/'JA@H'*WS(ZVR8EGUF>?UO."<=G.$
M=@L-[*W!3 W,?SR@1+D^6(;Y/-GR$8YIM(Q4>01N1>8I^.[,Y!Y&3VVH"_G
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M/GC!3EZ.M A6QZ]_JW6ZE90V4=:#-M/9"HOE]PJ=,[GCI9"L@D]O^#8OAC-
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M1C')?^B9B[@S\ \?QU@1]NX1E;^$K*_ #I@1%G8THKW*8=V55:%3DODO'W]
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M/A.:,(U=005PDP5>X2M#@8<FR!5Q!:1</TXM,>XGGIOLCGW,:J>!G: 82[<
MNG&N:&X7ATSTO;YGZ'YL/S1;D$"RT]4>;.RSY8%"([]!3CAKZG^U5?$_VEY[
M%GG9M8.GA>*[LFW?^.5/ZNI]E[J,)E*\)JE[Y\_EQ8:7%ZK\ B<J_-.121 A
MD>U81EIS8M]:PI?FTM=C<[2'8B7LUCY%!-,Q5]09T.NUF NY)N5XR*=J8Q75
M*U(H7-D/%5S\L*](X(02=+[Z1\(;2N*@JM9W5"'B1I 5\"&D&A(<]W*OD4#Y
M_KZD RW-(=NR8W Q 74 1QX*=]DL/SE\TLK!GKU50MWH&?(YUG%Z^,)N [6
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M,DTRJ&7BM@X2 %"_W+HR0-PC"D0"&[S@_=X_IF;=:R(4.(I#K0PF<-9K/23
MTIPA!D4!E6^<2]Q7@"WL H?YUVMQ:]_"-M"*43"(&KIHHO3GF.3^+I-V#-)#
MVT,SD 99)#^\=P,(F, Q$GX5KC<&[28GP"CD@%#UH"(?]E=FV8%7B2P(UW^
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M'1&0N -3\]+M7GC5G6^2"CI-9KTPC,)_?OA+9TUF0>#D'J1@&GT0 &JJ*2X
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M?,GGBO,Z,"7CS%-J(NY4=G,C &'O3>YW:QX!10MF]\'6<7V.;(\G(#UW3E#
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M_VO_W:N=*;1#FS\L@<3)5^0^JQ!HK>M@:N6.YYS^:L?JF+!IX46%IW<()CA
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M[ZWS>+'W8^,$Y9#F/P^&$-E?!L.B#%@GS*3RB*1V+E]KH[X'(UW@T? "YP,
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M OCH('ND,#"( 4#"!X'Q07\' 5H  *& _IL _UU 2&!D%%0T= Q,K'\*K7@
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MJKV9#]:)O:GV/E%&/O!7'3#PJ+\M\]KN0G;/1V]?F_().PCT2,23/=D_:_G
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ML%_"[]:W_"%(_JO+NEE![SSQVO7G!521"Y6P1E=W/K"+[8/4M/=H?7W-H''
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MMVQGV5-YE=>I10K9#APG;H3<UX8I6)0FF/NW\0O4S'(_!)ND@6N6\F?&>H.
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M">8.>HVF)X8<*W'-X&]IHM!K<[0=0X%GMO;.:%K.20S#= Q@(J8<,7FD0 Z
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M0:#/D7A<$)SL*VI'SL>#[_7R8"7E:^1V<7P?G!7-%#0*7HUJJ&_ID[#A9>K
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MG Q#$[H;>^16^0M@4$^2Z!.:RJ#;GS!W2/.$]PN01HZ.]CTZ?C^I3X;Z<A9
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MCK?\5MT.>;=K(HPBINQK*F.'!J4*I?U<.W'H*I%IK,8'=50?':DUBD9=4_K
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MS@2P K_3^PX6EEDI9<?'FGBS]DAJ%B_%JGN=(5\2YQ3OOU -7=9N2E3Y&-[
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M/>T?!\<&RS]DQ$D1.-<@U@DZ+G47;(!>QDW=BQM5DA6+N0G:*G9&H[3LC)4
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MKW$)J<AIJ*G(*2EI@9Q,M/3L#)24S$(L[-P\_/S\-$PB$L*\XIQ\_+S_#(*
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M"#]SF;\ U]UMPPO@)_8+H&^J7NL%D!>K_G"Z^@CBYM34N78TNSAS> $$4;P
M8@MLBUX 4L1Y-^L_;]L K7+:BZ7!$WTE3[>NSYSQ61F/CT;!JY$O@(T]Q&TB
M]7_M*_BOHWS#_*PK\:^]_V64D/]^RDW.DCGL>GY>1]2'F^(K,LI\P.J;2>'+
M_IG!<<?3,]2&<#:G!9KV+[^)ES^/-(N!0A^^W7M-S.JK_"L5Q;_RSGG0LWLT
MW3=U2G34ES$ N<E"\ 3A-0/;NZ3.WT[%-LJ7P5F7^Y.RKNR\Z@[L,7*UH]8%
MXA"F\@]E,L=N(+TQE><@#JF3GN S3Z?9G[L;,\^/0B\ $KD%B\6OH]#^<J2A
MK6@J,ED%/J-VWV.&MPRP1XIH%W_+QH;L(SW_\XQ:E,AWR;/H,7<VUE $IBJ9
MB74CBG\;#+9OM;)*+;8+7I_(P9E$UO(RK-RZ=_)O4P#]@7S&7O_>VX7]L?_>
MW:$9_UW\ 2;YI8?_PB7_+[P([C$E_]:K_[Q&SOV7SC,<VQVGF%'-D,+ *&L;
M16'A_8'I6 2_&.9"!#DBZ3%?@>U>#7'TI#0:<9MHH%T]KA'@Y[_-+7CH_\K,
M_QH6:9+_=V#1A/RQ'_8]CA(NCE8=4<F(LH>(;\G0<GZNH,5MS9+;W'RBK:^+
M&_ "*DX6H#5ATMT!;"Y_B6]=[6;M__M,K[)T\D@7DF3JA%AER3AWPL8L7%/)
MT-56OR#$_]G-J^1V[&),/:R:K_L]_9ZHX%P&04;'Z2L!KP\WO,\3]F\123 I
M*_@.FJYK3OR;S?-%CE5;'%[?)'YEDOUE^@$B4HDM>-!+8 ;KW$\+S;1*X0("
MT-+:@_QV?4CAXVS@?YM?^>M6W.%,<9/]S6[L&GD\XR\ 3G>%5U(?G0]R6S?G
MF_?_732T_L_GI1=1;UM$A:G'B-,>F8SF:T09<]%CR08#^7A"346+?_>56@/:
M?6V/;-P<,+HX4,IT/SO[O__!6\,$]E0P=-=TYXXAZC7@F!L#8,Z/ ;"25O9J
M3S!;ON\ED. &/*<)*/"?PMY-3[#*D3_M)H>%7KT) >:WGMRJ=7#MWDG!TOTO
MXGR_!@6R>6.LMT;8A!EL1W<=]'>'/LH)9BWIO_NL*4<70:1\83A]>7+[-%MQ
ME%@X4Q;,9Q@U($F$W7 ;KC;Q%, AQ@.B0B'*=MB@(M&@<[KR)_OS L#R01\X
M1VTH-?@O/#%DDX">95BHN"F3[B,,\$NQ1[C49W0[$^IN6D E67 >00K3X$.X
M#8W9XQ^S4IVO[)HJ7NGV(O&.[K$Z@-_."2NQ-2A_-HW.L,^ON0HFM2<'YF,N
M*].Y0XSMZX&%]TXF64I"-;#:5CEWAGZ_B,470+391X'LCU+>QA$J-E(WB\OW
M&EX3Y%YFJ,:;4XW6$\^AZFFQF51>1(-YA+>1"S0NI[K/$D['EGDTD3JS\\%X
MXA(>'YH6A'CAS1R_HC0C*O\\80)PU^RW+483\F/D;+RP*L@4!VFWR(U2PKZW
M-9-HD&;&A.EL^>,%%ZG* 0@U_QM;2*8'38OFW]?^JE(86!%,_"WJSOZJ;E\(
M<,?3+(=4WMS<['?*H6T\>U4>+ED0*-"3^I6/JF!/]-5*#HE 4*1[5D+4G.88
MX4@;"_Y 60W__9W@@%;7]#&Q/^;041$:78&[E)315=XKR(#Q63>(Z K=<]'J
M4\,"=Y5MCD=B$DV:>NGN'^T<-"+_/>;9]Y<<=GWD7%&_X]4U(C%HCF5SIJ6F
M4)4>RTDA/?JS(E,!##_&HX[' @[LXT\B1X(W&\OS(2IRDQ@IXY,",\$5[5_O
M4@<##6%9L J79+_ZY >%7K+S(:OU XNGQ2K&I&?'_$2I#2Q:DMK3HXFR'O&I
MO$<(^<&/@NQ!CAUWFM., T'* TF\60N9>6,RXB.%M1;7Z<9+5\*]K&=]M5GZ
M=)N'T]=U.O??NVG2G/0$&]=!%&;0FWGP]<<7@+X7/L\8V96^";[<#":?;<R&
MT4&O)-;.7?%"@\"!>^ESAE-754$TH5]"8+Q7$WE$<:D5T5%$KP_Q=-56NN"@
MA5(Y-N_8?Q:KJH_!I@-56'Z88?0O@$^)?DZ Q7S1S",?]D<<W9,MYJW@"0$R
MAC-A(HU$_I37WOH\'>IG\9LM*0L]D_)[)0[M7ZR%VJI+6JN,:&*>.6(L&$QE
M6'<_0TC0SG?JV#D\85PX.6::#?X]'$/-D0@\\=*Z6*.*6[G2B$6SE9XYF,:Y
M+.RV7<WII,6-\24\1X:$@J2A*?)NH'T\(X-=]]3YW6H(UP8H([J06+^V,KT@
M+F+Y7"6A76DO,-ZL[>RW"4C%9KU3--#EF*]QA9Y@A>]YMB2QVQW<W:%: H-3
MTV9!9R#QQ$+X@S[\-I]YY"4&F8@N@R,Y*T\Z>(J7C64I>500:Q($7I6Y#0+\
M=UKW?_,TI(].\[K*6P5;0T9T1QPE:9NG-RR>"U1"^' ?'-[XWG-P/;(MBVJW
MW>@L<)FU9FLF(0;%2#^Q5564=B@5=@.G!#;(\L7>2Q.,KL3P7-"8V%$=4-M-
MMG,6*SRR)>+BMC2?-=^D:GRAF?!B>J03(@ZA8NL3W?YN^G9,N%7VB@ QV*C=
M;D,N1BC11*>F#<!;3(%3B"CX-6"45P:)B?;,6*]9PQ0ZX.%,FT*F[\Y]S.RB
M\D&9B=WET2$?:WG1"#S?4Y&N,-B"M#!BJ=L5$C,_):Y=!#X"ZJ76@?J>VZ8]
M><9('@9]'_WTQJS 720S7E<*+0J1YUQ7)$U'=?;J937/"@S0M)DE]OG^,:)!
M@P-H0N@/V8+;[\G3MHMVY?E'"1Z+0"H"]<GKRZJN5#URGU?,^4F_8YB_O6J+
M?^K**%XR6Y8<Y-CD%;DFNO")[M M@_3H<+ I;1'W=7[UI5-P0=.[J0;==KNQ
M2Z)8QR75+?6GX#\MI2:.OCKGPA0SAH%ODE*:]>[!_)P_?3&\]!@FCYBR#K\3
M%HQ;:"[_Z4F9WJ!(K%=Q9E7_=9[%2Y'GTMBY?D( EGPUIYEFET ODS5NPTH5
M%/7]4L!R5Z-%DN+TZ'&A?L S@X0[MD9%F1[%CW)KDR/!(4#CS 3B^BYK^A[T
M=IXIZTU;"XK-!0:61OA79M(!IM*JR),">7_'1%-)P;;Y=.$.IB*)A[:P&Q]@
MGS."1&9;/:[<(WQD[4E;MS<7>$:U=;<%==B"_I+H,LOY^?I6E^OC:R6N4$V3
ME%H3Q>B\][OW62?@B8SV-\F3:7.+$XNW%+_G*;N_&Z0S,19]4NR]WZX#*]I#
M#4 %JO68\"U.J333_/S#<@:<B^XN\I]:S:(XN7?[<FVEC[]0ZR9"I>J'4GNR
M=@J*A.$824LRESQ='R0_ZEO(2=I2_MA4C[[*PTG*99W1K1B@@;9!N/!N4J0Z
M\C230:"B[<:G0A\]CP&)C@)W)0I4/>I>G5Y$=%H\OW 3YQ= Y$F F!=G[3H1
M9LM)V]00#'NB-/'9=^A86&)O*E;'VU//-+S:$!*K:@Q[8Q')PLZ+72=+NY_0
M^:E2.;U"XS^O5>B/O@ ('GV]-@(=P12&F?RQ=BR4]I#,*!38PA\__2E1F&(6
M:O[I[IBQH;+5@D-?0/O:!Q*CMG9HI4!11-\H0J0;?<GPG^N#6WUO C;#KBCJ
M-^J*G"5B0*VW,&!\<MMZ!FJ#)X>'UNE*$4Y1\>CI8$G>\:!8.<Y&FSWM;(#=
MNJJHR(Y_I>R# 4Q.O,0#/8OC$&-?FD$JWN2L,V?CEDOA[QYH<IVNIZ_=0S!$
M/5V[CECO7SM4=<._RB8\2WZ3#,]B TOA7_YI%.M4>>"2RZ!S:H#CYKS!P<WD
MTMVMVSP 12:NC]%(1XU,7^YQU-_DZ'.NZHGG]2Z@G;)LNZ*"RG='C.?/G[/U
MI:K LVR#%:VV&TT2HNI9K.]C=O97QE\+C)[UX-&2)(?%Y7[-&IX-4'*V\$X&
MU,M_$Y@MI>VK2P'8WJ?>(3I2N6RP/0QZ?K&T:TE0W$U1+7!"QW'WF$U"'^C4
MGN9OO9(0X++L3'W?E,=K;/0GGYZ>ILV8U8>'E*E9N&+:N X6B),@\788'.I*
MM(3+H\Y-/XC!]G3HYS^]8@!U%#QR]0=CCW+,BR2)YOU:H'+^P ^&<W$Y;;"5
MD-&V^BOJ2K,3S3L7M'-AB73#0;_H0AB^[T16\!^[G4,$3]Y9N:UCRU74#LVX
M**5,JYOC\CSI/!/YO#MS\KD94)IS-E:9G[2&*O^*5KC)#TKXJ:;@!F*T 3]3
MUYX1?6KJD->77T7IM7.J$=[;6XXGZ=IH;!*PKU+O@6Y?%?\(X-L0U"YES6AH
MQVSDRJ?IE: ,)GAFB#E@$; H^><Z)]8_@NZ_LKN!#>?'C"Z)V7<?CYI@KW"E
M"6EV5%7 5H5&IO99$BM9&02.W/TW)/+R!/(V4EP9X:$)HN&Y8)6-YU".Q&@2
MO7=2-ET:9"'KUIIAN+/FSUY1X T.=BK.^_/Q?55UU4\*>/*:A#!W*ZY<>3Y8
M%=M40HV>2&Z*#T6!P[TQ9Z.-%QBX,#]_T?;>##U;&)EYW^- YY'*GS$JCC_V
M4S3V]>>XS1:KAL3YXLG&0,[!5?4?E9<90LDJF*2"S@CWN;YC#H_"DVKUFP8V
M$4!!8J[=^D&1S6.D!%XU*=92,28W#J/:2SE"35.+V?_4242]^UF@A8]<10N7
MZ$:JDO*KI7"W!%*?++K% 2VT%>HKF*:J&$9Y6@77D9<*.E=%L6%EB?398$DD
M:L4"D;W4.O:9.WQS>_*JE*PR"@RNJB2]U">C]0L_ %5B&[QN^5N[D43;J^27
M=V^F/(]D$%B<^8!?#BFQ:,:D'\&SCE4%)3#'-L]KDN1HCMVW"24SCX[KG(9O
MWJ?-)695<#6,Q /@Y!49W.P^4O:1$ 8"+U#%1P+1-3SP6VP/N=8SHOX2OV;N
M3Y8)'"+OWFI2_R(R[)=71!*&IQZIGN&&"E"Q&7?4SA1D:,4LZBE --+CC<5D
M0U<3YB)P8LN6WM-'O>_PQ?BEB61WIY_?:EV5.59&42;0D7&N!/9R\P:*91EN
M_CG<K9)7][LW_BWJF:7^T;.=3!X8LRR+]"=7\0D\WH%VVK1#\<?+%4^^]M,G
MB--%BG%M<$F1WY.[_H^<_/C2ODI#T^<C)W;;=LA6LJ56GY5)[?VKK35PO/PY
MZ?=68]W9HO0=A:9D@P%R9%!,#ZT8 2;^":C(+<,[XR#0G]W(><E4=2J7(M8G
M<6L8H%PJ)>Q$->QV-&9%L&4T>]F=+T<TES:WD#1=*(2G(J9(9O)QJ2B:=:V&
M-E%67UP@P'2YH3]:]@]]KVUTN-P;W@[\R<>.TBW;.F+_(U.Y#/]]3>.(9-4&
M,++CMGMEI"7H%^UF"&ZG9Q8AK_&>GL88($PG6G=&I/M*<K=Z4Q:FR7')_[<H
MPH;;$G(<RATN#,Q^I<+>MUO'#R 'YUZ-08+N3][.O0#6B>:9'.HB+MN'<(7P
M<6IK7P"YT0.SYO<+9@9!;)/9H*DL,5_QG+?+?7V?GS8R?;4O)7!K!90NK1OG
M*#[K*41Z-9[AA#K_<#HO,M>"J!L4:3=./I&2+Q3.Q1A%_-606&;$]BH;4E@K
M#IF(2J]Y>)Y)*$L?#W9@_CDJ/5D-V3+-'5&>6@/TB.CBO'6YZ )7-A]H\,7%
MBL$^HC8_FI ,.K_(4<)[@"HC]7XA$O[)($)']X=J*Y;^^X)^X-F;(L[O*'"(
M+.Q[ G,Z"CY];MEKTNX)_@S1R-(-MEACVD]'[3:=C0WT_%C+'\J7;@3@>:<%
M&Q?U3YU,:7GMUQ;M-*#5Z78S+ B)W&F537U$43L#ZHY5Z]F>&.[OYC1'!Q#>
M=Z96U]]&>*>[D4X-2^% AS8]JJ7SU4KG*;D/S3[>GHSF?]>B_[Q!B-!WF_([
M&&??>>.)FC@ ( !6? %L[^"_ #@ _WAT8<E:'^3@@_+T5<B[KJ+I@C9%2+N'
MA0RUB):;-D1F+=S$)V+@D:&+85:<N3?V+?9U9F[8&REQJZ>%/0GR<D^UT<,?
M^3$I87\5%;(-5I$!(GHW:I?5F6UXZ:/(67);G18':/&(T7HI+OYK_Z]3"!#/
M+^;>N^4GQ;NLY]*"6XVR#GVM[/85$6-(N[^+)8ED9E4,D2_CU@U/I7J.;Y[(
M?M;3? E5AZ1N9U%CJVT,IN)C@YYKQTKA5QQ5T95-_07SVM.G.HDAPYSU>!EV
MP[.O>6IH,UDWV8EA7?A9:X/)*V\+MP8H=UW7DU2])*E/@R+6(<-P/?S?A]PS
M0F,,@087H)2^&95E!=8>U9^^<:=V4:]_=Q'73X>CIB'X?O5TH$B74EN-<)V2
M\TUQ43L\46*TMKC-XD^ 0L^<<U4^N3"PL6NZ0OI]U]QER$AO*OQ!:B=*86#C
M8$X*^Z@O2?OX;2JOB']AUG GN__"PI.7%H#JJE0*CE]OK/A_04Z!">Y]21',
ME1"]I I$X;_GX?<0!96F@IJ%]'RT4NHF@,W$#VA9WB%/BDCV4#3-VYUV<N;"
MY?ZTOWXNY"/IHZ91QX.;*BL[GWQSDTB;?MI[0^,5U6PI%N;01;B0;3KU./*E
M(UY^<:SSDN9BW.:A9\\OT9+-O>5@_06 ?M,K)K9UY]0X]\#XZY 3[_7K0.5C
MLU^Z'+K1?F(Y\82:6AK_YB8J0L0F@WD7_FR>5K-*K.?'9(K@UR\ ' D<M\%J
MCKRUKO)K1<:&60ZH7KR1@2V*-P]EB+Q'S"47V4]H(Q>./4RH<N<;XV>[9\/>
MHHE]XC;HO  CRG<<5G7MWLN)L+:O]4BE^X*G;W'I :")&6'$3KNWD_PG. [E
M5B6RV_TBMN+US>74.PT'3+U<;M1Y^$W+.X'%^.<IO$)QNU2UVEH-6>T"!7+*
MCFPJ6;/Z-#[ECJ*J_=^]]Z;?<<XSH(_@9C%B-'PU=^T/*O[B56G[VCV:=\54
M1N03#"B,\LXXUCJX\9D*G T#^F%REC)ZSG4&2K$=7XJ)LL6U+PC8<^IRV#WH
M,&ITY*\>(TIZ;SY\I0QN3)ACV+^?@64R>"KPWCE%<AOQ[$0@X_ST3)VH)O2W
MCWT0+4IM6YAX1EB8,K&9+RKOQP=:?*CV !IP6R$P2E,D;+TV:E.KE#BNYZ?I
M$'Q6^-)EB6+CO&6^64*5R#^GL_PI%[60;L)S_@60<9<]JZD;W' HU1!<WP5S
MO5YN?Y[8P>5SK5IIJ51[+=7GQ[+0(>)E0^'4!E !TQY0#OHPX/:^"HX42*Z^
M=1G0@C4I%5 [6E$ *84?2<GGV0D)% %>;UI> %'GP.2#(WM9>&7YZ'S"3Z_0
M5R:EQT(G.^6'J;.']OD_]A?TFXP\FXF)WUY#^M]1V_[NZ<+!E9S#7C29QO-(
MB3DXY]+Q&*/J[$@=[K:*5ZFG_H65:F(7$00TO(W2#!3=GX7?^/8JGKO@^,>M
M67265W?51VG6M-2U:$V:R$\I(M"F,2!;^^O,E)+'G/E1D58P!C"JVQD)!B]H
MYYW2B]^_/M NAN68VG9\\(L0E_\9AE*5G]_8%#,^36'PVIH[?X#\GID4Z9R(
MPWYY>?Q=15@,VR>/,H&YBJ;II4SSMHZD=P9':;J1> ]X:A+8=B+GEZ*GM\'.
MP;YL/G=_';KA?:G_NGA9F9W_X<YHP\<+Z@RT,T2U<1*^HL5/\N=R.6IHGDT9
M46YWV-%-L4]Y1R!&<C?$O@@?^%O@3Y7W5%Q<]0YCWG<'SZ:Y=C:N8%<[L@3H
M"C->K64MK8;2_@>QV;E?4-52!<L:EU82DODA0EHQ025WJB$IK[3@(OO,D]6>
MD<)D=ZZX%X"E Y+%8^U$9ON"7;"18^,]\OD-B8M-9Y?1\CV;P8%]%<&&LQ:$
M/BZZKZ_R\]2H; U=\J0KZ7JV*\-"UA[_;>@9RD%D6OZY!61$S'EH.05!^+*$
M/,.[-L>$I#XV->,J>,'#)68KP'\3YHIHL+AD8C#A[5+$4];_-N+7$#!OTJ=X
MX(Q&.47 K1A\:X[^]ZSQ?N".PW7XR&-\1[_& >F!9(.ZNBB!HU%87RO$FP"I
M3D/R)UN0UQ]]-.)O7HF$T-OT8Z@SF_STT78"2_7"D'\T(Q1WV/<5XLU6ZG3S
MSW6!TX4GU,,7P,GV^UW23M/BRP]79<7P[L:M["?L?;:LKC.[*)?#HC I_&ZG
MXQ;#_"07V7T^4[>21YFY *D-H7"MV07]F6BH=5SX^;7-0+ &. OR1:;\<$(?
M,V6CECLUIJ&@,LOAI_Q<E[Y$72LVW7CU&:[Q3XXV;$[FRULT\RW?%)IJ9K:2
MNLZF6:>-]H9,VS#=I822,%;%;Y&OZ6* <8.PI?S0UD[UTINJPKD&<4.Y$@?[
M*<:_>@ Q9FB^JHJCBK\6P6IGV<E3"_7JSP#E$XH5UZ=JI]XP@]YXB:7KZ_W'
M9&9S? Q**XJ?)UGCNH2@S$45-*T*P@+GX/'5HO&NF"WC/OV:7JK-QL\-];)-
M'*MMS.L^4DP)OG!HCE0,E_.5:\V7(VLS?GE;U5]<@*VXW%:HR,.?HJ-\AZ<<
ML[J'AV"S;8^*_%:#1]G2T72L].N]YGA2G/T@55BT%E^*-%*NV"SF!K@Y4!RD
M@%BQ;<U!O5[C8B.RFYM9 'M'##(>J39=> $PU.;77CI;7+&5MQBP&.@)*>BP
MM8CN)BF] -XTL2D.*8$HO1R4/[<RMNC3;7Y_RH4*?4K==A:\(K9] 103Y'&^
M?W O>48"!5I ID?-;IF,FAC$*K9I_2. 0=]T!SQ8G%RF#*$HBS]/=S(A SNY
MTRP4^QJOE;V.J)30]&J0/\BTJDD914XO3>-]?29<S7<]EX\@RGGZ61 \:=KS
M D#4?@2/=LAM//GWB&ZYPP[TVHJ_G+3J&@D*'\<W)P4>D*=MJH)R$S#9JF.S
M2ZAH5(JKMW(J@[47RK].7Y9W;X)<#3OC6,4_0!>I?N6QR-A*+MK"C_0OL8,&
M>OU,?.9Y;=1QHD[DEV?GBUS)WE2UY7H9:9<(O8H9<_E'GX3DM[X \(IZ0,9?
M]/3,ZD%(-91VY@-J=W #[[\*F16^D.B7/@5O3=ACXZ'+Y27J-# /$TVKL-$:
MGY=X9<"HE2>696HV\XASPI"@P-]:)2@&'M-['+@.KOO69#]O7E%6J'(S2?TQ
M(21O5)>K;O^-Q JHGR%B\4NY*\"DEA'WINE<0HY)]YH_ 9%+@3_O[G'\.6:;
M?_<GR/]!S<!%KO%!7,Y8.%[_2=MYOQ6A_OFTC"!>PWA?7QUE14#%X9.:>OHP
M;CJ LDH[L8KE <1EJ8=XOKT+DGPN#\IZ&O!H\8LQ;1R0^/P"L&Y+,/;FC85Y
M:R3GA/'5,P:*4O4L"/QA+6/6U2@3!F AZ).)>(J43^E4V@7#@[\TCCR^;?!/
M1%E5!Z#N##@? J\A7Z3.4=MB*G_ *N<S?%QZV-@Y/_J%%>I%+RYM.^YYI4V;
M&1B#!IZK(.FZ]]S(P:*YK=51"Z@'Z]<1;)1Y=?2[3RM219X- G;F:OOK<H1:
MI/^5CAATM!J_+?WV75RF9%D1K9W0# X*="<OMK@M6H>C;VST[^,%SA;HF^ER
M?JSZ+D?8G\XO[("OCH2\6:T^7EA #+)3;8T/@KW&3AW4]$[?>3UR]L=K)[HQ
M1TR]1:XIT=]DJ6QX#V=RM'5(^* !*<;#?IY[JQ/&>9TC::<YVDL@64"IPR!;
MPWOG\*,Y ZN4OP9-O:.TF:-?FH$HHHPZ*_VU[7([V'5_^Z+*87TCWH8#.%51
MFT_'OO\K2?J>12I"SXS ".^<FUN.JD?Z1)@MITQ-'["[YZ9[]"@!IBZ@K'6L
M:]PN9,&R8GYOCT#*EK#>EB>C-;*>+?;'6J$M;<,_\FL$6T]RPT6B:5!^SCYB
M H:8(/0%$/8"4 DX-@H,^BV$7S_XAEU_^'S\+&)YYFD%_);,JB7T343X 'V4
M'A4I?A*8$JZGN1ROMO/8T!Z3"4K3V?9VOMS,ZZ^"*EF5&!L[_#[GF.Q/SN^(
M[0SY*\WV-\<"U8R&PV*NG5=+@UK +X ((YR2398.)1]&V CKXR1[D;8WS]<X
M(9D9X:J=CNL7P(:_ >39%>L%\%LBV+V6UE5TV:>=THZ.Y\;?3J#!MVMHB,U+
M(+''%5,(UX(]=MET7ZMD7\A#[<PTL:(IU-EJ78FA[MP$B=):X=SJFT1K,0VU
M GE&1D\N?0+/B$@-$]("(!5$G%EF"!;UU+\/_*WNS#PL^OSM'A^NJ<6IV1!_
M.M<9H:N'(=@FX'6A\#>9?PN="3V'\;X ULP+)2ENLU#5BF@'GB1?7;,6E#N4
ME\.G#97<Q'E&>AJP&S\=\^V!H]<9G"D>)KY%X>FZ*^O BU:3^7;@SHUB/_$%
MVA1=KMYD(ZP%PO)FN9^]+H.B<;Z[%ACUE8VGKI0AL'_BQG@N6>VTA7ATDPM%
M,J7X,^?LNC6/93;S)LK 05@I0,V&%-%\YA$^2H#$&*F)6)$/4SG6C7!)PE:)
MLN2A'W3LYY0O3GZR 6^D%CH#;<)E(S1@4HL  /R*L%*0LK/"HL7"% \,;HM;
M([['N82-N#89JCI90WI_:+0%KN&B$?+TO9F[YF,75W+P!S/V#  9W^#3<X](
MGK3HX(R*$,+%90 I&P(Q<N?(<H5IRJ4K'] \\GX79/0T8;@1UHQ>CXLWQJ$B
MN[P_$A89ZK9(E%6^!Q4MCPT'VY/D])KZL=$Y]<-"&2C]]*0Z:O>D2B] IJL2
M@@^7K?9@;_8?4X/3+E'C"'@IKX6'+O>"&31@MPG]:\K#C.@I%8I]D+282(I
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M*JW+A28(+X" A:\&$-=G E<"B?10++@U+I^)NZ94QY^K0[:]<P12!OHD@"A
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M(@QJ9J?O=W90Y.6;S2L[0HQ774W\J"\1)I["M1MF.;D*FE-<+[,C(VD!/;R
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M/BNA?U"DCQ<^9LD"ZLGU$3.8O;I-92*)=+\NI&\N_S5$FV!<DV >>L;'0H1
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MZZJ0UW&*-("(DM7 ##U3N,CX7&F !6N8=5V%[L,]9<.]Y'D?J*OQ:H (3"R
MK=74XJI?)4NB6G2EN>AQ/4#^$]<52KR C0WDO ]D/;:EKJ\/M_5X;5B4O6<3
M";[6.)WCO;/(R+MQ:4AX] >6S31U8C#FWV]GR%OI*<[R,*3T>%;OU'WTK6#>
M))]_Q^C>Z# R-WI->+]]4K:$:2+]1J4H&T:\'6Z\V&K>)3TV_Z>)D6VTKF2S
M200" -<Z^(Y"#EISJ;^&H4 ;CKO/M@IXX=W8IH*WXT_:99G[6,K[T3[(@,^7
MY,JU-FQ=]^!EZ;/E&=4Z(39F\]]RY"M3RN8DF+KQ(^Z!G15[UYA[O&Z<5O.#
MJ"%LF23K]V6"@EY0AL#\[-?%UA'-S=ILH/3E+0X:MHA^)4&2J$DMEQ_I82YH
MG039,29L.%_ $J]U_.G2B_)%.RLI3N.'PQAU;KH'M>64)B<-7QS2/@'\7<+O
M^;9UB=C!FI.T*,'$A6\K>L'%Q0PJ@E'Y^\"\X+1.8F_T(V+[2M8^!"-FG;??
M)SFV!3Z&FY)<%(?E[NY_8M."QT?I"MQXR G'CO2+T>;U(6ZL]V*@"R6,:.YT
MB)9; (3'9,ALGV0M_.0*65.(KN)41/Y6MU0-SZQ@B ZDNRE$F[,!L2K,L23#
M6XESM<J2\],##WOA56D3\V@X?DU_GQ@! @0<:3YH?MWO1GP_$B7G]9C(QTYW
MS(8VA%,\SJ,6PG'1\6!-[(NNIXO*0? 57G*V+UB,BS+6X9K?;'MAWH\/5#-
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M#BA?A+"_^*K_:>% ::A@NC.@@F& \)PS:>O3]_GW?%A.LQ+ML7^MW9*W/-#
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M[UNR6@&3F_SL\JK$/=;LZJ_'6(:T%AW.]Q29!=IN?K^/QVVZ!LD;OINL',(
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MTC##P#_"]N_CL21!]OU<EJ @I.)V@GN,JY@< E=I2FV>FNHZ^8'5TZ?Y49X
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M-$U&23#SSO-<Q/7[<,)#(P))_H6'2K'K$D+G<-0F>#5B4#+ ".MK1A/QSA4
MR],84W6F&:=:J*[7T+DUQNB66;?@1S]A&X6$D!9Y!CH'NN58C)#1!#)Z8PBH
MUF3TX:DZC.+!H$UD&\Y1GWSB9=]%\$R3C?YO_9R1'UU^4+VYK6GJZ$\8J;2X
M5>4KD"$E2UTM)<CG56;3I#-3J+"ZYH(CA'O<G;DY!YU+4L-EAN9UX[-FZ41(
M]X1"P9[TVV1E628YG7'?CIF'O(H8:]07%2)M;T=M&G"XIF94O\D9+=(<,C3+
M=22G.67^P"%)HOV;8'D;SDSYG:VNAZ'TCMY'?/E$JZ'?J8RJVX623#G&/X.7
M5ZP@W-.YZ94?MQ*F-8OM>U1VU(]NJDXF\24&9I4J)M?B9A9.29DLD@[O;%?X
M7#'JZ9/]1&6/\PNN]<T.*"8J_>JL?4O:U.UF:Q>J.70R<S9&"7^L6!%Z;[::
M=*#AB_43424[Y2_\OE^&PY9T1"]/_%.N&C6:8,#0"?$/S_./YIQI6GCCB;]4
M\ZL?U*!Q]60YMV[#PI;=^$6OVUMX?45LD-&/^CQP*1IF@7\Y:I9[44G2$LEA
M:;/+2,\4;[KDR<LOA*&(7R*$(?W5?]G*:*^J%:B%TKGD&GHP81^C[B8ZW&T=
MALH'R/+A-L;&X"[_[9W#7V;_#!ICN\+$M;RY=_H<S6Q$7$H^UE.! X91&"(S
M9QQ<+<,/MUU;Q:V>(8FKLR4HH6T:Q-7D&M"PZ7[_T^;.E;Q8WK<5,F&1CBDP
MWLQ2I 6A()=;1-JLFSCJ?S#AR-V.]4<O268/QSL"G(6N\XU/V[Z7M%*WUN"]
MY2ZN"]BR9;=[_5J#/2(C6)%2V/Y\-F=<C,*SX-;7(%1GAO52T)95L'LH4"O&
ML571)B"06$31H=C^![O6\!HFCI[E16?^8K>[M[<I?..J'$=<I9/9H$=J1F5+
MKTC-OI,B(F9N)VOXNK6![@S7A3E>AG7)RA(R_H8ZB)/Q5?=<-)CFZ]?$/-]L
MB,=H",T9]S>745M29BSFL/&^F2UBDS]?ZYCO.HCO$&L\:/%@MK1].X_4%\7C
M!K87)M;-!1R+4D+PWG<.?8 )^X(Y//VU8T]/(;3:6O]>3GH<Y??8XC"1LUU8
M0"W\@GTO<%E:&0*LEPF)ENC>RNN):*%/55A1.X6XU[E?'S 8DO(VACG>SCCG
M^7.#A:0A!5R*<]K>E9XQGYM YWB]) $=\ [=8%H/\Q(/;CR83LL5XIGJ483]
MVMJ+8H^4H8EF:N%@XV6FMW?M_8(*7ALY*C&=*VQU%ZV#^7I@4J$!9;FA*@G:
ML)Y"F3O-O 1>EU'NW6I%Q 2YM32B95U-[TSS:#[Z"#>OP?+?<\P1]E2])T2O
MTG@?1-,^_FE"=_PX6>J[1M64J/7KY_.]I+,RX;8I36;,"*:"N-Y']2G?34)7
M**!K  7$N5*#\TLM0>)/+5E08$R[%PJ\PGVT>%X9AP*[+,90X"OR,S=="I[O
M?%Q:D\'5F\6GJ ]39=;5389<Y5Q)R=0@"U1.BLYS;J9?69:,[#':SY2;]-?7
MD2\+0R@?D13.LAX\7UJ9])K(9SCZVVFF-NR]VAAQ;#\M$D]'1\IX H=Z^HOU
MZF+SNBEFPZ80[O,MO<XO]G<J-P$>PFDK;7VA?_-T'^OKQF Y6RZ'GF4*'C3,
M]3=>^5!@)_%9+24#8-X! )%I7H6;8::F^?">)/^?MCEU=0;OE/_*O=__(,=0
M$G.&NU-CG1TA5K.NV.]'R1N3B8DP\+PA\=6WW_.\(SC=&TH3,)<7NY9JSXN3
M=-"(9>Z^[G4[SQ*<Z2WVVW+$14@NM.-PB&1%:97?&KSW@[S)FLS F><*MWW=
M;V(I<M?/#[JAYX+QM]Q@D3"M@83JH#I-<=U,L9A8SA7+-(%QDGV=._I.HDZ4
MK%+Y6\I/"9)*:U/+5U8J(ZL$J@-4-^-0W@[QA,]M )N7):.W$H^"USI)MH?Y
M7DD_YZE-*ZI<CK+28AU'$."UTSH3U492T+]=MYHVL[123?";")U3"@8I"USR
MI:.!O0SMO @M2[6U>YV.!^)9,/:H_:LC>/ST5/TG#Q17O60FK:,UK2>/>/V(
M5H3#'WZA5C)T7A-'*=#P'>GTKWD3L- ZY1>K,^$[',#)]Z6GUG<0D;OM*6$B
MNCF;I2IE+R*D<N+Y(UHJ S2VXC<:Z8<,L)A*9W%%>=I6^=<\R@9[51*!7+'7
M2W?I>)JW(Q?)GYX@6;-7D8<*F$M6M'A](7#V3=;H-%B%V=>DP=M%_7]&,?OA
M%%M34;K94TB'[=8E>(Y7F^SY-D"7.;:8W-._H8"E ??33P=DZNI$I&L:V//D
MKS&1#MZ[L+$QZ[I;EP&! \L+Y_@<TMOL(K8IF]56[=9$_/R?S2FNQBT$5O+R
MP26H<];83@>!=0:@6KW8=R8[Z7<!VE#@F[08A1N)7N/WBVUX.-AXS,FZ(9B-
M%@OQ/&WMIZ*^K[A'RL3FO6<5 (XOP ";.B[D:%ZD8&HU<Y%]PY#6K D%'+>Y
M]&W&%$1=Z7/4Z\]JIC@''9@-!4P\HB:1+S"33<AL%\.LEWLXDQWUX/,"+ST)
M XZ*J;]G?#J+'1V0</_THJ'(E'D#J\VG%I4@2.&3Y$./?VIYCA>3;7I)*](\
M@-^G;>%;LQ1\I8<3"Z;EO(Z9#=9!-#;"XNIP))H^((MS/$OKLJ,U$XT+TR 4
M_"R.-W]2"TONU)_J@BZ3!"-%5GH8MAX8YT^41J-;<'<97Z]9HZOA699;BWT5
MA_N"C<+PB!=U.X8H6.@E4ULWR9HXT'-4PV!L*3+,I3F7H>;?BKG<6?8N%0*1
M//-)*MV/U_9.2.ZW(74*)\:NG5E85*BR?^=&WVEK%7>4(S'.1 !4X3@ _/S]
M1,"GL_;+W'UMUK0\R\24X93R0)T .N6P=AR9?E@^XI,PLQ@7#=9D_NVLY10$
MZ?PLFBEUBS&N8LQ+!BC ^<S5=AJY9W"Q17GPS%5&(Z=T_+SU;!;QK]-<'VGN
M-1[OI.^A0#CE?TSS[+ 27EUJ&QKON\)K0,PH7KV5OBR[.X^\@@(D)>CA-9'?
M/^EH?I.]=HA#D<>@$/+EO)MHT@E7R0/=Z31^/%K<MOY_:R!@M.600-%@I$\3
M:.R(C_>8 W$+/2MC,:\^]\$2_X'94[.1RJ9K>(N6186-WO[I;/3BZ<V]QVI1
MVR(2C=7&#_=TU/],UO_,\'64H, /O=4G>]\GN.G$DI?JUL=Z\ES?]NQG*?S+
MZ9E[OXWK'?R0NC:<A@9Z)1'+^V@> <92\&. ?7P;G@^EE?J*Y$IN99?,9Z)L
MLH@@*K-&88-G\!$4>/++A@+C4JU"!HTBL?,!&205KIY$ZU9\'Q>;'N<OF]R@
MP%K20&72U$J(FDR$^!=O]BN^RR,-:Q%&-Y21%4&(M9+Q=SXUK#;*'*\&V;0#
MW*>UQX.2/X;+R8/8K+U+@!\,.;J9A<'9CNB3]T<HD)$X'OFD_01O_I^'SE:[
M(N4I?\</7G'M9H9D 9DA#*]J%D<",4'L"(ID\*.#*P62=,6S#'HN72:;UF28
M"KF"5\.ZS2T$UDAOFH:\6^PCSPJ_ES M(PGY<=*U+P8B;40=S/)=IJ-K_U>E
M[? 9XN.74BBP])Q97<3;17G^JNDE=^]#?CTR+V(^6GB4#8U3.GF_(2L/#T$K
M1X2=FHA\.:M-?:[;7L\U6_P5B],]@HML4GN: 7%^10_CE=H\>37R3,<!68&J
M$I*\X A_3B0SPHZI LAGG&8;17YB-!FX*UCNHHQEJ\F55;HL8LWX079*-@LX
M_P;Q$_](_1;("\^N97"SW0,++R5@&PJ@B/[MU\7]6$_B!PM7X?,J6B@0E3K[
MW)S[PL_KA?HH9VBMC*<YJ17<C3K-#U4D/&*=V+.G194OP3(*@0+Z*KZ[]AJT
M[]</'U)^DA\_IFU:CDOB#?TS^8D2^,QNSP6CV2Q7O_D%\\/%;8B<L(3@C.E[
M9T:8NP#YF5-!3B'VJK=WWQ7!]Y-Q?-/SXWB<QHXP_9?#@,A_5=$668F>H[X<
M>2G;"Y\G5JG54-[!+T.!6<(74!_IJUC3>EHTML-2_D' 7E.400'0-11X[E#V
MW<TRH&!;II2]XH " 8\1NN8]3P;;+(R^Q0HW01?9.0I7WY]/GYUW6R)H&ZXO
M??=G=YD$):! )#\4.-BW?4*;"?O[L=FAMN\42Z(!;/'[+R>%+P4CB:<(YS",
M1PM76JA76^J9&*:O?>?'SFB[6L[VH%I'$*5'-)34YK(8B"$J4$80"<'+5#1E
M:W-GWCP6<G[\^L^S72U-J:JVR6_&<IH^+7ALY\71F#U%O,%<-4T0]<9%@<8>
MM2S#0".QS3 '\9T<EN?O"!GN^).#0@Y2;X5JV_GXE7V^;:HJ6_Q8&JD3M6C0
MN.@:XD7C5_J"U"L>%NF8",R^I-5?J044KV+Y]J&</(WN,\E6>8E# 2JFMAO1
M_(*TW\/E4* GJ/!Q&/M&>J)5_;8%"M#RJMW_);)0[K.]QR_+8EO9?/L_3OM$
MO>B_5RUHF&>4&=W!M_+4(0QENFLB^;<OJX$&9>_!?Z7U7LY_#LU2\S7$QQ@6
MICWZYT!(;ORSE*?!_7D2%'@7TNJ(_2B][\EGG79K\%<XXM,9OAPRS/_"$*Q'
M?C%/ZLK$TXGR2SQ-_N"[N7[Z"#;,:TF..!%-U!)[J-][=LL=+A#2(,1&TKBQ
MC&5^>$?!)V0_6U:1I[F/[LX<8L@>H"A.G^HMQ9>..O4W+M"Z[]0K^?& 9<R6
MT+ X:^OQ<5ZW7CI5EK=F&(4)G?4J>!;=0O,<;)B,V7Y]>7*@$'*@[K[ISE+[
M+2 D=X6\LGY'6&:4O&7??;RJ$^QLX,%C44SC7#*0WS/W+AK_)WHO>=_.WK#E
MWI'3S%R3(JU*'96QW55NCLM'60R4H[(8%B5)Q#QRJ[!7(9N9!KBEL;Y(8/2E
M7^?9T:IWF#"U&^E"1Z,?'#6XX&8U%!L$\D7 X4)5S5A(L&$8>:7R\( 3UW^#
M)4SVH<"Y@BT4.,2G?P[A/EM_>O%L^97O'7T=%+A&B8$"DB2W9SZ[]QH%\8]L
MFPX;(KPO3[!;JCP9^3:+IM#^6T*521[:LXS6O30&ZFWB6@N$C^ZC4,#@I<"8
M51O__5BKZ:/,]=KC&Z\V%?D0AL*W?]5=1OV%0;NQA*TW%3<4,J-;,T50P&S(
MEF!CE.8FZ1=L+:*\OZC!2+'^J#VJ&%48GVOGJ3SBVD2A=+Y!OP/6PE'8@ :M
MPO(&Y;NPY,LC,9)_=Z4R#M#/E_Y#X <#C$56R7]PM4;4H]M4V>4RO32$]"!)
MW7V)W4\]K'Q!X,^%?H,^]X.$;Q_E>RA0]EWT$EN/R-0C?Z2L?93H10)F=8E>
M4DR+GG*\]"O/.+Y8+K,UXI?-,8\0QI#K.^.YB[LTQ_E6^ .2W*SU82FF(]GS
M?>Z*I0*APS_D!WUP5V6>92E0P!P*W)%QB]Z?0H&%4(/W&I&AZH6'KDJW+]6O
M]-VG_[LS$L[,PK61&-<!K?*8&'9JG&QLH$N:D1_ P?_:+LQ8O6#"*<<<=@[+
ML+ HS[<AF@K/$I>"_IV.SC$6]8+L,AWUY[^X33>RBY(4"OQ&S=9>??(_:O7N
MC:D:/K]^S*E*II3-[^Z?1ZZ.G<]R+M)?O(UB^<#\N?95MZ$9/=7C8A 9#X+
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MO?&Q RH;8(\1NM?S%WEP ?0>DUW>\'>C$4=^FW0U*[2'6A1G)>H-M(H]/'7
MLENBV7YP9?;.6<,;[7%=.V!KXD@QXKJ1>MDJM^FZ::-\'?ICTR!\+=;+$Q>$
MAN-.J!)N7MP>7_U3WE!SPLI+RF O0=_I\B0.-4L$FY' FWME85N2L45 )8Q?
M/G %9HV!6O]&1 "I]1SU$R3#$_@*HC7^/A[B]EBW)F3%,+:K&!B_L+;[ZP[D
MU(W]W(&P'9%=U>GK9PDR3%L\A6S]0(.>4@69RF4#WXV/#,T&!0V]\AHTM#/!
MT'9'@&Z%'O;LZV+$^AW\HH\H\) _233^\AW.3/(+K(K3M%P'2 O@L_8X'G)
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M7&&)2!R4?=*L]A.[A>>"=3KR<E74&YWKK5R%[\8N:[+-?9)74Z2:'8QT'QE
MM+4KGR()8IB%4,T3+-XE/'%0(S*MXALE\;X:L9L<"LW-Z9#[2B-V=H-=*2"<
M]#I?;D49?U]S"#@D6>&__!]02P,$%     @ ((!_5KG\<T!V?0  5XD   T
M  !I;6%G95\P,C(N:G!G[+IE5%U1%RUV<(?@+N%>W-TM"1:"NR:X7MP)01+\
M0G""$]S=W=V=B[L%=PDTWVO?Z^CHJ[SV3W]TGS'_G&UK[G7&6FN.LU\77S>
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M*>"EIC3F@,S5GRT!0]LSV!/O\9\U9F_F&S(8RTI_U[_;^)%B,61-0(6&5B6
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MLB^[VT5&H:RI.'-E]K?PJH06<K^#8O7&W<<-E;UEMP]A\T:/U4HX^Y:>^KG
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M!S,6BQ+Z,"N;>_.)\4XYZHH^2E1JF(2:(M]U)+?\?OKUL4S*IFA3KA5!;<3
M\ !%% K*I":,<=<PXK:.&.;G\PIPU\+<(L=6M-67ED=<<!Z;,N@LE7^#0.>%
M"W(S1%L*03-EB--X9M&2+6G14N!M!IJ8^Y06:8J22N8ZO.JXI_6'>(G*ZY]5
MOA%/["-_4N\>J"T54]O<MTGO"A1SK9,X,"8*]#Y.EB]&=)::4D7$_"OU84S.
M Y5_Z_37D_^>E?_U3JC@/::4I&FK:6C"31^D#_ML?4-*H:Z44,!WV&:+H>XJ
M9RH4Y!&+#+<*/6=>)7C0-F:N^3BLM%;Q/'J5=;!KHIZ[&(-*^_;6]0$.G-[J
M%"N_/9^7JC!S^L63H;(ND=@%U']>PB)Q%PI"?)IK_I]WEJW@^8_9J3+3*XP0
M_M$?F,2<'.11VU$B&<H=O&=_RD0F&C/_$+6[=<=G*--Y?"PH-(V2K2IQ5=\U
M##JQ\?O/W!AI""+[! %N_RFA;@P Q@8DE.:TG\CZP6E+4H30*_;YQKHPO$^^
M[IFS9!W2%(6$\F6I+QT2Z</RN8OT<52)\U4*YA2V),$:V+GL7-'>URC'GPPQ
M9!4$:@R9>_5:'*RDF^TL;EB@^&=Z!&J[/XV?;#I&[]K/OCV=[7U@@W3]"*5%
MA@L-E7JJ@AK["FZ'AU/R=Z^-*PC:E677Q;W=E$M0K>D:#OB><6,3[O[A:L2V
MHRUA0;E:1DM!P8WE;8(<%%.(A%7P.(KG4)X_W=Q%(E,LO;7Z!&U/].-8+><7
M;EG)3@IOZ%P*8S6.M<C:V9G?GGKCM.MRHQYYNOBT58JR4*R<9GR'XB+HS.>F
M:*<^4&=:Z&WD%*DN8?R;/"6-@,5 9#%F/<9J%#5[6)OH^D.TX2+L<V^5D5Z7
M"UFE8YP,!3(E-LXW&][IZ_MPDC\0E?S5/&/5!GOW[2BNIJK#N&.M@^P11TWZ
M)&;[?QX>CLRS'B.-+&7[2&#&;&P ,6T*YIK,D#OURE/D[A;,"6.%) K&Y$1^
M^ C/XKN+0($0$+-6IBK+_$?"5MW>\J[CBHD_,J]UA,>Z'L+,7-P4H #D$@+;
M632XAP&*F;)U:7HTZH1MM6O>77C%.8)"B%#+X(=&4$93R;7:KF%PB8;>E9CH
M*U#^!]J%UJC_'8\TX2,:?V27/"+TIE]R>U%#H4"G-$ZNWGUS#\G<&&]/TCM8
M<%_\QN+?F3,-V0TKY!R&B>+GIUI4+Q?*F;UAM(JWA%,2I,A *<J?R(&-L[UA
M"E^#.8A]"=-43:,(E.'I^;J".V$P]\CD7-[W9)/4P?/TU]>GHRV(0%7#[/_H
MO]?_MZ J[X*H-D 0UQ\K?X>;!K\NM>9/E_V[L:6^1O). %?RQP9O.0'^X1B:
M!X3U#-$#5W00SFJNRYPJUXT CH\04\!]@8-6RHF@#'>9-B>8T1=;6&W !7%:
MGD)=Y@RW-[P<[?VIB&L6FE4A.P>$C91H[XA$]V4C5C*O/?E8.7"+O/##_)4L
MK^)_[D6]T/J#_X?R1E,'M37GL3C2?-FZ<M2C6W7ZB:G5AU+ZRU]OI0(]=C9P
M)T2UL3QR;,F(B@C/@O^4LWX;R]+_MC?=]\EE9#_VHG+1JPM\TN,Q!GB?$'8>
M"F=&6-Q'>$"^4K'1T2<3$37$C7 A4>GG!F*UA.V<_OJ[1RX%:-J6Z?<I$%5O
MUKDV1[T"PV_Z"ECZD K2BNE^/)B-O8U@BQR'&]=P9$28.JC@^!>@R5=@L $'
MM^(^?$KYQ)/:@WDO-<[\E<%(JC=5*UD0M9Y*!CZCE[/^:$.;I/D[LN'5%:M;
M'KUEMIC$57JVL'CV;L*D\NFN4-,T?WY_[S["[923J":'[;HFD-837SHL88Z-
M-S?6'7GPMVDU'OAAD6-5Q-D)ZI3[>!?UI:$^:F_^WG!E\7 T&P.'"T^=G[V!
M\]V;!]_W5#R7DRB%4T823M01)WP^86S+&K.GD!N?@H; QR%P@"G_)2][[*\
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M2 #8I^4\F ]LU9;^ONIB5[S\\G-4=(/_#SQ_5(XO_,O/D3IU\4,?M5;P(H!
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M4ZN [I<A  (8HS_!*VURHS\[-73A9=NK!Y<N<-@L GC1([_(<85S:G!]IFV
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M6(E1B72]91Z@Y8P[]>#N4H]"%IL;FF62L+D6.XAC,^0=EG17-B2>Y0H'2@X
M%I>.;4+Z,<L/';;'7E16.MJ%H(YHLYIV&D78O0:N7%!2[%,NB@2J#0A)S3CE
M"Q0=U\KC9R \LJB:8@ZHP8(BY0U$!L]XDM,P4-!0O=W3+A7>0Z8SQDWJ*^K#
M47CZZ*MR>&>2YU@;G>4DAC#D%\%".2DBO*J1A2"5H"%57EU?H+F'ZV/V.9J#
MVL4[.6%%0SZ! <!0J?0R>&9.9@J?M>)M3=:H[DR6$A#,A]?^9DGBY&,17A?S
M7B URAM\[2.KPQMYH@Q/>P>.5EWL"J$!"'%<'. 9Z&CCY>*&:N@3Y3LQ_;0Q
M4T\$T\T&J[87<MM1&2]'X5)Q?\:$Y%4\*L184/21)/M(:9.P6<X" C">9OL:
MEFAE=LQS4>O?C<X::%R4YGA 0^LS],2;D[7DX]OC+@\71^=6_IJP/;;=">-8
M$0PS^W49.A('N1Y=W  *:5-M ]<"!""+#[9EYWUH&2C$ <-5ZT]1!9@AM.Q(
M7<C<4]&RRB4<A//:WRMW&G3=/8OG9-[2!Z\.]H7EFA;@0-[S'R:0/AQZ;J.R
M/,#UT)V-)*2>7;<A/GA4-IQ/-53J&0FY7*XHFAMMJ+<#=N%E^SOW54=%>UL"
M:_%(O$ZKYSZ,.%]Z9W#D7UIL)).%O"=3"/MJVIQY6&.[1Z:GX!&TF_A23*II
MB.DUL<.+8#FV\+Q,DKG"[L<-T- /HB_;V6RR^SLYB9.M6?4M[3I(7?+FLEB,
M C3#P<*UP]TFOU37BBC$^402HW<T68OH":;0HB!)-V=M^:X\%G"/PK%__)3B
MJ8ZB3@+5NZ!^!QVA"F\2BN[>^U2O=)OP+G-51@^2?D'>S),I,@1/%YVW(1.&
M*JU!?'P;;E<,L63UPO0THE84E12.X4S&'F_W?AD]B&;R4XB,I#=^S(MR+\&[
MWVU7DF!GB-(R/K@=:JGK7Q<^/5"2)I*A=^03^84!E1Q9A38T\CX:-"#WB#W#
M*;<FV\V1HD&GA\X'XNS63V\&5G18[Q_UXU?CTR$_P^9U2B[%'2HPT-:>WRX7
M='ME%*BB9E,#5R2,,N=,Z3:P[#R9(A,8@,RZSBI$+U]CUD2/[-$E*HJ\=GM?
M?D9S[L\6[HRL0U'0[L4QDFV):]YPDOOE1QD94WO&#PV:3*9Z,4V-/H OTMU1
M@KRZ,^9I4(:KPJ_I,V$Y"$KB^MCI6KQE2*?\W<R+7JX!WX^5XS&#VH7:<Z[!
MTQ9UX^+5'U9<>%[KS5E=N\S0GTC'HE@J10/^[=Z16<@^+E@G<_JNR0IEXU,J
M=:F2=AT$N[51(Z2#N-K2KPOZ[9#+45<-';BZ132_Z48^:48EX++A;,A#0HF4
M)\$B\'US^\.) *G[:>'*2QD]6^62)_>J$$ 9DFG;[FP(:<W= 7_H ]$:!(!;
MGR$/)=>GAVGQ-G99OPW%U_L98AU$\>HX+X">%#VWVSWB^X(#!YDEOL)1\?B*
M*8=@U&Z.W/E3_L@UY.CL6)Q'D@*=KCE]*V%H)*@5*LX/+-2PSSU;$A68*VTB
MS,]:&_BI[7Z<KGL+SC_>Z6BHKBYNNFB(BZX^S9N"FAIP]^"P,(E!F@RQGY7U
M!#F&8MVM//P^"2O8GJ%]%U(@RZ6K\W(R)#>NYC[$Q^VQ4N(C>@N][$[@!M;N
MOE-*9*4181=QWFEI:-6BR!2L4) 1$7_C+&?GZ,\ RVBC.8H/8];"IQ]7<GDL
M5\B6TFNB:9QG*FQ/8H[*9(QBN)@$_$C3&N<YP-D)P^+^GO2K!Y\MSB>Q/V=P
M8H5M+<.DQ[Z^;O/!#\!LF[B9H8$;!;I,\IJ)==VELFQV+<^UO8"P^'@CWC8J
M"]T*E?%*IZ9LXI2$9V>VCW&@.%:->XBQ(IK A>U$@![M4$63E*+GFP'!3VFH
MBPU6#*;TW69M;9*5E"DR,IV%'5F 0HQ?BH^?! DE)WS$3W>L]/W3"6.S,9M,
M^:(BL6%]X^'8L*[X%BD(733Q_MU:D:CR0>=,*"5#1=W-&\'RIF-#W_E9 ?1>
M7/[IFN@?@&S*ZH$ AFS?_,)EY<NQ4T4]O?AC#YW$%5_QRAFY8S3G&7YJL@1T
MW_N#KBW&2*6V*Q"F_=+B_>F]QZ/R;YJBY-<J.AN#?KUAWZL7YJY#2E%%%Z29
MJK(R'?M0[T1U*C$R.RN;W<FFC83T1&D+QX"['TYHR-W9[Z@\SB%B8E2P>7XX
MKSN$&MEZ/$"?_T1>6VJ=SI?%8J:@4:)/^B)<J\Q^7-<UI]_5X]5$,9Y6<VN1
MJ:]EZB\)4#,S)ZQZ5-RH83\U7==,F:HJC_P#ON=A7-PD"W[XD)A:8\Z#61ZD
M/M?1J3=)&^VJ'6+%O-^G G,4/00@M]V4D&C?^OMR7II4SUB5!3OOV>+\<AU2
MM*BN;/Q>YV/Q7O\NAHN\W5\35T<Q=LYT50:[%\G._73,=4>BMN9D-?40T!4Q
M4:[CDJVU,C[Z?$'=EM$'/%K:T8[7[DC-<'&$O+>PJ(%4<.O(1>WO$TX_+Z=H
MC0D_13*?R/80H%RD3LQ4HY9XOM\E@)YB,964%,P(Y.T_X9Y5O.\0\(*ESDDW
MU#PK;Q]/GBU;SL"TZ!,M OBP KJY5HS"(\25AC@$KW6PK3?0EO6F[JH.Q9M%
MHW5J5R,$;57 PC:*+V^NHPQ-&1AD_I3DG$$?JQKB1Y"W_\MX3ACG@7%FU G2
M\2,/\]*?4CQ$(>1[#1*#T$GB'ZQR9!$,@,^EZKVD__3NLB "((=V)^2#U3XG
M LC V&1).^JZ#7)/NW.DNL8I\:TT(#LUR)\6OW@+#3:(?1[,6/P(K'$94?@4
M%=<G;H^>\06(!HCS)NS\(!GZ>+;7I6WF'W=6/?[42JJUK.S]G'#T[FS#LU4.
M"?E!E@XX_4?9(W.?E7G9EV.\!D\&<8FZX4/X)IR%E%KRVRKN8Y=2*T-XEYD=
M"1I"@]GGR:;E;G$BG\<>43Y[I"ZYV752DAN0%%BU:5K0E1Q[&O%?]RNCE\GP
MYUX4"*#T' &,<+UVQ82_$"6&?]=HVD0 A A +\*\]"9,W&!2EN%H!2Y_*WZ&
M *C@OF>+E.1@3Y4I#Q+^A)YRZB. ?WO['/^28_WCF>TRE<4K:<)5BFP*:[B$
M=N"=!S@C/>FRHGEL$K9Z+P\Z595V_: TA&7\!X0V!K=!+.7?=1IK7@^@/?RU
MX!I!T%/F[2:PN7NB48\ ]/&AFVA-MYI=XHGS?I=;UZ4#CX7^\B!"7>\O'4DA
M?5GN_]R#F%PFR-5-5OV$%-N$%06YH,(=HNJ1Y4CB>LO8N@!?4=>B("\**\=M
M(N*Q7_I*]E9<0\UO?/JC'X3.!G&N/3 9BE?% 3;1A*X949*A]ZQ.)!TA]O9.
MHD4''^!2L3-IEO19*!@/R+Y$1=NGO<0PCUB$<$N_(3H69#2C+O[>!%P%%SB4
MM0?;$1BNB*1$/T-7D08<CETI1XI*=E?&;?$F]XRTC"R+UV4XOZ4+1#]%C7LQ
MZ+I"C3&OQ[=P0V[E<) TNXL +&QY^[ASYG,=G>C"<XI'),A+@A;9.)Y;:]1$
M]>GH>>9CS.I(U3<E/FESXWRZ5*,A<I+B&.K'(X994>MT?&#[B0;B\^G+>:4D
M8Q3YU^3*J*I%;TD1"]0/L:KH'/F7V/(3'Y*5Q)QC(%D5B@016/@XNM%M[\L;
M3!A*YD(?N:_?+00:U=64*5KW)3_8Q>^KK:MZ&Q>'X<]2'=E5Y2TPZ^,3:EQC
MF?Y($DYAY;"=\/A3K4NTBCV*Q/[. X?''(QIW'TGV.2+Y:KN@$#A==JGXC/!
M]K09XLG>85E;'CN2\\&H<M.']0](6!<^E#@.6J>#>'QZZ995DV^21Q820Q]3
MV$E*8_.BF -K)$'_K2]N+.Z4J+6.TC#M6-'^>^WS[>U6]>.5ZCK<75\QKQ?,
M/I];NOK?+CYRW] /!M:&?-FR:RTY>"&OCXCFB\&T&L%78-\+D:P/F&B3;SK:
MGX[&OD__O54O3$<U_L@L6C/)@(';]H6&!O(SY&6>FW1*H2EY:< ^2=,[K";0
MQ-:M:*$F$W*OR7ZNTUC<G!.[$8=SL925:[M?5DU[1M9_<:34?X[XHD*PENBX
M*(?K*;(\'=9/"2FT>)4&B8U(.Q;G8&#]0(34VHD4]QW_>30INU:V=^?;HKV&
M%U<C :,2G6@RZ+PLE\K#6Z]_2KFYH=WD[4^Z]I+21F'@:#K$=74+4)^)!]P1
M( WINPJ_A%7&3Z[E1C.9IUJ@EK(QQ]DN;?*38P_QS&.WN#M[3^Z]V]5&CYN"
M?&]""BGPBPO@4?/V0R<]8PC]\$$5C?# ?^G[^,S)S?-SDM5HINSJSUUKBJRF
M!)%KF,@8N4C>PFB2&X()S2BUGBPW8C/KSL&*W?M/^?'V::F+=F'L+@JAVVT^
MB22A>(X_7TF0$^;ZE"SH3ZZ.O^ZZX5?3&C5@,5%D=.DU_2(5EGDSVOW=U\>[
M84;3Y\/ $UXYNI@UK00F6UO@B:I/!8@'.=Q0<HL2QTXA=T:4F)I+CZQ9:ZYW
MQM:!\7(O486DON9PDMXMALJYH@#E*&4HR,D,;0-<'@-\Q\OKUB&%)"N?E>PA
MUK0*8/"@5C'8\.-^.<?CC)9#=1I712/ZNJ0H?)_WK6FJ=?4$:=APW!.)69^'
MQ^V?LR*5W_IVA<;X!.-_%!O=&(6W7FA^(CD7*7D2V?UQ03!Q(C(3;[J;6584
M#8G"C #)NQF_,J+UT/*9[ES+PZ8@5NYV6CR9+>HH.3(^N[:<.9/0UZ OE&!5
M\3-;&_%,%DDN]Q+6K4PL?W[8"J#S@*L/@_;YE;98S*]RN'8>1!YQ[C':*1O^
MZQ<:*6!'$T9<^SKK9(JDW?'R\>#Z\E+6N!-V9?^8T(P?3OC3N%I!M4IG^8UU
M8S1EEKQOW@(<A*Y/;EY/9HY_R+0TXZK:O? GZTXPE2L*/I2[CTPH<(],O!-I
M):/ZL%?;NC:IW3UL88:# BM=%KF0>>.^<R<F(' OR! -!2ME_\_GM+)V!X15
M%2]238/]X\2;)!;?Q%&TM_Z:T>J-Q\WPS,S_,<B(\ABB\RKXOK8P0Y(,EPWR
M_!0UW_CBW5RXFPC2/LOK5JO<*BT&O=+ZKNN*1*3/Z%:KI@#T\4!".\O#(K4O
MW^PZVE!3\(_+7U69L-7YA0/%+)BPFAG62\EXIRLJAZ]%FM2+IN3FWJPC?_YO
M-S7Z> %:+J4GLB3;@S^0+I,\-9M\V-F:ZNDM \X,MV4D-;"$?(6"@0\)\2-8
M/8X8#S..!]%[E9&N39=SP+JHN\1KI2T)TN]!UY1F&TW=E02S(Z3^L%?E]7W0
MVHV [EUZ- #@2Y"(_=\=&1)^JK!>'N1<)4J9>Z%;*<-)1.Q*LE*R*+QX/;%'
M7SHSC  L<Z;;W$MI47)^37>?+5<)])V">>9C^5$(7"&\]-0/ ;S(AGQ$!A?=
MOX"W1$,W?Q82KQ#?QK$9;*'#@Q1F+N\A -KY@SL_.C!-EVM6<ES81K7"0DY$
M2]L7CO$/#^Z@M?"@Z)@?!L<TF["S[:KFIP@@,BT0NG,'.WT9F_J;,;8TF"G5
M2],BC@S.?EXSP_9Y[J!:Y&E=$5<,AV I< N]QISR=G6$RX0QP&%&8+KM\$
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M^(OO*O#ZB+O[&@,'MZZZT*FG</6POV0Z'7[8T9(] M!-OM*,H5H6E[Y.K4(
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MVRG@-MJ%?>X:V/O-:1;B,+AO^2UD8($&0"$EZ25&O;8#TUIA$@##3ER574<
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MFQAVV1Y216;L+49=-'%6GLZ]P7]+=5@F0@_:]E[$W2UH6_1/L$W#<E#VV)+
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M[;/QJ=XAY#>0<2L^(Y+UR]WJJ$MO*6F=3<E#_+F#%YNL"RA#="%CT8/=O<T
MFXMV*QIISVT&#A#8EM28OBW:;62=->*AE-\7?/%Q]G.QK\"X-?ER)QP@M(C/
M*RFTU)CKK>=.U]1]^K:]3=CL;=3"*"I7R)QA;H;?=_[Z[*$X*T'5D+1P,_%-
M"@7QV"C6I C^1Q0=\3LIT<$V)A,UR0+,'&M1DP=W+S_\BB63PVYR]'0(ZVW6
MGS\*2'GA664@SS#%\2TRG\',R\D1Q2S:X'.OA/58=0;*M9=,"\FTI_O=&_5B
M\7'^TLQ+]8WUXTSL?#@0-TOR$#X$!W*1&DHD.]MGTME/<M(9E9G[&\.*!'Z'
M?2?H>Y4LTN-DR(:PH$T(=+)Y^5:5C4OJ>"FT[#JZ%Z/84BLI>7(*6?GQ>\U3
MDQ4AM6MR8.SZ[58DB;I.NMO8C.IG2PX1AL@ZTG;QA,4FL@.#Y0BM([T9EV@\
MG22355RVWT7YH0PH"O:0HR7B6G&Q-;[5:!SW<.6I0W+=9EX=MOYE\=I--RF%
M0_D;ISW6UL!FAG4LZ*->.$#$D5O1NNCF8,>86/GX]'Z0+#SBHO?5)&@G42AF
M3Y#XJG:D!2LD46=^2L<4*IJ[9O@>@NMNISJ50W;'S[[7NF0;UAI*ZRLPY,WC
M47W "P<ZDN(Q;,\IX@%O$V^.LZY?O[GEX8#?I!%$OP1J,'K/E&_(T#PN[\(6
M:L0E8!*%+VAK$!$4$WVWY<=WC_O68:652.Z;D?S!0],;KN34;:%"6#-N@1GD
MF+QF?<"'<;]W"3?80%]K8M M=WK7+]K^Q7SJ2>IYD23O6+-VGH[>=>*1\4<U
M6$>:W0L\RPYBT[O*1^W1%%@.!WI&].$J,Y*T[C3#04N7_6M+EYJZJJ+"/#VO
M5TZ.I BKQ6P8Y]><5=W%>YP3*V+V^JSN#CXE4VMQ*P9#!*4.U*ZOVHU(*^I&
MYV:>580,?9^7>2+OMQ#1R^H3::D_U[X"#7&M353CJ TNZ^FGE0Y9;7[E^"W[
MZ.6Q:$(Q%%^XYOCH(=@&<DXG1846NUI"(NUAK##!\7U.%26(M",1.<\ZXV3[
M/JB9" Z\[4*$E+JVM8%*-'1#8*7L#H<)%A;GQV7ER])BZ+HN.WJN4;@X]R)N
MD:1!!Y_VYE<#[6:(NJ?)4B,65FCI[R?I:]-*"FG2[O1O]/AVY%=FR-:$Q2$.
M)0O+>M=Y$EC&U2%R_,6BG!LTO*$FOE0>MV?M)2.HUB0I<.#C^<$K&$/4EGN?
M3YBF/HI?&[74&]"]!7+<B<[XZG6\M5#$4^U1TTJ\7PKV?#9$/>NMT#?=#@&+
MQ06&%%*CXCS%"ODZ+YQW5^+6K-TSKAPC@Y]XM*'@3 EFK7%AUQQ,!Q=9$6/Q
M9B?;E)&]YBW_N7K]]GS(/@5__CDXVJ8:XV4Z2=3H0Y(U<2 3#R2E@N;P86$]
MXCP3IPA"8'E+$\#/5LS!^])8#EO4]RO6H^XTQP*,%8 OS@NSS&Y=PMV]:$!Z
M4IR]MLI0=H+]FZK<<_(8TNC/9D'2; 8M30Z7*L$0W,/(GQ4ZIC4Q5FATS'5V
M] ?].#J"KC"!XE4?.943<$3F9 T-P>[57&Y-4Z>YF3566T50SV7G_6 7Z!S)
M3R"C5RA)[[(XVP)&DWY[]^H+7=7+I\&64NWAL>TBM,PH)RGC8^(*N"'./C*E
M[/0U#94>'&4?<M]T4W+*+PC3!J!+M']?1D74F]GUZ#L,1*1ETQ4M4<&!F*LN
MFML[XP<F/:#MQ"C']!J[TD*/N6["]GO/3G>;<676VU[Q6D>Y=4/BF@)V([PH
M%7QW(^8U_7F+I]7Z"3&.>P4WJCS5Z>E30XMX< #[9[ XU%P&#GPC;HP.73YE
MFH,#OQ0'X(!<+F!U_;'[4<X>L>>KC/R^0JLKJW&9#W'H4R9&I8?NFGW(+<KD
MT! !!1NNX=S5I@&EIA<X3\)DDFUY<5!LN3'642A-PCHFCVS.:<(O9VYS"NW,
M"RS1QK&2]3]8LRHU9YFTT5-&7'0;G3!%'I3<\Y09N7NN/7IV]])/C-VX^06[
M/0;=1_\X*8D"4.2ZA/&KIBK1JR!CE8DC)B7G!J6N+SV']@$RP!L"_YA7&,6^
M="<QHP*+8O+*G%NP?=4P.7^.GWVF;.TC@%-<U\J[YJON.-TT+CG7DZ&>*@^'
M@CGANBCY07;Q*8;:I_=%8J:WF <U)G" Q*T3>HG3#',81?U!UYV41/X[A;KB
MF^#70@HG)]OLU?=1SF P#M")'!$@MM5PA.7^L=M-DN,$A6 G2)[XDM[%1@:]
M2H-\@[EWJ'>HATU;!Y'.&U:C;X]_P($Y%^-.S\#$M/4CTCFCQ78[!XG%YE@Y
M?G_LL#%45*>9&#E"T-*8#"&@]E\D+>=&M$B)HWFS<7;ZQF'OJ]IG-Q>+$=.1
MA,",3"RF:) L*:NL-%&&^>H!@4K#G7)B=/Z\"AR0>%O[PFX0>SJ!$(2Z&)F7
M!8[ULGXT* (>2.'>CUU&*V *;)8@#*?WQ$F,RN&MG.U!I\L"$Y7( $246L?Z
MR=C<O62Q RW=R$[4.>N%5X7,F>AQ<^C;B<Y! BD&'G&L?B-1R1(GKU6"^05_
M")5\L]S:J5WGJ57^(]A6]4XF^M(2&6.4>9!@(ON-[6OBE\?V7N^#Z@*W%>9(
MYRS:7\<4L&=> !=D;7_X#C6CK=IB\R1/*6(H1K:KT)N72A25P$)SK4JC"W83
MW3ZDTAE(51+=FE)J[C&#*GIB92MZPD*^819Q ^=(WY3TW4O-ZJ.6Z--54>**
M@&'PR_1\(@%"D.*5W/@%BTDB'%"N:HR#U$^TE6KOR*_EZRN9*JC9K&E^B6?]
M!(C0@=W**)TTU*2PPYA70Y^&$@N/HKZ6]LMT!EP)E;&U'S?S=<5UK5M_*S![
MNR.]KY+M1T'IT(DO@\\JZ\>:'8&*G(E<GB=CAX+VG)"GQ^S=*:&J4%WAA>0%
M!R$H#3?XW-J))UB^/&($5IU;B<N7>O^+\FQ$X)L,(8A<OYUP?(B2)Z=R?=!%
ME>RDK>\HC+8N8)J+=8ET-9K^(/)91'R<O<2>(C,20TV=?GZCSE,2G"QRU8]>
MS#L8>S+J&9US'%,[S?7C[ R-X*<>'+$9DDTA0Y9J4G@J-JB#[\1"3!*0T;">
M!@$?8SP.'RDAKD@SNW*G,N?]Y?XAW?AKM>U\ZL&(@7FJ.D)V7+9N;(?FDD99
M&:#)A$PR'WA=K8IJ6;U/$92<5U7W>3#+C N_]AA'ZD.4U$%*%8(5_KQ4$KX!
M/=[W4Z",5HK,#R&10XKD$- H])04-JHQP'M <;DMYC1#=J ^)O4HCC]%*.J%
M=F2[EA89-JZJ7.Z+6JV04=ZYCKQ%Q6<OWG@HRJ(;2_N)OCY71='0E[8WX7M.
M&<2$2^8"-L%9E\#]P3Y];(!"T$F912EZI#JOXTPG@7Z!\!FD[,0EC#G&%-(-
MBZ_>9I/XD1-T$KA,*8EA0)9'UBYY9,>"L:6KM@83%OWESF_)3Q%3*TA^ ( #
M$")TXW@N.WZA^DUMXL.1H,]RM52ES:TI>3J;DH4-:H[6B=P'DC>!JBA8NW5Y
MK%;,R/$GLOX%*AY9>WKL6HZ2L725OPSP8^6_?_55!\T-_%I'9BQ4SG$/[[H=
MCG4HWKTDU\Q+=N9L"UL?2=$&_+)J_8I')(;9&K+]Z**6T$T3Y;,BJ;46Z5C]
M#-;)F!JZG^KK]YPV2N-7]_(F2&&EFG#L]U).(@1T>OO^0TN7#:W@E_D-#Y/W
M$H+GW9)>[IPF>"/8CIEOVDU5.VDW**E7$%-12!(%4R*K])?FVIV0'4U2N/>@
MR-V"$RJ5Y;5W FDYQ-/WL#W2#BX)=V2B]V' <-THO[4T;>WXAR?XW.:G![%N
MCQTQVK;!*8W3QQ(=!OP\R3%$"IB1_;BJN*HXJ HR@.R_'*\>"RA\HJHKO0?:
MX_-7-;#4<UE<T'83)*XRZ(0563[1<CXZK2"C"=3_;][7XY6PIM,;F7>.,(=)
MCL#"/3>=CR J5<<77S%,:^K313*=AGOFNM<E%S9\Z6K,6%-+IR4PA;FLE965
MC):26C<?=,Z!MC@0&96L)7*Q.3:.Q"/[6NJ7?%(5%%Z)IC%D=&AB.?UQWA?;
M;OG"VZ2%-OP>K>4'7#(E"2G=;P:'/J@D2[[KH=FD;CCZ6:BI/TL^ $+WUJBS
M@2C#@=*YM$(7,*J?Y%::D0]#ZEEW@3)18-I8U/@O&E'><>;3!I9#L/#/K=RF
ME*W?G2YYW0+GHB_QOI2BA FU((O0IL9I(.\I<]EL0'Y/SE4_N![D&Y7DEGW5
MI]IRF(Y-UC[BIM$PZ&D5NAS7U=%[SC HA/=0I$;ICYL4';,1>_^"YOJ1>;&A
MM9!KU+26-DGYKP'*T27.3?SB N&5E?CET2G16E?Y_G1P"J9C0EW+G.O=G%=:
M12Q86^UZHC$B;+6$_T%RK?>9>5V0)?E!G+$@WF=A[Q[IOHYT@*F\--J@W@L+
MRP$E8)HX^6G<FV^/>[S.VG[SC;Y/M3(4_%G\22W5LGMO?M'5]0+6/&3%%IFA
MUZ0SP)@S&X7J9=!&<E#6$,3M>:[66VH)!SY,;C"DGRI7+1KHW4B#?V;I%(+)
M?M*5<%DUD3QDB!G67,.!I*2="]%[/UYEH@X](T,X8%*H-,$O>%GKI9F@PR<&
M=*4ZRO(<R-1FN5G;B>HL\T^0<0GIA;1S^QD4.X\L]1KA6'J9_1K;K)QBX:#)
M.&_E#':3$MDUT+PL>?C&BEZ#Q)%ES4(M'P)2$K/MNT?S80G_;I3;''SP;'%=
MV\LBD:%[XJ84\WP[.P+'8XAZUB A<=+2NFSD%M&W%H\>,I?J#<,!-:%C)8X)
M?B?CH0]OF 6+@"ZG&=JH:O> K:T! _UPCP7AB8W3]1[-J/.^7D<0$_64T9C>
M)9\.BVA8!F^3\L/TQ,G"'L+M*-%0;I%UYC@VDCA\2)ONS*I?9E.DXGYE2R2C
MI*39CIKZF+-S%;=SZ[-84A/YO;S'5#>+:>C+ 2V;=^:;.(P^"687P4KT59+F
M?#:]Y;!60^AKUU5_>B1>T3 A)'D44]=2V>[J=G/S2U"::4?;[Y$O]+_</!9/
MFNX63\+"N,I]HI5@([V7(U])TJ(O%J%>6U<]0B[K>6+JE[D/<EJE=S;[Q3,V
M0K",]^CT?M)T)1R.GLB[=7IC7U\FH@0Q+TDRH.GGL?/^YDO%ME<1OWTM^>1'
MPJ&MS>8/;@\WP8%'I6-WFYR?:CW3'7E%WT5;'YYAO-$O^1U?F^2F][ \U7@A
MQLH6K.RE#;&*429)*1:\<WS.+Z8/?$*F0TY7$7"Q.\QMJ D:T8@[Y)@0^E+!
M?.9:%)/5B!<?$9V+6?F6O3''S?KDP'?Y^(%?M)$MJ/8$+?N#D6[9XZ,HWCM=
M+&DZ;A1J[O!)JEDZHL<G:#GLB7(MAA7*HE2YSW\2EB[F^FFOI*-AF8<9+3%F
MS&J63LW8(G*!)]4%&5FOY\;WBTC9=>/3.9TUXVI2V, 34'-) S8)1=6R2*]5
MS1K%P%?]+N+Q7BR?.-DS*K[JX B7]EZ4.S<)UA]%-8/4F%;9>7--VK#6%8.=
M71!8F':M_#SMF?X([D)_CV5.]*"JM+HQ<N3W9J',IY7-S"?ZACQ\\_SO^[EX
MY=&ZM/M(XYF2<3R/W7?EJK6-WEZ(,$_:[--T_7;C/&@*.GHY/O/$JGS^.FDP
MP,*V-+\I1IE@'C61J'?IT54Y-YKG8_?"&J5%!1>*Y:IE?K5V@6J+ (&WH=RD
MJ5&>8P?.33+B!$YJ$8W&AN*M9<U[%J7"RU;1[(GA!?(MTDT/1XFY&0._-,1-
MKJ.GL^H;)\V4Y#<:"/J>5#88\P@6-54A21JOKJA?#E0H<<9[]OE*YMM)"Y,)
M]"X:6A$W#LVK\'/;Z5MLI-,J=I/QFK78!HN;9PXIX>0Z0 (%]#\Z<J:0;4:Q
MZ/$$:;X!D[;#JKTT*[A ;"R,*:[W4-R];6U9Z\2JUDG)990XPZINCOOI'@)2
MS,=H=.D-:T7[^T^F[=3LZ"/3V.^KA6E]KP/:W'HOLJ;&+]%7] M_;M2V&NWZ
MYIO+.&A[MN3;\%0)?7T7M:8S-!E(MU/4GQ,;O2;1T&VU)QJYV/IIM=DZ9+7>
MCFDPF815B#= BFXTQ:K([92P7.#I>M%56M*%W363M(RCZ^W"J+%LE?'W1OL4
M^>F#-BRFPTY0;'NG+1!57T2L?35#,-^?Q$%9EV&F:XK.%U!)X.<.]E>:?SIM
MJ*&UE '9OQ!K9 N#34T=?/^6<6!C?UK2?V 11#+@D^6''!\1OZ_16V!LL-QI
M9E/$7UOF5&[$RL+9HO8N<QV,#88$4L^Z@I.4#<_8N(R^GL.!X-W)_8)2S*.N
ME A7[I^<ER.4^E_M-?%A%_%/[)4HN6C?8#8)EA3,SBD4\1_Q/SM4<@*D_7BU
MQ!TR?M1E>!K-T7F8:5K7E(9/_F;^[J.UMZX\2N>6W#)V5[_TAM"[RT^!*9!Z
M._?-+RO1Q +)P9E#)(Y?'(]16CK\17KOY&)$BA)>I$44OLE5Q\FVZKM)JR%J
MU]F[_>3P2[_3B_1%;=UI1&EK*[ND+[<2WI7[;I35^EY*;FD:3J8MM5VUBD!Y
M1&:'B&,%GO_H8]#M9%%?261NXF1X'>_I\LA]J_)P3YBI8A\^6^TE)LA.8U^E
M9(0C\'_RE(64^K.:%$:--!,R4V$W!Z$J*$P*V.%1D@%(D6O^-H8&SD5!XI:5
M(51%LJ&T%]X]4/+?171"_E([J #@"(R4<! "7[5)YWAVPP2CA"F=<[/]L'$5
MN3' 5 AD\1A  P!/3#WF3!1,$#TH?G*L&ND5FHI&F!XS*(N0,A"X]5=\31"'
M9FF1R<D(T*^87O#_><+[Y_J,4]N;E!?K)12O_02C) K_3$!S\L_0,T">"V,&
M < ;;%PKP5+T.9&-DS^S_SZ&J\B<B8P\'O'G-^9,K9IQ^Z;B.">I:+.MYN>H
M3^3Z;,P?.)I#I.?C!G4VJ@CB% Z5=;(3$@Z-JY.X&,X18K]$<O)/T6.)>:(J
MBX[B%19T.$RQ@\(7H.'9 NIEE:8I*-S)*HY4Z%[$J'&(_$;]Y1OR* )9?T0>
MCV%&2(V$ +W*Q;W(T58!6\-L520I^A]LZ=$I,+N<?QY]')G4#&,1</R<:CCZ
M&+V=C- /-(JIQQ+'.+6^2>F\GBOM8$8T6*[ N;XA>2%EG]N$+[9>@Q"M5#T^
MO/&M#*$&/?.?1W?_/_V=2KVZECCJCCOU0P^84I4HXRI""G[%^NG<=YG>+X#Z
MLL]Z/)4;N.>;%I?)XE"J(UV;Q+;MEMIZ^V=%VMHS<8+"-DN]K1^E5H6>S^>&
M#78EG2$%VAB]M &GU@HA*6X#TU%?R_*RON_I:<R.V#F]H3-?TDR8.JL.R%FY
MS__X<=Q/D+G4N"-=H.9$PQ#=9@Z$T7$4@W\M_-9_T?WG-D6P^*2>4!<'G:9K
ME$M<^^ [B^YV=?IH'$?,.!"2(#TE)2:P;U&J#R/XREC3W!HTOF4CN'@?Z_K5
M@3VG #WLU7I<FSGP/MEM_<MO_@?9K6V%)@7G'FDOM.L!V0B0%MB5]+$G<NI)
M&+#/_-U&KBO1T_">^ I";V?#,%G%T]%)GD F<<.)^IPFLEF(57&_J+N68>%&
MBY0B(/U;P3L0%:*MM!LS&%R2&,6?'PXX-@#1R^]]M%0]]?"*^FU/\7$WS%E2
M>'3#58'S$[L=]3"M[)% 0L"&S4B_$H#1#3A_UO(-+<JKR>GVCN77'Z"3[64@
MTRE&OOZH]U^_>?*_C^BHBEYAM V#-:2P9$QEBA;*!VL=GS#WON^,:4M%\KDN
M_&!WR&F+XMA>X6KN.DUVM5U79\2,K!C&&I1?/+?[%+<Z<? 4?92Y;[OADA#D
M&]8%!SYEC]QQ*L$!QO4!N=>L&H^"@&*7'6FP@&VG=MVD[>%!MBZQTKNF.E
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M)J+.U,$&K3<J_K&2G9\L(UV(V,,! M$_IH@OOV%:L[O__ ,*:Y&#^=4L^HY
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M8IX@3F.N4Y.W;1+NA26,HQ?H AA)BDVG'-^)SSQ:8^O0GLV3@F_TD;-^RY4
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M'?<CG'RG6+^W<89?3PS+.D^^:)1X+OBJ3)$G^1MCF=ZWH)G/DT*E.[..D&>
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M5(LI>)04IBGZ[M:ABM!Z+*_R36<OWMQ9:YB!*CHHKM+0_\N(./>;R;2/'FQ
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M]D9'*4)-8Y+&&-/LW5G-T\N_RQE/I-.K?E-)USX9%Y-"8JY9_M8'%.GBGPL
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M\ K>8ZDA[.F28;X8:Y/I#>A,O"Z2M2IH^#_U?RI1-5D;X)_M04/C4?\1120
M<__RI>ER(TNB6](O6F8N%4/?#$^8$0IW;L0N(9^<(38J&V_<AQGE7BOFC<6Z
ME7@'AUW> -Q?PG0PLEWG:.Q'E4H)11B%(\?$-6M).N:ME0,2/@:=J>=O[ZKL
M/_-;6G[AC=5L MAXA7BVC@RH7O1F(B22SBK?M87FXB2;M9<X#RUP6O1YR/9+
M=UUO[GPQY^/Z6NU/(Z]8,I#.45BB0X<WXXP;(!PP+85*R$OY843NZ-EN%#(
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M_\O\9V://?"2SG"&(X+?OT<$\+\B0MQ_A B@6]8L.GA0H4_)A:"8C$L!D;B
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MY][[H_\\TE6U:^^UUJZG9*,K''Q;=P&]T'MUT.JH*^=\SO63S!W&C9(Y_.+
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M?H!((+%GZN1\_=/3*X!.V\ GF:%Q$S] 9@">I!62P-Y+-^/\T'3HK#%.JTE
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MX,9WL(8_IC*_-Y=S&9R$$!-6XSB,<!+Y E2LAU2=TND!P2=&.V';*SH+EW+
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MN^\D"EU1U'"N/^O4RZ1PNT!A\K&(2'.^O:[?\;#5KH\5<\PZ[U<,]R+X2IM
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MH!9^2FM[FIF\QXUPP5W3R79BX^^Z9;FV>[941U9!.BT\K*4S?I2P;^/QM_&
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MT_B[3!C7P%;159%X)U!S)F'M$]/4Y<(DQ/D?ANPQQ.ZK5;15R0ZCSX]""W%
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M(<,XJ&O?H'WX1H><P&>SCKMT-/]F&[*Y(^O3#J$(UK_#X^Q>VCF.->EV=FU
M$GTD$<P)(KX84WRL"&/DU&-Y_P41@.7F'\LFL!EI<8>=HVZ'=\>Q\*^BYVCG
MZ_<7$TXG;<9EQM_A.1 <I#M%U@^ZO+!L2DB?8=1AO!,GD912&9"BG']['?V;
MQL(.T(E+Z%]>53?>51"DP6O%RU$:4<2D*VC//F[O@6M AJVMA,SF$BF1D+M(
MP9@NTAL8Z1DI?. $:I%#U2Z[[&K^\W?'@++ZYME7'C!;FS&3+!$I)$F^$("$
MFNQD8]?Z>'@Q)=BBI7!B".!3HI?9#-LB/=ZBX\3>76=(O__?S*].,5=N2Z/U
MK1F=$MJUF)\X9H+8$=U0MLQNDY'_\PFC!SUQ%>$I;-WWI[%P>_HK4 LCNOK:
MBB?AOR$4^J:@UME86T0-_-+>*9'#3BCG [':6=6!2GX5];'%!]5+NT$P%" 6
M75'+URA)R"O^?"ZA8Z$DYQ^N\U=37#)8.HIZ7)@X] :$*DKOJ:)'[?$ 7F%.
MUF"C!X\VI54,/$"FG W!5J3[;I:05]R-YYL'[!K^;81Q'RMJ7D6*F(H*_/*K
M\&_2!+:<<5%6 5M]*HL@G"0--TRFDET:UZPD2OZ>+<!VE/RCJE/8H9K]G&EN
MU$W7]O>_P<[8\#X5_-MCTX(F^E/T>/+ !D&T_X0>U$-8FV4)\]@,N)T5Y8AP
M&/>G8/1%M%1S/S=?DW68EF=-E&!DT,3?+E7B<O\M]I2W*5FXO:8/"C1N\M2\
MYW_3KU?=)7=?8"HI%:81]OF[J98/G[ $DDP;A6R0-"A5[N/$W\%37,I.]"_C
M.!_^.R$JYOK]O]S"H#.(K_\KG5!E!Q?4I*-<B.&P7'M9CX32Q@]U3',)*O))
MK8KJA%NX7BPWC'(JX(Q?<G)4;_/#A2BFJ%R7.MQGO.L5KH&63G1A%WFF0/&U
M329G5;1:)GRIZ(]/4@'12T1+MNBW#1V$OWA=YQ]4'%O5<&/5)@9J]C9:DM06
MKL\?[H=WLS. '. I22RSSL/!R'7VL<-$>]V"6M[WRVA2E)$A!1RB&/41C 5Y
M7!\L<J-V 1E'L4K"<,Q)H=FML>"5]106,W4F?T<\<@RG@S%6D[;W-0E=*7%:
M[IX3"C$Z2_8PL,&]6&(#CI)2.&3HVO$IG"PT819INR>4MG8+!1I*.$L^N;IN
MP5^XW%#1_BSP@X"SOIT)U*!0Y@5IKR/W5?%$M2^7.PDR0D]?HXJ+CA/GL?OG
M[%*&ENN<<G7UA?HS);!U?5+%T-4(0)/AJ9%VZ(MCG@M9;!D_!7^BP _CX5.2
M )ZM<"^8B ;N3=5-X40,9)9''A/XBG7[;QUT\X90EK(LQ/#.F@A@LGROO;@>
M$8U*I2S?LUR3-5I)2F4D3E7 U?6%P UL*KH?1/+=E>CVWIIJ$@4RG=F'VR]I
MWW\+8 \G-"NH1.4X2;3HFIJ'HO"^U&J$]K_'5K##$H-59<+B;@^Z8!$;F,I,
MF3"@]Z+N"+EI;91+LSNZ>0]$^:.G+SQ"\+D*NMNU\1T4/-]!)D D+RQ4B+HH
MQVPT?%>)BWT QG8EFCVRHX-!95/0\0^;?(Z^L2NYC08M_KC'P:R#@AT&$YX;
MNY[8<,RPBNQZ;)X%D\>-/?M\E"EI/Y.-<WGAD.GY2_J%$G':8 :E#.!W .8O
M-,!6G,PK .&F<\G>+*%SM(!\+1@A>8!-2L@X;@(Z5M^7+Z\^NH>%Q9@EU+^M
M=$MHW?Z-;S4R<Q"QGL>+Q0W$:0&^I;[A=+=R-:*ZI?6[D,;G>F9]B\0%^>WZ
MGU1!7Q.4UZ7]8J&>)Q3[IH=RP4/F;E;RF?JSG<[)0H$@);MX=>H+A<Q=EM@@
M$(!&UXU?SW,=.\KX2]-/F^#D)HC\+H]CSL=+>T3: W^EQ<J^<@4YZK&F?46P
M1$M7[(6,C"G8$$ <S89 9>)P<*!=]'N0^UT"BXDT=;!:BIJ?7HO>13A4T,EJ
MX2O@1^'$J,5SREWQ0_!:ZV(W[/7>? IM&/.)! B\Z?Y<1.$P?BX0<THO('/-
M@M]:#=9G4A3B_MKIV\L0&C,9Y/V5'W8+\H"+=:_:3:#5GC_6+C,("%Z*!A [
MADD*TRN%5HP.$?:SZ(>55O?XVB/P=Q/ 5XBP8H@[E5'_0-)NPMB^AK$F%<7]
M\-8)O5K#(R>U%O5R[C<X71[4L0<RU'\B??6;NT_"RHKNK8AL6"['G;(:]+CZ
M\LCB=H<!2G?V]!.;7E3)$CO+>"/OH$7;F@ 0;;(,S:Q^V9KA*1V^RUDL$\HS
MDC46J-NC,ZE:_=#'%5W=M*:-4A90MEB<!\3[A#]A=[6/+"7)<@M_ %[6M"FX
MW(:*%6U=]\5,3+"%RC@JJ>J[&OIFF>-Q=-]$=;7;!'+0N(_21[[KDI#0"F3R
MR\+>KP& @6E[HJHJV_J7V&,RW;(F=L)[Q2%5$VQY5:U8/'@[NA:07<?00^M<
M<;V@M6M\=S]L4!J1VGJ3@?00_.3C3-[<IHUV_:T&EDG0=X=N>(*;W6+6L$T)
M5B=K)I6$!VF*VD5*>#)9V=C]$"932V]5L[&@>!V7>(WHT\LM6%00;5S6D08C
MS99>)*,[E9;):$G7KF$K+T/ZTTZ0IB$..&F7W_4B&B]^#]YM*Y)AUGGR]Y==
M6U7/.L^P@<"^Q"9"G3403B%MVE X,31H(:Z[$!UGL2E1 SD1"WKDYP.#X.8O
M#MN(8<:LY@N;>//OWY+71:0AQ'Y*VX["EEO]/*8PR;;0F'=A%T,40"%"?BU]
MHGH-E\HZN+GC^3+B,BK&EB$R.B$3\RX5]1.7#1^@G9T=#,**]LH:,<OD2*17
M,)DLT^_]Q=PP>I3_N*J8]*CW?,5PS-/4) /,48ECRK.-@9X'+5X1-MRU8#23
M:2@ MH])(#4#:%!A!U%=N@L!(VAQF0D*!.KRS^"-$)YY<31$35&)X"*,I-R'
MOI;-I-^0YA'/6;3S"R7AR;@XGUA-_SY(QXO._^:HU$+\(GSTY<E-87RM 76Q
M6[^(MDJ1_ZGHDBO$8*8/0VDOBL%T&?&IEQPSX2C3A\$G]MBV9B[AY60XVMWN
MN+$0W\Y4K_V[(AN1R3<V>REBF(4*"<N-SW5!E'*-1E$XI:.!9P-LZ).1:Q6Z
M2MB6-IR4R^6??/O,UV6Z^4G7V/96,\&0S#J$YVD1=2-M)#\BOL.WDL.$P[V0
MC^8:[IJNZ7F#$XGT]6,E4[WN(]?M\T8??E+.Q(HDEU0XXP7T*JC8:YQ.OK>4
M7B99QMB.<I0IJSX2\+XJ9U\NB0_X>$)^D1XI!1\(TJETN?^,R+NX2W?!_3LF
M\AO^R,T=L4N.JGY71<^658/9*Z!,][3& (A2T*?:?:>T/<2H*#F5Q1Y?PG^]
MG0Z4I3UOQT,ZH.Y+(]DT T#=89N)8JHVA7X/.$7F] [_LQ1N[ 8_^5QT?5,2
MV6+;6#LZ1)N"_#T1%]":[J?(.9-9[T5W"Q=1WABC[<U7>#B^J5OHP2S4$(4
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MT],?7P$W$Q4\9&A:XJXLT;+45][+#R%G3H].T[\>@G[FQGUJ#F5*W:7_H9R
M2I5^@B*^)QSF=.#_^=SB?:.*XF\RJFI,#IG8OFHR>GBJ;;3,!*Y.XIE"*1E*
M5PW^'B<0T[(ODX*(_KMA:VLOQ\J:GM\_;%H(8 ,C%P%3SN_-'.4V1M)JX!,S
MK=F)8]D<FL/W(*F.PCI51;?J';-V*%,Y"CWM+9)3/:*\(B=1%63G49:;9/0J
MW3" $'XRM_170/?[/%*\&?]Q&MIP,JYS28_'J_E?V76DB0+40Y?&[Z<;4=+>
MRZ<37RT4T5Z5$.]?(C2-?5_"^$&C[*LL+OR$2_"HNF21J!$;2BFYRAFKE;[]
M=;=T8L.+8)K<))V+_<&!/4X07EA4=.<M,KJ,SN\2AU$+!\3Z$)N7HCD7"L4>
MU]73!$]8/MQ&*Z&8";6$-P_"QBH9I&.K)_T&.X[6H8N.J5QV)3NB.<6<I6H_
M<YOR*)K Y<L0GXZ?E.O>#,'_F<JVTIFYL>"F<0GFC\_>;C=!R_]*&I)3=@V*
M<AWE9)D?Q]D2 8&S5)7_?ZQ#_M]_ZG8-@J@<%,PO)QVEI!%".5#/8QHSSQ*Y
MA[4>KH0-":-9RV$N9L_^8X+L^H0N/<_*%_?GBA&$.K!QZFW#2V6.&&B54MZN
M)&-N"5>L(,O"N$W:) H1/0V'GSW7_+0W%?02LAHF:G'AMI$B=B>B6(HNJ)JJ
MB=IFCL73\ G;PK]+ _U$&4P:P4U!=D:MC:U>'C#><;J#XO" ]4=BS)[*D-^Q
MX#5+#'"T]Y,,@ON0(+4,4< ?\@V9 <[PF"PK4GJ>QD;75OWBA!TF6WU%!X2O
M8A(D8A#6>XS*D2/C1+#>G5(0&2;9@(YSHT"H2ID.'8O:5_D,7O\_>X$WN/LW
MEQ,]EJ91FS9A_>DR.*7K;OHMD*^:LW,@'0:.R<,"6KI#' W35\#/>GT&)997
M@$9M8]Q3['CI6J*3QG<71A)%,I[?EZN'(B<H_MW/98(<I[_45"0H_G'6%4EQ
M7L-_G'&CIN0$:].P%Z'E:@Z8A*U7LQ92;$M4,QWGP,?,DHWC.WI[)"VD.,_^
M!@=0KVI+FAO1.ZL,/273[!G&BZXBABQ!LW%(MRPL 6#^[X^%!RZ_/?9_^E/!
M33K/DLKTL[)V2B0 IH0FK[&ML;U!KLSZ9V%3C!M53;/IMT.$;,3BTEO-V]2(
M+C!394Y+"+7WH)[ M@L!KM'_]\X>EW8$S_8SUX)#SB]8BRY$R:':-&9]#*N!
MQ$T;_F>Z77CMGT1#VN$<YRN-6]H=K"(%BK^?4JY9<%^%!!_#+2?5':_.1WN$
M=1JF#'UM07[^;.X_,]]*_T7!27H@'^PJ!;1Y$KL/98'1LTQUKMZ+5SAT.'8$
M)GB^ @)\*2Q)^1J!-8D!MQ0I%=24CE'*P%"?HVY6KAKN\G,],"*IH%NR?DE$
M6#1G0Q@ )S"2?]SSNM*Z5V=G(D1(PKA,IT4S0%D+YF[R94>DSZPA@6[(LB6U
MA*Y#J=ZB4.+#&))L",,A/IFQ4B5E\5^3[(M*#QMU:-)X<HJ7J3O*&5NV;=<V
M?<KZN-? 2/O+]9[O$Y"6 OV9-ZC3UBS(T4=GR<C:/W&!YY)"MAR9LW_JR>;=
M9]2^\_7S;>BW\/Q"0C.^R<2H+Y16 $Z'Y>MQ&\X^FXQ5:G#Y4D1J8$E\57QF
MXI9*=@+GVL20>AJ'O!07R)Q"D;1FC86^R[A4GZ$#TINAF'4^^M'<D.(8V37X
M2&;UP-GGJA(APKAA>BNCT!,4L&6]X=2,V8OVY$?B &Y;\Q.A2$5UO1*+&6IL
M^3F!E;41XY#N(_X"ATO/8F 1ADO&G7)-@J.B5R3]?T! D^R";*!D/0LUK7C.
MI*O9CF&>YZ"-N.86)FNX#>GAZC8H]LLF">$'I=C&RF%!6]; 1R@=U;#X6!.U
M)";;*/Z$&U:<E;$2JZ8F/"S.D_$9RC87\$\!@(B?@_*:19/.1RDOE#4:M9!/
M#5NT?./H\(&3Y];FO_'>W_%\L8P=&+#8YG4(&L)"3Y"M)A$;.';K5]B,#QY?
MK&^S]D"]V89\C\F-+L6(1LH^: Z'$%Q7+AT9QX+U;M #N[!L&Q;LT*V_>#35
MY'A9!S]-%Q]6'/96>H6E;9G[V[H<(7"O<+Q/O1Q"4L!"J8]Q&209Y-^:?-*,
M?.:W7+^/RT'H9<JR1AB9W()E$PVV/AK>+7EJ6:4YO]LP\S8M<@]68)[47=3-
M+:/PML5B5T5?&Y>B+-">$Y+ J2&K)OB0<5[!)T[T$_29"3]QCSC=N:K@9BTX
M$_L"MU=O]8"]HI>XOIH]-.VHJ4(J]YGYW#?(ONE]JZR,0'IY$I,I@T^3@^9)
M3D?HK2IX#_O\4W>3CD52'SB=&:4.M /^O(6"<:D7N;A%NGA3 F%_EFZ=3/$6
MSATUZD@4ON-%OLO]-*4Y%:5WBWN,>TG65T*=M"G9:49KW\K N2@&\$W@>@5X
M"-86G7X<G&B:HNY$Y)Z]3*D$>/\<31,7$@J71D)?X-HWG_?&*Y=P,G:?OPJO
ME<$FJ83J@74CP"=?4,]MZ*S)^\3E"C%IG.1NGVPEP'2M%(>9>P$N?FCIPDXN
M[) C$2$*9;YN'F6EQ-H3#.47]J,E"W*F=3/[.I<P4=A)=C_ 2GAOQ/S)"N1&
M<%F92X(+<CB6^M!:>FZWN*K=N5#U&?'2]7.?*VHBS/68UYB#6EAXJI0>]1C1
M&VYJ)^*XYD;. OYK]_/"?VXV\8^3\!Q]^6;/*M9GKBLX#&FNU)HOW]M>5%U@
MGBF+G_?VAF+@L2NY\&JF:J<Y9>Y5T(8#MVW.@2^^HI  QOIL=.) Q0!A5OWI
MC2O*1GW/59P_($>6=3Z1SINC=]AVWW"8&4>5X3BD'<<B]U9;E&!*&VLVJ[O)
M[E.P!V\K?Q^]:&Z)X>SG^O?@0"'I+TGO4#:'IO-,Y_20/_K&%^X"(G<M?M,R
M+07C-7$GIPKV[$P0A;(8)P_F2E+PG-):=&]5=4AR64?537P?@ _;P)&6X8?E
M-P* *-.5W_4E84BTC:9R@=O2G*#\9[CF6IOLD92PH0L&B!WS2AZ1AO2Q-FS?
M;T\0UU'HV<&CX#R7 M$@[=,*.4KLF4 >NE,333HUK.)1#])#J7=^W) %F]T'
M0XM?HS"N8UM\ \ $=!<[[ ]#0K+3/MWC[\X*3!MC[">);"8?#"R39<:?M_ /
M9H2O9AI8;VVV)!CX&EZ>&9$S1F7A\(<O)BKY>K)111N6$,-%W_[O2T#:@'B)
M>L* >B!*3+17V* ^P]Z(M5F"R%BM!"QV$I-CN20?^=V$U72#GZZ.!  "!\CZ
ML@RA306D%C2] O0:<.7L("T6T"?_-<^4F.X^9N-I#>=P]7U7:,4TF$?&O)7"
M*-H8I3V33\B\PH-DH5_.AN622 %>LC%.:2;\?%%H]"@Y_Y G\/D*5. 5$E:Q
MWE;7/DT^O9WZ]*4NX;V)WW=\?*)M(33I;I%TS2'"R#2/?,.Q;T"8'A>8[S'X
MSJ*SFNIT_>DWIE1>7<'/#D66ABC:[02Y,CP%L($3U0R7N&9/TU@=FC-%!P9E
MV6OZAYZH$2<W:=KZ2DCMC2?S/,)EOR&X?QU3V.>P<E2D-F,T5YFM^SY4.M*5
M*'@!Q"?8YA]C^'%>757ID^Q?>YC)IUJ<K,=ZI%.IE+@93P(X%,2+K'A2&\+=
M$CG+YR_-K:N\B0D'#F]YMI-8A>O!.Z6,&7//#MG[GKF6=PNFYM]MP4$!YH5;
MX%9<4V>4?([J0<H<G/C-)9ECRR_H&NG&_/T%S&FZC\@2..KX_^E$35*;BR[I
MM"_WOE?=0> !EV93F'M[]:AU(NZKLZ!5704#\+-^CPVL8U!"09+MSBG[[(6A
MB1R.T^\+V;"+U@33;]'=Y^)5,!=9W67[5=3MYW52W&6Q:\8)M^V^PTJPGN99
M%<Y3Q;$[9KCD2[M2_&4$K/4_F2HJI^$R*"T_55-OBBTR-E4*7G+V.[AZVMU6
MME@7669^'W-B )$E^VO%>JYC@WP;YA:?.>\#.=)@9UBRFYRNF)*0:LBJQEX8
M_W02>],WGCN] BRML I6*T<:M*6& ,(?]TKN*O2E>VQ-LK=OA;' F#;6.,AW
MQF*!Y_@EEG%R).VL7.,U_82);L9^V2Y4"S_OR[:6I-RHBX*9MA*Y!7T7'!'1
M?-2E[)P>-*F^T0NCE<A(.2U;5*4>=PK>U\YO$QUY$14_#1BQIWMA6(.?<;?&
M& <>O11,=(B*:_; @[[N5VO+7C,)]%(:=+/A]5(1WM[3- T7094E]6E>(U_]
M:[J=UZ,& _76?A1:XUA[E0W".LDA@VQI5-=/"?@.(O(OHCW=<*]!8=ZL1>YM
MGY/D9J/C[5+Y\<X^;^71WU1E<J\%=#)/5VIIZ](4V63%2A,S8I[FAQ.NIL]$
M,;*G$R9Q<+1+!YQ,;Y[>_Q)4TZ(,(R>5B-^NK5Z'F=VC]8-S?@5 <856MILZ
ME<*)FM<VFK)&(G<!?,522PJ>*2] /UD^*.CZ)-0Z[.J/=<0#:[.S#@Q> 1N&
MR):K&%.4,US;@E K5!5W!4YS:<\7$K*A4@FPY,N58ZT,1&7%3!4F+2W14BC&
M+'O9N'&O ,2HD*Y]>O1MX._F],TF<Q\!7"O&W\Q55(LM$M]> ;^--\X>D3X]
MD)WG0;#)T(&3JF2#KX @5DNT_9E#]ZR'.]:65T!,BX2Q92;=M(O7(C,SBYM\
MB)]:Q-:LE\:8FDE^94J$CCJ]7&*^CN\W X\+MQ[.^[;>F(FBPA?9[I0/BI<Y
M3X/"][ ^PD>3^V7AZ?I3<3)EG)N#+KH5W 9S-C9;7U&^()(_+&5^PIY0.=$A
M3 J-/9T71Z&A+X#%PM4<ACVU+Q<Q6_;QU)SI)+\';D1A#YO-7A=GKM]D<A@[
MW5!6;6F#-7\KO;/D971X'TL;HZBV/#CMY_MCL]6GW:UFXKA@^2HK0 2N-4Z5
ME&'VF\7)IBK3W !*N#OK-0R?\%"5PQRW'#.>0IKR+ O6ZCSN\B7_.C#TMLRJ
M- Q73!T& .4'Y_T*N'CJXU0H7W3WY66T@?VXJ4[6=Q+=\@CU.*\SEUF8^B54
MI.U)7.^E(&_2N?@'8%W!7<;L#HP VE20RH5,N@TYEE4<L,G8*G'H8%5VWAN)
MOS &3UX7"BAD]&EIM'KPRC7P(3@$G"6(K^5095E5; K2#63AGM<^416N_^YQ
M:#AO64;8"/'I1FL^T2<=)]+JS?1:?NR5F*]_!6 <*!_JF/Z>L*9[T'*!;Z:L
M(4W8S")J1W5,S7JF]O1^I^N!JW&#8Y*'!A/S,LV&/K-:"X&Y#_!B?2^7RQEG
M[8/-]]%=&\.<\I!#E.&1/T%?MAHE_VL !T*EF^>7R16=?*6([\]R3"@U0Y96
M\QZ".9'D[9B!@0\N8X29)30U3!J-#L-G5$%IW]^ZG CFM(H8 #A:F^_\?QJ[
MSJBFNFT;BB"*1*ITD"(=I$L-J'0!Z=)11)KT7D-1D-Y!I41Z[QU$FA!ZZ+V'
M%I#>(807_.YWRW?O>_?].!DC(VNN->?<:Y^3DS.R=_R8).$9CU:]=8A #':X
MX\*[F SL*XP.RS.O%B/*O>]IMDG9'=1GT+1S#]!NYLA>,7J0Y&%32H6\*!)W
M/F/<LU=A8W?SYLN^NJ 6H3T0OZT=9;=X-8,*6Y5?&XH]7;_7!?Y/2Q*B;VA$
MHB@MDAI24U-W$G4NE512#*2*AZYT]HM@9Z]T;(!3(VT7I2<Y0N<X/-'"E_,)
MM<O6'K9DDS++8A'D 5./,X231P*_TZ;-5W]P]MKK4/T9MB?5W:>-!,/C,4H7
MFPBVY$98DM3,1"..MIWL2?:*P!]\.'Q7B!]@B4^PBS.7QD#.5([MD+B!Z!O-
M3!0A#1@5W*2/GM^+UX!E5BRP-=@9I6ECMP/I*0,M$4Y< S:\QIKW:($HAJBS
MYR[7@ O:/\'?[ET5;X#9(TT%+/!?4NB#W,3<D=;$?\UX#?@@9WP-2-_5O@:T
MN(/.0@%CQ$:F*'%RNHL-MA\N._(HF)WI&H$U_W\'CO+-^W?X@TX&U;,F7G0W
M=(_I[Q*UKR(Y./X[=&%Z/O@@T]J3[O^EZFKD7#,:\Q$%[D&)TU]RL^V[:Q@I
MJ,U *0L+RICO?2=_C3AEQ2K^_>_  JNOJ3D1.; \X[Z'-?YN8C$I.LS+0!)+
M(4*$+ZNAWFKQHXBET'GBA/C' U?!A6Q8Q2^R$M>.\E0*%3G W$V1BT<E0/4]
M[3SQ>_F(D].]3=&^ _%R(R.I]*!ER9<>K0 3ROPE$/DK][B?O 8TVB=XWZH(
M?4)]"N)J]Q6@%"<EE>V^Z.N%1'%'1]8#0B:^SU$IR6Y>H2^+'U2B8FH8>8IE
M)-V;N'R$FK:W:J7%V<P+9\[>M $)>VD&\BG7='& (D_6Z[&:0!VBJ:B8;_T>
M.;I4C0GLV.XL@#057!;2"A4<98]QR/Z;@4.C2^H:Y5MAO)KU/'%05P/[>\I6
M,9&QKN^_XQ!46XK&(P[S=*OG7'=+$W-6<\.KX-]D'(H5[A7/++/]FMG%E:A)
MLY<3WX?IK7\7W*>2JU'+4K*U^7"/GB@@0R(]A+QU*W396[7$,HU^3-#RG9P7
M-)6^_+/0)#Q$!4^R?@M6K#:R-N;-4[!);+%-<T2VV"&. 'ZYRW9\TG7%T9_(
M[MTSP]T\D7X2[T@MEBXH,)K]+LY5 5$Y86MM7>@C(&9\]KP8Q6"59$1?VRB4
MR-?'.%7KU$4"T"_M36MKTI['KJD)O1W$&(+)*NEGHA/F?E>WH;Q>MKPZ5JE?
M$3&4#I[3)[U;1_K^/CGU_H9U8WWM?M4/]I%UW6+3$1SQLW3O$I$!-X#"48?S
MZW5:(Q<:H_68E->%HKU T7R- ._\'[VVQ4V<R0L5D[_R,D)W)>7_MXW%;XZ#
MJ"C17]-N'[F<NZC31]]QL-' I?#H0CB,6);T'S4\.&BC*'D3\?P- W9*#9ZZ
MIP/2\*,7"+I-:;V _VHS.OWU:Q&B19]1>QSPX^94=[?@=T'M+T,OK,^VAY08
M94F_9*G?9I>BQDHQ1W+4).T=B;![>Z9R9[_9SC+&&Q8I+MX.CS&T>R?YFO&.
M$G)JG9':)(V#JH7R%XIV_T>2!W%T%%\[7V"[[ HF<!W25G.<3EN8^[1S%5Z!
M"XN))M,E? D07F2U:?7#A20+!B_.T9\%0O4,$\+5.667F.Q_D6=9/>-EPD @
MYHN]N5<:#SGH7JO)D*ZG_EX"//PX:[IYCBZ!BP20K'.9>9!I=0UP]M6L>OF
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M6!17*/<>@<<3QIDH/< NX; FD(HC$S]((]IR3%_U %QIXSL0]$0\_F PG-0
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MSIS\5FFJG[S<K4R;D,N86KJC=\/KU,9>$.K\M^=1W>-U%$]U,T%AX<>P!?O
ME+]F739Z;CJ,<3\>\Q-&M"Z,APGB%<)YV[V &3OQHM/7(AZPC&C8_EWLL5>\
M5MS2)8458S0&51;S5%7N].4MEPDN?:H7FDNH^A*-LRO!9%T]#6$E5/R0P &\
M!4M*TF@[X7E_&-2'<AO7*]PK<B&SEG;!V/>*6>D((7HPT_PU<$[MZ#K.LGB
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M)'W)8;A%(N++D-6):ZZ>F%\U?#R7##>.?F)/[4/H*EA7>'LOQ5P.!7FYN+T
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M9YR9O@UQW#=1D6 /-;AJF @*[ZE3%K-7B@']_%RH"'&$Z6T+G<M:\R#?0!M
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M$2^G=B^;SIF;!DGSR%NE_;-4SVJINDM)\61'WB*>J[^X)(4?4]2'-W9_.[F
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M,97#"TOYF^I/*QV.YN,$ZD=JZCL')EL70ND5VMU8Z\TVJEQDP]D7UXM\L2^
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MO6/A:?D ]$.+[.&.6++OS20M,6N()-LOY*SQ\?0DF :;Y6BG'Z9A-^%.IMV
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MBOW[,[D_%7 ^<\<@!,5P9R=TOJ@ONU$N7K'Q.Q2+KPM@/!YL-)I %-W#=\]
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MRZ#EA"77<DU>JKM7I["YV/)#J2.LOZ!"YXBY<A" (RTYC_WIO75S07Z^MM
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MX@T=I$PM]^.J,:^0OOX,:/3"?22,4XH1PM12<VJ:JF$EWH_-?.^]3#V2XS6
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MHU<FM),1AWH]6/&9X$#.?/,_$7EZ361'#E +NG"U<[!Y*MO6.OZ\6@*,'94
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ME*5-  N?#+AIBUN[NX[<TO'O0W@'O\&8'8QQ9!%60SP\3&)W*L@1]J]:J?(
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M(_*_P8Y)$M*F_W=;3O\;0GF:^U]02P,$%     @ ((!_5J5N0Z%C7   $6T
M  T   !I;6%G95\P,C8N:G!G[+ME6%S+UBXZ<0T$=TB0X!#<(0F!1H*[![<
MP9W&"037! _N%MP=@KM[XP[!I?NR]MG?.6OMO;]S]SD_[CW/O=_L9_#TZ%%=
ML]ZBZJWQ5M>$S<'6@.<RDM*2 !P<'/#QZ07 %@%Q !49&049"14%!04-#14=
M$_\9)@8&)@DN'C8^!2D5)04I.?D+6C;Z%]0L-.3D#'R,+*\YN+FYJ>@%1/@Y
MA=FXN#G_J 0.%0T-$P.3^-DS8LZ7Y"\Y_Y<O6#N @PIG >^+ $<-P./ (>#
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MLWS"[\!@IY8<'>K:=Z.2V6VE]3*QT2>IMGO6U&.REG,=:&,)^IS^]61J&AP
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M!G>#/@<# O%ZP!?L5E37F^,P )4^[ ]=,"5V\JM,AVO7.Y?MX)03.=='.-5
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M!(+S.OO8_=_;YW_[/W?<,>[JGJ.KJV9]LV95K2EKU=WTW1)P_ZF<HAP  H$
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M.6'ZZ5I9C=NQ,N3VKI$\7,J\4NFZ]5M"NOS 2%O*Y1Z.CEZ6M+/LR.N;ECL
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M-=5A!_-+G\!RJZB(U--NHWN/VS+AE729\3?GQGP]@0^@CH :Q$2X&YR<N%^
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M[3]Y=_^_0W)(@1E15'??_Q]02P,$%     @ ((!_5NU(!W9@>P  MXD   T
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M-ZR<BZ2!@,CN].ZSAB(?'0@"),7Z;$B\?.[KC7=)8GH^@ "!@).CDAB ]7]
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M?8']JTH"'7+VI\Q"[-VL#Q>#R3O1B((AC;=Q7LI@K95)<TV.%"U\-<.>1^=
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M]!^W5PL#6B#BG5'4SRSS6I8L3Z.?^BWGVO925NP"FDVB*ZNFU)<Y:+5F>6$
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M#]O-(Z$4^A%)-$:<OSJP/6;&R.IR/8IGB[IZG5TIA])53_&CF68&:TY9<MV
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MAPS>R\!+')TI('YO':)K/2+P&=-[!?1/[5=_O55GRZ>/5?*=DG(5Y>"L@Z!
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MWNP9Z$(G<,9!Q417[YJ4WO<NE@EVQQTA)HFOJA_(#N6M@WB[?WNW5^+=#HC
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MK)$[F8? G[G]DD83  +<&&#+7N5-D4S*:#9$]'YKK0F79S9U1X_/W-&(6EV
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MVB1'^Q0]O#I5CT0W 7<NVP:7<@ID!S ;#"&Y$G8/X78A0S-V[G6%<7!\9A]
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M@/]I/(J5-E[!N;XQ;(' X+TOL,;NIA:)B)CX/.-!;E25ZL&7JHFOHCY&VE.
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MZQ.O#7R\.+;AH8]-::V#'Z>/B>$<P$+>R+CJX8%\ A&(G&GAK@>Z-A&"]MN
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M>'J(33]:K!E/*OV+?$MQ\(RC<_QI20WQ6K?[11_4);S?00&&AXC6D/6%];P
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M"'-HD9BCO2>GB!FB31-)@1&&V.;9;$C.O%\>JDR1?G%LO)J#/L-H' $OL<]
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MS*(DB:&#V/$\53]]=YU#OFO-3&,_9E9SG%)7R7OD.]/+RVLYJHVEC6\*R8[
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MM;&4QXZM3@D7YQ2M9Z=X=]-J>'Z6"D9QVX(0.W3L.L\TI!T*B:6^,W6D[@\
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M??LI4WH>"KB,O3-%K5X]2^4(N91-$;:DA!7PUNWPZZ!-FR@$FR]!YL6!!<Z
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MZ;UIM(8O;YMD&@I*M4B4-[S V@%-F7Q^1IDM<QW@XFJ-><M]+EKQ73$/$U;
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M@+OI7P\5P=R]]PC2W(LO1\KAD-KZ2SGA UO_4L[1 Z_M$N,-8FM=X7/B(M>
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M:PJU]O:L%GC]8PX;A> 'U<! WVR+'.*/:EE=Q7VW>]5B]>X8.SS6S>B(MH_
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M8OZ$F9:[5@\D9#US49P)B]T9[5U#?=!,L3J4>!T'^7JT:C[K0>[J-.7Z/ V
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M:D:+N.7OZ5!*T4-UO'/W+V@T%:<O4VWUJ/#<X<^!G>!^+!4P Q8-6IH=F9%
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M@46(C86)B46&3X!+2$4.HJ8BIZ2DH>=DHJ%EIZ.D9'[-POZ*BY>7%\0D*"K
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M^X"VU<1DVY'7)DQ;<TR_:22^IGN!+2#!=.UTR8<UCTU8#0-8OJBWI;'VX.H
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M*2)R/9I;ZQSC.32<Y8S<(NFMJ1A%S;)H!]@?>ITK]@EZ$RC&7HIZXYZ6F,,
M?;&:5 ./AEE]O&B.].T6VQ>4"H%C3&=\QO-#B=$(!QG-*@?@E]OZ0G//"$%O
MP2.5I:N#:0:_#B^R<4Z)W :_^H5*X.*A,E%&:&GC^!^D^J2TB8 M&SU[I1S$
M$I X9RTN!(H4!W*HASY+ZWW[U2-Z-_5]7T%*."[N[4QMO/%2:4NUM)Q!=J!1
M8L::0 +2ZA*/X"&E",+-3&](M>:$Z[:5VE5A@(U!_87)[RH1J0W,>VS%A85J
MV4^OYBWZZ6>-A%AGK=),\!>K7:4S3UN_5Z!-,P"NPK=%HYE+<W%7!&0DS2JS
MI_DV=:,%UK1Z(>;6JRY6A61;VGGQ=(,_Y_OIB-V#%;@.E%E&<95MAXED0*&Y
M#,S#^TM=>ED-V%C]-7?< D5T'98^N2F80?;H6Q'F3T0S2W-SR\MOG%Z3<,$
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M&MSJ+^Y!E>@IZOFC=M93=<EUV^OUF$VE@*NF#G!^$Z]VKQ_Z\E.G2ZCO9RF
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MI>Y?<X79,^ V88J_ +[0Q49789?BY*S&-<CR%8N0?M"%1WB]X"<^8CD$GL=
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MVR+(5S=B)7SV5(S\;8< LNT5-BV_\[A=6.H[(F2 \ T<^N]4V*D1Q>FCV]5
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MKG0S 0JI24>"GJ?^<_ @'"T[WLV_KO/EK+J<SN'3HS0%=$03F/PZ'DSRU0F
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M7-TA*&W PGZ:*L-Q MG?=@L84WTQ$I9B0HMA <*=\S&L/:H" ?G%(U*E:%Q
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MEQ+8?O)>C@\BE?-.*=0^C)I_ZK(P.,@#:0U#1CQ4DI(PVLM)B\_Y:]+OR+R
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MHS]]=6]O:VUK2Q!IGH2!?X<L\ X4-W.$D##P)6I9:NC1,_3B_#>MK-/4W*-
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MF[#03)P=0SH?16PF]+%]^#+R6@!Y>!.0YJ078K<VF%=7S^YN=9]GVLT]GT=
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MW#[F2//J.,VTB'PI^>>XT6[WKGGT',\GCI%$*R. #O*&")'/3=[$8%F="DY
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M[U'<HAE3ZW0W<-4XCZW]Q!"KI#8%;Q)P!GV/G4J>@?]H  K;/&J1<.8/9&#
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M0:P*+6_88S5T!8G9EUFI70HZNJJ'@*&:Z+/O,6YI&K8$H+!Q(LF:>.=J2T-
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MET23Q4EWQF&IMZ):8 M#88I^PO>AL^9JPKL.HV7ES/5QCK*2O\73)WDHB!(
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M5OMC?P%02P$"% ,4    "  @@']62QCC8N'" P %F1\ &
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MT0, 9C(P9C(P,C)E>#$S+3%?:6YS<&ER871E8V@N:'1M4$L! A0#%     @
M((!_5NX8Y_I# P  !@P  !X              ( !O=0# &8R,&8R,#(R97@Q
M,RTR7VEN<W!I<F%T96-H+FAT;5!+ 0(4 Q0    ( "" ?U:*G[:'@@,  ,T,
M   >              "  3S8 P!F,C!F,C R,F5X,34M,5]I;G-P:7)A=&5C
M:"YH=&U02P$"% ,4    "  @@']6.K"=3M4C  #5MP  '0
M@ 'ZVP, 9C(P9C(P,C)E>#(M,5]I;G-P:7)A=&5C:"YH=&U02P$"% ,4
M"  @@']6M66R+KHE  ![]P$ $0              @ $*  0 :6EN;BTR,#(R
M,3(S,2YX<V102P$"% ,4    "  @@']6W=Z?0%8,  #AB@  %0
M    @ 'S)00 :6EN;BTR,#(R,3(S,5]C86PN>&UL4$L! A0#%     @ ((!_
M5GHULKN64@  13L% !4              ( !?#($ &EI;FXM,C R,C$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( "" ?U:'D: ,6=(  ' _"@ 5
M  "  46%! !I:6YN+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  @@']6
MH0$\;W93   F<P4 %0              @ '15P4 :6EN;BTR,#(R,3(S,5]P
M<F4N>&UL4$L! A0#%     @ ((!_5NJMTIO(&0  6AH   T
M ( !>JL% &EM86=E7S P,2YJ<&=02P$"% ,4    "  @@']6)JJJ&F$2  #Q
M$@  #0              @ %MQ04 :6UA9V5?,# R+FIP9U!+ 0(4 Q0    (
M "" ?U8 /";()!,  *P3   -              "  ?G7!0!I;6%G95\P,#,N
M:G!G4$L! A0#%     @ ((!_5C0;*#0U%@  GQ<   T              ( !
M2.L% &EM86=E7S P-"YJ<&=02P$"% ,4    "  @@']6ZAYSQTD4   .%0
M#0              @ &H 08 :6UA9V5?,# U+FIP9U!+ 0(4 Q0    ( ""
M?U9 JV'QWI(  )>9   -              "  1P6!@!I;6%G95\P,#8N:G!G
M4$L! A0#%     @ ((!_5C!<]>3:<   578   T              ( !):D&
M &EM86=E7S P-RYJ<&=02P$"% ,4    "  @@']671M"H/2!  #=D0  #0
M            @ $J&@< :6UA9V5?,# X+FIP9U!+ 0(4 Q0    ( "" ?U9M
M-0TTU&(  (EM   -              "  4F<!P!I;6%G95\P,#DN:G!G4$L!
M A0#%     @ ((!_5HD<3D&A7   T6,   T              ( !2/\' &EM
M86=E7S Q,"YJ<&=02P$"% ,4    "  @@']6E)# 9F-0  !]5@  #0
M        @ $47 @ :6UA9V5?,#$Q+FIP9U!+ 0(4 Q0    ( "" ?U:C=2LC
MC(P  .6<   -              "  :*L" !I;6%G95\P,3(N:G!G4$L! A0#
M%     @ ((!_5D(R'0 !O@  P;X   T              ( !63D) &EM86=E
M7S Q,RYJ<&=02P$"% ,4    "  @@']6L/;MV]X5  !]&0  #0
M    @ &%]PD :6UA9V5?,#$T+FIP9U!+ 0(4 Q0    ( "" ?U8E^#>^;PH
M .,-   -              "  8X-"@!I;6%G95\P,34N:G!G4$L! A0#%
M  @ ((!_5L.\#MB;?   VH\   T              ( !*!@* &EM86=E7S Q
M-BYJ<&=02P$"% ,4    "  @@']6#AJ7[U9J  #F=0  #0
M@ 'NE H :6UA9V5?,#$W+FIP9U!+ 0(4 Q0    ( "" ?U8](4D;"6T  )%]
M   -              "  6__"@!I;6%G95\P,3@N:G!G4$L! A0#%     @
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M2P$"% ,4    "  @@']6H:&07=),  #^6@  #0              @ &!. T
M:6UA9V5?,#(S+FIP9U!+ 0(4 Q0    ( "" ?U:?W)U&+J<  !ZP   -
M          "  7Z%#0!I;6%G95\P,C0N:G!G4$L! A0#%     @ ((!_5N#P
MR8.C?@  H(8   T              ( !URP. &EM86=E7S R-2YJ<&=02P$"
M% ,4    "  @@']6I6Y#H6-<   1;0  #0              @ &EJPX :6UA
M9V5?,#(V+FIP9U!+ 0(4 Q0    ( "" ?U;S72C*(BX  !,U   -
M      "  3,(#P!I;6%G95\P,C<N:G!G4$L! A0#%     @ ((!_5NU(!W9@
M>P  MXD   T              ( !@#8/ &EM86=E7S R."YJ<&=02P$"% ,4
M    "  @@']6HBT=_5UI  #)>   #0              @ $+L@\ :6UA9V5?
M,#(Y+FIP9U!+ 0(4 Q0    ( "" ?U8U".0&^Y$  -B9   -
M  "  9,;$ !I;6%G95\P,S N:G!G4$L! A0#%     @ ((!_5@'G&LKTBP
M,I0   T              ( !N:T0 &EM86=E7S S,2YJ<&=02P4&     "L
,*P!]"@  V#D1

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
